<SEC-DOCUMENT>0001494650-23-000020.txt : 20230307
<SEC-HEADER>0001494650-23-000020.hdr.sgml : 20230307
<ACCEPTANCE-DATETIME>20230307163448
ACCESSION NUMBER:		0001494650-23-000020
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		101
CONFORMED PERIOD OF REPORT:	20221231
FILED AS OF DATE:		20230307
DATE AS OF CHANGE:		20230307

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			OptiNose, Inc.
		CENTRAL INDEX KEY:			0001494650
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				421771610
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38241
		FILM NUMBER:		23713051

	BUSINESS ADDRESS:	
		STREET 1:		1020 STONY HILL ROAD
		STREET 2:		SUITE 300
		CITY:			YARDLEY
		STATE:			PA
		ZIP:			19067
		BUSINESS PHONE:		267-364-3500

	MAIL ADDRESS:	
		STREET 1:		1020 STONY HILL ROAD
		STREET 2:		SUITE 300
		CITY:			YARDLEY
		STATE:			PA
		ZIP:			19067
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>optn-20221231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:738bcfbc-a4cb-4b05-a396-7d259cbbc32b,g:9b54bffb-0962-498f-9b57-5d3747805ca8,d:451bcb3eabba4f87bdc579718207a3b8--><html xmlns:srt="http://fasb.org/srt/2022" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:optn="http://www.optinose.com/20221231" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>optn-20221231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF80L2ZyYWc6ZTU2MWM2ZWQ2MWUzNDZjZGFmZWJiYWI3ODgwOTMxMTcvdGFibGU6Y2YxNjc5ZGEwZTQ4NDc2YjkxOTUyYTMxYmQ4ZWFjMDMvdGFibGVyYW5nZTpjZjE2NzlkYTBlNDg0NzZiOTE5NTJhMzFiZDhlYWMwM18xLTEtMS0xLTU4Mzcy_cf04982f-cc6e-4f63-a699-37654030d76f">0001494650</ix:nonNumeric><ix:nonNumeric contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF80L2ZyYWc6ZTU2MWM2ZWQ2MWUzNDZjZGFmZWJiYWI3ODgwOTMxMTcvdGFibGU6Y2YxNjc5ZGEwZTQ4NDc2YjkxOTUyYTMxYmQ4ZWFjMDMvdGFibGVyYW5nZTpjZjE2NzlkYTBlNDg0NzZiOTE5NTJhMzFiZDhlYWMwM18yLTEtMS0xLTU4Mzcy_585028bf-3e81-4111-9f31-d41055c55507">2022</ix:nonNumeric><ix:nonNumeric contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF80L2ZyYWc6ZTU2MWM2ZWQ2MWUzNDZjZGFmZWJiYWI3ODgwOTMxMTcvdGFibGU6Y2YxNjc5ZGEwZTQ4NDc2YjkxOTUyYTMxYmQ4ZWFjMDMvdGFibGVyYW5nZTpjZjE2NzlkYTBlNDg0NzZiOTE5NTJhMzFiZDhlYWMwM18zLTEtMS0xLTU4Mzcy_5c5a16f8-5f85-468c-92b2-391b097aa363">FY</ix:nonNumeric><ix:nonNumeric contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF80L2ZyYWc6ZTU2MWM2ZWQ2MWUzNDZjZGFmZWJiYWI3ODgwOTMxMTcvdGFibGU6Y2YxNjc5ZGEwZTQ4NDc2YjkxOTUyYTMxYmQ4ZWFjMDMvdGFibGVyYW5nZTpjZjE2NzlkYTBlNDg0NzZiOTE5NTJhMzFiZDhlYWMwM180LTEtMS0xLTU4Mzcy_ffb2dcf8-fffc-431e-9071-dfa058b83094">false</ix:nonNumeric><ix:nonNumeric contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" name="us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzY1L2ZyYWc6MzgyNzViMTRmNmU2NDY1ZjlmNDQ0MmU4MzkxYzE5Y2IvdGFibGU6NWM3ZDZiYjczNjFkNDc5M2E4MTIxMjhkOWM4MWIzZDMvdGFibGVyYW5nZTo1YzdkNmJiNzM2MWQ0NzkzYTgxMjEyOGQ5YzgxYjNkM180LTAtMS0xLTExMDU2NQ_cf1ef344-6e8b-4404-9fc4-62d43ef2dafc">http://www.optinose.com/20221231#UnrealizedGainLossOnFairValueOfWarrants</ix:nonNumeric><ix:nonNumeric contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231" name="us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNTEvZnJhZzoyNzE1YjlkZmFkYWQ0MzJmODM0NjNlNTc4MDU5NjVkNS90YWJsZTplNmRjNTY4MzJmZTU0MjZlODE2Nzg1Yzg1OWM5ZWExMC90YWJsZXJhbmdlOmU2ZGM1NjgzMmZlNTQyNmU4MTY3ODVjODU5YzllYTEwXzEtMi0xLTEtNTgzNzI_24ba613c-7389-4e11-9675-21345271c945">http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="id970dfd2674c4d6b895febb9c14d0fd1_I20211231" name="us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNTEvZnJhZzoyNzE1YjlkZmFkYWQ0MzJmODM0NjNlNTc4MDU5NjVkNS90YWJsZTplNmRjNTY4MzJmZTU0MjZlODE2Nzg1Yzg1OWM5ZWExMC90YWJsZXJhbmdlOmU2ZGM1NjgzMmZlNTQyNmU4MTY3ODVjODU5YzllYTEwXzEtMi0xLTEtNTgzNzI_68a7407f-9d3d-42c1-b7e8-60a846da90dd">http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="id970dfd2674c4d6b895febb9c14d0fd1_I20211231" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNTEvZnJhZzoyNzE1YjlkZmFkYWQ0MzJmODM0NjNlNTc4MDU5NjVkNS90YWJsZTplNmRjNTY4MzJmZTU0MjZlODE2Nzg1Yzg1OWM5ZWExMC90YWJsZXJhbmdlOmU2ZGM1NjgzMmZlNTQyNmU4MTY3ODVjODU5YzllYTEwXzMtMi0xLTEtNTgzNzI_81e615e1-5430-4b3f-a024-d8c112dd845e">http://fasb.org/us-gaap/2022#AccountsPayableAndOtherAccruedLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNTEvZnJhZzoyNzE1YjlkZmFkYWQ0MzJmODM0NjNlNTc4MDU5NjVkNS90YWJsZTplNmRjNTY4MzJmZTU0MjZlODE2Nzg1Yzg1OWM5ZWExMC90YWJsZXJhbmdlOmU2ZGM1NjgzMmZlNTQyNmU4MTY3ODVjODU5YzllYTEwXzMtMi0xLTEtNTgzNzI_c6470abf-49c1-414a-9b43-5932ca6cb8de">http://fasb.org/us-gaap/2022#AccountsPayableAndOtherAccruedLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231" name="us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNTEvZnJhZzoyNzE1YjlkZmFkYWQ0MzJmODM0NjNlNTc4MDU5NjVkNS90YWJsZTplNmRjNTY4MzJmZTU0MjZlODE2Nzg1Yzg1OWM5ZWExMC90YWJsZXJhbmdlOmU2ZGM1NjgzMmZlNTQyNmU4MTY3ODVjODU5YzllYTEwXzQtMi0xLTEtNTgzNzI_51c56e55-3624-4972-bd9f-e5d6619b61c3">http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="id970dfd2674c4d6b895febb9c14d0fd1_I20211231" name="us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNTEvZnJhZzoyNzE1YjlkZmFkYWQ0MzJmODM0NjNlNTc4MDU5NjVkNS90YWJsZTplNmRjNTY4MzJmZTU0MjZlODE2Nzg1Yzg1OWM5ZWExMC90YWJsZXJhbmdlOmU2ZGM1NjgzMmZlNTQyNmU4MTY3ODVjODU5YzllYTEwXzQtMi0xLTEtNTgzNzI_f473c9e3-1f7a-40d1-9ce5-a76980ea7120">http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="optn-20221231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied2db99cce6e4199865af70756a669a5_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i94f2af01a3404575802c3ac9b3d117d4_I20230301"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="ie179c2aa474648c5a81e099ecf55e73a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id970dfd2674c4d6b895febb9c14d0fd1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i7d7389924c8a481f922afd27c2d98be6_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i86422cbece424367a1550b9f28481643_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb05b53856a04e6fb8d77b2615fef7b5_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a537887f3924b21a34b339e3a39c085_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e3006d0e61345298119d94aa76e7fc3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i14c26b9820bc4dfbbdaf3a90822b4aa3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i97d8a5bb4b224ce58ea3ebd003189203_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia1487e10814a476c9f4946ac6b21c5f8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i49ae796ea1484c519d91607656f24c24_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i370c96450d8f471da8faee4fea65af41_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab515f21eb974f95af61d257257b1b11_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i810445cfd7f9438195dd0d77cfeedd7e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idacbe771db9246aba4c1a2401b11b0c0_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibacfe7c370de4063881a058b1ca33cf7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f0715d972fd4e5cb7aaeea6b7297684_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib5641003d7214a1987d7612d9a529d7f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i789260e8b4914bc7a8d855feb02dc33c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3377b70595804aa5abe93bd7f81df039_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic9fdf918fabe4dea9acdfa65692fe619_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c484ff51d4d492594a9bf004bc92efb_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i342496e82be2474596067223f1d6134a_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i97a20c4e2d9543ea933245a9227cf00f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd9a9b2d424d466ca469cf5987572ab0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id3708c2b1f2b41dfa7d806c5987de5d7_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3cc6af243d904524abfec5259351ae3f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i57b30631121b485ab3ea36fafacd9bba_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i77cd59ff576d44dd94fde4a159bcfd79_I20221123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">optn:NotePurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad0d9b5ed2334bfd8a9fd9842e362c70_I20221123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">optn:NotePurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9c9d8c25cbd84a1dbfec87c26799aca0_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">optn:FiveCustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="customer"><xbrli:measure>optn:customer</xbrli:measure></xbrli:unit><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i453f6ff7522f4a12b35a0b401b71aadf_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">optn:FiveCustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i096da31e1c4b4962a9749727b86a9251_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i51129fc2a039416488ae6cf33f207331_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6dceb2856a724c7cb132bb0edc4d035c_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9941fdaa85054a3a9340530990beb6a2_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i84fb7ecf7b8a41a6af4d113e7add2b46_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib7a618edb3b34dc88ad18ed5ca86c14d_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia91696961e0b4593a33c03f9b00c5dec_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i12305500621f4b93b85c82aa1da3b266_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4915e82cfd2f4c5f8a1d6e09c40ecdef_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id7cd0da0eea14521a316e6ae095e19a2_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia3b834ad368d4672b0476f096fe3f60f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ac7a3a3a80b4d7b8a3d2ffc47f38e20_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i930ccddc00c24cfd9e7d29dd5a34e0aa_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i25abfe2f91764951ba1d5af64bcb7a2a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i32cf8e8f75054575965e3fdf63fcc596_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib72acf71ad414bdb820e66430a66f4f1_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3c2fa1e023784c819a8dc44bb99e322a_I20221123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">optn:MonteCarloSimulationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i656202f27e9648aa9f71018965d5db85_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">optn:MonteCarloSimulationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i12526027af124d2eaf2e45c5cc5128ba_I20221123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">optn:MonteCarloSimulationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">optn:MeasurementInputStrikePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i81d87324f9ac42a2804e01597b73f13e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">optn:MonteCarloSimulationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">optn:MeasurementInputStrikePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7fd98223b0e8487ab4e9f06a6b0e2e17_I20221123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">optn:MonteCarloSimulationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia683400064104d94bb65e13224b47fa4_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">optn:MonteCarloSimulationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i07561160b4b640b58284b5ac37678580_I20221123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">optn:MonteCarloSimulationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib8ec0a4f643d4b8691f7c64824d1ef26_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">optn:MonteCarloSimulationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if38bd004cc9c47cb8ed2b5ced602d8de_I20221123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">optn:MonteCarloSimulationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i77f645c2ad1f45eb87448af2f7350083_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">optn:MonteCarloSimulationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic2035d08305a4a15b86bb7d1dbc471a9_I20221123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">optn:MonteCarloSimulationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i076a98514cf1491bb4e37cb056d5866a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">optn:MonteCarloSimulationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ddeb1efeb7744f8bed2dbb7f03f66da_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">optn:ComputerEquipmentandSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic532296dc81545c39388340e3d3dfb1d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">optn:ComputerEquipmentandSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd6adcb5fdd94a8cafa3e6dcc446470f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6d6764d492fa4ab49a7a65da317dfa94_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i77c83aa040f64e5ab765b0b3cec00b48_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i97b05fd39c994e718b96dc21927444c5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie3474fbb67a5493091eb870124741f97_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i20b9366590cd439eac871165deb4cd22_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaaea96eb926c4215a782ea03cfe873f7_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5d86a8ea69c742f89c18f27139c4e7e8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b8fb31b2cb74f1986dbdb60db29474c_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InventoriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i08cfc0852d87426baff11fe941ec7bfa_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5fd2ee54427b485b93f8b56d2a73b716_D20210101-20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:RoyaltyAgreementTermsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i62f6f90c47544ada9c32250b077bb99b_I20190912"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">optn:NotePurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i047f781d92bd40e5b05937913709530f_I20200213"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">optn:NotePurchaseAgreementFirstDelayedDrawNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2dd470baef924f409cb50332bb1d158a_D20191001-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">optn:NotePurchaseAgreementFirstDelayedDrawNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="optn:MeasurementPeriodAxis">optn:QuarterEndedDecember312019Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c43759aacc744b2ab7dc2cf4563d669_I20201201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">optn:NotePurchaseAgreementThirdDelayedDrawNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib972721f09ce4ecca02118dff9ab3a54_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="optn:MeasurementPeriodAxis">optn:QuarterEndedSeptember302020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">optn:NotePurchaseAgreementThirdDelayedDrawNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic1354dd9142c4406bb996b9f79066753_I20220809"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">optn:NotePurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0ae63187f7984cadbfb811136622697c_I20220810"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">optn:NotePurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib61af200b06045878d1f67070415e25a_I20220810"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">optn:NotePurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaf72692f99ed46b5a83cb937a4981bae_I20221109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">optn:NotePurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i96634d78ca80401db240ea2a9de1645e_I20221120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="optn:TrailingTwelveMonthEndingAxisAxis">optn:March312023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i50b0b50bbf134c7f97db3df38c151093_I20221120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="optn:TrailingTwelveMonthEndingAxisAxis">optn:June302023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d657bd081aa4998b54cb136b25d210a_I20221120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="optn:TrailingTwelveMonthEndingAxisAxis">optn:September302023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie07879a277ed48fc8b5450fd9f7f1ad9_I20221120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="optn:TrailingTwelveMonthEndingAxisAxis">optn:December312023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib294e78ab7cc4fb7b0a4c74b9ced9b5f_I20221120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="optn:TrailingTwelveMonthEndingAxisAxis">optn:March312024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iebab32ba35ab45b7950eabc69c4f19f4_I20221121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="optn:TrailingTwelveMonthEndingAxisAxis">optn:March312024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia42f4722c6ea4c0ba9424cbb5b7db442_I20221120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="optn:TrailingTwelveMonthEndingAxisAxis">optn:June302024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ied0332f696c74d02b9bca94cd69b5f71_I20221121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="optn:TrailingTwelveMonthEndingAxisAxis">optn:June302024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie0d86211c30f4dcc99c47c2ccac871ce_I20221121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="optn:TrailingTwelveMonthEndingAxisAxis">optn:September302024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i33d3c0e47ba74ff5a8b749a97af8db65_I20221121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="optn:TrailingTwelveMonthEndingAxisAxis">optn:December312024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9044805836a742b1ad16a4f9886ba9a4_I20221121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="optn:TrailingTwelveMonthEndingAxisAxis">optn:March312025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3364391e55a8465f8779312aa2de8ee3_I20221121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="optn:TrailingTwelveMonthEndingAxisAxis">optn:June302025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1362d0ef4cda4d66927a9a59de67480a_I20221121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="optn:TrailingTwelveMonthEndingAxisAxis">optn:September302025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icb311cdcf8a9432c86887963e33e45f4_I20221121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="optn:TrailingTwelveMonthEndingAxisAxis">optn:December312025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib965e05b5c0041c399de4fe3b2ae4e52_I20221121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="optn:TrailingTwelveMonthEndingAxisAxis">optn:March312026Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i03d054262028474889eca1899fe6608a_I20221121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="optn:TrailingTwelveMonthEndingAxisAxis">optn:June302026Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i482f0725fc2c4ff7b615761825e52e2e_I20221121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="optn:TrailingTwelveMonthEndingAxisAxis">optn:September302026Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5b4176cedeca41789b0e80197b83e051_I20221121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="optn:TrailingTwelveMonthEndingAxisAxis">optn:December312026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia4c59ac4f7d84023ba6dbab73c1e6899_I20221121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="optn:TrailingTwelveMonthEndingAxisAxis">optn:March312027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f50064d7872407bb6b3b9a2c50c62eb_I20221121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="optn:TrailingTwelveMonthEndingAxisAxis">optn:June302027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6fc5337d1b3e406b8ce2787d51ed4dc1_I20221121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="optn:TrailingTwelveMonthEndingAxisAxis">optn:September302027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i536baadaab72454d98e7f61dc860283b_D20221121-20221121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">optn:NotePurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">optn:SecuredOvernightFinancingRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-21</xbrli:startDate><xbrli:endDate>2022-11-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic6a19df6a9ed4b9a96606c2aeae2cd03_D20221121-20221121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">optn:NotePurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-21</xbrli:startDate><xbrli:endDate>2022-11-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ec8ef0a77c840fe941543a77bb688a7_I20221121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">optn:NotePurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibd48856bcb224069b298e05dfdf34fc8_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">optn:NotePurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4af8cd3923a14bf4bd1655d4e950bb46_D20221121-20221121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">optn:NotePurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-21</xbrli:startDate><xbrli:endDate>2022-11-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4bfb752944e54d3faa2837a8b3afb6b2_D20221121-20221121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">optn:NotePurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-21</xbrli:startDate><xbrli:endDate>2022-11-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i94c26246ced94d6ebc3cf4dc56035b01_D20221121-20221121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">optn:NotePurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-21</xbrli:startDate><xbrli:endDate>2022-11-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f6060dc084947d8b5a97c9542a55c23_I20221121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">optn:NotePurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i48ae5fa4e9e144c09f6e99f5f4994a45_I20221121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">optn:NotePurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ida56878d1ff24c82a2ce1db8be8bfdec_I20221121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">optn:NotePurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i238287e400564d288f6e8227556282ab_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">optn:NotePurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i714fce477c634b15806608bc880b077f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">optn:NotePurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7561e1a29a044dc9ad808ce4adaaca18_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">optn:NotePurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idbd6780d660f4418a87f188eb442ef29_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="optn:DefinedContributionPlanTranchesAxisAxis">optn:DefinedContributionPlanTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i670307f3af404f3b9d62b585c525267b_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="optn:DefinedContributionPlanTranchesAxisAxis">optn:DefinedContributionPlanTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d4fcc93e3a14fe6962ee2598dc6066e_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idad19395ab8f44dd9a2eb5f01f801543_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i35f1c252618f404c810efc41abf15787_D20211118-20211118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">optn:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-18</xbrli:startDate><xbrli:endDate>2021-11-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1fba48bbd9c94f17a4a169948d5b5dfa_I20211118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">optn:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic6fffb430e45481abf555ff9d6505776_D20221123-20221123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">optn:PublicOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-23</xbrli:startDate><xbrli:endDate>2022-11-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e2cc5b3626b4c0eb0a50fe312b92bbe_I20221123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">optn:PublicOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea2a2b3820084672a2ce5363d5379529_I20221123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">optn:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i056c6dc8158e43c386a653bfe93f59db_D20221123-20221123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">optn:PublicOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">optn:UnderwritersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-23</xbrli:startDate><xbrli:endDate>2022-11-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0cf7d2872aa9438888847621f710368c_I20221123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">optn:PublicOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">optn:UnderwritersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id8480f44fd004d44a17fe3165e3accc2_D20221201-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">optn:PublicOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">optn:UnderwritersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i26def91352024f8bb0467900afb32de9_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">optn:PublicOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">optn:UnderwritersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="vote"><xbrli:measure>optn:vote</xbrli:measure></xbrli:unit><xbrli:context id="ie839a1db16084835ad6af8b8758ce33c_I20211118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">optn:WarrantsExpiringNovember182024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iabcd2c4e164b4cb3923eed31231d712e_I20211118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">optn:WarrantsExpiringSeptember122022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iecd24838e7ea4897a980acb7f05e8f07_I20211118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i34d7dc335ebb4c258e92af8033ba7854_I20211118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i81ae26cc8b16489db793cfa1a11fdb41_I20211118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad23ea7b6ce14473a74ab1026b1d8111_I20211118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib2361c2f31ea4a84ae18d655231f351d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7231baf73d71425f945cdbbe619d491b_D20221123-20221123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">optn:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-23</xbrli:startDate><xbrli:endDate>2022-11-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee3e30fe89cc40238e90a7ecb6f01185_I20221121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i79d8665c06414820bf676315cc093d4a_I20221123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-11-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i24bb67187a7b4b71897cb83c06184e0c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">optn:WarrantsExpiringNovember152024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia2ede8c8918a4e5a90c0ff1a8e33f0c0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">optn:WarrantsExpiringNovember232027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic8103889fc054805b787fcb8d7245e95_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">optn:AmendedandRestated2010StockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b3d9a0e4d704073937d74fdc55db85b_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">optn:AmendedandRestated2010StockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia6f6f949224a4e3db7362e44a8479806_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">optn:ServiceBasedStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icdfa0ea8b62148fe8c31ae85f2e9f203_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">optn:MarketBasedStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f825eaecdc54225baf8219928d46fdb_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">optn:ServiceBasedStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i28c4ea3872514bf9a8d5fe2d1d621221_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">optn:ServiceBasedStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i34d0a9c04a2f4859a044c9e6cc370e55_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">optn:NASDAQInducementGrantExceptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">optn:ServiceBasedStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7dc5537455904ed088d5e7907081fa28_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idbf17e5750434c4fa4c7af6d79eb5f3b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i15fbdc49b67e41af98201248589f1f68_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icae44ec705a54e90b329084893ffe064_D20220615-20220615"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-15</xbrli:startDate><xbrli:endDate>2022-06-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d238e610edc4182b197232b0495fdf4_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">optn:RestrictedStockUnitsServiceBasedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i516c5d169f6840f49a095d9630b5c9ae_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">optn:RestrictedStockUnitsServiceBasedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if23267985b9b470489888a9e025653a4_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">optn:RestrictedStockUnitsPerformanceBasedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if62b2d5afbd04093b3379124f22b23c5_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">optn:NASDAQInducementGrantExceptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i846ff334c7ce400c8af0db347b91f620_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">optn:TwoThousandSeventeenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idfcc4aa88cd04b0498643a728bb0b299_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">optn:TwoThousandSeventeenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i412f04e9b5124c22a267cc2e9474aa46_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">optn:TwoThousandSeventeenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaaa623bfd2b7461d815938764c60cf18_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1ec6ce002f784a1f8f8a3b2b9b9b06ae_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaee85c4768314a529b0fa7b1be860d0c_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1cd280125c384cd5a45521262a35af31_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff00e227a0ed47e8ac87706a2be40407_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c74ce02c1434fc183c30fe05522e194_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9975a7e3c2704c8988c1154b5ae900d4_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i411a7889aa7b40c59ba3d11c1d63d29e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i65dbad508d2444f4bb357feedbc9cad4_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i497d60fef0fd413ba91eb9a5009d1d39_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i451bcb3eabba4f87bdc579718207a3b8_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center;text-indent:9pt"><span><br/></span></div><div style="text-align:center;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">UNITED STATES SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, D.C.&#160;&#160;20549</span></div><div style="text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xL2ZyYWc6YWY2ZjJmNjZlYjlhNDRlNTg0ZDg3NWQ5YTE4M2MyYzAvdGV4dHJlZ2lvbjphZjZmMmY2NmViOWE0NGU1ODRkODc1ZDlhMTgzYzJjMF84OA_f6b3c3ff-88ac-4168-b0af-1ddac641ebcf">10-K</ix:nonNumeric></span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:2.565%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.325%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.810%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" name="dei:DocumentAnnualReport" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xL2ZyYWc6YWY2ZjJmNjZlYjlhNDRlNTg0ZDg3NWQ5YTE4M2MyYzAvdGFibGU6YThhMmZiNmEyZDEyNDE0MThiYmQ3YTAwMjVlMDNkZGIvdGFibGVyYW5nZTphOGEyZmI2YTJkMTI0MTQxOGJiZDdhMDAyNWUwM2RkYl8wLTEtMS0xLTU4Mzcy_f6ad109d-261c-4ed3-9b81-31ec66f55abd">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</span></td></tr></table></div><div style="text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the fiscal year ended <ix:nonNumeric contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xL2ZyYWc6YWY2ZjJmNjZlYjlhNDRlNTg0ZDg3NWQ5YTE4M2MyYzAvdGV4dHJlZ2lvbjphZjZmMmY2NmViOWE0NGU1ODRkODc1ZDlhMTgzYzJjMF8xMjA_82790ec2-bdaa-4633-80c3-83bc99d2518a"><ix:nonNumeric contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xL2ZyYWc6YWY2ZjJmNjZlYjlhNDRlNTg0ZDg3NWQ5YTE4M2MyYzAvdGV4dHJlZ2lvbjphZjZmMmY2NmViOWE0NGU1ODRkODc1ZDlhMTgzYzJjMF8xMjA_3a95026a-c8c4-44dd-9b10-aff52fcd32be">December 31</ix:nonNumeric>, 2022</ix:nonNumeric> </span></div><div style="text-align:center;text-indent:9pt"><span><br/></span></div><div style="text-align:center;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:2.565%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.325%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.810%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xL2ZyYWc6YWY2ZjJmNjZlYjlhNDRlNTg0ZDg3NWQ5YTE4M2MyYzAvdGFibGU6OTljOGZjN2RhZmM1NGFkMmI3MmI1MTUxOWY1MjE5NDMvdGFibGVyYW5nZTo5OWM4ZmM3ZGFmYzU0YWQyYjcyYjUxNTE5ZjUyMTk0M18wLTEtMS0xLTU4Mzcy_d02ab63c-2384-4876-992d-a5beddaf330b">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</span></td></tr></table></div><div style="text-align:center;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the transition period from ___________ to ______________.</span></div><div style="text-align:center;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission file number: <ix:nonNumeric contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xL2ZyYWc6YWY2ZjJmNjZlYjlhNDRlNTg0ZDg3NWQ5YTE4M2MyYzAvdGV4dHJlZ2lvbjphZjZmMmY2NmViOWE0NGU1ODRkODc1ZDlhMTgzYzJjMF8zNDQ2_d1698a48-8aee-406d-be88-ce166532eb7f">001-38241</ix:nonNumeric></span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><span><br/></span></div><div style="text-align:center;text-indent:9pt"><img src="optn-20221231_g1.jpg" alt="optn-20221231_g1.jpg" style="height:64px;margin-bottom:5pt;vertical-align:text-bottom;width:254px"/></div><div style="text-align:center;text-indent:9pt"><span><br/></span></div><div style="text-align:center;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xL2ZyYWc6YWY2ZjJmNjZlYjlhNDRlNTg0ZDg3NWQ5YTE4M2MyYzAvdGV4dHJlZ2lvbjphZjZmMmY2NmViOWE0NGU1ODRkODc1ZDlhMTgzYzJjMF8zNDU1_f154de72-1cc1-45b3-833c-7afc2167bb70">OPTINOSE, INC.</ix:nonNumeric> </span></div><div style="text-align:center;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:73.684%"><tr><td style="width:1.0%"></td><td style="width:37.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.146%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.766%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xL2ZyYWc6YWY2ZjJmNjZlYjlhNDRlNTg0ZDg3NWQ5YTE4M2MyYzAvdGFibGU6OTJmNjUzZTI3Y2VjNDliYTlkNWZiYTBlMmJlMmQ5ZWIvdGFibGVyYW5nZTo5MmY2NTNlMjdjZWM0OWJhOWQ1ZmJhMGUyYmUyZDllYl8wLTAtMS0xLTU4Mzcy_ec721f1b-c01c-4879-939c-7150d3901147">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xL2ZyYWc6YWY2ZjJmNjZlYjlhNDRlNTg0ZDg3NWQ5YTE4M2MyYzAvdGFibGU6OTJmNjUzZTI3Y2VjNDliYTlkNWZiYTBlMmJlMmQ5ZWIvdGFibGVyYW5nZTo5MmY2NTNlMjdjZWM0OWJhOWQ1ZmJhMGUyYmUyZDllYl8wLTItMS0xLTU4Mzcy_6853fb8d-7b99-4832-ad7f-5394131c6a6d">42-1771610</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(State of other jurisdiction of incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(I.R.S. Employer Identification Number)</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xL2ZyYWc6YWY2ZjJmNjZlYjlhNDRlNTg0ZDg3NWQ5YTE4M2MyYzAvdGV4dHJlZ2lvbjphZjZmMmY2NmViOWE0NGU1ODRkODc1ZDlhMTgzYzJjMF8zNDQ1_941c9ad9-fed9-444b-ad6a-8aa46cb484fb">1020 Stony Hill Road</ix:nonNumeric>, <ix:nonNumeric contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xL2ZyYWc6YWY2ZjJmNjZlYjlhNDRlNTg0ZDg3NWQ5YTE4M2MyYzAvdGV4dHJlZ2lvbjphZjZmMmY2NmViOWE0NGU1ODRkODc1ZDlhMTgzYzJjMF8zNDQz_0e3865bf-eddb-462f-8012-62b8b3064d1f">Suite 300</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xL2ZyYWc6YWY2ZjJmNjZlYjlhNDRlNTg0ZDg3NWQ5YTE4M2MyYzAvdGV4dHJlZ2lvbjphZjZmMmY2NmViOWE0NGU1ODRkODc1ZDlhMTgzYzJjMF8zNDQ4_415a6ea3-f570-49a4-945d-78955a53b465">Yardley</ix:nonNumeric>, <ix:nonNumeric contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xL2ZyYWc6YWY2ZjJmNjZlYjlhNDRlNTg0ZDg3NWQ5YTE4M2MyYzAvdGV4dHJlZ2lvbjphZjZmMmY2NmViOWE0NGU1ODRkODc1ZDlhMTgzYzJjMF8zNDU2_144fd037-678b-4bc6-9755-0488a54944f0">Pennsylvania</ix:nonNumeric> <ix:nonNumeric contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xL2ZyYWc6YWY2ZjJmNjZlYjlhNDRlNTg0ZDg3NWQ5YTE4M2MyYzAvdGV4dHJlZ2lvbjphZjZmMmY2NmViOWE0NGU1ODRkODc1ZDlhMTgzYzJjMF8zNDQ0_4d549ea1-ed88-4764-987a-c63d2dd81ccc">19067</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Address of principal executive offices, including zip code)</span></div><div style="text-align:center;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xL2ZyYWc6YWY2ZjJmNjZlYjlhNDRlNTg0ZDg3NWQ5YTE4M2MyYzAvdGV4dHJlZ2lvbjphZjZmMmY2NmViOWE0NGU1ODRkODc1ZDlhMTgzYzJjMF8zNDQ5_42149492-ef63-4b09-b7bf-1994f90baffe">267</ix:nonNumeric>) <ix:nonNumeric contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xL2ZyYWc6YWY2ZjJmNjZlYjlhNDRlNTg0ZDg3NWQ5YTE4M2MyYzAvdGV4dHJlZ2lvbjphZjZmMmY2NmViOWE0NGU1ODRkODc1ZDlhMTgzYzJjMF8zNDUx_ae5809c3-8666-4152-84c7-96871b815215">364-3500</ix:nonNumeric> </span></div><div style="text-align:center;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="text-align:center;text-indent:9pt"><span><br/></span></div><div style="margin-top:0.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:0.8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.184%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.383%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.067%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.383%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.283%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Title of Each Class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name of each exchange on which registered </span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xL2ZyYWc6YWY2ZjJmNjZlYjlhNDRlNTg0ZDg3NWQ5YTE4M2MyYzAvdGFibGU6MTVjYjUxYWFmNDUzNDQ4NGI2MzIxMjIzYzVjZWJkZTAvdGFibGVyYW5nZToxNWNiNTFhYWY0NTM0NDg0YjYzMjEyMjNjNWNlYmRlMF8xLTAtMS0xLTU4Mzcy_51eeb01f-3876-4982-bcae-75ceed04e157">Common Stock, $0.001 par value</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xL2ZyYWc6YWY2ZjJmNjZlYjlhNDRlNTg0ZDg3NWQ5YTE4M2MyYzAvdGFibGU6MTVjYjUxYWFmNDUzNDQ4NGI2MzIxMjIzYzVjZWJkZTAvdGFibGVyYW5nZToxNWNiNTFhYWY0NTM0NDg0YjYzMjEyMjNjNWNlYmRlMF8xLTItMS0xLTU4Mzcy_ce68ec33-81d5-49cd-857b-88c3ba389621">OPTN</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xL2ZyYWc6YWY2ZjJmNjZlYjlhNDRlNTg0ZDg3NWQ5YTE4M2MyYzAvdGFibGU6MTVjYjUxYWFmNDUzNDQ4NGI2MzIxMjIzYzVjZWJkZTAvdGFibGVyYW5nZToxNWNiNTFhYWY0NTM0NDg0YjYzMjEyMjNjNWNlYmRlMF8xLTQtMS0xLTU4Mzcy_df97bed6-8817-43a3-99e1-be5ff593a8ee">The Nasdaq Global Select Market</ix:nonNumeric> <br/></span></td></tr></table></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(g) of the Act: None</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.     Yes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" name="dei:EntityWellKnownSeasonedIssuer" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xL2ZyYWc6YWY2ZjJmNjZlYjlhNDRlNTg0ZDg3NWQ5YTE4M2MyYzAvdGV4dHJlZ2lvbjphZjZmMmY2NmViOWE0NGU1ODRkODc1ZDlhMTgzYzJjMF83NjA_4438dbdf-37d7-40c2-b96e-732f55f93532"><ix:nonNumeric contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" name="dei:EntityWellKnownSeasonedIssuer" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xL2ZyYWc6YWY2ZjJmNjZlYjlhNDRlNTg0ZDg3NWQ5YTE4M2MyYzAvdGV4dHJlZ2lvbjphZjZmMmY2NmViOWE0NGU1ODRkODc1ZDlhMTgzYzJjMF83NjA_772280d8-c3c9-4081-afa3-f013aac5c72e">No</ix:nonNumeric></ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160; </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.     Yes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" name="dei:EntityVoluntaryFilers" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xL2ZyYWc6YWY2ZjJmNjZlYjlhNDRlNTg0ZDg3NWQ5YTE4M2MyYzAvdGV4dHJlZ2lvbjphZjZmMmY2NmViOWE0NGU1ODRkODc1ZDlhMTgzYzJjMF85MDE_833a2a17-56c2-4140-b1fd-775fe84c1b11"><ix:nonNumeric contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" name="dei:EntityVoluntaryFilers" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xL2ZyYWc6YWY2ZjJmNjZlYjlhNDRlNTg0ZDg3NWQ5YTE4M2MyYzAvdGV4dHJlZ2lvbjphZjZmMmY2NmViOWE0NGU1ODRkODc1ZDlhMTgzYzJjMF85MDE_c876bcf7-05a3-4dba-8f4e-bab2eda74eda">No</ix:nonNumeric></ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160; </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant: (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.       <ix:nonNumeric contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xL2ZyYWc6YWY2ZjJmNjZlYjlhNDRlNTg0ZDg3NWQ5YTE4M2MyYzAvdGV4dHJlZ2lvbjphZjZmMmY2NmViOWE0NGU1ODRkODc1ZDlhMTgzYzJjMF8xMjU5_9253532e-83a2-4a0f-9478-6621e18f98e5"><ix:nonNumeric contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xL2ZyYWc6YWY2ZjJmNjZlYjlhNDRlNTg0ZDg3NWQ5YTE4M2MyYzAvdGV4dHJlZ2lvbjphZjZmMmY2NmViOWE0NGU1ODRkODc1ZDlhMTgzYzJjMF8xMjU5_b745a982-ef78-4669-92d9-e1a5a558aae8">Yes</ix:nonNumeric></ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160; </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).       <ix:nonNumeric contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xL2ZyYWc6YWY2ZjJmNjZlYjlhNDRlNTg0ZDg3NWQ5YTE4M2MyYzAvdGV4dHJlZ2lvbjphZjZmMmY2NmViOWE0NGU1ODRkODc1ZDlhMTgzYzJjMF8xNTg3_792a160b-ad61-4113-8c00-261e15c58f63">Yes</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160; </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="text-indent:45pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act. </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.139%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.141%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Large&#160;accelerated&#160;filer&#160;&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xL2ZyYWc6YWY2ZjJmNjZlYjlhNDRlNTg0ZDg3NWQ5YTE4M2MyYzAvdGFibGU6ZWUxOTAzNGZjZDllNDQxMDkyNGM4NzFkOTJlZmUwMGMvdGFibGVyYW5nZTplZTE5MDM0ZmNkOWU0NDEwOTI0Yzg3MWQ5MmVmZTAwY18xLTAtMS0xLTU4MzcyL3RleHRyZWdpb246MWMyZWE4ODUxYWM2NDEzMDkwNGY3NDk5ZmFlOTEwMWNfNA_60363aac-e8d1-414a-9f32-7e5cfccf0bbe">Non-accelerated filer</ix:nonNumeric> &#9746;&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;<ix:nonNumeric contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" name="dei:EntitySmallBusiness" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xL2ZyYWc6YWY2ZjJmNjZlYjlhNDRlNTg0ZDg3NWQ5YTE4M2MyYzAvdGFibGU6ZWUxOTAzNGZjZDllNDQxMDkyNGM4NzFkOTJlZmUwMGMvdGFibGVyYW5nZTplZTE5MDM0ZmNkOWU0NDEwOTI0Yzg3MWQ5MmVmZTAwY18xLTItMS0xLTU4MzcyL3RleHRyZWdpb246OGI2MTkxOTY4NjMzNDZiZDkwNTEyNGYwYjRiNDAyMmJfNQ_2b41a414-24f2-4bb0-9b73-8627f8d0145e">&#9746;</ix:nonNumeric></span></div></td></tr></table></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an <ix:nonNumeric contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xL2ZyYWc6YWY2ZjJmNjZlYjlhNDRlNTg0ZDg3NWQ5YTE4M2MyYzAvdGV4dHJlZ2lvbjphZjZmMmY2NmViOWE0NGU1ODRkODc1ZDlhMTgzYzJjMF8yNzQ4Nzc5MDcyOTA2_55e9218e-bd8c-49eb-bdd9-fac16d525881">emerging growth</ix:nonNumeric> company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" name="dei:EntityExTransitionPeriod" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xL2ZyYWc6YWY2ZjJmNjZlYjlhNDRlNTg0ZDg3NWQ5YTE4M2MyYzAvdGV4dHJlZ2lvbjphZjZmMmY2NmViOWE0NGU1ODRkODc1ZDlhMTgzYzJjMF80OTQ3ODAyMzI4NDcw_b3493734-22e7-4af8-b37a-674e1ef296b9">&#9744;</ix:nonNumeric></span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;</span></div><div style="margin-top:5pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.   </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" name="dei:IcfrAuditorAttestationFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xL2ZyYWc6YWY2ZjJmNjZlYjlhNDRlNTg0ZDg3NWQ5YTE4M2MyYzAvdGV4dHJlZ2lvbjphZjZmMmY2NmViOWE0NGU1ODRkODc1ZDlhMTgzYzJjMF8zNDUy_bc88f3ed-2d30-4529-a9a0-d5b80d9a352b">&#9744;</ix:nonNumeric></span></div><div style="text-indent:9pt"><span><br/></span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:nonNumeric contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" name="dei:EntityExTransitionPeriod" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xL2ZyYWc6YWY2ZjJmNjZlYjlhNDRlNTg0ZDg3NWQ5YTE4M2MyYzAvdGV4dHJlZ2lvbjphZjZmMmY2NmViOWE0NGU1ODRkODc1ZDlhMTgzYzJjMF8yMTk5MDIzMjU5Mjc3_b3493734-22e7-4af8-b37a-674e1ef296b9">&#9744;</ix:nonNumeric></span></div><div style="text-indent:9pt"><span><br/></span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive o&#64259;cers during the relevant recovery period pursuant to &#167;240.10D-1(b). </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:nonNumeric contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" name="dei:EntityExTransitionPeriod" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xL2ZyYWc6YWY2ZjJmNjZlYjlhNDRlNTg0ZDg3NWQ5YTE4M2MyYzAvdGV4dHJlZ2lvbjphZjZmMmY2NmViOWE0NGU1ODRkODc1ZDlhMTgzYzJjMF8yMTk5MDIzMjYwMDY2_b3493734-22e7-4af8-b37a-674e1ef296b9">&#9744;</ix:nonNumeric></span></div><div style="text-indent:9pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Act).Yes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;No</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xL2ZyYWc6YWY2ZjJmNjZlYjlhNDRlNTg0ZDg3NWQ5YTE4M2MyYzAvdGV4dHJlZ2lvbjphZjZmMmY2NmViOWE0NGU1ODRkODc1ZDlhMTgzYzJjMF8zNDUw_5e248e19-33e9-45c7-aa82-5292e0810be5">&#9746;</ix:nonNumeric></span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2022 (the last business day of the registrant's most recently completed second fiscal quarter), the aggregate market value of the registrant's common stock held by non-affiliates was approximately $<ix:nonFraction unitRef="usd" contextRef="ied2db99cce6e4199865af70756a669a5_I20220630" decimals="-5" name="dei:EntityPublicFloat" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xL2ZyYWc6YWY2ZjJmNjZlYjlhNDRlNTg0ZDg3NWQ5YTE4M2MyYzAvdGV4dHJlZ2lvbjphZjZmMmY2NmViOWE0NGU1ODRkODc1ZDlhMTgzYzJjMF8yODc5_116cca2d-6795-4d4e-9728-c8853ed59a89">201.7</ix:nonFraction>&#160;million based on the last reported sale price of the registrant's common stock on the Nasdaq Global Select Market on June 30, 2022. </span></div><div style="text-indent:9pt"><span><br/></span></div><div style="text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of shares of common stock outstanding at March 1, 2023 was <ix:nonFraction unitRef="shares" contextRef="i94f2af01a3404575802c3ac9b3d117d4_I20230301" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xL2ZyYWc6YWY2ZjJmNjZlYjlhNDRlNTg0ZDg3NWQ5YTE4M2MyYzAvdGV4dHJlZ2lvbjphZjZmMmY2NmViOWE0NGU1ODRkODc1ZDlhMTgzYzJjMF8zMDc4_153e96d0-971c-45b2-9d6d-62a1861385b5">111,810,073</ix:nonFraction> shares.</span></div><div style="text-indent:45pt"><span><br/></span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DOCUMENTS INCORPORATED BY REFERENCE </span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xL2ZyYWc6YWY2ZjJmNjZlYjlhNDRlNTg0ZDg3NWQ5YTE4M2MyYzAvdGV4dHJlZ2lvbjphZjZmMmY2NmViOWE0NGU1ODRkODc1ZDlhMTgzYzJjMF8zNDU0_266ca9d9-c84c-46d5-82c6-97a41a8b565f" escape="true">Portions of the registrant&#8217;s definitive proxy statement for its 2023 annual meeting of stockholders are incorporated by reference into Part III of this Form 10-K where indicated. Such definitive proxy statement will be filed with the U.S. Securities and Exchange Commission within 120 days after the year ended December 31, 2022.</ix:nonNumeric></span></div><div style="text-align:center;text-indent:45pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i451bcb3eabba4f87bdc579718207a3b8_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:81.916%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.824%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.319%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_13">NOTE REGARDING FORWARD-LOOKING STATEMENTS</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i451bcb3eabba4f87bdc579718207a3b8_13">1</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_16">RISK FACTOR SUMMARY</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i451bcb3eabba4f87bdc579718207a3b8_16">3</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_19">MARKET, INDUSTRY AND OTHER DATA</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i451bcb3eabba4f87bdc579718207a3b8_19">5</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_22">PART I </a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_25">ITEM 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_25">BUSINESS</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i451bcb3eabba4f87bdc579718207a3b8_25">5</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_28">ITEM 1A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_28">RISK FACTORS</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i451bcb3eabba4f87bdc579718207a3b8_28">40</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_31">ITEM 1B.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_31">UNRESOLVED STAFF COMMENTS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i451bcb3eabba4f87bdc579718207a3b8_31">84</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_34">ITEM 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_34">PROPERTIES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i451bcb3eabba4f87bdc579718207a3b8_34">84</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_37">ITEM 3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_37">LEGAL PROCEEDINGS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i451bcb3eabba4f87bdc579718207a3b8_37">84</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_40">ITEM 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_40">MINE SAFETY DISCLOSURE</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i451bcb3eabba4f87bdc579718207a3b8_40">84</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_43">PART II</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_46">ITEM 5.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_46">MARKET FOR REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i451bcb3eabba4f87bdc579718207a3b8_46">84</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_49">ITEM 6.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_49">RESERVED</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i451bcb3eabba4f87bdc579718207a3b8_49">84</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_52">ITEM 7.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_52">MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i451bcb3eabba4f87bdc579718207a3b8_52">84</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_64">ITEM 7A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_64">QUANTITATIVE AND QUALITATIVE DISCLOSURE ABOUT MARKET RISK</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i451bcb3eabba4f87bdc579718207a3b8_64">98</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_67">ITEM 8.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_67">FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i451bcb3eabba4f87bdc579718207a3b8_67">98</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_70">ITEM 9.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_70">CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i451bcb3eabba4f87bdc579718207a3b8_70">98</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_73">ITEM 9A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_73">CONTROLS AND PROCEDURES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i451bcb3eabba4f87bdc579718207a3b8_73">98</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_76">ITEM 9B.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_76">OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i451bcb3eabba4f87bdc579718207a3b8_76">99</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_79">ITEM 9C.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_79">DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTION</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i451bcb3eabba4f87bdc579718207a3b8_79">98</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_82">PART III</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_85">ITEM 10.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_85">DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i451bcb3eabba4f87bdc579718207a3b8_85">99</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_88">ITEM 11.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_88">EXECUTIVE COMPENSATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i451bcb3eabba4f87bdc579718207a3b8_88">100</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_91">ITEM 12.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_91">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i451bcb3eabba4f87bdc579718207a3b8_91">100</a></span></div><div style="text-align:right"><span><br/></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_94">ITEM 13.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_94">CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i451bcb3eabba4f87bdc579718207a3b8_94">100</a></span></div><div style="text-align:right"><span><br/></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_97">ITEM 14.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_97">PRINCIPAL ACCOUNTANT FEES AND SERVICES</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i451bcb3eabba4f87bdc579718207a3b8_97">100</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_100">PART IV</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_103">ITEM 15.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_103">EXHIBITS AND FINANCIAL STATEMENT SCHEDULES</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i451bcb3eabba4f87bdc579718207a3b8_103">100</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_109">SIGNATURE PAGE</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_103">EXHIBIT INDEX</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_________________________</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span><br/></span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless the context otherwise requires, all references in this Form 10-K to "Optinose," "Company," "we," "us," and "our" refer to OptiNose, Inc. and its subsidiaries. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_________________________</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Trademark Notice</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Form 10-K contains references to our trademarks and to trademarks belonging to other entities.  OPTINOSE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, XHANCE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, EDS</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and EXHALATION DELIVERY SYSTEM</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are trademarks of Optinose in the United States.  All other trademarks, trade names and service marks appearing in this Form 10-K are the property of their respective owners. We do not intend our use or display of other companies' trade names or trademarks to imply a relationship with, or endorsement or sponsorship of us by, any other companies. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i451bcb3eabba4f87bdc579718207a3b8_13"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Contents</a></span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Form 10-K contains &#8220;forward-looking statements&#8221; within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, among others, statements relating to:</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">the potential uses for and advantages of XHANCE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, our product candidates and the Exhalation Delivery System (EDS) and related technologies;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">our planned activities in pursuit of a follow-on indication for chronic sinusitis;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">the potential for XHANCE to be the first product approved by the U.S. Food and Drug Administration (FDA) for the treatment of chronic sinusitis;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">our expectation that the FDA will accept for filing the supplemental new drug application (sNDA) that we submitted in February 2023 for XHANCE for the treatment of chronic sinusitis, and our expectation that, assuming FDA acceptance of the sNDA submission and a standard review period, that the FDA target action date will be in December 2023;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">the potential to expand into the primary care segment and our plans to seek a partner for such expansion;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">our belief that the current practice of postoperative intranasal steroid (INS) use could support XHANCE&#8217;s adoption as a maintenance therapy to improve outcomes following sinus surgery; </span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">the potential for XHANCE to be the standard of care for the treatment of chronic rhinosinusitis with and without nasal polyps;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">the potential for direct-to-consumer (DTC) advertising to be a future driver of XHANCE prescription growth;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">the potential benefits of our patient affordability programs and their potential effect on XHANCE demand and financial results;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">our ability to maintain sufficient inventory of XHANCE and for our manufacturers to timely supply XHANCE;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">our expectation for XHANCE prescriptions to be impacted by the seasonality observed in the INS market and the seasonal variation in patient visits with their doctor;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">our expectation for XHANCE prescriptions and average net revenue per prescription to be adversely impacted by the annual resetting of patient healthcare insurance plan deductibles and changes in individual patients' healthcare insurance coverage, both of which often occur in January;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">XHANCE prescription, net revenue, market share and other business trends;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">the potential for increasing rates of enforcement of payor utilization management criteria to negatively impact XHANCE prescription volumes;  </span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">our belief that the restrictions imposed on the logistics and frequency of territory managers' visits during the COVID-19 pandemic have now become permanent in some physician offices;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">our expectation that the research and development costs will significantly decrease in 2023 as compared to 2022;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">our expectation that our operating expenses consisting of selling, general and administrative and research and development in 2023 will be between $90.0 million and $95.0 million and that our non-cash stock-based compensation expense will be approximately $8.0 million;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">our expectation that XHANCE net product revenues for the full year of 2023 will be between $62.0 million and $68.0 million and our expectation that XHANCE net product revenues for the first quarter 2023 will be approximately $10.0 million; </span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">our expectation that the average net product revenue per prescription for XHANCE for the full year of 2023 will be approximately $200;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Contents</a></span></div></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">our potential non-compliance with certain covenants of the A&amp;R Note Purchase Agreement, and the consequences of failing to achieve compliance with such covenants or obtain a waiver or modification of such covenants;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.78pt">our belief that our existing cash and cash equivalents will be sufficient to fund our operations and debt service obligations for approximately the next 12 months if we are able to maintain compliance with the financial and other covenants and terms of the A&amp;R Note Purchase Agreement or obtain a waiver to or modification of such covenants;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">our expectations and the accuracy of our estimates regarding our future expenses, revenue, capital requirements, potential sources of capital and consequences of failing to obtain additional capital;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.11pt">our ability to continue as a going concern;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">the rate and degree of market acceptance and market opportunity of XHANCE;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">our ability to maintain regulatory approval of XHANCE;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">our ability to attract collaborators with development, regulatory and commercialization expertise;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">regulatory developments in the United States and foreign countries;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">our ability to operate our business without infringing the intellectual property rights of others;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">the scope and duration of patent protection and other barriers to entry that we expect to benefit XHANCE;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">the performance of our third-party suppliers, manufacturers, wholesalers, distributors and preferred pharmacy network (PPN) partners;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">the potential for us to decrease our reliance on sole-source suppliers and increase the third party manufacturing capacity that is available to us;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">the success of competing products that are or become available;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">our belief that our facilities meet our needs and that we could obtain alternative space on commercially reasonable terms;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">our expectations regarding our ability to obtain and adequately maintain sufficient intellectual property protection for XHANCE;</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as well as other statements relating to our future operations, financial performance and financial condition, prospects, strategies, objectives or other future events. Forward-looking statements appear primarily in the sections of this Form 10-K entitled "Item 1 - Business," "Item 1A - Risk Factors," and "Item 7 - Management's Discussion and Analysis of Financial Condition and Results of Operations".  In some cases, you can identify forward-looking statements by words such as "may,&#8221; "will,&#8221; "could," "would," "should," "expect," "intend," "plan," "anticipate," "target," "believe," "estimate," "predict," "project," "potential," "continue," "ongoing," "scheduled" and similar expressions, although not all forward-looking statements contain these identifying words.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forward-looking statements are based upon our current expectations and assumptions and are subject to a number of known and unknown risks, uncertainties and other factors that could cause actual results to differ materially and adversely from those expressed or implied by such statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed under section "Item 1A - Risk Factors" of this Form 10-K. As a result, you should not place undue reliance on forward-looking statements.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the forward-looking statements contained in this Form 10-K represent our views only as of the date of this Form 10-K (or any earlier date indicated in such statement). While we may update certain forward-looking statements from time to time, we specifically disclaim any obligation to do so, even if new information becomes available in the future. However, you are advised to consult any further disclosures we make on related subjects in the reports that we file with the SEC.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The foregoing cautionary statements are intended to qualify all forward-looking statements wherever they may appear in this Form 10-K. For all forward-looking statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i451bcb3eabba4f87bdc579718207a3b8_16"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Contents</a></span></div></div><div style="margin-top:8pt;text-align:center"><span><br/></span></div><div style="margin-top:8pt;text-align:center"><span><br/></span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RISK FACTOR SUMMARY</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The risk factors summarized below could materially harm our business, operating results and/or financial condition, impair our future prospects and/or cause the price of our common stock to decline. For more information, see &#8220;Item 1A. Risk Factors&#8221; in this Annual Report on Form 10-K for the year ended December 31, 2022. Material risks that may affect our business, operating results and financial condition include, but are not necessarily limited to, the following: </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Financial Position and Capital Resources</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have identified conditions and events that raise substantial doubt about our ability to continue as a going concern.</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have incurred significant losses since our inception and anticipate that we will incur continued losses in the future.  We may never achieve or maintain profitability, and will likely require additional capital to fund our operations.</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our failure to comply with the covenants or other terms of the A&amp;R Note Purchase Agreement, including as a result of events beyond our control, could result in a default under the A&amp;R Note Purchase Agreement that could materially and adversely affect the ongoing viability of our business.</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The A&amp;R Note Purchase Agreement contains restrictions that limit our flexibility in operating our business.</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Provisions of the Pharmakon Senior Secured Notes and the 2022 Warrants could impede a sale of the Company.</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The 2022 Warrants contain anti-dilution provisions that may result in the reduction of their exercise prices in the future.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The coronavirus (COVID-19) pandemic has and may continue to adversely affect our business, results of operations and financial condition.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Commercialization of XHANCE</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we are unable to successfully commercialize XHANCE, our business, financial condition and results of operations may be materially adversely affected and the price of our common stock may decline.</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The commercial success of XHANCE will depend upon its acceptance by multiple stakeholders, including physicians, patients and healthcare payors.</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If third-party payors do not reimburse patients for XHANCE or if reimbursement levels are set too low for us to sell XHANCE at a profit, our ability to successfully commercialize XHANCE and our results of operations will be harmed.</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we are unable to differentiate XHANCE from current and future products or existing methods of treatments, our ability to successfully commercialize XHANCE would be adversely affected. </span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If the market opportunities for XHANCE are smaller than we believe, our revenue may be adversely affected.</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We rely on PPN partners for distribution of XHANCE in the U.S., and the failure of those PPN partners to distribute XHANCE effectively would adversely affect sales of XHANCE.</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we cannot implement and maintain effective patient affordability programs or improve formulary access for XHANCE in the face of increasing pressure to reduce the price of medications, the adoption of XHANCE by physicians and patients may decline.</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If the U.S. Food and Drug Administration (FDA) or other applicable regulatory authorities approve generic or similar products that compete with XHANCE, or if the FDA or other applicable regulatory authorities change or create new pathways that may expedite approval of such products, it could decrease our expected sales of XHANCE.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Contents</a></span></div></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Even though we have obtained regulatory approval for XHANCE, we still face extensive FDA regulatory requirements and may face future regulatory difficulties.</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our relationships with physicians, patients, payors and pharmacies in the U.S. are subject to applicable anti-kickback, fraud and abuse laws and regulations. Our failure to comply with these laws could expose us to criminal, civil and administrative sanctions, reputational harm, and could harm our results of operations and financial conditions.</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Regulatory approval for any approved product is limited by the FDA to those specific indications and conditions for which clinical safety and efficacy have been demonstrated.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Clinical Development and Regulatory Approval of XHANCE for the Treatment of Chronic Sinusitis and Our Other Product Candidates</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The design and execution of clinical trials to support FDA-approval of XHANCE for the treatment of chronic sinusitis is subject to substantial risk and uncertainty.</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The clinical development and regulatory approval processes of the FDA are lengthy, time consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for our product candidates or maintain regulatory approval for our approved products, our business may be substantially harmed.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Reliance on Third Parties</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we encounter difficulties in maintaining commercial manufacturing and supply agreements with our third-party manufacturers and suppliers of XHANCE or if we encounter issues with our contract manufacturers or suppliers, our ability to commercialize and manufacture XHANCE would be impaired.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Business Operations and Industry</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our long-term growth depends on our ability to develop and commercialize additional ENT and allergy products.  </span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our sales force and other employees, PPN partners, CMOs, CROs, principal investigators, collaborators, independent contractors, consultants and other vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Intellectual Property</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we are unable to protect our intellectual property rights or if our intellectual property rights are inadequate to protect our technology, XHANCE or our other product candidates, our competitors could develop and commercialize technology similar to ours, and our competitive position could be harmed.</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may become involved in lawsuits to protect or enforce our patents or the patents of our licensors, which could be expensive, time consuming and unsuccessful.</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Third parties may initiate legal proceedings alleging that we are infringing their intellectual property rights, the outcome of which could be uncertain and could harm our business.</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our competitors may be able to circumvent our patents by developing similar or alternative technologies or products in a non-infringing manner.</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Changes in either U.S. or foreign patent law or interpretation of such laws could diminish the value of patents in general, thereby impairing our ability to protect our products.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Ownership of Our Common Stock</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The price of our common stock may be volatile and you may lose all or part of your investment.</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Future issuances of our common stock or rights to purchase common stock, including pursuant to our equity incentive plans, could result in additional dilution of the percentage ownership of our stockholders and could cause our stock price to fall.</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Some provisions of our charter documents and Delaware law may have anti-takeover effects that could discourage an acquisition of us by others.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Contents</a></span></div></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div id="i451bcb3eabba4f87bdc579718207a3b8_19"></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MARKET, INDUSTRY AND OTHER DATA</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Annual Report on Form 10-K contains estimates, projections, market research and other information concerning our industry, our business, markets for XHANCE and the size of those markets, the prevalence of certain medical conditions, XHANCE market access, prescription data and other physician, patient and payor data. Unless otherwise expressly stated, we obtain this information from reports, research surveys, studies and similar data prepared by market research firms and other third parties, industry, medical and general publications, government data and similar sources as well as from our own internal estimates and research and from publications, research, surveys and studies conducted by third parties on our behalf. Information that is based on estimates, projections, market research or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances that are reflected in this information. As a result, you are cautioned not to give undue weight to such information.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span><br/></span></div><div id="i451bcb3eabba4f87bdc579718207a3b8_22"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I</span></div><div><span><br/></span></div><div id="i451bcb3eabba4f87bdc579718207a3b8_25"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1. BUSINESS</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our Company</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">W</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e are a specialty pharmaceutical company focused on the development and commercialization of products for patients treated by ear, nose and throat (ENT) and allergy specialists. Our first commercial product, XHANCE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (fluticasone propionate) nasal spray, 93 microgram (mcg), is a therapeutic utilizing our proprietary Exhalation Delivery System&#8482; (EDS</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps and, if approved, chronic rhinosinusitis without nasal polyps (also known as chronic sinusitis). Chronic rhinosinusitis is a serious nasal inflammatory disease that is treated using therapies, such as intranasal steroids (INS), which have significant limitations. We believe XHANCE has a differentiated clinical profile with the potential to become part of the standard of care for this disease because it is able to deliver medication to the primary site of inflammation high and deep in the nasal passages in regions not adequately reached by conventional INS.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2017, the U.S. Food and Drug Administration (FDA) approved XHANCE for the treatment of nasal polyps in patients 18&#160;years of age or older.&#160;XHANCE was made widely available through commercial channels in April 2018.</span></div><div style="margin-bottom:8pt"><span><br/></span></div><div style="margin-bottom:8pt"><img src="optn-20221231_g2.jpg" alt="optn-20221231_g2.jpg" style="height:200px;margin-bottom:5pt;vertical-align:text-bottom;width:310px"/><img src="optn-20221231_g3.jpg" alt="optn-20221231_g3.jpg" style="height:200px;margin-bottom:5pt;vertical-align:text-bottom;width:310px"/></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We completed two Phase 3b clinical trials of XHANCE for a follow-on indication for the treatment of chronic sinusitis. Positive top-line results from the trials (which we refer to as ReOpen1 and ReOpen2) were announced in March and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Contents</a></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June 2022, respectively. In September 2022, we met with FDA to discuss our planned supplemental new drug application (sNDA) for XHANCE as a treatment for adults with chronic sinusitis and submitted the application in February 2023. Assuming the FDA's acceptance of the sNDA submission and a standard review period, we expect the FDA's target action date to be in December 2023. If the sNDA is approved, XHANCE has the potential to be the first drug therapy approved by the FDA for the treatment of chronic sinusitis.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The Unmet Need</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chronic rhinosinusitis is a serious nasal inflammatory disease characterized by chronic inflammation affecting tissues high and deep in the nasal passages, including the area where the openings from the sinuses normally ventilate and drain. This disease significantly impacts the quality of life and daily functioning of an estimated 30&#160;million adults in the U.S. The U.S. healthcare system spends approximately $60&#160;billion annually in direct costs treating patients with chronic rhinosinusitis and its associated symptoms, including an estimated $5&#160;billion on sinus surgeries. In the U.S., physicians perform over 500,000 sinus surgeries each year, and we estimate that as of 2017, over seven&#160;million adults had undergone sinus surgery to treat chronic rhinosinusitis with and without nasal polyps.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In medical literature and medical practice, chronic rhinosinusitis is commonly divided into two subgroups: chronic rhinosinusitis with nasal polyps and chronic rhinosinusitis without nasal polyps. Chronic rhinosinusitis patients with and without nasal polyps suffer from chronic inflammation of the lining of the deep nasal passages and sinuses. Patients with chronic rhinosinusitis with nasal polyps also develop non-cancerous polyps on these chronically inflamed surfaces, typically originating in the deep crevices or sinus cavities on both sides of the nose. We estimate that up to 10&#160;million adults in the U.S. have chronic rhinosinusitis with nasal polyps.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Both subgroups of chronic rhinosinusitis share the same four defining diagnostic symptoms: nasal congestion/obstruction; facial pain and pressure; purulent runny nose and postnasal drip; and loss of sense of smell and taste. Additional symptoms may include headaches, chronic sleep problems, fatigue, frequent episodes of acute rhinosinusitis and mood disorders. There is evidence suggesting that the harm to a sufferer's quality of life from chronic rhinosinusitis, as measured in multiple domains, such as bodily pain, social functioning and mental health, is comparable to or worse than other serious diseases, including chronic obstructive pulmonary disease, congestive heart failure and angina. As a result, many patients eventually seek surgery for symptom relief.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although the term chronic rhinosinusitis is often used in medical literature and medical practice, the FDA did not historically recognize chronic rhinosinusitis as an indication for drug development purposes. Instead, the FDA recognized chronic sinusitis and nasal polyps as indications for drug development purposes rather than the terminology chronic rhinosinusitis with or without nasal polyps. Recently, the FDA has approved drug products for the treatment of chronic rhinosinusitis with nasal polyps and issued a guidance document in November 2021 for clinical trial programs for nasal polyps in which it adopted the different terminology &#8220;treatment of chronic rhinosinusitis with nasal polyps&#8221; to replace the terminology &#8220;treatment of nasal polyps.&#8221; Subsequent to issuance of that guidance, FDA requested that previously approved labels for multiple drugs, including XHANCE, with an indication for &#8220;treatment of nasal polyps&#8221; be changed to reflect the new terminology, and accordingly the XHANCE indication was changed from &#8220;nasal polyps&#8221; to &#8220;chronic rhinosinusitis with nasal polyps.&#8221; This modification is the result of a change in terminology and was not based on new XHANCE clinical trial data. As a result of the FDA's evolving view on the terminology to be applied to what was historically labeled &#8220;chronic sinusitis&#8221; and &#8220;nasal polyps&#8221;, it is uncertain whether the phase 3 clinical trial program that we conducted for XHANCE will, if approved, result in an additional indication using the language &#8220;for the treatment of chronic sinusitis&#8221;, &#8220;for the treatment of chronic rhinosinusitis&#8221;, &#8220;for the treatment of chronic rhinosinusitis without nasal polyps&#8221;, or other similar language. It is our view that these variations in terminology are synonymous from a promotional perspective and that all are distinct from XHANCE's current indication. In this Annual Report on Form 10-K, we use the terms "chronic sinusitis" and "chronic rhinosinusitis without nasal polyps" as being synonymous.  </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Limitations of Therapies</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Multiple clinical practice guidelines specify the use of INS early in the treatment algorithm for chronic rhinosinusitis with and without nasal polyps. Steroids are generally pharmacologically effective at treating inflammation. However, conventional INS, including nasal sprays and nasal aerosols, are topically-acting and unable to effectively and consistently place the steroids onto the primary site of inflammation and nasal polyp origin, high and deep in the nasal passages. These products deposit a majority of the drug in the front of the nose or on the floor of the nasal passages, reducing their effectiveness and leaving many patients without sufficient symptomatic relief. These recognized limitations cause some physicians to seek out alternative treatment regimens such as high-volume steroid nasal rinses. This approach, however, has not been well studied, is difficult to administer, can be costly and may risk systemic side effects. Physicians may also prescribe oral steroids on an episodic basis to patients who have not received sufficient symptomatic relief from INS. Oral steroids, which are often effective in reducing inflammation and nasal polyps, offer only temporary benefit and are limited by the risk of significant systemic side effects associated with both short- and long-term use.</span><span style="background-color:#fff7c3;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, in June 2019, December 2020, and July 2021, the FDA approved the first three monoclonal antibodies as add-on maintenance treatments (to an INS) in adult patients with inadequately controlled chronic rhinosinusitis with nasal polyposis, and other monoclonal antibodies are in development. The cost of currently approved monoclonal antibodies range from approximately $33,000 to $47,000 per year. We believe the high costs of these monoclonal antibodies, the need for subcutaneous injection or intravenous administration and the systemic nature of these treatments, which target components of the immune response, may limit the use by certain physicians and patients.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In cases where patients remain symptomatic despite medical management, physicians often recommend various forms of sinus surgery to help restore normal sinus ventilation or drainage. The effectiveness of sinus surgery can vary significantly, many patients experience persistent or recurrent symptoms, and surgery may not address the underlying cause of inflammation. In patients with nasal polyps, regrowth of the nasal polyps has been reported in as high as 60% of cases within four years. In addition, it has been reported that up to 80% of patients continue to have symptoms within two years of surgery. Because sinus surgery is often not curative and may not address the underlying cause of the inflammation, many patients continue to receive short- and long-term courses of INS after surgery.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our Solution</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">XHANCE combines the EDS with a liquid formulation of fluticasone propionate, a well-characterized, second-generation corticosteroid. XHANCE is designed to deliver medication into the high and deep regions of the nasal passages where both nasal polyps and inflamed and swollen membranes can obstruct normal sinus ventilation and drainage. In multiple studies utilizing advanced imaging, the EDS produced a differentiated pattern of drug delivery in healthy subjects with significant drug deposited in the high and deep regions of the nasal passages, areas not well accessed by conventional INS delivery mechanisms. We believe XHANCE has the potential to become part of the standard of care for the treatment of patients with chronic rhinosinusitis before they progress to more costly treatment alternatives. We also believe that the current treatment practice of postoperative INS use could support XHANCE's adoption as a maintenance therapy to improve outcomes following sinus surgery.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">To support FDA approval of XHANCE as a treatment for nasal polyps, we conducted five clinical trials evaluating over 1,500 adult patients, including two randomized, double-blinded, placebo-controlled Phase&#160;3 pivotal clinical trials in adults with nasal polyps and two supportive open-label Phase&#160;3 clinical trials in adults with symptoms of chronic sinusitis with or without nasal polyps. In both Phase&#160;3 pivotal clinical trials, patients treated with XHANCE experienced statistically significant reductions of both nasal congestion/obstruction symptoms and total polyp grade, which were the co-primary endpoints. Treatment benefits were also observed in all four defining symptoms of chronic rhinosinusitis, as well as in polyp elimination (reduction of polyp to grade 0), quality of life measures, need for sinus surgery based on study-defined criteria and patient global impression of change. In addition, the magnitude of improvement for patients treated by XHANCE in our Phase 3 pivotal clinical trials, as measured by the Sinonasal Outcome Test-22, a validated clinical outcome assessment, was comparable to the reported benefits in third-party studies of endoscopic sinus surgery (ESS) and balloon sinus dilation. In our supportive open-label Phase&#160;3 clinical trials, which evaluated approximately 900 patients with symptoms of chronic sinusitis with and without nasal polyps for a period of up to one year, XHANCE was generally well tolerated and produced results on efficacy measures similar to those observed in our Phase&#160;3 pivotal clinical trials. In these supportive trials, we observed comparable symptom improvements in patients with and without nasal polyps and continuing incremental polyp reduction and symptom improvement through 12&#160;months. XHANCE had an adverse event profile generally comparable to the profile reported in similarly designed trials with conventional INS. The most common adverse reactions (incidence &#8805; 3%) are epistaxis, nasal septal ulceration, nasopharyngitis, nasal mucosal erythema, nasal mucosal ulcerations, nasal congestion, acute sinusitis, nasal septal erythema, headache, and pharyngitis.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe XHANCE offers a cost-effective treatment solution to payors who are increasingly being asked to pay for multiple high-cost therapies for a variety of diseases priced at tens of thousands of dollars per year. As of January 1, 2023, the wholesale acquisition cost for XHANCE was $596.97. XHANCE is priced significantly higher than low cost generic INS and over-the-counter (OTC) INS products.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We expect XHANCE to be adopted by physicians at a natural point in the care pathway for use in patients with chronic rhinosinusitis with or without nasal polyps after treatment failure with cheaper generic or OTC traditional INS therapies but before they progress to costly surgical interventions and monoclonal antibodies. We estimate that sinus surgery costs on average $13,500 per procedure, and monoclonal antibodies cost approximately $33,000 to $47,000 per year based on the wholesale acquisition cost and recommended dosing for XOLAIR&#8482; (omalizumab), NUCALA&#8482; (mepolizumab), and DUPIXENT&#8482; (dupilumab). </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">U.S. Market Opportunity</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe there is a market opportunity for XHANCE consisting of ENT physicians, allergists and primary care physicians in the U.S. that most frequently prescribe INS. This group of approximately 5,000 primary care physicians, which we refer to as "specialty-like" primary care physicians, account for approximately 25% of all INS prescriptions written by primary care physicians. We refer to these ENT physicians, allergists and high-decile INS-prescribing primary care physicians collectively as the "specialty segment" of our target market. We believe the approximately 15,000 physicians in this specialty segment together treat an estimated 3.5 million U.S. patients with chronic rhinosinusitis, an estimated 1.2 million of whom have chronic rhinosinusitis with nasal polyps. We believe the total annual U.S. market opportunity for XHANCE in this specialty segment is over $3.4 billion, of which approximately one-third consists of patients with chronic rhinosinusitis with nasal polyps. If we obtain approval for the follow-on indication of chronic sinusitis, we intend to broaden, through potential collaborations, our commercialization efforts to target additional primary care physicians that we believe treat an additional estimated 6.25 million U.S. patients with chronic rhinosinusitis, an estimated one-third of whom have chronic rhinosinusitis with nasal polyps. We refer to these additional primary care physicians as the "primary care segment" of our target market. We believe the total additional annual U.S. market opportunity for XHANCE in this primary care segment is over $6.0 billion, of which approximately one-third consists of patients with chronic rhinosinusitis with nasal polyps. Therefore, we estimate the total annual U.S. market opportunity for the combined specialty and primary care segments is over $9.5 billion, of which approximately one-third consists of patients with chronic rhinosinusitis with nasal polyps.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intellectual Property and Barriers to Entry</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">XHANCE benefits from substantial intellectual property and other technical barriers to entry, including drug delivery complexities. Our XHANCE U.S. patent portfolio consists of 13 issued device and method of use patents expiring on various dates from 2023 through 2036 and three issued design patents expiring through 2030, as well as pending patent applications. The 13 issued device and method of use patents are published in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the Orange Book.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe the unique features of the EDS, as well as its delivery of a topically-acting drug, will present generic and 505(b)(2) new drug application (NDA) competitors of XHANCE with technical and human factors engineering challenges specific to drug-device combination products and chemistry, manufacturing and controls challenges unique to suspension and respiratory products. We also believe that any future substitutable generic competitors may be required to conduct, among other things, non-inferiority clinical trials demonstrating equivalent efficacy and safety outcomes to establish clinical bioequivalence to XHANCE. We believe these clinical trials, if required, would necessitate a significant amount of time and capital investment and present clinical development uncertainties.  However, XHANCE is referenced on the list of product specific guidances for complex generic drug products that the FDA plans to issue, which may provide clarity for generic competitors to develop generic products that compete with XHANCE.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Growth Strategy</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our goal is to become a leading specialty pharmaceutical company dedicated to developing proprietary products that become a part of the standard of care for diseases in the ENT and allergy segments. The key elements of our strategy are to:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:103%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:103%;padding-left:14.5pt">Continue to commercialize XHANCE in the ENT and allergy specialty segments in the U.S.  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:103%">We believe that approximately 15,000 targeted physicians treat an estimated 3.5&#160;million chronic rhinosinusitis patients, an estimated 1.2&#160;million of whom have chronic rhinosinusitis with nasal polyps. We have a sales </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Contents</a></span></div></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:103%">force of approximately 77 territory managers who target approximately 7,000 ENT and allergy specialists and "specialty-like" primary care physicians. </span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:103%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:103%;padding-left:14.11pt">Seek regulatory approval of XHANCE for the treatment of chronic sinusitis and expansion into the primary care segment to broaden our market opportunity</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:103%">.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:103%">  We completed two Phase 3b clinical trials in pursuit of a follow-on indication for XHANCE for the treatment of chronic sinusitis. We announced positive top-line results from these trials in March and June 2022 and believe XHANCE has the potential to be the first drug therapy approved by the FDA for the treatment of chronic sinusitis. In addition to increasing the number of patients for whom the product can be promoted within the currently targeted physician segment, we believe approval of the new indication by FDA could be a catalyst for us to enter into one or more collaborations to broaden the marketing of XHANCE to additional primary care physicians that we believe treat an additional estimated 6.25 million patients in the U.S. with chronic rhinosinusitis, an estimated two-thirds of whom have chronic sinusitis but do not have nasal polyps. In addition, at some point in the future, we, together with any potential partner secured for the primary care segment, intend to consider directing promotional resources to an additional estimated 20 million adult chronic rhinosinusitis sufferers who are not regularly under the care of physicians for this disease using programs such as direct-to-consumer and direct-to-patient promotion.</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.46pt">Seek additional development candidates or approved therapies focused on the ENT and allergy specialty segments.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;We continue to evaluate strategic licensing, acquisition, development and commercial partnerships. These targeted opportunities could increase our growth and leverage our existing infrastructure and capabilities. </span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.46pt">Explore business development activities for the EDS outside of the ENT and allergy segments.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;We evaluate potential opportunities for additional uses of the EDS to support development and commercialization outside of ENT and allergy. We currently have two agreements in place that include an out-license of the EDS and related technology. In January 2019, OptiNose AS, our wholly-owned subsidiary, completed a licensing agreement with Inexia Limited (now Orexia Therapeutics, a subsidiary of Centessa Pharmaceuticals, a novel asset-centric pharmaceutical company) (the Centessa License Agreement). Pursuant to the terms of the Centessa License Agreement, we granted Orexia an exclusive license to the EDS and related intellectual property for the research, development and commercialization of products containing orexin receptor agonist and/or orexin receptor positive modulator molecules. In September 2019, OptiNose AS, entered into a licensing agreement (Currax License Agreement) with Currax Pharmaceuticals LLC (Currax) whereby we granted Currax an exclusive license to certain OptiNose patents and a non-exclusive license to certain OptiNose know-how related to Onzetra</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Xsail</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (sumatriptan nasal powder) in the U.S., Canada and Mexico. </span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.46pt">Expand XHANCE into international markets.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;We intend to remain opportunistic in pursuit of select international opportunities in order to maximize the commercial potential and the availability of XHANCE to patients.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Chronic Rhinosinusitis and Market Opportunity</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Chronic Rhinosinusitis</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chronic rhinosinusitis (CRS) is a serious nasal inflammatory disease significantly impacting patients' quality of life and daily functioning. CRS, unlike allergic rhinitis, is characterized by chronic inflammation affecting tissues high and deep in the nasal passages, including the area where the openings from the sinuses normally ventilate and drain, causing symptoms that persist for a period of 8 to 12&#160;weeks or longer. CRS patients typically suffer from these symptoms four to six months a year, with symptoms often persisting for many years.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In medical literature and medical practice, CRS is commonly divided into two subgroups: CRS with nasal polyps (CRSwNP) and CRS without nasal polyps (CRSsNP). CRS patients with and without nasal polyps suffer from chronic inflammation of the lining of the deep nasal passages and sinuses. Patients with CRSwNP also develop non-cancerous polyps on these chronically inflamed surfaces, typically originating in the deep crevices or sinus cavities on both sides of the nose. We estimate that up to 10&#160;million adults in the U.S. have CRSwNP. Both subgroups of CRS share the same four defining diagnostic symptoms: (1) nasal congestion/obstruction; (2) facial pain and pressure; (3) purulent runny nose, and postnasal drip; and (4) loss of sense of smell and taste. Additional symptoms may include headaches, chronic sleep problems, fatigue, frequent episodes of acute rhinosinusitis and mood disorders. There is evidence suggesting that the harm to a sufferer's quality of life from CRS, as measured in multiple domains, such as bodily pain, social functioning and mental health, is comparable to or worse than other </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">serious diseases, including chronic obstructive pulmonary disease, congestive heart failure and angina. As a result, many patients eventually seek surgery for symptom relief.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The American Academy of Otolaryngology-Head and Neck Surgery estimates that approximately 30&#160;million adults in the U.S. have CRS, and it is estimated that up to 10&#160;million adults have CRSwNP. CRS imposes a significant healthcare burden on insurers and employers. It has been reported that the U.S. healthcare system spends approximately $60&#160;billion annually in direct costs treating patients with CRS and its associated symptoms, including an estimated $5&#160;billion on sinus surgeries. In the U.S., physicians perform over 500,000 sinus surgeries each year, and we estimate that as of 2017, over seven&#160;million adults had undergone sinus surgery to treat CRS with and without nasal polyps. CRS has been reported to account for an aggregate of 73&#160;million restricted activity days per year. Additionally, people with CRS have been reported to be absent from work because of this disease 6.5% of the time and to suffer a 38% loss of productivity.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">U.S. Market Opportunity</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate that approximately 9.75&#160;million CRS patients are currently being treated in physician offices in the U.S. We derived this estimate from a large patient claims database that reflects actual treatment patterns of CRS over a two-year period from 2010 to 2012. We also estimate that approximately 10,000 ENT and allergy specialists, as well as approximately 5,000 "specialty-like" primary care physicians, treat approximately 36% of all CRS patients in the U.S., or approximately 3.5&#160;million patients, an estimated 1.2&#160;million of whom have CRSwNP. In accordance with multiple published clinical practice guidelines, physicians typically medically manage CRS patients by prescribing INS despite the fact that there are no FDA-approved products for the treatment of CRSsNP. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we obtain FDA approval for the follow-on indication for the treatment of chronic sinusitis (CS), we intend to broaden, through potential collaborations, our marketing outreach to additional primary care physicians that treat an additional estimated 6.25&#160;million U.S. patients with CRS, an estimated one-third of whom have CRSwNP.  We expect to execute this expansion primarily through one or more collaborations with third parties that already have a sales force calling on primary care physicians.  We may also direct promotional resources to an additional estimated 20&#160;million CRS sufferers who are not regularly under the care of physicians for this disease using programs such as direct-to-consumer and direct-to-patient promotion. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on internal estimates, we believe the total annual U.S. market opportunity for XHANCE in the specialty segment is over $3.4&#160;billion, of which approximately one-third consists of patients with CRSwNP. Based on these same estimates, we believe the total additional annual U.S. market opportunity for XHANCE in the primary care segment is over $6.0&#160;billion, of which approximately one-third consists of patients with CRSwNP. Therefore, we estimate the total annual U.S. market opportunity for the combined specialty and primary care segments is over $9.5&#160;billion, of which approximately one-third consists of patients with CRSwNP.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Treatment Landscape</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The treatment of CRS with and without nasal polyps typically begins with medical management. In cases where patients remain symptomatic despite medical management, physicians often recommend various forms of sinus surgery to help restore normal sinus ventilation and drainage. The following is a brief description of the current treatment landscape and product candidates in development for CRS with and without nasal polyps:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:20.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Current Therapies</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%;padding-left:14.46pt">Intranasal Steroids.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#160;Multiple published clinical practice guidelines generally recommend topically-acting INS as the first line of prescription therapy for the treatment of CRS with and without polyps. As a result, physicians typically prescribe INS nasal sprays or nasal aerosols despite the fact that there are no FDA-approved products for the treatment of CRSsNP. Therefore, the majority of chronic rhinosinusitis sufferers being treated have tried INS. We estimate that physicians in the U.S. prescribe approximately 17&#160;million INS prescriptions each year for the treatment of chronic rhinosinusitis, which includes, among other INS products, a generic fluticasone propionate nasal spray. The only other branded INS to receive an indication for the treatment of nasal polyps is Nasonex&#8482;, which was marketed by Merck &amp; Co., Inc. before being removed from the prescription market but is available over-the-counter without a prescription for other indications. Generic versions of Nasonex&#8482;, mometasone furoate monohydrate, remain available as prescription drugs. Physicians not only prescribe INS as a standalone therapy, but also typically prescribe INS following sinus surgery as some third-party clinical trials suggest that INS treatment can improve symptoms and delay symptom recurrence. In lieu of prescription INS nasal sprays, physicians may recommend use of over-the-counter INS nasal sprays including over-the-counter products containing fluticasone propionate and mometasone furoate monohydrate. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Contents</a></span></div></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.46pt">Oral steroids.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;Physicians may prescribe oral steroids on an episodic basis to patients who have not received sufficient symptomatic relief from INS. Oral steroids are often effective at treating the underlying inflammation associated with the disease and reducing postoperative scarring, but the benefit is temporary. As inflammation returns, many patients resume INS therapy.</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.46pt">Monoclonal antibodies</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2019, the FDA approved DUPIXENT&#8482; as an add-on (to an INS) maintenance treatment in adult patients with inadequately controlled chronic rhinosinusitis with nasal polyposis. In November 2020, the FDA approved XOLAIR&#8482; add-on maintenance treatment of nasal polyps in adult patients with inadequate response to nasal corticosteroids. In July 2021, the FDA approved NUCALA&#8482; add-on maintenance treatment of chronic rhinosinusitis with nasal polyps in adult patients with inadequate response to nasal corticosteroids. In addition, these monoclonal antibodies are being, or are expected to be, studied as potential treatments for patients with chronic rhinosinusitis without nasal polyps.</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.46pt">Other medical management.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;Physicians commonly employ a variety of other non-surgical treatments in the medical management of chronic rhinosinusitis, including nasal saline rinses, multi-week courses of antibiotics, leukotriene antagonists, decongestants, aspirin desensitization and antifungals. The recognized limitations of drug deposition with current INS cause some physicians to seek out alternative treatment regimens, such as high doses of locally compounded liquid budesonide in high-volume nasal rinses. Chronic rhinosinusitis is one of the most common reasons for adult outpatient antibiotic use in the U.S., comprised of approximately 37&#160;million prescriptions per year.</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.46pt">Sinus surgery and other procedures.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;Physicians generally recommend surgical treatment of chronic rhinosinusitis with and without nasal polyps only after patients fail medical management. The primary surgical alternative is Endoscopic Sinus Surgery (ESS), which attempts to open the sinus drainage pathways while preserving as much bone and sinus tissue lining as possible. The physician typically uses rigid steel instruments and powered cutting tools to remove inflamed tissue, including any nasal polyps, and underlying bone and cartilage to create a larger passage through the nasal anatomy to the sinuses. At the conclusion of the procedure, patients often have their nasal passages packed with a material that acts as a spacer to prevent surgical adhesions and control bleeding. Patients typically require one or more follow-up debridement treatments in which the physician may remove more tissue, crusting, scabs or scar tissue at the area of surgery in order to keep the sinus drainage pathway open and promote proper healing.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Several companies have developed less invasive technologies for the treatment of chronic rhinosinusitis since the introduction of ESS, such as balloon sinus dilation devices and steroid-releasing sinus implants. Balloon sinus dilation employs a high pressure inflated balloon to open blocked sinus pathways to increase ventilation and mucus drainage. Steroid-releasing sinus implants are used to hold open the surgically enlarged sinus, while releasing a steroid over a period of time in order to reduce postoperative sinus inflammation and scarring. SINUVA</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (mometasone furoate) sinus implant is a commercially available corticosteroid-eluting implant indicated for the treatment of nasal polyps in adult patients who have had ethmoid sinus surgery that can be placed in the ethmoid sinus under endoscopic visualization for up to 90 days. In the SINUVA clinical studies, patients were advised to use nasal steroid sprays and sinus rinses for the duration of the study.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:20.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Potential Future Therapies</span></div><div style="margin-top:8pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional potential future therapies include but are not limited to monoclonal antibodies, and corticosteroid-eluting implants. Benralizumab, which is already approved for other indications, is being developed for the treatment of nasal polyps, and is believed to inhibit specific pathways of inflammation present in nasal polyps. Lyra Therapeutics is developing corticosteroid-eluting implants as potential treatment for patients with chronic rhinosinusitis. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Limitations of Therapies</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The current and potential future therapies to treat patients suffering from chronic rhinosinusitis with and without nasal polyps have a number of limitations, including:</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.46pt">Limited efficacy of INS treatments using traditional nasal sprays and nasal aerosols.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;Although steroids are generally pharmacologically effective, conventional INS, including nasal sprays and nasal aerosols, are unable to effectively and consistently place the steroids onto the primary site of inflammation and nasal polyp origin, high and deep in the nasal passages. These products deposit a majority of the drug in the front of the nose or on the floor of the nasal passages, reducing their effectiveness and leaving many patients without sufficient symptomatic relief.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Contents</a></span></div></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.46pt">Short-term benefits of oral steroids outweighed by significant side effects.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;Oral steroids offer only temporary benefit and are limited by the risk of significant systemic side effects associated with both short- and long-term use. These side effects include, among others, weight gain; increased risk of infections; loss of bone mineral density; death of bone tissue; cataract formation; glaucoma; adrenal suppression; and psychiatric complications, including mania, depression, and psychosis.</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.46pt">Varying degrees of efficacy with other medical management.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;Other non-surgical treatments have varying degrees of supporting data and efficacy. In addition, high-volume steroid nasal rinses are difficult to administer, can be costly, may risk systemic side effects due to the absorption of the steroid into the body, can be associated with fluid draining from the nose after the procedure and are difficult for patients to comply with over prolonged courses of outpatient therapy.</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.46pt">Sinus surgery and other procedures are costly and may not be a complete solution.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;The effectiveness of sinus surgery varies significantly and many patients experience persistent or recurrent symptoms. Reports indicate that nasal polyp regrowth following surgery occurs in as high as 60% of cases within four years. In addition, it has been reported that up to 80% of patients continued to have symptoms within two years of surgery. Because sinus surgery is often not curative and may not address the underlying cause of the inflammation, many patients receive short- and long-term courses of INS after surgery and approximately 20% of patients elect surgical revisions. Postoperative scarring and persistent inflammation are common and can compromise symptom outcomes and also negatively impact the ability of the sinuses to heal. Sinus surgery is also a costly procedure, with estimated costs on average $13,500 per procedure. While balloon sinus dilation has the ability to open sinuses in a less invasive manner, it also may not address the underlying cause of the inflammation associated with chronic rhinosinusitis and is costly. Similarly, steroid-releasing sinus implants have limited duration of anti-inflammatory effect, are costly and face reimbursement challenges.</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.46pt">Treatment with monoclonal antibodies is costly, difficult to administer and may have negative side effects.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  The current FDA-approved monoclonal antibodies for the treatment of nasal polyps cost approximately $33,000 to $47,000 per year. Monoclonal antibodies also require subcutaneous injections or intravenous administration. We believe the systemic nature of these treatments, which target components of the immune response, may result in more adverse side effects than treatments with topically-acting steroids.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Solution</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">XHANCE</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">XHANCE combines the EDS with a liquid formulation of fluticasone propionate, a potent, well-characterized, second-generation anti-inflammatory corticosteroid for the treatment of serious nasal diseases characterized by chronic inflammation, such as chronic rhinosinusitis. XHANCE is designed to deliver fluticasone propionate into the high and deep regions of the nasal passages where nasal polyps or inflamed and swollen membranes can obstruct normal sinus ventilation and drainage. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In September 2017, the FDA approved our NDA for XHANCE for the treatment of nasal polyps in patients 18 years of age or older.  In January 2023, the indication statement for XHANCE was changed from &#8220;for the treatment of nasal polyps&#8221; to &#8220;for the treatment of chronic rhinosinusitis with nasal polyps&#8221; to reflect current FDA labeling terminology and not based on new XHANCE clinical data.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In March and June 2022, we announced positive top line results from our two Phase 3b clinical trials in of XHANCE for a follow-on indication for the treatment of chronic sinusitis. In February 2023, we submitted a prior approval efficacy supplement (sNDA) to support the approval of a new indication for XHANCE for the treatment of chronic sinusitis.  Assuming the FDA's acceptance of the sNDA submission and a standard review period, we expect the FDA's target action date to be in December 2023.  If the sNDA is approved, XHANCE has the potential to be the first drug therapy approved by the FDA for the treatment of chronic sinusitis.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe XHANCE could become a part of the standard of care for the treatment of patients with chronic rhinosinusitis with and without nasal polyps before they progress to more costly treatment alternatives and could also be adopted as a maintenance therapy to improve outcomes following sinus surgery.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The Exhalation Delivery System (EDS)</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The EDS enables the development of drug-device combination products intended for self-administration. We have developed both a liquid delivery EDS and a powder delivery EDS utilizing natural functional behaviors of the upper </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nasal airways intended to offer better drug deposition. The EDS is designed to overcome many limitations inherent in conventional nasal spray and nasal aerosol delivery systems, most notably, enabling higher and deeper intranasal drug delivery.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Liquid Exhalation Delivery System </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The liquid EDS depicted below, which is the EDS used in XHANCE, consists of the primary drug container for the liquid drug formulation, an amber glass vial sealed by a crimp-fitted metering spray pump, enclosed within a proprietary liquid delivery subassembly. The nasal spray applicator, which is a component of the subassembly, is attached to the pump and extends to the top of the nosepiece of the liquid delivery subassembly. The EDS includes a flexible mouthpiece and an asymmetrically-shaped nosepiece, covered by an orange cap, as part of a mechanism that uses the patient's exhaled breath to naturally seal closed the soft palate and to facilitate delivery of drug to the nasal passages through the sealing nosepiece. The nosepiece is designed to create a seal with the nostril and also to expand and stent the upper part of the nasal valve, which is an important anatomical structure that is the narrowest part of the entire respiratory tract and a barrier that causes most medication delivered by conventional INS to deposit in the front part of the nose.</span></div><div style="margin-bottom:8pt;text-align:center"><img src="optn-20221231_g4.jpg" alt="optn-20221231_g4.jpg" style="height:300px;margin-bottom:5pt;vertical-align:text-bottom;width:150px"/></div><div style="margin-bottom:8pt;text-align:center"><span><br/></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:20.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Powder Exhalation Delivery System </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The powder EDS depicted below, which is the EDS used in Onzetra</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Xsail</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, consists of a reusable device body incorporating a flexible mouthpiece to adjust to individual anatomic variations, and a white button piercing assembly to pierce the medication capsule. Disposable nosepieces are provided in a foil pouch to be inserted into the drug delivery device body. Each pre-filled nosepiece section contains a medication capsule containing a dry powder formulation and a clear release tab. The capsule is pierced by pressing and releasing the white button piercing assembly. The flexible mouthpiece and an asymmetrically-shaped nosepiece are part of the mechanism that uses the patient's exhaled breath to naturally seal closed the soft palate and to facilitate delivery of drug to the nasal passages through the sealing nosepiece. The medication capsule is intended for single dose administration and is not refillable or removable from the nosepiece.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following drug administration, the disposable nosepiece, including the dose-expended medication capsule, is then removed and discarded.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><img src="optn-20221231_g5.jpg" alt="optn-20221231_g5.jpg" style="height:337px;margin-bottom:5pt;vertical-align:text-bottom;width:240px"/></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:20.25pt"><span><br/></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:20.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">How the Exhalation Delivery System (EDS) works</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When exhaling into the EDS, the soft palate automatically elevates and creates an air-tight seal separating the nasal cavity from the throat and lungs. This natural action is the same as that which prevents air from escaping from the nose when trying to blow up a balloon or blow a trumpet. The exhaled air is then routed through the EDS which introduces medication into the air flow and then directs the air and medication through the sealing nosepiece. The positive air pressure, which is the opposite of the negative pressure produced by sniffing with ordinary nasal sprays, acts to dynamically expand the nasal valve and the narrowed nasal passages, helping to deliver the drug around obstructing anatomic barriers and fill one side of the nasal cavity. This enables high and deep deposition of medication in the nasal passages. The positive air pressure, proportional to the pressure on the other side of the soft palate, helps to open a passage between the two sides of the nasal cavity, behind the back edge of the nasal septum. The picture below illustrates this action, which allows the exhaled air pressure to escape from the opposite nostril.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><img src="optn-20221231_g6.jpg" alt="optn-20221231_g6.jpg" style="height:259px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"/></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The drug delivery mechanism of the EDS is designed to overcome the drug deposition shortcomings of conventional nasal sprays and nasal aerosols. In conventional nasal sprays and nasal aerosols, the medication is inhaled or sniffed into the nose creating negative pressure within the nasal passages, which does not facilitate the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">expansion of the nasal valve or the nasal passages and may obstruct the drug from reaching deep into the nose where most nasal polyps and inflamed and swollen sinus membranes exist.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pattern of drug deposition produced by conventional nasal sprays and the EDS has been evaluated in multiple studies using a combination of advanced imaging modalities to depict the regions of the nasal passages where drug is deposited after administration in healthy human volunteers. In an open label, crossover study conducted by a third party in nine patients with allergic rhinitis, investigators examined the nasal deposition of radio-labeled materials that allow for traceability following use of Qnasl&#8482; (HFA-beclomethasone, nasal aerosol), Flonase&#8482; (fluticasone propionate, nasal spray) and Nasonex&#8482; (mometasone furoate monohydrate, nasal spray). In this study, gamma cameras were used to capture emitted radiation from these tracers to create two-dimensional images in a similar process to the capture of x-ray images. These gamma images were merged with magnetic resonance images (MRI) to quantify regional deposition within the nasal passages. The images below illustrate how the pattern of drug deposition in the nasal passages produced by Qnasl&#8482;, Flonase&#8482; and Nasonex&#8482; was concentrated in the front and lower regions of the nasal passages, as opposed to the high and deep regions of the nasal passages targeted in the treatment of CRS.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><img src="optn-20221231_g7.jpg" alt="optn-20221231_g7.jpg" style="height:147px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"/></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:20.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Reprinted with permission from JOURNAL OF AEROSOL MEDICINE &amp; PULMONARY DRUG DELIVERY 28/8, 2015, by Leach et al, published by Mary Ann Liebert, Inc., New Rochelle, NY.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted six deposition studies evaluating 53 healthy subjects that produced approximately 250 images. As depicted in the representative figures below, the EDS produced a differentiated pattern of drug delivery with significantly more drug deposited in the high and deep regions of the nasal passages.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><img src="optn-20221231_g8.jpg" alt="optn-20221231_g8.jpg" style="height:284px;margin-bottom:5pt;vertical-align:text-bottom;width:588px"/></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:20.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">The pictures above use gamma camera image information, which was then superimposed on the corresponding MRI section. These images represent deposition in healthy subjects two minutes after delivery using a traditional liquid nasal spray and a version of the liquid EDS. Deposition with traditional liquid nasal spray was greatest in the front parts of the nose, whereas deposition with the EDS was greatest in the high and deep regions of the nose.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pictures below illustrate how the liquid EDS (with exhalation) places medication higher and deeper in the nasal passages than a conventional nasal spray (without sniffing) in nasal cast models.  As depicted below, although conventional nasal spray systems can reach, and therefore treat, large nasal polyps, they are not generally suitable </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for reaching nasal polyps or inflammation in the higher and deeper regions where obstruction of the sinus openings occurs.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><img src="optn-20221231_g9.jpg" alt="optn-20221231_g9.jpg" style="height:207px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"/></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The liquid EDS is also designed to address user dissatisfaction with conventional nasal delivery by reducing drug drip-out from the front and back of the nose and the bad taste that often accompanies drug entering the throat. By reducing the loss of drug to non-targeted sites, such as the gastrointestinal tract by swallowing, or lungs, the EDS has the potential to improve the efficiency of drug activity and to improve tolerability by reducing off-target effects.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Pipeline</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">XHANCE for Chronic Sinusitis</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to XHANCE&#8217;s existing indication for the treatment of nasal polyps, in order to broaden our U.S. market opportunity, we conducted a clinical trial program in pursuit of a follow-on indication for the treatment of CS in the U.S. We announced positive top-line results from the clinical trials in March and June 2022 and submitted a supplemental new drug application (sNDA) in February 2023.  Assuming the FDA's acceptance of the sNDA submission and a standard review period, we expect the FDA's target action date to be in December 2023.  If the sNDA is approved, XHANCE has the potential to be the first drug therapy approved by the FDA for the treatment of chronic sinusitis.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:103%">In</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:103%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:103%">the</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:103%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:103%">future,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:103%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:103%">as</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:103%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:103%">appropriate,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:103%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:103%">we</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:103%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:103%">intend</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:103%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:103%">to</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:103%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:103%">broaden,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:103%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:103%">through</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:103%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:103%">potential</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:103%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:103%">collaborations,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:103%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:103%">our</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:103%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:103%">commercialization</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:103%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:103%">efforts</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:103%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:103%">to additional primary care physicians that we believe treat an additional estimated 6.25 million U.S. patients with chronic rhinosinusitis, an estimated one-third of whom have chronic rhinosinusitis with nasal polyps. In addition, at some point in the future, we intend to consider, with a collaboration partner, directing promotional resources to an additional estimated 20 million adults who are not regularly under the care of physicians for this disease using programs such as direct-to-consumer and direct-to-patient promotion.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">EDS Technology</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We opportunistically evaluate opportunities to develop product candidates using the EDS and related technologies for indications and markets outside of our ENT and allergy focus through business development and partnering activities.Although our current focus is to prioritize the successful commercialization of XHANCE for the ENT and allergy specialty segment and the pursuit of FDA approval of XHANCE for the treatment of chronic sinusitis, we may apply or out-license the EDS and related technology to other product candidates across a broad range of disease areas. For example, by placing drug high and deep in the nose, in regions where cranial nerves connect directly with the brain, we believe it may be possible to deliver medications directly into the brain and avoid the difficulties of getting drug past the blood-brain barrier. This may enable treatment of brain diseases using small or large molecules that otherwise do not readily enter the nervous system.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Sales and Marketing</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have established a commercial infrastructure designed to drive adoption and sales of XHANCE with healthcare professionals who treat patients with nasal polyps. We believe that approximately 15,000 physicians treat an estimated 3.5 million chronic rhinosinusitis patients, an estimated 1.2 million of whom have chronic rhinosinusitis with nasal polyps.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline">Customer Model</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">. At the start of 2022 we had a sales force of approximately 90 territory managers who targeted over 10,000 ENTs, allergists and &#8220;specialty-like&#8221; primary care physicians. At the end of 2022 we had reduced the size of our sales force to approximately 77 territory managers, as part of actions intended to reduce our operating expenses, who target approximately 7,000 ENTs, allergists and &#8220;specialty-like&#8221; primary care physicians. In addition </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Contents</a></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">to in-person promotion by our territory managers we target additional physicians through digital and non-personal promotion in areas where we do and do not have territory managers. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Our sales team is equipped with educational materials demonstrating the benefit and safety profile of XHANCE. In the future, particularly after receipt of a potential future new indication for the treatment of chronic sinusitis, we may increase the number of geographic territories as well as hire additional territory managers in order to increase the number of called-on target physicians and frequency of calls. We believe that in the long term, direct to consumer (DTC) advertising could be an effective way to increase XHANCE prescription growth.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">XHANCE Co-Pay Savings Program</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We believe our co-pay savings program provides an affordability solution for patients that physicians will support. This program provides patient co-pay assistance to eligible commercially insured patients. These patients may obtain XHANCE for as little as $0 out-of-pocket. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Market Access</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">.&#160;Based on currently available third-party data and our internal analyses as of December 31, 2022, we believe that approximately 80% of commercially insured lives are currently in a plan that covers XHANCE. However, payors may change coverage levels for XHANCE, positively or negatively, at any time. Additionally, payors generally impose restrictions on access to or usage of XHANCE, such as by requiring prior authorizations or "step-edits". For example, insurers may require that a physician attest that they are treating a patient for an approved indication prior to becoming eligible for coverage for XHANCE. Approximately half of the commercially covered lives as of December 31, 2022 are in a plan that requires a prior authorization and most of those prior authorizations request information regarding prior use of INS and patient diagnosis. In some cases, patients do not meet the payors' utilization management criteria, and in other cases, healthcare providers may not complete the administrative process required to demonstrate or document that the patients for whom XHANCE has been prescribed meet the payors&#8217; utilization management criteria (i.e., prior authorizations or step-edits) and, as a result, patients may not gain access to XHANCE treatment. In our contract negotiations with payors we seek to balance patient access and affordability, breadth of coverage, payor utilization management and rebates levels. We have also contracted with the Centers for Medicare and Medicaid Services for coverage of certain government insured lives and continue to expand XHANCE market access for other government-insured populations.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Trade and Distribution.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> We currently sell XHANCE primarily to PPN partners. We established this channel to offer patients the option of filling prescriptions through a network of preferred pharmacies that may be able to better serve the needs of patients through services including delivery of XHANCE by mail and performing certain patient services such as patient insurance benefit verification. We also sell XHANCE to wholesale pharmaceutical distributors, who, in turn, sell XHANCE to retail pharmacies, hospitals and other customers. We have contracted with a third-party logistics provider for key services related to logistics, warehousing and inventory management, and distribution. Further, our third-party logistics provider provides customer order fulfillment services and accounts receivable management.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Customers</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Approximately 81% of our XHANCE net revenues during the&#160;fiscal year ended&#160;December 31, 2022 were to PPN partners. The three leading PPNs accounted for approximately 22% of our XHANCE net revenues. Additionally, approximately 19% of our XHANCE net revenues during the&#160;fiscal year ended&#160;December 31, 2022 were to the three largest wholesale pharmaceutical distributors, Cardinal Health, McKesson Corporation, and AmerisourceBergen Drug Corporation.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Manufacturing</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We contract with third parties for the manufacture, testing and storage of XHANCE. In our experience, contract manufacturers (CMOs) are generally cost-efficient and reliable and therefore we currently have no plans to build our own manufacturing capabilities. Because we rely on CMOs, we employ personnel with extensive technical, manufacturing, analytical and quality experience to oversee contract manufacturing and testing activities, and to compile manufacturing and quality information for our regulatory submissions. Manufacturing is subject to extensive regulations that impose various procedural and documentation requirements, and which govern record-keeping, manufacturing processes and controls, personnel, quality control and quality assurance, among other activities. Our systems and our contractors are required to comply with these regulations, and we assess this compliance regularly through monitoring of performance and a formal audit program. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into the following key supply agreements for the commercial manufacture and supply of XHANCE:</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.17pt">A supply agreement with Hovione Inter Ltd for the supply of fluticasone propionate, the active pharmaceutical ingredient included in the liquid suspension formulation. This agreement terminates in </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Contents</a></span></div></div><div style="margin-top:8pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 2023, although we are currently in discussions to enter into an extension of the term. We have also been actively pursuing a second source for supply that we anticipate will be online in early 2024. In the event we cannot reach an agreement on an extension, we have existing materials on hand to support production through 2023, and the ability to spot purchase to bridge to a new supplier. </span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">A manufacture and supply agreement with Contract Pharmaceuticals Limited Canada (CPL) for the formulation and assembly of the finished drug product during the fill/pack operation. This agreement was amended and renewed in February 2021 and now terminates on December 31, 2024, subject to earlier termination or extension in accordance with the terms of the agreement. </span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A manufacturing services agreement with Advance Mold &amp; Manufacturing, Inc. for the manufacture of the liquid delivery sub-assembly, which consists of injection molded parts and other purchased components. The agreement expires in October 2023 (subject to earlier termination or extension in accordance with its terms) but will automatically renew for successive one-year terms unless either party provides at least ninety days prior written notice to the other that it does not intend to renew the agreement.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our third-party manufacturers have adequate capacity to manufacture sufficient quantities of XHANCE to meet anticipated commercial demands and we are pursuing opportunities to decrease our reliance on sole-source suppliers and increase the third party manufacturing capacity that is available to us. We have initiated the process of qualifying alternate third party suppliers for select components of XHANCE.  Alternate third party suppliers of XHANCE components are subject to qualification and approval from the FDA.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Competition</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our industry is highly competitive and subject to rapid and significant technological change as research provides a deeper understanding of the pathology of diseases and new technologies and treatments are developed. We believe our scientific knowledge, technology, and development capabilities provide us with substantial competitive advantages, but we face potential competition from multiple sources, including large pharmaceutical, biotechnology, specialty pharmaceutical and, to a lesser degree, medical device companies.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">XHANCE competes primarily with INS, oral steroids, monoclonal antibodies and other medical management products, including locally compounded liquid budesonide in high-volume nasal rinses. XHANCE also competes with surgical procedures, balloon sinus dilation products and steroid-releasing sinus implants. Key competitive factors affecting the commercial success of XHANCE and any other product candidates we may develop are likely to be efficacy, safety and tolerability profile, reliability, convenience of administration, price and reimbursement.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The only other branded INS to receive an indication for the treatment of nasal polyps is Nasonex&#8482;, which was marketed by Merck&#160;&amp;&#160;Co.,&#160;Inc. before being removed from the prescription market but is available over-the-counter without a prescription for other treatment indications. Generic versions of Nasonex&#8482;, mometasone furoate monohydrate, were first approved by the FDA for, among other indications, the treatment of nasal polyps and launched in 2016 and remain available by prescription. Also, Beconase AQ&#8482;, which is an INS marketed by GlaxoSmithKline, is indicated for the prophylaxis of nasal polyps after surgical resection. In addition, SINUVA&#8482; is a commercially available corticosteroid-eluting implant indicated for the treatment of nasal polyps in adult patients who have had ethmoid sinus surgery that can be placed in the ethmoid sinus under endoscopic visualization for up to 90 days. In the SINUVA&#8482; clinical studies, patients were advised to use INS and sinus rinses for the duration of the study. Also, Lyra Therapeutics is developing corticosteroid-eluting implants as potential treatment for patients with chronic rhinosinusitis.      </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no products approved for the treatment of chronic sinusitis without nasal polyps. There are two categories of INS: first-generation INS products, which include Rhinocort&#8482;, Nasacort AQ&#8482; and Qnasl&#8482;; and second-generation INS products, which include Flonase&#8482;, Veramyst&#8482;, Omnaris&#8482; and Zetonna&#8482;. The primary difference between first- and second-generation INS products is that first-generation INS are absorbed into the blood to a greater extent than second-generation INS, with systemic bioavailability ranging from 10% to 50% compared to a systemic bioavailability with fluticasone propionate, a second-generation INS, of less than 2%. Many of the most widely-prescribed INS products are available in generic form and some, such as Flonase&#8482; (which contains fluticasone propionate the same active pharmaceutical ingredient as XHANCE), Nasonex (which contains mometasone furoate monohydrate) and other products containing fluticasone propionate and mometasone furoate monohydrate, are available over-the-counter without a prescription at prices generally ranging from approximately $15-30 per month supply.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Contents</a></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Several companies have developed or are currently developing monoclonal antibodies for the treatment of nasal polyps. These monoclonal antibodies, which inhibit specific pathways of inflammation present in nasal polyps, include benralizumab, DUPIXENT&#8482;, XOLAIR&#8482;, and NUCALA&#8482;. In June 2019, the FDA approved DUPIXENT&#8482; as an add-on (to an INS) maintenance treatment in adult patients with inadequately controlled chronic rhinosinusitis with nasal polyposis. In November 2020, the FDA approved XOLAIR&#8482; as an add-on maintenance treatment of nasal polyps in adult patients with inadequate response to nasal corticosteroids. In July 2021, the FDA approved NUCALA&#8482; as an add-on maintenance treatment of chronic rhinosinusitis with nasal polyps in adult patients with inadequate response to nasal corticosteroids. In addition these monoclonal antibodies are being, or are expected to be, studied as potential treatments for patients with chronic rhinosinusitis without nasal polyps. Monoclonal antibodies could represent significant competition for XHANCE.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Seasonality</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A seasonal effect has historically been observed in the INS prescription market in which market volume generally peaks near the middle of the second quarter and declines into the early part of the third quarter of each calendar year. Based on third-party prescription data, INS market prescriptions decreased 4% from the fourth quarter of 2020 to the first quarter of 2021, increased 14% from the first quarter of 2021 to the second quarter of 2021, decreased 4% from the second quarter of 2021 to the third quarter of 2021, increased 1% from the third quarter of 2021 to the fourth quarter of 2021, were flat from the fourth quarter of 2021 to the first quarter of 2022, increased 7% from the first quarter of 2022 to the second quarter of 2022, decreased 7% from the second quarter of 2022 to the third quarter of 2022, and increased 4% from the third quarter of 2022 to the fourth quarter of 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although the underlying disease that we are treating is chronic and causes symptoms year-round, we believe the variation in patient flow through the offices of relevant physician specialists, and seasonality in disease flare-ups, has an impact on the number of patients that present themselves and who are therefore available to receive a new prescription for XHANCE. Demand has historically been, and we expect will continue to be, impacted by the INS market seasonality and the seasonal variation in patient visits with their doctor resulting in reduced XHANCE prescription demand in the third quarter. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, as we experienced in 2021 and 2022, we expect that the first quarter prescription demand and average net revenue per prescription for XHANCE will be adversely impacted in 2023 and future years by the annual resetting of patient healthcare insurance plan deductibles and changes in individual patients' healthcare insurance coverage, both of which often occur in January.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">XHANCE Clinical Development</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Nasal Polyps Program </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our clinical trial program for nasal polyps evaluated XHANCE in the following five clinical trials comprised of over 1,500 patients:</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">two randomized, double-blinded, placebo-controlled Phase&#160;3 pivotal clinical trials designed to compare the safety and efficacy of XHANCE to a placebo EDS in adults with bilateral nasal polyps, which we refer to as NAVIGATE I and NAVIGATE II or collectively, our pivotal clinical trials.  Each of NAVIGATE I and NAVIGATE II had co-primary endpoints of (i) change in subjective nasal congestion/obstruction symptoms from baseline to week 4 and (ii) change in objectively measured total (bilateral) nasal polyp grade from baseline to week 16.  These trials also evaluated several secondary endpoints, including the impact of XHANCE treatment on study-defined surgical eligibility criteria and changes in Sinonasal Outcome Test 22 score, which considers the core defining signs and symptoms of nasal polyps and the impact on functioning, quality of life and sleep.  We also conducted a complete response analysis to evaluate the percentage of patients with a recorded nasal polyp grade of zero on at least one side of the nasal cavity.</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">two open-label Phase&#160;3 clinical trials which we refer to as EXHANCE-3 and EXHANCE-12 or collectively, as our supportive clinical trials, to evaluate the safety of XHANCE in adults with symptoms of chronic sinusitis with or without nasal polyps over an extended period of time (3 months in the case of EXHANCE-3 and 12 months in the case of EXHANCE-12).  In these trials we also assessed a variety of objective and subjective efficacy parameters, including an assessment of each patient's symptoms and functioning and the impact of XHANCE treatment on study-defined surgical eligibility criteria.</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">one Phase&#160;1, open-label, randomized, single-dose, bioavailability study to compare the bioavailability of fluticasone propionate from XHANCE to Flonase&#8482; and Flovent HFA&#8482; in healthy patients and patients with mild-to-moderate asthma. We conducted this Phase 1 trial to establish a bridge between XHANCE, which </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Contents</a></span></div></div><div style="margin-top:8pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consists of our fluticasone propionate formulation combined with our EDS device, and Flonase&#8482; and Flovent HFA&#8482;, the referenced listed drugs for our NDA.  In our NDA, we relied in part on the FDA's previous findings of safety for Flonase&#8482; and Flovent HFA&#8482;, including non-clinical toxicology findings and finding related to hypothalamic pituitary adrenal (HPA) axis suppression, which is a known side effect of corticosteroids.  To do so, we were required to establish that the systemic exposure, or the amount of drug absorbed into the body, to fluticasone propionate following use of XHANCE did not exceed the exposure produced by Flovent HFA&#8482;. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Clinical Trial Highlights</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Phase&#160;3 clinical development program for nasal polyps included a population of patients generally reflective of our intended patient population, with approximately 90% having previously tried INS therapy and almost one-third having previously undergone sinus surgery. Key results from this Phase 3 clinical trial program include:</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">In our pivotal clinical trials, XHANCE produced statistically significant benefits on both of the co-primary endpoints: a reduction of nasal congestion/obstruction symptoms at week&#160;4 and a reduction in total polyp grade at week&#160;16.</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">In our Phase 3 clinical trials, patients with nasal polyps generally experienced greater improvements in symptoms and reductions in polyp grade with longer duration of use.</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">In our pivotal clinical trials, approximately 16% of patients treated with XHANCE had nasal polyps eliminated (reduced to polyp grade 0) in at least one nostril after 16&#160;weeks of treatment, and approximately 27% had nasal polyps eliminated in at least one nostril after an additional eight weeks of treatment. In our supportive trials, we observed complete response rates in at least one nostril of 48% of patients in EXHANCE-3 and 47.1% of patients in EXHANCE-12.</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">In our pivotal clinical trials, XHANCE produced improvement across all four defining symptoms of chronic rhinosinusitis with nasal polyps.</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Over 85% of patients receiving XHANCE across our pivotal clinical trials reported improvement, and approximately two-thirds reported being "much" or "very much" improved, compared to approximately one-third of patients in the placebo EDS group. In our supportive clinical trials, approximately 70% of patients with symptoms of chronic sinusitis, both with and without nasal polyps, reported that they were "much" or "very much" improved after treatment with XHANCE.</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">On a Sinonasal Outcome Test-22, the improvement with the 186- and 372- mcg doses of XHANCE was superior to the placebo EDS in both NAVIGATE I and NAVIGATE II. The magnitude of improvement associated with treatment with XHANCE was approximately 20&#160;points. Although cross-trial comparisons have significant limitations and must be interpreted with caution, in a previous third-party study evaluating a large cohort (n=1468) of patients who were underwent sinus surgery, the degree of change on this outcome measure was approximately 18&#160;points.</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">After 12&#160;months of treatment with XHANCE in our supportive clinical trials, at least 50% of patients had a Sinonasal Outcome Test-22 score that was at or below 9.3, which is the average score that has been reported for healthy individuals.</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">XHANCE was well tolerated and had an adverse event profile generally similar to that observed in several comparably designed third party studies with traditional INS. The most common adverse reactions (incidence &#8805; 3%) are epistaxis, nasal septal ulceration, nasopharyngitis, nasal mucosal erythema, nasal mucosal ulcerations, nasal congestion, acute sinusitis, nasal septal erythema, headache, and pharyngitis.  <br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In connection with the approval of our NDA for XHANCE, the FDA required that we complete a clinical trial of XHANCE for the treatment of nasal polyps in pediatric patients by January 2022. Although this trial is ongoing, we will need to submit a request to the FDA to extend this deadline due to enrollment rates.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Chronic Sinusitis Program</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition to XHANCE&#8217;s existing indication for the treatment of nasal polyps, in order to broaden our U.S. market opportunity, we conducted a clinical trial program in pursuit of a follow-on indication for the treatment of chronic sinusitis in the U.S. We believe XHANCE has the potential to be the first drug therapy approved by the FDA for the treatment of chronic sinusitis. We announced positive top-line results for ReOpen1 and ReOpen2 in March and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">June 2022, respectively. In September 2022, we met with the FDA to discuss our planned sNDA for XHANCE as a treatment for adults with chronic sinusitis and submitted the sNDA in February 2023. </span></div><div><span><br/></span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">ReOpen1</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Re-Open1 was a randomized double-blinded, placebo controlled Phase 3 clinical trial examining the safety and efficacy of XHANCE versus a placebo EDS in adults with chronic sinusitis with or without nasal polyps. ReOpen1 served as one of two pivotal clinical trials we submitted to the FDA with our sNDA in February 2023 for XHANCE for the treatment of adults with chronic sinusitis. This clinical trial was conducted in the United States, Canada, Sweden, Poland, Bulgaria, The Republic of Georgia and Russia.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Top-line results from ReOpen1 are summarized below. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Study Design</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The clinical trial included a single-blind EDS-placebo lead-in and an EDS-placebo control group, a multi-center, multi-national study population to increase generalizability and an assessment of the safety and efficacy of multiple doses (186 or 372 mcg twice daily) over a 24-week period.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">A total of 332 adult subjects were enrolled in this study.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.204%"><tr><td style="width:1.0%"></td><td style="width:31.801%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.266%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.266%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.267%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Placebo EDS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">(N=110)</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">OPN-375 186 &#181;g</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">(N=110)</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">OPN-375 372 &#181;g</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">(N=107)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Full Analysis Set</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">110</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">110</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">107</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Completed Study</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">96</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">102</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">101</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Subjects Discontinuing Early</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">16</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">9</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">8</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Subjects with Nasal Polyps</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">69</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">69</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">67</span></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Subjects without Nasal Polyps</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">41</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">41</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">40</span></div></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">ReOpen1 had co-primary endpoints of (i) change in a composite score of nasal congestion/obstruction symptoms, nasal discharge, and facial pain and pressure from baseline to week, and (ii) change in average percent of opacified volume of the ethmoid and maxillary sinuses from baseline to week 24. The severity of nasal symptoms was recorded by patients in an electronic diary immediately before dosing in the morning (AM) and evening (PM), and was measured using 7-day average instantaneous AM diary scores. Each symptom was scored from 0-3. The volume of the ethmoid and maxillary sinuses occupied by disease was assessed using computer-assisted assessment of CT scans to determine the percentage (0-100%) of the sinus cavity space summed across all ethmoid and maxillary sinuses that was opacified.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">CT scans were performed at screening and at Week 24.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">This trial also evaluated several secondary endpoints, including the proportion of patients with acute disease exacerbations and their time to exacerbation and the Sinonasal Outcome Test-22 score, which considers the core defining signs and symptoms of chronic sinusitis and the impact on functioning, quality of life and sleep.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">   </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Top-Line Efficacy Results</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The 186- and 372-mcg treatment groups achieved statistically significant reductions in the primary assessments of composite symptom scores at week 4 and reductions in the opacified volume of the maxillary and ethmoid sinuses on CT scans at week 24 relative to a placebo EDS. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following table summarizes the mean change in composite symptom scores (or CSS) from baseline to week 4 and the change in the percent of opacified volume (or APOV) of the ethmoid and maxillary sinuses from baseline to week 24.</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.935%"><tr><td style="width:1.0%"></td><td style="width:19.961%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.295%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.208%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.208%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.208%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.208%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.212%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Difference from Placebo EDS</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Treatment</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:112%">n</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Baseline Score (Standard Deviation)</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Mean (Standard Error) Change from Baseline</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Mean</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:112%">95% confidence interval</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:112%">P-value (1)</span></div></td></tr><tr><td colspan="21" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Change in CSS from Baseline to Week 4</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">XHANCE 372 mcg</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">107</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">5.48 (1.83)</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#160;-1.60 (0.16)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">-0.98</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#160;-1.43, -0.54</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&lt;0.001</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">XHANCE 186 mcg</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">110</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">5.42 (1.81)</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#160;-1.58 (0.16)</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">-0.97</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#160;-1.41, -0.52</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&lt;0.001</span></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Placebo EDS</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">110</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">5.77 (1.78)</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#160;-0.62 (0.16)</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">-</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">-</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">-</span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Contents</a></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.935%"><tr><td style="width:1.0%"></td><td style="width:19.961%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.295%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.208%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.208%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.208%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.208%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.212%"></td><td style="width:0.1%"></td></tr><tr><td colspan="21" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Change in APOV in the Ethmoid and Maxillary Sinuses from Baseline to Week 24</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">XHANCE 372 mcg</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">107</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">68.95 (18.84)</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">-6.20 (1.41)</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">-4.59</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">-8.41, -0.78</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">0.018</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">XHANCE 186 mcg</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">110</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">68.88 (19.51)</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">-5.58 (1.44)</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">-3.98</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">-7.86, -0.09</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">0.045</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Placebo EDS</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">110</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">68.94 (20.33)</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">-1.60 (1.42)</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">-</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">-</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">-</span></div></td></tr><tr><td colspan="21" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">The p-value, or probability value, is a measure of statistical significance reflecting the likelihood that an observed result occurred by chance.</span></div></td></tr></table></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition to the co-primary efficacy endpoints described above, we also assessed a number of secondary endpoints in the trial, including the following:  </span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.46pt">Defining Symptoms (secondary endpoint</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">).  The XHANCE 186- and 372-mcg treatment groups achieved statistically significant improvement relative to the subjects receiving placebo EDS on all four of the core defining symptoms of chronic sinusitis (nasal congestion, rhinorrhea, facial pain/pressure, and sense of smell) at week 4.</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.46pt">Acute exacerbations (secondary endpoint)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The XHANCE 186- and 372-mcg treatment groups had a reduced occurrence of acute exacerbations of sinusitis relative to the subjects receiving placebo EDS which reached statistical significance in the high dose group.  </span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.46pt">Sinonasal Outcome Test-22 (secondary endpoint)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The XHANCE 186- and 372-mcg treatment groups had statistically significant improvements in SNOT-22 scores by week 4 relative to the subjects receiving placebo EDS.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Although ReOpen1 was not designed or powered to detect statistical differences between the XHANCE treatment groups and placebo EDS in patient subgroups, we also performed the following subgroup analyses:</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.46pt">Subgroup Analysis - CSS</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The subgroup of chronic sinusitis patients without nasal polyps receiving XHANCE and the subgroup of chronic sinusitis patients with concomitant nasal polyps receiving XHANCE had statistically significant reductions in CSS scores relative to the subjects receiving placebo EDS in each of these subgroups despite the lack of powering for this subgroup analysis.</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.46pt">Subgroup Analysis - APOV</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The subgroup of chronic sinusitis patients with concomitant nasal polyps receiving XHANCE achieved a statistically significant reduction in APOV relative to the subjects receiving placebo EDS in this subgroup despite the lack of powering for this subgroup analysis. The subgroup of chronic sinusitis patients without nasal polyps receiving XHANCE did not achieve a statistically significant change in APOV relative to the subjects receiving placebo EDS in this subgroup.    </span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Top-Line Safety Results</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">XHANCE was well tolerated across the 186- and 372-mcg dose groups and the safety profile in this trial was generally consistent with the safety profile contained in XHANCE&#8217;s currently approved label.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">No serious adverse events were reported in ReOpen1. The table below summarizes adverse events that occurred at a rate of more than 3% with XHANCE and more common than the placebo EDS in this trial. </span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Summary of Adverse Events with XHANCE Reported in &#8805; 3% </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">and More Common Than Placebo EDS in ReOpen1</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.058%"><tr><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Adverse Event (AE)</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Placebo EDS BID</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">(N =112)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">n (%)</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">XHANCE 186 mcg BID</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">(N =111)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">n (%)</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">XHANCE 372 mcg BID</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">(N =109)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">n (%)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Epistaxis</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">1 (0.9)</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">5 (4.5)</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">13 (11.9)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Nasopharyngitis</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">3 (2.7)</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">6 (5.4)</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">3 (2.8)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Asthma</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">1 (0.9)</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">5 (4.5)</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">4 (3.7)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Nuclear Cataract</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">0</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">5 (4.5)</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">4 (3.7)</span></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Cortical Cataract</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">1 (0.9)</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">6 (5.4)</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2 (1.8)</span></div></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Contents</a></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">ReOpen2</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ReOpen2 was a randomized double-blinded, placebo controlled Phase 3 clinical trial examining the safety and efficacy of XHANCE versus a placebo EDS in adults with chronic sinusitis without nasal polyps. ReOpen2 served as the second of two pivotal clinical trials we submitted to the FDA with our sNDA in February 2023 for XHANCE for the treatment of adults with chronic sinusitis. This clinical trial was conducted in the United States, Australia, Bulgaria, Czechia, New Zealand, Poland, Romania, Spain, The Republic of Georgia and the United Kingdom.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Top-line results from ReOpen2 are summarized below.</span></div><div><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Study Design</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The clinical trial included a single-blind EDS-placebo lead-in and an EDS-placebo control group, a multi-center, multi-national study population to increase generalizability and an assessment of the safety and efficacy of multiple doses (186 or 372 mcg twice daily) over a 24-week period.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">A total of 222 adult subjects were enrolled in this study.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.204%"><tr><td style="width:1.0%"></td><td style="width:31.801%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.266%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.266%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.267%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Placebo EDS<br/>(N=110)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">OPN-375 186 &#181;g<br/>(N=110)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">OPN-375 372 &#181;g<br/>(N=107)</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Full Analysis Set</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">75</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">72</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">73</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Completed Study</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">69</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">70</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">71</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Subjects Discontinuing Early</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">6</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">3</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">3</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">ReOpen2 had co-primary endpoints of (i) change in a composite score of nasal congestion/obstruction symptoms, nasal discharge, and facial pain and pressure from baseline to week, and (ii) change in average percent of opacified volume of the ethmoid and maxillary sinuses from baseline to week 24. The severity of nasal symptoms was recorded by patients in an electronic diary immediately before dosing in the morning (AM) and evening (PM), and was measured using 7-day average instantaneous AM diary scores. Each symptom was scored from 0-3. The volume of the ethmoid and maxillary sinuses occupied by disease was assessed using computer-assisted assessment of CT scans to determine the percentage (0-100%) of the sinus cavity space summed across all ethmoid and maxillary sinuses that was opacified.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">CT scans were performed at screening and at Week 24.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">This trial also evaluated several secondary endpoints, including the proportion of patients with acute disease exacerbations and their time to exacerbation and the Sinonasal Outcome Test-22 score, which considers the core defining signs and symptoms of chronic sinusitis and the impact on functioning, quality of life and sleep.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">   </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Top-Line Efficacy Results</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The 186- and 372-mcg treatment groups achieved statistically significant reductions in the primary assessments of composite symptom scores at week 4 and reductions in the opacified volume of the maxillary and ethmoid sinuses on CT scans at week 24 relative to a placebo EDS. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following table summarizes the mean change in composite symptom scores (or CSS) from baseline to week 4 and the change in the percent of opacified volume (or APOV) of the ethmoid and maxillary sinuses from baseline to week 24.</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.935%"><tr><td style="width:1.0%"></td><td style="width:19.961%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.295%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.208%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.208%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.208%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.208%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.212%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Difference from Placebo EDS</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Treatment</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">n</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Baseline Score (Standard Deviation)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Mean (Standard Error) Change from Baseline</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Mean</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">95% confidence interval</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">P-value (1)</span></td></tr><tr><td colspan="21" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Change in CSS from Baseline to Week 4</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">XHANCE 372 mcg</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">73</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">5.97 (1.59)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">-1.74 (0.20)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">-0.93</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">-1.49, -0.37</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">0.001</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">XHANCE 186 mcg</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">72</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">5.87 (1.48)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">-1.54 (0.20)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">-0.73</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">-1.29, -0.17</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">0.011</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Placebo EDS</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">75</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">6.15 (1.77)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">-0.81 (0.20)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">-</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">-</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">-</span></td></tr><tr><td colspan="21" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Change in APOV in the Ethmoid and Maxillary Sinuses from Baseline to Week 24</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">XHANCE 372 mcg</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">73</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">61.50 (18.46)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">-5.14 (1.74)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">-6.33</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">-11.08, -1.58</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">0.009</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Contents</a></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.935%"><tr><td style="width:1.0%"></td><td style="width:19.961%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.295%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.208%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.208%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.208%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.208%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.212%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">XHANCE 186 mcg</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">72</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">60.51 (19.37)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">-7.00 (1.73)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">-8.19</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">-12.93, -3.45</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&lt;0.001</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Placebo EDS</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">75</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">64.09 (17.74)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">+1.19 (1.74)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">-</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">-</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">-</span></td></tr><tr><td colspan="21" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">1 - The p-value, or probability value, is a measure of statistical significance reflecting the likelihood that an observed result occurred by chance.</span></div></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Top-Line Safety Results</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">XHANCE was well tolerated across the 186- and 372-mcg dose groups and the safety profile in this trial was generally consistent with the safety profile contained in XHANCE&#8217;s currently approved label.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">No serious adverse events were reported in ReOpen2. The table below summarizes adverse events that occurred at a rate of more than 3% with XHANCE and more common than the placebo EDS in this trial. </span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Summary of Adverse Events with XHANCE Reported in &#8805; 3% </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">and More Common Than Placebo EDS in ReOpen2</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.058%"><tr><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Adverse Event (AE)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Placebo EDS BID<br/>(N =75)<br/>n (%)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">XHANCE 186 mcg BID<br/>(N =73)<br/>n (%)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">XHANCE 372 mcg BID<br/>(N =74)<br/>n (%)</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">COVID-19</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2 (2.7)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">3 (4.1)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">7 (9.5)</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Epistaxis</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">0</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">4 (5.5)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">7 (9.5)</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Headache</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">6 (8.0)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2 (2.7)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">7 (9.5)</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Depression</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">1 (1.3)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">0</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">3 (4.1)</span></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Pooled Results from the ReOpen Program </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In July 2022, we announced selected pooled results from the ReOpen program. First, to inform possible differences in response of patients previously using a standard nasal steroid spray, a pre-planned analysis of pooled data assessed symptom improvement for patients entering the trials with at least moderate symptoms despite reporting use of a standard nasal steroid spray. For this subgroup, patients receiving XHANCE improved more from baseline than patients receiving placebo comparator. Second, a pooled analysis was performed to assess change in CT scans, measured by APOV at week 24, for the subgroup of patients receiving XHANCE who had chronic sinusitis without nasal polyps. Compared to patients treated with placebo comparator, XHANCE treatment produced greater reduction in sinus opacification in this subgroup. Differences between active and placebo in 186 mcg or 372 mcg XHANCE treatment groups were similar and nominally statistically significant. Finally, an analysis of pooled data found that the 372  mcg treatment group achieved a type 1 error controlled statistically significant reduction of 66% in the incidence of exacerbations compared to placebo comparator. Reductions in the number of exacerbations, ranging from 53 to 80%, were found for subgroups of chronic sinusitis patients with or without nasal polyps in the 186 mcg or 372 mcg XHANCE treatment groups in additional pre-planned exploratory analyses that were not type 1 error controlled. Exacerbations were defined as a worsening of at least one of the four cardinal symptoms of chronic sinusitis (nasal congestion/obstruction, rhinorrhea, facial pain/pressure, and loss of sense of smell) lasting at least 3 days accompanied by an escalation in medical care, such as doctor visits or antibiotic or steroid prescription. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition, we completed an analysis of mean change in APOV by Patient-Reported Global Change Score (PGIC). The PGIC is a 7-point Likert scale on which the subject directly reports their perceived overall change in disease since initiating study medication. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following three tables summarize these results.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.081%"><tr><td style="width:1.0%"></td><td style="width:28.434%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.086%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.469%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.469%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.469%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.473%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Difference from Placebo EDS</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Treatment</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">n</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Baseline Score</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">LS Mean Change from Baseline</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">LS Mean</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Nominal<br/>P-value (1)</span></td></tr><tr><td colspan="18" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Change in Symptoms in Prior Nasal Steroid Users from Baseline to Week 4 (Pooled)</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">XHANCE 186 or 372 mcg</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">172</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">5.63</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">-1.46</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">-0.7</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&lt;0.001</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Placebo EDS</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">108</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">5.84</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">-0.77</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">-</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">-</span></td></tr><tr><td colspan="18" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Change in APOV in CS Patients without Nasal Polyps from Baseline to Week 24 (Pooled)</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">XHANCE 186 or 372 mcg</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">225</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">61.33</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">-6.31</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">-4.76</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">0.004</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.081%"><tr><td style="width:1.0%"></td><td style="width:28.434%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.086%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.469%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.469%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.469%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.473%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">XHANCE 372 mcg</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">112</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">61.26</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">-6.5</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">-4.95</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">0.01</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">XHANCE 186 mcg</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">113</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">61.4</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">-6.12</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">-4.57</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">0.019</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Placebo EDS</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">116</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">63.32</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">-1.55</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">-</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">-</span></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.497%"><tr><td style="width:1.0%"></td><td style="width:27.817%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.108%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.108%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.055%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.294%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.018%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Treatment Group</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">n</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Events</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">LS Mean</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Incidence Rate Ratio (Active/PBO)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">P-value </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="18" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Frequency of Exacerbations over 24 Weeks (Full Analysis Set/All Patients)<br/></span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">XHANCE 186 or 372 mcg</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">362</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">35</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">0.081</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">0.389</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">0.001</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">XHANCE 372 mcg</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">180</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">15</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">0.072</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">0.343</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">0.002</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">XHANCE 186 mcg</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">182</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">20</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">0.092</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">0.441</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">0.012</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Placebo EDS</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">185</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">41</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">0.208</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">-</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">-</span></td></tr><tr><td colspan="18" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Frequency of Exacerbations over 24 Weeks (Patients with Nasal Polyps)</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">XHANCE 186 or 372 mcg</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">137</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">12</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">0.052</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">0.276</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">0.005</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">XHANCE 372 mcg</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">68</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">4</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">0.038</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">0.203</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">0.01</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">XHANCE 186 mcg</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">69</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">8</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">0.07</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">0.376</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">0.055</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Placebo EDS</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">69</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">17</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">0.187</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">-</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">-</span></td></tr><tr><td colspan="18" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Frequency of Exacerbations over 24 Weeks (Patients without Nasal Polyps)</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">XHANCE 186 or 372 mcg</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">225</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">23</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">0.113</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">0.472</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">0.032</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">XHANCE 372 mcg</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">112</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">11</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">0.113</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">0.47</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">0.077</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">XHANCE 186 mcg</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">113</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">12</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">0.113</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">0.474</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">0.076</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Placebo EDS</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">116</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">24</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">0.239</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">-</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">-</span></td></tr><tr><td colspan="18" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">1.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%;padding-left:11.34pt">The p-value, or probability value, is a measure of statistical significance reflecting the likelihood that an observed result occurred by chance and compares the indicated group to the relevant placebo EDS group. Unless otherwise noted, all p-values shown in this table represent nominal p-values (meaning they are exploratory, not type 1 error controlled) and therefore have an increased possibility of being a chance finding</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">2.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%;padding-left:11.34pt">This p-value for all patients receiving XHANCE 372 mcg in the ReOpen Program is a type 1 error controlled statistically significant result. All other p-values shown in this table are nominal p-values.</span></div><div><span><br/></span></div></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.567%"><tr><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="24" rowspan="2" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Mean change in APOV by Patient-Reported Global Change Score at Week 24</span></td></tr><tr style="height:15pt"><td colspan="24" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" rowspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="21" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PGIC Category</span></td></tr><tr style="height:15pt"><td colspan="3" rowspan="2" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Very Much Improved</span></td><td colspan="3" rowspan="2" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Much Improved</span></td><td colspan="3" rowspan="2" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Minimally Improved</span></td><td colspan="3" rowspan="2" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">No Change</span></td><td colspan="3" rowspan="2" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Minimally Worsened</span></td><td colspan="3" rowspan="2" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Much Worsened</span></td><td colspan="3" rowspan="2" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Very Much Worsened</span></td></tr><tr style="height:15pt"><td colspan="24" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subjects</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mean Change in APOV</span></td><td colspan="2" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.53)</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.26)</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.86)</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.32)</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.01&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.82&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.30&#160;</span></td><td style="border-bottom:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Pooled Safety Results from the ReOpen Program</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">XHANCE was well tolerated across the 186- and 372-mcg dose groups and the safety profile in the ReOpen program was generally consistent with the safety profile contained in XHANCE&#8217;s currently approved label.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">No serious adverse events were reported in the ReOpen program. The table below summarizes adverse events that occurred at a rate of more than 3% with XHANCE and more common than the placebo EDS in this trial. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.660%"><tr><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="12" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Summary of Adverse Events with XHANCE Reported in &#8805; 3%<br/>and More Common Than Placebo EDS in Pooled data</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.660%"><tr><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Adverse Event (AE)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Placebo EDS BID<br/>(N =187)<br/>n (%)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">XHANCE 186 mcg BID<br/>(N =184)<br/>n (%)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">XHANCE 372 mcg BID<br/>(N =183)<br/>n (%)</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Epistaxis</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">1 (0.5)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">9 (4.9)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">20 (10.9)</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">COVID-19</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">8 (4.3)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">5 (2.7)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">12 (6.7)</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Nasopharyngitis</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">8 (4.3)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">9 (4.9)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">7 (3.8)</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Headache</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">7 (3.7)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">4 (2.2)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">10 (5.5)</span></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Intellectual Property and Barriers to Entry</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">XHANCE benefits from substantial intellectual property and barriers to entry, including the following:</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:15.08pt">Strong patent protection.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160; Our XHANCE U.S. patent portfolio consists of 13 issued device and method of use patents expiring on various dates from 2023 through 2036, three issued design patents expiring through 2030 and pending patent applications. We rely primarily on the protections afforded by device and method of use patents. Our issued U.S. patents and patent applications for XHANCE are based on the EDS and related technology, including the combination of this technology with fluticasone propionate.  </span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.46pt">Complex drug-delivery system.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;We believe the unique features of our liquid EDS device, as well as its delivery of a topical-acting corticosteroid, affords us significant protection against generic competition, as well as against a potential 505(b)(2) NDA, that seeks to reference XHANCE in order to obtain approval for a therapeutically equivalent, substitutable competitor product. XHANCE, utilizing our liquid EDS device, presents technical and human factors engineering complexities for drug-device combination products and chemistry, manufacturing and controls challenges unique to suspension and respiratory products. Any future substitutable generic entrant will need to have considerable combination product know-how to develop and validate a substitutable drug delivery device or technology to compete with XHANCE.<br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;padding-left:14.46pt">Clinical and regulatory complexity.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;&#160;We conducted a clinical development program comprised of over 1,500 patients to support FDA approval of our NDA for XHANCE for the treatment of nasal polyps, including human factors studies and Phase&#160;3 clinical trial assessments evaluating and validating the use of XHANCE. As with other drugs that primarily have local activity, we believe the regulatory pathway for products seeking approval as substitutable generic equivalents to XHANCE will be more complex and costly than the pharmacokinetic studies generally required for systemically-acting medications. We believe that any future substitutable generic competitors may be required to conduct, among other things, non-inferiority clinical trials demonstrating equivalent efficacy and safety outcomes to establish clinical bioequivalence to XHANCE. We believe these clinical trials, if required, would necessitate a significant amount of time and capital investment and present clinical development uncertainties. However, the FDA has included XHANCE on the list of upcoming product specific guidances for complex generic drug products that the FDA plans to issue, which may provide clarity for generic competitors to develop generic products that compete with XHANCE.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intellectual Property</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We strive to protect our proprietary technology that we believe is important to our business, including seeking and maintaining patents intended to cover our product candidates and technologies that are important to the development of our business. We also rely on trade secrets to protect aspects of our business that are not amenable to, or that we do not consider appropriate for, patent protection, as well as know-how, trademarks, continuing technological innovation and in-licensing opportunities to develop and maintain our proprietary position. We internally developed our intellectual property related to XHANCE, Onzetra Xsail, the Exhalation Delivery System and related technologies. We have sought and intend to continue to seek appropriate patent protection for our product candidates, as well as other proprietary technologies and their uses by filing patent applications in the U.S. and other select countries.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Patents</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of February 1, 2023, we owned over 60 U.S. patents expiring between 2023 and 2036, and pending U.S. patent applications. In addition to our U.S. intellectual property, as of February 1, 2023, we also owned over 200 foreign issued patents expiring between 2022 and 2035, and foreign patent applications.  As part of actions intended to reduce operating expenses, we intend to reduce the scope of our patent portfolio primarily in certain foreign countries where we believe commercial potential is more limited.     </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our XHANCE U.S. patent portfolio consists of 13 issued device and method of use patents expiring on various dates from 2023 through 2036, three issued design patents expiring between 2029 and 2030 and pending patent applications. The 13 device and method of use patents are published in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the Orange Book. Drugs listed in the Orange Book can, in turn, be cited by potential generic competitors in support of approval of an abbreviated NDA (ANDA), or a 505(b)(2) NDA. If any of these potential generic competitors claim that their product will not infringe XHANCE's listed patents, or that such patents are invalid, then they must send notice to us once the ANDA or 505(b)(2) NDA has been accepted for filing by the FDA. We may then initiate a patent infringement lawsuit in response to the notice of the Paragraph&#160;IV certification, which would automatically prevent the FDA from approving the ANDA or 505(b)(2) NDA until the earlier of 30&#160;months, expiration of the patent, settlement of the lawsuit, or a decision in the infringement case that is favorable to the ANDA or 505(b)(2) NDA applicant.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The rest of our patent portfolio largely relates to patents and applications owned by us and directed to Onzetra Xsail and other product candidates, and the powder EDS, liquid EDS and related technologies.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Trade Secrets and Other Proprietary Information</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We seek to protect our proprietary information, including our trade secrets and proprietary know-how, by requiring our employees, consultants and other advisors to execute confidentiality agreements upon the commencement of their employment or engagement. These agreements generally provide that all confidential information developed or made known during the course of the relationship with us be kept confidential and not be disclosed to third parties except in specific circumstances. In the case of our employees, the agreements also typically provide that all inventions resulting from work performed for us, utilizing our property or relating to our business and conceived or completed during employment shall be our exclusive property to the extent permitted by law. Where appropriate, agreements we obtain with our consultants also typically contain similar assignment of invention provisions. Further, we generally require confidentiality agreements from business partners and other third parties that receive our confidential information.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Trademarks</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also rely on trademarks and trade designs to develop and maintain our competitive position. OPTINOSE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, XHANCE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Exhalation Delivery System&#8482; and EDS</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are trademarks of ours in the U.S.  </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Licensing of the Exhalation Delivery System (Outside of ENT/Allergy Indications)</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Currax License Agreement</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 25, 2019, OptiNose AS, our wholly-owned subsidiary, entered into the Currax License Agreement. Under the terms of the Currax License Agreement, we granted Currax an exclusive license to certain OptiNose patents and a non-exclusive license to certain OptiNose know-how to use, sell, offer for sale, have sold and import Onzetra&#174; Xsail&#174; (sumatriptan nasal powder) in the U.S., Canada and Mexico. </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Currax License Agreement, we received a $3.7 million upfront payment in 2019, and an additional $0.75 million in December 2020 upon expiration of the escrow that was established for a limited period to cover potential indemnification obligations, and an additional $1.0 million milestone payment in January 2021 upon the achievement of a specified regulatory milestone.&#160;We do not expect to receive any further payments from Currax under the terms of the License Agreement other than reimbursement for certain expenses.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License Agreement with Centessa Pharmaceuticals</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 31, 2019, OptiNose AS entered into a licensing agreement with Inexia Limited (now Orexia Therapeutics, which is a wholly-owned subsidiary of Centessa Pharmaceuticals (the Centessa License Agreement).  Under the terms of the Centessa License Agreement, we granted Orexia an exclusive, royalty-bearing, worldwide, non-transferable, sublicensable license to the EDS and other intellectual property for the development, sale, import and manufacture of products containing orexin receptor agonist and/or orexin receptor positive modulator </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Contents</a></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">molecule(s) as the sole active pharmaceutical ingredient(s) for the treatment, diagnosis or prevention of human diseases or conditions associated primarily with orexin receptor agonism and orexin receptor positive modulation. The license excludes the treatment of any disease or condition affecting the ear, nose or throat, or the treatment of any disease or condition associated primarily with another receptor, other than the Orexin 1 and Orexin 2 receptors. Orexia is solely responsible for all costs and activities related to its identification, development and commercialization of products under the Centessa License Agreement. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Centessa License Agreement, we received a $0.5 million upfront payment. For each product developed under the Centessa License Agreement, we are eligible to receive up to $8.0 million of development milestone payments and up to $37.0 million of sales milestone payments. In addition, we are eligible to receive tiered, low-to-mid single digit royalties based on net sales of any products successfully developed and commercialized under the Centessa License Agreement. We do not anticipate the receipt of any milestone or royalty payments from Orexia in the near term. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Regulation</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to extensive regulation by the FDA and other federal, state, and local regulatory agencies. The Federal Food, Drug and Cosmetic Act (the FD&amp;C Act) and the FDA's implementing regulations set forth, among other things, requirements for the testing, development, manufacture, quality control, safety, effectiveness, approval, labeling, storage, record-keeping, reporting, distribution, import, export, sale, advertising and promotion of our products and product candidates. Although the discussion below focuses on regulation in the U.S., because that is currently our primary focus, we may seek approval for, and market, our products in other countries in the future. Generally, our activities in other countries will be subject to regulation that is similar in nature and scope as that imposed in the U.S., although there can be important differences.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Development and Approval</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the FD&amp;C Act, FDA approval of an NDA is required before any new drug can be marketed in the U.S. NDAs require extensive studies and submission of a large amount of data by the applicant.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Preclinical Testing.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Before testing any compound in human patients in the U.S., a company must generate extensive preclinical data. Preclinical testing generally includes laboratory evaluation of product chemistry and formulation, as well as toxicological and pharmacological studies in several animal species to assess the toxicity and dosing of the product. Certain animal studies must be performed in compliance with the FDA's Good Laboratory Practice (GLP) regulations and the U.S. Department of Agriculture's Animal Welfare Act.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">IND Application.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Human clinical trials in the U.S. cannot commence until an investigational new drug (IND) application is submitted and becomes effective. A company must submit preclinical testing results to the FDA as part of the IND, and the FDA must evaluate whether there is an adequate basis for testing the drug in initial clinical studies in human volunteers. Unless the FDA raises concerns, the IND becomes effective 30&#160;days following its receipt by the FDA, and the clinical trial proposed in the IND may begin. Once human clinical trials have commenced, the FDA may stop a clinical trial by placing it on "clinical hold" because of concerns about the safety of the product being tested, or for other reasons.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Clinical Trials.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Clinical trials involve the administration of a drug to healthy human volunteers or to patients, under the supervision of a qualified investigator. The conduct of clinical trials is subject to extensive regulation, including compliance with the FDA's bioresearch monitoring regulations and current Good Clinical Practice (cGCP) requirements, which establish standards for conducting, recording data from, and reporting the results of, clinical trials, and are intended to assure that the data and reported results are credible and accurate, and that the rights, safety, and well-being of study participants are protected. Clinical trials must be conducted under protocols that detail the study objectives, parameters for monitoring safety, and the efficacy criteria, if any, to be evaluated. Each protocol is reviewed by the FDA as part of the IND. In addition, each clinical trial must be reviewed and approved by, and conducted under the auspices of, an Institutional Review Board (IRB) for each clinical site. Companies sponsoring the clinical trials, investigators, and IRBs also must comply with, as applicable, regulations and guidelines for obtaining informed consent from the study patients, following the protocol and investigational plan, adequately monitoring the clinical trial, and timely reporting of adverse events (AEs). Foreign studies conducted under an IND must meet the same requirements that apply to studies being conducted in the U.S. Data from a foreign study not conducted under an IND may be submitted in support of an NDA if the study was conducted in accordance with cGCP and the FDA is able to validate the data.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A study sponsor is required to publicly post specified details about certain clinical trials and clinical trial results on government or independent websites (e.g.,&#160;http://clinicaltrials.gov). Human clinical trials typically are conducted in three sequential phases, although the phases may overlap, be combined, or be subdivided in some cases:</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Phase&#160;1 clinical trials involve the initial administration of the investigational drug to humans, typically to a small group of healthy human subjects, but occasionally to a group of patients with the targeted disease or disorder. Phase&#160;1 clinical trials generally are intended to evaluate the safety, metabolism and pharmacologic actions of the drug, the side effects associated with increasing doses, and, if possible, to gain early evidence of effectiveness.</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Phase&#160;2 clinical trials generally are controlled studies that involve a relatively small sample of the intended patient population, and are designed to develop initial data regarding the product's effectiveness, to determine dose response and the optimal dose range, and to gather additional information relating to safety and potential AEs.</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Phase&#160;3 clinical trials are conducted after preliminary evidence of effectiveness has been obtained, and are intended to gather the additional information about safety and effectiveness necessary to evaluate the drug's overall risk-benefit profile, and to provide a basis for physician labeling. Generally, Phase&#160;3 clinical development programs consist of expanded,multi-site, large-scale studies of patients with the target disease or disorder to obtain statistical evidence of the efficacy and safety of the drug at the proposed dosing regimen.Phase 3 data often form the core basis on which the FDA evaluates a drug&#8217;s safety and effectiveness when considering the product application.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The sponsoring company, the FDA, or the IRB may suspend or terminate a clinical trial at any time on various grounds, including a finding that the patients are being exposed to an unacceptable health risk. Further, success in early-stage clinical trials does not assure success in later-stage clinical trials. Data obtained from clinical activities are not always conclusive and may be subject to alternative interpretations that could delay, limit or prevent regulatory approval.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">NDA Submission and Review.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The FD&amp;C Act provides two pathways for the approval of new drugs through an NDA. An NDA under Section&#160;505(b)(1) of the FD&amp;C Act is a comprehensive application to support approval of a product candidate that includes, among other things, data and information to demonstrate that the proposed drug is safe and effective for its proposed uses, that production methods are adequate to ensure its identity, strength, quality, and purity of the drug, and that proposed labeling is appropriate and contains all necessary information. A 505(b)(1) NDA contains results of the full set of preclinical studies and clinical trials conducted by or on behalf of the applicant to characterize and evaluate the product candidate.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section&#160;505(b)(2) of the FD&amp;C Act provides an alternate regulatory pathway to obtain FDA approval that permits the filing of an NDA where at least some of the information required for approval comes from studies not conducted by or for the applicant and for which the applicant has not obtained a right of reference. The applicant may rely to some extent upon the FDA's findings of safety and effectiveness for an approved product that acts as the reference drug and submit its own product-specific data&#160;&#8212; which may include data from preclinical studies or clinical trials conducted by or on behalf of the applicant&#160;&#8212; to address differences between the product candidate and the reference drug. We obtained FDA approval of XHANCE through the Section&#160;505(b)(2) regulatory approval pathway, with Flonase&#8482; and Flovent HFA&#8482; as the reference drugs. Flonase&#8482; and Flovent HFA&#8482; contain fluticasone propionate, which is also the active ingredient in XHANCE.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The submission of an NDA under either Section&#160;505(b)(1) or Section&#160;505(b)(2) generally requires payment of a substantial user fee to the FDA. The FDA reviews applications to determine, among other things, whether a product is safe and effective for its intended use and whether the manufacturing controls are adequate to assure and preserve the product's identity, strength, quality, and purity. For some NDAs, the FDA may convene an advisory committee to seek insights and recommendations on issues relevant to approval of the application. Although the FDA is not bound by the recommendation of an advisory committee, the agency considers such recommendations carefully when making decisions.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product and product candidates include products that combine drug and device components in a manner that the FDA considers to meet the definition of a "combination product" under FDA regulations. The FDA exercises significant discretion over the regulation of combination products, including the discretion to require separate marketing applications for the drug and device components in a combination product. For XHANCE, FDA's Center for Drug Evaluation and Research (CDER) had primary jurisdiction for review of the NDA, and both the drug and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">device were reviewed under one marketing application. However, for a drug-device combination product CDER typically consults with the Center for Devices and Radiological Health in the NDA review process.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may determine that a Risk Evaluation and Mitigation Strategy (REMS) is necessary to ensure that the benefits of a new product outweigh its risks, and the product can therefore be approved. A REMS may include various elements, ranging from a medication guide or patient package insert to limitations on who may prescribe or dispense the drug, depending on what the FDA considers necessary for the safe use of the drug. Under the Pediatric Research Equity Act, certain applications for approval must also include an assessment, generally based on clinical study data, of the safety and effectiveness of the subject drug in relevant pediatric populations. Before approving an NDA, the FDA will inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with current Good Manufacturing Practice (cGMP) requirements and adequate to assure consistent production of the product within required specifications.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once the FDA accepts an NDA submission&#160;&#8212; which occurs, if at all, within 60&#160;days after submission of the NDA&#160;&#8212; the FDA's goal for a non-priority review of an NDA is ten months. The review process can be and often is significantly extended, however, by FDA requests for additional information, studies, or clarification. After review of an NDA and the facilities where the product is manufactured, the FDA either issues an approval letter or a complete response letter (CRL) outlining the deficiencies in the submission. The CRL may require additional testing or information, including additional preclinical or clinical data. Even if such additional information and data are submitted, the FDA may decide that the NDA still does not meet the standards for approval. Data from clinical trials are not always conclusive and the FDA may interpret data differently than the sponsor.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Obtaining regulatory approval often takes a number of years, involves the expenditure of substantial resources, and depends on a number of factors, including the severity of the disease in question, the availability of alternative treatments, and the risks and benefits demonstrated in clinical trials. Additionally, as a condition of approval, the FDA may impose restrictions that could affect the commercial success of a drug or require post-approval commitments, including the completion within a specified time period of additional clinical studies, which often are referred to as "Phase&#160;4" or "post-marketing" studies. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Post-approval modifications to the drug, such as changes in indications, labeling, or manufacturing processes or facilities, may require a sponsor to develop additional data or conduct additional preclinical studies or clinical trials, to be submitted in a new or supplemental NDA, which would require FDA approval. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Post-Approval Regulation</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once approved, drug products are subject to continuing regulation by the FDA. If ongoing regulatory requirements are not met or if safety or manufacturing problems occur after the product reaches the market, the FDA may at any time withdraw product approval or take actions that would limit or suspend marketing. Additionally, the FDA may require post-marketing studies or clinical trials, changes to a product&#8217;s approved labeling, including the addition of new warnings and contraindications, or the implementation of other risk management measures, including distribution-related restrictions, if there are new safety information developments.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Good Manufacturing Practices.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Companies engaged in manufacturing drug products or their components must comply with applicable cGMP requirements and product-specific regulations enforced by the FDA and other regulatory agencies. Compliance with cGMP includes adhering to requirements relating to organization and training of personnel, buildings and facilities, equipment, control of components and drug product containers and closures, production and process controls, quality control and quality assurance, packaging and labeling controls, holding and distribution, laboratory controls, and records and reports. The FDA regulates and inspects equipment, facilities, and processes used in manufacturing pharmaceutical products prior to approval. If, after receiving approval, a company makes a material change in manufacturing equipment, location, or process (all of which are, to some degree, incorporated in the NDA), additional regulatory review and approval may be required. The FDA also conducts regular, periodic visits to re-inspect equipment, facilities, and processes following the initial approval of a product. Failure to comply with applicable cGMP requirements and conditions of product approval may lead the FDA to take enforcement action or seek sanctions, including fines, issuance of warning letters, civil penalties, injunctions, suspension of manufacturing operations, operating restrictions, withdrawal of FDA approval, seizure or recall of products, and criminal prosecution. Although we periodically monitor the FDA compliance of our third-party manufacturers, we cannot be certain that our present or future third-party manufacturers will consistently comply with cGMP and other applicable FDA regulatory requirements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also need to comply with some of the FDA's manufacturing and safety regulations for devices.  In addition to cGMP, the FDA requires that our drug-device combination product comply with the Quality System Regulation (QSR), which sets forth the FDA's manufacturing quality standards for medical devices.  The FDA also requires that we comply with some device safety reporting requirements for our drug-device combination product. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Advertising and Promotion.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The FDA and other federal regulatory agencies closely regulate the marketing and promotion of drugs through, among other things, standards and regulations for direct-to-consumer advertising, advertising and promotion to healthcare professionals, communications regarding unapproved uses, industry-sponsored scientific and educational activities, and promotional activities involving the Internet. A product cannot be commercially promoted before it is approved. After approval, product promotion can include only those claims relating to safety and effectiveness that are consistent with the labeling approved by the FDA. Healthcare providers are permitted to prescribe drugs for "off-label" uses&#160;&#8212; that is, uses not approved by the FDA and not described in the product's labeling&#160;&#8212; because the FDA does not regulate the practice of medicine. However, FDA regulations impose restrictions on manufacturers' communications regarding off-label uses. Broadly speaking, a manufacturer may not promote a drug for off-label use, but under certain conditions may engage in non-promotional, balanced, scientific communication regarding off-label use. In addition to FDA restrictions on marketing of pharmaceutical products, state and federal fraud and abuse laws have been applied to restrict certain marketing practices in the pharmaceutical industry. Failure to comply with applicable FDA requirements and restrictions in this area may subject a company to adverse publicity and enforcement action by the FDA, the Department of Justice, or the Office of the Inspector General of the Department of Health and Human Services, as well as state authorities. This could subject a company to a range of penalties that could have a significant commercial impact, including civil and criminal fines and agreements that materially restrict the manner in which a company promotes or distributes a drug.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Requirements.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;NDA holders must comply with other regulatory requirements, including submitting annual reports, reporting information about adverse drug experiences, and maintaining certain records.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Hatch-Waxman Act</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Drug Price Competition and Patent Term Restoration Act of 1984 (the Hatch-Waxman Act) establishes two abbreviated approval pathways for pharmaceutical products that are in some way follow-on versions of already approved products.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Generic Drugs.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;A generic version of an approved drug is approved by means of an ANDA, by which the sponsor demonstrates that the proposed product is the same as the approved, brand-name drug, which is referred to as the reference listed drug (RLD). Generally, an ANDA must contain data and information showing that the proposed generic product and RLD (i)&#160;have the same active ingredient, in the same strength and dosage form, to be delivered via the same route of administration, (ii)&#160;are intended for the same uses, and (iii)&#160;are bioequivalent. This is instead of independently demonstrating the proposed product's safety and effectiveness, which are inferred from the fact that the product is the same as the RLD, which the FDA previously found to be safe and effective.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">505(b)(2) NDAs.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;As discussed above, if a product is similar, but not identical, to an already approved product, it may be submitted for approval via an NDA under section&#160;505(b)(2) of the FD&amp;C Act. Unlike an ANDA, this does not excuse the sponsor from demonstrating the proposed product's safety and effectiveness. Rather, the sponsor is permitted to rely to some degree on information from investigations that were not conducted by or for the applicant and for which the applicant has not obtained a right of reference, and must submit its own product-specific data of safety and effectiveness to an extent necessary because of the differences between the products. An NDA approved under 505(b)(2) may in turn serve as an RLD for subsequent applications from other sponsors.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">RLD Patents.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In an NDA, a sponsor must identify patents that claim the drug substance or drug product or a method of using the drug. When the drug is approved, those patents are among the information about the product that is listed in the FDA publication, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Approved Drug Products with Therapeutic Equivalence Evaluations</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which is referred to as the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Orange Book</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The sponsor of an ANDA or 505(b)(2) application seeking to rely on an approved product as the RLD must make one of several certifications regarding each listed patent. A &#8220;Paragraph I&#8221; certification is the sponsor&#8217;s statement that patent information has not been filed for the RLD. A &#8220;Paragraph II&#8221; certification is the sponsor&#8217;s statement that the RLD&#8217;s patents have expired. A "Paragraph&#160;III" certification is the sponsor's statement that it will wait for the patent to expire before obtaining approval for its product. A "Paragraph&#160;IV" certification is an assertion that the patent does not block approval of the later product, either because the patent is invalid or unenforceable or because the patent, even if valid, is not infringed by the new product.  </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Regulatory Exclusivities.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The Hatch-Waxman Act provides periods of regulatory exclusivity for products that would serve as RLDs for an ANDA or 505(b)(2) application. If a product is a "new chemical entity," or NCE&#160;&#8212; generally meaning that the active moiety has never before been approved in any drug&#160;&#8212; there is a period of five years from the product's approval during which the FDA may not accept for filing any ANDA or 505(b)(2) application for a drug with the same active moiety. An ANDA or 505(b)(2) application may be submitted after four years, however, if the sponsor of the application makes a Paragraph&#160;IV certification.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A product that is not an NCE may qualify for a three-year period of exclusivity if the NDA contains new clinical data, (other than bioavailability studies) derived from studies conducted by or for the sponsor, that were necessary for approval. In that instance, the exclusivity period does not preclude filing or review of an ANDA or 505(b)(2) application; rather, the FDA is precluded from granting final approval to the ANDA or 505(b)(2) application until three years after approval of the RLD. Additionally, the exclusivity applies only to the conditions of approval that required submission of the clinical data.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once the FDA accepts for filing an ANDA or 505(b)(2) application containing a Paragraph&#160;IV certification, the applicant must within 20&#160;days provide notice to the RLD or listed drug NDA holder and patent owner that the application has been submitted, and provide the factual and legal basis for the applicant's assertion that the patent is invalid or not infringed. If the NDA holder or patent owner files suit against the ANDA or 505(b)(2) applicant for patent infringement within 45&#160;days of receiving the Paragraph&#160;IV notice, the FDA is prohibited from approving the ANDA or 505(b)(2) application for a period of 30&#160;months or the resolution of the underlying suit, whichever is earlier. If the RLD has NCE exclusivity and the notice is given and suit filed during the fifth year of exclusivity, the regulatory stay extends until 7.5 years after the RLD approval. The FDA may approve the proposed product before the expiration of the regulatory stay if a court finds the patent invalid or not infringed or if the court shortens the period because the parties have failed to cooperate in expediting the litigation.  In connection with the submission of our sNDA for XHANCE in February 2023, we provided Paragraph IV certification notices to the NDA holder and patent owner of the two unexpired Orange Book-listed patents covering Flovent HFA. As noted above, these parties have 45 days from receiving the Paragraph IV certification notices to file a patent infringement suit which would prohibit the FDA from approving our sNDA for up to 30-months.    </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If the RLD has NCE exclusivity and the notice is given and suit filed during the fifth year of exclusivity, the regulatory stay extends until 7.5 years after the RLD approval. The FDA may approve the proposed product before the expiration of the regulatory stay if a court finds the patent invalid or not infringed or if the court shortens the period because the parties have failed to cooperate in expediting the litigation.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Patent Term Restoration.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;A portion of the patent term lost during product development and FDA review of an NDA is restored if approval of the application is the first permitted commercial marketing of a drug containing the active ingredient. The patent term restoration period is generally one-half the time between the effective date of the IND or the date of patent grant (whichever is later) and the date of submission of the NDA, plus the time between the date of submission of the NDA and the date of FDA approval of the product. The maximum period of restoration is five years, and the patent cannot be extended to more than 14&#160;years from the date of FDA approval of the product. Only one patent claiming each approved product is eligible for restoration and the patent holder must apply for restoration within 60&#160;days of approval. The U.S. Patent and Trademark Office (USPTO) in consultation with the FDA, reviews and approves the application for patent term restoration. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Exclusivities</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pediatric Exclusivity.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Section&#160;505A of the FD&amp;C Act provides for six months of additional exclusivity or patent protection if an NDA sponsor submits pediatric data that fairly respond to a written request from the FDA for such data. The data does not need to show that the product is effective in the pediatric population studied; rather, if the clinical trial is deemed to fairly respond to the FDA's request, the additional protection is granted. If reports of requested pediatric studies are submitted to and accepted by FDA within the statutory time limits, whatever statutory or regulatory periods of exclusivity or </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Orange Book</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> listed patent protection that cover the drug are extended by six months. This is not a patent term extension, but it effectively extends the regulatory period during which the FDA cannot approve an ANDA or 505(b)(2) application owing to regulatory exclusivity or listed patents. When any product is approved, we will evaluate seeking pediatric exclusivity as appropriate.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Orphan Drug Exclusivity.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The Orphan Drug Act provides incentives for the development of drugs intended to treat rare diseases or conditions, which generally are diseases or conditions affecting less than 200,000 individuals in the U.S. If a sponsor demonstrates that a drug product qualifies for orphan drug designation, the FDA grants orphan drug designation to the product for that use. The benefits of orphan drug designation include research and development tax credits and exemption from user fees. A drug that is approved for the orphan drug designated </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">indication generally is granted seven years of orphan drug exclusivity. During that period, the FDA generally may not approve any other application for the same product for the same indication, although there are exceptions, most notably when the later product is shown to be clinically superior to the product with exclusivity. The FDA can revoke a product&#8217;s orphan drug exclusivity under certain circumstances, including when the product sponsor is unable to assure the availability of sufficient quantities of the product to meet patient needs. Orphan drug exclusivity does not prevent the FDA from approving a different drug for the same disease or condition, or the same drug for a different disease or condition.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">U.S. Healthcare Reform  </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Patient Protection and Affordable Care Act, as amended (the "Affordable Care Act"), is a sweeping measure intended to expand healthcare coverage within the U.S., primarily through the imposition of health insurance mandates on employers and individuals and expansion of the Medicaid program. This law substantially changed the way healthcare is financed by both governmental and private insurers and significantly impacts the pharmaceutical industry. Changes that may affect our business include those governing enrollment in federal healthcare programs, reimbursement changes, benefits for patients within a coverage gap in the Medicare Part&#160;D prescription drug program (commonly known as the "donut hole"), rules regarding prescription drug benefits under the health insurance exchanges, changes to the Medicaid Drug Rebate program, expansion of the Public Health Service Act's 340B drug pricing program (340B Program), fraud and abuse, and enforcement. These changes impact existing government healthcare programs and have resulted in the development of new programs, including Medicare payment for performance initiatives. Details of the changes to the Medicaid Drug Rebate program and the 340B Program are discussed under the risk factor "</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">If we fail to comply with our reporting and payment obligations under the Medicaid drug rebate program, or other governmental pricing programs, we could be subject to additional reimbursement requirements, penalties, sanctions and fines which could have a material adverse effect on our business, financial condition, results of operations and growth prospects</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">" in the "Risk Factors" section of this Annual Report on Form 10-K.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some states have elected not to expand their Medicaid programs to individuals with an income of up to 133% of the federal poverty level, as is permitted under the Affordable Care Act. For each state that does not choose to expand its Medicaid program, there may be fewer insured patients overall, which could impact our sales of products and product candidates for which we receive regulatory approval, and our business and financial condition. Where new patients receive insurance coverage under any of the new Medicaid options made available through the Affordable Care Act, the possibility exists that manufacturers may be required to pay Medicaid rebates on drugs used under these circumstances, a decision that could impact manufacturer revenues. </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain provisions of the Affordable Care Act have been subject to judicial challenges, as well as efforts to modify them or to alter their interpretation and implementation. For example, on December 22, 2017, the U.S. government signed into law comprehensive tax legislation, referred to as the Tax Cuts and Jobs Act (the Tax Act), which includes a provision repealing, effective January 1, 2019, the tax-based shared responsibility payment imposed by the Affordable Care Act on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the &#8220;individual mandate.&#8221; Further, the Bipartisan Budget Act of 2018, among other things, amended the Medicare statute to reduce the coverage gap in most Medicare drug plans, commonly known as the &#8220;donut hole,&#8221; by raising the required manufacturer point-of-sale discount for pharmaceutical manufacturers who participate in Medicare Part D  from 50% to 70% off the negotiated price effective as of January 1, 2019. The IRA (defined below) replaces the Part D coverage gap discount program with a new Part D manufacturer discount program beginning in 2025.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">It is unclear how efforts to modify or invalidate the Affordable Care Act or its implementing regulations, or portions thereof, will affect the Affordable Care Act or our business.  Additional legislative changes, regulatory changes, and further judicial challenges related to the Affordable Care Act remain possible. Any such changes could decrease the number of individuals with health coverage. It is possible that the Affordable Care Act, as currently enacted or as it or its implementation may be modified in the future, and other healthcare reform measures that may be adopted in the future, could have a material adverse effect on our industry generally and on our ability to maintain or increase sales of our products or product candidates for which we receive regulatory approval or to successfully commercialize our products and product candidates.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, on December 20, 2019, then-President Trump signed the Further Consolidated Appropriations Act for 2020 into law (P.L. 116-94) that includes a piece of bipartisan legislation called the Creating and Restoring Equal Access to Equivalent Samples Act of 2019 or &#8220;the CREATES Act.&#8221; The CREATES Act aims to address the concern articulated by both the FDA and others in the industry that some brand manufacturers have improperly restricted the distribution of their products, including by invoking the existence of a REMS for certain products, to deny generic </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">product developers access to samples of brand products. Because generic product developers need samples to conduct certain comparative testing required by the FDA, some have attributed the inability to timely obtain samples as a cause of delay in the entry of generic products. To remedy this concern, the CREATES Act establishes a private cause of action that permits a generic product developer to sue the brand manufacturer to compel it to furnish the necessary samples on &#8220;commercially reasonable, market-based terms.&#8221;  In 2021 and 2022 we provided units of XHANCE to a generic manufacturer in compliance with the CREATES Act.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Coverage and Reimbursement </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant uncertainty exists as to the coverage and reimbursement status of our products and any product candidates for which we may obtain regulatory approval. Sales of any of our products and product candidates, if approved, will depend, in part, on the extent to which the costs of the products will be covered by third-party payors, including government healthcare programs such as Medicare and Medicaid, and private payors, such as commercial health insurers and managed care organizations. Third-party payors determine which drugs they will cover and the amount of reimbursement they will provide for a covered drug. In the U.S., there is no uniform system among payors for making coverage and reimbursement decisions. In addition, the process for determining whether a payor will provide coverage for a product may be separate from the process for setting the price or reimbursement rate that the payor will pay for the product once coverage is approved. Third-party payors may limit coverage to specific products on an approved list, or formulary, which might not include all of the FDA-approved products for a particular indication.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to secure coverage and reimbursement for our products we may need to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of the product, in addition to the costly studies required to obtain FDA or other comparable regulatory approvals. Even if we conduct pharmacoeconomic studies, our products and product candidates may not be considered medically necessary or cost-effective by payors. Further, a payor's decision to provide coverage for a product does not imply that an adequate reimbursement rate will be approved.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the past, payors have implemented reimbursement metrics and periodically revised those metrics as well as the methodologies used as the basis for reimbursement rates or rebates, such as average sales price (ASP), average manufacturer price (AMP), and actual acquisition cost. The existing data for reimbursement based on these metrics is relatively limited, although certain states have begun to survey acquisition cost data for the purpose of setting Medicaid reimbursement rates. The Centers for Medicare and Medicaid Services (CMS) surveys and publishes retail pharmacy acquisition cost information in the form of National Average Drug Acquisition Cost files to provide state Medicaid agencies with a basis of comparison for their own reimbursement and pricing methodologies and rates.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Participation in the Medicaid Drug Rebate Program requires us to pay a rebate for each unit of drug reimbursed by Medicaid. The amount of the "basic" portion of the rebate for each product is set by law as the larger of: (i)&#160;23.1% of quarterly AMP, or (ii)&#160;the difference between quarterly AMP and the quarterly best price (Best Price), which, in general, represents the lowest price available from the manufacturer to any entity in the U.S. in any pricing structure, calculated to include all applicable sales and associated rebates, discounts and other price concessions. AMP must be reported on a monthly and quarterly basis, and Best Price is reported on a quarterly basis, to CMS, the federal agency that administers the Medicaid Drug Rebate Program. In addition, the rebate also includes the "additional" portion, which adjusts the overall rebate amount upward as an "inflation penalty" when the drug's latest quarter's AMP exceeds the drug's AMP from the first full quarter of sales after launch, adjusted for increases in the Consumer Price Index-Urban. The upward adjustment in the rebate amount per unit is equal to the excess amount of the current AMP over the inflation-adjusted AMP from the first full quarter of sales. The rebate amount is recomputed each quarter based on our report to CMS of current quarterly AMP and Best Price for the relevant drug. On March 11, 2021, President Biden signed the American Rescue Plan Act of 2021 into law, which eliminates the statutory Medicaid drug rebate cap, currently set at 100% of AMP, for single-source and innovator multiple-source drugs, beginning January 1, 2024.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The terms of our participation in the Medicaid Drug Rebate Program require us to report revisions to AMP or Best Price within a period not to exceed 12 quarters from the quarter in which the data was originally due, and CMS may request or require restatements for earlier periods as well. Any such revisions could have the impact of increasing or decreasing our rebate liability for prior quarters, depending on the direction of the revision.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Affordable Care Act made significant changes to the Medicaid Drug Rebate Program, and CMS issued a final regulation, which became effective on April 1, 2016, to implement the changes to the Medicaid Drug Rebate program under the Affordable Care Act. On December 21, 2020, CMS issued a final regulation that (i) modified existing Medicaid Drug Rebate Program regulations to permit reporting multiple Best Price figures with regard to value&#8209;based purchasing </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Contents</a></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">arrangements; and (ii) provided definitions for &#8220;line extension,&#8221; &#8220;new formulation,&#8221; and related terms with the practical effect of expanding the scope of drugs considered to be line extensions, with such changes taking effect in 2022. Our failure to comply with the aforementioned price reporting and rebate obligations, as well as pharmacy benefit manager &#8220;accumulator&#8221; programs, could negatively impact our financial results. In addition, statutory and regulatory changes or other agency action regarding the Medicaid Drug Rebate Program could negatively affect our financial results or expand our rebate liability.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Manufacturers have obligations to report the ASP to the Medicare Program as a part of the agreement to participate in the Medicaid Drug Rebate Program. For calendar quarters beginning January 1, 2022, manufacturers will need to report the ASP for certain drugs under the Medicare program regardless of whether they participate in the Medicaid Drug Rebate Program. Statutory or regulatory changes or CMS guidance could affect the ASP for products and the resulting Medicare payment rate, and could negatively affect results of operations.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal law requires that any manufacturer that participates in the Medicaid Drug Rebate Program also participate in the 340B Program in order for federal funds to be available for the manufacturer's drugs under Medicaid and Medicare Part&#160;B. The 340B Program, which is administered by the Health Resource and Services Administration (HRSA) requires participating manufacturers to agree to charge statutorily defined covered entities no more than the 340B "ceiling price" for the manufacturer's covered outpatient drugs. These 340B covered entities include a variety of community health clinics and other entities that receive health services grants from the Public Health Service, as well as hospitals that serve a disproportionate share of low-income patients. The 340B ceiling price is calculated using a statutory formula, which is based on the AMP and rebate amount for the covered outpatient drug as calculated under the Medicaid Drug Rebate Program. Any changes to the definition of AMP and the Medicaid rebate amount under federal legislation could affect our 340B ceiling price calculations and negatively impact our results of operations. HRSA issued a final regulation regarding the calculation of the 340B ceiling price and the imposition of civil monetary penalties on manufacturers that knowingly and intentionally overcharge covered entities, which became effective on January 1, 2019.  It is currently unclear how HRSA will apply its enforcement authority under the regulation. HRSA also has implemented a ceiling price reporting requirement related to the 340B Program under which we are required to report 340B ceiling prices to HRSA on a quarterly basis, and HRSA then publishes that information to covered entities. Moreover, under a final regulation effective January 13, 2021, HRSA newly established an administrative dispute resolution, or ADR, process for claims by covered entities that a manufacturer has engaged in overcharging, and by manufacturers that a covered entity violated the prohibitions against diversion or duplicate discounts. Such claims are to be resolved through an ADR panel of government officials rendering a decision that could be appealed only in federal court. An ADR proceeding could subject us to onerous procedural requirements and could result in additional liability. In addition, legislation may be introduced that, if passed, would further expand the 340B Program to additional covered entities or would require participating manufacturers to agree to provide 340B discounted pricing on drugs used in an inpatient setting.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S. Medicare program, outpatient prescription drugs may be covered under Medicare Part&#160;D. Medicare Part&#160;D is a voluntary prescription drug benefit, through which Medicare beneficiaries may enroll in prescription drug plans offered by private entities for coverage of outpatient prescription drugs. Part&#160;D plans include both stand-alone prescription drug benefit plans and prescription drug coverage as a supplement to Medicare Advantage plans provided for under Medicare Part&#160;C.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Coverage and reimbursement for covered outpatient drugs under Part&#160;D are not standardized. Part&#160;D prescription drug plan sponsors are not required to pay for all covered Part&#160;D drugs, and each drug plan can develop its own drug formulary that identifies which drugs it will cover and at what tier or level. Any formulary used by a Part&#160;D prescription drug plan must be developed and reviewed by a pharmacy and therapeutic committee. Although Part&#160;D prescription drug formularies must include drugs within each therapeutic category and class of covered Part&#160;D drugs, they have some flexibility to establish those categories and classes and are not required to cover all of the drugs in each category or class. Medicare Part&#160;D prescription drug plans may use formularies to limit the number of drugs that will be covered in any therapeutic class and/or impose differential cost sharing or other utilization management techniques.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The availability of coverage under Medicare Part&#160;D may increase demand for our products and any product candidates for which we receive marketing approval. However, in order for the products that we market to be included on the formularies of Part&#160;D prescription drug plans, we likely will have to offer pricing that is lower than the prices we might otherwise obtain. Changes to Medicare Part&#160;D that give plans more freedom to limit coverage or manage utilization, and other cost reduction initiatives in the program could decrease the coverage and price that we receive for any approved products and could harm our business.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, manufacturers are required to provide to CMS a 70% discount on brand name prescription drugs utilized by Medicare Part D beneficiaries when those beneficiaries are in the coverage gap phase of the Part D benefit design. Civil monetary penalties can be applied if a manufacturer fails to provide discounts in the amount of 125% of the discount that was due. Congress could enact legislation that sunsets this discount program and replaces it with a new manufacturer discount program.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to be eligible to have our products or any future products paid for with federal funds under the Medicaid and Medicare Part&#160;B programs, as applicable, and purchased by certain federal agencies and grantees, we also participate in the U.S. Department of Veterans Affairs (VA) Federal Supply Schedule (FSS) pricing program. Under this program, we are obligated to make our "innovator" drugs available for procurement on an FSS contract and charge a price to four federal agencies&#160;&#8212; the VA, U.S. Department of Defense (DoD) Public Health Service and U.S. Coast Guard&#160;&#8212; that is no higher than the statutory Federal Ceiling Price (FCP). The FCP is based on the non-federal average manufacturer price (Non-FAMP), which we calculate and report to the VA on a quarterly and annual basis. We also participate in the Tricare Retail Pharmacy program, under which we pay quarterly rebates on utilization of innovator products that are dispensed through the Tricare Retail Pharmacy network to Tricare beneficiaries. The rebates are calculated as the difference between the annual Non-FAMP and FCP.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pricing and rebate calculations vary across products and programs, are complex, and are often subject to interpretation by us, governmental or regulatory agencies, and the courts. Significant civil monetary penalties can be applied if we are found to have knowingly submitted any false AMP, best price, or Non-FAMP information to the government or fail to submit the required price data on a timely basis. Such conduct also could be grounds for CMS to terminate the Medicaid drug rebate agreement, in which case federal payments may not be available under Medicaid or Medicare Part&#160;B for our covered outpatient drugs. Civil monetary penalties could also be applied if we are found to have charged 340B covered entities more than the statutorily mandated ceiling price. In addition, claims submitted to federally-funded healthcare programs, such as Medicare and Medicaid, for drugs priced based on incorrect pricing data provided by a manufacturer can implicate the False Claims Act.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The containment of healthcare costs has become a priority of federal, state and foreign governments, and the prices of drugs have been a focus in this effort. The U.S. government, state legislatures, and foreign governments have shown significant interest in implementing cost-containment programs to limit the growth of government-paid healthcare costs, including price controls, restrictions on reimbursement, and requirements for substitution of generic products for branded prescription drugs. For example, Congress could enact a drug price negotiation program under which the prices for certain high Medicare spend single source drugs would be capped by reference to the non-federal AMP. This or any other legislative change could impact the market conditions for our products. We expect continued scrutiny on government price reporting and pricing more generally from Congress, agencies, and other bodies and are seeing an increase in state interest in price reporting, transparency, and other policies to address drug pricing concerns.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Beginning April&#160;1, 2013, Medicare payments for all items and services, including drugs, were reduced by, on average, 2% per fiscal year under the sequestration (i.e.,&#160;automatic spending reductions) required by the Budget Control Act of 2011, as amended by the American Taxpayer Relief Act of 2012. Sequestration is currently set at 2% and will increase to 2.25% for the first half of fiscal year 2030, to 3% for the second half of fiscal year 2030, and to 4% for the remainder of the sequestration period that last through the first six months of fiscal year 2031. As long as these cuts remain in effect, they could adversely impact payment for any of our products that are reimbursed under Medicare. Other legislative or regulatory cost containment legislation could have a similar effect.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, the Affordable Care Act may reduce the profitability of drug products. It expanded manufacturers' rebate liability under the Medicaid program from fee-for-service Medicaid utilization to include the utilization of Medicaid managed care organizations as well, and increased the minimum Medicaid rebate due for most innovator drugs.  The Affordable Care Act and subsequent legislation also changed the definition of AMP. On February&#160;1, 2016, CMS issued final regulations to implement the changes to the Medicaid Drug Rebate Program under the Affordable Care Act. These regulations became effective on April&#160;1, 2016.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 16, 2022, President Biden signed into law the Inflation Reduction Act of 2022, or the IRA, which, among other things, establishes a Medicare Part B inflation rebate scheme, under which, generally speaking, manufacturers will owe rebates if the average sales price of a Part B drug increases faster than the pace of inflation. Failure to timely pay a Part B inflation rebate is subject to a civil monetary penalty. The IRA also establishes a Medicare Part D inflation rebate scheme, under which, generally speaking, manufacturers will owe rebates if the AMP of a Part D drug increases faster than the pace of inflation. The IRA also creates a drug price negotiation program under which the prices for Medicare units of certain high Medicare spend drugs and biologics without generic or biosimilar competition will be capped by reference to, among other things, a specified non-federal AMP, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Contents</a></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">starting in 2026. Failure to comply with requirements under the drug price negotiation program is subject to an excise tax and/or a civil monetary penalty. The IRA further makes changes to the Medicare Part D benefit, including a limit on annual out-of-pocket costs, and a change in manufacturer liability under the program that could negatively affect the profitability of our products. Failure to pay a discount under this new program will be subject to a civil monetary penalty. Congress continues to examine various policy proposals that may result in pressure on the prices of prescription drugs in the government health benefit programs. The IRA or other legislative change could impact the market conditions for our products. Payment methodologies may be subject to changes in healthcare legislation and regulatory initiatives as well. For example, CMS may develop new payment and delivery models, such as bundled payment models.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Affordable Care Act requires pharmaceutical manufacturers of branded prescription drugs to pay a branded prescription drug fee to the federal government. Each such manufacturer pays a prorated share of the branded prescription drug fee of $2.8&#160;billion in fee year 2020 and subsequent fee years, based on the dollar value of its branded prescription drug sales to certain federal programs identified in the law. The Affordable Care Act also expanded the Public Health Service's 340B Program to include additional types of covered entities. Substantial new provisions affecting compliance have also been enacted, which may affect our business practices with healthcare practitioners. It appears likely that the Affordable Care Act will continue the pressure on pharmaceutical pricing, especially under the Medicare and Medicaid programs, and may also increase our regulatory burdens and operating costs.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional legislative changes, regulatory changes and judicial challenges related to the Affordable Care Act remain possible, as discussed above under the heading "U.S. Healthcare Reform." In addition, there likely will continue to be proposals by legislators at both the federal and state levels, regulators, and third-party payors to contain healthcare costs. Thus, even if we obtain favorable coverage and reimbursement status for our products and any product candidates for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional information regarding these programs is discussed under the risk factor "</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">If we fail to comply with our reporting and payment obligations under the Medicaid drug rebate program, or other governmental pricing programs, we could be subject to additional reimbursement requirements, penalties, sanctions and fines which could have a material adverse effect on our business, financial condition, results of operations and growth prospects</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">" in the "Risk Factors" section of this Annual Report on Form 10-K.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Healthcare Fraud and Abuse Laws</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to FDA restrictions on marketing of pharmaceutical products, our business is subject to healthcare fraud and abuse regulation and enforcement by both the federal government and the states in which we conduct our business. These laws include, but are not limited to, the following:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">The federal Anti-Kickback Statute prohibits, among other things, knowingly and willfully offering, paying, soliciting or receiving remuneration, directly or indirectly, in cash or in kind, to induce or in return for purchasing, leasing, ordering or arranging for or recommending the purchase, lease or order of any healthcare item or service reimbursable, in whole or in part, under Medicare, Medicaid or other federally financed healthcare programs. This statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on one hand and prescribers, purchasers, and formulary managers on the other. A violation of the Anti-Kickback Statute may be established without proving actual knowledge of the statute or specific intent to violate it. In addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal civil False Claims Act. Violations of the federal Anti-Kickback Statute are punishable by imprisonment, criminal fines, damages, civil monetary penalties, and exclusion from participation in federal healthcare programs. Although there are a number of statutory exceptions and regulatory safe harbors protecting certain common activities from prosecution, the exceptions and safe harbors are drawn narrowly and practices that involve remuneration intended to induce prescribing, purchasing, or recommending pharmaceuticals, including certain discounts, or engaging such individuals as consultants, speakers or advisors, may be subject to scrutiny if they do not fit squarely within the exception or safe harbor. Our practices may not in all cases meet all of the criteria for safe harbor protection from anti-kickback liability. Moreover, there are no safe harbors for many common practices, such as educational and research grants, charitable donations, product support and patient assistance programs. Arrangements that implicate the Anti-Kickback Statute and do not fit within an exception or safe harbor are reviewed on a case-by-case basis to determine whether, based on the facts and circumstances, they violate the statute.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The federal civil False Claims Act prohibits any person from, among other things, knowingly presenting, or causing to be presented, a false or fraudulent claim for payment of government funds, or knowingly making, using, or causing to be made or used, a false record or statement material to an obligation to pay money to the government or knowingly concealing or knowingly and improperly avoiding, decreasing, or concealing an obligation to pay money to the U.S. federal government. Actions under the False Claims Act may be brought by private individuals known as qui tam relators in the name of the government, and who may share in any monetary recovery. In recent years, several pharmaceutical and other healthcare companies have faced enforcement actions under the False Claims Act for, among other things, providing free product to customers with the expectation that the customers would bill federal programs for the product, and other interactions with prescribers and other customers including interactions that may have affected customers' billing or coding practices on claims submitted to the federal government. Other companies have faced enforcement actions for causing false claims to be submitted because of the company's marketing the product for unapproved, and thus non-reimbursable, uses. Federal enforcement agencies also have shown increased interest in pharmaceutical companies' product and patient assistance programs, including reimbursement and co-pay support services, and a number of investigations into these programs have resulted in significant civil and criminal settlements.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Health Insurance Portability and Accountability Act of 1996 and its implementing regulations (collectively, HIPAA), prohibits, among other things, knowingly and willfully executing a scheme to defraud any healthcare benefit program, including private third-party payors. HIPAA also prohibits knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement or representation, or making or using any false writing or document knowing the same to contain any materially false, fictitious or fraudulent statement or entry in connection with the delivery of or payment for healthcare benefits, items or services. HIPAA also imposes requirements relating to the privacy, security and transmission of individually identifiable health information. HIPAA imposes privacy and security obligations on covered entity health care providers, health plans, and health care clearinghouses, as well as their "business associates" &#8211; certain persons or entities that create, receive, maintain, or transmit protected health information in connection with providing a specified service or performing a function on behalf of a covered entity. HIPAA has four tiers of civil monetary penalties and grants state attorneys enforcement authority. The Department of Justice also may impose criminal penalties. Additionally, certain states have adopted comparable privacy and security laws and regulations, some of which may be more stringent than HIPAA, and numerous federal and state laws, including state data breach notification laws, state health information privacy laws, and federal and state consumer protection laws, including, for example, Section 5 of the Federal Trade Commission Act, as amended, and the California Consumer Privacy Act (CCPA), govern the collection, use, and disclosure and protection of certain health-related and other personal information.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Although we are not directly subject to HIPAA, other than potentially with respect to providing certain employee benefits, we may obtain health information from third parties that are subject to privacy and security requirements under HIPAA, and other privacy and data security and consumer protection laws, and we could potentially be subject to criminal penalties if we, our affiliates, or our agents knowingly receive individually identifiable health information maintained by a HIPAA-covered entity in a manner that is not authorized or permitted by HIPAA, and could also potentially be subject to other civil and/or criminal penalties if we obtain, use or disclose information in a manner not permitted by other privacy and data security and consumer protection laws.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The majority of states also have statutes or regulations similar to the federal anti-kickback and false claims laws, which apply to items and services reimbursed under Medicaid and other state programs, or, in several states, apply regardless of the payor. Several states now require pharmaceutical companies to report expenses relating to the marketing and promotion of pharmaceutical products in those states and to report gifts and payments to individual health care providers in those states. Some of these states also prohibit certain marketing-related activities including the provision of gifts, meals, or other items to certain health care providers. Other states have laws requiring pharmaceutical sales representatives to be registered or licensed, and still others impose limits on co-pay assistance that pharmaceutical companies can offer to patients. In addition, several states require pharmaceutical companies to implement compliance programs or marketing codes.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Physician Payments Sunshine Act, implemented as the Open Payments program, and its implementing regulations, requires manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children's Health Insurance Program (with certain exceptions) to </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Contents</a></span></div></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">report annually to CMS information related to direct or indirect payments and other transfers of value to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), other healthcare professionals (such as physician assistants and nurse practitioners) and teaching hospitals, as well as ownership and investment interests held in the company by physicians and their immediate family members. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compliance with such laws and regulations requires substantial resources. Because of the breadth of these various fraud and abuse laws, it is possible that some of our business activities could be subject to challenge under one or more of such laws. Such a challenge could have material adverse effects on our business, financial condition and results of operations. In the event governmental authorities conclude that our business practices do not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations, they may impose sanctions under these laws, which are potentially significant and may include civil monetary penalties, damages, exclusion of an entity or individual from participation in government health care programs, criminal fines and imprisonment, additional reporting requirements if we become subject to a corporate integrity agreement or other settlement to resolve allegations of violations of these laws, as well as the potential curtailment or restructuring of our operations. Even if we are not determined to have violated these laws, government investigations into these issues typically require the expenditure of significant resources and generate negative publicity.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Healthcare Privacy Laws</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be subject to laws and regulations covering data privacy and the protection of health-related and other personal information. The legislative and regulatory landscape for privacy and data protection continues to evolve, and there has been an increasing focus on privacy and data protection issues which may affect our business. Numerous federal and state laws and regulations, including state security breach notification laws, state health information privacy laws and federal and state consumer protection laws, govern the collection, use, disclosure, and protection of personal information. Failure to comply with such laws and regulations could result in government enforcement actions and create liability for us (including the imposition of significant penalties), private litigation and/or adverse publicity that could negatively affect our business. In addition, healthcare providers who prescribe our products and research institutions we collaborate with are subject to privacy and security requirements under HIPAA.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Corrupt Practices Act</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the U.S. Foreign Corrupt Practices Act of 1997 prohibits corporations and their intermediaries from engaging in certain activities to obtain or retain business or to influence a person working in an official capacity. It is illegal to pay, offer to pay or authorize the payment of anything of value to any official of another country, government staff member, political party or political candidate in an attempt to obtain or retain business or to otherwise influence a person working in that capacity.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Human Capital</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Culture is a critical element in the management of our organization. Our colleagues are focused on driving our business with the Optinose values as the foundation for all our efforts. Our goal is that each colleague feels a deep connection to what they do, loves coming to work and is aligned to our One Mission &#8211; to improve lives. Our values of Authenticity, Fearless Conversations, Friendship, Openness, Perseverance and Possibility Thinking guide our actions and decisions.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of February 20, 2023, we had a total of 141 full-time employees all of whom are in the United States, and no part-time employees. 70% of our employees are in customer-facing roles. Most of our employees have significant prior experience within the pharmaceutical, biotech or device industries.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to focus on building a high performing organization through our emphasis on accountability for results as measured by our performance development process. To help ensure that employees fully understand the Company&#8217;s long-term strategy, and how their work contributes to the Company&#8217;s success, we utilize a variety of channels to facilitate open and direct communication, including: regular calls with all colleagues, ongoing update communications as needed, regular executive field visits and annual colleague engagement surveys.  </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We provide our colleagues with competitive salaries and bonuses, opportunities for equity ownership, opportunities for professional development and a robust benefits package. Our compensation programs, including short- and long-term incentives, are designed to enable us to attract and retain individuals whose skills are critical to our current and long-term success. Our compensation philosophy is to ensure that our colleague salaries fall within an </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">appropriate range around the median of the marketplace for like positions, with differentiation based on performance and contribution, time in position, and criticality of skill set.  Within our compensation programs, we also aim to align the interests of our colleagues with those of our shareholders.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We value diversity and are focused on maintaining an inclusive work environment that supports our culture and the needs of the communities we serve and in which we work. Currently, women represent 57% of our colleagues. None of our colleagues are represented by any collective bargaining unit. We believe that we maintain good relations with our colleagues.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the evolution of the COVID-19 pandemic and the ways in which work has changed, we offer a hybrid work environment in our Yardley headquarters in which colleagues work in the office three days and may work remotely the other two days, if desired. This enables us to provide colleagues with flexibility as well as provide an environment in which creativity and innovation are fostered.  </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Properties</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our principal office is located in Yardley, Pennsylvania, where we lease approximately 30,000 square feet of office space pursuant to a lease that expires in May 2024. We also lease a facility in Ewing, New Jersey. We believe our facilities are adequate to meet our current needs, although we may seek to negotiate new leases or to re-evaluate the location and amount of space needed for our operations. We believe appropriate alternative space will be readily available on commercially reasonable terms.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are not a party to any material pending legal proceedings.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Corporate Information </span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We were incorporated under the laws of the State of Delaware in May 2010. Our corporate office is located at 1020 Stony Hill Road, Suite 300, Yardley, PA 19067. Our telephone number is (267) 364-3500. We maintain an Internet website at www.optinose.com. The information contained on our website is not incorporated by reference into this Form 10-K. </span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We make available free of charge under the &#8220;Investors&#8212;SEC Filings&#8221; section of our website all of our filings with the SEC, including our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, proxy statements and amendments to such documents, each of which is provided on our website as soon as reasonably practicable after we electronically file or furnish, as applicable, the information with the SEC. </span></div><div id="i451bcb3eabba4f87bdc579718207a3b8_28"></div><div style="margin-bottom:8pt;margin-top:8pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1A. RISK FACTORS</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risk Factors</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing in our common stock involves a high degree of risk. Before deciding to invest in our common stock, you should consider carefully the risks and uncertainties described below, together with general economic and business risks and all of the other information contained in this Annual Report on Form 10-K, including our consolidated financial statements and the related notes and the section titled "Management's Discussion and Analysis of Financial Condition and Results of Operations." If any of the following risks actually occur, our business, financial condition, results of operations and prospects could be harmed. In that event, the price of our common stock could decline and you could lose all or part of your investment. This Annual Report on Form 10-K also contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in the forward-looking statements as a result of specific factors, including the risks described below. See "Note Regarding Forward-Looking Statements."</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Financial Position and Capital Resources</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We have identified conditions and events that raise substantial doubt about our ability to continue as a going concern.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, we had cash and cash equivalents of $94.2 million and have $130.0 million of outstanding Pharmakon Senior Secured Notes under the A&amp;R Note Purchase Agreement. Our accumulated deficit as of December 31, 2022 was $684.9 million. We have incurred significant net losses since inception and also expect to incur substantial losses in future periods. Our continuation as a going concern is dependent on our ability </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Contents</a></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to maintain compliance with the financial covenants and other terms under the A&amp;R Note Purchase Agreement, and our ability to generate sufficient cash flows from operations and/or obtain additional capital through equity or debt financings, partnerships, collaborations, or other sources to meet the debt service obligations under our outstanding Pharmakon Senior Secured Notes, including repayment, and to carry out our planned development and commercial activities.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We believe it is probable that we will not achieve the trailing twelve-month minimum consolidated XHANCE net sales and royalties thresholds that we are required to achieve under the A&amp;R Note Purchase Agreement commencing with the period ending March 31, 2024, which will constitute a default under the A&amp;R Note Purchase Agreement if we are unable to obtain a modification or waiver of such minimum consolidated XHANCE net sales and royalties thresholds. In addition, the A&amp;R Note Purchase Agreement contains financial covenants requiring us to maintain at all times a minimum of $30.0 million of cash and cash equivalents. We believe that it is probable that our existing cash and cash equivalents will not be adequate to fund our operations and maintain at least $30.0 million of cash and cash equivalents as required under the A&amp;R Note Purchase Agreement for at least twelve months following the filing of this Form 10-K, which will constitute a default of the liquidity financial covenant under the A&amp;R Note Purchase Agreement if we are unable to obtain additional capital or obtain a waiver or modification to this liquidity covenant prior to falling below such $30.0 million threshold. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Further, the A&amp;R Note Purchase Agreement includes a requirement that, commencing with our financial statements for the year ending December 31, 2023, our annual and quarterly financial statements and any auditor opinion relating thereto may not be subject to any "going concern" uncertainty disclosure.  As a general matter, financial statements are subject to a "going concern" uncertainty disclosure if it is probable that the company's available capital is not sufficient to fund its operations and obligations for at least twelve months following the issuance of such financial statements (including obligations that may become due during such twelve month period as a result of some future event).  We believe it is unlikely that we will be able comply with this covenant when it becomes effective commencing with our financial statements for the year ending December 31, 2023.  Failure to comply with this covenant would also constitute an event of default under the A&amp;R Note Purchase Agreement.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In the event that any one of the foregoing defaults were to occur, the holders of the Pharmakon Senior Secured Notes may declare an event of default under the A&amp;R Note Purchase Agreement and may elect to accelerate the repayment of all unpaid principal, accrued interest and other amounts due under such holders&#8217; Pharmakon Senior Secured Notes, which may require us to delay or curtail our operations until we are able to obtain additional capital which may not be available on a timely basis, on favorable terms, or at all, and such capital, if obtained, may not be sufficient to meet our payment obligations or enable us to continue to implement our long-term business strategy. In such an event, our business, prospects, financial condition and results of operations will be materially and adversely affected, and we may be unable to continue as a going concern. These factors raise substantial doubt about our ability to continue as a going concern. If we are unable to continue as a going concern, we may have to liquidate our assets and may receive less than the fair value for such assets or less than the value at which those assets are carried on our financial statements, and it is likely that investors will lose all or a part of their investment. Additionally, if we seek additional financing to fund our debt service obligations and business activities in the future and there remains substantial doubt about our ability to continue as a going concern, investors or other financing sources may be unwilling to provide funding to us on commercially reasonable terms, if at all.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We have incurred significant losses since our inception and anticipate that we will incur continued losses in the future.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are a specialty pharmaceutical company with a limited operating history. To date, we have focused primarily on XHANCE and ONZETRA Xsail, as well as other product candidates using our proprietary EDS device technology. Since inception, we have incurred significant net losses and expect to continue to incur net losses for the foreseeable future. To date, we have generated revenue from sales of XHANCE since its launch in 2018, as well as from licensing revenues from ONZETRA Xsail and our proprietary EDS device technology. We incurred net losses of $74.8 million and $82.3 million for the years ended December 31, 2022 and 2021, respectively.  As of December 31, 2022, we had an accumulated deficit of $684.9 million.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to incur losses for the foreseeable future as we:</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">continue to commercialize XHANCE and further scale up external manufacturing and distribution capabilities to commercialize XHANCE or any other product candidate for which we may obtain regulatory approval;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">continue to focus our regulatory compliance efforts on requirements applicable to marketed drugs;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">continue clinical development activities for XHANCE, including mandated post-marketing pediatric studies;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Contents</a></span></div></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">continue pre-clinical and clinical development activities with respect to our other product candidates;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">seek to discover and develop, in-license or acquire additional products, product candidates and technology;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">maintain, expand and protect our intellectual property portfolio;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">hire additional personnel to continue to support company growth; and</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">incur additional legal, accounting and other expenses in operating as a publicly traded commercial-stage company.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the numerous risks and uncertainties associated with drug development and commercialization, we are unable to accurately predict the timing or amount of expenses or when, or if, we will be able to achieve profitability. If we are required by regulatory authorities to perform studies in addition to those expected, or if there are any delays in the initiation and completion of our clinical trials or the development of any of our product candidates, our expenses could increase.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We may never achieve or maintain profitability</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to become and remain profitable will depend on our ability to generate revenue. Our ability to generate revenue depends upon our ability to successfully commercialize XHANCE and any of our other product candidates, if approved, that we may in-license or acquire in the future, as well as from our ability to successfully out-license any of our products or technology. Our ability to generate revenue from our current or future products and product candidates will depend on a number of factors, including:</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">our ability to successfully commercialize XHANCE for the treatment of nasal polyps;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">our ability to obtain regulatory approval for, and successfully commercialize, XHANCE for the treatment of chronic sinusitis;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">our ability to complete and submit applications to, and obtain regulatory approval from, foreign regulatory authorities, if we choose to commercialize XHANCE outside the U.S.;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">the size of the markets in the territories for which we gain regulatory approval;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">the performance of our sales team, in marketing and promoting XHANCE;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">our ability to maintain and further develop a commercial organization capable of sales, marketing and distribution for XHANCE and any of our other product candidates for which we may obtain marketing approval;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">our ability to maintain commercially reasonable agreements with wholesalers, distributors and other third parties in our supply chain;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">our success in establishing a commercially viable price for our products;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">our success in defending against potential generic competition and other developments in our market generally;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">our ability to have commercial quantities of our products manufactured at acceptable cost levels;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">our ability to obtain coverage and adequate reimbursement from third parties, including government payors; and</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">our ability to successfully complete development activities, including the necessary clinical trials, with respect to our other product candidates.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">XHANCE, as well as any of our other product candidates if approved for commercial sale, may not gain market acceptance or achieve commercial success. Even if we obtain regulatory approval to market XHANCE for the treatment of chronic sinusitis, our future revenues will depend upon our ability to achieve sufficient market acceptance and reimbursement from third-party payors. If our addressable market is not as significant as we estimate or the treatment population is narrowed by competition, physician choice, clinical practice guidelines or utilization management criteria imposed by payors, we may not generate significant revenue from sales of XHANCE. In addition, we would anticipate incurring significant costs associated with commercializing any approved product. We may not achieve profitability. If we are unable to generate enough product revenues to cover our </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">operating expenses and service our debt, we will not become profitable and may be unable to continue operations without continued funding.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would depress the value of our company and could impair our ability to raise capital, expand our business, maintain our development efforts, obtain drug approvals, diversify our offerings or continue our operations. A decline in the value of our company could also cause you to lose all or part of your investment.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We will likely require additional capital to fund our operations and, if we fail to obtain necessary financing, we may be unable to continue the commercialization of XHANCE, service and repay our debt and pursue FDA-approval of XHANCE for the treatment of chronic sinusitis.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations have consumed substantial amounts of cash. To date, we have financed our operations primarily through the sale and issuance of common and preferred stock, debt, licensing revenues, XHANCE revenue and research grants. We expect to continue to spend substantial amounts to commercialize XHANCE and pursue FDA- approval of XHANCE for the treatment of chronic sinusitis. As of December 31, 2022, we had cash and cash equivalents of $94.2 million. Although it is difficult to predict our future liquidity requirements, we will likely require additional capital in the future secured through equity or debt financings, partnerships, collaborations, or other sources in order to meet our debt service obligations under our debt, and to carry out our planned development and commercial activities. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future funding requirements, both near and long-term, will depend on many factors, including, but not limited to:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">the success of our commercialization of XHANCE for the treatment of nasal polyps including, among other things, patient and physician acceptance of XHANCE and our ability to maintain adequate insurance coverage and reimbursement for XHANCE; </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">the outcome, timing and cost of the regulatory approval process of XHANCE for chronic sinusitis by the FDA, including the potential for the FDA to require that we perform more studies and clinical trials than those that we currently expect; </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">if XHANCE is approved by the FDA for the treatment of chronic sinusitis, the success of our commercialization of XHANCE for this new indication including, among other things, patient and physician acceptance of XHANCE for this new indication and our ability to obtain adequate insurance coverage and reimbursement for XHANCE for this new indication, and the speed at which we are able to obtain these outcomes, if at all; </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">the cost of commercialization activities for XHANCE, including product manufacturing, distribution, marketing and sales; </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">net product revenues received from sales of XHANCE;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">the level of co-pay assistance and other patient affordability programs offered for XHANCE; </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">our clinical development plans for XHANCE, including our ongoing FDA-mandated post-marketing pediatric study; </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">the costs involved in preparing, filing and prosecuting patent applications, and maintaining and enforcing our intellectual property rights;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">the cost of defending intellectual property disputes, including patent infringement actions brought by third parties against us; </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">the initiation, progress, timing, costs and results of clinical trials and other research and development related to additional product candidates; and </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">the extent to which we in-license, acquire or otherwise partner in the development of other products, product candidates or technologies. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot be certain that additional funding will be available when needed on acceptable terms, or at all. If we are unable to raise additional capital in sufficient amounts, when required or on acceptable terms, we also could be required to (to the extent permissible under the A&amp;R Note Purchase Agreement):</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">significantly delay, scale back or discontinue the commercialization of XHANCE and the development and pursuit of FDA-approval of XHANCE for the treatment of chronic sinusitis;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">relinquish or license on unfavorable terms our rights to our product, EDS technologies or other product candidates that we otherwise would seek to develop or commercialize ourselves;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">seek strategic collaborations to assist in the commercialization of XHANCE in the U.S. and other markets at an earlier stage than otherwise would be desirable or on terms that are less favorable than might otherwise be available;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">delay, limit, reduce or terminate the drug development of our current or future product candidates, or seek collaborators for one or more of our current or future product candidates at an earlier stage than otherwise would be desirable or on terms that are less favorable than might otherwise be available; or</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">significantly curtail our operations, liquidate our assets or seek bankruptcy.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to meet our business objectives in the necessary timeframes or at all, our business would be jeopardized and we may not be able to continue operations.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the Note Purchase Agreement contains various covenants that limit our ability to obtain additional capital through the sale, transfer, lease or disposition of our assets, merger, consolidation, the incurrence of additional debt and the granting of certain license rights related to our products, technology and other intellectual property rights.  Furthermore, the warrants to purchase shares of our common stock issues in our November 2022 public offering (2022 Warrants) contain anti-dilution provisions which may adversely impact investor interest and participation in future equity financings or make such future equity financings more dilutive as a result of triggering the anti-dilution provisions of the 2022 Warrants or otherwise.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our failure to comply with the covenants or other terms of the A&amp;R Note Purchase Agreement, including as a result of events beyond our control, could result in a default under the A&amp;R Note Purchase Agreement that could materially and adversely affect the ongoing viability of our business.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Each holder of the Pharmakon Senior Secured Notes may elect to accelerate the repayment of all unpaid principal and accrued interest under such holders&#8217; Pharmakon Senior Secured Notes upon consummation of a specified change of control transaction or occurrence of certain events of default (as specified in the A&amp;R Note Purchase Agreement), including, among other things:</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;our default in a payment obligation under the Pharmakon Senior Secured Notes;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;our breach of the financial covenants, affirmative covenants, restrictive covenants or other terms of the A&amp;R Note Purchase Agreement, including (i) the trailing twelve-month minimum consolidated XHANCE net sales and royalties covenant, (ii) the requirement to maintain at least $30.0 million of cash and cash equivalents and (iii) the requirement to deliver quarterly and annual financial statements that, commencing with the fiscal period ending December 31, 2023, are not subject to a "going concern" qualification;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;our breach of reporting obligations;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;our failure to properly maintain the collateral;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;any circumstance that could reasonably be expected to have a material adverse effect (as defined in the A&amp;R Note Purchase Agreement) on us;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;certain regulatory and/or commercial actions that cause an ongoing delay in commercialization of XHANCE; and</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;certain specified insolvency and bankruptcy-related events.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to any applicable cure period set forth in the Pharmakon Senior Secured Notes, all amounts outstanding with respect to the Pharmakon Senior Secured Notes (principal and accrued interest), as well as any applicable prepayment premiums or interest &#8220;make-whole&#8221; payments, would become due and payable immediately upon an event of default and shall be subject to a default interest rate of an additional 3%. Our assets or cash flow may not be sufficient to fully repay our obligations under the Pharmakon Senior Secured Notes if the obligations thereunder </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Contents</a></span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">are accelerated upon any events of default. Further, if we are unable to repay, refinance or restructure our obligations under the Pharmakon Senior Secured Notes, or obtain a waiver or modification to the financial covenants or any other terms under the A&amp;R Note Purchase Agreement as may be required in the future, the holders of such Pharmakon Senior Secured Notes could proceed to protect and enforce their rights under the Pharmakon Senior Secured Notes by exercising such remedies (including foreclosure on the assets securing our obligations under the Pharmakon Senior Secured Notes and the A&amp;R Note Purchase Agreement) as are available to the holders thereunder and in respect thereof under applicable law, either by suit in equity or by action at law, or both, whether for specific performance of any covenant or other agreement contained in the Pharmakon Senior Secured Notes or in aid of the exercise of any power granted in the Pharmakon Senior Secured Notes. Any such action would materially and adversely affect the ongoing viability of our business.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In the event that we maintain compliance with the trailing twelve-month minimum consolidated XHANCE net sales and royalties that we are required to meet each quarter, maintain at least $30.0 million of cash and cash equivalents and deliver quarterly and annual financial statements that, commencing with the fiscal period ending December 31, 2023, are not subject to a "going concern" qualification, and maintain compliance with all other terms of the A&amp;R Note Purchase Agreement, in each case, to avoid an acceleration of payments due under the Pharmakon Senior Secured Notes, then we will be required to repay the notes in eight equal quarterly payments of $16.25 million starting on September 30, 2025. The Pharmakon Senior Secured Notes are guaranteed by us, OptiNose AS and certain of our subsidiaries and are secured by a pledge of substantially all of our and their assets. We are required to achieve the following minimum trailing twelve-month XHANCE net sales and royalties under the A&amp;R Note Purchase Agreement (in thousands):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.514%"><tr><td style="width:0.1%"></td><td style="width:2.798%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:53.022%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.030%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.801%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trailing Twelve-Months Ending</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Requirement under the A&amp;R Note Purchase Agreement ($)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">September 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">March 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">June 30, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">September 30, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">December 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">March 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$82,500</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">June 30, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,000</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">September 30, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,500</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">December 31, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,000</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">March 31, 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,000</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">June 30, 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,000</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">September 30, 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125,000</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">December 31, 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130,000</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">March 31, 2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135,000</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">June 30, 2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140,000</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">September 30, 2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145,000</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">December 31, 2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150,000</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">March 31, 2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155,000</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">June 30, 2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160,000</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">September 30, 2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165,000</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Our A&amp;R Note Purchase Agreement contains restrictions that limit our flexibility in operating our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The A&amp;R Note Purchase Agreement contains various covenants that limit our ability to engage in specified types of transactions without our lenders&#8217; prior consent. These covenants limit our ability to, among other things:</span></div><div style="margin-top:8pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226; sell, transfer, lease or dispose of our assets;</span></div><div style="margin-top:8pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226; create, incur or assume additional indebtedness;</span></div><div style="margin-top:8pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226; encumber or permit liens on certain of our assets;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Contents</a></span></div></div><div style="margin-top:8pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226; make restricted payments, including paying dividends on, repurchasing or making distributions with respect to our common stock;</span></div><div style="margin-top:8pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226; make specified investments (including loans and advances);</span></div><div style="margin-top:8pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226; consolidate, merge, sell or otherwise dispose of all or substantially all of our assets;</span></div><div style="margin-top:8pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226; enter into certain transactions with our affiliates;</span></div><div style="margin-top:8pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226; grant certain license rights related to our products, technology and other intellectual property rights; and</span></div><div style="margin-top:8pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226; permit our cash and cash equivalents held in certain deposit accounts to be less than $30.0 million at any time.</span></div><div style="margin-top:8pt;padding-left:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the A&amp;R Note Purchase Agreement provides for, among other things, modifications to the affirmative and negative covenants and events of default, including, without limitation, the removal of certain exceptions to the negative covenants which previously permitted us to enter into certain transactions without the consent of the holders of the Pharmakon Senior Secured Notes, including permitted acquisitions, swap contracts, convertible bonds and a revolving credit facility.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The covenants in our A&amp;R Note Purchase Agreement and related security agreements may limit our ability to take certain actions that may be in our long-term best interests.  In the event that we breach one or more covenants, our lenders may choose to declare an event of default and require that we immediately repay all amounts outstanding under the Pharmakon Senior Secured Notes, plus penalties and interest, terminate their commitments to purchase additional Pharmakon Senior Secured Notes and foreclose on the collateral granted to them to secure the Pharmakon Senior Secured Notes. Such repayment could have a material adverse effect on our business, operating results and financial condition.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Provisions of the Pharmakon Senior Secured Notes and the 2022 Warrants provide for certain potential payments to the holders of such securities which could impede a sale of the Company.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Subject to certain exceptions, we are required to make mandatory prepayments of the Pharmakon Senior Secured Notes, with the proceeds of asset sales, extraordinary receipts and prohibited debt issuances, and upon the occurrence of a change of control (as defined in the A&amp;R Note Purchase Agreement). In addition, we may make voluntary prepayments of the Pharmakon Senior Secured Notes, in whole or in part. All mandatory and voluntary prepayments of the Pharmakon Senior Secured Notes are subject to the payment of prepayment premiums as follows: (i) if prepayment occurs on or after September 12, 2022 but prior to September 12, 2023, an amount equal to 1% of the principal prepaid; and (ii) if prepayment occurs on or after September 12, 2023, no prepayment premium is due. We are also required to pay a &#8220;make-whole&#8221; amount in respect of any principal prepayments (whether mandatory or voluntary) made prior to the 36-month anniversary of the effective date of the A&amp;R Note Purchase Agreement, as follows: (i) for any prepayment date occurring up until and including the 18-month anniversary of the date of the A&amp;R Note Purchase Agreement, the foregone interest from such prepayment date through the 18-month anniversary of such prepayment date; and (ii) for any prepayment after the 18-month anniversary of the date of the A&amp;R Note Purchase Agreement, the foregone interest from such prepayment date through the 3-year anniversary of the date of the A&amp;R Note Purchase Agreement; provided, however, that in no event shall the amount of all make-whole premium payments exceed $24.0 million in the aggregate. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition, in the event of a fundamental transaction, as defined in the 2022 Warrants, in certain circumstances a holder of the 2022 Warrants will have the right to require us to repurchase such 2022 Warrants for cash at the Black Scholes Value (as defined in the 2022 Warrants).  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">These provisions may make it more costly for a potential acquirer to engage in a business combination transaction with us. Provisions that have the effect of discouraging, delaying or preventing a change in control could limit the opportunity for our stockholders to receive a premium for their shares of our common stock and could also affect the price that some investors are willing to pay for our common stock. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Raising additional capital may cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have any committed external source of funds. Until such a time, if ever, that we can generate substantial revenue, we may seek to raise additional capital through a combination of private and public equity offerings, debt financings, collaborations, strategic alliances and licensing arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms may include liquidation or other preferences that adversely affect your rights as a stockholder. Debt financings may be coupled with an equity component, such as warrants to purchase shares, which could also result in dilution of our existing stockholders' ownership. The incurrence of additional indebtedness would result in increased fixed payment obligations and could also result in certain restrictive covenants, such as limitations on our ability to incur additional debt, limitations on our ability to acquire or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business and may result in liens being placed on our assets and intellectual property. If we were to default on such indebtedness, we could lose such assets and intellectual property.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we raise additional funds through collaborations, or strategic alliance, grants, marketing, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, product candidates or future revenue streams or grant licenses on terms that are not favorable to us or at an earlier stage than would otherwise be desirable.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As noted below, the 2022 Warrants contain price protection anti-dilution provisions. If the exercise price of the 2022 Warrants is reduced as a result of our future issuance of shares or other securities at prices below the exercise price of the 2022 Warrants, this may result in additional warrant exercises and additional dilution to stockholders.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">We have a significant number of warrants outstanding that contain anti-dilution provisions that may result in the reduction of their exercise prices in the future.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The 2022 Warrants contain anti-dilution provisions, which provisions require the lowering of the exercise price, as applicable, to the purchase price of future offerings. If in the future we issue or are deemed to issue securities for less than the exercise price of the 2022 Warrants, we may be required to reduce the exercise prices of the 2022 Warrants. During the term that the 2022 Warrants are outstanding, the holders of those securities are given the opportunity to profit from a rise in the market price of our common stock. In addition, we may find it more difficult to raise additional equity capital while these warrants are outstanding. Any future adjustments to the exercise prices of the 2022 Warrants may have a negative impact on the trading price of our common stock. Additionally, raising additional capital with new investors may be difficult as a result of the adjustment feature.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our ability to use our net operating loss carry forwards and other tax attributes may be limited.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, we had U.S. federal net operating loss (NOL) carry forwards of approximately $335.0 million available to offset future U.S. taxable income and U.S. federal research and development (R&amp;D) tax credits of $2.4 million.&#160;While some of our federal NOL carry forwards will carry forward indefinitely, some of our U.S. NOL and credit carry forwards will expire if not utilized with the first expiration occurring in 2030.&#160;We also had state NOL carry forwards of $252.3 million as of December 31, 2022. These state NOL carry forwards can only offset income in the same state in which they were generated and thus there is a possibility that they may not be utilized. The carry forward period varies among the states, with the first expiration in 2028. In addition, our Norwegian and UK subsidiaries, had total foreign NOL carry forwards of $9.1 million as of December 31, 2022. These foreign NOL carry forwards do not expire but can only be used to offset profits generated in Norway or the United Kingdom, respectively, and may be limited in use based on the laws of those countries. In order to simplify the corporate structure, our board of directors approved the liquidation of our Norwegian and UK subsidiaries, which is expected to be completed in 2023.  </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our U.S. NOL and tax credit carry forwards could expire unused and be unavailable to offset future income tax liabilities because of their limited duration or because of other restrictions under U.S. tax law. Under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended (the Code), if a corporation undergoes an &#8220;ownership change&#8221;, generally defined as a greater than 50% change, by value, in equity ownership during a three-year period, the corporation&#8217;s ability to offset pre-change tax attributes, such as NOLs and R&amp;D tax credits, against post-change income or tax may be limited. We have not performed an analysis under Section 382 of the Code and cannot predict or otherwise determine whether utilization of our federal tax attribute carry forwards may be limited. As a result, if we have taxable income in the future, our ability to use existing U.S. NOL and R&amp;D tax credit carry forwards to reduce U.S. taxable income or tax liability may be subject to limitation resulting in increased future tax liabilities. Similar rules at the state level may also limit our ability to use state NOLs. Also, there may be periods </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">when the use of NOLs is suspended or otherwise limited at the state level, which could accelerate or permanently increase state taxes owed.  Furthermore, the losses could expire before we generate sufficient income to utilize them.  </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may have ownership changes in the future due to additional changes in our stock ownership which could be outside of our control. If an ownership change occurs and our ability to use our historical net operating loss and tax credit carry forwards is limited, it could adversely impact our future operating results by increasing our tax obligations.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The coronavirus (COVID-19) pandemic has and may continue to adversely affect our business, results of operations and financial condition. </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to monitor the effects of the COVID-19 pandemic, which has caused significant disruptions around the world since March 2020. We may continue to experience disruptions as a result of the COVID-19 pandemic that could severely impact our business, including:</span></div><div><span><br/></span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">restrictions that remain in some physicians' offices, including not accepting visits from sales representatives or limiting or placing restrictions on visits, which will negatively impact our ability to drive prescription growth from the physicians targeted by our sales representatives; </span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a reduced number of patients visiting physicians&#8217; offices and changes in insurance coverage or reimbursement levels by governmental authorities, private health insurers and other third-party payors;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">volatile market conditions in the U.S. and around the world, which could harm our business, including our ability to obtain future financing; and</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">supply constraints, which could cause us to have an insufficient level of finished product inventories on hand.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The global outbreak of COVID-19 continues to evolve, including with the emergence of new variants, and the extent to which the COVID-19 pandemic may further impact our business, our customers, and the third parties on whom we rely, such as our contract manufacturers, suppliers, PPN partners, wholesalers, distributors, third party logistics, contract research organizations, investigators for our clinical trials and other vendors, will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the pandemic, travel restrictions and social distancing in the U.S. and around the world, and the speed with which and the extent to which normal economic and operating conditions resume, among others.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Commercialization of XHANCE</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">If we are unable to successfully commercialize XHANCE, our business, financial condition and results of operations may be materially adversely affected and the price of our common stock may decline.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to successfully commercialize XHANCE depends on many factors, including:</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain regulatory approval for XHANCE for a follow-on indication for the treatment of chronic sinusitis;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">our ability to have commercial quantities of XHANCE manufactured at a reasonable cost and with sufficient speed to meet commercial demand;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">the ability of our sales team to effectively market, promote and sell XHANCE;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">our success in educating physicians, patients and caregivers about the benefits, administration and use of XHANCE; </span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">patient and physician acceptable of XHANCE;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">the availability, perceived advantages, relative cost, relative safety and relative efficacy of competing products;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">the availability of coverage and adequate reimbursement for XHANCE;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">our ability to commercialize XHANCE at a profitable average net revenue per prescription;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Contents</a></span></div></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">our ability to obtain and maintain contracts with wholesalers, distributors and/or PPN partners on acceptable terms;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">our ability to obtain regulatory approval for XHANCE for a follow-on indication for the treatment of chronic rhinosinusitis;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">the effectiveness of our marketing campaigns;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">our ability to attract and retain qualified pharmaceutical industry personnel;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">a continued acceptable safety profile for XHANCE;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">our ability to obtain and maintain required state licenses to sell XHANCE; and</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">our ability to successfully defend any challenges to our intellectual property relating to XHANCE.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is difficult for us to predict future performance. As we gain additional commercial experience, a number of factors over which we have limited control may contribute to fluctuations in our financial results. We expect that first quarter prescription demand and average net revenue per prescription for XHANCE will be adversely impacted by the annual resetting of patient healthcare insurance plan deductibles and changes in individual patients' healthcare insurance coverage, both of which often occur in January. Additionally, demand has historically been, and we expect will continue to be, impacted by the seasonal variation in patient visits with their doctor and INS market seasonality resulting in reduced XHANCE prescription demand in the third quarter.   </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of these matters are beyond our control and are subject to other risks described elsewhere in this "Risk Factors" section. Accordingly, we cannot assure you that we will be able to successfully commercialize or generate enough revenue from XHANCE to achieve profitability or maintain compliance with minimum trailing twelve-month XHANCE net sales and royalties thresholds under the A&amp;R Note Purchase Agreement. If we cannot do so, or are significantly delayed in doing so, our business, financial condition and results of operations may be materially adversely affected and the price of our common stock may decline.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The commercial success of XHANCE depends upon its acceptance by multiple stakeholders, including physicians, patients and healthcare payors.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The degree of market acceptance of XHANCE depends on a number of factors, including:</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">demonstration of clinical safety and efficacy;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">relative convenience and ease of administration;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">pricing and cost-effectiveness;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">availability of alternative treatments and perceived advantages over such alternative treatments;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">the clinical indications for which XHANCE is approved;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">the prevalence and severity of any AEs;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">limitations or warnings contained in the FDA-approved label for XHANCE;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">the effectiveness of our or any future collaborators' sales and marketing strategies;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">consolidation among healthcare providers, which increases the impact of the loss of any relationship;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">our ability to obtain and maintain sufficient third-party coverage and adequate reimbursement; </span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">adequacy and accessibility of our patient assistance programs; and</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">the willingness of patients to pay out-of-pocket in the absence of third-party coverage.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If XHANCE does not achieve an adequate level of acceptance by physicians, patients and healthcare payors, we may not generate sufficient revenue in order to become or remain profitable.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Contents</a></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">If third-party payors do not reimburse patients for XHANCE or if reimbursement levels are set too low for us to sell XHANCE at a profit, our ability to successfully commercialize XHANCE and our results of operations will be harmed.   </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our ability to commercialize XHANCE successfully depends in part on the extent to which coverage and adequate reimbursement for XHANCE will be available in a timely manner and remains available from third-party payors, including governmental healthcare programs such as Medicare and Medicaid, commercial health insurers and managed care organizations. Government authorities and other third-party payors, such as private health insurers and health maintenance organizations, determine which medications they will cover and establish reimbursement levels. Reimbursement decisions by particular third-party payors depend upon a number of factors, including each third-party payor's determination that use of a product is:</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">a covered benefit under its health plan;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">appropriate and medically necessary for the specific condition or disease;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">cost effective; and</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">neither experimental nor investigational.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Obtaining coverage and reimbursement approval for XHANCE from government authorities or other third-party payors is a time consuming and costly process that could require us to provide supporting scientific, clinical and cost-effectiveness data, including expensive pharmacoeconomic studies beyond the data required to obtain marketing approval, for the use of XHANCE to each government authority or other third-party payor. We may not be able to provide data sufficient to gain or maintain acceptance with respect to coverage and reimbursement from government authorities or other third-party payors.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third-party payors may deny reimbursement for covered products if they determine that a medical product was not used in accordance with cost-effective diagnosis methods, as determined by the third-party payor, or was used for an unapproved indication. Third-party payors also may refuse to reimburse for procedures and devices deemed to be experimental. Third-party payors may also limit coverage to specific products on an approved list, or formulary, which might not include all of the FDA-approved products for a particular indication.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Third-party payors are increasingly attempting to contain healthcare costs by limiting both coverage and the level of reimbursement for medical products and services. The process for determining whether a payor will provide coverage for a product may be separate from the process for setting the price or reimbursement rate that the payor will pay for the product once coverage is approved. Levels of reimbursement may also decrease in the future, and future legislation, regulation or reimbursement policies of third-party payors may adversely affect the demand for and reimbursement available for XHANCE, which in turn, could negatively impact pricing.  Further, payors, including healthcare insurers, pharmacy benefit managers and group purchasing organizations, increasingly seek ways to reduce their costs. Many payors continue to adopt benefit plan changes that shift a greater portion of prescription costs to patients. Such measures include more limited benefit plan designs, higher patient co-pay or co-insurance obligations and limitations on patients&#8217; use of commercial manufacturer co-pay assistance programs (including through co-pay accumulator adjustment or maximization programs). Payors also increasingly seek price discounts or rebates in connection with the placement of our products on their formularies or those they manage. Payors may also control costs by imposing restrictions on access to or usage of our products, such as by requiring prior authorizations or "step-edits," and may choose to exclude certain indications for which our products are approved or even choose to exclude coverage entirely. For example, some insurers have established a step-edit system that requires a patient to first use a lower price generic or other alternative product prior to becoming eligible for reimbursement for XHANCE and some insurers also require that a physician attest that XHANCE is being used to treat a patient for an indication for which XHANCE is approved. We estimate that approximately half of the commercially covered lives as of December 31, 2022 are in a plan that requires a prior authorization and most of those prior authorizations request information regarding patient diagnosis and prior use of INS. Some providers may not complete the burdensome administrative process required to demonstrate or document that the patients for whom XHANCE has been prescribed meet the payors&#8217; utilization management criteria (i.e., prior authorizations or step-edits) and, as a result, patients will not gain access to XHANCE treatment. We believe increasing rates of enforcement of the utilization management criteria had a negative effect on XHANCE prescription volume growth in 2022 and may continue to effect prescription volume growth in the future. These requirements include physician attestation to a diagnosis of nasal polyps which can be a hurdle for some physicians in our target audience because it is not a diagnosis they make commonly. Further, other patients may obtain coverage for XHANCE but abandon their prescriptions rather than pay their co-pay payment which would result in a significant shortfall in achieving our revenue expectations and negatively impact our business, prospects, results of operations and financial condition.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant consolidation in the health insurance industry has resulted in a few large insurers and pharmacy benefit managers exerting greater pressure in pricing and usage negotiations with drug manufacturers, significantly increasing discounts and rebates required of manufacturers and limiting patient access and usage. Further consolidation among insurers, pharmacy benefit managers and other payors, including through integrated delivery systems, would increase the negotiating leverage such entities have over us and other drug manufacturers. Ultimately, further discounts, rebates, coverage or plan changes, restrictions or exclusions as described above could have a material adverse effect on sales of our affected products.  </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">If we are unable to differentiate XHANCE from current and future products or existing methods of treatments, our ability to successfully commercialize XHANCE will be adversely affected.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are currently commercializing XHANCE for the treatment of nasal polyps and are seeking FDA approval for a follow-on indication of XHANCE for the treatment of chronic rhinosinusitis. Nasonex&#8482; is the only other branded drug therapy approved by the FDA for the treatment of nasal polyps.  Nasonex was marketed by Merck until it removal from the prescription market, but remains available over-the-counter without a prescription for other indications. Generic versions of Nasonex&#8482;, mometasone furoate monohydrate, continue to be available by prescription. In addition, Beconase AQ&#8482;, which is an INS marketed by GlaxoSmithKline, is indicated for the prophylaxis of nasal polyps after surgical resection, while SINUVA&#8482; is a commercially available corticosteroid-eluting implant indicated for the treatment of nasal polyps in adult patients who have had ethmoid sinus surgery that can be placed in the ethmoid sinus under endoscopic visualization for up to 90 days. We are not aware of any drug product approved for the treatment of chronic rhinosinusitis without nasal polyps (or chronic sinusitis).  In addition to competition from Nasonex&#8482; and Beconase&#160;AQ&#8482;, we also need to differentiate XHANCE from other products and treatments identified in current clinical practice guidelines for the treatment of chronic rhinosinusitis with and without nasal polyps. Such products and treatments include the use of nasal rinses, decongestants, over-the-counter and prescription INS products, oral steroids, antibiotics, and sinus surgery and other procedures, including functional endoscopic sinus surgery, balloon sinus dilation and steroid-releasing sinus implants. In addition, several monoclonal antibodies have been approved for the treatment of nasal polyps and are in clinical development for the treatment of chronic rhinosinusitis without nasal polyps.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In June 2019, the FDA approved DUPIXENT&#8482; (dupilumab) as an add-on maintenance treatment (to an intranasal steroid) in adult patients with inadequately controlled chronic rhinosinusitis with nasal polyposis. In November 2020, the FDA approved XOLAIR&#8482; add-on maintenance treatment of nasal polyps in adult patients with inadequate response to nasal corticosteroids. In July 2021, the FDA approved NUCALA&#8482; add-on maintenance treatment of chronic rhinosinusitis with nasal polyps in adult patients with inadequate response to nasal corticosteroids.  In addition, these monoclonal antibodies are being, or are expected to be, studied as potential treatments for patients with chronic sinusitis without nasal polyps. Lyra Therapeutics is developing corticosteroid-eluting implants as potential treatment for patients with chronic rhinosinusitis. If we are unable to achieve significant differentiation for XHANCE against these other products and treatments, including on the basis of efficacy, safety and tolerability profile, reliability, convenience of administration, price and reimbursement, the opportunity for XHANCE to be commercialized successfully would be adversely affected.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">If the market opportunities for XHANCE are smaller than we believe, our revenue may be adversely affected, and our business may suffer.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe there is a market opportunity for XHANCE consisting of ENT physicians, allergists and high-decile INS-prescribing primary care physicians that we believe treat an estimated 3.5&#160;million U.S. patients with chronic rhinosinusitis, an estimated 1.2&#160;million of whom have chronic rhinosinusitis with nasal polyps. If we are able to obtain a follow-on indication of XHANCE for the treatment of chronic rhinosinusitis, we intend to broaden, through potential collaborations, our reach and target primary care physicians that we believe treat an additional estimated 6.25&#160;million patients with chronic rhinosinusitis, an estimated one-third of whom have chronic rhinosinusitis with nasal polyps.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our projections of both the number of people who suffer from chronic rhinosinusitis with and without nasal polyps, as well as the subset of people with these diseases who have the potential to benefit from the use of XHANCE, are based on our beliefs and estimates. These estimates have been derived from a variety of sources, including scientific literature, surveys we commissioned, prescription data or other market research and may prove to be incorrect. Further, new studies may change the estimated incidence or prevalence of chronic rhinosinusitis or nasal polyps. The number of patients may turn out to be lower than expected. Additionally, the potentially addressable patient population for XHANCE may be limited or may not be amenable to treatment with XHANCE, and new patients may become increasingly difficult to identify or gain access to, which would adversely affect our results of operations and our business.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Clinical practice guidelines and recommendations published by various organizations could have significant influence on the use of XHANCE.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government agencies may promulgate clinical practice guidelines directly applicable to XHANCE. In addition, professional societies, practice management groups, private health and science foundations and organizations involved in various diseases from time to time may also publish guidelines or recommendations to the healthcare and patient communities. Recommendations of government agencies or these other groups or organizations may relate to such matters as usage, dosage, route of administration and use of concomitant therapies. Recommendations or guidelines suggesting the reduced use of XHANCE or the use of competitive or alternative products as the standard of care to be followed by patients and healthcare providers could result in decreased use of XHANCE.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">A significant portion of our sales are to a limited number of PPN partners and pharmaceutical wholesalers. Changes in terms required by these PPN partners or wholesalers, disruptions in these relationships or a default could harm our results of operations and financial condition.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Approximately 81% of our XHANCE net revenues during the&#160;fiscal year ended&#160;December 31, 2022 were to PPN partners. The three leading PPNs accounted for approximately 22% of our XHANCE net revenues. Additionally, approximately 19% of our XHANCE net revenues during the&#160;fiscal year ended&#160;December 31, 2022 were to the three largest wholesale pharmaceutical distributors, Cardinal Health, McKesson Corporation and AmerisourceBergen Drug Corporation.  If any of these PPN partners or wholesalers ceases to purchase our product for any reason, then unless and until the remaining PPN partners or wholesalers increase their purchases of XHANCE or alternative distribution channels are established:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">our commercial operations could be significantly disrupted;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">the availability of XHANCE to patients could be disrupted; and</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">we may not achieve sales of XHANCE that we expect, which would decrease our revenues.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not require collateral from our wholesalers or PPN partners but rather maintain credit limits and, as a result, we have an exposure to credit risk in our accounts receivable. A default by a large PPN partner or wholesaler could harm our results of operations and financial condition. In the fourth quarter of 2020 and 2021, we established bad debt reserves for two customer with past due balances. Our inability to collect these past due balances or any other balances that may become past due as a result of our extension of credit to customers may harm our results of operations.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We rely on PPN partners for distribution of XHANCE in the U.S., and the failure of those PPN partners to distribute XHANCE effectively would adversely affect sales of XHANCE. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our reliance on PPN partners for the distribution of XHANCE in the U.S. involves certain risks, including, but not limited to, risks that these PPN partners will: </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">not provide us accurate or timely information regarding their inventories, the number of patients who are using our products or complaints about our products;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">not devote the necessary resources, or reduce or discontinue their efforts, to sell or support or otherwise not effectively sell or support our products, including, without limitation, the discontinuation of their refill programs for XHANCE and other patient support services; </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">engage in unlawful or inappropriate business practices that result in legal or regulatory enforcement activity which could result in liability to our Company or damage our goodwill with patients; or </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">be unable to satisfy financial obligations to us or others. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event that any of the PPN partners with whom we work do not fulfill their contractual obligations to us or refuse to or fail to adequately serve patients, or the agreements are terminated without adequate notice, shipments of XHANCE, and associated revenues, would be adversely affected. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">If we cannot implement and maintain effective patient affordability programs or improve formulary access for XHANCE in the face of increasing pressure to reduce the price of medications, the adoption of XHANCE by physicians and patients may decline. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We offer patient affordability programs through traditional retail pharmacies and PPN partners to help reduce eligible patients&#8217; out-of-pocket costs for XHANCE prescriptions. The utilization of our patient affordability programs will depend on physician and patient awareness and acceptance of the programs.  Additionally, certain co-pay assistance benefits are only available through PPN partners. As a result, eligible patients&#8217; out-of-pocket cost for XHANCE, when dispensed through PPN partners, may be lower than such costs when XHANCE is dispensed from traditional retail pharmacies. However, to the extent physicians are not willing to prescribe through PPN partners or patients are not willing to receive XHANCE through PPN partners, access to and utilization of XHANCE may decline. In addition, our patient affordability programs are not available to federal health care program (such as Medicare and Medicaid) beneficiaries. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have also contracted with certain PBMs and other payors to secure formulary status and reimbursement for XHANCE, which generally require us to pay administrative fees and rebates to the PBMs and other payors for qualifying prescriptions. While we have agreements with three of the largest PBMs, as well as other PBMs and payors, in order to facilitate formulary status for XHANCE, we cannot guarantee that we will be able to agree to terms with other PBMs and payors, or that such terms will be commercially reasonable to us.  Additionally, our contracts with PBMs and payors are of limited duration and PBMs and payors with whom we contract may seek to renegotiate more favorable terms prior to the expiration of such contracts or in connection with renewals. Despite our agreements with PBMs, the extent of formulary status and reimbursement will ultimately depend to a large extent upon individual healthcare plan formulary decisions. If healthcare plans that contract with PBMs with which we have agreements do not adopt formulary changes recommended by the PBMs with respect to XHANCE, we may not realize the expected access and reimbursement benefits from these agreements. Consequently, the success of our PBM contracting strategy will depend not only on our ability to expand formulary adoption among healthcare plans, but also upon the relative mix of healthcare plans that have PBM-chosen formularies versus custom formularies. If we are unable to realize the expected benefits of our contractual arrangements with the PBMs the adoption of XHANCE by physicians and patients may decline. If we are unable to increase adoption of PPN partners for filling prescriptions of XHANCE by physicians or to secure formulary status and reimbursement through arrangements with PBMs and other payors, particularly with healthcare plans that use custom formularies, our ability to achieve net sales growth for XHANCE would be impaired.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The negative publicity regarding specialty pharmacies or patient support service providers may result in physicians being less willing to send prescriptions to PPN partners or participate in our patient affordability programs, which would limit patient access and utilization of XHANCE.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There has been negative publicity and inquiries from Congress and enforcement authorities regarding the use of specialty pharmacies and patient support services providers and drug pricing. We contract with PPN partners (who may be considered specialty pharmacies) and patient support services providers that provide certain services in connection with our patient affordability programs.  These programs are in place to assist in ensuring that when a physician determines XHANCE offers a potential clinical benefit to their patients and they prescribe it for an eligible patient, financial assistance may be available to reduce the patient&#8217;s out-of-pocket costs. We do not own or possess any option to purchase an ownership stake in any pharmacy that distributes XHANCE or in any patient support services provider, and our relationship with each pharmacy and patient support services provider is non-exclusive and arm&#8217;s length. All of our sales are processed through pharmacies independent of us. Despite this, the negative publicity and interest from Congress and enforcement authorities regarding specialty pharmacies or patient support services providers may result in physicians being less willing to send prescriptions to PPN partners or participate in our patient affordability programs and thereby limit patient access and utilization of XHANCE.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We may be unable to form and maintain relationships with pharmacies that participate in our PPN and patient affordability programs, which could adversely affect the commercialization of XHANCE and our operating results.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may encounter difficulty in forming and maintaining relationships with pharmacies that participate in our PPN and patient affordability programs. We currently depend on a limited number of PPN partners to fulfill patient prescriptions. If these PPN partners are unable to process and fulfill the volume of patient prescriptions directed to them, our ability to maintain or increase prescriptions for XHANCE will be impaired. The commercialization of XHANCE and our operating results could be affected should any of the PPN partners choose not to continue to fulfill XHANCE prescriptions or by any adverse market events at any of the PPN partners. For example, pharmacies that dispense XHANCE could lose contracts that they currently maintain with payors or managed care organizations (MCOs), including PBMs. They may be required to abide by certain terms and conditions to maintain access to payors or MCO networks, including terms and conditions that could limit their ability to participate in patient affordability programs like ours. Failure to comply with the terms of their agreements with payors or MCOs could </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">result in a variety of penalties, including termination of their agreement, which could negatively impact the ability of those pharmacies to dispense XHANCE and collect reimbursement from payors or MCOs for such medicines.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our patient affordability programs are subject to certain federal and state laws, the violation of which could have an adverse impact on our business and subject us to significant penalties.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our patient affordability programs may implicate certain federal and state laws related to, among other things, unlawful schemes to defraud, fraud and abuse, excessive fees for services, tortious interference with patient contracts and statutory or common law fraud. We have a comprehensive compliance program in place to address adherence with various laws and regulations relating to the selling, marketing and manufacturing of XHANCE. Despite our compliance efforts, to the extent the patient affordability programs are found to be inconsistent with applicable laws or the pharmacies that participate in our patient affordability programs do not comply with applicable laws or our business rules, we may be required to restructure or discontinue such programs, terminate our relationship with certain pharmacies, or be subject to other significant penalties. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">If the cost of maintaining our patient affordability programs increases relative to our sales revenue, we could be forced to reduce or eliminate our financial assistance programs, which could have an adverse effect on our financial results.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the cost of maintaining our patient affordability programs increases relative to our sales revenues, we could be forced to reduce the amount of patient financial assistance that we offer or otherwise scale back or eliminate such programs, which could in turn have a negative impact on physicians&#8217; willingness to prescribe and patients&#8217; willingness to fill prescriptions of XHANCE. While we believe that our arrangements with PBMs and other payors will result in broader inclusion of XHANCE on healthcare plan formularies, and lower our cost of providing patient affordability programs, these arrangements generally require us to pay administrative and rebate payments to the PBMs and/or other payors and their effectiveness will ultimately depend to a large extent upon individual healthcare plan formulary decisions that are beyond the control of the PBMs. If our arrangements with PBMs and other payors do not result in increased prescriptions and reductions in our costs to provide our patient affordability programs that are sufficient to offset the administrative fees and rebate payments to the PBMs and/or other payors, our financial results may continue to be harmed.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">XHANCE may become associated with undesirable adverse reactions or have other properties that could result in significant negative consequences following regulatory approval.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or others identify adverse events associated with XHANCE, a number of potentially significant negative consequences could result, including:</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">we may be forced to suspend marketing of XHANCE;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">the FDA may withdraw its approval of XHANCE or impose restrictions on its distribution;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">the FDA may require additional warnings or contradictions in the label that could diminish the usage or otherwise limit the commercial success of XHANCE;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">we may be required to conduct additional post-marketing studies;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">we could be sued and held liable for harm caused to patients; and</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">our reputation may suffer.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of these events could prevent us from achieving or maintaining market acceptance of XHANCE.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">If the FDA or other applicable regulatory authorities approve generic or similar products that compete with XHANCE, or if the FDA or other applicable regulatory authorities change or create new pathways that may expedite approval of such products, it could decrease our expected sales of XHANCE.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Once an NDA, including a Section&#160;505(b)(2) application, is approved, the product covered thereby becomes a "listed drug" which can, in turn, be cited by potential competitors in support of approval of an ANDA or 505(b)(2) NDA. The FD&amp;C Act, FDA regulations and other applicable regulations and policies provide incentives to manufacturers to create modified, non-infringing versions of a drug to facilitate the approval of an ANDA for generic substitutes. Manufacturers may be able to bring a generic product to market in a much more cost-efficient pathway than we currently anticipate. If the costs involved in bringing such a product to market are significantly less than our costs with respect to the development of XHANCE, companies that produce generic equivalents to XHANCE may be able to offer their products at lower prices. Further, if the timeline for bringing such a product to market is </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Contents</a></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">expedited, companies that produce generic equivalents to XHANCE may compete with XHANCE faster than we currently anticipate. For example, the FDA has communicated a priority to build on initiatives to accelerate generic entry of&#160;complex generics, which include locally acting nasal drug products and the FDA has included XHANCE on the updated list of product specific guidances for complex generic drug products that the FDA plans to issue, which may provide clarity for competitors to develop generic products that compete with XHANCE. If the FDA accepts alternatives to comparative clinical endpoint bioequivalence studies for generic versions of XHANCE, we may face generic competition faster than we currently anticipate and a significant percentage of any future sales of XHANCE could be lost to such generic products. In 2019, the FDA published a draft product-specific guidance for 0.05mg/spray fluticasone propionate nasal spray that states that a comparative clinical endpoint bioequivalence study is recommended for a fluticasone propionate nasal spray product because of an inability to adequately characterize drug particle size distribution (PSD) in aerosols and sprays using commonly used analytical methods. However, the draft guidance also provides that if a product's PSD can be accurately measured using a validated analytical method such as morphology-directed Raman spectroscopy or any other advanced methodology, the product's sponsor could submit comparative PSD data as part of their drug characterization within their ANDA application as a potential alternative to a bioequivalence study. Moreover, in addition to generic competition, we could face competition from other companies seeking approval of products that are similar to ours using the Section&#160;505(b)(2) pathway. Such applicants may be able to rely on XHANCE or other approved drug products or published literature to develop drug products that are similar to ours. Furthermore, in 2021 and 2022 we provided units of XHANCE to a generic manufacturer in compliance with the CREATES Act. The introduction of a drug product similar to our products or product candidates could expose us to increased competition, leading to a decrease in sales of XHANCE. Competition that we may face from generic or similar versions of XHANCE could materially and adversely impact our future revenue, profitability, and cash flows.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Even though we have obtained regulatory approval for XHANCE, we still face extensive FDA regulatory requirements and may face future regulatory difficulties.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even though we have obtained regulatory approval in the U.S. for XHANCE for the treatment of nasal polyps in adults, the FDA and state regulatory authorities may still impose significant restrictions on the indicated uses or marketing of XHANCE, or impose ongoing requirements for potentially costly post-approval studies or post-marketing surveillance. For example, as part of its approval of XHANCE for the treatment of nasal polyps in adults, the FDA is requiring that we conduct a randomized, double-blind, placebo controlled clinical trial in adolescents 12 to 17 years of age with nasal polyposis to assess the safety, efficacy, and pharmacokinetics of XHANCE in this population.  We have contracted with various clinical trial sites and continue patient enrollment in this trial.  The post-marketing requirement at XHANCE approval was to complete the trial by January 2022 and to submit a final report with respect to the trial by July 2022, however, due to enrollment rates, we have submitted a request to the FDA to extend these deadlines. FDA granted an extension of these milestone dates, and acknowledged revised milestone dates for study completion by October 2022 and final report submission by April 2023.  We have submitted an additional request to FDA to extend these deadlines further to allow for completion of ongoing discussions with FDA on partial extrapolation of adult data to the pediatric population.  If the FDA declines our request, we may be in violation of this requirement relating to the FDA's approval of our NDA for XHANCE. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to ongoing FDA requirements governing the labeling, packaging, storage, distribution, safety surveillance, advertising, promotion, record-keeping and reporting of safety and other post-marketing information. The holder of an approved NDA is obligated to monitor and report AEs and any failure of a product to meet the specifications in the NDA. The holder of an approved NDA must also submit new or supplemental applications and obtain FDA approval for certain changes to the approved product, product labeling or manufacturing process. Advertising and promotional materials must comply with FDA regulations and may be subject to other potentially applicable federal and state laws. The applicable regulations in countries outside the U.S. grant similar powers to the competent authorities and impose similar obligations on companies.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, manufacturers of drug products and their facilities are subject to payment of substantial user fees and continual review and periodic inspections by the FDA and other regulatory authorities for compliance with cGMP regulations and adherence to commitments made in the NDA. Since XHANCE is a combination product, we also need to comply with some of the FDA's manufacturing regulations for devices. In addition to cGMP, the FDA requires that our drug-device combination product comply with the Quality System Regulation (QSR), which sets forth the FDA's manufacturing quality standards for medical devices, and other applicable government regulations and corresponding foreign standards. If we, or a regulatory authority, discover previously unknown problems with XHANCE, such as AEs, of unanticipated severity or frequency, or problems with a facility where the product is manufactured, a regulatory authority may impose restrictions relative to XHANCE or the manufacturing facility, including requiring recall or withdrawal of the product from the market, suspension of manufacturing, or other FDA action or other action by foreign regulatory authorities.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we fail to comply with applicable regulatory requirements following approval of XHANCE, a regulatory authority may:</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">issue a warning letter asserting that we or our manufacturing partners are in violation of the law;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">seek an injunction or impose civil or criminal penalties or monetary fines;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">suspend, modify or withdraw regulatory approval;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">suspend any ongoing clinical trials;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">refuse to approve a pending NDA or a pending application for marketing authorization or supplements to an NDA or to an application for marketing authorization submitted by us;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">seize our product or product candidate; and/or</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">refuse to allow us to enter into supply contracts, including government contracts.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our relationships with physicians, patients, payors and pharmacies in the U.S. are subject to applicable anti-kickback, fraud and abuse laws and regulations. Our failure to comply with these laws could expose us to criminal, civil and administrative sanctions, reputational harm, and could harm our results of operations and financial conditions.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current and future operations with respect to the commercialization of XHANCE, as well as potential future development programs, are subject to various U.S. federal and state healthcare laws and regulations. These laws impact, among other things, our proposed sales, marketing, support and education programs and constrain our business and financial arrangements and relationships with third-party payors, healthcare professionals, pharmacies and others who may prescribe, recommend, purchase or provide XHANCE, and other parties through which we market, sell and distribute XHANCE. Finally, our current and future operations are subject to additional healthcare-related statutory and regulatory requirements and enforcement by foreign regulatory authorities in jurisdictions in which we conduct our business. The laws are described in greater detail in the previous section under "Business&#160;&#8212; Government Regulation&#160;&#8212; Healthcare Fraud and Abuse Laws," and include, but are not limited to:</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">the federal Anti-Kickback Statute, prohibits persons or entities from, among other things, knowingly and willfully soliciting, offering, receiving or paying any remuneration, directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, lease, order, or arranging for or recommending the purchase, lease or order of, any good or service, for which payment may be made, in whole or in part, under federal healthcare programs such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation.</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">the federal civil False Claims Act (which can be enforced through "qui tam," or whistleblower actions, by private citizens on behalf of the federal government) prohibits any person from, among other things, knowingly presenting, or causing to be presented false or fraudulent claims for payment of government funds or knowingly making, using or causing to be made or used, a false record or statement material to an obligation to pay money to the government or knowingly and improperly avoiding, decreasing or concealing an obligation to pay money to the U.S. federal government.</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">the federal Health Insurance Portability and Accountability Act of 1996 (HIPAA) imposes criminal and civil liability for, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement, in connection with the delivery of, or payment for healthcare benefits, items or services by a healthcare benefit program, which includes both government and privately funded benefits programs; similar to the U.S. federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation.</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">numerous federal and state laws and regulations that address privacy and data security, including state data breach notification laws, state health information privacy laws, and federal and state consumer protection laws (e.g., Section 5 of the Federal Trade Commission Act (FTC Act)), govern the collection, use, disclosure and protection of health-related and other personal information, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating relevant compliance </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Contents</a></span></div></div><div style="margin-top:8pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">efforts. Compliance with these laws is difficult, constantly evolving, time consuming, and requires a flexible privacy framework and substantial resources. Compliance efforts will likely be an increasing and substantial cost in the future. Federal regulators, state attorneys general, and plaintiffs&#8217; attorneys have been and will likely continue to be active in this space.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">a majority of states whom have adopted laws and regulations analogous to federal laws, including state anti-kickback and false claims laws, that may apply to our business practices, including but not limited to, research, distribution, sales and marketing arrangements and claims involving healthcare items or services reimbursed by any third-party payor, including private insurers. Other states have adopted laws that, among other things, require pharmaceutical companies to comply with the pharmaceutical industry's voluntary compliance guidelines and the relevant compliance guidance promulgated by the U.S. federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; and state laws and regulations that require drug manufacturers to file reports relating to pricing and marketing information, which requires tracking gifts and other remuneration and items of value provided to healthcare professionals and entities. In addition, some states have laws requiring pharmaceutical sales representatives to be registered or licensed, and still others impose limits on co-pay assistance that pharmaceutical companies can offer to patients.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the Physician Payments Sunshine Act, implemented as the Open Payments program, and its implementing regulations, requires manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid, or the Children's Health Insurance Program (with certain exceptions) to report annually to CMS information related to direct or indirect payments and other transfers of value to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), other healthcare professionals (such as physician assistants and nurse practitioners) and teaching hospitals, as well as ownership and investment interests held in the company by physicians and their immediate family members.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The shifting commercial compliance environment and the need to build and maintain robust and expandable systems to comply with different compliance or reporting requirements in multiple jurisdictions increase the possibility that a healthcare or pharmaceutical company may fail to comply fully with one or more of these requirements. Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations may involve substantial costs. It is possible that governmental authorities will conclude that our business practices do not comply with applicable fraud and abuse or other healthcare laws and regulations or guidance. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, imprisonment, exclusion from government funded healthcare programs, such as Medicare and Medicaid, additional oversight and reporting requirements if we become subject to a corporate integrity agreement or other settlement agreement to resolve allegations of non-compliance with these laws and the curtailment or restructuring of our operations. If any of the physicians or other providers or entities with whom we expect to do business is found not to be in compliance with applicable laws, they may be subject to the same criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs. Even if we are not determined to have violated these laws, government investigations into these issues typically require the expenditure of significant resources and generate negative publicity, which could harm our financial condition and divert resources and the attention of our management from operating our business.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The occurrence of any event or penalty described above may inhibit our ability to commercialize and further develop XHANCE and generate revenues which would have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">If we fail to comply with our reporting and payment obligations under the Medicaid Drug Rebate Program, or other governmental pricing programs, we could be subject to additional reimbursement requirements, penalties, sanctions and fines which could have a material adverse effect on our business, financial condition, results of operations and growth prospects.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We participate in the Medicaid Drug Rebate Program, and other governmental pricing programs, and therefore we are obligated to pay certain specified rebates and report pricing information with respect to XHANCE. Pricing and rebate calculations vary across product and programs, are complex and are often subject to interpretation by us, governmental and regulatory agencies and the courts. We cannot assure you that our submissions will not be found by CMS to be incomplete or incorrect. Governmental agencies may also make changes in program interpretations, requirements or conditions of participation, some of which may have implications for amounts previously estimated or paid. The Medicaid rebate amount is computed each quarter based on our submission to CMS of our current </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AMP and Best Price for the quarter. If we become aware that our reporting for a prior quarter was incorrect, or has changed as a result of recalculation of the pricing data, we are obligated to resubmit the corrected data for a period not to exceed twelve quarters from the quarter in which the data originally were due, and CMS may request or require restatements for earlier periods as well. Such restatements and recalculations increase our costs for complying with the laws and regulations governing the Medicaid Drug Rebate Program. Any corrections to our rebate calculations could result in an overage or underage in our rebate liability for past quarters, depending on the nature of the correction. Price recalculations also may affect the ceiling price at which we are required to offer our products to certain covered entities, such as safety-net providers, under the Public Health Service's 340B Program and under other similar government pricing programs. These programs are described in greater detail in the previous section under "Business &#8212; Government Regulation &#8212; Coverage and Reimbursement."</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our failure to comply with our reporting and payment obligations under the Medicaid Drug Rebate Program and other governmental programs could negatively impact our financial results. The issuance of federal regulations and coverage expansion by various governmental agencies relating to the Medicaid Drug Rebate Program has increased and will continue to increase our costs and the complexity of compliance, has been and will continue to be time-consuming to implement, and could have a material adverse effect on our results of operations, particularly if CMS challenges the approach we take in our implementation of federal regulation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also are liable for errors associated with our submission of pricing data. In addition to retroactive rebates and the potential for 340B Program refunds, if we are found to have knowingly submitted false AMP or Best Price information to the government, we may be liable for significant civil monetary penalties. Our failure to submit monthly/quarterly AMP and Best Price data on a timely basis also could result in a significant civil monetary penalty per day for each day the information is late beyond the due date. Further, if we are found to have knowingly misclassified a drug (e.g., by knowingly classifying it as a generic drug for Medicaid Drug Rebate Program purposes, which are subject to lower rebates, instead of a single-source or innovator multiple-source drug), we could be subject to civil monetary penalties no greater than two times the difference between the rebates we should have paid and the rebates we actually paid, which penalties are in addition to the penalties discussed previously. Such failures also could be grounds for CMS to terminate our Medicaid drug rebate agreement, pursuant to which we participate in the Medicaid Drug Rebate Program. In the event that CMS terminates our rebate agreement, federal payments may not be available under Medicaid or Medicare Part B for XHANCE. If we are found to have made a misrepresentation in the reporting of our ASP, the Medicare statute provides for significant civil monetary penalties for each misrepresentation for each day in which the misrepresentation was applied.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">HRSA issued a final regulation regarding the calculation of the 340B ceiling price and the imposition of civil monetary penalties on manufacturers that knowingly and intentionally overcharge covered entities, which became effective on January 1, 2019.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is currently unclear how HRSA will apply its enforcement authority under the regulation. HRSA also has implemented a ceiling price reporting requirement related to the 340B Program under which we are required to report 340B ceiling prices to HRSA on a quarterly basis, and HRSA then publishes that information to covered entities. Moreover, under a final regulation effective January 13, 2021, HRSA newly established an administrative dispute resolution, or ADR, process for claims by covered entities that a manufacturer has engaged in overcharging, and by manufacturers that a covered entity violated the prohibitions against diversion or duplicate discounts. Such claims are to be resolved through an ADR panel of government officials rendering a decision that could be appealed only in federal court. An ADR proceeding could subject us to onerous procedural requirements and could result in additional liability. In addition, changes to legislation, regulations, or guidance could modify 340B Program compliance or expand discount liability.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Civil monetary penalties can also be applied if we are found to have knowingly and intentionally charged 340B covered entities more than the statutorily mandated ceiling price. A covered entity or association representing covered entities can also bring claims against us through HRSA&#8217;s 340B ADR process. HRSA could terminate our 340B program Pharmaceutical Pricing Agreement for good cause, which could cause our Medicaid National Drug Rebate Agreement to be terminated, rendering federal funds for our covered outpatient drugs unavailable under Medicaid and Medicare Part B. Finally, we note again that civil monetary penalties could apply if a manufacturer fails to provide discounts under the Medicare Part D coverage gap discount program in the amount of 125% of the discount that was due.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal law requires that a company must participate in the U.S. Department of Veterans Affairs (VA) Federal Supply Schedule (FSS) pricing program to be eligible to have its products paid for with federal funds. As part of this program, we are obligated to make XHANCE available for procurement on an FSS contract under which we must </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Contents</a></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">comply with standard government terms and conditions and charge a price that is no higher than the statutory Federal Ceiling Price (FCP) to four federal agencies (VA, U.S. Department of Defense (DOD) Public Health Service, and U.S. Coast Guard). The FCP is based on the Non-Federal Average Manufacturer Price (Non-FAMP), which we calculate and report to the VA on a quarterly and annual basis. If we overcharge the government in connection with our FSS contract or Tricare Retail Pharmacy Agreement, whether due to a misstated FCP or otherwise, we are required to refund the difference to the government. Failure to make necessary disclosures and/or to identify contract overcharges can result in allegations against us under the U.S. civil False Claims Act and other laws and regulations. Unexpected refunds to the government, and responding to a government investigation or enforcement action, would be expensive and time-consuming, and could have a material adverse effect on our business, financial condition, results of operations and growth prospects.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Regulatory approval for any approved product is limited by the FDA to those specific indications and conditions for which clinical safety and efficacy have been demonstrated.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our promotional materials, statements and training methods must comply with applicable laws and regulations, including FDA's prohibition of the promotion of unapproved, or off-label, use. Physicians may use our products off-label, as the FDA does not restrict or regulate a physician's independent choice of treatment within the practice of medicine. As healthcare professionals frequently prescribe corticosteroids for the treatment of chronic nasal inflammatory diseases, such as chronic rhinosinusitis, doctors often prescribe XHANCE for the treatment of chronic rhinosinusitis and other chronic nasal inflammatory diseases, even though the FDA has granted approval of XHANCE only for the treatment of nasal polyps and we promote the use of XHANCE only for the treatment of nasal polyps. If the FDA determines that our promotional materials, statements or activities constitute promotion of an off-label use, we could be required to modify our promotional materials, statements or training methods or subject us to regulatory or enforcement actions, such as the issuance of an untitled letter, a warning letter, injunction, seizure, civil fine, disgorgement of money, operating restrictions or criminal penalties. We may also be subject to actions by other governmental entities or private parties, such as the U.S. civil False Claims Act, civil whistleblower or "qui tam" actions. It is also possible that other federal, state or foreign enforcement authorities might take action if they consider our promotional materials or activities to constitute promotion of an off-label use, which could result in significant fines or penalties under other statutory authorities. In that event, our reputation could be damaged and market adoption of XHANCE could be impaired.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Even though we have obtained FDA approval for XHANCE in the U.S., we may never obtain approval for or successfully commercialize XHANCE outside of the U.S., which would limit our ability to realize its full market potential.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to market XHANCE outside of the U.S., we must obtain marketing authorizations and comply with numerous and varying regulatory requirements of other countries regarding quality, safety and efficacy. Clinical trials conducted in one country may not be accepted by foreign regulatory authorities, and regulatory approval in one country does not mean that regulatory approval will be obtained in any other country. Approval processes vary among countries and can involve additional product testing and validation and additional administrative review periods. Seeking foreign regulatory approval could result in difficulties and costs for us and require additional non-clinical studies or clinical trials, which could be costly and time consuming. Regulatory requirements can vary widely from country to country and could delay or prevent the introduction of XHANCE in those countries. While our management team has experience in obtaining foreign regulatory approvals at other companies, we do not have any product candidates approved for sale in any foreign jurisdiction, and we, as a company, do not have experience in obtaining regulatory approval in international markets. If we fail to comply with regulatory requirements in international markets or to obtain and maintain required approvals, or if regulatory approval in international markets is delayed, our target market for XHANCE will be reduced and we would not be able to realize the full market potential of XHANCE.  Furthermore, in addition to the costs to commercialize XHANCE in international markets, the pricing of XHANCE outside of the U.S. at levels acceptable to patients, prescribing physicians or a foreign government payor may be a challenge.  If we are unable to achieve, or do not believe we will be able to achieve, acceptable pricing, we may not be able to profitably commercialize XHANCE in international markets. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The Affordable Care Act and any other healthcare reform measures may increase the difficulty and cost for us to commercialize XHANCE and affect the prices we may obtain.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. and many foreign jurisdictions have proposed and enacted legislative and regulatory changes affecting the healthcare system that could restrict or regulate post-approval activities and affect our ability to profitably sell XHANCE. The U.S. government, state legislatures and foreign governments also have shown significant interest in implementing cost-containment programs to limit the growth of government-paid healthcare costs, including price </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">controls, restrictions on reimbursement and requirements for substitution of generic products for branded prescription drugs.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Affordable Care Act was intended to broaden access to health insurance, reduce or constrain the growth of healthcare spending, enhance remedies against fraud and abuse, add transparency requirements for the healthcare and health insurance industries, impose new taxes and fees on the health industry and impose additional health policy reforms. These intended reforms are described in greater detail in the previous section under "Business&#160;&#8212; Government Regulation&#160;&#8212; U.S. Healthcare Reform."</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Among the provisions of the Affordable Care Act that have been implemented since enactment and are of importance to the commercialization of XHANCE are the following:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">an annual, nondeductible fee on any entity that manufactures or imports specified branded prescription drugs or biologic agents;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">expansion of healthcare fraud and abuse laws, including the U.S. civil False Claims Act and the Anti-Kickback Statute, new government investigative powers, and enhanced penalties for noncompliance;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">a new Medicare Part&#160;D coverage gap discount program, in which manufacturers must agree to offer 70% (as of January 1, 2019) point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for a manufacturer's outpatient drugs to be covered under Medicare Part&#160;D;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">extension of manufacturers' Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care organizations;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">price reporting requirements for drugs that are inhaled, infused, instilled, implanted, or injected;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">expansion of eligibility criteria for Medicaid programs;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">expansion of the entity types eligible for discounts under the Public Health Service Act's 340B drug pricing program;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">a requirement to annually report certain information regarding drug samples that manufacturers and distributors provide to physicians; and</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">a Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain provisions of the Affordable Care Act have been subject to judicial challenges, as well as efforts to modify them or alter their interpretation and implementation. For example, on December 22, 2017, the U.S. government signed into law the Tax Act, which includes a provision repealing, effective January 1, 2019, the tax-based shared responsibility payment imposed by the Affordable Care Act on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the &#8220;individual mandate.&#8221;  It is unclear how efforts to modify or invalidate the Affordable Care Act or its implementing regulations, or portions thereof, will affect the Affordable Care Act or our business.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, the Bipartisan Budget Act of 2018, among other things, amended the Medicare statute to reduce the coverage gap in most Medicare drugs plans, commonly known as the &#8220;donut hole,&#8221; by raising the required manufacturer point-of-sale discount from 50% to 70% off the negotiated price effective as of January 1, 2019. Additional legislative changes, regulatory changes, and judicial challenges related to the Affordable Care Act remain possible. We expect that the Affordable Care Act, as currently enacted or as it may be amended in the future, and other healthcare reform measures that may be adopted in the future, could have a material adverse effect on our industry generally and on our ability to maintain or increase sales of XHANCE or to successfully commercialize it.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also expect that the Affordable Care Act, as well as other healthcare reform measures that have been adopted and may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that we receive for XHANCE and could seriously harm our future revenues. Any reduction in reimbursement from Medicare, Medicaid, or other government programs may result in a similar reduction in </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenues, attain profitability or successfully commercialize XHANCE.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product liability lawsuits against us could cause us to incur substantial liabilities and to limit commercialization of XHANCE and any other product candidates that we may develop.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently face an inherent risk of product liability exposure related to the testing of our product candidates in human clinical trials and from our commercialization of XHANCE, and this risk will increase as we further commercialize XHANCE and other product candidates that we may develop. We may face product liability claims, regardless of FDA approval for commercial manufacturing and sale as product liability claims may be brought against us by patients who have used XHANCE in any of our clinical trials, future patients, healthcare providers or others using, administering or selling XHANCE and any of our product candidates, if and when approved. On occasion, large judgments have been awarded in class action lawsuits based on drugs that had unanticipated adverse effects. If we cannot successfully defend ourselves against claims that our product candidates or products caused injuries, we could incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in:</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">decreased demand for XHANCE;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">injury to our reputation and significant negative media attention;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">termination of clinical trial sites or entire trial programs that we conduct now or in the future relating to XHANCE or our other product candidates;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">withdrawal of clinical trial participants from any current or future clinical trial relating to XHANCE or our other product candidates;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">significant costs to defend the related litigation;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">substantial monetary awards to patients;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">loss of revenue;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">diversion of management and scientific resources from our business operations; and</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">an increase in product liability insurance premiums or an inability to maintain product liability insurance coverage.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently carry product liability insurance with coverage up to $10.0&#160;million in the aggregate, with a per incident limit of $10.0&#160;million, which may not be adequate to cover all liabilities that we may incur. Further, we may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise. Our inability to maintain sufficient product liability insurance at an acceptable cost could adversely affect our XHANCE product revenues, result in additional liabilities, inhibit the development of XHANCE for additional indications or inhibit the development of our other product candidates.  A successful product liability claim or series of claims brought against us could cause our stock price to decline and, if judgments exceed our insurance coverage, could adversely affect our financial condition, results of operations and business.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, any agreements we may enter into in the future with collaborators in connection with the development or commercialization of XHANCE, our EDS technology or any of our other product candidates may entitle us to indemnification against product liability losses, but such indemnification may not be available or adequate should any claim arise. In addition, several of our agreements require us to indemnify third parties and these indemnifications obligations may exceed the coverage under our product liability insurance policy. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We are subject to intense competition and, if we are unable to compete effectively, our product candidates, if approved, may not reach their commercial potential.   </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The development and commercialization of new drugs is highly competitive and subject to rapid and significant technological change as research provides a deeper understanding of the pathology of diseases and new technologies and treatments are developed. We face competition with respect to XHANCE from prescription and over-the-counter INS, monoclonal antibodies, oral steroids and other medical management products, and will face competition with respect to any other product candidates that we may seek to develop or commercialize in the future, from many different sources, including large pharmaceutical, biotechnology, specialty pharmaceutical and, to a lesser degree, medical device companies.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The key competitive factors that we expect to impact the commercial success of XHANCE and any other product candidates we may develop are likely to be their efficacy, safety and tolerability profile, reliability, convenience of administration, price and reimbursement. Nasonex&#8482; (mometasone furoate monohydrate) is the only other branded INS drug therapy approved by the FDA for the treatment of nasal polyps.  Nasonex was marketed by Merck before being removed from the prescription market, but is available over-the-counter without a prescription for other indications. Generic versions of Nasonex&#8482;, mometasone furoate monohydrate, remain available as prescription drugs. In addition, Beconase AQ&#8482;, which is an INS marketed by GlaxoSmithKline, is indicated for the prophylaxis of nasal polyps after surgical resection, SINUVA&#8482; is a commercially available corticosteroid-eluting implant indicated for the treatment of nasal polyps in adult patients who have had ethmoid sinus surgery that can be placed in the ethmoid sinus under endoscopic visualization for up to 90 days. To date, four monoclonal antibodies have been studied in nasal polyps: omalizumab, benralizumab, mepolizumab and dupilumab. DUPIXENT&#8482;  (dupilumab), which is a monoclonal antibody marketed by Sanofi and Regeneron, was approved by the FDA in 2019 as an add-on maintenance treatment (to an intranasal steroid) in adult patients with inadequately controlled chronic rhinosinusitis with nasal polyposis; XOLAIR&#8482; (omalizumab), which is a monoclonal antibody marketed by Genentech USA, Inc. and Novartis Pharmaceuticals Corporation, was approved by the FDA in 2020 as an add-on maintenance treatment of nasal polyps in adult patients with inadequate response to nasal corticosteroids; and NUCALA&#8482; (mepolizumab), which is a monoclonal antibody marketed by GlaxoSmithKline, was approved by the FDA in 2021 as an add-on maintenance treatment of chronic rhinosinusitis with nasal polyps in adult patients with inadequate response to nasal corticosteroids.  Although we are not aware of any drug therapy approved by the FDA or foreign regulatory agencies for the treatment of chronic rhinosinusitis (or chronic sinusitis) without nasal polyps, the above referenced monoclonal antibodies are being, or are expected to be, studied as potential treatments for patients with chronic rhinosinusitis without nasal polyps. In addition, Lyra Therapeutics is developing corticosteroid-eluting implants as potential treatment for patients with chronic rhinosinusitis. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even though they have not been approved for the treatment of such indications, published clinical practice guidelines do recommend the use of INS products for the treatment of chronic rhinosinusitis with and without nasal polyps in an effort to maximize medical therapy prior to surgical intervention. Currently approved branded INS products include Rhinocort&#8482;, marketed by AstraZeneca, Nasacort AQ&#8482;, marketed by Sanofi-Aventis, Beconase AQ&#8482;, Flonase&#8482; (which contains the same active pharmaceutical ingredient as XHANCE), and Veramyst&#8482;, each marketed by GlaxoSmithKline, Qnasl&#8482;, marketed by Teva Pharmaceuticals, and Omnaris&#8482; and Zetonna&#8482;, each marketed by Sunovion Pharmaceuticals. In lieu of prescription INS nasal sprays, physicians may recommend, and patients may elect to use, over-the-counter INS nasal sprays including over-the-counter products containing fluticasone propionate and mometasone furoate monohydrate.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Most of these INS and monoclonal antibody companies, as well as other potential competitors, have substantially greater financial, technical and human resources than we do and significantly greater experience in the discovery and development of product candidates, obtaining FDA and other regulatory approvals of products and the commercialization of those products.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a small number of our competitors. Accordingly, our competitors may be more successful than we may be in obtaining FDA approval of drugs and achieving widespread market acceptance. Our competitors' drugs, or drugs they may develop in the future, may be more effective, or more effectively marketed and sold, than any drug we may commercialize and may render XHANCE or any of our other product candidates we may develop obsolete or non-competitive before we can recover the expenses of developing and commercializing XHANCE or any of our other product candidates. Our competitors may also obtain FDA or other regulatory approval of products more rapidly than expected or may obtain better or preferred market access by offering large rebates to payors or by other means. We may not have accurately or completely predicted the development of new and improved or low-cost surgical interventions, alternative medical therapies or other market-disrupting events. If we are unable to manufacture, distribute, stimulate demand reaching the predicted market share, overcome barriers to access or otherwise effectively commercialize the product, all of which factors may be influenced by current or future competition, then our opportunity to generate revenue from the sale of XHANCE or any of our other product candidates, if approved, will be compromised.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Risks Related to Clinical Development and Regulatory Approval of XHANCE for the Treatment of Sinusitis and Our Other Product Candidates</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The design and execution of clinical trials to support FDA-approval of XHANCE for the treatment of chronic sinusitis is subject to substantial risk and uncertainty.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have conducted a clinical program to support a follow-on indication of XHANCE for the treatment of chronic sinusitis. Although the term chronic rhinosinusitis is often used in medical literature and medical practice, the FDA did not historically recognize chronic rhinosinusitis as an indication for drug development purposes. Instead, the FDA recognized "chronic sinusitis" and "nasal polyps" as indications for drug development purposes rather than the terminology "chronic rhinosinusitis with or without nasal polyps."  Recently, the FDA has approved drug products for the treatment of chronic rhinosinusitis with nasal polyps and issued a guidance document in November 2021 for clinical trial programs for nasal polyps in which it supports use of the terminology "chronic rhinosinusitis with nasal polyps" instead of "nasal polyps" and "chronic rhinosinusitis without nasal polyps" instead of "chronic sinusitis". In addition, in January 2023, at the request of the FDA, the indication statement for XHANCE was changed from "the treatment of nasal polyps" to "the treatment of chronic rhinosinusitis with nasal polyps" to conform to the FDA's current labeling terminology and not as a result of additional clinical data.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In February 2022, we submitted a prior approval efficacy supplement under our currently approved 505(b)(2) NDA for a follow-on indication for XHANCE for the treatment of chronic rhinosinusitis. However, as a result of the FDA's evolving view on terminology for nasal polyps, it is uncertain whether the phase 3 clinical trial program that we have conducted for XHANCE would support a follow-on indication for the "treatment of chronic sinusitis," the "treatment of chronic rhinosinusitis" or the "treatment of chronic rhinosinusitis without nasal polyps" or other similar terminology.  It is our belief that these variations in terminology are synonymous from a promotional perspective. Furthermore, because there is no FDA-approved product for the treatment of chronic rhinosinusitis (or the treatment of chronic rhinosinusitis or chronic sinusitis), we believe there is substantial risk and uncertainty in planning and conducting adequate clinical trials to meet FDA requirements to support approval for this indication.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Generally, the FDA requires, among other things, that safety and efficacy be established in two adequate and well-controlled studies in the target indication. We designed and conducted the ReOpen program to include chronic sinusitis patients that had objectively verified sinus disease as measured by CT scan.  In ReOpen1, we enrolled 205 subjects with chronic sinusitis with nasal polyps and 122 subjects with chronic sinusitis without nasal polyps. In ReOpen2, we only enrolled subjects with chronic sinusitis without nasal polyps. In the ReOpen1 total patient population, we demonstrated a statistically significant benefit for both primary endpoints, composite symptom relief and change in inflammation inside the sinus cavities, as measured by the change in average of percentages of volume occupied by disease (APOV). In addition, although ReOpen1 was not powered to demonstrate statistical significance in either endpoint for the subgroup of patients with chronic sinusitis without nasal polyps, we demonstrated statistical significance for the composite symptom relief endpoint within this subgroup, but not APOV. In ReOpen2, in which only patients with chronic sinusitis without nasal polyps were enrolled, we demonstrated statistically significant benefit in both the composite symptom relief and APOV endpoints.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If the FDA does not find the results of the ReOpen studies to be adequate to sufficiently demonstrate safety and efficacy of XHANCE for the treatment of chronic rhinosinusitis, we may not be successful in obtaining FDA approval for the follow-on indication without having to conduct additional trials. If we do not obtain a follow-on indication for the treatment of chronic rhinosinusitis, our promotion of XHANCE will be limited to nasal polyps, which would limit our potential sales of XHANCE, in which case our business, prospects, financial condition and results of operations will be materially and adversely affected, and we may be unable to maintain compliance with the financial and liquidity covenants of the A&amp;R Note Purchase Agreement or continue as a going concern.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">The clinical and regulatory approval processes of the FDA are lengthy, time consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for our product candidates, our business may be substantially harmed.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The time required to obtain approval by the FDA is unpredictable but typically takes many years following the commencement of clinical trials and depends upon numerous factors, including the substantial discretion of the FDA. In addition, approval policies, regulations, or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate's clinical development. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidates could fail to receive regulatory approval for many reasons, including the following:</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">the FDA may not accept our NDA filing or prior approval efficacy supplement;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">the FDA may disagree with the design, scope or implementation of our clinical trials;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">we may be unable to demonstrate to the satisfaction of the FDA that a product candidate is safe and effective for its proposed indication;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">we may be unable to demonstrate that a product candidate's clinical and other benefits outweigh its safety risks;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Contents</a></span></div></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">the FDA may disagree with our interpretation of data from preclinical studies or clinical trials;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">the data collected from clinical trials of our product candidates may not be sufficient to support the approval of an NDA or prior approval efficacy supplement;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">the FDA may fail to approve the manufacturing processes or facilities of third-party manufacturers with which we contract for clinical and commercial supplies; and</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">the approval policies or regulations of the FDA may change in a manner rendering our clinical data insufficient for approval.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The failure to obtain regulatory approval for a particular product candidate, could substantially harm our business. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Clinical development is a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results. Clinical failure can occur at any stage of clinical development.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials are expensive, can take many years to complete and have highly uncertain outcomes. Failure can occur at any time during the clinical trial process as a result of inadequate performance of a drug, inadequate adherence by patients or investigators to clinical trial protocols, investigators failure to comply with applicable laws, or other factors. Drug candidates in later stages of clinical trials may fail to show the desired safety and efficacy traits despite having progressed through earlier clinical trials. A number of companies in the pharmaceutical industry have suffered significant setbacks in advanced clinical trials as a result of a lack of efficacy or adverse safety profiles, despite promising results in earlier trials. Our clinical trials for the follow-on indication of XHANCE for the treatment of chronic rhinosinusitis or our other product candidates may not be successful or may be more expensive or time-consuming than we currently expect. If clinical trials for this or any other product candidate fail to demonstrate safety or efficacy to the satisfaction of the FDA, the FDA may not approve the follow-on indication of XHANCE or any other product candidate and we would not be able to commercialize it, which could substantially harm our business.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Delays in clinical trials are common and have many causes, and any delay could result in increased costs to us and jeopardize or delay our ability to obtain regulatory approval and commence product sales, or our ability to maintain regulatory approval.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our ongoing and future clinical trials may not begin on time, have an effective design, enroll a sufficient number of patients, timely enroll patients, or be completed on schedule, if at all. We have experienced and may experience further delays in clinical trials of our product candidates or for our FDA-mandated post-marketing pediatric study for XHANCE.  Our clinical trials can be delayed or terminated for a variety of reasons, including, but not limited to:</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">inability to raise funding necessary to initiate or continue a clinical trial;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">delays in obtaining regulatory approval to commence a clinical trial;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">delays in reaching agreement with the FDA or foreign regulatory authorities on final trial design or the scope of the development program;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">imposition of a clinical hold following an inspection of our clinical trial operations or trial sites by the FDA or foreign regulatory authorities;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">delays in reaching agreement on acceptable terms with prospective contract research organizations (CROs), and clinical trial sites;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">delays in obtaining required IRB approval;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">inability to attract clinical investigators for trials;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">delays in recruiting suitable patients to participate in a clinical trial;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">delays as a result of interim analyses, if any, of clinical trials that indicate futility of the trial or necessitate an increase in the number of patients enrolled in trial; </span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">patients' delays or failure to complete participation in a clinical trial or return for post-treatment follow-up;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">adverse side effects;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Contents</a></span></div></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">clinical sites dropping out of a clinical trial;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">time required to add new clinical sites;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">delays by our CMOs to produce and deliver a sufficient supply of clinical trial materials; or</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">governmental or regulatory delays, or changes in approval policies or regulations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, previous guidance related to the expected timing of results from our chronic sinusitis trials indicated that top-line results from both trials would be available in the second half of 2021. Pauses in patient enrollment due to factors related to the COVID-19 pandemic had varying effects in different geographies and over time led to a delay in the availability of data from our chronic sinusitis trials.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If clinical trials for our product candidates or for our FDA-mandated post-marketing pediatric study for XHANCE are delayed for any of the above reasons or other reasons, our development costs may increase, our approval process could be delayed or negatively impacted and our ability to commercialize our product or product candidates could be materially harmed.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Reliance on Third Parties</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">If we encounter difficulties in maintaining commercial manufacturing and supply agreements with our third-party manufacturers and suppliers of XHANCE, our ability to commercialize XHANCE would be impaired.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">We do not own any manufacturing facilities. We currently have no plans to build our own clinical or commercial scale manufacturing facility. We lack the resources to manufacture and test, on a commercial scale, the technical performance of XHANCE and our other product candidates. We currently rely, and expect to continue to rely, on a limited number of experienced personnel and CMOs and suppliers who assist in the production, assembly, test, supply, storage and distribution of XHANCE and its components for commercial and clinical supplies, and we control only some of the aspects of their activities. We may not be able to maintain terms that are favorable to us.  We may not be able to enter into commercial manufacturing and supply agreements with any necessary third parties, should such additional agreements become necessary. If we are unable to enter into such agreements or maintain existing agreements, each on commercially reasonable terms, our ability to commercialize XHANCE would be impaired, and our business, financial condition and results of operations would be materially adversely affected. We have initiated the process of qualifying alternate third-party suppliers for select components of XHANCE.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:107%">  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Alternate third party suppliers of XHANCE components are subject to qualification and approval from the FDA which can be a lengthy and expensive process.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">If we encounter issues with our contract manufacturers or suppliers, we may need to qualify alternative manufacturers or suppliers, which could impair our ability to sufficiently and timely manufacture and supply XHANCE.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently depend on contract manufacturers and suppliers for XHANCE and its components. Although we could obtain each of these components from other third-party suppliers, we would need to qualify and obtain FDA approval for another contract manufacturer or supplier as an alternative source for each such component, which could be costly and cause significant delays. For example, we estimate that it would take at least one year to identify and qualify an alternate contract manufacturer for XHANCE.  Additionally, our commercial manufacturing and supply agreements generally include limitations on our ability to utilize alternative manufacturers or suppliers for these components above certain specified thresholds during the terms of the agreements, or may include purchase minimums, which impairs our ability to fully implement any future manufacturing strategies to prevent supply shortages or quality issues.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, some of our suppliers, including our active pharmaceutical ingredient (API) supplier and our contract manufacturers, conduct their manufacturing operations for us at a single facility. Unless and until we qualify additional facilities, we may face limitations in our ability to respond to manufacturing and supply issues. For example, if regulatory, manufacturing or other problems require one of these manufacturers or suppliers to discontinue production at their respective facility, or if the equipment used for the production of XHANCE in these facilities is significantly damaged or destroyed by fire, flood, earthquake, power loss or similar events, the ability of such manufacturer or supplier to provide components or API needed for XHANCE, or to manufacture XHANCE may be significantly impaired. In the event that these parties suffer a temporary or protracted loss of its facility or equipment, we would still be required to obtain FDA approval to qualify a new manufacturer or supplier, as applicable, as an alternate manufacturer or source for the respective component before any components manufactured by such manufacturer or by such supplier could be sold or used.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Contents</a></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Any production shortfall that impairs the supply of XHANCE or any of its components could have a material adverse effect on our business, financial condition and results of operations and adversely affect our ability to satisfy demand for XHANCE, which could adversely affect our product sales and operating results materially.  For example, the sole supplier of the pump incorporated into XHANCE is discontinuing the manufacture of the pump. As a result, we are currently in the process of evaluating and testing replacement pumps. Although we have purchased excess pumps, any delay in identifying and obtaining FDA-approval of a replacement pump would have a material adverse impact in our ability to supply XHANCE.  We have also initiated the process of qualifying alternate third-party suppliers for select components of XHANCE.  Alternate third party suppliers of XHANCE components are subject to qualification and approval from the FDA.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">If third-party manufacturers, wholesalers, distributors and PPN partners fail to devote sufficient time and resources to XHANCE or their performance is substandard, our product supply may be negatively impacted.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our reliance on a limited number of manufacturers, wholesalers, distributors and PPN partners exposes us to the following risks, any of which could limit commercial supply of our products, result in higher costs, or result in a loss of potential product revenues:</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">our CMOs, or other third parties we rely on, may encounter difficulties in achieving the volume of production needed to satisfy commercial demand, may experience technical issues that impact quality or compliance with applicable and strictly enforced regulations governing the manufacture of pharmaceutical products, and may experience shortages of qualified personnel to adequately staff production operations;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">our wholesalers, distributors and PPN partners could become unable to sell and deliver XHANCE for regulatory, compliance and other reasons;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">our CMOs, wholesalers, distributors and PPN partners could default on their agreements with us to meet our requirements for commercial supply and distribution of XHANCE;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">our CMOs, wholesalers, distributors and PPN partners may not perform as agreed or may not remain in business for the time required to successfully produce, store, sell and distribute our products and we may incur additional cost; and</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">if our CMOs, wholesalers, distributors and PPN partners were to terminate our arrangements or fail to meet their contractual obligations, we may be forced to delay or cease sales and ongoing development of XHANCE, or find alternatives that may be more expensive than originally anticipated.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Our reliance on third parties reduces our control over our product candidate development and commercialization activities but does not relieve us of our responsibility to ensure compliance with all required legal, regulatory and scientific standards. For example, the FDA and other regulatory authorities require that our product candidates and any products that we may eventually commercialize be manufactured according to cGMP and similar foreign standards. Any failure by our third-party manufacturers to comply with cGMP or failure to scale up manufacturing processes, including any failure to deliver sufficient quantities of product candidates in a timely manner, could lead to a delay in, or failure to obtain, regulatory approval of any of our product candidates or supply our commercial volume of XHANCE. In addition, such failure could be the basis for the FDA to issue a warning or untitled letter, withdraw approvals for product candidates previously granted to us, or take other regulatory or legal action, including recall or seizure, total or partial suspension of production, suspension of ongoing clinical trials, refusal to approve pending applications or supplemental applications, detention or product, refusal to permit the import or export of products, injunction, imposing civil penalties or pursuing criminal prosecution.We have initiated the process of qualifying an alternate third-party supplier for select components of XHANCE.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:107%">  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Alternate third party suppliers of XHANCE components are subject to qualification and approval from the FDA.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Manufacturing issues may arise that could increase product and regulatory approval costs or delay commercialization.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Issues may arise involving product manufacturing of XHANCE or any of our products that may be under development, including but not limited to delays in receiving finished product or product components or raw materials, analytical testing issues, product-packaging problems and equipment malfunctions. These issues may require refinement or resolution in order to continue and not delay the commercialization of XHANCE or development of any of our products under development. In addition, quality issues may arise during commercial manufacturing processes or the scale-up of any of our products that may be under development. Any issues in our product or delivery devices could result in increased scrutiny by regulatory authorities, delays in our regulatory approval process, increases in our operating expenses, shortages in our products available for sales or clinical trial use, decreases in sales to customers, or failure to obtain or maintain approval for our products. We have initiated </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Contents</a></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">the process of qualifying alternate third-party suppliers for select components of XHANCE.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:107%">  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Alternate third party suppliers of XHANCE components are subject to qualification and approval from the FDA.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We rely on third parties to conduct our clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, or if they terminate their agreement with us, we may not be able to obtain regulatory approval for or commercialize our product candidates.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have relied upon and plan to continue to rely upon CROs to monitor and manage data for our prospective preclinical and clinical programs. We rely on these parties for execution of our clinical trials, and we control only some of the aspects of their activities. Nevertheless, we are responsible for ensuring that each of our studies and clinical trials are conducted in accordance with the applicable protocol, legal, regulatory and scientific standards, and our reliance on the CROs does not relieve us of our regulatory responsibilities. We and our CROs are required to comply with federal regulations and cGCP, which are international standards meant to protect the rights and health of patients and to define the roles of clinical trial sponsors, advisors and monitors. cGCPs are enforced by the FDA and foreign regulatory authorities in the form of International Conference on Harmonization (ICH) guidelines for all of our product candidates in clinical development. Regulatory authorities enforce cGCP through periodic inspections of trial sponsors, principal investigators and trial sites. If we or any of our CROs fail to comply with applicable cGCP and other regulations, including as a result of any recent changes in such regulations, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials comply with cGCP requirements. While we have agreements governing activities of our CROs, we have limited influence over their actual performance. Failure to comply with applicable regulations in the conduct of the clinical trials for our product candidates may require us to repeat preclinical studies and clinical trials, which would increase our operating expenses and delay the regulatory approval process.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our CROs are not our employees, and except for remedies available to us under our agreements with such CROs, we cannot control whether or not they devote sufficient time and resources to our ongoing clinical and preclinical programs. If our CROs do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols, regulatory requirements or for other reasons or if we receive additional FDA notices that do require corrective action, our clinical trials may be extended, delayed or terminated and we may not be able to obtain regulatory approval for or successfully commercialize our product candidates. As a result, the commercial prospects for our product candidates would be harmed, our costs could increase substantially and our ability to generate revenue could be delayed.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Switching or adding additional CROs involves additional cost and requires management time and focus. Identifying, qualifying and managing performance of third-party service providers can be difficult, time-consuming and cause delays in our development programs. In addition, there is a natural transition period when a new CRO commences work and the new CRO may not provide the same type or level of services as the original provider. Though we carefully manage our relationships with our CROs, there can be no assurance that we will not encounter challenges or delays in the future or that these delays or challenges will not have a material adverse impact on our business, financial condition and prospects. If any of our relationships with our CROs terminate, we may not be able to enter into arrangements with alternative CROs or to do so on commercially reasonable terms. As a result, delays may occur, which can materially impact our ability to meet our desired clinical development timelines.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because we have relied on third parties, our internal capacity to perform these functions is limited. Outsourcing these functions involves risks that third parties may not perform to our standards, may not produce results in a timely manner or may fail to perform at all. In addition, the use of third-party service providers requires us to disclose our proprietary information to these parties, which could increase the risk that this information will be misappropriated. We currently have a small number of employees, which limits the internal resources we have available to identify and monitor our third-party providers. To the extent we are unable to identify and successfully manage the performance of third-party service providers in the future, our ability to advance our product candidates through clinical trials will be compromised. Though we carefully manage our relationships with our CROs, there can be no assurance that we will not encounter similar challenges or delays in the future or that these delays or challenges will not have a material adverse impact on our business, financial condition and prospects.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Business Operations and Industry</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our long-term growth depends on our ability to develop and commercialize additional ENT and allergy products.    </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is important to our business that we continue to build a more complete product offering within the ENT and allergy markets. Developing additional product candidates is expensive and time-consuming and could divert management's attention away from the commercialization of XHANCE. Even if we are successful in developing additional product candidates, the success of any new product candidates or enhancement to any existing product candidates will depend on several factors, including our ability to:</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">properly identify and anticipate ENT and allergy physician and patient needs;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">develop, obtain necessary regulatory clearances or approvals, and introduce new product candidates or product enhancements in a timely manner;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">demonstrate, if required, the safety and efficacy of new product candidates with data from preclinical studies and clinical trials;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">avoid infringing upon the intellectual property rights of third parties;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">comply with all regulations relating to the marketing of new product candidates, including any new or modified EDS technologies; and</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">provide adequate training to potential users of our product candidates.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unsuccessful in developing, acquiring or licensing additional product candidates in other areas of the ENT and allergy markets, our ability to gain and maintain profitability may be impaired.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We are subject to risks inherent in foreign operations.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We historically operated portions of our business through our foreign subsidiaries, including through our Norwegian subsidiary, OptiNose AS, which, until 2022, owned a substantial portion of our intellectual property and conducted certain development activities.  We also operated a United Kingdom subsidiary, OptiNose UK&#160;Ltd..  We are in the process of dissolving both OptiNose AS and OptiNose UK, Ltd. The operations we conduct in other countries, including clinical trials, and the operations conducted by third party suppliers and vendors with whom we do business, are subject to foreign laws. We are subject to a number of risks associated with our international business operations and activities that may increase liability, costs, and require significant management attention. These risks include:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">compliance with the laws of the U.S., the United Kingdom, Norway, and other countries that apply to our international operations, including import and export legislation;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">compliance with foreign data protection laws and regulations in the United Kingdom, Norway and other countries that apply to our international operations;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">the complexities and expenses of administering a business abroad;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">complications in compliance with, and unexpected changes in, tariffs, trade barriers, price and exchange controls and other foreign regulatory requirements, including potential trade conflicts, changes to trade agreements/treaties, and the implementation of trade restrictions;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">instability in economic or political conditions, including inflation, recession and actual or anticipated military conflicts, social upheaval or political uncertainty;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">uncertainties of laws and enforcement relating to the protection of intellectual property or secured technology;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">litigation in foreign court systems;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">language barriers;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">changes in tax laws and regulations in the jurisdictions in which we operate;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">compliance with tax, employment, immigration and labor laws, regulations and restrictions for employees living or traveling abroad;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">difficulties staffing and managing foreign operations; and</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">workforce uncertainty in countries where labor unrest is more common than in the U.S.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There can be no assurance that the policies and procedures we implement to address or mitigate these risks will be successful, that our personnel will comply with them or that we will not experience these risks in the future or that they will not have a material adverse effect on our business, results of operations and financial condition.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our corporate structure and foreign operations may have adverse tax consequences and expose us to additional tax liabilities. In addition, tax returns we file are subject to examination by U.S. federal, state and foreign tax authorities.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to 2023, we had operations in Norway and the UK and a substantial portion of our intellectual property, including certain rights to XHANCE, were owned by OptiNose AS, our Norwegian subsidiary, until 2022.  We file tax returns in various jurisdictions and those returns are subject to examination by the tax authorities.  During an examination, a tax authority could challenge positions taken on a return.  Such a challenge could result in the loss of tax attributes or in the payment of tax which could have an unfavorable impact on our financial condition.   </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to 2023, we operated pursuant to written intercompany license, service and related agreements that establish prices for intellectual property and for services provided such as production, marketing, management, and technology development activities that are performed by one group company for another group company. The amounts paid under these intercompany agreements are commonly considered for tax purposes as transfer prices.  If the affiliated companies are located in different countries, the tax laws and regulations of each country generally require that transfer prices be at arm&#8217;s length as if between unrelated companies. Our transfer pricing arrangements consider requirements of the jurisdictions in which we operate but are not binding on the tax authorities.  If any tax authority is successful in challenging our transfer prices, there could be an increase in taxable income in that jurisdiction which could increase our tax liabilities. Further, if the tax authority in the other country does not agree with the adjustment, both countries could tax the same income, resulting in double taxation.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any income earned by our foreign subsidiaries, including a portion of the sales of XHANCE in the U.S., may be subject to additional tax liabilities. If our foreign operations generate cash that we want to repatriate to the U.S. or if cash generated by our U.S. operations is not sufficient to fund our U.S. operations, we may face additional tax liabilities in returning or otherwise providing such cash to support our U.S. operations or other strategic opportunities in the U.S. If we are forced to repatriate any foreign-held cash, we could incur a significant tax charge, and our business, operating results or financial condition could be adversely impacted.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If foreign subsidiary income is subject to the Subpart F, investment in US property or global intangible low-taxed income provisions, or similar provisions of the U.S. Internal Revenue Code, collectively referred to in this paragraph as Subpart F, the income may be subject to U.S. corporate income tax even if there is no cash distribution of those earnings to the U.S. For example, Subpart&#160;F income includes certain "passive" income, certain income from intercompany transactions, foreign subsidiary income over a legislative threshold or income of a foreign subsidiary which makes an "investment in U.S. property", such as holding the stock in a U.S. corporation. Any foreign subsidiary income subject to the Subpart&#160;F provisions would be included in determining U.S. taxable income and potentially subject to federal corporate income tax at rates up to 21%.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Intellectual Property</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">If we are unable to protect our intellectual property rights or if our intellectual property rights are inadequate to protect our technology, XHANCE or our other product candidates, our competitors could develop and commercialize technology similar to ours, and our competitive position could be harmed.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success will depend in large part on our ability to obtain and maintain patent and other intellectual property protection in the U.S. and other countries with respect to our proprietary technology and products. We rely on trade secret, patent, copyright and trademark laws, and confidentiality and other agreements with employees and third parties, all of which offer only limited protection. Our strategy is to seek patent protection for XHANCE, our other product candidates and their compositions, their methods of use and processes for their manufacture, and any other aspects of inventions that are commercially important to the development of our business.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent prosecution process is expensive and time-consuming, and we and any future licensors and licensees may not be able to apply for or prosecute patents on certain aspects of our product candidates or delivery technologies at a reasonable cost, in a timely fashion, or at all. We may not have the right to control the preparation, filing and prosecution of patent applications, or to maintain the rights to patents licensed to third parties. Therefore, these patents and applications may not be prosecuted and enforced in a manner consistent with the best interests of our business. It is also possible that we, or any future licensors or licensees, will fail to identify patentable aspects </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of inventions made in the course of development and commercialization activities before it is too late to obtain patent protection on them. Therefore, our patents and applications may not be prosecuted and enforced in a manner consistent with the best interests of our business. It is possible that defects of form in the preparation or filing of our patents or patent applications may exist, or may arise in the future, such as with respect to proper priority claims, inventorship, claim scope or patent term adjustments. If any future licensors or licensees are not fully cooperative or disagree with us as to the prosecution, maintenance, or enforcement of any patent rights, such patent rights could be compromised and we might not be able to prevent third parties from making, using, and selling competing products. If there are material defects in the form or preparation of our patents or patent applications, such patents or applications may be invalid or unenforceable. Moreover, our competitors may independently develop equivalent knowledge, methods, and know-how. Any of these outcomes could impair our ability to prevent competition from third parties, which may have an adverse impact on our business, financial condition, and operating results.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent positions of pharmaceutical companies generally are highly uncertain, involve complex legal and factual questions and have in recent years been the subject of much litigation. As a result, the issuance, scope, validity, enforceability and commercial value of any patents that issue, are highly uncertain. The steps we have taken to protect our proprietary rights may not be adequate to preclude misappropriation of our proprietary information or infringement of our intellectual property rights, both inside and outside the U.S. Further, the examination process may require us to narrow the claims of pending patent applications, which may limit the scope of patent protection that may be obtained if these applications issue. The rights that may be granted under future issued patents may not provide us with the proprietary protection or competitive advantages we are seeking. If we are unable to obtain and maintain patent protection for our technology and products, or if the scope of the patent protection obtained is not sufficient, our competitors could develop and commercialize technology and products similar or superior to ours, and our ability to successfully commercialize our technology and products may be impaired.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of February 1, 2023, we owned over 60 U.S. issued patents and pending U.S. patent applications. Our issued U.S. patents expire between 2023 and 2036. We do not know whether any of our patent applications will result in issued patents or, if any of our patent applications do issue, whether such patents will protect our technology and drugs, in whole or in part, or whether such patents will effectively prevent others from commercializing competitive technologies and products. There is no guarantee that any of our issued or granted patents will not later be found invalid or unenforceable. Furthermore, as our issued patents expire, the risk that competitors may be able to circumvent our remaining patents by developing similar or alternate technologies or products in a non-infringing manner is increased. Two of our 13 patents listed in the FDA's Orange Book for XHANCE are set to expire from 2023 to 2025. These patents cover certain aspects of our exhalation deliver system technology utilized by XHANCE. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The laws of foreign countries may not protect our rights to the same extent as the laws of the U.S. or vice versa. For example, European patent law restricts the patentability of methods of treatment of the human body more than U.S. law does. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the U.S. and other jurisdictions are typically not published until 18&#160;months after filing or in some cases not at all, until they are issued as a patent. Therefore, we cannot be certain that we were the first to make the inventions claimed in our pending patent applications, that we were the first to file for patent protection of such inventions, or that we have found all of the potentially relevant prior art relating to our patents and patent applications that could invalidate one or more of our patents or prevent one or more of our patent applications from issuing. Even if patents do successfully issue and even if such patents cover our product candidates, third parties may initiate oppositions, interferences, re-examinations, post-grant reviews, inter partes reviews, nullification or derivation actions in court or before patent offices or similar proceedings challenging the validity, enforceability, or scope of such patents, which may result in the patent claims being narrowed or invalidated. For example, the issuance of three of our patents in Europe are subject to opposition proceedings - these patent applications cover certain aspects of our flexible mouthpiece, nosepiece and liquid EDS. Furthermore, even if our patents are not challenged, our patents and patent applications may not adequately protect our intellectual property, provide exclusivity for our product candidates, or prevent others from designing around our claims. Any of these outcomes could impair our ability to prevent competition from third parties.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, the issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our owned and licensed patents may be challenged in the courts or patent offices in the U.S. and abroad. Such challenges may result in loss of exclusivity or freedom to operate or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar or identical technology and drugs, or limit the duration of the patent protection of our technology and drugs. Given the amount of time required for the development, testing and regulatory review of new drug candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing drugs similar or identical to ours.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We may become involved in lawsuits to protect or enforce our patents or the patents of our licensors, which could be expensive, time consuming and unsuccessful.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Competitors or other third parties may infringe our patents or the patents of any party from whom we may license patents from in the future. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming. In a patent litigation in the U.S., defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, for example, lack of novelty, obviousness or non-enablement. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO or made a misleading statement, during prosecution. The outcome following legal assertions of invalidity and unenforceability during patent litigation is unpredictable. A court may decide that a patent of ours or of any of our future licensors is not valid or is unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. In addition, to the extent that we have to file patent litigation in a federal court against a U.S. patent holder, we would be required to initiate the proceeding in the state of incorporation or residency of such entity. With respect to the validity question, for example, we cannot be certain that no invalidating prior art exists. An adverse result in any litigation or defense proceedings could put one or more of our patents at risk of being invalidated, found unenforceable, or interpreted narrowly, and it could put our patent applications at risk of not issuing. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. If a defendant were to prevail on a legal assertion of invalidity or unenforceability, we would lose at least part, and perhaps all, of the patent protection on one or more of our products or certain aspects of our EDS technology. Such a loss of patent protection could compromise our ability to pursue our business strategy.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interference proceedings brought by the USPTO may be necessary to determine the priority of inventions with respect to our patents and patent applications or those of our collaborators or licensors. An unfavorable outcome could require us to cease using the technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if a prevailing party does not offer us a license on terms that are acceptable to us. Litigation or interference proceedings may fail and, even if successful, may result in substantial costs and distraction of our management and other employees. We may not be able to prevent, alone, with our licensees, or with any of our future licensors, misappropriation of our proprietary rights, particularly in countries where the laws may not protect those rights as fully as in the U.S. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, we may be subject to a third-party pre-issuance submission of prior art to the USPTO or other foreign patent offices, or become involved in opposition, derivation, reexamination, inter partes review, post-grant review or interference proceedings challenging our patent rights or the patent rights of others. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate, our patent rights, allow third parties to commercialize our technology or drugs and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize drugs without infringing third-party patent rights. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, it could dissuade companies from collaborating with us to license, develop, or commercialize current or future product candidates.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We may not be able to protect our intellectual property rights throughout the world.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Filing, prosecuting and defending patents on XHANCE, our other product candidates and our EDS technology throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the U.S. may be less extensive than those in the U.S. In addition, the laws and practices of some foreign countries do not protect intellectual property rights, especially those relating to life sciences, to the same extent as federal and state laws in the U.S. For example, novel formulations of existing drugs and manufacturing processes may not be patentable in certain jurisdictions, and the requirements for patentability may differ in certain countries, particularly developing countries. Also, some foreign countries, including European Union countries, India, Japan and China, have compulsory licensing laws under which a patent owner may be compelled under certain circumstances to grant licenses to third parties. Consequently, we may have limited remedies if patents are infringed or if we are compelled to grant a license to a third party, and we may not be able to prevent third parties from practicing our inventions in all countries outside the U.S., or from selling or importing products made using our inventions into or </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Contents</a></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">within the U.S. or other jurisdictions. This could limit our potential revenue opportunities. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products, and may export otherwise infringing products to territories where we have patent protection, but where enforcement is not as strong as that in the U.S. These products may compete with our products in jurisdictions where we do not have any issued patents and our patent claims or other intellectual property rights may not be effective or sufficient to prevent them from competing with us in these jurisdictions. Furthermore, the prevalence of counterfeit medicines, which is one that has been deliberately and fraudulently mislabeled as to its identity and source, is a significant and growing industry-wide issue that could impact our revenue and our reputation for which we may have limited or no recourse. Accordingly, our efforts to enforce intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from our intellectual property. We may not prevail in any lawsuits that we initiate in these foreign countries and the damages or other remedies awarded, if any, may not be commercially meaningful.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and applications are required to be paid to the USPTO and various governmental patent agencies outside of the U.S. in several stages over the lifetime of the patents and applications. The USPTO and various non-U.S. governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process and after a patent has issued. There are situations in which non-compliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Third parties may initiate legal proceedings alleging that we are infringing their intellectual property rights, the outcome of which could be uncertain and could harm our business.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success depends upon our ability to develop, manufacture, market and sell XHANCE and our other product candidates and use our proprietary technologies without infringing the proprietary rights of third parties. While our product candidates are in preclinical studies and clinical trials, we believe that the use of our product candidates in these preclinical studies and clinical trials falls within the scope of the exemptions provided by 35 U.S.C. Section&#160;271(e) in the U.S., which exempts from patent infringement liability activities reasonably related to the development and submission of information to the FDA. As XHANCE and Onzetra Xsail are commercialized and our other product candidates progress toward commercialization, the possibility of a patent infringement claim against us increases. If we use the Section&#160;505(b)(2) regulatory pathway for the follow-on indication of chronic rhinosinusitis or any of our other product candidates it will require us to provide a Paragraph&#160;IV certification to the NDA and patent holders of the RLD pursuant to the Hatch-Waxman Act if the RLD is covered by Orange Book-listed patents. If the NDA or patent holder files&#160;a patent infringement lawsuit against us within 45&#160;days of its receipt of notice of our certification, the FDA is prevented from approving our Section&#160;505(b)(2) NDA until the earliest of 30&#160;months, expiration of the patents, settlement of the lawsuit or a court decision in the infringement case that is favorable to us. In connection with our submission of the prior approval efficacy supplement for a follow-on indication for XHANCE for chronic rhinosinusitis in February 2023, we provided Paragraph IV certifications to the FDA and notice of such certifications to the NDA and patent holders for the two Orange Book-listed patents for Flovent HFA (one of the RLDs for XHANCE's original NDA). If these NDA and patent holders file a patent infringement action against us within 45 days from receipt of our notice of certification, the potential follow-on indication for XHANCE for chronic rhinosinusitis may be delayed and we may incur significant expenses defending such action.  Accordingly, we may invest significant time and expense in the development of our product candidates only to be subject to significant delay and expensive and time-consuming patent litigation before our product candidates may be commercialized. There can be no assurance that our product candidates do not infringe other parties' patents or other proprietary rights and competitors or other parties may assert that we infringe their proprietary rights in any event.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is considerable intellectual property litigation in the biotechnology and pharmaceutical industries. We may become party to, or threatened with, future adversarial proceedings or litigation regarding intellectual property rights with respect to our product candidates, including interference or derivation proceedings before the USPTO. Numerous U.S. and foreign issued patents and pending patent applications owned by third parties exist in the fields in which we are developing our drug candidates. Third parties may assert infringement claims against us based on existing patents or patents that may be granted in the future.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are found to infringe a third party's intellectual property rights, we could be required to obtain a license from such third party to continue commercializing our product candidates. However, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if a license can be obtained on acceptable terms, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the rights may be non-exclusive, which could give our competitors access to the same technology or intellectual property rights licensed to us. If we fail to obtain a required license, we may be unable to effectively market product candidates based on our technology, which could limit our ability to generate revenue or achieve profitability and possibly prevent us from generating revenue sufficient to sustain our operations. Alternatively, we may need to redesign our infringing products, which may be impossible or require substantial time and monetary expenditure. Under certain circumstances, we could be forced, including by court order, to cease commercializing our product candidates. In addition, in any such proceeding or litigation, we could be found liable for substantial monetary damages, potentially including treble damages and attorneys' fees, if we are found to have willfully infringed. A finding of infringement could prevent us from commercializing our product candidates or force us to cease some of our business operations, which could harm our business. Any claims by third parties that we have misappropriated their confidential information or trade secrets could have a similar negative impact on our business.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cost to us in defending or initiating any litigation or other proceeding relating to patent or other proprietary rights, even if resolved in our favor, could be substantial, and litigation would divert our management's attention. Some of our competitors may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could compromise our commercialization efforts, delay our research and development efforts and limit our ability to continue our operations. There could also be public announcements of the results of the hearing, motions, or other interim proceedings or developments. If securities analysts or investors perceive those results to be negative, it could cause the price of shares of our common stock to decline.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our competitors may be able to circumvent our patents by developing similar or alternative technologies or products in a non-infringing manner.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our competitors may seek to market generic versions of XHANCE or any other product for which we obtain approval by submitting ANDAs to the FDA or new products that use our approved products as the RLD, in each case where our competitors claim that our patents are invalid, unenforceable or not infringed. Alternatively, our competitors may seek approval to market their own products that are the same as, similar to or otherwise competitive with XHANCE and any future product candidates we may develop. In these circumstances, we may need to defend or assert our patents, by means including filing lawsuits alleging patent infringement requiring us to engage in complex, lengthy and costly litigation or other proceedings. In any of these types of proceedings, a court or government agency with jurisdiction may find our patents invalid, unenforceable or not infringed. We may also fail to identify patentable aspects of our research and development before it is too late to obtain patent protection. Even if we have valid and enforceable patents, these patents still may not provide protection against competing products or processes sufficient to achieve our business objectives. Furthermore, as our issued patents expire, the risk that competitors may be able to circumvent our remaining patents by developing similar or alternate technologies or products in a non-infringing manner is increased. Two of our 13 remaining patents listed in the FDA's Orange Book for XHANCE are set to expire from 2023 to 2025. These patents cover certain aspects of our exhalation deliver system technology utilized by XHANCE. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in either U.S. or foreign patent law or interpretation of such laws could diminish the value of patents in general, thereby impairing our ability to protect our products.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As is the case with other pharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the pharmaceutical industry involve both technological and legal complexity, and it therefore is costly, time-consuming and inherently uncertain. In addition, on September&#160;16, 2011, the Leahy-Smith America Invents Act (the AIA) was signed into law. The AIA includes a number of significant changes to U.S. patent law, including provisions that affect the way patent applications will be prosecuted and may also affect patent litigation.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An important change introduced by the AIA is that, as of March&#160;16, 2013, the U.S. transitioned to a "first-to-file" system for deciding which party should be granted a patent when two or more patent applications are filed by different parties claiming the same invention. A third party that files&#160;a patent application in the USPTO after that date, but before us, could therefore be awarded a patent covering an invention of ours even if we had made the invention before it was made by the third party. This will require us to be cognizant going forward of the time from invention to filing of a patent application.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Among some of the other changes introduced by the AIA are changes that limit where a patentee may file&#160;a patent infringement suit and providing opportunities for third parties to challenge any issued patent in the USPTO. This applies to all of our U.S. patents, even those issued before March&#160;16, 2013. Because of a lower evidentiary standard necessary to invalidate a patent claim in USPTO proceedings compared to the evidentiary standard in </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. federal court, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action. Accordingly, a third party may attempt to use the USPTO procedures to invalidate our patent claims that would not have been invalidated if first challenged by the third party as a defendant in a district court action.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depending on decisions by the U.S. Congress, the federal courts, the USPTO, or similar authorities in foreign jurisdictions, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We may be subject to claims asserting that our employees, consultants, independent contractors and advisors have wrongfully used or disclosed confidential information and/or alleged trade secrets of their current or former employers or claims asserting ownership of what we regard as our own intellectual property.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we try to ensure that our employees, consultants, independent contractors and advisors do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that these individuals or we have inadvertently or otherwise used or disclosed confidential information and/or intellectual property, including trade secrets or other proprietary information, of the companies that any such individual currently or formerly worked for or provided services to. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to our business.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, while we require our employees and contractors who may be involved in the conception or development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual property that we regard as our own. The assignment of intellectual property rights may not be self-executing or the assignment agreements may be breached, and we may be forced to bring claims against third parties, or defend claims that they may bring against us, to determine the ownership of what we regard as our intellectual property.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intellectual property rights do not prevent all potential threats to competitive advantages we may have.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations, and intellectual property rights may not adequately protect our business or permit us to maintain our competitive advantage.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following examples are illustrative:</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Others may be able to make drug and device components that are the same as or similar to XHANCE and our other product candidates but that are not covered by the claims of the patents that we own or have exclusively licensed;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">We or any of our licensors or collaborators might not have been the first to make the inventions covered by the issued patent or pending patent application that we own or have exclusively licensed;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">We or any of our licensors or collaborators might not have been the first to file patent applications covering certain of our inventions;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">The prosecution of our pending patent applications may not result in granted patents;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Granted patents that we own or have licensed may not cover our products or may be held not infringed, invalid or unenforceable, as a result of legal challenges by our competitors;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">With respect to granted patents that we own or have licensed, especially patents that we either acquire or in-license, if certain information was withheld from or misrepresented to the patent examiner, such patents might be held to be unenforceable;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Patent protection on our product candidates may expire before we are able to develop and commercialize the product, or before we are able to recover our investment in the product;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Contents</a></span></div></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Our competitors might conduct research and development activities in the U.S. and other countries that provide a safe harbor from patent infringement claims for such activities, as well as in countries in which we do not have patent rights, and may then use the information learned from such activities to develop competitive products for sale in markets where we intend to market our product candidates;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">We may not develop additional proprietary technologies that are patentable;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">The patents of others may have an adverse effect on our business; and</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">We may choose not to file&#160;a patent application for certain technologies, trade secrets or know-how, and a third party may subsequently file&#160;a patent covering such intellectual property.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Should any of these events occur, they could significantly harm our business, financial condition, results of operations and prospects.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to seeking patent protection for certain aspects of our product candidates and delivery technologies, we also consider trade secrets, including confidential and unpatented know-how, important to the maintenance of our competitive position. We protect trade secrets and confidential and unpatented know-how, in part, by customarily entering into non-disclosure and confidentiality agreements with parties who have access to such knowledge, such as our employees, outside scientific and commercial collaborators, CROs, CMOs, consultants, advisors and other third parties. We also enter into confidentiality and invention or patent assignment agreements with our employees and consultants that obligate them to maintain confidentiality and assign their inventions to us. Despite these efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. In addition, our trade secrets may otherwise become known, including through a potential cybersecurity breach, or may be independently developed by competitors.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts in the U.S. and certain foreign jurisdictions are less willing or unwilling to protect trade secrets. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent them from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor, our competitive position would be harmed.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">If our trademarks are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to rely on trademarks as one means to distinguish any of our product candidates that are approved for marketing from the products of our competitors. OPTINOSE&#174;, XHANCE&#174;, EDS&#174; and Exhalation Delivery System&#8482; are trademarks of ours in the U.S. Our trademarks may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks or may be forced to stop using these names, which we need for name recognition by potential partners or customers in our markets of interest. If we are unable to establish name recognition based on our trademarks, we may not be able to compete effectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Ownership of Our Common Stock</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The price of our common stock may be volatile and you may lose all or part of your investment.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The market price of our common stock is likely to be highly volatile and could be subject to wide fluctuations in response to various factors, some of which are beyond our control. In addition to the factors discussed in this "Risk Factors" section and elsewhere in this Annual Report on Form 10-K, these factors include:</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">our ability to successfully commercialize XHANCE;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">any delay in our regulatory approval or filings for XHANCE for a follow-on indication for the treatment of chronic sinusitis or any other product candidate we may develop, and any adverse development or perceived adverse development with respect to the applicable regulatory authority's review of such filings, including without limitation the FDA's issuance of a "refusal to file" letter, a request for additional information, or a CRL;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Contents</a></span></div></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">the success of competitive products, technologies or services;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">adverse regulatory actions with respect to our product candidates, including the failure to receive regulatory approval, or our competitors' products or product candidates;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">discovery of previously unknown problems with XHANCE, such as AEs of unanticipated severity or frequency,</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">issues involving manufacturing of XHANCE or any of our products that may be under development;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">actual or anticipated changes in our growth rate relative to our competitors;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">announcements by us or our competitors of significant acquisitions or divestitures, strategic collaborations, joint ventures, collaborations or capital commitments;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">the impact of COVID-19 on our business, including the manufacture, supply, distribution and sale of XHANCE;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">the commencement, enrollment or results of planned clinical trials of our product candidates or any future clinical trials we may conduct, or any changes generally in the development status of our product candidates or those of our competitors;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">regulatory or legal developments in the U.S. and other countries;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">the outcome of any investigations or regulatory scrutiny of our operations or litigation that may be brought against us;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">developments or disputes concerning patent applications, issued patents or other proprietary rights;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">the level of expenses related to any of our product candidates or clinical development programs;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">actual or anticipated variations in our quarterly operating results;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">our ability to develop, acquire or license additional product candidates in other areas of the ENT and allergy markets;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">failure to meet the estimates and projections of the investment community or financial guidance that we may otherwise provide to the public;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities analysts;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">actual or anticipated changes in estimates as to development timelines that we may provide to the public;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">variations in our financial results or those of companies that are perceived to be similar to us;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">fluctuations in the valuation of companies perceived by investors to be comparable to us;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">share price and volume fluctuations attributable to inconsistent trading volume levels of our shares;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">announcement or expectation of additional financing efforts;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">sales of our common stock by us, our insiders or our other stockholders;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">significant lawsuits, including patent or stockholder litigation;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">changes in the structure of healthcare payment systems;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">market conditions in the pharmaceutical and biotechnology sectors;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">general political, economic, industry and market conditions;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">investors' general perception of our company and our business;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">publication of research reports about us, our competitors or our industry, or positive or negative recommendations or withdrawal of research coverage by securities or industry analysts; and</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">other events or factors, many of which are beyond our control.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the stock market in general, and pharmaceutical companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. Broad market and industry factors may negatively affect the market price of our common stock, regardless of our actual operating performance. The realization of any of the above risks or any of a broad range of other risks stated above could have a material adverse effect on the market price of our common stock.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Sales of a substantial number of shares of our common stock in the public market could cause our stock price to fall, even if our business is doing well.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of a substantial number of shares of our common stock in the public market could occur at any time. If our stockholders sell, or the market perceives that the holders of a large number of shares intend to sell, substantial amounts of our common stock in the public market, the market price of our common stock could decline significantly.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 1, 2023, there were </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">111,810,073</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> outstanding shares of our common stock. Holders of an aggregate of 14,461,137 shares of our common stock have rights, subject to specified conditions, that require us to file registration statements covering their shares or to include their shares in registration statements that we may file for ourselves or other stockholders. Of these shares, 14,273,017 are already covered by a registration statement and may be sold in the public market pursuant to such registration statement. Additionally, these shares are also eligible for sale without registration under Rule 144, subject to volume limitations applicable to affiliates. If these additional shares are sold, or if it is perceived that they will be sold, in the public market, the trading price of our common stock could decline.    </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Future issuances of our common stock or rights to purchase common stock, including pursuant to our equity incentive plans, could result in additional dilution of the percentage ownership of our stockholders  and could cause our stock price to fall. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will likely require additional capital in the future to execute our business plan. To raise capital, we may sell substantial amounts of common stock or securities convertible into or exchangeable for common stock. These future issuances of common stock or common stock-related securities, together with the exercise of outstanding options, restricted stock units, warrants and any additional shares issued in connection with acquisitions, if any, may result in material dilution to our investors and may cause our stock price to fall. Such sales may also result in new investors receiving rights, preferences and privileges senior to those of holders of our common stock.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our principal stockholders and management own a substantial percentage of our stock and are able to exert significant control over matters subject to stockholder approval, which could prevent new investors from influencing significant corporate decisions.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our executive officers, directors, beneficial owners of 5% or more of our capital stock and their respective affiliates, in the aggregate, beneficially own approximately&#160;59.0% of our outstanding common stock as of December 31, 2022. Entities associated with MVM Partners, LLC (MVM) and Fidelity, our largest stockholders, each hold approximately 13.1% of our common stock as of December 31, 2022.   Additionally, entities associated with Avista Capital Partners II, L.P. (Avista) collectively hold as a group approximately 12.8% of our outstanding stock as of December 31, 2022.  As a result, Avista, Fidelity and MVM can significantly influence the outcome of matters requiring stockholder approval, including the election of directors, amendments of our organizational documents, or approval of any merger, sale of assets or other major corporate transaction. This may prevent or discourage unsolicited acquisition proposals or offers for our common stock that you may feel are in your best interest. The interests of Avista, Fidelity and MVM may not always coincide with your interests or the interests of other stockholders and they may act in a manner that advances their best interests and not necessarily those of other stockholders, including seeking a premium value for their common stock. In addition, because Avista and certain of our other principal stockholders have held their shares for several years, they may be more interested in selling our company than other investors, or they may want us to pursue strategies that deviate from the interests of other stockholders. Such concentration of ownership control may also:</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">delay, defer or prevent a change in control;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">entrench our management and/or the board of directors; or</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">impede a merger, consolidation, takeover or other business combination involving us that other stockholders may desire.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also take actions that our other stockholders do not view as beneficial, which may adversely affect our results of operations and financial condition and cause the value of your investment to decline.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Some provisions of our charter documents and Delaware law may have anti-takeover effects that could discourage an acquisition of us by others, even if an acquisition would be beneficial to our stockholders, and may prevent attempts by our stockholders to replace or remove our current management.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions in our fourth amended and restated certificate of incorporation and our amended and restated bylaws, as well as provisions of Delaware law, could make it more difficult for a third party to acquire us or increase the cost of acquiring us, even if doing so would benefit our stockholders, or remove our current management. These include provisions that:</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">permit our board of directors to issue up to&#160;five&#160;million shares of preferred stock, with any rights, preferences and privileges as it may designate, which issuance could result in the loss of voting control by other stockholders;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">provide that our board of directors will be classified into three classes with staggered, three-year terms and that, directors may only be removed for cause by the affirmative vote of the holders of at least a majority of the voting power of outstanding shares of our capital stock;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">provide that all vacancies on our board of directors, including as a result of newly created directorships, may, except as otherwise required by law, be filled only by the affirmative vote of a majority of directors then in office, even if less than a quorum;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">require that any action to be taken by our stockholders must be effected at a duly called annual or special meeting of stockholders and not be taken by written consent;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">provide that stockholders seeking to present proposals before a meeting of stockholders or to nominate candidates for election as directors at a meeting of stockholders must provide advance notice in writing, and also specify requirements as to the form and content of a stockholder's notice;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">require that the amendment of certain provisions of our certificate of incorporation relating to anti-takeover measures may only be approved by a vote of 66</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">% of our outstanding common stock;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">require that the amendment of our bylaws be approved by the affirmative vote of a majority of directors then in office or 66</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">% of our outstanding common stock entitled to vote thereon;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">do not provide for cumulative voting rights, thereby allowing the holders of a majority of the shares of common stock entitled to vote in any election of directors to elect all of the directors standing for election; and</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">provide that special meetings of our stockholders may be called only by the chairman or vice chairman of our board of directors, our chief executive officer, or a majority of our board of directors.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors, who are responsible for appointing the members of our management. We are also governed by the provisions of Section&#160;203 of the Delaware General Corporation Law. These provisions may discourage, delay or prevent someone from acquiring us or merging with us whether or not it is desired by or beneficial to our stockholders. Under Section&#160;203, a corporation may not, in general, engage in a business combination with any holder of 15% or more of its capital stock unless the holder has held the stock for three years or, among other things, prior to the time the stockholder has become an interested stockholder, the board of directors has approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These provisions of our fourth amended and restated certificate of incorporation, our amended and restated bylaws and Delaware law could have the effect of discouraging potential acquisition proposals and delaying or preventing a change in control. They could also have the effect of discouraging others from making tender offers for our common stock, including transactions that may be in your best interests or provide an opportunity for our stockholders to receive a premium for their shares of our common stock. These provisions could also affect the price that some investors are willing to pay for our common stock.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our certificate of incorporation also provides that the Court of Chancery of the State of Delaware will be the exclusive forum for substantially all disputes between us and our stockholders, which could limit our </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">stockholders' ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our fourth amended and restated certificate of incorporation provides that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware will be the exclusive forum for any derivative action or proceeding brought on our behalf; any action asserting a breach of fiduciary duty owed by any of our directors, officers or other employees to us or our stockholders; any action asserting a claim against us arising pursuant to the Delaware General Corporation Law, our certificate of incorporation or our bylaws; or any action asserting a claim against us that is governed by the internal affairs doctrine. Our fourth amended and restated certificate of incorporation also provides that the U.S. District Court for the District of Delaware and any appellate courts thereof will be the exclusive forum for resolving any such complaint for which subject matter jurisdiction of such claim is vested exclusively in the federal courts of the U.S. These choice of forum provisions may limit a stockholder's ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage such lawsuits against us and our directors, officers and other employees. Alternatively, if a court were to find the choice of forum provisions contained in our certificate of incorporation to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General Risk Factors</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We may acquire other assets or businesses, or form collaborations or make investments in other companies or technologies, which could negatively impact our operating results, dilute our stockholders' ownership, increase our debt or cause us to incur significant expense.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of our business strategy, we may pursue acquisitions of assets, including preclinical, clinical or commercial-stage products or product candidates, businesses or strategic alliances and collaborations, to expand our existing technologies and operations. We may not identify or complete these transactions in a timely manner, on a cost-effective basis, or at all, and we may not realize the anticipated benefits of any such transaction. We may not be able to find suitable acquisition candidates, and if we make any acquisitions, we may not be able to complete technology transfers and integrate these acquisitions successfully into our existing business and we may incur additional debt or assume unknown or contingent liabilities as part of the transaction. Integration of an acquired company or assets may also disrupt ongoing operations, require the hiring of additional personnel and the implementation of additional internal systems and infrastructure, especially the acquisition of commercial assets, and require management resources that would otherwise focus on developing our existing business. We may not be able to find suitable strategic collaborators or identify other investment opportunities, and we may experience losses related to any such investments.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To finance any acquisitions or collaborations, we may choose to issue debt or shares of our common or preferred stock as consideration. Any such issuance of shares would dilute the ownership of our stockholders. If the price of our common stock is low or volatile, we may not be able to acquire other assets or companies or fund a transaction using our stock as consideration. Alternatively, it may be necessary for us to raise additional funds for acquisitions through public or private financings. Additional funds may not be available on terms that are favorable to us, or at all.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our sales force and other employees, PPN partners, CMOs, CROs, principal investigators, co-promotion partners, collaborators, independent contractors, consultants and other vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to the risk that our sales force and other employees, PPN partners, CMOs, CROs, principal investigators, collaborators, independent contractors, consultants and other vendors may engage in fraudulent or other illegal activity with respect to our business. Misconduct by these employees could include intentional, reckless and/or negligent conduct or unauthorized activity that violates:</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">FDA promotion or other regulations, including those laws requiring the reporting of true, complete and accurate information to the FDA;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">manufacturing standards;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">federal and state healthcare fraud and abuse laws and regulations; or</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">laws that require the true, complete and accurate reporting of financial information or data.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Misconduct by these parties could also involve individually identifiable information, including, without limitation, the improper use of information obtained in the course of clinical trials, or illegal misappropriation of drug product, which could result in regulatory sanctions and serious harm to our reputation. Any incidents or any other conduct that leads to an employee receiving an FDA debarment could result in a loss of business from third parties and severe reputational harm.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a Code of Business Conduct and Ethics to govern and deter such behaviors, but it is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of civil, criminal and administrative penalties, damages, monetary fines, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, and curtailment of our operations.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">If we fail to comply with data and privacy protection laws and regulations, we could be subject to government enforcement actions, which could include civil or criminal penalties, as well as private litigation and/or adverse publicity, any of which could negatively affect our operating results and business.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business is subject to complex and evolving U.S., state and international data and privacy protection laws. In the U.S., numerous federal and state laws and regulations, including state data breach notification laws, state health information privacy laws, and federal and state consumer protection laws (e.g., Section 5 of the Federal Trade Commission Act) govern the collection, use, disclosure, and protection of health-related and other personal information. Compliance with these laws is difficult, constantly evolving, and time consuming. These laws may differ from each other in significant ways, thus complicating compliance efforts. Many of the state laws enable a state attorney general to bring actions and provide private rights of action to consumers as enforcement mechanisms. Failure to comply with data protection laws and regulations could result in government enforcement actions and create liability for us (which could include civil and/or criminal penalties), private litigation and/or adverse publicity. Federal regulators, state attorneys general, and plaintiffs&#8217; attorneys have been and will likely continue to be active in this space. We may also obtain health information from third parties (e.g., healthcare providers who prescribe our products) that are subject to privacy and security requirements under HIPAA, and other privacy and data security and consumer protection laws. Although we are not directly subject to HIPAA, other than potentially with respect to providing certain employee benefits, we could potentially be subject to criminal penalties if we, our affiliates, or our agents knowingly receive individually identifiable health information maintained by a HIPAA-covered entity in a manner that is not authorized or permitted by HIPAA, and could also potentially be subject to other civil and/or criminal penalties if we obtain, use or disclose information in a manner not permitted by other privacy and data security and consumer protection laws. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Federal Trade Commission (the &#8220;FTC&#8221;) also sets expectations for failing to take appropriate steps to keep consumers&#8217; personal information secure, or failing to provide a level of security commensurate to promises made to individual about the security of their personal information (such as in a privacy notice) may constitute unfair or deceptive acts or practices in violation of Section 5(a) of the FTC Act. The FTC expects a company&#8217;s data security measures to be reasonable and appropriate in light of the sensitivity and volume of consumer information it holds, the size and complexity of its business, and the cost of available tools to improve security and reduce vulnerabilities. Individually identifiable health information is considered sensitive data that merits stronger safeguards. With respect to privacy, the FTC also sets expectations that companies honor the privacy promises made to individuals about how the company handles consumers&#8217; personal information; any failure to honor promises, such as the statements made in a privacy policy or on a website, may also constitute unfair or deceptive acts or practices in violation of the FTC Act. While we do not intend to engage in unfair or deceptive acts or practices, the FTC has the power to enforce promises as it interprets them, and events that we cannot fully control, such as data breaches, may be result in FTC enforcement. Enforcement by the FTC under the FTC Act can result in civil penalties or enforcement actions.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Contents</a></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the General Data Protection Regulation (GDPR), applicable in the European Union (EU), applies to our activities conducted from an establishment in the EU or related to products and services that we may offer to EU users that involve the collection, use, storage, transfer, and other processing of personal data, including personal health data. The GDPR creates a range of new compliance obligations and restrictions on the ability to collect, analyze and transfer personal data, which could cause us to change our business practices, and has significantly increased financial penalties for noncompliance (including possible fines of up to 4% of global annual turnover for the preceding financial year or &#8364;20 million (whichever is higher) for the most serious infringements). In particular, these obligations and restrictions concern the consent of the individuals to whom the personal data relates, the information provided to the individuals, the sharing of personal data with third parties, the transfer of personal data out of the EU, security breach notifications, security and confidentiality of the personal data and imposition of substantial potential fines for violations of the data protection obligations. Specifically regarding the transfer of personal data outside of the EU, while there are legal mechanisms available to lawfully transfer personal data outside of the EU, including to the United States, there are certain unsettled legal issues regarding such data transfers, the resolution of which may adversely affect our ability to transfer personal data or otherwise may cause us to incur significant costs to come into compliance with applicable data transfer impact assessments and implementation of legal data transfer mechanisms. On July 16, 2020, the European Court of Justice ruled the EU-US Privacy Shield to be an invalid data transfer mechanism and confirmed that the Model Clauses remain valid, and in June 2021, the European Commission published updated versions of the Model Clauses, which must be incorporated into new and existing agreements within prescribed timeframes in order to continue to lawfully transfer personal data outside of the EU. Data protection authorities from the different EU member states, as well as in the United Kingdom and Switzerland, have promulgated national privacy laws that impose additional requirements, which add to the complexity of processing and transferring EU personal data, with the United Kingdom and Switzerland following the EU with the publication of new Model Clauses to be incorporated in all applicable contracts within a specified timeframe in order to legitimize data transfers from those jurisdictions. Our ability to continue to transfer personal data outside of the EU, United Kingdom, or Switzerland may become significantly more costly and may subject us to increased scrutiny and liability under the GDPR or similar local laws, and we may experience operating disruptions if we are unable to conduct these transfers in the future.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The California Consumer Privacy Act, or CCPA, establishes certain</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">requirements for data use and sharing transparency and provides California residents certain rights concerning the use, disclosure, and retention of their personal data. The CCPA and its implementing regulations have already been amended multiple times since their enactment. In November 2020, California voters approved the California Privacy Rights Act (&#8220;CPRA&#8221;) ballot initiative, which introduced significant amendments to the CCPA and established and funded a dedicated California privacy regulator, the California Privacy Protection Agency. The amendments introduced by the CPRA went into effect on January 1, 2023, and new implementing regulations are expected to be introduced by the California Privacy Protection Agency. Failure to comply with the CCPA may result in, among other things, significant civil penalties and injunctive relief, or potential statutory or actual damages. In addition, California residents have the right to bring a private right of action in connection with certain types of incidents. These claims may result in significant liability and damages. We implemented processes to manage compliance with the CCPA and continue to assess the impact of the CPRA, and other state legislation, on our business as additional information and guidance becomes available. These laws and regulations are evolving and subject to interpretation, and may impose limitations on our activities or otherwise adversely affect our business. Similarly, there are a number of legislative proposals in the European Union, the United States, at both the federal and state level, and in other jurisdictions that could impose new obligations or limitations in areas affecting our business. For example, other states, including Virginia, Colorado, Utah, and Connecticut have enacted privacy laws similar to the CCPA that impose new obligations or limitations in areas affecting our business and we continue to assess the impact of these state legislations on our business as additional information and guidance becomes available.  In addition, some countries are considering or have passed legislation implementing data protection requirements or requiring local storage and processing of data or similar requirements that could increase the cost and complexity of delivering our services and research activities. These laws and regulations, as well as any associated claims, inquiries, or investigations or any other government actions may lead to unfavorable outcomes including increased compliance costs, delays or impediments in the development of new products, negative publicity, increased operating costs, diversion of management time and attention, and remedies that harm our business, including fines or demands or orders that we modify or cease existing business practices.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Certain of these laws and regulations are described in greater detail in the previous section under "Business &#8212; Government Regulation &#8212; Healthcare Privacy Laws." If we, our agents, or our third party partners fail to comply or are alleged to have failed to comply with these or other applicable data protection and privacy  laws and regulations, or if we were to experience a data breach involving personal information, we could be subject to government enforcement actions or private lawsuits. Any associated claims, inquiries, or investigations or other government </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Contents</a></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">actions could lead to unfavorable outcomes that have a material impact on our business including through significant penalties or fines, monetary judgments or settlements including criminal and civil liability for us and our officers and directors, increased compliance costs, delays or impediments in the development of new products, negative publicity, increased operating costs, diversion of management time and attention, or other remedies that harm our business, including orders that we modify or cease existing business practices.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our business and operations would suffer in the event of computer system failures, cyberattacks or a deficiency in our cybersecurity or those of any business partners.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Despite the implementation of security measures, our internal computer systems and those of our contractors, vendors, customers and consultants are vulnerable to damage from computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures, cyberattacks or cyber-intrusions over the Internet, loss of funds or information from phishing or other fraudulent schemes, attachments to emails, persons inside our organization, or persons with access to systems inside our organization or those with whom we do business. The risk of a security breach or disruption, particularly through cyber-attacks or cyber intrusion, including by computer hackers, foreign governments, and cyber terrorists, has generally increased as the number, intensity and sophistication of attempted attacks and intrusions from around the world have increased. Such an event could cause interruption of our operations or loss of Company funds and have a negative financial consequence on our business. For example, the loss of data from completed or ongoing clinical trials for our product candidates could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data, or could result in a delay of the services provided by our vendor. Although we are targeted for cyber-attacks from time to time, we are only aware of one instance where an unauthorized third party accessed certain parts of our computer systems and we believe we have addressed the matter without any known financial implication, loss of data or exposure of confidential or personal information. To the extent that any disruption or security breach were to result in a loss of or damage to our data, misappropriation of funds to unintended recipients, or inappropriate disclosure of confidential, proprietary or personal information, we could incur material legal claims and liabilities and damage to our reputation and the development and commercialization of XHANCE and our other product candidates could be delayed. Additionally, breach remediation costs may be significant.&#160;Despite our efforts</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and the ever-changing threat landscape, the possibility of these events occurring cannot be eliminated entirely and there can be no assurance that any measures we take will prevent cyber-attacks or security breaches that could adversely affect our business.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">We may be exposed to liabilities under the U.S. Foreign Corrupt Practices Act and other U.S. and foreign anti-corruption anti-money laundering, export control, sanctions, and other trade laws and regulations, and any determination that we violated these laws could have a material adverse effect on our business.   </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to export control and import laws and regulations, including the U.S. Export Administration Regulations, U.S. Customs regulations, and various economic and trade sanctions regulations administered by the U.S. Treasury Department's Office of Foreign Assets Control. We are also subject to the U.S. Foreign Corrupt Practices Act of 1977, as amended (FCPA), the U.S. domestic bribery statute contained in 18&#160;U.S.C. &#167;&#160;201, the U.S. Travel Act, the USA PATRIOT Act, the United Kingdom Bribery Act 2010, the Proceeds of Crime Act 2002, and possibly other anti-bribery and anti-money laundering laws in countries outside of the U.S. in which we conduct our activities. Anti-corruption laws are interpreted broadly and prohibit companies and their employees and third-party intermediaries from authorizing, promising, offering, providing, soliciting, or accepting, directly or indirectly, improper payments or benefits to or from any person whether in the public or private sector. As we commercialize XHANCE and any other product candidates that we may develop, we may engage with third-party manufacturers and collaborators who operate abroad and are required to obtain certain necessary permits, licenses and other regulatory approvals with respect to our business. Our activities abroad create the risk of unauthorized payments or offers of payments by employees, consultants, sales agents or distributors, even though they may not always be subject to our control. We have implemented policies to discourage these practices by our employees, consultants, sales agents and distributors. However, our employees, consultants, sales agents, or distributors of our company may engage in conduct for which we might be held responsible, even if we do not explicitly authorize such activities.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Noncompliance with anti-corruption, anti-money laundering, export control, sanctions, and other trade laws could subject us to whistleblower complaints, investigations, sanctions, settlements, prosecution, other enforcement actions, disgorgement of profits, significant fines, damages, other civil and criminal penalties or injunctions, suspension and/or debarment from contracting with certain persons, the loss of export privileges, reputational harm, adverse media coverage and other collateral consequences. If any subpoenas or investigations are launched, or governmental or other sanctions are imposed, or if we do not prevail in any possible civil or criminal litigation, our business, results of operations and financial condition could be materially harmed. Responding to any action will </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">likely result in a materially significant diversion of management's attention and resources and significant defense and compliance costs and other professional fees. In addition, the U.S. government may seek to hold us liable for successor liability FCPA violations committed by companies in which we invest or that we acquire. As a general matter, enforcement actions and sanctions could harm our business, results of operations, and financial condition.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83</span></div></div></div><div id="i451bcb3eabba4f87bdc579718207a3b8_31"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Contents</a></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1B. UNRESOLVED STAFF COMMENTS</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div><span><br/></span></div><div id="i451bcb3eabba4f87bdc579718207a3b8_34"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2. PROPERTIES</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our principal office is located in Yardley, Pennsylvania, where we lease approximately 30,000 square feet of office space pursuant to a lease that expires in May 2024. We also lease facilities in Ewing, New Jersey. We believe our facilities are adequate to meet our current needs, although we may seek to negotiate new leases or evaluate additional or alternate space for our operations. We believe appropriate alternative space will be readily available on commercially reasonable terms. </span></div><div><span><br/></span></div><div id="i451bcb3eabba4f87bdc579718207a3b8_37"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3. LEGAL PROCEEDINGS</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are not currently a party to any material pending legal proceedings.</span></div><div><span><br/></span></div><div id="i451bcb3eabba4f87bdc579718207a3b8_40"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;4. MINE SAFETY DISCLOSURES</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i451bcb3eabba4f87bdc579718207a3b8_43"></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II</span></div><div><span><br/></span></div><div id="i451bcb3eabba4f87bdc579718207a3b8_46"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 5. MARKET FOR REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock is traded on The Nasdaq Global Select Market under the symbol &#8220;OPTN&#8221;. As of March 1, 2023, there were 111,810,073 shares of our common stock outstanding. There were approximately 18 stockholders of record at March 1, 2023. Because many of our shares are held by brokers and other institutions on behalf of stockholders, we are unable to estimate the total number of stockholders represented by these record holders. </span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities Authorized for Issuance under Equity Compensation Plans</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information required by Item 5 of Form 10-K regarding our equity compensation plans is incorporated herein by reference to Item 12 of Part III of this Annual Report on Form 10-K. </span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Sales of Unregistered Securities</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than as previously disclosed on our Current Reports on Form 8-K or Quarterly Reports on Form 10-Q filed with the SEC, we did not issue any unregistered equity securities during the twelve months ended December 31, 2022.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Purchases of Equity Securities by the Issuer and Affiliated Purchasers</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i451bcb3eabba4f87bdc579718207a3b8_49"></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 6. RESERVED</span></div><div style="margin-top:8pt"><span><br/></span></div><div id="i451bcb3eabba4f87bdc579718207a3b8_52"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">You should read the following discussion and analysis of our financial condition and results of operations together with our historical consolidated financial statements and the related notes thereto appearing in this Annual Report. In addition to historical information, some of the information contained in this discussion and analysis or set forth elsewhere in this Annual Report, includes forward-looking statements that involve risks and uncertainties. As a result of many factors, including those factors set forth in the &#8220;Risk Factors&#8221; section of this Annual Report, our actual results could differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.  See "Note Regarding Forward-Looking Statements"</span></div><div id="i451bcb3eabba4f87bdc579718207a3b8_55"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Company Overview</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">W</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e are a specialty pharmaceutical company focused on the development and commercialization of products for patients treated by ear, nose and throat (ENT) and allergy specialists. Our first commercial product, XHANCE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Contents</a></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(fluticasone propionate) nasal spray, 93 micrograms (mcg), is a therapeutic utilizing our proprietary Exhalation Delivery System (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps and, if approved, chronic rhinosinusitis without nasal polyps (also known as chronic sinusitis). Chronic rhinosinusitis is a serious nasal inflammatory disease that is treated using therapies, such as intranasal steroids (INS), which have significant limitations. We believe XHANCE has a differentiated clinical profile with the potential to become part of the standard of care for this disease because it is able to deliver medication to the primary site of inflammation high and deep in the nasal passages in regions not adequately reached by conventional INS.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2017, the U.S. Food and Drug Administration (FDA) approved XHANCE for the treatment of nasal polyps in patients 18&#160;years of age or older.&#160;XHANCE was made widely available through commercial channels in April 2018. In January 2023, the indication statement for XHANCE was changed from &#8220;for the treatment of nasal polyps&#8221; to &#8220;for the treatment of chronic rhinosinusitis with nasal polyps&#8221; to reflect current FDA labeling terminology and not based on new XHANCE clinical trial data.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In March and June 2022, we announced positive top line results from our two Phase 3b clinical trials in of XHANCE for a follow-on indication for the treatment of chronic sinusitis. In February 2023, we submitted a prior approval efficacy supplement (sNDA) to support the approval of a new indication for XHANCE for the treatment of chronic sinusitis.  Assuming the FDA's acceptance of the sNDA submission and a standard review period, we expect the FDA's target action date to be in December 2023.  If the sNDA is approved, XHANCE has the potential to be the first drug therapy approved by the FDA for the treatment of chronic sinusitis.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe XHANCE could become a part of the standard of care for the treatment of patients with chronic rhinosinusitis with and without nasal polyps before they progress to more costly treatment alternatives and could also be adopted as a maintenance therapy to improve outcomes following sinus surgery.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span><br/></span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Business Updates</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We track and report metrics that we believe are an important part of assessing our progress in key strategic areas including: </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline">XHANCE Prescriptions and Market Share.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Based on third-party prescription data as well as data from PPN partners, the total estimated number of XHANCE prescriptions in the fourth quarter of 2022 was 86,200, which represents an 8% decrease for prescriptions when compared to estimated fourth quarter 2021 prescriptions of 93,700. The INS prescription market increased approximately 3% from fourth quarter 2021 to fourth quarter 2022 based on third-party prescription data. In addition, the total estimated number of XHANCE prescriptions was 80,600 in the first quarter of 2022, 87,600 in the second quarter of 2022, and 86,600 in the third quarter of 2022.   </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A seasonal effect has historically been observed in the INS prescription market in which market volume generally peaks near the middle of the second quarter and declines into the early part of the third quarter of each calendar year.  Based on third-party prescription data, INS market prescriptions decreased 4% from the fourth quarter of 2020 to the first quarter of 2021, increased 14% from the first quarter of 2021 to the second quarter of 2021, decreased 4% from the second quarter of 2021 to the third quarter of 2021, increased 1% from the third quarter of 2021 to the fourth quarter of 2021, were flat from the fourth quarter of 2021 to the first quarter of 2022, increased 7% from the first quarter of 2022 to the second quarter of 2022, decreased 7% from the second quarter of 2022 to the third quarter of 2022, and increased 4% from the third quarter of 2022 to the fourth quarter of 2022. In addition, based on third-party prescription data, INS market prescriptions decreased 7% from full year 2019 to full year 2020, were flat from full year 2020 to full year 2021, and increased 4% from full year 2021 to full year 2022.  </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although the underlying disease that we are treating is chronic and causes symptoms year-round, we believe the variation in patient flow through the offices of relevant physician specialists, and seasonality in disease flare-ups, has an impact on the number of patients that present themselves and who are therefore available to receive a new prescription for XHANCE. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we believe that first quarter prescription demand and average net revenue per prescription for XHANCE is adversely impacted by the annual resetting of patient healthcare insurance plan deductibles and changes in individual patients' healthcare insurance coverage, both of which often occur in January.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We believe our co-pay savings program and market access influence prescription volume. In January 2021 we adjusted the terms of our co-pay savings program to decrease the number and proportion of total </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">prescriptions filled by patients in commercial insurance plans that do not cover XHANCE. In January 2022 we adjusted the terms of our co-pay savings program to decrease the number and proportion of total prescriptions filled by patients in commercial insurance plans that have high deductibles. In the future we may make additional changes to our co-pay savings program that could influence prescription volume.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, while we believe that as of December 31, 2022, approximately 80% of commercially insured lives are currently in a plan that covers XHANCE, payors generally impose restrictions on access to or usage of XHANCE, such as by requiring prior authorizations or "step-edits". For example, insurers may require that a physician attest that they are treating a patient for an approved indication prior to becoming eligible for coverage for XHANCE. Approximately half of the commercially covered lives as of December 31, 2022 are in a plan that requires a prior authorization and most of those prior authorizations request information regarding prior use of INS and patient diagnosis. In some cases, patients do not meet the payors' utilization management criteria.  Some providers may not complete the burdensome administrative process required to demonstrate or document that the patients for whom XHANCE has been prescribed meet the payors&#8217; utilization management criteria (i.e., prior authorizations or step-edits) and, as a result, patients will not gain access to XHANCE treatment. We believe increasing rates of enforcement of the utilization management criteria had a negative effect on XHANCE prescription volume growth in 2022 and may continue to have a negative effect on prescription volume in the future. These requirements include physician attestation to a diagnosis of nasal polyps which can be a hurdle for some physicians in our target audience because it is not a diagnosis they make commonly.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We track the market share of XHANCE within our current target audience. For this purpose, we calculate market share as the proportion of XHANCE prescriptions to the number of prescriptions written for other INS within our current target audience of approximately 21,000 physicians. Our target physician audience includes all ENT and Allergy specialist physicians who, based on third-party data, write intranasal steroid spray prescriptions. In addition, our current target audience includes specialty-like primary care physicians called on by our territory managers.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We believe market share, in addition to XHANCE prescription volume, can provide information regarding XHANCE utilization because market share normalizes XHANCE prescriptions for market effects including the INS market seasonality, seasonal variation in patient visits with their doctor, annual deductible resets and annual changes in individual patient's healthcare insurance coverage referenced above. Based on third-party prescription data as well as data from PPN partners, we estimate XHANCE had a market share in our current target audience of 21,000 physicians of 4.8% in the fourth quarter of 2020, 5.0% in the first quarter of 2021, 5.2% in the second quarter of 2021, 5.7% in the third quarter of 2021, 5.9% in the fourth quarter of 2021, 5.4% in the first quarter of 2022, 5.6% in the second quarter of 2022, 5.7% in the third quarter of 2022, and 5.7% in the fourth quarter of 2022. Note that most of the INS prescriptions written within our target physician audience are for chronic sinusitis, allergic rhinitis and other conditions outside of our nasal polyp indication. Our target physician audience is subject to revision each quarter to account for changes such as revised sales target prioritization, and physician retirements. Changes to the target physician audience can contribute to some of the quarter-over-quarter change in market share.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline">XHANCE New Prescriptions and Refill Prescriptions.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The underlying disease that we are treating is chronic and, as a result, many patients may fill multiple prescriptions per year. We monitor new prescriptions as they create the potential for future refill prescriptions. Based on third-party prescription data as well as data from PPN partners, the total estimated number of XHANCE new prescriptions in the fourth quarter of 2022 was 27,700, which represents a 7% decrease for new prescriptions when compared to estimated fourth quarter 2021 new prescriptions of 29,900. In addition, the total estimated number of XHANCE new prescriptions was 28,200 in first quarter 2022, 29,200 in second quarter 2022, and 28,000 in third quarter 2022. Based on third-party prescription data, the INS market for new prescriptions increased 5% from the fourth quarter of 2021 to the fourth quarter of 2022 and increased 7% from the third quarter of 2022 to the fourth quarter of 2022. In addition, based on third-party prescription data, the INS market for new prescriptions decreased 13% from full year 2019 to full year 2020, increased 4% from full year 2020 to full year 2021, and increased 7% from full year 2021 to full year 2022.  </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We track refill prescriptions and provide patient assistance to support refill programs that are administered by our PPN partners. Based on third-party prescription data as well as data from PPN partners, the total estimated number of XHANCE refill prescriptions in the fourth quarter of 2022 was 58,500, which represents an 8% decrease for refill prescriptions when compared to estimated fourth quarter 2021 refill prescriptions of 63,800. In addition, the total estimated number of XHANCE refill prescriptions was 52,400   in first quarter 2022, 58,400 in second quarter 2022, and 58,600 in third quarter 2022. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Contents</a></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline">Prescribing Breadth and Depth.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We track the number of physicians who prescribe XHANCE in a time period to evaluate the breadth of prescribing. Based on third-party prescription data as well as data from PPN partners, the total estimated number of physicians who had at least one patient fill a prescription for XHANCE in the fourth quarter of 2022 was 8,104, which represents 8% growth when compared to the estimated 7,532 physicians who had at least one patient fill a prescription for XHANCE in the fourth quarter of 2021. In addition, the total estimated number of physicians who had at least one patient fill a prescription for XHANCE was 7,690 in the first quarter of 2022, 7,851 in the second quarter of 2022, and 7,892 in the third quarter of 2022.</span></div><div style="margin-top:8pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also track the number of prescriptions filled by a prescribing physician's patients in a time period to evaluate depth of prescribing. Based on third-party prescription data as well as data from PPN partners, the total estimated number of physicians who had more than 15 XHANCE prescriptions filled by their patients in the fourth quarter of 2022 was 1,449, which represents a decrease of  9% when compared to the estimated 1,589 physicians who had more than 15 XHANCE prescriptions filled by their patients in the fourth quarter of 2021. In addition, the total estimated number of physicians who had more than 15 XHANCE prescriptions filled by their patients was 1,468 in the first quarter of 2022, 1,500 in the second quarter of 2022, and 1,491 in the third quarter of 2022.</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline">XHANCE Net Product Revenues per Prescription.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We calculate average net product revenues per prescription, one metric that we use to gauge the profitability of XHANCE, by dividing net product revenues for the quarter by the estimated number of XHANCE prescriptions dispensed during the quarter. Average XHANCE net product revenues per prescription were $242 in the fourth quarter of 2022 which represents a 1% increase when compared to the $240 average XHANCE net product revenues per prescription in the fourth quarter of 2021. In addition, average XHANCE net revenues per prescription were $183 in the first quarter of 2022, $235 in the second quarter of 2022, and $232 in the third quarter of 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span><br/></span></div><div id="i451bcb3eabba4f87bdc579718207a3b8_58"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Updates in Response to the COVID-19 Pandemic</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic has caused business and economic disruption, and may cause future disruption.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Where permitted by governmental requirements and the policies of physician offices, our territory managers began to return to in-person detailing of physicians in May and June 2020. Given the localized nature of the restrictions that are in place and the potential for restrictions to return, we have equipped our territory managers to operate in an environment that will include a mix of virtual and in-person physician detailing with dependencies on geography and time. We are currently operating under a hybrid-model for our office-based employees which includes a mix of in-office and work-from-home days.  </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Federal, state and local government requirements and guidances have impacted virtually all of the physicians' offices in which our territory managers detail XHANCE. These impacts include reduced patient visits, temporary halt of territory managers' visits, restrictions imposed on the logistics and frequency of territory managers' visits, physician office staff turnover, and temporary closings of physicians' offices. We believe the restrictions imposed on the logistics and frequency of territory managers' visits have now become permanent in some physician officers which is adversely impacting the effectiveness of our sales force.  </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Although XHANCE prescriptions have grown since the start of the pandemic, the rate of growth was below our pre-pandemic expectations. The duration and magnitude of the impact of the COVID-19 pandemic on XHANCE prescriptions and XHANCE net revenue has had and could in the future continue to affect our ability to remain in compliance with the financial covenant to achieve certain minimum trailing twelve month consolidated XHANCE net product sales and royalties and other covenants under that certain Note Purchase Agreement dated as of September 12, 2019 that we entered into with funds managed by Pharmakon Advisors, LP (Pharmakon), the investment manager of the BioPharma Credit Funds (BioPharma), as amended pursuant to that certain letter agreement dated as of August 13, 2020, as further amended by that certain First Amendment to Note Purchase Agreement dated as of March 2, 2021, as further amended pursuant to that certain Second Amendment to Note Purchase Agreement dated as of November 16, 2021, as further amended pursuant to that certain Third Amendment dated as of August 10, 2022, as further amended pursuant to that certain Fourth Amendment to Note Purchase Agreement dated as of November 9, 2022, and as further amended pursuant to that certain Amended and Restated Note </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Purchase Agreement dated as of November 23, 2023 (as so amended and restated, the "A&amp;R Note Purchase Agreement").</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We believe we are maintaining appropriate levels of finished product inventories in the event of future supply disruption; however, the duration and magnitude of a future negative impact from the COVID-19 pandemic could constrain our supply of XHANCE.  </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">For subjects that participated in our two chronic sinusitis trials, procedures to facilitate ongoing treatment and capture of data during periods of in-person care restrictions were put in place. Pauses in patient enrollment due to factors related to the COVID-19 pandemic had varying effects in different geographies which resulted in delays and additional costs associated with our chronic sinusitis trials. </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The COVID-19 pandemic has had, and may continue to have, adverse impacts on XHANCE prescription volume and net revenues as a result of fewer patients visiting physician offices, the restrictions imposed on the logistics and frequency of territory managers' visits becoming permanent in some physician offices, turnover of physician office staff, changes in employment that can adversely affect availability of insurance coverage of XHANCE, our ability to maintain compliance with the financial and other covenants under the A&amp;R Note Purchase Agreement, and the availability and cost of capital for us to fund our business operations and service our debt. We will continue to assess the evolving impact of the COVID-19 pandemic and will make adjustments to our operations as necessary. </span></div><div style="margin-bottom:8pt"><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Operations Overview</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following discussion sets forth certain components of our consolidated statements of operations as well as factors that impact those items.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net product revenues</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of XHANCE generated $76.3 million and $73.7 million in net product revenues for the years ended December 31, 2022 and 2021, respectively. In accordance with GAAP, we determine net product revenues for XHANCE, with specific assumptions for variable consideration components including but not limited to trade discounts and allowances, co-pay assistance programs and payor rebates.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on available XHANCE prescription data purchased from third parties and data from our PPN partners, our average net product revenue per prescription for the fourth quarter of 2022 was $242 which represents a 1% increase when compared to the $240 in the fourth quarter of 2020. Average net product revenue per prescription for the year ended December 31, 2022 was $224, which represents a 2% increase compared to our average net product revenue per prescription of approximately $219 for the year ended December 31, 2021.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We calculate average net product revenues per prescription, one metric that we use to gauge the profitability of XHANCE, by dividing net product revenues for the quarter by the estimated number of XHANCE prescriptions dispensed during the quarter. As a result, average net product revenues per prescription is subject to variability. That variability is impacted by factors that do not necessarily reflect a change in the price that is paid for an individual unit of XHANCE, including but not limited to ordering patterns and inventory levels for our wholesale customers and PPN partners, patient utilization rates of affordability programs and the proportion of patients acquiring XHANCE through an insurance benefit. There is also the potential for variability that results from changes in estimation methodology by the third parties that we rely upon to provide prescription data which may lead to revisions of historical estimates of prescription volumes and our calculated average net product revenues per prescription.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We expect full year 2023 net product revenues will be between $62.0 to $68.0 million. In December 2022, we reduced our number of territory managers from approximately 90 to approximately 77 as part of actions intended to reduce total operating expenses for full year 2023 by approximately $30.0 million compared to 2022, of which approximately half is related to sales and marketing. In addition, the expectation of full year 2023 net product revenues between $62.0 and $68.0 million does not assume net product revenues attributable to a launch of XHANCE as a treatment for patients with chronic sinusitis. Our expectation for full year 2023 net product revenues includes our expectation that first quarter 2023 net product revenues will be approximately $10.0 million. The year-over-year decrease to net product revenues for first quarter 2023 is attributable to an expected increase in gross-to-net deductions and an expected decrease in units shipped. The expected increase in gross-to-net deductions includes increased rebates and changes in business mix that also affect our expectations for full year 2023 net product revenues and average net product revenues per prescription. For the full year 2023, we believe average net product revenues per prescription will be approximately $200. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Licensing revenues</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2019, OptiNose AS, a wholly owned subsidiary of the Company, entered into the Currax License Agreement. Under the terms of the Currax License Agreement, Currax paid us a $3.7 million upfront payment in 2019 and an additional $0.8 million in December 2020 upon expiration of the escrow that was established for a limited period to cover potential indemnification obligations.  In January 2021, a specified regulatory milestone was met and the Company received a $1.0 million milestone payment.  We do not expect to receive any further payments from Currax under the terms of the License Agreement other than reimbursement for certain expenses.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Costs of product sales</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs of product sales includes the cost of inventory sold, which includes direct and indirect manufacturing and supply chain costs.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and development expense</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expense consists primarily of expenses incurred to prepare for, initiate and conduct our planned clinical trials, ongoing research efforts of new products and device improvements. We expense research and development costs as incurred. These expenses include:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">personnel expenses, including salaries, benefits and stock-based compensation expense;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">costs of funding clinical development performed by third parties, including pursuant to agreements with contract research organizations (CROs), as well as investigative sites and consultants that conduct or support our nonclinical studies and clinical trials;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">expenses associated with the continued development of our EDS devices;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">expenses related to the continued development of our product sample portfolio;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">expenses incurred under agreements with contract manufacturing organizations (CMOs), including manufacturing scale-up expenses prior to regulatory approval of products for commercial sale and the cost of acquiring and manufacturing preclinical study and clinical trial materials;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">consultant fees and expenses associated with outsourced professional scientific development services;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">expenses for regulatory activities, including filing fees paid to regulatory agencies and costs incurred to compile and respond to filings with the FDA prior to regulatory approval of products for commercial sale; and</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">allocated expenses for facility costs, including rent, utilities, depreciation and maintenance.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We typically use our employee, consultant and infrastructure resources across our research and development programs. Although we track certain outsourced development costs by product candidate, we do not allocate personnel costs or other internal costs to specific product candidates.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assuming we do not need to conduct additional studies to support an FDA approval of XHANCE for the treatment of chronic sinusitis and we do not undertake new development programs, we expect significantly lower research and development expenses beginning in 2023.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling, general and administrative expense</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expense consists primarily of personnel expenses, including salaries, benefits and stock-based compensation expense, for employees in executive, finance, accounting, business development, information technology, legal and human resource functions. General and administrative expense also includes corporate facility costs, including rent, utilities, depreciation and maintenance, not otherwise included in research and development expense, as well as regulatory fees and professional fees for legal, patent, accounting and other consulting services.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales and marketing expenses include our sales team and supporting promotional materials, digital promotion, peer-to-peer education, congresses / conventions, samples, and marketing activities such as direct-to-patient / direct-to-consumer initiatives. Additionally, sales and marketing-related expenses include fees paid to our PPN partners for services unrelated to traditional distribution functions, such as data fees and benefit claims adjudication.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrant Liability</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2022, the Company issued warrants in connection with a public offering. These warrants are required to be measured at fair value and reported as a liability in the consolidated balance sheet. We recorded the fair value of the warrants upon issuance using a Monte Carlo simulation and are required to revalue the warrants at each reporting date with any changes in fair value recorded on our statement of operations. The valuation of the warrants is considered under Level 3 of the fair value hierarchy due to the need to use assumptions in the valuation that are both significant to the fair value measurement and unobservable. The change in the fair value of the Level 3 warrants liabilities is reflected in the statement of operations for the year ended December 31, 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest (income) expense</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest (income) expense consists of interest earned on our cash and cash equivalents held with institutional banks and interest expense is primarily related to the outstanding senior secured notes issued pursuant to the A&amp;R Note Purchase Agreement (Pharmakon Senior Secured Notes).</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other (income) expense</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other (income) expense consists of foreign currency (income) losses due to exchange rate fluctuations on transactions denominated in a currency other than our functional currency as well as grant income and gains on sale of property and equipment.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical accounting policies and use of estimates</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our consolidated financial statements are prepared in accordance with U.S. generally accepted accounting principles (GAAP). The preparation of our consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reported period. We base our estimates on historical experience, known trends and events and various other factors that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates under different assumptions and conditions.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While our significant accounting policies are described in more detail in the notes to our consolidated financial statements appearing elsewhere in this report, we believe that the following accounting policies are those most critical to the preparation of our consolidated financial statements.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Warrant Liability</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2022, we issued warrants in connection with a public offering. Pursuant to the terms of the warrants, we could be required to settle the warrants in cash in the event of a "fundamental transaction" as defined in the warrant (which includes, among other things, an acquisition of the Company) and, as a result, the warrants are required to be measured at fair value and reported as a liability in the consolidated balance sheet. We recorded the fair value of the warrants upon issuance using a Monte Carlo simulation and are required to revalue the warrants at each reporting date with any changes in fair value recorded on our statement of operations. The valuation of the warrants is considered under Level 3 of the fair value hierarchy due to the need to use assumptions in the valuation that are both significant to the fair value measurement and unobservable. The change in the fair value of the Level 3 warrants liabilities is reflected in the statement of operations for the year ended December 31, 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue recognition</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for revenue in accordance with Accounting Standards Codification (ASC) Topic 606, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which was adopted on January 1, 2018. We perform the following five steps to recognize revenue under ASC Topic 606: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. We only recognize revenue when it is probable that we will collect the consideration to which we are entitled in exchange for the goods or services that will be transferred to the customer. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Net product revenues</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize XHANCE revenue at the point the customer obtains control of the product, which generally occurs upon delivery. The transaction price that is recognized as revenue for products includes an estimate of variable consideration. Payment terms with customers do not exceed one year and, therefore, we do not account for a financing component in our arrangements. Incremental costs of obtaining a contract with a customer (for example, sales commissions) are expensed when incurred as the period of benefit is less than one year. Shipping and handling costs for product shipments to customers are recorded as selling, general and administrative expenses. Our estimates of variable consideration and determination of whether to include estimated amounts in the transaction price are based largely on an assessment of our anticipated performance and all information (historical, current and forecasted) that is reasonably available. As of December 31, 2022, we did not make any material adjustment to our prior estimates of variable consideration.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, we believe that reasonable variations in our estimates of variable consideration would not result in material changes to our financial statements. The components of our variable consideration include the following:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Provider Chargebacks and Discounts.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Chargebacks for fees and discounts to providers represent the estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list prices charged to customers who directly purchase the product from us.&#160;Customers charge us for the difference between what they pay for the product and the ultimate selling price to the qualified healthcare providers.&#160;These components of variable consideration are established in the same period that the related revenue is recognized, resulting in a reduction of product revenue and accounts receivable. Our provision for chargebacks and discounts consists of our estimates for these credits, which we evaluate based on historical data, estimated future trends, and estimates of inventory held by our customers.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Trade Discounts and Allowances.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  We generally provide customers with discounts that include incentive fees which are explicitly stated in the Company&#8217;s contracts. These discounts are recorded as a reduction of revenue and accounts receivable in the period in which the related product revenue is recognized.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Returns.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Consistent with industry practice, we have a product returns policy that provides customers a right of return for product purchased within a specified period prior to and subsequent to the product&#8217;s expiration date. We estimate the amount of our product that may be returned and present this amount as a reduction of revenue in the period the related product revenue is recognized, in addition to establishing a current liability. We consider several factors in the estimation process, including expiration dates of product shipped to customers, inventory levels within the distribution channel, product shelf life, prescription trends and other relevant factors.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Rebates.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  We are subject to discount obligations under state Medicaid programs and Medicare. Reserves related to these discount obligations are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability. Our liability for these rebates consists of estimates of claims for the current quarter and estimated future claims that will be made for product that has been recognized as revenue but remains in the distribution channel inventories at the end of the reporting period.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Payor Rebates.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  We contract with certain third-party payors, primarily health insurance companies and pharmacy benefit managers, for the payment of rebates with respect to utilization of its products. These rebates are based on contractual percentages applied to the amount of product prescribed to patients who are covered by the plan or the organization with which it contracts. We estimate these rebates and record such estimates in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Patient Assistance.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Other programs that we offer include voluntary co-pay patient assistance programs intended to provide financial assistance to eligible patients with prescription drug co-payments required by payors and coupon programs for cash payors.&#160;The calculation of the current liability for this assistance is based on an estimate of claims and the cost per claim that we expect to receive associated with product that has been recognized as revenue but remains in the distribution channel inventories at the end of each reporting period.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Distribution and Other Fees</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We pay distribution and other fees to certain customers in connection with the sales of our products. We record distribution and other fees paid to our customers as a reduction of revenue, unless the payment is for a distinct good or service from the customer and we can reasonably estimate the fair value of the goods or services received. If both conditions are met, we record the consideration paid to the customer as an operating expense. These costs are typically known at the time of sale, resulting in minimal adjustments subsequent to the period of sale.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-based compensation</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for stock-based compensation awards in accordance with the FASB ASC Topic 718,&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation&#160;&#8212; Stock Compensation (</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC 718). ASC 718 requires all stock-based compensation awards to employees to be recognized as expense based on their grant date fair values. We use the Black-Scholes option pricing model to value our stock option and restricted stock option awards and shares issued under our employee stock purchase plan. Restricted stock units are valued at the fair market value per share of our common stock on the date of grant. We account for forfeitures of stock option awards as they occur. For awards issued to employees, we recognize compensation expense on a straight-line basis over the requisite service period, which is generally the vesting period of the award. The resulting increase or decrease in value, if any, is recognized as expense or a reduction to expense, respectively, during the period the related services are rendered. Expense for awards with performance conditions is estimated and adjusted on a quarterly basis based upon our assessment of the probability that the performance condition will be met. In January 2022, we issued awards with vesting subject to specific market conditions.  The calculation of the value of awards that are subject to market conditions, as well as the derived service period for these awards, are determined using a Monte Carlo simulation. Stock based compensation for awards that are subject to a market condition is recognized based over the derived service period.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimating the fair value of stock option awards and shares issued under the employee stock purchase plan requires the input of subjective assumptions, including the estimated fair value of our common stock, the expected life of the option, stock price volatility, the risk-free interest rate and expected dividends. The assumptions used in our Black-Scholes option-pricing model represent management's best estimates and involve a number of variables, uncertainties and assumptions and the application of management's judgment, as they are inherently subjective. If any assumptions change, our stock-based compensation expense could be materially different in the future.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These assumptions used in our Black-Scholes option-pricing model are estimated as follows:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Expected Term.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;Due to the lack of sufficient company-specific historical data, the expected term of employee options is determined using the "simplified" method, as prescribed in SEC's Staff Accounting Bulletin (SAB) No.&#160;107, whereby the expected life equals the arithmetic average of the vesting term and the original contractual term of the option. The expected term of non-employee options is equal to the contractual term.&#160;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Expected Volatility.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;The expected volatility is based on historical volatilities of similar entities within our industry which were commensurate with the expected term assumption as described in SAB No.&#160;107.&#160;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Risk-Free Interest Rate.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;The risk-free interest rate is based on the interest rate payable on U.S. Treasury securities in effect at the time of grant for a period that is commensurate with the assumed expected term.&#160;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Expected Dividends.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;The expected dividend yield is 0% because we have not historically paid, and do not expect for the foreseeable future to pay, a dividend on our common stock.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reflects the weighted average assumptions used to estimate the fair value of stock option awards granted and shares issued under the employee stock purchase plan during the year ended December 31, 2022.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:71.252%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.872%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2010 A&amp;R Stock Incentive Plan</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2017 Employee Stock Purchase Plan</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk free interest rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.22&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.17&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.08</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.5</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">73.23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">88.13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Annual dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) Includes options granted outside the 2010 A&amp;R Stock Incentive Plan. The grants were made pursuant to the Nasdaq inducement grant exception in accordance with Nasdaq Listing Rule 5635(c)(4). </span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For information about our employee stock purchase plan, see </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_175">Note 1</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_175">4</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to the Consolidated Financial Statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 3 of our audited consolidated financial statements beginning on page F-1 of this Annual Report on Form 10-K for a description of recent accounting pronouncements applicable to our consolidated financial statements.</span></div><div id="i451bcb3eabba4f87bdc579718207a3b8_61"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Results of Operations</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the years ended December 31, 2022 and 2021 </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth our selected consolidated statements of operations data for the periods indicated (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"></td><td style="width:76.038%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.961%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.964%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net product revenues</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">76,276&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">73,652&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Licensing revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Total revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">76,276&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">74,652&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Costs and expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Cost of product sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,263&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,151&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,260&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,318&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">107,649&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">106,633&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">132,172&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">141,102&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(55,896)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(66,450)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other (income) expense:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized loss on fair value of warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,211&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest (income) expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,330&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,921&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other (income) expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,396&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(75)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total other (income) expense</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,937&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,846&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(74,833)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(82,296)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net product revenues</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net product revenues related to sales of XHANCE were $76.3 million and $73.7 million for the years ended December 31, 2022 and 2021, respectively. Revenue growth was attributable primarily to an increase in average net product revenue per prescription in 2022. We believe increasing rates of payor enforcement of the utilization management criteria had a negative effect on XHANCE prescription volume growth in 2022 and may continue to have a negative effect on prescription volume in the future.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Licensing revenues</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Licensing revenues were $1.0 million for the year ended December 31, 2021 as a result of payments received under the terms of the Currax License Agreement entered into in September 2019. There were no Licensing revenues for the year ended December 31, 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of product sales</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of product sales related to XHANCE were $9.3 million and $9.2 million for the years ended December 31, 2022 and 2021, respectively, with the increase attributable primarily to an increase in period costs related to the qualification of an alternative third party supplier for select components of XHANCE.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development expense </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses were $15.3 million and $25.3 million for the years ended</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2022 and 2021, respectively. The $10.1 million decrease in 2022 was attributable primarily to a $10.1 million decrease in clinical expenses related to our clinical trial program in pursuit of a follow-on indication for XHANCE for the treatment of chronic sinusitis in adults in the U.S. and the FDA-mandated post-marketing pediatric study.  This decrease was partially offset by a $0.3 million increase in regulatory and quality costs.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, general and administrative expense</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses were $107.6 million and $106.6 million for the years ended December 31, 2022 and 2021, respectively. The $1.0 million increase was due primarily to a $0.8&#160;million increase in consulting and professional fees; and a $0.2 million increase in personnel costs.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest (income) expense, net</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense, net, was $16.3 million and $15.9 million for the years ended December 31, 2022 and 2021, respectively, which was primarily comprised of interest expense on the Pharmakon Senior Secured Notes during both periods. The increase was primarily driven by the increased interest rate on the Pharmakon Senior Secured Notes in November 2022 as a result of the A&amp;R Note Purchase Agreement. The Company also recognized offering related expenses and an unrealized loss on the fair value of liability classified warrants issued as part of an underwritten public offering during the year ended December 31, 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since inception, we have incurred significant net losses and expect to continue to incur net losses for the foreseeable future. We incurred net losses of $74.8 million and $82.3 million for the years ended December 31, 2022 and 2021, respectively. As of December 31, 2022, we had an accumulated deficit of $684.9 million. We have funded our operations primarily through the sale of stock and the issuance of debt, as well as through licensing revenues received under the terms of our license agreements and revenues from sales of XHANCE. As of December 31, 2022, we had $94.2 million in cash and cash equivalents. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows a summary of our cash flows for the periods indicated (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:77.167%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.032%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.033%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(67,651)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(76,935)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(63)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(62)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51,436&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43,320&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effects of exchange rates on cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net decrease in cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16,271)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(33,664)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating activities</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash used in operating activities decreased by $9.3 million, from $76.9 million for the year ended December 31, 2021 to $67.7 million for the year ended December 31, 2022. The decrease in cash used in operating activities was attributable primarily to decreased operating expenses and the timing of payment of those expenses.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing activities</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Cash used in investing activities increased from the year ended December 31, 2021 to the year ended December 31, 2022. The increase in cash used in investing activities was attributable to proceeds from the sale of property and equipment in 2021 that did not recur in 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financing activities</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash provided by financing activities for the year ended December 31, 2022, was driven primarily by net proceeds of $51.1 million from the issuance of shares of Company common stock and accompanying warrants as a result of a November 2022 underwritten public offering of 27,861,299 shares at a price of $1.89 per share. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash provided by financing activities for the year ended December 31, 2021, was driven primarily by net proceeds of $43.1 million from the issuance of shares of Company common stock as a result of a November 2021 underwritten public offering of 28,750,000 shares at a price of $1.60 per share.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amended and Restated Note Purchase Agreement </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 12, 2019 (the Closing Date), we entered into a Note Purchase Agreement with funds managed by Pharmakon Advisors, LP (Pharmakon), the investment manager of BioPharma Credit Funds (BioPharma). The Note Purchase Agreement provided us with $130.0 million in debt financing, of which $80.0 million of Pharmakon Senior Secured Notes was issued on the Closing Date, $30.0 million was issued on February 13, 2020, and $20.0 million was issued on December 1, 2020.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">94</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 10, 2022, we entered into a Third Amendment to the Note Purchase Agreement (the Third Amendment).  The Third Amendment reduced the minimum c</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">onsolidated XHANCE net sales and royalties required to be achieved under the Note Purchase Agreement for the trailing twelve-month period ending December 31, 2022 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in exchange for a $0.8 million fee due on the repayment of the Pharmakon Senior Secured Notes.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 9, 2022, we entered into a Fourth Amendment to the Note Purchase Agreement (the Fourth Amendment).  The Fourth Amendment resulted in the waiver of the minimum consolidated XHANCE net sales and royalties required to be achieved under the Note Purchase Agreement for the trailing twelve-month period ending September 30, 2022 and December 31, 2022 in exchange for a $1.3 million fee due upon repayment of the Pharmakon Senior Secured Notes.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On November 23, 2022, we amended and restated the Note Purchase Agreement (the A&amp;R Note Purchase Agreement), among us, our subsidiaries, OptiNose US, Inc., OptiNose AS and OptiNose UK, Ltd. and BioPharma Credit PLC, as collateral agent, and the purchasers party thereto from time to time. Pursuant to the A&amp;R Note Purchase Agreement, certain modifications to the affirmative and negative covenants, events of default and other terms were made, including, without limitation, (i) the requirement for us to deliver quarterly and annual financial statements that, commencing with our financial statements for the year ending December 31, 2023, are not subject to a &#8220;going concern&#8221; statement and (ii) the removal of certain exceptions to the negative covenants which previously permitted us to enter into certain transactions without the consent of the holders of the Pharmakon Senior Secured Notes, including permitted acquisitions, swap contracts, convertible bonds and revolving credit facilities. The financial covenants requiring us to achieve minimum trailing twelve-month consolidated XHANCE net product sales and royalties were also modified as follows (shown in millions):</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:2.723%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.455%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.332%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.332%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.728%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trailing Twelve-Months Ending</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Requirement Prior to A&amp;R Note Purchase Agreement</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Requirement under the A&amp;R Note Purchase Agreement</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">September 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">March 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$98.75</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">June 30, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102.50</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">September 30, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106.25</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">December 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110.00</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">March 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113.75</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$82.50</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">June 30, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117.50</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90.00</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">September 30, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102.50</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">December 31, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110.00</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">March 31, 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115.00</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">June 30, 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120.00</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">September 30, 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125.00</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">December 31, 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130.00</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">March 31, 2026</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135.00</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">June 30, 2026</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140.00</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">September 30, 2026</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145.00</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">December 31, 2026</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150.00</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">March 31, 2027</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155.00</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">June 30, 2027</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160.00</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">September 30, 2027</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165.00</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The A&amp;R Note Purchase Agreement provided for an extension of the maturity date of the Pharmakon Senior Secured Notes from September 12, 2024 to June 30, 2027 (New Maturity Date), an extension of the interest-only period from September 2023 to September 2025, after which principal repayments will commence starting on September 30, 2025 and would be made in eight equal quarterly installments of principal and interest through the New Maturity Date. As part of the A&amp;R Note Purchase Agreement the Pharmakon Senior Secured Notes now bear an amended interest rate through the New Maturity Date equal to the 3-month Secured Overnight Financing Rate (subject to a 2.50% floor), determined as of the date that is two business days prior to the commencement of each quarter, plus 8.50% per annum, which interest rate shall be increased by an additional 3.00% per annum upon the occurrence and during the continuation of any event of default. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">95</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Contents</a></span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In conjunction with the A&amp;R Note Purchase Agreement, a modification was made to the &#8220;make-whole&#8221; premium payment due in connection with any principal prepayments (whether mandatory or voluntary) made prior to the 3-year anniversary of the date of the A&amp;R Note Purchase Agreement. On any such prepayment date, we will be required to pay a make-whole premium in the amount of (i) for any prepayment date occurring up until and including the 18-month anniversary of the date of the A&amp;R Note Purchase Agreement, the foregone interest from such prepayment date through the 18-month anniversary of such prepayment date; and (ii) for any prepayment after the 18-month anniversary of the date of the A&amp;R Note Purchase Agreement, the foregone interest from such prepayment date through the 3-year anniversary of the date of the A&amp;R Note Purchase Agreement; provided, however, that in no event shall the amount of all make-whole premium payments exceed $24.0 million in the aggregate; </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As an inducement for the holders of the Pharmakon Senior Secured Notes to enter into the A&amp;R Note Purchase Agreement, we will be required to pay the holders of the Pharmakon Senior Secured Notes an amendment fee of $3.9 million (representing 3.00% of the outstanding principal balance of such notes) due on the New Maturity Date or the earlier repayment of the Pharmakon Senior Secured Notes, which amendment fee shall be (i) reduced to $1.3 million in the event that we repay the Pharmakon Senior Secured Notes in full prior to the one-year anniversary of the date of the A&amp;R Note Purchase Agreement and (ii) reduced to $2.6 million in the event that we repay the Pharmakon Senior Secured Notes in full on or after the one-year anniversary of the date of the A&amp;R Note Purchase Agreement and prior to second anniversary of the date of the A&amp;R Note Purchase Agreement. Additionally, the $1.3 million fee payable under the Fourth Amendment to the Note Purchase Agreement that we entered into on November 9, 2022 will be credited against the amendment fee payable in connection with the A&amp;R Note Purchase Agreement.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Projected 2023 operating expenses</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that our total operating expenses, consisting of selling, general &amp; administrative expenses and research &amp; development expenses for 2023 will be between $90.0 million and $95.0 million of which approximately $8.0 million is expected to be stock-based compensation expense. As a result, total GAAP operating expenses excluding stock-based compensation expense are expected to be between $82.0 million and $87.0 million. The $90.0 million to $95.0 million range is approximately a $30.0 million reduction compared to 2022, of which approximately half is related to reductions in sales and marketing.  The decrease in selling, general, and administrative expenses from 2022 to 2023 is anticipated as the result of actions taken to reduce near-term employee-related and third party expenses while preserving necessary capabilities to launch XHANCE as a treatment for patients with chronic sinusitis. In addition, the completion in 2022 of our clinical trial program in pursuit of a follow-on indication for XHANCE for the treatment of chronic sinusitis is the primary driver of an expected decrease in research and development expenses. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Future funding requirements</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to continue to incur significant expenses in connection with our ongoing activities, particularly as we:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">continue advertising and other promotional activities to support the commercialization of XHANCE;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">continue to provide co-pay and other patient affordability programs for XHANCE;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">continue clinical development activities for XHANCE, including studies mandated under the Pediatric Research Equity Act, and activities in pursuit of a follow-on indication for the treatment of chronic sinusitis;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">evaluate product candidates;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">continue to contract to manufacture XHANCE;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">maintain and protect our patent portfolio; </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">service our debt obligations under the Pharmakon Senior Secured Notes;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">maintain infrastructure necessary to operate as a publicly-traded, commercial-stage company; and</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">hire additional staff and add operational, financial and information systems to execute our business plan. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future funding requirements, both near and long-term, will depend on many factors, including, but not limited to:</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">96</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">the success of our commercialization of XHANCE for the treatment of nasal polyps including, among other things, continued patient and physician adoption of XHANCE and our ability to maintain adequate insurance coverage and reimbursement for XHANCE;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">the outcome, timing and cost of the FDA regulatory approval process of XHANCE for chronic sinusitis, including the potential for the FDA to require that we perform additional studies and clinical trials;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">the cost of commercialization activities for XHANCE, including product manufacturing, distribution, marketing and sales;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">net product revenues received from sales of XHANCE;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">the level of co-pay assistance and other patient affordability programs offered for XHANCE; </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">our clinical development plans for XHANCE, including the outcome, timing and cost studies mandated under the Pediatric Research Equity Act, and activities in pursuit of a follow-on indication for the treatment of chronic sinusitis;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">the costs involved in preparing, filing and prosecuting patent applications and annuity fees relating to issued patents; </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">the cost of maintaining and enforcing our intellectual property rights, as well as the cost of defending intellectual property disputes, including patent infringement actions brought by third parties against us; </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">the initiation, progress, timing, costs and results of clinical trials and other research and development related to additional product candidates, </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">the duration and impact of COVID-19 restrictions on our business; </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">the extent to which we in-license, acquire or otherwise partner in development or commercialization of other products, product candidates or technologies; and</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">our ability to maintain compliance with the financial covenants (including the requirement for us to achieve certain minimum trailing twelve-month consolidated XHANCE net sales and royalties thresholds and the requirement for us to maintain at least $30.0 million of cash and cash equivalents at all times), and the other provisions under the A&amp;R Note Purchase Agreement, and, if needed and available from the holders of the Pharmakon Senior Secured Notes, the costs and conditions associated with obtaining a waiver or modification of such covenants or other provisions.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As of December 31, 2022, we had $94.2 million in cash and cash equivalents. We will likely require additional capital in the near term in order to maintain compliance with the financial covenants and other terms under the A&amp;R Note Purchase Agreement and to meet the debt service obligations under our outstanding Pharmakon Senior Secured Notes and to continue to fund our operations. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our continuation as a going concern is dependent on our ability to maintain compliance with our covenants under the A&amp;R Note Purchase Agreement, including minimum trailing twelve-month consolidated XHANCE net sales and royalties we are required to achieve commencing with the trailing twelve months ending March 31, 2024, and our ability to generate sufficient cash flows from operations to meet our obligations and/or obtain additional capital through equity or debt financings, partnerships, collaborations, or other sources, as may be required. The A&amp;R Note Purchase Agreement includes events of default, in certain cases subject to customary periods to cure, following which Pharmakon may accelerate all amounts outstanding pursuant to the A&amp;R Note Purchase Agreement. The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We believe it is probable that we will not achieve the trailing twelve-month minimum consolidated XHANCE net sales and royalties thresholds under the A&amp;R Note Purchase Agreement for the initial period ending March 31, 2024, which will constitute a default under the A&amp;R Note Purchase Agreement if we are unable to obtain a modification or waiver of such minimum consolidated XHANCE net sales and royalties threshold. Further, the A&amp;R Note Purchase Agreement includes a requirement that commencing with the report and opinion on the consolidated financial statements commencing with the year ending December 31, 2023 and that all of our subsequent quarterly and annual financial statements, not be subject to any statement as to &#8220;going concern.&#8221; We have concluded that it is unlikely that we will be able comply with these provisions in 2024.  Failure to comply with these provisions would also constitute an event of default under the A&amp;R Note Purchase Agreement. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">97</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The A&amp;R Note Purchase Agreement also requires us to maintain at all times a minimum of $30.0&#160;million of cash and cash equivalents. We believe that it is probable that our existing cash and cash equivalents will not be adequate to fund our operations and maintain at least $30.0&#160;million of cash and cash equivalents as required under the A&amp;R Note Purchase Agreement for at least twelve- months following the filing of this Form 10-K, which will also constitute a default of the liquidity financial covenant under the A&amp;R Note Purchase Agreement if we are unable to obtain additional capital or obtain a waiver or modification to this liquidity covenant prior to falling below such $30.0&#160;million threshold. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In the event of any of the foregoing defaults, the holders of the Pharmakon Senior Secured Notes may declare an event of default under the A&amp;R Note Purchase</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Agreement and may elect to accelerate the repayment of all unpaid principal, accrued interest and other amounts due, which may require us to delay or curtail our operations until additional funding is received.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">These factors raise substantial doubt about our ability to continue as a going concern.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The terms of the</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">A&amp;R Note Purchase</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Agreement and the Pharmakon Senior Secured Notes, including applicable covenants, are described in </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_163">Note </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_163">10</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. In the event we are able to maintain compliance with the financial and other covenants and terms of the A&amp;R Pharmakon Note Purchase Agreement or obtain a waiver to or modification of such covenants, we believe our existing cash and cash equivalents will be sufficient to fund our operations and debt service obligations for approximately the next 12 months. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We will likely require additional capital in the future secured through equity or debt financings, partnerships, collaborations, or other sources in order to meet our debt service obligations, including repayment, under our outstanding senior secured notes, and to carry out our planned development and commercial activities. If additional capital is not obtained when required, we may need to delay or curtail our operations until additional funding is received.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Additionally, we may never become profitable, or if we do, may not be able to sustain profitability on a recurring basis.</span></div><div id="i451bcb3eabba4f87bdc579718207a3b8_64"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934 and are not required to provide the information under this item. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span><br/></span></div><div id="i451bcb3eabba4f87bdc579718207a3b8_67"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by Item 8 including the financial statements and notes thereto, and report of the independent registered public accounting firm thereon, are included in this Form 10-K as set forth in the &#8220;Index to Consolidated Financial Statements&#8221; on page F-1.</span></div><div><span><br/></span></div><div id="i451bcb3eabba4f87bdc579718207a3b8_70"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i451bcb3eabba4f87bdc579718207a3b8_73"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9A. CONTROLS AND PROCEDURES</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The term "disclosure controls and procedures," as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Act, refers to controls and procedures that are designed to ensure that information required to be disclosed by a</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC's rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that such information is accumulated and communicated to a company's management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In designing and evaluating our disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the disclosure controls and procedures are met. Additionally, in designing disclosure controls and procedures, our management was required to apply its judgment in evaluating the cost-benefit relationship of possible disclosure controls and procedures. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">98</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Contents</a></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a control system, misstatements due to error or fraud may occur and may not be detected.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Chief Executive Officer and our Principal Financial Officer evaluated the effectiveness of our disclosure controls and procedures, as defined in Rules 13a 15(e) and 15d 15(e) under the Exchange Act, as of the end of the period covered by this report. Based on this evaluation, our Chief Executive Officer and Principal Financial Officer concluded that our disclosure controls and procedures were effective as of December 31, 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Management's Report on Internal Control over Financial Reporting</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over financial reporting is a process designed to provide reasonable assurance of the reliability of financial reporting and of the preparation of financial statements for external reporting purposes, in accordance with U.S. generally accepted accounting principles.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Internal control over financial reporting includes policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect transactions and disposition of assets; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with U.S. generally accepted accounting principles, and that receipts and expenditures are being made only in accordance with the authorization of its management and directors; and (3) provide reasonable assurance regarding the prevention or timely detection of unauthorized acquisition, use, or disposition of our assets that could have a material effect on its financial statements.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of the effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies and procedures included in such controls may deteriorate.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management has assessed the effectiveness of our internal control over financial reporting as of December 31, 2022. In making this assessment, management used the criteria established by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control - Integrated Framework (2013). These criteria are in the areas of control environment, risk assessment, control activities, information and communication, and monitoring. Management&#8217;s assessment included extensive documentation, evaluating and testing the design and operating effectiveness of its internal controls over financial reporting.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on management&#8217;s processes and assessment, as described above, management has concluded that, as of December 31, 2022, our internal control over financial reporting was effective.</span></div><div><span><br/></span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes in our internal control over financial reporting that occurred during the quarter ended December 31, 2022 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div id="i451bcb3eabba4f87bdc579718207a3b8_76"></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9B. OTHER INFORMATION</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Not Applicable</span></div><div id="i451bcb3eabba4f87bdc579718207a3b8_79"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not Applicable</span></div><div id="i451bcb3eabba4f87bdc579718207a3b8_82"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART III</span></div><div><span><br/></span></div><div id="i451bcb3eabba4f87bdc579718207a3b8_85"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item is incorporated by reference to our Proxy Statement for the 2023 Annual Meeting of Stockholders to be filed with the Securities and Exchange Commission within 120 days of the fiscal year ended December 31, 2022.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Contents</a></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Board has adopted a written Code of Conduct applicable to all officers, directors and employees, which is available on our website (www.optinose.com) under "Corporate Governance" within the &#8220;Investors&#8221; section. We intend to satisfy the disclosure requirement under Item 5.05 of Form 8-K regarding amendment to, or waiver from, a provision of this Code of Conduct by posting such information on the website address and location specified above.</span></div><div><span><br/></span></div><div id="i451bcb3eabba4f87bdc579718207a3b8_88"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 11. EXECUTIVE COMPENSATION</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item is incorporated by reference to our Proxy Statement for the 2023 Annual Meeting of Stockholders to be filed with the Securities and Exchange Commission within 120 days of the fiscal year ended December 31, 2022.</span></div><div><span><br/></span></div><div id="i451bcb3eabba4f87bdc579718207a3b8_91"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item is incorporated by reference to our Proxy Statement for the 2023 Annual Meeting of Stockholders to be filed with the Securities and Exchange Commission within 120 days of the fiscal year ended December 31, 2022.</span></div><div><span><br/></span></div><div id="i451bcb3eabba4f87bdc579718207a3b8_94"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item is incorporated by reference to our Proxy Statement for the 2023 Annual Meeting of Stockholders to be filed with the Securities and Exchange Commission within 120 days of the fiscal year ended December 31, 2022.</span></div><div><span><br/></span></div><div id="i451bcb3eabba4f87bdc579718207a3b8_97"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item is incorporated by reference to our Proxy Statement for the 2023 Annual Meeting of Stockholders to be filed with the Securities and Exchange Commission within 120 days of the fiscal year ended December 31, 2022.</span></div><div><span><br/></span></div><div id="i451bcb3eabba4f87bdc579718207a3b8_100"></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART IV</span></div><div><span><br/></span></div><div id="i451bcb3eabba4f87bdc579718207a3b8_103"></div><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)  (1)&#160; Consolidated Financial Statements.</span></div><div><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Consolidated Financial Statements are filed as part of this report. See the Index to the Consolidated Financial Statements on page&#160;F-1.</span></div><div><span><br/></span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)&#160; Consolidated Financial Statement Schedule.</span></div><div><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Schedules are omitted because they are not applicable, or are not required, or because the information is included in the Consolidated Financial Statements and Notes thereto.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)&#160;The exhibits listed under Item&#160;15(b), which are incorporated herein by reference, are filed or furnished as part of this report or are incorporated into this report by reference.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160; Exhibits.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:6.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.148%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.325%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.738%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.857%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.980%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Incorporated by Reference</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Exhibit Description</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Form</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Date</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Filed Herewith</span></td></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1494650/000110465917062762/a17-15165_17ex3d1.htm">Fourth Amended and Restated Certificate of Incorporation of OptiNose,&#160;Inc. </a></span></div></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10/18/17</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1494650/000110465917062762/a17-15165_17ex3d2.htm">Amended and Restated Bylaws of OptiNose,&#160;Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10/18/17</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1494650/000104746917006175/a2233379zex-4_1.htm">Form of Common Stock Certificate.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10/3/17</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Table of </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Contents</a></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:6.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.148%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.325%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.738%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.857%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.980%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1494650/000104746917005928/a2233286zex-4_2.htm">Second Amended and Restated Registration Rights Agreement, dated March&#160;24, 2017, by and among the Registrant and certain of its stockholders.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/18/17</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1494650/000104746917006300/a2233453zex-4_7.htm">First Amendment to the Second Amended and Restated Registration Rights Agreement, dated October 2, 2017, by and among the Registrant and certain of its stockholders.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10/11/17</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.7</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1494650/000149465021000132/formofwarrant111621.htm">Common Stock Warrant issued by OptiNose, Inc. dated November 16, 202</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1494650/000149465021000132/formofwarrant111621.htm">1</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1494650/000149465021000132/formofwarrant111621.htm">.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11/16/21</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="descriptionofsecuritiesex4.htm">Description of Securities of OptiNose, Inc. </a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">x</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.6</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1494650/000149465021000132/formofwarrant111621.htm">Form of </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1494650/000149465021000132/formofwarrant111621.htm">Common Stock </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1494650/000149465021000132/formofwarrant111621.htm">Warrant</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1494650/000149465021000132/formofwarrant111621.htm"> issued by OptiNose, Inc. on November 23, 2022</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11/23/22</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.7</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1494650/000149465022000124/exhibit42-warrantagencyagr.htm">Warrant Agency Agreement, dated November 23, 2022, by and between OptiNose, Inc. and Broadridge Corporate Issuer Solutions, Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11/23/22</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="formindemnificationagreeme.htm">Form of Indemnification Agreement.</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">+</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">x</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1494650/000104746917006175/a2233379zex-10_7.htm">Amended and Restated 2010 Stock Incentive Plan</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">.+</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10/3/17</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.7</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1494650/000104746917006175/a2233379zex-10_8.htm">Form of Non-Qualified Stock Option Agreement Granted Under the 2010 Stock Incentive Plan (Relating to Success Pool Grants).</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">+</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10/3/17</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.8</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1494650/000104746917006175/a2233379zex-10_9.htm">Form of Non-Qualified Stock Option Agreement Granted Under the 2010 Stock Incentive Plan (Relating to Option Pool Grants).</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">+</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10/3/17</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.9</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1494650/000104746917006175/a2233379zex-10_10.htm">Form of Non-Qualified Stock Option Agreement Granted Under the 2010 Stock Incentive Plan</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">.+</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10/3/17</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.10</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.6</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1494650/000104746917005928/a2233286zex-10_14.htm">Supply Agreement, dated July&#160;1, 2017, by and between Hovione Inter&#160;Ltd and OptiNose US,&#160;Inc., OptiNose UK,&#160;Ltd and OptiNose AS.</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/18/17</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.14</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.7</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1494650/000104746917005928/a2233286zex-10_15.htm">Manufacture and Supply Agreement, dated as of August&#160;18, 2017, by and among OptiNose US,&#160;Inc., OptiNose UK&#160;Ltd. and OptiNose AS and Contract Pharmaceuticals Limited Canada.</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/18/17</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.15</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.8</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1494650/000104746917006175/a2233379zex-10_17.htm">Form of Non-Qualified Stock Option Agreement Under the Amended and Restated 2010 Stock Incentive Plan</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">+</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10/3/17</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.17</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.9</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1494650/000104746917006175/a2233379zex-10_18.htm">2017 Employee Stock Purchase Plan.</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">+</span></div><div><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10/3/17</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.18</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.10</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1494650/000149465019000020/exhibit1020_optn-vtmopnass.htm">Manufacturing Services Agreement, dated December 21, 2018, by and among OptiNose US, Inc., OptiNose UK Ltd. and Optinose AS and Advance Mold &amp; Manufacturing, Inc. d/b/a Vision Technical Molding</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">.&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3/6/19</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.11</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1494650/000149465019000072/optinoseformrsugrantagreem.htm">Form of Restricted Stock Unit Agreement Under the  Amended and Restated 2010 Stock Incentive Plan.</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">+</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8/12/19</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.12</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1494650/000149465020000008/nqstockoptionagreement.htm">Form of Non-Qualified Stock Option Agreement (Inducement Grant)</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">.+</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2/19/20</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">99.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.13</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1494650/000149465020000136/flexagrmtamend1redact.htm">Amendment No.1, dated September 15, 2020, to the Manufacturing Services Agreement, dated December 21, 2018, by and among OptiNose US, Inc., OptiNose UK Ltd. and Optinose AS and Advance Mold &amp; Manufacturing, Inc. d/b/a Vision Technical Molding.  &#8224;</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11/5/20</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.14</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1494650/000149465020000052/restrictedstockunitagr.htm">Form of Restricted Stock Unit Agreement (Inducement Grant).+</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5/7/20</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.15</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1494650/000149465021000055/cplsupplyagmtrenewalandame.htm">Renewal and Amendment No. 1, dated February 22, 2021 to Manufacture and Supply Agreement, dated as of August 18, 2017, by and among OptiNose US, Inc., OptiNose UK Ltd. and OptiNose AS and Contract Pharmaceuticals Limited Canada.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5/5/21</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.17</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1494650/000149465021000099/optinoseatm-salesagreement.htm">Open Market Sale Agreement (the Sale Agreement), dated August 11, 2021, between the Company and Jefferies LLC.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8/11/21</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.20</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1494650/000149465022000019/amendedandrestatedemploymea.htm">Amended and Restated Employment Agreement, dated March 2, 2022, between OptiNose US, Inc. and Michael F. Marino +</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3/3/21</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.25</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.21</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1494650/000149465022000049/cooperationagreement1.htm">Cooperation Agreement, dated April 25, 2022, by and among OptiNose, Inc. M. Kingdon Offshore Master Fund L.P., Velan Capital Partners LP and certain other affiliated investors listed therein</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5/12/22</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.24</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1494650/000149465022000119/pharmakon-optinosexxamende.htm">Amended and Restated Note Purchase Agreement, dated November 21, 2022, among OptiNose US, Inc., OptiNose, Inc., and OptiNose AS, BioPharma Credit PLC, as collateral agent and the purchasers from time to time party thereto.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11/21/22</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.26</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1494650/000149465022000108/amd2toflexagmtdsa2022090.htm">Amendment No.2, dated September 20, 2022, to the Manufacturing Services Agreement, dated December 21, 2018, by and among OptiNose US, Inc. and Advance Mold &amp; Manufacturing, Inc. d/b/a Vision Technical Molding.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/23/22</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.27</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1494650/000149465022000110/krickofficeremploymentagre.htm">Employment Agreement dated 23, between OptiNose US, Inc. and Anthony J. Krick</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/27/22</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">99.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.29</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1494650/000149465022000128/optinosepsexecutiveemploym.htm">Employment Agreement, dated December 15, 2022, between OptiNose US, Inc. and Paul Spence, Jr.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12/15/22</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.30</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1494650/000149465022000134/optinoseconsultingagreemen.htm">Consulting Agreement, dated December 16, 2022, between OptiNose US, Inc. and Janis Consulting LLC</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12/16/22</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Table of </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Contents</a></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:6.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.148%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.325%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.738%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.857%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.980%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.31</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1494650/000149465023000014/a101amendedandrestatedempl.htm">Amended and Restated Employment Agreement, dated January 30, 2023, between OptiNose US, Inc. and Ramy A. Mahmoud</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1/31/23</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.32</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1494650/000149465023000014/a102formofseparationagreem.htm">Separation Agreement and Relea</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1494650/000149465023000014/a102formofseparationagreem.htm">se, dated January 30, 2023, between Peter K. Miller and OptiNose</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1494650/000149465023000014/a102formofseparationagreem.htm"> US, Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1/31/23</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.33</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1494650/000149465023000014/a103consultingagreementdat.htm">Consulting Agreement, dated January 30, 2023, between Peter K. Miller and OptiNose US, Inc. </a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1/31/23</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="listofsubsidiariesex2112022.htm">List of Subsidiaries</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">x</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="auditorconsentex2312022.htm">Consent of Ernst&#160;&amp; Young&#160;LLP, independent registered public accounting firm.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">x</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="optn12-31x202210xkex311.htm">Certification of Chief Executive Officer pursuant to Rule 13a-14(a) or 15a-14(a) under the Exchange Act.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">x</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="optn12-31x202210xkex312.htm">Certification of Principal Financial Officer pursuant to Rule 13a-14(a) or 15a-14(a) under the Exchange Act.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">x</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="optn12-31x202210xkex321.htm">Certification Pursuant to 18 U.S.C. Section 1350 of principal executive officer and principal financial officer.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">x</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="optn12-31x202210xkex322.htm">Certification Pursuant to 18 U.S.C. Section 1350 of principal executive officer and principal financial officer.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">x</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">XBRL Instance Document. </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">x</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Schema Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">x</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Calculation Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">x</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Definition Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">x</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Label Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">x</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Presentation Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">x</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">x</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8224;</span></td><td colspan="30" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Portions of this exhibit (indicated by asterisks) have been omitted in compliance with Item 601 of Regulation S-K.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">+</span></td><td colspan="30" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Indicates management contract or compensatory arrangement.</span></td></tr></table></div><div><span><br/></span></div><div id="i451bcb3eabba4f87bdc579718207a3b8_106"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 16. FORM 10-K SUMMARY</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable. </span></div><div id="i451bcb3eabba4f87bdc579718207a3b8_109"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">102</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span><br/></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized in the capacities and on the date indicated. </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.783%"><tr><td style="width:1.0%"></td><td style="width:54.942%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.676%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.884%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.676%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.754%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.555%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.713%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OPTINOSE,&#160;INC.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:  March 7, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;RAMY MAHMOUD</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ramy Mahmoud</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Executive Officer</span></td></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:25.292%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:56.964%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.973%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.538%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Signature</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Title</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Date</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">/s/ RAMY MAHMOUD</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Chief Executive Officer and Director (Principal Executive Officer)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 7, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Ramy Mahmoud</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">/s/ ANTHONY J. KRICK</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Chief Accounting Officer (Principal Financial Officer and Principal Accounting Officer)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 7, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Anthony J. Krick</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">/s/ JOSEPH C. SCODARI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Chairman of the Board of Directors</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 7, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Joseph C. Scodari</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">/s/ WILHELMUS GROENHUYSEN</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 7, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Wilhelmus Groenhuysen</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">/s/ SANDRA L. HELTON</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 7, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sandra L. Helton</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">/s/ TOMAS J. HEYMAN</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 7, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tomas J. Heyman</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">/s/ CATHERINE E. OWEN</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 7, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Catherine E. Owen</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">/s/ ERIC BEDNARSKI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 7, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Eric Bednarski</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">/s/ KYLE DEMPSEY</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 7, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Kyle Dempsey</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">/s/ R. JOHN FLETCHER</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 7, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">R. John Fletcher</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">103</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Contents</a></span></div></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">104</span></div></div></div><div id="i451bcb3eabba4f87bdc579718207a3b8_112"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span><br/></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:90.395%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.672%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Audited Consolidated Financial Statements</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_115">Report of Independent Registered Public Accounting Firm</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, <ix:nonNumeric contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" name="dei:AuditorName" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMTIvZnJhZzpmYTM5ODFjMDU5ODE0OWU2YTk0ZThiYzU5M2Q0NmYxMC90YWJsZTo3MGM0ZjM4MjRkYTc0YjBlYjFlYzA2NDRhNWExNDMxYy90YWJsZXJhbmdlOjcwYzRmMzgyNGRhNzRiMGViMWVjMDY0NGE1YTE0MzFjXzMtMC0xLTEtNTgzNzIvdGV4dHJlZ2lvbjpiY2Y1YTJmM2Y1MzQ0NzUxOGY3OTdhYWY2NGMwMTgwZl82MQ_ca3b4c15-d6df-4809-a810-6c5fc08ccc3b">Ernst &amp; Young LLP</ix:nonNumeric> (<ix:nonNumeric contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" name="dei:AuditorLocation" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMTIvZnJhZzpmYTM5ODFjMDU5ODE0OWU2YTk0ZThiYzU5M2Q0NmYxMC90YWJsZTo3MGM0ZjM4MjRkYTc0YjBlYjFlYzA2NDRhNWExNDMxYy90YWJsZXJhbmdlOjcwYzRmMzgyNGRhNzRiMGViMWVjMDY0NGE1YTE0MzFjXzMtMC0xLTEtNTgzNzIvdGV4dHJlZ2lvbjpiY2Y1YTJmM2Y1MzQ0NzUxOGY3OTdhYWY2NGMwMTgwZl82NQ_e3f2b122-d215-4c92-9b64-781ea06c8c0e">Philadelphia, PA</ix:nonNumeric>) (PCAOB ID: <ix:nonNumeric contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" name="dei:AuditorFirmId" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMTIvZnJhZzpmYTM5ODFjMDU5ODE0OWU2YTk0ZThiYzU5M2Q0NmYxMC90YWJsZTo3MGM0ZjM4MjRkYTc0YjBlYjFlYzA2NDRhNWExNDMxYy90YWJsZXJhbmdlOjcwYzRmMzgyNGRhNzRiMGViMWVjMDY0NGE1YTE0MzFjXzMtMC0xLTEtNTgzNzIvdGV4dHJlZ2lvbjpiY2Y1YTJmM2Y1MzQ0NzUxOGY3OTdhYWY2NGMwMTgwZl84MA_8739bcd5-7c6d-46a8-8495-890d0cdc82b4">42</ix:nonNumeric>)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_115">F-</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_115">2</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_118">Consolidated Balance Sheets as of December&#160;31, 2022 and 2021</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_118">F-</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_118">5</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_121">Consolidated Statements of Operations for the years ended December&#160;31, 2022 and 2021</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_121">F-</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_121">6</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_124">Consolidated Statements of Comprehensive Loss for the years ended December&#160;31, 2022 and 2021</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_124">F-</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_124">7</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_127">Consolidated Statements of Changes in Stockholders' Equity (Deficit) for the years ended December&#160;31, 2022 and 2021</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_127">F-</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_127">8</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_130">Consolidated Statements of Cash Flows for the years ended December&#160;31, 2022 and 2021</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_130">F-</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_130">9</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_133">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_133">F-</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_133">10</a></span></div></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span><br/></span></div><div style="margin-bottom:8pt;margin-top:8pt"><span><br/></span></div><div style="margin-bottom:8pt;margin-top:8pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-1</span></div></div></div><div id="i451bcb3eabba4f87bdc579718207a3b8_115"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Contents</a></span></div></div><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Shareholders and Board of Directors of OptiNose,&#160;Inc.</span></div><div style="margin-bottom:8pt;margin-top:6.2pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on the Financial Statements</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the accompanying consolidated balance sheets of OptiNose, Inc. (the Company) as of December 31, 2022 and 2021, the related consolidated statements of operations, comprehensive loss, stockholders&#8217; equity (deficit) and cash flows for the years then ended, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2022 and 2021, and the results of its operations and its cash flows for the years then ended, in conformity with U.S. generally accepted accounting principles.</span></div><div style="margin-top:6.4pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The Company&#8217;s Ability to Continue as a Going Concern</span></div><div style="margin-top:6.4pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the consolidated financial statements, the Company has incurred recurring losses from operations, has a working capital deficiency and expects to not be in compliance with certain debt covenants, and has stated that substantial doubt exists about the Company&#8217;s ability to continue as a going concern. Management&#8217;s evaluation of the events and conditions and management&#8217;s plans regarding these matters are also described in Note 2. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.</span></div><div style="margin-top:6.4pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion</span></div><div style="margin-top:6.4pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div style="margin-top:6.4pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Audit Matters</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The critical audit matters communicated below are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.</span></div><div style="margin-bottom:6.25pt;margin-top:6.25pt;padding-right:6.75pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:6.25pt;margin-top:6.25pt;padding-right:6.75pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:6.25pt;margin-top:6.25pt;padding-right:6.75pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:6.25pt;margin-top:6.25pt;padding-right:6.75pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Contents</a></span></div></div><div style="margin-bottom:6.25pt;margin-top:6.25pt;padding-right:6.75pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.812%"><tr><td style="width:1.0%"></td><td style="width:13.231%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:81.066%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:112%">Product revenue allowances for payor rebates and patient assistance programs</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%">Description of the matter</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company sells XHANCE to preferred pharmacy network partners and wholesalers in the US (collectively, &#8220;Customers&#8221;). As described in Note 3 to the consolidated financial statements, the Company recognizes revenues for sales of XHANCE to its Customers reduced by estimates of variable consideration, including payor rebates to health insurance companies and pharmacy benefit managers (&#8220;payor rebates&#8221;), and incentives offered under voluntary patient assistance programs to provide financial assistance to qualified patients (&#8220;patient assistance&#8221;). Liabilities related to these reductions to gross product revenues are presented within accrued expenses on the consolidated balance sheet. The determination of these estimates of variable consideration at December 31, 2022, requires management to make estimates and assumptions about the amounts of rebates and incentives that will be payable by the Company as a result of the sale of products for which control has transferred.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%">How we addressed the matter in our audit</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">To test the estimates of variable consideration for payor rebates and the patient assistance programs, we performed audit procedures that included, among others, evaluating the methodologies used, testing the significant assumptions and testing the completeness and accuracy of the underlying data used by the Company in its analyses.  Specifically, for variable consideration for payor rebates, we compared the significant assumptions to third party reports used by the Company to estimate product remaining in the distribution channel at December 31, 2022, historical payor mix data for XHANCE, and the applicable contractual rebate percentages. In addition, we inspected the underlying payor rebate agreements and compared the rebate percentages used in the Company&#8217;s analyses with the contractual percentages.  For variable consideration for patient assistance, we compared the significant assumptions to third party reports used by the Company to estimate product remaining in the distribution channel at December 31, 2022, historical data related to the percentage of patients receiving patient assistance, and the historical data about the average amount of assistance received. For both patient assistance and payor rebates, we assessed the historical accuracy of management&#8217;s estimates by comparing previous estimates of payor rebates and patient assistance to the amount of actual payments in subsequent periods.</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:112%">Valuation of warrant liability</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%">Description of the matter</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company&#8217;s warrant liability totaled $21.5 million as of December 31, 2022. As discussed in Note 13 to the consolidated financial statements, certain warrants for the purchase of shares of common stock issued by the Company require liability classification and are recorded at fair value at each reporting period. The Company determines the fair value of the warrants utilizing a Monte Carlo simulation model. Auditing the Company&#8217;s valuation of its warrant liability was especially challenging as the fair value is based on various inputs and significant assumptions used in the Monte Carlo simulation model such as the probability and timing of equity financing and volatility. In addition, certain of the assumptions were based on management&#8217;s judgement, and therefore are not objectively verifiable.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%">How we addressed the matter in our audit</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">To test the warrant liability, our audit procedures included, among others, testing the Monte Carlo simulation model, and assessing the reasonableness of the significant assumptions, as described above. We involved valuation specialists to assess the valuation models and to assist in auditing certain significant assumptions. We tested the significant assumptions by agreeing amounts to contracts, third-party data and analyses prepared by the Company. In addition, we performed sensitivity analyses to evaluate the materiality of reasonable changes in management&#8217;s assumptions.</span></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6.25pt;margin-top:6.25pt;padding-right:6.75pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Ernst &amp; Young LLP</span></div><div style="margin-bottom:6.25pt;margin-top:6.25pt;padding-right:6.75pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have served as the Company&#8217;s auditor since 2016.</span></div><div style="margin-bottom:6.25pt;margin-top:6.25pt;padding-right:6.75pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Philadelphia, Pennsylvania</span></div><div style="margin-bottom:118.45pt;margin-top:6.25pt;padding-right:6.75pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;7, 2023 </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Contents</a></span></div></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-4</span></div></div></div><div id="i451bcb3eabba4f87bdc579718207a3b8_118"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OptiNose, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Balance Sheets</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:78.225%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.872%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231" decimals="-3" name="us-gaap:CashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMTgvZnJhZzpjNGZhMzAzZmMzNGM0ZWM1OTBjZGQ0ODcyNDY5NDEyZC90YWJsZTpjOTdjMDFkZTBiNzE0YTU1YmM4MGExNDI1NjYzNTlmNC90YWJsZXJhbmdlOmM5N2MwMWRlMGI3MTRhNTViYzgwYTE0MjU2NjM1OWY0XzQtMS0xLTEtNTgzNzI_e0f1930c-76a4-4276-86e6-a976065ca130">94,244</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id970dfd2674c4d6b895febb9c14d0fd1_I20211231" decimals="-3" name="us-gaap:CashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMTgvZnJhZzpjNGZhMzAzZmMzNGM0ZWM1OTBjZGQ0ODcyNDY5NDEyZC90YWJsZTpjOTdjMDFkZTBiNzE0YTU1YmM4MGExNDI1NjYzNTlmNC90YWJsZXJhbmdlOmM5N2MwMWRlMGI3MTRhNTViYzgwYTE0MjU2NjM1OWY0XzQtMy0xLTEtNTgzNzI_13e472e5-78a9-475e-9d5c-c175ad5c3f7b">110,502</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMTgvZnJhZzpjNGZhMzAzZmMzNGM0ZWM1OTBjZGQ0ODcyNDY5NDEyZC90YWJsZTpjOTdjMDFkZTBiNzE0YTU1YmM4MGExNDI1NjYzNTlmNC90YWJsZXJhbmdlOmM5N2MwMWRlMGI3MTRhNTViYzgwYTE0MjU2NjM1OWY0XzUtMS0xLTEtNTgzNzI_d197ab25-87fb-4e16-a378-3b173431f96d">33,932</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id970dfd2674c4d6b895febb9c14d0fd1_I20211231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMTgvZnJhZzpjNGZhMzAzZmMzNGM0ZWM1OTBjZGQ0ODcyNDY5NDEyZC90YWJsZTpjOTdjMDFkZTBiNzE0YTU1YmM4MGExNDI1NjYzNTlmNC90YWJsZXJhbmdlOmM5N2MwMWRlMGI3MTRhNTViYzgwYTE0MjU2NjM1OWY0XzUtMy0xLTEtNTgzNzI_bb056244-5335-4ffa-875e-44af21c95b13">35,449</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMTgvZnJhZzpjNGZhMzAzZmMzNGM0ZWM1OTBjZGQ0ODcyNDY5NDEyZC90YWJsZTpjOTdjMDFkZTBiNzE0YTU1YmM4MGExNDI1NjYzNTlmNC90YWJsZXJhbmdlOmM5N2MwMWRlMGI3MTRhNTViYzgwYTE0MjU2NjM1OWY0XzYtMS0xLTEtNTgzNzI_8514d1ae-a243-43ef-ba27-cc4e0cec8de0">9,443</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id970dfd2674c4d6b895febb9c14d0fd1_I20211231" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMTgvZnJhZzpjNGZhMzAzZmMzNGM0ZWM1OTBjZGQ0ODcyNDY5NDEyZC90YWJsZTpjOTdjMDFkZTBiNzE0YTU1YmM4MGExNDI1NjYzNTlmNC90YWJsZXJhbmdlOmM5N2MwMWRlMGI3MTRhNTViYzgwYTE0MjU2NjM1OWY0XzYtMy0xLTEtNTgzNzI_6b5a0b3b-f9b6-4a29-a967-090f0b5e41e2">11,847</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231" decimals="-3" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMTgvZnJhZzpjNGZhMzAzZmMzNGM0ZWM1OTBjZGQ0ODcyNDY5NDEyZC90YWJsZTpjOTdjMDFkZTBiNzE0YTU1YmM4MGExNDI1NjYzNTlmNC90YWJsZXJhbmdlOmM5N2MwMWRlMGI3MTRhNTViYzgwYTE0MjU2NjM1OWY0XzctMS0xLTEtNTgzNzI_cdc625c9-2659-404a-9fab-a843739331d1">2,865</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id970dfd2674c4d6b895febb9c14d0fd1_I20211231" decimals="-3" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMTgvZnJhZzpjNGZhMzAzZmMzNGM0ZWM1OTBjZGQ0ODcyNDY5NDEyZC90YWJsZTpjOTdjMDFkZTBiNzE0YTU1YmM4MGExNDI1NjYzNTlmNC90YWJsZXJhbmdlOmM5N2MwMWRlMGI3MTRhNTViYzgwYTE0MjU2NjM1OWY0XzctMy0xLTEtNTgzNzI_a0c280c1-a472-4553-82fd-0f13c746b74d">2,581</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMTgvZnJhZzpjNGZhMzAzZmMzNGM0ZWM1OTBjZGQ0ODcyNDY5NDEyZC90YWJsZTpjOTdjMDFkZTBiNzE0YTU1YmM4MGExNDI1NjYzNTlmNC90YWJsZXJhbmdlOmM5N2MwMWRlMGI3MTRhNTViYzgwYTE0MjU2NjM1OWY0XzgtMS0xLTEtNTgzNzI_3e835eab-7366-4406-a91d-383606083910">140,484</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id970dfd2674c4d6b895febb9c14d0fd1_I20211231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMTgvZnJhZzpjNGZhMzAzZmMzNGM0ZWM1OTBjZGQ0ODcyNDY5NDEyZC90YWJsZTpjOTdjMDFkZTBiNzE0YTU1YmM4MGExNDI1NjYzNTlmNC90YWJsZXJhbmdlOmM5N2MwMWRlMGI3MTRhNTViYzgwYTE0MjU2NjM1OWY0XzgtMy0xLTEtNTgzNzI_da2b12bf-9dbd-43ba-9134-564ab52ce69e">160,379</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMTgvZnJhZzpjNGZhMzAzZmMzNGM0ZWM1OTBjZGQ0ODcyNDY5NDEyZC90YWJsZTpjOTdjMDFkZTBiNzE0YTU1YmM4MGExNDI1NjYzNTlmNC90YWJsZXJhbmdlOmM5N2MwMWRlMGI3MTRhNTViYzgwYTE0MjU2NjM1OWY0XzktMS0xLTEtNTgzNzI_dc5f6564-8de7-4711-9c45-335938c22fe5">795</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id970dfd2674c4d6b895febb9c14d0fd1_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMTgvZnJhZzpjNGZhMzAzZmMzNGM0ZWM1OTBjZGQ0ODcyNDY5NDEyZC90YWJsZTpjOTdjMDFkZTBiNzE0YTU1YmM4MGExNDI1NjYzNTlmNC90YWJsZXJhbmdlOmM5N2MwMWRlMGI3MTRhNTViYzgwYTE0MjU2NjM1OWY0XzktMy0xLTEtNTgzNzI_efc666ed-1220-4af4-b872-5574a5421875">1,347</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMTgvZnJhZzpjNGZhMzAzZmMzNGM0ZWM1OTBjZGQ0ODcyNDY5NDEyZC90YWJsZTpjOTdjMDFkZTBiNzE0YTU1YmM4MGExNDI1NjYzNTlmNC90YWJsZXJhbmdlOmM5N2MwMWRlMGI3MTRhNTViYzgwYTE0MjU2NjM1OWY0XzEwLTEtMS0xLTU4Mzcy_f62ff372-1a19-4d89-bd00-54c6335fb0b5">2,943</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id970dfd2674c4d6b895febb9c14d0fd1_I20211231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMTgvZnJhZzpjNGZhMzAzZmMzNGM0ZWM1OTBjZGQ0ODcyNDY5NDEyZC90YWJsZTpjOTdjMDFkZTBiNzE0YTU1YmM4MGExNDI1NjYzNTlmNC90YWJsZXJhbmdlOmM5N2MwMWRlMGI3MTRhNTViYzgwYTE0MjU2NjM1OWY0XzEwLTMtMS0xLTU4Mzcy_05eb9c8d-4f17-4550-9fa4-43d20b9b80e8">4,345</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMTgvZnJhZzpjNGZhMzAzZmMzNGM0ZWM1OTBjZGQ0ODcyNDY5NDEyZC90YWJsZTpjOTdjMDFkZTBiNzE0YTU1YmM4MGExNDI1NjYzNTlmNC90YWJsZXJhbmdlOmM5N2MwMWRlMGI3MTRhNTViYzgwYTE0MjU2NjM1OWY0XzExLTEtMS0xLTU4Mzcy_37467284-c290-4473-9592-9244efda0675">144,222</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id970dfd2674c4d6b895febb9c14d0fd1_I20211231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMTgvZnJhZzpjNGZhMzAzZmMzNGM0ZWM1OTBjZGQ0ODcyNDY5NDEyZC90YWJsZTpjOTdjMDFkZTBiNzE0YTU1YmM4MGExNDI1NjYzNTlmNC90YWJsZXJhbmdlOmM5N2MwMWRlMGI3MTRhNTViYzgwYTE0MjU2NjM1OWY0XzExLTMtMS0xLTU4Mzcy_6c090f54-f0bf-4ada-8b52-955db21f6e17">166,071</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liabilities and stockholders' deficit</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMTgvZnJhZzpjNGZhMzAzZmMzNGM0ZWM1OTBjZGQ0ODcyNDY5NDEyZC90YWJsZTpjOTdjMDFkZTBiNzE0YTU1YmM4MGExNDI1NjYzNTlmNC90YWJsZXJhbmdlOmM5N2MwMWRlMGI3MTRhNTViYzgwYTE0MjU2NjM1OWY0XzE0LTEtMS0xLTU4Mzcy_99317594-8562-4e1b-84a5-2cc91a3c9289">5,291</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id970dfd2674c4d6b895febb9c14d0fd1_I20211231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMTgvZnJhZzpjNGZhMzAzZmMzNGM0ZWM1OTBjZGQ0ODcyNDY5NDEyZC90YWJsZTpjOTdjMDFkZTBiNzE0YTU1YmM4MGExNDI1NjYzNTlmNC90YWJsZXJhbmdlOmM5N2MwMWRlMGI3MTRhNTViYzgwYTE0MjU2NjM1OWY0XzE0LTMtMS0xLTU4Mzcy_efea1ba2-34f8-4444-8953-d34ae9fe2f23">8,013</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231" decimals="-3" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMTgvZnJhZzpjNGZhMzAzZmMzNGM0ZWM1OTBjZGQ0ODcyNDY5NDEyZC90YWJsZTpjOTdjMDFkZTBiNzE0YTU1YmM4MGExNDI1NjYzNTlmNC90YWJsZXJhbmdlOmM5N2MwMWRlMGI3MTRhNTViYzgwYTE0MjU2NjM1OWY0XzE1LTEtMS0xLTU4Mzcy_6460eb52-de8c-42ce-9fd2-f06e09da99b5">44,864</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id970dfd2674c4d6b895febb9c14d0fd1_I20211231" decimals="-3" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMTgvZnJhZzpjNGZhMzAzZmMzNGM0ZWM1OTBjZGQ0ODcyNDY5NDEyZC90YWJsZTpjOTdjMDFkZTBiNzE0YTU1YmM4MGExNDI1NjYzNTlmNC90YWJsZXJhbmdlOmM5N2MwMWRlMGI3MTRhNTViYzgwYTE0MjU2NjM1OWY0XzE1LTMtMS0xLTU4Mzcy_22d72502-7996-4f36-a66a-c330fc529dd9">51,222</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short term debt, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMTgvZnJhZzpjNGZhMzAzZmMzNGM0ZWM1OTBjZGQ0ODcyNDY5NDEyZC90YWJsZTpjOTdjMDFkZTBiNzE0YTU1YmM4MGExNDI1NjYzNTlmNC90YWJsZXJhbmdlOmM5N2MwMWRlMGI3MTRhNTViYzgwYTE0MjU2NjM1OWY0XzE2LTEtMS0xLTk5NjA4_7c7c0c13-d36d-4839-8f82-1536b20e583c">128,575</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id970dfd2674c4d6b895febb9c14d0fd1_I20211231" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMTgvZnJhZzpjNGZhMzAzZmMzNGM0ZWM1OTBjZGQ0ODcyNDY5NDEyZC90YWJsZTpjOTdjMDFkZTBiNzE0YTU1YmM4MGExNDI1NjYzNTlmNC90YWJsZXJhbmdlOmM5N2MwMWRlMGI3MTRhNTViYzgwYTE0MjU2NjM1OWY0XzE2LTMtMS0xLTk5NjE3_3d332f6d-72b1-4517-9095-dbae143334cd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMTgvZnJhZzpjNGZhMzAzZmMzNGM0ZWM1OTBjZGQ0ODcyNDY5NDEyZC90YWJsZTpjOTdjMDFkZTBiNzE0YTU1YmM4MGExNDI1NjYzNTlmNC90YWJsZXJhbmdlOmM5N2MwMWRlMGI3MTRhNTViYzgwYTE0MjU2NjM1OWY0XzE2LTEtMS0xLTU4Mzcy_bca92ab1-2290-45cf-8048-dec3245e00c0">178,730</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id970dfd2674c4d6b895febb9c14d0fd1_I20211231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMTgvZnJhZzpjNGZhMzAzZmMzNGM0ZWM1OTBjZGQ0ODcyNDY5NDEyZC90YWJsZTpjOTdjMDFkZTBiNzE0YTU1YmM4MGExNDI1NjYzNTlmNC90YWJsZXJhbmdlOmM5N2MwMWRlMGI3MTRhNTViYzgwYTE0MjU2NjM1OWY0XzE2LTMtMS0xLTU4Mzcy_0d9f8f78-4a86-4ca2-9f6c-c01283563d90">59,235</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term debt, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMTgvZnJhZzpjNGZhMzAzZmMzNGM0ZWM1OTBjZGQ0ODcyNDY5NDEyZC90YWJsZTpjOTdjMDFkZTBiNzE0YTU1YmM4MGExNDI1NjYzNTlmNC90YWJsZXJhbmdlOmM5N2MwMWRlMGI3MTRhNTViYzgwYTE0MjU2NjM1OWY0XzE3LTEtMS0xLTU4Mzcy_322c99f2-e4ab-4b33-8528-6ee74105a828">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id970dfd2674c4d6b895febb9c14d0fd1_I20211231" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMTgvZnJhZzpjNGZhMzAzZmMzNGM0ZWM1OTBjZGQ0ODcyNDY5NDEyZC90YWJsZTpjOTdjMDFkZTBiNzE0YTU1YmM4MGExNDI1NjYzNTlmNC90YWJsZXJhbmdlOmM5N2MwMWRlMGI3MTRhNTViYzgwYTE0MjU2NjM1OWY0XzE3LTMtMS0xLTU4Mzcy_efd15c7b-01d7-47fa-8b39-afce4951385a">126,418</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Warrant liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231" decimals="-3" name="optn:WarrantLiabilityNonCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMTgvZnJhZzpjNGZhMzAzZmMzNGM0ZWM1OTBjZGQ0ODcyNDY5NDEyZC90YWJsZTpjOTdjMDFkZTBiNzE0YTU1YmM4MGExNDI1NjYzNTlmNC90YWJsZXJhbmdlOmM5N2MwMWRlMGI3MTRhNTViYzgwYTE0MjU2NjM1OWY0XzE5LTEtMS0xLTEwMDE3NQ_36163005-35ec-4aa3-9b8f-b48ddfc41408">21,490</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id970dfd2674c4d6b895febb9c14d0fd1_I20211231" decimals="-3" name="optn:WarrantLiabilityNonCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMTgvZnJhZzpjNGZhMzAzZmMzNGM0ZWM1OTBjZGQ0ODcyNDY5NDEyZC90YWJsZTpjOTdjMDFkZTBiNzE0YTU1YmM4MGExNDI1NjYzNTlmNC90YWJsZXJhbmdlOmM5N2MwMWRlMGI3MTRhNTViYzgwYTE0MjU2NjM1OWY0XzE5LTMtMS0xLTEwMDE4Mw_24b014c0-7b3c-4119-81bd-4b89a4af747c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMTgvZnJhZzpjNGZhMzAzZmMzNGM0ZWM1OTBjZGQ0ODcyNDY5NDEyZC90YWJsZTpjOTdjMDFkZTBiNzE0YTU1YmM4MGExNDI1NjYzNTlmNC90YWJsZXJhbmdlOmM5N2MwMWRlMGI3MTRhNTViYzgwYTE0MjU2NjM1OWY0XzE4LTEtMS0xLTU4Mzcy_14c0227c-2d24-444f-a800-115f3782a41a">626</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id970dfd2674c4d6b895febb9c14d0fd1_I20211231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMTgvZnJhZzpjNGZhMzAzZmMzNGM0ZWM1OTBjZGQ0ODcyNDY5NDEyZC90YWJsZTpjOTdjMDFkZTBiNzE0YTU1YmM4MGExNDI1NjYzNTlmNC90YWJsZXJhbmdlOmM5N2MwMWRlMGI3MTRhNTViYzgwYTE0MjU2NjM1OWY0XzE4LTMtMS0xLTU4Mzcy_534a9219-1962-498c-a998-3cad8cff5e97">2,190</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMTgvZnJhZzpjNGZhMzAzZmMzNGM0ZWM1OTBjZGQ0ODcyNDY5NDEyZC90YWJsZTpjOTdjMDFkZTBiNzE0YTU1YmM4MGExNDI1NjYzNTlmNC90YWJsZXJhbmdlOmM5N2MwMWRlMGI3MTRhNTViYzgwYTE0MjU2NjM1OWY0XzE5LTEtMS0xLTU4Mzcy_ea49b819-da49-4773-8432-d06f358d9696">200,846</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id970dfd2674c4d6b895febb9c14d0fd1_I20211231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMTgvZnJhZzpjNGZhMzAzZmMzNGM0ZWM1OTBjZGQ0ODcyNDY5NDEyZC90YWJsZTpjOTdjMDFkZTBiNzE0YTU1YmM4MGExNDI1NjYzNTlmNC90YWJsZXJhbmdlOmM5N2MwMWRlMGI3MTRhNTViYzgwYTE0MjU2NjM1OWY0XzE5LTMtMS0xLTU4Mzcy_e76c3ae3-5d10-4953-a5b4-91ab91f338bf">187,843</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stockholders' deficit:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="id970dfd2674c4d6b895febb9c14d0fd1_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMTgvZnJhZzpjNGZhMzAzZmMzNGM0ZWM1OTBjZGQ0ODcyNDY5NDEyZC90YWJsZTpjOTdjMDFkZTBiNzE0YTU1YmM4MGExNDI1NjYzNTlmNC90YWJsZXJhbmdlOmM5N2MwMWRlMGI3MTRhNTViYzgwYTE0MjU2NjM1OWY0XzIyLTAtMS0xLTU4MzcyL3RleHRyZWdpb246ZmM2NTJlYmRkYjRlNDY4NGJjNDA4Mjk0NTU4ODBkZDVfMTg_2c9e7476-f691-49d9-8eb3-5d05cdf7eb26"><ix:nonFraction unitRef="usdPerShare" contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMTgvZnJhZzpjNGZhMzAzZmMzNGM0ZWM1OTBjZGQ0ODcyNDY5NDEyZC90YWJsZTpjOTdjMDFkZTBiNzE0YTU1YmM4MGExNDI1NjYzNTlmNC90YWJsZXJhbmdlOmM5N2MwMWRlMGI3MTRhNTViYzgwYTE0MjU2NjM1OWY0XzIyLTAtMS0xLTU4MzcyL3RleHRyZWdpb246ZmM2NTJlYmRkYjRlNDY4NGJjNDA4Mjk0NTU4ODBkZDVfMTg_b61dc5f6-7dcf-4970-8600-d119f49b453d">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="id970dfd2674c4d6b895febb9c14d0fd1_I20211231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMTgvZnJhZzpjNGZhMzAzZmMzNGM0ZWM1OTBjZGQ0ODcyNDY5NDEyZC90YWJsZTpjOTdjMDFkZTBiNzE0YTU1YmM4MGExNDI1NjYzNTlmNC90YWJsZXJhbmdlOmM5N2MwMWRlMGI3MTRhNTViYzgwYTE0MjU2NjM1OWY0XzIyLTAtMS0xLTU4MzcyL3RleHRyZWdpb246ZmM2NTJlYmRkYjRlNDY4NGJjNDA4Mjk0NTU4ODBkZDVfMzI_64e6d33b-0fdb-484e-a9a6-8d751b293fbd"><ix:nonFraction unitRef="shares" contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMTgvZnJhZzpjNGZhMzAzZmMzNGM0ZWM1OTBjZGQ0ODcyNDY5NDEyZC90YWJsZTpjOTdjMDFkZTBiNzE0YTU1YmM4MGExNDI1NjYzNTlmNC90YWJsZXJhbmdlOmM5N2MwMWRlMGI3MTRhNTViYzgwYTE0MjU2NjM1OWY0XzIyLTAtMS0xLTU4MzcyL3RleHRyZWdpb246ZmM2NTJlYmRkYjRlNDY4NGJjNDA4Mjk0NTU4ODBkZDVfMzI_83472d63-92bb-47f1-a075-e134bb584817">200,000,000</ix:nonFraction></ix:nonFraction> shares authorized at December 31, 2022 and 2021; <ix:nonFraction unitRef="shares" contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMTgvZnJhZzpjNGZhMzAzZmMzNGM0ZWM1OTBjZGQ0ODcyNDY5NDEyZC90YWJsZTpjOTdjMDFkZTBiNzE0YTU1YmM4MGExNDI1NjYzNTlmNC90YWJsZXJhbmdlOmM5N2MwMWRlMGI3MTRhNTViYzgwYTE0MjU2NjM1OWY0XzIyLTAtMS0xLTU4MzcyL3RleHRyZWdpb246ZmM2NTJlYmRkYjRlNDY4NGJjNDA4Mjk0NTU4ODBkZDVfODI0NjMzNzIwODQ1NA_233544f3-2726-41e0-8bc2-c1bfce6d2541"><ix:nonFraction unitRef="shares" contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMTgvZnJhZzpjNGZhMzAzZmMzNGM0ZWM1OTBjZGQ0ODcyNDY5NDEyZC90YWJsZTpjOTdjMDFkZTBiNzE0YTU1YmM4MGExNDI1NjYzNTlmNC90YWJsZXJhbmdlOmM5N2MwMWRlMGI3MTRhNTViYzgwYTE0MjU2NjM1OWY0XzIyLTAtMS0xLTU4MzcyL3RleHRyZWdpb246ZmM2NTJlYmRkYjRlNDY4NGJjNDA4Mjk0NTU4ODBkZDVfODI0NjMzNzIwODQ1NA_da3140b7-82d0-45f7-81fa-2b47ecee0256">111,492,761</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="id970dfd2674c4d6b895febb9c14d0fd1_I20211231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMTgvZnJhZzpjNGZhMzAzZmMzNGM0ZWM1OTBjZGQ0ODcyNDY5NDEyZC90YWJsZTpjOTdjMDFkZTBiNzE0YTU1YmM4MGExNDI1NjYzNTlmNC90YWJsZXJhbmdlOmM5N2MwMWRlMGI3MTRhNTViYzgwYTE0MjU2NjM1OWY0XzIyLTAtMS0xLTU4MzcyL3RleHRyZWdpb246ZmM2NTJlYmRkYjRlNDY4NGJjNDA4Mjk0NTU4ODBkZDVfODI0NjMzNzIwODQ1OA_16ef56c4-09f0-4267-aa8e-708cd032712d"><ix:nonFraction unitRef="shares" contextRef="id970dfd2674c4d6b895febb9c14d0fd1_I20211231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMTgvZnJhZzpjNGZhMzAzZmMzNGM0ZWM1OTBjZGQ0ODcyNDY5NDEyZC90YWJsZTpjOTdjMDFkZTBiNzE0YTU1YmM4MGExNDI1NjYzNTlmNC90YWJsZXJhbmdlOmM5N2MwMWRlMGI3MTRhNTViYzgwYTE0MjU2NjM1OWY0XzIyLTAtMS0xLTU4MzcyL3RleHRyZWdpb246ZmM2NTJlYmRkYjRlNDY4NGJjNDA4Mjk0NTU4ODBkZDVfODI0NjMzNzIwODQ1OA_e8ed257d-cded-43ce-852e-cf3f733c9e6c">82,238,900</ix:nonFraction></ix:nonFraction> shares issued and outstanding at December 31, 2022 and December 31, 2021, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMTgvZnJhZzpjNGZhMzAzZmMzNGM0ZWM1OTBjZGQ0ODcyNDY5NDEyZC90YWJsZTpjOTdjMDFkZTBiNzE0YTU1YmM4MGExNDI1NjYzNTlmNC90YWJsZXJhbmdlOmM5N2MwMWRlMGI3MTRhNTViYzgwYTE0MjU2NjM1OWY0XzIyLTEtMS0xLTU4Mzcy_28edb870-fd97-49f0-a0f2-0a24f6190eb5">111</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id970dfd2674c4d6b895febb9c14d0fd1_I20211231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMTgvZnJhZzpjNGZhMzAzZmMzNGM0ZWM1OTBjZGQ0ODcyNDY5NDEyZC90YWJsZTpjOTdjMDFkZTBiNzE0YTU1YmM4MGExNDI1NjYzNTlmNC90YWJsZXJhbmdlOmM5N2MwMWRlMGI3MTRhNTViYzgwYTE0MjU2NjM1OWY0XzIyLTMtMS0xLTU4Mzcy_912ae8b2-a8e9-463c-b45c-de16e64e2a21">82</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMTgvZnJhZzpjNGZhMzAzZmMzNGM0ZWM1OTBjZGQ0ODcyNDY5NDEyZC90YWJsZTpjOTdjMDFkZTBiNzE0YTU1YmM4MGExNDI1NjYzNTlmNC90YWJsZXJhbmdlOmM5N2MwMWRlMGI3MTRhNTViYzgwYTE0MjU2NjM1OWY0XzIzLTEtMS0xLTU4Mzcy_93c3dda8-a376-4b7b-b01a-80949a1e5242">628,242</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id970dfd2674c4d6b895febb9c14d0fd1_I20211231" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMTgvZnJhZzpjNGZhMzAzZmMzNGM0ZWM1OTBjZGQ0ODcyNDY5NDEyZC90YWJsZTpjOTdjMDFkZTBiNzE0YTU1YmM4MGExNDI1NjYzNTlmNC90YWJsZXJhbmdlOmM5N2MwMWRlMGI3MTRhNTViYzgwYTE0MjU2NjM1OWY0XzIzLTMtMS0xLTU4Mzcy_1f7bf97a-a7c3-4370-85a9-e78549e1a27d">588,288</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMTgvZnJhZzpjNGZhMzAzZmMzNGM0ZWM1OTBjZGQ0ODcyNDY5NDEyZC90YWJsZTpjOTdjMDFkZTBiNzE0YTU1YmM4MGExNDI1NjYzNTlmNC90YWJsZXJhbmdlOmM5N2MwMWRlMGI3MTRhNTViYzgwYTE0MjU2NjM1OWY0XzI0LTEtMS0xLTU4Mzcy_bf2a07f6-22f0-409a-a739-62ac11647867">684,893</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id970dfd2674c4d6b895febb9c14d0fd1_I20211231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMTgvZnJhZzpjNGZhMzAzZmMzNGM0ZWM1OTBjZGQ0ODcyNDY5NDEyZC90YWJsZTpjOTdjMDFkZTBiNzE0YTU1YmM4MGExNDI1NjYzNTlmNC90YWJsZXJhbmdlOmM5N2MwMWRlMGI3MTRhNTViYzgwYTE0MjU2NjM1OWY0XzI0LTMtMS0xLTU4Mzcy_2fcdcfe1-7935-42f8-9496-9c5da6d92979">610,061</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMTgvZnJhZzpjNGZhMzAzZmMzNGM0ZWM1OTBjZGQ0ODcyNDY5NDEyZC90YWJsZTpjOTdjMDFkZTBiNzE0YTU1YmM4MGExNDI1NjYzNTlmNC90YWJsZXJhbmdlOmM5N2MwMWRlMGI3MTRhNTViYzgwYTE0MjU2NjM1OWY0XzI1LTEtMS0xLTU4Mzcy_ccb2d06b-69c4-4be8-a58f-a16e01b15e45">84</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id970dfd2674c4d6b895febb9c14d0fd1_I20211231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMTgvZnJhZzpjNGZhMzAzZmMzNGM0ZWM1OTBjZGQ0ODcyNDY5NDEyZC90YWJsZTpjOTdjMDFkZTBiNzE0YTU1YmM4MGExNDI1NjYzNTlmNC90YWJsZXJhbmdlOmM5N2MwMWRlMGI3MTRhNTViYzgwYTE0MjU2NjM1OWY0XzI1LTMtMS0xLTU4Mzcy_4c22cbb8-72ca-408f-810e-36713de2be82">81</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total stockholders' deficit</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMTgvZnJhZzpjNGZhMzAzZmMzNGM0ZWM1OTBjZGQ0ODcyNDY5NDEyZC90YWJsZTpjOTdjMDFkZTBiNzE0YTU1YmM4MGExNDI1NjYzNTlmNC90YWJsZXJhbmdlOmM5N2MwMWRlMGI3MTRhNTViYzgwYTE0MjU2NjM1OWY0XzI2LTEtMS0xLTU4Mzcy_ddc18304-a8cd-4a8e-b00c-0c9735b67808">56,624</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id970dfd2674c4d6b895febb9c14d0fd1_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMTgvZnJhZzpjNGZhMzAzZmMzNGM0ZWM1OTBjZGQ0ODcyNDY5NDEyZC90YWJsZTpjOTdjMDFkZTBiNzE0YTU1YmM4MGExNDI1NjYzNTlmNC90YWJsZXJhbmdlOmM5N2MwMWRlMGI3MTRhNTViYzgwYTE0MjU2NjM1OWY0XzI2LTMtMS0xLTU4Mzcy_5a7157fc-4860-4dea-917c-5730ef51999e">21,772</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities and stockholders' deficit</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMTgvZnJhZzpjNGZhMzAzZmMzNGM0ZWM1OTBjZGQ0ODcyNDY5NDEyZC90YWJsZTpjOTdjMDFkZTBiNzE0YTU1YmM4MGExNDI1NjYzNTlmNC90YWJsZXJhbmdlOmM5N2MwMWRlMGI3MTRhNTViYzgwYTE0MjU2NjM1OWY0XzI3LTEtMS0xLTU4Mzcy_e29efc67-c77f-48af-ab21-c26d5b5b4935">144,222</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id970dfd2674c4d6b895febb9c14d0fd1_I20211231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMTgvZnJhZzpjNGZhMzAzZmMzNGM0ZWM1OTBjZGQ0ODcyNDY5NDEyZC90YWJsZTpjOTdjMDFkZTBiNzE0YTU1YmM4MGExNDI1NjYzNTlmNC90YWJsZXJhbmdlOmM5N2MwMWRlMGI3MTRhNTViYzgwYTE0MjU2NjM1OWY0XzI3LTMtMS0xLTU4Mzcy_a78ab594-3ec0-4044-a91d-c2d321201f36">166,071</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span><br/></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-5</span></div></div></div><div id="i451bcb3eabba4f87bdc579718207a3b8_121"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OptiNose,&#160;Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Operations</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:76.319%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.457%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.458%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net product revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d7389924c8a481f922afd27c2d98be6_D20220101-20221231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjEvZnJhZzo4NTJiMDQ1MDI0MjM0YWNiYTY5ZGIyOWQwZTg2M2ZiMi90YWJsZTo1MzYwMzE3NzMzM2E0ODBkODRiMTJhNTg4ZGEyMzE0Zi90YWJsZXJhbmdlOjUzNjAzMTc3MzMzYTQ4MGQ4NGIxMmE1ODhkYTIzMTRmXzMtMi0xLTEtNTgzNzI_b298272e-4829-4fba-b3e7-7ed5519c0d2b">76,276</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86422cbece424367a1550b9f28481643_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjEvZnJhZzo4NTJiMDQ1MDI0MjM0YWNiYTY5ZGIyOWQwZTg2M2ZiMi90YWJsZTo1MzYwMzE3NzMzM2E0ODBkODRiMTJhNTg4ZGEyMzE0Zi90YWJsZXJhbmdlOjUzNjAzMTc3MzMzYTQ4MGQ4NGIxMmE1ODhkYTIzMTRmXzMtNC0xLTEtNTgzNzI_aea095cc-a8c1-4bd5-a630-9438e39655ef">73,652</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Licensing revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb05b53856a04e6fb8d77b2615fef7b5_D20220101-20221231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjEvZnJhZzo4NTJiMDQ1MDI0MjM0YWNiYTY5ZGIyOWQwZTg2M2ZiMi90YWJsZTo1MzYwMzE3NzMzM2E0ODBkODRiMTJhNTg4ZGEyMzE0Zi90YWJsZXJhbmdlOjUzNjAzMTc3MzMzYTQ4MGQ4NGIxMmE1ODhkYTIzMTRmXzQtMi0xLTEtNTgzNzI_e8765185-e54a-4df4-bc8b-303cbe7fa6de">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a537887f3924b21a34b339e3a39c085_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjEvZnJhZzo4NTJiMDQ1MDI0MjM0YWNiYTY5ZGIyOWQwZTg2M2ZiMi90YWJsZTo1MzYwMzE3NzMzM2E0ODBkODRiMTJhNTg4ZGEyMzE0Zi90YWJsZXJhbmdlOjUzNjAzMTc3MzMzYTQ4MGQ4NGIxMmE1ODhkYTIzMTRmXzQtNC0xLTEtNTgzNzI_adca1f7b-00ac-40f9-aedc-9b9d85c6e1c7">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Total revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjEvZnJhZzo4NTJiMDQ1MDI0MjM0YWNiYTY5ZGIyOWQwZTg2M2ZiMi90YWJsZTo1MzYwMzE3NzMzM2E0ODBkODRiMTJhNTg4ZGEyMzE0Zi90YWJsZXJhbmdlOjUzNjAzMTc3MzMzYTQ4MGQ4NGIxMmE1ODhkYTIzMTRmXzUtMi0xLTEtNTgzNzI_a3f13825-aee5-43c4-babd-40ee04bbb94f">76,276</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjEvZnJhZzo4NTJiMDQ1MDI0MjM0YWNiYTY5ZGIyOWQwZTg2M2ZiMi90YWJsZTo1MzYwMzE3NzMzM2E0ODBkODRiMTJhNTg4ZGEyMzE0Zi90YWJsZXJhbmdlOjUzNjAzMTc3MzMzYTQ4MGQ4NGIxMmE1ODhkYTIzMTRmXzUtNC0xLTEtNTgzNzI_1c5d13b4-e499-4d4c-bcd8-1b6ffa94b058">74,652</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Costs and expenses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of product sales</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjEvZnJhZzo4NTJiMDQ1MDI0MjM0YWNiYTY5ZGIyOWQwZTg2M2ZiMi90YWJsZTo1MzYwMzE3NzMzM2E0ODBkODRiMTJhNTg4ZGEyMzE0Zi90YWJsZXJhbmdlOjUzNjAzMTc3MzMzYTQ4MGQ4NGIxMmE1ODhkYTIzMTRmXzctMi0xLTEtNTgzNzI_76e8a4cb-4924-440f-9e02-008a31305a89">9,263</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjEvZnJhZzo4NTJiMDQ1MDI0MjM0YWNiYTY5ZGIyOWQwZTg2M2ZiMi90YWJsZTo1MzYwMzE3NzMzM2E0ODBkODRiMTJhNTg4ZGEyMzE0Zi90YWJsZXJhbmdlOjUzNjAzMTc3MzMzYTQ4MGQ4NGIxMmE1ODhkYTIzMTRmXzctNC0xLTEtNTgzNzI_3e633e64-507a-4b44-a0a2-25bd283c7f01">9,151</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjEvZnJhZzo4NTJiMDQ1MDI0MjM0YWNiYTY5ZGIyOWQwZTg2M2ZiMi90YWJsZTo1MzYwMzE3NzMzM2E0ODBkODRiMTJhNTg4ZGEyMzE0Zi90YWJsZXJhbmdlOjUzNjAzMTc3MzMzYTQ4MGQ4NGIxMmE1ODhkYTIzMTRmXzgtMi0xLTEtNTgzNzI_b00164b4-a58b-43c5-b121-29fe4386c4f8">15,260</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjEvZnJhZzo4NTJiMDQ1MDI0MjM0YWNiYTY5ZGIyOWQwZTg2M2ZiMi90YWJsZTo1MzYwMzE3NzMzM2E0ODBkODRiMTJhNTg4ZGEyMzE0Zi90YWJsZXJhbmdlOjUzNjAzMTc3MzMzYTQ4MGQ4NGIxMmE1ODhkYTIzMTRmXzgtNC0xLTEtNTgzNzI_c321f07b-c6d4-47a9-8243-d85c2557c5ca">25,318</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjEvZnJhZzo4NTJiMDQ1MDI0MjM0YWNiYTY5ZGIyOWQwZTg2M2ZiMi90YWJsZTo1MzYwMzE3NzMzM2E0ODBkODRiMTJhNTg4ZGEyMzE0Zi90YWJsZXJhbmdlOjUzNjAzMTc3MzMzYTQ4MGQ4NGIxMmE1ODhkYTIzMTRmXzktMi0xLTEtNTgzNzI_68807eac-81a9-4c35-aa48-97fe36835a81">107,649</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjEvZnJhZzo4NTJiMDQ1MDI0MjM0YWNiYTY5ZGIyOWQwZTg2M2ZiMi90YWJsZTo1MzYwMzE3NzMzM2E0ODBkODRiMTJhNTg4ZGEyMzE0Zi90YWJsZXJhbmdlOjUzNjAzMTc3MzMzYTQ4MGQ4NGIxMmE1ODhkYTIzMTRmXzktNC0xLTEtNTgzNzI_5d96acad-a774-4812-a28d-cd4d7fa79ce5">106,633</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total costs and expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjEvZnJhZzo4NTJiMDQ1MDI0MjM0YWNiYTY5ZGIyOWQwZTg2M2ZiMi90YWJsZTo1MzYwMzE3NzMzM2E0ODBkODRiMTJhNTg4ZGEyMzE0Zi90YWJsZXJhbmdlOjUzNjAzMTc3MzMzYTQ4MGQ4NGIxMmE1ODhkYTIzMTRmXzEwLTItMS0xLTU4Mzcy_5a715da2-db1e-45fd-8c8f-adfceff5de30">132,172</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjEvZnJhZzo4NTJiMDQ1MDI0MjM0YWNiYTY5ZGIyOWQwZTg2M2ZiMi90YWJsZTo1MzYwMzE3NzMzM2E0ODBkODRiMTJhNTg4ZGEyMzE0Zi90YWJsZXJhbmdlOjUzNjAzMTc3MzMzYTQ4MGQ4NGIxMmE1ODhkYTIzMTRmXzEwLTQtMS0xLTU4Mzcy_66b006e4-076c-4544-a510-61e06ee1095e">141,102</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjEvZnJhZzo4NTJiMDQ1MDI0MjM0YWNiYTY5ZGIyOWQwZTg2M2ZiMi90YWJsZTo1MzYwMzE3NzMzM2E0ODBkODRiMTJhNTg4ZGEyMzE0Zi90YWJsZXJhbmdlOjUzNjAzMTc3MzMzYTQ4MGQ4NGIxMmE1ODhkYTIzMTRmXzExLTItMS0xLTU4Mzcy_500a6c08-ae5b-4859-89fc-d0d66c9c4c2c">55,896</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjEvZnJhZzo4NTJiMDQ1MDI0MjM0YWNiYTY5ZGIyOWQwZTg2M2ZiMi90YWJsZTo1MzYwMzE3NzMzM2E0ODBkODRiMTJhNTg4ZGEyMzE0Zi90YWJsZXJhbmdlOjUzNjAzMTc3MzMzYTQ4MGQ4NGIxMmE1ODhkYTIzMTRmXzExLTQtMS0xLTU4Mzcy_afb0af3c-b4c8-40e8-98c8-1cd0cc65d946">66,450</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other (income) expense:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized loss on fair value of warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" decimals="-3" sign="-" name="optn:UnrealizedGainLossOnFairValueOfWarrants" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjEvZnJhZzo4NTJiMDQ1MDI0MjM0YWNiYTY5ZGIyOWQwZTg2M2ZiMi90YWJsZTo1MzYwMzE3NzMzM2E0ODBkODRiMTJhNTg4ZGEyMzE0Zi90YWJsZXJhbmdlOjUzNjAzMTc3MzMzYTQ4MGQ4NGIxMmE1ODhkYTIzMTRmXzEzLTItMS0xLTEwMTg3MQ_0e5ba270-ca01-4e12-9bc3-0f318017c333">1,211</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231" decimals="-3" name="optn:UnrealizedGainLossOnFairValueOfWarrants" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjEvZnJhZzo4NTJiMDQ1MDI0MjM0YWNiYTY5ZGIyOWQwZTg2M2ZiMi90YWJsZTo1MzYwMzE3NzMzM2E0ODBkODRiMTJhNTg4ZGEyMzE0Zi90YWJsZXJhbmdlOjUzNjAzMTc3MzMzYTQ4MGQ4NGIxMmE1ODhkYTIzMTRmXzEzLTQtMS0xLTEwMTg3OQ_b095b3a0-dcc4-4a20-92bf-f832cd3d6bdb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other (income) expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" decimals="-3" sign="-" name="optn:GrantAndOtherIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjEvZnJhZzo4NTJiMDQ1MDI0MjM0YWNiYTY5ZGIyOWQwZTg2M2ZiMi90YWJsZTo1MzYwMzE3NzMzM2E0ODBkODRiMTJhNTg4ZGEyMzE0Zi90YWJsZXJhbmdlOjUzNjAzMTc3MzMzYTQ4MGQ4NGIxMmE1ODhkYTIzMTRmXzEzLTItMS0xLTU4Mzcy_ae75a009-7a84-4bae-bcf0-f5f634a025aa">1,396</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231" decimals="-3" name="optn:GrantAndOtherIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjEvZnJhZzo4NTJiMDQ1MDI0MjM0YWNiYTY5ZGIyOWQwZTg2M2ZiMi90YWJsZTo1MzYwMzE3NzMzM2E0ODBkODRiMTJhNTg4ZGEyMzE0Zi90YWJsZXJhbmdlOjUzNjAzMTc3MzMzYTQ4MGQ4NGIxMmE1ODhkYTIzMTRmXzEzLTQtMS0xLTU4Mzcy_d40a41f4-0114-4658-9c60-62563b17b929">75</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjEvZnJhZzo4NTJiMDQ1MDI0MjM0YWNiYTY5ZGIyOWQwZTg2M2ZiMi90YWJsZTo1MzYwMzE3NzMzM2E0ODBkODRiMTJhNTg4ZGEyMzE0Zi90YWJsZXJhbmdlOjUzNjAzMTc3MzMzYTQ4MGQ4NGIxMmE1ODhkYTIzMTRmXzE0LTItMS0xLTU4Mzcy_3a899b74-64ee-4323-9fab-db515b2ff0bb">513</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjEvZnJhZzo4NTJiMDQ1MDI0MjM0YWNiYTY5ZGIyOWQwZTg2M2ZiMi90YWJsZTo1MzYwMzE3NzMzM2E0ODBkODRiMTJhNTg4ZGEyMzE0Zi90YWJsZXJhbmdlOjUzNjAzMTc3MzMzYTQ4MGQ4NGIxMmE1ODhkYTIzMTRmXzE0LTQtMS0xLTU4Mzcy_35e794eb-7eea-4874-bf5b-77e934e9c394">52</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjEvZnJhZzo4NTJiMDQ1MDI0MjM0YWNiYTY5ZGIyOWQwZTg2M2ZiMi90YWJsZTo1MzYwMzE3NzMzM2E0ODBkODRiMTJhNTg4ZGEyMzE0Zi90YWJsZXJhbmdlOjUzNjAzMTc3MzMzYTQ4MGQ4NGIxMmE1ODhkYTIzMTRmXzE1LTItMS0xLTU4Mzcy_e2c01b69-38f8-4d4c-b7c2-7b975ffdc69c">16,843</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjEvZnJhZzo4NTJiMDQ1MDI0MjM0YWNiYTY5ZGIyOWQwZTg2M2ZiMi90YWJsZTo1MzYwMzE3NzMzM2E0ODBkODRiMTJhNTg4ZGEyMzE0Zi90YWJsZXJhbmdlOjUzNjAzMTc3MzMzYTQ4MGQ4NGIxMmE1ODhkYTIzMTRmXzE1LTQtMS0xLTU4Mzcy_7d5ef8c8-dddb-463b-aef3-df41d19d4c6a">15,973</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjEvZnJhZzo4NTJiMDQ1MDI0MjM0YWNiYTY5ZGIyOWQwZTg2M2ZiMi90YWJsZTo1MzYwMzE3NzMzM2E0ODBkODRiMTJhNTg4ZGEyMzE0Zi90YWJsZXJhbmdlOjUzNjAzMTc3MzMzYTQ4MGQ4NGIxMmE1ODhkYTIzMTRmXzE4LTItMS0xLTU4Mzcy_9942a75e-d81f-4c3e-90c5-f4b721f15483">74,833</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjEvZnJhZzo4NTJiMDQ1MDI0MjM0YWNiYTY5ZGIyOWQwZTg2M2ZiMi90YWJsZTo1MzYwMzE3NzMzM2E0ODBkODRiMTJhNTg4ZGEyMzE0Zi90YWJsZXJhbmdlOjUzNjAzMTc3MzMzYTQ4MGQ4NGIxMmE1ODhkYTIzMTRmXzE4LTQtMS0xLTU4Mzcy_9e9228fb-8e24-4636-9cbf-b3a7fe535a91">82,296</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss per share of common stock, basic and diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjEvZnJhZzo4NTJiMDQ1MDI0MjM0YWNiYTY5ZGIyOWQwZTg2M2ZiMi90YWJsZTo1MzYwMzE3NzMzM2E0ODBkODRiMTJhNTg4ZGEyMzE0Zi90YWJsZXJhbmdlOjUzNjAzMTc3MzMzYTQ4MGQ4NGIxMmE1ODhkYTIzMTRmXzE5LTItMS0xLTU4Mzcy_627d29a7-8aca-4095-8d50-148962fc4e53"><ix:nonFraction unitRef="usdPerShare" contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjEvZnJhZzo4NTJiMDQ1MDI0MjM0YWNiYTY5ZGIyOWQwZTg2M2ZiMi90YWJsZTo1MzYwMzE3NzMzM2E0ODBkODRiMTJhNTg4ZGEyMzE0Zi90YWJsZXJhbmdlOjUzNjAzMTc3MzMzYTQ4MGQ4NGIxMmE1ODhkYTIzMTRmXzE5LTItMS0xLTU4Mzcy_aa3c7ce3-e009-447d-96d1-486c681b581b">0.87</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjEvZnJhZzo4NTJiMDQ1MDI0MjM0YWNiYTY5ZGIyOWQwZTg2M2ZiMi90YWJsZTo1MzYwMzE3NzMzM2E0ODBkODRiMTJhNTg4ZGEyMzE0Zi90YWJsZXJhbmdlOjUzNjAzMTc3MzMzYTQ4MGQ4NGIxMmE1ODhkYTIzMTRmXzE5LTQtMS0xLTU4Mzcy_17b9e13b-fb8d-42ce-81ba-a99ba3a1179e"><ix:nonFraction unitRef="usdPerShare" contextRef="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjEvZnJhZzo4NTJiMDQ1MDI0MjM0YWNiYTY5ZGIyOWQwZTg2M2ZiMi90YWJsZTo1MzYwMzE3NzMzM2E0ODBkODRiMTJhNTg4ZGEyMzE0Zi90YWJsZXJhbmdlOjUzNjAzMTc3MzMzYTQ4MGQ4NGIxMmE1ODhkYTIzMTRmXzE5LTQtMS0xLTU4Mzcy_1ea527e6-b292-45db-bc9b-2cd0e1b57d99">1.45</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average common shares outstanding, basic and diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjEvZnJhZzo4NTJiMDQ1MDI0MjM0YWNiYTY5ZGIyOWQwZTg2M2ZiMi90YWJsZTo1MzYwMzE3NzMzM2E0ODBkODRiMTJhNTg4ZGEyMzE0Zi90YWJsZXJhbmdlOjUzNjAzMTc3MzMzYTQ4MGQ4NGIxMmE1ODhkYTIzMTRmXzIwLTItMS0xLTU4Mzcy_3ada0b41-0730-4ff9-9810-9c99bf1980f3"><ix:nonFraction unitRef="shares" contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjEvZnJhZzo4NTJiMDQ1MDI0MjM0YWNiYTY5ZGIyOWQwZTg2M2ZiMi90YWJsZTo1MzYwMzE3NzMzM2E0ODBkODRiMTJhNTg4ZGEyMzE0Zi90YWJsZXJhbmdlOjUzNjAzMTc3MzMzYTQ4MGQ4NGIxMmE1ODhkYTIzMTRmXzIwLTItMS0xLTU4Mzcy_c63172e5-7468-48b3-a937-7bae97bd7b65">85,900,139</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjEvZnJhZzo4NTJiMDQ1MDI0MjM0YWNiYTY5ZGIyOWQwZTg2M2ZiMi90YWJsZTo1MzYwMzE3NzMzM2E0ODBkODRiMTJhNTg4ZGEyMzE0Zi90YWJsZXJhbmdlOjUzNjAzMTc3MzMzYTQ4MGQ4NGIxMmE1ODhkYTIzMTRmXzIwLTQtMS0xLTU4Mzcy_118fa196-953d-4cea-a4e8-3b7d30ef607b"><ix:nonFraction unitRef="shares" contextRef="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjEvZnJhZzo4NTJiMDQ1MDI0MjM0YWNiYTY5ZGIyOWQwZTg2M2ZiMi90YWJsZTo1MzYwMzE3NzMzM2E0ODBkODRiMTJhNTg4ZGEyMzE0Zi90YWJsZXJhbmdlOjUzNjAzMTc3MzMzYTQ4MGQ4NGIxMmE1ODhkYTIzMTRmXzIwLTQtMS0xLTU4Mzcy_65630f25-0e40-4e05-9e2d-dd3465a8259d">56,851,921</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span><br/></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-6</span></div></div></div><div id="i451bcb3eabba4f87bdc579718207a3b8_124"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OptiNose,&#160;Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Comprehensive Loss</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:76.905%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.310%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.019%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjQvZnJhZzo2YWEyMzgxZjFhODg0OWY2YmZhOGY1Nzc0ODA3NGQ4Ni90YWJsZTo5NjgwNjIwMzVlNjY0ZThmYjAxN2E4YWY5NTZlNzY2MS90YWJsZXJhbmdlOjk2ODA2MjAzNWU2NjRlOGZiMDE3YThhZjk1NmU3NjYxXzItMi0xLTEtNTgzNzI_7713a0be-04f4-435e-a740-f5cf70fe647a">74,833</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjQvZnJhZzo2YWEyMzgxZjFhODg0OWY2YmZhOGY1Nzc0ODA3NGQ4Ni90YWJsZTo5NjgwNjIwMzVlNjY0ZThmYjAxN2E4YWY5NTZlNzY2MS90YWJsZXJhbmdlOjk2ODA2MjAzNWU2NjRlOGZiMDE3YThhZjk1NmU3NjYxXzItNC0xLTEtNTgzNzI_f18822b0-8b4c-484d-944e-8e220ef5be5a">82,296</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive loss:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjQvZnJhZzo2YWEyMzgxZjFhODg0OWY2YmZhOGY1Nzc0ODA3NGQ4Ni90YWJsZTo5NjgwNjIwMzVlNjY0ZThmYjAxN2E4YWY5NTZlNzY2MS90YWJsZXJhbmdlOjk2ODA2MjAzNWU2NjRlOGZiMDE3YThhZjk1NmU3NjYxXzQtMi0xLTEtNTgzNzI_8a8f884c-2fbe-495d-a383-7b75fd3ee438">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjQvZnJhZzo2YWEyMzgxZjFhODg0OWY2YmZhOGY1Nzc0ODA3NGQ4Ni90YWJsZTo5NjgwNjIwMzVlNjY0ZThmYjAxN2E4YWY5NTZlNzY2MS90YWJsZXJhbmdlOjk2ODA2MjAzNWU2NjRlOGZiMDE3YThhZjk1NmU3NjYxXzQtNC0xLTEtNTgzNzI_daca053a-96a6-4e13-9ed8-6e796c8d07ba">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Comprehensive loss</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjQvZnJhZzo2YWEyMzgxZjFhODg0OWY2YmZhOGY1Nzc0ODA3NGQ4Ni90YWJsZTo5NjgwNjIwMzVlNjY0ZThmYjAxN2E4YWY5NTZlNzY2MS90YWJsZXJhbmdlOjk2ODA2MjAzNWU2NjRlOGZiMDE3YThhZjk1NmU3NjYxXzUtMi0xLTEtNTgzNzI_c4d1b9a1-ae59-4c7d-a317-d051d8cd274f">74,836</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjQvZnJhZzo2YWEyMzgxZjFhODg0OWY2YmZhOGY1Nzc0ODA3NGQ4Ni90YWJsZTo5NjgwNjIwMzVlNjY0ZThmYjAxN2E4YWY5NTZlNzY2MS90YWJsZXJhbmdlOjk2ODA2MjAzNWU2NjRlOGZiMDE3YThhZjk1NmU3NjYxXzUtNC0xLTEtNTgzNzI_3ea2c096-ec83-4771-97f8-36d2cb8c9e5a">82,292</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span><br/></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-7</span></div></div></div><div id="i451bcb3eabba4f87bdc579718207a3b8_127"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OptiNose,&#160;Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Changes in Stockholders' Equity (Deficit)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share data)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.578%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.402%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.214%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stockholders' Equity (Deficit)</span></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>Paid -in<br/>Capital</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Loss</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Stockholders'<br/>Equity (Deficit)</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4e3006d0e61345298119d94aa76e7fc3_I20201231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjcvZnJhZzpkYjdmMTdjMDhmM2M0NGI3YTA5N2Q4YTkyMjk2MjM5Zi90YWJsZTo2ZmRlN2FiYTY3MWE0MTE2ODc1Y2FlNGVhZTk4MWQ4NC90YWJsZXJhbmdlOjZmZGU3YWJhNjcxYTQxMTY4NzVjYWU0ZWFlOTgxZDg0XzMtMi0xLTEtNTgzNzI_d0e58617-fd1c-43f8-82fc-c6c1e4d4a878">52,945,865</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e3006d0e61345298119d94aa76e7fc3_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjcvZnJhZzpkYjdmMTdjMDhmM2M0NGI3YTA5N2Q4YTkyMjk2MjM5Zi90YWJsZTo2ZmRlN2FiYTY3MWE0MTE2ODc1Y2FlNGVhZTk4MWQ4NC90YWJsZXJhbmdlOjZmZGU3YWJhNjcxYTQxMTY4NzVjYWU0ZWFlOTgxZDg0XzMtNC0xLTEtNTgzNzI_4ab518a7-cefc-4f92-8300-5731a8012381">53</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14c26b9820bc4dfbbdaf3a90822b4aa3_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjcvZnJhZzpkYjdmMTdjMDhmM2M0NGI3YTA5N2Q4YTkyMjk2MjM5Zi90YWJsZTo2ZmRlN2FiYTY3MWE0MTE2ODc1Y2FlNGVhZTk4MWQ4NC90YWJsZXJhbmdlOjZmZGU3YWJhNjcxYTQxMTY4NzVjYWU0ZWFlOTgxZDg0XzMtNi0xLTEtNTgzNzI_35e0c5de-7f25-4918-8fce-286a1a8a45f6">534,585</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i97d8a5bb4b224ce58ea3ebd003189203_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjcvZnJhZzpkYjdmMTdjMDhmM2M0NGI3YTA5N2Q4YTkyMjk2MjM5Zi90YWJsZTo2ZmRlN2FiYTY3MWE0MTE2ODc1Y2FlNGVhZTk4MWQ4NC90YWJsZXJhbmdlOjZmZGU3YWJhNjcxYTQxMTY4NzVjYWU0ZWFlOTgxZDg0XzMtOC0xLTEtNTgzNzI_87bc3665-a80c-447d-9dbb-ab243c6c0fc7">527,765</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia1487e10814a476c9f4946ac6b21c5f8_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjcvZnJhZzpkYjdmMTdjMDhmM2M0NGI3YTA5N2Q4YTkyMjk2MjM5Zi90YWJsZTo2ZmRlN2FiYTY3MWE0MTE2ODc1Y2FlNGVhZTk4MWQ4NC90YWJsZXJhbmdlOjZmZGU3YWJhNjcxYTQxMTY4NzVjYWU0ZWFlOTgxZDg0XzMtMTAtMS0xLTU4Mzcy_d5e4acb5-7a06-425f-9804-044c1d36a712">85</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49ae796ea1484c519d91607656f24c24_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjcvZnJhZzpkYjdmMTdjMDhmM2M0NGI3YTA5N2Q4YTkyMjk2MjM5Zi90YWJsZTo2ZmRlN2FiYTY3MWE0MTE2ODc1Y2FlNGVhZTk4MWQ4NC90YWJsZXJhbmdlOjZmZGU3YWJhNjcxYTQxMTY4NzVjYWU0ZWFlOTgxZDg0XzMtMTItMS0xLTU4Mzcy_4752d24d-2fe4-4a0d-8011-3aab52a1f824">6,788</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock compensation expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i370c96450d8f471da8faee4fea65af41_D20210101-20211231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjcvZnJhZzpkYjdmMTdjMDhmM2M0NGI3YTA5N2Q4YTkyMjk2MjM5Zi90YWJsZTo2ZmRlN2FiYTY3MWE0MTE2ODc1Y2FlNGVhZTk4MWQ4NC90YWJsZXJhbmdlOjZmZGU3YWJhNjcxYTQxMTY4NzVjYWU0ZWFlOTgxZDg0XzQtNi0xLTEtNTgzNzI_945c1efc-903f-4cbe-a3ea-73a6ad4cf32a">9,977</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjcvZnJhZzpkYjdmMTdjMDhmM2M0NGI3YTA5N2Q4YTkyMjk2MjM5Zi90YWJsZTo2ZmRlN2FiYTY3MWE0MTE2ODc1Y2FlNGVhZTk4MWQ4NC90YWJsZXJhbmdlOjZmZGU3YWJhNjcxYTQxMTY4NzVjYWU0ZWFlOTgxZDg0XzQtMTItMS0xLTU4Mzcy_b7355e5f-f943-4005-b232-3a19bc79823e">9,977</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vesting of restricted stock units</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iab515f21eb974f95af61d257257b1b11_D20210101-20211231" decimals="INF" name="optn:StockIssuedDuringPeriodSharesVestedRestrictedStockUnits" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjcvZnJhZzpkYjdmMTdjMDhmM2M0NGI3YTA5N2Q4YTkyMjk2MjM5Zi90YWJsZTo2ZmRlN2FiYTY3MWE0MTE2ODc1Y2FlNGVhZTk4MWQ4NC90YWJsZXJhbmdlOjZmZGU3YWJhNjcxYTQxMTY4NzVjYWU0ZWFlOTgxZDg0XzUtMi0xLTEtNTgzNzI_7b1cd858-e523-42c4-a524-79c7078d77e7">383,631</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sale of common stock, net of issuance costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iab515f21eb974f95af61d257257b1b11_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjcvZnJhZzpkYjdmMTdjMDhmM2M0NGI3YTA5N2Q4YTkyMjk2MjM5Zi90YWJsZTo2ZmRlN2FiYTY3MWE0MTE2ODc1Y2FlNGVhZTk4MWQ4NC90YWJsZXJhbmdlOjZmZGU3YWJhNjcxYTQxMTY4NzVjYWU0ZWFlOTgxZDg0XzYtMi0xLTEtNTgzNzI_d225faad-61d3-471b-b560-0dd213930e2b">28,750,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab515f21eb974f95af61d257257b1b11_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjcvZnJhZzpkYjdmMTdjMDhmM2M0NGI3YTA5N2Q4YTkyMjk2MjM5Zi90YWJsZTo2ZmRlN2FiYTY3MWE0MTE2ODc1Y2FlNGVhZTk4MWQ4NC90YWJsZXJhbmdlOjZmZGU3YWJhNjcxYTQxMTY4NzVjYWU0ZWFlOTgxZDg0XzYtNC0xLTEtNTgzNzI_93a15b1d-ad7b-4d78-be5b-cf0e6d7f5080">29</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i370c96450d8f471da8faee4fea65af41_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjcvZnJhZzpkYjdmMTdjMDhmM2M0NGI3YTA5N2Q4YTkyMjk2MjM5Zi90YWJsZTo2ZmRlN2FiYTY3MWE0MTE2ODc1Y2FlNGVhZTk4MWQ4NC90YWJsZXJhbmdlOjZmZGU3YWJhNjcxYTQxMTY4NzVjYWU0ZWFlOTgxZDg0XzYtNi0xLTEtNTgzNzI_d0bca345-f5b8-4db8-a0c3-e32e77af6a17">42,785</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjcvZnJhZzpkYjdmMTdjMDhmM2M0NGI3YTA5N2Q4YTkyMjk2MjM5Zi90YWJsZTo2ZmRlN2FiYTY3MWE0MTE2ODc1Y2FlNGVhZTk4MWQ4NC90YWJsZXJhbmdlOjZmZGU3YWJhNjcxYTQxMTY4NzVjYWU0ZWFlOTgxZDg0XzYtMTItMS0xLTU4Mzcy_38ec32b6-d181-43b0-92c1-fc1dbf7a3ca8">42,814</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of warrants in connection with Pharmakon Second Amendment, net of cancellation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i370c96450d8f471da8faee4fea65af41_D20210101-20211231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjcvZnJhZzpkYjdmMTdjMDhmM2M0NGI3YTA5N2Q4YTkyMjk2MjM5Zi90YWJsZTo2ZmRlN2FiYTY3MWE0MTE2ODc1Y2FlNGVhZTk4MWQ4NC90YWJsZXJhbmdlOjZmZGU3YWJhNjcxYTQxMTY4NzVjYWU0ZWFlOTgxZDg0XzctNi0xLTEtNTgzNzI_4d36cf5f-a188-4149-8742-d2004935541c">534</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjcvZnJhZzpkYjdmMTdjMDhmM2M0NGI3YTA5N2Q4YTkyMjk2MjM5Zi90YWJsZTo2ZmRlN2FiYTY3MWE0MTE2ODc1Y2FlNGVhZTk4MWQ4NC90YWJsZXJhbmdlOjZmZGU3YWJhNjcxYTQxMTY4NzVjYWU0ZWFlOTgxZDg0XzctMTItMS0xLTU4Mzcy_83dd47cc-e2b3-4bae-8002-0d3fdb1a8f88">534</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercise of common stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iab515f21eb974f95af61d257257b1b11_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjcvZnJhZzpkYjdmMTdjMDhmM2M0NGI3YTA5N2Q4YTkyMjk2MjM5Zi90YWJsZTo2ZmRlN2FiYTY3MWE0MTE2ODc1Y2FlNGVhZTk4MWQ4NC90YWJsZXJhbmdlOjZmZGU3YWJhNjcxYTQxMTY4NzVjYWU0ZWFlOTgxZDg0XzgtMi0xLTEtNTgzNzI_2806b335-f385-479b-a29f-40f770634f13">23,879</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i370c96450d8f471da8faee4fea65af41_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjcvZnJhZzpkYjdmMTdjMDhmM2M0NGI3YTA5N2Q4YTkyMjk2MjM5Zi90YWJsZTo2ZmRlN2FiYTY3MWE0MTE2ODc1Y2FlNGVhZTk4MWQ4NC90YWJsZXJhbmdlOjZmZGU3YWJhNjcxYTQxMTY4NzVjYWU0ZWFlOTgxZDg0XzgtNi0xLTEtNTgzNzI_09023a23-d135-428d-865e-27138fe2ff2d">39</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjcvZnJhZzpkYjdmMTdjMDhmM2M0NGI3YTA5N2Q4YTkyMjk2MjM5Zi90YWJsZTo2ZmRlN2FiYTY3MWE0MTE2ODc1Y2FlNGVhZTk4MWQ4NC90YWJsZXJhbmdlOjZmZGU3YWJhNjcxYTQxMTY4NzVjYWU0ZWFlOTgxZDg0XzgtMTItMS0xLTU4Mzcy_ed9e4919-908b-47f9-97b4-ceb3920eb1b0">39</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock under employee stock purchase plan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iab515f21eb974f95af61d257257b1b11_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjcvZnJhZzpkYjdmMTdjMDhmM2M0NGI3YTA5N2Q4YTkyMjk2MjM5Zi90YWJsZTo2ZmRlN2FiYTY3MWE0MTE2ODc1Y2FlNGVhZTk4MWQ4NC90YWJsZXJhbmdlOjZmZGU3YWJhNjcxYTQxMTY4NzVjYWU0ZWFlOTgxZDg0XzktMi0xLTEtNTgzNzI_28ac3c9a-d991-4219-9438-10d0d578be9a">135,525</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i370c96450d8f471da8faee4fea65af41_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjcvZnJhZzpkYjdmMTdjMDhmM2M0NGI3YTA5N2Q4YTkyMjk2MjM5Zi90YWJsZTo2ZmRlN2FiYTY3MWE0MTE2ODc1Y2FlNGVhZTk4MWQ4NC90YWJsZXJhbmdlOjZmZGU3YWJhNjcxYTQxMTY4NzVjYWU0ZWFlOTgxZDg0XzktNi0xLTEtNTgzNzI_efbf184e-4aaa-4b7d-9443-da07c408fbcc">368</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjcvZnJhZzpkYjdmMTdjMDhmM2M0NGI3YTA5N2Q4YTkyMjk2MjM5Zi90YWJsZTo2ZmRlN2FiYTY3MWE0MTE2ODc1Y2FlNGVhZTk4MWQ4NC90YWJsZXJhbmdlOjZmZGU3YWJhNjcxYTQxMTY4NzVjYWU0ZWFlOTgxZDg0XzktMTItMS0xLTU4Mzcy_be7b4aed-ef68-4f78-af17-587b5fba7dda">368</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i810445cfd7f9438195dd0d77cfeedd7e_D20210101-20211231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjcvZnJhZzpkYjdmMTdjMDhmM2M0NGI3YTA5N2Q4YTkyMjk2MjM5Zi90YWJsZTo2ZmRlN2FiYTY3MWE0MTE2ODc1Y2FlNGVhZTk4MWQ4NC90YWJsZXJhbmdlOjZmZGU3YWJhNjcxYTQxMTY4NzVjYWU0ZWFlOTgxZDg0XzEwLTEwLTEtMS05ODYyMg_1e49a756-20a5-414d-a9be-f6cc6f9422e9">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjcvZnJhZzpkYjdmMTdjMDhmM2M0NGI3YTA5N2Q4YTkyMjk2MjM5Zi90YWJsZTo2ZmRlN2FiYTY3MWE0MTE2ODc1Y2FlNGVhZTk4MWQ4NC90YWJsZXJhbmdlOjZmZGU3YWJhNjcxYTQxMTY4NzVjYWU0ZWFlOTgxZDg0XzEwLTEyLTEtMS05OTg1Mg_de0d2471-334f-4531-affe-2d9edf7a482e">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idacbe771db9246aba4c1a2401b11b0c0_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjcvZnJhZzpkYjdmMTdjMDhmM2M0NGI3YTA5N2Q4YTkyMjk2MjM5Zi90YWJsZTo2ZmRlN2FiYTY3MWE0MTE2ODc1Y2FlNGVhZTk4MWQ4NC90YWJsZXJhbmdlOjZmZGU3YWJhNjcxYTQxMTY4NzVjYWU0ZWFlOTgxZDg0XzEwLTgtMS0xLTU4Mzcy_eaef1b98-2bc7-4b41-b680-f0a4bf1127a1">82,296</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjcvZnJhZzpkYjdmMTdjMDhmM2M0NGI3YTA5N2Q4YTkyMjk2MjM5Zi90YWJsZTo2ZmRlN2FiYTY3MWE0MTE2ODc1Y2FlNGVhZTk4MWQ4NC90YWJsZXJhbmdlOjZmZGU3YWJhNjcxYTQxMTY4NzVjYWU0ZWFlOTgxZDg0XzEwLTEyLTEtMS01ODM3Mg_7d2718b4-dbd7-44da-a24c-5af74fea4420">82,296</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibacfe7c370de4063881a058b1ca33cf7_I20211231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjcvZnJhZzpkYjdmMTdjMDhmM2M0NGI3YTA5N2Q4YTkyMjk2MjM5Zi90YWJsZTo2ZmRlN2FiYTY3MWE0MTE2ODc1Y2FlNGVhZTk4MWQ4NC90YWJsZXJhbmdlOjZmZGU3YWJhNjcxYTQxMTY4NzVjYWU0ZWFlOTgxZDg0XzExLTItMS0xLTU4Mzcy_a0399363-d416-42f9-9bb1-cc76d317ccc5">82,238,900</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibacfe7c370de4063881a058b1ca33cf7_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjcvZnJhZzpkYjdmMTdjMDhmM2M0NGI3YTA5N2Q4YTkyMjk2MjM5Zi90YWJsZTo2ZmRlN2FiYTY3MWE0MTE2ODc1Y2FlNGVhZTk4MWQ4NC90YWJsZXJhbmdlOjZmZGU3YWJhNjcxYTQxMTY4NzVjYWU0ZWFlOTgxZDg0XzExLTQtMS0xLTU4Mzcy_d7102ec9-56ab-477e-adf7-d19997250e3f">82</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f0715d972fd4e5cb7aaeea6b7297684_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjcvZnJhZzpkYjdmMTdjMDhmM2M0NGI3YTA5N2Q4YTkyMjk2MjM5Zi90YWJsZTo2ZmRlN2FiYTY3MWE0MTE2ODc1Y2FlNGVhZTk4MWQ4NC90YWJsZXJhbmdlOjZmZGU3YWJhNjcxYTQxMTY4NzVjYWU0ZWFlOTgxZDg0XzExLTYtMS0xLTU4Mzcy_3144a545-2b04-4df2-b96b-bd1a9b9108fc">588,288</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib5641003d7214a1987d7612d9a529d7f_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjcvZnJhZzpkYjdmMTdjMDhmM2M0NGI3YTA5N2Q4YTkyMjk2MjM5Zi90YWJsZTo2ZmRlN2FiYTY3MWE0MTE2ODc1Y2FlNGVhZTk4MWQ4NC90YWJsZXJhbmdlOjZmZGU3YWJhNjcxYTQxMTY4NzVjYWU0ZWFlOTgxZDg0XzExLTgtMS0xLTU4Mzcy_0961a458-62e0-4caa-b503-32e08301797c">610,061</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i789260e8b4914bc7a8d855feb02dc33c_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjcvZnJhZzpkYjdmMTdjMDhmM2M0NGI3YTA5N2Q4YTkyMjk2MjM5Zi90YWJsZTo2ZmRlN2FiYTY3MWE0MTE2ODc1Y2FlNGVhZTk4MWQ4NC90YWJsZXJhbmdlOjZmZGU3YWJhNjcxYTQxMTY4NzVjYWU0ZWFlOTgxZDg0XzExLTEwLTEtMS01ODM3Mg_bf4f4952-ddb7-4068-b0ad-2214f6a93b26">81</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id970dfd2674c4d6b895febb9c14d0fd1_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjcvZnJhZzpkYjdmMTdjMDhmM2M0NGI3YTA5N2Q4YTkyMjk2MjM5Zi90YWJsZTo2ZmRlN2FiYTY3MWE0MTE2ODc1Y2FlNGVhZTk4MWQ4NC90YWJsZXJhbmdlOjZmZGU3YWJhNjcxYTQxMTY4NzVjYWU0ZWFlOTgxZDg0XzExLTEyLTEtMS01ODM3Mg_1def60f8-4a4e-49fa-95d8-08a91d2962f0">21,772</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3377b70595804aa5abe93bd7f81df039_D20220101-20221231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjcvZnJhZzpkYjdmMTdjMDhmM2M0NGI3YTA5N2Q4YTkyMjk2MjM5Zi90YWJsZTo2ZmRlN2FiYTY3MWE0MTE2ODc1Y2FlNGVhZTk4MWQ4NC90YWJsZXJhbmdlOjZmZGU3YWJhNjcxYTQxMTY4NzVjYWU0ZWFlOTgxZDg0XzEyLTYtMS0xLTU4Mzcy_f375f0d4-4265-41a8-a8cd-670c5194a8cf">8,889</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjcvZnJhZzpkYjdmMTdjMDhmM2M0NGI3YTA5N2Q4YTkyMjk2MjM5Zi90YWJsZTo2ZmRlN2FiYTY3MWE0MTE2ODc1Y2FlNGVhZTk4MWQ4NC90YWJsZXJhbmdlOjZmZGU3YWJhNjcxYTQxMTY4NzVjYWU0ZWFlOTgxZDg0XzEyLTEyLTEtMS01ODM3Mg_075286ee-5288-4f4a-a3f4-ed72cb576cb8">8,889</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vesting of restricted stock units</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic9fdf918fabe4dea9acdfa65692fe619_D20220101-20221231" decimals="INF" name="optn:StockIssuedDuringPeriodSharesVestedRestrictedStockUnits" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjcvZnJhZzpkYjdmMTdjMDhmM2M0NGI3YTA5N2Q4YTkyMjk2MjM5Zi90YWJsZTo2ZmRlN2FiYTY3MWE0MTE2ODc1Y2FlNGVhZTk4MWQ4NC90YWJsZXJhbmdlOjZmZGU3YWJhNjcxYTQxMTY4NzVjYWU0ZWFlOTgxZDg0XzEzLTItMS0xLTU4Mzcy_67e582e9-91c8-48d6-86a9-57d21456be7b">949,857</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9fdf918fabe4dea9acdfa65692fe619_D20220101-20221231" decimals="-3" name="optn:StockIssuedDuringPeriodVestedRestrictedStockUnits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjcvZnJhZzpkYjdmMTdjMDhmM2M0NGI3YTA5N2Q4YTkyMjk2MjM5Zi90YWJsZTo2ZmRlN2FiYTY3MWE0MTE2ODc1Y2FlNGVhZTk4MWQ4NC90YWJsZXJhbmdlOjZmZGU3YWJhNjcxYTQxMTY4NzVjYWU0ZWFlOTgxZDg0XzEzLTQtMS0xLTU4Mzcy_170f6f61-b9e3-4298-be46-408b90955b98">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3377b70595804aa5abe93bd7f81df039_D20220101-20221231" decimals="-3" name="optn:StockIssuedDuringPeriodVestedRestrictedStockUnits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjcvZnJhZzpkYjdmMTdjMDhmM2M0NGI3YTA5N2Q4YTkyMjk2MjM5Zi90YWJsZTo2ZmRlN2FiYTY3MWE0MTE2ODc1Y2FlNGVhZTk4MWQ4NC90YWJsZXJhbmdlOjZmZGU3YWJhNjcxYTQxMTY4NzVjYWU0ZWFlOTgxZDg0XzEzLTYtMS0xLTU4Mzcy_6e50d0a3-6bc9-413a-9f31-a00ba62fb244">93</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" decimals="-3" name="optn:StockIssuedDuringPeriodVestedRestrictedStockUnits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjcvZnJhZzpkYjdmMTdjMDhmM2M0NGI3YTA5N2Q4YTkyMjk2MjM5Zi90YWJsZTo2ZmRlN2FiYTY3MWE0MTE2ODc1Y2FlNGVhZTk4MWQ4NC90YWJsZXJhbmdlOjZmZGU3YWJhNjcxYTQxMTY4NzVjYWU0ZWFlOTgxZDg0XzEzLTEyLTEtMS01ODM3Mg_f314854c-d0a8-486b-babc-04950ed28277">94</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sale of common stock, net of issuance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic9fdf918fabe4dea9acdfa65692fe619_D20220101-20221231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjcvZnJhZzpkYjdmMTdjMDhmM2M0NGI3YTA5N2Q4YTkyMjk2MjM5Zi90YWJsZTo2ZmRlN2FiYTY3MWE0MTE2ODc1Y2FlNGVhZTk4MWQ4NC90YWJsZXJhbmdlOjZmZGU3YWJhNjcxYTQxMTY4NzVjYWU0ZWFlOTgxZDg0XzE0LTItMS0xLTU4Mzcy_9abed966-81b8-426f-8b02-00daaea5e822">27,861,300</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9fdf918fabe4dea9acdfa65692fe619_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjcvZnJhZzpkYjdmMTdjMDhmM2M0NGI3YTA5N2Q4YTkyMjk2MjM5Zi90YWJsZTo2ZmRlN2FiYTY3MWE0MTE2ODc1Y2FlNGVhZTk4MWQ4NC90YWJsZXJhbmdlOjZmZGU3YWJhNjcxYTQxMTY4NzVjYWU0ZWFlOTgxZDg0XzE0LTQtMS0xLTU4Mzcy_ccaf6379-78ca-49d7-999d-25cd849cf55b">28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3377b70595804aa5abe93bd7f81df039_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjcvZnJhZzpkYjdmMTdjMDhmM2M0NGI3YTA5N2Q4YTkyMjk2MjM5Zi90YWJsZTo2ZmRlN2FiYTY3MWE0MTE2ODc1Y2FlNGVhZTk4MWQ4NC90YWJsZXJhbmdlOjZmZGU3YWJhNjcxYTQxMTY4NzVjYWU0ZWFlOTgxZDg0XzE0LTYtMS0xLTU4Mzcy_985f829c-2d61-4f0a-9a89-156ce9493f0c">30,418</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjcvZnJhZzpkYjdmMTdjMDhmM2M0NGI3YTA5N2Q4YTkyMjk2MjM5Zi90YWJsZTo2ZmRlN2FiYTY3MWE0MTE2ODc1Y2FlNGVhZTk4MWQ4NC90YWJsZXJhbmdlOjZmZGU3YWJhNjcxYTQxMTY4NzVjYWU0ZWFlOTgxZDg0XzE0LTEyLTEtMS01ODM3Mg_36e8a6aa-4e2b-41ee-9312-92fd8e1a81f6">30,446</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercise of common stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic9fdf918fabe4dea9acdfa65692fe619_D20220101-20221231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjcvZnJhZzpkYjdmMTdjMDhmM2M0NGI3YTA5N2Q4YTkyMjk2MjM5Zi90YWJsZTo2ZmRlN2FiYTY3MWE0MTE2ODc1Y2FlNGVhZTk4MWQ4NC90YWJsZXJhbmdlOjZmZGU3YWJhNjcxYTQxMTY4NzVjYWU0ZWFlOTgxZDg0XzE2LTItMS0xLTU4Mzcy_49bc0b3f-c1c8-481d-932d-a32761378f09">55,360</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock under employee stock purchase plan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic9fdf918fabe4dea9acdfa65692fe619_D20220101-20221231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjcvZnJhZzpkYjdmMTdjMDhmM2M0NGI3YTA5N2Q4YTkyMjk2MjM5Zi90YWJsZTo2ZmRlN2FiYTY3MWE0MTE2ODc1Y2FlNGVhZTk4MWQ4NC90YWJsZXJhbmdlOjZmZGU3YWJhNjcxYTQxMTY4NzVjYWU0ZWFlOTgxZDg0XzE3LTItMS0xLTU4Mzcy_f21189c5-593d-4d84-9857-17ae2fa21e73">387,344</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3377b70595804aa5abe93bd7f81df039_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjcvZnJhZzpkYjdmMTdjMDhmM2M0NGI3YTA5N2Q4YTkyMjk2MjM5Zi90YWJsZTo2ZmRlN2FiYTY3MWE0MTE2ODc1Y2FlNGVhZTk4MWQ4NC90YWJsZXJhbmdlOjZmZGU3YWJhNjcxYTQxMTY4NzVjYWU0ZWFlOTgxZDg0XzE3LTYtMS0xLTU4Mzcy_82e89b60-537e-4b16-8dbe-6ccd9afb11d3">554</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjcvZnJhZzpkYjdmMTdjMDhmM2M0NGI3YTA5N2Q4YTkyMjk2MjM5Zi90YWJsZTo2ZmRlN2FiYTY3MWE0MTE2ODc1Y2FlNGVhZTk4MWQ4NC90YWJsZXJhbmdlOjZmZGU3YWJhNjcxYTQxMTY4NzVjYWU0ZWFlOTgxZDg0XzE3LTEyLTEtMS01ODM3Mg_630c9b50-e382-44c7-bde5-a95e80f0300c">554</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8c484ff51d4d492594a9bf004bc92efb_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjcvZnJhZzpkYjdmMTdjMDhmM2M0NGI3YTA5N2Q4YTkyMjk2MjM5Zi90YWJsZTo2ZmRlN2FiYTY3MWE0MTE2ODc1Y2FlNGVhZTk4MWQ4NC90YWJsZXJhbmdlOjZmZGU3YWJhNjcxYTQxMTY4NzVjYWU0ZWFlOTgxZDg0XzE5LTEwLTEtMS01ODM3Mg_0d97d483-51a3-43c2-8721-82245fc316fe">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjcvZnJhZzpkYjdmMTdjMDhmM2M0NGI3YTA5N2Q4YTkyMjk2MjM5Zi90YWJsZTo2ZmRlN2FiYTY3MWE0MTE2ODc1Y2FlNGVhZTk4MWQ4NC90YWJsZXJhbmdlOjZmZGU3YWJhNjcxYTQxMTY4NzVjYWU0ZWFlOTgxZDg0XzE5LTEyLTEtMS01ODM3Mg_f85fae6b-e33a-401b-8b56-1995771966de">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i342496e82be2474596067223f1d6134a_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjcvZnJhZzpkYjdmMTdjMDhmM2M0NGI3YTA5N2Q4YTkyMjk2MjM5Zi90YWJsZTo2ZmRlN2FiYTY3MWE0MTE2ODc1Y2FlNGVhZTk4MWQ4NC90YWJsZXJhbmdlOjZmZGU3YWJhNjcxYTQxMTY4NzVjYWU0ZWFlOTgxZDg0XzIwLTgtMS0xLTU4Mzcy_214efbef-bd77-4e4f-b25f-93b047211714">74,833</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjcvZnJhZzpkYjdmMTdjMDhmM2M0NGI3YTA5N2Q4YTkyMjk2MjM5Zi90YWJsZTo2ZmRlN2FiYTY3MWE0MTE2ODc1Y2FlNGVhZTk4MWQ4NC90YWJsZXJhbmdlOjZmZGU3YWJhNjcxYTQxMTY4NzVjYWU0ZWFlOTgxZDg0XzIwLTEyLTEtMS01ODM3Mg_e79701ca-f69b-44b3-8e9d-48cf2c6a156e">74,833</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i97a20c4e2d9543ea933245a9227cf00f_I20221231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjcvZnJhZzpkYjdmMTdjMDhmM2M0NGI3YTA5N2Q4YTkyMjk2MjM5Zi90YWJsZTo2ZmRlN2FiYTY3MWE0MTE2ODc1Y2FlNGVhZTk4MWQ4NC90YWJsZXJhbmdlOjZmZGU3YWJhNjcxYTQxMTY4NzVjYWU0ZWFlOTgxZDg0XzIxLTItMS0xLTU4Mzcy_dac37852-58ca-44d2-a91a-bd54d0f32a92">111,492,761</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97a20c4e2d9543ea933245a9227cf00f_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjcvZnJhZzpkYjdmMTdjMDhmM2M0NGI3YTA5N2Q4YTkyMjk2MjM5Zi90YWJsZTo2ZmRlN2FiYTY3MWE0MTE2ODc1Y2FlNGVhZTk4MWQ4NC90YWJsZXJhbmdlOjZmZGU3YWJhNjcxYTQxMTY4NzVjYWU0ZWFlOTgxZDg0XzIxLTQtMS0xLTU4Mzcy_5083ee69-47d2-4b00-bfba-5862ec9f915c">111</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd9a9b2d424d466ca469cf5987572ab0_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjcvZnJhZzpkYjdmMTdjMDhmM2M0NGI3YTA5N2Q4YTkyMjk2MjM5Zi90YWJsZTo2ZmRlN2FiYTY3MWE0MTE2ODc1Y2FlNGVhZTk4MWQ4NC90YWJsZXJhbmdlOjZmZGU3YWJhNjcxYTQxMTY4NzVjYWU0ZWFlOTgxZDg0XzIxLTYtMS0xLTU4Mzcy_8b4b522e-6ae2-49ca-ae7d-a4bc43a70a52">628,242</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id3708c2b1f2b41dfa7d806c5987de5d7_I20221231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjcvZnJhZzpkYjdmMTdjMDhmM2M0NGI3YTA5N2Q4YTkyMjk2MjM5Zi90YWJsZTo2ZmRlN2FiYTY3MWE0MTE2ODc1Y2FlNGVhZTk4MWQ4NC90YWJsZXJhbmdlOjZmZGU3YWJhNjcxYTQxMTY4NzVjYWU0ZWFlOTgxZDg0XzIxLTgtMS0xLTU4Mzcy_e32db113-3c23-405f-a751-7f053ffe447a">684,893</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3cc6af243d904524abfec5259351ae3f_I20221231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjcvZnJhZzpkYjdmMTdjMDhmM2M0NGI3YTA5N2Q4YTkyMjk2MjM5Zi90YWJsZTo2ZmRlN2FiYTY3MWE0MTE2ODc1Y2FlNGVhZTk4MWQ4NC90YWJsZXJhbmdlOjZmZGU3YWJhNjcxYTQxMTY4NzVjYWU0ZWFlOTgxZDg0XzIxLTEwLTEtMS01ODM3Mg_a74c76af-7b82-47d2-a90b-d9a0c347a274">84</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjcvZnJhZzpkYjdmMTdjMDhmM2M0NGI3YTA5N2Q4YTkyMjk2MjM5Zi90YWJsZTo2ZmRlN2FiYTY3MWE0MTE2ODc1Y2FlNGVhZTk4MWQ4NC90YWJsZXJhbmdlOjZmZGU3YWJhNjcxYTQxMTY4NzVjYWU0ZWFlOTgxZDg0XzIxLTEyLTEtMS01ODM3Mg_7d37360d-9f2e-4dc8-90f6-51471aacb039">56,624</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span><br/></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-8</span></div></div></div><div id="i451bcb3eabba4f87bdc579718207a3b8_130"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OptiNose,&#160;Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Cash Flows</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:77.932%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.017%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.018%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMzAvZnJhZzo3YTVjZGEzNmQ0YTU0MTA4YmM0ZTViMWQ0MmE5N2EyNS90YWJsZTo2YTkzZmY3ODU0ZDg0YmM0ODY5MWFiNzliMGZjNjlhNy90YWJsZXJhbmdlOjZhOTNmZjc4NTRkODRiYzQ4NjkxYWI3OWIwZmM2OWE3XzMtMS0xLTEtNTgzNzI_414a191f-9779-49ed-9731-4dca7e285444">74,833</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMzAvZnJhZzo3YTVjZGEzNmQ0YTU0MTA4YmM0ZTViMWQ0MmE5N2EyNS90YWJsZTo2YTkzZmY3ODU0ZDg0YmM0ODY5MWFiNzliMGZjNjlhNy90YWJsZXJhbmdlOjZhOTNmZjc4NTRkODRiYzQ4NjkxYWI3OWIwZmM2OWE3XzMtMy0xLTEtNTgzNzI_ce5a870b-5173-4bdf-a383-36c29bebb199">82,296</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMzAvZnJhZzo3YTVjZGEzNmQ0YTU0MTA4YmM0ZTViMWQ0MmE5N2EyNS90YWJsZTo2YTkzZmY3ODU0ZDg0YmM0ODY5MWFiNzliMGZjNjlhNy90YWJsZXJhbmdlOjZhOTNmZjc4NTRkODRiYzQ4NjkxYWI3OWIwZmM2OWE3XzUtMS0xLTEtNTgzNzI_e90f3341-b82b-4f72-9341-c484146fe30e">532</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMzAvZnJhZzo3YTVjZGEzNmQ0YTU0MTA4YmM0ZTViMWQ0MmE5N2EyNS90YWJsZTo2YTkzZmY3ODU0ZDg0YmM0ODY5MWFiNzliMGZjNjlhNy90YWJsZXJhbmdlOjZhOTNmZjc4NTRkODRiYzQ4NjkxYWI3OWIwZmM2OWE3XzUtMy0xLTEtNTgzNzI_c6fe8e3f-5a6c-43cc-82f2-9390f62ce2e1">646</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMzAvZnJhZzo3YTVjZGEzNmQ0YTU0MTA4YmM0ZTViMWQ0MmE5N2EyNS90YWJsZTo2YTkzZmY3ODU0ZDg0YmM0ODY5MWFiNzliMGZjNjlhNy90YWJsZXJhbmdlOjZhOTNmZjc4NTRkODRiYzQ4NjkxYWI3OWIwZmM2OWE3XzYtMS0xLTEtNTgzNzI_71071b5a-8eb2-430a-973f-c1707e3587c2">8,877</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMzAvZnJhZzo3YTVjZGEzNmQ0YTU0MTA4YmM0ZTViMWQ0MmE5N2EyNS90YWJsZTo2YTkzZmY3ODU0ZDg0YmM0ODY5MWFiNzliMGZjNjlhNy90YWJsZXJhbmdlOjZhOTNmZjc4NTRkODRiYzQ4NjkxYWI3OWIwZmM2OWE3XzYtMy0xLTEtNTgzNzI_96f51a0b-8eff-44a1-bde3-cb675bb15c44">10,003</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in fair value of warrant liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" decimals="-3" name="us-gaap:FairValueAdjustmentOfWarrants" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMzAvZnJhZzo3YTVjZGEzNmQ0YTU0MTA4YmM0ZTViMWQ0MmE5N2EyNS90YWJsZTo2YTkzZmY3ODU0ZDg0YmM0ODY5MWFiNzliMGZjNjlhNy90YWJsZXJhbmdlOjZhOTNmZjc4NTRkODRiYzQ4NjkxYWI3OWIwZmM2OWE3XzctMS0xLTEtMTAwMDEw_c05a3bfb-78d4-4441-b318-5b43911cc646">1,211</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231" decimals="-3" name="us-gaap:FairValueAdjustmentOfWarrants" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMzAvZnJhZzo3YTVjZGEzNmQ0YTU0MTA4YmM0ZTViMWQ0MmE5N2EyNS90YWJsZTo2YTkzZmY3ODU0ZDg0YmM0ODY5MWFiNzliMGZjNjlhNy90YWJsZXJhbmdlOjZhOTNmZjc4NTRkODRiYzQ4NjkxYWI3OWIwZmM2OWE3XzctMy0xLTEtMTAwMDE1_5d9907c2-a38d-425b-9cdf-fbc118b06a04">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of debt discount and issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMzAvZnJhZzo3YTVjZGEzNmQ0YTU0MTA4YmM0ZTViMWQ0MmE5N2EyNS90YWJsZTo2YTkzZmY3ODU0ZDg0YmM0ODY5MWFiNzliMGZjNjlhNy90YWJsZXJhbmdlOjZhOTNmZjc4NTRkODRiYzQ4NjkxYWI3OWIwZmM2OWE3XzctMS0xLTEtNTgzNzI_251ee55d-39fc-410e-90d2-0823467dd47c">2,318</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMzAvZnJhZzo3YTVjZGEzNmQ0YTU0MTA4YmM0ZTViMWQ0MmE5N2EyNS90YWJsZTo2YTkzZmY3ODU0ZDg0YmM0ODY5MWFiNzliMGZjNjlhNy90YWJsZXJhbmdlOjZhOTNmZjc4NTRkODRiYzQ4NjkxYWI3OWIwZmM2OWE3XzctMy0xLTEtNTgzNzI_05e2262e-67bf-492b-8ef5-dee9d2a3f832">1,795</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Allowance for doubtful accounts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" decimals="-3" name="us-gaap:ProvisionForDoubtfulAccounts" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMzAvZnJhZzo3YTVjZGEzNmQ0YTU0MTA4YmM0ZTViMWQ0MmE5N2EyNS90YWJsZTo2YTkzZmY3ODU0ZDg0YmM0ODY5MWFiNzliMGZjNjlhNy90YWJsZXJhbmdlOjZhOTNmZjc4NTRkODRiYzQ4NjkxYWI3OWIwZmM2OWE3XzgtMS0xLTEtNTgzNzI_3a1d81c8-5062-4bc4-b64c-3d7dd46eefac">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:ProvisionForDoubtfulAccounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMzAvZnJhZzo3YTVjZGEzNmQ0YTU0MTA4YmM0ZTViMWQ0MmE5N2EyNS90YWJsZTo2YTkzZmY3ODU0ZDg0YmM0ODY5MWFiNzliMGZjNjlhNy90YWJsZXJhbmdlOjZhOTNmZjc4NTRkODRiYzQ4NjkxYWI3OWIwZmM2OWE3XzgtMy0xLTEtNTgzNzI_c5ded295-9911-4642-8213-9b2473faa7f5">233</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain on sale of equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" decimals="-3" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMzAvZnJhZzo3YTVjZGEzNmQ0YTU0MTA4YmM0ZTViMWQ0MmE5N2EyNS90YWJsZTo2YTkzZmY3ODU0ZDg0YmM0ODY5MWFiNzliMGZjNjlhNy90YWJsZXJhbmdlOjZhOTNmZjc4NTRkODRiYzQ4NjkxYWI3OWIwZmM2OWE3XzEwLTEtMS0xLTU4Mzcy_38c568ab-496c-48ce-97ff-53650a2229c6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231" decimals="-3" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMzAvZnJhZzo3YTVjZGEzNmQ0YTU0MTA4YmM0ZTViMWQ0MmE5N2EyNS90YWJsZTo2YTkzZmY3ODU0ZDg0YmM0ODY5MWFiNzliMGZjNjlhNy90YWJsZXJhbmdlOjZhOTNmZjc4NTRkODRiYzQ4NjkxYWI3OWIwZmM2OWE3XzEwLTMtMS0xLTU4Mzcy_f26ed884-4a29-4816-bacb-c07c66d4e402">67</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMzAvZnJhZzo3YTVjZGEzNmQ0YTU0MTA4YmM0ZTViMWQ0MmE5N2EyNS90YWJsZTo2YTkzZmY3ODU0ZDg0YmM0ODY5MWFiNzliMGZjNjlhNy90YWJsZXJhbmdlOjZhOTNmZjc4NTRkODRiYzQ4NjkxYWI3OWIwZmM2OWE3XzEyLTEtMS0xLTU4Mzcy_9a8c7fee-9d9b-4562-982e-858f9e6c86ba">1,517</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMzAvZnJhZzo3YTVjZGEzNmQ0YTU0MTA4YmM0ZTViMWQ0MmE5N2EyNS90YWJsZTo2YTkzZmY3ODU0ZDg0YmM0ODY5MWFiNzliMGZjNjlhNy90YWJsZXJhbmdlOjZhOTNmZjc4NTRkODRiYzQ4NjkxYWI3OWIwZmM2OWE3XzEyLTMtMS0xLTU4Mzcy_fcd002d2-ed67-4c3e-afbf-fbbc57314194">11,823</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Grants and other receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" decimals="-3" name="optn:IncreaseDecreaseInGrantsandOtherReceivables" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMzAvZnJhZzo3YTVjZGEzNmQ0YTU0MTA4YmM0ZTViMWQ0MmE5N2EyNS90YWJsZTo2YTkzZmY3ODU0ZDg0YmM0ODY5MWFiNzliMGZjNjlhNy90YWJsZXJhbmdlOjZhOTNmZjc4NTRkODRiYzQ4NjkxYWI3OWIwZmM2OWE3XzEzLTEtMS0xLTU4Mzcy_47e4298f-1f32-47f9-bc74-b7b572f89dd0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231" decimals="-3" sign="-" name="optn:IncreaseDecreaseInGrantsandOtherReceivables" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMzAvZnJhZzo3YTVjZGEzNmQ0YTU0MTA4YmM0ZTViMWQ0MmE5N2EyNS90YWJsZTo2YTkzZmY3ODU0ZDg0YmM0ODY5MWFiNzliMGZjNjlhNy90YWJsZXJhbmdlOjZhOTNmZjc4NTRkODRiYzQ4NjkxYWI3OWIwZmM2OWE3XzEzLTMtMS0xLTU4Mzcy_ea1a9f62-f9c4-45b3-a22c-8e48fbd219bc">43</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" decimals="-3" sign="-" name="optn:IncreaseDecreaseinDepositsandOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMzAvZnJhZzo3YTVjZGEzNmQ0YTU0MTA4YmM0ZTViMWQ0MmE5N2EyNS90YWJsZTo2YTkzZmY3ODU0ZDg0YmM0ODY5MWFiNzliMGZjNjlhNy90YWJsZXJhbmdlOjZhOTNmZjc4NTRkODRiYzQ4NjkxYWI3OWIwZmM2OWE3XzE0LTEtMS0xLTU4Mzcy_ec743599-bd50-4230-b221-ca99cff0ac33">1,963</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231" decimals="-3" sign="-" name="optn:IncreaseDecreaseinDepositsandOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMzAvZnJhZzo3YTVjZGEzNmQ0YTU0MTA4YmM0ZTViMWQ0MmE5N2EyNS90YWJsZTo2YTkzZmY3ODU0ZDg0YmM0ODY5MWFiNzliMGZjNjlhNy90YWJsZXJhbmdlOjZhOTNmZjc4NTRkODRiYzQ4NjkxYWI3OWIwZmM2OWE3XzE0LTMtMS0xLTU4Mzcy_2fbef4bd-9da2-4c2c-903a-4164b4f1bb7a">3,543</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMzAvZnJhZzo3YTVjZGEzNmQ0YTU0MTA4YmM0ZTViMWQ0MmE5N2EyNS90YWJsZTo2YTkzZmY3ODU0ZDg0YmM0ODY5MWFiNzliMGZjNjlhNy90YWJsZXJhbmdlOjZhOTNmZjc4NTRkODRiYzQ4NjkxYWI3OWIwZmM2OWE3XzE1LTEtMS0xLTU4Mzcy_b2f67c74-a3f1-416c-9dc9-c3d72ba19ce2">2,492</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMzAvZnJhZzo3YTVjZGEzNmQ0YTU0MTA4YmM0ZTViMWQ0MmE5N2EyNS90YWJsZTo2YTkzZmY3ODU0ZDg0YmM0ODY5MWFiNzliMGZjNjlhNy90YWJsZXJhbmdlOjZhOTNmZjc4NTRkODRiYzQ4NjkxYWI3OWIwZmM2OWE3XzE1LTMtMS0xLTU4Mzcy_9b3cc84a-4a2b-4746-8bac-611e737b3d86">2,713</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMzAvZnJhZzo3YTVjZGEzNmQ0YTU0MTA4YmM0ZTViMWQ0MmE5N2EyNS90YWJsZTo2YTkzZmY3ODU0ZDg0YmM0ODY5MWFiNzliMGZjNjlhNy90YWJsZXJhbmdlOjZhOTNmZjc4NTRkODRiYzQ4NjkxYWI3OWIwZmM2OWE3XzE2LTEtMS0xLTU4Mzcy_6a30ddb8-90f1-49a5-8b15-ad0cca3d47ee">2,723</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMzAvZnJhZzo3YTVjZGEzNmQ0YTU0MTA4YmM0ZTViMWQ0MmE5N2EyNS90YWJsZTo2YTkzZmY3ODU0ZDg0YmM0ODY5MWFiNzliMGZjNjlhNy90YWJsZXJhbmdlOjZhOTNmZjc4NTRkODRiYzQ4NjkxYWI3OWIwZmM2OWE3XzE2LTMtMS0xLTU4Mzcy_f37de849-800f-4491-9576-de1bf7e4bf90">2,564</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expenses and other liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMzAvZnJhZzo3YTVjZGEzNmQ0YTU0MTA4YmM0ZTViMWQ0MmE5N2EyNS90YWJsZTo2YTkzZmY3ODU0ZDg0YmM0ODY5MWFiNzliMGZjNjlhNy90YWJsZXJhbmdlOjZhOTNmZjc4NTRkODRiYzQ4NjkxYWI3OWIwZmM2OWE3XzE3LTEtMS0xLTU4Mzcy_024cc48d-7f29-4e0c-b702-1df1698a8916">9,005</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMzAvZnJhZzo3YTVjZGEzNmQ0YTU0MTA4YmM0ZTViMWQ0MmE5N2EyNS90YWJsZTo2YTkzZmY3ODU0ZDg0YmM0ODY5MWFiNzliMGZjNjlhNy90YWJsZXJhbmdlOjZhOTNmZjc4NTRkODRiYzQ4NjkxYWI3OWIwZmM2OWE3XzE3LTMtMS0xLTU4Mzcy_be767b78-6b0f-4d7b-a19b-0874bbdb5bf9">1,603</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash used in operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMzAvZnJhZzo3YTVjZGEzNmQ0YTU0MTA4YmM0ZTViMWQ0MmE5N2EyNS90YWJsZTo2YTkzZmY3ODU0ZDg0YmM0ODY5MWFiNzliMGZjNjlhNy90YWJsZXJhbmdlOjZhOTNmZjc4NTRkODRiYzQ4NjkxYWI3OWIwZmM2OWE3XzE4LTEtMS0xLTU4Mzcy_5b22e1e9-10b6-4d31-bc62-af280c0d8c9b">67,651</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMzAvZnJhZzo3YTVjZGEzNmQ0YTU0MTA4YmM0ZTViMWQ0MmE5N2EyNS90YWJsZTo2YTkzZmY3ODU0ZDg0YmM0ODY5MWFiNzliMGZjNjlhNy90YWJsZXJhbmdlOjZhOTNmZjc4NTRkODRiYzQ4NjkxYWI3OWIwZmM2OWE3XzE4LTMtMS0xLTU4Mzcy_4fd25622-ab8b-4452-aaa6-3158482df028">76,935</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investing activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMzAvZnJhZzo3YTVjZGEzNmQ0YTU0MTA4YmM0ZTViMWQ0MmE5N2EyNS90YWJsZTo2YTkzZmY3ODU0ZDg0YmM0ODY5MWFiNzliMGZjNjlhNy90YWJsZXJhbmdlOjZhOTNmZjc4NTRkODRiYzQ4NjkxYWI3OWIwZmM2OWE3XzIwLTEtMS0xLTU4Mzcy_5baa0da9-6ce0-4fdd-baf0-1cfad9bccdff">63</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMzAvZnJhZzo3YTVjZGEzNmQ0YTU0MTA4YmM0ZTViMWQ0MmE5N2EyNS90YWJsZTo2YTkzZmY3ODU0ZDg0YmM0ODY5MWFiNzliMGZjNjlhNy90YWJsZXJhbmdlOjZhOTNmZjc4NTRkODRiYzQ4NjkxYWI3OWIwZmM2OWE3XzIwLTMtMS0xLTU4Mzcy_eb2ef311-8e9f-4946-b47c-be90c56e9434">167</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from sale of property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" decimals="-3" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMzAvZnJhZzo3YTVjZGEzNmQ0YTU0MTA4YmM0ZTViMWQ0MmE5N2EyNS90YWJsZTo2YTkzZmY3ODU0ZDg0YmM0ODY5MWFiNzliMGZjNjlhNy90YWJsZXJhbmdlOjZhOTNmZjc4NTRkODRiYzQ4NjkxYWI3OWIwZmM2OWE3XzIxLTEtMS0xLTU4Mzcy_2e265af1-47a2-42d0-9fb0-e74034669f7a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMzAvZnJhZzo3YTVjZGEzNmQ0YTU0MTA4YmM0ZTViMWQ0MmE5N2EyNS90YWJsZTo2YTkzZmY3ODU0ZDg0YmM0ODY5MWFiNzliMGZjNjlhNy90YWJsZXJhbmdlOjZhOTNmZjc4NTRkODRiYzQ4NjkxYWI3OWIwZmM2OWE3XzIxLTMtMS0xLTU4Mzcy_bfc5759b-4087-48dc-a961-8b0c986b8d17">105</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash used in investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMzAvZnJhZzo3YTVjZGEzNmQ0YTU0MTA4YmM0ZTViMWQ0MmE5N2EyNS90YWJsZTo2YTkzZmY3ODU0ZDg0YmM0ODY5MWFiNzliMGZjNjlhNy90YWJsZXJhbmdlOjZhOTNmZjc4NTRkODRiYzQ4NjkxYWI3OWIwZmM2OWE3XzIyLTEtMS0xLTU4Mzcy_6b58de48-bf3f-49f7-82ca-c1e2cbbfaf9b">63</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMzAvZnJhZzo3YTVjZGEzNmQ0YTU0MTA4YmM0ZTViMWQ0MmE5N2EyNS90YWJsZTo2YTkzZmY3ODU0ZDg0YmM0ODY5MWFiNzliMGZjNjlhNy90YWJsZXJhbmdlOjZhOTNmZjc4NTRkODRiYzQ4NjkxYWI3OWIwZmM2OWE3XzIyLTMtMS0xLTU4Mzcy_bbf7fcc4-9f38-4925-8f9e-6975447aa215">62</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financing activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from the sale of common stock and warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMzAvZnJhZzo3YTVjZGEzNmQ0YTU0MTA4YmM0ZTViMWQ0MmE5N2EyNS90YWJsZTo2YTkzZmY3ODU0ZDg0YmM0ODY5MWFiNzliMGZjNjlhNy90YWJsZXJhbmdlOjZhOTNmZjc4NTRkODRiYzQ4NjkxYWI3OWIwZmM2OWE3XzI0LTEtMS0xLTU4Mzcy_0afd5d53-e833-430e-9ba2-af1c1685f1e5">51,086</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMzAvZnJhZzo3YTVjZGEzNmQ0YTU0MTA4YmM0ZTViMWQ0MmE5N2EyNS90YWJsZTo2YTkzZmY3ODU0ZDg0YmM0ODY5MWFiNzliMGZjNjlhNy90YWJsZXJhbmdlOjZhOTNmZjc4NTRkODRiYzQ4NjkxYWI3OWIwZmM2OWE3XzI0LTMtMS0xLTU4Mzcy_3e12bf88-2f6c-4d70-9a97-d87369137af5">43,140</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from the issuance of common stock under employee stock purchase plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" decimals="-3" name="optn:ProceedsfromIssuanceofCommonStockUnderEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMzAvZnJhZzo3YTVjZGEzNmQ0YTU0MTA4YmM0ZTViMWQ0MmE5N2EyNS90YWJsZTo2YTkzZmY3ODU0ZDg0YmM0ODY5MWFiNzliMGZjNjlhNy90YWJsZXJhbmdlOjZhOTNmZjc4NTRkODRiYzQ4NjkxYWI3OWIwZmM2OWE3XzI3LTEtMS0xLTU4Mzcy_2a58ba9e-1c08-42ac-9f49-79670d4d85bf">554</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231" decimals="-3" name="optn:ProceedsfromIssuanceofCommonStockUnderEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMzAvZnJhZzo3YTVjZGEzNmQ0YTU0MTA4YmM0ZTViMWQ0MmE5N2EyNS90YWJsZTo2YTkzZmY3ODU0ZDg0YmM0ODY5MWFiNzliMGZjNjlhNy90YWJsZXJhbmdlOjZhOTNmZjc4NTRkODRiYzQ4NjkxYWI3OWIwZmM2OWE3XzI3LTMtMS0xLTU4Mzcy_1bc55c41-5055-425b-8776-e1832c29159b">368</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from the exercise of stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMzAvZnJhZzo3YTVjZGEzNmQ0YTU0MTA4YmM0ZTViMWQ0MmE5N2EyNS90YWJsZTo2YTkzZmY3ODU0ZDg0YmM0ODY5MWFiNzliMGZjNjlhNy90YWJsZXJhbmdlOjZhOTNmZjc4NTRkODRiYzQ4NjkxYWI3OWIwZmM2OWE3XzI4LTEtMS0xLTU4Mzcy_0994672d-73e0-4ca0-88ec-56dcbe18a78d">94</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMzAvZnJhZzo3YTVjZGEzNmQ0YTU0MTA4YmM0ZTViMWQ0MmE5N2EyNS90YWJsZTo2YTkzZmY3ODU0ZDg0YmM0ODY5MWFiNzliMGZjNjlhNy90YWJsZXJhbmdlOjZhOTNmZjc4NTRkODRiYzQ4NjkxYWI3OWIwZmM2OWE3XzI4LTMtMS0xLTU4Mzcy_bbe3390a-ed78-4d5a-b4df-c218368a98f2">39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid for financing costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" decimals="-3" name="us-gaap:PaymentsOfFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMzAvZnJhZzo3YTVjZGEzNmQ0YTU0MTA4YmM0ZTViMWQ0MmE5N2EyNS90YWJsZTo2YTkzZmY3ODU0ZDg0YmM0ODY5MWFiNzliMGZjNjlhNy90YWJsZXJhbmdlOjZhOTNmZjc4NTRkODRiYzQ4NjkxYWI3OWIwZmM2OWE3XzI5LTEtMS0xLTU4Mzcy_28485965-c021-4844-beb0-47e815f41fef">298</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsOfFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMzAvZnJhZzo3YTVjZGEzNmQ0YTU0MTA4YmM0ZTViMWQ0MmE5N2EyNS90YWJsZTo2YTkzZmY3ODU0ZDg0YmM0ODY5MWFiNzliMGZjNjlhNy90YWJsZXJhbmdlOjZhOTNmZjc4NTRkODRiYzQ4NjkxYWI3OWIwZmM2OWE3XzI5LTMtMS0xLTU4Mzcy_e0003e80-9ddd-4127-b615-1ee3f718ae89">227</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMzAvZnJhZzo3YTVjZGEzNmQ0YTU0MTA4YmM0ZTViMWQ0MmE5N2EyNS90YWJsZTo2YTkzZmY3ODU0ZDg0YmM0ODY5MWFiNzliMGZjNjlhNy90YWJsZXJhbmdlOjZhOTNmZjc4NTRkODRiYzQ4NjkxYWI3OWIwZmM2OWE3XzMxLTEtMS0xLTU4Mzcy_bbd34802-9e6d-43c0-8c5e-03eb2be038d1">51,436</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMzAvZnJhZzo3YTVjZGEzNmQ0YTU0MTA4YmM0ZTViMWQ0MmE5N2EyNS90YWJsZTo2YTkzZmY3ODU0ZDg0YmM0ODY5MWFiNzliMGZjNjlhNy90YWJsZXJhbmdlOjZhOTNmZjc4NTRkODRiYzQ4NjkxYWI3OWIwZmM2OWE3XzMxLTMtMS0xLTU4Mzcy_33e8239a-bad3-49eb-90a2-ee46f31295f1">43,320</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effects of exchange rate changes on cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" decimals="-3" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMzAvZnJhZzo3YTVjZGEzNmQ0YTU0MTA4YmM0ZTViMWQ0MmE5N2EyNS90YWJsZTo2YTkzZmY3ODU0ZDg0YmM0ODY5MWFiNzliMGZjNjlhNy90YWJsZXJhbmdlOjZhOTNmZjc4NTRkODRiYzQ4NjkxYWI3OWIwZmM2OWE3XzMyLTEtMS0xLTU4Mzcy_9600e440-02d5-4359-81ad-9d8d2ed7e283">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231" decimals="-3" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMzAvZnJhZzo3YTVjZGEzNmQ0YTU0MTA4YmM0ZTViMWQ0MmE5N2EyNS90YWJsZTo2YTkzZmY3ODU0ZDg0YmM0ODY5MWFiNzliMGZjNjlhNy90YWJsZXJhbmdlOjZhOTNmZjc4NTRkODRiYzQ4NjkxYWI3OWIwZmM2OWE3XzMyLTMtMS0xLTU4Mzcy_9bba47a5-a477-42d5-813c-5648eb7a23fb">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net decrease in cash, cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMzAvZnJhZzo3YTVjZGEzNmQ0YTU0MTA4YmM0ZTViMWQ0MmE5N2EyNS90YWJsZTo2YTkzZmY3ODU0ZDg0YmM0ODY5MWFiNzliMGZjNjlhNy90YWJsZXJhbmdlOjZhOTNmZjc4NTRkODRiYzQ4NjkxYWI3OWIwZmM2OWE3XzMzLTEtMS0xLTU4Mzcy_5222a3b2-42a8-4671-b2fe-45f8e71e969e">16,271</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMzAvZnJhZzo3YTVjZGEzNmQ0YTU0MTA4YmM0ZTViMWQ0MmE5N2EyNS90YWJsZTo2YTkzZmY3ODU0ZDg0YmM0ODY5MWFiNzliMGZjNjlhNy90YWJsZXJhbmdlOjZhOTNmZjc4NTRkODRiYzQ4NjkxYWI3OWIwZmM2OWE3XzMzLTMtMS0xLTU4Mzcy_064c57fe-b53c-4d16-bd6a-2a9272568427">33,664</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash at beginning of period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id970dfd2674c4d6b895febb9c14d0fd1_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMzAvZnJhZzo3YTVjZGEzNmQ0YTU0MTA4YmM0ZTViMWQ0MmE5N2EyNS90YWJsZTo2YTkzZmY3ODU0ZDg0YmM0ODY5MWFiNzliMGZjNjlhNy90YWJsZXJhbmdlOjZhOTNmZjc4NTRkODRiYzQ4NjkxYWI3OWIwZmM2OWE3XzM0LTEtMS0xLTU4Mzcy_4ad2f0fe-8248-4738-be50-e558070ab48b">110,515</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49ae796ea1484c519d91607656f24c24_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMzAvZnJhZzo3YTVjZGEzNmQ0YTU0MTA4YmM0ZTViMWQ0MmE5N2EyNS90YWJsZTo2YTkzZmY3ODU0ZDg0YmM0ODY5MWFiNzliMGZjNjlhNy90YWJsZXJhbmdlOjZhOTNmZjc4NTRkODRiYzQ4NjkxYWI3OWIwZmM2OWE3XzM0LTMtMS0xLTU4Mzcy_311b42a2-c752-46ba-a7fb-b9b57270d352">144,179</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash at end of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMzAvZnJhZzo3YTVjZGEzNmQ0YTU0MTA4YmM0ZTViMWQ0MmE5N2EyNS90YWJsZTo2YTkzZmY3ODU0ZDg0YmM0ODY5MWFiNzliMGZjNjlhNy90YWJsZXJhbmdlOjZhOTNmZjc4NTRkODRiYzQ4NjkxYWI3OWIwZmM2OWE3XzM1LTEtMS0xLTU4Mzcy_56ec4438-05be-4bed-8b1f-33335d5052f7">94,244</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id970dfd2674c4d6b895febb9c14d0fd1_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMzAvZnJhZzo3YTVjZGEzNmQ0YTU0MTA4YmM0ZTViMWQ0MmE5N2EyNS90YWJsZTo2YTkzZmY3ODU0ZDg0YmM0ODY5MWFiNzliMGZjNjlhNy90YWJsZXJhbmdlOjZhOTNmZjc4NTRkODRiYzQ4NjkxYWI3OWIwZmM2OWE3XzM1LTMtMS0xLTU4Mzcy_4156d3bd-6d4c-4344-950f-1467b8070fed">110,515</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Supplemental disclosure of cash flow information:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid for interest</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMzAvZnJhZzo3YTVjZGEzNmQ0YTU0MTA4YmM0ZTViMWQ0MmE5N2EyNS90YWJsZTo2YTkzZmY3ODU0ZDg0YmM0ODY5MWFiNzliMGZjNjlhNy90YWJsZXJhbmdlOjZhOTNmZjc4NTRkODRiYzQ4NjkxYWI3OWIwZmM2OWE3XzM3LTEtMS0xLTU4Mzcy_0b17cd2f-c313-43ee-998d-926a770d0200">15,091</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMzAvZnJhZzo3YTVjZGEzNmQ0YTU0MTA4YmM0ZTViMWQ0MmE5N2EyNS90YWJsZTo2YTkzZmY3ODU0ZDg0YmM0ODY5MWFiNzliMGZjNjlhNy90YWJsZXJhbmdlOjZhOTNmZjc4NTRkODRiYzQ4NjkxYWI3OWIwZmM2OWE3XzM3LTMtMS0xLTU4Mzcy_1dbfa608-2ee4-4d29-ab33-4df1f3432c07">14,170</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Supplemental disclosure of noncash activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fixed asset purchases within accounts payable and accrued expenses</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" decimals="-3" name="us-gaap:NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMzAvZnJhZzo3YTVjZGEzNmQ0YTU0MTA4YmM0ZTViMWQ0MmE5N2EyNS90YWJsZTo2YTkzZmY3ODU0ZDg0YmM0ODY5MWFiNzliMGZjNjlhNy90YWJsZXJhbmdlOjZhOTNmZjc4NTRkODRiYzQ4NjkxYWI3OWIwZmM2OWE3XzM5LTEtMS0xLTU4Mzcy_04c48690-58c8-4804-a2e6-c1033edd256f">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231" decimals="-3" name="us-gaap:NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMzAvZnJhZzo3YTVjZGEzNmQ0YTU0MTA4YmM0ZTViMWQ0MmE5N2EyNS90YWJsZTo2YTkzZmY3ODU0ZDg0YmM0ODY5MWFiNzliMGZjNjlhNy90YWJsZXJhbmdlOjZhOTNmZjc4NTRkODRiYzQ4NjkxYWI3OWIwZmM2OWE3XzM5LTMtMS0xLTU4Mzcy_85ccd148-16fd-42c3-b296-5c9d8d203934">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of warrants issued</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMzAvZnJhZzo3YTVjZGEzNmQ0YTU0MTA4YmM0ZTViMWQ0MmE5N2EyNS90YWJsZTo2YTkzZmY3ODU0ZDg0YmM0ODY5MWFiNzliMGZjNjlhNy90YWJsZXJhbmdlOjZhOTNmZjc4NTRkODRiYzQ4NjkxYWI3OWIwZmM2OWE3XzQwLTEtMS0xLTU4Mzcy_f1bc4d0c-69ad-44e1-93ee-72682157b66c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMzAvZnJhZzo3YTVjZGEzNmQ0YTU0MTA4YmM0ZTViMWQ0MmE5N2EyNS90YWJsZTo2YTkzZmY3ODU0ZDg0YmM0ODY5MWFiNzliMGZjNjlhNy90YWJsZXJhbmdlOjZhOTNmZjc4NTRkODRiYzQ4NjkxYWI3OWIwZmM2OWE3XzQwLTMtMS0xLTU4Mzcy_636a5057-4155-4ed0-ac4c-760d192fed6d">534</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financing costs within accounts payable and accrued expenses</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" decimals="-3" name="optn:DeferredOfferingCostsWIthinAccountsPayableandAccruedExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMzAvZnJhZzo3YTVjZGEzNmQ0YTU0MTA4YmM0ZTViMWQ0MmE5N2EyNS90YWJsZTo2YTkzZmY3ODU0ZDg0YmM0ODY5MWFiNzliMGZjNjlhNy90YWJsZXJhbmdlOjZhOTNmZjc4NTRkODRiYzQ4NjkxYWI3OWIwZmM2OWE3XzQyLTEtMS0xLTU4Mzcy_bf9e6072-cf1c-4183-9e36-a7f2f1d4c67b">408</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231" decimals="-3" name="optn:DeferredOfferingCostsWIthinAccountsPayableandAccruedExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMzAvZnJhZzo3YTVjZGEzNmQ0YTU0MTA4YmM0ZTViMWQ0MmE5N2EyNS90YWJsZTo2YTkzZmY3ODU0ZDg0YmM0ODY5MWFiNzliMGZjNjlhNy90YWJsZXJhbmdlOjZhOTNmZjc4NTRkODRiYzQ4NjkxYWI3OWIwZmM2OWE3XzQyLTMtMS0xLTU4Mzcy_09fa99d3-e7d2-4a08-9e01-2e8a20730158">318</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Recognition of right-of-use assets and lease liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMzAvZnJhZzo3YTVjZGEzNmQ0YTU0MTA4YmM0ZTViMWQ0MmE5N2EyNS90YWJsZTo2YTkzZmY3ODU0ZDg0YmM0ODY5MWFiNzliMGZjNjlhNy90YWJsZXJhbmdlOjZhOTNmZjc4NTRkODRiYzQ4NjkxYWI3OWIwZmM2OWE3XzQzLTEtMS0xLTU4Mzcy_4562336a-6ce6-4ca0-bf43-46e735a566b8">704</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMzAvZnJhZzo3YTVjZGEzNmQ0YTU0MTA4YmM0ZTViMWQ0MmE5N2EyNS90YWJsZTo2YTkzZmY3ODU0ZDg0YmM0ODY5MWFiNzliMGZjNjlhNy90YWJsZXJhbmdlOjZhOTNmZjc4NTRkODRiYzQ4NjkxYWI3OWIwZmM2OWE3XzQzLTMtMS0xLTU4Mzcy_f99a4914-502f-4e75-b53e-ed4f11035d10">157</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-9</span></div></div></div><div id="i451bcb3eabba4f87bdc579718207a3b8_133"></div><hr style="page-break-after:always"/><div style="min-height:112.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OptiNose,&#160;Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span><br/></span></div><div id="i451bcb3eabba4f87bdc579718207a3b8_136"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" name="us-gaap:NatureOfOperations" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMzYvZnJhZzo3MDRiYmExYWU0ZmM0MDdmYmYyOWFiNDEwY2Q0MTBmOC90ZXh0cmVnaW9uOjcwNGJiYTFhZTRmYzQwN2ZiZjI5YWI0MTBjZDQxMGY4XzEyNTU_9bb09213-984d-4723-b6bd-fa4a716fe198" continuedAt="i7c4748deea1448b5ad641f51122e7d26" escape="true">Organization and Description of Business</ix:nonNumeric></span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i7c4748deea1448b5ad641f51122e7d26" continuedAt="i6341c06af6eb4b7484bc16d9c55f1549">OptiNose,&#160;Inc. (the Company) was incorporated in Delaware in May 2010 (inception) and has facilities in Yardley, Pennsylvania and Ewing, New Jersey. The Company's predecessor entity, OptiNose AS, was formed under the laws of Norway in September 2000. In 2010, OptiNose AS became a wholly-owned subsidiary of the Company as part of an internal reorganization.  During 2022, the Company's board of directors approved the liquidation of Optionse AS and Optinose UK, which is expected to be completed in 2023, in order to simplify the corporate structure.  </ix:continuation></span></div><div style="margin-bottom:8pt"><ix:continuation id="i6341c06af6eb4b7484bc16d9c55f1549" continuedAt="i78bcd1d6f39645feb5c40a2a265fdddb"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is a specialty pharmaceutical company focused on the development and commercialization of products for patients treated by ear, nose and throat (ENT) and allergy specialists. The Company's first commercial product, XHANCE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></ix:continuation><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i78bcd1d6f39645feb5c40a2a265fdddb"> (fluticasone propionate) nasal spray, 93 microgram (mcg), is a therapeutic utilizing the Company's proprietary Exhalation Delivery System (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps and, if approved, chronic rhinosinusitis without nasal polyps (also known as chronic sinusitis). XHANCE was approved by the United States (US) Food and Drug Administration (FDA) in September 2017 for the treatment of nasal polyps in patients 18&#160;years of age or older. XHANCE was made widely available through commercial channels in April 2018.  In January 2023, the indication statement for XHANCE was changed from &#8220;for the treatment of nasal polyps&#8221; to &#8220;for the treatment of chronic rhinosinusitis with nasal polyps&#8221; to reflect current FDA labeling terminology and not based on new XHANCE clinical trial data.</ix:continuation> </span></div><div id="i451bcb3eabba4f87bdc579718207a3b8_139"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" name="optn:FutureLiquidityTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMzkvZnJhZzoyODhkZDRlNTdmN2Q0ODE2OTA2ZGNiNzlmMjllMjUzYi90ZXh0cmVnaW9uOjI4OGRkNGU1N2Y3ZDQ4MTY5MDZkY2I3OWYyOWUyNTNiXzIzOTI_1e428b65-956c-408f-973d-0c3c85ac3e32" continuedAt="i479892686591426f8ea250475fbd9f32" escape="true">Liquidity</ix:nonNumeric></span></div><ix:continuation id="i479892686591426f8ea250475fbd9f32" continuedAt="i92806082c0f644eab59785e117f6b22c"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since inception, the Company's operations have focused on organization and staffing, business planning, raising capital, establishing an intellectual property portfolio, conducting preclinical studies and clinical trials, pursuing regulatory approvals and most recently, launching XHANCE in the US. As of December 31, 2022, the Company had cash and cash equivalents of $<ix:nonFraction unitRef="usd" contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231" decimals="-3" name="us-gaap:CashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMzkvZnJhZzoyODhkZDRlNTdmN2Q0ODE2OTA2ZGNiNzlmMjllMjUzYi90ZXh0cmVnaW9uOjI4OGRkNGU1N2Y3ZDQ4MTY5MDZkY2I3OWYyOWUyNTNiXzM3Mg_e0f1930c-76a4-4276-86e6-a976065ca130">94,244</ix:nonFraction> and a working capital deficiency of $<ix:nonFraction unitRef="usd" contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231" decimals="-3" sign="-" name="optn:WorkingCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMzkvZnJhZzoyODhkZDRlNTdmN2Q0ODE2OTA2ZGNiNzlmMjllMjUzYi90ZXh0cmVnaW9uOjI4OGRkNGU1N2Y3ZDQ4MTY5MDZkY2I3OWYyOWUyNTNiXzIxOTkwMjMzNzU0MzQ_21bdbfb0-c7ec-447b-b18c-07d0beef53d4">38,246</ix:nonFraction>.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to a number of risks similar to other life sciences companies, including successful discovery, development and commercialization of its products and product candidates, raising additional capital, the development by its competitors of new technological innovations, protection of proprietary technology and market acceptance of the Company's products. The Company has incurred recurring net losses since its inception and has accumulated a deficit of $<ix:nonFraction unitRef="usd" contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMzkvZnJhZzoyODhkZDRlNTdmN2Q0ODE2OTA2ZGNiNzlmMjllMjUzYi90ZXh0cmVnaW9uOjI4OGRkNGU1N2Y3ZDQ4MTY5MDZkY2I3OWYyOWUyNTNiXzIxOTkwMjMzNzU1NTE_842e30e2-37f4-4b8d-8f69-1c11479681e5">684,893</ix:nonFraction> as of December 31, 2022.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company entered into a Note Purchase Agreement (the Note Purchase Agreement) on September 12, 2019 with funds managed by Pharmakon Advisors, LP (Pharmakon), the investment manager of the BioPharma Credit Funds (BioPharma) which was subsequently amended on August 13, 2020, March 2, 2021, November 16, 2021, August 10, 2022, and November 9, 2022.  On November 23, 2022, the Company amended and restated the Note Purchase Agreement (the A&amp;R Note Purchase Agreement). Pursuant to the A&amp;R Note Purchase Agreement, the financial covenants requiring the Company to achieve minimum trailing twelve-month consolidated XHANCE net product sales and royalties were modified (See </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_163">Note </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_163">10</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">). The principal balance outstanding under the A&amp;R Note Purchase Agreement was $<ix:nonFraction unitRef="usd" contextRef="i57b30631121b485ab3ea36fafacd9bba_I20221231" decimals="-6" name="us-gaap:NotesPayable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMzkvZnJhZzoyODhkZDRlNTdmN2Q0ODE2OTA2ZGNiNzlmMjllMjUzYi90ZXh0cmVnaW9uOjI4OGRkNGU1N2Y3ZDQ4MTY5MDZkY2I3OWYyOWUyNTNiXzIxOTkwMjMzNzU3Mzc_7cccc1c6-1198-45bd-bb59-4e17f18e774b">130</ix:nonFraction>&#160;million at December 31, 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company's continuation as a going concern is dependent on its ability to maintain compliance with its covenants under the A&amp;R Note Purchase Agreement, including minimum trailing twelve-month consolidated XHANCE net sales and royalties the Company is required to achieve commencing with the trailing twelve months ending March 31, 2024 and its ability to generate sufficient cash flows from operations to meet its obligations and/or obtain additional capital through equity or debt financings, partnerships, collaborations, or other sources, as may be required. The A&amp;R Note Purchase Agreement includes events of default, in certain cases subject to customary periods to cure, following which Pharmakon may accelerate all amounts outstanding pursuant to the Note Purchase Agreement. The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The A&amp;R Note Purchase Agreement also requires the Company to maintain at all times a minimum of $<ix:nonFraction unitRef="usd" contextRef="i77cd59ff576d44dd94fde4a159bcfd79_I20221123" decimals="-5" name="optn:DebtInstrumentCovenantCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMzkvZnJhZzoyODhkZDRlNTdmN2Q0ODE2OTA2ZGNiNzlmMjllMjUzYi90ZXh0cmVnaW9uOjI4OGRkNGU1N2Y3ZDQ4MTY5MDZkY2I3OWYyOWUyNTNiXzIxOTkwMjMzNzgwMzk_5c3a882c-6182-4199-8983-fbe174e9baad">30,000</ix:nonFraction> of cash and cash equivalents. The Company believes that it is probable that its existing cash and cash equivalents will not be adequate to fund its operations and maintain at least $<ix:nonFraction unitRef="usd" contextRef="i77cd59ff576d44dd94fde4a159bcfd79_I20221123" decimals="-5" name="optn:DebtInstrumentCovenantCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMzkvZnJhZzoyODhkZDRlNTdmN2Q0ODE2OTA2ZGNiNzlmMjllMjUzYi90ZXh0cmVnaW9uOjI4OGRkNGU1N2Y3ZDQ4MTY5MDZkY2I3OWYyOWUyNTNiXzIxOTkwMjMzNzgyMjQ_cd4aae9b-9cf9-4390-a7df-91751eef346d">30,000</ix:nonFraction> of cash and cash equivalents as required </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:112.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OptiNose,&#160;Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div></div><ix:continuation id="i92806082c0f644eab59785e117f6b22c"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">under the A&amp;R Note Purchase Agreement for at least twelve-months following the filing of this Form 10-K, which will also constitute a default of the liquidity financial covenant under the A&amp;R Note Purchase Agreement if the Company is unable to obtain additional capital or obtain a waiver or modification to this liquidity covenant prior to falling below such $<ix:nonFraction unitRef="usd" contextRef="iad0d9b5ed2334bfd8a9fd9842e362c70_I20221123" decimals="-5" name="optn:DebtInstrumentCovenantCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMzkvZnJhZzoyODhkZDRlNTdmN2Q0ODE2OTA2ZGNiNzlmMjllMjUzYi90ZXh0cmVnaW9uOjI4OGRkNGU1N2Y3ZDQ4MTY5MDZkY2I3OWYyOWUyNTNiXzIxOTkwMjMzNzg2MzA_2dcc569f-b8ed-4776-b778-2fd6c00e7aa7">30,000</ix:nonFraction> threshold. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company also believes it is probable that it will not achieve the trailing twelve-month minimum consolidated XHANCE net sales and royalties thresholds under the A&amp;R Note Purchase Agreement for the initial period ending March 31, 2024, which will constitute a default under the A&amp;R Note Purchase Agreement if the Company is unable to obtain a modification or waiver of such minimum consolidated XHANCE net sales and royalties thresholds. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Further, the A&amp;R Note Purchase Agreement includes a requirement that the report and opinion on the consolidated financial statements commencing with the year ending December 31, 2023, not be subject to any statement as to &#8220;going concern.&#8221; In addition, the consolidated financial statements commencing with the quarter ended March 31, 2024, shall also not be subject to any statement as to &#8220;going concern.&#8221; The Company has concluded that it is unlikely that it will be able comply with these provisions in 2024.  Failure to comply with these provisions would also constitute an event of default under the A&amp;R Note Purchase Agreement. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In the event of any of the foregoing defaults, the holders of the Pharmakon Senior Secured Notes may declare an event of default under the A&amp;R Note Purchase</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Agreement and may elect to accelerate the repayment of all unpaid principal, accrued interest and other amounts due, which may require the Company to delay or curtail its operations until additional funding is received.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The terms of the</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">A&amp;R Note Purchase</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Agreement and the Pharmakon Senior Secured Notes, including applicable covenants, are described in </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_163">Note </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_163">10</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Management&#8217;s plans to mitigate this risk may include reducing expenses, raising additional capital through equity or debt financings, partnerships, collaborations or other sources and requesting a modification or waiver of the covenants under the A&amp;R Note Purchase Agreement.  However, there can be no assurance that the Company will be successful in reducing expenses, raising additional capital, or obtaining a modification or waiver of the covenants under the A&amp;R Note Purchase Agreement. If the Company is unable to reduce expenses, raise additional capital or obtain a modification or waiver of the covenants under the A&amp;R Note Purchase Agreement, the Company may need to delay or curtail its operations. As a result of these factors, management has concluded that substantial doubt exists about the Company&#8217;s ability to continue as a going concern within one year after the date these consolidated financial statements are issued.</span></div></ix:continuation><div id="i451bcb3eabba4f87bdc579718207a3b8_142"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDIvZnJhZzo5M2I1YmRhMDg4ZWQ0ZWFlYjc4M2I1ZTU0N2JkZjA5My90ZXh0cmVnaW9uOjkzYjViZGEwODhlZDRlYWViNzgzYjVlNTQ3YmRmMDkzXzI1MDM2_97ab9bbb-d721-4977-9b3e-da9bf5f79f99" continuedAt="i3a7fbd660baa4f8196adee093331e685" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="i3a7fbd660baa4f8196adee093331e685" continuedAt="i7f87ac8f5c2d480398a4af8dcdded9be"><ix:nonNumeric contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDIvZnJhZzo5M2I1YmRhMDg4ZWQ0ZWFlYjc4M2I1ZTU0N2JkZjA5My90ZXh0cmVnaW9uOjkzYjViZGEwODhlZDRlYWViNzgzYjVlNTQ3YmRmMDkzXzI1MDEx_88cdafc9-0806-40de-911b-5a6bf6a13c99" escape="true"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of presentation</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements have been prepared in conformity with US generally accepted accounting principles (GAAP). Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification (ASC) and Accounting Standards Updates (ASU) of the Financial Accounting Standards Board (FASB).</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDIvZnJhZzo5M2I1YmRhMDg4ZWQ0ZWFlYjc4M2I1ZTU0N2JkZjA5My90ZXh0cmVnaW9uOjkzYjViZGEwODhlZDRlYWViNzgzYjVlNTQ3YmRmMDkzXzI1MDE1_ff273b1d-a7d3-4700-8c5a-52daaeefff12" escape="true"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of consolidation</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of OptiNose,&#160;Inc. and its wholly-owned subsidiaries, OptiNose US,&#160;Inc., OptiNose AS and OptiNose UK&#160;Ltd. All inter-company balances and transactions have been eliminated in consolidation.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDIvZnJhZzo5M2I1YmRhMDg4ZWQ0ZWFlYjc4M2I1ZTU0N2JkZjA5My90ZXh0cmVnaW9uOjkzYjViZGEwODhlZDRlYWViNzgzYjVlNTQ3YmRmMDkzXzI1MDAx_7d5e8302-2b73-46d2-a052-9c56ecc4e5a7" escape="true"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of estimates</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and reported amounts of expenses during the reporting period. Due to the uncertainty of factors surrounding the estimates or judgments used in the preparation of the consolidated financial statements, actual results may materially vary from these estimates. Estimates and assumptions are periodically reviewed and the effects of revisions are reflected in the consolidated financial statements in the period they are determined to be necessary.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:112.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OptiNose,&#160;Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements (Continued)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div></div><ix:continuation id="i7f87ac8f5c2d480398a4af8dcdded9be" continuedAt="i641d4634bc3142e2a837f6dcf5a87e4d"><ix:nonNumeric contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" name="us-gaap:ConcentrationRiskCreditRisk" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDIvZnJhZzo5M2I1YmRhMDg4ZWQ0ZWFlYjc4M2I1ZTU0N2JkZjA5My90ZXh0cmVnaW9uOjkzYjViZGEwODhlZDRlYWViNzgzYjVlNTQ3YmRmMDkzXzI1MDA2_71acbfee-2500-453f-a45e-6f0250c5fd51" continuedAt="i1bb34545197f414f820561c6727b0ae9" escape="true"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of credit risk</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to concentrations of credit risk are primarily cash and accounts receivable. The Company generally invests its cash in deposits with high credit quality financial institutions. Additionally, the Company performs periodic evaluations of the relative credit standing of these financial institutions.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Customer and supplier concentration</span></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i1bb34545197f414f820561c6727b0ae9">The Company has exposure to credit risk in accounts receivable from sales of product. XHANCE is sold to wholesale pharmaceutical distributors and preferred pharmacy network (PPN) partners, who, in turn, sell XHANCE to pharmacies, hospitals and other customers.</ix:continuation>&#160;<ix:nonFraction unitRef="customer" contextRef="i9c9d8c25cbd84a1dbfec87c26799aca0_D20220101-20221231" decimals="INF" name="optn:NumberOfCustomers" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDIvZnJhZzo5M2I1YmRhMDg4ZWQ0ZWFlYjc4M2I1ZTU0N2JkZjA5My90ZXh0cmVnaW9uOjkzYjViZGEwODhlZDRlYWViNzgzYjVlNTQ3YmRmMDkzXzIxNTg_94dd223d-1f6b-4625-8bee-3901377e8a1d">Five</ix:nonFraction> customers represented approximately <ix:nonFraction unitRef="number" contextRef="i9c9d8c25cbd84a1dbfec87c26799aca0_D20220101-20221231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDIvZnJhZzo5M2I1YmRhMDg4ZWQ0ZWFlYjc4M2I1ZTU0N2JkZjA5My90ZXh0cmVnaW9uOjkzYjViZGEwODhlZDRlYWViNzgzYjVlNTQ3YmRmMDkzXzIxOTc_51697396-a8b1-47f3-874c-36ba918ff775">52</ix:nonFraction>% of the Company's accounts receivable at December 31, 2022 and <ix:nonFraction unitRef="customer" contextRef="i453f6ff7522f4a12b35a0b401b71aadf_D20220101-20221231" decimals="INF" name="optn:NumberOfCustomers" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDIvZnJhZzo5M2I1YmRhMDg4ZWQ0ZWFlYjc4M2I1ZTU0N2JkZjA5My90ZXh0cmVnaW9uOjkzYjViZGEwODhlZDRlYWViNzgzYjVlNTQ3YmRmMDkzXzIyNDc_4d30cc8c-d45a-45a8-bdfe-55ca2f26efeb">five</ix:nonFraction> customers represented approximately <ix:nonFraction unitRef="number" contextRef="i453f6ff7522f4a12b35a0b401b71aadf_D20220101-20221231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDIvZnJhZzo5M2I1YmRhMDg4ZWQ0ZWFlYjc4M2I1ZTU0N2JkZjA5My90ZXh0cmVnaW9uOjkzYjViZGEwODhlZDRlYWViNzgzYjVlNTQ3YmRmMDkzXzIyODY_21983b8a-9143-41b5-8a54-0ca8a4b6b3b3">33</ix:nonFraction>% of the Company's net product sales for the year ended December 31, 2022.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The Company purchases XHANCE and its components from several third-party suppliers and manufacturing partners, certain of which are available through a single source. Although the Company could obtain each of these components from alternative third-party suppliers, it would need to qualify and obtain FDA approval for another supplier as a source for each such component.  The Company has initiated the process of qualifying an alternate third-party supplier for select components of XHANCE.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:107%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Alternate third party suppliers of XHANCE components are subject to qualification and approval from the FDA.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDIvZnJhZzo5M2I1YmRhMDg4ZWQ0ZWFlYjc4M2I1ZTU0N2JkZjA5My90ZXh0cmVnaW9uOjkzYjViZGEwODhlZDRlYWViNzgzYjVlNTQ3YmRmMDkzXzI1MDE3_a1a8bcc4-117c-446b-8eda-1ff49323f6d3" continuedAt="ic56dc4a5febc4d76a5c0c742dc9f1690" escape="true">Cash and cash equivalents</ix:nonNumeric></span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ic56dc4a5febc4d76a5c0c742dc9f1690">All highly liquid investments purchased with an original maturity date of three months or less at the date of purchase are considered to be cash equivalents. The Company maintains its cash and cash equivalent balances at foreign and domestic financial institutions.</ix:continuation> Bank deposits with Norwegian banks are insured up to approximately 2,000 Norwegian krone by the Norwegian Banks' Guarantee Fund. Bank deposits with US banks are insured up to $250 by the Federal Deposits Insurance Corporation. The Company had uninsured cash balances of $<ix:nonFraction unitRef="usd" contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231" decimals="-3" name="us-gaap:CashUninsuredAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDIvZnJhZzo5M2I1YmRhMDg4ZWQ0ZWFlYjc4M2I1ZTU0N2JkZjA5My90ZXh0cmVnaW9uOjkzYjViZGEwODhlZDRlYWViNzgzYjVlNTQ3YmRmMDkzXzM1MDY_d671709c-0050-4c36-b675-fd93b2d9e2a1">92,988</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="id970dfd2674c4d6b895febb9c14d0fd1_I20211231" decimals="-3" name="us-gaap:CashUninsuredAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDIvZnJhZzo5M2I1YmRhMDg4ZWQ0ZWFlYjc4M2I1ZTU0N2JkZjA5My90ZXh0cmVnaW9uOjkzYjViZGEwODhlZDRlYWViNzgzYjVlNTQ3YmRmMDkzXzM1MTM_b5fb02d0-cfe8-4d53-a274-80d13b3fd616">109,017</ix:nonFraction> at December 31, 2022 and 2021, respectively.</span></div><ix:nonNumeric contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDIvZnJhZzo5M2I1YmRhMDg4ZWQ0ZWFlYjc4M2I1ZTU0N2JkZjA5My90ZXh0cmVnaW9uOjkzYjViZGEwODhlZDRlYWViNzgzYjVlNTQ3YmRmMDkzXzI1MDA3_65e78607-2919-4a09-9514-f456808a84da" continuedAt="i2014b52673374dfcb5cfefe984268ee9" escape="true"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair value of financial instruments</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures certain assets and liabilities at fair value, which is defined as the price that would be received to sell an asset or paid to transfer a liability (the exit price) in an orderly transaction between market participants at the measurement date. The FASB accounting guidance outlines a valuation framework and creates a fair value hierarchy in order to increase the consistency and comparability of fair value measurements and the related disclosures. In determining fair value, the Company uses quoted prices and observable inputs. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from independent sources. The fair value hierarchy is broken down into three levels based on the source of the inputs as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;1&#160;&#8212; Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;2&#160;&#8212; Valuations based on observable inputs (other than Level&#160;1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;3&#160;&#8212; Valuations based on inputs that are unobservable and models that are significant to the overall fair value measurement.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">At December 31, 2022 and 2021, the Company's financial instruments included cash and cash equivalents, accounts receivable, grants receivable, accounts payable, accrued expenses and certain liability classified warrants. The carrying amounts reported in the Company's financial statements for cash and cash equivalents, accounts receivable, grants receivable, accounts payable and accrued expenses approximates their respective fair values because of the short-term nature of these instruments. In addition, at December 31, 2022, the Company believed </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:112.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OptiNose,&#160;Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements (Continued)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div></div><ix:continuation id="i641d4634bc3142e2a837f6dcf5a87e4d" continuedAt="id2d6248bf20e419a9364e7ee078d0acb"><ix:continuation id="i2014b52673374dfcb5cfefe984268ee9"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">the carrying value of debt approximates fair value as the interest rates were reflective of the rate the Company could obtain on debt with similar terms and conditions. At December 31, 2022 and 2021, there were no financial assets or liabilities measured at fair value on a recurring basis other than the liability classified warrants shown below.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2022, the Company issued warrants in connection with the a public offering. Pursuant to the terms of the warrant agreement, the Company could be required to settle the warrants in cash in the event of an acquisition of the Company and, as a result, the warrants are required to be measured at fair value and reported as liability in the consolidated balance sheet. The Company recorded the fair value of the warrants upon issuance using a Monte Carlo simulation and is required to revalue the warrants at each reporting date with any changes in fair value recorded on our statement of operations. The valuation of the warrants is considered under Level 3 of the fair value hierarchy due to the need to use assumptions in the valuation that are both significant to the fair value measurement and unobservable. The change in the fair value of the Level 3 warrants liabilities is reflected in the statement of operations for the years ended December 31, 2022.</span></div></ix:continuation><ix:nonNumeric contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" name="us-gaap:TradeAndOtherAccountsReceivablePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDIvZnJhZzo5M2I1YmRhMDg4ZWQ0ZWFlYjc4M2I1ZTU0N2JkZjA5My90ZXh0cmVnaW9uOjkzYjViZGEwODhlZDRlYWViNzgzYjVlNTQ3YmRmMDkzXzI1MDI5_ac9368c3-1072-42f0-987a-88eee3ae2777" escape="true"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts receivable</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable primarily relates to amounts due from customers, which are typically due within 31 to 61 days. The Company analyzes accounts that are past due for collectability. There was <ix:nonFraction unitRef="usd" contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231" decimals="INF" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDIvZnJhZzo5M2I1YmRhMDg4ZWQ0ZWFlYjc4M2I1ZTU0N2JkZjA5My90ZXh0cmVnaW9uOjkzYjViZGEwODhlZDRlYWViNzgzYjVlNTQ3YmRmMDkzXzQ5NDc4MDIzNjY0Nzk_5fca00a5-ad3a-410d-860b-d2ee3eee009c">no</ix:nonFraction> allowance for doubtful accounts related to customers subject to credit risk at December 31, 2022. The Company recognized an allowance for doubtful accounts related to customers subject to credit risk of $<ix:nonFraction unitRef="usd" contextRef="id970dfd2674c4d6b895febb9c14d0fd1_I20211231" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDIvZnJhZzo5M2I1YmRhMDg4ZWQ0ZWFlYjc4M2I1ZTU0N2JkZjA5My90ZXh0cmVnaW9uOjkzYjViZGEwODhlZDRlYWViNzgzYjVlNTQ3YmRmMDkzXzYwOTE_11887530-df85-4a93-bffb-e998d163116f">444</ix:nonFraction> at December 31, 2021. The accounts receivable balance at December 31, 2021 on the accompanying balance sheet is net of the allowance.</span></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" name="us-gaap:InventoryPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDIvZnJhZzo5M2I1YmRhMDg4ZWQ0ZWFlYjc4M2I1ZTU0N2JkZjA5My90ZXh0cmVnaW9uOjkzYjViZGEwODhlZDRlYWViNzgzYjVlNTQ3YmRmMDkzXzI1MDA4_a1b44337-a224-43d3-8e2a-38d4ab8da344" continuedAt="i8dad1e0aa6b845768f6e665ade4ca177" escape="true">Inventory </ix:nonNumeric></span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i8dad1e0aa6b845768f6e665ade4ca177">Inventories are stated at the lower of cost or net realizable value. Costs of inventories, which include amounts related to materials and manufacturing overhead, are determined on a first-in, first-out basis. An assessment of the recoverability of capitalized inventory is performed during each reporting period and any excess and obsolete inventories are written down to their estimated net realizable value in the period in which the impairment is first identified.</ix:continuation> </span></div><ix:nonNumeric contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDIvZnJhZzo5M2I1YmRhMDg4ZWQ0ZWFlYjc4M2I1ZTU0N2JkZjA5My90ZXh0cmVnaW9uOjkzYjViZGEwODhlZDRlYWViNzgzYjVlNTQ3YmRmMDkzXzI1MDE0_1d4c4084-8c02-410e-bfe6-2dd5910dcd50" escape="true"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and equipment</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment is recorded at cost less accumulated depreciation. Significant additions or improvements are capitalized and expenditures for repairs and maintenance are charged to expense as incurred. Gains and losses on disposal of assets are included in the consolidated statements of operations. Depreciation is calculated on a straight-line basis over the estimated useful lives of the respective assets.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><ix:nonNumeric contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDIvZnJhZzo5M2I1YmRhMDg4ZWQ0ZWFlYjc4M2I1ZTU0N2JkZjA5My90ZXh0cmVnaW9uOjkzYjViZGEwODhlZDRlYWViNzgzYjVlNTQ3YmRmMDkzXzI1MDA5_99d53f5b-4b4a-4ea8-84b2-bc1ba1c2a8b2" continuedAt="if6f03fedb95c4a6ca3e61668bbbcde16" escape="true"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated useful lives of property and equipment are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:54.031%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.457%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.603%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.603%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.607%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="21" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i096da31e1c4b4962a9749727b86a9251_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDIvZnJhZzo5M2I1YmRhMDg4ZWQ0ZWFlYjc4M2I1ZTU0N2JkZjA5My90YWJsZTo4ODQyNjI5ZDUxNmI0MTg3OGQ0YjNjZmE3NDNmZDI4MS90YWJsZXJhbmdlOjg4NDI2MjlkNTE2YjQxODc4ZDRiM2NmYTc0M2ZkMjgxXzAtMS0xLTEtNTgzNzIvdGV4dHJlZ2lvbjpiOTUzMjE2NjkzMTI0MTY3YjAxMGUyMTA2NzNlZDJmZl80_1763b6af-113b-47d3-b538-9ca3f8dbad9d">2</ix:nonNumeric>-<ix:nonNumeric contextRef="i51129fc2a039416488ae6cf33f207331_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDIvZnJhZzo5M2I1YmRhMDg4ZWQ0ZWFlYjc4M2I1ZTU0N2JkZjA5My90YWJsZTo4ODQyNjI5ZDUxNmI0MTg3OGQ0YjNjZmE3NDNmZDI4MS90YWJsZXJhbmdlOjg4NDI2MjlkNTE2YjQxODc4ZDRiM2NmYTc0M2ZkMjgxXzAtMS0xLTEtNTgzNzIvdGV4dHJlZ2lvbjpiOTUzMjE2NjkzMTI0MTY3YjAxMGUyMTA2NzNlZDJmZl83_3d8b19a3-5fde-4a0c-b696-f34df2983381">3</ix:nonNumeric> years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Software</span></td><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6dceb2856a724c7cb132bb0edc4d035c_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDIvZnJhZzo5M2I1YmRhMDg4ZWQ0ZWFlYjc4M2I1ZTU0N2JkZjA5My90YWJsZTo4ODQyNjI5ZDUxNmI0MTg3OGQ0YjNjZmE3NDNmZDI4MS90YWJsZXJhbmdlOjg4NDI2MjlkNTE2YjQxODc4ZDRiM2NmYTc0M2ZkMjgxXzEtMS0xLTEtNTgzNzIvdGV4dHJlZ2lvbjpiMDMzYjFhYzFmODQ0ZjM4YTQ5ZDBhMWYzNGZjMjY5OV80_3f95017b-cc74-4782-917e-4e3ee469e5c6">3</ix:nonNumeric> years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Machinery &amp; production equipment</span></td><td colspan="21" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9941fdaa85054a3a9340530990beb6a2_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDIvZnJhZzo5M2I1YmRhMDg4ZWQ0ZWFlYjc4M2I1ZTU0N2JkZjA5My90YWJsZTo4ODQyNjI5ZDUxNmI0MTg3OGQ0YjNjZmE3NDNmZDI4MS90YWJsZXJhbmdlOjg4NDI2MjlkNTE2YjQxODc4ZDRiM2NmYTc0M2ZkMjgxXzItMS0xLTEtNTgzNzIvdGV4dHJlZ2lvbjpjMmExNDlmYzE2NmM0NmUzODU4NDg1M2UyMmJlZDNhMl80_38f6c67f-19b8-4c10-b4ff-fef199424fb2">5</ix:nonNumeric>-<ix:nonNumeric contextRef="i84fb7ecf7b8a41a6af4d113e7add2b46_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDIvZnJhZzo5M2I1YmRhMDg4ZWQ0ZWFlYjc4M2I1ZTU0N2JkZjA5My90YWJsZTo4ODQyNjI5ZDUxNmI0MTg3OGQ0YjNjZmE3NDNmZDI4MS90YWJsZXJhbmdlOjg4NDI2MjlkNTE2YjQxODc4ZDRiM2NmYTc0M2ZkMjgxXzItMS0xLTEtNTgzNzIvdGV4dHJlZ2lvbjpjMmExNDlmYzE2NmM0NmUzODU4NDg1M2UyMmJlZDNhMl83_d80d435c-0e6e-4fa2-bd30-981d4c6644ef">10</ix:nonNumeric> years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Furniture &amp; fixtures</span></td><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib7a618edb3b34dc88ad18ed5ca86c14d_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDIvZnJhZzo5M2I1YmRhMDg4ZWQ0ZWFlYjc4M2I1ZTU0N2JkZjA5My90YWJsZTo4ODQyNjI5ZDUxNmI0MTg3OGQ0YjNjZmE3NDNmZDI4MS90YWJsZXJhbmdlOjg4NDI2MjlkNTE2YjQxODc4ZDRiM2NmYTc0M2ZkMjgxXzMtMS0xLTEtNTgzNzIvdGV4dHJlZ2lvbjozMTM0YWVkMGVjYzc0YTg5OTljOTU5YzEyNGMyNzkyMF80_422de7bf-6659-48e4-9efe-fc1fab821ec9">3</ix:nonNumeric>-<ix:nonNumeric contextRef="ia91696961e0b4593a33c03f9b00c5dec_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDIvZnJhZzo5M2I1YmRhMDg4ZWQ0ZWFlYjc4M2I1ZTU0N2JkZjA5My90YWJsZTo4ODQyNjI5ZDUxNmI0MTg3OGQ0YjNjZmE3NDNmZDI4MS90YWJsZXJhbmdlOjg4NDI2MjlkNTE2YjQxODc4ZDRiM2NmYTc0M2ZkMjgxXzMtMS0xLTEtNTgzNzIvdGV4dHJlZ2lvbjozMTM0YWVkMGVjYzc0YTg5OTljOTU5YzEyNGMyNzkyMF83_08970b6b-71a5-40c0-bfd9-91a1abdcaf60">5</ix:nonNumeric> years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="21" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shorter of lease term or useful life</span></td></tr></table></ix:nonNumeric></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDIvZnJhZzo5M2I1YmRhMDg4ZWQ0ZWFlYjc4M2I1ZTU0N2JkZjA5My90ZXh0cmVnaW9uOjkzYjViZGEwODhlZDRlYWViNzgzYjVlNTQ3YmRmMDkzXzI1MDQw_a8d72945-49cb-43b7-bc04-86f9f361109e" continuedAt="id822569c1433411198a1cc5d0b56b7f5" escape="true">Long lived assets</ix:nonNumeric></span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="id822569c1433411198a1cc5d0b56b7f5">Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future net cash flows expected to be generated. Impairment charges are recognized at the amount by which the carrying amount of an asset exceeds the fair value of the asset. Assets to be disposed of are reported at the lower of the carrying amount or the fair value less costs to sell.</ix:continuation> The Company did <ix:nonFraction unitRef="usd" contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" decimals="INF" name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDIvZnJhZzo5M2I1YmRhMDg4ZWQ0ZWFlYjc4M2I1ZTU0N2JkZjA5My90ZXh0cmVnaW9uOjkzYjViZGEwODhlZDRlYWViNzgzYjVlNTQ3YmRmMDkzXzc4MDc_25af8a9d-0cbb-49be-a5a8-85958e521b66"><ix:nonFraction unitRef="usd" contextRef="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231" decimals="INF" name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDIvZnJhZzo5M2I1YmRhMDg4ZWQ0ZWFlYjc4M2I1ZTU0N2JkZjA5My90ZXh0cmVnaW9uOjkzYjViZGEwODhlZDRlYWViNzgzYjVlNTQ3YmRmMDkzXzc4MDc_6790e29f-0289-4458-bb6e-3cd3eb5f850c">no</ix:nonFraction></ix:nonFraction>t recognize any impairment or disposition of long-lived assets for the years ended December 31, 2022 and 2021.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" name="us-gaap:LesseeLeasesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDIvZnJhZzo5M2I1YmRhMDg4ZWQ0ZWFlYjc4M2I1ZTU0N2JkZjA5My90ZXh0cmVnaW9uOjkzYjViZGEwODhlZDRlYWViNzgzYjVlNTQ3YmRmMDkzXzQ5NDc4MDIzNzcyMDQ_f33d7bf9-d72e-47de-b059-8267f3ecc499" continuedAt="i86c253ca1c5f4ca9ac29707ff6c38c95" escape="true">Leases </ix:nonNumeric></span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:112.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OptiNose,&#160;Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements (Continued)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div></div><ix:continuation id="id2d6248bf20e419a9364e7ee078d0acb" continuedAt="ia6ca7bcc1d414d858dc8ba160c5e1409"><ix:continuation id="i86c253ca1c5f4ca9ac29707ff6c38c95"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the terms of the arrangement. The Company accounts for a contract as a lease when it has the right to control the asset for a period of time while obtaining substantially all of the asset&#8217;s economic benefits. The Company determines the initial classification and measurement of its operating right-of-use (&#8220;ROU&#8221;) assets and operating lease liabilities at the lease commencement date, and thereafter if modified.  The lease term includes any renewal options that the Company is reasonably assured to exercise. The Company&#8217;s policy is to not record leases with a lease term of 12 months or less on its balance sheets. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The ROU asset represents the right to use the leased asset for the lease term. The lease liability represents the present value of the lease payments under the lease. The present value of lease payments is determined by using the interest rate implicit in the lease, if that rate is readily determinable; otherwise, the Company uses its estimated secured incremental borrowing rate for that lease term.  Lease expense for operating leases is recognized on a straight-line basis over the reasonably assured lease term based on the total lease payments and is included in operating expense in the statements of operations. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Payments due under each lease agreement include fixed and variable payments. Variable payments relate to the Company&#8217;s share of the lessor&#8217;s operating costs associated with the underlying asset and are recognized when the event on which those payments are assessed occurs. Variable payments have been excluded from the lease liability and associated right-of-use asset. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:103%">The interest rate implicit in lease agreements is typically not readily determinable, and as such, the Company utilizes the incremental borrowing rate to calculate lease liabilities, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment.</span></div></ix:continuation><ix:nonNumeric contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDIvZnJhZzo5M2I1YmRhMDg4ZWQ0ZWFlYjc4M2I1ZTU0N2JkZjA5My90ZXh0cmVnaW9uOjkzYjViZGEwODhlZDRlYWViNzgzYjVlNTQ3YmRmMDkzXzI1MDI1_14cb746c-cd03-4857-975f-1800756ab2e4" continuedAt="ic80dd4a59639408cadeca93cf91c604d" escape="true"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net product revenues</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for revenue in accordance with ASC Topic 606, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ASC 606), which was adopted on January 1, 2018. The Company performs the following five steps to recognize revenue under ASC 606: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only recognizes revenue when it is probable that it will collect the consideration to which it is entitled in exchange for the goods or services that will be transferred to the customer. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company sells XHANCE to preferred pharmacy network partners and wholesalers in the US (collectively, Customers). These Customers subsequently resell the Company&#8217;s products to healthcare providers, patients and other retail pharmacies. In addition to agreements with Customers, the Company enters into arrangements with healthcare providers and payors that provide for government-mandated and/or privately-negotiated rebates, chargebacks and discounts for the purchase of the Company&#8217;s products.  </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue from XHANCE sales at the point Customers obtain control of the product, which generally occurs upon delivery. The transaction price that is recognized as revenue for products includes an estimate of variable consideration which is described below. Payment terms with Customers do not exceed one year and, therefore, the Company does not account for a financing component in its arrangements. The Company expenses incremental costs of obtaining a contract with a Customer (for example, sales commissions) when incurred as the period of benefit is less than one year. Shipping and handling costs for product shipments to Customers are recorded as selling, general and administrative expenses.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Transaction Price, including Estimates of Variable Consideration</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from products is recognized at the estimated net sales price (transaction price), which includes estimates of variable consideration. The Company includes estimated amounts in the transaction price to the extent it is determined probable that a significant reversal of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is resolved. The Company&#8217;s estimates of variable consideration and determination of whether to include estimated amounts in the transaction price are based largely on an assessment </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:112.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OptiNose,&#160;Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements (Continued)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div></div><ix:continuation id="ia6ca7bcc1d414d858dc8ba160c5e1409" continuedAt="if6dab80ad3b44e23b03fdece79d23a66"><ix:continuation id="ic80dd4a59639408cadeca93cf91c604d" continuedAt="i09164dd28395423a9bc7f453a1bf03ec"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of its anticipated performance and all information (historical, current and forecasted) that is reasonably available.  The components of the Company's variable consideration include the following:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline">Provider Chargebacks and Discounts.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chargebacks for fees and discounts to providers represent the estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list prices charged to Customers who directly purchase the product from the Company.&#160;Customers charge the Company for the difference between what they pay for the product and the ultimate selling price to the qualified healthcare providers.&#160;These components of variable consideration are established in the same period that the related revenue is recognized, resulting in a reduction of product revenue and accounts receivable.&#160;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt;text-decoration:underline">Trade Discounts and Allowances.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  The Company generally provides Customers with discounts that include incentive fees which are explicitly stated in the Company&#8217;s contracts. These discounts are recorded as a reduction of revenue and accounts receivable in the period in which the related product revenue is recognized. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt;text-decoration:underline">Product Returns.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Consistent with industry practice, the Company has a product returns policy that provides Customers a right of return for product purchased within a specified period prior to and subsequent to the product&#8217;s expiration date. The Company estimates the amount of its products that may be returned and presents this amount as a reduction of revenue in the period the related product revenue is recognized, in addition to establishing a current liability. The Company considers several factors in the estimation process, including expiration dates of product shipped to Customers, inventory levels within the distribution channel, product shelf life, prescription trends and other relevant factors.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt;text-decoration:underline">Government Rebates</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The Company is subject to discount obligations under state Medicaid programs and Medicare. Reserves related to these discount obligations are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability. The Company&#8217;s liability for these rebates consists of estimates of claims for the current reporting period and estimated future claims that will be made for product that has been recognized as revenue but remains in the distribution channel inventories at the end of the reporting period.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt;text-decoration:underline">Payor Rebates.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  The Company contracts with certain third-party payors, primarily health insurance companies and pharmacy benefit managers, for the payment of rebates with respect to utilization of its products. These rebates are based on contractual percentages applied to the amount of product prescribed to patients who are covered by the plan or the organization with which it contracts. The Company estimates these rebates and records such estimates in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt;text-decoration:underline">Patient Assistance.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Other programs that the Company offers include voluntary co-pay patient assistance programs intended to provide financial assistance to eligible patients with prescription drug co-payments required by payors and coupon programs for cash payors.&#160;The calculation of the current liability for this assistance is based on an estimate of claims and the cost per claim that the Company expects to receive associated with product that has been recognized as revenue but remains in the distribution channel inventories at the end of each reporting period.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt;text-decoration:underline">Distribution and Other Fees</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We pay distribution and other fees to certain customers in connection with the sales of our products. We record distribution and other fees paid to our customers as a reduction of revenue, unless the payment is for a distinct good or service from the customer and we can reasonably estimate the fair value of the goods or services received. If both conditions are met, we record the consideration paid to the customer as an operating expense. These costs are typically known at the time of sale, resulting in minimal adjustments subsequent to the period of sale.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Licensing Revenues</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a license agreement with Currax Pharmaceuticals LLC (Currax) (</span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_160">Note </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_160">9</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). This license agreement provides for exclusive licensed rights to certain intellectual property, a non-refundable up-front payment, potential </span></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:112.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OptiNose,&#160;Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements (Continued)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div></div><ix:continuation id="if6dab80ad3b44e23b03fdece79d23a66" continuedAt="icc4075b0233c471eafa9fcd18b164d23"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i09164dd28395423a9bc7f453a1bf03ec">milestone payment(s) and potential royalty payment(s). The Company analyzed the performance obligations under the license agreement, the consideration received to date and the consideration the Company could receive in the future as part of its analysis related to ASC 606.</ix:continuation> There was <ix:nonFraction unitRef="usd" contextRef="ifb05b53856a04e6fb8d77b2615fef7b5_D20220101-20221231" decimals="INF" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDIvZnJhZzo5M2I1YmRhMDg4ZWQ0ZWFlYjc4M2I1ZTU0N2JkZjA5My90ZXh0cmVnaW9uOjkzYjViZGEwODhlZDRlYWViNzgzYjVlNTQ3YmRmMDkzXzY1OTcwNjk4MDgxNjI_7112d885-ac27-493f-a496-ff95dcc4115b">no</ix:nonFraction> licensing revenue recognized during the year ended December 31, 2022. The Company recognized $<ix:nonFraction unitRef="usd" contextRef="i0a537887f3924b21a34b339e3a39c085_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDIvZnJhZzo5M2I1YmRhMDg4ZWQ0ZWFlYjc4M2I1ZTU0N2JkZjA5My90ZXh0cmVnaW9uOjkzYjViZGEwODhlZDRlYWViNzgzYjVlNTQ3YmRmMDkzXzE1Mzgw_adca1f7b-00ac-40f9-aedc-9b9d85c6e1c7">1,000</ix:nonFraction> as licensing revenue during the year ended December 31, 2021.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" name="us-gaap:AdvertisingCostsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDIvZnJhZzo5M2I1YmRhMDg4ZWQ0ZWFlYjc4M2I1ZTU0N2JkZjA5My90ZXh0cmVnaW9uOjkzYjViZGEwODhlZDRlYWViNzgzYjVlNTQ3YmRmMDkzXzI1MDQx_afb8ff27-c186-4cd5-8897-2275c5704aa5" continuedAt="ic419c44e5ba34d84a44de544ba3e284f" escape="true">Advertising expenses</ix:nonNumeric></span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ic419c44e5ba34d84a44de544ba3e284f">The Company expenses the costs of advertising, including promotional expenses, as incurred.</ix:continuation>  Advertising expenses were $<ix:nonFraction unitRef="usd" contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" decimals="-3" name="us-gaap:AdvertisingExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDIvZnJhZzo5M2I1YmRhMDg4ZWQ0ZWFlYjc4M2I1ZTU0N2JkZjA5My90ZXh0cmVnaW9uOjkzYjViZGEwODhlZDRlYWViNzgzYjVlNTQ3YmRmMDkzXzE1NTkz_e5cf7dd2-7941-4c67-8607-94e71459efa1">16,575</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231" decimals="-3" name="us-gaap:AdvertisingExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDIvZnJhZzo5M2I1YmRhMDg4ZWQ0ZWFlYjc4M2I1ZTU0N2JkZjA5My90ZXh0cmVnaW9uOjkzYjViZGEwODhlZDRlYWViNzgzYjVlNTQ3YmRmMDkzXzE1NjAw_ec25a8a4-a5af-42cc-93fc-48536d5488ed">15,638</ix:nonFraction> for the years ended December 31, 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021, respectively.</span></div><ix:nonNumeric contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDIvZnJhZzo5M2I1YmRhMDg4ZWQ0ZWFlYjc4M2I1ZTU0N2JkZjA5My90ZXh0cmVnaW9uOjkzYjViZGEwODhlZDRlYWViNzgzYjVlNTQ3YmRmMDkzXzI1MDM4_955c1806-4ec2-4a2d-88d1-61691928e44c" escape="true"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and development</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred. Research and development costs consist primarily of device development, clinical trial related costs and regulatory related costs. The Company enters into agreements with contract research organizations (CROs) to facilitate, coordinate and perform agreed upon research and development activities for the Company's clinical trials. These CRO contracts typically call for the payment of fees for services at the initiation of the contract and/or upon the achievement of certain clinical trial milestones. The Company prepays certain CRO fees whereby the prepayments are recorded as a current or non-current prepaid asset and are amortized into research and development expense over the period of time the contracted research and development services were performed. The Company's CRO contracts generally also include other fees such as project management and pass through fees whereby the Company expenses these costs as incurred, using the Company's best estimate. Pass through fees include, but are not limited to, regulatory expenses, investigator fees, travel costs, and other miscellaneous costs. Pass through fees incurred are based on the amount of work completed for the clinical trials and are monitored through reporting provided by the Company's CROs.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDIvZnJhZzo5M2I1YmRhMDg4ZWQ0ZWFlYjc4M2I1ZTU0N2JkZjA5My90ZXh0cmVnaW9uOjkzYjViZGEwODhlZDRlYWViNzgzYjVlNTQ3YmRmMDkzXzI1MDE5_3465a9b4-c0d3-443e-b60c-cffbd1621046" escape="true"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-based compensation</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures and recognizes compensation expense for all stock options and restricted stock units (RSUs) awarded to employees and non-employees and shares issued under the employee stock purchase plan based on the estimated fair value of the awards on the respective grant dates. The Company uses the Black-Scholes option pricing model to value its time-based and performance-based stock options and shares issued under the employee stock purchase plan. The Company uses a Monte Carlo simulation to value its market-based stock options.  RSUs are valued at the fair market value per share of the Company's common stock on the date of grant. The Company recognizes compensation expense for time-based awards on a straight-line basis over the requisite service period, which is generally the vesting period of the award. The Company recognizes compensation expense for performance-based awards when the performance condition is probable of achievement. The Company recognizes compensation expense for market-based awards over the derived service period, estimated at the time of the grant. The Company recognizes expense for The Company accounts for forfeitures of stock option awards as they occur.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimating the fair value of options and shares issued under the employee stock purchase plan requires the input of subjective assumptions, including the estimated fair value of the Company's common stock, the expected life of the options, stock price volatility, the risk-free interest rate and expected dividends. The assumptions used in the Company's Black-Scholes option-pricing model and Monte Carlo simulation represent management's best estimates and involve a number of variables, uncertainties and assumptions and the application of management's judgment, as they are inherently subjective.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDIvZnJhZzo5M2I1YmRhMDg4ZWQ0ZWFlYjc4M2I1ZTU0N2JkZjA5My90ZXh0cmVnaW9uOjkzYjViZGEwODhlZDRlYWViNzgzYjVlNTQ3YmRmMDkzXzI1MDIw_ef9db5ad-637d-485c-839b-6ea6b9b31a85" continuedAt="ifb0cfd5a4c6d4e149c5659d7c8c0910d" escape="true"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income taxes</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes are accounted for under the asset and liability method. The Company recognizes deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of the Company's assets and liabilities and the expected benefits of net operating loss carryforwards. The impact of changes in tax rates and laws on deferred taxes, if any, applied during the period in which temporary differences are expected to be settled, is reflected in the Company's financial statements in the period of enactment. The measurement of deferred tax assets is reduced, if necessary, if, based on the weight of the evidence, it is more likely than not that some, or </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:112.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OptiNose,&#160;Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements (Continued)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div></div><ix:continuation id="icc4075b0233c471eafa9fcd18b164d23"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ifb0cfd5a4c6d4e149c5659d7c8c0910d">all, of the deferred tax assets will not be realized. As of December 31, 2022 and 2021, the Company concluded that a full valuation allowance was necessary for all of its net deferred tax assets. The Company had no amounts recorded for uncertain tax positions, interest or penalties in the accompanying consolidated financial statements.</ix:continuation></span></div><ix:nonNumeric contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDIvZnJhZzo5M2I1YmRhMDg4ZWQ0ZWFlYjc4M2I1ZTU0N2JkZjA5My90ZXh0cmVnaW9uOjkzYjViZGEwODhlZDRlYWViNzgzYjVlNTQ3YmRmMDkzXzI1MDA0_7f9bfd99-9c4d-4567-94df-5164e1a2a40e" escape="true"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net income (loss) per common share</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net income (loss) per common share is determined by dividing net income (loss) applicable to common stockholders by the weighted average common shares outstanding during the period. For the years ended December 31, 2022 and 2021, outstanding common stock options and common stock warrants have been excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive. Therefore, the weighted average shares used to calculate both basic and diluted net loss per share are the same.</span></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt"><ix:nonNumeric contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDIvZnJhZzo5M2I1YmRhMDg4ZWQ0ZWFlYjc4M2I1ZTU0N2JkZjA5My90ZXh0cmVnaW9uOjkzYjViZGEwODhlZDRlYWViNzgzYjVlNTQ3YmRmMDkzXzI1MDI4_91a39996-035b-4fba-a74d-b4cc9c531c1e" escape="true"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Diluted net loss per common share for the periods presented does not reflect the following potential common shares, as the effect would be antidilutive:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.092%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.576%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i12305500621f4b93b85c82aa1da3b266_D20220101-20221231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDIvZnJhZzo5M2I1YmRhMDg4ZWQ0ZWFlYjc4M2I1ZTU0N2JkZjA5My90YWJsZTo0ZGQ0Yzg0MGYyMGY0YmJhYTg4YmUyN2ZlZDNjNGNmNS90YWJsZXJhbmdlOjRkZDRjODQwZjIwZjRiYmFhODhiZTI3ZmVkM2M0Y2Y1XzItMi0xLTEtNTgzNzI_d31f1028-264c-49c0-a4d6-660925336022">9,364,070</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4915e82cfd2f4c5f8a1d6e09c40ecdef_D20210101-20211231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDIvZnJhZzo5M2I1YmRhMDg4ZWQ0ZWFlYjc4M2I1ZTU0N2JkZjA5My90YWJsZTo0ZGQ0Yzg0MGYyMGY0YmJhYTg4YmUyN2ZlZDNjNGNmNS90YWJsZXJhbmdlOjRkZDRjODQwZjIwZjRiYmFhODhiZTI3ZmVkM2M0Y2Y1XzItNC0xLTEtNTgzNzI_31648c53-349b-4feb-80c2-5ad798c9cc14">7,958,781</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id7cd0da0eea14521a316e6ae095e19a2_D20220101-20221231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDIvZnJhZzo5M2I1YmRhMDg4ZWQ0ZWFlYjc4M2I1ZTU0N2JkZjA5My90YWJsZTo0ZGQ0Yzg0MGYyMGY0YmJhYTg4YmUyN2ZlZDNjNGNmNS90YWJsZXJhbmdlOjRkZDRjODQwZjIwZjRiYmFhODhiZTI3ZmVkM2M0Y2Y1XzMtMi0xLTEtNTgzNzI_13537c67-d518-43fd-8cfb-29916b49d092">1,477,660</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia3b834ad368d4672b0476f096fe3f60f_D20210101-20211231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDIvZnJhZzo5M2I1YmRhMDg4ZWQ0ZWFlYjc4M2I1ZTU0N2JkZjA5My90YWJsZTo0ZGQ0Yzg0MGYyMGY0YmJhYTg4YmUyN2ZlZDNjNGNmNS90YWJsZXJhbmdlOjRkZDRjODQwZjIwZjRiYmFhODhiZTI3ZmVkM2M0Y2Y1XzMtNC0xLTEtNTgzNzI_c6cc1517-2e28-4caa-b0a3-981cf52d0af0">1,959,358</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7ac7a3a3a80b4d7b8a3d2ffc47f38e20_D20220101-20221231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDIvZnJhZzo5M2I1YmRhMDg4ZWQ0ZWFlYjc4M2I1ZTU0N2JkZjA5My90YWJsZTo0ZGQ0Yzg0MGYyMGY0YmJhYTg4YmUyN2ZlZDNjNGNmNS90YWJsZXJhbmdlOjRkZDRjODQwZjIwZjRiYmFhODhiZTI3ZmVkM2M0Y2Y1XzQtMi0xLTEtNTgzNzI_fc448ef4-cb69-4e35-871c-942f2de33b03">32,768,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i930ccddc00c24cfd9e7d29dd5a34e0aa_D20210101-20211231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDIvZnJhZzo5M2I1YmRhMDg4ZWQ0ZWFlYjc4M2I1ZTU0N2JkZjA5My90YWJsZTo0ZGQ0Yzg0MGYyMGY0YmJhYTg4YmUyN2ZlZDNjNGNmNS90YWJsZXJhbmdlOjRkZDRjODQwZjIwZjRiYmFhODhiZTI3ZmVkM2M0Y2Y1XzQtNC0xLTEtNTgzNzI_cad6ece1-c991-4238-a68e-a837c86f01b9">2,500,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDIvZnJhZzo5M2I1YmRhMDg4ZWQ0ZWFlYjc4M2I1ZTU0N2JkZjA5My90YWJsZTo0ZGQ0Yzg0MGYyMGY0YmJhYTg4YmUyN2ZlZDNjNGNmNS90YWJsZXJhbmdlOjRkZDRjODQwZjIwZjRiYmFhODhiZTI3ZmVkM2M0Y2Y1XzYtMi0xLTEtNTgzNzI_8952d089-8711-4342-aa42-66765d821994">43,609,730</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDIvZnJhZzo5M2I1YmRhMDg4ZWQ0ZWFlYjc4M2I1ZTU0N2JkZjA5My90YWJsZTo0ZGQ0Yzg0MGYyMGY0YmJhYTg4YmUyN2ZlZDNjNGNmNS90YWJsZXJhbmdlOjRkZDRjODQwZjIwZjRiYmFhODhiZTI3ZmVkM2M0Y2Y1XzYtNC0xLTEtNTgzNzI_743a39e1-8ada-4b7c-a94e-837cb9fe6162">12,418,139</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><ix:nonNumeric contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDIvZnJhZzo5M2I1YmRhMDg4ZWQ0ZWFlYjc4M2I1ZTU0N2JkZjA5My90ZXh0cmVnaW9uOjkzYjViZGEwODhlZDRlYWViNzgzYjVlNTQ3YmRmMDkzXzI1MDIx_2467f89c-2037-47d3-a4fe-952ed5d3927a" escape="true"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent accounting pronouncements</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, the FASB issued ASU No. 2022-02, Financial Instruments - Credit Losses (Topic 326): Troubled Debt Restructurings and Vintage Disclosures. Since the issuance of ASU No. 2016-13, Financial Instruments&#8212;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, the Board has provided resources to monitor and assist stakeholders with the implementation of Topic 326. Post-Implementation Review (PIR) activities have included forming a Credit Losses Transition Resource Group, conducting outreach with stakeholders of all types, developing educational materials and staff question-and-answer guidance, conducting educational workshops, and performing an archival review of financial reports. ASU No. 2022-02 is intended to respond to feedback received during the PIR process. The new standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2022, with early adoption permitted. The Company does not expect ASU No. 2022-02 to have a significant impact on its results of operations, financial position and cash flows and related disclosures.</span></div></ix:nonNumeric></ix:continuation><div id="i451bcb3eabba4f87bdc579718207a3b8_1765"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzY1L2ZyYWc6MzgyNzViMTRmNmU2NDY1ZjlmNDQ0MmU4MzkxYzE5Y2IvdGV4dHJlZ2lvbjozODI3NWIxNGY2ZTY0NjVmOWY0NDQyZTgzOTFjMTljYl81NDk3NTU4MTU0NDQ3_56b97942-b9bc-479a-95c9-1a8da301990a" continuedAt="ib764f2cc885f4d28b6346a458dc7fcbc" escape="true"><ix:nonNumeric contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzY1L2ZyYWc6MzgyNzViMTRmNmU2NDY1ZjlmNDQ0MmU4MzkxYzE5Y2IvdGV4dHJlZ2lvbjozODI3NWIxNGY2ZTY0NjVmOWY0NDQyZTgzOTFjMTljYl81NDk3NTU4MTU0NDQ4_598e6f1f-f17a-47eb-a1a8-a358961cdc18" continuedAt="i9345a7071a1e448490d84d99fbdbd228" escape="true">Fair Value Measurements</ix:nonNumeric></ix:nonNumeric></span></div><ix:continuation id="ib764f2cc885f4d28b6346a458dc7fcbc" continuedAt="iaf954126fa5f41c4983337cf38f87c18"><ix:continuation id="i9345a7071a1e448490d84d99fbdbd228" continuedAt="i1a50360cbfcc402f9d85e8e4d08d0109"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Assets and Liabilities Measured at Fair Value on a Recurring Basis</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company applies the guidance in ASC 820, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to account for financial assets and liabilities measured on a recurring basis. Fair value is measured as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that is determined based on assumptions that market participants would use in pricing an asset or liability.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses a fair value hierarchy, which distinguishes between assumptions based on market data (observable inputs) and an entity's own assumptions (unobservable inputs). The guidance requires that fair value measurements be classified and disclosed in one of the following 3 categories:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level l: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2: Quoted prices in markets that are not active or inputs which are observable, either directly or indirectly, for substantially the full te1m of the asset or liability; and</span></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:112.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OptiNose,&#160;Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements (Continued)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div></div><ix:continuation id="iaf954126fa5f41c4983337cf38f87c18" continuedAt="i8126c0f11b3640d3883741c8713470b6"><ix:continuation id="i1a50360cbfcc402f9d85e8e4d08d0109"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span><br/></span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Determining which category an asset or liability falls within the hierarchy requires significant judgment. The Company evaluates its hierarchy disclosures each reporting period. There were no transfers between Level I, 2 and 3 during the years ended December 31, 2022 and December 31, 2021.</span></div></ix:continuation><ix:nonNumeric contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzY1L2ZyYWc6MzgyNzViMTRmNmU2NDY1ZjlmNDQ0MmU4MzkxYzE5Y2IvdGV4dHJlZ2lvbjozODI3NWIxNGY2ZTY0NjVmOWY0NDQyZTgzOTFjMTljYl80OTQ3ODAyMzQwNTU2_aaf6abb4-2d9c-456b-b792-dcaee15734ac" escape="true"><ix:nonNumeric contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzY1L2ZyYWc6MzgyNzViMTRmNmU2NDY1ZjlmNDQ0MmU4MzkxYzE5Y2IvdGV4dHJlZ2lvbjozODI3NWIxNGY2ZTY0NjVmOWY0NDQyZTgzOTFjMTljYl80OTQ3ODAyMzQwNTU2_d61cd3c9-1fd6-4a20-b366-03776b13ca94" escape="true"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents the liabilities (in thousands) measured and recorded in the financial statements at fair value on a recurring basis at December 31, 2022 categorized by the level of inputs used in the valuation of each liability.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:44.635%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.252%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.417%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.252%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.417%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.252%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.417%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.258%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Warrant Liability</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231" decimals="-3" name="us-gaap:WarrantsNotSettleableInCashFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzY1L2ZyYWc6MzgyNzViMTRmNmU2NDY1ZjlmNDQ0MmU4MzkxYzE5Y2IvdGFibGU6MGY5YjJjYzE5MTEyNDcyN2ExZjEyZjViYTg2YzA5NDUvdGFibGVyYW5nZTowZjliMmNjMTkxMTI0NzI3YTFmMTJmNWJhODZjMDk0NV83LTEtMS0xLTExMDU3Mw_a57eadd8-395d-4f68-acdf-d36e7b5b70f4">21,490</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25abfe2f91764951ba1d5af64bcb7a2a_I20221231" decimals="-3" name="us-gaap:WarrantsNotSettleableInCashFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzY1L2ZyYWc6MzgyNzViMTRmNmU2NDY1ZjlmNDQ0MmU4MzkxYzE5Y2IvdGFibGU6MGY5YjJjYzE5MTEyNDcyN2ExZjEyZjViYTg2YzA5NDUvdGFibGVyYW5nZTowZjliMmNjMTkxMTI0NzI3YTFmMTJmNWJhODZjMDk0NV83LTMtMS0xLTExMDA4NQ_0f2f0807-6eeb-4097-badd-23f9e2d597f8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32cf8e8f75054575965e3fdf63fcc596_I20221231" decimals="-3" name="us-gaap:WarrantsNotSettleableInCashFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzY1L2ZyYWc6MzgyNzViMTRmNmU2NDY1ZjlmNDQ0MmU4MzkxYzE5Y2IvdGFibGU6MGY5YjJjYzE5MTEyNDcyN2ExZjEyZjViYTg2YzA5NDUvdGFibGVyYW5nZTowZjliMmNjMTkxMTI0NzI3YTFmMTJmNWJhODZjMDk0NV83LTUtMS0xLTExMDA4NQ_7605841f-3fe2-4d26-8814-b28abe0acb22">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib72acf71ad414bdb820e66430a66f4f1_I20221231" decimals="-3" name="us-gaap:WarrantsNotSettleableInCashFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzY1L2ZyYWc6MzgyNzViMTRmNmU2NDY1ZjlmNDQ0MmU4MzkxYzE5Y2IvdGFibGU6MGY5YjJjYzE5MTEyNDcyN2ExZjEyZjViYTg2YzA5NDUvdGFibGVyYW5nZTowZjliMmNjMTkxMTI0NzI3YTFmMTJmNWJhODZjMDk0NV83LTctMS0xLTExMDExMA_864b6a6c-bf0b-4411-936f-12c505767cdd">21,490</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total Liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzY1L2ZyYWc6MzgyNzViMTRmNmU2NDY1ZjlmNDQ0MmU4MzkxYzE5Y2IvdGFibGU6MGY5YjJjYzE5MTEyNDcyN2ExZjEyZjViYTg2YzA5NDUvdGFibGVyYW5nZTowZjliMmNjMTkxMTI0NzI3YTFmMTJmNWJhODZjMDk0NV84LTEtMS0xLTExMDU3Mw_414ab5bc-7905-4414-aa52-775c7cf5bc3b">21,490</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25abfe2f91764951ba1d5af64bcb7a2a_I20221231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzY1L2ZyYWc6MzgyNzViMTRmNmU2NDY1ZjlmNDQ0MmU4MzkxYzE5Y2IvdGFibGU6MGY5YjJjYzE5MTEyNDcyN2ExZjEyZjViYTg2YzA5NDUvdGFibGVyYW5nZTowZjliMmNjMTkxMTI0NzI3YTFmMTJmNWJhODZjMDk0NV84LTMtMS0xLTExMDU3Mw_ede0b701-73df-48a9-bd06-6bcac0e71d12">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32cf8e8f75054575965e3fdf63fcc596_I20221231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzY1L2ZyYWc6MzgyNzViMTRmNmU2NDY1ZjlmNDQ0MmU4MzkxYzE5Y2IvdGFibGU6MGY5YjJjYzE5MTEyNDcyN2ExZjEyZjViYTg2YzA5NDUvdGFibGVyYW5nZTowZjliMmNjMTkxMTI0NzI3YTFmMTJmNWJhODZjMDk0NV84LTUtMS0xLTExMDU3Mw_5b172c4b-768d-45ea-ad7e-6da9c078a574">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib72acf71ad414bdb820e66430a66f4f1_I20221231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzY1L2ZyYWc6MzgyNzViMTRmNmU2NDY1ZjlmNDQ0MmU4MzkxYzE5Y2IvdGFibGU6MGY5YjJjYzE5MTEyNDcyN2ExZjEyZjViYTg2YzA5NDUvdGFibGVyYW5nZTowZjliMmNjMTkxMTI0NzI3YTFmMTJmNWJhODZjMDk0NV84LTctMS0xLTExMDU3Mw_0562b0b7-63fd-472d-a17c-89e95bf65e61">21,490</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:nonNumeric><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As of December 31, 2021, the Company had no assets or liabilities measured and recorded at fair value on a recurring basis.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in Level 3 Liabilities Measured at Fair Value on a Recurring Basis</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Warrant Liability</span></div><ix:nonNumeric contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzY1L2ZyYWc6MzgyNzViMTRmNmU2NDY1ZjlmNDQ0MmU4MzkxYzE5Y2IvdGV4dHJlZ2lvbjozODI3NWIxNGY2ZTY0NjVmOWY0NDQyZTgzOTFjMTljYl80OTQ3ODAyMzQwNTU3_e4bc1699-91f1-4700-b584-6e9d6eb3c14c" escape="true"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliation of the Company's warrant liability measured at fair value on a recurring basis using unobservable inputs (Level 3) is as follows (in thousands):</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:86.528%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.272%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Warrant Liability</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance, December 31, 2021</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id970dfd2674c4d6b895febb9c14d0fd1_I20211231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzY1L2ZyYWc6MzgyNzViMTRmNmU2NDY1ZjlmNDQ0MmU4MzkxYzE5Y2IvdGFibGU6NWM3ZDZiYjczNjFkNDc5M2E4MTIxMjhkOWM4MWIzZDMvdGFibGVyYW5nZTo1YzdkNmJiNzM2MWQ0NzkzYTgxMjEyOGQ5YzgxYjNkM18yLTEtMS0xLTExMDExOQ_e8ea3ed9-67af-4c16-bd52-d7c477437138">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Warrants issued</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzY1L2ZyYWc6MzgyNzViMTRmNmU2NDY1ZjlmNDQ0MmU4MzkxYzE5Y2IvdGFibGU6NWM3ZDZiYjczNjFkNDc5M2E4MTIxMjhkOWM4MWIzZDMvdGFibGVyYW5nZTo1YzdkNmJiNzM2MWQ0NzkzYTgxMjEyOGQ5YzgxYjNkM18zLTEtMS0xLTExMDExOQ_e8b9bed7-65b9-4595-9526-c7d37358dd5a">20,279</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzY1L2ZyYWc6MzgyNzViMTRmNmU2NDY1ZjlmNDQ0MmU4MzkxYzE5Y2IvdGFibGU6NWM3ZDZiYjczNjFkNDc5M2E4MTIxMjhkOWM4MWIzZDMvdGFibGVyYW5nZTo1YzdkNmJiNzM2MWQ0NzkzYTgxMjEyOGQ5YzgxYjNkM180LTAtMS0xLTExMDU2NQ_cf1ef344-6e8b-4404-9fc4-62d43ef2dafc">Change in fair value of liability</span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzY1L2ZyYWc6MzgyNzViMTRmNmU2NDY1ZjlmNDQ0MmU4MzkxYzE5Y2IvdGFibGU6NWM3ZDZiYjczNjFkNDc5M2E4MTIxMjhkOWM4MWIzZDMvdGFibGVyYW5nZTo1YzdkNmJiNzM2MWQ0NzkzYTgxMjEyOGQ5YzgxYjNkM180LTEtMS0xLTExMDExOQ_f56247ba-fd5d-43db-9020-0d54b5a888fa">1,211</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance, December 31, 2022</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzY1L2ZyYWc6MzgyNzViMTRmNmU2NDY1ZjlmNDQ0MmU4MzkxYzE5Y2IvdGFibGU6NWM3ZDZiYjczNjFkNDc5M2E4MTIxMjhkOWM4MWIzZDMvdGFibGVyYW5nZTo1YzdkNmJiNzM2MWQ0NzkzYTgxMjEyOGQ5YzgxYjNkM181LTEtMS0xLTExMDU1OA_a30e457b-4906-4fc1-8f7b-a85be2b8cec9">21,490</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Assumptions Used in Determining Fair Value of Liability-Classified Warrants</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:105%">The Company utilizes a Monte Carlo simulation valuation model which incorporates assumptions as to the stock price volatility, the expected life of the warrants, a risk-free interest rate, as well as timing and probability of equity financing. The Company values the Warrant Liability at each reporting period, with changes in fair value recognized in the consolidated statements of operations. The estimated fair value of the warrant liability is determined using Level 3 inputs. The inputs and values were as follows:</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:112.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OptiNose,&#160;Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements (Continued)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><ix:continuation id="i8126c0f11b3640d3883741c8713470b6"><ix:nonNumeric contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzY1L2ZyYWc6MzgyNzViMTRmNmU2NDY1ZjlmNDQ0MmU4MzkxYzE5Y2IvdGV4dHJlZ2lvbjozODI3NWIxNGY2ZTY0NjVmOWY0NDQyZTgzOTFjMTljYl80OTQ3ODAyMzQwNTU4_53249423-1f55-45e6-b6ff-c04177d751e2" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.182%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">November 23, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock price</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3c2fa1e023784c819a8dc44bb99e322a_I20221123" decimals="2" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzY1L2ZyYWc6MzgyNzViMTRmNmU2NDY1ZjlmNDQ0MmU4MzkxYzE5Y2IvdGFibGU6NjcwYTJmYWY2ZTgwNDAzOWI1ZGQ2MGQzMmI5OTRjOTIvdGFibGVyYW5nZTo2NzBhMmZhZjZlODA0MDM5YjVkZDYwZDMyYjk5NGM5Ml8yLTEtMS0xLTExMDIyNA_6308b115-7b49-4b37-a74b-0c19260b5c78">1.77</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i656202f27e9648aa9f71018965d5db85_I20221231" decimals="2" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzY1L2ZyYWc6MzgyNzViMTRmNmU2NDY1ZjlmNDQ0MmU4MzkxYzE5Y2IvdGFibGU6NjcwYTJmYWY2ZTgwNDAzOWI1ZGQ2MGQzMmI5OTRjOTIvdGFibGVyYW5nZTo2NzBhMmZhZjZlODA0MDM5YjVkZDYwZDMyYjk5NGM5Ml8yLTMtMS0xLTExMDIyNA_e073deda-f1a9-466f-a692-2bd857ae13e4">1.85</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Strike price</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i12526027af124d2eaf2e45c5cc5128ba_I20221123" decimals="2" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzY1L2ZyYWc6MzgyNzViMTRmNmU2NDY1ZjlmNDQ0MmU4MzkxYzE5Y2IvdGFibGU6NjcwYTJmYWY2ZTgwNDAzOWI1ZGQ2MGQzMmI5OTRjOTIvdGFibGVyYW5nZTo2NzBhMmZhZjZlODA0MDM5YjVkZDYwZDMyYjk5NGM5Ml8zLTEtMS0xLTExMDIyNA_942dd72c-8295-46f1-b5a4-bd423a7d04db">2.57</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i81d87324f9ac42a2804e01597b73f13e_I20221231" decimals="2" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzY1L2ZyYWc6MzgyNzViMTRmNmU2NDY1ZjlmNDQ0MmU4MzkxYzE5Y2IvdGFibGU6NjcwYTJmYWY2ZTgwNDAzOWI1ZGQ2MGQzMmI5OTRjOTIvdGFibGVyYW5nZTo2NzBhMmZhZjZlODA0MDM5YjVkZDYwZDMyYjk5NGM5Ml8zLTMtMS0xLTExMDIyNA_38b71ab7-bdff-4765-a646-c4eabf4a1db8">2.57</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7fd98223b0e8487ab4e9f06a6b0e2e17_I20221123" decimals="3" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzY1L2ZyYWc6MzgyNzViMTRmNmU2NDY1ZjlmNDQ0MmU4MzkxYzE5Y2IvdGFibGU6NjcwYTJmYWY2ZTgwNDAzOWI1ZGQ2MGQzMmI5OTRjOTIvdGFibGVyYW5nZTo2NzBhMmZhZjZlODA0MDM5YjVkZDYwZDMyYjk5NGM5Ml80LTEtMS0xLTExMDIyNA_ed609ca9-3c82-4145-a359-9e047f10e0be">45.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia683400064104d94bb65e13224b47fa4_I20221231" decimals="3" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzY1L2ZyYWc6MzgyNzViMTRmNmU2NDY1ZjlmNDQ0MmU4MzkxYzE5Y2IvdGFibGU6NjcwYTJmYWY2ZTgwNDAzOWI1ZGQ2MGQzMmI5OTRjOTIvdGFibGVyYW5nZTo2NzBhMmZhZjZlODA0MDM5YjVkZDYwZDMyYjk5NGM5Ml80LTMtMS0xLTExMDIyNA_29822c1f-250e-44a4-9dac-559472bcc1e3">45.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i07561160b4b640b58284b5ac37678580_I20221123" decimals="3" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzY1L2ZyYWc6MzgyNzViMTRmNmU2NDY1ZjlmNDQ0MmU4MzkxYzE5Y2IvdGFibGU6NjcwYTJmYWY2ZTgwNDAzOWI1ZGQ2MGQzMmI5OTRjOTIvdGFibGVyYW5nZTo2NzBhMmZhZjZlODA0MDM5YjVkZDYwZDMyYjk5NGM5Ml81LTEtMS0xLTExMDIyNA_c5a080c9-95d7-4908-879d-7362dad8ec7e">3.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib8ec0a4f643d4b8691f7c64824d1ef26_I20221231" decimals="3" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzY1L2ZyYWc6MzgyNzViMTRmNmU2NDY1ZjlmNDQ0MmU4MzkxYzE5Y2IvdGFibGU6NjcwYTJmYWY2ZTgwNDAzOWI1ZGQ2MGQzMmI5OTRjOTIvdGFibGVyYW5nZTo2NzBhMmZhZjZlODA0MDM5YjVkZDYwZDMyYjk5NGM5Ml81LTMtMS0xLTExMDIyNA_83556df8-c9d4-48cc-896c-ed4ecb067acf">3.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if38bd004cc9c47cb8ed2b5ced602d8de_I20221123" decimals="3" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzY1L2ZyYWc6MzgyNzViMTRmNmU2NDY1ZjlmNDQ0MmU4MzkxYzE5Y2IvdGFibGU6NjcwYTJmYWY2ZTgwNDAzOWI1ZGQ2MGQzMmI5OTRjOTIvdGFibGVyYW5nZTo2NzBhMmZhZjZlODA0MDM5YjVkZDYwZDMyYjk5NGM5Ml82LTEtMS0xLTExMDIyNA_d5d5729a-1faa-45ab-b073-bb121b42180f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i77f645c2ad1f45eb87448af2f7350083_I20221231" decimals="3" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzY1L2ZyYWc6MzgyNzViMTRmNmU2NDY1ZjlmNDQ0MmU4MzkxYzE5Y2IvdGFibGU6NjcwYTJmYWY2ZTgwNDAzOWI1ZGQ2MGQzMmI5OTRjOTIvdGFibGVyYW5nZTo2NzBhMmZhZjZlODA0MDM5YjVkZDYwZDMyYjk5NGM5Ml82LTMtMS0xLTExMDIyNA_7f5f1986-f486-4dc2-8f69-579c42921eb5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected life (years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic2035d08305a4a15b86bb7d1dbc471a9_I20221123" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzY1L2ZyYWc6MzgyNzViMTRmNmU2NDY1ZjlmNDQ0MmU4MzkxYzE5Y2IvdGFibGU6NjcwYTJmYWY2ZTgwNDAzOWI1ZGQ2MGQzMmI5OTRjOTIvdGFibGVyYW5nZTo2NzBhMmZhZjZlODA0MDM5YjVkZDYwZDMyYjk5NGM5Ml83LTEtMS0xLTExMDIyNA_593f996e-5dae-4c5f-8139-83fbc1c7af8b">5.00</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i076a98514cf1491bb4e37cb056d5866a_I20221231" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzY1L2ZyYWc6MzgyNzViMTRmNmU2NDY1ZjlmNDQ0MmU4MzkxYzE5Y2IvdGFibGU6NjcwYTJmYWY2ZTgwNDAzOWI1ZGQ2MGQzMmI5OTRjOTIvdGFibGVyYW5nZTo2NzBhMmZhZjZlODA0MDM5YjVkZDYwZDMyYjk5NGM5Ml83LTMtMS0xLTExMDIyNA_ea354c76-4bf1-4be8-87e4-0a737872b7ca">4.90</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value per warrant</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic2035d08305a4a15b86bb7d1dbc471a9_I20221123" decimals="2" name="optn:FairValueOfWarrant" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzY1L2ZyYWc6MzgyNzViMTRmNmU2NDY1ZjlmNDQ0MmU4MzkxYzE5Y2IvdGFibGU6NjcwYTJmYWY2ZTgwNDAzOWI1ZGQ2MGQzMmI5OTRjOTIvdGFibGVyYW5nZTo2NzBhMmZhZjZlODA0MDM5YjVkZDYwZDMyYjk5NGM5Ml84LTEtMS0xLTExMDIyNA_ef3a8a4a-c552-4a8e-b06c-54df0bf581c6">0.67</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i076a98514cf1491bb4e37cb056d5866a_I20221231" decimals="2" name="optn:FairValueOfWarrant" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzY1L2ZyYWc6MzgyNzViMTRmNmU2NDY1ZjlmNDQ0MmU4MzkxYzE5Y2IvdGFibGU6NjcwYTJmYWY2ZTgwNDAzOWI1ZGQ2MGQzMmI5OTRjOTIvdGFibGVyYW5nZTo2NzBhMmZhZjZlODA0MDM5YjVkZDYwZDMyYjk5NGM5Ml84LTMtMS0xLTExMDIyNA_bf772c62-e68a-4b08-a7bd-72d15b626e19">0.71</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></ix:continuation></div><div id="i451bcb3eabba4f87bdc579718207a3b8_145"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" name="us-gaap:InventoryDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDUvZnJhZzo0Yzk0ZDY1OGMwODQ0MDY2OTk0Yzk0NGU2M2Q5OGUxYS90ZXh0cmVnaW9uOjRjOTRkNjU4YzA4NDQwNjY5OTRjOTQ0ZTYzZDk4ZTFhXzU4_9218f3fc-4144-4614-b4dc-baabd69a4c72" continuedAt="i3674112a0401422ab1d7b562354630a2" escape="true">Inventory</ix:nonNumeric></span></div><ix:continuation id="i3674112a0401422ab1d7b562354630a2"><div style="margin-bottom:8pt;margin-top:8pt"><ix:nonNumeric contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDUvZnJhZzo0Yzk0ZDY1OGMwODQ0MDY2OTk0Yzk0NGU2M2Q5OGUxYS90ZXh0cmVnaW9uOjRjOTRkNjU4YzA4NDQwNjY5OTRjOTQ0ZTYzZDk4ZTFhXzU5_f5f38e62-2ce5-45ac-bcf3-66928a7e45b4" escape="true"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory consisted of the following: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:72.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.271%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.272%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231" decimals="-3" name="us-gaap:InventoryRawMaterials" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDUvZnJhZzo0Yzk0ZDY1OGMwODQ0MDY2OTk0Yzk0NGU2M2Q5OGUxYS90YWJsZToyZTMyMTI2OTA0Mjg0OTg1OTI1Y2VkMjY2YWU4M2Y2Yi90YWJsZXJhbmdlOjJlMzIxMjY5MDQyODQ5ODU5MjVjZWQyNjZhZTgzZjZiXzItMS0xLTEtNTgzNzI_de764f50-7486-4482-b4db-e64fae7dc6ec">1,691</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id970dfd2674c4d6b895febb9c14d0fd1_I20211231" decimals="-3" name="us-gaap:InventoryRawMaterials" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDUvZnJhZzo0Yzk0ZDY1OGMwODQ0MDY2OTk0Yzk0NGU2M2Q5OGUxYS90YWJsZToyZTMyMTI2OTA0Mjg0OTg1OTI1Y2VkMjY2YWU4M2Y2Yi90YWJsZXJhbmdlOjJlMzIxMjY5MDQyODQ5ODU5MjVjZWQyNjZhZTgzZjZiXzItMy0xLTEtNTgzNzI_a893edc7-320c-41b5-a889-14ce24fb6f0a">3,504</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231" decimals="-3" name="us-gaap:InventoryWorkInProcess" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDUvZnJhZzo0Yzk0ZDY1OGMwODQ0MDY2OTk0Yzk0NGU2M2Q5OGUxYS90YWJsZToyZTMyMTI2OTA0Mjg0OTg1OTI1Y2VkMjY2YWU4M2Y2Yi90YWJsZXJhbmdlOjJlMzIxMjY5MDQyODQ5ODU5MjVjZWQyNjZhZTgzZjZiXzMtMS0xLTEtNTgzNzI_39e4a5bc-0add-4f9c-9daa-b6cc4d1d5728">5,010</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id970dfd2674c4d6b895febb9c14d0fd1_I20211231" decimals="-3" name="us-gaap:InventoryWorkInProcess" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDUvZnJhZzo0Yzk0ZDY1OGMwODQ0MDY2OTk0Yzk0NGU2M2Q5OGUxYS90YWJsZToyZTMyMTI2OTA0Mjg0OTg1OTI1Y2VkMjY2YWU4M2Y2Yi90YWJsZXJhbmdlOjJlMzIxMjY5MDQyODQ5ODU5MjVjZWQyNjZhZTgzZjZiXzMtMy0xLTEtNTgzNzI_b0838f9b-c271-4cb5-a410-5b889a3e79b9">4,816</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231" decimals="-3" name="us-gaap:InventoryFinishedGoods" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDUvZnJhZzo0Yzk0ZDY1OGMwODQ0MDY2OTk0Yzk0NGU2M2Q5OGUxYS90YWJsZToyZTMyMTI2OTA0Mjg0OTg1OTI1Y2VkMjY2YWU4M2Y2Yi90YWJsZXJhbmdlOjJlMzIxMjY5MDQyODQ5ODU5MjVjZWQyNjZhZTgzZjZiXzQtMS0xLTEtNTgzNzI_c87ac3dc-e6d7-40db-b9bd-dbc927e663f6">2,742</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id970dfd2674c4d6b895febb9c14d0fd1_I20211231" decimals="-3" name="us-gaap:InventoryFinishedGoods" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDUvZnJhZzo0Yzk0ZDY1OGMwODQ0MDY2OTk0Yzk0NGU2M2Q5OGUxYS90YWJsZToyZTMyMTI2OTA0Mjg0OTg1OTI1Y2VkMjY2YWU4M2Y2Yi90YWJsZXJhbmdlOjJlMzIxMjY5MDQyODQ5ODU5MjVjZWQyNjZhZTgzZjZiXzQtMy0xLTEtNTgzNzI_7bbd3635-9212-4a36-8b79-4dfa3073f618">3,527</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total inventory</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231" decimals="-3" name="us-gaap:InventoryGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDUvZnJhZzo0Yzk0ZDY1OGMwODQ0MDY2OTk0Yzk0NGU2M2Q5OGUxYS90YWJsZToyZTMyMTI2OTA0Mjg0OTg1OTI1Y2VkMjY2YWU4M2Y2Yi90YWJsZXJhbmdlOjJlMzIxMjY5MDQyODQ5ODU5MjVjZWQyNjZhZTgzZjZiXzUtMS0xLTEtNTgzNzI_55186063-74d3-41b1-a16d-76f51e5dc0d6">9,443</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id970dfd2674c4d6b895febb9c14d0fd1_I20211231" decimals="-3" name="us-gaap:InventoryGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDUvZnJhZzo0Yzk0ZDY1OGMwODQ0MDY2OTk0Yzk0NGU2M2Q5OGUxYS90YWJsZToyZTMyMTI2OTA0Mjg0OTg1OTI1Y2VkMjY2YWU4M2Y2Yi90YWJsZXJhbmdlOjJlMzIxMjY5MDQyODQ5ODU5MjVjZWQyNjZhZTgzZjZiXzUtMy0xLTEtNTgzNzI_94e70164-1214-4862-b97c-c9cb9a158541">11,847</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are stated at the lower of cost or net realizable value, as determined on a first-in, first-out basis.</span></div></ix:continuation><div id="i451bcb3eabba4f87bdc579718207a3b8_148"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDgvZnJhZzo1OGY0OGY2ZmFlNTk0NTJjOWI0OWRlNjAwYmNmMzQyYS90ZXh0cmVnaW9uOjU4ZjQ4ZjZmYWU1OTQ1MmM5YjQ5ZGU2MDBiY2YzNDJhXzM5MA_4cdd2bb4-aa03-418c-af2a-269f52be343d" continuedAt="i571d7eb3fa0b4b4abe326f13118a4a60" escape="true">Property and Equipment</ix:nonNumeric></span></div><ix:continuation id="i571d7eb3fa0b4b4abe326f13118a4a60"><div style="margin-bottom:8pt;margin-top:8pt"><ix:continuation id="if6f03fedb95c4a6ca3e61668bbbcde16"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net, consisted of:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.607%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.329%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ddeb1efeb7744f8bed2dbb7f03f66da_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDgvZnJhZzo1OGY0OGY2ZmFlNTk0NTJjOWI0OWRlNjAwYmNmMzQyYS90YWJsZTo5NWVkNDExN2Q0NjI0YmJlYmM4MjNlNGM4OWYzNzU0NC90YWJsZXJhbmdlOjk1ZWQ0MTE3ZDQ2MjRiYmViYzgyM2U0Yzg5ZjM3NTQ0XzItMS0xLTEtNTgzNzI_4b3425bf-e90f-4669-a092-ab6de4094bee">1,203</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic532296dc81545c39388340e3d3dfb1d_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDgvZnJhZzo1OGY0OGY2ZmFlNTk0NTJjOWI0OWRlNjAwYmNmMzQyYS90YWJsZTo5NWVkNDExN2Q0NjI0YmJlYmM4MjNlNGM4OWYzNzU0NC90YWJsZXJhbmdlOjk1ZWQ0MTE3ZDQ2MjRiYmViYzgyM2U0Yzg5ZjM3NTQ0XzItMy0xLTEtNTgzNzI_33c09cb7-fd75-4667-877a-c6c44aba7d8c">1,173</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd6adcb5fdd94a8cafa3e6dcc446470f_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDgvZnJhZzo1OGY0OGY2ZmFlNTk0NTJjOWI0OWRlNjAwYmNmMzQyYS90YWJsZTo5NWVkNDExN2Q0NjI0YmJlYmM4MjNlNGM4OWYzNzU0NC90YWJsZXJhbmdlOjk1ZWQ0MTE3ZDQ2MjRiYmViYzgyM2U0Yzg5ZjM3NTQ0XzMtMS0xLTEtNTgzNzI_43f663ab-f430-42e2-a9b4-8ab2574a3122">366</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d6764d492fa4ab49a7a65da317dfa94_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDgvZnJhZzo1OGY0OGY2ZmFlNTk0NTJjOWI0OWRlNjAwYmNmMzQyYS90YWJsZTo5NWVkNDExN2Q0NjI0YmJlYmM4MjNlNGM4OWYzNzU0NC90YWJsZXJhbmdlOjk1ZWQ0MTE3ZDQ2MjRiYmViYzgyM2U0Yzg5ZjM3NTQ0XzMtMy0xLTEtNTgzNzI_c801acd2-e2a8-4df4-8b3e-306722d03055">366</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77c83aa040f64e5ab765b0b3cec00b48_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDgvZnJhZzo1OGY0OGY2ZmFlNTk0NTJjOWI0OWRlNjAwYmNmMzQyYS90YWJsZTo5NWVkNDExN2Q0NjI0YmJlYmM4MjNlNGM4OWYzNzU0NC90YWJsZXJhbmdlOjk1ZWQ0MTE3ZDQ2MjRiYmViYzgyM2U0Yzg5ZjM3NTQ0XzQtMS0xLTEtNTgzNzI_31c5bc03-d0ac-4094-8bf5-c9677904389f">3,067</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97b05fd39c994e718b96dc21927444c5_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDgvZnJhZzo1OGY0OGY2ZmFlNTk0NTJjOWI0OWRlNjAwYmNmMzQyYS90YWJsZTo5NWVkNDExN2Q0NjI0YmJlYmM4MjNlNGM4OWYzNzU0NC90YWJsZXJhbmdlOjk1ZWQ0MTE3ZDQ2MjRiYmViYzgyM2U0Yzg5ZjM3NTQ0XzQtMy0xLTEtNTgzNzI_9b411d9a-f6b4-45a8-9d7d-aa4a6de55085">3,367</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3474fbb67a5493091eb870124741f97_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDgvZnJhZzo1OGY0OGY2ZmFlNTk0NTJjOWI0OWRlNjAwYmNmMzQyYS90YWJsZTo5NWVkNDExN2Q0NjI0YmJlYmM4MjNlNGM4OWYzNzU0NC90YWJsZXJhbmdlOjk1ZWQ0MTE3ZDQ2MjRiYmViYzgyM2U0Yzg5ZjM3NTQ0XzUtMS0xLTEtNTgzNzI_8e1f0f73-7efd-496e-8d4e-74365d6a941f">609</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20b9366590cd439eac871165deb4cd22_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDgvZnJhZzo1OGY0OGY2ZmFlNTk0NTJjOWI0OWRlNjAwYmNmMzQyYS90YWJsZTo5NWVkNDExN2Q0NjI0YmJlYmM4MjNlNGM4OWYzNzU0NC90YWJsZXJhbmdlOjk1ZWQ0MTE3ZDQ2MjRiYmViYzgyM2U0Yzg5ZjM3NTQ0XzUtMy0xLTEtNTgzNzI_c608d6d0-10e2-4734-89d7-d6ba7e01d32a">609</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Construction in process</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaaea96eb926c4215a782ea03cfe873f7_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDgvZnJhZzo1OGY0OGY2ZmFlNTk0NTJjOWI0OWRlNjAwYmNmMzQyYS90YWJsZTo5NWVkNDExN2Q0NjI0YmJlYmM4MjNlNGM4OWYzNzU0NC90YWJsZXJhbmdlOjk1ZWQ0MTE3ZDQ2MjRiYmViYzgyM2U0Yzg5ZjM3NTQ0XzYtMS0xLTEtNTgzNzI_ce6325b0-01c1-4fdd-87a5-1a0c8b23316b">115</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d86a8ea69c742f89c18f27139c4e7e8_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDgvZnJhZzo1OGY0OGY2ZmFlNTk0NTJjOWI0OWRlNjAwYmNmMzQyYS90YWJsZTo5NWVkNDExN2Q0NjI0YmJlYmM4MjNlNGM4OWYzNzU0NC90YWJsZXJhbmdlOjk1ZWQ0MTE3ZDQ2MjRiYmViYzgyM2U0Yzg5ZjM3NTQ0XzYtMy0xLTEtNTgzNzI_542d1830-4db0-41a6-b376-0c014cd355f4">115</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDgvZnJhZzo1OGY0OGY2ZmFlNTk0NTJjOWI0OWRlNjAwYmNmMzQyYS90YWJsZTo5NWVkNDExN2Q0NjI0YmJlYmM4MjNlNGM4OWYzNzU0NC90YWJsZXJhbmdlOjk1ZWQ0MTE3ZDQ2MjRiYmViYzgyM2U0Yzg5ZjM3NTQ0XzctMS0xLTEtNTgzNzI_40c989aa-d357-458d-874b-e8734d3059ee">5,360</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id970dfd2674c4d6b895febb9c14d0fd1_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDgvZnJhZzo1OGY0OGY2ZmFlNTk0NTJjOWI0OWRlNjAwYmNmMzQyYS90YWJsZTo5NWVkNDExN2Q0NjI0YmJlYmM4MjNlNGM4OWYzNzU0NC90YWJsZXJhbmdlOjk1ZWQ0MTE3ZDQ2MjRiYmViYzgyM2U0Yzg5ZjM3NTQ0XzctMy0xLTEtNTgzNzI_6349cb20-f9c1-466a-a3ac-46fffc66d936">5,630</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDgvZnJhZzo1OGY0OGY2ZmFlNTk0NTJjOWI0OWRlNjAwYmNmMzQyYS90YWJsZTo5NWVkNDExN2Q0NjI0YmJlYmM4MjNlNGM4OWYzNzU0NC90YWJsZXJhbmdlOjk1ZWQ0MTE3ZDQ2MjRiYmViYzgyM2U0Yzg5ZjM3NTQ0XzgtMS0xLTEtNTgzNzI_dfc3d68f-d53b-4829-8b5c-d54c71c58861">4,565</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id970dfd2674c4d6b895febb9c14d0fd1_I20211231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDgvZnJhZzo1OGY0OGY2ZmFlNTk0NTJjOWI0OWRlNjAwYmNmMzQyYS90YWJsZTo5NWVkNDExN2Q0NjI0YmJlYmM4MjNlNGM4OWYzNzU0NC90YWJsZXJhbmdlOjk1ZWQ0MTE3ZDQ2MjRiYmViYzgyM2U0Yzg5ZjM3NTQ0XzgtMy0xLTEtNTgzNzI_13673de7-e3b4-4af9-a503-ccbdf7b41c18">4,283</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDgvZnJhZzo1OGY0OGY2ZmFlNTk0NTJjOWI0OWRlNjAwYmNmMzQyYS90YWJsZTo5NWVkNDExN2Q0NjI0YmJlYmM4MjNlNGM4OWYzNzU0NC90YWJsZXJhbmdlOjk1ZWQ0MTE3ZDQ2MjRiYmViYzgyM2U0Yzg5ZjM3NTQ0XzktMS0xLTEtNTgzNzI_17a3d850-2639-4dc2-979c-74a140fa71cd">795</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id970dfd2674c4d6b895febb9c14d0fd1_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDgvZnJhZzo1OGY0OGY2ZmFlNTk0NTJjOWI0OWRlNjAwYmNmMzQyYS90YWJsZTo5NWVkNDExN2Q0NjI0YmJlYmM4MjNlNGM4OWYzNzU0NC90YWJsZXJhbmdlOjk1ZWQ0MTE3ZDQ2MjRiYmViYzgyM2U0Yzg5ZjM3NTQ0XzktMy0xLTEtNTgzNzI_02847002-4134-472d-adbd-526016ade19e">1,347</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense was $<ix:nonFraction unitRef="usd" contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" decimals="-3" name="us-gaap:Depreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDgvZnJhZzo1OGY0OGY2ZmFlNTk0NTJjOWI0OWRlNjAwYmNmMzQyYS90ZXh0cmVnaW9uOjU4ZjQ4ZjZmYWU1OTQ1MmM5YjQ5ZGU2MDBiY2YzNDJhXzEwMA_838ef037-8a3a-4b19-ae92-4639d1903527">530</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and $<ix:nonFraction unitRef="usd" contextRef="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231" decimals="-3" name="us-gaap:Depreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDgvZnJhZzo1OGY0OGY2ZmFlNTk0NTJjOWI0OWRlNjAwYmNmMzQyYS90ZXh0cmVnaW9uOjU4ZjQ4ZjZmYWU1OTQ1MmM5YjQ5ZGU2MDBiY2YzNDJhXzEwNw_c9735527-9883-4471-8a97-82ccd944a38f">645</ix:nonFraction> for the years ended December 31, 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and 2021, respectively. In addition, depreciation expense of $<ix:nonFraction unitRef="usd" contextRef="i3b8fb31b2cb74f1986dbdb60db29474c_D20220101-20221231" decimals="-3" name="us-gaap:Depreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDgvZnJhZzo1OGY0OGY2ZmFlNTk0NTJjOWI0OWRlNjAwYmNmMzQyYS90ZXh0cmVnaW9uOjU4ZjQ4ZjZmYWU1OTQ1MmM5YjQ5ZGU2MDBiY2YzNDJhXzE5Mg_2dcd75e0-b4b9-4298-92c7-1caa0881c38b">665</ix:nonFraction> was charged to inventory and <ix:nonFraction unitRef="usd" contextRef="i08cfc0852d87426baff11fe941ec7bfa_D20220101-20221231" decimals="INF" name="us-gaap:Depreciation" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDgvZnJhZzo1OGY0OGY2ZmFlNTk0NTJjOWI0OWRlNjAwYmNmMzQyYS90ZXh0cmVnaW9uOjU4ZjQ4ZjZmYWU1OTQ1MmM5YjQ5ZGU2MDBiY2YzNDJhXzQ5NDc4MDIzMjU2Nzc_758ffe19-5b61-4528-95d9-9eb54ac7f236">no</ix:nonFraction> depreciation was charged to prepaid expenses and other assets as of December 31, 2022, which represents depreciation expense related to equipment involved in the manufacturing process.</span></div></ix:continuation><div id="i451bcb3eabba4f87bdc579718207a3b8_151"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNTEvZnJhZzoyNzE1YjlkZmFkYWQ0MzJmODM0NjNlNTc4MDU5NjVkNS90ZXh0cmVnaW9uOjI3MTViOWRmYWRhZDQzMmY4MzQ2M2U1NzgwNTk2NWQ1XzI5NjQ_aa56d47b-ff38-4cd9-873d-801282548fe2" continuedAt="ibce43c128caf45ecbb34efe2366fce5b" escape="true">Leases</ix:nonNumeric></span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ibce43c128caf45ecbb34efe2366fce5b" continuedAt="idd24b008304a410a8a18bfa58fd6e29d">The Company leases office space, storage space and equipment (primarily vehicles). The Company evaluates renewal options at lease inception on an ongoing basis and includes renewal options that it is reasonably certain to exercise in its expected lease terms when classifying leases and measuring lease liabilities. Lease agreements generally do not require material variable lease payments, residual value guarantees or restrictive covenants. </ix:continuation></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:112.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OptiNose,&#160;Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div></div><ix:continuation id="idd24b008304a410a8a18bfa58fd6e29d" continuedAt="ibc4d6d41a31d4a1d862de4fdb16def97"><div style="margin-bottom:8pt;margin-top:8pt"><ix:nonNumeric contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" name="optn:AssetsAndLiabilitiesLesseeTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNTEvZnJhZzoyNzE1YjlkZmFkYWQ0MzJmODM0NjNlNTc4MDU5NjVkNS90ZXh0cmVnaW9uOjI3MTViOWRmYWRhZDQzMmY4MzQ2M2U1NzgwNTk2NWQ1XzI5NjU_a7f84bf7-6efb-4ef0-92b7-fc23643fc73a" continuedAt="ia514fa33d6ae4418900b2b9db1e4e4fe" escape="true"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents the operating lease assets and liabilities recognized on the Company's consolidated balance sheets:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.063%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.689%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.963%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance Sheet Line Item</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-current operating lease assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNTEvZnJhZzoyNzE1YjlkZmFkYWQ0MzJmODM0NjNlNTc4MDU5NjVkNS90YWJsZTplNmRjNTY4MzJmZTU0MjZlODE2Nzg1Yzg1OWM5ZWExMC90YWJsZXJhbmdlOmU2ZGM1NjgzMmZlNTQyNmU4MTY3ODVjODU5YzllYTEwXzEtMi0xLTEtNTgzNzI_24ba613c-7389-4e11-9675-21345271c945"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNTEvZnJhZzoyNzE1YjlkZmFkYWQ0MzJmODM0NjNlNTc4MDU5NjVkNS90YWJsZTplNmRjNTY4MzJmZTU0MjZlODE2Nzg1Yzg1OWM5ZWExMC90YWJsZXJhbmdlOmU2ZGM1NjgzMmZlNTQyNmU4MTY3ODVjODU5YzllYTEwXzEtMi0xLTEtNTgzNzI_68a7407f-9d3d-42c1-b7e8-60a846da90dd">Other assets</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNTEvZnJhZzoyNzE1YjlkZmFkYWQ0MzJmODM0NjNlNTc4MDU5NjVkNS90YWJsZTplNmRjNTY4MzJmZTU0MjZlODE2Nzg1Yzg1OWM5ZWExMC90YWJsZXJhbmdlOmU2ZGM1NjgzMmZlNTQyNmU4MTY3ODVjODU5YzllYTEwXzEtNC0xLTEtNTgzNzI_b8339169-f135-43f0-a47a-af7ea9d39e87">2,445</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id970dfd2674c4d6b895febb9c14d0fd1_I20211231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNTEvZnJhZzoyNzE1YjlkZmFkYWQ0MzJmODM0NjNlNTc4MDU5NjVkNS90YWJsZTplNmRjNTY4MzJmZTU0MjZlODE2Nzg1Yzg1OWM5ZWExMC90YWJsZXJhbmdlOmU2ZGM1NjgzMmZlNTQyNmU4MTY3ODVjODU5YzllYTEwXzEtNi0xLTEtNTgzNzI_6be045cd-0f9a-43ff-a543-3fd54fee9ff5">4,051</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Current operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNTEvZnJhZzoyNzE1YjlkZmFkYWQ0MzJmODM0NjNlNTc4MDU5NjVkNS90YWJsZTplNmRjNTY4MzJmZTU0MjZlODE2Nzg1Yzg1OWM5ZWExMC90YWJsZXJhbmdlOmU2ZGM1NjgzMmZlNTQyNmU4MTY3ODVjODU5YzllYTEwXzMtMi0xLTEtNTgzNzI_81e615e1-5430-4b3f-a024-d8c112dd845e"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNTEvZnJhZzoyNzE1YjlkZmFkYWQ0MzJmODM0NjNlNTc4MDU5NjVkNS90YWJsZTplNmRjNTY4MzJmZTU0MjZlODE2Nzg1Yzg1OWM5ZWExMC90YWJsZXJhbmdlOmU2ZGM1NjgzMmZlNTQyNmU4MTY3ODVjODU5YzllYTEwXzMtMi0xLTEtNTgzNzI_c6470abf-49c1-414a-9b43-5932ca6cb8de">Accrued expenses and other current liabilities</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNTEvZnJhZzoyNzE1YjlkZmFkYWQ0MzJmODM0NjNlNTc4MDU5NjVkNS90YWJsZTplNmRjNTY4MzJmZTU0MjZlODE2Nzg1Yzg1OWM5ZWExMC90YWJsZXJhbmdlOmU2ZGM1NjgzMmZlNTQyNmU4MTY3ODVjODU5YzllYTEwXzMtNC0xLTEtNTgzNzI_30666a05-c851-4c0f-b2dc-d961069bb4f4">1,971</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id970dfd2674c4d6b895febb9c14d0fd1_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNTEvZnJhZzoyNzE1YjlkZmFkYWQ0MzJmODM0NjNlNTc4MDU5NjVkNS90YWJsZTplNmRjNTY4MzJmZTU0MjZlODE2Nzg1Yzg1OWM5ZWExMC90YWJsZXJhbmdlOmU2ZGM1NjgzMmZlNTQyNmU4MTY3ODVjODU5YzllYTEwXzMtNi0xLTEtNTgzNzI_7055b1a5-c521-46e8-9680-3055af72441e">2,094</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Non-current operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNTEvZnJhZzoyNzE1YjlkZmFkYWQ0MzJmODM0NjNlNTc4MDU5NjVkNS90YWJsZTplNmRjNTY4MzJmZTU0MjZlODE2Nzg1Yzg1OWM5ZWExMC90YWJsZXJhbmdlOmU2ZGM1NjgzMmZlNTQyNmU4MTY3ODVjODU5YzllYTEwXzQtMi0xLTEtNTgzNzI_51c56e55-3624-4972-bd9f-e5d6619b61c3"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNTEvZnJhZzoyNzE1YjlkZmFkYWQ0MzJmODM0NjNlNTc4MDU5NjVkNS90YWJsZTplNmRjNTY4MzJmZTU0MjZlODE2Nzg1Yzg1OWM5ZWExMC90YWJsZXJhbmdlOmU2ZGM1NjgzMmZlNTQyNmU4MTY3ODVjODU5YzllYTEwXzQtMi0xLTEtNTgzNzI_f473c9e3-1f7a-40d1-9ce5-a76980ea7120">Other liabilities</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNTEvZnJhZzoyNzE1YjlkZmFkYWQ0MzJmODM0NjNlNTc4MDU5NjVkNS90YWJsZTplNmRjNTY4MzJmZTU0MjZlODE2Nzg1Yzg1OWM5ZWExMC90YWJsZXJhbmdlOmU2ZGM1NjgzMmZlNTQyNmU4MTY3ODVjODU5YzllYTEwXzQtNC0xLTEtNTgzNzI_dea14e16-2d67-4d37-b632-8e8916acc6af">625</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id970dfd2674c4d6b895febb9c14d0fd1_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNTEvZnJhZzoyNzE1YjlkZmFkYWQ0MzJmODM0NjNlNTc4MDU5NjVkNS90YWJsZTplNmRjNTY4MzJmZTU0MjZlODE2Nzg1Yzg1OWM5ZWExMC90YWJsZXJhbmdlOmU2ZGM1NjgzMmZlNTQyNmU4MTY3ODVjODU5YzllYTEwXzQtNi0xLTEtNTgzNzI_8e60968e-7774-48cc-93f5-9da0e3b484e7">2,190</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Total operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNTEvZnJhZzoyNzE1YjlkZmFkYWQ0MzJmODM0NjNlNTc4MDU5NjVkNS90YWJsZTplNmRjNTY4MzJmZTU0MjZlODE2Nzg1Yzg1OWM5ZWExMC90YWJsZXJhbmdlOmU2ZGM1NjgzMmZlNTQyNmU4MTY3ODVjODU5YzllYTEwXzUtNC0xLTEtNTgzNzI_f13c2655-b757-4da1-a1af-9828a91c3a88">2,596</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id970dfd2674c4d6b895febb9c14d0fd1_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNTEvZnJhZzoyNzE1YjlkZmFkYWQ0MzJmODM0NjNlNTc4MDU5NjVkNS90YWJsZTplNmRjNTY4MzJmZTU0MjZlODE2Nzg1Yzg1OWM5ZWExMC90YWJsZXJhbmdlOmU2ZGM1NjgzMmZlNTQyNmU4MTY3ODVjODU5YzllYTEwXzUtNi0xLTEtNTgzNzI_1de565a3-712a-4253-a748-c09bd094e4f7">4,284</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The depreciable lives of operating lease asset leasehold improvements are limited by the lease term. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's leases generally do not provide an implicit rate, and therefore, the Company uses its incremental borrowing rate as the discount rate when measuring operating leases liabilities. The incremental borrowing rate represents an estimate of the interest rate the Company would incur at lease commencement to borrow an amount equal to the lease payments on a collateralized basis over the term of a lease. The Company used the incremental borrowing rates as of January 1, 2019 for operating leases that commenced prior to that date. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><ix:continuation id="ia514fa33d6ae4418900b2b9db1e4e4fe"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's weighted average remaining lease term and weighted average discount rate for operating leases as of December 31, 2022 are:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:79.747%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.323%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average remaining lease term (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNTEvZnJhZzoyNzE1YjlkZmFkYWQ0MzJmODM0NjNlNTc4MDU5NjVkNS90YWJsZTo5ZGQyYTVhZWVmYzY0OGE5OWE1YTRlMmE1ZTA0N2QyNC90YWJsZXJhbmdlOjlkZDJhNWFlZWZjNjQ4YTk5YTVhNGUyYTVlMDQ3ZDI0XzEtMi0xLTEtNTgzNzI_78e29987-7013-4253-813c-d2d46a471ac9">2.04</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231" decimals="4" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNTEvZnJhZzoyNzE1YjlkZmFkYWQ0MzJmODM0NjNlNTc4MDU5NjVkNS90YWJsZTo5ZGQyYTVhZWVmYzY0OGE5OWE1YTRlMmE1ZTA0N2QyNC90YWJsZXJhbmdlOjlkZDJhNWFlZWZjNjQ4YTk5YTVhNGUyYTVlMDQ3ZDI0XzItMi0xLTEtNTgzNzI_cc3d1e85-9f0b-4a85-8363-72e1c8089fcb">5.24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></ix:continuation></div><div style="margin-bottom:8pt;margin-top:8pt"><ix:nonNumeric contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNTEvZnJhZzoyNzE1YjlkZmFkYWQ0MzJmODM0NjNlNTc4MDU5NjVkNS90ZXh0cmVnaW9uOjI3MTViOWRmYWRhZDQzMmY4MzQ2M2U1NzgwNTk2NWQ1XzI5Njc_ed589b59-18c9-4db8-b0bb-32b6b69bdd63" escape="true"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below reconciles the undiscounted future minimum lease payments (displayed in aggregate by year) under non-cancelable operating leases with terms of more than one year to the total operating lease liabilities recognized on the consolidated balance sheets as of December 31, 2022:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:80.478%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.592%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNTEvZnJhZzoyNzE1YjlkZmFkYWQ0MzJmODM0NjNlNTc4MDU5NjVkNS90YWJsZTozY2UyYWE4NmJjNzA0YjZlOTllYWI5MGFiYzM5ZWQ3Ny90YWJsZXJhbmdlOjNjZTJhYTg2YmM3MDRiNmU5OWVhYjkwYWJjMzllZDc3XzEtMi0xLTEtNTgzNzI_d9fe76dc-d38d-42b9-bc5b-263e57491e8d">2,153</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNTEvZnJhZzoyNzE1YjlkZmFkYWQ0MzJmODM0NjNlNTc4MDU5NjVkNS90YWJsZTozY2UyYWE4NmJjNzA0YjZlOTllYWI5MGFiYzM5ZWQ3Ny90YWJsZXJhbmdlOjNjZTJhYTg2YmM3MDRiNmU5OWVhYjkwYWJjMzllZDc3XzItMi0xLTEtNTgzNzI_87e5c745-83eb-4c25-b471-6f3a44f9c31a">548</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNTEvZnJhZzoyNzE1YjlkZmFkYWQ0MzJmODM0NjNlNTc4MDU5NjVkNS90YWJsZTozY2UyYWE4NmJjNzA0YjZlOTllYWI5MGFiYzM5ZWQ3Ny90YWJsZXJhbmdlOjNjZTJhYTg2YmM3MDRiNmU5OWVhYjkwYWJjMzllZDc3XzMtMi0xLTEtNTgzNzI_4f807406-7442-4149-8a16-00d6028f56df">82</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231" decimals="-3" name="optn:LesseeOperatingLeaseLiabilityPaymentsDueThereafter" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNTEvZnJhZzoyNzE1YjlkZmFkYWQ0MzJmODM0NjNlNTc4MDU5NjVkNS90YWJsZTozY2UyYWE4NmJjNzA0YjZlOTllYWI5MGFiYzM5ZWQ3Ny90YWJsZXJhbmdlOjNjZTJhYTg2YmM3MDRiNmU5OWVhYjkwYWJjMzllZDc3XzQtMi0xLTEtNTgzNzI_b8a887e0-439a-447c-acc8-3c6958e8589e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Total undiscounted future minimum lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNTEvZnJhZzoyNzE1YjlkZmFkYWQ0MzJmODM0NjNlNTc4MDU5NjVkNS90YWJsZTozY2UyYWE4NmJjNzA0YjZlOTllYWI5MGFiYzM5ZWQ3Ny90YWJsZXJhbmdlOjNjZTJhYTg2YmM3MDRiNmU5OWVhYjkwYWJjMzllZDc3XzUtMi0xLTEtNTgzNzI_3834103b-ca0b-4d4a-a204-89a76ded3afb">2,783</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: difference between undiscounted lease payments and discounted operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNTEvZnJhZzoyNzE1YjlkZmFkYWQ0MzJmODM0NjNlNTc4MDU5NjVkNS90YWJsZTozY2UyYWE4NmJjNzA0YjZlOTllYWI5MGFiYzM5ZWQ3Ny90YWJsZXJhbmdlOjNjZTJhYTg2YmM3MDRiNmU5OWVhYjkwYWJjMzllZDc3XzYtMi0xLTEtNTgzNzI_67495460-3f1b-4568-98b6-068659245465">187</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Total operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNTEvZnJhZzoyNzE1YjlkZmFkYWQ0MzJmODM0NjNlNTc4MDU5NjVkNS90YWJsZTozY2UyYWE4NmJjNzA0YjZlOTllYWI5MGFiYzM5ZWQ3Ny90YWJsZXJhbmdlOjNjZTJhYTg2YmM3MDRiNmU5OWVhYjkwYWJjMzllZDc3XzctMi0xLTEtNTgzNzI_468cd6bc-2577-43fd-a927-73ae13103c0f">2,596</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" decimals="INF" name="optn:OperatingLeaseCostForExtension" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNTEvZnJhZzoyNzE1YjlkZmFkYWQ0MzJmODM0NjNlNTc4MDU5NjVkNS90ZXh0cmVnaW9uOjI3MTViOWRmYWRhZDQzMmY4MzQ2M2U1NzgwNTk2NWQ1XzIzNzg_4375f90f-b815-4c6f-8586-0e7d2a35d13f">No</ix:nonFraction> operating lease payments include options to extend lease terms that are reasonably certain of being exercised for the year ended December 31, 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease costs were $<ix:nonFraction unitRef="usd" contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNTEvZnJhZzoyNzE1YjlkZmFkYWQ0MzJmODM0NjNlNTc4MDU5NjVkNS90ZXh0cmVnaW9uOjI3MTViOWRmYWRhZDQzMmY4MzQ2M2U1NzgwNTk2NWQ1XzI1NDE_1a132c1a-2d0b-479f-9eeb-4121651e6214">2,985</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNTEvZnJhZzoyNzE1YjlkZmFkYWQ0MzJmODM0NjNlNTc4MDU5NjVkNS90ZXh0cmVnaW9uOjI3MTViOWRmYWRhZDQzMmY4MzQ2M2U1NzgwNTk2NWQ1XzI1NDg_c5d2f81c-54d9-45fc-90de-17ed72c85bd6">2,843</ix:nonFraction> for the years ended December 31, 2022 and 2021, respectively. Operating lease costs are included within selling, general and administrative expenses on the consolidated statements of operations. </span></div></ix:continuation><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ibc4d6d41a31d4a1d862de4fdb16def97">Cash paid for amounts included in the measurement of operating lease liabilities were $<ix:nonFraction unitRef="usd" contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNTEvZnJhZzoyNzE1YjlkZmFkYWQ0MzJmODM0NjNlNTc4MDU5NjVkNS90ZXh0cmVnaW9uOjI3MTViOWRmYWRhZDQzMmY4MzQ2M2U1NzgwNTk2NWQ1XzI4MTY_e5d89f19-09e4-4f4d-9673-f2ee69535de2">2,570</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNTEvZnJhZzoyNzE1YjlkZmFkYWQ0MzJmODM0NjNlNTc4MDU5NjVkNS90ZXh0cmVnaW9uOjI3MTViOWRmYWRhZDQzMmY4MzQ2M2U1NzgwNTk2NWQ1XzI4MjM_dc6ef342-0d09-4423-a0fe-15e81bd911fb">2,466</ix:nonFraction> for the years ended December 31, 2022 and 2021, respectively. This amount is included in operating activities in the consolidated statements of cash flows.</ix:continuation> </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-20</span></div></div></div><div id="i451bcb3eabba4f87bdc579718207a3b8_157"></div><hr style="page-break-after:always"/><div style="min-height:112.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OptiNose,&#160;Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNTcvZnJhZzoxN2I3ZmRiMGZlM2E0ZDlmYTVjYzA4ODU5NjVmNWI1Ni90ZXh0cmVnaW9uOjE3YjdmZGIwZmUzYTRkOWZhNWNjMDg4NTk2NWY1YjU2XzExNw_3efc7cf8-e8e2-40ba-84f0-5df30034f24c" continuedAt="i8fdf5fc8e71e4866844a29299e94195f" escape="true">Accrued Expenses and Other Current Liabilities</ix:nonNumeric></span></div><ix:continuation id="i8fdf5fc8e71e4866844a29299e94195f"><ix:nonNumeric contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNTcvZnJhZzoxN2I3ZmRiMGZlM2E0ZDlmYTVjYzA4ODU5NjVmNWI1Ni90ZXh0cmVnaW9uOjE3YjdmZGIwZmUzYTRkOWZhNWNjMDg4NTk2NWY1YjU2XzExOQ_72681ee3-8839-40a7-af95-56371272fa68" escape="true"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities consisted of:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.022%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.914%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Product revenue allowances</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231" decimals="-3" name="optn:AccruedProductAllowancesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNTcvZnJhZzoxN2I3ZmRiMGZlM2E0ZDlmYTVjYzA4ODU5NjVmNWI1Ni90YWJsZTphNTNhOTQxMjIxYjg0ODk3YjFmN2Y3NzJjYjNiODAzMC90YWJsZXJhbmdlOmE1M2E5NDEyMjFiODQ4OTdiMWY3Zjc3MmNiM2I4MDMwXzMtMS0xLTEtNTgzNzI_ecb823f0-c845-4199-be38-25d1ffcbe827">27,993</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id970dfd2674c4d6b895febb9c14d0fd1_I20211231" decimals="-3" name="optn:AccruedProductAllowancesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNTcvZnJhZzoxN2I3ZmRiMGZlM2E0ZDlmYTVjYzA4ODU5NjVmNWI1Ni90YWJsZTphNTNhOTQxMjIxYjg0ODk3YjFmN2Y3NzJjYjNiODAzMC90YWJsZXJhbmdlOmE1M2E5NDEyMjFiODQ4OTdiMWY3Zjc3MmNiM2I4MDMwXzMtMy0xLTEtNTgzNzI_f65f7ca1-cf47-4eb5-9eed-4abb82f457b1">26,521</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Selling, general and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231" decimals="-3" name="optn:AccruedSellingGeneralandAdministrativeCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNTcvZnJhZzoxN2I3ZmRiMGZlM2E0ZDlmYTVjYzA4ODU5NjVmNWI1Ni90YWJsZTphNTNhOTQxMjIxYjg0ODk3YjFmN2Y3NzJjYjNiODAzMC90YWJsZXJhbmdlOmE1M2E5NDEyMjFiODQ4OTdiMWY3Zjc3MmNiM2I4MDMwXzQtMS0xLTEtNTgzNzI_db268b25-c291-4556-803e-8fb66eaa4ae2">3,799</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id970dfd2674c4d6b895febb9c14d0fd1_I20211231" decimals="-3" name="optn:AccruedSellingGeneralandAdministrativeCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNTcvZnJhZzoxN2I3ZmRiMGZlM2E0ZDlmYTVjYzA4ODU5NjVmNWI1Ni90YWJsZTphNTNhOTQxMjIxYjg0ODk3YjFmN2Y3NzJjYjNiODAzMC90YWJsZXJhbmdlOmE1M2E5NDEyMjFiODQ4OTdiMWY3Zjc3MmNiM2I4MDMwXzQtMy0xLTEtNTgzNzI_c0ba9b2b-3835-41b7-a034-8a8fed28308e">6,124</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Research and development expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231" decimals="-3" name="optn:AccruedResearchandDevelopmentCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNTcvZnJhZzoxN2I3ZmRiMGZlM2E0ZDlmYTVjYzA4ODU5NjVmNWI1Ni90YWJsZTphNTNhOTQxMjIxYjg0ODk3YjFmN2Y3NzJjYjNiODAzMC90YWJsZXJhbmdlOmE1M2E5NDEyMjFiODQ4OTdiMWY3Zjc3MmNiM2I4MDMwXzUtMS0xLTEtNTgzNzI_28a0d79b-5492-49dc-a541-525d67785f67">1,298</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id970dfd2674c4d6b895febb9c14d0fd1_I20211231" decimals="-3" name="optn:AccruedResearchandDevelopmentCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNTcvZnJhZzoxN2I3ZmRiMGZlM2E0ZDlmYTVjYzA4ODU5NjVmNWI1Ni90YWJsZTphNTNhOTQxMjIxYjg0ODk3YjFmN2Y3NzJjYjNiODAzMC90YWJsZXJhbmdlOmE1M2E5NDEyMjFiODQ4OTdiMWY3Zjc3MmNiM2I4MDMwXzUtMy0xLTEtNTgzNzI_c1d68098-fd82-41aa-a35f-060af3d61e95">6,857</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Payroll expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231" decimals="-3" name="us-gaap:AccruedEmployeeBenefitsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNTcvZnJhZzoxN2I3ZmRiMGZlM2E0ZDlmYTVjYzA4ODU5NjVmNWI1Ni90YWJsZTphNTNhOTQxMjIxYjg0ODk3YjFmN2Y3NzJjYjNiODAzMC90YWJsZXJhbmdlOmE1M2E5NDEyMjFiODQ4OTdiMWY3Zjc3MmNiM2I4MDMwXzYtMS0xLTEtNTgzNzI_637e4872-bd90-4bfd-b8bd-4fc825f2b519">7,888</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id970dfd2674c4d6b895febb9c14d0fd1_I20211231" decimals="-3" name="us-gaap:AccruedEmployeeBenefitsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNTcvZnJhZzoxN2I3ZmRiMGZlM2E0ZDlmYTVjYzA4ODU5NjVmNWI1Ni90YWJsZTphNTNhOTQxMjIxYjg0ODk3YjFmN2Y3NzJjYjNiODAzMC90YWJsZXJhbmdlOmE1M2E5NDEyMjFiODQ4OTdiMWY3Zjc3MmNiM2I4MDMwXzYtMy0xLTEtNTgzNzI_9ab24173-bbbc-4bd2-8683-6e340aca45ae">7,569</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNTcvZnJhZzoxN2I3ZmRiMGZlM2E0ZDlmYTVjYzA4ODU5NjVmNWI1Ni90YWJsZTphNTNhOTQxMjIxYjg0ODk3YjFmN2Y3NzJjYjNiODAzMC90YWJsZXJhbmdlOmE1M2E5NDEyMjFiODQ4OTdiMWY3Zjc3MmNiM2I4MDMwXzctMS0xLTEtNTgzNzI_fe777c0a-57e6-4fce-98b6-85b57c0cad39">1,915</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id970dfd2674c4d6b895febb9c14d0fd1_I20211231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNTcvZnJhZzoxN2I3ZmRiMGZlM2E0ZDlmYTVjYzA4ODU5NjVmNWI1Ni90YWJsZTphNTNhOTQxMjIxYjg0ODk3YjFmN2Y3NzJjYjNiODAzMC90YWJsZXJhbmdlOmE1M2E5NDEyMjFiODQ4OTdiMWY3Zjc3MmNiM2I4MDMwXzctMy0xLTEtNTgzNzI_eb38846a-4d16-4320-986e-8b1e49396ae9">2,057</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;Total accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNTcvZnJhZzoxN2I3ZmRiMGZlM2E0ZDlmYTVjYzA4ODU5NjVmNWI1Ni90YWJsZTphNTNhOTQxMjIxYjg0ODk3YjFmN2Y3NzJjYjNiODAzMC90YWJsZXJhbmdlOmE1M2E5NDEyMjFiODQ4OTdiMWY3Zjc3MmNiM2I4MDMwXzgtMS0xLTEtNTgzNzI_138c1823-1e3f-4905-941a-692b955809e6">42,893</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id970dfd2674c4d6b895febb9c14d0fd1_I20211231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNTcvZnJhZzoxN2I3ZmRiMGZlM2E0ZDlmYTVjYzA4ODU5NjVmNWI1Ni90YWJsZTphNTNhOTQxMjIxYjg0ODk3YjFmN2Y3NzJjYjNiODAzMC90YWJsZXJhbmdlOmE1M2E5NDEyMjFiODQ4OTdiMWY3Zjc3MmNiM2I4MDMwXzgtMy0xLTEtNTgzNzI_02ebca83-f6f1-4667-b191-32404bf15691">49,128</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Lease liability</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNTcvZnJhZzoxN2I3ZmRiMGZlM2E0ZDlmYTVjYzA4ODU5NjVmNWI1Ni90YWJsZTphNTNhOTQxMjIxYjg0ODk3YjFmN2Y3NzJjYjNiODAzMC90YWJsZXJhbmdlOmE1M2E5NDEyMjFiODQ4OTdiMWY3Zjc3MmNiM2I4MDMwXzEwLTEtMS0xLTU4Mzcy_1b4bee0f-e598-4fdb-9701-26890475605a">1,971</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id970dfd2674c4d6b895febb9c14d0fd1_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNTcvZnJhZzoxN2I3ZmRiMGZlM2E0ZDlmYTVjYzA4ODU5NjVmNWI1Ni90YWJsZTphNTNhOTQxMjIxYjg0ODk3YjFmN2Y3NzJjYjNiODAzMC90YWJsZXJhbmdlOmE1M2E5NDEyMjFiODQ4OTdiMWY3Zjc3MmNiM2I4MDMwXzEwLTMtMS0xLTU4Mzcy_c9719e03-4359-47f4-ad16-f21a0e521642">2,094</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;Total other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNTcvZnJhZzoxN2I3ZmRiMGZlM2E0ZDlmYTVjYzA4ODU5NjVmNWI1Ni90YWJsZTphNTNhOTQxMjIxYjg0ODk3YjFmN2Y3NzJjYjNiODAzMC90YWJsZXJhbmdlOmE1M2E5NDEyMjFiODQ4OTdiMWY3Zjc3MmNiM2I4MDMwXzExLTEtMS0xLTU4Mzcy_d041681f-f6fc-4dab-af9b-f8eae869bb30">1,971</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id970dfd2674c4d6b895febb9c14d0fd1_I20211231" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNTcvZnJhZzoxN2I3ZmRiMGZlM2E0ZDlmYTVjYzA4ODU5NjVmNWI1Ni90YWJsZTphNTNhOTQxMjIxYjg0ODk3YjFmN2Y3NzJjYjNiODAzMC90YWJsZXJhbmdlOmE1M2E5NDEyMjFiODQ4OTdiMWY3Zjc3MmNiM2I4MDMwXzExLTMtMS0xLTU4Mzcy_f9db6424-2a01-47c9-8e17-d9a16b45fcf3">2,094</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;Total accrued expenses and other current liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231" decimals="-3" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNTcvZnJhZzoxN2I3ZmRiMGZlM2E0ZDlmYTVjYzA4ODU5NjVmNWI1Ni90YWJsZTphNTNhOTQxMjIxYjg0ODk3YjFmN2Y3NzJjYjNiODAzMC90YWJsZXJhbmdlOmE1M2E5NDEyMjFiODQ4OTdiMWY3Zjc3MmNiM2I4MDMwXzEyLTEtMS0xLTU4Mzcy_90726ddd-3d74-4de8-b97b-73d94c573d60">44,864</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id970dfd2674c4d6b895febb9c14d0fd1_I20211231" decimals="-3" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNTcvZnJhZzoxN2I3ZmRiMGZlM2E0ZDlmYTVjYzA4ODU5NjVmNWI1Ni90YWJsZTphNTNhOTQxMjIxYjg0ODk3YjFmN2Y3NzJjYjNiODAzMC90YWJsZXJhbmdlOmE1M2E5NDEyMjFiODQ4OTdiMWY3Zjc3MmNiM2I4MDMwXzEyLTMtMS0xLTU4Mzcy_b347b14a-47ca-4cba-81c4-2e41d03ecf04">51,222</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-align:center"><span><br/></span></div><div id="i451bcb3eabba4f87bdc579718207a3b8_160"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9. <ix:nonNumeric contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" name="us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNjAvZnJhZzozOWY1MDRmNjYzMjk0MWYyYmNhZWY0MGVjNjE0MjE5NC90ZXh0cmVnaW9uOjM5ZjUwNGY2NjMyOTQxZjJiY2FlZjQwZWM2MTQyMTk0XzIzOTY_b9be10b5-7916-4b56-a768-d43f383261f4" continuedAt="i4008e4c8683d4915a81b526664c56135" escape="true">License Agreements</ix:nonNumeric></span></div><ix:continuation id="i4008e4c8683d4915a81b526664c56135"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Currax License Agreement</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 25, 2019, OptiNose AS entered into a license agreement (the Currax License Agreement) with Currax pursuant to which the Company granted Currax an exclusive license to certain intellectual property for the commercialization of Onzetra Xsail in the US, Canada and Mexico.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, a specified regulatory milestone was met and the Company received a $<ix:nonFraction unitRef="usd" contextRef="i5fd2ee54427b485b93f8b56d2a73b716_D20210101-20210131" decimals="-3" name="optn:ResearchAndDevelopmentArrangementContractToPerformForOthersMilestonePaymentsMaximumEligible" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNjAvZnJhZzozOWY1MDRmNjYzMjk0MWYyYmNhZWY0MGVjNjE0MjE5NC90ZXh0cmVnaW9uOjM5ZjUwNGY2NjMyOTQxZjJiY2FlZjQwZWM2MTQyMTk0Xzc4Mg_2cd48ba5-9990-4c1f-b34f-875d380e75dd">1,000</ix:nonFraction> milestone payment. The Company does not expect to receive any further payments from Currax under the terms of the License Agreement other than reimbursement for certain expenses.</span></div></ix:continuation><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div><div id="i451bcb3eabba4f87bdc579718207a3b8_163"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10. <ix:nonNumeric contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNjMvZnJhZzo2MDhmMjg1NzYwMTY0NDM2OGExYTY4NmEyNjgwZGYyYi90ZXh0cmVnaW9uOjYwOGYyODU3NjAxNjQ0MzY4YTFhNjg2YTI2ODBkZjJiXzY3NzE_f50530b3-4d68-42c5-9b25-f918bcef11e9" continuedAt="i2e262733847d41c1b1d5c5cf5b59024c" escape="true">Debt, net</ix:nonNumeric></span></div><ix:continuation id="i2e262733847d41c1b1d5c5cf5b59024c" continuedAt="i3463c85c91714df6b80f58f84ce3bd91"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 12, 2019 (the Closing Date), the Company entered into a Note Purchase Agreement with funds managed by Pharmakon Advisors, LP (Pharmakon), the investment manager of BioPharma Credit Funds (BioPharma). The Note Purchase Agreement provided the Company with $<ix:nonFraction unitRef="usd" contextRef="i62f6f90c47544ada9c32250b077bb99b_I20190912" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNjMvZnJhZzo2MDhmMjg1NzYwMTY0NDM2OGExYTY4NmEyNjgwZGYyYi90ZXh0cmVnaW9uOjYwOGYyODU3NjAxNjQ0MzY4YTFhNjg2YTI2ODBkZjJiXzIxOTkwMjMyODY5NjI_680237c7-1eb9-41ec-bca3-58a71f39d6cc">130,000</ix:nonFraction> in debt financing, of which $<ix:nonFraction unitRef="usd" contextRef="i62f6f90c47544ada9c32250b077bb99b_I20190912" decimals="-3" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNjMvZnJhZzo2MDhmMjg1NzYwMTY0NDM2OGExYTY4NmEyNjgwZGYyYi90ZXh0cmVnaW9uOjYwOGYyODU3NjAxNjQ0MzY4YTFhNjg2YTI2ODBkZjJiXzIxOTkwMjMyODQwNzM_e9444fee-7295-4ac8-ab07-b2615790f30f">80,000</ix:nonFraction> of senior secured notes (the Pharmakon Senior Secured Notes) was issued on the Closing Date, $<ix:nonFraction unitRef="usd" contextRef="i047f781d92bd40e5b05937913709530f_I20200213" decimals="-3" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNjMvZnJhZzo2MDhmMjg1NzYwMTY0NDM2OGExYTY4NmEyNjgwZGYyYi90ZXh0cmVnaW9uOjYwOGYyODU3NjAxNjQ0MzY4YTFhNjg2YTI2ODBkZjJiXzIxOTkwMjMyODQwNzc_aa0e820c-025f-4c18-b86b-30796bfb1d00">30,000</ix:nonFraction> was issued on February 13, 2020 after achieving the $<ix:nonFraction unitRef="usd" contextRef="i2dd470baef924f409cb50332bb1d158a_D20191001-20191231" decimals="-3" name="optn:DebtInstrumentIssuanceCriteriaTermNetSalesAndRoyaltiesBenchmark" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNjMvZnJhZzo2MDhmMjg1NzYwMTY0NDM2OGExYTY4NmEyNjgwZGYyYi90ZXh0cmVnaW9uOjYwOGYyODU3NjAxNjQ0MzY4YTFhNjg2YTI2ODBkZjJiXzIxOTkwMjMyODQwODU_2c49136f-bc59-4444-a597-d06ca2dbc22e">9,000</ix:nonFraction> consolidated XHANCE net sales and royalties threshold for the quarter ended December 31, 2019 and $<ix:nonFraction unitRef="usd" contextRef="i2c43759aacc744b2ab7dc2cf4563d669_I20201201" decimals="-3" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNjMvZnJhZzo2MDhmMjg1NzYwMTY0NDM2OGExYTY4NmEyNjgwZGYyYi90ZXh0cmVnaW9uOjYwOGYyODU3NjAxNjQ0MzY4YTFhNjg2YTI2ODBkZjJiXzIxOTkwMjMyODQwODE_f5747d37-129a-4778-9167-2e83797beceb">20,000</ix:nonFraction> was issued on December 1, 2020 after achieving the $<ix:nonFraction unitRef="usd" contextRef="ib972721f09ce4ecca02118dff9ab3a54_D20200701-20200930" decimals="-3" name="optn:DebtInstrumentIssuanceCriteriaTermNetSalesAndRoyaltiesBenchmark" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNjMvZnJhZzo2MDhmMjg1NzYwMTY0NDM2OGExYTY4NmEyNjgwZGYyYi90ZXh0cmVnaW9uOjYwOGYyODU3NjAxNjQ0MzY4YTFhNjg2YTI2ODBkZjJiXzIxOTkwMjMyODQwODk_fa8b5fe5-189a-4e94-903f-da9dfedeadd1">14,500</ix:nonFraction> consolidated XHANCE net sales and royalties threshold for the quarter ended September 30, 2020.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 10, 2022, the Company entered into a Third Amendment to the Note Purchase Agreement (the Third Amendment).  The Third Amendment reduced the minimum c</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">onsolidated XHANCE net sales and royalties required to be achieved under the Note Purchase Agreement for the trailing twelve-month period ending December 31, 2022 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">from $<ix:nonFraction unitRef="usd" contextRef="ic1354dd9142c4406bb996b9f79066753_I20220809" decimals="-3" name="optn:TrailingTwelveMonthNetRevenueCovenant" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNjMvZnJhZzo2MDhmMjg1NzYwMTY0NDM2OGExYTY4NmEyNjgwZGYyYi90ZXh0cmVnaW9uOjYwOGYyODU3NjAxNjQ0MzY4YTFhNjg2YTI2ODBkZjJiXzIxOTkwMjMyODQxNDU_1913a767-539a-46ac-88eb-c28f12ede5e0">90,000</ix:nonFraction> to $<ix:nonFraction unitRef="usd" contextRef="i0ae63187f7984cadbfb811136622697c_I20220810" decimals="-3" name="optn:TrailingTwelveMonthNetRevenueCovenant" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNjMvZnJhZzo2MDhmMjg1NzYwMTY0NDM2OGExYTY4NmEyNjgwZGYyYi90ZXh0cmVnaW9uOjYwOGYyODU3NjAxNjQ0MzY4YTFhNjg2YTI2ODBkZjJiXzIxOTkwMjMyODQxMTc_77107892-8531-4981-9765-b9cf2e7c4982">85,000</ix:nonFraction> in exchange for a $<ix:nonFraction unitRef="usd" contextRef="ib61af200b06045878d1f67070415e25a_I20220810" decimals="-3" name="optn:FeeDueOnTheMaturityDateOfTheNotePurchaseAgreement" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNjMvZnJhZzo2MDhmMjg1NzYwMTY0NDM2OGExYTY4NmEyNjgwZGYyYi90ZXh0cmVnaW9uOjYwOGYyODU3NjAxNjQ0MzY4YTFhNjg2YTI2ODBkZjJiXzIxOTkwMjMyODQxMjk_a48fca13-717a-4723-8fe9-db9cb7ca4650">780</ix:nonFraction> fee due on the repayment of the Pharmakon Senior Secured Notes.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 9, 2022, the Company entered into a Fourth Amendment to the Note Purchase Agreement (the Fourth Amendment).  The Fourth Amendment resulted in the waiver of the minimum consolidated XHANCE net sales and royalties required to be achieved under the Note Purchase Agreement for the trailing twelve-month period ending September 30, 2022 and December 31, 2022 in exchange for a $<ix:nonFraction unitRef="usd" contextRef="iaf72692f99ed46b5a83cb937a4981bae_I20221109" decimals="-3" name="optn:FeeDueOnTheMaturityDateOfTheNotePurchaseAgreement" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNjMvZnJhZzo2MDhmMjg1NzYwMTY0NDM2OGExYTY4NmEyNjgwZGYyYi90ZXh0cmVnaW9uOjYwOGYyODU3NjAxNjQ0MzY4YTFhNjg2YTI2ODBkZjJiXzIxOTkwMjMyODQxMzc_b6f20e8d-edae-4c66-92ae-dfa8e31f7985">1,300</ix:nonFraction> fee due upon repayment of the Pharmakon Senior Secured Notes.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:112.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OptiNose,&#160;Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div></div><ix:continuation id="i3463c85c91714df6b80f58f84ce3bd91" continuedAt="i555906ff4202437dab62e97d2c8aa9fd"><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On November 23, 2022, the Company amended and restated the Note Purchase Agreement, initially entered into on September 12, 2019 and amended through November 9, 2022, among the Company, its subsidiaries, OptiNose US, Inc., OptiNose AS and OptiNose UK, Ltd. and BioPharma Credit PLC, as collateral agent, and the purchasers party thereto from time to time (the A&amp;R Note Purchase Agreement). <ix:nonNumeric contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNjMvZnJhZzo2MDhmMjg1NzYwMTY0NDM2OGExYTY4NmEyNjgwZGYyYi90ZXh0cmVnaW9uOjYwOGYyODU3NjAxNjQ0MzY4YTFhNjg2YTI2ODBkZjJiXzQ5NDc4MDIzNDUzNDE_2971321d-c8f5-411b-9db5-004274fbe35a" continuedAt="i99201238124f4ba39a9454c09b0136fa" escape="true">Pursuant to the A&amp;R Note Purchase Agreement, certain modifications to the affirmative and negative covenants, events of default and other provisions were made, including, without limitation, (i) the requirement for the Company to deliver quarterly and annual financial statements that, commencing with the Company's consolidated financial statements for the year ending December 31, 2023, are not subject to a &#8220;going concern&#8221; statement (the Going Concern Covenant) and (ii) the removal of certain exceptions to the negative covenants which previously permitted the Company to enter into certain transactions without the consent of the holders of the Pharmakon Senior Secured Notes, including permitted acquisitions, swap contracts, convertible bonds and revolving credit facilities. The financial covenants requiring the Company to achieve minimum trailing twelve-month consolidated XHANCE net product sales and royalties were also modified as follows (in thousands):</ix:nonNumeric></span></div><div><span><br/></span></div><div><ix:continuation id="i99201238124f4ba39a9454c09b0136fa" continuedAt="i6a5336a813484375895ead3d8586e289"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:2.723%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.455%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.332%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.332%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.728%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trailing Twelve-Months Ending</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Requirement Prior to A&amp;R Note Purchase Agreement</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Requirement under the A&amp;R Note Purchase Agreement</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">September 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">March 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="i96634d78ca80401db240ea2a9de1645e_I20221120" decimals="-3" name="optn:NotePurchaseAgreementCovenantXHANCENetProductSalesAndRoyalties" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNjMvZnJhZzo2MDhmMjg1NzYwMTY0NDM2OGExYTY4NmEyNjgwZGYyYi90YWJsZTphN2FkMTY1NWFlOWY0ZGE0Yjc5YWFhOTkyM2ZjOTFhYi90YWJsZXJhbmdlOmE3YWQxNjU1YWU5ZjRkYTRiNzlhYWE5OTIzZmM5MWFiXzQtMi0xLTEtOTk4ODk_1f481ffa-80bc-4e65-bb5d-a222e83f1f8a">98,750</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">June 30, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50b0b50bbf134c7f97db3df38c151093_I20221120" decimals="-3" name="optn:NotePurchaseAgreementCovenantXHANCENetProductSalesAndRoyalties" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNjMvZnJhZzo2MDhmMjg1NzYwMTY0NDM2OGExYTY4NmEyNjgwZGYyYi90YWJsZTphN2FkMTY1NWFlOWY0ZGE0Yjc5YWFhOTkyM2ZjOTFhYi90YWJsZXJhbmdlOmE3YWQxNjU1YWU5ZjRkYTRiNzlhYWE5OTIzZmM5MWFiXzUtMi0xLTEtOTk4ODk_e66ae27e-c264-40f1-9744-488e0f08af4a">102,500</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">September 30, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d657bd081aa4998b54cb136b25d210a_I20221120" decimals="-3" name="optn:NotePurchaseAgreementCovenantXHANCENetProductSalesAndRoyalties" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNjMvZnJhZzo2MDhmMjg1NzYwMTY0NDM2OGExYTY4NmEyNjgwZGYyYi90YWJsZTphN2FkMTY1NWFlOWY0ZGE0Yjc5YWFhOTkyM2ZjOTFhYi90YWJsZXJhbmdlOmE3YWQxNjU1YWU5ZjRkYTRiNzlhYWE5OTIzZmM5MWFiXzYtMi0xLTEtOTk4ODk_5b9040a9-5427-4106-8f2e-a4fe60946aed">106,250</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">December 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie07879a277ed48fc8b5450fd9f7f1ad9_I20221120" decimals="-3" name="optn:NotePurchaseAgreementCovenantXHANCENetProductSalesAndRoyalties" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNjMvZnJhZzo2MDhmMjg1NzYwMTY0NDM2OGExYTY4NmEyNjgwZGYyYi90YWJsZTphN2FkMTY1NWFlOWY0ZGE0Yjc5YWFhOTkyM2ZjOTFhYi90YWJsZXJhbmdlOmE3YWQxNjU1YWU5ZjRkYTRiNzlhYWE5OTIzZmM5MWFiXzctMi0xLTEtOTk4ODk_8d06964d-afbe-48b2-80b2-87c993fffea1">110,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">March 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib294e78ab7cc4fb7b0a4c74b9ced9b5f_I20221120" decimals="-3" name="optn:NotePurchaseAgreementCovenantXHANCENetProductSalesAndRoyalties" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNjMvZnJhZzo2MDhmMjg1NzYwMTY0NDM2OGExYTY4NmEyNjgwZGYyYi90YWJsZTphN2FkMTY1NWFlOWY0ZGE0Yjc5YWFhOTkyM2ZjOTFhYi90YWJsZXJhbmdlOmE3YWQxNjU1YWU5ZjRkYTRiNzlhYWE5OTIzZmM5MWFiXzgtMi0xLTEtOTk4ODk_c0df1fbb-5c16-4d40-a120-2d6efddf7b1f">113,750</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="iebab32ba35ab45b7950eabc69c4f19f4_I20221121" decimals="-3" name="optn:NotePurchaseAgreementCovenantXHANCENetProductSalesAndRoyalties" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNjMvZnJhZzo2MDhmMjg1NzYwMTY0NDM2OGExYTY4NmEyNjgwZGYyYi90YWJsZTphN2FkMTY1NWFlOWY0ZGE0Yjc5YWFhOTkyM2ZjOTFhYi90YWJsZXJhbmdlOmE3YWQxNjU1YWU5ZjRkYTRiNzlhYWE5OTIzZmM5MWFiXzgtNC0xLTEtOTk4OTE_cfb36eda-9fbe-4cbd-a658-d82e021a1b61">82,500</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">June 30, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia42f4722c6ea4c0ba9424cbb5b7db442_I20221120" decimals="-3" name="optn:NotePurchaseAgreementCovenantXHANCENetProductSalesAndRoyalties" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNjMvZnJhZzo2MDhmMjg1NzYwMTY0NDM2OGExYTY4NmEyNjgwZGYyYi90YWJsZTphN2FkMTY1NWFlOWY0ZGE0Yjc5YWFhOTkyM2ZjOTFhYi90YWJsZXJhbmdlOmE3YWQxNjU1YWU5ZjRkYTRiNzlhYWE5OTIzZmM5MWFiXzktMi0xLTEtOTk4ODk_dcf87d0a-e17f-4550-9830-3aa222cdfde8">117,500</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied0332f696c74d02b9bca94cd69b5f71_I20221121" decimals="-3" name="optn:NotePurchaseAgreementCovenantXHANCENetProductSalesAndRoyalties" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNjMvZnJhZzo2MDhmMjg1NzYwMTY0NDM2OGExYTY4NmEyNjgwZGYyYi90YWJsZTphN2FkMTY1NWFlOWY0ZGE0Yjc5YWFhOTkyM2ZjOTFhYi90YWJsZXJhbmdlOmE3YWQxNjU1YWU5ZjRkYTRiNzlhYWE5OTIzZmM5MWFiXzktNC0xLTEtOTk4OTE_30f85e1a-5494-4cf3-886e-f4768a521415">90,000</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">September 30, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0d86211c30f4dcc99c47c2ccac871ce_I20221121" decimals="-3" name="optn:NotePurchaseAgreementCovenantXHANCENetProductSalesAndRoyalties" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNjMvZnJhZzo2MDhmMjg1NzYwMTY0NDM2OGExYTY4NmEyNjgwZGYyYi90YWJsZTphN2FkMTY1NWFlOWY0ZGE0Yjc5YWFhOTkyM2ZjOTFhYi90YWJsZXJhbmdlOmE3YWQxNjU1YWU5ZjRkYTRiNzlhYWE5OTIzZmM5MWFiXzEwLTQtMS0xLTk5ODkx_d2f34158-dd16-49af-81d1-5aaf7017f67b">102,500</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">December 31, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33d3c0e47ba74ff5a8b749a97af8db65_I20221121" decimals="-3" name="optn:NotePurchaseAgreementCovenantXHANCENetProductSalesAndRoyalties" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNjMvZnJhZzo2MDhmMjg1NzYwMTY0NDM2OGExYTY4NmEyNjgwZGYyYi90YWJsZTphN2FkMTY1NWFlOWY0ZGE0Yjc5YWFhOTkyM2ZjOTFhYi90YWJsZXJhbmdlOmE3YWQxNjU1YWU5ZjRkYTRiNzlhYWE5OTIzZmM5MWFiXzExLTQtMS0xLTk5ODkx_acc45d1c-6ccf-4e6a-816b-b03231396f14">110,000</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">March 31, 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9044805836a742b1ad16a4f9886ba9a4_I20221121" decimals="-3" name="optn:NotePurchaseAgreementCovenantXHANCENetProductSalesAndRoyalties" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNjMvZnJhZzo2MDhmMjg1NzYwMTY0NDM2OGExYTY4NmEyNjgwZGYyYi90YWJsZTphN2FkMTY1NWFlOWY0ZGE0Yjc5YWFhOTkyM2ZjOTFhYi90YWJsZXJhbmdlOmE3YWQxNjU1YWU5ZjRkYTRiNzlhYWE5OTIzZmM5MWFiXzEyLTQtMS0xLTk5ODkx_b2165f51-0c3b-41a6-91d1-da19c44b28d9">115,000</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">June 30, 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3364391e55a8465f8779312aa2de8ee3_I20221121" decimals="-3" name="optn:NotePurchaseAgreementCovenantXHANCENetProductSalesAndRoyalties" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNjMvZnJhZzo2MDhmMjg1NzYwMTY0NDM2OGExYTY4NmEyNjgwZGYyYi90YWJsZTphN2FkMTY1NWFlOWY0ZGE0Yjc5YWFhOTkyM2ZjOTFhYi90YWJsZXJhbmdlOmE3YWQxNjU1YWU5ZjRkYTRiNzlhYWE5OTIzZmM5MWFiXzEzLTQtMS0xLTk5ODkx_2dd99f41-4067-423a-9564-f0506a6342fc">120,000</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">September 30, 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1362d0ef4cda4d66927a9a59de67480a_I20221121" decimals="-3" name="optn:NotePurchaseAgreementCovenantXHANCENetProductSalesAndRoyalties" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNjMvZnJhZzo2MDhmMjg1NzYwMTY0NDM2OGExYTY4NmEyNjgwZGYyYi90YWJsZTphN2FkMTY1NWFlOWY0ZGE0Yjc5YWFhOTkyM2ZjOTFhYi90YWJsZXJhbmdlOmE3YWQxNjU1YWU5ZjRkYTRiNzlhYWE5OTIzZmM5MWFiXzE0LTQtMS0xLTk5ODkx_3be3befb-6784-47fc-a41d-45d5186ee204">125,000</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">December 31, 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb311cdcf8a9432c86887963e33e45f4_I20221121" decimals="-3" name="optn:NotePurchaseAgreementCovenantXHANCENetProductSalesAndRoyalties" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNjMvZnJhZzo2MDhmMjg1NzYwMTY0NDM2OGExYTY4NmEyNjgwZGYyYi90YWJsZTphN2FkMTY1NWFlOWY0ZGE0Yjc5YWFhOTkyM2ZjOTFhYi90YWJsZXJhbmdlOmE3YWQxNjU1YWU5ZjRkYTRiNzlhYWE5OTIzZmM5MWFiXzE1LTQtMS0xLTk5ODkx_f0542d7b-a6ed-4569-abc9-e0be53817bfc">130,000</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">March 31, 2026</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib965e05b5c0041c399de4fe3b2ae4e52_I20221121" decimals="-3" name="optn:NotePurchaseAgreementCovenantXHANCENetProductSalesAndRoyalties" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNjMvZnJhZzo2MDhmMjg1NzYwMTY0NDM2OGExYTY4NmEyNjgwZGYyYi90YWJsZTphN2FkMTY1NWFlOWY0ZGE0Yjc5YWFhOTkyM2ZjOTFhYi90YWJsZXJhbmdlOmE3YWQxNjU1YWU5ZjRkYTRiNzlhYWE5OTIzZmM5MWFiXzE2LTQtMS0xLTk5ODkx_1ed5f5ea-9ea2-4533-9a63-5bc1c07c86e8">135,000</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">June 30, 2026</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03d054262028474889eca1899fe6608a_I20221121" decimals="-3" name="optn:NotePurchaseAgreementCovenantXHANCENetProductSalesAndRoyalties" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNjMvZnJhZzo2MDhmMjg1NzYwMTY0NDM2OGExYTY4NmEyNjgwZGYyYi90YWJsZTphN2FkMTY1NWFlOWY0ZGE0Yjc5YWFhOTkyM2ZjOTFhYi90YWJsZXJhbmdlOmE3YWQxNjU1YWU5ZjRkYTRiNzlhYWE5OTIzZmM5MWFiXzE3LTQtMS0xLTk5ODkx_e1311190-11e7-48cb-82fe-cc485fb4415c">140,000</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">September 30, 2026</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i482f0725fc2c4ff7b615761825e52e2e_I20221121" decimals="-3" name="optn:NotePurchaseAgreementCovenantXHANCENetProductSalesAndRoyalties" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNjMvZnJhZzo2MDhmMjg1NzYwMTY0NDM2OGExYTY4NmEyNjgwZGYyYi90YWJsZTphN2FkMTY1NWFlOWY0ZGE0Yjc5YWFhOTkyM2ZjOTFhYi90YWJsZXJhbmdlOmE3YWQxNjU1YWU5ZjRkYTRiNzlhYWE5OTIzZmM5MWFiXzE4LTQtMS0xLTk5ODkx_dd042c83-7720-4e94-a8fe-8930834463a9">145,000</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">December 31, 2026</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b4176cedeca41789b0e80197b83e051_I20221121" decimals="-3" name="optn:NotePurchaseAgreementCovenantXHANCENetProductSalesAndRoyalties" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNjMvZnJhZzo2MDhmMjg1NzYwMTY0NDM2OGExYTY4NmEyNjgwZGYyYi90YWJsZTphN2FkMTY1NWFlOWY0ZGE0Yjc5YWFhOTkyM2ZjOTFhYi90YWJsZXJhbmdlOmE3YWQxNjU1YWU5ZjRkYTRiNzlhYWE5OTIzZmM5MWFiXzE5LTQtMS0xLTk5ODkx_7d5edd70-fa8d-40e8-88bb-346166f30edf">150,000</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">March 31, 2027</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4c59ac4f7d84023ba6dbab73c1e6899_I20221121" decimals="-3" name="optn:NotePurchaseAgreementCovenantXHANCENetProductSalesAndRoyalties" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNjMvZnJhZzo2MDhmMjg1NzYwMTY0NDM2OGExYTY4NmEyNjgwZGYyYi90YWJsZTphN2FkMTY1NWFlOWY0ZGE0Yjc5YWFhOTkyM2ZjOTFhYi90YWJsZXJhbmdlOmE3YWQxNjU1YWU5ZjRkYTRiNzlhYWE5OTIzZmM5MWFiXzIwLTQtMS0xLTk5ODkx_141a198b-a44a-4d55-bc73-7f5d63a0b3c8">155,000</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">June 30, 2027</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f50064d7872407bb6b3b9a2c50c62eb_I20221121" decimals="-3" name="optn:NotePurchaseAgreementCovenantXHANCENetProductSalesAndRoyalties" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNjMvZnJhZzo2MDhmMjg1NzYwMTY0NDM2OGExYTY4NmEyNjgwZGYyYi90YWJsZTphN2FkMTY1NWFlOWY0ZGE0Yjc5YWFhOTkyM2ZjOTFhYi90YWJsZXJhbmdlOmE3YWQxNjU1YWU5ZjRkYTRiNzlhYWE5OTIzZmM5MWFiXzIxLTQtMS0xLTk5ODkx_c2a2508f-b849-458a-a729-3535d922e3a2">160,000</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">September 30, 2027</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fc5337d1b3e406b8ce2787d51ed4dc1_I20221121" decimals="-3" name="optn:NotePurchaseAgreementCovenantXHANCENetProductSalesAndRoyalties" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNjMvZnJhZzo2MDhmMjg1NzYwMTY0NDM2OGExYTY4NmEyNjgwZGYyYi90YWJsZTphN2FkMTY1NWFlOWY0ZGE0Yjc5YWFhOTkyM2ZjOTFhYi90YWJsZXJhbmdlOmE3YWQxNjU1YWU5ZjRkYTRiNzlhYWE5OTIzZmM5MWFiXzIyLTQtMS0xLTk5ODkx_0697273b-8b7c-4b14-9c37-4091a0bf1ce1">165,000</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></ix:continuation></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The A&amp;R Note Purchase Agreement provided for an extension of the maturity date of the Pharmakon Senior Secured Notes from September 12, 2024 to June 30, 2027 (New Maturity Date), an extension of the interest-only period from September 2023 to September 2025, after which principal repayments will commence starting on September 30, 2025 and will be made in eight equal quarterly installments of principal and interest through the New Maturity Date. As part of the A&amp;R Note Purchase Agreement the Pharmakon Senior Secured Notes will now bear an amended interest rate through the New Maturity Date equal to the <ix:nonNumeric contextRef="i536baadaab72454d98e7f61dc860283b_D20221121-20221121" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNjMvZnJhZzo2MDhmMjg1NzYwMTY0NDM2OGExYTY4NmEyNjgwZGYyYi90ZXh0cmVnaW9uOjYwOGYyODU3NjAxNjQ0MzY4YTFhNjg2YTI2ODBkZjJiXzIxOTkwMjMyODQxNjA_7807bc47-d943-4f5b-b5d6-5dbf3375aa55">3</ix:nonNumeric>-month Secured Overnight Financing Rate (subject to a <ix:nonFraction unitRef="number" contextRef="ic6a19df6a9ed4b9a96606c2aeae2cd03_D20221121-20221121" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNjMvZnJhZzo2MDhmMjg1NzYwMTY0NDM2OGExYTY4NmEyNjgwZGYyYi90ZXh0cmVnaW9uOjYwOGYyODU3NjAxNjQ0MzY4YTFhNjg2YTI2ODBkZjJiXzIxOTkwMjMyODQxNjQ_0e8c5bc2-ce08-4e44-9a27-63e44f301500">2.50</ix:nonFraction>% floor), determined as of the date that is two business days prior to the commencement of each quarter, plus <ix:nonFraction unitRef="number" contextRef="i0ec8ef0a77c840fe941543a77bb688a7_I20221121" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNjMvZnJhZzo2MDhmMjg1NzYwMTY0NDM2OGExYTY4NmEyNjgwZGYyYi90ZXh0cmVnaW9uOjYwOGYyODU3NjAxNjQ0MzY4YTFhNjg2YTI2ODBkZjJiXzIxOTkwMjMyODQxNjg_4854bed4-6459-4ad8-abb8-4e5cdfbd5fd9">8.50</ix:nonFraction>% per annum (effective rate of <ix:nonFraction unitRef="number" contextRef="ibd48856bcb224069b298e05dfdf34fc8_I20221231" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNjMvZnJhZzo2MDhmMjg1NzYwMTY0NDM2OGExYTY4NmEyNjgwZGYyYi90ZXh0cmVnaW9uOjYwOGYyODU3NjAxNjQ0MzY4YTFhNjg2YTI2ODBkZjJiXzIxOTkwMjMyOTIwODE_ea6a7264-89fb-418b-888e-6c8d11db503d">13.62</ix:nonFraction>% at December 31, 2022), which interest rate shall be increased by an additional <ix:nonFraction unitRef="number" contextRef="i4af8cd3923a14bf4bd1655d4e950bb46_D20221121-20221121" decimals="4" name="optn:PotentialDebtInstrumentInterestRateIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNjMvZnJhZzo2MDhmMjg1NzYwMTY0NDM2OGExYTY4NmEyNjgwZGYyYi90ZXh0cmVnaW9uOjYwOGYyODU3NjAxNjQ0MzY4YTFhNjg2YTI2ODBkZjJiXzIxOTkwMjMyODQxNzI_5ffbcd7e-f7e9-4eaf-b023-58069b9309ff">3.00</ix:nonFraction>% per annum upon the occurrence and during the continuation of any event of default. </span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:112.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OptiNose,&#160;Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div></div><ix:continuation id="i555906ff4202437dab62e97d2c8aa9fd" continuedAt="ib2bbccff2c0946b2b966d4e8aea76ee1"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In conjunction with the A&amp;R Note Purchase Agreement, a modification was made to the &#8220;make-whole&#8221; premium payment due in connection with any principal prepayments (whether mandatory or voluntary) made prior to the 3-year anniversary of the date of the A&amp;R Note Purchase Agreement. On any such prepayment date, the Company will be required to pay a make-whole premium in the amount of (i) for any prepayment date occurring up until and including the 18-month anniversary of the date of the A&amp;R Note Purchase Agreement, the foregone interest from such prepayment date through the <ix:nonNumeric contextRef="i4bfb752944e54d3faa2837a8b3afb6b2_D20221121-20221121" name="optn:DebtInstrumentMakeWholeProvisionPaymentAccrualPeriod" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNjMvZnJhZzo2MDhmMjg1NzYwMTY0NDM2OGExYTY4NmEyNjgwZGYyYi90ZXh0cmVnaW9uOjYwOGYyODU3NjAxNjQ0MzY4YTFhNjg2YTI2ODBkZjJiXzIxOTkwMjMyODQxODg_d1162dbd-cbe6-424a-b341-d45e0f272081">18</ix:nonNumeric>-month anniversary of such prepayment date; and (ii) for any prepayment after the <ix:nonNumeric contextRef="i4bfb752944e54d3faa2837a8b3afb6b2_D20221121-20221121" name="optn:DebtInstrumentMakeWholeProvisionPaymentAccrualPeriod" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNjMvZnJhZzo2MDhmMjg1NzYwMTY0NDM2OGExYTY4NmEyNjgwZGYyYi90ZXh0cmVnaW9uOjYwOGYyODU3NjAxNjQ0MzY4YTFhNjg2YTI2ODBkZjJiXzIxOTkwMjMyODQxOTI_1f317d93-06ca-43ab-96fe-8e055bbc2520">18</ix:nonNumeric>-month anniversary of the date of the A&amp;R Note Purchase Agreement, the foregone interest from such prepayment date through the <ix:nonNumeric contextRef="i94c26246ced94d6ebc3cf4dc56035b01_D20221121-20221121" name="optn:DebtInstrumentMakeWholeProvisionPaymentAccrualPeriod" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNjMvZnJhZzo2MDhmMjg1NzYwMTY0NDM2OGExYTY4NmEyNjgwZGYyYi90ZXh0cmVnaW9uOjYwOGYyODU3NjAxNjQ0MzY4YTFhNjg2YTI2ODBkZjJiXzIxOTkwMjMyODQxODQ_4b3859ae-849c-463b-8ba6-5755aa40e19c">3</ix:nonNumeric>-year anniversary of the date of the A&amp;R Note Purchase Agreement; provided, however, that in no event shall the amount of all make-whole premium payments exceed $<ix:nonFraction unitRef="usd" contextRef="i0ec8ef0a77c840fe941543a77bb688a7_I20221121" decimals="-3" name="optn:DebtInstrumentMaximumAggregateMakeWholePremiumAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNjMvZnJhZzo2MDhmMjg1NzYwMTY0NDM2OGExYTY4NmEyNjgwZGYyYi90ZXh0cmVnaW9uOjYwOGYyODU3NjAxNjQ0MzY4YTFhNjg2YTI2ODBkZjJiXzIxOTkwMjMyODQxOTU_e33e0a4a-e910-4d92-896d-11052cdd6ca8">24,000</ix:nonFraction> in the aggregate; </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As an inducement for the holders of the Pharmakon Senior Secured Notes to enter into the A&amp;R Note Purchase Agreement, the Company is required to pay the holders of the Pharmakon Senior Secured Notes an amendment fee of $<ix:nonFraction unitRef="usd" contextRef="i2f6060dc084947d8b5a97c9542a55c23_I20221121" decimals="-3" name="optn:AmendmentFee" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNjMvZnJhZzo2MDhmMjg1NzYwMTY0NDM2OGExYTY4NmEyNjgwZGYyYi90ZXh0cmVnaW9uOjYwOGYyODU3NjAxNjQ0MzY4YTFhNjg2YTI2ODBkZjJiXzIxOTkwMjMyODQyMTI_5abbea9e-8f8e-4bcb-9d13-2c30cc86c510">3,900</ix:nonFraction> (representing <ix:nonFraction unitRef="number" contextRef="i4af8cd3923a14bf4bd1655d4e950bb46_D20221121-20221121" decimals="3" name="optn:AmendmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNjMvZnJhZzo2MDhmMjg1NzYwMTY0NDM2OGExYTY4NmEyNjgwZGYyYi90ZXh0cmVnaW9uOjYwOGYyODU3NjAxNjQ0MzY4YTFhNjg2YTI2ODBkZjJiXzIxOTkwMjMyODQyMDQ_d97575ae-0a4e-4ab1-a255-ca54b794a7db">3.00</ix:nonFraction>% of the outstanding principal balance of such notes) due on the New Maturity Date or the earlier repayment of the Pharmakon Senior Secured Notes, which amendment fee shall be (i) reduced to $<ix:nonFraction unitRef="usd" contextRef="i48ae5fa4e9e144c09f6e99f5f4994a45_I20221121" decimals="-3" name="optn:AmendmentFee" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNjMvZnJhZzo2MDhmMjg1NzYwMTY0NDM2OGExYTY4NmEyNjgwZGYyYi90ZXh0cmVnaW9uOjYwOGYyODU3NjAxNjQ0MzY4YTFhNjg2YTI2ODBkZjJiXzIxOTkwMjMyODQyMDg_2e73e502-8b87-421b-9074-585708a1b9e5">1,300</ix:nonFraction> in the event that the Company repays the Pharmakon Senior Secured Notes in full prior to the one-year anniversary of the date of the A&amp;R Note Purchase Agreement and (ii) reduced to $<ix:nonFraction unitRef="usd" contextRef="ida56878d1ff24c82a2ce1db8be8bfdec_I20221121" decimals="-3" name="optn:AmendmentFee" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNjMvZnJhZzo2MDhmMjg1NzYwMTY0NDM2OGExYTY4NmEyNjgwZGYyYi90ZXh0cmVnaW9uOjYwOGYyODU3NjAxNjQ0MzY4YTFhNjg2YTI2ODBkZjJiXzIxOTkwMjMyODQyMjA_99beb63f-862f-4874-85d9-5f131c26d001">2,600</ix:nonFraction> in the event that the Company repays the Pharmakon Senior Secured Notes in full on or after the one-year anniversary of the date of the A&amp;R Note Purchase Agreement and prior to second anniversary of the date of the A&amp;R Note Purchase Agreement. Additionally, the $<ix:nonFraction unitRef="usd" contextRef="i0ec8ef0a77c840fe941543a77bb688a7_I20221121" decimals="-3" name="optn:AmendmentFeePayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNjMvZnJhZzo2MDhmMjg1NzYwMTY0NDM2OGExYTY4NmEyNjgwZGYyYi90ZXh0cmVnaW9uOjYwOGYyODU3NjAxNjQ0MzY4YTFhNjg2YTI2ODBkZjJiXzIxOTkwMjMyODQyMTY_37240b54-81ee-40ab-bf09-24cee952536a">1,300</ix:nonFraction> fee payable under the Fourth Amendment to the Note Purchase Agreement that the Company entered into on November 9, 2022 will be credited against the amendment fee payable in connection with the A&amp;R Note Purchase Agreement.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Pharmakon Senior Secured Notes are secured by a pledge of substantially all of the assets of the Company and the Guarantors and the A&amp;R Note Purchase Agreement contains affirmative and negative covenants customary for financings of this type, including limitations on the Company&#8217;s and its subsidiaries&#8217; ability, among other things, to incur additional debt, grant or permit additional liens, make investments and acquisitions, merge or consolidate with others, dispose of assets, pay dividends and distributions, repay junior indebtedness, incur a material adverse change and enter into affiliate transactions, in each case, subject to certain exceptions. In addition, the A&amp;R Note Purchase Agreement contains financial covenants requiring the Company to maintain certain minimum trailing twelve-month consolidated XHANCE net sales and royalties, tested on a quarterly basis as noted in the table above, and to have at least $<ix:nonFraction unitRef="usd" contextRef="ibd48856bcb224069b298e05dfdf34fc8_I20221231" decimals="-3" name="optn:DebtInstrumentCovenantCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNjMvZnJhZzo2MDhmMjg1NzYwMTY0NDM2OGExYTY4NmEyNjgwZGYyYi90ZXh0cmVnaW9uOjYwOGYyODU3NjAxNjQ0MzY4YTFhNjg2YTI2ODBkZjJiXzQ5NDc4MDIzNjE2NjM_8469fb6c-7f39-4d0b-975e-8fbbbf47b9f2">30,000</ix:nonFraction> of cash and cash equivalents at all times. The A&amp;R Note Purchase Agreement also includes events of default customary for financings of this type, in certain cases subject to customary periods to cure, following which BioPharma may accelerate all amounts outstanding under the Pharmakon Senior Secured Notes.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company believes that it is probable that it will not achieve the trailing twelve-month minimum consolidated XHANCE net sales and royalties thresholds that it is required to achieve commencing with the period ending March 31, 2024.  Additionally, without additional capital, the Company believes that it is probable that it will not be able to maintain at least $<ix:nonFraction unitRef="usd" contextRef="ibd48856bcb224069b298e05dfdf34fc8_I20221231" decimals="-3" name="optn:DebtInstrumentCovenantCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNjMvZnJhZzo2MDhmMjg1NzYwMTY0NDM2OGExYTY4NmEyNjgwZGYyYi90ZXh0cmVnaW9uOjYwOGYyODU3NjAxNjQ0MzY4YTFhNjg2YTI2ODBkZjJiXzQ5NDc4MDIzNjE2NzI_9bf3ee5f-b51a-4f1c-805f-425c064ffca7">30,000</ix:nonFraction> of cash and cash equivalents for at least twelve-months following the filing of this Form 10-K. In addition, the Company believes that it is unlikely that it will be able to maintain compliance with the Going Concern Covenant in 2024.  As a result, in accordance with FASB Accounting Standards Codification 470, the Company has classified all outstanding principal and the payment of additional fees upon maturity as a current liability in the accompanying consolidated balance sheet as of December 31, 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded interest expense of $<ix:nonFraction unitRef="usd" contextRef="i238287e400564d288f6e8227556282ab_D20220101-20221231" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNjMvZnJhZzo2MDhmMjg1NzYwMTY0NDM2OGExYTY4NmEyNjgwZGYyYi90ZXh0cmVnaW9uOjYwOGYyODU3NjAxNjQ0MzY4YTFhNjg2YTI2ODBkZjJiXzY1NjA_0884df73-0810-48fc-9a28-fe1710227d03">16,843</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i714fce477c634b15806608bc880b077f_D20210101-20211231" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNjMvZnJhZzo2MDhmMjg1NzYwMTY0NDM2OGExYTY4NmEyNjgwZGYyYi90ZXh0cmVnaW9uOjYwOGYyODU3NjAxNjQ0MzY4YTFhNjg2YTI2ODBkZjJiXzY1Njc_5169fdbc-fbc8-4611-b11c-0dfd9bf245bc">15,973</ix:nonFraction> during the years ended December 31, 2022 and 2021, respectively. Interest expense included total coupon interest and the amortization of debt issuance costs. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:112.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OptiNose,&#160;Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><ix:continuation id="ib2bbccff2c0946b2b966d4e8aea76ee1"><ix:continuation id="i6a5336a813484375895ead3d8586e289"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The debt balance is comprised of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:76.206%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.588%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.117%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.589%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Face amount</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd48856bcb224069b298e05dfdf34fc8_I20221231" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNjMvZnJhZzo2MDhmMjg1NzYwMTY0NDM2OGExYTY4NmEyNjgwZGYyYi90YWJsZTo5MWMyMmY0MWQwNzA0ZGM5OTFlMGMwZGQ1NjM2YWMzZC90YWJsZXJhbmdlOjkxYzIyZjQxZDA3MDRkYzk5MWUwYzBkZDU2MzZhYzNkXzMtMS0xLTEtNTgzNzI_5be662ab-e449-4951-83e9-b014a9370318">130,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7561e1a29a044dc9ad808ce4adaaca18_I20211231" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNjMvZnJhZzo2MDhmMjg1NzYwMTY0NDM2OGExYTY4NmEyNjgwZGYyYi90YWJsZTo5MWMyMmY0MWQwNzA0ZGM5OTFlMGMwZGQ1NjM2YWMzZC90YWJsZXJhbmdlOjkxYzIyZjQxZDA3MDRkYzk5MWUwYzBkZDU2MzZhYzNkXzMtMy0xLTEtNTgzNzI_9097d54c-af55-4c38-be2a-14d1a50bc798">130,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Front end fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibd48856bcb224069b298e05dfdf34fc8_I20221231" decimals="-3" name="optn:DebtInstrumentFeeAmountFrontEnd" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNjMvZnJhZzo2MDhmMjg1NzYwMTY0NDM2OGExYTY4NmEyNjgwZGYyYi90YWJsZTo5MWMyMmY0MWQwNzA0ZGM5OTFlMGMwZGQ1NjM2YWMzZC90YWJsZXJhbmdlOjkxYzIyZjQxZDA3MDRkYzk5MWUwYzBkZDU2MzZhYzNkXzQtMS0xLTEtNTgzNzI_c44ee488-1425-4eb5-b16a-c955b851bdf5">666</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7561e1a29a044dc9ad808ce4adaaca18_I20211231" decimals="-3" name="optn:DebtInstrumentFeeAmountFrontEnd" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNjMvZnJhZzo2MDhmMjg1NzYwMTY0NDM2OGExYTY4NmEyNjgwZGYyYi90YWJsZTo5MWMyMmY0MWQwNzA0ZGM5OTFlMGMwZGQ1NjM2YWMzZC90YWJsZXJhbmdlOjkxYzIyZjQxZDA3MDRkYzk5MWUwYzBkZDU2MzZhYzNkXzQtMy0xLTEtNTgzNzI_226299d6-ec2b-4550-af0a-4eb487981e43">717</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibd48856bcb224069b298e05dfdf34fc8_I20221231" decimals="-3" name="us-gaap:UnamortizedDebtIssuanceExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNjMvZnJhZzo2MDhmMjg1NzYwMTY0NDM2OGExYTY4NmEyNjgwZGYyYi90YWJsZTo5MWMyMmY0MWQwNzA0ZGM5OTFlMGMwZGQ1NjM2YWMzZC90YWJsZXJhbmdlOjkxYzIyZjQxZDA3MDRkYzk5MWUwYzBkZDU2MzZhYzNkXzUtMS0xLTEtNTgzNzI_a5c91282-c95b-4802-bfaf-61aa8309aba9">6,739</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7561e1a29a044dc9ad808ce4adaaca18_I20211231" decimals="-3" name="us-gaap:UnamortizedDebtIssuanceExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNjMvZnJhZzo2MDhmMjg1NzYwMTY0NDM2OGExYTY4NmEyNjgwZGYyYi90YWJsZTo5MWMyMmY0MWQwNzA0ZGM5OTFlMGMwZGQ1NjM2YWMzZC90YWJsZXJhbmdlOjkxYzIyZjQxZDA3MDRkYzk5MWUwYzBkZDU2MzZhYzNkXzUtMy0xLTEtNTgzNzI_dc36670e-74a5-43de-ba68-70e2ae85cfa6">4,165</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Back end fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd48856bcb224069b298e05dfdf34fc8_I20221231" decimals="-3" name="optn:DebtInstrumentFeeAmountBackEnd" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNjMvZnJhZzo2MDhmMjg1NzYwMTY0NDM2OGExYTY4NmEyNjgwZGYyYi90YWJsZTo5MWMyMmY0MWQwNzA0ZGM5OTFlMGMwZGQ1NjM2YWMzZC90YWJsZXJhbmdlOjkxYzIyZjQxZDA3MDRkYzk5MWUwYzBkZDU2MzZhYzNkXzYtMS0xLTEtNTgzNzI_ef6f3c3a-f76b-41be-90ec-fc5ea415bd8d">5,980</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7561e1a29a044dc9ad808ce4adaaca18_I20211231" decimals="-3" name="optn:DebtInstrumentFeeAmountBackEnd" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNjMvZnJhZzo2MDhmMjg1NzYwMTY0NDM2OGExYTY4NmEyNjgwZGYyYi90YWJsZTo5MWMyMmY0MWQwNzA0ZGM5OTFlMGMwZGQ1NjM2YWMzZC90YWJsZXJhbmdlOjkxYzIyZjQxZDA3MDRkYzk5MWUwYzBkZDU2MzZhYzNkXzYtMy0xLTEtNTgzNzI_70f71053-226b-40f8-af90-4a5f91149b2e">1,300</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd48856bcb224069b298e05dfdf34fc8_I20221231" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNjMvZnJhZzo2MDhmMjg1NzYwMTY0NDM2OGExYTY4NmEyNjgwZGYyYi90YWJsZTo5MWMyMmY0MWQwNzA0ZGM5OTFlMGMwZGQ1NjM2YWMzZC90YWJsZXJhbmdlOjkxYzIyZjQxZDA3MDRkYzk5MWUwYzBkZDU2MzZhYzNkXzctMS0xLTEtNTgzNzI_bfa595c1-0653-4aaa-927a-e699249a8a6b">128,575</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7561e1a29a044dc9ad808ce4adaaca18_I20211231" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNjMvZnJhZzo2MDhmMjg1NzYwMTY0NDM2OGExYTY4NmEyNjgwZGYyYi90YWJsZTo5MWMyMmY0MWQwNzA0ZGM5OTFlMGMwZGQ1NjM2YWMzZC90YWJsZXJhbmdlOjkxYzIyZjQxZDA3MDRkYzk5MWUwYzBkZDU2MzZhYzNkXzctMy0xLTEtNTgzNzI_5d3d04af-82f0-4832-86b7-c20913a104f8">126,418</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></ix:continuation></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span><br/></span></div><div id="i451bcb3eabba4f87bdc579718207a3b8_166"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11. <ix:nonNumeric contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNjYvZnJhZzo5NDNlMGRmMGJhMGQ0Zjk0YjExNzgyMzc1ODQ5YmI3My90ZXh0cmVnaW9uOjk0M2UwZGYwYmEwZDRmOTRiMTE3ODIzNzU4NDliYjczXzEzMTQ_f00b9fe1-3b37-4b17-9c33-6631888f834d" continuedAt="ie93ebcea89c34a8f80755dd06fc8c9e6" escape="true">Employee Benefit Plans</ix:nonNumeric></span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ie93ebcea89c34a8f80755dd06fc8c9e6" continuedAt="i5bb503fee6e546f9968d80a4dcc4006f">The Company maintains a defined contribution 401(k) retirement plan, which covers all eligible US employees. Employees are eligible to participate in the plan on the first of the month following their date of hire. Under the 401(k)&#160;retirement plan, participating employees may defer up to <ix:nonFraction unitRef="number" contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" decimals="INF" name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNjYvZnJhZzo5NDNlMGRmMGJhMGQ0Zjk0YjExNzgyMzc1ODQ5YmI3My90ZXh0cmVnaW9uOjk0M2UwZGYwYmEwZDRmOTRiMTE3ODIzNzU4NDliYjczXzMyMQ_9c3feae2-1b39-4e7f-a148-d00c00094982">100</ix:nonFraction>% of their pre-tax salary, but not more than statutory limits. The Company matches <ix:nonFraction unitRef="number" contextRef="idbd6780d660f4418a87f188eb442ef29_D20220101-20221231" decimals="INF" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNjYvZnJhZzo5NDNlMGRmMGJhMGQ0Zjk0YjExNzgyMzc1ODQ5YmI3My90ZXh0cmVnaW9uOjk0M2UwZGYwYmEwZDRmOTRiMTE3ODIzNzU4NDliYjczXzQwNQ_1405d309-302e-455c-bd46-24fb5f406ca6">100</ix:nonFraction>% of the first <ix:nonFraction unitRef="number" contextRef="idbd6780d660f4418a87f188eb442ef29_D20220101-20221231" decimals="INF" name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNjYvZnJhZzo5NDNlMGRmMGJhMGQ0Zjk0YjExNzgyMzc1ODQ5YmI3My90ZXh0cmVnaW9uOjk0M2UwZGYwYmEwZDRmOTRiMTE3ODIzNzU4NDliYjczXzQyMQ_e83b36a1-a565-4b66-ab80-bf8d23727a0a">3</ix:nonFraction>% of participating employee contributions and <ix:nonFraction unitRef="number" contextRef="i670307f3af404f3b9d62b585c525267b_D20220101-20221231" decimals="INF" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNjYvZnJhZzo5NDNlMGRmMGJhMGQ0Zjk0YjExNzgyMzc1ODQ5YmI3My90ZXh0cmVnaW9uOjk0M2UwZGYwYmEwZDRmOTRiMTE3ODIzNzU4NDliYjczXzQ2OA_3432d7f1-0344-4d6f-b2af-a23561555a79">50</ix:nonFraction>% of the next <ix:nonFraction unitRef="number" contextRef="i670307f3af404f3b9d62b585c525267b_D20220101-20221231" decimals="INF" name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNjYvZnJhZzo5NDNlMGRmMGJhMGQ0Zjk0YjExNzgyMzc1ODQ5YmI3My90ZXh0cmVnaW9uOjk0M2UwZGYwYmEwZDRmOTRiMTE3ODIzNzU4NDliYjczXzQ4Mw_20f0785c-3345-496b-b46a-c6071a827681">2</ix:nonFraction>% of participating employee contributions, subject to applicable IRC limits. The Company incurred costs of $<ix:nonFraction unitRef="usd" contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" decimals="-3" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNjYvZnJhZzo5NDNlMGRmMGJhMGQ0Zjk0YjExNzgyMzc1ODQ5YmI3My90ZXh0cmVnaW9uOjk0M2UwZGYwYmEwZDRmOTRiMTE3ODIzNzU4NDliYjczXzU5MQ_31851a2f-4345-4e7e-9f8b-e36f8a2f9c55">1,112</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231" decimals="-3" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNjYvZnJhZzo5NDNlMGRmMGJhMGQ0Zjk0YjExNzgyMzc1ODQ5YmI3My90ZXh0cmVnaW9uOjk0M2UwZGYwYmEwZDRmOTRiMTE3ODIzNzU4NDliYjczXzU5OA_c66b54b0-ba8a-4df4-b62a-eeba9d6a569c">1,340</ix:nonFraction> related to the Company match applicable to employee contributions for the years ended December 31, 2022 and 2021, respectively. The Company's contributions are made in cash. The Company's common stock is not currently an investment option available to participants in the 401(k) retirement plan.  As of December 31, 2022, approximately $<ix:nonFraction unitRef="usd" contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNjYvZnJhZzo5NDNlMGRmMGJhMGQ0Zjk0YjExNzgyMzc1ODQ5YmI3My90ZXh0cmVnaW9uOjk0M2UwZGYwYmEwZDRmOTRiMTE3ODIzNzU4NDliYjczXzkwNQ_e2335c77-37ad-45f4-a17b-c06bd8216a0d">256</ix:nonFraction> was recorded in accrued expenses related to the Company match. </ix:continuation></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i5bb503fee6e546f9968d80a4dcc4006f">For former Norway employees, the Company maintained a defined contribution pension plan which met the statutory requirements. The Company incurred costs of $<ix:nonFraction unitRef="usd" contextRef="i2d4fcc93e3a14fe6962ee2598dc6066e_D20220101-20221231" decimals="-3" name="us-gaap:DefinedContributionPlanCostRecognized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNjYvZnJhZzo5NDNlMGRmMGJhMGQ0Zjk0YjExNzgyMzc1ODQ5YmI3My90ZXh0cmVnaW9uOjk0M2UwZGYwYmEwZDRmOTRiMTE3ODIzNzU4NDliYjczXzEyMjk_c383101a-1866-474f-95b8-0f4ad7a99908">11</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="idad19395ab8f44dd9a2eb5f01f801543_D20210101-20211231" decimals="-3" name="us-gaap:DefinedContributionPlanCostRecognized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNjYvZnJhZzo5NDNlMGRmMGJhMGQ0Zjk0YjExNzgyMzc1ODQ5YmI3My90ZXh0cmVnaW9uOjk0M2UwZGYwYmEwZDRmOTRiMTE3ODIzNzU4NDliYjczXzEyMzY_53aba448-53c4-44f2-b7d8-9f31af640e2d">6</ix:nonFraction> related to the pension plans for the years ended December 31, 2022 and 2021, respectively.</ix:continuation> </span></div><div><span><br/></span></div><div id="i451bcb3eabba4f87bdc579718207a3b8_169"></div><div style="margin-bottom:8pt;margin-top:8pt"><span><br/></span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12. <ix:nonNumeric contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNjkvZnJhZzozODM3NjU3NDA4ODE0ZjM5OTFlOWFjNGFhYjU5YTJlNC90ZXh0cmVnaW9uOjM4Mzc2NTc0MDg4MTRmMzk5MWU5YWM0YWFiNTlhMmU0XzEwMTk_cb805a92-19df-4a49-8d28-fcb256ee00d1" continuedAt="i0a2f24cef7ba47f1aeb7c3eb282370bb" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="i0a2f24cef7ba47f1aeb7c3eb282370bb"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Purchase commitments</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, the Company had <ix:nonFraction unitRef="usd" contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231" decimals="INF" name="us-gaap:PurchaseObligation" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNjkvZnJhZzozODM3NjU3NDA4ODE0ZjM5OTFlOWFjNGFhYjU5YTJlNC90ZXh0cmVnaW9uOjM4Mzc2NTc0MDg4MTRmMzk5MWU5YWM0YWFiNTlhMmU0Xzg2_0e8eef5d-b26e-46cf-abb0-b7ed661485ac">no</ix:nonFraction> material outstanding non-cancellable purchase commitments related to inventory and other goods and services, including pre-commercial manufacturing scale-up and sales and marketing activities.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employment agreements</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into employment contracts with its officers and certain employees that provide for severance and continuation of benefits in the event of termination of employment by the Company without cause or by the employee for good reason. In addition, in the event of termination of employment following a change in control, the vesting of certain equity awards may be accelerated.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liabilities for loss contingencies arising from claims, assessments, litigation, fines, penalties, and other sources are recorded when it is probable that a liability has been incurred and the amount can be reasonably estimated. The Company is not currently a party to any material pending legal proceedings.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-24</span></div></div></div><div id="i451bcb3eabba4f87bdc579718207a3b8_172"></div><hr style="page-break-after:always"/><div style="min-height:112.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OptiNose,&#160;Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13. <ix:nonNumeric contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzIvZnJhZzo1ZmQ5ZDMzNzdkYTk0ZGNiODViODcwZDU1NTM4YmIxNi90ZXh0cmVnaW9uOjVmZDlkMzM3N2RhOTRkY2I4NWI4NzBkNTU1MzhiYjE2XzIyODU_4d667e22-b958-41af-ab09-a3ae04d214f7" continuedAt="ibd3b8499158d4fb891e2e85bf65d5872" escape="true">Stockholders' Equity</ix:nonNumeric></span></div><ix:continuation id="ibd3b8499158d4fb891e2e85bf65d5872" continuedAt="i524a1f6e5ac040ea9e67aadd0518afe9"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common stock</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 18, 2021, the Company closed an underwritten public offering (the 2021 Offering) of <ix:nonFraction unitRef="shares" contextRef="i35f1c252618f404c810efc41abf15787_D20211118-20211118" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzIvZnJhZzo1ZmQ5ZDMzNzdkYTk0ZGNiODViODcwZDU1NTM4YmIxNi90ZXh0cmVnaW9uOjVmZDlkMzM3N2RhOTRkY2I4NWI4NzBkNTU1MzhiYjE2Xzg5MA_48e71ac5-a57e-4f43-bf85-903c7dad4643">28,750,000</ix:nonFraction> shares of Company common stock (Common Stock) at a price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i1fba48bbd9c94f17a4a169948d5b5dfa_I20211118" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzIvZnJhZzo1ZmQ5ZDMzNzdkYTk0ZGNiODViODcwZDU1NTM4YmIxNi90ZXh0cmVnaW9uOjVmZDlkMzM3N2RhOTRkY2I4NWI4NzBkNTU1MzhiYjE2Xzk1Mw_cb270a28-a401-48eb-a100-bd9ac057ea7d">1.60</ix:nonFraction> per share. As a result of the Offering, the Company received $<ix:nonFraction unitRef="usd" contextRef="i35f1c252618f404c810efc41abf15787_D20211118-20211118" decimals="-3" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzIvZnJhZzo1ZmQ5ZDMzNzdkYTk0ZGNiODViODcwZDU1NTM4YmIxNi90ZXh0cmVnaW9uOjVmZDlkMzM3N2RhOTRkY2I4NWI4NzBkNTU1MzhiYjE2XzEwMTc_cf48cbbc-e852-4c48-b7ff-628a798c3842">42,842</ix:nonFraction> in net proceeds, after deducting commissions and expenses of $<ix:nonFraction unitRef="usd" contextRef="i35f1c252618f404c810efc41abf15787_D20211118-20211118" decimals="-3" name="optn:SaleOfStockCommissionsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzIvZnJhZzo1ZmQ5ZDMzNzdkYTk0ZGNiODViODcwZDU1NTM4YmIxNi90ZXh0cmVnaW9uOjVmZDlkMzM3N2RhOTRkY2I4NWI4NzBkNTU1MzhiYjE2XzIxOTkwMjMyNzA1MzI_88ade87a-bb57-4e25-996c-951749709be5">2,860</ix:nonFraction> and offering costs payable by the Company of $<ix:nonFraction unitRef="usd" contextRef="i1fba48bbd9c94f17a4a169948d5b5dfa_I20211118" decimals="-3" name="us-gaap:DeferredOfferingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzIvZnJhZzo1ZmQ5ZDMzNzdkYTk0ZGNiODViODcwZDU1NTM4YmIxNi90ZXh0cmVnaW9uOjVmZDlkMzM3N2RhOTRkY2I4NWI4NzBkNTU1MzhiYjE2XzExMjk_b4858808-cdd9-4873-9f50-4f02072a4b79">298</ix:nonFraction>.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On November 23, 2022, the Company closed an underwritten public offering (the 2022 Offering) of <ix:nonFraction unitRef="shares" contextRef="ic6fffb430e45481abf555ff9d6505776_D20221123-20221123" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzIvZnJhZzo1ZmQ5ZDMzNzdkYTk0ZGNiODViODcwZDU1NTM4YmIxNi90ZXh0cmVnaW9uOjVmZDlkMzM3N2RhOTRkY2I4NWI4NzBkNTU1MzhiYjE2XzIxOTkwMjMyNjkwMjU_631ae3ae-9937-40b9-b0f4-dfb5abdc7874">26,320,000</ix:nonFraction> shares of Common Stock at a price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i1e2cc5b3626b4c0eb0a50fe312b92bbe_I20221123" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzIvZnJhZzo1ZmQ5ZDMzNzdkYTk0ZGNiODViODcwZDU1NTM4YmIxNi90ZXh0cmVnaW9uOjVmZDlkMzM3N2RhOTRkY2I4NWI4NzBkNTU1MzhiYjE2XzIxOTkwMjMyNjkwOTY_11de2a8c-7b3f-4aee-bef6-f84176ede735">1.89</ix:nonFraction> per share and accompanying warrants to purchase <ix:nonFraction unitRef="shares" contextRef="iea2a2b3820084672a2ce5363d5379529_I20221123" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzIvZnJhZzo1ZmQ5ZDMzNzdkYTk0ZGNiODViODcwZDU1NTM4YmIxNi90ZXh0cmVnaW9uOjVmZDlkMzM3N2RhOTRkY2I4NWI4NzBkNTU1MzhiYjE2XzIxOTkwMjMyNjkxNDg_aa307f37-3d04-47a6-b3d8-7ea6de154119">26,320,000</ix:nonFraction> shares of Common Stock at a public offering price of $<ix:nonFraction unitRef="usdPerShare" contextRef="iea2a2b3820084672a2ce5363d5379529_I20221123" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzIvZnJhZzo1ZmQ5ZDMzNzdkYTk0ZGNiODViODcwZDU1NTM4YmIxNi90ZXh0cmVnaW9uOjVmZDlkMzM3N2RhOTRkY2I4NWI4NzBkNTU1MzhiYjE2XzIxOTkwMjMyNjkyMDU_1079900c-8402-4805-84b7-0ab40e063abe">0.01</ix:nonFraction> per warrant. In addition, the Company granted the underwriters an option for a period of 30 days to purchase up to an additional <ix:nonFraction unitRef="shares" contextRef="i056c6dc8158e43c386a653bfe93f59db_D20221123-20221123" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzIvZnJhZzo1ZmQ5ZDMzNzdkYTk0ZGNiODViODcwZDU1NTM4YmIxNi90ZXh0cmVnaW9uOjVmZDlkMzM3N2RhOTRkY2I4NWI4NzBkNTU1MzhiYjE2XzIxOTkwMjMyNjkzMzk_918b5d2f-f86f-4111-88a4-b42824f81607">3,948,000</ix:nonFraction> shares of Common Stock (the Option Shares) and/or warrants to purchase <ix:nonFraction unitRef="shares" contextRef="i0cf7d2872aa9438888847621f710368c_I20221123" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzIvZnJhZzo1ZmQ5ZDMzNzdkYTk0ZGNiODViODcwZDU1NTM4YmIxNi90ZXh0cmVnaW9uOjVmZDlkMzM3N2RhOTRkY2I4NWI4NzBkNTU1MzhiYjE2XzIxOTkwMjMyNjkzOTQ_2cb843c6-7f77-4a35-a4d5-f6fd453ac213">3,948,000</ix:nonFraction> shares of Common Stock (The Option Warrants). The underwriters exercised their option to purchase the Option Warrants on November 22, 2022. In December 2022, the Underwriter partially exercised the option to purchase an additional <ix:nonFraction unitRef="shares" contextRef="id8480f44fd004d44a17fe3165e3accc2_D20221201-20221231" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzIvZnJhZzo1ZmQ5ZDMzNzdkYTk0ZGNiODViODcwZDU1NTM4YmIxNi90ZXh0cmVnaW9uOjVmZDlkMzM3N2RhOTRkY2I4NWI4NzBkNTU1MzhiYjE2XzIxOTkwMjMyNjk2MDU_a2801f6e-1380-4ca6-ad46-267f237d4b6a">1,541,299</ix:nonFraction> of the Option Shares. As a result of the 2022 Offering and the exercise of the options, the Company received $<ix:nonFraction unitRef="usd" contextRef="id8480f44fd004d44a17fe3165e3accc2_D20221201-20221231" decimals="-3" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzIvZnJhZzo1ZmQ5ZDMzNzdkYTk0ZGNiODViODcwZDU1NTM4YmIxNi90ZXh0cmVnaW9uOjVmZDlkMzM3N2RhOTRkY2I4NWI4NzBkNTU1MzhiYjE2XzIxOTkwMjMyNjk3NDQ_efcbf1cd-c1f1-43e2-9834-e59679cf22aa">49,296</ix:nonFraction> in net proceeds, after deducting commissions of $<ix:nonFraction unitRef="usd" contextRef="id8480f44fd004d44a17fe3165e3accc2_D20221201-20221231" decimals="-3" name="optn:SaleOfStockCommissionsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzIvZnJhZzo1ZmQ5ZDMzNzdkYTk0ZGNiODViODcwZDU1NTM4YmIxNi90ZXh0cmVnaW9uOjVmZDlkMzM3N2RhOTRkY2I4NWI4NzBkNTU1MzhiYjE2XzIxOTkwMjMyNjk3OTY_4f9c1bab-fd66-4a09-b0cf-b3fd60adfd43">3,238</ix:nonFraction> and offering costs payable by the Company of $<ix:nonFraction unitRef="usd" contextRef="i26def91352024f8bb0467900afb32de9_I20221231" decimals="-3" name="us-gaap:DeferredOfferingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzIvZnJhZzo1ZmQ5ZDMzNzdkYTk0ZGNiODViODcwZDU1NTM4YmIxNi90ZXh0cmVnaW9uOjVmZDlkMzM3N2RhOTRkY2I4NWI4NzBkNTU1MzhiYjE2XzIxOTkwMjMyNjk4NDU_5f8e69a3-a17f-40de-82fe-1fc06281eb1f">359</ix:nonFraction>. </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each share of common stock entitles the holder to <ix:nonFraction unitRef="vote" contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231" decimals="INF" name="optn:VotePerShare" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzIvZnJhZzo1ZmQ5ZDMzNzdkYTk0ZGNiODViODcwZDU1NTM4YmIxNi90ZXh0cmVnaW9uOjVmZDlkMzM3N2RhOTRkY2I4NWI4NzBkNTU1MzhiYjE2XzExODM_b88e9ec2-2b04-4dfb-a119-ad69c14731ca">one</ix:nonFraction> vote on all matters submitted to a vote of the Company&#8217;s stockholders. Subject to preferences that may apply to any outstanding preferred stock, holders of common stock are entitled to receive ratably any dividends that the Company&#8217;s board of directors may declare out of funds legally available for that purpose on a non-cumulative basis. <ix:nonFraction unitRef="usdPerShare" contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzIvZnJhZzo1ZmQ5ZDMzNzdkYTk0ZGNiODViODcwZDU1NTM4YmIxNi90ZXh0cmVnaW9uOjVmZDlkMzM3N2RhOTRkY2I4NWI4NzBkNTU1MzhiYjE2XzE1MjY_d2a1e5a2-3c82-4cbd-bc16-5a5b8d19f4f1">No</ix:nonFraction> dividends had been declared through December 31, 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common stock warrants</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 18, 2021, in conjunction with the Second Amendment to the original Note Purchase Agreement (Second Amendment), the Company issued warrants to purchase an aggregate of <ix:nonFraction unitRef="shares" contextRef="ie839a1db16084835ad6af8b8758ce33c_I20211118" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzIvZnJhZzo1ZmQ5ZDMzNzdkYTk0ZGNiODViODcwZDU1NTM4YmIxNi90ZXh0cmVnaW9uOjVmZDlkMzM3N2RhOTRkY2I4NWI4NzBkNTU1MzhiYjE2XzIxOTkwMjMyNjc5MDk_06d83d12-6a66-46ad-a25a-90cd76c4446a">2,500,000</ix:nonFraction> shares of Common Stock at a per share exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ie839a1db16084835ad6af8b8758ce33c_I20211118" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzIvZnJhZzo1ZmQ5ZDMzNzdkYTk0ZGNiODViODcwZDU1NTM4YmIxNi90ZXh0cmVnaW9uOjVmZDlkMzM3N2RhOTRkY2I4NWI4NzBkNTU1MzhiYjE2XzIxOTkwMjMyNjc5MTc_fdd7d2a4-142c-497b-8ae1-307e9484ebc2">1.60</ix:nonFraction> and fair value of $<ix:nonFraction unitRef="usd" contextRef="ie839a1db16084835ad6af8b8758ce33c_I20211118" decimals="-3" name="us-gaap:WarrantsAndRightsOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzIvZnJhZzo1ZmQ5ZDMzNzdkYTk0ZGNiODViODcwZDU1NTM4YmIxNi90ZXh0cmVnaW9uOjVmZDlkMzM3N2RhOTRkY2I4NWI4NzBkNTU1MzhiYjE2XzIxOTkwMjMyNjc5MjE_229f712b-7b79-47d8-86b2-09587ad9644c">2,009</ix:nonFraction>.  Upon execution of the Second Amendment, previously issued warrants to purchase <ix:nonFraction unitRef="shares" contextRef="iabcd2c4e164b4cb3923eed31231d712e_I20211118" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzIvZnJhZzo1ZmQ5ZDMzNzdkYTk0ZGNiODViODcwZDU1NTM4YmIxNi90ZXh0cmVnaW9uOjVmZDlkMzM3N2RhOTRkY2I4NWI4NzBkNTU1MzhiYjE2XzE4NTc_dc7f9d26-055e-4532-81da-40fba12ad29f">810,357</ix:nonFraction> shares of Common Stock at a per share exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="iabcd2c4e164b4cb3923eed31231d712e_I20211118" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzIvZnJhZzo1ZmQ5ZDMzNzdkYTk0ZGNiODViODcwZDU1NTM4YmIxNi90ZXh0cmVnaW9uOjVmZDlkMzM3N2RhOTRkY2I4NWI4NzBkNTU1MzhiYjE2XzE4ODA_0f1c7f83-d62b-4b0f-bca7-855ec521b8b0">6.72</ix:nonFraction> which were set to expire on September 12, 2022, were cancelled.</span></div><ix:nonNumeric contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" name="optn:ScheduleOfGrantDateFairValueOfWarrantValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzIvZnJhZzo1ZmQ5ZDMzNzdkYTk0ZGNiODViODcwZDU1NTM4YmIxNi90ZXh0cmVnaW9uOjVmZDlkMzM3N2RhOTRkY2I4NWI4NzBkNTU1MzhiYjE2XzIyODE_c470c35f-bfb4-4a37-8239-3a19e43b4348" escape="true"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The grant date fair value of the <ix:nonFraction unitRef="shares" contextRef="ie839a1db16084835ad6af8b8758ce33c_I20211118" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzIvZnJhZzo1ZmQ5ZDMzNzdkYTk0ZGNiODViODcwZDU1NTM4YmIxNi90ZXh0cmVnaW9uOjVmZDlkMzM3N2RhOTRkY2I4NWI4NzBkNTU1MzhiYjE2XzIxOTkwMjMyNjc5Mjk_250d590c-15df-41d5-85b4-455ea939d0a8">2,500,000</ix:nonFraction> warrants issued in connection with the Pharmakon Senior Secured Notes was estimated at the time of grant using the Black-Scholes option-pricing model using the following weighted average assumptions:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:83.695%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.105%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iecd24838e7ea4897a980acb7f05e8f07_I20211118" decimals="4" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzIvZnJhZzo1ZmQ5ZDMzNzdkYTk0ZGNiODViODcwZDU1NTM4YmIxNi90YWJsZTo4NmRjNWM0NGEyYzk0MDQ0ODBiNTA3ZGYwNmM5Y2EwOC90YWJsZXJhbmdlOjg2ZGM1YzQ0YTJjOTQwNDQ4MGI1MDdkZjA2YzljYTA4XzAtMS0xLTEtNTgzNzI_d3ee246d-cb8a-4545-8e0b-bd434159d566">0.87</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i34d7dc335ebb4c258e92af8033ba7854_I20211118" decimals="2" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzIvZnJhZzo1ZmQ5ZDMzNzdkYTk0ZGNiODViODcwZDU1NTM4YmIxNi90YWJsZTo4NmRjNWM0NGEyYzk0MDQ0ODBiNTA3ZGYwNmM5Y2EwOC90YWJsZXJhbmdlOjg2ZGM1YzQ0YTJjOTQwNDQ4MGI1MDdkZjA2YzljYTA4XzEtMS0xLTEtNTgzNzI_84c8b053-d62d-48eb-95af-b46ad82d1c72">3</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i81ae26cc8b16489db793cfa1a11fdb41_I20211118" decimals="4" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzIvZnJhZzo1ZmQ5ZDMzNzdkYTk0ZGNiODViODcwZDU1NTM4YmIxNi90YWJsZTo4NmRjNWM0NGEyYzk0MDQ0ODBiNTA3ZGYwNmM5Y2EwOC90YWJsZXJhbmdlOjg2ZGM1YzQ0YTJjOTQwNDQ4MGI1MDdkZjA2YzljYTA4XzItMS0xLTEtNTgzNzI_5af9d8a5-b249-4afa-9080-fd12644f8bc2">78.25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Annual dividend yield</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iad23ea7b6ce14473a74ab1026b1d8111_I20211118" decimals="INF" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzIvZnJhZzo1ZmQ5ZDMzNzdkYTk0ZGNiODViODcwZDU1NTM4YmIxNi90YWJsZTo4NmRjNWM0NGEyYzk0MDQ0ODBiNTA3ZGYwNmM5Y2EwOC90YWJsZXJhbmdlOjg2ZGM1YzQ0YTJjOTQwNDQ4MGI1MDdkZjA2YzljYTA4XzMtMS0xLTEtNTgzNzI_df53d32c-50bd-4976-8b50-58c10f46e0ce">0.00</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of common stock</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib2361c2f31ea4a84ae18d655231f351d_I20221231" decimals="2" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzIvZnJhZzo1ZmQ5ZDMzNzdkYTk0ZGNiODViODcwZDU1NTM4YmIxNi90YWJsZTo4NmRjNWM0NGEyYzk0MDQ0ODBiNTA3ZGYwNmM5Y2EwOC90YWJsZXJhbmdlOjg2ZGM1YzQ0YTJjOTQwNDQ4MGI1MDdkZjA2YzljYTA4XzQtMS0xLTEtNTgzNzI_3f1bc9d4-5469-473f-bbc9-2e3c23adcab5">1.60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As part of the 2022 Offering, the Company issued warrants to purchase <ix:nonFraction unitRef="shares" contextRef="i7231baf73d71425f945cdbbe619d491b_D20221123-20221123" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzIvZnJhZzo1ZmQ5ZDMzNzdkYTk0ZGNiODViODcwZDU1NTM4YmIxNi90ZXh0cmVnaW9uOjVmZDlkMzM3N2RhOTRkY2I4NWI4NzBkNTU1MzhiYjE2XzIxOTkwMjMyNjk4NTE_e367a367-3783-4e78-ad36-909dc9d9542e">30,268,000</ix:nonFraction> shares of Common Stock at a public offering price of $<ix:nonFraction unitRef="usdPerShare" contextRef="iea2a2b3820084672a2ce5363d5379529_I20221123" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzIvZnJhZzo1ZmQ5ZDMzNzdkYTk0ZGNiODViODcwZDU1NTM4YmIxNi90ZXh0cmVnaW9uOjVmZDlkMzM3N2RhOTRkY2I4NWI4NzBkNTU1MzhiYjE2XzIxOTkwMjMyNjUwMzc_1079900c-8402-4805-84b7-0ab40e063abe">0.01</ix:nonFraction> per warrant (the Warrants). Each Warrant has an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="iee3e30fe89cc40238e90a7ecb6f01185_I20221121" decimals="3" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzIvZnJhZzo1ZmQ5ZDMzNzdkYTk0ZGNiODViODcwZDU1NTM4YmIxNi90ZXh0cmVnaW9uOjVmZDlkMzM3N2RhOTRkY2I4NWI4NzBkNTU1MzhiYjE2XzIxOTkwMjMyNjgwMjE_dae2c96f-fec1-44b8-89ac-e395cff44b9d">2.565</ix:nonFraction> per share of Common Stock and is exercisable until the expiration date, which is the fifth anniversary of the date of issuance (November 23, 2027). After such date, any unexercised Warrants will expire and have no further value. If the Company issues or sells, or is deemed pursuant to the terms of the Warrants to have issued or sold, any shares of Common Stock (which includes, among other things, options and securities convertible into shares of Common Stock), excluding certain issuances defined in the Warrants as "excluded issuances, for a price per share less than the exercise price of the Warrants in effect immediately prior to such issuance or sale or deemed issuance or sale (such event, a dilutive issuance), then immediately after such dilutive issuance the exercise price then in effect of the Warrants shall be reduced to the price of the shares of Common Stock issued or sold or deemed to be issued or sold in the dilutive issuance in the manner set forth in the Warrant.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:112.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OptiNose,&#160;Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div></div><ix:continuation id="i524a1f6e5ac040ea9e67aadd0518afe9"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">A holder of Warrants will not have the right to exercise any portion of a Warrant if the holder (together with its affiliates) would beneficially own in excess of <ix:nonFraction unitRef="number" contextRef="i79d8665c06414820bf676315cc093d4a_I20221123" decimals="4" name="optn:ClassOfWarrantOrRightRestrictionCommonSharesMaximumOwnershipIfExercisedPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzIvZnJhZzo1ZmQ5ZDMzNzdkYTk0ZGNiODViODcwZDU1NTM4YmIxNi90ZXh0cmVnaW9uOjVmZDlkMzM3N2RhOTRkY2I4NWI4NzBkNTU1MzhiYjE2XzQ5NDc4MDIzMzc0ODk_ca27ac15-1ff7-47e5-9b9c-bfd62a735bab">4.99</ix:nonFraction>% (or on election of such holder, prior to the issuance of any Warrants, <ix:nonFraction unitRef="number" contextRef="i79d8665c06414820bf676315cc093d4a_I20221123" decimals="4" name="optn:ClassOfWarrantOrRightRestrictionCommonSharesMaximumOwnershipPriorToExecutionPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzIvZnJhZzo1ZmQ5ZDMzNzdkYTk0ZGNiODViODcwZDU1NTM4YmIxNi90ZXh0cmVnaW9uOjVmZDlkMzM3N2RhOTRkY2I4NWI4NzBkNTU1MzhiYjE2XzQ5NDc4MDIzMzc0OTY_e6b95719-ef4e-478c-a703-53c31ac64ec4">9.99</ix:nonFraction>%) of the number of shares of Common Stock outstanding immediately after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the Warrants; provided, however, such holder may increase or decrease such percentage to any other percentage not in excess of <ix:nonFraction unitRef="number" contextRef="i79d8665c06414820bf676315cc093d4a_I20221123" decimals="4" name="optn:ClassOfWarrantOrRightRestrictionCommonSharesMaximumOwnershipAfterEffectiveWaitingPeriodPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzIvZnJhZzo1ZmQ5ZDMzNzdkYTk0ZGNiODViODcwZDU1NTM4YmIxNi90ZXh0cmVnaW9uOjVmZDlkMzM3N2RhOTRkY2I4NWI4NzBkNTU1MzhiYjE2XzQ5NDc4MDIzMzc1MDM_156be3a5-d43a-4137-8918-cf79f7a62859">19.99</ix:nonFraction>%, provided that any increase in such percentage shall not be effective until 61 days after such notice is delivered to the Company.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Pursuant to the terms of the Warrant, the Company could be required to settle the Warrants in cash in the event of a "fundamental transaction" as defined in the Warrant (which includes, among other things, an acquisition of the Company) and, as a result, the Warrants are required to be measured at fair value and reported as liability in the consolidated balance sheet. The Company recorded the fair value of the Warrants upon issuance using a Monte Carlo simulation and are required to revalue the Warrants at each reporting date with any changes in fair value recorded on our statement of operations.</span></div><div><span><br/></span></div><div><ix:nonNumeric contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzIvZnJhZzo1ZmQ5ZDMzNzdkYTk0ZGNiODViODcwZDU1NTM4YmIxNi90ZXh0cmVnaW9uOjVmZDlkMzM3N2RhOTRkY2I4NWI4NzBkNTU1MzhiYjE2XzIyODI_25fe3c16-2e27-4c59-8c33-232ab836447a" escape="true"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, the Company had the following warrants outstanding to purchase shares of Common Stock: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.847%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.847%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.847%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.931%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercise Price Per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Expiration Date</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i24bb67187a7b4b71897cb83c06184e0c_I20221231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzIvZnJhZzo1ZmQ5ZDMzNzdkYTk0ZGNiODViODcwZDU1NTM4YmIxNi90YWJsZTowY2E0Njc5ODRhMzI0ZjI3ODkzZTk0ZWU0YTllNjhmYS90YWJsZXJhbmdlOjBjYTQ2Nzk4NGEzMjRmMjc4OTNlOTRlZTRhOWU2OGZhXzEtMC0xLTEtNTgzNzI_9c59f624-24bb-450a-98e5-26f7b13a5984">2,500,000</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i24bb67187a7b4b71897cb83c06184e0c_I20221231" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzIvZnJhZzo1ZmQ5ZDMzNzdkYTk0ZGNiODViODcwZDU1NTM4YmIxNi90YWJsZTowY2E0Njc5ODRhMzI0ZjI3ODkzZTk0ZWU0YTllNjhmYS90YWJsZXJhbmdlOjBjYTQ2Nzk4NGEzMjRmMjc4OTNlOTRlZTRhOWU2OGZhXzEtMi0xLTEtNTgzNzI_313b6659-4317-4c27-acb6-d4be2398e275">1.60</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">November 15, 2024</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia2ede8c8918a4e5a90c0ff1a8e33f0c0_I20221231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzIvZnJhZzo1ZmQ5ZDMzNzdkYTk0ZGNiODViODcwZDU1NTM4YmIxNi90YWJsZTowY2E0Njc5ODRhMzI0ZjI3ODkzZTk0ZWU0YTllNjhmYS90YWJsZXJhbmdlOjBjYTQ2Nzk4NGEzMjRmMjc4OTNlOTRlZTRhOWU2OGZhXzItMC0xLTEtMTAyNTY3_0d3b02cb-a444-45ed-8223-f3a232d62884">30,268,000</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Liability</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="ia2ede8c8918a4e5a90c0ff1a8e33f0c0_I20221231" decimals="3" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzIvZnJhZzo1ZmQ5ZDMzNzdkYTk0ZGNiODViODcwZDU1NTM4YmIxNi90YWJsZTowY2E0Njc5ODRhMzI0ZjI3ODkzZTk0ZWU0YTllNjhmYS90YWJsZXJhbmdlOjBjYTQ2Nzk4NGEzMjRmMjc4OTNlOTRlZTRhOWU2OGZhXzItMi0xLTEtMTAzMzk3_75bf05bf-9872-441f-92da-e5e0c9ab0e1d">2.565</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">November 23, 2027</span></td></tr></table></ix:nonNumeric></div></ix:continuation><div style="margin-bottom:8pt;margin-top:8pt"><span><br/></span></div><div style="margin-bottom:8pt;margin-top:8pt"><span><br/></span></div><div id="i451bcb3eabba4f87bdc579718207a3b8_175"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14. <ix:nonNumeric contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90ZXh0cmVnaW9uOjM5ZTVmMjgzN2UzNjRmMWQ4NDA3OGY1NTkyYjA5YzA0Xzk3OTQ_70ab806a-be13-442c-8063-bf7297a7a186" continuedAt="i27a2ec00069b422e961743f51433822e" escape="true">Stock-based Compensation</ix:nonNumeric></span></div><ix:continuation id="i27a2ec00069b422e961743f51433822e" continuedAt="id731d97d5f93430e9eb5f14f2a64796a"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company issues stock-based awards pursuant to its 2010 Stock Incentive Plan. Effective as of October 12, 2017, the Company's 2010 Stock Incentive Plan was amended and restated (A&amp;R Plan). The A&amp;R Plan provides for the grant of incentive stock options, non-statutory stock options, restricted stock awards, restricted stock units, deferred stock units, performance shares, stock appreciation rights and other equity-based awards. The Company's employees, officers, directors and other persons are eligible to receive awards under the A&amp;R Plan. As of December 31, 2022, <ix:nonFraction unitRef="shares" contextRef="ic8103889fc054805b787fcb8d7245e95_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90ZXh0cmVnaW9uOjM5ZTVmMjgzN2UzNjRmMWQ4NDA3OGY1NTkyYjA5YzA0XzU5MQ_b3d0025a-4e1a-495e-9b39-6cb5ffb4188b">17,299,284</ix:nonFraction> shares of the Company's common stock were authorized to be issued under the A&amp;R Plan, and <ix:nonFraction unitRef="shares" contextRef="ic8103889fc054805b787fcb8d7245e95_I20221231" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90ZXh0cmVnaW9uOjM5ZTVmMjgzN2UzNjRmMWQ4NDA3OGY1NTkyYjA5YzA0XzY4NA_bf8dc365-f13e-4ae2-8480-6796e2003c9f">3,607,066</ix:nonFraction>&#160;shares were reserved for future awards under the A&amp;R Plan. The number of shares of the Company's common stock authorized under the A&amp;R Plan will automatically increase on January&#160;1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">st</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of each year until the expiration of the A&amp;R Plan, in an amount equal to <ix:nonFraction unitRef="number" contextRef="ic8103889fc054805b787fcb8d7245e95_I20221231" decimals="INF" name="optn:CommonStockCapitalSharesReservedforFutureIssuanceYearlyIncrease" format="ixt-sec:numwordsen" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90ZXh0cmVnaW9uOjM5ZTVmMjgzN2UzNjRmMWQ4NDA3OGY1NTkyYjA5YzA0Xzk0Mw_40405c4e-132e-4369-ad76-8bcfa5c86d0b">four</ix:nonFraction> percent of the total number of shares of the Company's common stock outstanding on December&#160;31</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">st</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the preceding calendar year, subject to the discretion of the Company's board of directors or compensation committee to determine a lesser number of shares shall be added for such year.&#160;</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount, terms of grants, and exercisability provisions are determined and set by the Company's board of directors or compensation committee. The Company measures stock-based awards at grant-date fair value and records compensation expense on a straight-line basis over the vesting period of the award.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock options</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has issued service-based, performance-based and market-based stock options that generally have a contractual life of up to <ix:nonNumeric contextRef="i4b3d9a0e4d704073937d74fdc55db85b_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90ZXh0cmVnaW9uOjM5ZTVmMjgzN2UzNjRmMWQ4NDA3OGY1NTkyYjA5YzA0XzE3NjM_ef7578c4-dbd8-44ed-a9fc-7f6efa3d03e1">10</ix:nonNumeric>&#160;years and may be exercisable in cash or as otherwise determined by the board of directors. Vesting generally occurs over a period of not greater than <ix:nonNumeric contextRef="i4b3d9a0e4d704073937d74fdc55db85b_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90ZXh0cmVnaW9uOjM5ZTVmMjgzN2UzNjRmMWQ4NDA3OGY1NTkyYjA5YzA0XzE5MTY_704bad17-386e-40df-915a-ae352cd6df2e">four years</ix:nonNumeric>. Performance-based options may vest upon the achievement of certain milestones in connection with the Company's development programs. As of December 31, 2022, all of the performance conditions related to performance-based stock options issued by the Company have been achieved. Market-based options may vest upon the achievement of certain market-based objectives relating to the trading price of the Company's Common Stock.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:112.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OptiNose,&#160;Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div></div><ix:continuation id="id731d97d5f93430e9eb5f14f2a64796a" continuedAt="i8767f646878246a49f8a3b18603d10cc"><ix:nonNumeric contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90ZXh0cmVnaW9uOjM5ZTVmMjgzN2UzNjRmMWQ4NDA3OGY1NTkyYjA5YzA0Xzk3OTk_4061887b-74ab-4769-9b3a-ecfb5ec576a3" escape="true"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity related to stock option grants to employees and non-employees for the year ended December 31, 2022:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.326%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.770%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>average<br/>exercise price<br/>per share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>average<br/>remaining<br/>contractual life</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id970dfd2674c4d6b895febb9c14d0fd1_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90YWJsZTpiMzZkNWQ1ZmYxOTA0NjJiOTM0NGI1YjU5YjAyNTA2ZC90YWJsZXJhbmdlOmIzNmQ1ZDVmZjE5MDQ2MmI5MzQ0YjViNTliMDI1MDZkXzEtMS0xLTEtNTgzNzI_f3c13ed2-2a5d-4ec8-adbd-30236161411d">7,958,781</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id970dfd2674c4d6b895febb9c14d0fd1_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90YWJsZTpiMzZkNWQ1ZmYxOTA0NjJiOTM0NGI1YjU5YjAyNTA2ZC90YWJsZXJhbmdlOmIzNmQ1ZDVmZjE5MDQ2MmI5MzQ0YjViNTliMDI1MDZkXzEtMy0xLTEtNTgzNzI_10500763-4ee2-4fa8-b384-70b14df08ae3">8.87</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90YWJsZTpiMzZkNWQ1ZmYxOTA0NjJiOTM0NGI1YjU5YjAyNTA2ZC90YWJsZXJhbmdlOmIzNmQ1ZDVmZjE5MDQ2MmI5MzQ0YjViNTliMDI1MDZkXzEtNS0xLTEtNTgzNzI_ab288be0-3890-4a66-b0b7-c46d571e6887">6.50</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90YWJsZTpiMzZkNWQ1ZmYxOTA0NjJiOTM0NGI1YjU5YjAyNTA2ZC90YWJsZXJhbmdlOmIzNmQ1ZDVmZjE5MDQ2MmI5MzQ0YjViNTliMDI1MDZkXzItMS0xLTEtNTgzNzI_322875bf-04cc-410a-b450-39250c44ccec">3,473,370</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90YWJsZTpiMzZkNWQ1ZmYxOTA0NjJiOTM0NGI1YjU5YjAyNTA2ZC90YWJsZXJhbmdlOmIzNmQ1ZDVmZjE5MDQ2MmI5MzQ0YjViNTliMDI1MDZkXzItMy0xLTEtNTgzNzI_209cd7b0-cffb-4dff-8edc-83ce3eac4f3e">1.88</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90YWJsZTpiMzZkNWQ1ZmYxOTA0NjJiOTM0NGI1YjU5YjAyNTA2ZC90YWJsZXJhbmdlOmIzNmQ1ZDVmZjE5MDQ2MmI5MzQ0YjViNTliMDI1MDZkXzMtMS0xLTEtNTgzNzI_4e145989-af71-4d3e-837a-8046d8635cff">95,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90YWJsZTpiMzZkNWQ1ZmYxOTA0NjJiOTM0NGI1YjU5YjAyNTA2ZC90YWJsZXJhbmdlOmIzNmQ1ZDVmZjE5MDQ2MmI5MzQ0YjViNTliMDI1MDZkXzMtMy0xLTEtNTgzNzI_0d11dbcd-4a71-4d7c-baa5-c99ff2074408">2.18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90YWJsZTpiMzZkNWQ1ZmYxOTA0NjJiOTM0NGI1YjU5YjAyNTA2ZC90YWJsZXJhbmdlOmIzNmQ1ZDVmZjE5MDQ2MmI5MzQ0YjViNTliMDI1MDZkXzQtMS0xLTEtNTgzNzI_8c9b570e-d737-4f71-8d83-ba7a9fa4f8f0">947,999</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90YWJsZTpiMzZkNWQ1ZmYxOTA0NjJiOTM0NGI1YjU5YjAyNTA2ZC90YWJsZXJhbmdlOmIzNmQ1ZDVmZjE5MDQ2MmI5MzQ0YjViNTliMDI1MDZkXzQtMy0xLTEtNTgzNzI_8e5f0f93-899a-4db6-b23c-15997546c8fa">9.56</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90YWJsZTpiMzZkNWQ1ZmYxOTA0NjJiOTM0NGI1YjU5YjAyNTA2ZC90YWJsZXJhbmdlOmIzNmQ1ZDVmZjE5MDQ2MmI5MzQ0YjViNTliMDI1MDZkXzUtMS0xLTEtNTgzNzI_144fa648-2760-4a39-ad26-29cbb2af20d6">1,025,082</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90YWJsZTpiMzZkNWQ1ZmYxOTA0NjJiOTM0NGI1YjU5YjAyNTA2ZC90YWJsZXJhbmdlOmIzNmQ1ZDVmZjE5MDQ2MmI5MzQ0YjViNTliMDI1MDZkXzUtMy0xLTEtNTgzNzI_885f5296-39b5-41b5-84e9-dc3ee45aa33a">3.35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding at December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90YWJsZTpiMzZkNWQ1ZmYxOTA0NjJiOTM0NGI1YjU5YjAyNTA2ZC90YWJsZXJhbmdlOmIzNmQ1ZDVmZjE5MDQ2MmI5MzQ0YjViNTliMDI1MDZkXzYtMS0xLTEtNTgzNzI_79952eaa-8bfb-463e-9a7f-9f3efab76984">9,364,070</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90YWJsZTpiMzZkNWQ1ZmYxOTA0NjJiOTM0NGI1YjU5YjAyNTA2ZC90YWJsZXJhbmdlOmIzNmQ1ZDVmZjE5MDQ2MmI5MzQ0YjViNTliMDI1MDZkXzYtMy0xLTEtNTgzNzI_5a651216-23d4-4d7f-ac4c-274241e21ab5">6.88</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90YWJsZTpiMzZkNWQ1ZmYxOTA0NjJiOTM0NGI1YjU5YjAyNTA2ZC90YWJsZXJhbmdlOmIzNmQ1ZDVmZjE5MDQ2MmI5MzQ0YjViNTliMDI1MDZkXzYtNS0xLTEtNTgzNzI_acec959c-4aa1-4c4f-90e6-bd5cb92efb74">6.05</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercisable at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90YWJsZTpiMzZkNWQ1ZmYxOTA0NjJiOTM0NGI1YjU5YjAyNTA2ZC90YWJsZXJhbmdlOmIzNmQ1ZDVmZjE5MDQ2MmI5MzQ0YjViNTliMDI1MDZkXzctMS0xLTEtNTgzNzI_b787a838-0ebb-4943-aa31-4f180455efbc">5,521,738</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90YWJsZTpiMzZkNWQ1ZmYxOTA0NjJiOTM0NGI1YjU5YjAyNTA2ZC90YWJsZXJhbmdlOmIzNmQ1ZDVmZjE5MDQ2MmI5MzQ0YjViNTliMDI1MDZkXzctMy0xLTEtNTgzNzI_3bb8b0a5-7a20-4bdb-a305-1384491a524c">9.98</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90YWJsZTpiMzZkNWQ1ZmYxOTA0NjJiOTM0NGI1YjU5YjAyNTA2ZC90YWJsZXJhbmdlOmIzNmQ1ZDVmZjE5MDQ2MmI5MzQ0YjViNTliMDI1MDZkXzctNS0xLTEtNTgzNzI_0e34aa10-21d7-4ad8-a265-9c6e8605e764">4.55</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2022, stock options to purchase <ix:nonFraction unitRef="shares" contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90ZXh0cmVnaW9uOjM5ZTVmMjgzN2UzNjRmMWQ4NDA3OGY1NTkyYjA5YzA0XzI1ODY_322875bf-04cc-410a-b450-39250c44ccec">3,473,370</ix:nonFraction> shares of common stock were granted to employees that generally vest over <ix:nonNumeric contextRef="ia6f6f949224a4e3db7362e44a8479806_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90ZXh0cmVnaW9uOjM5ZTVmMjgzN2UzNjRmMWQ4NDA3OGY1NTkyYjA5YzA0XzI2NjM_11d51337-05b4-458d-a7f9-1dfeb20eafa5">four years</ix:nonNumeric>. Included in the total stock options granted were market-based options to purchase <ix:nonFraction unitRef="shares" contextRef="icdfa0ea8b62148fe8c31ae85f2e9f203_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90ZXh0cmVnaW9uOjM5ZTVmMjgzN2UzNjRmMWQ4NDA3OGY1NTkyYjA5YzA0XzgyNDYzMzcyMTgzMDU_13cd829d-1402-46eb-a401-4f072aad0c14">959,215</ix:nonFraction> shares of Common Stock. The stock options, including the market-based options, had an estimated weighted average grant date fair value of $<ix:nonFraction unitRef="usdPerShare" contextRef="ia6f6f949224a4e3db7362e44a8479806_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90ZXh0cmVnaW9uOjM5ZTVmMjgzN2UzNjRmMWQ4NDA3OGY1NTkyYjA5YzA0XzI3Mzg_2d42a2a3-ae9c-42ef-8ac9-2457f2bf4694">1.21</ix:nonFraction>. The grant date fair value of each service-based and performance-based option grant was estimated at the time of grant using the Black-Scholes option-pricing model. The grant date fair value of each market-based stock option grant was estimated at the time of grant using a Monte Carlo simulation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total aggregate intrinsic value of stock options, other than market-based stock options, exercised during the years ended December 31, 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021 was $<ix:nonFraction unitRef="usd" contextRef="ia6f6f949224a4e3db7362e44a8479806_D20220101-20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90ZXh0cmVnaW9uOjM5ZTVmMjgzN2UzNjRmMWQ4NDA3OGY1NTkyYjA5YzA0XzI5NzI_1426ce04-ffd3-43de-866e-01023e075bad">111</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and $<ix:nonFraction unitRef="usd" contextRef="i6f825eaecdc54225baf8219928d46fdb_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90ZXh0cmVnaW9uOjM5ZTVmMjgzN2UzNjRmMWQ4NDA3OGY1NTkyYjA5YzA0XzI5Nzk_0fb4a8c2-6a15-448b-a8fb-245998a316c1">35</ix:nonFraction>, respectively. The aggregate intrinsic value of stock options outstanding and stock options exercisable, other than market-based stock options, as of December 31, 2022 was $<ix:nonFraction unitRef="usd" contextRef="i28c4ea3872514bf9a8d5fe2d1d621221_I20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90ZXh0cmVnaW9uOjM5ZTVmMjgzN2UzNjRmMWQ4NDA3OGY1NTkyYjA5YzA0XzMwNjk_cb2cdc57-acfb-41e7-b75b-33e62cf44619">81</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i28c4ea3872514bf9a8d5fe2d1d621221_I20221231" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90ZXh0cmVnaW9uOjM5ZTVmMjgzN2UzNjRmMWQ4NDA3OGY1NTkyYjA5YzA0XzgyNDYzMzcyMTg1MDE_19e4776f-82a7-4edd-874c-33c4d2d4e665">8</ix:nonFraction>, respectively. At December 31, 2022, the unrecognized compensation cost related to unvested stock options, other than market-based stock options, expected to vest was $<ix:nonFraction unitRef="usd" contextRef="i28c4ea3872514bf9a8d5fe2d1d621221_I20221231" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90ZXh0cmVnaW9uOjM5ZTVmMjgzN2UzNjRmMWQ4NDA3OGY1NTkyYjA5YzA0XzMyMzE_456c7d58-4bb3-4b59-9b0d-aacb300f2821">4,368</ix:nonFraction>. This unrecognized compensation will be recognized over an estimated weighted-average amortization period of <ix:nonNumeric contextRef="ia6f6f949224a4e3db7362e44a8479806_D20220101-20221231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90ZXh0cmVnaW9uOjM5ZTVmMjgzN2UzNjRmMWQ4NDA3OGY1NTkyYjA5YzA0XzMzNDM_44a833b9-4f29-477c-b236-1637acfb9da2">2.35</ix:nonNumeric> years.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2022, market-based options to purchase <ix:nonFraction unitRef="shares" contextRef="icdfa0ea8b62148fe8c31ae85f2e9f203_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90ZXh0cmVnaW9uOjM5ZTVmMjgzN2UzNjRmMWQ4NDA3OGY1NTkyYjA5YzA0XzgyNDYzMzcyMjAwNzc_13cd829d-1402-46eb-a401-4f072aad0c14">959,215</ix:nonFraction> shares of Common Stock were granted to employees and generally become eligible to vest over four years, subject to the achievement of certain market-based objectives relating to the trading price of the Common Stock.  Stock based compensation for these awards is recognized over the derived service period of approximately <ix:nonNumeric contextRef="icdfa0ea8b62148fe8c31ae85f2e9f203_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90ZXh0cmVnaW9uOjM5ZTVmMjgzN2UzNjRmMWQ4NDA3OGY1NTkyYjA5YzA0XzgyNDYzMzcyMTk4NDM_6fea3222-ac21-4f6f-99c5-a4ca345f2604">2</ix:nonNumeric> years.  The grant date fair value of each stock option grant, as well as the derived service period for these awards, was estimated at the time of grant using a Monte Carlo simulation. During the year ended December 31, 2022, <ix:nonFraction unitRef="shares" contextRef="icdfa0ea8b62148fe8c31ae85f2e9f203_D20220101-20221231" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90ZXh0cmVnaW9uOjM5ZTVmMjgzN2UzNjRmMWQ4NDA3OGY1NTkyYjA5YzA0XzgyNDYzMzcyMjAzNjg_42c4ca62-1403-4e3a-8f86-93ffecbce529">297,677</ix:nonFraction> market-based options vested upon the achievement of certain market-based objectives relating to the trading price of the Company's Common Stock.  </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in the table above are <ix:nonFraction unitRef="shares" contextRef="i34d0a9c04a2f4859a044c9e6cc370e55_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90ZXh0cmVnaW9uOjM5ZTVmMjgzN2UzNjRmMWQ4NDA3OGY1NTkyYjA5YzA0XzMzODU_ba197acd-e89c-4a05-bde9-61cf2b0de91e">753,500</ix:nonFraction> options granted outside the A&amp;R Plan. The grants were made pursuant to the Nasdaq inducement grant exception in accordance with Nasdaq Listing Rule 5635(c)(4). </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:112.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OptiNose,&#160;Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div></div><ix:continuation id="i8767f646878246a49f8a3b18603d10cc" continuedAt="i7795235feffb4804bcc1c21094d4f1c4"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted stock units</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has issued service-based and performance-based restricted stock units (RSUs). Vesting generally occurs over a period not greater than <ix:nonNumeric contextRef="i7dc5537455904ed088d5e7907081fa28_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90ZXh0cmVnaW9uOjM5ZTVmMjgzN2UzNjRmMWQ4NDA3OGY1NTkyYjA5YzA0XzM3MTg_6c9b3191-58fe-4c60-8679-2ef4fe740c20">four years</ix:nonNumeric>. Vesting of the performance-based RSUs is subject to the achievement of certain milestones in connection with the Company's development programs.</span></div><div style="margin-top:8pt"><ix:nonNumeric contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90ZXh0cmVnaW9uOjM5ZTVmMjgzN2UzNjRmMWQ4NDA3OGY1NTkyYjA5YzA0Xzk4MDE_957cbbd9-1589-4fb9-a9fd-9f03e72d5c15" escape="true"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity related to RSUs granted to employees for the year ended December 31, 2022:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:88.227%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.573%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idbf17e5750434c4fa4c7af6d79eb5f3b_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90YWJsZTo2NjI1YzY1YmM2ZjU0NzJiYjQ4MGFiNmViYTA2NjIwNi90YWJsZXJhbmdlOjY2MjVjNjViYzZmNTQ3MmJiNDgwYWI2ZWJhMDY2MjA2XzEtMS0xLTEtNTgzNzI_d809ee36-c9fc-4e67-9d6f-ea513672dcea">1,959,358</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7dc5537455904ed088d5e7907081fa28_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90YWJsZTo2NjI1YzY1YmM2ZjU0NzJiYjQ4MGFiNmViYTA2NjIwNi90YWJsZXJhbmdlOjY2MjVjNjViYzZmNTQ3MmJiNDgwYWI2ZWJhMDY2MjA2XzItMS0xLTEtNTgzNzI_486c76a7-307d-4444-ac65-ee3e187651a3">1,105,246</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vested and settled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i7dc5537455904ed088d5e7907081fa28_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90YWJsZTo2NjI1YzY1YmM2ZjU0NzJiYjQ4MGFiNmViYTA2NjIwNi90YWJsZXJhbmdlOjY2MjVjNjViYzZmNTQ3MmJiNDgwYWI2ZWJhMDY2MjA2XzMtMS0xLTEtNTgzNzI_f5dc86d8-51dd-4d69-86cb-8320d7d4b704">949,857</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expired/forfeited/canceled</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i7dc5537455904ed088d5e7907081fa28_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90YWJsZTo2NjI1YzY1YmM2ZjU0NzJiYjQ4MGFiNmViYTA2NjIwNi90YWJsZXJhbmdlOjY2MjVjNjViYzZmNTQ3MmJiNDgwYWI2ZWJhMDY2MjA2XzQtMS0xLTEtNTgzNzI_76aff7f4-0b05-4d24-98a6-68ef31cf6d34">637,087</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i15fbdc49b67e41af98201248589f1f68_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90YWJsZTo2NjI1YzY1YmM2ZjU0NzJiYjQ4MGFiNmViYTA2NjIwNi90YWJsZXJhbmdlOjY2MjVjNjViYzZmNTQ3MmJiNDgwYWI2ZWJhMDY2MjA2XzUtMS0xLTEtNTgzNzI_94391573-c22f-4b22-b85e-b559b0f5131a">1,477,660</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected to vest at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i15fbdc49b67e41af98201248589f1f68_I20221231" decimals="INF" name="optn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90YWJsZTo2NjI1YzY1YmM2ZjU0NzJiYjQ4MGFiNmViYTA2NjIwNi90YWJsZXJhbmdlOjY2MjVjNjViYzZmNTQ3MmJiNDgwYWI2ZWJhMDY2MjA2XzYtMS0xLTEtNTgzNzI_d4c9da1f-adff-49f9-8f82-6b4aed66f0ee">1,477,660</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2022, the Company granted <ix:nonFraction unitRef="shares" contextRef="i7dc5537455904ed088d5e7907081fa28_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90ZXh0cmVnaW9uOjM5ZTVmMjgzN2UzNjRmMWQ4NDA3OGY1NTkyYjA5YzA0XzQwMTg_9441b548-98fb-4407-ab63-7d085fb77a4f">1,105,246</ix:nonFraction> RSUs at a weighted-average grant date fair value of $<ix:nonFraction unitRef="usdPerShare" contextRef="i7dc5537455904ed088d5e7907081fa28_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90ZXh0cmVnaW9uOjM5ZTVmMjgzN2UzNjRmMWQ4NDA3OGY1NTkyYjA5YzA0XzQwNzM_55424e5f-74a3-4cd5-8d44-e97df76e665e">1.85</ix:nonFraction>, all of which were service-based RSUs. No performance-based RSUs were granted in 2022. As of December 31, 2022, the milestone associated with the previously granted performance based-RSUs was achieved. As a result <ix:nonFraction unitRef="shares" contextRef="icae44ec705a54e90b329084893ffe064_D20220615-20220615" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90ZXh0cmVnaW9uOjM5ZTVmMjgzN2UzNjRmMWQ4NDA3OGY1NTkyYjA5YzA0XzgyNDYzMzcyMTg5MjY_1c644461-3a28-46f9-9f00-f68d658cf93f">248,827</ix:nonFraction> RSUs vested on June 15, 2022. At December 31, 2022, the recognized compensation cost related to vested performance-based RSUs was $<ix:nonFraction unitRef="usd" contextRef="i7dc5537455904ed088d5e7907081fa28_D20220101-20221231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90ZXh0cmVnaW9uOjM5ZTVmMjgzN2UzNjRmMWQ4NDA3OGY1NTkyYjA5YzA0XzgyNDYzMzcyMTg5MzE_a12f7874-b1a6-414a-a5c4-f8343ba8d3fa">1,669</ix:nonFraction>. At December 31, 2022, the unrecognized compensation cost related to unvested service-based</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> RSUs expected to vest was </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i4d238e610edc4182b197232b0495fdf4_I20221231" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90ZXh0cmVnaW9uOjM5ZTVmMjgzN2UzNjRmMWQ4NDA3OGY1NTkyYjA5YzA0XzQ0NjY_8eb0d99e-c4e1-41ee-8c54-f25d8eb41e13">3,123</ix:nonFraction></span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to be recognized over an estimated weighted-average amortization period of</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="i516c5d169f6840f49a095d9630b5c9ae_D20220101-20221231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90ZXh0cmVnaW9uOjM5ZTVmMjgzN2UzNjRmMWQ4NDA3OGY1NTkyYjA5YzA0XzQ1NDU_f953ac69-9d06-420c-9d9c-68ec9663c2e0">2.24</ix:nonNumeric></span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> years. The unrecognized compensation cost related to unvested performance-based RSUs was </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="if23267985b9b470489888a9e025653a4_I20221231" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90ZXh0cmVnaW9uOjM5ZTVmMjgzN2UzNjRmMWQ4NDA3OGY1NTkyYjA5YzA0XzQ2Mzc_d5969539-afe5-45c4-8782-2a60cc0d7188">942</ix:nonFraction></span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, whic</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">h will be recognized over the remaining service period.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in the table above are <ix:nonFraction unitRef="shares" contextRef="if62b2d5afbd04093b3379124f22b23c5_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90ZXh0cmVnaW9uOjM5ZTVmMjgzN2UzNjRmMWQ4NDA3OGY1NTkyYjA5YzA0XzQ4Mjc_11ae6615-76e2-46e8-8216-78ff743adf28">60,000</ix:nonFraction> RSUs granted outside the A&amp;R Plan. The grants were made pursuant to the Nasdaq inducement grant exception in accordance with Nasdaq Listing Rule 5635(c)(4). </span></div><div style="margin-bottom:8pt"><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2017 Employee Stock Purchase Plan </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's 2017 Employee Stock Purchase Plan (the 2017 Plan) became effective on October 12, 2017. As of December 31, 2022,&#160;<ix:nonFraction unitRef="shares" contextRef="i846ff334c7ce400c8af0db347b91f620_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90ZXh0cmVnaW9uOjM5ZTVmMjgzN2UzNjRmMWQ4NDA3OGY1NTkyYjA5YzA0XzUxMzY_bea89dcd-2a68-4d7c-9db4-289ebdd72aba">2,021,813</ix:nonFraction> shares of the Company's common stock were authorized to be issued pursuant to purchase rights granted to its employees or to employees of any of its participating affiliates under the 2017 Plan. <ix:nonFraction unitRef="shares" contextRef="i846ff334c7ce400c8af0db347b91f620_I20221231" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90ZXh0cmVnaW9uOjM5ZTVmMjgzN2UzNjRmMWQ4NDA3OGY1NTkyYjA5YzA0XzUzMzQ_cb090a7c-71a6-47cd-b8a0-70b5f8a4e053">982,989</ix:nonFraction> shares of the Company's common stock were reserved for future issuance under the 2017 Plan. The number of shares of the Company's common stock that may be issued pursuant to rights granted under the 2017 Plan shall automatically increase on January&#160;1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">st</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of each year until the expiration of the 2017 Plan, in an amount equal to <ix:nonFraction unitRef="number" contextRef="idfcc4aa88cd04b0498643a728bb0b299_D20220101-20221231" decimals="INF" name="optn:SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedIncrementEachYear" format="ixt-sec:numwordsen" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90ZXh0cmVnaW9uOjM5ZTVmMjgzN2UzNjRmMWQ4NDA3OGY1NTkyYjA5YzA0XzU2NjQ_fb581b6f-5cda-4dfc-a766-cc85d4a6da34">one</ix:nonFraction> percent of the total number of shares of the Company's common stock outstanding on December&#160;31</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">st </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of the preceding calendar year, subject to the discretion of the board of directors or compensation committee to determine a lesser number of shares shall be added for such year.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the 2017 Plan, eligible employees can purchase the Company&#8217;s common stock through accumulated payroll deductions at such times as are established by the administrator. The 2017 Plan is administered by the compensation committee. Eligible employees may contribute up to <ix:nonFraction unitRef="number" contextRef="idfcc4aa88cd04b0498643a728bb0b299_D20220101-20221231" decimals="2" name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90ZXh0cmVnaW9uOjM5ZTVmMjgzN2UzNjRmMWQ4NDA3OGY1NTkyYjA5YzA0XzYyMTg_8b2ee76c-6b9b-40da-b600-821518086be4">15</ix:nonFraction>% of their eligible compensation. A participant may not accrue rights to purchase more than $<ix:nonFraction unitRef="usdPerShare" contextRef="i846ff334c7ce400c8af0db347b91f620_I20221231" decimals="INF" name="optn:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeAccruedRightsToPurchaseCommonStock" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90ZXh0cmVnaW9uOjM5ZTVmMjgzN2UzNjRmMWQ4NDA3OGY1NTkyYjA5YzA0XzYzMTE_1e0e77ba-fa60-46f3-9d1c-b6322f7a871f">25</ix:nonFraction> worth of the Company&#8217;s common stock for each calendar year in which such right is outstanding.&#160;</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payroll withholdings accumulate during the following six month offering periods each calendar year while the Purchase Plan is effective:</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">January 1 through June 30, and</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">July 1 through December 31.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:112.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OptiNose,&#160;Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div></div><ix:continuation id="i7795235feffb4804bcc1c21094d4f1c4" continuedAt="i493d91bd5c0749af83c78cae256b86d2"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the end of each offering period, shares of the Company&#8217;s common stock may be purchased at <ix:nonFraction unitRef="number" contextRef="idfcc4aa88cd04b0498643a728bb0b299_D20220101-20221231" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90ZXh0cmVnaW9uOjM5ZTVmMjgzN2UzNjRmMWQ4NDA3OGY1NTkyYjA5YzA0XzY3MDA_ea332e52-db37-4ee4-b5b3-a6840ba9bd31">85</ix:nonFraction>% of the lesser of the average of the high and low sales price of the Company&#8217;s common stock on (i) the first trading day of the relevant offering period and (ii) the last trading day of the relevant offering period (or, if the relevant offering period has multiple purchase periods, the last trading day of the relevant purchase period). In accordance with the guidance in ASC 718-50 &#8211;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;Compensation &#8211; Stock Compensation</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the ability to purchase shares of the Company&#8217;s common stock at the lower of the price on the first day of the offering period or the last day of the offering period (i.e. the purchase date) represents an option and, therefore, the 2017 Plan is a compensatory plan under this guidance. Accordingly, stock-based compensation expense is determined based on the option&#8217;s grant-date fair value as estimated by applying the Black-Scholes option-pricing model and is recognized over the requisite service period of the option. The Company has recognized stock-based compensation expense of $<ix:nonFraction unitRef="usd" contextRef="idfcc4aa88cd04b0498643a728bb0b299_D20220101-20221231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90ZXh0cmVnaW9uOjM5ZTVmMjgzN2UzNjRmMWQ4NDA3OGY1NTkyYjA5YzA0Xzc3MDc_6845a954-af23-4cb3-bba1-4b6da502902d">253</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i412f04e9b5124c22a267cc2e9474aa46_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90ZXh0cmVnaW9uOjM5ZTVmMjgzN2UzNjRmMWQ4NDA3OGY1NTkyYjA5YzA0Xzc3MTQ_55901ddb-4c21-4bc7-9063-b6c1d8607bff">402</ix:nonFraction> during the years ended December 31, 2022 and 2021, respectively, related to the 2017 Plan.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-based compensation expense</span></div><div style="margin-bottom:8pt;margin-top:8pt"><ix:nonNumeric contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90ZXh0cmVnaW9uOjM5ZTVmMjgzN2UzNjRmMWQ4NDA3OGY1NTkyYjA5YzA0Xzk3OTY_9dd3a29c-2431-4de9-af7b-a6c777b287fb" escape="true"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded stock-based compensation expense in the following expense categories of its accompanying consolidated statements of operations for the years ended December 31, 2022 and 2021:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.285%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.844%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of product sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaaa623bfd2b7461d815938764c60cf18_D20220101-20221231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90YWJsZTo2Nzc3OTc1ZTkxMzM0ZTc3ODNlOTU1MjM0Y2Y4MDg5Yi90YWJsZXJhbmdlOjY3Nzc5NzVlOTEzMzRlNzc4M2U5NTUyMzRjZjgwODliXzItMS0xLTEtNTgzNzI_54176db1-b1ac-4c5b-bbc4-a04d90e1d126">35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ec6ce002f784a1f8f8a3b2b9b9b06ae_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90YWJsZTo2Nzc3OTc1ZTkxMzM0ZTc3ODNlOTU1MjM0Y2Y4MDg5Yi90YWJsZXJhbmdlOjY3Nzc5NzVlOTEzMzRlNzc4M2U5NTUyMzRjZjgwODliXzItMy0xLTEtNTgzNzI_da124212-9e76-4347-a02f-4cdeae8bda9e">50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaee85c4768314a529b0fa7b1be860d0c_D20220101-20221231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90YWJsZTo2Nzc3OTc1ZTkxMzM0ZTc3ODNlOTU1MjM0Y2Y4MDg5Yi90YWJsZXJhbmdlOjY3Nzc5NzVlOTEzMzRlNzc4M2U5NTUyMzRjZjgwODliXzMtMS0xLTEtNTgzNzI_bd14ffbb-2535-4b9d-8bfb-cd63e93f4ab8">809</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cd280125c384cd5a45521262a35af31_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90YWJsZTo2Nzc3OTc1ZTkxMzM0ZTc3ODNlOTU1MjM0Y2Y4MDg5Yi90YWJsZXJhbmdlOjY3Nzc5NzVlOTEzMzRlNzc4M2U5NTUyMzRjZjgwODliXzMtMy0xLTEtNTgzNzI_a39e0581-3ccb-46f6-a4ed-d93210a34daa">1,079</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff00e227a0ed47e8ac87706a2be40407_D20220101-20221231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90YWJsZTo2Nzc3OTc1ZTkxMzM0ZTc3ODNlOTU1MjM0Y2Y4MDg5Yi90YWJsZXJhbmdlOjY3Nzc5NzVlOTEzMzRlNzc4M2U5NTUyMzRjZjgwODliXzQtMS0xLTEtNTgzNzI_27d2e5ef-2b03-4718-a568-bbef0c7e8fca">8,033</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c74ce02c1434fc183c30fe05522e194_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90YWJsZTo2Nzc3OTc1ZTkxMzM0ZTc3ODNlOTU1MjM0Y2Y4MDg5Yi90YWJsZXJhbmdlOjY3Nzc5NzVlOTEzMzRlNzc4M2U5NTUyMzRjZjgwODliXzQtMy0xLTEtNTgzNzI_b2b0dfeb-4352-4706-ba72-abbbf5141293">8,874</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90YWJsZTo2Nzc3OTc1ZTkxMzM0ZTc3ODNlOTU1MjM0Y2Y4MDg5Yi90YWJsZXJhbmdlOjY3Nzc5NzVlOTEzMzRlNzc4M2U5NTUyMzRjZjgwODliXzUtMS0xLTEtNTgzNzI_35bd53d8-ccff-4bbe-a17e-c820dd046ecb">8,877</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90YWJsZTo2Nzc3OTc1ZTkxMzM0ZTc3ODNlOTU1MjM0Y2Y4MDg5Yi90YWJsZXJhbmdlOjY3Nzc5NzVlOTEzMzRlNzc4M2U5NTUyMzRjZjgwODliXzUtMy0xLTEtNTgzNzI_d845a06a-d1c2-489a-a378-7cdcc97f1d09">10,003</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-bottom:8pt;margin-top:8pt;padding-right:15.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, stock-based compensation expense of $<ix:nonFraction unitRef="usd" contextRef="i3b8fb31b2cb74f1986dbdb60db29474c_D20220101-20221231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90ZXh0cmVnaW9uOjM5ZTVmMjgzN2UzNjRmMWQ4NDA3OGY1NTkyYjA5YzA0XzgwNTM_1822c6ac-be63-4934-9c8d-4d2bbf98b4c6">83</ix:nonFraction> was charged to inventory as of December 31, 2022. No stock-based compensation expense was charged to prepaid expenses and other assets as of December 31, 2022. These charges represent the total stock-based compensation expense incurred related to employees involved in the manufacturing process of finished goods and samples during the period. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company utilized the Black-Scholes valuation model for estimating the fair value of stock options issued under the 2017 Plan. <ix:nonNumeric contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90ZXh0cmVnaW9uOjM5ZTVmMjgzN2UzNjRmMWQ4NDA3OGY1NTkyYjA5YzA0Xzk3ODk_31ec80b9-788c-4b82-bde7-a6f6c9c1cb22" continuedAt="i659dd42b5eca46d49af4bb2213f806b9" escape="true"><ix:nonNumeric contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90ZXh0cmVnaW9uOjM5ZTVmMjgzN2UzNjRmMWQ4NDA3OGY1NTkyYjA5YzA0Xzk4MDA_cd34f8c2-12d3-4d62-b20b-dda4508a7d7c" continuedAt="i804e5b71d0b440799d0a7860b172e1bd" escape="true">The Company calculated the fair value of each option grant and the shares issued under the 2017 Plan on the respective dates of grant using the following weighted average assumptions: </ix:nonNumeric></ix:nonNumeric></span><ix:continuation id="i659dd42b5eca46d49af4bb2213f806b9"><ix:continuation id="i804e5b71d0b440799d0a7860b172e1bd"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.145%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.387%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2010 A&amp;R Stock Incentive Plan</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2017 Employee Stock Purchase Plan</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk free interest rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9975a7e3c2704c8988c1154b5ae900d4_D20220101-20221231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90YWJsZTpkNTc2ZTg2MWNjN2I0NjY2ODAwZTNiNzQ4NzM3MmZhZi90YWJsZXJhbmdlOmQ1NzZlODYxY2M3YjQ2NjY4MDBlM2I3NDg3MzcyZmFmXzItMS0xLTEtNTgzNzI_8aab67e1-3e5a-4299-b300-8ab99360fcd3">2.22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idfcc4aa88cd04b0498643a728bb0b299_D20220101-20221231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90YWJsZTpkNTc2ZTg2MWNjN2I0NjY2ODAwZTNiNzQ4NzM3MmZhZi90YWJsZXJhbmdlOmQ1NzZlODYxY2M3YjQ2NjY4MDBlM2I3NDg3MzcyZmFmXzItMy0xLTEtNTgzNzI_65db4a36-3d3e-4303-b651-d63eeedb5f2f">0.17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9975a7e3c2704c8988c1154b5ae900d4_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90YWJsZTpkNTc2ZTg2MWNjN2I0NjY2ODAwZTNiNzQ4NzM3MmZhZi90YWJsZXJhbmdlOmQ1NzZlODYxY2M3YjQ2NjY4MDBlM2I3NDg3MzcyZmFmXzMtMS0xLTEtNTgzNzI_3172d46d-b892-4218-87b5-990551eeda68">6.08</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="idfcc4aa88cd04b0498643a728bb0b299_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90YWJsZTpkNTc2ZTg2MWNjN2I0NjY2ODAwZTNiNzQ4NzM3MmZhZi90YWJsZXJhbmdlOmQ1NzZlODYxY2M3YjQ2NjY4MDBlM2I3NDg3MzcyZmFmXzMtMy0xLTEtNTgzNzI_530c1afc-aa2c-4d9b-a531-d0003a4b577d">0.50</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9975a7e3c2704c8988c1154b5ae900d4_D20220101-20221231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90YWJsZTpkNTc2ZTg2MWNjN2I0NjY2ODAwZTNiNzQ4NzM3MmZhZi90YWJsZXJhbmdlOmQ1NzZlODYxY2M3YjQ2NjY4MDBlM2I3NDg3MzcyZmFmXzQtMS0xLTEtNTgzNzI_38687dc1-8eea-4605-a842-aeebac3161f7">73.23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idfcc4aa88cd04b0498643a728bb0b299_D20220101-20221231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90YWJsZTpkNTc2ZTg2MWNjN2I0NjY2ODAwZTNiNzQ4NzM3MmZhZi90YWJsZXJhbmdlOmQ1NzZlODYxY2M3YjQ2NjY4MDBlM2I3NDg3MzcyZmFmXzQtMy0xLTEtNTgzNzI_41d5eba2-d90c-4157-859a-30a56a11b0ba">88.13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Annual dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9975a7e3c2704c8988c1154b5ae900d4_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90YWJsZTpkNTc2ZTg2MWNjN2I0NjY2ODAwZTNiNzQ4NzM3MmZhZi90YWJsZXJhbmdlOmQ1NzZlODYxY2M3YjQ2NjY4MDBlM2I3NDg3MzcyZmFmXzUtMS0xLTEtNTgzNzI_356bcdf2-8125-4501-b5bb-c794b5275983">0.00</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idfcc4aa88cd04b0498643a728bb0b299_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90YWJsZTpkNTc2ZTg2MWNjN2I0NjY2ODAwZTNiNzQ4NzM3MmZhZi90YWJsZXJhbmdlOmQ1NzZlODYxY2M3YjQ2NjY4MDBlM2I3NDg3MzcyZmFmXzUtMy0xLTEtNTgzNzI_66fa7b15-a966-4fe4-abf5-615f873c29e9">0.00</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></ix:continuation></ix:continuation></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Option valuation methods, including Black-Scholes, require the input of subjective assumptions, which are discussed below.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The expected term of employee options is determined using the "simplified" method, as prescribed in SEC's Staff Accounting Bulletin (SAB) No.&#160;107, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share Based Payment </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(SAB No. 107), whereby the expected life equals the arithmetic average of the vesting term and the original contractual term of the option due to the Company's lack of sufficient historical data. The expected term of non-employee options is equal to the contractual term.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The expected volatility is based on a weighted average of the Company's historical volatility and the volatilities of similar entities within the Company's industry which were commensurate with the expected term assumption as described in SAB No.&#160;107.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The risk-free interest rate is based on the interest rate payable on US Treasury securities in effect at the time of grant for a period that is commensurate with the assumed expected term.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:112.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OptiNose,&#160;Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><ix:continuation id="i493d91bd5c0749af83c78cae256b86d2"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The expected dividend yield is <ix:nonFraction unitRef="number" contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90ZXh0cmVnaW9uOjM5ZTVmMjgzN2UzNjRmMWQ4NDA3OGY1NTkyYjA5YzA0Xzk2NTQ_47b867da-7daf-455e-af0e-3ec47973624a">0</ix:nonFraction>% because the Company has not historically paid, and does not expect for the foreseeable future to pay, a dividend on its common stock.</span></ix:continuation></div><div id="i451bcb3eabba4f87bdc579718207a3b8_178"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">15. <ix:nonNumeric contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzgvZnJhZzpkNjc4MzlkZGQwMzU0YWI1OTRmOGFjMDE4ZDQzYzRkYy90ZXh0cmVnaW9uOmQ2NzgzOWRkZDAzNTRhYjU5NGY4YWMwMThkNDNjNGRjXzUyNzg_8e94a139-7173-406b-990e-7f7d7a7700dc" continuedAt="i059b32b29064425e8bdb6f9277d9a078" escape="true">Income Taxes</ix:nonNumeric></span></div><ix:continuation id="i059b32b29064425e8bdb6f9277d9a078" continuedAt="i6c75f152f2a7460ba686cdb18dec512d"><div style="margin-bottom:8pt"><ix:nonNumeric contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzgvZnJhZzpkNjc4MzlkZGQwMzU0YWI1OTRmOGFjMDE4ZDQzYzRkYy90ZXh0cmVnaW9uOmQ2NzgzOWRkZDAzNTRhYjU5NGY4YWMwMThkNDNjNGRjXzUyODE_a6a6dbdd-3bab-45bd-8b1e-24f985f12b3b" escape="true"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes are based on the following book income (loss) before income tax expense:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.012%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Domestic operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzgvZnJhZzpkNjc4MzlkZGQwMzU0YWI1OTRmOGFjMDE4ZDQzYzRkYy90YWJsZTpkMzNlOTkwNDU1OTY0ZWYwODU2MmE0MjJhN2Y0MjExYi90YWJsZXJhbmdlOmQzM2U5OTA0NTU5NjRlZjA4NTYyYTQyMmE3ZjQyMTFiXzItMi0xLTEtNTgzNzI_82b9f9e2-ba61-4b36-b6ad-a650d268b0e4">72,750</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzgvZnJhZzpkNjc4MzlkZGQwMzU0YWI1OTRmOGFjMDE4ZDQzYzRkYy90YWJsZTpkMzNlOTkwNDU1OTY0ZWYwODU2MmE0MjJhN2Y0MjExYi90YWJsZXJhbmdlOmQzM2U5OTA0NTU5NjRlZjA4NTYyYTQyMmE3ZjQyMTFiXzItNC0xLTEtNTgzNzI_b308934f-338f-4424-8e7b-e83dd1dd35a6">78,801</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign operations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzgvZnJhZzpkNjc4MzlkZGQwMzU0YWI1OTRmOGFjMDE4ZDQzYzRkYy90YWJsZTpkMzNlOTkwNDU1OTY0ZWYwODU2MmE0MjJhN2Y0MjExYi90YWJsZXJhbmdlOmQzM2U5OTA0NTU5NjRlZjA4NTYyYTQyMmE3ZjQyMTFiXzMtMi0xLTEtNTgzNzI_60b3b708-f989-452d-b95b-ca00f58386ff">2,083</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzgvZnJhZzpkNjc4MzlkZGQwMzU0YWI1OTRmOGFjMDE4ZDQzYzRkYy90YWJsZTpkMzNlOTkwNDU1OTY0ZWYwODU2MmE0MjJhN2Y0MjExYi90YWJsZXJhbmdlOmQzM2U5OTA0NTU5NjRlZjA4NTYyYTQyMmE3ZjQyMTFiXzMtNC0xLTEtNTgzNzI_d2209b3c-8bbf-4ecc-9214-f08ad2454b3d">3,495</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss before provision for income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzgvZnJhZzpkNjc4MzlkZGQwMzU0YWI1OTRmOGFjMDE4ZDQzYzRkYy90YWJsZTpkMzNlOTkwNDU1OTY0ZWYwODU2MmE0MjJhN2Y0MjExYi90YWJsZXJhbmdlOmQzM2U5OTA0NTU5NjRlZjA4NTYyYTQyMmE3ZjQyMTFiXzQtMi0xLTEtNTgzNzI_092d5f5a-f223-4648-9e9a-55f994cad1cf">74,833</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzgvZnJhZzpkNjc4MzlkZGQwMzU0YWI1OTRmOGFjMDE4ZDQzYzRkYy90YWJsZTpkMzNlOTkwNDU1OTY0ZWYwODU2MmE0MjJhN2Y0MjExYi90YWJsZXJhbmdlOmQzM2U5OTA0NTU5NjRlZjA4NTYyYTQyMmE3ZjQyMTFiXzQtNC0xLTEtNTgzNzI_85abdbfa-7b8e-4d96-8164-0dba7a697632">82,296</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-top:8pt"><ix:nonNumeric contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzgvZnJhZzpkNjc4MzlkZGQwMzU0YWI1OTRmOGFjMDE4ZDQzYzRkYy90ZXh0cmVnaW9uOmQ2NzgzOWRkZDAzNTRhYjU5NGY4YWMwMThkNDNjNGRjXzUyODI_098ea10f-b723-4a50-9944-1d9d6be7ee09" escape="true"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of income tax expense (benefit) at the US federal statutory income tax rate and the income tax provision in the financial statements is as follows: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.644%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.505%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.994%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.405%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.852%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income tax expense at statutory rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzgvZnJhZzpkNjc4MzlkZGQwMzU0YWI1OTRmOGFjMDE4ZDQzYzRkYy90YWJsZTo1NTJkMmQzODNiODU0N2Q2OGFlM2Y5YzlkNTk1NDE4Ni90YWJsZXJhbmdlOjU1MmQyZDM4M2I4NTQ3ZDY4YWUzZjljOWQ1OTU0MTg2XzItMi0xLTEtNTgzNzI_40535a25-c182-46a1-a98b-9833d9469b68">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzgvZnJhZzpkNjc4MzlkZGQwMzU0YWI1OTRmOGFjMDE4ZDQzYzRkYy90YWJsZTo1NTJkMmQzODNiODU0N2Q2OGFlM2Y5YzlkNTk1NDE4Ni90YWJsZXJhbmdlOjU1MmQyZDM4M2I4NTQ3ZDY4YWUzZjljOWQ1OTU0MTg2XzItNC0xLTEtNTgzNzI_8909c27c-131d-4003-b95c-6fddf5d17608">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Permanent items</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzgvZnJhZzpkNjc4MzlkZGQwMzU0YWI1OTRmOGFjMDE4ZDQzYzRkYy90YWJsZTo1NTJkMmQzODNiODU0N2Q2OGFlM2Y5YzlkNTk1NDE4Ni90YWJsZXJhbmdlOjU1MmQyZDM4M2I4NTQ3ZDY4YWUzZjljOWQ1OTU0MTg2XzMtMi0xLTEtNTgzNzI_ff0f0ec9-2da1-45e8-b1a1-01b92f3aa880">1.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzgvZnJhZzpkNjc4MzlkZGQwMzU0YWI1OTRmOGFjMDE4ZDQzYzRkYy90YWJsZTo1NTJkMmQzODNiODU0N2Q2OGFlM2Y5YzlkNTk1NDE4Ni90YWJsZXJhbmdlOjU1MmQyZDM4M2I4NTQ3ZDY4YWUzZjljOWQ1OTU0MTg2XzMtNC0xLTEtNTgzNzI_81072896-99a2-4529-9050-8f098d29bb55">0.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Foreign rate differential</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzgvZnJhZzpkNjc4MzlkZGQwMzU0YWI1OTRmOGFjMDE4ZDQzYzRkYy90YWJsZTo1NTJkMmQzODNiODU0N2Q2OGFlM2Y5YzlkNTk1NDE4Ni90YWJsZXJhbmdlOjU1MmQyZDM4M2I4NTQ3ZDY4YWUzZjljOWQ1OTU0MTg2XzQtMi0xLTEtNTgzNzI_24fe6602-2f92-4935-a671-c3ba014f0c10">0.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzgvZnJhZzpkNjc4MzlkZGQwMzU0YWI1OTRmOGFjMDE4ZDQzYzRkYy90YWJsZTo1NTJkMmQzODNiODU0N2Q2OGFlM2Y5YzlkNTk1NDE4Ni90YWJsZXJhbmdlOjU1MmQyZDM4M2I4NTQ3ZDY4YWUzZjljOWQ1OTU0MTg2XzQtNC0xLTEtNTgzNzI_cab2594c-d34d-4281-8b85-7aac0323ebee">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Impact of foreign operations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" decimals="3" sign="-" name="optn:EffectiveIncomeTaxRateReconciliationForeignOperationsImpactPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzgvZnJhZzpkNjc4MzlkZGQwMzU0YWI1OTRmOGFjMDE4ZDQzYzRkYy90YWJsZTo1NTJkMmQzODNiODU0N2Q2OGFlM2Y5YzlkNTk1NDE4Ni90YWJsZXJhbmdlOjU1MmQyZDM4M2I4NTQ3ZDY4YWUzZjljOWQ1OTU0MTg2XzUtMi0xLTEtNTgzNzI_069e6e43-23f1-4dc8-af7d-ed8cdbd53ced">14.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231" decimals="3" name="optn:EffectiveIncomeTaxRateReconciliationForeignOperationsImpactPercent" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzgvZnJhZzpkNjc4MzlkZGQwMzU0YWI1OTRmOGFjMDE4ZDQzYzRkYy90YWJsZTo1NTJkMmQzODNiODU0N2Q2OGFlM2Y5YzlkNTk1NDE4Ni90YWJsZXJhbmdlOjU1MmQyZDM4M2I4NTQ3ZDY4YWUzZjljOWQ1OTU0MTg2XzUtNC0xLTEtNTgzNzI_0514c75d-3ecf-4740-bf1e-9cb6fb071009">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;State taxes, net of federal benefit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzgvZnJhZzpkNjc4MzlkZGQwMzU0YWI1OTRmOGFjMDE4ZDQzYzRkYy90YWJsZTo1NTJkMmQzODNiODU0N2Q2OGFlM2Y5YzlkNTk1NDE4Ni90YWJsZXJhbmdlOjU1MmQyZDM4M2I4NTQ3ZDY4YWUzZjljOWQ1OTU0MTg2XzYtMi0xLTEtNTgzNzI_cdb1d96c-6e95-4d78-9870-bc6680cfa4d6">2.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzgvZnJhZzpkNjc4MzlkZGQwMzU0YWI1OTRmOGFjMDE4ZDQzYzRkYy90YWJsZTo1NTJkMmQzODNiODU0N2Q2OGFlM2Y5YzlkNTk1NDE4Ni90YWJsZXJhbmdlOjU1MmQyZDM4M2I4NTQ3ZDY4YWUzZjljOWQ1OTU0MTg2XzYtNC0xLTEtNTgzNzI_4034f5d8-2618-4fcf-b094-174dc9e814a5">4.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Tax rate changes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzgvZnJhZzpkNjc4MzlkZGQwMzU0YWI1OTRmOGFjMDE4ZDQzYzRkYy90YWJsZTo1NTJkMmQzODNiODU0N2Q2OGFlM2Y5YzlkNTk1NDE4Ni90YWJsZXJhbmdlOjU1MmQyZDM4M2I4NTQ3ZDY4YWUzZjljOWQ1OTU0MTg2XzctMi0xLTEtNTgzNzI_45a8c4af-a943-46f5-87bf-3fa107a364b4">2.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzgvZnJhZzpkNjc4MzlkZGQwMzU0YWI1OTRmOGFjMDE4ZDQzYzRkYy90YWJsZTo1NTJkMmQzODNiODU0N2Q2OGFlM2Y5YzlkNTk1NDE4Ni90YWJsZXJhbmdlOjU1MmQyZDM4M2I4NTQ3ZDY4YWUzZjljOWQ1OTU0MTg2XzctNC0xLTEtNTgzNzI_48854fe5-7a5b-461a-8957-227937a420e4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Foreign exchange and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" decimals="3" sign="-" name="optn:EffectiveIncomeTaxRateReconciliationForeignExchangeOtherPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzgvZnJhZzpkNjc4MzlkZGQwMzU0YWI1OTRmOGFjMDE4ZDQzYzRkYy90YWJsZTo1NTJkMmQzODNiODU0N2Q2OGFlM2Y5YzlkNTk1NDE4Ni90YWJsZXJhbmdlOjU1MmQyZDM4M2I4NTQ3ZDY4YWUzZjljOWQ1OTU0MTg2XzgtMi0xLTEtNTgzNzI_7eca5bfa-39c7-468c-9dbe-f566e4918988">1.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231" decimals="3" sign="-" name="optn:EffectiveIncomeTaxRateReconciliationForeignExchangeOtherPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzgvZnJhZzpkNjc4MzlkZGQwMzU0YWI1OTRmOGFjMDE4ZDQzYzRkYy90YWJsZTo1NTJkMmQzODNiODU0N2Q2OGFlM2Y5YzlkNTk1NDE4Ni90YWJsZXJhbmdlOjU1MmQyZDM4M2I4NTQ3ZDY4YWUzZjljOWQ1OTU0MTg2XzgtNC0xLTEtNTgzNzI_4cfbd1a7-097e-49d3-ace6-1095d7391570">0.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Stock based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzgvZnJhZzpkNjc4MzlkZGQwMzU0YWI1OTRmOGFjMDE4ZDQzYzRkYy90YWJsZTo1NTJkMmQzODNiODU0N2Q2OGFlM2Y5YzlkNTk1NDE4Ni90YWJsZXJhbmdlOjU1MmQyZDM4M2I4NTQ3ZDY4YWUzZjljOWQ1OTU0MTg2XzktMi0xLTEtMTEwNzA1_97a3cd2d-a5b6-4c43-9b32-64909923da30">2.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzgvZnJhZzpkNjc4MzlkZGQwMzU0YWI1OTRmOGFjMDE4ZDQzYzRkYy90YWJsZTo1NTJkMmQzODNiODU0N2Q2OGFlM2Y5YzlkNTk1NDE4Ni90YWJsZXJhbmdlOjU1MmQyZDM4M2I4NTQ3ZDY4YWUzZjljOWQ1OTU0MTg2XzktNC0xLTEtMTExMDUy_b3b73a30-d0f4-4db9-bcc6-daf283350268">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Prepaid royalty write off</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" decimals="3" sign="-" name="optn:EffectiveIncomeTaxRateReconciliationPrepaidRoyaltyWriteOffPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzgvZnJhZzpkNjc4MzlkZGQwMzU0YWI1OTRmOGFjMDE4ZDQzYzRkYy90YWJsZTo1NTJkMmQzODNiODU0N2Q2OGFlM2Y5YzlkNTk1NDE4Ni90YWJsZXJhbmdlOjU1MmQyZDM4M2I4NTQ3ZDY4YWUzZjljOWQ1OTU0MTg2XzEwLTItMS0xLTExMzI3MQ_c31056e2-1622-42a8-961c-36efb7b0ef7d">11.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231" decimals="3" name="optn:EffectiveIncomeTaxRateReconciliationPrepaidRoyaltyWriteOffPercent" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzgvZnJhZzpkNjc4MzlkZGQwMzU0YWI1OTRmOGFjMDE4ZDQzYzRkYy90YWJsZTo1NTJkMmQzODNiODU0N2Q2OGFlM2Y5YzlkNTk1NDE4Ni90YWJsZXJhbmdlOjU1MmQyZDM4M2I4NTQ3ZDY4YWUzZjljOWQ1OTU0MTg2XzEwLTQtMS0xLTExMzI0NA_0d4c928b-13f8-4e7f-9518-c73ce2aecad9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Change in valuation allowance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzgvZnJhZzpkNjc4MzlkZGQwMzU0YWI1OTRmOGFjMDE4ZDQzYzRkYy90YWJsZTo1NTJkMmQzODNiODU0N2Q2OGFlM2Y5YzlkNTk1NDE4Ni90YWJsZXJhbmdlOjU1MmQyZDM4M2I4NTQ3ZDY4YWUzZjljOWQ1OTU0MTg2XzktMi0xLTEtNTgzNzI_30cb48e8-9e63-4add-bb21-22a8d0844488">12.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzgvZnJhZzpkNjc4MzlkZGQwMzU0YWI1OTRmOGFjMDE4ZDQzYzRkYy90YWJsZTo1NTJkMmQzODNiODU0N2Q2OGFlM2Y5YzlkNTk1NDE4Ni90YWJsZXJhbmdlOjU1MmQyZDM4M2I4NTQ3ZDY4YWUzZjljOWQ1OTU0MTg2XzktNC0xLTEtNTgzNzI_c61b3605-fe61-415a-b502-5d742b1a1b50">24.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effective income tax rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzgvZnJhZzpkNjc4MzlkZGQwMzU0YWI1OTRmOGFjMDE4ZDQzYzRkYy90YWJsZTo1NTJkMmQzODNiODU0N2Q2OGFlM2Y5YzlkNTk1NDE4Ni90YWJsZXJhbmdlOjU1MmQyZDM4M2I4NTQ3ZDY4YWUzZjljOWQ1OTU0MTg2XzEwLTItMS0xLTU4Mzcy_2e53db7a-addf-410d-a145-9ed3e31c600c">0.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzgvZnJhZzpkNjc4MzlkZGQwMzU0YWI1OTRmOGFjMDE4ZDQzYzRkYy90YWJsZTo1NTJkMmQzODNiODU0N2Q2OGFlM2Y5YzlkNTk1NDE4Ni90YWJsZXJhbmdlOjU1MmQyZDM4M2I4NTQ3ZDY4YWUzZjljOWQ1OTU0MTg2XzEwLTQtMS0xLTU4Mzcy_c3c34ca7-2437-49a5-bebb-e6b1a54fad6d">0.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></ix:nonNumeric></div></ix:continuation><div><span><br/></span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:112.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OptiNose,&#160;Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div></div><ix:continuation id="i6c75f152f2a7460ba686cdb18dec512d" continuedAt="if8851fa8f9ab44759166a706196c8ee1"><div><ix:nonNumeric contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzgvZnJhZzpkNjc4MzlkZGQwMzU0YWI1OTRmOGFjMDE4ZDQzYzRkYy90ZXh0cmVnaW9uOmQ2NzgzOWRkZDAzNTRhYjU5NGY4YWMwMThkNDNjNGRjXzUyNzY_40bb4e00-80c7-4d7f-b67a-9e4e38f67a22" escape="true"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The principal components of the Company&#8217;s deferred tax assets and liabilities are as follows: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"><tr><td style="width:1.0%"></td><td style="width:54.241%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.523%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.027%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.432%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.177%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Accrued expenses and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzgvZnJhZzpkNjc4MzlkZGQwMzU0YWI1OTRmOGFjMDE4ZDQzYzRkYy90YWJsZTplNWZmMjEzNzdjNmY0Y2YyYmViNDA2N2JkMmEyMmYxYy90YWJsZXJhbmdlOmU1ZmYyMTM3N2M2ZjRjZjJiZWI0MDY3YmQyYTIyZjFjXzMtMi0xLTEtNTgzNzI_5a25d944-bcc5-4357-bc1e-fd8d0cf4dcb6">5,144</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id970dfd2674c4d6b895febb9c14d0fd1_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzgvZnJhZzpkNjc4MzlkZGQwMzU0YWI1OTRmOGFjMDE4ZDQzYzRkYy90YWJsZTplNWZmMjEzNzdjNmY0Y2YyYmViNDA2N2JkMmEyMmYxYy90YWJsZXJhbmdlOmU1ZmYyMTM3N2M2ZjRjZjJiZWI0MDY3YmQyYTIyZjFjXzMtNC0xLTEtNTgzNzI_58675629-6649-425e-8da2-2e595c984362">6,712</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Prepaid licensing arrangement</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231" decimals="-3" name="optn:DeferredTaxAssetsPrepaidLicenseArrangement" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzgvZnJhZzpkNjc4MzlkZGQwMzU0YWI1OTRmOGFjMDE4ZDQzYzRkYy90YWJsZTplNWZmMjEzNzdjNmY0Y2YyYmViNDA2N2JkMmEyMmYxYy90YWJsZXJhbmdlOmU1ZmYyMTM3N2M2ZjRjZjJiZWI0MDY3YmQyYTIyZjFjXzQtMi0xLTEtNTgzNzI_a37b6de3-21fa-4012-8cc3-881d5c93f84a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id970dfd2674c4d6b895febb9c14d0fd1_I20211231" decimals="-3" name="optn:DeferredTaxAssetsPrepaidLicenseArrangement" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzgvZnJhZzpkNjc4MzlkZGQwMzU0YWI1OTRmOGFjMDE4ZDQzYzRkYy90YWJsZTplNWZmMjEzNzdjNmY0Y2YyYmViNDA2N2JkMmEyMmYxYy90YWJsZXJhbmdlOmU1ZmYyMTM3N2M2ZjRjZjJiZWI0MDY3YmQyYTIyZjFjXzQtNC0xLTEtNTgzNzI_c2092f73-2dd4-44ca-a4bf-896f05bacfa3">9,441</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Interest expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231" decimals="-3" name="optn:DeferredTaxAssetsInterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzgvZnJhZzpkNjc4MzlkZGQwMzU0YWI1OTRmOGFjMDE4ZDQzYzRkYy90YWJsZTplNWZmMjEzNzdjNmY0Y2YyYmViNDA2N2JkMmEyMmYxYy90YWJsZXJhbmdlOmU1ZmYyMTM3N2M2ZjRjZjJiZWI0MDY3YmQyYTIyZjFjXzUtMi0xLTEtNTgzNzI_60dd2a7a-adee-44d1-b09f-0edafb4c72b7">14,304</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id970dfd2674c4d6b895febb9c14d0fd1_I20211231" decimals="-3" name="optn:DeferredTaxAssetsInterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzgvZnJhZzpkNjc4MzlkZGQwMzU0YWI1OTRmOGFjMDE4ZDQzYzRkYy90YWJsZTplNWZmMjEzNzdjNmY0Y2YyYmViNDA2N2JkMmEyMmYxYy90YWJsZXJhbmdlOmU1ZmYyMTM3N2M2ZjRjZjJiZWI0MDY3YmQyYTIyZjFjXzUtNC0xLTEtNTgzNzI_c3954307-7ad4-458a-a18a-a29910ea071e">10,708</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Stock compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzgvZnJhZzpkNjc4MzlkZGQwMzU0YWI1OTRmOGFjMDE4ZDQzYzRkYy90YWJsZTplNWZmMjEzNzdjNmY0Y2YyYmViNDA2N2JkMmEyMmYxYy90YWJsZXJhbmdlOmU1ZmYyMTM3N2M2ZjRjZjJiZWI0MDY3YmQyYTIyZjFjXzYtMi0xLTEtNTgzNzI_641a3d15-6f2f-438a-898d-648d4bea0a99">7,193</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id970dfd2674c4d6b895febb9c14d0fd1_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzgvZnJhZzpkNjc4MzlkZGQwMzU0YWI1OTRmOGFjMDE4ZDQzYzRkYy90YWJsZTplNWZmMjEzNzdjNmY0Y2YyYmViNDA2N2JkMmEyMmYxYy90YWJsZXJhbmdlOmU1ZmYyMTM3N2M2ZjRjZjJiZWI0MDY3YmQyYTIyZjFjXzYtNC0xLTEtNTgzNzI_7164fe1a-6e54-45d7-9bfa-8353e331b050">8,583</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Lease liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231" decimals="-3" name="optn:DeferredTaxAssetsLeasingArrangement" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzgvZnJhZzpkNjc4MzlkZGQwMzU0YWI1OTRmOGFjMDE4ZDQzYzRkYy90YWJsZTplNWZmMjEzNzdjNmY0Y2YyYmViNDA2N2JkMmEyMmYxYy90YWJsZXJhbmdlOmU1ZmYyMTM3N2M2ZjRjZjJiZWI0MDY3YmQyYTIyZjFjXzctMi0xLTEtNTgzNzI_fc59fc54-ebf8-4193-8915-a41b02936e61">642</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id970dfd2674c4d6b895febb9c14d0fd1_I20211231" decimals="-3" name="optn:DeferredTaxAssetsLeasingArrangement" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzgvZnJhZzpkNjc4MzlkZGQwMzU0YWI1OTRmOGFjMDE4ZDQzYzRkYy90YWJsZTplNWZmMjEzNzdjNmY0Y2YyYmViNDA2N2JkMmEyMmYxYy90YWJsZXJhbmdlOmU1ZmYyMTM3N2M2ZjRjZjJiZWI0MDY3YmQyYTIyZjFjXzctNC0xLTEtNTgzNzI_82d11050-3109-4ecf-b54c-b4e48a821409">1,081</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Research and development credits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzgvZnJhZzpkNjc4MzlkZGQwMzU0YWI1OTRmOGFjMDE4ZDQzYzRkYy90YWJsZTplNWZmMjEzNzdjNmY0Y2YyYmViNDA2N2JkMmEyMmYxYy90YWJsZXJhbmdlOmU1ZmYyMTM3N2M2ZjRjZjJiZWI0MDY3YmQyYTIyZjFjXzgtMi0xLTEtNTgzNzI_74d6ad5e-a0d0-4420-bef1-f9def8fe78bb">2,460</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id970dfd2674c4d6b895febb9c14d0fd1_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzgvZnJhZzpkNjc4MzlkZGQwMzU0YWI1OTRmOGFjMDE4ZDQzYzRkYy90YWJsZTplNWZmMjEzNzdjNmY0Y2YyYmViNDA2N2JkMmEyMmYxYy90YWJsZXJhbmdlOmU1ZmYyMTM3N2M2ZjRjZjJiZWI0MDY3YmQyYTIyZjFjXzgtNC0xLTEtNTgzNzI_aeb2286c-b11c-4b10-9535-29e4f1345eeb">2,461</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Capitalized R&amp;D</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231" decimals="-3" name="optn:DeferredTaxAssetsFinancingCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzgvZnJhZzpkNjc4MzlkZGQwMzU0YWI1OTRmOGFjMDE4ZDQzYzRkYy90YWJsZTplNWZmMjEzNzdjNmY0Y2YyYmViNDA2N2JkMmEyMmYxYy90YWJsZXJhbmdlOmU1ZmYyMTM3N2M2ZjRjZjJiZWI0MDY3YmQyYTIyZjFjXzktMi0xLTEtMTEwNzIx_412e46a5-4d40-47c8-98ca-f77e1f6cc594">3,377</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="id970dfd2674c4d6b895febb9c14d0fd1_I20211231" xsi:nil="true" name="optn:DeferredTaxAssetsFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzgvZnJhZzpkNjc4MzlkZGQwMzU0YWI1OTRmOGFjMDE4ZDQzYzRkYy90YWJsZTplNWZmMjEzNzdjNmY0Y2YyYmViNDA2N2JkMmEyMmYxYy90YWJsZXJhbmdlOmU1ZmYyMTM3N2M2ZjRjZjJiZWI0MDY3YmQyYTIyZjFjXzEwLTQtMS0xLTExMTA1Ng_4a7890cf-4feb-4f15-a31d-10be32b44efa"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Net operating losses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzgvZnJhZzpkNjc4MzlkZGQwMzU0YWI1OTRmOGFjMDE4ZDQzYzRkYy90YWJsZTplNWZmMjEzNzdjNmY0Y2YyYmViNDA2N2JkMmEyMmYxYy90YWJsZXJhbmdlOmU1ZmYyMTM3N2M2ZjRjZjJiZWI0MDY3YmQyYTIyZjFjXzktMi0xLTEtNTgzNzI_c5efbbf1-c17d-4ebe-a8a4-7e8446174549">83,376</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id970dfd2674c4d6b895febb9c14d0fd1_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzgvZnJhZzpkNjc4MzlkZGQwMzU0YWI1OTRmOGFjMDE4ZDQzYzRkYy90YWJsZTplNWZmMjEzNzdjNmY0Y2YyYmViNDA2N2JkMmEyMmYxYy90YWJsZXJhbmdlOmU1ZmYyMTM3N2M2ZjRjZjJiZWI0MDY3YmQyYTIyZjFjXzktNC0xLTEtNTgzNzI_808e9de6-50cb-445a-9027-314af3202479">87,324</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Total deferred tax assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzgvZnJhZzpkNjc4MzlkZGQwMzU0YWI1OTRmOGFjMDE4ZDQzYzRkYy90YWJsZTplNWZmMjEzNzdjNmY0Y2YyYmViNDA2N2JkMmEyMmYxYy90YWJsZXJhbmdlOmU1ZmYyMTM3N2M2ZjRjZjJiZWI0MDY3YmQyYTIyZjFjXzEwLTItMS0xLTU4Mzcy_05d0dbfd-70bd-446c-adaf-f67a4ea63276">116,496</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id970dfd2674c4d6b895febb9c14d0fd1_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzgvZnJhZzpkNjc4MzlkZGQwMzU0YWI1OTRmOGFjMDE4ZDQzYzRkYy90YWJsZTplNWZmMjEzNzdjNmY0Y2YyYmViNDA2N2JkMmEyMmYxYy90YWJsZXJhbmdlOmU1ZmYyMTM3N2M2ZjRjZjJiZWI0MDY3YmQyYTIyZjFjXzEwLTQtMS0xLTU4Mzcy_c39ffa8b-4cfb-49a2-ad05-c4874883d19f">126,310</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Fixed assets, including leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzgvZnJhZzpkNjc4MzlkZGQwMzU0YWI1OTRmOGFjMDE4ZDQzYzRkYy90YWJsZTplNWZmMjEzNzdjNmY0Y2YyYmViNDA2N2JkMmEyMmYxYy90YWJsZXJhbmdlOmU1ZmYyMTM3N2M2ZjRjZjJiZWI0MDY3YmQyYTIyZjFjXzEyLTItMS0xLTU4Mzcy_7e85e40d-ea45-43e6-9799-408c1b915908">171</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id970dfd2674c4d6b895febb9c14d0fd1_I20211231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzgvZnJhZzpkNjc4MzlkZGQwMzU0YWI1OTRmOGFjMDE4ZDQzYzRkYy90YWJsZTplNWZmMjEzNzdjNmY0Y2YyYmViNDA2N2JkMmEyMmYxYy90YWJsZXJhbmdlOmU1ZmYyMTM3N2M2ZjRjZjJiZWI0MDY3YmQyYTIyZjFjXzEyLTQtMS0xLTU4Mzcy_26914e17-b418-4d22-a948-d86be1b3f10b">210</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Right-to-use asset</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzgvZnJhZzpkNjc4MzlkZGQwMzU0YWI1OTRmOGFjMDE4ZDQzYzRkYy90YWJsZTplNWZmMjEzNzdjNmY0Y2YyYmViNDA2N2JkMmEyMmYxYy90YWJsZXJhbmdlOmU1ZmYyMTM3N2M2ZjRjZjJiZWI0MDY3YmQyYTIyZjFjXzEzLTItMS0xLTU4Mzcy_1a178044-b292-416f-9739-f3511e56d3e6">605</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id970dfd2674c4d6b895febb9c14d0fd1_I20211231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzgvZnJhZzpkNjc4MzlkZGQwMzU0YWI1OTRmOGFjMDE4ZDQzYzRkYy90YWJsZTplNWZmMjEzNzdjNmY0Y2YyYmViNDA2N2JkMmEyMmYxYy90YWJsZXJhbmdlOmU1ZmYyMTM3N2M2ZjRjZjJiZWI0MDY3YmQyYTIyZjFjXzEzLTQtMS0xLTU4Mzcy_666fd347-49c2-4a59-9237-f0fca7b6953b">1,024</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Total deferred tax liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzgvZnJhZzpkNjc4MzlkZGQwMzU0YWI1OTRmOGFjMDE4ZDQzYzRkYy90YWJsZTplNWZmMjEzNzdjNmY0Y2YyYmViNDA2N2JkMmEyMmYxYy90YWJsZXJhbmdlOmU1ZmYyMTM3N2M2ZjRjZjJiZWI0MDY3YmQyYTIyZjFjXzE0LTItMS0xLTU4Mzcy_2b92e62d-50d7-4179-bcf4-ae39a2abdbd5">776</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id970dfd2674c4d6b895febb9c14d0fd1_I20211231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzgvZnJhZzpkNjc4MzlkZGQwMzU0YWI1OTRmOGFjMDE4ZDQzYzRkYy90YWJsZTplNWZmMjEzNzdjNmY0Y2YyYmViNDA2N2JkMmEyMmYxYy90YWJsZXJhbmdlOmU1ZmYyMTM3N2M2ZjRjZjJiZWI0MDY3YmQyYTIyZjFjXzE0LTQtMS0xLTU4Mzcy_5d0ae4e6-e216-407b-a132-f17f8bfcb833">1,234</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Less: Valuation allowance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzgvZnJhZzpkNjc4MzlkZGQwMzU0YWI1OTRmOGFjMDE4ZDQzYzRkYy90YWJsZTplNWZmMjEzNzdjNmY0Y2YyYmViNDA2N2JkMmEyMmYxYy90YWJsZXJhbmdlOmU1ZmYyMTM3N2M2ZjRjZjJiZWI0MDY3YmQyYTIyZjFjXzE1LTItMS0xLTU4Mzcy_fd0dada4-3373-4780-9b24-d52fcb7b8afb">115,720</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id970dfd2674c4d6b895febb9c14d0fd1_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzgvZnJhZzpkNjc4MzlkZGQwMzU0YWI1OTRmOGFjMDE4ZDQzYzRkYy90YWJsZTplNWZmMjEzNzdjNmY0Y2YyYmViNDA2N2JkMmEyMmYxYy90YWJsZXJhbmdlOmU1ZmYyMTM3N2M2ZjRjZjJiZWI0MDY3YmQyYTIyZjFjXzE1LTQtMS0xLTU4Mzcy_8fabdad7-001f-49d0-8a9f-705406d4b426">125,076</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total net deferred tax assets (liabilities)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzgvZnJhZzpkNjc4MzlkZGQwMzU0YWI1OTRmOGFjMDE4ZDQzYzRkYy90YWJsZTplNWZmMjEzNzdjNmY0Y2YyYmViNDA2N2JkMmEyMmYxYy90YWJsZXJhbmdlOmU1ZmYyMTM3N2M2ZjRjZjJiZWI0MDY3YmQyYTIyZjFjXzE2LTItMS0xLTU4Mzcy_6fdfb8d5-e112-47b9-9af4-6dc25baf9ffe">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id970dfd2674c4d6b895febb9c14d0fd1_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzgvZnJhZzpkNjc4MzlkZGQwMzU0YWI1OTRmOGFjMDE4ZDQzYzRkYy90YWJsZTplNWZmMjEzNzdjNmY0Y2YyYmViNDA2N2JkMmEyMmYxYy90YWJsZXJhbmdlOmU1ZmYyMTM3N2M2ZjRjZjJiZWI0MDY3YmQyYTIyZjFjXzE2LTQtMS0xLTU4Mzcy_63cf7259-f442-4ca7-aa85-cfb20ae62786">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-bottom:8pt;margin-top:8pt"><span><br/></span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, the Company had foreign net operating loss (NOL) carry forwards of $<ix:nonFraction unitRef="usd" contextRef="i411a7889aa7b40c59ba3d11c1d63d29e_I20221231" decimals="-3" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzgvZnJhZzpkNjc4MzlkZGQwMzU0YWI1OTRmOGFjMDE4ZDQzYzRkYy90ZXh0cmVnaW9uOmQ2NzgzOWRkZDAzNTRhYjU5NGY4YWMwMThkNDNjNGRjXzQ1Mg_565a2e7e-00f5-4526-9d61-acb7862c24c6">9,073</ix:nonFraction>, primarily from its operations in Norway. As of December 31, 2022, the Company had federal and state NOLs of $<ix:nonFraction unitRef="usd" contextRef="i65dbad508d2444f4bb357feedbc9cad4_I20221231" decimals="-3" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzgvZnJhZzpkNjc4MzlkZGQwMzU0YWI1OTRmOGFjMDE4ZDQzYzRkYy90ZXh0cmVnaW9uOmQ2NzgzOWRkZDAzNTRhYjU5NGY4YWMwMThkNDNjNGRjXzU0OA_524ad29a-7bf7-40b6-9a3f-f6b7df785a60">335,009</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i497d60fef0fd413ba91eb9a5009d1d39_I20221231" decimals="-3" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzgvZnJhZzpkNjc4MzlkZGQwMzU0YWI1OTRmOGFjMDE4ZDQzYzRkYy90ZXh0cmVnaW9uOmQ2NzgzOWRkZDAzNTRhYjU5NGY4YWMwMThkNDNjNGRjXzU1NQ_6d08ca67-da6b-47e0-8844-3459be63ae30">252,324</ix:nonFraction>, respectively. These domestic NOL carry forwards may be subject to an annual limitation in the event of cumulative changes in the ownership interests of significant stockholders over a three-year period in excess of 50%. This could limit the amount of NOLs that the Company can utilize annually to offset future domestic taxable income, if any. The amount of the annual limitation, if any, will be determined based on the value of the Company immediately prior to the ownership change. Subsequent ownership changes may further affect the limitation in future years. The federal NOLs generated after 2017 have an indefinite carry forward period. The federal NOLs generated prior to 2018 will expire from 2030 through 2037. Some state NOLs will not expire while other state NOLs expire over various periods depending on the rules of the jurisdiction in which they were generated. The earliest state NOL expiration is in 2030.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. NOL and tax credit carry forwards could expire unused and be unavailable to offset future income tax liabilities because of their limited duration or because of other restrictions under U.S. tax law. Under Sections 382 and 383, if a corporation undergoes an &#8220;ownership change&#8221;, generally defined as a greater than 50% change, by value, in equity ownership during a three-year period, the corporation&#8217;s ability to offset pre-change tax attributes, such as NOLs and R&amp;D tax credits, against post-change income or tax may be limited. We have not performed an analysis under Section 382 and cannot predict or otherwise determine whether utilization of our federal tax attribute carry forwards may be limited. As a result, if we have taxable income in the future, our ability to use existing U.S. NOL and R&amp;D tax credit carry forwards to reduce U.S. taxable income or tax liability may be subject to limitation resulting in increased future tax liabilities. Similar rules at the state level may also limit our ability to use state NOLs. Also, there may be periods when the use of NOLs is suspended or otherwise limited at the state level, which could accelerate or permanently increase state taxes owed.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:103%">The company also has federal and state R&amp;D credit carryforwards of $<ix:nonFraction unitRef="usd" contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzgvZnJhZzpkNjc4MzlkZGQwMzU0YWI1OTRmOGFjMDE4ZDQzYzRkYy90ZXh0cmVnaW9uOmQ2NzgzOWRkZDAzNTRhYjU5NGY4YWMwMThkNDNjNGRjXzI3NTk_3ff3378e-1a8a-4b38-982d-05acf7b0bb42">2,487</ix:nonFraction> which can be carried forward for <ix:nonNumeric contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" name="optn:DeferredTaxAssetsTaxCreditCarryforwardsResearchTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzgvZnJhZzpkNjc4MzlkZGQwMzU0YWI1OTRmOGFjMDE4ZDQzYzRkYy90ZXh0cmVnaW9uOmQ2NzgzOWRkZDAzNTRhYjU5NGY4YWMwMThkNDNjNGRjXzI3OTU_3c753210-2b68-4918-8053-6b05ba087396">20</ix:nonNumeric> years beginning to expire in 2031</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:103%">.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:112.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i451bcb3eabba4f87bdc579718207a3b8_10">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OptiNose,&#160;Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div></div><ix:continuation id="if8851fa8f9ab44759166a706196c8ee1"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC 740 requires the establishment of a valuation allowance to reduce deferred tax assets if, based on the weight of the available positive and negative evidence it is more likely than not that all or a portion of the deferred tax assets will not be realized. There is insufficient positive evidence to overcome the negative evidence attributable to the Company&#8217;s cumulative operating losses. Consequently, the Company established a full valuation allowance against its net deferred tax assets at December 31, 2022 and 2021, respectively, because the Company&#8217;s management was unable to conclude that it is more likely than not that these assets will be fully realized. The Company had a net decrease in its valuation allowance of $<ix:nonFraction unitRef="usd" contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzgvZnJhZzpkNjc4MzlkZGQwMzU0YWI1OTRmOGFjMDE4ZDQzYzRkYy90ZXh0cmVnaW9uOmQ2NzgzOWRkZDAzNTRhYjU5NGY4YWMwMThkNDNjNGRjXzM1NDA_cba4e985-ce94-4741-9bcb-5fb668a1cb24">9,356</ix:nonFraction> during the year ended December 31, 2022, primarily related to material deferred tax asset write offs from prepaid royalty and equity compensation as well as Norway NOL utilization in the current year.  </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company files income tax returns in Norway, the UK, the US, and various states. The Company is subject to examination by federal, state and foreign jurisdictions. The Company&#8217;s tax years in the US are open under statute from inception to present. All open years may be examined to the extent that tax credits or net operating loss carry forwards are used in future periods. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s policy is to record interest and penalties related to uncertain tax positions in income tax expense.  As of December 31, 2022, the Company had <ix:nonFraction unitRef="usd" contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231" decimals="INF" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzgvZnJhZzpkNjc4MzlkZGQwMzU0YWI1OTRmOGFjMDE4ZDQzYzRkYy90ZXh0cmVnaW9uOmQ2NzgzOWRkZDAzNTRhYjU5NGY4YWMwMThkNDNjNGRjXzQwOTI_08ca9907-c5ef-4249-8310-fc2175c5d26b">no</ix:nonFraction> accrued interest or penalties related to uncertain tax positions and no amounts have been recognized in the Company&#8217;s statement of operations. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (CARES Act) was enacted into law in response to the COVID-19 pandemic. The CARES Act contains income tax provisions, such an enhanced interest deductibility, repeal of the 80% limitation with respect to net operating losses arising in taxable years 2018-2020, and additional depreciation deductions related to qualified improvement property. The Company has concluded the analysis of these provisions as of year-end and the CARES Act did not have a material impact on the Company&#8217;s income taxes for 2021.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 27, 2020, the Consolidated Appropriations Act, 2021 (CAA) was signed into law. Along with providing funding for normal government operations ($1.4 trillion), this bill provides for additional COVID-19 focused relief ($900 billion). The CAA extends certain provisions of the CARES Act, provides additional funding for others and contains new relief provisions. The CAA did not have a material impact on the Company&#8217;s income taxes for 2021.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 16, 2022, the Inflation Reduction Act of 2022 was enacted into law containing corporate income tax provisions such as the corporate alternative minimum tax and an excise tax on the repurchase of corporate stock. These provisions are not expected to have a material impact on the Company's income taxes in the near term.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-32</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.5
<SEQUENCE>2
<FILENAME>descriptionofsecuritiesex4.htm
<DESCRIPTION>EX-4.5
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ifb673ca05bec4a2eb431dfea1be70e27_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exhibit 4.5</font></div></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:110%">DESCRIPTION OF THE REGISTRANT&#8217;S SECURITIES</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:110%">REGISTERED PURSUANT TO SECTION 12 OF THE </font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:110%">SECURITIES EXCHANGE ACT OF 1934</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:24.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">As of the date of the Annual Report on Form 10-K of which this exhibit forms a part, the only class of securities of OptiNose, Inc. (&#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221;) registered under Section 12 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), is our common stock, $0.001 par value per share. </font></div><div><font><br></font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:110%">COMMON</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:110%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:110%">STOCK</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:24.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">The following description of our common stock summarizes provisions of our fourth amended and restated certificate of incorporation, our amended and restated bylaws, and the Delaware General Corporation Law. For a complete description, refer to our fourth amended and restated certificate of incorporation and our amended and restated bylaws, which are incorporated by reference as exhibits to the Annual Report on Form 10-K of which this exhibit is a part, and to the applicable provisions of the Delaware General Corporation Law. </font></div><div><font><br></font></div><div style="text-indent:24.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our fourth amended and restated certificate of incorporation authorizes us to issue up to 205,000,000 shares, 200,000,000 of which is designated as common stock with a par value of $0.001 per share. The shares of common stock currently outstanding are fully paid and nonassessable.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Rights</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Voting Rights. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Each holder of our common stock is entitled to one vote for each share on all matters submitted to a vote of the stockholders, other than election of directors, which is determined by a plurality of the votes cast by the stockholders entitled to vote on the election of such director. In addition, the affirmative vote of the holders of at least 66</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:115%;position:relative;top:-2.44pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#47;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:115%;position:relative;top:0.98pt;vertical-align:baseline">3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">% of the voting power of all of the then outstanding voting stock is required to take certain actions, including amending certain provisions of our fourth amended and restated certificate of incorporation, such as the provisions relating to director liability, amending our bylaws or changing the Court of Chancery of the State of Delaware and United States District Court for the District of Delaware and any appellate courts thereof from being the sole and exclusive forums for certain actions brought by our stockholders against us or our directors, officers or employees.</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under our fourth amended and restated certificate of incorporation and amended and restated bylaws, our stockholders do not have cumulative voting rights. Because of this, the holders of a majority of the shares of common stock entitled to vote in any election of directors can elect all of the directors standing for election, if they should so choose.</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Dividends</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Subject to the preferences that may be applicable to any outstanding preferred stock, holders of our common stock are entitled to receive ratably any dividends that may be declared by our board of directors out of funds legally available for that purpose.</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Liquidation Rights. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the event of our liquidation, dissolution or winding up, holders of our common stock are entitled to share ratably in all assets remaining after payment of liabilities and the liquidation preference of any outstanding preferred stock.</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">No Preemptive or Similar Rights. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our common stock is not entitled to preemptive rights and is not subject to conversion, redemption or sinking fund provisions. The common stock is not subject to future calls or assessments by us. The rights, preferences and privileges of the holders of common stock are subject to, and may be adversely affected by, the rights of the holders of shares of any series of preferred stock that we may designate in the future. </font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exhibit 4.5</font></div></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Anti-Takeover Effects of Our Certificate of Incorporation and Bylaws and Delaware Law</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Certificate of Incorporation and Bylaws.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Provisions of our fourth amended and restated certificate of incorporation and our amended and restated bylaws may delay or discourage transactions involving an actual or potential change of control or change in our management, including transactions in which stockholders might otherwise receive a premium for their shares, or transactions that our stockholders might otherwise deem to be in their best interests. Therefore, these provisions could adversely affect the price of our common stock. Among other things, our fourth amended and restated certificate of incorporation and our amended and restated bylaws&#58;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:2.364%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.883%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.242%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:92.811%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">permit our board of directors to issue up to 5,000,000 shares of preferred stock, with any rights, preferences and privileges as it may designate, which issuance could result in the loss of voting control by other stockholders&#59;</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:2.364%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.883%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.242%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:92.811%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">provide that our board of directors is classified into three classes with staggered, three-year terms and that directors may only be removed for cause by the affirmative vote of the holders of at least a majority of the voting power of outstanding shares of our capital stock&#59;</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:2.364%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.883%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.242%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:92.811%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">provide that all vacancies on our board of directors, including as a result of newly created directorships, may, except as otherwise required by law, be filled only by the affirmative vote of a majority of directors then in office, even if less than a quorum&#59;</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:2.364%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.883%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.242%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:92.811%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">require that any action to be taken by our stockholders must be effected at a duly called annual or special meeting of stockholders and not be taken by written consent&#59;</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:2.364%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.883%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.242%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:92.811%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">provide that stockholders seeking to present proposals before a meeting of stockholders or to nominate candidates for election as directors at a meeting of stockholders must provide advance notice in writing, and also specify requirements as to the form and content of a stockholder&#8217;s notice&#59;</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:2.364%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.883%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.242%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:92.811%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">require that the amendment of certain provisions of our certificate of incorporation relating to several anti&#8209;takeover measures and other provisions may only be approved by a vote of 66-2&#47;3% of our outstanding common stock&#59;</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:2.364%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.883%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.242%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:92.811%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">require that the amendment of our bylaws be approved by the affirmative vote of a majority of directors then in office or 66-2&#47;3% of our outstanding common stock entitled to vote thereon&#59;</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:2.364%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.203%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.242%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:92.491%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">do not provide for cumulative voting rights, thereby allowing the holders of a majority of the shares of common stock entitled to vote in any election of directors to elect all of the directors standing for election&#59; and</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:2.364%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.883%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.242%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:92.811%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">provide that special meetings of our stockholders may be called only by the chairman or vice chairman of our board of directors, our chief executive officer, or a majority of our board of directors.</font></td></tr></table></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Delaware Anti&#8209;Takeover Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our fourth amended and restated certificate of incorporation provides that we are governed by the provisions of Section 203 of the Delaware General Corporation Law, or Section</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:13.5pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">203. Section 203 generally prohibits a public Delaware corporation from engaging in a &#8220;business combination&#8221; with an &#8220;interested stockholder&#8221; for a period of three years after the date of the transaction in which the person became an interested stockholder, unless&#58;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:2.364%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.883%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.242%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:92.811%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">prior to the date of the transaction, the board of directors of the corporation approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder&#59;</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exhibit 4.5</font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:2.364%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.883%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.242%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:92.811%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">the interested stockholder owned at least 85% of the voting stock of the corporation outstanding upon consummation of the transaction, excluding for purposes of determining the number of shares outstanding (1) shares owned by persons who are directors and also officers and (2) shares owned by employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer&#59; or</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:2.364%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.883%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.242%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:92.811%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">on or subsequent to the consummation of the transaction, the business combination is approved by the board of directors and authorized at an annual or special meeting of stockholders, and not by written consent, by the affirmative vote of at least 66-2&#47;3% of the outstanding voting stock which is not owned by the interested stockholder.</font></div></td></tr></table></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Section 203 defines a business combination to include&#58;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:2.364%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.883%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.242%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:92.811%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">any merger or consolidation involving the corporation and the interested stockholder&#59;</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:2.364%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.883%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.242%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:92.811%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">any sale, transfer, lease, pledge or other disposition involving the interested stockholder of 10% or more of the assets of the corporation&#59;</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:2.364%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.883%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.242%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:92.811%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">subject to exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the interested stockholder&#59;</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:2.364%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.883%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.242%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:92.811%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">subject to exceptions, any transaction involving the corporation that has the effect of increasing the proportionate share of the stock of any class or series of the corporation beneficially owned by the interested stockholder&#59; and</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:2.364%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.883%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.242%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:92.811%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial benefits provided by or through the corporation.</font></div></td></tr></table></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In general, Section 203 defines an interested stockholder as any entity or person beneficially owning 15% or more of the outstanding voting stock of the corporation and any entity or person affiliated with or controlling or controlled by the entity or person.</font></div><div style="text-indent:36pt"><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">The Nasdaq Global Select Market</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our common stock is listed on the Nasdaq Global Select Market under the symbol &#8220;OPTN.&#8221;</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Transfer Agent and Registrar</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The transfer agent and registrar for our common stock is Broadridge Corporate Issuer Solutions, Inc. The transfer agent&#8217;s address is 1717 Arch St., Suite 1300, Philadelphia, Pennsylvania 19103.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>3
<FILENAME>formindemnificationagreeme.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ia0d4cd105bad420ebf284f34d6fe1684_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">INDEMNIFICATION AGREEMENT</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Indemnification Agreement (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) is made as of __________, 201___ by and between OptiNose,&#160;Inc., a Delaware corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Corporation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), in its own name and on behalf of its direct and indirect subsidiaries, and __________________, an individual (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Indemnitee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;).  This Agreement supersedes and replaces any and all previous Agreements between the Corporation and Indemnitee covering the subject matter of this Agreement. </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">RECITALS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#58;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, directors, officers, employees, controlling persons, fiduciaries and other agents (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Representatives</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) in service to corporations or business enterprises are being increasingly subjected to expensive and time-consuming litigation relating to, among other things, matters that traditionally would have been brought only against the corporation or business enterprise itself&#59;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Board of Directors of the Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) believes that highly competent persons have become more reluctant to serve corporations as Representatives unless they are provided with adequate protection through insurance and adequate indemnification against inordinate risks of claims and actions against them arising out of their service to and activities on behalf of the corporation or business enterprise&#59;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Board has determined that the increased difficulty in attracting and retaining highly competent persons is detrimental to the best interests of the Corporation and its stockholders and that the Corporation should act to assure such persons that there will be increased certainty of protection against inordinate risks of claims and actions against them arising out of their service to and activities on behalf of the Corporation&#59;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, it is reasonable, prudent and necessary for the Corporation contractually to obligate itself to indemnify, and to advance expenses on behalf of, such persons to the fullest extent permitted by applicable law so that they will serve or continue to serve the Corporation free from undue concern regarding such risks&#59;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, (a)&#160;the Amended and Restated Bylaws of the Corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Bylaws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) require indemnification of the officers and directors of the Corporation, (b)&#160;Indemnitee may also be entitled to indemnification pursuant to the General Corporation Law of the State of Delaware, as it may be amended from time to time (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">DGCL</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) and (c)&#160;the Bylaws and the DGCL expressly provide that the indemnification provisions set forth therein are not exclusive and thereby contemplate that contracts may be entered into between the Corporation and its Representatives with respect to indemnification&#59;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, this Agreement is a supplement to and in furtherance of the Bylaws and any resolutions adopted pursuant thereto, and shall not be deemed a substitute therefore, nor to diminish or abrogate any rights of Indemnitee thereunder&#59; and</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, (a)&#160;Indemnitee does not regard the protection available under the Bylaws and insurance as adequate in the present circumstances, (b)&#160;Indemnitee may not be willing to serve or continue to serve as a Representative without adequate protection, (c)&#160;the Corporation desires Indemnitee to serve or continue to serve in such capacity and (d)&#160;Indemnitee is willing to serve, continue to serve and to take on additional service for or on behalf of the Corporation on the condition that he&#47;she be so indemnified.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">AGREEMENT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#58;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOW, THEREFORE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in consideration of the premises and the covenants contained herein, the Corporation and Indemnitee do hereby covenant and agree as follows&#58;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.04pt;text-decoration:underline">Definitions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;As used in this Agreement&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; shall have the meaning ascribed to such term in the Preamble hereto.</font></div><div style="margin-bottom:12pt;padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Beneficial Owner</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; shall have the meaning given to such term in Rule 13d-3 under the Exchange Act (as defined below)&#59; provided, however, that Beneficial Owner shall exclude any Person otherwise becoming a Beneficial Owner by reason of the stockholders of the Corporation approving a merger of the Corporation with another entity.</font></div><div style="margin-bottom:12pt;padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; shall have the meaning ascribed to such term in the Recitals hereto.</font></div><div style="margin-bottom:12pt;padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Bylaws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; shall have the meaning ascribed to such term in the Recitals hereto.</font></div><div style="margin-bottom:12pt;padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Certificate of Incorporation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; shall mean the Fourth Amended and Restated Certificate of Incorporation of the Corporation.</font></div><div style="margin-bottom:12pt;padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Change in Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; shall be deemed to occur upon the earliest to occur after the date of this Agreement of any of the following events&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i.&#160;&#160;&#160;&#160;Acquisition of Stock by Third Party.  Any Person (as defined below), other than the Sponsor Entities (as defined below), is or becomes the Beneficial Owner (as defined below), directly or indirectly, of securities of the Corporation representing fifteen percent (15%) or more of the combined voting power of the Corporation&#8217;s then outstanding securities, unless the change in relative Beneficial Ownership of the Corporation&#8217;s securities by any Person results solely from a reduction in the aggregate number of outstanding shares of securities entitled to vote generally in the election of directors&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii.&#160;&#160;&#160;&#160;Change in Board of Directors.  During any period of two (2) consecutive years (not including any period prior to the execution of this Agreement), individuals who at the beginning of such period constitute the Board, and any new director (other than a director designated by a person who has entered into an agreement with the Corporation to effect a transaction described herein) whose election by the Board or nomination for election by the Corporation&#8217;s stockholders was approved by a vote of at least two-thirds of the directors then still in office who either were directors at the beginning of the period or whose election or nomination for election was previously so approved, cease for any reason to constitute at least a majority of the members of the Board&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iii.&#160;&#160;&#160;&#160;Corporate Transactions.  The effective date of a merger or consolidation of the Corporation with any other entity, other than a merger or consolidation which would result in the voting securities of the Corporation outstanding immediately prior to such merger or consolidation continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity in any such transaction) more than fifty percent (50%) of the combined voting power of the voting securities of such surviving entity outstanding immediately after such merger or consolidation and with the power to elect at least a majority of the board of directors or other governing body of such Surviving Entity&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iv.&#160;&#160;&#160;&#160;Liquidation.  The approval by the stockholders of the Corporation of a complete liquidation of the Corporation or an agreement for the sale or disposition by the Corporation of all or substantially all of the Corporation&#8217;s assets&#59; and</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">v.&#160;&#160;&#160;&#160;Other Events.  There occurs any other event of a nature that would be required to be reported in response to Item 6(e) of Schedule 14A of Regulation 14A (or a response to any similar item on any similar schedule or form) promulgated under the Exchange Act (as defined below), whether or not the Corporation is then subject to such reporting requirement.</font></div><div style="margin-bottom:12pt;padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Corporate Status</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; describes the status of an individual who is or was a Representative of an Enterprise.</font></div><div style="margin-bottom:12pt;padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Corporation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; shall have the meaning ascribed to such term in the Preamble hereto.</font></div><div style="margin-bottom:12pt;padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">DGCL</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; shall have the meaning ascribed to such term in the Recitals hereto.</font></div><div style="margin-bottom:12pt;padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Enterprise</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; shall mean the Corporation and any other Person, employee benefit plan, joint venture or other enterprise of which Indemnitee is or was serving at the request of the Corporation as a Representative.</font></div><div style="margin-bottom:12pt;padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Exchange Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; shall mean the Securities Exchange Act of 1934, as amended from time to time, and the rules&#160;and regulations thereunder.</font></div><div style="margin-bottom:12pt;padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; shall include all reasonable costs, expenses, fees and charges, including, without limitation, attorneys&#8217; fees, retainers, court costs, transcript costs, fees of experts, witness fees, travel expenses, duplicating costs, printing and binding costs, telephone charges, postage, delivery service fees, and all other disbursements or expenses of the types customarily incurred in connection with prosecuting, defending, preparing to prosecute or defend, investigating, being or preparing to be a witness in, or otherwise participating in, a Proceeding. Expenses also shall include, without limitation, (i)&#160;expenses incurred in connection with any appeal resulting from any Proceeding, including, without limitation, the premium, security for, and other costs relating to any cost bond, supersedes bond, or other appeal bond or its equivalent, (ii)&#160;for purposes of Section&#160;12(d)&#160;only, expenses incurred by Indemnitee in connection with the interpretation, enforcement or defense of Indemnitee&#8217;s rights under this Agreement, by litigation or otherwise, (iii)&#160;any federal, state, local or foreign taxes imposed on Indemnitee as a result of the actual or deemed receipt of any payments under this Agreement (on a grossed up basis), (iv) excise taxes and penalties under the Employee Retirement Income Security Act of 1974, and (v)&#160;any interest, assessments or other charges in respect of the foregoing.</font></div><div style="margin-bottom:12pt;padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Indemnitee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; shall have the meaning ascribed to such term in the Preamble hereto.</font></div><div style="margin-bottom:12pt;padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Indemnity Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; shall mean all obligations of the Corporation to Indemnitee under this Agreement, including, without limitation, the Corporation&#8217;s obligations to provide indemnification to Indemnitee and advance Expenses to Indemnitee under this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Independent Counsel</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; shall mean a law firm, or a member of a law firm, that is experienced in matters of corporation law and neither presently is, nor in the past five (5)&#160;years has been, retained to represent&#58; (i)&#160;the Corporation or Indemnitee in any matter material to either such party (other than with respect to matters concerning the Indemnitee under this Agreement, or of other indemnitees under similar indemnification agreements) or (ii)&#160;any other party to the Proceeding giving rise to a claim for indemnification hereunder&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, that the term &#8220;Independent Counsel&#8221; shall not include any person who, under the applicable standards of professional conduct then prevailing, would have a conflict of interest in representing either the Corporation or Indemnitee in an action to determine Indemnitee&#8217;s rights under this Agreement.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Liabilities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; shall mean all claims, liabilities, damages, losses, judgments, orders, fines, penalties and other amounts payable in connection with, arising out of, in respect of, relating to or occurring as a direct or indirect consequence of, any Proceeding, including, without limitation, amounts paid in whole or partial settlement of any Proceeding, all Expenses incurred in complying with any judgment, order or decree issued or entered in connection with any Proceeding or any settlement agreement, stipulation or consent decree entered into or issued in settlement of any Proceeding, and any consequential damages resulting from any Proceeding or the settlement, judgment, or result thereof.</font></div><div style="margin-bottom:12pt;padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Person</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; shall mean any individual, corporation, partnership, limited partnership, limited liability company, trust, governmental agency or body or any other legal entity.</font></div><div style="margin-bottom:12pt;padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Proceeding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; shall include any threatened, pending or completed action, claim, suit, counterclaim, cross claim, arbitration, mediation, alternate dispute resolution mechanism, formal or informal hearing, inquiry or investigation,  administrative hearing or any other actual, threatened or completed judicial, administrative or arbitration proceeding (including, without limitation, any such proceeding under the Securities Act of 1933, as amended, or the Exchange Act or any other federal law, state law, statute or regulation), whether brought in the right of the Corporation or otherwise, and whether of a civil, criminal, administrative legislative or investigative nature, including any appeal therefrom, in which Indemnitee was, is or will be, or is threatened to be, involved as a party, potential party, non-party witness or otherwise (i)&#160;by reason of the fact that Indemnitee is or was a Representative of the Corporation, (ii)&#160;by reason of any actual or alleged action taken by Indemnitee (or a failure to take action by Indemnitee) or of any action (or failure to act) on Indemnitee&#8217;s part while acting as Representative of the Corporation or (iii)&#160;by reason of the fact that Indemnitee is or was serving at the request of the Corporation as a Representative of another Person, whether or not serving in such capacity at the time any liability or Expense is incurred for which indemnification, reimbursement, or advancement of Expenses can be provided under this Agreement.  If the Indemnitee believes in good faith that a given situation may lead to or culminate in the institution of a Proceeding, this shall be considered a Proceeding under this paragraph.</font></div><div style="margin-bottom:12pt;padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Representative</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; shall have the meaning ascribed to such term in the Recitals hereto.&#160;</font></div><div style="margin-bottom:12pt;padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Sponsor Entities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; shall mean funds affiliated with Avista Capital Partners and any of their respective Affiliates who beneficially own shares of common stock, par value $0.001 per share, of the Corporation, and any securities into which such shares of common stock shall have been changed or any securities resulting from any reclassification or recapitalization of such shares of common stock from time to time&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, that neither the Corporation nor any of its subsidiaries shall be considered Sponsor Entities hereunder.</font></div><div style="margin-bottom:12pt;padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Submission Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; shall have the meaning ascribed to such term in Section&#160;11(a).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;For the purpose hereof, references to &#8220;fines&#8221; shall include any excise tax assessed with respect to any employee benefit plan&#59; references to &#8220;serving at the request of the Corporation&#8221; shall include any service as a Representative of the Corporation which imposes duties on, or involves services by, such Representative with respect to an employee benefit plan, its participants or beneficiaries&#59; and a Person who acted in good faith and in a manner he&#47;she reasonably believed to be in the best interests of the participants and beneficiaries of an employee benefit plan shall be deemed to have acted in manner &#8220;not opposed to the best interests of the Corporation&#8221; as referred to in this Agreement.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Indemnity in Third-Party Proceedings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Corporation shall indemnify and hold harmless Indemnitee, to the fullest extent permitted by applicable law, from and against all Liabilities and Expenses suffered or incurred by Indemnitee or on Indemnitee&#8217;s behalf in connection with or as a consequence of any Proceeding (other than any Proceeding brought by or in the right of the Corporation to procure a judgment in its favor which </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">shall be governed by the provisions set forth in Section&#160;3 below), if Indemnitee acted in good faith and in a manner he&#47;she reasonably believed to be in, or not opposed to, the best interests of the Corporation and, in the case of a criminal proceeding, had no reasonable cause to believe that his conduct was unlawful. For the avoidance of doubt, a finding, admission or stipulation that an Indemnitee has not met such applicable standard of conduct or that Indemnitee acted with gross negligence or recklessness shall not, of itself, be a defense to any action pursuant to this Agreement or create a presumption that such Indemnitee has failed to meet the standard of conduct required for indemnification in this Section&#160;2.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Indemnity in Proceedings by or in the Right of the Corporation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Corporation shall indemnify and hold harmless Indemnitee, to the fullest extent permitted by applicable law, from and against all Liabilities and Expenses suffered or incurred by Indemnitee or on Indemnitee&#8217;s behalf in connection with or as a consequence of any Proceeding brought by or in the right of the Corporation to procure a judgment in its favor, or any claim, issue or matter therein, if Indemnitee acted in good faith and in a manner he&#47;she reasonably believed to be in, or not opposed, to the best interests of the Corporation. No indemnification for Liabilities and Expenses shall be made under this Section&#160;3 in respect of any claim, issue or matter as to which Indemnitee shall have been finally adjudged by a court to be liable to the Corporation, unless and only to the extent that the Delaware Court of Chancery or any court in which the Proceeding was brought shall determine upon application that, despite the adjudication of liability, but in view of all the circumstances of the case,&#160;Indemnitee is fairly and reasonably entitled to indemnification for such Liabilities and Expenses which the Court of Chancery or such other court shall deem proper. For the avoidance of doubt, a finding, admission or stipulation that an Indemnitee has not met such applicable standard of conduct or that Indemnitee acted with gross negligence or recklessness shall not, of itself, be a defense to any action pursuant to this Agreement or create a presumption that such Indemnitee has failed to meet the standard of conduct required for indemnification in this Section&#160;3.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Indemnification for Expenses of a Party Who is Wholly or Partly Successful</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Notwithstanding any other provisions of this Agreement, and without limiting the rights of Indemnitee under any other provision hereof, to the extent that Indemnitee is a party to (or a participant in) any Proceeding and is successful on the merits or otherwise (including, without limitation, settlement thereof), as to one or more but less than all claims, issues or matters in such Proceeding, in whole or in part, then the Corporation shall indemnify Indemnitee, to the fullest extent permitted by applicable law, against all Liabilities and Expenses actually and reasonably incurred by Indemnitee or on Indemnitee&#8217;s behalf, in connection with or as a consequence of each successfully resolved claim, issue or matter. For purposes of this Section&#160;4 and without limitation, the termination of any claim, issue or matter in such a Proceeding by dismissal, with or without prejudice, shall be deemed to be a successful result as to such claim, issue or matter.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 5.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Partial Indemnification</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. If Indemnitee is entitled under any provision of this Agreement to indemnification by the Corporation for some or a portion of Expenses, but not, however, for the total amount thereof, the Corporation shall nevertheless indemnify Indemnitee for the portion thereof to which Indemnitee is entitled.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 6.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Indemnification for Expenses of a Witness</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Notwithstanding any other provision of this Agreement, to the extent that Indemnitee is, by reason of Indemnitee&#8217;s Corporate Status, a witness in any Proceeding to which Indemnitee is not a party,&#160;Indemnitee shall be indemnified to the fullest extent permitted by applicable law against all Liabilities and Expenses suffered or incurred by him or on his behalf in connection therewith.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 7.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Additional Indemnification</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Notwithstanding any limitation in Sections 2, 3, 4 or 5, the Corporation shall indemnify Indemnitee to the fullest extent permitted by applicable law if Indemnitee is a party to, or threatened to be made a party to, any Proceeding (including, without limitation, a Proceeding by or in the right of the Corporation to procure a judgment in its favor), by reason of Indemnitee&#8217;s Corporate Status.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;For purposes of Section 7(a), the meaning of the phrase &#8220;to the fullest extent permitted by applicable law&#8221; shall include, but not be limited to&#58; </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;to the fullest extent permitted by the provision of the DGCL that authorizes or contemplates additional indemnification by agreement, or the corresponding provision of any amendment to, or replacement of, the DGCL, and</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;to the fullest extent authorized or permitted by any amendments to, or replacements of, the DGCL adopted after the date of this Agreement that increase the extent to which a corporation may indemnify its officers and directors.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 8.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Exclusions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Notwithstanding any provision in this Agreement, the Corporation shall not be obligated under this Agreement to make any indemnification payment in connection with any claim involving Indemnitee&#58; </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;for which payment has actually been made to or on behalf of Indemnitee under any insurance policy or other indemnity provision, except with respect to any excess beyond the amount paid under any insurance policy or other indemnity provision&#59; or</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;subject to Section 14, for (i) an accounting of profits made from the purchase and sale (or sale and purchase) by Indemnitee of securities of the Corporation within the meaning of Section 16(b) of the Exchange Act (as defined in Section 1(a) hereof) or similar provisions of state statutory law or common law, (ii) any reimbursement of the Corporation by the Indemnitee of any bonus or other incentive-based or equity-based compensation or of any profits realized by the Indemnitee from the sale of securities of the Corporation, as required in each case under the Exchange Act (including any such reimbursements that arise from an accounting restatement of the Corporation pursuant to Section 304 of the Sarbanes-Oxley Act of 2002 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Sarbanes-Oxley Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), or the payment to the Corporation of profits arising from the purchase and sale by Indemnitee of securities in violation of Section 306 of the Sarbanes-Oxley Act) or (iii) any reimbursement of the Corporation by Indemnitee of any compensation pursuant to any compensation recoupment or clawback policy adopted by the Board or the compensation committee of the Board to comply with stock exchange listing requirements implementing Section 10D of the Exchange Act&#59; or</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;except as provided in Section 13(d) of this Agreement, in connection with any Proceeding (or any part of any Proceeding) initiated by Indemnitee, including any Proceeding (or any part of any Proceeding) initiated by Indemnitee against the Corporation or its directors, officers, employees or other indemnitees, unless (i) the Board authorized the Proceeding (or any part of any Proceeding) prior to its initiation or (ii) the Corporation provides the indemnification, in its sole discretion, pursuant to the powers vested in the Corporation under applicable law.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 9.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Advances of Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Notwithstanding any provision of this Agreement to the contrary (other than Section 13(d)), the Corporation shall advance, to the fullest extent permitted by law, Expenses incurred by Indemnitee in connection with any Proceeding (or part of any Proceeding) not initiated by Indemnitee or any Proceeding initiated by Indemnitee with the prior approval of the Board, and such advancement shall be made within ten (10)&#160;days after the receipt by the Corporation of a statement or statements requesting such advances from time to time, whether prior to, or after, final disposition of any Proceeding. Advances shall be unsecured and interest free. Indemnitee shall be entitled to continue to receive advancement of Expenses pursuant to this Section 9 unless and until the matter of Indemnitee&#8217;s entitlement to indemnification hereunder has been finally adjudicated by court order or judgment from which no further right or appeal exists. Advances shall be made without regard to Indemnitee&#8217;s ability to repay Expenses and without regard to Indemnitee&#8217;s ultimate entitlement to indemnification under the other provisions of this Agreement. In accordance with Section 13(d), advances shall include any and all Expenses incurred pursuing an action to enforce this right of advancement, including, without limitation, Expenses incurred preparing and forwarding statements to the Corporation to support the advances claimed. Indemnitee shall qualify for advances upon the execution and delivery to the Corporation of this Agreement, which shall constitute an undertaking, providing that Indemnitee undertakes to repay the amounts advanced (without interest) to the extent that it is ultimately determined that Indemnitee is not entitled to be indemnified by the Corporation.  No other form of undertaking shall be required other than the execution of this Agreement.  This Section 9 shall not apply to any claim made by Indemnitee for which indemnity is excluded pursuant to Section 8.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 10.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Procedure for Notification and Defense of Claim</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Indemnitee shall notify the Corporation in writing of any Proceeding with respect to which Indemnitee intends to seek indemnification or advancement of Expenses hereunder as soon as reasonably practicable following the receipt by Indemnitee of written notice thereof. The written notification to the Corporation shall include a description of the nature of the Proceeding and the facts underlying the Proceeding. To obtain indemnification under this Agreement,&#160;Indemnitee shall submit to the Corporation a written request, including therein or therewith such documentation and information as is reasonably available to Indemnitee and is reasonably necessary to determine whether and to what extent Indemnitee is entitled to indemnification following the final disposition of such Proceeding. Any delay or failure by Indemnitee to notify the Corporation hereunder will not relieve the Corporation from any liability which it may have to Indemnitee hereunder or otherwise than under this Agreement, nor shall such delay or failure constitute a waiver by Indemnitee of any rights under this Agreement.  The Secretary of the Corporation shall, promptly upon receipt of such a request for indemnification, advise the Board in writing that Indemnitee has requested indemnification. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In the event Indemnitee seeks indemnification and&#47;or advancement of Expenses with respect to any Proceeding,&#160;Indemnitee may, at Indemnitee&#8217;s option, (i)&#160;retain legal counsel selected by Indemnitee and approved by the Corporation (which approval shall not to be unreasonably withheld, conditioned or delayed) to defend Indemnitee in such Proceeding, at the sole expense of the Corporation or (ii)&#160;have the Corporation assume the defense of Indemnitee in the Proceeding, in which case the Corporation shall assume the defense of such Proceeding with legal counsel selected by the Corporation and approved by Indemnitee (which approval shall not be unreasonably withheld, conditioned or delayed) within ten (10)&#160;days of the Corporation&#8217;s receipt of written notice of Indemnitee&#8217;s election to cause the Corporation to do so. If the Corporation is required to assume the defense of any such Proceeding, it shall engage legal counsel for such defense, and shall be solely responsible for all Expenses of such legal counsel and otherwise of such defense. Such legal counsel may represent both Indemnitee and the Corporation (and&#47;or any other party or parties entitled to be indemnified by the Corporation with respect to such matter) unless, in the reasonable opinion of legal counsel to Indemnitee, there is a conflict of interest between Indemnitee and the Corporation (or any other such party or parties) or there are legal defenses available to Indemnitee that are not available to the Corporation (or any such other party or parties). Notwithstanding either party&#8217;s assumption of responsibility for defense of a Proceeding, each party shall have the right to engage separate legal counsel at its own expense. The party having responsibility for defense of a Proceeding shall provide the other party and its legal counsel with all copies of pleadings and material correspondence relating to the Proceeding. Indemnitee and the Corporation shall reasonably cooperate in the defense of any Proceeding with respect to which indemnification is sought hereunder, regardless of whether the Corporation or Indemnitee assumes the defense thereof. Indemnitee may not settle or compromise any Proceeding without the prior written consent of the Corporation (which consent shall not be unreasonably withheld, conditioned or delayed). The Corporation may not settle or compromise any Proceeding without the prior written consent of Indemnitee (which consent shall not be unreasonably withheld, conditioned or delayed).</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 11.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Procedure Upon Application for Indemnification</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Upon receipt of a written request by Indemnitee for indemnification pursuant to Section&#160;10(a) (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Submission Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), if any determination by the Corporation is required by applicable law with respect to Indemnitee&#8217;s ultimate entitlement to indemnification, such determination shall be made (i) if a Change in Control shall have occurred, by Independent Counsel in a written opinion to the Board, a copy of which shall be delivered to Indemnitee&#59; or (ii) if a Change in Control shall not have occurred, (A) by a majority vote of the Disinterested Directors, even though less than a quorum of the Board, (B) by a committee of Disinterested Directors designated by a majority vote of the Disinterested Directors, even though less than a quorum of the Board, (C) if there are no such Disinterested Directors or, if such Disinterested Directors so direct, by Independent Counsel in a written opinion to the Board, a copy of which shall be delivered to Indemnitee or (D) if so directed by the Board, by the stockholders of the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporation. If it is so determined that Indemnitee is entitled to indemnification, payment to Indemnitee shall be made within ten (10) days after such determination. Indemnitee shall cooperate with the Person(s)&#160;making such determination with respect to Indemnitee&#8217;s entitlement to indemnification, including, without limitation, providing to such Person(s), upon reasonable advance request, any documentation or information which is not privileged or otherwise protected from disclosure and which is reasonably available to Indemnitee and reasonably necessary to such determination. Any Expenses incurred by Indemnitee in so cooperating with the Person(s)&#160;making such determination shall be borne by the Corporation (irrespective of the determination as to Indemnitee&#8217;s entitlement to indemnification) and the Corporation hereby indemnifies and agrees to hold Indemnitee harmless therefrom. The Corporation will not deny any written request for indemnification hereunder made in good faith by Indemnitee unless a determination as to Indemnitee&#8217;s entitlement to such indemnification described in this Section&#160;11(a)&#160;has been made. The Corporation agrees to pay Expenses of the Independent Counsel referred to above and to fully indemnify the Independent Counsel against any and all Expenses, claims, liabilities and damages arising out of or relating to this Agreement or its engagement pursuant hereto.  </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In the event that the determination of entitlement to indemnification is to be made by the Independent Counsel pursuant to Section&#160;11(a)&#160;hereof, the Independent Counsel shall be selected as provided in this Section&#160;11(b).  If a Change in Control has not occurred, the Independent Counsel shall be selected by the Board, and the Corporation shall give written notice to Indemnitee advising Indemnitee of the identity of the Independent Counsel so selected.  If a Change in Control has occurred, the Independent Counsel shall be selected by Indemnitee (unless Indemnitee shall request that such selection be made by the Board, in which event the preceding sentence shall apply), and Indemnitee shall give written notice to the Corporation advising it of the identity of the Independent Counsel so selected.  In either event, Indemnitee or the Corporation, as the case may be, may, within ten (10) days after such written notice of selection shall have been given, deliver to the Corporation or to Indemnitee, as the case may be, a written objection to such selection&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, that such objection may be asserted only on the ground that the Independent Counsel so selected does not meet the requirements of &#8220;Independent Counsel&#8221; as defined in Section&#160;1(a) of this Agreement, and the objection shall set forth with particularity the factual basis of such assertion.  Absent a proper and timely objection, the person so selected shall act as Independent Counsel.  If such written objection is so made and substantiated, the Independent Counsel so selected may not serve as Independent Counsel unless and until such objection is withdrawn or the Delaware Court of Chancery has determined that such objection is without merit.  If, within twenty (20) days after the later of submission by Indemnitee of a written request for indemnification pursuant to Section&#160;10(a) hereof and the final disposition of the Proceeding, no Independent Counsel shall have been selected and not objected to, either the Corporation or Indemnitee may petition the Delaware Court of Chancery for resolution of any objection which shall have been made by the Corporation or Indemnitee to the other's selection of Independent Counsel and&#47;or for the appointment as Independent Counsel of a person selected by such court or by such other person as such court shall designate, and the person with respect to whom all objections are so resolved or the person so appointed shall act as Independent Counsel under Section&#160;11(a) hereof.  Upon the due commencement of any judicial proceeding or arbitration pursuant to Section 13(a) of this Agreement, Independent Counsel shall be discharged and relieved of any further responsibility in such capacity (subject to the applicable standards of professional conduct then prevailing).</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 12.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Presumptions and Effect of Certain Proceedings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In making a determination with respect to entitlement to indemnification hereunder, the Person(s)&#160;making such determination shall, to the fullest extent permitted by law, presume that Indemnitee is entitled to indemnification under this Agreement if Indemnitee has submitted a request for indemnification in accordance with Section&#160;10(a)&#160;of this Agreement, and the Corporation shall, to the fullest extent permitted by law, have the burden of proof to overcome that presumption with clear and convincing evidence in connection with the making by any Person(s)&#160;of any determination contrary to that presumption. Neither the failure of the Corporation (including, without limitation, by its directors or independent legal counsel) to have made a determination prior to the commencement of any action pursuant to this Agreement that indemnification is proper in the circumstances because Indemnitee has met the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">applicable standard of conduct, nor an actual determination by the Corporation (including, without limitation, by its directors or independent legal counsel) that Indemnitee has not met such applicable standard of conduct, shall be a defense to the action or create a presumption that Indemnitee has not met the applicable standard of conduct.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Subject to Section&#160;12(e), if the Person(s)&#160;empowered or selected under Section&#160;10 hereof to determine whether Indemnitee is entitled to indemnification shall not have made a determination within sixty (60) days after receipt by the Corporation of the request therefore, the requisite determination of entitlement to indemnification shall, to the fullest extent permitted by law, be deemed to have been made and Indemnitee shall be entitled to such indemnification, absent a prohibition of such indemnification under applicable law&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, that such sixty (60) day period may be extended for a reasonable time, not to exceed an additional thirty (30) days, if (i)&#160;the determination is to be made by the Independent Counsel and there is an objection to the selection of the Independent Counsel and (ii)&#160;the Person(s) making such determination requires such additional time for the obtaining or evaluating of documentation and&#47;or information relating thereto&#59; and provided, further, that the foregoing provisions of this Section 12(b) shall not apply (i) if the determination of entitlement to indemnification is to be made by the stockholders pursuant to Section 11(a) of this Agreement and if </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A) within fifteen (15) days after receipt by the Corporation of the request for such determination the Board has resolved to submit such determination to the stockholders for their consideration at an annual meeting thereof to be held within seventy-five (75) days after such receipt and such determination is made thereat, or (B) a special meeting of stockholders is called within fifteen (15) days after such receipt for the purpose of making such determination, such meeting is held for such purpose within sixty (60) days after having been so called and such determination is made thereat. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The termination of any Proceeding or of any claim, issue or matter therein, by judgment, order, settlement or conviction, or upon a plea of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">nolo contendere</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or its equivalent, shall not (except as otherwise expressly provided in this Agreement) of itself adversely affect the right of Indemnitee to indemnification or create a presumption that Indemnitee did not act in good faith and in a manner which he&#47;she reasonably believed to be in, or not opposed to, the best interests of the Corporation or, with respect to any criminal Proceeding, that Indemnitee had reasonable cause to believe that Indemnitee&#8217;s conduct was unlawful.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Reliance as Safe Harbor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. For purposes of any determination of good faith,&#160;Indemnitee shall be deemed to have acted in good faith if Indemnitee&#8217;s action is based on the records or books of account of the Enterprise, including financial statements, or on information supplied to Indemnitee by the officers of the Enterprise in the course of their duties, or on the advice of legal counsel for the Enterprise, or on information or records given or reports made to the Enterprise by an independent certified public accountant or by an appraiser or other expert selected with reasonable care by the Enterprise. The provisions of this Section&#160;12(d)&#160;shall not be deemed to be exclusive or to limit in any way the other circumstances in which Indemnitee may be deemed to have met the applicable standard of conduct set forth in this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Actions of Others</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The knowledge and&#47;or actions, or failure to act, of any Representative (other than Indemnitee) of the Enterprise shall not be imputed to Indemnitee for purposes of determining the right to indemnification under this Agreement.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 13.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Remedies of Indemnitee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Subject to Section&#160;12(d), in the event that (i)&#160;a determination is made pursuant to Section&#160;11 of this Agreement that Indemnitee is not entitled to indemnification under this Agreement, (ii)&#160;advancement of Expenses is not timely made pursuant to Section&#160;9 of this Agreement, (iii)&#160;no determination of entitlement to indemnification shall have been made pursuant to Section&#160;11(a)&#160;of this Agreement within ninety (90) days after the Submission Date, (iv)&#160;payment of indemnification is not made pursuant to Section&#160;4, 5, 6 or 11(a)&#160;of this Agreement within ten (10)&#160;days after receipt by the Corporation of a written </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">request therefore, (v)&#160;payment of indemnification pursuant to Section&#160;2, 3 or 7 of this Agreement is not made within ten (10)&#160;days after a determination has been made that Indemnitee is entitled to indemnification or (vi)&#160;in the event that the Corporation or any other person takes or threatens to take any action to declare this Agreement void or unenforceable, or institutes any litigation or other action or Proceeding designed to deny, or to recover from,&#160;Indemnitee, the benefits provided or intended to be provided to Indemnitee hereunder,&#160;Indemnitee shall be entitled to an adjudication by a court of Indemnitee&#8217;s entitlement to such indemnification and&#47;or advancement of Expenses. Alternatively,&#160;Indemnitee, at Indemnitee&#8217;s option, may seek an award in arbitration to be conducted by a single arbitrator pursuant to the Commercial Arbitration Rules&#160;of the American Arbitration Association. Indemnitee shall commence such proceeding seeking an adjudication or an award in arbitration within one hundred and eighty (180) days following the date on which Indemnitee first has the right to commence such proceeding pursuant to this Section 13(a). The Corporation shall not oppose Indemnitee&#8217;s right to seek any such adjudication or award in arbitration.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In the event that a determination shall have been made pursuant to Section&#160;11&#160;of this Agreement that Indemnitee is not entitled to indemnification, any judicial proceeding or arbitration commenced pursuant to this Section&#160;13 shall be conducted in all respects as a </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">de novo</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> trial, or arbitration, on the merits and Indemnitee shall not be prejudiced by reason of that adverse determination. In any judicial proceeding or arbitration commenced pursuant to this Section&#160;13, the Corporation shall have the burden of proving by clear and convincing evidence Indemnitee is not entitled to indemnification or advancement of Expenses, as the case may be.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;If a determination shall have been made pursuant to Section&#160;11&#160;of this Agreement that Indemnitee is entitled to indemnification, the Corporation shall be bound by such determination in any judicial proceeding or arbitration commenced pursuant to this Section&#160;13, absent (i)&#160;a misstatement by the Indemnitee of a material fact, or an omission by the Indemnitee of a material fact necessary to make the Indemnitee&#8217;s statement not materially misleading, in connection with the request for indemnification, or (ii)&#160;a prohibition of such indemnification under applicable law.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The Corporation shall, to the fullest extent not prohibited by law, be precluded from asserting in any judicial proceeding or arbitration commenced pursuant to this Section&#160;13 that the procedures and presumptions of this Agreement are not valid, binding and enforceable and shall stipulate in any such court or before any such arbitrator that the Corporation is bound by all the provisions of this Agreement. It is the intent of the Corporation that, to the fullest extent permitted by law, Indemnitee not be required to incur legal fees or other Expenses associated with the interpretation, enforcement or defense of Indemnitee&#8217;s rights under this Agreement by litigation or otherwise because the cost and expense thereof would substantially detract from the benefits intended to be extended to Indemnitee hereunder. In addition, the Corporation shall, to the fullest extent permitted by law, indemnify Indemnitee against any and all such Expenses and, if requested by Indemnitee, shall (within ten (10)&#160;days after receipt by the Corporation of a written request therefore) advance, to the fullest extent not prohibited by law, such Expenses to Indemnitee, which are incurred by Indemnitee in connection with any action brought by Indemnitee for indemnification or advancement of Expenses from the Corporation under this Agreement or under any directors&#8217; and officers&#8217; liability insurance policies maintained by the Corporation if, in the case of indemnification, Indemnitee is wholly successful on the underlying claims&#59; if Indemnitee is not wholly successful on the underlying claims, then such indemnification shall be only in connection with each successfully resolved claim, issue or matter, or otherwise as permitted by law, whichever is greater.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Notwithstanding anything in this Agreement to the contrary, no determination as to entitlement to indemnification under this Agreement shall be required to be made prior to the final disposition of the Proceeding&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">provided,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> that in absence of any such determination with respect to such Proceeding, the Corporation shall pay Liabilities and advance Expenses with respect to such Proceeding as if Indemnitee has been determined to be entitled to indemnification and advancement of Expenses with respect to such Proceeding.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 14.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Non-Exclusivity&#59; Survival of Rights&#59; Insurance&#59; Subrogation.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The rights of indemnification and to receive advancement of Expenses as provided by this Agreement shall not be deemed exclusive of any other rights to which Indemnitee may at any time be entitled under applicable law, the Certificate of Incorporation, the Bylaws, any agreement, a vote of stockholders, a resolution of directors or otherwise. No amendment, alteration or repeal of this Agreement or of any provision hereof shall limit or restrict any right of Indemnitee under this Agreement in respect of any action taken or omitted by such Indemnitee in Indemnitee&#8217;s Corporate Status prior to such amendment, alteration or repeal. To the extent that a change in applicable law, whether by statute or judicial decision, permits greater indemnification or advancement of Expenses than would be afforded currently under the Certificate of Incorporation, the Bylaws and&#47;or this Agreement, it is the intent of the parties hereto that Indemnitee shall enjoy by this Agreement the greater benefits so afforded by such change. No right or remedy herein conferred is intended to be exclusive of any other right or remedy, and every other right and remedy shall be cumulative and in addition to every other right and remedy given hereunder or now or hereafter existing at law or in equity or otherwise. The assertion or employment of any right or remedy hereunder, or otherwise, shall not prevent the concurrent assertion or employment of any other right or remedy.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The Corporation hereby acknowledges that Indemnitee may have certain rights to indemnification, advancement of Expenses and&#47;or insurance provided by one or more Persons with whom or which Indemnitee may be associated (including, without limitation, any Sponsor Entity). The Corporation hereby acknowledges and agrees that (i)&#160;the Corporation shall be the indemnitor of first resort with respect to any Proceeding, Expense, Liability or matter that is the subject of the Indemnity Obligations, (ii)&#160;the Corporation shall be primarily liable for all Indemnity Obligations and any indemnification afforded to Indemnitee in respect of any Proceeding, Expense, Liability or matter that is the subject of Indemnity Obligations, whether created by law, organizational or constituent documents, contract (including, without limitation, this Agreement) or otherwise, (iii)&#160;any obligation of any other Persons with whom or which Indemnitee may be associated (including, without limitation, any Sponsor Entity) to indemnify Indemnitee and&#47;or advance Expenses to Indemnitee in respect of any proceeding shall be secondary to the obligations of the Corporation hereunder, (iv)&#160;the Corporation shall be required to indemnify Indemnitee and advance Expenses to Indemnitee hereunder to the fullest extent provided herein without regard to any rights Indemnitee may have against any other Person with whom or which Indemnitee may be associated (including, without limitation, any Sponsor Entity) or insurer of any such Person and (v)&#160;the Corporation irrevocably waives, relinquishes and releases any other Person with whom or which Indemnitee may be associated (including, without limitation, any Sponsor Entity) from any claim of contribution, subrogation or any other recovery of any kind in respect of amounts paid by the Corporation hereunder. In the event that any other Person with whom or which Indemnitee may be associated (including, without limitation, any Sponsor Entity) or their insurers advances or extinguishes any liability or loss which is the subject of any Indemnity Obligation owed by the Corporation or payable under any insurance policy provided under this Agreement, such payor shall have a right of subrogation against the Corporation or its insurer or insurers for all amounts so paid which would otherwise be payable by the Corporation or its insurer or insurers under this Agreement. In no event will payment of an Indemnity Obligation of the Corporation under this Agreement by any other Person with whom or which Indemnitee may be associated (including, without limitation, any Sponsor Entity) or their insurers, affect the obligations of the Corporation hereunder or shift primary liability for any Indemnity Obligation to any other Person with whom or which Indemnitee may be associated (including, without limitation, any Sponsor Entity). Any indemnification and&#47;or insurance or advancement of Expenses provided by any other Person with whom or which Indemnitee may be associated (including, without limitation, any Sponsor Entity), with respect to any liability arising as a result of Indemnitee&#8217;s Corporate Status or capacity as an officer or director of any Person, is specifically in excess of any Indemnity Obligation of the Corporation or valid and any collectible insurance (including, without limitation, any malpractice insurance or professional errors and omissions insurance) provided by the Corporation under this Agreement, and any obligation to provide indemnification and&#47;or insurance or advance Expenses provided by any other Person with whom or which Indemnitee may be associated (including, without limitation, any Sponsor Entity) shall be reduced </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">by any amount that Indemnitee collects from the Corporation as an indemnification payment or advancement of Expenses pursuant to this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The Corporation shall use its best efforts to obtain and maintain in full force and effect an insurance policy or policies providing liability insurance for Representatives of the Corporation or of any other Enterprise, and Indemnitee shall be covered by such policy or policies in accordance with its or their terms to the maximum extent of the coverage available for any such Representative under such policy or policies. If, at the time of the receipt of a notice of a claim pursuant to the terms hereof, the Corporation maintains an insurance policy or policies providing liability insurance for Representatives of the Corporation or of any other Enterprise, the Corporation shall give prompt notice of the commencement of such Proceeding to the insurers in accordance with the procedures set forth in the respective policy or policies. The Corporation shall thereafter take all necessary or desirable action to cause such insurers to pay, on behalf of Indemnitee, all amounts payable as a result of such Proceeding in accordance with the terms of such policies.  In the event of a Change in Control or the Corporation&#8217;s becoming insolvent, the Corporation shall maintain in force any and all insurance policies then maintained by the Corporation in providing insurance (directors&#8217; and officers&#8217; liability, fiduciary, employment practices or otherwise) in respect of Indemnitee for a period of six years thereafter.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In the event of any payment under this Agreement, the Corporation shall not be subrogated to, and hereby waives any rights to be subrogated to, any rights of recovery of Indemnitee, including, without limitation, rights of indemnification provided to Indemnitee from any other Person or entity with whom Indemnitee may be associated (including, without limitation, any Sponsor Entity) as well as any rights to contribution that might otherwise exist&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, that the Corporation shall be subrogated to the extent of any such payment of all rights of recovery of Indemnitee under insurance policies of the Corporation or any of its subsidiaries, and the Indemnitee shall execute all papers required and take all action necessary to secure such rights, including execution of such documents as are necessary to enable the Corporation to brings suit to enforce such rights.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The indemnification and contribution provided for in this Agreement will remain in full force and effect regardless of any investigation made by or on behalf of Indemnitee.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 15.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Duration of Agreement&#59; Not Employment Contract</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This Agreement shall continue until and terminate upon the latest of&#58; (a)&#160;ten (10)&#160;years after the date that Indemnitee shall have ceased to serve as a Representative of the Corporation or any other Enterprise and (b)&#160;one (1)&#160;year after the final termination of any Proceeding then pending in respect of which Indemnitee is granted rights of indemnification or advancement of Expenses hereunder and of any proceeding commenced by Indemnitee pursuant to Section&#160;13 of this Agreement relating thereto. This Agreement shall be binding upon the Corporation and its successors and assigns and shall inure to the benefit of Indemnitee and Indemnitee&#8217;s heirs, executors and administrators. The Corporation shall require and cause any direct or indirect successor (whether by purchase, merger, consolidation or otherwise) to all or substantially all of the business or assets of the Corporation, by written agreement, expressly or to assume and agree to perform this agreement in the same manner and to the same extent that the Corporation would be required to perform if no such succession had taken place.&#160; This Agreement shall not be deemed an employment contract between the Corporation (or any of its subsidiaries or any Enterprise) and Indemnitee. Indemnitee specifically acknowledges that Indemnitee&#8217;s employment with the Corporation (or any of its subsidiaries or any Enterprise), if any, is at will, and Indemnitee may be discharged at any time for any reason, with or without cause, except as may be otherwise provided in any written employment contract between Indemnitee and the Corporation (or any of its subsidiaries or any Enterprise), other applicable formal severance policies duly adopted by the Board, or, with respect to service as a Representative of the Corporation, by the Certificate of Incorporation, Bylaws and the DGCL.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 16.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. If any provision or provisions of this Agreement shall be held to be invalid, illegal or unenforceable for any reason whatsoever&#58; (a)&#160;the validity, legality and enforceability of the remaining provisions of this Agreement (including, without limitation, each portion of any Section&#160;of this Agreement containing any such provision held to be invalid, illegal or unenforceable, that is not itself invalid, illegal or unenforceable) shall not in any way be affected or impaired thereby and shall remain enforceable to the fullest extent </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">permitted by law&#59; (b)&#160;such provision or provisions shall be deemed reformed to the extent necessary to conform to applicable law and to give the maximum effect to the intent of the parties hereto&#59; and (c)&#160;to the fullest extent possible, the provisions of this Agreement (including, without limitation, each portion of any Section&#160;of this Agreement containing any such provision held to be invalid, illegal or unenforceable, that is not itself invalid, illegal or unenforceable) shall be construed so as to give effect to the intent manifested thereby.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 17.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Enforcement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The Corporation expressly confirms and agrees that it has entered into this Agreement and assumed the obligations imposed on it hereby in order to induce Indemnitee to serve as a Representative of the Corporation, and the Corporation acknowledges that Indemnitee is relying upon this Agreement in serving or continuing to serve as a Representative of the Corporation.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;This Agreement constitutes the entire agreement between the parties hereto with respect to the subject matter hereof and supersedes all prior agreements and understandings, oral, written and implied, between the parties hereto with respect to the subject matter hereof&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, that this Agreement is a supplement to and in furtherance of the Bylaws and applicable law, and shall not be deemed a substitute therefore, nor to diminish or abrogate any rights of Indemnitee thereunder.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160; The Corporation shall not seek from a court, or agree to, a &#8220;bar order&#8221; which would have the effect of prohibiting or limiting the Indemnitee&#8217;s right to receive advancement of expenses under this Agreement.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 18.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Modification and Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. No supplement, modification or amendment of this Agreement shall be binding unless executed in writing by the parties thereto. No waiver of any of the provisions of this Agreement shall be deemed or shall constitute a waiver of any other provisions of this Agreement nor shall any waiver constitute a continuing waiver. The failure of any party to enforce any of the provisions of this Agreement shall in no way be construed as a waiver of such provisions and shall not affect the right of such party thereafter to enforce each and every provision of this Agreement in accordance with its terms.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 19.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. All notices, requests, demands and other communications under this Agreement shall be in writing and shall be deemed to have been duly given if (a)&#160;delivered by hand and receipted for by the party to whom said notice or other communication shall have been directed, (b)&#160;mailed by certified or registered mail with postage prepaid, on the third business day after the date on which it is so mailed, (c)&#160;mailed by reputable overnight courier and receipted for by the party to whom said notice or other communication shall have been directed or (d)&#160;sent by facsimile transmission, with receipt of oral confirmation that such transmission has been received&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;If to Indemnitee, at the address indicated on the signature page&#160;of this Agreement, or such other address as Indemnitee shall provide to the Corporation.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;If to the Corporation to&#58;</font></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">OptiNose,&#160;Inc.</font></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1020 Stony Hill Road, Suite&#160;300</font></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Yardley, Pennsylvania 19067</font></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Attn&#58; Chief Legal Officer</font></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Facsimile&#58; (267) 395-2119</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;</font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or to any other address as may have been furnished to Indemnitee by the Corporation.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 20.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Contribution</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. To the fullest extent permissible under applicable law, if the indemnification provided for in this Agreement is unavailable to Indemnitee for any reason whatsoever, the Corporation, in lieu of indemnifying Indemnitee, shall contribute to the amount incurred by Indemnitee, whether for judgments, fines, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">penalties, excise taxes, amounts paid or to be paid in settlement and&#47;or for Expenses, in connection with any claim relating to an indemnifiable event under this Agreement, in such proportion as is deemed fair and reasonable in light of all of the circumstances of the Proceeding in order to reflect (a)&#160;the relative benefits received by the Corporation and Indemnitee as a result of the event(s)&#160;and&#47;or transaction(s)&#160;giving cause to such Proceeding&#59; and&#47;or (b)&#160;the relative fault of the Corporation (and its directors, officers, employees and agents) and Indemnitee in connection with such event(s)&#160;and&#47;or transaction(s).</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 21.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Applicable Law and Consent to Jurisdiction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This Agreement and the legal relations among the parties shall be governed by, and construed and enforced in accordance with, the laws of the State of Delaware, without regard to its conflict of laws rules. Except with respect to any arbitration commenced by Indemnitee pursuant to Section 13(a), the Corporation and Indemnitee hereby irrevocably and unconditionally (a)&#160;agree that any action or proceeding arising out of or in connection with this Agreement shall be brought only in the Delaware Court of Chancery, and not in any other state or federal court in the United States of America or any court in any other country, (b)&#160;consent to submit to the exclusive jurisdiction of the Delaware Court of Chancery for purposes of any action or proceeding arising out of or in connection with this Agreement, (c)&#160;waive any objection to the laying of venue of any such action or proceeding in the Delaware Court of Chancery and (d)&#160;waive, and agree not to plead or to make, any claim that any such action or proceeding brought in the Delaware Court of Chancery has been brought in an improper or inconvenient forum.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 22.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This Agreement may be executed in one or more counterparts, each of which shall for all purposes be deemed to be an original but all of which together shall constitute one and the same Agreement. Only one such counterpart signed by the party against whom enforceability is sought needs to be produced to evidence the existence of this Agreement.&#160; Counterparts may be delivered via facsimile, electronic mail (including pdf or any electronic signature) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 23.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Third-Party Beneficiaries</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Sponsor Entities are intended third-party beneficiaries of this Agreement.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 24.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Miscellaneous</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Use of the masculine pronoun shall be deemed to include usage of the feminine pronoun where appropriate. The headings of the paragraphs of this Agreement are inserted for convenience only and shall not be deemed to constitute part of this Agreement or to affect the construction thereof.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;SIGNATURE PAGE FOLLOWS&#93;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div></div></div><div id="ia0d4cd105bad420ebf284f34d6fe1684_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IN WITNESS WHEREOF, the parties have caused this Agreement to be signed as of the day and year first above written.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OPTINOSE,&#160;INC.</font></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;  Ramy Mahmoud</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;  Chief Executive Officer</font></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;Signature Page&#160;to Indemnification Agreement&#93;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">15</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">INDEMNITEE&#58;</font></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;&#160;&#160;&#93;</font></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;Signature Page&#160;to Indemnification Agreement&#93;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">16</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Schedule to Exhibit 10.1</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following directors and executive officers are parties to an Indemnification Agreement with the Company, each of which are substantially identical in all material respects to the representative Indemnification Agreement filed herewith as Exhibit&#160;10.1 except as to the name of the signatory and the date of each signatory&#8217;s Indemnification Agreement, which are listed below. The actual Indemnification Agreements are omitted pursuant to Instruction 2 to Item 601 of Regulation S-K.</font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.612%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">INDEMNITEE</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">DATE</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ramy A. Mahmoud, M.D., M.P.H.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2, 2017</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michael F. Marino</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2, 2017</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Joseph C. Scodari</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 5, 2017</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Wilhelmus Groenhuysen</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 5, 2017</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sandra K. Helton</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 22, 2018</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Catherine E. Owen</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 29, 2020</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tomas J. Heyman</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 1, 2020</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eric Bednarski</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 10, 2021</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kyle Dempsey</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 10, 2021</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R. John Fletcher</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 26, 2022</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anthony J. Krick</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 2, 2022</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Paul Spence Jr.</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 15, 2022</font></td></tr></table></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">17</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>4
<FILENAME>listofsubsidiariesex2112022.htm
<DESCRIPTION>EX-21.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="if1b201ac9e374b8b8e93b75ad0f146cd_1"></div><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exhibit 21.1</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OPTINOSE, INC.</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LIST OF SUBSIDIARIES</font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:43.328%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.504%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.402%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jurisdiction of Incorporation</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Percent Owned</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OptiNose US, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Optinose AS</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Norway</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Optinose UK, Ltd.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100%</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>5
<FILENAME>auditorconsentex2312022.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ic3576c6567454cc585d2653fa27c09f4_1"></div><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exhibit 23.1</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consent of Independent Registered Public Accounting Firm</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#333333;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consent to the incorporation by reference in the following Registration Statements&#58;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#333333;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.78pt">Registration Statement (Form S-8 No. 333-221047) pertaining to the Amended and Restated 2010 Stock Incentive Plan and the 2017 Employee Stock Purchase Plan of OptiNose, Inc.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#333333;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.78pt">Registration Statement (Form S-8 No. 333-223617) pertaining to the Amended and Restated 2010 Stock Incentive Plan and the 2017 Employee Stock Purchase Plan of OptiNose, Inc.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#333333;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</font><font style="color:#333333;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.78pt">Registration Statement (Form S-8 No. 333-230083) pertaining to the Amended and Restated 2010 Stock Incentive Plan and the 2017 Employee Stock Purchase Plan of OptiNose, Inc.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#333333;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(4)</font><font style="color:#333333;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:5.78pt">Registration Statement (Form S-8 No. 333-236978) pertaining to the Amended and Restated 2020 Stock Incentive Plan, the Non-Qualified Stock Option Award (Inducement Grant) and the Restricted Stock Unit Award (Inducement Grant) of OptiNose, Inc.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#333333;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5)</font><font style="color:#333333;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.78pt">Registration Statement (Form S-8 No. 333-253814) pertaining to the Amended and Restated 2010 Stock inventive Plan, 2017 Employee Stock Purchase Plan and the Non-Qualified Stock Option Awards (Inducement Grant) of Optinose Inc.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#333333;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6)</font><font style="color:#333333;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.78pt">Registration Statement (Form S-8 No. 333-263362) pertaining to the Amended and Restated 2010 Stock inventive Plan, 2017 Employee Stock Purchase Plan and the Non-Qualified Stock Option Awards (Inducement Grant) of OptiNose, Inc.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#333333;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7)</font><font style="color:#333333;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.78pt">Registration Statement (Form S-3 No. 333-228122) of OptiNose, Inc.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#333333;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8)</font><font style="color:#333333;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.78pt">Registration Statement (Form S-3 No. 333-258707) of OptiNose, Inc.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#333333;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of our report dated March 7, 2022, with respect to the consolidated financial statements of OptiNose, Inc. included in this Annual Report (Form 10-K) for the year ended December 31, 2022.</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; Ernst &#38; Young LLP</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Philadelphia, Pennsylvania</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 7, 2023 </font></div><div style="margin-bottom:8pt"><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>6
<FILENAME>optn12-31x202210xkex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i07fb04a26fe942f48e05a0311eb06fa1_1"></div><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Exhibit 31.1</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO SECTION 302 OF THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SARBANES-OXLEY ACT OF 2002</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">I, Ramy Mahmoud, certify that&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">1. &#160;&#160;&#160;&#160;I have reviewed this Annual Report on Form 10-K of OptiNose, Inc.&#59;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. &#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. &#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. &#160;&#160;&#160;&#160;The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a. &#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.     Designed such&#160;internal control over financial reporting, or caused such&#160;internal control over financial reporting&#160;to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c. &#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d. &#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5. &#160;&#160;&#160;&#160;The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a. &#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b. &#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:40.334%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:54.538%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; March 7, 2023</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Ramy Mahmoud</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ramy Mahmoud</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></div></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>7
<FILENAME>optn12-31x202210xkex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ic29594fb1dd841638f213774ff70dd4a_1"></div><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Exhibit 31.2</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL FINANCIAL </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OFFICER PURSUANT TO  SECTION 302 </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OF THE SARBANES-OXLEY ACT OF 2002</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">I, Anthony J. Krick, certify that&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">1. &#160;&#160;&#160;&#160;I have reviewed this Annual Report on Form 10-K of OptiNose, Inc.&#59;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. &#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. &#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. &#160;&#160;&#160;&#160;The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a. &#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.     Designed such&#160;internal control over financial reporting, or caused such&#160;internal control over financial reporting&#160;to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c. &#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d. &#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5. &#160;&#160;&#160;&#160;The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a. &#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b. &#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:40.334%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:54.538%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; March 7, 2023</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Anthony J. Krick</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Accounting Officer</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial Officer and Principal Accounting Officer)</font></div></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>8
<FILENAME>optn12-31x202210xkex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i856fb316555c4cc691e2349778ccbdb4_1"></div><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Exhibit 32.1</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL EXECUTIVE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OFFICER PURSUANT TO 18 U.S.C</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 1350, AS ADOPTED PURSUANTTO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Peter K. Miller, Chief Executive Officer of OptiNose, Inc. (the &#8220;Company&#8221;), do hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:9.67pt">the Annual Report on Form 10-K of the Company for the year ended December 31, 2020 (the &#8220;Report&#8221;) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:9.67pt">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company for the periods presented therein.</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.274%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.000%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; March 7, 2023</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Ramy Mahmoud</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ramy Mahmoud</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></div></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>9
<FILENAME>optn12-31x202210xkex322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="if194e40ad82f4d75a664a4cfef01fce5_1"></div><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Exhibit 32.2</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL FINANCIAL</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OFFICER PURSUANT TO U.S.C SECTION</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1350, AS ADOPTED PURSUANT TO </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Keith A. Goldan, Chief Financial Officer of OptiNose, Inc. (the &#8220;Company&#8221;), do hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:9.67pt">the Annual Report on Form 10-K of the Company for the year ended December&#160;31, 2022 (the &#8220;Report&#8221;) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:9.67pt">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company for the periods presented therein.</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:40.334%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:54.538%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">&#160;</td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; March 7, 2023</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Anthony J. Krick</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anthony J. Krick</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Accounting Officer</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial Officer and Principal Accounting Officer)</font></div></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>10
<FILENAME>optn-20221231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:738bcfbc-a4cb-4b05-a396-7d259cbbc32b,g:9b54bffb-0962-498f-9b57-5d3747805ca8-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:optn="http://www.optinose.com/20221231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.optinose.com/20221231">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="optn-20221231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="optn-20221231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="optn-20221231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="optn-20221231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.optinose.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://www.optinose.com/role/AuditInformation">
        <link:definition>0000002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://www.optinose.com/role/ConsolidatedBalanceSheets">
        <link:definition>0000003 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.optinose.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>0000004 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofOperations" roleURI="http://www.optinose.com/role/ConsolidatedStatementsofOperations">
        <link:definition>0000005 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofComprehensiveLoss" roleURI="http://www.optinose.com/role/ConsolidatedStatementsofComprehensiveLoss">
        <link:definition>0000006 - Statement - Consolidated Statements of Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofChangesinStockholdersEquityDeficit" roleURI="http://www.optinose.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit">
        <link:definition>0000007 - Statement - Consolidated Statements of Changes in Stockholders' Equity (Deficit)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlows" roleURI="http://www.optinose.com/role/ConsolidatedStatementsofCashFlows">
        <link:definition>0000008 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandDescriptionofBusiness" roleURI="http://www.optinose.com/role/OrganizationandDescriptionofBusiness">
        <link:definition>0000009 - Disclosure - Organization and Description of Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Liquidity" roleURI="http://www.optinose.com/role/Liquidity">
        <link:definition>0000010 - Disclosure - Liquidity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://www.optinose.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>0000011 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.optinose.com/role/FairValueMeasurements">
        <link:definition>0000012 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventory" roleURI="http://www.optinose.com/role/Inventory">
        <link:definition>0000013 - Disclosure - Inventory</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipment" roleURI="http://www.optinose.com/role/PropertyandEquipment">
        <link:definition>0000014 - Disclosure - Property and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.optinose.com/role/Leases">
        <link:definition>0000015 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesandOtherCurrentLiabilities" roleURI="http://www.optinose.com/role/AccruedExpensesandOtherCurrentLiabilities">
        <link:definition>0000016 - Disclosure - Accrued Expenses and Other Current Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseAgreements" roleURI="http://www.optinose.com/role/LicenseAgreements">
        <link:definition>0000017 - Disclosure - License Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Debtnet" roleURI="http://www.optinose.com/role/Debtnet">
        <link:definition>0000018 - Disclosure - Debt, net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlans" roleURI="http://www.optinose.com/role/EmployeeBenefitPlans">
        <link:definition>0000019 - Disclosure - Employee Benefit Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.optinose.com/role/CommitmentsandContingencies">
        <link:definition>0000020 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://www.optinose.com/role/StockholdersEquity">
        <link:definition>0000021 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensation" roleURI="http://www.optinose.com/role/StockbasedCompensation">
        <link:definition>0000022 - Disclosure - Stock-based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.optinose.com/role/IncomeTaxes">
        <link:definition>0000023 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.optinose.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>0000024 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesTables" roleURI="http://www.optinose.com/role/SummaryofSignificantAccountingPoliciesTables">
        <link:definition>0000025 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.optinose.com/role/FairValueMeasurementsTables">
        <link:definition>0000026 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryTables" roleURI="http://www.optinose.com/role/InventoryTables">
        <link:definition>0000027 - Disclosure - Inventory (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentTables" roleURI="http://www.optinose.com/role/PropertyandEquipmentTables">
        <link:definition>0000028 - Disclosure - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.optinose.com/role/LeasesTables">
        <link:definition>0000029 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesandOtherCurrentLiabilitiesTables" roleURI="http://www.optinose.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables">
        <link:definition>0000030 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtnetTables" roleURI="http://www.optinose.com/role/DebtnetTables">
        <link:definition>0000031 - Disclosure - Debt, net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityTables" roleURI="http://www.optinose.com/role/StockholdersEquityTables">
        <link:definition>0000032 - Disclosure - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensationTables" roleURI="http://www.optinose.com/role/StockbasedCompensationTables">
        <link:definition>0000033 - Disclosure - Stock-based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.optinose.com/role/IncomeTaxesTables">
        <link:definition>0000034 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LiquidityNarrativeDetails" roleURI="http://www.optinose.com/role/LiquidityNarrativeDetails">
        <link:definition>0000035 - Disclosure - Liquidity - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesConcentrationriskDetails" roleURI="http://www.optinose.com/role/SummaryofSignificantAccountingPoliciesConcentrationriskDetails">
        <link:definition>0000036 - Disclosure - Summary of Significant Accounting Policies - Concentration risk (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesCashandcashequivalentsDetails" roleURI="http://www.optinose.com/role/SummaryofSignificantAccountingPoliciesCashandcashequivalentsDetails">
        <link:definition>0000037 - Disclosure - Summary of Significant Accounting Policies - Cash and cash equivalents (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesAccountsreceivableDetails" roleURI="http://www.optinose.com/role/SummaryofSignificantAccountingPoliciesAccountsreceivableDetails">
        <link:definition>0000038 - Disclosure - Summary of Significant Accounting Policies - Accounts receivable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPropertyandequipmentDetails" roleURI="http://www.optinose.com/role/SummaryofSignificantAccountingPoliciesPropertyandequipmentDetails">
        <link:definition>0000039 - Disclosure - Summary of Significant Accounting Policies - Property and equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesLonglivedassetsDetails" roleURI="http://www.optinose.com/role/SummaryofSignificantAccountingPoliciesLonglivedassetsDetails">
        <link:definition>0000040 - Disclosure - Summary of Significant Accounting Policies - Long lived assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesLicensingrevenuesDetails" roleURI="http://www.optinose.com/role/SummaryofSignificantAccountingPoliciesLicensingrevenuesDetails">
        <link:definition>0000041 - Disclosure - Summary of Significant Accounting Policies - Licensing revenues (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesAdvertisingexpenseDetails" roleURI="http://www.optinose.com/role/SummaryofSignificantAccountingPoliciesAdvertisingexpenseDetails">
        <link:definition>0000042 - Disclosure - Summary of Significant Accounting Policies - Advertising expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesNetincomelosspercommonshareDetails" roleURI="http://www.optinose.com/role/SummaryofSignificantAccountingPoliciesNetincomelosspercommonshareDetails">
        <link:definition>0000043 - Disclosure - Summary of Significant Accounting Policies - Net income (loss) per common share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsFairvalueassetsandliabilitiesmeasuredonrecurringbasisDetails" roleURI="http://www.optinose.com/role/FairValueMeasurementsFairvalueassetsandliabilitiesmeasuredonrecurringbasisDetails">
        <link:definition>0000044 - Disclosure - Fair Value Measurements - Fair value, assets and liabilities measured on recurring basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsFairvalueliabilitiesmeasuredonrecurringbasisusingunobservableinputsDetails" roleURI="http://www.optinose.com/role/FairValueMeasurementsFairvalueliabilitiesmeasuredonrecurringbasisusingunobservableinputsDetails">
        <link:definition>0000045 - Disclosure - Fair Value Measurements - Fair value liabilities measured on recurring basis using unobservable inputs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsValuationofwarrantsDetails" roleURI="http://www.optinose.com/role/FairValueMeasurementsValuationofwarrantsDetails">
        <link:definition>0000046 - Disclosure - Fair Value Measurements - Valuation of warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryDetails" roleURI="http://www.optinose.com/role/InventoryDetails">
        <link:definition>0000047 - Disclosure - Inventory (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentDetails" roleURI="http://www.optinose.com/role/PropertyandEquipmentDetails">
        <link:definition>0000048 - Disclosure - Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesNarrativeDetails" roleURI="http://www.optinose.com/role/LeasesNarrativeDetails">
        <link:definition>0000049 - Disclosure - Leases - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesOperatingleaseassetsandliabilitiesDetails" roleURI="http://www.optinose.com/role/LeasesOperatingleaseassetsandliabilitiesDetails">
        <link:definition>0000050 - Disclosure - Leases - Operating lease assets and liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesWeightedaverageremainingleasetermandweightedaveragediscountrateDetails" roleURI="http://www.optinose.com/role/LeasesWeightedaverageremainingleasetermandweightedaveragediscountrateDetails">
        <link:definition>0000051 - Disclosure - Leases - Weighted average remaining lease term and weighted average discount rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesOperatingleasematuritiesDetails" roleURI="http://www.optinose.com/role/LeasesOperatingleasematuritiesDetails">
        <link:definition>0000052 - Disclosure - Leases - Operating lease maturities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesOperatingleasematuritiesDetails_1" roleURI="http://www.optinose.com/role/LeasesOperatingleasematuritiesDetails_1">
        <link:definition>0000052 - Disclosure - Leases - Operating lease maturities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesandOtherCurrentLiabilitiesDetails" roleURI="http://www.optinose.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails">
        <link:definition>0000053 - Disclosure - Accrued Expenses and Other Current Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseAgreementsDetails" roleURI="http://www.optinose.com/role/LicenseAgreementsDetails">
        <link:definition>0000054 - Disclosure - License Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtnetNarrativeDetails" roleURI="http://www.optinose.com/role/DebtnetNarrativeDetails">
        <link:definition>0000055 - Disclosure - Debt, net - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtnetARNotePurchaseAgreementDetails" roleURI="http://www.optinose.com/role/DebtnetARNotePurchaseAgreementDetails">
        <link:definition>0000056 - Disclosure - Debt, net - A&amp;R Note Purchase Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtnetScheduleoflongtermdebtDetails" roleURI="http://www.optinose.com/role/DebtnetScheduleoflongtermdebtDetails">
        <link:definition>0000057 - Disclosure - Debt, net - Schedule of long term debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlansDetails" roleURI="http://www.optinose.com/role/EmployeeBenefitPlansDetails">
        <link:definition>0000058 - Disclosure - Employee Benefit Plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesDetails" roleURI="http://www.optinose.com/role/CommitmentsandContingenciesDetails">
        <link:definition>0000059 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityNarrativeDetails" roleURI="http://www.optinose.com/role/StockholdersEquityNarrativeDetails">
        <link:definition>0000060 - Disclosure - Stockholders' Equity - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityGrantdatefairvalueofwarrantsvaluationassumptionsDetails" roleURI="http://www.optinose.com/role/StockholdersEquityGrantdatefairvalueofwarrantsvaluationassumptionsDetails">
        <link:definition>0000061 - Disclosure - Stockholders' Equity - Grant date fair value of warrants, valuation assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityWarrantsOutstandingDetails" roleURI="http://www.optinose.com/role/StockholdersEquityWarrantsOutstandingDetails">
        <link:definition>0000062 - Disclosure - Stockholders' Equity - Warrants Outstanding (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensationNarrativeDetails" roleURI="http://www.optinose.com/role/StockbasedCompensationNarrativeDetails">
        <link:definition>0000063 - Disclosure - Stock-based Compensation - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensationServicebasedstockoptionsDetails" roleURI="http://www.optinose.com/role/StockbasedCompensationServicebasedstockoptionsDetails">
        <link:definition>0000064 - Disclosure - Stock-based Compensation - Service-based stock options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensationScheduleofRSUsDetails" roleURI="http://www.optinose.com/role/StockbasedCompensationScheduleofRSUsDetails">
        <link:definition>0000065 - Disclosure - Stock-based Compensation - Schedule of RSUs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensationStockbasedcompensationexpenseDetails" roleURI="http://www.optinose.com/role/StockbasedCompensationStockbasedcompensationexpenseDetails">
        <link:definition>0000066 - Disclosure - Stock-based Compensation - Stock-based compensation expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensationBlackScholespricingmodeloptionsDetails" roleURI="http://www.optinose.com/role/StockbasedCompensationBlackScholespricingmodeloptionsDetails">
        <link:definition>0000067 - Disclosure - Stock-based Compensation - Black-Scholes pricing model options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofincomebeforeincometaxdomesticandforeignDetails" roleURI="http://www.optinose.com/role/IncomeTaxesScheduleofincomebeforeincometaxdomesticandforeignDetails">
        <link:definition>0000068 - Disclosure - Income Taxes - Schedule of income before income tax, domestic and foreign (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofeffectiveincometaxratereconciliationDetails" roleURI="http://www.optinose.com/role/IncomeTaxesScheduleofeffectiveincometaxratereconciliationDetails">
        <link:definition>0000069 - Disclosure - Income Taxes - Schedule of effective income tax rate reconciliation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofdeferredtaxassetsandliabilitiesDetails" roleURI="http://www.optinose.com/role/IncomeTaxesScheduleofdeferredtaxassetsandliabilitiesDetails">
        <link:definition>0000070 - Disclosure - Income Taxes - Schedule of deferred tax assets and liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesNarrativeDetails" roleURI="http://www.optinose.com/role/IncomeTaxesNarrativeDetails">
        <link:definition>0000071 - Disclosure - Income Taxes - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="optn_RestrictedStockUnitsServiceBasedMember" abstract="true" name="RestrictedStockUnitsServiceBasedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="optn_CommonStockCapitalSharesReservedforFutureIssuanceYearlyIncrease" abstract="false" name="CommonStockCapitalSharesReservedforFutureIssuanceYearlyIncrease" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="optn_GrantAndOtherIncome" abstract="false" name="GrantAndOtherIncome" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="optn_LesseeOperatingLeaseLiabilityPaymentsDueThereafter" abstract="false" name="LesseeOperatingLeaseLiabilityPaymentsDueThereafter" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="optn_MeasurementPeriodDomain" abstract="true" name="MeasurementPeriodDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="optn_September302025Member" abstract="true" name="September302025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="optn_TwoThousandSeventeenEmployeeStockPurchasePlanMember" abstract="true" name="TwoThousandSeventeenEmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="optn_September302027Member" abstract="true" name="September302027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="optn_TrailingTwelveMonthNetRevenueCovenant" abstract="false" name="TrailingTwelveMonthNetRevenueCovenant" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="optn_TrailingTwelveMonthEndingAxisDomain" abstract="true" name="TrailingTwelveMonthEndingAxisDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="optn_ClassOfWarrantOrRightRestrictionCommonSharesMaximumOwnershipAfterEffectiveWaitingPeriodPercent" abstract="false" name="ClassOfWarrantOrRightRestrictionCommonSharesMaximumOwnershipAfterEffectiveWaitingPeriodPercent" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="optn_WarrantsExpiringNovember182024Member" abstract="true" name="WarrantsExpiringNovember182024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="optn_NASDAQInducementGrantExceptionMember" abstract="true" name="NASDAQInducementGrantExceptionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="optn_MeasurementInputStrikePriceMember" abstract="true" name="MeasurementInputStrikePriceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="optn_September302026Member" abstract="true" name="September302026Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="optn_DebtInstrumentIssuanceCriteriaTermNetSalesAndRoyaltiesBenchmark" abstract="false" name="DebtInstrumentIssuanceCriteriaTermNetSalesAndRoyaltiesBenchmark" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="optn_ScheduleOfGrantDateFairValueOfWarrantValuationAssumptionsTableTextBlock" abstract="false" name="ScheduleOfGrantDateFairValueOfWarrantValuationAssumptionsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="optn_AssetsAndLiabilitiesLesseeTableTextBlock" abstract="false" name="AssetsAndLiabilitiesLesseeTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="optn_EffectiveIncomeTaxRateReconciliationForeignExchangeOtherPercent" abstract="false" name="EffectiveIncomeTaxRateReconciliationForeignExchangeOtherPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="optn_December312025Member" abstract="true" name="December312025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="optn_PublicOfferingMember" abstract="true" name="PublicOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="optn_DefinedContributionPlanTranchesAxisDomain" abstract="true" name="DefinedContributionPlanTranchesAxisDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="optn_DeferredTaxAssetsFinancingCosts" abstract="false" name="DeferredTaxAssetsFinancingCosts" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="optn_DeferredTaxAssetsLeasingArrangement" abstract="false" name="DeferredTaxAssetsLeasingArrangement" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="optn_AmendedandRestated2010StockIncentivePlanMember" abstract="true" name="AmendedandRestated2010StockIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="optn_NotePurchaseAgreementThirdDelayedDrawNotesMember" abstract="true" name="NotePurchaseAgreementThirdDelayedDrawNotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="optn_ComputerEquipmentandSoftwareMember" abstract="true" name="ComputerEquipmentandSoftwareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="optn_DebtInstrumentFeeAmountFrontEnd" abstract="false" name="DebtInstrumentFeeAmountFrontEnd" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="optn_QuarterEndedSeptember302020Member" abstract="true" name="QuarterEndedSeptember302020Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="optn_OperatingLeaseLiabilityAbstractAbstract" abstract="true" name="OperatingLeaseLiabilityAbstractAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="optn_June302026Member" abstract="true" name="June302026Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="optn_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeAccruedRightsToPurchaseCommonStock" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeAccruedRightsToPurchaseCommonStock" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="optn_ProceedsfromIssuanceofCommonStockUnderEmployeeStockPurchasePlan" abstract="false" name="ProceedsfromIssuanceofCommonStockUnderEmployeeStockPurchasePlan" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="optn_ClassOfWarrantOrRightRestrictionCommonSharesMaximumOwnershipIfExercisedPercent" abstract="false" name="ClassOfWarrantOrRightRestrictionCommonSharesMaximumOwnershipIfExercisedPercent" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="optn_DeferredTaxAssetsPrepaidLicenseArrangement" abstract="false" name="DeferredTaxAssetsPrepaidLicenseArrangement" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="optn_FeeDueOnTheMaturityDateOfTheNotePurchaseAgreement" abstract="false" name="FeeDueOnTheMaturityDateOfTheNotePurchaseAgreement" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="optn_OperatingLeaseCostForExtension" abstract="false" name="OperatingLeaseCostForExtension" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="optn_September302024Member" abstract="true" name="September302024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="optn_NumberOfCustomers" abstract="false" name="NumberOfCustomers" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="optn_June302024Member" abstract="true" name="June302024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="optn_UnderwritersMember" abstract="true" name="UnderwritersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="optn_FairValueOfWarrant" abstract="false" name="FairValueOfWarrant" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="optn_AccruedProductAllowancesCurrent" abstract="false" name="AccruedProductAllowancesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="optn_ClassOfWarrantOrRightRestrictionCommonSharesMaximumOwnershipPriorToExecutionPercent" abstract="false" name="ClassOfWarrantOrRightRestrictionCommonSharesMaximumOwnershipPriorToExecutionPercent" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="optn_WarrantLiabilityNonCurrent" abstract="false" name="WarrantLiabilityNonCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="optn_EffectiveIncomeTaxRateReconciliationForeignOperationsImpactPercent" abstract="false" name="EffectiveIncomeTaxRateReconciliationForeignOperationsImpactPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="optn_DeferredTaxAssetsTaxCreditCarryforwardsResearchTerm" abstract="false" name="DeferredTaxAssetsTaxCreditCarryforwardsResearchTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="optn_June302027Member" abstract="true" name="June302027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="optn_June302023Member" abstract="true" name="June302023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="optn_DebtInstrumentCovenantCashAndCashEquivalents" abstract="false" name="DebtInstrumentCovenantCashAndCashEquivalents" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="optn_MonteCarloSimulationMember" abstract="true" name="MonteCarloSimulationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="optn_WarrantsExpiringNovember232027Member" abstract="true" name="WarrantsExpiringNovember232027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="optn_AmendmentFee" abstract="false" name="AmendmentFee" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="optn_RestrictedStockUnitsPerformanceBasedMember" abstract="true" name="RestrictedStockUnitsPerformanceBasedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="optn_June302025Member" abstract="true" name="June302025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="optn_NotePurchaseAgreementCovenantXHANCENetProductSalesAndRoyalties" abstract="false" name="NotePurchaseAgreementCovenantXHANCENetProductSalesAndRoyalties" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="optn_DeferredTaxAssetsInterestExpense" abstract="false" name="DeferredTaxAssetsInterestExpense" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="optn_StockIssuedDuringPeriodSharesVestedRestrictedStockUnits" abstract="false" name="StockIssuedDuringPeriodSharesVestedRestrictedStockUnits" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="optn_MeasurementPeriodAxis" abstract="true" name="MeasurementPeriodAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="optn_PotentialDebtInstrumentInterestRateIncrease" abstract="false" name="PotentialDebtInstrumentInterestRateIncrease" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="optn_AmendmentFeePayable" abstract="false" name="AmendmentFeePayable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="optn_DeferredOfferingCostsWIthinAccountsPayableandAccruedExpenses" abstract="false" name="DeferredOfferingCostsWIthinAccountsPayableandAccruedExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="optn_NotePurchaseAgreementFirstDelayedDrawNotesMember" abstract="true" name="NotePurchaseAgreementFirstDelayedDrawNotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="optn_ServiceBasedStockOptionsMember" abstract="true" name="ServiceBasedStockOptionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="optn_DefinedContributionPlanTranchesAxisAxis" abstract="true" name="DefinedContributionPlanTranchesAxisAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="optn_DebtInstrumentMaximumAggregateMakeWholePremiumAmount" abstract="false" name="DebtInstrumentMaximumAggregateMakeWholePremiumAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="optn_DefinedContributionPlanTrancheTwoMember" abstract="true" name="DefinedContributionPlanTrancheTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="optn_IncreaseDecreaseinDepositsandOtherAssets" abstract="false" name="IncreaseDecreaseinDepositsandOtherAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="optn_FiveCustomersMember" abstract="true" name="FiveCustomersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="optn_March312023Member" abstract="true" name="March312023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="optn_NotePurchaseAgreementMember" abstract="true" name="NotePurchaseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="optn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestNumber" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestNumber" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="optn_December312023Member" abstract="true" name="December312023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="optn_AmendmentFeePercentage" abstract="false" name="AmendmentFeePercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="optn_DefinedContributionPlanTrancheOneMember" abstract="true" name="DefinedContributionPlanTrancheOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="optn_DebtInstrumentFeeAmountBackEnd" abstract="false" name="DebtInstrumentFeeAmountBackEnd" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="optn_TrailingTwelveMonthEndingAxisAxis" abstract="true" name="TrailingTwelveMonthEndingAxisAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="optn_MarketBasedStockOptionsMember" abstract="true" name="MarketBasedStockOptionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="optn_FutureLiquidityTextBlock" abstract="false" name="FutureLiquidityTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="optn_WarrantsExpiringNovember152024Member" abstract="true" name="WarrantsExpiringNovember152024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="optn_March312027Member" abstract="true" name="March312027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="optn_March312024Member" abstract="true" name="March312024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="optn_VotePerShare" abstract="false" name="VotePerShare" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="optn_AccruedResearchandDevelopmentCurrent" abstract="false" name="AccruedResearchandDevelopmentCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="optn_SecuredOvernightFinancingRateMember" abstract="true" name="SecuredOvernightFinancingRateMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="optn_StockIssuedDuringPeriodVestedRestrictedStockUnits" abstract="false" name="StockIssuedDuringPeriodVestedRestrictedStockUnits" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="optn_September302023Member" abstract="true" name="September302023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="optn_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestonePaymentsMaximumEligible" abstract="false" name="ResearchAndDevelopmentArrangementContractToPerformForOthersMilestonePaymentsMaximumEligible" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="optn_WarrantsExpiringSeptember122022Member" abstract="true" name="WarrantsExpiringSeptember122022Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="optn_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedIncrementEachYear" abstract="false" name="SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedIncrementEachYear" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="optn_QuarterEndedDecember312019Member" abstract="true" name="QuarterEndedDecember312019Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="optn_DebtInstrumentMakeWholeProvisionPaymentAccrualPeriod" abstract="false" name="DebtInstrumentMakeWholeProvisionPaymentAccrualPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="optn_March312026Member" abstract="true" name="March312026Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="optn_EffectiveIncomeTaxRateReconciliationPrepaidRoyaltyWriteOffPercent" abstract="false" name="EffectiveIncomeTaxRateReconciliationPrepaidRoyaltyWriteOffPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="optn_December312024Member" abstract="true" name="December312024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="optn_AccruedSellingGeneralandAdministrativeCurrent" abstract="false" name="AccruedSellingGeneralandAdministrativeCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="optn_IncreaseDecreaseInGrantsandOtherReceivables" abstract="false" name="IncreaseDecreaseInGrantsandOtherReceivables" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="optn_SaleOfStockCommissionsAndExpenses" abstract="false" name="SaleOfStockCommissionsAndExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="optn_March312025Member" abstract="true" name="March312025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="optn_December312026Member" abstract="true" name="December312026Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="optn_UnrealizedGainLossOnFairValueOfWarrants" abstract="false" name="UnrealizedGainLossOnFairValueOfWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="optn_WorkingCapital" abstract="false" name="WorkingCapital" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="optn_AuditorInformationAbstract" abstract="true" name="AuditorInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>11
<FILENAME>optn-20221231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:738bcfbc-a4cb-4b05-a396-7d259cbbc32b,g:9b54bffb-0962-498f-9b57-5d3747805ca8-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.optinose.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="optn-20221231.xsd#ConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.optinose.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_70727fe2-73c1-4449-8d1b-82808c77e3aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_75a6aa03-d580-4776-842f-3f836635e7e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_70727fe2-73c1-4449-8d1b-82808c77e3aa" xlink:to="loc_us-gaap_LiabilitiesCurrent_75a6aa03-d580-4776-842f-3f836635e7e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_17bf8cfa-11d8-4ecf-8752-e83904b54904" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_70727fe2-73c1-4449-8d1b-82808c77e3aa" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_17bf8cfa-11d8-4ecf-8752-e83904b54904" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_5353e045-759a-481a-8560-2722799b592c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_70727fe2-73c1-4449-8d1b-82808c77e3aa" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_5353e045-759a-481a-8560-2722799b592c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_WarrantLiabilityNonCurrent_36c31c22-9953-4ea6-8296-d0ada2d4a062" xlink:href="optn-20221231.xsd#optn_WarrantLiabilityNonCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_70727fe2-73c1-4449-8d1b-82808c77e3aa" xlink:to="loc_optn_WarrantLiabilityNonCurrent_36c31c22-9953-4ea6-8296-d0ada2d4a062" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_3c21b49f-4a93-44aa-9ee9-52674353860c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_f9ce7ed8-f818-49ea-9c12-79b231c9aa7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_3c21b49f-4a93-44aa-9ee9-52674353860c" xlink:to="loc_us-gaap_AccountsPayableCurrent_f9ce7ed8-f818-49ea-9c12-79b231c9aa7d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_9d8dfc89-92a0-43fe-86ad-fc5750e38416" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_3c21b49f-4a93-44aa-9ee9-52674353860c" xlink:to="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_9d8dfc89-92a0-43fe-86ad-fc5750e38416" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_870a320c-d903-4c6d-baab-e9333592d247" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_3c21b49f-4a93-44aa-9ee9-52674353860c" xlink:to="loc_us-gaap_LongTermDebtCurrent_870a320c-d903-4c6d-baab-e9333592d247" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_ee45d152-b110-4212-bd6f-605c9645c5a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_8f35fb78-bf30-45f8-be58-ce0415adc3d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_ee45d152-b110-4212-bd6f-605c9645c5a5" xlink:to="loc_us-gaap_CommonStockValue_8f35fb78-bf30-45f8-be58-ce0415adc3d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_4d7c20b1-460d-454a-8685-ba9afb57fe26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_ee45d152-b110-4212-bd6f-605c9645c5a5" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_4d7c20b1-460d-454a-8685-ba9afb57fe26" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ab668874-6247-4789-97e0-e1759b2361fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_ee45d152-b110-4212-bd6f-605c9645c5a5" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ab668874-6247-4789-97e0-e1759b2361fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_d2cc345f-a2b0-4b72-957e-cbf1fdf52fdb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_ee45d152-b110-4212-bd6f-605c9645c5a5" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_d2cc345f-a2b0-4b72-957e-cbf1fdf52fdb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_318876b8-c297-46c4-9ce2-405e78265627" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_484b2b48-ab2b-4312-b998-1376e0523a7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_318876b8-c297-46c4-9ce2-405e78265627" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_484b2b48-ab2b-4312-b998-1376e0523a7f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_ca160822-2780-4d45-88ef-6d9645fc2476" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_318876b8-c297-46c4-9ce2-405e78265627" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_ca160822-2780-4d45-88ef-6d9645fc2476" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_dfaf2162-0fdd-4355-a153-9eb02eef52bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_318876b8-c297-46c4-9ce2-405e78265627" xlink:to="loc_us-gaap_InventoryNet_dfaf2162-0fdd-4355-a153-9eb02eef52bd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_664087f2-5694-423d-a008-e9ed17d1f5c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_318876b8-c297-46c4-9ce2-405e78265627" xlink:to="loc_us-gaap_OtherAssetsCurrent_664087f2-5694-423d-a008-e9ed17d1f5c8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_7c7e512d-813d-438d-8aca-6b21677938fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_d41c0801-faf5-4a52-94e9-df98aa34c93b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_7c7e512d-813d-438d-8aca-6b21677938fc" xlink:to="loc_us-gaap_AssetsCurrent_d41c0801-faf5-4a52-94e9-df98aa34c93b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_265f6e55-cbd8-45c3-abae-480aa9a82456" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_7c7e512d-813d-438d-8aca-6b21677938fc" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_265f6e55-cbd8-45c3-abae-480aa9a82456" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_c0b33647-c5f4-4318-9168-2a7fe22e7ed1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_7c7e512d-813d-438d-8aca-6b21677938fc" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_c0b33647-c5f4-4318-9168-2a7fe22e7ed1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_dbc7b6a5-8556-49d2-b093-571ba3c43f99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_c417fa8b-6055-4a77-b3af-a51e6088ea89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_dbc7b6a5-8556-49d2-b093-571ba3c43f99" xlink:to="loc_us-gaap_Liabilities_c417fa8b-6055-4a77-b3af-a51e6088ea89" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_fa801b09-909c-435d-93c3-8d5205d50b37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_dbc7b6a5-8556-49d2-b093-571ba3c43f99" xlink:to="loc_us-gaap_StockholdersEquity_fa801b09-909c-435d-93c3-8d5205d50b37" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.optinose.com/role/ConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="optn-20221231.xsd#ConsolidatedStatementsofOperations"/>
  <link:calculationLink xlink:role="http://www.optinose.com/role/ConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_27f78a44-3ebf-42a7-ad39-abc895a96cfc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ae2ee719-bb33-47cc-a37f-57a9c3121e40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_27f78a44-3ebf-42a7-ad39-abc895a96cfc" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ae2ee719-bb33-47cc-a37f-57a9c3121e40" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_96ff213e-c949-4a74-ae33-445e0efa6c36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_27f78a44-3ebf-42a7-ad39-abc895a96cfc" xlink:to="loc_us-gaap_CostsAndExpenses_96ff213e-c949-4a74-ae33-445e0efa6c36" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_3731b99a-7e84-441e-8fa7-9efc198059c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_8716ea87-c68c-438b-ac7c-e28a3cd16bae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_3731b99a-7e84-441e-8fa7-9efc198059c9" xlink:to="loc_us-gaap_InvestmentIncomeInterest_8716ea87-c68c-438b-ac7c-e28a3cd16bae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_5bae46a4-e4d1-4ae0-9ef6-9b18e857775b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_3731b99a-7e84-441e-8fa7-9efc198059c9" xlink:to="loc_us-gaap_InterestExpense_5bae46a4-e4d1-4ae0-9ef6-9b18e857775b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_3de81413-90f5-40fa-925a-48b0274089c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_3731b99a-7e84-441e-8fa7-9efc198059c9" xlink:to="loc_us-gaap_OperatingIncomeLoss_3de81413-90f5-40fa-925a-48b0274089c9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_GrantAndOtherIncome_7d534ea7-ab5a-430e-837e-d0ed6fc21945" xlink:href="optn-20221231.xsd#optn_GrantAndOtherIncome"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_3731b99a-7e84-441e-8fa7-9efc198059c9" xlink:to="loc_optn_GrantAndOtherIncome_7d534ea7-ab5a-430e-837e-d0ed6fc21945" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_UnrealizedGainLossOnFairValueOfWarrants_a9cc8a2d-0c1e-48c5-8ff0-4478113e4706" xlink:href="optn-20221231.xsd#optn_UnrealizedGainLossOnFairValueOfWarrants"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_3731b99a-7e84-441e-8fa7-9efc198059c9" xlink:to="loc_optn_UnrealizedGainLossOnFairValueOfWarrants_a9cc8a2d-0c1e-48c5-8ff0-4478113e4706" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_0d5403e8-51dc-4d8d-9ebe-a05e400e731b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_069c97b6-448f-4951-8711-5ab1f214273a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_0d5403e8-51dc-4d8d-9ebe-a05e400e731b" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_069c97b6-448f-4951-8711-5ab1f214273a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_66a316c7-b4ea-4c00-905b-1666087d0287" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_0d5403e8-51dc-4d8d-9ebe-a05e400e731b" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_66a316c7-b4ea-4c00-905b-1666087d0287" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_2cd383df-3bf5-4ef5-a71c-83c5b79c42e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_0d5403e8-51dc-4d8d-9ebe-a05e400e731b" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_2cd383df-3bf5-4ef5-a71c-83c5b79c42e0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.optinose.com/role/ConsolidatedStatementsofComprehensiveLoss" xlink:type="simple" xlink:href="optn-20221231.xsd#ConsolidatedStatementsofComprehensiveLoss"/>
  <link:calculationLink xlink:role="http://www.optinose.com/role/ConsolidatedStatementsofComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_87b040f7-0112-4b30-ab58-273de2d1629a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_aa85a4d0-d39b-45d5-b751-5a3ebaf2f554" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_87b040f7-0112-4b30-ab58-273de2d1629a" xlink:to="loc_us-gaap_NetIncomeLoss_aa85a4d0-d39b-45d5-b751-5a3ebaf2f554" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_671cb750-596b-4c5e-bc83-e4af19f2d1ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_87b040f7-0112-4b30-ab58-273de2d1629a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_671cb750-596b-4c5e-bc83-e4af19f2d1ae" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.optinose.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="optn-20221231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.optinose.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_524043f8-0ec3-48a1-8362-d1226da0ca98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_52bed0b5-f556-48a2-aeca-33d9d2e5e94a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_524043f8-0ec3-48a1-8362-d1226da0ca98" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_52bed0b5-f556-48a2-aeca-33d9d2e5e94a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6b6902a1-2c38-4b1e-ae44-e73df336c4b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_524043f8-0ec3-48a1-8362-d1226da0ca98" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6b6902a1-2c38-4b1e-ae44-e73df336c4b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_fcd46759-d37c-4253-bc9e-73e8747dc1a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_524043f8-0ec3-48a1-8362-d1226da0ca98" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_fcd46759-d37c-4253-bc9e-73e8747dc1a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_577116c8-17bb-4d0e-a985-8c347fc82847" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_524043f8-0ec3-48a1-8362-d1226da0ca98" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_577116c8-17bb-4d0e-a985-8c347fc82847" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2cd679a9-efa6-45c2-8fdc-0157ead070d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_4b384e7c-928e-4970-bd7a-c0392e656b50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2cd679a9-efa6-45c2-8fdc-0157ead070d0" xlink:to="loc_us-gaap_NetIncomeLoss_4b384e7c-928e-4970-bd7a-c0392e656b50" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_459e606b-17d0-4612-8405-c57e37a70fca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2cd679a9-efa6-45c2-8fdc-0157ead070d0" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_459e606b-17d0-4612-8405-c57e37a70fca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_19368de6-9931-4932-a1a2-e1aaba3d5ce5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2cd679a9-efa6-45c2-8fdc-0157ead070d0" xlink:to="loc_us-gaap_ShareBasedCompensation_19368de6-9931-4932-a1a2-e1aaba3d5ce5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_bdd37a4b-7269-4582-aa7e-e575c6b78a06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2cd679a9-efa6-45c2-8fdc-0157ead070d0" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_bdd37a4b-7269-4582-aa7e-e575c6b78a06" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_faf812aa-fb88-48aa-b007-3309269a5bef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2cd679a9-efa6-45c2-8fdc-0157ead070d0" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_faf812aa-fb88-48aa-b007-3309269a5bef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_3db358cf-6985-46b6-a6ca-b84c2dbfd732" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2cd679a9-efa6-45c2-8fdc-0157ead070d0" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_3db358cf-6985-46b6-a6ca-b84c2dbfd732" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_IncreaseDecreaseInGrantsandOtherReceivables_1d3c9874-676c-4304-bc6e-e82f77cd3522" xlink:href="optn-20221231.xsd#optn_IncreaseDecreaseInGrantsandOtherReceivables"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2cd679a9-efa6-45c2-8fdc-0157ead070d0" xlink:to="loc_optn_IncreaseDecreaseInGrantsandOtherReceivables_1d3c9874-676c-4304-bc6e-e82f77cd3522" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_IncreaseDecreaseinDepositsandOtherAssets_98bca9a0-aa3c-44b5-81ca-d3abfdd7118b" xlink:href="optn-20221231.xsd#optn_IncreaseDecreaseinDepositsandOtherAssets"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2cd679a9-efa6-45c2-8fdc-0157ead070d0" xlink:to="loc_optn_IncreaseDecreaseinDepositsandOtherAssets_98bca9a0-aa3c-44b5-81ca-d3abfdd7118b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_f562f455-1a85-435d-a01d-2d80f5d070ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2cd679a9-efa6-45c2-8fdc-0157ead070d0" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_f562f455-1a85-435d-a01d-2d80f5d070ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_e8837eb1-bfad-415a-9a2e-2fe7842234f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2cd679a9-efa6-45c2-8fdc-0157ead070d0" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_e8837eb1-bfad-415a-9a2e-2fe7842234f2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_28887f0a-c457-4736-8c53-bd99275a276b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2cd679a9-efa6-45c2-8fdc-0157ead070d0" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_28887f0a-c457-4736-8c53-bd99275a276b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_6af9d13f-c972-49c7-a55b-b8ff44918aa7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2cd679a9-efa6-45c2-8fdc-0157ead070d0" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_6af9d13f-c972-49c7-a55b-b8ff44918aa7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_3175fe39-a1bb-4558-bc4d-309cf7aaa3a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2cd679a9-efa6-45c2-8fdc-0157ead070d0" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_3175fe39-a1bb-4558-bc4d-309cf7aaa3a9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7e9de6bd-ade0-49d4-85bb-e317099a1bdc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_17d13a6d-63d8-4664-a2d3-f72fe95e4ba3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7e9de6bd-ade0-49d4-85bb-e317099a1bdc" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_17d13a6d-63d8-4664-a2d3-f72fe95e4ba3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_03416db7-71ed-4da2-b309-60f2100632e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7e9de6bd-ade0-49d4-85bb-e317099a1bdc" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_03416db7-71ed-4da2-b309-60f2100632e2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_88b0b259-cdd7-4fba-a44e-bb10b0b42634" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_ProceedsfromIssuanceofCommonStockUnderEmployeeStockPurchasePlan_02751fdd-7f54-40dd-a778-cb537f83a282" xlink:href="optn-20221231.xsd#optn_ProceedsfromIssuanceofCommonStockUnderEmployeeStockPurchasePlan"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_88b0b259-cdd7-4fba-a44e-bb10b0b42634" xlink:to="loc_optn_ProceedsfromIssuanceofCommonStockUnderEmployeeStockPurchasePlan_02751fdd-7f54-40dd-a778-cb537f83a282" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_7c7f9e51-a09a-4009-8d0f-29ac7dc9eca8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_88b0b259-cdd7-4fba-a44e-bb10b0b42634" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_7c7f9e51-a09a-4009-8d0f-29ac7dc9eca8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts_394833eb-bca0-4cbe-afd6-55599a7c65d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfFinancingCosts"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_88b0b259-cdd7-4fba-a44e-bb10b0b42634" xlink:to="loc_us-gaap_PaymentsOfFinancingCosts_394833eb-bca0-4cbe-afd6-55599a7c65d6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_96ee9fc4-26c3-4680-9c8a-c12f32a74dd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_88b0b259-cdd7-4fba-a44e-bb10b0b42634" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_96ee9fc4-26c3-4680-9c8a-c12f32a74dd0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.optinose.com/role/FairValueMeasurementsFairvalueassetsandliabilitiesmeasuredonrecurringbasisDetails" xlink:type="simple" xlink:href="optn-20221231.xsd#FairValueMeasurementsFairvalueassetsandliabilitiesmeasuredonrecurringbasisDetails"/>
  <link:calculationLink xlink:role="http://www.optinose.com/role/FairValueMeasurementsFairvalueassetsandliabilitiesmeasuredonrecurringbasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_cbb84a72-29f6-4ca3-a81d-8d0f2e20a422" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_dd5e30c5-ad97-459e-883b-d5bdd6cdd9c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_cbb84a72-29f6-4ca3-a81d-8d0f2e20a422" xlink:to="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_dd5e30c5-ad97-459e-883b-d5bdd6cdd9c3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.optinose.com/role/InventoryDetails" xlink:type="simple" xlink:href="optn-20221231.xsd#InventoryDetails"/>
  <link:calculationLink xlink:role="http://www.optinose.com/role/InventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_dfa9c7c2-9d6b-4669-b01c-2045c87d1c7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials_7b4ca2ae-fe57-4278-b4f8-e61577383869" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterials"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_dfa9c7c2-9d6b-4669-b01c-2045c87d1c7c" xlink:to="loc_us-gaap_InventoryRawMaterials_7b4ca2ae-fe57-4278-b4f8-e61577383869" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess_eaa3a76a-c0e5-4c8d-ad59-6732bac37a8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_dfa9c7c2-9d6b-4669-b01c-2045c87d1c7c" xlink:to="loc_us-gaap_InventoryWorkInProcess_eaa3a76a-c0e5-4c8d-ad59-6732bac37a8c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_16032b12-d2da-4b29-ae4f-af1074a323e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_dfa9c7c2-9d6b-4669-b01c-2045c87d1c7c" xlink:to="loc_us-gaap_InventoryFinishedGoods_16032b12-d2da-4b29-ae4f-af1074a323e3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.optinose.com/role/PropertyandEquipmentDetails" xlink:type="simple" xlink:href="optn-20221231.xsd#PropertyandEquipmentDetails"/>
  <link:calculationLink xlink:role="http://www.optinose.com/role/PropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_b9a48293-466a-45a6-9959-11c40151c14a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_113ee45a-1353-4838-acc4-81b2542b3f04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_b9a48293-466a-45a6-9959-11c40151c14a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_113ee45a-1353-4838-acc4-81b2542b3f04" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_610c56e8-a5cb-44c8-8b5c-a2af8146953e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_b9a48293-466a-45a6-9959-11c40151c14a" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_610c56e8-a5cb-44c8-8b5c-a2af8146953e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.optinose.com/role/LeasesOperatingleaseassetsandliabilitiesDetails" xlink:type="simple" xlink:href="optn-20221231.xsd#LeasesOperatingleaseassetsandliabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.optinose.com/role/LeasesOperatingleaseassetsandliabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_8458ac04-e7e4-48f9-b4d4-9e0ca9a9d265" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_31c0e503-c1d7-4759-a981-934559cdf7cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_8458ac04-e7e4-48f9-b4d4-9e0ca9a9d265" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_31c0e503-c1d7-4759-a981-934559cdf7cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_7aff5bbb-bb16-4645-b6ca-50c3cf36fa03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_8458ac04-e7e4-48f9-b4d4-9e0ca9a9d265" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_7aff5bbb-bb16-4645-b6ca-50c3cf36fa03" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.optinose.com/role/LeasesOperatingleasematuritiesDetails" xlink:type="simple" xlink:href="optn-20221231.xsd#LeasesOperatingleasematuritiesDetails"/>
  <link:calculationLink xlink:role="http://www.optinose.com/role/LeasesOperatingleasematuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_972ec262-704d-4a1c-baea-d9193779fe3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_59b11fc3-1b51-41b8-89c7-52095a72aeae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_972ec262-704d-4a1c-baea-d9193779fe3b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_59b11fc3-1b51-41b8-89c7-52095a72aeae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_d03477b9-ef49-4869-922d-8816833ae0a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_972ec262-704d-4a1c-baea-d9193779fe3b" xlink:to="loc_us-gaap_OperatingLeaseLiability_d03477b9-ef49-4869-922d-8816833ae0a8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.optinose.com/role/LeasesOperatingleasematuritiesDetails_1" xlink:type="simple" xlink:href="optn-20221231.xsd#LeasesOperatingleasematuritiesDetails_1"/>
  <link:calculationLink xlink:role="http://www.optinose.com/role/LeasesOperatingleasematuritiesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_894d7030-5f36-4588-a00c-1d4b1c9e6889" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_1c3cb6a5-5375-4149-8b1a-c6baf7e569fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_894d7030-5f36-4588-a00c-1d4b1c9e6889" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_1c3cb6a5-5375-4149-8b1a-c6baf7e569fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_0ece3f7e-c809-475f-9a89-59136624383f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_894d7030-5f36-4588-a00c-1d4b1c9e6889" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_0ece3f7e-c809-475f-9a89-59136624383f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_45c41b0b-6438-4f7e-93ab-a8788cc4f822" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_894d7030-5f36-4588-a00c-1d4b1c9e6889" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_45c41b0b-6438-4f7e-93ab-a8788cc4f822" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_LesseeOperatingLeaseLiabilityPaymentsDueThereafter_24d656b9-a725-46ef-ba61-c1fe7c7c4b06" xlink:href="optn-20221231.xsd#optn_LesseeOperatingLeaseLiabilityPaymentsDueThereafter"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_894d7030-5f36-4588-a00c-1d4b1c9e6889" xlink:to="loc_optn_LesseeOperatingLeaseLiabilityPaymentsDueThereafter_24d656b9-a725-46ef-ba61-c1fe7c7c4b06" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.optinose.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="optn-20221231.xsd#AccruedExpensesandOtherCurrentLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.optinose.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_3a0f6945-f262-4fc2-b4db-8d103303bc15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_392dd11f-0c5e-4e07-a8ee-e1f2aa75f1c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_3a0f6945-f262-4fc2-b4db-8d103303bc15" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_392dd11f-0c5e-4e07-a8ee-e1f2aa75f1c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_7e1cacc1-c2a1-4522-ab5b-629c6dc9bdef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_3a0f6945-f262-4fc2-b4db-8d103303bc15" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_7e1cacc1-c2a1-4522-ab5b-629c6dc9bdef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_0d024e60-70f9-44ef-a342-988ae8945c9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_AccruedResearchandDevelopmentCurrent_f1f61a4e-0862-4c38-bf62-ff591d6e318c" xlink:href="optn-20221231.xsd#optn_AccruedResearchandDevelopmentCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_0d024e60-70f9-44ef-a342-988ae8945c9f" xlink:to="loc_optn_AccruedResearchandDevelopmentCurrent_f1f61a4e-0862-4c38-bf62-ff591d6e318c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_AccruedSellingGeneralandAdministrativeCurrent_1215ab2e-daa0-49fe-868d-352c064bebda" xlink:href="optn-20221231.xsd#optn_AccruedSellingGeneralandAdministrativeCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_0d024e60-70f9-44ef-a342-988ae8945c9f" xlink:to="loc_optn_AccruedSellingGeneralandAdministrativeCurrent_1215ab2e-daa0-49fe-868d-352c064bebda" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_d977309e-8f2a-48e4-9b5f-9febd9631cc5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_0d024e60-70f9-44ef-a342-988ae8945c9f" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_d977309e-8f2a-48e4-9b5f-9febd9631cc5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent_e0fc0f5a-e845-4ad1-8b8d-0ca0ab41bacc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_0d024e60-70f9-44ef-a342-988ae8945c9f" xlink:to="loc_us-gaap_AccruedEmployeeBenefitsCurrent_e0fc0f5a-e845-4ad1-8b8d-0ca0ab41bacc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_AccruedProductAllowancesCurrent_2d814cdc-e9f0-41b7-a67d-68a0e3533346" xlink:href="optn-20221231.xsd#optn_AccruedProductAllowancesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_0d024e60-70f9-44ef-a342-988ae8945c9f" xlink:to="loc_optn_AccruedProductAllowancesCurrent_2d814cdc-e9f0-41b7-a67d-68a0e3533346" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_ef389270-0605-4455-8106-d0b3b01ba829" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_c8710920-dac4-4255-b478-2cd05415f491" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_ef389270-0605-4455-8106-d0b3b01ba829" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_c8710920-dac4-4255-b478-2cd05415f491" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.optinose.com/role/DebtnetScheduleoflongtermdebtDetails" xlink:type="simple" xlink:href="optn-20221231.xsd#DebtnetScheduleoflongtermdebtDetails"/>
  <link:calculationLink xlink:role="http://www.optinose.com/role/DebtnetScheduleoflongtermdebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_75e7f9c6-d43d-4cd4-a9be-658faf81ad0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnamortizedDebtIssuanceExpense_4e035f1b-b33f-493d-bce8-7b985bb567d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnamortizedDebtIssuanceExpense"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_75e7f9c6-d43d-4cd4-a9be-658faf81ad0b" xlink:to="loc_us-gaap_UnamortizedDebtIssuanceExpense_4e035f1b-b33f-493d-bce8-7b985bb567d2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_4186bbd1-c0fd-4fdb-9819-c2e6e900053f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_75e7f9c6-d43d-4cd4-a9be-658faf81ad0b" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_4186bbd1-c0fd-4fdb-9819-c2e6e900053f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_DebtInstrumentFeeAmountFrontEnd_dbe7c8ab-9167-4f7e-bc06-71b95253d12c" xlink:href="optn-20221231.xsd#optn_DebtInstrumentFeeAmountFrontEnd"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_75e7f9c6-d43d-4cd4-a9be-658faf81ad0b" xlink:to="loc_optn_DebtInstrumentFeeAmountFrontEnd_dbe7c8ab-9167-4f7e-bc06-71b95253d12c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_DebtInstrumentFeeAmountBackEnd_eb6fc971-29db-4c30-9834-ac3703c9c8b4" xlink:href="optn-20221231.xsd#optn_DebtInstrumentFeeAmountBackEnd"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_75e7f9c6-d43d-4cd4-a9be-658faf81ad0b" xlink:to="loc_optn_DebtInstrumentFeeAmountBackEnd_eb6fc971-29db-4c30-9834-ac3703c9c8b4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.optinose.com/role/IncomeTaxesScheduleofincomebeforeincometaxdomesticandforeignDetails" xlink:type="simple" xlink:href="optn-20221231.xsd#IncomeTaxesScheduleofincomebeforeincometaxdomesticandforeignDetails"/>
  <link:calculationLink xlink:role="http://www.optinose.com/role/IncomeTaxesScheduleofincomebeforeincometaxdomesticandforeignDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_3d19f8db-414a-4c3b-ba0c-2e823fd36c92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_b9dfba34-0557-4fc5-b8a8-c528b17d88ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_3d19f8db-414a-4c3b-ba0c-2e823fd36c92" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_b9dfba34-0557-4fc5-b8a8-c528b17d88ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_634a10a7-7521-4691-97a2-e51b1a8353c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_3d19f8db-414a-4c3b-ba0c-2e823fd36c92" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_634a10a7-7521-4691-97a2-e51b1a8353c5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.optinose.com/role/IncomeTaxesScheduleofeffectiveincometaxratereconciliationDetails" xlink:type="simple" xlink:href="optn-20221231.xsd#IncomeTaxesScheduleofeffectiveincometaxratereconciliationDetails"/>
  <link:calculationLink xlink:role="http://www.optinose.com/role/IncomeTaxesScheduleofeffectiveincometaxratereconciliationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_0d006fcc-bf03-4a4f-9b74-dd9557792903" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1c0613ed-e4aa-4334-ab33-a254b50bb491" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_0d006fcc-bf03-4a4f-9b74-dd9557792903" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1c0613ed-e4aa-4334-ab33-a254b50bb491" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_27610f04-7227-42ad-a962-5c636d708248" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_0d006fcc-bf03-4a4f-9b74-dd9557792903" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_27610f04-7227-42ad-a962-5c636d708248" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_3a191ad7-1e77-43ce-b3cf-a1788a631905" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_0d006fcc-bf03-4a4f-9b74-dd9557792903" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_3a191ad7-1e77-43ce-b3cf-a1788a631905" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_3cda83f9-5683-4a3f-8895-5f8d6b4108b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_0d006fcc-bf03-4a4f-9b74-dd9557792903" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_3cda83f9-5683-4a3f-8895-5f8d6b4108b7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_46b96680-3f7a-4850-b6e3-99bbce11f65d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_0d006fcc-bf03-4a4f-9b74-dd9557792903" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_46b96680-3f7a-4850-b6e3-99bbce11f65d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_43cb8bff-75f1-4cae-befc-856c8c9255d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_0d006fcc-bf03-4a4f-9b74-dd9557792903" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_43cb8bff-75f1-4cae-befc-856c8c9255d6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_EffectiveIncomeTaxRateReconciliationForeignExchangeOtherPercent_f657b680-4b6a-4999-9b42-afdd0cdcc682" xlink:href="optn-20221231.xsd#optn_EffectiveIncomeTaxRateReconciliationForeignExchangeOtherPercent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_0d006fcc-bf03-4a4f-9b74-dd9557792903" xlink:to="loc_optn_EffectiveIncomeTaxRateReconciliationForeignExchangeOtherPercent_f657b680-4b6a-4999-9b42-afdd0cdcc682" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_EffectiveIncomeTaxRateReconciliationForeignOperationsImpactPercent_617d9b7b-11d0-4f25-9568-8c16a5806382" xlink:href="optn-20221231.xsd#optn_EffectiveIncomeTaxRateReconciliationForeignOperationsImpactPercent"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_0d006fcc-bf03-4a4f-9b74-dd9557792903" xlink:to="loc_optn_EffectiveIncomeTaxRateReconciliationForeignOperationsImpactPercent_617d9b7b-11d0-4f25-9568-8c16a5806382" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_fa932216-f36b-4199-8677-066d0af98764" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_0d006fcc-bf03-4a4f-9b74-dd9557792903" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_fa932216-f36b-4199-8677-066d0af98764" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_EffectiveIncomeTaxRateReconciliationPrepaidRoyaltyWriteOffPercent_5e232141-dfb6-43c9-a43c-689e37990d37" xlink:href="optn-20221231.xsd#optn_EffectiveIncomeTaxRateReconciliationPrepaidRoyaltyWriteOffPercent"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_0d006fcc-bf03-4a4f-9b74-dd9557792903" xlink:to="loc_optn_EffectiveIncomeTaxRateReconciliationPrepaidRoyaltyWriteOffPercent_5e232141-dfb6-43c9-a43c-689e37990d37" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.optinose.com/role/IncomeTaxesScheduleofdeferredtaxassetsandliabilitiesDetails" xlink:type="simple" xlink:href="optn-20221231.xsd#IncomeTaxesScheduleofdeferredtaxassetsandliabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.optinose.com/role/IncomeTaxesScheduleofdeferredtaxassetsandliabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_5a55a1b1-fcaa-4e14-9cd8-0e3419a99f1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_DeferredTaxAssetsFinancingCosts_d7aa81c5-88dc-4e53-90d7-a6768bdedeac" xlink:href="optn-20221231.xsd#optn_DeferredTaxAssetsFinancingCosts"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_5a55a1b1-fcaa-4e14-9cd8-0e3419a99f1f" xlink:to="loc_optn_DeferredTaxAssetsFinancingCosts_d7aa81c5-88dc-4e53-90d7-a6768bdedeac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_54a0958d-d37a-4e39-88c4-ef419417d4bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_5a55a1b1-fcaa-4e14-9cd8-0e3419a99f1f" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_54a0958d-d37a-4e39-88c4-ef419417d4bf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_DeferredTaxAssetsInterestExpense_716e3d32-67b8-435b-ab6e-69d9f47191c7" xlink:href="optn-20221231.xsd#optn_DeferredTaxAssetsInterestExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_5a55a1b1-fcaa-4e14-9cd8-0e3419a99f1f" xlink:to="loc_optn_DeferredTaxAssetsInterestExpense_716e3d32-67b8-435b-ab6e-69d9f47191c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpense_5e637525-9e29-4cb5-a6cb-3aad12dbbb00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_5a55a1b1-fcaa-4e14-9cd8-0e3419a99f1f" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpense_5e637525-9e29-4cb5-a6cb-3aad12dbbb00" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_DeferredTaxAssetsPrepaidLicenseArrangement_67b9b2bc-b3fd-495c-9f2a-e9c125140c62" xlink:href="optn-20221231.xsd#optn_DeferredTaxAssetsPrepaidLicenseArrangement"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_5a55a1b1-fcaa-4e14-9cd8-0e3419a99f1f" xlink:to="loc_optn_DeferredTaxAssetsPrepaidLicenseArrangement_67b9b2bc-b3fd-495c-9f2a-e9c125140c62" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_d2e3c284-dfda-4740-9e52-e29a6df6ae95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_5a55a1b1-fcaa-4e14-9cd8-0e3419a99f1f" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_d2e3c284-dfda-4740-9e52-e29a6df6ae95" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_6f4822bb-f27a-4cc4-bc6b-dd4e508fef23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_5a55a1b1-fcaa-4e14-9cd8-0e3419a99f1f" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_6f4822bb-f27a-4cc4-bc6b-dd4e508fef23" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_DeferredTaxAssetsLeasingArrangement_495cd812-d4e3-49af-8a11-9da2425efe31" xlink:href="optn-20221231.xsd#optn_DeferredTaxAssetsLeasingArrangement"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_5a55a1b1-fcaa-4e14-9cd8-0e3419a99f1f" xlink:to="loc_optn_DeferredTaxAssetsLeasingArrangement_495cd812-d4e3-49af-8a11-9da2425efe31" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_910e11e9-0a1c-4317-81cf-8012d418a537" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_6ac3526b-b2e7-4118-a699-2729e62b1437" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_910e11e9-0a1c-4317-81cf-8012d418a537" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_6ac3526b-b2e7-4118-a699-2729e62b1437" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_c67491c7-4e3f-4df7-8637-0385fd817f96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_910e11e9-0a1c-4317-81cf-8012d418a537" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_c67491c7-4e3f-4df7-8637-0385fd817f96" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_7eb6fce1-8a85-4f64-8ccb-2424f1eb5fea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_bb3956d7-a1be-4795-8019-533b911a1b62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_7eb6fce1-8a85-4f64-8ccb-2424f1eb5fea" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_bb3956d7-a1be-4795-8019-533b911a1b62" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_0a0c00aa-0c3a-4e84-aaec-c80ec7ffc78b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_7eb6fce1-8a85-4f64-8ccb-2424f1eb5fea" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_0a0c00aa-0c3a-4e84-aaec-c80ec7ffc78b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_c0259629-5d4f-4634-954d-e1512ecf130c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_7eb6fce1-8a85-4f64-8ccb-2424f1eb5fea" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_c0259629-5d4f-4634-954d-e1512ecf130c" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>12
<FILENAME>optn-20221231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:738bcfbc-a4cb-4b05-a396-7d259cbbc32b,g:9b54bffb-0962-498f-9b57-5d3747805ca8-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.optinose.com/role/ConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="optn-20221231.xsd#ConsolidatedStatementsofOperations"/>
  <link:definitionLink xlink:role="http://www.optinose.com/role/ConsolidatedStatementsofOperations" xlink:type="extended" id="i5e3038a5f1e044eda2ac0ec926049267_ConsolidatedStatementsofOperations">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_31dc93ea-3d66-4cf1-8c90-82aaa784f58d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_73633cab-ae77-40ae-bc3c-38fa8c00af02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_31dc93ea-3d66-4cf1-8c90-82aaa784f58d" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_73633cab-ae77-40ae-bc3c-38fa8c00af02" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_f58087b4-3fbb-46ce-ac0d-d2c1e0db979b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_31dc93ea-3d66-4cf1-8c90-82aaa784f58d" xlink:to="loc_us-gaap_OperatingExpensesAbstract_f58087b4-3fbb-46ce-ac0d-d2c1e0db979b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_09634b0c-0d5a-420e-955c-18c061677ac5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_f58087b4-3fbb-46ce-ac0d-d2c1e0db979b" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_09634b0c-0d5a-420e-955c-18c061677ac5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_340a3f9a-517a-4676-beb9-9669e0b33113" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_f58087b4-3fbb-46ce-ac0d-d2c1e0db979b" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_340a3f9a-517a-4676-beb9-9669e0b33113" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_375f469f-048f-446a-b1bb-5b9c99aa75f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_f58087b4-3fbb-46ce-ac0d-d2c1e0db979b" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_375f469f-048f-446a-b1bb-5b9c99aa75f9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_5c866246-655c-403d-9b38-46109b8b6f9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_f58087b4-3fbb-46ce-ac0d-d2c1e0db979b" xlink:to="loc_us-gaap_CostsAndExpenses_5c866246-655c-403d-9b38-46109b8b6f9c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_a13d3e09-160d-47b2-95ab-a2204f1c656d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_31dc93ea-3d66-4cf1-8c90-82aaa784f58d" xlink:to="loc_us-gaap_OperatingIncomeLoss_a13d3e09-160d-47b2-95ab-a2204f1c656d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_f4daba37-3f20-471a-a63a-636bb2595bc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_31dc93ea-3d66-4cf1-8c90-82aaa784f58d" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_f4daba37-3f20-471a-a63a-636bb2595bc3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_UnrealizedGainLossOnFairValueOfWarrants_a5bc5785-45e5-4f3b-8c9d-aad162569507" xlink:href="optn-20221231.xsd#optn_UnrealizedGainLossOnFairValueOfWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_f4daba37-3f20-471a-a63a-636bb2595bc3" xlink:to="loc_optn_UnrealizedGainLossOnFairValueOfWarrants_a5bc5785-45e5-4f3b-8c9d-aad162569507" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_GrantAndOtherIncome_281ef494-4668-4018-9579-2b4ca446c8d4" xlink:href="optn-20221231.xsd#optn_GrantAndOtherIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_f4daba37-3f20-471a-a63a-636bb2595bc3" xlink:to="loc_optn_GrantAndOtherIncome_281ef494-4668-4018-9579-2b4ca446c8d4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_63744cda-5f00-451c-a3a8-69e652d3bcdf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_f4daba37-3f20-471a-a63a-636bb2595bc3" xlink:to="loc_us-gaap_InvestmentIncomeInterest_63744cda-5f00-451c-a3a8-69e652d3bcdf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_b8cf1098-b246-460f-974c-4dbdbc173882" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_f4daba37-3f20-471a-a63a-636bb2595bc3" xlink:to="loc_us-gaap_InterestExpense_b8cf1098-b246-460f-974c-4dbdbc173882" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_6a7fa52f-a4ad-44b8-a69a-3d8ad05887b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_31dc93ea-3d66-4cf1-8c90-82aaa784f58d" xlink:to="loc_us-gaap_NetIncomeLoss_6a7fa52f-a4ad-44b8-a69a-3d8ad05887b2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_1c9536ce-ad02-4428-b6f3-fdb03619606d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_31dc93ea-3d66-4cf1-8c90-82aaa784f58d" xlink:to="loc_us-gaap_EarningsPerShareBasic_1c9536ce-ad02-4428-b6f3-fdb03619606d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_d83c3ab3-1943-40c1-9de2-014870ae42cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_31dc93ea-3d66-4cf1-8c90-82aaa784f58d" xlink:to="loc_us-gaap_EarningsPerShareDiluted_d83c3ab3-1943-40c1-9de2-014870ae42cb" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_eed85cc8-49bd-4100-b110-1b4117906129" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_31dc93ea-3d66-4cf1-8c90-82aaa784f58d" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_eed85cc8-49bd-4100-b110-1b4117906129" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2d2b95c4-41bb-42c5-b47d-7d428687c2b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_31dc93ea-3d66-4cf1-8c90-82aaa784f58d" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2d2b95c4-41bb-42c5-b47d-7d428687c2b4" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_58656ea1-d0aa-46be-90c7-20730d0bed12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_31dc93ea-3d66-4cf1-8c90-82aaa784f58d" xlink:to="loc_us-gaap_StatementTable_58656ea1-d0aa-46be-90c7-20730d0bed12" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_38e6fc05-5515-4253-83a2-862200f50f69" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_58656ea1-d0aa-46be-90c7-20730d0bed12" xlink:to="loc_srt_ProductOrServiceAxis_38e6fc05-5515-4253-83a2-862200f50f69" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_38e6fc05-5515-4253-83a2-862200f50f69_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_38e6fc05-5515-4253-83a2-862200f50f69" xlink:to="loc_srt_ProductsAndServicesDomain_38e6fc05-5515-4253-83a2-862200f50f69_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_92e3e8f6-d0e1-4fee-9d50-a4c6925bdab0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_38e6fc05-5515-4253-83a2-862200f50f69" xlink:to="loc_srt_ProductsAndServicesDomain_92e3e8f6-d0e1-4fee-9d50-a4c6925bdab0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_c38a2e92-fe2a-4208-9a55-2f1b4c0071a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_92e3e8f6-d0e1-4fee-9d50-a4c6925bdab0" xlink:to="loc_us-gaap_ProductMember_c38a2e92-fe2a-4208-9a55-2f1b4c0071a7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_f7ea6c26-5437-4c7a-b933-61ce75e28280" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_92e3e8f6-d0e1-4fee-9d50-a4c6925bdab0" xlink:to="loc_us-gaap_LicenseMember_f7ea6c26-5437-4c7a-b933-61ce75e28280" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.optinose.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit" xlink:type="simple" xlink:href="optn-20221231.xsd#ConsolidatedStatementsofChangesinStockholdersEquityDeficit"/>
  <link:definitionLink xlink:role="http://www.optinose.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit" xlink:type="extended" id="ifcd4137430654bbc91985f01adaa0096_ConsolidatedStatementsofChangesinStockholdersEquityDeficit">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_4791b288-60b9-47cf-8597-1067ef9be3e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_12ab529b-3609-4f45-b73e-fb51c56c6da5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4791b288-60b9-47cf-8597-1067ef9be3e5" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_12ab529b-3609-4f45-b73e-fb51c56c6da5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_e4f07065-81cf-420a-864c-14989d9189ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_12ab529b-3609-4f45-b73e-fb51c56c6da5" xlink:to="loc_us-gaap_StockholdersEquity_e4f07065-81cf-420a-864c-14989d9189ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_e60907f6-1ce3-4833-befc-aac2fc7e9b3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_12ab529b-3609-4f45-b73e-fb51c56c6da5" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_e60907f6-1ce3-4833-befc-aac2fc7e9b3c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_963c9a33-5610-4a24-ab8e-3679d1644224" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_12ab529b-3609-4f45-b73e-fb51c56c6da5" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_963c9a33-5610-4a24-ab8e-3679d1644224" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_StockIssuedDuringPeriodVestedRestrictedStockUnits_93a4bc98-05b1-46ea-b0e6-68149091c725" xlink:href="optn-20221231.xsd#optn_StockIssuedDuringPeriodVestedRestrictedStockUnits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_12ab529b-3609-4f45-b73e-fb51c56c6da5" xlink:to="loc_optn_StockIssuedDuringPeriodVestedRestrictedStockUnits_93a4bc98-05b1-46ea-b0e6-68149091c725" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_StockIssuedDuringPeriodSharesVestedRestrictedStockUnits_4b3c3a7e-b939-4692-84c3-521ad9e9cdfb" xlink:href="optn-20221231.xsd#optn_StockIssuedDuringPeriodSharesVestedRestrictedStockUnits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_12ab529b-3609-4f45-b73e-fb51c56c6da5" xlink:to="loc_optn_StockIssuedDuringPeriodSharesVestedRestrictedStockUnits_4b3c3a7e-b939-4692-84c3-521ad9e9cdfb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_c9f55fda-3e81-404b-8941-0f1e3680a33c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_12ab529b-3609-4f45-b73e-fb51c56c6da5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_c9f55fda-3e81-404b-8941-0f1e3680a33c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_45f10ca9-b163-47d3-8fec-f046c6dd37fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_12ab529b-3609-4f45-b73e-fb51c56c6da5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_45f10ca9-b163-47d3-8fec-f046c6dd37fc" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_52136aa7-5d4b-49f2-96d8-b831733cf5e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_12ab529b-3609-4f45-b73e-fb51c56c6da5" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_52136aa7-5d4b-49f2-96d8-b831733cf5e3" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_97559801-0aa9-4b89-8780-039f8d07fd23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_12ab529b-3609-4f45-b73e-fb51c56c6da5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_97559801-0aa9-4b89-8780-039f8d07fd23" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_8aba943d-8f1d-47bd-92e5-1027af50dee9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_12ab529b-3609-4f45-b73e-fb51c56c6da5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_8aba943d-8f1d-47bd-92e5-1027af50dee9" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan_31ad68fb-378e-4a0f-bb7e-b6816465063a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_12ab529b-3609-4f45-b73e-fb51c56c6da5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan_31ad68fb-378e-4a0f-bb7e-b6816465063a" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan_f6c4ab45-15d1-4f3e-9b36-624bf589dc94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_12ab529b-3609-4f45-b73e-fb51c56c6da5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan_f6c4ab45-15d1-4f3e-9b36-624bf589dc94" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_4e6a0f0a-17ed-41ad-be26-3f557e2d2c92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_12ab529b-3609-4f45-b73e-fb51c56c6da5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_4e6a0f0a-17ed-41ad-be26-3f557e2d2c92" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_ba48f130-7ae2-4b16-970c-dc599025d690" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_12ab529b-3609-4f45-b73e-fb51c56c6da5" xlink:to="loc_us-gaap_NetIncomeLoss_ba48f130-7ae2-4b16-970c-dc599025d690" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_d1e1a9ab-2d5e-4b9d-9344-2e1de0aa37dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_0d2c0f01-5114-4471-8f4c-b53dee94dbeb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_8f3e2b10-9464-4c8f-ba75-de3d2c2c84d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_4791b288-60b9-47cf-8597-1067ef9be3e5" xlink:to="loc_us-gaap_StatementTable_8f3e2b10-9464-4c8f-ba75-de3d2c2c84d4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2f15a7bd-c269-4b6a-aeda-d5c35126e6a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_8f3e2b10-9464-4c8f-ba75-de3d2c2c84d4" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2f15a7bd-c269-4b6a-aeda-d5c35126e6a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_2f15a7bd-c269-4b6a-aeda-d5c35126e6a7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2f15a7bd-c269-4b6a-aeda-d5c35126e6a7" xlink:to="loc_us-gaap_EquityComponentDomain_2f15a7bd-c269-4b6a-aeda-d5c35126e6a7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_87764d65-eaf8-4135-bde5-e2d827759e90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2f15a7bd-c269-4b6a-aeda-d5c35126e6a7" xlink:to="loc_us-gaap_EquityComponentDomain_87764d65-eaf8-4135-bde5-e2d827759e90" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_4d28deac-f991-4259-bf23-53084bbecb6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_87764d65-eaf8-4135-bde5-e2d827759e90" xlink:to="loc_us-gaap_CommonStockMember_4d28deac-f991-4259-bf23-53084bbecb6e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_63fd44b0-f94a-4ab0-84db-0316fb6d22c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_87764d65-eaf8-4135-bde5-e2d827759e90" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_63fd44b0-f94a-4ab0-84db-0316fb6d22c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_dd44f19d-d937-45ba-a805-e997c3ae3194" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_87764d65-eaf8-4135-bde5-e2d827759e90" xlink:to="loc_us-gaap_RetainedEarningsMember_dd44f19d-d937-45ba-a805-e997c3ae3194" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_f6384a81-cf1f-49a8-b273-cd6539c1c449" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_87764d65-eaf8-4135-bde5-e2d827759e90" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_f6384a81-cf1f-49a8-b273-cd6539c1c449" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.optinose.com/role/LiquidityNarrativeDetails" xlink:type="simple" xlink:href="optn-20221231.xsd#LiquidityNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.optinose.com/role/LiquidityNarrativeDetails" xlink:type="extended" id="id1a3c1c89d1c44fbb2d548363c7257f5_LiquidityNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_505c2e59-8f2f-4453-87d3-23fbb561c159" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_dab71fc1-4dea-446c-ba87-4ec7651f86db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_505c2e59-8f2f-4453-87d3-23fbb561c159" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_dab71fc1-4dea-446c-ba87-4ec7651f86db" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_WorkingCapital_982bc1fe-4ecb-4a90-a615-1989822bfd6a" xlink:href="optn-20221231.xsd#optn_WorkingCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_505c2e59-8f2f-4453-87d3-23fbb561c159" xlink:to="loc_optn_WorkingCapital_982bc1fe-4ecb-4a90-a615-1989822bfd6a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_bf21c44a-2357-48a9-a00f-e787ba933236" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_505c2e59-8f2f-4453-87d3-23fbb561c159" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_bf21c44a-2357-48a9-a00f-e787ba933236" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayable_bfbd45d2-8384-4969-8c2d-5aa11b8c5515" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_505c2e59-8f2f-4453-87d3-23fbb561c159" xlink:to="loc_us-gaap_NotesPayable_bfbd45d2-8384-4969-8c2d-5aa11b8c5515" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_DebtInstrumentCovenantCashAndCashEquivalents_0085e662-cb8b-4d82-a40a-f1016968854f" xlink:href="optn-20221231.xsd#optn_DebtInstrumentCovenantCashAndCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_505c2e59-8f2f-4453-87d3-23fbb561c159" xlink:to="loc_optn_DebtInstrumentCovenantCashAndCashEquivalents_0085e662-cb8b-4d82-a40a-f1016968854f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_c1b1d824-8848-48cf-ad83-1b56768d284c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_505c2e59-8f2f-4453-87d3-23fbb561c159" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_c1b1d824-8848-48cf-ad83-1b56768d284c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_667dd1ab-8d82-475a-b135-b264065aba09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_c1b1d824-8848-48cf-ad83-1b56768d284c" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_667dd1ab-8d82-475a-b135-b264065aba09" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_667dd1ab-8d82-475a-b135-b264065aba09_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_667dd1ab-8d82-475a-b135-b264065aba09" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_667dd1ab-8d82-475a-b135-b264065aba09_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_915957a1-6539-4e88-8325-bc64dc2b636c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_667dd1ab-8d82-475a-b135-b264065aba09" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_915957a1-6539-4e88-8325-bc64dc2b636c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_97b5590f-79c4-46dc-91f5-5aa76cfd96c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_915957a1-6539-4e88-8325-bc64dc2b636c" xlink:to="loc_us-gaap_SeniorNotesMember_97b5590f-79c4-46dc-91f5-5aa76cfd96c6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_00bd15ea-b56d-499c-bfa5-dd74a651bce2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_c1b1d824-8848-48cf-ad83-1b56768d284c" xlink:to="loc_us-gaap_DebtInstrumentAxis_00bd15ea-b56d-499c-bfa5-dd74a651bce2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_00bd15ea-b56d-499c-bfa5-dd74a651bce2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_00bd15ea-b56d-499c-bfa5-dd74a651bce2" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_00bd15ea-b56d-499c-bfa5-dd74a651bce2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_e397c2c9-82a5-4593-a68e-f80cde87c64b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_00bd15ea-b56d-499c-bfa5-dd74a651bce2" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_e397c2c9-82a5-4593-a68e-f80cde87c64b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_NotePurchaseAgreementMember_1c1901c5-9b50-49f3-9845-55c9a5afecbc" xlink:href="optn-20221231.xsd#optn_NotePurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e397c2c9-82a5-4593-a68e-f80cde87c64b" xlink:to="loc_optn_NotePurchaseAgreementMember_1c1901c5-9b50-49f3-9845-55c9a5afecbc" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.optinose.com/role/SummaryofSignificantAccountingPoliciesConcentrationriskDetails" xlink:type="simple" xlink:href="optn-20221231.xsd#SummaryofSignificantAccountingPoliciesConcentrationriskDetails"/>
  <link:definitionLink xlink:role="http://www.optinose.com/role/SummaryofSignificantAccountingPoliciesConcentrationriskDetails" xlink:type="extended" id="i326c083c6a07452bb4e4cf3292667ca3_SummaryofSignificantAccountingPoliciesConcentrationriskDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_e264c9fa-7231-4cf1-b074-e5715df443c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_NumberOfCustomers_3d9cc762-37a6-4237-a4ab-36212400858e" xlink:href="optn-20221231.xsd#optn_NumberOfCustomers"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_e264c9fa-7231-4cf1-b074-e5715df443c0" xlink:to="loc_optn_NumberOfCustomers_3d9cc762-37a6-4237-a4ab-36212400858e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_685e6462-179a-4d54-ada2-1ffb8cc9c248" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_e264c9fa-7231-4cf1-b074-e5715df443c0" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_685e6462-179a-4d54-ada2-1ffb8cc9c248" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_9effa335-fec0-4d89-9b3a-d53e845fcce3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_e264c9fa-7231-4cf1-b074-e5715df443c0" xlink:to="loc_us-gaap_ConcentrationRiskTable_9effa335-fec0-4d89-9b3a-d53e845fcce3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_79d78d0d-1b59-4a07-901f-57ed97290f43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_9effa335-fec0-4d89-9b3a-d53e845fcce3" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_79d78d0d-1b59-4a07-901f-57ed97290f43" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_79d78d0d-1b59-4a07-901f-57ed97290f43_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_79d78d0d-1b59-4a07-901f-57ed97290f43" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_79d78d0d-1b59-4a07-901f-57ed97290f43_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_df20937a-5f39-4abe-8984-a1cf27bc0d9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_79d78d0d-1b59-4a07-901f-57ed97290f43" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_df20937a-5f39-4abe-8984-a1cf27bc0d9a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_fde23558-93a7-4a40-9d0e-5203a744a39c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_df20937a-5f39-4abe-8984-a1cf27bc0d9a" xlink:to="loc_us-gaap_AccountsReceivableMember_fde23558-93a7-4a40-9d0e-5203a744a39c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_7938f2d2-f42a-4c3b-a760-83d5989ea8a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_df20937a-5f39-4abe-8984-a1cf27bc0d9a" xlink:to="loc_us-gaap_SalesRevenueNetMember_7938f2d2-f42a-4c3b-a760-83d5989ea8a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_5a3e27df-37ea-48f9-bacf-f6c5e411413b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_9effa335-fec0-4d89-9b3a-d53e845fcce3" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_5a3e27df-37ea-48f9-bacf-f6c5e411413b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_5a3e27df-37ea-48f9-bacf-f6c5e411413b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_5a3e27df-37ea-48f9-bacf-f6c5e411413b" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_5a3e27df-37ea-48f9-bacf-f6c5e411413b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_4872274b-0bc0-4239-a9df-0aa8e03bd622" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_5a3e27df-37ea-48f9-bacf-f6c5e411413b" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_4872274b-0bc0-4239-a9df-0aa8e03bd622" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_87834a67-9bfe-40e8-9d57-2ad5c86fff4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_4872274b-0bc0-4239-a9df-0aa8e03bd622" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_87834a67-9bfe-40e8-9d57-2ad5c86fff4d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_c683d180-a0b3-4c4b-8540-77b56d725eee" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_9effa335-fec0-4d89-9b3a-d53e845fcce3" xlink:to="loc_srt_MajorCustomersAxis_c683d180-a0b3-4c4b-8540-77b56d725eee" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_c683d180-a0b3-4c4b-8540-77b56d725eee_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_c683d180-a0b3-4c4b-8540-77b56d725eee" xlink:to="loc_srt_NameOfMajorCustomerDomain_c683d180-a0b3-4c4b-8540-77b56d725eee_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_2ab09996-d2b0-4dc6-bdde-7944078bed4a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_c683d180-a0b3-4c4b-8540-77b56d725eee" xlink:to="loc_srt_NameOfMajorCustomerDomain_2ab09996-d2b0-4dc6-bdde-7944078bed4a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_FiveCustomersMember_42076563-dd56-4295-9354-b6b251cf22e9" xlink:href="optn-20221231.xsd#optn_FiveCustomersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_2ab09996-d2b0-4dc6-bdde-7944078bed4a" xlink:to="loc_optn_FiveCustomersMember_42076563-dd56-4295-9354-b6b251cf22e9" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.optinose.com/role/SummaryofSignificantAccountingPoliciesPropertyandequipmentDetails" xlink:type="simple" xlink:href="optn-20221231.xsd#SummaryofSignificantAccountingPoliciesPropertyandequipmentDetails"/>
  <link:definitionLink xlink:role="http://www.optinose.com/role/SummaryofSignificantAccountingPoliciesPropertyandequipmentDetails" xlink:type="extended" id="i73a002ea3a49412fbbadf3354ab3a593_SummaryofSignificantAccountingPoliciesPropertyandequipmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cf3d4762-6680-4c74-819e-777d512e342d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_1112789e-04dd-447d-a61e-918780e66d92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cf3d4762-6680-4c74-819e-777d512e342d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_1112789e-04dd-447d-a61e-918780e66d92" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_29173d47-6fe6-4caf-b075-0e6f92a1f874" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cf3d4762-6680-4c74-819e-777d512e342d" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_29173d47-6fe6-4caf-b075-0e6f92a1f874" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_81819585-e5cd-454d-942a-737a23162843" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_29173d47-6fe6-4caf-b075-0e6f92a1f874" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_81819585-e5cd-454d-942a-737a23162843" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_81819585-e5cd-454d-942a-737a23162843_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_81819585-e5cd-454d-942a-737a23162843" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_81819585-e5cd-454d-942a-737a23162843_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a6ef0a1d-60eb-4445-92b0-9fc92d581755" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_81819585-e5cd-454d-942a-737a23162843" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a6ef0a1d-60eb-4445-92b0-9fc92d581755" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_25f8d453-d61f-434e-a34f-3ce0afcb4db9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a6ef0a1d-60eb-4445-92b0-9fc92d581755" xlink:to="loc_us-gaap_ComputerEquipmentMember_25f8d453-d61f-434e-a34f-3ce0afcb4db9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_47490df9-91a7-4561-bf68-7123bf0bc9b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a6ef0a1d-60eb-4445-92b0-9fc92d581755" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_47490df9-91a7-4561-bf68-7123bf0bc9b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_117efef7-41ef-499b-a7a2-ac0baedf44df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a6ef0a1d-60eb-4445-92b0-9fc92d581755" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_117efef7-41ef-499b-a7a2-ac0baedf44df" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_d6d81063-e7d1-4ec6-aed3-89a0ab54bd80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a6ef0a1d-60eb-4445-92b0-9fc92d581755" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_d6d81063-e7d1-4ec6-aed3-89a0ab54bd80" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_6792bc8f-d970-442d-85b5-b32212d3aec4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_29173d47-6fe6-4caf-b075-0e6f92a1f874" xlink:to="loc_srt_RangeAxis_6792bc8f-d970-442d-85b5-b32212d3aec4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6792bc8f-d970-442d-85b5-b32212d3aec4_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_6792bc8f-d970-442d-85b5-b32212d3aec4" xlink:to="loc_srt_RangeMember_6792bc8f-d970-442d-85b5-b32212d3aec4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d41dea6c-1399-4829-85bd-f668f0f13d71" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_6792bc8f-d970-442d-85b5-b32212d3aec4" xlink:to="loc_srt_RangeMember_d41dea6c-1399-4829-85bd-f668f0f13d71" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_804decd7-9554-45c1-906c-fe59025634ef" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_d41dea6c-1399-4829-85bd-f668f0f13d71" xlink:to="loc_srt_MinimumMember_804decd7-9554-45c1-906c-fe59025634ef" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_d0b6bb13-c8ba-4fcc-8693-6b594b313702" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_d41dea6c-1399-4829-85bd-f668f0f13d71" xlink:to="loc_srt_MaximumMember_d0b6bb13-c8ba-4fcc-8693-6b594b313702" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.optinose.com/role/SummaryofSignificantAccountingPoliciesLicensingrevenuesDetails" xlink:type="simple" xlink:href="optn-20221231.xsd#SummaryofSignificantAccountingPoliciesLicensingrevenuesDetails"/>
  <link:definitionLink xlink:role="http://www.optinose.com/role/SummaryofSignificantAccountingPoliciesLicensingrevenuesDetails" xlink:type="extended" id="icbc7d8f947ab401082111564db384078_SummaryofSignificantAccountingPoliciesLicensingrevenuesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_4e34a4d4-b68b-4899-bf1a-420adbecab2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_433b134c-6c1f-474e-8c78-4aa682521de0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_4e34a4d4-b68b-4899-bf1a-420adbecab2c" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_433b134c-6c1f-474e-8c78-4aa682521de0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_63ec7982-d3db-48b5-9429-34f80d2e49d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_4e34a4d4-b68b-4899-bf1a-420adbecab2c" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_63ec7982-d3db-48b5-9429-34f80d2e49d3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_d20f5d1a-4809-4208-a019-1af6213eef59" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_63ec7982-d3db-48b5-9429-34f80d2e49d3" xlink:to="loc_srt_ProductOrServiceAxis_d20f5d1a-4809-4208-a019-1af6213eef59" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d20f5d1a-4809-4208-a019-1af6213eef59_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_d20f5d1a-4809-4208-a019-1af6213eef59" xlink:to="loc_srt_ProductsAndServicesDomain_d20f5d1a-4809-4208-a019-1af6213eef59_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_275b5233-200f-4904-8696-59176415ac4e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_d20f5d1a-4809-4208-a019-1af6213eef59" xlink:to="loc_srt_ProductsAndServicesDomain_275b5233-200f-4904-8696-59176415ac4e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_d9958409-9382-40b6-af77-1974e159122b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_275b5233-200f-4904-8696-59176415ac4e" xlink:to="loc_us-gaap_LicenseMember_d9958409-9382-40b6-af77-1974e159122b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.optinose.com/role/SummaryofSignificantAccountingPoliciesNetincomelosspercommonshareDetails" xlink:type="simple" xlink:href="optn-20221231.xsd#SummaryofSignificantAccountingPoliciesNetincomelosspercommonshareDetails"/>
  <link:definitionLink xlink:role="http://www.optinose.com/role/SummaryofSignificantAccountingPoliciesNetincomelosspercommonshareDetails" xlink:type="extended" id="i6a92232f47654d9e83a475940b7346b5_SummaryofSignificantAccountingPoliciesNetincomelosspercommonshareDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_e8c9415c-8ab6-4f49-95f8-3172a5e3a4ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_34a4dac4-38c9-45a5-a5af-6908d4f71c0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_e8c9415c-8ab6-4f49-95f8-3172a5e3a4ad" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_34a4dac4-38c9-45a5-a5af-6908d4f71c0c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_14bf591f-ec80-4e6b-8805-3913bbb9234d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_e8c9415c-8ab6-4f49-95f8-3172a5e3a4ad" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_14bf591f-ec80-4e6b-8805-3913bbb9234d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8ac92316-a773-4759-9873-2a51b3343658" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_14bf591f-ec80-4e6b-8805-3913bbb9234d" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8ac92316-a773-4759-9873-2a51b3343658" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8ac92316-a773-4759-9873-2a51b3343658_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8ac92316-a773-4759-9873-2a51b3343658" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8ac92316-a773-4759-9873-2a51b3343658_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_d670aafb-3f5f-4d8f-b2cf-5e15077b49ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8ac92316-a773-4759-9873-2a51b3343658" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_d670aafb-3f5f-4d8f-b2cf-5e15077b49ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_4a64bbc0-0290-4bcc-bc14-91123bea2947" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_d670aafb-3f5f-4d8f-b2cf-5e15077b49ad" xlink:to="loc_us-gaap_EmployeeStockOptionMember_4a64bbc0-0290-4bcc-bc14-91123bea2947" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_b2fc0ea1-b0bc-4b5f-bbc0-e240c5c1c336" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_d670aafb-3f5f-4d8f-b2cf-5e15077b49ad" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_b2fc0ea1-b0bc-4b5f-bbc0-e240c5c1c336" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_3e9f2b72-dce5-4d80-be94-b96198b36fdb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_d670aafb-3f5f-4d8f-b2cf-5e15077b49ad" xlink:to="loc_us-gaap_WarrantMember_3e9f2b72-dce5-4d80-be94-b96198b36fdb" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.optinose.com/role/FairValueMeasurementsFairvalueassetsandliabilitiesmeasuredonrecurringbasisDetails" xlink:type="simple" xlink:href="optn-20221231.xsd#FairValueMeasurementsFairvalueassetsandliabilitiesmeasuredonrecurringbasisDetails"/>
  <link:definitionLink xlink:role="http://www.optinose.com/role/FairValueMeasurementsFairvalueassetsandliabilitiesmeasuredonrecurringbasisDetails" xlink:type="extended" id="i5412554e46534e8a8934bcd30f364690_FairValueMeasurementsFairvalueassetsandliabilitiesmeasuredonrecurringbasisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_0e3fd283-e65d-4fdf-b240-fb37a5366cab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_032106bb-52aa-42fd-8e90-ec2239592ce9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_0e3fd283-e65d-4fdf-b240-fb37a5366cab" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_032106bb-52aa-42fd-8e90-ec2239592ce9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_c721b215-61a9-42bb-9091-5518c4b43414" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_032106bb-52aa-42fd-8e90-ec2239592ce9" xlink:to="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_c721b215-61a9-42bb-9091-5518c4b43414" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_0661fe38-b993-491a-acbb-9359a40965e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_032106bb-52aa-42fd-8e90-ec2239592ce9" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_0661fe38-b993-491a-acbb-9359a40965e2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_07daf8cc-79f7-45e4-9cd1-3b880cbe7c11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_0e3fd283-e65d-4fdf-b240-fb37a5366cab" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_07daf8cc-79f7-45e4-9cd1-3b880cbe7c11" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_95b01a8b-e6ef-4b3b-88c2-7c52bd33a79f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_07daf8cc-79f7-45e4-9cd1-3b880cbe7c11" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_95b01a8b-e6ef-4b3b-88c2-7c52bd33a79f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_95b01a8b-e6ef-4b3b-88c2-7c52bd33a79f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_95b01a8b-e6ef-4b3b-88c2-7c52bd33a79f" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_95b01a8b-e6ef-4b3b-88c2-7c52bd33a79f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_cf1d3527-29dc-4fc5-b716-f0f80bee4a09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_95b01a8b-e6ef-4b3b-88c2-7c52bd33a79f" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_cf1d3527-29dc-4fc5-b716-f0f80bee4a09" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_8b532233-0b6b-48e2-8756-5fc5a7519a83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_cf1d3527-29dc-4fc5-b716-f0f80bee4a09" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_8b532233-0b6b-48e2-8756-5fc5a7519a83" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_5f4628cf-a3cb-46cf-8be4-eaa5acd9a516" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_cf1d3527-29dc-4fc5-b716-f0f80bee4a09" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_5f4628cf-a3cb-46cf-8be4-eaa5acd9a516" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_32272661-d7d1-4b40-bd0f-43366209bc9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_cf1d3527-29dc-4fc5-b716-f0f80bee4a09" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_32272661-d7d1-4b40-bd0f-43366209bc9f" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.optinose.com/role/FairValueMeasurementsValuationofwarrantsDetails" xlink:type="simple" xlink:href="optn-20221231.xsd#FairValueMeasurementsValuationofwarrantsDetails"/>
  <link:definitionLink xlink:role="http://www.optinose.com/role/FairValueMeasurementsValuationofwarrantsDetails" xlink:type="extended" id="i496294afa4804022a179ad14a32ab6f2_FairValueMeasurementsValuationofwarrantsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_a39e891e-8f05-40c2-9176-8dbe07970219" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_235fe769-28ee-4ff0-9e8b-a6587c415d11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_a39e891e-8f05-40c2-9176-8dbe07970219" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_235fe769-28ee-4ff0-9e8b-a6587c415d11" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_5203d4fe-625e-435d-8c97-0a63dd877eeb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_a39e891e-8f05-40c2-9176-8dbe07970219" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_5203d4fe-625e-435d-8c97-0a63dd877eeb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_FairValueOfWarrant_2aeca7b0-1bb2-4a7f-a398-0e4e36534ae3" xlink:href="optn-20221231.xsd#optn_FairValueOfWarrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_a39e891e-8f05-40c2-9176-8dbe07970219" xlink:to="loc_optn_FairValueOfWarrant_2aeca7b0-1bb2-4a7f-a398-0e4e36534ae3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_37ef9ec5-27ed-4c3d-8c79-a6fbbab6fbf9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_a39e891e-8f05-40c2-9176-8dbe07970219" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_37ef9ec5-27ed-4c3d-8c79-a6fbbab6fbf9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_f7c74647-8ff1-435f-a33f-9354e39fbe9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_37ef9ec5-27ed-4c3d-8c79-a6fbbab6fbf9" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_f7c74647-8ff1-435f-a33f-9354e39fbe9c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_f7c74647-8ff1-435f-a33f-9354e39fbe9c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_f7c74647-8ff1-435f-a33f-9354e39fbe9c" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_f7c74647-8ff1-435f-a33f-9354e39fbe9c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_285fb883-8ad6-4790-8e58-fd1082938a90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_f7c74647-8ff1-435f-a33f-9354e39fbe9c" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_285fb883-8ad6-4790-8e58-fd1082938a90" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputSharePriceMember_94f37320-3e01-4940-9e36-1471da6fc7f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputSharePriceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_285fb883-8ad6-4790-8e58-fd1082938a90" xlink:to="loc_us-gaap_MeasurementInputSharePriceMember_94f37320-3e01-4940-9e36-1471da6fc7f8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_MeasurementInputStrikePriceMember_d100b42c-f482-4a0d-9b6b-a83a7e58e321" xlink:href="optn-20221231.xsd#optn_MeasurementInputStrikePriceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_285fb883-8ad6-4790-8e58-fd1082938a90" xlink:to="loc_optn_MeasurementInputStrikePriceMember_d100b42c-f482-4a0d-9b6b-a83a7e58e321" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_cf78af61-b253-420b-8eb1-82a1b62912b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_285fb883-8ad6-4790-8e58-fd1082938a90" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_cf78af61-b253-420b-8eb1-82a1b62912b8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_bebc2722-867e-46d3-8fd3-722c472de47a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_285fb883-8ad6-4790-8e58-fd1082938a90" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_bebc2722-867e-46d3-8fd3-722c472de47a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_6ab52b98-caed-4b51-a784-6ce2b2e6db68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_285fb883-8ad6-4790-8e58-fd1082938a90" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_6ab52b98-caed-4b51-a784-6ce2b2e6db68" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis_924597c5-c747-4eb9-b723-e1764597a65b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_37ef9ec5-27ed-4c3d-8c79-a6fbbab6fbf9" xlink:to="loc_us-gaap_ValuationTechniqueAxis_924597c5-c747-4eb9-b723-e1764597a65b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_924597c5-c747-4eb9-b723-e1764597a65b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationTechniqueAxis_924597c5-c747-4eb9-b723-e1764597a65b" xlink:to="loc_us-gaap_ValuationTechniqueDomain_924597c5-c747-4eb9-b723-e1764597a65b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_0b720877-a539-4c4d-b6e1-00af91af1d73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationTechniqueAxis_924597c5-c747-4eb9-b723-e1764597a65b" xlink:to="loc_us-gaap_ValuationTechniqueDomain_0b720877-a539-4c4d-b6e1-00af91af1d73" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_MonteCarloSimulationMember_82f613e5-d0c7-4a08-a997-a23060714e61" xlink:href="optn-20221231.xsd#optn_MonteCarloSimulationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationTechniqueDomain_0b720877-a539-4c4d-b6e1-00af91af1d73" xlink:to="loc_optn_MonteCarloSimulationMember_82f613e5-d0c7-4a08-a997-a23060714e61" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.optinose.com/role/PropertyandEquipmentDetails" xlink:type="simple" xlink:href="optn-20221231.xsd#PropertyandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://www.optinose.com/role/PropertyandEquipmentDetails" xlink:type="extended" id="iadb1b5d0ff964f5fb15f6c9449b9e98a_PropertyandEquipmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4cd66e91-9741-493c-8d4b-b3fbcde7e30a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_0b5a4055-da17-4838-ada2-4e7e63031a79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4cd66e91-9741-493c-8d4b-b3fbcde7e30a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_0b5a4055-da17-4838-ada2-4e7e63031a79" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_66bd444a-a5ce-4741-b51d-864829df3e37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4cd66e91-9741-493c-8d4b-b3fbcde7e30a" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_66bd444a-a5ce-4741-b51d-864829df3e37" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_bc8dabd8-2a08-4cbd-be0c-829e3b81f44c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4cd66e91-9741-493c-8d4b-b3fbcde7e30a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_bc8dabd8-2a08-4cbd-be0c-829e3b81f44c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_060379e9-267b-4e73-a778-e86fd6238700" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4cd66e91-9741-493c-8d4b-b3fbcde7e30a" xlink:to="loc_us-gaap_Depreciation_060379e9-267b-4e73-a778-e86fd6238700" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_19a648b9-508b-4bad-ad2c-0c858ea86014" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4cd66e91-9741-493c-8d4b-b3fbcde7e30a" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_19a648b9-508b-4bad-ad2c-0c858ea86014" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_a9ea1fe6-dd26-49c1-ba9e-3500f371de28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_19a648b9-508b-4bad-ad2c-0c858ea86014" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_a9ea1fe6-dd26-49c1-ba9e-3500f371de28" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_a9ea1fe6-dd26-49c1-ba9e-3500f371de28_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_a9ea1fe6-dd26-49c1-ba9e-3500f371de28" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_a9ea1fe6-dd26-49c1-ba9e-3500f371de28_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_1e63c189-9a06-4cfe-8986-26bc7040ca2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_a9ea1fe6-dd26-49c1-ba9e-3500f371de28" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_1e63c189-9a06-4cfe-8986-26bc7040ca2f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoriesMember_508d84c7-2a2d-4676-9ff9-1e72de9c1669" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoriesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_1e63c189-9a06-4cfe-8986-26bc7040ca2f" xlink:to="loc_us-gaap_InventoriesMember_508d84c7-2a2d-4676-9ff9-1e72de9c1669" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_8bf5f7e8-fc62-42f7-9cda-9d2a8e242123" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_1e63c189-9a06-4cfe-8986-26bc7040ca2f" xlink:to="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_8bf5f7e8-fc62-42f7-9cda-9d2a8e242123" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b83f6860-2fb3-40ae-8dac-f586b28b842a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_19a648b9-508b-4bad-ad2c-0c858ea86014" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b83f6860-2fb3-40ae-8dac-f586b28b842a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b83f6860-2fb3-40ae-8dac-f586b28b842a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b83f6860-2fb3-40ae-8dac-f586b28b842a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b83f6860-2fb3-40ae-8dac-f586b28b842a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_06c4052c-e0e4-46bb-95d6-92e7f343d973" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b83f6860-2fb3-40ae-8dac-f586b28b842a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_06c4052c-e0e4-46bb-95d6-92e7f343d973" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_ComputerEquipmentandSoftwareMember_cea2f6fd-2e93-4e60-ae76-dbdf0e387e98" xlink:href="optn-20221231.xsd#optn_ComputerEquipmentandSoftwareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_06c4052c-e0e4-46bb-95d6-92e7f343d973" xlink:to="loc_optn_ComputerEquipmentandSoftwareMember_cea2f6fd-2e93-4e60-ae76-dbdf0e387e98" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_eb32abe3-06df-44f8-9d16-e9845bbcdee4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_06c4052c-e0e4-46bb-95d6-92e7f343d973" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_eb32abe3-06df-44f8-9d16-e9845bbcdee4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_e110b2d5-f758-4708-b69a-491662e4db4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_06c4052c-e0e4-46bb-95d6-92e7f343d973" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_e110b2d5-f758-4708-b69a-491662e4db4f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_9bc9d7ed-16bf-4a41-9fd3-12b2958eafa2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_06c4052c-e0e4-46bb-95d6-92e7f343d973" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_9bc9d7ed-16bf-4a41-9fd3-12b2958eafa2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_a5ed31ee-6f6a-47ed-b046-c802e3b50da6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_06c4052c-e0e4-46bb-95d6-92e7f343d973" xlink:to="loc_us-gaap_ConstructionInProgressMember_a5ed31ee-6f6a-47ed-b046-c802e3b50da6" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.optinose.com/role/LicenseAgreementsDetails" xlink:type="simple" xlink:href="optn-20221231.xsd#LicenseAgreementsDetails"/>
  <link:definitionLink xlink:role="http://www.optinose.com/role/LicenseAgreementsDetails" xlink:type="extended" id="idc1cb665021646c487e128b677174e33_LicenseAgreementsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_f5a03128-fe8d-44c0-8283-bf04182f97f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestonePaymentsMaximumEligible_f053c7f6-74dc-446f-9d64-77fe18017f2a" xlink:href="optn-20221231.xsd#optn_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestonePaymentsMaximumEligible"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_f5a03128-fe8d-44c0-8283-bf04182f97f7" xlink:to="loc_optn_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestonePaymentsMaximumEligible_f053c7f6-74dc-446f-9d64-77fe18017f2a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_f7c96407-d11f-4e6d-8880-b507a4606e46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_f5a03128-fe8d-44c0-8283-bf04182f97f7" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_f7c96407-d11f-4e6d-8880-b507a4606e46" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_f664a25d-d96c-4c64-b734-49a80a22cfaa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_f7c96407-d11f-4e6d-8880-b507a4606e46" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_f664a25d-d96c-4c64-b734-49a80a22cfaa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_f664a25d-d96c-4c64-b734-49a80a22cfaa_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_f664a25d-d96c-4c64-b734-49a80a22cfaa" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_f664a25d-d96c-4c64-b734-49a80a22cfaa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_b0fd0360-a1e0-438e-873d-f3f90afc8083" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_f664a25d-d96c-4c64-b734-49a80a22cfaa" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_b0fd0360-a1e0-438e-873d-f3f90afc8083" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyAgreementTermsMember_b5b8f686-0a88-4c8a-b10f-e12699590269" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyAgreementTermsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_b0fd0360-a1e0-438e-873d-f3f90afc8083" xlink:to="loc_us-gaap_RoyaltyAgreementTermsMember_b5b8f686-0a88-4c8a-b10f-e12699590269" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.optinose.com/role/DebtnetNarrativeDetails" xlink:type="simple" xlink:href="optn-20221231.xsd#DebtnetNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.optinose.com/role/DebtnetNarrativeDetails" xlink:type="extended" id="i6641a14ad7044b2387e7b3617c4686c8_DebtnetNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_e0a130af-bd2b-4a68-96d7-f7e7f3d35448" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_c4c4e574-f072-4d06-bbc0-6ee4539a9db7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e0a130af-bd2b-4a68-96d7-f7e7f3d35448" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_c4c4e574-f072-4d06-bbc0-6ee4539a9db7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_1593e3ae-e5eb-4295-9391-b0460e055b43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e0a130af-bd2b-4a68-96d7-f7e7f3d35448" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_1593e3ae-e5eb-4295-9391-b0460e055b43" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_DebtInstrumentIssuanceCriteriaTermNetSalesAndRoyaltiesBenchmark_4a62bc5e-356b-4f99-8f5c-8caca1a12460" xlink:href="optn-20221231.xsd#optn_DebtInstrumentIssuanceCriteriaTermNetSalesAndRoyaltiesBenchmark"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e0a130af-bd2b-4a68-96d7-f7e7f3d35448" xlink:to="loc_optn_DebtInstrumentIssuanceCriteriaTermNetSalesAndRoyaltiesBenchmark_4a62bc5e-356b-4f99-8f5c-8caca1a12460" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_TrailingTwelveMonthNetRevenueCovenant_34f461e9-536c-48b2-baed-aba4ad2903c9" xlink:href="optn-20221231.xsd#optn_TrailingTwelveMonthNetRevenueCovenant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e0a130af-bd2b-4a68-96d7-f7e7f3d35448" xlink:to="loc_optn_TrailingTwelveMonthNetRevenueCovenant_34f461e9-536c-48b2-baed-aba4ad2903c9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_FeeDueOnTheMaturityDateOfTheNotePurchaseAgreement_fff38c6d-0593-489d-b724-7c3b3376cbd1" xlink:href="optn-20221231.xsd#optn_FeeDueOnTheMaturityDateOfTheNotePurchaseAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e0a130af-bd2b-4a68-96d7-f7e7f3d35448" xlink:to="loc_optn_FeeDueOnTheMaturityDateOfTheNotePurchaseAgreement_fff38c6d-0593-489d-b724-7c3b3376cbd1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_5f4e22dc-b276-49a7-bcfd-f3271fc40c82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e0a130af-bd2b-4a68-96d7-f7e7f3d35448" xlink:to="loc_us-gaap_DebtInstrumentTerm_5f4e22dc-b276-49a7-bcfd-f3271fc40c82" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_db07bae4-35b4-41e3-bc5e-85b0e281fa42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e0a130af-bd2b-4a68-96d7-f7e7f3d35448" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_db07bae4-35b4-41e3-bc5e-85b0e281fa42" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_ae864612-c177-4d27-a891-08af35d6cb83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e0a130af-bd2b-4a68-96d7-f7e7f3d35448" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_ae864612-c177-4d27-a891-08af35d6cb83" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_PotentialDebtInstrumentInterestRateIncrease_5d19f340-a3d9-4eea-ab0d-5ff60a5a2161" xlink:href="optn-20221231.xsd#optn_PotentialDebtInstrumentInterestRateIncrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e0a130af-bd2b-4a68-96d7-f7e7f3d35448" xlink:to="loc_optn_PotentialDebtInstrumentInterestRateIncrease_5d19f340-a3d9-4eea-ab0d-5ff60a5a2161" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_DebtInstrumentMakeWholeProvisionPaymentAccrualPeriod_09cb3090-978e-48d0-9ac1-434f4d101f0c" xlink:href="optn-20221231.xsd#optn_DebtInstrumentMakeWholeProvisionPaymentAccrualPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e0a130af-bd2b-4a68-96d7-f7e7f3d35448" xlink:to="loc_optn_DebtInstrumentMakeWholeProvisionPaymentAccrualPeriod_09cb3090-978e-48d0-9ac1-434f4d101f0c" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_DebtInstrumentMaximumAggregateMakeWholePremiumAmount_dc8935cb-cbcb-4aa1-a6c6-b881baae7b6a" xlink:href="optn-20221231.xsd#optn_DebtInstrumentMaximumAggregateMakeWholePremiumAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e0a130af-bd2b-4a68-96d7-f7e7f3d35448" xlink:to="loc_optn_DebtInstrumentMaximumAggregateMakeWholePremiumAmount_dc8935cb-cbcb-4aa1-a6c6-b881baae7b6a" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_AmendmentFee_254e94d2-d7f5-48da-aa1d-904bf4172009" xlink:href="optn-20221231.xsd#optn_AmendmentFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e0a130af-bd2b-4a68-96d7-f7e7f3d35448" xlink:to="loc_optn_AmendmentFee_254e94d2-d7f5-48da-aa1d-904bf4172009" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_AmendmentFeePercentage_133e1277-954f-4080-ad2b-68e0d39f0e09" xlink:href="optn-20221231.xsd#optn_AmendmentFeePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e0a130af-bd2b-4a68-96d7-f7e7f3d35448" xlink:to="loc_optn_AmendmentFeePercentage_133e1277-954f-4080-ad2b-68e0d39f0e09" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_AmendmentFeePayable_c07aa212-8a0f-4af4-9cd9-e2ec670fd5c2" xlink:href="optn-20221231.xsd#optn_AmendmentFeePayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e0a130af-bd2b-4a68-96d7-f7e7f3d35448" xlink:to="loc_optn_AmendmentFeePayable_c07aa212-8a0f-4af4-9cd9-e2ec670fd5c2" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_DebtInstrumentCovenantCashAndCashEquivalents_202fd7f6-2a56-48ca-ae4a-13d7f967f4e3" xlink:href="optn-20221231.xsd#optn_DebtInstrumentCovenantCashAndCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e0a130af-bd2b-4a68-96d7-f7e7f3d35448" xlink:to="loc_optn_DebtInstrumentCovenantCashAndCashEquivalents_202fd7f6-2a56-48ca-ae4a-13d7f967f4e3" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_a2d429c8-2c60-4928-b3a7-29dff0cfd3f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e0a130af-bd2b-4a68-96d7-f7e7f3d35448" xlink:to="loc_us-gaap_InterestExpenseDebt_a2d429c8-2c60-4928-b3a7-29dff0cfd3f0" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_NotePurchaseAgreementCovenantXHANCENetProductSalesAndRoyalties_2363891c-bc22-4e62-88c2-2eacfa1b46b2" xlink:href="optn-20221231.xsd#optn_NotePurchaseAgreementCovenantXHANCENetProductSalesAndRoyalties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e0a130af-bd2b-4a68-96d7-f7e7f3d35448" xlink:to="loc_optn_NotePurchaseAgreementCovenantXHANCENetProductSalesAndRoyalties_2363891c-bc22-4e62-88c2-2eacfa1b46b2" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_3c0846db-065e-404e-b0d5-b5ffa7bdaca8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e0a130af-bd2b-4a68-96d7-f7e7f3d35448" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_3c0846db-065e-404e-b0d5-b5ffa7bdaca8" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_5f90692c-d04c-4985-8c55-137630366806" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e0a130af-bd2b-4a68-96d7-f7e7f3d35448" xlink:to="loc_us-gaap_DebtInstrumentTable_5f90692c-d04c-4985-8c55-137630366806" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_c9d1f550-93bf-4260-b2f1-7af641cfbddf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_5f90692c-d04c-4985-8c55-137630366806" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_c9d1f550-93bf-4260-b2f1-7af641cfbddf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_c9d1f550-93bf-4260-b2f1-7af641cfbddf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_c9d1f550-93bf-4260-b2f1-7af641cfbddf" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_c9d1f550-93bf-4260-b2f1-7af641cfbddf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_e4c1a176-ac4d-429b-ac72-17a1a7d7592a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_c9d1f550-93bf-4260-b2f1-7af641cfbddf" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_e4c1a176-ac4d-429b-ac72-17a1a7d7592a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_4d821ff7-9e29-4094-91b6-ca69770002c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_e4c1a176-ac4d-429b-ac72-17a1a7d7592a" xlink:to="loc_us-gaap_SeniorNotesMember_4d821ff7-9e29-4094-91b6-ca69770002c9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_5c00c79e-0027-4992-b475-40abe0ec6191" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_5f90692c-d04c-4985-8c55-137630366806" xlink:to="loc_us-gaap_DebtInstrumentAxis_5c00c79e-0027-4992-b475-40abe0ec6191" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_5c00c79e-0027-4992-b475-40abe0ec6191_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_5c00c79e-0027-4992-b475-40abe0ec6191" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_5c00c79e-0027-4992-b475-40abe0ec6191_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_b1925a8c-9dd8-453e-98ec-ca0e221de3a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_5c00c79e-0027-4992-b475-40abe0ec6191" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_b1925a8c-9dd8-453e-98ec-ca0e221de3a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_NotePurchaseAgreementMember_300b35f3-4058-4446-a394-d81dd0d0b1fa" xlink:href="optn-20221231.xsd#optn_NotePurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b1925a8c-9dd8-453e-98ec-ca0e221de3a0" xlink:to="loc_optn_NotePurchaseAgreementMember_300b35f3-4058-4446-a394-d81dd0d0b1fa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_NotePurchaseAgreementFirstDelayedDrawNotesMember_e21c8ff4-1d66-4d00-a265-d523959dd04d" xlink:href="optn-20221231.xsd#optn_NotePurchaseAgreementFirstDelayedDrawNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b1925a8c-9dd8-453e-98ec-ca0e221de3a0" xlink:to="loc_optn_NotePurchaseAgreementFirstDelayedDrawNotesMember_e21c8ff4-1d66-4d00-a265-d523959dd04d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_NotePurchaseAgreementThirdDelayedDrawNotesMember_bce0fa94-d380-47e2-bbfc-b59de542d8c3" xlink:href="optn-20221231.xsd#optn_NotePurchaseAgreementThirdDelayedDrawNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b1925a8c-9dd8-453e-98ec-ca0e221de3a0" xlink:to="loc_optn_NotePurchaseAgreementThirdDelayedDrawNotesMember_bce0fa94-d380-47e2-bbfc-b59de542d8c3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_MeasurementPeriodAxis_160f18cc-42a3-40a7-8f64-c7ae50c2c436" xlink:href="optn-20221231.xsd#optn_MeasurementPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_5f90692c-d04c-4985-8c55-137630366806" xlink:to="loc_optn_MeasurementPeriodAxis_160f18cc-42a3-40a7-8f64-c7ae50c2c436" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_MeasurementPeriodDomain_160f18cc-42a3-40a7-8f64-c7ae50c2c436_default" xlink:href="optn-20221231.xsd#optn_MeasurementPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_optn_MeasurementPeriodAxis_160f18cc-42a3-40a7-8f64-c7ae50c2c436" xlink:to="loc_optn_MeasurementPeriodDomain_160f18cc-42a3-40a7-8f64-c7ae50c2c436_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_MeasurementPeriodDomain_7283f547-6781-4e0d-b806-72fd78604726" xlink:href="optn-20221231.xsd#optn_MeasurementPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_optn_MeasurementPeriodAxis_160f18cc-42a3-40a7-8f64-c7ae50c2c436" xlink:to="loc_optn_MeasurementPeriodDomain_7283f547-6781-4e0d-b806-72fd78604726" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_QuarterEndedDecember312019Member_1e82f7e1-a086-4a29-9cdc-fdaeafef8cdb" xlink:href="optn-20221231.xsd#optn_QuarterEndedDecember312019Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_optn_MeasurementPeriodDomain_7283f547-6781-4e0d-b806-72fd78604726" xlink:to="loc_optn_QuarterEndedDecember312019Member_1e82f7e1-a086-4a29-9cdc-fdaeafef8cdb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_QuarterEndedSeptember302020Member_3839b36e-59d0-41bf-9d33-c7821ea4001c" xlink:href="optn-20221231.xsd#optn_QuarterEndedSeptember302020Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_optn_MeasurementPeriodDomain_7283f547-6781-4e0d-b806-72fd78604726" xlink:to="loc_optn_QuarterEndedSeptember302020Member_3839b36e-59d0-41bf-9d33-c7821ea4001c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_0b829804-bc36-4fdd-81eb-12dd1cdf7c73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_5f90692c-d04c-4985-8c55-137630366806" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_0b829804-bc36-4fdd-81eb-12dd1cdf7c73" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_0b829804-bc36-4fdd-81eb-12dd1cdf7c73_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_0b829804-bc36-4fdd-81eb-12dd1cdf7c73" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_0b829804-bc36-4fdd-81eb-12dd1cdf7c73_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_e0588736-6f0e-47e4-bb41-30c04e3c6370" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_0b829804-bc36-4fdd-81eb-12dd1cdf7c73" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_e0588736-6f0e-47e4-bb41-30c04e3c6370" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_d2746c84-8c62-4187-ae72-838e730033de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_e0588736-6f0e-47e4-bb41-30c04e3c6370" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_d2746c84-8c62-4187-ae72-838e730033de" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_f670a3bb-4dea-4a28-9483-f946dda145f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_e0588736-6f0e-47e4-bb41-30c04e3c6370" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_f670a3bb-4dea-4a28-9483-f946dda145f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_c04c481a-bbeb-4c9b-8021-864baae5ca4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_e0588736-6f0e-47e4-bb41-30c04e3c6370" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_c04c481a-bbeb-4c9b-8021-864baae5ca4a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_936db076-936c-4310-a814-d4955570f207" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_5f90692c-d04c-4985-8c55-137630366806" xlink:to="loc_us-gaap_VariableRateAxis_936db076-936c-4310-a814-d4955570f207" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_936db076-936c-4310-a814-d4955570f207_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_936db076-936c-4310-a814-d4955570f207" xlink:to="loc_us-gaap_VariableRateDomain_936db076-936c-4310-a814-d4955570f207_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_b337b5d4-7ea8-47e7-b807-eed54227830f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_936db076-936c-4310-a814-d4955570f207" xlink:to="loc_us-gaap_VariableRateDomain_b337b5d4-7ea8-47e7-b807-eed54227830f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_SecuredOvernightFinancingRateMember_551b4b3b-7c28-4bc1-b3de-35e7d863a69f" xlink:href="optn-20221231.xsd#optn_SecuredOvernightFinancingRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_b337b5d4-7ea8-47e7-b807-eed54227830f" xlink:to="loc_optn_SecuredOvernightFinancingRateMember_551b4b3b-7c28-4bc1-b3de-35e7d863a69f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_b307814b-386f-423f-9ede-9c8b730f49fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_b337b5d4-7ea8-47e7-b807-eed54227830f" xlink:to="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_b307814b-386f-423f-9ede-9c8b730f49fd" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.optinose.com/role/DebtnetARNotePurchaseAgreementDetails" xlink:type="simple" xlink:href="optn-20221231.xsd#DebtnetARNotePurchaseAgreementDetails"/>
  <link:definitionLink xlink:role="http://www.optinose.com/role/DebtnetARNotePurchaseAgreementDetails" xlink:type="extended" id="i3671e5f7082649f8884225398bab0b58_DebtnetARNotePurchaseAgreementDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_8ab9a782-f6d4-41f2-9f72-b42da5d1f04e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_NotePurchaseAgreementCovenantXHANCENetProductSalesAndRoyalties_65becee9-e00c-4f32-8c30-71c4da07c063" xlink:href="optn-20221231.xsd#optn_NotePurchaseAgreementCovenantXHANCENetProductSalesAndRoyalties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8ab9a782-f6d4-41f2-9f72-b42da5d1f04e" xlink:to="loc_optn_NotePurchaseAgreementCovenantXHANCENetProductSalesAndRoyalties_65becee9-e00c-4f32-8c30-71c4da07c063" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_27b37454-475d-476b-9999-7c456b60e090" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8ab9a782-f6d4-41f2-9f72-b42da5d1f04e" xlink:to="loc_us-gaap_DebtInstrumentTable_27b37454-475d-476b-9999-7c456b60e090" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_f5a6e89b-ee10-44c6-90d9-e2d0ab5b78d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_27b37454-475d-476b-9999-7c456b60e090" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_f5a6e89b-ee10-44c6-90d9-e2d0ab5b78d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_f5a6e89b-ee10-44c6-90d9-e2d0ab5b78d9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_f5a6e89b-ee10-44c6-90d9-e2d0ab5b78d9" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_f5a6e89b-ee10-44c6-90d9-e2d0ab5b78d9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_25b32f93-2cc8-4ff8-bf7a-efdf44ed1381" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_f5a6e89b-ee10-44c6-90d9-e2d0ab5b78d9" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_25b32f93-2cc8-4ff8-bf7a-efdf44ed1381" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_10278dea-de92-483a-9d38-fad89103ba02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_25b32f93-2cc8-4ff8-bf7a-efdf44ed1381" xlink:to="loc_us-gaap_SeniorNotesMember_10278dea-de92-483a-9d38-fad89103ba02" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_TrailingTwelveMonthEndingAxisAxis_db3b516d-875c-49e5-b619-2f70a6f715e8" xlink:href="optn-20221231.xsd#optn_TrailingTwelveMonthEndingAxisAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_27b37454-475d-476b-9999-7c456b60e090" xlink:to="loc_optn_TrailingTwelveMonthEndingAxisAxis_db3b516d-875c-49e5-b619-2f70a6f715e8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_TrailingTwelveMonthEndingAxisDomain_db3b516d-875c-49e5-b619-2f70a6f715e8_default" xlink:href="optn-20221231.xsd#optn_TrailingTwelveMonthEndingAxisDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_optn_TrailingTwelveMonthEndingAxisAxis_db3b516d-875c-49e5-b619-2f70a6f715e8" xlink:to="loc_optn_TrailingTwelveMonthEndingAxisDomain_db3b516d-875c-49e5-b619-2f70a6f715e8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_TrailingTwelveMonthEndingAxisDomain_3e2046cb-6534-44f3-88f6-7b436f1fcf63" xlink:href="optn-20221231.xsd#optn_TrailingTwelveMonthEndingAxisDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_optn_TrailingTwelveMonthEndingAxisAxis_db3b516d-875c-49e5-b619-2f70a6f715e8" xlink:to="loc_optn_TrailingTwelveMonthEndingAxisDomain_3e2046cb-6534-44f3-88f6-7b436f1fcf63" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_March312023Member_9f83f684-02c2-44a5-bed9-a4284ea79260" xlink:href="optn-20221231.xsd#optn_March312023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_optn_TrailingTwelveMonthEndingAxisDomain_3e2046cb-6534-44f3-88f6-7b436f1fcf63" xlink:to="loc_optn_March312023Member_9f83f684-02c2-44a5-bed9-a4284ea79260" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_June302023Member_5add417d-43d6-4d36-897b-d0f0a7f614bd" xlink:href="optn-20221231.xsd#optn_June302023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_optn_TrailingTwelveMonthEndingAxisDomain_3e2046cb-6534-44f3-88f6-7b436f1fcf63" xlink:to="loc_optn_June302023Member_5add417d-43d6-4d36-897b-d0f0a7f614bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_September302023Member_cffa3e1d-7a8f-4e8f-8d2e-16c43de1b18f" xlink:href="optn-20221231.xsd#optn_September302023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_optn_TrailingTwelveMonthEndingAxisDomain_3e2046cb-6534-44f3-88f6-7b436f1fcf63" xlink:to="loc_optn_September302023Member_cffa3e1d-7a8f-4e8f-8d2e-16c43de1b18f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_December312023Member_b7ce9581-75a0-47a8-b8bb-5736e5766ed9" xlink:href="optn-20221231.xsd#optn_December312023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_optn_TrailingTwelveMonthEndingAxisDomain_3e2046cb-6534-44f3-88f6-7b436f1fcf63" xlink:to="loc_optn_December312023Member_b7ce9581-75a0-47a8-b8bb-5736e5766ed9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_March312024Member_54708063-90ef-4ab5-973e-e7657d7e7468" xlink:href="optn-20221231.xsd#optn_March312024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_optn_TrailingTwelveMonthEndingAxisDomain_3e2046cb-6534-44f3-88f6-7b436f1fcf63" xlink:to="loc_optn_March312024Member_54708063-90ef-4ab5-973e-e7657d7e7468" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_June302024Member_effda656-00f9-4a55-85a5-3a6875b95b4d" xlink:href="optn-20221231.xsd#optn_June302024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_optn_TrailingTwelveMonthEndingAxisDomain_3e2046cb-6534-44f3-88f6-7b436f1fcf63" xlink:to="loc_optn_June302024Member_effda656-00f9-4a55-85a5-3a6875b95b4d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_September302024Member_d0bf5936-c5ba-409c-af36-0547cac8456f" xlink:href="optn-20221231.xsd#optn_September302024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_optn_TrailingTwelveMonthEndingAxisDomain_3e2046cb-6534-44f3-88f6-7b436f1fcf63" xlink:to="loc_optn_September302024Member_d0bf5936-c5ba-409c-af36-0547cac8456f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_December312024Member_bda50f91-2af0-4e64-9496-9887752e6eed" xlink:href="optn-20221231.xsd#optn_December312024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_optn_TrailingTwelveMonthEndingAxisDomain_3e2046cb-6534-44f3-88f6-7b436f1fcf63" xlink:to="loc_optn_December312024Member_bda50f91-2af0-4e64-9496-9887752e6eed" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_March312025Member_10f350b3-0f38-43c6-8186-9baaf93adc1a" xlink:href="optn-20221231.xsd#optn_March312025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_optn_TrailingTwelveMonthEndingAxisDomain_3e2046cb-6534-44f3-88f6-7b436f1fcf63" xlink:to="loc_optn_March312025Member_10f350b3-0f38-43c6-8186-9baaf93adc1a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_June302025Member_002ccdac-25f3-4f4d-92c7-7b6b352a8a31" xlink:href="optn-20221231.xsd#optn_June302025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_optn_TrailingTwelveMonthEndingAxisDomain_3e2046cb-6534-44f3-88f6-7b436f1fcf63" xlink:to="loc_optn_June302025Member_002ccdac-25f3-4f4d-92c7-7b6b352a8a31" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_September302025Member_825812f0-9396-4c4d-8ff9-082e86920a88" xlink:href="optn-20221231.xsd#optn_September302025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_optn_TrailingTwelveMonthEndingAxisDomain_3e2046cb-6534-44f3-88f6-7b436f1fcf63" xlink:to="loc_optn_September302025Member_825812f0-9396-4c4d-8ff9-082e86920a88" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_December312025Member_1f5dff62-1b2f-41ad-b788-f7daa8b5ac87" xlink:href="optn-20221231.xsd#optn_December312025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_optn_TrailingTwelveMonthEndingAxisDomain_3e2046cb-6534-44f3-88f6-7b436f1fcf63" xlink:to="loc_optn_December312025Member_1f5dff62-1b2f-41ad-b788-f7daa8b5ac87" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_March312026Member_ef46824c-fbc9-4420-a657-2b0164060bbb" xlink:href="optn-20221231.xsd#optn_March312026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_optn_TrailingTwelveMonthEndingAxisDomain_3e2046cb-6534-44f3-88f6-7b436f1fcf63" xlink:to="loc_optn_March312026Member_ef46824c-fbc9-4420-a657-2b0164060bbb" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_June302026Member_a46f6729-6adf-44c1-8009-7aa5ab0710c1" xlink:href="optn-20221231.xsd#optn_June302026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_optn_TrailingTwelveMonthEndingAxisDomain_3e2046cb-6534-44f3-88f6-7b436f1fcf63" xlink:to="loc_optn_June302026Member_a46f6729-6adf-44c1-8009-7aa5ab0710c1" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_September302026Member_c91365f2-a781-4c93-825b-c4984fe0dc9b" xlink:href="optn-20221231.xsd#optn_September302026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_optn_TrailingTwelveMonthEndingAxisDomain_3e2046cb-6534-44f3-88f6-7b436f1fcf63" xlink:to="loc_optn_September302026Member_c91365f2-a781-4c93-825b-c4984fe0dc9b" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_December312026Member_7b9d1fd0-22c8-462b-b820-0512ea6effc6" xlink:href="optn-20221231.xsd#optn_December312026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_optn_TrailingTwelveMonthEndingAxisDomain_3e2046cb-6534-44f3-88f6-7b436f1fcf63" xlink:to="loc_optn_December312026Member_7b9d1fd0-22c8-462b-b820-0512ea6effc6" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_March312027Member_921d313d-0d9c-406e-b75c-6dadb63983c6" xlink:href="optn-20221231.xsd#optn_March312027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_optn_TrailingTwelveMonthEndingAxisDomain_3e2046cb-6534-44f3-88f6-7b436f1fcf63" xlink:to="loc_optn_March312027Member_921d313d-0d9c-406e-b75c-6dadb63983c6" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_June302027Member_468a2e67-2b6a-4d59-ac21-67bc25c520e2" xlink:href="optn-20221231.xsd#optn_June302027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_optn_TrailingTwelveMonthEndingAxisDomain_3e2046cb-6534-44f3-88f6-7b436f1fcf63" xlink:to="loc_optn_June302027Member_468a2e67-2b6a-4d59-ac21-67bc25c520e2" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_September302027Member_977d1063-5441-41cc-85b8-863f6bb98672" xlink:href="optn-20221231.xsd#optn_September302027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_optn_TrailingTwelveMonthEndingAxisDomain_3e2046cb-6534-44f3-88f6-7b436f1fcf63" xlink:to="loc_optn_September302027Member_977d1063-5441-41cc-85b8-863f6bb98672" xlink:type="arc" order="18"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.optinose.com/role/DebtnetScheduleoflongtermdebtDetails" xlink:type="simple" xlink:href="optn-20221231.xsd#DebtnetScheduleoflongtermdebtDetails"/>
  <link:definitionLink xlink:role="http://www.optinose.com/role/DebtnetScheduleoflongtermdebtDetails" xlink:type="extended" id="ib77b198a0d6d4e00a5c244573d18aa7c_DebtnetScheduleoflongtermdebtDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_7af04344-05bc-4d42-9a8a-8878852c96ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_8716f905-5caa-4f07-b70f-4690f3341819" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7af04344-05bc-4d42-9a8a-8878852c96ae" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_8716f905-5caa-4f07-b70f-4690f3341819" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_DebtInstrumentFeeAmountFrontEnd_c957351f-58cb-413c-84cb-4096bfc3695d" xlink:href="optn-20221231.xsd#optn_DebtInstrumentFeeAmountFrontEnd"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7af04344-05bc-4d42-9a8a-8878852c96ae" xlink:to="loc_optn_DebtInstrumentFeeAmountFrontEnd_c957351f-58cb-413c-84cb-4096bfc3695d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnamortizedDebtIssuanceExpense_2cee0e0f-67e0-4883-8732-3f277514f378" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnamortizedDebtIssuanceExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7af04344-05bc-4d42-9a8a-8878852c96ae" xlink:to="loc_us-gaap_UnamortizedDebtIssuanceExpense_2cee0e0f-67e0-4883-8732-3f277514f378" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_DebtInstrumentFeeAmountBackEnd_a24dd61d-d3a1-4b64-9f68-7a956b59c0ed" xlink:href="optn-20221231.xsd#optn_DebtInstrumentFeeAmountBackEnd"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7af04344-05bc-4d42-9a8a-8878852c96ae" xlink:to="loc_optn_DebtInstrumentFeeAmountBackEnd_a24dd61d-d3a1-4b64-9f68-7a956b59c0ed" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_8d19ef5f-8da5-4fc6-84b3-407dc2d8f07b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7af04344-05bc-4d42-9a8a-8878852c96ae" xlink:to="loc_us-gaap_LongTermDebt_8d19ef5f-8da5-4fc6-84b3-407dc2d8f07b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_c1f4beb3-5ec7-4806-a86d-b4d6ef7bb801" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7af04344-05bc-4d42-9a8a-8878852c96ae" xlink:to="loc_us-gaap_DebtInstrumentTable_c1f4beb3-5ec7-4806-a86d-b4d6ef7bb801" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_52c3ab11-8441-415e-af61-bdc92e3afff2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_c1f4beb3-5ec7-4806-a86d-b4d6ef7bb801" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_52c3ab11-8441-415e-af61-bdc92e3afff2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_52c3ab11-8441-415e-af61-bdc92e3afff2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_52c3ab11-8441-415e-af61-bdc92e3afff2" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_52c3ab11-8441-415e-af61-bdc92e3afff2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_43d19899-13b8-4492-baba-4327dbd8d690" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_52c3ab11-8441-415e-af61-bdc92e3afff2" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_43d19899-13b8-4492-baba-4327dbd8d690" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_4312fcac-eb47-4864-96f9-ce03889c8ae4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_43d19899-13b8-4492-baba-4327dbd8d690" xlink:to="loc_us-gaap_SeniorNotesMember_4312fcac-eb47-4864-96f9-ce03889c8ae4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_e7d9536f-020c-47e9-9c73-76f9591d3f02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_c1f4beb3-5ec7-4806-a86d-b4d6ef7bb801" xlink:to="loc_us-gaap_DebtInstrumentAxis_e7d9536f-020c-47e9-9c73-76f9591d3f02" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_e7d9536f-020c-47e9-9c73-76f9591d3f02_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_e7d9536f-020c-47e9-9c73-76f9591d3f02" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_e7d9536f-020c-47e9-9c73-76f9591d3f02_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_8a061bcb-25b1-4c8f-bca3-9f717578028a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_e7d9536f-020c-47e9-9c73-76f9591d3f02" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_8a061bcb-25b1-4c8f-bca3-9f717578028a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_NotePurchaseAgreementMember_76c92a3c-5bfb-4b7e-afe8-89d8aedbe47b" xlink:href="optn-20221231.xsd#optn_NotePurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8a061bcb-25b1-4c8f-bca3-9f717578028a" xlink:to="loc_optn_NotePurchaseAgreementMember_76c92a3c-5bfb-4b7e-afe8-89d8aedbe47b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.optinose.com/role/EmployeeBenefitPlansDetails" xlink:type="simple" xlink:href="optn-20221231.xsd#EmployeeBenefitPlansDetails"/>
  <link:definitionLink xlink:role="http://www.optinose.com/role/EmployeeBenefitPlansDetails" xlink:type="extended" id="ica79c780328541ecb3cb8cd14478b0e6_EmployeeBenefitPlansDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_ef41f4f0-8d27-44d4-94df-61d09a5f8179" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_a4b01087-6f91-49e0-9746-adf3d2873f88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_ef41f4f0-8d27-44d4-94df-61d09a5f8179" xlink:to="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_a4b01087-6f91-49e0-9746-adf3d2873f88" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_b164d14d-9f64-4118-bdef-697150ae51f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_ef41f4f0-8d27-44d4-94df-61d09a5f8179" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_b164d14d-9f64-4118-bdef-697150ae51f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_b41f5dcc-8e7c-4e30-bb5a-a6063c346136" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_ef41f4f0-8d27-44d4-94df-61d09a5f8179" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_b41f5dcc-8e7c-4e30-bb5a-a6063c346136" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_0f53d084-68bd-483b-b571-6b7dbfb81d0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_ef41f4f0-8d27-44d4-94df-61d09a5f8179" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_0f53d084-68bd-483b-b571-6b7dbfb81d0f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanTable_0f3a495f-6919-47e4-9103-987c1433a227" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_ef41f4f0-8d27-44d4-94df-61d09a5f8179" xlink:to="loc_us-gaap_DefinedContributionPlanTable_0f3a495f-6919-47e4-9103-987c1433a227" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_DefinedContributionPlanTranchesAxisAxis_98c791c9-ee0b-43ed-a172-49a82531bb76" xlink:href="optn-20221231.xsd#optn_DefinedContributionPlanTranchesAxisAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DefinedContributionPlanTable_0f3a495f-6919-47e4-9103-987c1433a227" xlink:to="loc_optn_DefinedContributionPlanTranchesAxisAxis_98c791c9-ee0b-43ed-a172-49a82531bb76" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_DefinedContributionPlanTranchesAxisDomain_98c791c9-ee0b-43ed-a172-49a82531bb76_default" xlink:href="optn-20221231.xsd#optn_DefinedContributionPlanTranchesAxisDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_optn_DefinedContributionPlanTranchesAxisAxis_98c791c9-ee0b-43ed-a172-49a82531bb76" xlink:to="loc_optn_DefinedContributionPlanTranchesAxisDomain_98c791c9-ee0b-43ed-a172-49a82531bb76_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_DefinedContributionPlanTranchesAxisDomain_55237285-e96e-4382-87a9-fa53964db4fa" xlink:href="optn-20221231.xsd#optn_DefinedContributionPlanTranchesAxisDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_optn_DefinedContributionPlanTranchesAxisAxis_98c791c9-ee0b-43ed-a172-49a82531bb76" xlink:to="loc_optn_DefinedContributionPlanTranchesAxisDomain_55237285-e96e-4382-87a9-fa53964db4fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_DefinedContributionPlanTrancheOneMember_eb4ee39d-c16b-4331-a510-373d35984d36" xlink:href="optn-20221231.xsd#optn_DefinedContributionPlanTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_optn_DefinedContributionPlanTranchesAxisDomain_55237285-e96e-4382-87a9-fa53964db4fa" xlink:to="loc_optn_DefinedContributionPlanTrancheOneMember_eb4ee39d-c16b-4331-a510-373d35984d36" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_DefinedContributionPlanTrancheTwoMember_0a8b399e-5497-456c-b479-f9c3463b854b" xlink:href="optn-20221231.xsd#optn_DefinedContributionPlanTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_optn_DefinedContributionPlanTranchesAxisDomain_55237285-e96e-4382-87a9-fa53964db4fa" xlink:to="loc_optn_DefinedContributionPlanTrancheTwoMember_0a8b399e-5497-456c-b479-f9c3463b854b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_9b38e63c-6ab3-4eb3-a519-0d2f19d7998f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DefinedContributionPlanTable_0f3a495f-6919-47e4-9103-987c1433a227" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_9b38e63c-6ab3-4eb3-a519-0d2f19d7998f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_9b38e63c-6ab3-4eb3-a519-0d2f19d7998f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_9b38e63c-6ab3-4eb3-a519-0d2f19d7998f" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_9b38e63c-6ab3-4eb3-a519-0d2f19d7998f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_dfbdb972-6e72-48a1-ae59-046d56f6abf1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_9b38e63c-6ab3-4eb3-a519-0d2f19d7998f" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_dfbdb972-6e72-48a1-ae59-046d56f6abf1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_0540360d-c151-4b79-9a8e-02ad8ffc7558" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_dfbdb972-6e72-48a1-ae59-046d56f6abf1" xlink:to="loc_us-gaap_ForeignPlanMember_0540360d-c151-4b79-9a8e-02ad8ffc7558" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.optinose.com/role/StockholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="optn-20221231.xsd#StockholdersEquityNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.optinose.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended" id="i8b5a86030dd14173bc868eb41917586c_StockholdersEquityNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_64862787-3f43-4da8-809e-c16565e9d9f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_c93e2dac-3de2-40e9-af43-71f22a893bbc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_64862787-3f43-4da8-809e-c16565e9d9f7" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_c93e2dac-3de2-40e9-af43-71f22a893bbc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_f39b4fbe-a965-471c-9bf5-481695d38223" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_64862787-3f43-4da8-809e-c16565e9d9f7" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_f39b4fbe-a965-471c-9bf5-481695d38223" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_26fdf71e-f9f4-44cf-925a-3ffbdabe5582" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_64862787-3f43-4da8-809e-c16565e9d9f7" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_26fdf71e-f9f4-44cf-925a-3ffbdabe5582" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_SaleOfStockCommissionsAndExpenses_408f2c64-c363-4ac9-ba34-002bbddb20c2" xlink:href="optn-20221231.xsd#optn_SaleOfStockCommissionsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_64862787-3f43-4da8-809e-c16565e9d9f7" xlink:to="loc_optn_SaleOfStockCommissionsAndExpenses_408f2c64-c363-4ac9-ba34-002bbddb20c2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredOfferingCosts_4f3e09ab-cf84-4c43-9be1-0c51d618578f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredOfferingCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_64862787-3f43-4da8-809e-c16565e9d9f7" xlink:to="loc_us-gaap_DeferredOfferingCosts_4f3e09ab-cf84-4c43-9be1-0c51d618578f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_33e4993c-4a8b-44c1-873f-cb903f9669ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_64862787-3f43-4da8-809e-c16565e9d9f7" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_33e4993c-4a8b-44c1-873f-cb903f9669ef" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_VotePerShare_2921bbfa-139a-4fd5-beab-80bf42f0484a" xlink:href="optn-20221231.xsd#optn_VotePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_64862787-3f43-4da8-809e-c16565e9d9f7" xlink:to="loc_optn_VotePerShare_2921bbfa-139a-4fd5-beab-80bf42f0484a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_c3d40b5a-8038-41e1-9631-2d63eb9b9e98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_64862787-3f43-4da8-809e-c16565e9d9f7" xlink:to="loc_us-gaap_CommonStockDividendsPerShareDeclared_c3d40b5a-8038-41e1-9631-2d63eb9b9e98" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_fa413757-39f3-4079-ad17-ba833694bae6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_64862787-3f43-4da8-809e-c16565e9d9f7" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_fa413757-39f3-4079-ad17-ba833694bae6" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_948b7d3f-5234-4dc8-a9f8-1f054e917f40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_64862787-3f43-4da8-809e-c16565e9d9f7" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_948b7d3f-5234-4dc8-a9f8-1f054e917f40" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_ClassOfWarrantOrRightRestrictionCommonSharesMaximumOwnershipIfExercisedPercent_de40a6c4-f7b2-4936-9d3c-c8ede10bcd4f" xlink:href="optn-20221231.xsd#optn_ClassOfWarrantOrRightRestrictionCommonSharesMaximumOwnershipIfExercisedPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_64862787-3f43-4da8-809e-c16565e9d9f7" xlink:to="loc_optn_ClassOfWarrantOrRightRestrictionCommonSharesMaximumOwnershipIfExercisedPercent_de40a6c4-f7b2-4936-9d3c-c8ede10bcd4f" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_ClassOfWarrantOrRightRestrictionCommonSharesMaximumOwnershipPriorToExecutionPercent_6fa00790-de34-4ff8-965a-d4e1a301e52c" xlink:href="optn-20221231.xsd#optn_ClassOfWarrantOrRightRestrictionCommonSharesMaximumOwnershipPriorToExecutionPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_64862787-3f43-4da8-809e-c16565e9d9f7" xlink:to="loc_optn_ClassOfWarrantOrRightRestrictionCommonSharesMaximumOwnershipPriorToExecutionPercent_6fa00790-de34-4ff8-965a-d4e1a301e52c" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_ClassOfWarrantOrRightRestrictionCommonSharesMaximumOwnershipAfterEffectiveWaitingPeriodPercent_6d69c386-dce6-43bc-906e-ff3599ed5112" xlink:href="optn-20221231.xsd#optn_ClassOfWarrantOrRightRestrictionCommonSharesMaximumOwnershipAfterEffectiveWaitingPeriodPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_64862787-3f43-4da8-809e-c16565e9d9f7" xlink:to="loc_optn_ClassOfWarrantOrRightRestrictionCommonSharesMaximumOwnershipAfterEffectiveWaitingPeriodPercent_6d69c386-dce6-43bc-906e-ff3599ed5112" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_b03b9004-7c04-484a-a092-dc82d3ef8780" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_64862787-3f43-4da8-809e-c16565e9d9f7" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_b03b9004-7c04-484a-a092-dc82d3ef8780" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_13eb4646-fd21-421e-adf2-743068b0fd0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_b03b9004-7c04-484a-a092-dc82d3ef8780" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_13eb4646-fd21-421e-adf2-743068b0fd0e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_13eb4646-fd21-421e-adf2-743068b0fd0e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_13eb4646-fd21-421e-adf2-743068b0fd0e" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_13eb4646-fd21-421e-adf2-743068b0fd0e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_bb9f6347-a5ac-4f4f-b8e0-b24b5cd7ace7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_13eb4646-fd21-421e-adf2-743068b0fd0e" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_bb9f6347-a5ac-4f4f-b8e0-b24b5cd7ace7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_PublicOfferingMember_f3000cee-375b-4b3c-a7df-1de8add9b5ec" xlink:href="optn-20221231.xsd#optn_PublicOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_bb9f6347-a5ac-4f4f-b8e0-b24b5cd7ace7" xlink:to="loc_optn_PublicOfferingMember_f3000cee-375b-4b3c-a7df-1de8add9b5ec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_6dc5a678-fd7e-4549-aa53-79c0bf99933e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_b03b9004-7c04-484a-a092-dc82d3ef8780" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_6dc5a678-fd7e-4549-aa53-79c0bf99933e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_6dc5a678-fd7e-4549-aa53-79c0bf99933e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_6dc5a678-fd7e-4549-aa53-79c0bf99933e" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_6dc5a678-fd7e-4549-aa53-79c0bf99933e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_c4c625e7-ad53-4f04-9e23-1bc27d736b33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_6dc5a678-fd7e-4549-aa53-79c0bf99933e" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_c4c625e7-ad53-4f04-9e23-1bc27d736b33" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_WarrantsExpiringNovember182024Member_283b1fc5-f906-4911-b140-3dbfa966b296" xlink:href="optn-20221231.xsd#optn_WarrantsExpiringNovember182024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_c4c625e7-ad53-4f04-9e23-1bc27d736b33" xlink:to="loc_optn_WarrantsExpiringNovember182024Member_283b1fc5-f906-4911-b140-3dbfa966b296" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_WarrantsExpiringSeptember122022Member_ed1e1ad4-5245-41fd-903d-6fa1184c10b4" xlink:href="optn-20221231.xsd#optn_WarrantsExpiringSeptember122022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_c4c625e7-ad53-4f04-9e23-1bc27d736b33" xlink:to="loc_optn_WarrantsExpiringSeptember122022Member_ed1e1ad4-5245-41fd-903d-6fa1184c10b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_c188bf07-7b13-4e6f-87c8-274228f1692b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_b03b9004-7c04-484a-a092-dc82d3ef8780" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_c188bf07-7b13-4e6f-87c8-274228f1692b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_c188bf07-7b13-4e6f-87c8-274228f1692b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_c188bf07-7b13-4e6f-87c8-274228f1692b" xlink:to="loc_us-gaap_EquityComponentDomain_c188bf07-7b13-4e6f-87c8-274228f1692b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_777aee41-1f45-44e9-9221-8d0557e65f16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_c188bf07-7b13-4e6f-87c8-274228f1692b" xlink:to="loc_us-gaap_EquityComponentDomain_777aee41-1f45-44e9-9221-8d0557e65f16" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_a7161601-5fd9-4125-83ad-7b98fbb1ff9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_777aee41-1f45-44e9-9221-8d0557e65f16" xlink:to="loc_us-gaap_CommonStockMember_a7161601-5fd9-4125-83ad-7b98fbb1ff9a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_d4e279d9-38e0-45e1-90dc-7fcf3971f3a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_777aee41-1f45-44e9-9221-8d0557e65f16" xlink:to="loc_us-gaap_WarrantMember_d4e279d9-38e0-45e1-90dc-7fcf3971f3a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_fa8f1fd0-856e-4947-8a22-90a4db0859aa" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_b03b9004-7c04-484a-a092-dc82d3ef8780" xlink:to="loc_srt_CounterpartyNameAxis_fa8f1fd0-856e-4947-8a22-90a4db0859aa" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fa8f1fd0-856e-4947-8a22-90a4db0859aa_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_fa8f1fd0-856e-4947-8a22-90a4db0859aa" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fa8f1fd0-856e-4947-8a22-90a4db0859aa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_822b1eb0-e254-4449-a60f-e78f7f526a30" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_fa8f1fd0-856e-4947-8a22-90a4db0859aa" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_822b1eb0-e254-4449-a60f-e78f7f526a30" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_UnderwritersMember_2d916933-6fe7-4231-ac15-500f668dded4" xlink:href="optn-20221231.xsd#optn_UnderwritersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_822b1eb0-e254-4449-a60f-e78f7f526a30" xlink:to="loc_optn_UnderwritersMember_2d916933-6fe7-4231-ac15-500f668dded4" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.optinose.com/role/StockholdersEquityGrantdatefairvalueofwarrantsvaluationassumptionsDetails" xlink:type="simple" xlink:href="optn-20221231.xsd#StockholdersEquityGrantdatefairvalueofwarrantsvaluationassumptionsDetails"/>
  <link:definitionLink xlink:role="http://www.optinose.com/role/StockholdersEquityGrantdatefairvalueofwarrantsvaluationassumptionsDetails" xlink:type="extended" id="if260be462964414d9f3b5b1cc6bb777a_StockholdersEquityGrantdatefairvalueofwarrantsvaluationassumptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_4f925435-637d-49be-ad03-f458f3cb510c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_6a92d8ac-5425-4b77-8a6c-fc6eaf9cc048" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_4f925435-637d-49be-ad03-f458f3cb510c" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_6a92d8ac-5425-4b77-8a6c-fc6eaf9cc048" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_59ab6c74-e4f4-45ca-a8a6-a18e7b2669b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_4f925435-637d-49be-ad03-f458f3cb510c" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_59ab6c74-e4f4-45ca-a8a6-a18e7b2669b4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_8fba62a4-3fbb-458e-a630-eeed337cc003" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_59ab6c74-e4f4-45ca-a8a6-a18e7b2669b4" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_8fba62a4-3fbb-458e-a630-eeed337cc003" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_8fba62a4-3fbb-458e-a630-eeed337cc003_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_8fba62a4-3fbb-458e-a630-eeed337cc003" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_8fba62a4-3fbb-458e-a630-eeed337cc003_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_db36615b-6050-48d5-92e4-6743f130c850" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_8fba62a4-3fbb-458e-a630-eeed337cc003" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_db36615b-6050-48d5-92e4-6743f130c850" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_1996c108-530c-40d7-ac62-1ae317cff112" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_db36615b-6050-48d5-92e4-6743f130c850" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_1996c108-530c-40d7-ac62-1ae317cff112" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_daf17837-8e88-4403-b0bc-ed5a4c103ca3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_db36615b-6050-48d5-92e4-6743f130c850" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_daf17837-8e88-4403-b0bc-ed5a4c103ca3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_2de5d485-a47d-4d4c-94d4-82cf47e67f29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_db36615b-6050-48d5-92e4-6743f130c850" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_2de5d485-a47d-4d4c-94d4-82cf47e67f29" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_51128778-b5c4-4c0d-a4ea-2200b2c1bbad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_db36615b-6050-48d5-92e4-6743f130c850" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_51128778-b5c4-4c0d-a4ea-2200b2c1bbad" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputSharePriceMember_521bf03f-ca5f-4501-9a7a-6a2161a1d6ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputSharePriceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_db36615b-6050-48d5-92e4-6743f130c850" xlink:to="loc_us-gaap_MeasurementInputSharePriceMember_521bf03f-ca5f-4501-9a7a-6a2161a1d6ca" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.optinose.com/role/StockholdersEquityWarrantsOutstandingDetails" xlink:type="simple" xlink:href="optn-20221231.xsd#StockholdersEquityWarrantsOutstandingDetails"/>
  <link:definitionLink xlink:role="http://www.optinose.com/role/StockholdersEquityWarrantsOutstandingDetails" xlink:type="extended" id="ibbf4a8de9c7840329b478e73cdaebf69_StockholdersEquityWarrantsOutstandingDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_e2bfe398-dc4e-482f-b79d-5ffeb700e2ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_6999405f-8be6-4b6b-8784-cc9376d12028" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_e2bfe398-dc4e-482f-b79d-5ffeb700e2ff" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_6999405f-8be6-4b6b-8784-cc9376d12028" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_d5ecce94-cbfb-40eb-a0a5-aedb39a1c0ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_e2bfe398-dc4e-482f-b79d-5ffeb700e2ff" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_d5ecce94-cbfb-40eb-a0a5-aedb39a1c0ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_21ac55f5-fe31-4ac2-b2e1-6888b8986583" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_e2bfe398-dc4e-482f-b79d-5ffeb700e2ff" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_21ac55f5-fe31-4ac2-b2e1-6888b8986583" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_509b7e95-cb03-4341-ba97-f50d90c14b3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_21ac55f5-fe31-4ac2-b2e1-6888b8986583" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_509b7e95-cb03-4341-ba97-f50d90c14b3f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_509b7e95-cb03-4341-ba97-f50d90c14b3f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_509b7e95-cb03-4341-ba97-f50d90c14b3f" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_509b7e95-cb03-4341-ba97-f50d90c14b3f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_179832a2-da57-408f-8dee-eb8ab07e12d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_509b7e95-cb03-4341-ba97-f50d90c14b3f" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_179832a2-da57-408f-8dee-eb8ab07e12d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_WarrantsExpiringNovember152024Member_15f0b8a0-7b01-4963-a9e0-775d3c3e3f5a" xlink:href="optn-20221231.xsd#optn_WarrantsExpiringNovember152024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_179832a2-da57-408f-8dee-eb8ab07e12d1" xlink:to="loc_optn_WarrantsExpiringNovember152024Member_15f0b8a0-7b01-4963-a9e0-775d3c3e3f5a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_WarrantsExpiringNovember232027Member_7dec5850-9796-4692-856f-311cd5c90d4a" xlink:href="optn-20221231.xsd#optn_WarrantsExpiringNovember232027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_179832a2-da57-408f-8dee-eb8ab07e12d1" xlink:to="loc_optn_WarrantsExpiringNovember232027Member_7dec5850-9796-4692-856f-311cd5c90d4a" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.optinose.com/role/StockbasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="optn-20221231.xsd#StockbasedCompensationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.optinose.com/role/StockbasedCompensationNarrativeDetails" xlink:type="extended" id="i854c1bfd47c14959a8a1aa316f2fdcc2_StockbasedCompensationNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2681e8f8-3512-49d8-bb13-5fffa2a0e18d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_cb940cd6-d9fe-4ccf-af95-507446a6eeed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2681e8f8-3512-49d8-bb13-5fffa2a0e18d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_cb940cd6-d9fe-4ccf-af95-507446a6eeed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_df40a9b4-fed9-49a5-8ff9-ca03615b146e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2681e8f8-3512-49d8-bb13-5fffa2a0e18d" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_df40a9b4-fed9-49a5-8ff9-ca03615b146e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_CommonStockCapitalSharesReservedforFutureIssuanceYearlyIncrease_d2d8e31c-8dc9-4790-b8e8-d528da5a7122" xlink:href="optn-20221231.xsd#optn_CommonStockCapitalSharesReservedforFutureIssuanceYearlyIncrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2681e8f8-3512-49d8-bb13-5fffa2a0e18d" xlink:to="loc_optn_CommonStockCapitalSharesReservedforFutureIssuanceYearlyIncrease_d2d8e31c-8dc9-4790-b8e8-d528da5a7122" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_592b1c61-f122-4f6f-818d-0f2e473e3893" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2681e8f8-3512-49d8-bb13-5fffa2a0e18d" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_592b1c61-f122-4f6f-818d-0f2e473e3893" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_881baac3-51ac-43b1-939b-e8f1f1fa5264" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2681e8f8-3512-49d8-bb13-5fffa2a0e18d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_881baac3-51ac-43b1-939b-e8f1f1fa5264" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_d4a69467-6912-428b-8299-f6841a9f5e92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2681e8f8-3512-49d8-bb13-5fffa2a0e18d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_d4a69467-6912-428b-8299-f6841a9f5e92" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_fa54deae-8fe6-4061-a656-b7c3bd0b47ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2681e8f8-3512-49d8-bb13-5fffa2a0e18d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_fa54deae-8fe6-4061-a656-b7c3bd0b47ed" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_c0a5dd18-f4d5-4297-8dca-c91f5f9b400e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2681e8f8-3512-49d8-bb13-5fffa2a0e18d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_c0a5dd18-f4d5-4297-8dca-c91f5f9b400e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_4ebf74da-6296-4bf2-9c8a-6472bb075310" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2681e8f8-3512-49d8-bb13-5fffa2a0e18d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_4ebf74da-6296-4bf2-9c8a-6472bb075310" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_ea6ab343-ddc7-4f2c-8c93-02ce39565cf4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2681e8f8-3512-49d8-bb13-5fffa2a0e18d" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_ea6ab343-ddc7-4f2c-8c93-02ce39565cf4" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_6298be41-b60a-42a4-9da9-f7332bd11a2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2681e8f8-3512-49d8-bb13-5fffa2a0e18d" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_6298be41-b60a-42a4-9da9-f7332bd11a2e" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_b4a373cb-9df1-4f3e-bfdc-dec87767e9e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2681e8f8-3512-49d8-bb13-5fffa2a0e18d" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_b4a373cb-9df1-4f3e-bfdc-dec87767e9e4" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_5594bc69-1ae4-4f76-9408-e10350526844" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2681e8f8-3512-49d8-bb13-5fffa2a0e18d" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_5594bc69-1ae4-4f76-9408-e10350526844" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_8609c29f-12e7-40cd-b794-8305ce234892" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2681e8f8-3512-49d8-bb13-5fffa2a0e18d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_8609c29f-12e7-40cd-b794-8305ce234892" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_6986d022-5522-4763-9609-56fe90230c6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2681e8f8-3512-49d8-bb13-5fffa2a0e18d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_6986d022-5522-4763-9609-56fe90230c6b" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_ab6445cb-9895-4148-b3ef-b0f3d984b7dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2681e8f8-3512-49d8-bb13-5fffa2a0e18d" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_ab6445cb-9895-4148-b3ef-b0f3d984b7dc" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedIncrementEachYear_7e83ae6f-4f85-4753-b4e5-3d25e0b8ae78" xlink:href="optn-20221231.xsd#optn_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedIncrementEachYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2681e8f8-3512-49d8-bb13-5fffa2a0e18d" xlink:to="loc_optn_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedIncrementEachYear_7e83ae6f-4f85-4753-b4e5-3d25e0b8ae78" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_35e57606-4e0e-487a-a4d5-4dbc4c8e0671" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2681e8f8-3512-49d8-bb13-5fffa2a0e18d" xlink:to="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_35e57606-4e0e-487a-a4d5-4dbc4c8e0671" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeAccruedRightsToPurchaseCommonStock_c8e906c3-3e19-44bc-9924-062e7d4dc7d9" xlink:href="optn-20221231.xsd#optn_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeAccruedRightsToPurchaseCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2681e8f8-3512-49d8-bb13-5fffa2a0e18d" xlink:to="loc_optn_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeAccruedRightsToPurchaseCommonStock_c8e906c3-3e19-44bc-9924-062e7d4dc7d9" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_18750214-301e-4484-88c4-ec68ba4bd2cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2681e8f8-3512-49d8-bb13-5fffa2a0e18d" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_18750214-301e-4484-88c4-ec68ba4bd2cd" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_3d5bebb2-90fb-478f-8ffb-3ada78534ea6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2681e8f8-3512-49d8-bb13-5fffa2a0e18d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_3d5bebb2-90fb-478f-8ffb-3ada78534ea6" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_18921e09-d812-4e84-b7e7-a81ea0fb3792" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2681e8f8-3512-49d8-bb13-5fffa2a0e18d" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_18921e09-d812-4e84-b7e7-a81ea0fb3792" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_82614622-74ab-4909-8dbc-6cbbb409215f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_18921e09-d812-4e84-b7e7-a81ea0fb3792" xlink:to="loc_us-gaap_PlanNameAxis_82614622-74ab-4909-8dbc-6cbbb409215f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_82614622-74ab-4909-8dbc-6cbbb409215f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_82614622-74ab-4909-8dbc-6cbbb409215f" xlink:to="loc_us-gaap_PlanNameDomain_82614622-74ab-4909-8dbc-6cbbb409215f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_83f4ac11-d10c-4fb6-a06f-dcfb248e061e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_82614622-74ab-4909-8dbc-6cbbb409215f" xlink:to="loc_us-gaap_PlanNameDomain_83f4ac11-d10c-4fb6-a06f-dcfb248e061e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_AmendedandRestated2010StockIncentivePlanMember_33af9df6-221e-41a9-a3ba-d002b010f367" xlink:href="optn-20221231.xsd#optn_AmendedandRestated2010StockIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_83f4ac11-d10c-4fb6-a06f-dcfb248e061e" xlink:to="loc_optn_AmendedandRestated2010StockIncentivePlanMember_33af9df6-221e-41a9-a3ba-d002b010f367" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_NASDAQInducementGrantExceptionMember_07153ec0-42c6-4e7c-9f55-285d99b5693a" xlink:href="optn-20221231.xsd#optn_NASDAQInducementGrantExceptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_83f4ac11-d10c-4fb6-a06f-dcfb248e061e" xlink:to="loc_optn_NASDAQInducementGrantExceptionMember_07153ec0-42c6-4e7c-9f55-285d99b5693a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_TwoThousandSeventeenEmployeeStockPurchasePlanMember_37231a2f-9e1c-4c11-aff9-f9d5c82dd3c0" xlink:href="optn-20221231.xsd#optn_TwoThousandSeventeenEmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_83f4ac11-d10c-4fb6-a06f-dcfb248e061e" xlink:to="loc_optn_TwoThousandSeventeenEmployeeStockPurchasePlanMember_37231a2f-9e1c-4c11-aff9-f9d5c82dd3c0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_7b0db9ba-0f49-4bdf-8536-f469387c871e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_18921e09-d812-4e84-b7e7-a81ea0fb3792" xlink:to="loc_us-gaap_AwardTypeAxis_7b0db9ba-0f49-4bdf-8536-f469387c871e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7b0db9ba-0f49-4bdf-8536-f469387c871e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_7b0db9ba-0f49-4bdf-8536-f469387c871e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7b0db9ba-0f49-4bdf-8536-f469387c871e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b8cd1087-c610-42e4-be13-1366951f4acd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_7b0db9ba-0f49-4bdf-8536-f469387c871e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b8cd1087-c610-42e4-be13-1366951f4acd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_ServiceBasedStockOptionsMember_1bd6b004-a7ef-459e-82b1-4de92cb3e9eb" xlink:href="optn-20221231.xsd#optn_ServiceBasedStockOptionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b8cd1087-c610-42e4-be13-1366951f4acd" xlink:to="loc_optn_ServiceBasedStockOptionsMember_1bd6b004-a7ef-459e-82b1-4de92cb3e9eb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_9c26c306-3a24-4bd5-96c8-41455f1c05f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b8cd1087-c610-42e4-be13-1366951f4acd" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_9c26c306-3a24-4bd5-96c8-41455f1c05f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_RestrictedStockUnitsPerformanceBasedMember_5cb0dbb4-ac2a-4bd4-bbea-601d30124eeb" xlink:href="optn-20221231.xsd#optn_RestrictedStockUnitsPerformanceBasedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b8cd1087-c610-42e4-be13-1366951f4acd" xlink:to="loc_optn_RestrictedStockUnitsPerformanceBasedMember_5cb0dbb4-ac2a-4bd4-bbea-601d30124eeb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_RestrictedStockUnitsServiceBasedMember_157cd6f0-f13f-42aa-af26-1164fa86b407" xlink:href="optn-20221231.xsd#optn_RestrictedStockUnitsServiceBasedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b8cd1087-c610-42e4-be13-1366951f4acd" xlink:to="loc_optn_RestrictedStockUnitsServiceBasedMember_157cd6f0-f13f-42aa-af26-1164fa86b407" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_MarketBasedStockOptionsMember_3ce3157c-2d10-4c1a-82e3-2a80108ed8ce" xlink:href="optn-20221231.xsd#optn_MarketBasedStockOptionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b8cd1087-c610-42e4-be13-1366951f4acd" xlink:to="loc_optn_MarketBasedStockOptionsMember_3ce3157c-2d10-4c1a-82e3-2a80108ed8ce" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_b1a981ba-2ec9-4316-bd43-6a83aa21ecd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_18921e09-d812-4e84-b7e7-a81ea0fb3792" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_b1a981ba-2ec9-4316-bd43-6a83aa21ecd6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_b1a981ba-2ec9-4316-bd43-6a83aa21ecd6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_b1a981ba-2ec9-4316-bd43-6a83aa21ecd6" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_b1a981ba-2ec9-4316-bd43-6a83aa21ecd6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_034e78a4-d97e-4109-b6c0-8f44a83b6323" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_b1a981ba-2ec9-4316-bd43-6a83aa21ecd6" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_034e78a4-d97e-4109-b6c0-8f44a83b6323" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoriesMember_2d0aae58-9f8c-4982-a56c-1f0aaf00561e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoriesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_034e78a4-d97e-4109-b6c0-8f44a83b6323" xlink:to="loc_us-gaap_InventoriesMember_2d0aae58-9f8c-4982-a56c-1f0aaf00561e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_244febd3-7782-43d6-8990-aeeddbea6999" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_034e78a4-d97e-4109-b6c0-8f44a83b6323" xlink:to="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_244febd3-7782-43d6-8990-aeeddbea6999" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.optinose.com/role/StockbasedCompensationScheduleofRSUsDetails" xlink:type="simple" xlink:href="optn-20221231.xsd#StockbasedCompensationScheduleofRSUsDetails"/>
  <link:definitionLink xlink:role="http://www.optinose.com/role/StockbasedCompensationScheduleofRSUsDetails" xlink:type="extended" id="i7c7948cf7da74bee98ebd41f5f5ec2da_StockbasedCompensationScheduleofRSUsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_73c64eff-9fce-4a56-a12b-dc232ff9f4dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_31b98a8a-352f-4cf1-bf36-2b59c7df6162" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_73c64eff-9fce-4a56-a12b-dc232ff9f4dd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_31b98a8a-352f-4cf1-bf36-2b59c7df6162" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_7891b3f4-e66e-4c6f-9a85-0471a72651fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_31b98a8a-352f-4cf1-bf36-2b59c7df6162" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_7891b3f4-e66e-4c6f-9a85-0471a72651fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_9a29f43a-7de9-4dde-a1cf-6530d22511d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_31b98a8a-352f-4cf1-bf36-2b59c7df6162" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_9a29f43a-7de9-4dde-a1cf-6530d22511d9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_c0b95973-75f0-4e66-b1b1-6b550e75178a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_31b98a8a-352f-4cf1-bf36-2b59c7df6162" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_c0b95973-75f0-4e66-b1b1-6b550e75178a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_30be3239-2c46-43d0-bb56-041eb104f2df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_31b98a8a-352f-4cf1-bf36-2b59c7df6162" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_30be3239-2c46-43d0-bb56-041eb104f2df" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4b13b215-fda6-44d5-8fdd-974293549882" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestNumber_d303a5a7-b645-4942-b6ab-e7f02a9bc889" xlink:href="optn-20221231.xsd#optn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_31b98a8a-352f-4cf1-bf36-2b59c7df6162" xlink:to="loc_optn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestNumber_d303a5a7-b645-4942-b6ab-e7f02a9bc889" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_acc81893-65a4-4beb-a022-0e0cff6cfd85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_73c64eff-9fce-4a56-a12b-dc232ff9f4dd" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_acc81893-65a4-4beb-a022-0e0cff6cfd85" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_8e95bfda-675b-4469-bf5d-5e5fdfbab2ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_acc81893-65a4-4beb-a022-0e0cff6cfd85" xlink:to="loc_us-gaap_AwardTypeAxis_8e95bfda-675b-4469-bf5d-5e5fdfbab2ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8e95bfda-675b-4469-bf5d-5e5fdfbab2ac_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_8e95bfda-675b-4469-bf5d-5e5fdfbab2ac" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8e95bfda-675b-4469-bf5d-5e5fdfbab2ac_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3b0ee265-c28c-4999-bef1-23ac9f92639f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_8e95bfda-675b-4469-bf5d-5e5fdfbab2ac" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3b0ee265-c28c-4999-bef1-23ac9f92639f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_13d9e043-24a1-4244-8f22-11be637f1167" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3b0ee265-c28c-4999-bef1-23ac9f92639f" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_13d9e043-24a1-4244-8f22-11be637f1167" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.optinose.com/role/StockbasedCompensationStockbasedcompensationexpenseDetails" xlink:type="simple" xlink:href="optn-20221231.xsd#StockbasedCompensationStockbasedcompensationexpenseDetails"/>
  <link:definitionLink xlink:role="http://www.optinose.com/role/StockbasedCompensationStockbasedcompensationexpenseDetails" xlink:type="extended" id="i54c8480b8f7844249d781b4f57b77fbf_StockbasedCompensationStockbasedcompensationexpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_de2a243d-ad69-4a11-8a5a-12c6dcfd425b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_a89cf20c-4284-41d6-972d-22675dc46239" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_de2a243d-ad69-4a11-8a5a-12c6dcfd425b" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_a89cf20c-4284-41d6-972d-22675dc46239" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_a116fc2f-d914-414f-9052-c2ecddcb0f9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_de2a243d-ad69-4a11-8a5a-12c6dcfd425b" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_a116fc2f-d914-414f-9052-c2ecddcb0f9f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_70d53fc7-c817-45e2-920b-ad347e6e15de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_a116fc2f-d914-414f-9052-c2ecddcb0f9f" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_70d53fc7-c817-45e2-920b-ad347e6e15de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_70d53fc7-c817-45e2-920b-ad347e6e15de_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_70d53fc7-c817-45e2-920b-ad347e6e15de" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_70d53fc7-c817-45e2-920b-ad347e6e15de_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_4dc8fbfb-1d5b-40b6-99e7-83df4d7b93bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_70d53fc7-c817-45e2-920b-ad347e6e15de" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_4dc8fbfb-1d5b-40b6-99e7-83df4d7b93bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_269038bb-5b08-481b-befe-e1d3c653f5e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_4dc8fbfb-1d5b-40b6-99e7-83df4d7b93bd" xlink:to="loc_us-gaap_CostOfSalesMember_269038bb-5b08-481b-befe-e1d3c653f5e2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1d0b1eec-e6ef-4c19-9a6c-2ac919d315e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_4dc8fbfb-1d5b-40b6-99e7-83df4d7b93bd" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1d0b1eec-e6ef-4c19-9a6c-2ac919d315e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_09958804-6a46-43c2-ac4c-cfe06471ad14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_4dc8fbfb-1d5b-40b6-99e7-83df4d7b93bd" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_09958804-6a46-43c2-ac4c-cfe06471ad14" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.optinose.com/role/StockbasedCompensationBlackScholespricingmodeloptionsDetails" xlink:type="simple" xlink:href="optn-20221231.xsd#StockbasedCompensationBlackScholespricingmodeloptionsDetails"/>
  <link:definitionLink xlink:role="http://www.optinose.com/role/StockbasedCompensationBlackScholespricingmodeloptionsDetails" xlink:type="extended" id="ibec53386a7654cbeae40199ecc520f1e_StockbasedCompensationBlackScholespricingmodeloptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d2d514f6-386f-4c2d-8301-68836bdc85db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_ccb42404-dc5a-4624-8f06-7e347e45e939" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d2d514f6-386f-4c2d-8301-68836bdc85db" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_ccb42404-dc5a-4624-8f06-7e347e45e939" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_df3aa0de-8973-4919-b55a-6c1034202fa7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d2d514f6-386f-4c2d-8301-68836bdc85db" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_df3aa0de-8973-4919-b55a-6c1034202fa7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_6924af8a-30b8-46d8-9c0b-0c4291cba855" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d2d514f6-386f-4c2d-8301-68836bdc85db" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_6924af8a-30b8-46d8-9c0b-0c4291cba855" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_2e29916d-0ce9-4a8b-8ddb-c48a864e0aab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d2d514f6-386f-4c2d-8301-68836bdc85db" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_2e29916d-0ce9-4a8b-8ddb-c48a864e0aab" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5786bb46-42c5-4976-92fc-bf92c9fa86ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d2d514f6-386f-4c2d-8301-68836bdc85db" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5786bb46-42c5-4976-92fc-bf92c9fa86ed" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_92e6c664-9199-4771-872f-02816bea9216" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5786bb46-42c5-4976-92fc-bf92c9fa86ed" xlink:to="loc_us-gaap_AwardTypeAxis_92e6c664-9199-4771-872f-02816bea9216" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_92e6c664-9199-4771-872f-02816bea9216_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_92e6c664-9199-4771-872f-02816bea9216" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_92e6c664-9199-4771-872f-02816bea9216_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d0bfd77e-14c2-4c3f-90c0-422b8492958a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_92e6c664-9199-4771-872f-02816bea9216" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d0bfd77e-14c2-4c3f-90c0-422b8492958a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_e2f2839a-225e-4544-bd02-6f028d0cb438" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d0bfd77e-14c2-4c3f-90c0-422b8492958a" xlink:to="loc_us-gaap_EmployeeStockOptionMember_e2f2839a-225e-4544-bd02-6f028d0cb438" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_e5ba88ca-675e-48c6-b8de-a4904ec64956" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5786bb46-42c5-4976-92fc-bf92c9fa86ed" xlink:to="loc_us-gaap_PlanNameAxis_e5ba88ca-675e-48c6-b8de-a4904ec64956" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_e5ba88ca-675e-48c6-b8de-a4904ec64956_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_e5ba88ca-675e-48c6-b8de-a4904ec64956" xlink:to="loc_us-gaap_PlanNameDomain_e5ba88ca-675e-48c6-b8de-a4904ec64956_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_60ba95e7-c60d-4e4d-9125-a10c7d68266f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_e5ba88ca-675e-48c6-b8de-a4904ec64956" xlink:to="loc_us-gaap_PlanNameDomain_60ba95e7-c60d-4e4d-9125-a10c7d68266f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_TwoThousandSeventeenEmployeeStockPurchasePlanMember_b4123aa8-9962-499b-ba44-fc0ff6cabd2e" xlink:href="optn-20221231.xsd#optn_TwoThousandSeventeenEmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_60ba95e7-c60d-4e4d-9125-a10c7d68266f" xlink:to="loc_optn_TwoThousandSeventeenEmployeeStockPurchasePlanMember_b4123aa8-9962-499b-ba44-fc0ff6cabd2e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.optinose.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="optn-20221231.xsd#IncomeTaxesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.optinose.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended" id="ie377f1c442ed47cfb9c11a67ca939529_IncomeTaxesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_e50b1a38-241f-4b7c-bd59-503e070fe486" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_f31a2b50-2cf3-42f2-b32f-c8ae81b8ec88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_e50b1a38-241f-4b7c-bd59-503e070fe486" xlink:to="loc_us-gaap_OperatingLossCarryforwards_f31a2b50-2cf3-42f2-b32f-c8ae81b8ec88" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_3a01d254-4e23-449c-85d6-40c571c92ffa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_e50b1a38-241f-4b7c-bd59-503e070fe486" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_3a01d254-4e23-449c-85d6-40c571c92ffa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_DeferredTaxAssetsTaxCreditCarryforwardsResearchTerm_d5950c99-9f9e-4515-97ca-73b30617df11" xlink:href="optn-20221231.xsd#optn_DeferredTaxAssetsTaxCreditCarryforwardsResearchTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_e50b1a38-241f-4b7c-bd59-503e070fe486" xlink:to="loc_optn_DeferredTaxAssetsTaxCreditCarryforwardsResearchTerm_d5950c99-9f9e-4515-97ca-73b30617df11" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_5aa43f10-fab3-4628-8e51-e7db815d273b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_e50b1a38-241f-4b7c-bd59-503e070fe486" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_5aa43f10-fab3-4628-8e51-e7db815d273b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_90554450-23ce-4bb0-ab55-2e6bae9f9428" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_e50b1a38-241f-4b7c-bd59-503e070fe486" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_90554450-23ce-4bb0-ab55-2e6bae9f9428" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_666ea1d4-4539-46d5-993b-6d5d84a738b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_e50b1a38-241f-4b7c-bd59-503e070fe486" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_666ea1d4-4539-46d5-993b-6d5d84a738b8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_67a11224-871c-4c62-a7e4-ccfe8d4a4218" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_666ea1d4-4539-46d5-993b-6d5d84a738b8" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_67a11224-871c-4c62-a7e4-ccfe8d4a4218" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_67a11224-871c-4c62-a7e4-ccfe8d4a4218_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_67a11224-871c-4c62-a7e4-ccfe8d4a4218" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_67a11224-871c-4c62-a7e4-ccfe8d4a4218_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_c1ac6684-1bd7-4e7a-92ad-b347c2df2362" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_67a11224-871c-4c62-a7e4-ccfe8d4a4218" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_c1ac6684-1bd7-4e7a-92ad-b347c2df2362" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_0d060e17-1929-40ad-89b1-cea1c64168c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_c1ac6684-1bd7-4e7a-92ad-b347c2df2362" xlink:to="loc_us-gaap_ForeignCountryMember_0d060e17-1929-40ad-89b1-cea1c64168c6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_c7ae0c7b-ed75-4743-820f-ed1cbd8ae110" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_c1ac6684-1bd7-4e7a-92ad-b347c2df2362" xlink:to="loc_us-gaap_DomesticCountryMember_c7ae0c7b-ed75-4743-820f-ed1cbd8ae110" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_5028cd02-e0e7-4545-8f2d-5eaa2a5949e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_c1ac6684-1bd7-4e7a-92ad-b347c2df2362" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_5028cd02-e0e7-4545-8f2d-5eaa2a5949e3" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd#eedm"/>
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_UnrealizedGainLossOnFairValueOfWarrants_4a5af257-6d55-446f-84ce-949b90c8789c" xlink:href="optn-20221231.xsd#optn_UnrealizedGainLossOnFairValueOfWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="loc_optn_UnrealizedGainLossOnFairValueOfWarrants_4a5af257-6d55-446f-84ce-949b90c8789c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="loc_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>13
<FILENAME>optn-20221231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:738bcfbc-a4cb-4b05-a396-7d259cbbc32b,g:9b54bffb-0962-498f-9b57-5d3747805ca8-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a9ac8a26-77cd-46dc-864c-b4bf2b9d7470_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_99de37f8-5345-4cc9-818f-f96e636db30a_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total undiscounted future minimum lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_5768f570-4adc-43bb-8f52-dda58db0627b_terseLabel_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for doubtful accounts</link:label>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_label_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Credit Loss Expense (Reversal)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:to="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:type="arc" order="1"/>
    <link:label id="lab_optn_FutureLiquidityTextBlock_b8c4d412-75f8-44f0-b1c9-ea2a77c71458_terseLabel_en-US" xlink:label="lab_optn_FutureLiquidityTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liquidity</link:label>
    <link:label id="lab_optn_FutureLiquidityTextBlock_label_en-US" xlink:label="lab_optn_FutureLiquidityTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future Liquidity [Text Block]</link:label>
    <link:label id="lab_optn_FutureLiquidityTextBlock_documentation_en-US" xlink:label="lab_optn_FutureLiquidityTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future Liquidity [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_optn_FutureLiquidityTextBlock" xlink:href="optn-20221231.xsd#optn_FutureLiquidityTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_FutureLiquidityTextBlock" xlink:to="lab_optn_FutureLiquidityTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_502ab5c4-3a35-474e-ac5b-3269073b45a2_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Face amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_optn_December312026Member_a89f49a2-6f11-44cd-a337-5563e08b1492_terseLabel_en-US" xlink:label="lab_optn_December312026Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 31, 2026</link:label>
    <link:label id="lab_optn_December312026Member_label_en-US" xlink:label="lab_optn_December312026Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 31, 2026 [Member]</link:label>
    <link:label id="lab_optn_December312026Member_documentation_en-US" xlink:label="lab_optn_December312026Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 31, 2026</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_optn_December312026Member" xlink:href="optn-20221231.xsd#optn_December312026Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_December312026Member" xlink:to="lab_optn_December312026Member" xlink:type="arc" order="1"/>
    <link:label id="lab_optn_LesseeOperatingLeaseLiabilityPaymentsDueThereafter_18486131-807a-48d2-98f9-f86d843424e8_terseLabel_en-US" xlink:label="lab_optn_LesseeOperatingLeaseLiabilityPaymentsDueThereafter" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_optn_LesseeOperatingLeaseLiabilityPaymentsDueThereafter_label_en-US" xlink:label="lab_optn_LesseeOperatingLeaseLiabilityPaymentsDueThereafter" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Thereafter</link:label>
    <link:label id="lab_optn_LesseeOperatingLeaseLiabilityPaymentsDueThereafter_documentation_en-US" xlink:label="lab_optn_LesseeOperatingLeaseLiabilityPaymentsDueThereafter" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Thereafter</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_optn_LesseeOperatingLeaseLiabilityPaymentsDueThereafter" xlink:href="optn-20221231.xsd#optn_LesseeOperatingLeaseLiabilityPaymentsDueThereafter"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_LesseeOperatingLeaseLiabilityPaymentsDueThereafter" xlink:to="lab_optn_LesseeOperatingLeaseLiabilityPaymentsDueThereafter" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_0c2f31cf-5f04-4522-a989-3a94dcff5584_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_optn_WarrantsExpiringSeptember122022Member_0e014f98-2cf5-4f93-9d43-2270b904cb7b_terseLabel_en-US" xlink:label="lab_optn_WarrantsExpiringSeptember122022Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Expiring September 12, 2022</link:label>
    <link:label id="lab_optn_WarrantsExpiringSeptember122022Member_label_en-US" xlink:label="lab_optn_WarrantsExpiringSeptember122022Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Expiring September 12, 2022 [Member]</link:label>
    <link:label id="lab_optn_WarrantsExpiringSeptember122022Member_documentation_en-US" xlink:label="lab_optn_WarrantsExpiringSeptember122022Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Expiring September 12, 2022</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_optn_WarrantsExpiringSeptember122022Member" xlink:href="optn-20221231.xsd#optn_WarrantsExpiringSeptember122022Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_WarrantsExpiringSeptember122022Member" xlink:to="lab_optn_WarrantsExpiringSeptember122022Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_8cdc5b73-24aa-438f-baa1-a63e2930b08f_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_optn_September302023Member_3d502a1c-587b-4ee6-b657-d41d85272563_terseLabel_en-US" xlink:label="lab_optn_September302023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">September 30, 2023</link:label>
    <link:label id="lab_optn_September302023Member_label_en-US" xlink:label="lab_optn_September302023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">September 30, 2023 [Member]</link:label>
    <link:label id="lab_optn_September302023Member_documentation_en-US" xlink:label="lab_optn_September302023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">September 30, 2023</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_optn_September302023Member" xlink:href="optn-20221231.xsd#optn_September302023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_September302023Member" xlink:to="lab_optn_September302023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_e16edfee-5694-412c-83ea-8bde69ac5d36_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_a8d97006-851e-4834-97eb-deb24ded2495_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_optn_TrailingTwelveMonthNetRevenueCovenant_2fd04b36-046c-4a5b-b5c5-67a4097f304f_terseLabel_en-US" xlink:label="lab_optn_TrailingTwelveMonthNetRevenueCovenant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trailing twelve month net revenue covenant</link:label>
    <link:label id="lab_optn_TrailingTwelveMonthNetRevenueCovenant_label_en-US" xlink:label="lab_optn_TrailingTwelveMonthNetRevenueCovenant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trailing Twelve Month Net Revenue Covenant</link:label>
    <link:label id="lab_optn_TrailingTwelveMonthNetRevenueCovenant_documentation_en-US" xlink:label="lab_optn_TrailingTwelveMonthNetRevenueCovenant" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trailing Twelve Month Net Revenue Covenant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_optn_TrailingTwelveMonthNetRevenueCovenant" xlink:href="optn-20221231.xsd#optn_TrailingTwelveMonthNetRevenueCovenant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_TrailingTwelveMonthNetRevenueCovenant" xlink:to="lab_optn_TrailingTwelveMonthNetRevenueCovenant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_4cf31ff4-3237-4d62-b994-f1587d4d8ce1_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt maximum borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_baadfb30-1f6e-4057-a606-92a8519c0016_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_16d79f93-7051-4a93-90dc-787e7f992daa_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed assets, including leases</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_11945719-452e-4090-bdba-2dd1c06156b8_terseLabel_en-US" xlink:label="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Software</link:label>
    <link:label id="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_label_en-US" xlink:label="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Software and Software Development Costs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:to="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedEmployeeBenefitsCurrent_f0130ca2-b294-4a42-973a-c8828de504d3_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payroll expenses</link:label>
    <link:label id="lab_us-gaap_AccruedEmployeeBenefitsCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Employee Benefits, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:to="lab_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_f41b048e-018d-42b8-b1b1-9ce01682f4bb_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of financial instruments</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_optn_GrantAndOtherIncome_d3ff9940-36c0-4814-a792-ac0d3847529d_negatedTerseLabel_en-US" xlink:label="lab_optn_GrantAndOtherIncome" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (income) expense</link:label>
    <link:label id="lab_optn_GrantAndOtherIncome_label_en-US" xlink:label="lab_optn_GrantAndOtherIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant And Other Income</link:label>
    <link:label id="lab_optn_GrantAndOtherIncome_documentation_en-US" xlink:label="lab_optn_GrantAndOtherIncome" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant And Other Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_optn_GrantAndOtherIncome" xlink:href="optn-20221231.xsd#optn_GrantAndOtherIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_GrantAndOtherIncome" xlink:to="lab_optn_GrantAndOtherIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_1001010f-af87-44b8-b3c9-612ecded15b3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_0bbbeba4-1667-4dd7-96f2-bbe4669e645b_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentAbstract_e7d42a7a-cf5d-4ed2-8d8e-c8555dbe0ea9_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development [Abstract]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentAbstract_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract" xlink:to="lab_us-gaap_ResearchAndDevelopmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_cfbb4276-9939-4b18-8db5-3fea361116fd_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_f6cd485a-09b7-4924-a426-316c0a6c41e9_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of common stock options (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_0e6dbabb-c684-4194-b06f-774c267c42d6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_6a9c8105-d172-42b7-a347-2eb4ec805745_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total net deferred tax assets (liabilities)</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_94f4c68f-2c05-442b-bca0-5fe9843e1a5a_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Floor interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_55a026d3-8718-49ca-8dc4-0dfa049df24a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_optn_SecuredOvernightFinancingRateMember_35fd4a81-277c-4e97-869c-eefaff7eb387_terseLabel_en-US" xlink:label="lab_optn_SecuredOvernightFinancingRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SOFR</link:label>
    <link:label id="lab_optn_SecuredOvernightFinancingRateMember_label_en-US" xlink:label="lab_optn_SecuredOvernightFinancingRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Overnight Financing Rate [Member]</link:label>
    <link:label id="lab_optn_SecuredOvernightFinancingRateMember_documentation_en-US" xlink:label="lab_optn_SecuredOvernightFinancingRateMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Overnight Financing Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_optn_SecuredOvernightFinancingRateMember" xlink:href="optn-20221231.xsd#optn_SecuredOvernightFinancingRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_SecuredOvernightFinancingRateMember" xlink:to="lab_optn_SecuredOvernightFinancingRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationTechniqueAxis_b636d81b-a6e3-41d4-a272-7da9bf473c7b_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationTechniqueAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Approach and Technique [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationTechniqueAxis_label_en-US" xlink:label="lab_us-gaap_ValuationTechniqueAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Approach and Technique [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationTechniqueAxis" xlink:to="lab_us-gaap_ValuationTechniqueAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3a90358b-f8bd-432d-b24f-f3e773edaed8_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_6404e46f-f63e-4fe8-8797-24f9a203937e_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_dbdf11af-04c7-49fc-a0b2-276371c12424_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period Three</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period Three [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticCountryMember_1513e780-463d-4b9b-8397-8f09d72c2860_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Tax Authority</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_a432a911-c250-4654-a4fb-e839dadee41e_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_e70b96d8-0f8a-41eb-9ad5-3e5e61e952d4_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_f8174716-a1a2-46ef-b074-4a57938d5144_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_da73f853-e7e2-4211-adab-7635db2f1317_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_cca55198-c31a-40c8-9d64-ba34b176a8e6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_747f5d0a-e3db-4ef3-9562-916c92b023e9_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_56c69998-d824-4213-a77b-2f1beef1c071_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securites excluded from computation of earnings per share (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_5054ffdf-4a9a-439a-8055-80e6ca2236b6_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_839d4fb2-92dc-406a-a012-05f4b2564a37_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_optn_June302025Member_20e27b55-6724-460d-985a-db0303665bfb_terseLabel_en-US" xlink:label="lab_optn_June302025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">June 30, 2025</link:label>
    <link:label id="lab_optn_June302025Member_label_en-US" xlink:label="lab_optn_June302025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">June 30, 2025 [Member]</link:label>
    <link:label id="lab_optn_June302025Member_documentation_en-US" xlink:label="lab_optn_June302025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">June 30, 2025</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_optn_June302025Member" xlink:href="optn-20221231.xsd#optn_June302025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_June302025Member" xlink:to="lab_optn_June302025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_optn_PotentialDebtInstrumentInterestRateIncrease_a63d66ea-de15-425e-873f-a793d9c97610_terseLabel_en-US" xlink:label="lab_optn_PotentialDebtInstrumentInterestRateIncrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in interest rate</link:label>
    <link:label id="lab_optn_PotentialDebtInstrumentInterestRateIncrease_label_en-US" xlink:label="lab_optn_PotentialDebtInstrumentInterestRateIncrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Debt Instrument, Interest Rate, Increase</link:label>
    <link:label id="lab_optn_PotentialDebtInstrumentInterestRateIncrease_documentation_en-US" xlink:label="lab_optn_PotentialDebtInstrumentInterestRateIncrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Debt Instrument, Interest Rate, Increase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_optn_PotentialDebtInstrumentInterestRateIncrease" xlink:href="optn-20221231.xsd#optn_PotentialDebtInstrumentInterestRateIncrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_PotentialDebtInstrumentInterestRateIncrease" xlink:to="lab_optn_PotentialDebtInstrumentInterestRateIncrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_bdfe2324-39b8-4d9a-8ad3-f9d6fc1ca55b_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_optn_OperatingLeaseLiabilityAbstractAbstract_706b80b8-1b1a-40ba-8dba-0fb7cb6885ce_terseLabel_en-US" xlink:label="lab_optn_OperatingLeaseLiabilityAbstractAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities:</link:label>
    <link:label id="lab_optn_OperatingLeaseLiabilityAbstractAbstract_label_en-US" xlink:label="lab_optn_OperatingLeaseLiabilityAbstractAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability Abstract [Abstract]</link:label>
    <link:label id="lab_optn_OperatingLeaseLiabilityAbstractAbstract_documentation_en-US" xlink:label="lab_optn_OperatingLeaseLiabilityAbstractAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability Abstract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_optn_OperatingLeaseLiabilityAbstractAbstract" xlink:href="optn-20221231.xsd#optn_OperatingLeaseLiabilityAbstractAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_OperatingLeaseLiabilityAbstractAbstract" xlink:to="lab_optn_OperatingLeaseLiabilityAbstractAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationTechniqueDomain_62a225b5-9f7b-4f94-91da-954445845457_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationTechniqueDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Approach and Technique [Domain]</link:label>
    <link:label id="lab_us-gaap_ValuationTechniqueDomain_label_en-US" xlink:label="lab_us-gaap_ValuationTechniqueDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Approach and Technique [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationTechniqueDomain" xlink:to="lab_us-gaap_ValuationTechniqueDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfFinancingCosts_7c5676aa-db95-4f99-adfe-2ef6125e31ef_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfFinancingCosts" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for financing costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfFinancingCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Financing Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfFinancingCosts" xlink:to="lab_us-gaap_PaymentsOfFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_09a3f3a3-9671-419f-b0e7-e8e2fd07c152_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_c5ba8d21-11b4-415f-afa7-b3a26291983a_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_optn_March312024Member_bc71082d-f09e-44e1-b23b-a82baa6cb2f4_terseLabel_en-US" xlink:label="lab_optn_March312024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">March 31, 2024</link:label>
    <link:label id="lab_optn_March312024Member_label_en-US" xlink:label="lab_optn_March312024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">March 31, 2024 [Member]</link:label>
    <link:label id="lab_optn_March312024Member_documentation_en-US" xlink:label="lab_optn_March312024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">March 31, 2024</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_optn_March312024Member" xlink:href="optn-20221231.xsd#optn_March312024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_March312024Member" xlink:to="lab_optn_March312024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_78279616-70fa-43e2-997d-c0bc1a238035_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputExpectedDividendRateMember_cc109818-db43-4c60-b484-5ea81ece4212_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_MeasurementInputExpectedDividendRateMember_92da10d9-6157-45a7-a3ec-fe111e277757_verboseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual dividend yield</link:label>
    <link:label id="lab_us-gaap_MeasurementInputExpectedDividendRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Expected Dividend Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:to="lab_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_6cc88245-3b96-4e65-922e-e3ea327e73dd_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of cash flow information:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_b4cb3071-9c91-451b-9858-1a18ac405e87_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited, Weighted average exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_optn_RestrictedStockUnitsPerformanceBasedMember_5e7ff666-4d99-4759-b1c9-841c95ecdce6_terseLabel_en-US" xlink:label="lab_optn_RestrictedStockUnitsPerformanceBasedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units, Performance-Based</link:label>
    <link:label id="lab_optn_RestrictedStockUnitsPerformanceBasedMember_label_en-US" xlink:label="lab_optn_RestrictedStockUnitsPerformanceBasedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units, Performance-Based [Member]</link:label>
    <link:label id="lab_optn_RestrictedStockUnitsPerformanceBasedMember_documentation_en-US" xlink:label="lab_optn_RestrictedStockUnitsPerformanceBasedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units, Performance-Based</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_optn_RestrictedStockUnitsPerformanceBasedMember" xlink:href="optn-20221231.xsd#optn_RestrictedStockUnitsPerformanceBasedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_RestrictedStockUnitsPerformanceBasedMember" xlink:to="lab_optn_RestrictedStockUnitsPerformanceBasedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_4d68a962-579c-4230-b026-52578f00275d_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation cost</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_7e30c330-fa22-4866-96f4-d748c17e56d7_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_5959b640-40eb-43af-8fd7-b7199bc66569_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_bdf3f3ca-cca8-41a5-8995-2234a564aaf5_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_7e28a910-9215-49d1-9d4f-16e8ce936136_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_092b0060-d4b5-4144-933d-0b587c7dfba5_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding, Weighted average remaining contractual life (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_de04e727-000c-4f70-be6b-c65f613bb221_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_1b38c6d4-a0ee-4598-a6bf-a0441530ddcd_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_9ae21151-b569-43e0-bb04-5aacd181ec67_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_b2770ba8-d755-4490-a431-f7850e450fa8_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_8075652f-745d-4b0f-b332-c11feea9da2a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_e03d547f-8fc7-4f11-a657-1025124f0744_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expired (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_optn_CommonStockCapitalSharesReservedforFutureIssuanceYearlyIncrease_795a4909-d6b1-4499-96f7-c9f71f450bcc_terseLabel_en-US" xlink:label="lab_optn_CommonStockCapitalSharesReservedforFutureIssuanceYearlyIncrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Yearly increase in shares reserved for future issuance</link:label>
    <link:label id="lab_optn_CommonStockCapitalSharesReservedforFutureIssuanceYearlyIncrease_label_en-US" xlink:label="lab_optn_CommonStockCapitalSharesReservedforFutureIssuanceYearlyIncrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance, Yearly Increase</link:label>
    <link:label id="lab_optn_CommonStockCapitalSharesReservedforFutureIssuanceYearlyIncrease_documentation_en-US" xlink:label="lab_optn_CommonStockCapitalSharesReservedforFutureIssuanceYearlyIncrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance, Yearly Increase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_optn_CommonStockCapitalSharesReservedforFutureIssuanceYearlyIncrease" xlink:href="optn-20221231.xsd#optn_CommonStockCapitalSharesReservedforFutureIssuanceYearlyIncrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_CommonStockCapitalSharesReservedforFutureIssuanceYearlyIncrease" xlink:to="lab_optn_CommonStockCapitalSharesReservedforFutureIssuanceYearlyIncrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_7efe63c3-fc31-4bf3-a196-0e13f01f6c62_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Permanent items</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_6c7406f0-38f3-44d5-ae83-1effcd88d8a7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_ded9493d-5b7a-477c-942f-87b9da898b0e_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum annual contributions per employee</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:to="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_optn_RestrictedStockUnitsServiceBasedMember_0cbc2f23-9777-4210-9bc4-0501b833f699_terseLabel_en-US" xlink:label="lab_optn_RestrictedStockUnitsServiceBasedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units, Service-Based</link:label>
    <link:label id="lab_optn_RestrictedStockUnitsServiceBasedMember_label_en-US" xlink:label="lab_optn_RestrictedStockUnitsServiceBasedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units, Service-Based [Member]</link:label>
    <link:label id="lab_optn_RestrictedStockUnitsServiceBasedMember_documentation_en-US" xlink:label="lab_optn_RestrictedStockUnitsServiceBasedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units, Service-Based</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_optn_RestrictedStockUnitsServiceBasedMember" xlink:href="optn-20221231.xsd#optn_RestrictedStockUnitsServiceBasedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_RestrictedStockUnitsServiceBasedMember" xlink:to="lab_optn_RestrictedStockUnitsServiceBasedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_88ce72f3-bf57-4379-97a7-fb936dce6864_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_d6c06132-33b9-44fc-ac57-0a6af3d7f2ff_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_12be9ff7-8d34-42f2-b049-5a1d3d794bf7_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_1400238c-2755-4a17-86aa-9f8ebbf224c4_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, net</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_optn_DeferredTaxAssetsLeasingArrangement_cdef9348-e434-40ed-8bb0-be96c3b40521_terseLabel_en-US" xlink:label="lab_optn_DeferredTaxAssetsLeasingArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liability</link:label>
    <link:label id="lab_optn_DeferredTaxAssetsLeasingArrangement_label_en-US" xlink:label="lab_optn_DeferredTaxAssetsLeasingArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Leasing Arrangement</link:label>
    <link:label id="lab_optn_DeferredTaxAssetsLeasingArrangement_documentation_en-US" xlink:label="lab_optn_DeferredTaxAssetsLeasingArrangement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Leasing Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_optn_DeferredTaxAssetsLeasingArrangement" xlink:href="optn-20221231.xsd#optn_DeferredTaxAssetsLeasingArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_DeferredTaxAssetsLeasingArrangement" xlink:to="lab_optn_DeferredTaxAssetsLeasingArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_optn_MonteCarloSimulationMember_46512606-365b-4a8e-a85a-0ed181034060_terseLabel_en-US" xlink:label="lab_optn_MonteCarloSimulationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Monte Carlo Simulation</link:label>
    <link:label id="lab_optn_MonteCarloSimulationMember_label_en-US" xlink:label="lab_optn_MonteCarloSimulationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Monte Carlo Simulation [Member]</link:label>
    <link:label id="lab_optn_MonteCarloSimulationMember_documentation_en-US" xlink:label="lab_optn_MonteCarloSimulationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Monte Carlo Simulation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_optn_MonteCarloSimulationMember" xlink:href="optn-20221231.xsd#optn_MonteCarloSimulationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_MonteCarloSimulationMember" xlink:to="lab_optn_MonteCarloSimulationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_a60ee2d9-fe7a-4509-96cb-43e966e37657_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_06ac25d5-c6a5-4ecb-84f8-96f4ffc01010_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining lease term (years)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ff2376e4-004d-42e4-af1b-2a9cd6eb0746_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_23ff8bbf-ddb2-4364-a353-4305489fd984_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_optn_DebtInstrumentFeeAmountFrontEnd_f4d7c9e1-9ef0-467b-af36-0453bde2c83d_negatedTerseLabel_en-US" xlink:label="lab_optn_DebtInstrumentFeeAmountFrontEnd" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Front end fees</link:label>
    <link:label id="lab_optn_DebtInstrumentFeeAmountFrontEnd_label_en-US" xlink:label="lab_optn_DebtInstrumentFeeAmountFrontEnd" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Fee Amount, Front End</link:label>
    <link:label id="lab_optn_DebtInstrumentFeeAmountFrontEnd_documentation_en-US" xlink:label="lab_optn_DebtInstrumentFeeAmountFrontEnd" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Fee Amount, Front End</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_optn_DebtInstrumentFeeAmountFrontEnd" xlink:href="optn-20221231.xsd#optn_DebtInstrumentFeeAmountFrontEnd"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_DebtInstrumentFeeAmountFrontEnd" xlink:to="lab_optn_DebtInstrumentFeeAmountFrontEnd" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_ebb20846-b9f5-4c4d-895c-a6d383bb06df_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of common stock, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_e7981826-67cd-403c-be86-aff6b0280dea_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding (in shares)</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0f3b06fd-3b19-455e-8dbb-1edd918ce9a4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_8a658d2e-3c15-4705-885a-4b045d09913d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_40d18490-6d4c-48bb-bf6a-d2b5edfccbbc_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Property and Equipment Useful Lives</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_cba15a68-a18e-4d55-a77e-9d7b123c00a6_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Property and Equipment, Net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_optn_June302027Member_225e1e11-e85e-415d-b0b4-7cad6307a85c_terseLabel_en-US" xlink:label="lab_optn_June302027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">June 30, 2027</link:label>
    <link:label id="lab_optn_June302027Member_label_en-US" xlink:label="lab_optn_June302027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">June 30, 2027 [Member]</link:label>
    <link:label id="lab_optn_June302027Member_documentation_en-US" xlink:label="lab_optn_June302027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">June 30, 2027</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_optn_June302027Member" xlink:href="optn-20221231.xsd#optn_June302027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_June302027Member" xlink:to="lab_optn_June302027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoriesMember_130ef5bb-c70c-44de-a50f-373b5124e95c_terseLabel_en-US" xlink:label="lab_us-gaap_InventoriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoriesMember_label_en-US" xlink:label="lab_us-gaap_InventoriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoriesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoriesMember" xlink:to="lab_us-gaap_InventoriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_464ade82-fff0-45c0-abd0-e42de2452214_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net product revenues and licensing revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_da927911-b2a8-47af-8543-816a478caebf_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_optn_March312026Member_55e6b312-9387-45a8-bb8c-590b86161217_terseLabel_en-US" xlink:label="lab_optn_March312026Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">March 31, 2026</link:label>
    <link:label id="lab_optn_March312026Member_label_en-US" xlink:label="lab_optn_March312026Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">March 31, 2026 [Member]</link:label>
    <link:label id="lab_optn_March312026Member_documentation_en-US" xlink:label="lab_optn_March312026Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">March 31, 2026</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_optn_March312026Member" xlink:href="optn-20221231.xsd#optn_March312026Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_March312026Member" xlink:to="lab_optn_March312026Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_fd4ded84-abe0-4315-a111-425aaa318f0d_terseLabel_en-US" xlink:label="lab_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SOFR</link:label>
    <link:label id="lab_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_label_en-US" xlink:label="lab_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:to="lab_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_4659456e-f2ff-40e4-87fd-f3205ff3bfc8_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Useful life</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_33523270-89ff-434c-8f62-6e37ef8de736_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_187eccf8-10a4-439f-8e9a-2a643deab974_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_71b54e6f-ef6d-47f2-a57e-0b9ff9ea1e56_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, net</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_ab9019c6-2179-4da3-9be0-2f2afd22549c_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_optn_AssetsAndLiabilitiesLesseeTableTextBlock_99df819a-02cc-423f-b923-dce23a8fb120_terseLabel_en-US" xlink:label="lab_optn_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Lease Assets, Liabilities, Term and Discount Rate</link:label>
    <link:label id="lab_optn_AssetsAndLiabilitiesLesseeTableTextBlock_label_en-US" xlink:label="lab_optn_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets And Liabilities, Lessee [Table Text Block]</link:label>
    <link:label id="lab_optn_AssetsAndLiabilitiesLesseeTableTextBlock_documentation_en-US" xlink:label="lab_optn_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets And Liabilities, Lessee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_optn_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:href="optn-20221231.xsd#optn_AssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:to="lab_optn_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_224c5248-99bb-4835-8bef-b7e7ffea1cd7_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_210cc273-b554-4763-9b02-494e24aa055f_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_optn_AmendedandRestated2010StockIncentivePlanMember_035d25c5-46f6-4a0f-a41c-868e5c236f53_verboseLabel_en-US" xlink:label="lab_optn_AmendedandRestated2010StockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended and Restated Plan</link:label>
    <link:label id="lab_optn_AmendedandRestated2010StockIncentivePlanMember_label_en-US" xlink:label="lab_optn_AmendedandRestated2010StockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended and Restated 2010 Stock Incentive Plan [Member]</link:label>
    <link:label id="lab_optn_AmendedandRestated2010StockIncentivePlanMember_documentation_en-US" xlink:label="lab_optn_AmendedandRestated2010StockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended and Restated 2010 Stock Incentive Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_optn_AmendedandRestated2010StockIncentivePlanMember" xlink:href="optn-20221231.xsd#optn_AmendedandRestated2010StockIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_AmendedandRestated2010StockIncentivePlanMember" xlink:to="lab_optn_AmendedandRestated2010StockIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_59b98163-996c-4d8c-be12-d95250d8cf64_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTable" xlink:to="lab_us-gaap_ConcentrationRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_1a6c0a33-94b4-450d-81ac-806343e8c02c_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_optn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestNumber_4caa122d-eb48-4672-80fd-0b38a835521b_terseLabel_en-US" xlink:label="lab_optn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected to vest (in shares)</link:label>
    <link:label id="lab_optn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestNumber_label_en-US" xlink:label="lab_optn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Expected to Vest, Number</link:label>
    <link:label id="lab_optn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestNumber_documentation_en-US" xlink:label="lab_optn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Expected to Vest, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_optn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestNumber" xlink:href="optn-20221231.xsd#optn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestNumber" xlink:to="lab_optn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_optn_NotePurchaseAgreementMember_e87c4fe8-aec7-442a-98b9-2fc47af90a29_terseLabel_en-US" xlink:label="lab_optn_NotePurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Note Purchase Agreement</link:label>
    <link:label id="lab_optn_NotePurchaseAgreementMember_label_en-US" xlink:label="lab_optn_NotePurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Note Purchase Agreement [Member]</link:label>
    <link:label id="lab_optn_NotePurchaseAgreementMember_documentation_en-US" xlink:label="lab_optn_NotePurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Note Purchase Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_optn_NotePurchaseAgreementMember" xlink:href="optn-20221231.xsd#optn_NotePurchaseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_NotePurchaseAgreementMember" xlink:to="lab_optn_NotePurchaseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_optn_DeferredTaxAssetsInterestExpense_d6a0d32e-03d4-4385-a288-9430309c7b19_terseLabel_en-US" xlink:label="lab_optn_DeferredTaxAssetsInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_optn_DeferredTaxAssetsInterestExpense_label_en-US" xlink:label="lab_optn_DeferredTaxAssetsInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Interest Expense</link:label>
    <link:label id="lab_optn_DeferredTaxAssetsInterestExpense_documentation_en-US" xlink:label="lab_optn_DeferredTaxAssetsInterestExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_optn_DeferredTaxAssetsInterestExpense" xlink:href="optn-20221231.xsd#optn_DeferredTaxAssetsInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_DeferredTaxAssetsInterestExpense" xlink:to="lab_optn_DeferredTaxAssetsInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_b1d7eb43-98aa-496b-b48b-5385a9553644_terseLabel_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities:</link:label>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Deferred Tax Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_optn_DeferredTaxAssetsPrepaidLicenseArrangement_143129a4-ca28-4fd8-aadc-f650189b22a0_terseLabel_en-US" xlink:label="lab_optn_DeferredTaxAssetsPrepaidLicenseArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid licensing arrangement</link:label>
    <link:label id="lab_optn_DeferredTaxAssetsPrepaidLicenseArrangement_label_en-US" xlink:label="lab_optn_DeferredTaxAssetsPrepaidLicenseArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Prepaid License Arrangement</link:label>
    <link:label id="lab_optn_DeferredTaxAssetsPrepaidLicenseArrangement_documentation_en-US" xlink:label="lab_optn_DeferredTaxAssetsPrepaidLicenseArrangement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Prepaid License Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_optn_DeferredTaxAssetsPrepaidLicenseArrangement" xlink:href="optn-20221231.xsd#optn_DeferredTaxAssetsPrepaidLicenseArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_DeferredTaxAssetsPrepaidLicenseArrangement" xlink:to="lab_optn_DeferredTaxAssetsPrepaidLicenseArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_56e93626-b439-4fa3-b01c-7df9f5bf0697_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Statement of Financial Position [Extensible List]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_optn_MeasurementPeriodDomain_6f858a47-7ab2-4bb2-b1f0-e89199874c8e_terseLabel_en-US" xlink:label="lab_optn_MeasurementPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Period [Domain]</link:label>
    <link:label id="lab_optn_MeasurementPeriodDomain_label_en-US" xlink:label="lab_optn_MeasurementPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Period [Domain]</link:label>
    <link:label id="lab_optn_MeasurementPeriodDomain_documentation_en-US" xlink:label="lab_optn_MeasurementPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_optn_MeasurementPeriodDomain" xlink:href="optn-20221231.xsd#optn_MeasurementPeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_MeasurementPeriodDomain" xlink:to="lab_optn_MeasurementPeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_d70b5b79-84ee-4bc8-a703-d5576e5be50f_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Revenue, Net</link:label>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_label_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNetMember" xlink:to="lab_us-gaap_SalesRevenueNetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_f285d606-f574-4fe2-a233-eb8c3343fae5_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_optn_WarrantsExpiringNovember152024Member_350ab726-df70-4c48-b8a9-4f9096c066e1_terseLabel_en-US" xlink:label="lab_optn_WarrantsExpiringNovember152024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Expiring November 15, 2024</link:label>
    <link:label id="lab_optn_WarrantsExpiringNovember152024Member_label_en-US" xlink:label="lab_optn_WarrantsExpiringNovember152024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Expiring November 15, 2024 [Member]</link:label>
    <link:label id="lab_optn_WarrantsExpiringNovember152024Member_documentation_en-US" xlink:label="lab_optn_WarrantsExpiringNovember152024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Expiring November 15, 2024</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_optn_WarrantsExpiringNovember152024Member" xlink:href="optn-20221231.xsd#optn_WarrantsExpiringNovember152024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_WarrantsExpiringNovember152024Member" xlink:to="lab_optn_WarrantsExpiringNovember152024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_e3ba7877-1278-46f0-9ba3-d9e35bb686f7_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_78006fd3-5d79-429a-be5d-a690ad2a194c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_5d38e9b1-fa1e-4200-bd7f-0270633ab794_terseLabel_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_label_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_5b0287cb-db7c-4120-bda9-ac93666091c2_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_f4e17518-f2d1-408b-b4a4-c139b6bfffce_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_e1710288-fff1-4358-a8d8-c34a6cdc5e7b_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_9c36fea2-9664-41c5-afa0-124189376afb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Expenses and Other Current Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_37318244-d3a7-4fa2-b8e6-6381cfbd5db5_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short term debt, net</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent" xlink:to="lab_us-gaap_LongTermDebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_03b6b097-a689-4f31-ba73-e42621572562_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised, Weighted average exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_f5303335-a72b-4881-9ad1-2b303a9370d2_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_optn_NotePurchaseAgreementCovenantXHANCENetProductSalesAndRoyalties_ba99749f-d65b-486f-ad33-a1d9e0706628_terseLabel_en-US" xlink:label="lab_optn_NotePurchaseAgreementCovenantXHANCENetProductSalesAndRoyalties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">XHANCE net product sales and royalties</link:label>
    <link:label id="lab_optn_NotePurchaseAgreementCovenantXHANCENetProductSalesAndRoyalties_label_en-US" xlink:label="lab_optn_NotePurchaseAgreementCovenantXHANCENetProductSalesAndRoyalties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Note Purchase Agreement Covenant, XHANCE Net Product Sales And Royalties</link:label>
    <link:label id="lab_optn_NotePurchaseAgreementCovenantXHANCENetProductSalesAndRoyalties_documentation_en-US" xlink:label="lab_optn_NotePurchaseAgreementCovenantXHANCENetProductSalesAndRoyalties" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Note Purchase Agreement Covenant, XHANCE Net Product Sales And Royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_optn_NotePurchaseAgreementCovenantXHANCENetProductSalesAndRoyalties" xlink:href="optn-20221231.xsd#optn_NotePurchaseAgreementCovenantXHANCENetProductSalesAndRoyalties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_NotePurchaseAgreementCovenantXHANCENetProductSalesAndRoyalties" xlink:to="lab_optn_NotePurchaseAgreementCovenantXHANCENetProductSalesAndRoyalties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_2c75974d-e9b4-4da6-a7d4-418c7f2960ca_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseDebt_f61ad207-7a48-4371-9e3e-c958b1c069bc_verboseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebt_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebt" xlink:to="lab_us-gaap_InterestExpenseDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_f407a276-b034-427b-b918-c2921d5eb149_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses related to the Company match</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_cf86d120-4bb5-4506-abdb-dff9b242e088_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss before provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_665dd7b4-1c8e-460b-a5c9-2f6fa0367fb3_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign rate differential</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_f15b7fc6-3741-4c3e-92d8-d7c10e5c12bf_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of debt discount and issuance costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrentAbstract_0e66fa38-8bd8-4678-ba01-09c34e108214_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities:</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_OtherLiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_10497c2c-8455-486c-a631-7364242a39bb_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_b204fffa-c63c-423c-bf13-6278dfc8f135_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value Options using Black-Scholes Pricing Model</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_optn_QuarterEndedSeptember302020Member_4b3c5967-c669-493b-b366-d22858de8863_terseLabel_en-US" xlink:label="lab_optn_QuarterEndedSeptember302020Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarter Ended September 30, 2020</link:label>
    <link:label id="lab_optn_QuarterEndedSeptember302020Member_label_en-US" xlink:label="lab_optn_QuarterEndedSeptember302020Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarter Ended September 30, 2020 [Member]</link:label>
    <link:label id="lab_optn_QuarterEndedSeptember302020Member_documentation_en-US" xlink:label="lab_optn_QuarterEndedSeptember302020Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarter Ended September 30, 2020</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_optn_QuarterEndedSeptember302020Member" xlink:href="optn-20221231.xsd#optn_QuarterEndedSeptember302020Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_QuarterEndedSeptember302020Member" xlink:to="lab_optn_QuarterEndedSeptember302020Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_80f90b85-cdb7-4842-a61f-7914f5e1bfde_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_204a711f-51fe-4109-b54d-1b955501d0ed_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_fb88fb4a-0a07-4495-acdb-1d0aa6099bd8_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_f36ed6cd-1e90-477b-bd32-fded93dc9dbc_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares called by warrants (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_0ff5e6b5-ff40-4685-9483-f15c4fab98e2_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation, estimated weighted-average amortization period</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_4d43e066-6374-4049-a73b-be2a05333724_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable, Weighted average remaining contractual life (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_optn_September302026Member_85408ba7-0a70-4229-b8f9-53adc57f5dc4_terseLabel_en-US" xlink:label="lab_optn_September302026Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">September 30, 2026</link:label>
    <link:label id="lab_optn_September302026Member_label_en-US" xlink:label="lab_optn_September302026Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">September 30, 2026 [Member]</link:label>
    <link:label id="lab_optn_September302026Member_documentation_en-US" xlink:label="lab_optn_September302026Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">September 30, 2026</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_optn_September302026Member" xlink:href="optn-20221231.xsd#optn_September302026Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_September302026Member" xlink:to="lab_optn_September302026Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_798ac55d-b34a-4fdc-9442-b7d1d1fe4512_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer equipment</link:label>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_label_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember" xlink:to="lab_us-gaap_ComputerEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_67e03b8a-7bba-4884-a101-a9a66ce75f6b_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoods" xlink:to="lab_us-gaap_InventoryFinishedGoods" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_423e637a-b051-484b-ad20-3cf48efb3881_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_f363c95c-3bd2-4367-b685-10b377b47a6b_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of common stock and warrants, net of issuance costs (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_1a387cf5-05de-48ba-84ab-3b17dd9e0223_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others [Line Items]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_optn_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestonePaymentsMaximumEligible_fa5bfa6c-7284-43d6-91b7-a09c914470c9_terseLabel_en-US" xlink:label="lab_optn_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestonePaymentsMaximumEligible" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales milestone payments eligible to be received (up to)</link:label>
    <link:label id="lab_optn_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestonePaymentsMaximumEligible_label_en-US" xlink:label="lab_optn_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestonePaymentsMaximumEligible" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Arrangement, Contract To Perform For Others, Milestone Payments, Maximum Eligible</link:label>
    <link:label id="lab_optn_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestonePaymentsMaximumEligible_documentation_en-US" xlink:label="lab_optn_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestonePaymentsMaximumEligible" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Arrangement, Contract To Perform For Others, Milestone Payments, Maximum Eligible</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_optn_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestonePaymentsMaximumEligible" xlink:href="optn-20221231.xsd#optn_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestonePaymentsMaximumEligible"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestonePaymentsMaximumEligible" xlink:to="lab_optn_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestonePaymentsMaximumEligible" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_fe52a16e-9055-4549-a6cd-3df74ea111f3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_8c23bfee-ebc6-4b32-ad4a-617c099597e1_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_optn_TrailingTwelveMonthEndingAxisDomain_34d00463-130a-4190-b75c-4c211430040a_terseLabel_en-US" xlink:label="lab_optn_TrailingTwelveMonthEndingAxisDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trailing Twelve Month Ending Axis [Domain]</link:label>
    <link:label id="lab_optn_TrailingTwelveMonthEndingAxisDomain_label_en-US" xlink:label="lab_optn_TrailingTwelveMonthEndingAxisDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trailing Twelve Month Ending Axis [Domain]</link:label>
    <link:label id="lab_optn_TrailingTwelveMonthEndingAxisDomain_documentation_en-US" xlink:label="lab_optn_TrailingTwelveMonthEndingAxisDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trailing Twelve Month Ending Axis [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_optn_TrailingTwelveMonthEndingAxisDomain" xlink:href="optn-20221231.xsd#optn_TrailingTwelveMonthEndingAxisDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_TrailingTwelveMonthEndingAxisDomain" xlink:to="lab_optn_TrailingTwelveMonthEndingAxisDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_8a28cf23-a561-4ac9-bf22-0a845881aa71_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_bcee837f-39d8-4e56-bd5d-779eb14499fb_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_optn_June302023Member_326a3cfc-fbfa-4908-ac9d-58771426885e_terseLabel_en-US" xlink:label="lab_optn_June302023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">June 30, 2023</link:label>
    <link:label id="lab_optn_June302023Member_label_en-US" xlink:label="lab_optn_June302023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">June 30, 2023 [Member]</link:label>
    <link:label id="lab_optn_June302023Member_documentation_en-US" xlink:label="lab_optn_June302023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">June 30, 2023</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_optn_June302023Member" xlink:href="optn-20221231.xsd#optn_June302023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_June302023Member" xlink:to="lab_optn_June302023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_cb9d9e64-be39-4698-aa3f-255f595f3235_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Benefit Plans</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_419ee34b-fcce-470d-b10b-61d604f73908_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputExpectedTermMember_7bcfa95a-ac38-44ba-a9f0-b6b506d93aa1_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedTermMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term (in years)</link:label>
    <link:label id="lab_us-gaap_MeasurementInputExpectedTermMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedTermMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Expected Term [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExpectedTermMember" xlink:to="lab_us-gaap_MeasurementInputExpectedTermMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_4d28c41d-890b-4666-9b12-58ff422db8c9_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating losses</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_44bbce47-2a55-4861-8593-e30206d230bf_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principles of consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_b034fc46-2645-4de6-bbe2-dddc77d53633_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_3ce195c1-342b-48a0-9ccb-9fe3ff5d024c_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_79c2758e-3e4a-478e-9029-866c1dae3325_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_f7fdec07-b2ad-43ca-bfbc-bfd2619c4afc_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_optn_VotePerShare_b0846f47-0193-4a66-bc5f-b73b2ad181c9_terseLabel_en-US" xlink:label="lab_optn_VotePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vote per share</link:label>
    <link:label id="lab_optn_VotePerShare_label_en-US" xlink:label="lab_optn_VotePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vote Per Share</link:label>
    <link:label id="lab_optn_VotePerShare_documentation_en-US" xlink:label="lab_optn_VotePerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vote Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_optn_VotePerShare" xlink:href="optn-20221231.xsd#optn_VotePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_VotePerShare" xlink:to="lab_optn_VotePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_optn_AuditorInformationAbstract_label_en-US" xlink:label="lab_optn_AuditorInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Information [Abstract]</link:label>
    <link:label id="lab_optn_AuditorInformationAbstract_documentation_en-US" xlink:label="lab_optn_AuditorInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_optn_AuditorInformationAbstract" xlink:href="optn-20221231.xsd#optn_AuditorInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_AuditorInformationAbstract" xlink:to="lab_optn_AuditorInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_d5ff1be5-00bc-4f7e-b40c-03be385554de_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_e38b3993-2549-4d1c-9565-1e1825851844_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_81e92eb4-6e12-4620-8ff1-dffa96b2f857_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_6d1ac20f-9216-4aa1-8875-f4b386c85cc9_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_06fbf014-75be-4a98-9024-d4d2da7126a3_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_a970d4fc-1671-4c52-8b10-b289306aa45a_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_optn_UnrealizedGainLossOnFairValueOfWarrants_f6e9a01c-505f-43ee-81ff-2a5042732c49_negatedTerseLabel_en-US" xlink:label="lab_optn_UnrealizedGainLossOnFairValueOfWarrants" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized loss on fair value of warrants</link:label>
    <link:label id="lab_optn_UnrealizedGainLossOnFairValueOfWarrants_label_en-US" xlink:label="lab_optn_UnrealizedGainLossOnFairValueOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain (Loss) on Fair Value Of Warrants</link:label>
    <link:label id="lab_optn_UnrealizedGainLossOnFairValueOfWarrants_documentation_en-US" xlink:label="lab_optn_UnrealizedGainLossOnFairValueOfWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain (Loss) on Fair Value Of Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_optn_UnrealizedGainLossOnFairValueOfWarrants" xlink:href="optn-20221231.xsd#optn_UnrealizedGainLossOnFairValueOfWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_UnrealizedGainLossOnFairValueOfWarrants" xlink:to="lab_optn_UnrealizedGainLossOnFairValueOfWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_optn_June302024Member_dc5d7972-6de4-4194-992f-d6da10a07910_terseLabel_en-US" xlink:label="lab_optn_June302024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">June 30, 2024</link:label>
    <link:label id="lab_optn_June302024Member_label_en-US" xlink:label="lab_optn_June302024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">June 30, 2024 [Member]</link:label>
    <link:label id="lab_optn_June302024Member_documentation_en-US" xlink:label="lab_optn_June302024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">June 30, 2024</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_optn_June302024Member" xlink:href="optn-20221231.xsd#optn_June302024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_June302024Member" xlink:to="lab_optn_June302024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_optn_DefinedContributionPlanTrancheTwoMember_16e73452-1170-4bef-a670-25c675874fa1_terseLabel_en-US" xlink:label="lab_optn_DefinedContributionPlanTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Tranche Two</link:label>
    <link:label id="lab_optn_DefinedContributionPlanTrancheTwoMember_label_en-US" xlink:label="lab_optn_DefinedContributionPlanTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Tranche Two [Member]</link:label>
    <link:label id="lab_optn_DefinedContributionPlanTrancheTwoMember_documentation_en-US" xlink:label="lab_optn_DefinedContributionPlanTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Tranche Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_optn_DefinedContributionPlanTrancheTwoMember" xlink:href="optn-20221231.xsd#optn_DefinedContributionPlanTrancheTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_DefinedContributionPlanTrancheTwoMember" xlink:to="lab_optn_DefinedContributionPlanTrancheTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_optn_September302025Member_6c791ca8-5f13-47dd-8004-eeda16c1b8ff_terseLabel_en-US" xlink:label="lab_optn_September302025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">September 30, 2025</link:label>
    <link:label id="lab_optn_September302025Member_label_en-US" xlink:label="lab_optn_September302025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">September 30, 2025 [Member]</link:label>
    <link:label id="lab_optn_September302025Member_documentation_en-US" xlink:label="lab_optn_September302025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">September 30, 2025</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_optn_September302025Member" xlink:href="optn-20221231.xsd#optn_September302025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_September302025Member" xlink:to="lab_optn_September302025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_7cbd3693-dae2-4046-8d83-af8629de91a1_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses:</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_13c32af6-b51c-419c-a641-79495bb0a789_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_70524ce1-bb68-4767-ae2b-2fc2f6374252_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_2b2707ce-a6c7-4222-b457-6fc7240a4838_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_40d3377e-5d0c-497b-a319-c8d4c8a807cf_totalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective income tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_optn_December312024Member_2b944ab7-cf14-4463-a1cb-48620ec88f81_terseLabel_en-US" xlink:label="lab_optn_December312024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 31, 2024</link:label>
    <link:label id="lab_optn_December312024Member_label_en-US" xlink:label="lab_optn_December312024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 31, 2024 [Member]</link:label>
    <link:label id="lab_optn_December312024Member_documentation_en-US" xlink:label="lab_optn_December312024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 31, 2024</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_optn_December312024Member" xlink:href="optn-20221231.xsd#optn_December312024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_December312024Member" xlink:to="lab_optn_December312024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_optn_FeeDueOnTheMaturityDateOfTheNotePurchaseAgreement_3b85bb48-39bf-4dde-981f-7f8d02945df2_terseLabel_en-US" xlink:label="lab_optn_FeeDueOnTheMaturityDateOfTheNotePurchaseAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fee due on the maturity date of the note purchase agreement</link:label>
    <link:label id="lab_optn_FeeDueOnTheMaturityDateOfTheNotePurchaseAgreement_label_en-US" xlink:label="lab_optn_FeeDueOnTheMaturityDateOfTheNotePurchaseAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fee Due On The Maturity Date Of The Note Purchase Agreement</link:label>
    <link:label id="lab_optn_FeeDueOnTheMaturityDateOfTheNotePurchaseAgreement_documentation_en-US" xlink:label="lab_optn_FeeDueOnTheMaturityDateOfTheNotePurchaseAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fee Due On The Maturity Date Of The Note Purchase Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_optn_FeeDueOnTheMaturityDateOfTheNotePurchaseAgreement" xlink:href="optn-20221231.xsd#optn_FeeDueOnTheMaturityDateOfTheNotePurchaseAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_FeeDueOnTheMaturityDateOfTheNotePurchaseAgreement" xlink:to="lab_optn_FeeDueOnTheMaturityDateOfTheNotePurchaseAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_f7824834-e295-41e7-b60f-d2fe7d7fc53e_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_6495b0df-f59d-42a4-b9e0-f9e2300d6745_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk free interest rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Risk Free Interest Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanTable_7f0be0af-94c3-47b7-adb8-dab1e738d6f8_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan [Table]</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanTable_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanTable" xlink:to="lab_us-gaap_DefinedContributionPlanTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_1bb2081f-1438-46be-baa2-d6a27491212a_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterials_3ef7de79-bec1-4101-baf1-1d46bcc57249_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterials_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterials"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterials" xlink:to="lab_us-gaap_InventoryRawMaterials" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_1a85fdb7-f1c6-425b-b6df-29d8b365e3e8_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_fea9717a-aafd-4f47-83d4-4ba09675efab_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, December 31, 2021</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_5933ba5f-74ce-4fea-8446-b237b64b7766_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, December 31, 2022</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" order="1"/>
    <link:label id="lab_optn_December312023Member_a475b77c-f4be-4f2a-b2f8-eb0a5a4c6ae9_terseLabel_en-US" xlink:label="lab_optn_December312023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 31, 2023</link:label>
    <link:label id="lab_optn_December312023Member_label_en-US" xlink:label="lab_optn_December312023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 31, 2023 [Member]</link:label>
    <link:label id="lab_optn_December312023Member_documentation_en-US" xlink:label="lab_optn_December312023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 31, 2023</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_optn_December312023Member" xlink:href="optn-20221231.xsd#optn_December312023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_December312023Member" xlink:to="lab_optn_December312023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_80066736-c7dd-45be-9a3c-f0a2dc83c1e4_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_57349dff-31fd-4ccd-b0b7-9cb7be5f5bf0_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_optn_TrailingTwelveMonthEndingAxisAxis_1639193c-5838-4cd2-b025-d409f191032d_terseLabel_en-US" xlink:label="lab_optn_TrailingTwelveMonthEndingAxisAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trailing Twelve Month Ending Axis [Axis]</link:label>
    <link:label id="lab_optn_TrailingTwelveMonthEndingAxisAxis_label_en-US" xlink:label="lab_optn_TrailingTwelveMonthEndingAxisAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trailing Twelve Month Ending Axis [Axis]</link:label>
    <link:label id="lab_optn_TrailingTwelveMonthEndingAxisAxis_documentation_en-US" xlink:label="lab_optn_TrailingTwelveMonthEndingAxisAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trailing Twelve Month Ending Axis</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_optn_TrailingTwelveMonthEndingAxisAxis" xlink:href="optn-20221231.xsd#optn_TrailingTwelveMonthEndingAxisAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_TrailingTwelveMonthEndingAxisAxis" xlink:to="lab_optn_TrailingTwelveMonthEndingAxisAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_optn_EffectiveIncomeTaxRateReconciliationPrepaidRoyaltyWriteOffPercent_28b4a1a8-1f10-4849-b74b-5e669b110b7d_terseLabel_en-US" xlink:label="lab_optn_EffectiveIncomeTaxRateReconciliationPrepaidRoyaltyWriteOffPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid royalty write off</link:label>
    <link:label id="lab_optn_EffectiveIncomeTaxRateReconciliationPrepaidRoyaltyWriteOffPercent_label_en-US" xlink:label="lab_optn_EffectiveIncomeTaxRateReconciliationPrepaidRoyaltyWriteOffPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Prepaid Royalty Write Off, Percent</link:label>
    <link:label id="lab_optn_EffectiveIncomeTaxRateReconciliationPrepaidRoyaltyWriteOffPercent_documentation_en-US" xlink:label="lab_optn_EffectiveIncomeTaxRateReconciliationPrepaidRoyaltyWriteOffPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Prepaid Royalty Write Off, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_optn_EffectiveIncomeTaxRateReconciliationPrepaidRoyaltyWriteOffPercent" xlink:href="optn-20221231.xsd#optn_EffectiveIncomeTaxRateReconciliationPrepaidRoyaltyWriteOffPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_EffectiveIncomeTaxRateReconciliationPrepaidRoyaltyWriteOffPercent" xlink:to="lab_optn_EffectiveIncomeTaxRateReconciliationPrepaidRoyaltyWriteOffPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_optn_UnderwritersMember_18773624-9f0c-489f-82f2-86b29a28eb5d_terseLabel_en-US" xlink:label="lab_optn_UnderwritersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underwriters</link:label>
    <link:label id="lab_optn_UnderwritersMember_label_en-US" xlink:label="lab_optn_UnderwritersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underwriters [Member]</link:label>
    <link:label id="lab_optn_UnderwritersMember_documentation_en-US" xlink:label="lab_optn_UnderwritersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underwriters</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_optn_UnderwritersMember" xlink:href="optn-20221231.xsd#optn_UnderwritersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_UnderwritersMember" xlink:to="lab_optn_UnderwritersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanDisclosureLineItems_fa394b76-b2ec-477f-b10b-4455716269a9_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan Disclosure</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanDisclosureLineItems_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="lab_us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_62a35e96-1cda-43f4-8132-80b9006d1c46_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock warrant exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_a77c2188-b878-4cfa-8ffe-afbe89c4b7f7_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_fcc98355-b6b0-4191-8965-6a39a7826eea_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (loss) income per share of common stock,&#160;basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_9ec48127-44e9-4d0e-bde1-80de51712680_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_2c3d5fe8-3901-4133-b367-7fbff62252cd_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock" xlink:to="lab_us-gaap_InventoryPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_7e282512-d05b-4c05-84c5-ee1e8d4e19d0_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_4c7b0275-5d38-48e7-afd9-d31b6728753d_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_c45c9bf2-8063-468d-8282-5bdf35ab9833_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders' deficit</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_e9143945-4ec0-4ebd-b93d-e01fdc68e381_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_6e1fff43-6d16-4794-ab61-85dffb70d299_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_10e653f4-f7ab-44da-821c-548c50ae42de_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_eb6fcc71-00de-4a9c-9f68-2a368516b00f_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_optn_DefinedContributionPlanTrancheOneMember_cd25f9bd-8ccc-4bce-a24c-650cb6c223ee_terseLabel_en-US" xlink:label="lab_optn_DefinedContributionPlanTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Tranche One</link:label>
    <link:label id="lab_optn_DefinedContributionPlanTrancheOneMember_label_en-US" xlink:label="lab_optn_DefinedContributionPlanTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Tranche One [Member]</link:label>
    <link:label id="lab_optn_DefinedContributionPlanTrancheOneMember_documentation_en-US" xlink:label="lab_optn_DefinedContributionPlanTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Tranche One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_optn_DefinedContributionPlanTrancheOneMember" xlink:href="optn-20221231.xsd#optn_DefinedContributionPlanTrancheOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_DefinedContributionPlanTrancheOneMember" xlink:to="lab_optn_DefinedContributionPlanTrancheOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_87d9f18f-e704-46a6-bdbc-c9dc54e671bd_verboseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expenses and Other Assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_label_en-US" xlink:label="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expenses and Other Current Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:to="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_12d8c5f8-02d5-4fb4-ba7d-d4c84b2e374e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e7f998d9-0239-4ece-b8d7-7617d1e79062_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_ffd00ae4-da59-464a-846a-ed6b9337dc4d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Liabilities Measured on Recurring Basis, Unobservable Inputs Reconciliation</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_fb11550e-f594-44bf-b500-1de83c68b8fd_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_optn_December312025Member_bc79ce47-de4c-4398-a61c-3b5751a0c04e_terseLabel_en-US" xlink:label="lab_optn_December312025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 31, 2025</link:label>
    <link:label id="lab_optn_December312025Member_label_en-US" xlink:label="lab_optn_December312025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 31, 2025 [Member]</link:label>
    <link:label id="lab_optn_December312025Member_documentation_en-US" xlink:label="lab_optn_December312025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 31, 2025</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_optn_December312025Member" xlink:href="optn-20221231.xsd#optn_December312025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_December312025Member" xlink:to="lab_optn_December312025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_a068d6ae-21f6-4829-b6f8-92d2e6446121_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease costs</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_f0f81ba6-35e7-4dff-b2b4-a4af82a70031_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_optn_September302024Member_3d76f795-9c39-456a-82a0-260ca69645ad_terseLabel_en-US" xlink:label="lab_optn_September302024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">September 30, 2024</link:label>
    <link:label id="lab_optn_September302024Member_label_en-US" xlink:label="lab_optn_September302024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">September 30, 2024 [Member]</link:label>
    <link:label id="lab_optn_September302024Member_documentation_en-US" xlink:label="lab_optn_September302024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">September 30, 2024</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_optn_September302024Member" xlink:href="optn-20221231.xsd#optn_September302024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_September302024Member" xlink:to="lab_optn_September302024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_b4ba49ec-c42d-4a59-b830-9979ddfeb0c0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Allocated Stock-based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_33b859e2-4538-4514-97cf-0ea88e69be7f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_e19e9408-e27f-48ad-9c62-076aa100e108_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_ddb63fd5-22bd-4180-8af9-77c97c30228f_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationAxis_4fac899d-0d3b-4c99-976d-d97b7568beea_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Sponsor Location [Axis]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationAxis_label_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Sponsor Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis" xlink:to="lab_us-gaap_RetirementPlanSponsorLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_f1fdd320-1d9e-4d57-b016-069ff46489dc_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_optn_ServiceBasedStockOptionsMember_08f12add-c471-44d4-997b-1a2ab388a16d_verboseLabel_en-US" xlink:label="lab_optn_ServiceBasedStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service Based Stock Options</link:label>
    <link:label id="lab_optn_ServiceBasedStockOptionsMember_label_en-US" xlink:label="lab_optn_ServiceBasedStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service Based Stock Options [Member]</link:label>
    <link:label id="lab_optn_ServiceBasedStockOptionsMember_documentation_en-US" xlink:label="lab_optn_ServiceBasedStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service Based Stock Options [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_optn_ServiceBasedStockOptionsMember" xlink:href="optn-20221231.xsd#optn_ServiceBasedStockOptionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_ServiceBasedStockOptionsMember" xlink:to="lab_optn_ServiceBasedStockOptionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_7aa63497-e70a-4c86-899d-7b7cb54be3c7_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture &amp; fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_fe66db98-ca07-496e-ab45-9b7caecae638_verboseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_68b4a76c-0681-4cbc-b7af-78b014a9804d_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_e6093aa0-c648-4515-be04-2523741e4c28_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_ca36123c-812e-4525-8f63-fb057dc64ec6_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets tax credit carryforwards research</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_2440e45b-3e2d-4ba6-91d5-5b70f5b8ff80_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Significant Unobservable Inputs in Valuation of Warrants</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_e07bbdb5-0eba-4b1b-86bc-a3bfa163e1cb_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined contribution plan, cost</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:to="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_4d9700dc-0c9d-426d-a2f5-e5f07e884663_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_71b8a6e2-229e-4331-b514-56e8209574f4_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_3852c117-7aba-4fab-b14c-49aa6b65539b_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_c9e61e99-8be8-4623-ba8f-47bd53f85593_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValue_72bb172d-8fdc-47dc-9b33-cadc95fb11a6_terseLabel_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_optn_IncreaseDecreaseInGrantsandOtherReceivables_a1b81f9a-3ea3-489f-8c11-4dbbcf6ab6df_negatedTerseLabel_en-US" xlink:label="lab_optn_IncreaseDecreaseInGrantsandOtherReceivables" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grants and other receivables</link:label>
    <link:label id="lab_optn_IncreaseDecreaseInGrantsandOtherReceivables_label_en-US" xlink:label="lab_optn_IncreaseDecreaseInGrantsandOtherReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Grants and Other Receivables</link:label>
    <link:label id="lab_optn_IncreaseDecreaseInGrantsandOtherReceivables_documentation_en-US" xlink:label="lab_optn_IncreaseDecreaseInGrantsandOtherReceivables" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Grants and Other Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_optn_IncreaseDecreaseInGrantsandOtherReceivables" xlink:href="optn-20221231.xsd#optn_IncreaseDecreaseInGrantsandOtherReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_IncreaseDecreaseInGrantsandOtherReceivables" xlink:to="lab_optn_IncreaseDecreaseInGrantsandOtherReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_aee5360b-d29d-40d5-a6de-73fcd93bf5a7_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_b4f5976e-be63-40f6-8dc9-6cfbf48425d6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable, Weighted average exercise price per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_5c5d086b-ab17-47db-8fd5-8caca71a184a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expired, Weighted average exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_bb3b6767-7818-4085-b7b0-4d38b5c7aafd_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document fiscal year focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignPlanMember_585b4b1f-374d-45d8-8c3e-d4d16ebbd96b_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Plan</link:label>
    <link:label id="lab_us-gaap_ForeignPlanMember_label_en-US" xlink:label="lab_us-gaap_ForeignPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignPlanMember" xlink:to="lab_us-gaap_ForeignPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_845f93c2-86d8-4cfc-8962-a0cf8da6cea5_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_3da7b5db-57ab-4879-8f32-7cd2e7360412_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingTerm_26371274-988c-4c0a-9ca7-0743dbe8c34d_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected life (years)</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingTerm_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and Rights Outstanding, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_6335c1a2-66f3-4d2f-8e13-175ceb5a1a0a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_95babe12-c298-43f9-9c1d-182a16a3c26c_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_39209e4e-01d8-4ac1-87f7-88eaec1a125b_totalLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_8da437f9-2ea7-4753-99e9-fdbdf8d68c8c_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development credits</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, in Process Research and Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_06e073be-7fcf-4cbc-b450-d641994f73d8_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at beginning (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_68019962-f136-4874-bd5e-646ea530d642_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at ending (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_74f4ea31-e603-4a52-a552-299791e86634_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_b924bfac-78e5-4d9f-b714-3809b40669b6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_c6c95735-a051-46b9-b43d-d1d7f3e9fd89_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_334b2a42-1870-4594-9e22-b6f8bce1308c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_0fdde89a-075d-4c38-8aa7-7ae6ecc29281_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net product revenues</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_f053863f-fdbd-4e1f-90ba-07b3e3f78408_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_optn_ClassOfWarrantOrRightRestrictionCommonSharesMaximumOwnershipIfExercisedPercent_0c249f59-3a2c-4d28-b1f1-b8e51d5baf0e_terseLabel_en-US" xlink:label="lab_optn_ClassOfWarrantOrRightRestrictionCommonSharesMaximumOwnershipIfExercisedPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of warrant or right restriction, common shares maximum ownership If exercised, percent</link:label>
    <link:label id="lab_optn_ClassOfWarrantOrRightRestrictionCommonSharesMaximumOwnershipIfExercisedPercent_label_en-US" xlink:label="lab_optn_ClassOfWarrantOrRightRestrictionCommonSharesMaximumOwnershipIfExercisedPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right Restriction, Common Shares Maximum Ownership If Exercised, Percent</link:label>
    <link:label id="lab_optn_ClassOfWarrantOrRightRestrictionCommonSharesMaximumOwnershipIfExercisedPercent_documentation_en-US" xlink:label="lab_optn_ClassOfWarrantOrRightRestrictionCommonSharesMaximumOwnershipIfExercisedPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right Restriction, Common Shares Maximum Ownership If Exercised, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_optn_ClassOfWarrantOrRightRestrictionCommonSharesMaximumOwnershipIfExercisedPercent" xlink:href="optn-20221231.xsd#optn_ClassOfWarrantOrRightRestrictionCommonSharesMaximumOwnershipIfExercisedPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_ClassOfWarrantOrRightRestrictionCommonSharesMaximumOwnershipIfExercisedPercent" xlink:to="lab_optn_ClassOfWarrantOrRightRestrictionCommonSharesMaximumOwnershipIfExercisedPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_1b0f4efd-0aa1-427c-9b3c-9bdcbc40460f_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long lived assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_cd3585af-6013-4966-a12f-885ccd870a20_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_optn_DebtInstrumentMakeWholeProvisionPaymentAccrualPeriod_168d7b08-73e7-4092-afdc-6e1745604d89_terseLabel_en-US" xlink:label="lab_optn_DebtInstrumentMakeWholeProvisionPaymentAccrualPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, make-whole provision, payment accrual period</link:label>
    <link:label id="lab_optn_DebtInstrumentMakeWholeProvisionPaymentAccrualPeriod_label_en-US" xlink:label="lab_optn_DebtInstrumentMakeWholeProvisionPaymentAccrualPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Make-Whole Provision, Payment Accrual Period</link:label>
    <link:label id="lab_optn_DebtInstrumentMakeWholeProvisionPaymentAccrualPeriod_documentation_en-US" xlink:label="lab_optn_DebtInstrumentMakeWholeProvisionPaymentAccrualPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Make-Whole Provision, Payment Accrual Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_optn_DebtInstrumentMakeWholeProvisionPaymentAccrualPeriod" xlink:href="optn-20221231.xsd#optn_DebtInstrumentMakeWholeProvisionPaymentAccrualPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_DebtInstrumentMakeWholeProvisionPaymentAccrualPeriod" xlink:to="lab_optn_DebtInstrumentMakeWholeProvisionPaymentAccrualPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_5fa630a2-66d9-47bc-9bb5-291a32633082_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCountryMember_4ae2bf1b-faed-4d70-b29c-51f9d951ed7a_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Tax Authority</link:label>
    <link:label id="lab_us-gaap_ForeignCountryMember_label_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCountryMember" xlink:to="lab_us-gaap_ForeignCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_a735cfab-758e-4eb3-8a46-a5808d1cd0ec_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredOfferingCosts_6de9bb50-3a61-4450-ba47-cce4c8beff3a_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredOfferingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred offering costs</link:label>
    <link:label id="lab_us-gaap_DeferredOfferingCosts_label_en-US" xlink:label="lab_us-gaap_DeferredOfferingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Offering Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredOfferingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredOfferingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredOfferingCosts" xlink:to="lab_us-gaap_DeferredOfferingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_feb9b84c-5f9b-4dfb-96d9-99e7b3f6e28d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_06aa6845-2a51-4398-8a85-8af2f6553e02_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_fa2d40c2-87c3-4c76-9a30-2a356f3f5d2e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_a1869bad-d8f9-49c2-9516-0ced624440fe_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent accounting pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_optn_AmendmentFeePercentage_72b59629-39a4-4503-8bca-afac669cbc45_terseLabel_en-US" xlink:label="lab_optn_AmendmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment fee, percentage</link:label>
    <link:label id="lab_optn_AmendmentFeePercentage_label_en-US" xlink:label="lab_optn_AmendmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Fee, Percentage</link:label>
    <link:label id="lab_optn_AmendmentFeePercentage_documentation_en-US" xlink:label="lab_optn_AmendmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Fee, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_optn_AmendmentFeePercentage" xlink:href="optn-20221231.xsd#optn_AmendmentFeePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_AmendmentFeePercentage" xlink:to="lab_optn_AmendmentFeePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_750bd96a-f7f5-4856-b0e8-9973e1ae1d2b_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Jurisdiction</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_4c442aa5-7283-43bd-a2a8-6f91ad2f7960_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_667f9bdc-f04d-48a7-b353-4646290092ce_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_c60dfe6b-a015-4e3b-9daa-1d6cfb6a7e19_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryGross_da7c718e-d5ed-4b1f-953c-8b940f79df02_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total inventory</link:label>
    <link:label id="lab_us-gaap_InventoryGross_label_en-US" xlink:label="lab_us-gaap_InventoryGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryGross" xlink:to="lab_us-gaap_InventoryGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_6888a71f-e8b3-442a-8e4a-3a14fefa6bb3_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_76bcb995-c3fa-44b5-8b34-66e6f820cbd6_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayable_ab4920fc-24d5-40d0-85e6-9675f062ed53_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal balance outstanding</link:label>
    <link:label id="lab_us-gaap_NotesPayable_label_en-US" xlink:label="lab_us-gaap_NotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayable" xlink:to="lab_us-gaap_NotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_optn_March312025Member_6f64a002-7a6f-42de-a4f2-4431b556bc4d_terseLabel_en-US" xlink:label="lab_optn_March312025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">March 31, 2025</link:label>
    <link:label id="lab_optn_March312025Member_label_en-US" xlink:label="lab_optn_March312025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">March 31, 2025 [Member]</link:label>
    <link:label id="lab_optn_March312025Member_documentation_en-US" xlink:label="lab_optn_March312025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">March 31, 2025</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_optn_March312025Member" xlink:href="optn-20221231.xsd#optn_March312025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_March312025Member" xlink:to="lab_optn_March312025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_optn_ClassOfWarrantOrRightRestrictionCommonSharesMaximumOwnershipAfterEffectiveWaitingPeriodPercent_55fd8cd1-c48c-4ed2-860f-9c6e84317399_terseLabel_en-US" xlink:label="lab_optn_ClassOfWarrantOrRightRestrictionCommonSharesMaximumOwnershipAfterEffectiveWaitingPeriodPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of warrant or right restriction, common shares maximum ownership after effective waiting period, percent</link:label>
    <link:label id="lab_optn_ClassOfWarrantOrRightRestrictionCommonSharesMaximumOwnershipAfterEffectiveWaitingPeriodPercent_label_en-US" xlink:label="lab_optn_ClassOfWarrantOrRightRestrictionCommonSharesMaximumOwnershipAfterEffectiveWaitingPeriodPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right Restriction, Common Shares Maximum Ownership After Effective Waiting Period, Percent</link:label>
    <link:label id="lab_optn_ClassOfWarrantOrRightRestrictionCommonSharesMaximumOwnershipAfterEffectiveWaitingPeriodPercent_documentation_en-US" xlink:label="lab_optn_ClassOfWarrantOrRightRestrictionCommonSharesMaximumOwnershipAfterEffectiveWaitingPeriodPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right Restriction, Common Shares Maximum Ownership After Effective Waiting Period, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_optn_ClassOfWarrantOrRightRestrictionCommonSharesMaximumOwnershipAfterEffectiveWaitingPeriodPercent" xlink:href="optn-20221231.xsd#optn_ClassOfWarrantOrRightRestrictionCommonSharesMaximumOwnershipAfterEffectiveWaitingPeriodPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_ClassOfWarrantOrRightRestrictionCommonSharesMaximumOwnershipAfterEffectiveWaitingPeriodPercent" xlink:to="lab_optn_ClassOfWarrantOrRightRestrictionCommonSharesMaximumOwnershipAfterEffectiveWaitingPeriodPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_optn_FairValueOfWarrant_190d3be5-2b48-4cf3-b88f-f891f6ae7b88_terseLabel_en-US" xlink:label="lab_optn_FairValueOfWarrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value per warrant</link:label>
    <link:label id="lab_optn_FairValueOfWarrant_label_en-US" xlink:label="lab_optn_FairValueOfWarrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Of Warrant</link:label>
    <link:label id="lab_optn_FairValueOfWarrant_documentation_en-US" xlink:label="lab_optn_FairValueOfWarrant" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Of Warrant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_optn_FairValueOfWarrant" xlink:href="optn-20221231.xsd#optn_FairValueOfWarrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_FairValueOfWarrant" xlink:to="lab_optn_FairValueOfWarrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3ef8ca8c-38e4-436a-aed0-6ac3903e6e76_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_optn_StockIssuedDuringPeriodSharesVestedRestrictedStockUnits_ca4759e4-c9c1-43e5-89c5-b3234922eff4_terseLabel_en-US" xlink:label="lab_optn_StockIssuedDuringPeriodSharesVestedRestrictedStockUnits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting of restricted stock units (in shares)</link:label>
    <link:label id="lab_optn_StockIssuedDuringPeriodSharesVestedRestrictedStockUnits_label_en-US" xlink:label="lab_optn_StockIssuedDuringPeriodSharesVestedRestrictedStockUnits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Vested Restricted Stock Units</link:label>
    <link:label id="lab_optn_StockIssuedDuringPeriodSharesVestedRestrictedStockUnits_documentation_en-US" xlink:label="lab_optn_StockIssuedDuringPeriodSharesVestedRestrictedStockUnits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Vested Restricted Stock Units</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_optn_StockIssuedDuringPeriodSharesVestedRestrictedStockUnits" xlink:href="optn-20221231.xsd#optn_StockIssuedDuringPeriodSharesVestedRestrictedStockUnits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_StockIssuedDuringPeriodSharesVestedRestrictedStockUnits" xlink:to="lab_optn_StockIssuedDuringPeriodSharesVestedRestrictedStockUnits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_68e1e32d-b97e-43cd-a6a6-690834ca1aef_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_944f1071-2a66-405f-8065-6017cdf357d2_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_label_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_f08d0f87-8bb0-4bd2-b936-e644c65bfbc5_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_e094f214-0942-4977-b91f-7f9d0aeb70f8_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_a91b2241-0c48-435f-b845-d195294766b9_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_6bb38a8f-e965-4e14-bc8d-9622b9f3bb8a_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_f63e3986-e0db-4119-a5b9-c6ba1ae5fa24_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid -in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_ec3f378c-6c35-41ca-b5e3-528cb6f3d72b_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_01126f65-cf67-46c6-a5e0-f97902e26f88_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document fiscal period focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_0c85d164-f7e9-443f-a9bc-524f505cd05d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intrinsic value of exercised options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_0c9d09e9-5884-48e8-b55e-60c1386754f2_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of product sales</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_d9809e95-37ab-4884-ab28-6969de3e2c26_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average common shares outstanding, diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_7d30794f-13e0-454c-97a2-42e2561f5940_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_optn_NumberOfCustomers_4dbb04fb-b434-49b4-a793-0a034d684a9d_terseLabel_en-US" xlink:label="lab_optn_NumberOfCustomers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of customers (customer)</link:label>
    <link:label id="lab_optn_NumberOfCustomers_label_en-US" xlink:label="lab_optn_NumberOfCustomers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Customers</link:label>
    <link:label id="lab_optn_NumberOfCustomers_documentation_en-US" xlink:label="lab_optn_NumberOfCustomers" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Customers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_optn_NumberOfCustomers" xlink:href="optn-20221231.xsd#optn_NumberOfCustomers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_NumberOfCustomers" xlink:to="lab_optn_NumberOfCustomers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_00e2df30-32b4-45b3-85a8-3729ac6a77db_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_153f6d5b-d708-4286-8f2b-269e59261dac_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_optn_June302026Member_328b78ec-29a1-4adb-ae23-f4a0208903ed_terseLabel_en-US" xlink:label="lab_optn_June302026Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">June 30, 2026</link:label>
    <link:label id="lab_optn_June302026Member_label_en-US" xlink:label="lab_optn_June302026Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">June 30, 2026 [Member]</link:label>
    <link:label id="lab_optn_June302026Member_documentation_en-US" xlink:label="lab_optn_June302026Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">June 30, 2026</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_optn_June302026Member" xlink:href="optn-20221231.xsd#optn_June302026Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_June302026Member" xlink:to="lab_optn_June302026Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableMember_8f8ac558-3a8d-46e5-92af-04f7101a2c44_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember" xlink:to="lab_us-gaap_AccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_f3e5b447-be41-41ba-97aa-bbcce840a8b7_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_optn_DefinedContributionPlanTranchesAxisAxis_9b78fd90-4c31-4e8b-a206-dd9dfee48d7b_terseLabel_en-US" xlink:label="lab_optn_DefinedContributionPlanTranchesAxisAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan Tranches Axis [Axis]</link:label>
    <link:label id="lab_optn_DefinedContributionPlanTranchesAxisAxis_label_en-US" xlink:label="lab_optn_DefinedContributionPlanTranchesAxisAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan Tranches Axis [Axis]</link:label>
    <link:label id="lab_optn_DefinedContributionPlanTranchesAxisAxis_documentation_en-US" xlink:label="lab_optn_DefinedContributionPlanTranchesAxisAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan Tranches Axis [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_optn_DefinedContributionPlanTranchesAxisAxis" xlink:href="optn-20221231.xsd#optn_DefinedContributionPlanTranchesAxisAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_DefinedContributionPlanTranchesAxisAxis" xlink:to="lab_optn_DefinedContributionPlanTranchesAxisAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_optn_DebtInstrumentFeeAmountBackEnd_09f00742-b6e9-4956-86b0-dbc2220794ca_terseLabel_en-US" xlink:label="lab_optn_DebtInstrumentFeeAmountBackEnd" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Back end fees</link:label>
    <link:label id="lab_optn_DebtInstrumentFeeAmountBackEnd_label_en-US" xlink:label="lab_optn_DebtInstrumentFeeAmountBackEnd" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Fee Amount, Back End</link:label>
    <link:label id="lab_optn_DebtInstrumentFeeAmountBackEnd_documentation_en-US" xlink:label="lab_optn_DebtInstrumentFeeAmountBackEnd" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Fee Amount, Back End</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_optn_DebtInstrumentFeeAmountBackEnd" xlink:href="optn-20221231.xsd#optn_DebtInstrumentFeeAmountBackEnd"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_DebtInstrumentFeeAmountBackEnd" xlink:to="lab_optn_DebtInstrumentFeeAmountBackEnd" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan_93615a2a-8f40-423c-b990-6203d61bf32e_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under employee stock purchase plan (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Ownership Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_67c374b3-946f-4d92-a1a0-e8591a35ed3d_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.001 par value; 200,000,000 shares authorized at December 31, 2022 and 2021; 111,492,761 and 82,238,900 shares issued and outstanding at December 31, 2022 and December 31, 2021, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_f87e66e5-9927-4c14-be1c-23feeefcc942_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeniorNotesMember_b20d6f1b-7f03-43b3-8fa4-15f544ec0397_terseLabel_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes</link:label>
    <link:label id="lab_us-gaap_SeniorNotesMember_label_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeniorNotesMember" xlink:to="lab_us-gaap_SeniorNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_optn_ComputerEquipmentandSoftwareMember_1f51093f-9789-4008-9a06-63393d067146_terseLabel_en-US" xlink:label="lab_optn_ComputerEquipmentandSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer equipment and software</link:label>
    <link:label id="lab_optn_ComputerEquipmentandSoftwareMember_label_en-US" xlink:label="lab_optn_ComputerEquipmentandSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment and Software [Member]</link:label>
    <link:label id="lab_optn_ComputerEquipmentandSoftwareMember_documentation_en-US" xlink:label="lab_optn_ComputerEquipmentandSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment and Software [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_optn_ComputerEquipmentandSoftwareMember" xlink:href="optn-20221231.xsd#optn_ComputerEquipmentandSoftwareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_ComputerEquipmentandSoftwareMember" xlink:to="lab_optn_ComputerEquipmentandSoftwareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_optn_AccruedSellingGeneralandAdministrativeCurrent_4789eb0b-8f14-449e-8c9e-0e6f63eb9154_terseLabel_en-US" xlink:label="lab_optn_AccruedSellingGeneralandAdministrativeCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative expenses</link:label>
    <link:label id="lab_optn_AccruedSellingGeneralandAdministrativeCurrent_label_en-US" xlink:label="lab_optn_AccruedSellingGeneralandAdministrativeCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Selling, General and Administrative, Current</link:label>
    <link:label id="lab_optn_AccruedSellingGeneralandAdministrativeCurrent_documentation_en-US" xlink:label="lab_optn_AccruedSellingGeneralandAdministrativeCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Selling, General and Administrative, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_optn_AccruedSellingGeneralandAdministrativeCurrent" xlink:href="optn-20221231.xsd#optn_AccruedSellingGeneralandAdministrativeCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_AccruedSellingGeneralandAdministrativeCurrent" xlink:to="lab_optn_AccruedSellingGeneralandAdministrativeCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_f9ba7c9a-a88e-4e2c-a536-fbb39cc527d9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Price issued (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_9b226873-ed9a-42a6-99dc-df553fea0add_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Shares Excluded from Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_13df302d-a566-41f3-af60-094fb54d155d_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intrinsic value of exercisable options</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1c2417df-955c-4d4e-9e0f-649c36bc4766_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e70dbdea-9ab9-4875-b3b0-1699a3c5f71e_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_b14f606d-758b-4d20-bcf6-32839cdb422a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_c4dea6e4-6d9e-4a2d-915c-21a4bd0bdf64_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_cc9cade9-26e1-4cf8-9348-e251e4c71696_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of warrants in connection with Pharmakon Second Amendment, net of cancellation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_11ece3dd-060c-42a4-b8dc-e37cc49e58fc_verboseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of warrants issued</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Warrant Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_555dee7b-f0df-4da9-870f-53a1e1e991fe_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants outstanding, measurement input</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and Rights Outstanding, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputSharePriceMember_540819c7-5bf7-4590-a983-9ec6ad3cc4c8_verboseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputSharePriceMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock price</link:label>
    <link:label id="lab_us-gaap_MeasurementInputSharePriceMember_27ca2354-2291-4d3a-a45b-f3ef10877766_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputSharePriceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of common stock</link:label>
    <link:label id="lab_us-gaap_MeasurementInputSharePriceMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputSharePriceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Share Price [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputSharePriceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputSharePriceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputSharePriceMember" xlink:to="lab_us-gaap_MeasurementInputSharePriceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_7d527302-8196-4dc9-80b1-20a7abb2d95f_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_461db45f-cb6f-45cc-8aee-ac7717bd3573_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from the exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_db1a2ffd-b08e-401b-823c-d05b009c8143_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_cfa2deb3-9e9c-4377-9b97-3798af0cf185_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskLineItems" xlink:to="lab_us-gaap_ConcentrationRiskLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_optn_AccruedProductAllowancesCurrent_82bd9755-ac96-4853-8120-731bf259e20e_terseLabel_en-US" xlink:label="lab_optn_AccruedProductAllowancesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product revenue allowances</link:label>
    <link:label id="lab_optn_AccruedProductAllowancesCurrent_label_en-US" xlink:label="lab_optn_AccruedProductAllowancesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Product Allowances, Current</link:label>
    <link:label id="lab_optn_AccruedProductAllowancesCurrent_documentation_en-US" xlink:label="lab_optn_AccruedProductAllowancesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Product Allowances, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_optn_AccruedProductAllowancesCurrent" xlink:href="optn-20221231.xsd#optn_AccruedProductAllowancesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_AccruedProductAllowancesCurrent" xlink:to="lab_optn_AccruedProductAllowancesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstanding_7cc09d7d-7869-467e-9e50-3e950822e589_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and rights outstanding</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstanding_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and Rights Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstanding" xlink:to="lab_us-gaap_WarrantsAndRightsOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_da418e54-537e-43c9-aebb-64c7af51c8bd_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_86fc95d7-8efd-4c98-a800-dc23930e7174_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_94836f19-dca5-4419-a213-bf6cc5a83927_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_57f782ce-1b08-4e20-88cc-de8626181e1a_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Face amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_15a0e930-a1b1-4295-a577-8239e9ce1227_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_06ecbd4c-7ad1-4e8e-9995-e97e60c05994_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Liabilities Measured on Recurring Basis</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_optn_SaleOfStockCommissionsAndExpenses_57ee84d5-ae3a-4b16-af43-9fbf7b7aeed8_terseLabel_en-US" xlink:label="lab_optn_SaleOfStockCommissionsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commissions</link:label>
    <link:label id="lab_optn_SaleOfStockCommissionsAndExpenses_label_en-US" xlink:label="lab_optn_SaleOfStockCommissionsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Commissions And Expenses</link:label>
    <link:label id="lab_optn_SaleOfStockCommissionsAndExpenses_documentation_en-US" xlink:label="lab_optn_SaleOfStockCommissionsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Commissions And Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_optn_SaleOfStockCommissionsAndExpenses" xlink:href="optn-20221231.xsd#optn_SaleOfStockCommissionsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_SaleOfStockCommissionsAndExpenses" xlink:to="lab_optn_SaleOfStockCommissionsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_c7ea0d91-fb1b-4924-ad36-b0ab602f16ec_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in process</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember" xlink:to="lab_us-gaap_ConstructionInProgressMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_cdcf926d-233a-4355-ac6e-98a52b33d20d_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment or disposition of long-lived assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Long-Lived Assets to be Disposed of</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:to="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_dccdd687-0b7d-44a3-a113-a15217d85b40_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_75bdb78e-5003-48bc-809f-f8ac17264f09_terseLabel_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets:</link:label>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_label_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Deferred Tax Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_cf15d8ac-0788-4f3b-945d-cf207f929fd6_totalLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_984e1701-ccfb-4324-a213-aa84b9144aa5_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_62336d26-e7b4-430e-b7a8-a303592148ae_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service-based stock options, additional disclosures</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_875d1fc2-190c-4520-8b85-e49efbd5145a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_16ed6fd9-5ddd-462b-ab73-9c46266845d4_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_2b208cbb-ac20-49e9-89f7-4feef2625a67_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase price of common stock percent</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_532cf234-0415-4859-ae78-c0f288456252_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_6ebd3938-eb54-4043-891c-dcf196bb91cd_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense at statutory rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_84ead4f5-f0ee-49cb-939f-218277cff62a_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_fc695811-2bf9-4d35-bf49-260b25783f4d_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares outstanding, beginning (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7b7096ff-2583-425b-8f5d-607dc1797611_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares outstanding, ending (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_7f49674c-65fb-4082-9f24-927296997242_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock based compensation</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_f9813a48-0d70-485c-a722-82616ae889c1_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Expenses and Other Current Liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_cafb4d7c-7417-4ba9-978f-3d1b95da988d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_1bb6e248-c256-447f-b0b0-1fa4f3754faa_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_55d8cafd-f647-4e98-a64c-762402d63243_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State taxes, net of federal benefit</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_86060817-5bf6-4b15-9a9b-749edf68032a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service-based stock options activity</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_optn_MarketBasedStockOptionsMember_b507d258-07b4-4308-84b8-87395bd35767_terseLabel_en-US" xlink:label="lab_optn_MarketBasedStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Market Based Stock Options</link:label>
    <link:label id="lab_optn_MarketBasedStockOptionsMember_label_en-US" xlink:label="lab_optn_MarketBasedStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Market Based Stock Options [Member]</link:label>
    <link:label id="lab_optn_MarketBasedStockOptionsMember_documentation_en-US" xlink:label="lab_optn_MarketBasedStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Market Based Stock Options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_optn_MarketBasedStockOptionsMember" xlink:href="optn-20221231.xsd#optn_MarketBasedStockOptionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_MarketBasedStockOptionsMember" xlink:to="lab_optn_MarketBasedStockOptionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_a6e156d8-293b-47d8-a398-3596ed435100_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0450074e-99a9-4fb7-a282-00252b62b5d9_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effects of exchange rate changes on cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_6418cec0-8d9e-48da-aa68-0ccdda3dc4cc_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_ae2959cd-a161-4341-892c-a1376c44df64_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_optn_QuarterEndedDecember312019Member_056cc8a6-c52e-4f6e-88a8-57936fd7f09b_terseLabel_en-US" xlink:label="lab_optn_QuarterEndedDecember312019Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarter Ended December 31, 2019</link:label>
    <link:label id="lab_optn_QuarterEndedDecember312019Member_label_en-US" xlink:label="lab_optn_QuarterEndedDecember312019Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarter Ended December 31, 2019 [Member]</link:label>
    <link:label id="lab_optn_QuarterEndedDecember312019Member_documentation_en-US" xlink:label="lab_optn_QuarterEndedDecember312019Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarter Ended December 31, 2019</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_optn_QuarterEndedDecember312019Member" xlink:href="optn-20221231.xsd#optn_QuarterEndedDecember312019Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_QuarterEndedDecember312019Member" xlink:to="lab_optn_QuarterEndedDecember312019Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_1609b336-c065-419a-99e5-4fc8b0aa3ba1_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for amounts included in the measurement of operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_a58087ac-b3bb-4139-a7cb-5b1a555a9314_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of liability</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_d5858323-9d87-47a6-ab88-bbfcbf604c7f_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_0fe0fc62-cdb5-4919-953e-e1ca6484f2cf_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2010 A&amp;R Stock Incentive Plan</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain_b693feec-9ee8-482c-b2e0-434d935a3fbc_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_0674a8d4-15d9-4238-ae38-59d2b5caf70b_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of common stock options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_527d1e87-b01b-4c7f-bb51-25f108a35f6c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expired/ forfeited/ canceled (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_optn_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedIncrementEachYear_ee807a80-2c2f-4685-9a77-db611a871721_terseLabel_en-US" xlink:label="lab_optn_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedIncrementEachYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in number of shares issuable each year</link:label>
    <link:label id="lab_optn_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedIncrementEachYear_label_en-US" xlink:label="lab_optn_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedIncrementEachYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized Increment Each Year</link:label>
    <link:label id="lab_optn_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedIncrementEachYear_documentation_en-US" xlink:label="lab_optn_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedIncrementEachYear" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized Increment Each Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_optn_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedIncrementEachYear" xlink:href="optn-20221231.xsd#optn_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedIncrementEachYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedIncrementEachYear" xlink:to="lab_optn_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedIncrementEachYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_38e4e151-0bb8-41eb-9275-39ddb5d25c46_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_234ea170-588a-4048-9f83-3a28351ec8ca_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_d46854f4-51a5-45f7-bc77-7435737047be_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Price per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_46db7d23-26fa-4231-bd9f-1f8fd9888dbf_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_3c29d4c4-cb09-42f9-8814-e616ff82f412_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_151ade1f-a785-4584-b759-87d8195db3c0_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_42be9f88-a896-4913-9fec-2b333ad9ac71_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_d05aa486-6ece-4688-97f0-dd4724fdb5d2_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_optn_DeferredOfferingCostsWIthinAccountsPayableandAccruedExpenses_0d2e8cca-0476-4a61-be7a-ece6a7902ab7_terseLabel_en-US" xlink:label="lab_optn_DeferredOfferingCostsWIthinAccountsPayableandAccruedExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing costs within accounts payable and accrued expenses</link:label>
    <link:label id="lab_optn_DeferredOfferingCostsWIthinAccountsPayableandAccruedExpenses_label_en-US" xlink:label="lab_optn_DeferredOfferingCostsWIthinAccountsPayableandAccruedExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Offering Costs WIthin Accounts Payable and Accrued Expenses</link:label>
    <link:label id="lab_optn_DeferredOfferingCostsWIthinAccountsPayableandAccruedExpenses_documentation_en-US" xlink:label="lab_optn_DeferredOfferingCostsWIthinAccountsPayableandAccruedExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Offering Costs WIthin Accounts Payable and Accrued Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_optn_DeferredOfferingCostsWIthinAccountsPayableandAccruedExpenses" xlink:href="optn-20221231.xsd#optn_DeferredOfferingCostsWIthinAccountsPayableandAccruedExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_DeferredOfferingCostsWIthinAccountsPayableandAccruedExpenses" xlink:to="lab_optn_DeferredOfferingCostsWIthinAccountsPayableandAccruedExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_e87f8021-fb0f-448f-ad48-e9960cc4f7f6_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work-in-process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcess" xlink:to="lab_us-gaap_InventoryWorkInProcess" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_651758f8-d93b-4711-ab38-fca0a8be1193_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_optn_EffectiveIncomeTaxRateReconciliationForeignOperationsImpactPercent_d39e009d-247e-48ea-936d-e30f7ea0ef0c_terseLabel_en-US" xlink:label="lab_optn_EffectiveIncomeTaxRateReconciliationForeignOperationsImpactPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impact of foreign operations</link:label>
    <link:label id="lab_optn_EffectiveIncomeTaxRateReconciliationForeignOperationsImpactPercent_label_en-US" xlink:label="lab_optn_EffectiveIncomeTaxRateReconciliationForeignOperationsImpactPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Operations Impact, Percent</link:label>
    <link:label id="lab_optn_EffectiveIncomeTaxRateReconciliationForeignOperationsImpactPercent_documentation_en-US" xlink:label="lab_optn_EffectiveIncomeTaxRateReconciliationForeignOperationsImpactPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Operations Impact, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_optn_EffectiveIncomeTaxRateReconciliationForeignOperationsImpactPercent" xlink:href="optn-20221231.xsd#optn_EffectiveIncomeTaxRateReconciliationForeignOperationsImpactPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_EffectiveIncomeTaxRateReconciliationForeignOperationsImpactPercent" xlink:to="lab_optn_EffectiveIncomeTaxRateReconciliationForeignOperationsImpactPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_18c341df-bd74-4d6b-abb4-f52c0b829ff3_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_fdb1594a-bbc0-40df-a526-a298a7bf0983_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_167bbc5f-9943-4925-8863-b10411354904_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_fe51ca32-018e-4491-88d3-a7d9be09f3c7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Warrants Outstanding</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_e0069d6f-354c-40f7-add8-a41f17545114_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_7ed48352-a8fd-427e-8f33-530558459d8b_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends declared (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_label_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Dividends, Per Share, Declared</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:to="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:type="arc" order="1"/>
    <link:label id="lab_optn_September302027Member_17034d9d-0aa2-4cf7-afe6-60395983a3d9_terseLabel_en-US" xlink:label="lab_optn_September302027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">September 30, 2027</link:label>
    <link:label id="lab_optn_September302027Member_label_en-US" xlink:label="lab_optn_September302027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">September 30, 2027 [Member]</link:label>
    <link:label id="lab_optn_September302027Member_documentation_en-US" xlink:label="lab_optn_September302027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">September 30, 2027</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_optn_September302027Member" xlink:href="optn-20221231.xsd#optn_September302027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_September302027Member" xlink:to="lab_optn_September302027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_7e3490dd-b278-495f-bd39-c22d60ee2d71_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets Measured on Recurring Basis</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_c9605c4f-39d0-4843-a75b-8c8a10114ef4_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:to="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_87b56da7-1b48-4fac-9e46-d0d2084b74f9_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_optn_PublicOfferingMember_f114d81c-ff31-47a2-917c-00e6a3cad843_terseLabel_en-US" xlink:label="lab_optn_PublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Offering</link:label>
    <link:label id="lab_optn_PublicOfferingMember_label_en-US" xlink:label="lab_optn_PublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Offering [Member]</link:label>
    <link:label id="lab_optn_PublicOfferingMember_documentation_en-US" xlink:label="lab_optn_PublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Offering [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_optn_PublicOfferingMember" xlink:href="optn-20221231.xsd#optn_PublicOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_PublicOfferingMember" xlink:to="lab_optn_PublicOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3f7553d6-88cc-4f72-bf26-8d2e5295158e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intrinsic value of options outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_f6277293-ad84-49fe-bdfc-b9ad3a382fda_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_optn_NASDAQInducementGrantExceptionMember_ed925c53-eddd-4cd9-adf1-9687f74f16ff_terseLabel_en-US" xlink:label="lab_optn_NASDAQInducementGrantExceptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NASDAQ Inducement Grant Exception</link:label>
    <link:label id="lab_optn_NASDAQInducementGrantExceptionMember_label_en-US" xlink:label="lab_optn_NASDAQInducementGrantExceptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NASDAQ Inducement Grant Exception [Member]</link:label>
    <link:label id="lab_optn_NASDAQInducementGrantExceptionMember_documentation_en-US" xlink:label="lab_optn_NASDAQInducementGrantExceptionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NASDAQ Inducement Grant Exception</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_optn_NASDAQInducementGrantExceptionMember" xlink:href="optn-20221231.xsd#optn_NASDAQInducementGrantExceptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_NASDAQInducementGrantExceptionMember" xlink:to="lab_optn_NASDAQInducementGrantExceptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_3005dc42-49c3-4075-9974-061d7d1b572b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_2e64a390-ae01-4f78-8150-b61e8f029753_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_6d346e70-f98e-4390-82a3-9a63cc05a17f_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationDomain_4e9064a2-7e04-43f4-876f-2b8bd1c3db12_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Sponsor Location [Domain]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationDomain_label_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Sponsor Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain" xlink:to="lab_us-gaap_RetirementPlanSponsorLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_optn_March312027Member_356c6751-3aa8-4cb0-8a1f-f25b4af8c30b_terseLabel_en-US" xlink:label="lab_optn_March312027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">March 31, 2027</link:label>
    <link:label id="lab_optn_March312027Member_label_en-US" xlink:label="lab_optn_March312027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">March 31, 2027 [Member]</link:label>
    <link:label id="lab_optn_March312027Member_documentation_en-US" xlink:label="lab_optn_March312027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">March 31, 2027</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_optn_March312027Member" xlink:href="optn-20221231.xsd#optn_March312027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_March312027Member" xlink:to="lab_optn_March312027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_390a4c69-ab4c-4b4c-9b58-223758502a6b_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total costs and expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_41991eb0-cc96-4b3e-8a55-804a0d4a163c_terseLabel_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_f7746fd2-20ef-4a3e-9ef1-ed1fea986547_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_15f2d98f-15e6-458c-8e86-92abc5fdeb2c_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_8070d312-33ab-4948-a9b9-64d45adc0995_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_80546eef-1e76-45ad-81d5-4b69dca7ede3_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_ec418f08-4c72-4408-aa97-f51d1c6e3b71_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputPriceVolatilityMember_516682e5-5f1e-4bd3-9ee5-a3b6b157b6b4_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_MeasurementInputPriceVolatilityMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Price Volatility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_83186467-ce1d-4280-a977-db27883e02d4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashUninsuredAmount_ba015e23-e0c3-4004-814c-49df1458bd4a_terseLabel_en-US" xlink:label="lab_us-gaap_CashUninsuredAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, uninsured amount</link:label>
    <link:label id="lab_us-gaap_CashUninsuredAmount_label_en-US" xlink:label="lab_us-gaap_CashUninsuredAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Uninsured Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashUninsuredAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashUninsuredAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashUninsuredAmount" xlink:to="lab_us-gaap_CashUninsuredAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0554a435-c171-498b-b0e7-7899e6e2860f_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and stockholders' deficit</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_optn_AmendmentFee_589ef3f6-698c-4aaf-8dac-80439ae795f4_terseLabel_en-US" xlink:label="lab_optn_AmendmentFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment fee</link:label>
    <link:label id="lab_optn_AmendmentFee_label_en-US" xlink:label="lab_optn_AmendmentFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Fee</link:label>
    <link:label id="lab_optn_AmendmentFee_documentation_en-US" xlink:label="lab_optn_AmendmentFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_optn_AmendmentFee" xlink:href="optn-20221231.xsd#optn_AmendmentFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_AmendmentFee" xlink:to="lab_optn_AmendmentFee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_15cd7807-0b58-4879-9611-fbfee3967f88_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_06dfb137-c5bb-483a-b074-0ecf79b68373_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted, Weighted average exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_162ce5e4-df01-4860-a19f-46d8cf7832a0_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration received on transaction</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_52ca0377-a26d-47e2-b008-92162bff450b_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_95759b7e-cf2e-498c-a9b9-7b001e97b3b8_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_7771cba3-9e6e-41bf-a511-68d82bd062e5_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive loss:</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_1ff4d03c-9b29-4b7b-8a07-2c8dbb969a75_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_67205a8f-aaa5-47c8-a76f-e25325baed32_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NatureOfOperations_4b3b17e5-ce2b-4e21-a154-4e2b59919428_terseLabel_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and Description of Business</link:label>
    <link:label id="lab_us-gaap_NatureOfOperations_label_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of Operations [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NatureOfOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations" xlink:to="lab_us-gaap_NatureOfOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_c0932336-7610-4577-af9e-f34836536206_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock warrants</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_a039288f-2045-4f4b-98e4-0c26de70d064_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_aeee456f-db50-4c83-a470-4cc168257769_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from the sale of common stock and warrants</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_518de7d6-8570-435b-b9f6-eab206ccbff2_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average common shares outstanding, basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_78b546e9-6462-49d2-a06e-bafd07542863_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' deficit:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_de942f6c-9ef3-4be2-b9fd-60c45d657c63_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_8e2079f4-9dcb-4b84-b103-a356d63b5f62_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_e0dccb38-2bd8-45dc-87e4-4a35804ff8fe_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of noncash activities:</link:label>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_label_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_7030dca4-29e2-4aaf-8004-08de8c2f07d2_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_518ff930-c840-4175-9028-3fbf1962048d_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance, Weighted average exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2b2c0227-f9d5-49d0-b721-3f4339281fb4_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance, Weighted average exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicenseMember_1dc9e089-11d7-4b69-a052-b83d5087c152_terseLabel_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing revenues</link:label>
    <link:label id="lab_us-gaap_LicenseMember_label_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseMember" xlink:to="lab_us-gaap_LicenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_888f91ec-10a6-429f-b440-e6882631677f_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_9663cc1a-aec0-489d-9a58-7df493e2e53d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service-based stock options weighted average exercise price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_optn_StockIssuedDuringPeriodVestedRestrictedStockUnits_b2a35a93-61a0-4570-9130-94ea0c19dfe6_terseLabel_en-US" xlink:label="lab_optn_StockIssuedDuringPeriodVestedRestrictedStockUnits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting of restricted stock units</link:label>
    <link:label id="lab_optn_StockIssuedDuringPeriodVestedRestrictedStockUnits_label_en-US" xlink:label="lab_optn_StockIssuedDuringPeriodVestedRestrictedStockUnits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Vested Restricted Stock Units</link:label>
    <link:label id="lab_optn_StockIssuedDuringPeriodVestedRestrictedStockUnits_documentation_en-US" xlink:label="lab_optn_StockIssuedDuringPeriodVestedRestrictedStockUnits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Vested Restricted Stock Units</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_optn_StockIssuedDuringPeriodVestedRestrictedStockUnits" xlink:href="optn-20221231.xsd#optn_StockIssuedDuringPeriodVestedRestrictedStockUnits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_StockIssuedDuringPeriodVestedRestrictedStockUnits" xlink:to="lab_optn_StockIssuedDuringPeriodVestedRestrictedStockUnits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_ae271694-5ef6-412c-b06f-4b2714a6d1bd_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_5e56a789-8e68-4b0f-a4dd-ca2f6bdb34b3_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_046540a0-1f32-44c6-bd37-64b12a752cf5_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_491198b1-0694-4d94-8223-07a29f88e1bc_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_optn_WarrantLiabilityNonCurrent_eb86bd4c-0869-44cb-bb7b-0e36d3fee3ff_terseLabel_en-US" xlink:label="lab_optn_WarrantLiabilityNonCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant liability</link:label>
    <link:label id="lab_optn_WarrantLiabilityNonCurrent_label_en-US" xlink:label="lab_optn_WarrantLiabilityNonCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Liability NonCurrent</link:label>
    <link:label id="lab_optn_WarrantLiabilityNonCurrent_documentation_en-US" xlink:label="lab_optn_WarrantLiabilityNonCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Liability NonCurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_optn_WarrantLiabilityNonCurrent" xlink:href="optn-20221231.xsd#optn_WarrantLiabilityNonCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_WarrantLiabilityNonCurrent" xlink:to="lab_optn_WarrantLiabilityNonCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_b47b9697-bc83-410f-85a4-b6d2c9245690_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employer matching contribution</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Match</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_abc65415-9fff-4d7c-bae1-dc59316c5a54_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares reserved for future issuance under plan (shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_cc92cfe7-3e20-4fc8-96b7-41a8debfdd44_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_be2a8c4e-d264-487e-8287-f6e6c1697b00_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_97eb92ed-1cff-447a-8e22-a8e98f159dfd_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_60b3b36a-ae6d-4da1-8238-28d07a5b38cf_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_optn_ClassOfWarrantOrRightRestrictionCommonSharesMaximumOwnershipPriorToExecutionPercent_dac298e7-4c31-4a8b-9994-4025397df541_terseLabel_en-US" xlink:label="lab_optn_ClassOfWarrantOrRightRestrictionCommonSharesMaximumOwnershipPriorToExecutionPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of warrant or right restriction, common shares maximum ownership prior to execution, percent</link:label>
    <link:label id="lab_optn_ClassOfWarrantOrRightRestrictionCommonSharesMaximumOwnershipPriorToExecutionPercent_label_en-US" xlink:label="lab_optn_ClassOfWarrantOrRightRestrictionCommonSharesMaximumOwnershipPriorToExecutionPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right Restriction, Common Shares Maximum Ownership Prior To Execution, Percent</link:label>
    <link:label id="lab_optn_ClassOfWarrantOrRightRestrictionCommonSharesMaximumOwnershipPriorToExecutionPercent_documentation_en-US" xlink:label="lab_optn_ClassOfWarrantOrRightRestrictionCommonSharesMaximumOwnershipPriorToExecutionPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right Restriction, Common Shares Maximum Ownership Prior To Execution, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_optn_ClassOfWarrantOrRightRestrictionCommonSharesMaximumOwnershipPriorToExecutionPercent" xlink:href="optn-20221231.xsd#optn_ClassOfWarrantOrRightRestrictionCommonSharesMaximumOwnershipPriorToExecutionPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_ClassOfWarrantOrRightRestrictionCommonSharesMaximumOwnershipPriorToExecutionPercent" xlink:to="lab_optn_ClassOfWarrantOrRightRestrictionCommonSharesMaximumOwnershipPriorToExecutionPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_4a2bd983-a374-440d-8779-bfe5fc1aa0b2_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_61f5a939-16d8-4f27-b5b5-d7c06791ddb7_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for doubtful accounts</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_optn_WarrantsExpiringNovember232027Member_4db2df85-d0a0-4edc-9678-c620bea5c5f3_terseLabel_en-US" xlink:label="lab_optn_WarrantsExpiringNovember232027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Expiring November 23, 2027</link:label>
    <link:label id="lab_optn_WarrantsExpiringNovember232027Member_label_en-US" xlink:label="lab_optn_WarrantsExpiringNovember232027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Expiring November 23, 2027 [Member]</link:label>
    <link:label id="lab_optn_WarrantsExpiringNovember232027Member_documentation_en-US" xlink:label="lab_optn_WarrantsExpiringNovember232027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Expiring November 23, 2027</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_optn_WarrantsExpiringNovember232027Member" xlink:href="optn-20221231.xsd#optn_WarrantsExpiringNovember232027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_WarrantsExpiringNovember232027Member" xlink:to="lab_optn_WarrantsExpiringNovember232027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_8fe8fcae-3e71-4428-961b-9e8c4474c5a5_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period Two</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_optn_AccruedResearchandDevelopmentCurrent_991ac12b-f218-41b5-9bb7-6fe95991e5a7_terseLabel_en-US" xlink:label="lab_optn_AccruedResearchandDevelopmentCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expenses</link:label>
    <link:label id="lab_optn_AccruedResearchandDevelopmentCurrent_label_en-US" xlink:label="lab_optn_AccruedResearchandDevelopmentCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Research and Development, Current</link:label>
    <link:label id="lab_optn_AccruedResearchandDevelopmentCurrent_documentation_en-US" xlink:label="lab_optn_AccruedResearchandDevelopmentCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Research and Development, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_optn_AccruedResearchandDevelopmentCurrent" xlink:href="optn-20221231.xsd#optn_AccruedResearchandDevelopmentCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_AccruedResearchandDevelopmentCurrent" xlink:to="lab_optn_AccruedResearchandDevelopmentCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_ee4b55cc-058c-4e56-a92c-8a0d907d08b3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_d83bc895-0769-4575-84cc-3544e8964003_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_optn_AmendmentFeePayable_87f3bff7-7911-4126-946e-0f7cf5cc9bcc_terseLabel_en-US" xlink:label="lab_optn_AmendmentFeePayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment fee payable</link:label>
    <link:label id="lab_optn_AmendmentFeePayable_label_en-US" xlink:label="lab_optn_AmendmentFeePayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Fee Payable</link:label>
    <link:label id="lab_optn_AmendmentFeePayable_documentation_en-US" xlink:label="lab_optn_AmendmentFeePayable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Fee Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_optn_AmendmentFeePayable" xlink:href="optn-20221231.xsd#optn_AmendmentFeePayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_AmendmentFeePayable" xlink:to="lab_optn_AmendmentFeePayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_c88c7842-1e3d-460d-ae08-9c93ee728468_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders' deficit</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_3fc752de-3f70-4df2-9548-caea7d742536_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt term</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTerm" xlink:to="lab_us-gaap_DebtInstrumentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_2dbb7ade-37dc-4b78-b000-ad4f075c1664_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_optn_NotePurchaseAgreementThirdDelayedDrawNotesMember_df0d4b91-9fca-456c-bb48-0a174a4f3bf1_terseLabel_en-US" xlink:label="lab_optn_NotePurchaseAgreementThirdDelayedDrawNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Note Purchase Agreement - Third Delayed Draw Notes</link:label>
    <link:label id="lab_optn_NotePurchaseAgreementThirdDelayedDrawNotesMember_label_en-US" xlink:label="lab_optn_NotePurchaseAgreementThirdDelayedDrawNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Note Purchase Agreement - Third Delayed Draw Notes [Member]</link:label>
    <link:label id="lab_optn_NotePurchaseAgreementThirdDelayedDrawNotesMember_documentation_en-US" xlink:label="lab_optn_NotePurchaseAgreementThirdDelayedDrawNotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Note Purchase Agreement - Third Delayed Draw Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_optn_NotePurchaseAgreementThirdDelayedDrawNotesMember" xlink:href="optn-20221231.xsd#optn_NotePurchaseAgreementThirdDelayedDrawNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_NotePurchaseAgreementThirdDelayedDrawNotesMember" xlink:to="lab_optn_NotePurchaseAgreementThirdDelayedDrawNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_2d3a7f5b-446c-413d-bb3a-5114cfe6e08d_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f1238b59-e00e-47ca-82eb-dc7385f84ac8_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_662291a0-1cf4-4736-978d-f097b0cdde5f_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_4e311b95-d880-45f8-9622-869a31d8efa0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Income (Loss) Before Income Tax, Domestic and Foreign</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_8b259901-c7c7-4cbb-a712-a31d774d4946_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants issued</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_08979f59-87d0-4196-9254-40837b1c0da3_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_bf30c33c-b0c6-46c2-908b-92150fa5a14c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_optn_EffectiveIncomeTaxRateReconciliationForeignExchangeOtherPercent_235bb9a6-7f4e-43f1-8ef9-44b4a0fd437e_terseLabel_en-US" xlink:label="lab_optn_EffectiveIncomeTaxRateReconciliationForeignExchangeOtherPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign exchange and other</link:label>
    <link:label id="lab_optn_EffectiveIncomeTaxRateReconciliationForeignExchangeOtherPercent_label_en-US" xlink:label="lab_optn_EffectiveIncomeTaxRateReconciliationForeignExchangeOtherPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Exchange Other, Percent</link:label>
    <link:label id="lab_optn_EffectiveIncomeTaxRateReconciliationForeignExchangeOtherPercent_documentation_en-US" xlink:label="lab_optn_EffectiveIncomeTaxRateReconciliationForeignExchangeOtherPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Exchange Other, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_optn_EffectiveIncomeTaxRateReconciliationForeignExchangeOtherPercent" xlink:href="optn-20221231.xsd#optn_EffectiveIncomeTaxRateReconciliationForeignExchangeOtherPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_EffectiveIncomeTaxRateReconciliationForeignExchangeOtherPercent" xlink:to="lab_optn_EffectiveIncomeTaxRateReconciliationForeignExchangeOtherPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember_541e0187-db7b-4a90-87f0-c630a1501cb1_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period One</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_663724cd-c58c-4f90-9324-dbd2868570f9_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_d5d391ca-f043-49d0-96aa-7d73880e6351_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits, income tax penalties and interest accrued</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_762d4998-89af-487b-9573-9eca509575db_verboseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: difference between undiscounted lease payments and discounted operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_5721cf7c-d181-4598-83c1-a44186d675fc_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (loss) income per share of common stock, diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_ca7a0fb0-ac77-4978-9df9-bdb748bd0e9c_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityDisclosureAbstract" xlink:to="lab_us-gaap_TemporaryEquityDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_debf1482-7d67-4120-9af2-7e644b8c03a2_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of property and equipment</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_33bfc1e7-192c-4101-9d9d-b51433cff089_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_optn_DebtInstrumentCovenantCashAndCashEquivalents_95ba8f3a-ae51-4ff3-8491-a5d1b13b3cf2_terseLabel_en-US" xlink:label="lab_optn_DebtInstrumentCovenantCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt covenant, cash and cash equivalents</link:label>
    <link:label id="lab_optn_DebtInstrumentCovenantCashAndCashEquivalents_label_en-US" xlink:label="lab_optn_DebtInstrumentCovenantCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Cash And Cash Equivalents</link:label>
    <link:label id="lab_optn_DebtInstrumentCovenantCashAndCashEquivalents_documentation_en-US" xlink:label="lab_optn_DebtInstrumentCovenantCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Cash And Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_optn_DebtInstrumentCovenantCashAndCashEquivalents" xlink:href="optn-20221231.xsd#optn_DebtInstrumentCovenantCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_DebtInstrumentCovenantCashAndCashEquivalents" xlink:to="lab_optn_DebtInstrumentCovenantCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_ddb4d342-6201-4ceb-a32c-2f072a9e51d4_negatedLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on sale of equipment</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_a4b12fda-971e-4955-b7fb-5c849781ebc4_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock compensation expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_f2d6a5fa-6d3e-4177-be27-18be44e23a39_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of warrant liability</link:label>
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_label_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Adjustment of Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAdjustmentOfWarrants" xlink:to="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_optn_DeferredTaxAssetsTaxCreditCarryforwardsResearchTerm_53c26397-5d15-4cb7-955c-154c5c95195d_terseLabel_en-US" xlink:label="lab_optn_DeferredTaxAssetsTaxCreditCarryforwardsResearchTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets tax credit carryforwards research term</link:label>
    <link:label id="lab_optn_DeferredTaxAssetsTaxCreditCarryforwardsResearchTerm_label_en-US" xlink:label="lab_optn_DeferredTaxAssetsTaxCreditCarryforwardsResearchTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Research, Term</link:label>
    <link:label id="lab_optn_DeferredTaxAssetsTaxCreditCarryforwardsResearchTerm_documentation_en-US" xlink:label="lab_optn_DeferredTaxAssetsTaxCreditCarryforwardsResearchTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Research, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_optn_DeferredTaxAssetsTaxCreditCarryforwardsResearchTerm" xlink:href="optn-20221231.xsd#optn_DeferredTaxAssetsTaxCreditCarryforwardsResearchTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_DeferredTaxAssetsTaxCreditCarryforwardsResearchTerm" xlink:to="lab_optn_DeferredTaxAssetsTaxCreditCarryforwardsResearchTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_a469dad4-9cbd-48d4-9afe-08e468bde9eb_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_fd5461f9-9de5-4751-b3c9-bc2a198d43ca_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_e589d7c6-2f75-42b6-9fb5-e52d7fb842e3_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares vested (in shares)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:type="arc" order="1"/>
    <link:label id="lab_optn_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeAccruedRightsToPurchaseCommonStock_8727b2c9-0fee-4333-ab39-1f7692b6dd4a_terseLabel_en-US" xlink:label="lab_optn_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeAccruedRightsToPurchaseCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum employee accrued rights to purchase common stock (in dollars per share)</link:label>
    <link:label id="lab_optn_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeAccruedRightsToPurchaseCommonStock_label_en-US" xlink:label="lab_optn_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeAccruedRightsToPurchaseCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award, Maximum Employee Accrued Rights To Purchase Common Stock</link:label>
    <link:label id="lab_optn_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeAccruedRightsToPurchaseCommonStock_documentation_en-US" xlink:label="lab_optn_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeAccruedRightsToPurchaseCommonStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award, Maximum Employee Accrued Rights To Purchase Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_optn_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeAccruedRightsToPurchaseCommonStock" xlink:href="optn-20221231.xsd#optn_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeAccruedRightsToPurchaseCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeAccruedRightsToPurchaseCommonStock" xlink:to="lab_optn_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeAccruedRightsToPurchaseCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_cd5f0653-38ef-4caa-9657-d1e948771a61_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_6ac73a47-a3bd-4295-a090-8a960666038a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_optn_ScheduleOfGrantDateFairValueOfWarrantValuationAssumptionsTableTextBlock_51618b7d-3315-4ea9-bd79-5ea6e24ee1f1_terseLabel_en-US" xlink:label="lab_optn_ScheduleOfGrantDateFairValueOfWarrantValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Grant Date Fair Value of Warrant, Valuation Assumptions</link:label>
    <link:label id="lab_optn_ScheduleOfGrantDateFairValueOfWarrantValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_optn_ScheduleOfGrantDateFairValueOfWarrantValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Grant Date Fair Value Of Warrant, Valuation Assumptions [Table Text Block]</link:label>
    <link:label id="lab_optn_ScheduleOfGrantDateFairValueOfWarrantValuationAssumptionsTableTextBlock_documentation_en-US" xlink:label="lab_optn_ScheduleOfGrantDateFairValueOfWarrantValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Grant Date Fair Value Of Warrant, Valuation Assumptions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_optn_ScheduleOfGrantDateFairValueOfWarrantValuationAssumptionsTableTextBlock" xlink:href="optn-20221231.xsd#optn_ScheduleOfGrantDateFairValueOfWarrantValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_ScheduleOfGrantDateFairValueOfWarrantValuationAssumptionsTableTextBlock" xlink:to="lab_optn_ScheduleOfGrantDateFairValueOfWarrantValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_8ee4fa32-3d51-4c99-9e1e-050089b249c2_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_70ca552a-239f-4f64-8377-c0eaf2138aff_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restricted Stock Unit Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityExTransitionPeriod_33f9d636-b9f5-4366-a6b5-73dd7c7a834e_terseLabel_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:label id="lab_dei_EntityExTransitionPeriod_label_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod" xlink:to="lab_dei_EntityExTransitionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_optn_WorkingCapital_18ac6a5c-1974-45a8-9989-604489612598_terseLabel_en-US" xlink:label="lab_optn_WorkingCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Working capital</link:label>
    <link:label id="lab_optn_WorkingCapital_label_en-US" xlink:label="lab_optn_WorkingCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Working Capital</link:label>
    <link:label id="lab_optn_WorkingCapital_documentation_en-US" xlink:label="lab_optn_WorkingCapital" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Working Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_optn_WorkingCapital" xlink:href="optn-20221231.xsd#optn_WorkingCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_WorkingCapital" xlink:to="lab_optn_WorkingCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_optn_MeasurementPeriodAxis_5ee00b46-3fb0-4bc6-8849-d6d764de9c9e_terseLabel_en-US" xlink:label="lab_optn_MeasurementPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Period [Axis]</link:label>
    <link:label id="lab_optn_MeasurementPeriodAxis_label_en-US" xlink:label="lab_optn_MeasurementPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Period [Axis]</link:label>
    <link:label id="lab_optn_MeasurementPeriodAxis_documentation_en-US" xlink:label="lab_optn_MeasurementPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_optn_MeasurementPeriodAxis" xlink:href="optn-20221231.xsd#optn_MeasurementPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_MeasurementPeriodAxis" xlink:to="lab_optn_MeasurementPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_92eaf446-1f02-4ed9-a928-d05b4659c17b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_e7b02172-309b-4b95-91ba-e9ab69c12b5e_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan options contractual life</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_d98165ba-f30f-41be-a53e-68cf20c804b9_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (income) expense:</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RoyaltyAgreementTermsMember_fd783828-04be-4293-8a62-b6213cbabadd_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyAgreementTermsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Agreement Terms</link:label>
    <link:label id="lab_us-gaap_RoyaltyAgreementTermsMember_label_en-US" xlink:label="lab_us-gaap_RoyaltyAgreementTermsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Agreement Terms [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyAgreementTermsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyAgreementTermsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyAgreementTermsMember" xlink:to="lab_us-gaap_RoyaltyAgreementTermsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_3ef3cf39-bbf0-4aa6-9162-fbb67473b30c_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Operating Lease Liability Maturities</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_1cb42b43-74c6-4dea-8cc0-f55a6c9ac989_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_c3baffad-f431-443d-a1e0-86e8a428b2d2_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_5916507e-c2ef-4b4e-918f-e9bf1bbefd85_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan_8d3b9ca2-75c4-4a3c-ac8e-f8b680c50930_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Ownership Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_2ea2f038-52a8-486e-b6b5-4641ca2e43f6_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_66d4d51a-c65b-4336-8804-a659fbe2b7e5_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in valuation allowance</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_3292cfb2-d6c0-4ca5-8dae-4281285f05d8_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax rate changes</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_8ba9d612-d80f-4ec5-aeaa-5c248c964131_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary, Sale of Stock</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_4acc6f04-8d57-4afe-bc7d-653e0815441e_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_6140f024-bc8c-4c94-9423-9917a4e5504c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_0aba834e-b939-4ed2-9ea9-d5ca577ccbc6_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_028be331-fcad-4393-a36f-acad834c8030_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of A&amp;R Note Purchase Agreement and long term balance</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_367b179b-3fea-462c-b741-64b85d571783_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MachineryAndEquipmentMember_094ab5ed-cc0f-4b5d-aa65-cb90281ac9b4_terseLabel_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Machinery &amp; production equipment</link:label>
    <link:label id="lab_us-gaap_MachineryAndEquipmentMember_c8108b94-ce8b-409d-abcb-9c3cb81e8170_verboseLabel_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Machinery and equipment</link:label>
    <link:label id="lab_us-gaap_MachineryAndEquipmentMember_label_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Machinery and Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MachineryAndEquipmentMember" xlink:to="lab_us-gaap_MachineryAndEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_978e91a4-26e7-4a88-a364-1d3e2785fe06_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-to-use asset</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Leasing Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_18620e97-870a-4351-8324-7101917151f0_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and settled (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_248a967f-33e9-4a80-aa54-bfda9e7653af_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_62f1427a-1952-4f2a-b11e-1642104bf20c_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_cb4f33f2-93c5-4a85-b9f8-b84acb92ece3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares authorized under plan (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnamortizedDebtIssuanceExpense_5734578e-32ec-4de3-92fe-ce26f3851582_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnamortizedDebtIssuanceExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt issuance costs</link:label>
    <link:label id="lab_us-gaap_UnamortizedDebtIssuanceExpense_label_en-US" xlink:label="lab_us-gaap_UnamortizedDebtIssuanceExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized Debt Issuance Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnamortizedDebtIssuanceExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnamortizedDebtIssuanceExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnamortizedDebtIssuanceExpense" xlink:to="lab_us-gaap_UnamortizedDebtIssuanceExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_optn_OperatingLeaseCostForExtension_2d12a152-ce00-44a4-b09e-b765d3d0fc1a_terseLabel_en-US" xlink:label="lab_optn_OperatingLeaseCostForExtension" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option to renew, extension of lease term</link:label>
    <link:label id="lab_optn_OperatingLeaseCostForExtension_label_en-US" xlink:label="lab_optn_OperatingLeaseCostForExtension" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost for Extension</link:label>
    <link:label id="lab_optn_OperatingLeaseCostForExtension_documentation_en-US" xlink:label="lab_optn_OperatingLeaseCostForExtension" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost for Extension</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_optn_OperatingLeaseCostForExtension" xlink:href="optn-20221231.xsd#optn_OperatingLeaseCostForExtension"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_OperatingLeaseCostForExtension" xlink:to="lab_optn_OperatingLeaseCostForExtension" xlink:type="arc" order="1"/>
    <link:label id="lab_optn_DefinedContributionPlanTranchesAxisDomain_2837cee2-4218-4355-ab3d-4dfad68e13f4_terseLabel_en-US" xlink:label="lab_optn_DefinedContributionPlanTranchesAxisDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan Tranches Axis [Domain]</link:label>
    <link:label id="lab_optn_DefinedContributionPlanTranchesAxisDomain_label_en-US" xlink:label="lab_optn_DefinedContributionPlanTranchesAxisDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan Tranches Axis [Domain]</link:label>
    <link:label id="lab_optn_DefinedContributionPlanTranchesAxisDomain_documentation_en-US" xlink:label="lab_optn_DefinedContributionPlanTranchesAxisDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Defined Contribution Plan Tranches Axis [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_optn_DefinedContributionPlanTranchesAxisDomain" xlink:href="optn-20221231.xsd#optn_DefinedContributionPlanTranchesAxisDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_DefinedContributionPlanTranchesAxisDomain" xlink:to="lab_optn_DefinedContributionPlanTranchesAxisDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_optn_DebtInstrumentIssuanceCriteriaTermNetSalesAndRoyaltiesBenchmark_74d71eac-5389-41c4-9db2-a484030e07ff_terseLabel_en-US" xlink:label="lab_optn_DebtInstrumentIssuanceCriteriaTermNetSalesAndRoyaltiesBenchmark" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt issuance criteria term, net sales and royalties benchmark</link:label>
    <link:label id="lab_optn_DebtInstrumentIssuanceCriteriaTermNetSalesAndRoyaltiesBenchmark_label_en-US" xlink:label="lab_optn_DebtInstrumentIssuanceCriteriaTermNetSalesAndRoyaltiesBenchmark" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Issuance Criteria Term, Net Sales And Royalties Benchmark</link:label>
    <link:label id="lab_optn_DebtInstrumentIssuanceCriteriaTermNetSalesAndRoyaltiesBenchmark_documentation_en-US" xlink:label="lab_optn_DebtInstrumentIssuanceCriteriaTermNetSalesAndRoyaltiesBenchmark" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Issuance Criteria Term, Net Sales And Royalties Benchmark</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_optn_DebtInstrumentIssuanceCriteriaTermNetSalesAndRoyaltiesBenchmark" xlink:href="optn-20221231.xsd#optn_DebtInstrumentIssuanceCriteriaTermNetSalesAndRoyaltiesBenchmark"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_DebtInstrumentIssuanceCriteriaTermNetSalesAndRoyaltiesBenchmark" xlink:to="lab_optn_DebtInstrumentIssuanceCriteriaTermNetSalesAndRoyaltiesBenchmark" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList_18b38d2e-5cab-4398-a30f-1ab5e927bebd_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList_label_en-US" xlink:label="lab_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" xlink:to="lab_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_optn_NotePurchaseAgreementFirstDelayedDrawNotesMember_6892c401-9c58-4fbf-bc2a-7b3661e80ff8_terseLabel_en-US" xlink:label="lab_optn_NotePurchaseAgreementFirstDelayedDrawNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Note Purchase Agreement - First Delayed Draw Notes</link:label>
    <link:label id="lab_optn_NotePurchaseAgreementFirstDelayedDrawNotesMember_label_en-US" xlink:label="lab_optn_NotePurchaseAgreementFirstDelayedDrawNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Note Purchase Agreement - First Delayed Draw Notes [Member]</link:label>
    <link:label id="lab_optn_NotePurchaseAgreementFirstDelayedDrawNotesMember_documentation_en-US" xlink:label="lab_optn_NotePurchaseAgreementFirstDelayedDrawNotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Note Purchase Agreement - First Delayed Draw Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_optn_NotePurchaseAgreementFirstDelayedDrawNotesMember" xlink:href="optn-20221231.xsd#optn_NotePurchaseAgreementFirstDelayedDrawNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_NotePurchaseAgreementFirstDelayedDrawNotesMember" xlink:to="lab_optn_NotePurchaseAgreementFirstDelayedDrawNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdvertisingExpense_e39b2917-0db9-4f93-b0d1-29296dcea268_terseLabel_en-US" xlink:label="lab_us-gaap_AdvertisingExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising expense</link:label>
    <link:label id="lab_us-gaap_AdvertisingExpense_label_en-US" xlink:label="lab_us-gaap_AdvertisingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvertisingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingExpense" xlink:to="lab_us-gaap_AdvertisingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_f406039d-6341-4567-a8e9-3d835c10e2f5_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_b9f51ec5-dbb2-43ed-a161-973effd0ef31_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax liabilities:</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_optn_DebtInstrumentMaximumAggregateMakeWholePremiumAmount_0f988cd0-b5f8-4caa-be45-67df0e90659f_terseLabel_en-US" xlink:label="lab_optn_DebtInstrumentMaximumAggregateMakeWholePremiumAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Make whole premium payment</link:label>
    <link:label id="lab_optn_DebtInstrumentMaximumAggregateMakeWholePremiumAmount_label_en-US" xlink:label="lab_optn_DebtInstrumentMaximumAggregateMakeWholePremiumAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Maximum Aggregate Make Whole Premium Amount</link:label>
    <link:label id="lab_optn_DebtInstrumentMaximumAggregateMakeWholePremiumAmount_documentation_en-US" xlink:label="lab_optn_DebtInstrumentMaximumAggregateMakeWholePremiumAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Maximum Aggregate Make Whole Premium Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_optn_DebtInstrumentMaximumAggregateMakeWholePremiumAmount" xlink:href="optn-20221231.xsd#optn_DebtInstrumentMaximumAggregateMakeWholePremiumAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_DebtInstrumentMaximumAggregateMakeWholePremiumAmount" xlink:to="lab_optn_DebtInstrumentMaximumAggregateMakeWholePremiumAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_optn_March312023Member_592239ab-5a85-4943-8603-d44508452307_terseLabel_en-US" xlink:label="lab_optn_March312023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">March 31, 2023</link:label>
    <link:label id="lab_optn_March312023Member_label_en-US" xlink:label="lab_optn_March312023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">March 31, 2023 [Member]</link:label>
    <link:label id="lab_optn_March312023Member_documentation_en-US" xlink:label="lab_optn_March312023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">March 31, 2023</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_optn_March312023Member" xlink:href="optn-20221231.xsd#optn_March312023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_March312023Member" xlink:to="lab_optn_March312023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_optn_TwoThousandSeventeenEmployeeStockPurchasePlanMember_0f735111-d270-4e90-8efb-4f660c0227b8_terseLabel_en-US" xlink:label="lab_optn_TwoThousandSeventeenEmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2017 Employee Stock Purchase Plan</link:label>
    <link:label id="lab_optn_TwoThousandSeventeenEmployeeStockPurchasePlanMember_4742ec59-03e9-4387-b2ca-732deb96e874_verboseLabel_en-US" xlink:label="lab_optn_TwoThousandSeventeenEmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2017 Employee Stock Purchase Plan</link:label>
    <link:label id="lab_optn_TwoThousandSeventeenEmployeeStockPurchasePlanMember_label_en-US" xlink:label="lab_optn_TwoThousandSeventeenEmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Seventeen Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_optn_TwoThousandSeventeenEmployeeStockPurchasePlanMember_documentation_en-US" xlink:label="lab_optn_TwoThousandSeventeenEmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Seventeen Employee Stock Purchase Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_optn_TwoThousandSeventeenEmployeeStockPurchasePlanMember" xlink:href="optn-20221231.xsd#optn_TwoThousandSeventeenEmployeeStockPurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_TwoThousandSeventeenEmployeeStockPurchasePlanMember" xlink:to="lab_optn_TwoThousandSeventeenEmployeeStockPurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_b5e7727c-ab0c-4057-a128-50744e3282c3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Liability</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_ce45f168-30e1-477c-9ddd-0c108f55da68_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_36d8f938-a32a-4eae-9e29-6047b49b2a18_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net decrease in cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_e02a6846-cea3-4914-aeb3-0c1420917b40_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Liability</link:label>
    <link:label id="lab_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Not Settleable in Cash, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:to="lab_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_2c4272a7-eb3e-4f5a-82da-175ca3aab448_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity central index key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_4448879e-1113-4617-ab77-31a96efd03ae_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1_c75496fd-f875-4bf7-bc8f-eeed06508bec_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed asset purchases within accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1_label_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash or Part Noncash Acquisition, Fixed Assets Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" xlink:to="lab_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_c3a1e012-1c87-42a4-8811-0ab75066fe46_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_79a34b9d-2493-4e1d-ba6a-2d02576058c6_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d36ad4da-528b-4175-90ea-fedb36c6821b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_78c40699-ace9-4463-91cd-383bffdfb41c_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration of credit risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_ebdec6b5-46aa-4877-9e2e-92dde21ddd35_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_b4ec8679-fdd7-4501-87c8-c168ab02f08f_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_6a3bede8-6f4d-4044-b52f-df2ed7adfd7e_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_7b2b428c-68d8-40af-bb97-7942e66ff64c_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_c0fae4fa-897e-4c96-8cbd-6e7f5d4017c3_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_5edd49aa-be6a-466b-b3f5-3f12b8c85ebd_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseObligation_287d1fda-2165-452d-8686-3fd3b82ef4ad_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase obligation</link:label>
    <link:label id="lab_us-gaap_PurchaseObligation_label_en-US" xlink:label="lab_us-gaap_PurchaseObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseObligation" xlink:to="lab_us-gaap_PurchaseObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_bcbfe303-6890-4dc9-bd4f-50890beaa2fc_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_278812a4-21cf-47a5-976c-b50445aad905_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdvertisingCostsPolicyTextBlock_01fa58e3-1150-435b-a7e2-dca94e8f5ade_terseLabel_en-US" xlink:label="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising expenses</link:label>
    <link:label id="lab_us-gaap_AdvertisingCostsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising Cost [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvertisingCostsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:to="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis_8c35b5fb-14c4-4d96-a62d-1064e47f31dc_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0a356498-3f95-4f9a-870a-3954c4f9f1cf_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_optn_FiveCustomersMember_2195654d-1a93-4485-8cb6-c30ba2b16102_terseLabel_en-US" xlink:label="lab_optn_FiveCustomersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Five Customers</link:label>
    <link:label id="lab_optn_FiveCustomersMember_label_en-US" xlink:label="lab_optn_FiveCustomersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Five Customers [Member]</link:label>
    <link:label id="lab_optn_FiveCustomersMember_documentation_en-US" xlink:label="lab_optn_FiveCustomersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Five Customers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_optn_FiveCustomersMember" xlink:href="optn-20221231.xsd#optn_FiveCustomersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_FiveCustomersMember" xlink:to="lab_optn_FiveCustomersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_9a79b31f-192a-415a-bea3-069d67a00bc2_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) per common share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_optn_IncreaseDecreaseinDepositsandOtherAssets_37dc422c-d954-4ea1-95c7-a875f259e99d_negatedTerseLabel_en-US" xlink:label="lab_optn_IncreaseDecreaseinDepositsandOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_optn_IncreaseDecreaseinDepositsandOtherAssets_label_en-US" xlink:label="lab_optn_IncreaseDecreaseinDepositsandOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Deposits and Other Assets</link:label>
    <link:label id="lab_optn_IncreaseDecreaseinDepositsandOtherAssets_documentation_en-US" xlink:label="lab_optn_IncreaseDecreaseinDepositsandOtherAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Deposits and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_optn_IncreaseDecreaseinDepositsandOtherAssets" xlink:href="optn-20221231.xsd#optn_IncreaseDecreaseinDepositsandOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_IncreaseDecreaseinDepositsandOtherAssets" xlink:to="lab_optn_IncreaseDecreaseinDepositsandOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_68ab6730-92a8-46d4-b4a9-4591c606f3c8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7b9730f9-db2c-462a-94f8-44789adb1e7e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of common stock (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_8c90d9e7-e4e4-4d0e-ac74-19ce1e243709_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_1197aec5-d1b0-4d83-b7ed-5d7e83f39231_verboseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of warrants outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_a484854f-c1b0-42b1-aa66-7350e8e301c4_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpense_fcf0001c-ee02-4bdf-aa5c-0978c4bea247_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpense_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpense" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_optn_MeasurementInputStrikePriceMember_34d54a6d-7f54-4102-90b6-d8261277613b_terseLabel_en-US" xlink:label="lab_optn_MeasurementInputStrikePriceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Strike price</link:label>
    <link:label id="lab_optn_MeasurementInputStrikePriceMember_label_en-US" xlink:label="lab_optn_MeasurementInputStrikePriceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Strike Price [Member]</link:label>
    <link:label id="lab_optn_MeasurementInputStrikePriceMember_documentation_en-US" xlink:label="lab_optn_MeasurementInputStrikePriceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Strike Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_optn_MeasurementInputStrikePriceMember" xlink:href="optn-20221231.xsd#optn_MeasurementInputStrikePriceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_MeasurementInputStrikePriceMember" xlink:to="lab_optn_MeasurementInputStrikePriceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_f1cc77c0-6e66-49a5-86e9-ca1531ada2d7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_379a5d4a-5b62-4211-ab3b-68aba4bb76c5_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_89fc9f09-72a3-45f9-8d4e-cedd4b8e0319_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_optn_ProceedsfromIssuanceofCommonStockUnderEmployeeStockPurchasePlan_da90fa40-1929-4a40-804e-4ad3018f7f2f_terseLabel_en-US" xlink:label="lab_optn_ProceedsfromIssuanceofCommonStockUnderEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from the issuance of common stock under employee stock purchase plan</link:label>
    <link:label id="lab_optn_ProceedsfromIssuanceofCommonStockUnderEmployeeStockPurchasePlan_label_en-US" xlink:label="lab_optn_ProceedsfromIssuanceofCommonStockUnderEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock Under Employee Stock Purchase Plan</link:label>
    <link:label id="lab_optn_ProceedsfromIssuanceofCommonStockUnderEmployeeStockPurchasePlan_documentation_en-US" xlink:label="lab_optn_ProceedsfromIssuanceofCommonStockUnderEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock Under Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_optn_ProceedsfromIssuanceofCommonStockUnderEmployeeStockPurchasePlan" xlink:href="optn-20221231.xsd#optn_ProceedsfromIssuanceofCommonStockUnderEmployeeStockPurchasePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_ProceedsfromIssuanceofCommonStockUnderEmployeeStockPurchasePlan" xlink:to="lab_optn_ProceedsfromIssuanceofCommonStockUnderEmployeeStockPurchasePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_7b25ee8a-6c58-4a7f-9d6f-95632e0e3483_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recognition of right-of-use assets and lease liabilities</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesMember_0e955f95-e252-420d-be6a-92acbe86b397_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of product sales</link:label>
    <link:label id="lab_us-gaap_CostOfSalesMember_label_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesMember" xlink:to="lab_us-gaap_CostOfSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_optn_DeferredTaxAssetsFinancingCosts_eae6d66b-1bef-485c-a4fa-f1eb337112d3_terseLabel_en-US" xlink:label="lab_optn_DeferredTaxAssetsFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized R&amp;D</link:label>
    <link:label id="lab_optn_DeferredTaxAssetsFinancingCosts_label_en-US" xlink:label="lab_optn_DeferredTaxAssetsFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Financing Costs</link:label>
    <link:label id="lab_optn_DeferredTaxAssetsFinancingCosts_documentation_en-US" xlink:label="lab_optn_DeferredTaxAssetsFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Financing Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_optn_DeferredTaxAssetsFinancingCosts" xlink:href="optn-20221231.xsd#optn_DeferredTaxAssetsFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_DeferredTaxAssetsFinancingCosts" xlink:to="lab_optn_DeferredTaxAssetsFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_e7673ef1-9ef8-445c-bb9e-a0a5cbe3c644_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreements</link:label>
    <link:label id="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research, Development, and Computer Software Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:to="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_optn_WarrantsExpiringNovember182024Member_e2d7bdb7-93cd-4e8c-bc8d-b48e26083a82_terseLabel_en-US" xlink:label="lab_optn_WarrantsExpiringNovember182024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Expiring November 18, 2024</link:label>
    <link:label id="lab_optn_WarrantsExpiringNovember182024Member_label_en-US" xlink:label="lab_optn_WarrantsExpiringNovember182024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Expiring November 18, 2024 [Member]</link:label>
    <link:label id="lab_optn_WarrantsExpiringNovember182024Member_documentation_en-US" xlink:label="lab_optn_WarrantsExpiringNovember182024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Expiring November 18, 2024</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_optn_WarrantsExpiringNovember182024Member" xlink:href="optn-20221231.xsd#optn_WarrantsExpiringNovember182024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_WarrantsExpiringNovember182024Member" xlink:to="lab_optn_WarrantsExpiringNovember182024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_416de920-bd60-4959-a4e3-6fc0c7fc609d_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>14
<FILENAME>optn-20221231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:738bcfbc-a4cb-4b05-a396-7d259cbbc32b,g:9b54bffb-0962-498f-9b57-5d3747805ca8-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.optinose.com/role/CoverPage" xlink:type="simple" xlink:href="optn-20221231.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.optinose.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_1e9555c6-f966-47d0-bd0f-668ffbfd718e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_1111003f-20e8-4dbb-97a9-a362111f0b9f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1e9555c6-f966-47d0-bd0f-668ffbfd718e" xlink:to="loc_dei_DocumentType_1111003f-20e8-4dbb-97a9-a362111f0b9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_b801dfa9-b43b-438e-b09e-f5105a9ad3e3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1e9555c6-f966-47d0-bd0f-668ffbfd718e" xlink:to="loc_dei_DocumentAnnualReport_b801dfa9-b43b-438e-b09e-f5105a9ad3e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_5fd2db42-eab1-46ab-822b-4d29d0041ede" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1e9555c6-f966-47d0-bd0f-668ffbfd718e" xlink:to="loc_dei_DocumentPeriodEndDate_5fd2db42-eab1-46ab-822b-4d29d0041ede" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_96681ad6-d6c6-4166-a26c-d5c24393a346" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1e9555c6-f966-47d0-bd0f-668ffbfd718e" xlink:to="loc_dei_CurrentFiscalYearEndDate_96681ad6-d6c6-4166-a26c-d5c24393a346" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_4b36e36d-3e2e-4a00-a3d8-3782300daca5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1e9555c6-f966-47d0-bd0f-668ffbfd718e" xlink:to="loc_dei_DocumentTransitionReport_4b36e36d-3e2e-4a00-a3d8-3782300daca5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_21ef8012-b819-4adc-9f50-5912355129c2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1e9555c6-f966-47d0-bd0f-668ffbfd718e" xlink:to="loc_dei_EntityFileNumber_21ef8012-b819-4adc-9f50-5912355129c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_b1bba5e0-c01c-4432-8dab-1e544d0b80f3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1e9555c6-f966-47d0-bd0f-668ffbfd718e" xlink:to="loc_dei_EntityRegistrantName_b1bba5e0-c01c-4432-8dab-1e544d0b80f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_58e53782-4efb-438c-99eb-b785e6b3261a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1e9555c6-f966-47d0-bd0f-668ffbfd718e" xlink:to="loc_dei_EntityIncorporationStateCountryCode_58e53782-4efb-438c-99eb-b785e6b3261a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_0f7dd813-e890-4417-ac7a-ee473236938f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1e9555c6-f966-47d0-bd0f-668ffbfd718e" xlink:to="loc_dei_EntityTaxIdentificationNumber_0f7dd813-e890-4417-ac7a-ee473236938f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_e208f42c-3168-4fb5-a30a-df20fcc7bc5d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1e9555c6-f966-47d0-bd0f-668ffbfd718e" xlink:to="loc_dei_EntityAddressAddressLine1_e208f42c-3168-4fb5-a30a-df20fcc7bc5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_fd7a9c91-8a8a-4e7e-abe3-999c10fe3e41" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1e9555c6-f966-47d0-bd0f-668ffbfd718e" xlink:to="loc_dei_EntityAddressAddressLine2_fd7a9c91-8a8a-4e7e-abe3-999c10fe3e41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_2bb5618c-e3a8-4786-9265-ee6da99fc2b1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1e9555c6-f966-47d0-bd0f-668ffbfd718e" xlink:to="loc_dei_EntityAddressCityOrTown_2bb5618c-e3a8-4786-9265-ee6da99fc2b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_aa80dc89-b1f4-416f-b212-4cb9e4ff3c4b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1e9555c6-f966-47d0-bd0f-668ffbfd718e" xlink:to="loc_dei_EntityAddressStateOrProvince_aa80dc89-b1f4-416f-b212-4cb9e4ff3c4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_52f5b924-c6ff-4ddf-a676-15e0c23aebf0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1e9555c6-f966-47d0-bd0f-668ffbfd718e" xlink:to="loc_dei_EntityAddressPostalZipCode_52f5b924-c6ff-4ddf-a676-15e0c23aebf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_70f3fa6d-61d6-4b53-b532-0bbff8d2f4f4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1e9555c6-f966-47d0-bd0f-668ffbfd718e" xlink:to="loc_dei_CityAreaCode_70f3fa6d-61d6-4b53-b532-0bbff8d2f4f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_ba2d2ce4-d3a4-41a6-bfdc-ee6a8f151dd6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1e9555c6-f966-47d0-bd0f-668ffbfd718e" xlink:to="loc_dei_LocalPhoneNumber_ba2d2ce4-d3a4-41a6-bfdc-ee6a8f151dd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_2bca4256-bbcc-469c-a5c6-8f3b3af5335b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1e9555c6-f966-47d0-bd0f-668ffbfd718e" xlink:to="loc_dei_Security12bTitle_2bca4256-bbcc-469c-a5c6-8f3b3af5335b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_f16cff16-e1df-4b36-9362-0e710085a4e5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1e9555c6-f966-47d0-bd0f-668ffbfd718e" xlink:to="loc_dei_TradingSymbol_f16cff16-e1df-4b36-9362-0e710085a4e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_6222897e-3016-4262-bccd-69d6f527363d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1e9555c6-f966-47d0-bd0f-668ffbfd718e" xlink:to="loc_dei_SecurityExchangeName_6222897e-3016-4262-bccd-69d6f527363d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_bda9f7ec-349e-4e6a-a680-94a38ddfc02b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1e9555c6-f966-47d0-bd0f-668ffbfd718e" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_bda9f7ec-349e-4e6a-a680-94a38ddfc02b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_3dfe91d8-c701-4146-b887-2c51958ad4a2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1e9555c6-f966-47d0-bd0f-668ffbfd718e" xlink:to="loc_dei_EntityVoluntaryFilers_3dfe91d8-c701-4146-b887-2c51958ad4a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_d1f95e0d-deee-48a9-8ba3-1b580467d0d8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1e9555c6-f966-47d0-bd0f-668ffbfd718e" xlink:to="loc_dei_EntityCurrentReportingStatus_d1f95e0d-deee-48a9-8ba3-1b580467d0d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_257d51d4-1691-4f46-9e27-27dc556c17fa" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1e9555c6-f966-47d0-bd0f-668ffbfd718e" xlink:to="loc_dei_EntityInteractiveDataCurrent_257d51d4-1691-4f46-9e27-27dc556c17fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_b24573c9-d1f7-438a-a0b8-d723c1987a99" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1e9555c6-f966-47d0-bd0f-668ffbfd718e" xlink:to="loc_dei_EntityFilerCategory_b24573c9-d1f7-438a-a0b8-d723c1987a99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_36734789-cfe4-4e4e-a831-b7caf8d5385b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1e9555c6-f966-47d0-bd0f-668ffbfd718e" xlink:to="loc_dei_EntitySmallBusiness_36734789-cfe4-4e4e-a831-b7caf8d5385b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_16f48a00-5b85-42f5-80d6-9a6e8d7d717a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1e9555c6-f966-47d0-bd0f-668ffbfd718e" xlink:to="loc_dei_EntityEmergingGrowthCompany_16f48a00-5b85-42f5-80d6-9a6e8d7d717a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod_e48fe76a-453b-4832-b76d-d1c053f43fa3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1e9555c6-f966-47d0-bd0f-668ffbfd718e" xlink:to="loc_dei_EntityExTransitionPeriod_e48fe76a-453b-4832-b76d-d1c053f43fa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_144cfda0-81fc-4e4d-b4c7-4a73d4f1ce51" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1e9555c6-f966-47d0-bd0f-668ffbfd718e" xlink:to="loc_dei_IcfrAuditorAttestationFlag_144cfda0-81fc-4e4d-b4c7-4a73d4f1ce51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_caa3f17a-d297-4b18-a769-a81142017496" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1e9555c6-f966-47d0-bd0f-668ffbfd718e" xlink:to="loc_dei_EntityShellCompany_caa3f17a-d297-4b18-a769-a81142017496" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_e7d640f7-1f47-4eeb-a110-72979dc3a7ed" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1e9555c6-f966-47d0-bd0f-668ffbfd718e" xlink:to="loc_dei_EntityPublicFloat_e7d640f7-1f47-4eeb-a110-72979dc3a7ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_60334d2f-b377-43a8-aa69-02f3ddc7ceb8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1e9555c6-f966-47d0-bd0f-668ffbfd718e" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_60334d2f-b377-43a8-aa69-02f3ddc7ceb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_bcd94d8a-c4bb-4b66-b73a-2006d9d29f6c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1e9555c6-f966-47d0-bd0f-668ffbfd718e" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_bcd94d8a-c4bb-4b66-b73a-2006d9d29f6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_bf7a80c3-c73c-424d-8c7f-479596099482" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1e9555c6-f966-47d0-bd0f-668ffbfd718e" xlink:to="loc_dei_EntityCentralIndexKey_bf7a80c3-c73c-424d-8c7f-479596099482" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_da4e3dd1-3453-4212-a4ca-630a3ca6f674" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1e9555c6-f966-47d0-bd0f-668ffbfd718e" xlink:to="loc_dei_DocumentFiscalYearFocus_da4e3dd1-3453-4212-a4ca-630a3ca6f674" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_a6db02da-1193-47ed-b114-68c961eadd7c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1e9555c6-f966-47d0-bd0f-668ffbfd718e" xlink:to="loc_dei_DocumentFiscalPeriodFocus_a6db02da-1193-47ed-b114-68c961eadd7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_10245721-9ba7-4992-aeb4-7fed56de6337" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="36" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1e9555c6-f966-47d0-bd0f-668ffbfd718e" xlink:to="loc_dei_AmendmentFlag_10245721-9ba7-4992-aeb4-7fed56de6337" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.optinose.com/role/AuditInformation" xlink:type="simple" xlink:href="optn-20221231.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://www.optinose.com/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_optn_AuditorInformationAbstract_bad60073-ec77-43e2-be88-fc5eec056e71" xlink:href="optn-20221231.xsd#optn_AuditorInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_994c591d-fcb9-46a8-b295-7940838ab19d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_optn_AuditorInformationAbstract_bad60073-ec77-43e2-be88-fc5eec056e71" xlink:to="loc_dei_AuditorName_994c591d-fcb9-46a8-b295-7940838ab19d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_27fa161a-a6e2-4e49-962f-00afb14c42e5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_optn_AuditorInformationAbstract_bad60073-ec77-43e2-be88-fc5eec056e71" xlink:to="loc_dei_AuditorLocation_27fa161a-a6e2-4e49-962f-00afb14c42e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_a3001ebe-2c43-4ff0-ba5b-587f86552b05" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_optn_AuditorInformationAbstract_bad60073-ec77-43e2-be88-fc5eec056e71" xlink:to="loc_dei_AuditorFirmId_a3001ebe-2c43-4ff0-ba5b-587f86552b05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.optinose.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="optn-20221231.xsd#ConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.optinose.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_09fc012d-3ac5-4cf6-a6d5-5150ab3cdf8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_de2e7cad-b3ca-4a10-9fa5-7c4756f64735" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_09fc012d-3ac5-4cf6-a6d5-5150ab3cdf8a" xlink:to="loc_us-gaap_AssetsAbstract_de2e7cad-b3ca-4a10-9fa5-7c4756f64735" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_7ee4f048-1c72-4a5f-8b59-97372ab24810" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_de2e7cad-b3ca-4a10-9fa5-7c4756f64735" xlink:to="loc_us-gaap_AssetsCurrentAbstract_7ee4f048-1c72-4a5f-8b59-97372ab24810" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_7f5c848a-c09c-4b7a-88ac-9fb7d39db168" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_7ee4f048-1c72-4a5f-8b59-97372ab24810" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_7f5c848a-c09c-4b7a-88ac-9fb7d39db168" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_d315cbf8-130f-41bb-b0cf-a1873c665609" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_7ee4f048-1c72-4a5f-8b59-97372ab24810" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_d315cbf8-130f-41bb-b0cf-a1873c665609" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_dc6f5347-684f-41a2-84d4-028c18c7de3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_7ee4f048-1c72-4a5f-8b59-97372ab24810" xlink:to="loc_us-gaap_InventoryNet_dc6f5347-684f-41a2-84d4-028c18c7de3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_0e250cbc-43f3-4011-8c5d-4c82541dc5fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_7ee4f048-1c72-4a5f-8b59-97372ab24810" xlink:to="loc_us-gaap_OtherAssetsCurrent_0e250cbc-43f3-4011-8c5d-4c82541dc5fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_c0f53a91-7f47-448f-81a1-6ed7a5131761" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_7ee4f048-1c72-4a5f-8b59-97372ab24810" xlink:to="loc_us-gaap_AssetsCurrent_c0f53a91-7f47-448f-81a1-6ed7a5131761" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_c54f6f9e-7375-4af1-b161-ca2e882a0efa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_de2e7cad-b3ca-4a10-9fa5-7c4756f64735" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_c54f6f9e-7375-4af1-b161-ca2e882a0efa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_ab2006e0-6ea3-42a8-9f77-e6e99d303851" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_de2e7cad-b3ca-4a10-9fa5-7c4756f64735" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_ab2006e0-6ea3-42a8-9f77-e6e99d303851" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_c9297137-fc3c-4241-817b-a4ec8119d61e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_de2e7cad-b3ca-4a10-9fa5-7c4756f64735" xlink:to="loc_us-gaap_Assets_c9297137-fc3c-4241-817b-a4ec8119d61e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_28ceebb3-116d-4d3a-b20a-16d547543449" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_09fc012d-3ac5-4cf6-a6d5-5150ab3cdf8a" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_28ceebb3-116d-4d3a-b20a-16d547543449" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_3d38cde3-bb50-45c6-81bb-a88b20ee782d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_28ceebb3-116d-4d3a-b20a-16d547543449" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_3d38cde3-bb50-45c6-81bb-a88b20ee782d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_9220a545-c2ab-4b63-8b47-a4ff57c097d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_3d38cde3-bb50-45c6-81bb-a88b20ee782d" xlink:to="loc_us-gaap_AccountsPayableCurrent_9220a545-c2ab-4b63-8b47-a4ff57c097d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_2bbb4c73-9c5e-487b-837e-75bba8aa0b7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_3d38cde3-bb50-45c6-81bb-a88b20ee782d" xlink:to="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_2bbb4c73-9c5e-487b-837e-75bba8aa0b7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_4bcfa021-9702-4a8a-b4d3-5f7ee63461ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_3d38cde3-bb50-45c6-81bb-a88b20ee782d" xlink:to="loc_us-gaap_LongTermDebtCurrent_4bcfa021-9702-4a8a-b4d3-5f7ee63461ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_41ed0ca9-54a0-46d5-97df-ea644ea4df96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_3d38cde3-bb50-45c6-81bb-a88b20ee782d" xlink:to="loc_us-gaap_LiabilitiesCurrent_41ed0ca9-54a0-46d5-97df-ea644ea4df96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_5e67230c-deb4-45e0-a1a4-fda02c817f7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_28ceebb3-116d-4d3a-b20a-16d547543449" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_5e67230c-deb4-45e0-a1a4-fda02c817f7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_WarrantLiabilityNonCurrent_411495b5-9022-47b1-9f9e-0fe422cb4eb8" xlink:href="optn-20221231.xsd#optn_WarrantLiabilityNonCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_28ceebb3-116d-4d3a-b20a-16d547543449" xlink:to="loc_optn_WarrantLiabilityNonCurrent_411495b5-9022-47b1-9f9e-0fe422cb4eb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_ecd2e10b-1e4c-4c93-b689-910f7015348b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_28ceebb3-116d-4d3a-b20a-16d547543449" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_ecd2e10b-1e4c-4c93-b689-910f7015348b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_67d76928-1f54-4328-8223-73a1907ebcbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_28ceebb3-116d-4d3a-b20a-16d547543449" xlink:to="loc_us-gaap_Liabilities_67d76928-1f54-4328-8223-73a1907ebcbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_e6844d94-79c5-487a-a6c7-6c21f91fe652" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_28ceebb3-116d-4d3a-b20a-16d547543449" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_e6844d94-79c5-487a-a6c7-6c21f91fe652" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_f32f6e33-ee2f-44b4-b0a3-180aeeacbfb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_e6844d94-79c5-487a-a6c7-6c21f91fe652" xlink:to="loc_us-gaap_CommonStockValue_f32f6e33-ee2f-44b4-b0a3-180aeeacbfb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_fa94d401-1f94-4cc7-a0fb-5506d1feff3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_e6844d94-79c5-487a-a6c7-6c21f91fe652" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_fa94d401-1f94-4cc7-a0fb-5506d1feff3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_43e29379-8794-4696-9de0-85b9e2595426" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_e6844d94-79c5-487a-a6c7-6c21f91fe652" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_43e29379-8794-4696-9de0-85b9e2595426" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_1333e4da-c0ce-420f-8435-c28e34598825" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_e6844d94-79c5-487a-a6c7-6c21f91fe652" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_1333e4da-c0ce-420f-8435-c28e34598825" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_a29357c3-ae9a-4af9-8873-7c08785a7ac9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_e6844d94-79c5-487a-a6c7-6c21f91fe652" xlink:to="loc_us-gaap_StockholdersEquity_a29357c3-ae9a-4af9-8873-7c08785a7ac9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_88cf8c2c-c05d-45fc-81ea-c4f0bdfacc32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_28ceebb3-116d-4d3a-b20a-16d547543449" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_88cf8c2c-c05d-45fc-81ea-c4f0bdfacc32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.optinose.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="optn-20221231.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.optinose.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_a6a7175d-c14a-4dc5-ae73-1533f94ce6b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_f3c811f2-294e-4fbd-911d-f31841078564" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_a6a7175d-c14a-4dc5-ae73-1533f94ce6b1" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_f3c811f2-294e-4fbd-911d-f31841078564" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_13bdca13-be82-4738-949a-526dd2488b68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_a6a7175d-c14a-4dc5-ae73-1533f94ce6b1" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_13bdca13-be82-4738-949a-526dd2488b68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_ad53a67d-34d2-4606-a3f5-5098f061c6aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_a6a7175d-c14a-4dc5-ae73-1533f94ce6b1" xlink:to="loc_us-gaap_CommonStockSharesIssued_ad53a67d-34d2-4606-a3f5-5098f061c6aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_aab82b80-6c46-4d6d-a0f5-ea8c5cacc8f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_a6a7175d-c14a-4dc5-ae73-1533f94ce6b1" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_aab82b80-6c46-4d6d-a0f5-ea8c5cacc8f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.optinose.com/role/ConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="optn-20221231.xsd#ConsolidatedStatementsofOperations"/>
  <link:presentationLink xlink:role="http://www.optinose.com/role/ConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_8d39fd2c-58b8-4f2a-b2a8-2fcea67a7ae5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_58656ea1-d0aa-46be-90c7-20730d0bed12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_8d39fd2c-58b8-4f2a-b2a8-2fcea67a7ae5" xlink:to="loc_us-gaap_StatementTable_58656ea1-d0aa-46be-90c7-20730d0bed12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_38e6fc05-5515-4253-83a2-862200f50f69" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_58656ea1-d0aa-46be-90c7-20730d0bed12" xlink:to="loc_srt_ProductOrServiceAxis_38e6fc05-5515-4253-83a2-862200f50f69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_92e3e8f6-d0e1-4fee-9d50-a4c6925bdab0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_38e6fc05-5515-4253-83a2-862200f50f69" xlink:to="loc_srt_ProductsAndServicesDomain_92e3e8f6-d0e1-4fee-9d50-a4c6925bdab0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_c38a2e92-fe2a-4208-9a55-2f1b4c0071a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_92e3e8f6-d0e1-4fee-9d50-a4c6925bdab0" xlink:to="loc_us-gaap_ProductMember_c38a2e92-fe2a-4208-9a55-2f1b4c0071a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_f7ea6c26-5437-4c7a-b933-61ce75e28280" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_92e3e8f6-d0e1-4fee-9d50-a4c6925bdab0" xlink:to="loc_us-gaap_LicenseMember_f7ea6c26-5437-4c7a-b933-61ce75e28280" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_31dc93ea-3d66-4cf1-8c90-82aaa784f58d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_58656ea1-d0aa-46be-90c7-20730d0bed12" xlink:to="loc_us-gaap_StatementLineItems_31dc93ea-3d66-4cf1-8c90-82aaa784f58d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_73633cab-ae77-40ae-bc3c-38fa8c00af02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_31dc93ea-3d66-4cf1-8c90-82aaa784f58d" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_73633cab-ae77-40ae-bc3c-38fa8c00af02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_f58087b4-3fbb-46ce-ac0d-d2c1e0db979b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_31dc93ea-3d66-4cf1-8c90-82aaa784f58d" xlink:to="loc_us-gaap_OperatingExpensesAbstract_f58087b4-3fbb-46ce-ac0d-d2c1e0db979b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_09634b0c-0d5a-420e-955c-18c061677ac5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_f58087b4-3fbb-46ce-ac0d-d2c1e0db979b" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_09634b0c-0d5a-420e-955c-18c061677ac5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_340a3f9a-517a-4676-beb9-9669e0b33113" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_f58087b4-3fbb-46ce-ac0d-d2c1e0db979b" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_340a3f9a-517a-4676-beb9-9669e0b33113" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_375f469f-048f-446a-b1bb-5b9c99aa75f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_f58087b4-3fbb-46ce-ac0d-d2c1e0db979b" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_375f469f-048f-446a-b1bb-5b9c99aa75f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_5c866246-655c-403d-9b38-46109b8b6f9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_f58087b4-3fbb-46ce-ac0d-d2c1e0db979b" xlink:to="loc_us-gaap_CostsAndExpenses_5c866246-655c-403d-9b38-46109b8b6f9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_a13d3e09-160d-47b2-95ab-a2204f1c656d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_31dc93ea-3d66-4cf1-8c90-82aaa784f58d" xlink:to="loc_us-gaap_OperatingIncomeLoss_a13d3e09-160d-47b2-95ab-a2204f1c656d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_f4daba37-3f20-471a-a63a-636bb2595bc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_31dc93ea-3d66-4cf1-8c90-82aaa784f58d" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_f4daba37-3f20-471a-a63a-636bb2595bc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_UnrealizedGainLossOnFairValueOfWarrants_a5bc5785-45e5-4f3b-8c9d-aad162569507" xlink:href="optn-20221231.xsd#optn_UnrealizedGainLossOnFairValueOfWarrants"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_f4daba37-3f20-471a-a63a-636bb2595bc3" xlink:to="loc_optn_UnrealizedGainLossOnFairValueOfWarrants_a5bc5785-45e5-4f3b-8c9d-aad162569507" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_GrantAndOtherIncome_281ef494-4668-4018-9579-2b4ca446c8d4" xlink:href="optn-20221231.xsd#optn_GrantAndOtherIncome"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_f4daba37-3f20-471a-a63a-636bb2595bc3" xlink:to="loc_optn_GrantAndOtherIncome_281ef494-4668-4018-9579-2b4ca446c8d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_63744cda-5f00-451c-a3a8-69e652d3bcdf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_f4daba37-3f20-471a-a63a-636bb2595bc3" xlink:to="loc_us-gaap_InvestmentIncomeInterest_63744cda-5f00-451c-a3a8-69e652d3bcdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_b8cf1098-b246-460f-974c-4dbdbc173882" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_f4daba37-3f20-471a-a63a-636bb2595bc3" xlink:to="loc_us-gaap_InterestExpense_b8cf1098-b246-460f-974c-4dbdbc173882" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_6a7fa52f-a4ad-44b8-a69a-3d8ad05887b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_31dc93ea-3d66-4cf1-8c90-82aaa784f58d" xlink:to="loc_us-gaap_NetIncomeLoss_6a7fa52f-a4ad-44b8-a69a-3d8ad05887b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_1c9536ce-ad02-4428-b6f3-fdb03619606d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_31dc93ea-3d66-4cf1-8c90-82aaa784f58d" xlink:to="loc_us-gaap_EarningsPerShareBasic_1c9536ce-ad02-4428-b6f3-fdb03619606d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_d83c3ab3-1943-40c1-9de2-014870ae42cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_31dc93ea-3d66-4cf1-8c90-82aaa784f58d" xlink:to="loc_us-gaap_EarningsPerShareDiluted_d83c3ab3-1943-40c1-9de2-014870ae42cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_eed85cc8-49bd-4100-b110-1b4117906129" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_31dc93ea-3d66-4cf1-8c90-82aaa784f58d" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_eed85cc8-49bd-4100-b110-1b4117906129" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2d2b95c4-41bb-42c5-b47d-7d428687c2b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_31dc93ea-3d66-4cf1-8c90-82aaa784f58d" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2d2b95c4-41bb-42c5-b47d-7d428687c2b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.optinose.com/role/ConsolidatedStatementsofComprehensiveLoss" xlink:type="simple" xlink:href="optn-20221231.xsd#ConsolidatedStatementsofComprehensiveLoss"/>
  <link:presentationLink xlink:role="http://www.optinose.com/role/ConsolidatedStatementsofComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_46e2f865-251d-4913-8fcf-b945bf6454f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_cf7b8641-b957-41de-b9ea-632808f0482a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_46e2f865-251d-4913-8fcf-b945bf6454f5" xlink:to="loc_us-gaap_NetIncomeLoss_cf7b8641-b957-41de-b9ea-632808f0482a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_fb9d935b-ac36-46ee-baa5-8d86b04de467" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_46e2f865-251d-4913-8fcf-b945bf6454f5" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_fb9d935b-ac36-46ee-baa5-8d86b04de467" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_2f92be6e-51d4-4987-8e4d-1220a584f38f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_fb9d935b-ac36-46ee-baa5-8d86b04de467" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_2f92be6e-51d4-4987-8e4d-1220a584f38f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_88e718f4-a8df-4d38-8830-981dc2f995f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_46e2f865-251d-4913-8fcf-b945bf6454f5" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_88e718f4-a8df-4d38-8830-981dc2f995f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.optinose.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit" xlink:type="simple" xlink:href="optn-20221231.xsd#ConsolidatedStatementsofChangesinStockholdersEquityDeficit"/>
  <link:presentationLink xlink:role="http://www.optinose.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_5d348758-260e-4102-9225-835f088e7f93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_8f3e2b10-9464-4c8f-ba75-de3d2c2c84d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_5d348758-260e-4102-9225-835f088e7f93" xlink:to="loc_us-gaap_StatementTable_8f3e2b10-9464-4c8f-ba75-de3d2c2c84d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2f15a7bd-c269-4b6a-aeda-d5c35126e6a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_8f3e2b10-9464-4c8f-ba75-de3d2c2c84d4" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2f15a7bd-c269-4b6a-aeda-d5c35126e6a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_87764d65-eaf8-4135-bde5-e2d827759e90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2f15a7bd-c269-4b6a-aeda-d5c35126e6a7" xlink:to="loc_us-gaap_EquityComponentDomain_87764d65-eaf8-4135-bde5-e2d827759e90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_4d28deac-f991-4259-bf23-53084bbecb6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_87764d65-eaf8-4135-bde5-e2d827759e90" xlink:to="loc_us-gaap_CommonStockMember_4d28deac-f991-4259-bf23-53084bbecb6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_63fd44b0-f94a-4ab0-84db-0316fb6d22c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_87764d65-eaf8-4135-bde5-e2d827759e90" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_63fd44b0-f94a-4ab0-84db-0316fb6d22c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_dd44f19d-d937-45ba-a805-e997c3ae3194" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_87764d65-eaf8-4135-bde5-e2d827759e90" xlink:to="loc_us-gaap_RetainedEarningsMember_dd44f19d-d937-45ba-a805-e997c3ae3194" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_f6384a81-cf1f-49a8-b273-cd6539c1c449" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_87764d65-eaf8-4135-bde5-e2d827759e90" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_f6384a81-cf1f-49a8-b273-cd6539c1c449" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_4791b288-60b9-47cf-8597-1067ef9be3e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_8f3e2b10-9464-4c8f-ba75-de3d2c2c84d4" xlink:to="loc_us-gaap_StatementLineItems_4791b288-60b9-47cf-8597-1067ef9be3e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_12ab529b-3609-4f45-b73e-fb51c56c6da5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4791b288-60b9-47cf-8597-1067ef9be3e5" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_12ab529b-3609-4f45-b73e-fb51c56c6da5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_e4f07065-81cf-420a-864c-14989d9189ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_12ab529b-3609-4f45-b73e-fb51c56c6da5" xlink:to="loc_us-gaap_StockholdersEquity_e4f07065-81cf-420a-864c-14989d9189ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_e60907f6-1ce3-4833-befc-aac2fc7e9b3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_12ab529b-3609-4f45-b73e-fb51c56c6da5" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_e60907f6-1ce3-4833-befc-aac2fc7e9b3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_963c9a33-5610-4a24-ab8e-3679d1644224" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_12ab529b-3609-4f45-b73e-fb51c56c6da5" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_963c9a33-5610-4a24-ab8e-3679d1644224" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_StockIssuedDuringPeriodVestedRestrictedStockUnits_93a4bc98-05b1-46ea-b0e6-68149091c725" xlink:href="optn-20221231.xsd#optn_StockIssuedDuringPeriodVestedRestrictedStockUnits"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_12ab529b-3609-4f45-b73e-fb51c56c6da5" xlink:to="loc_optn_StockIssuedDuringPeriodVestedRestrictedStockUnits_93a4bc98-05b1-46ea-b0e6-68149091c725" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_StockIssuedDuringPeriodSharesVestedRestrictedStockUnits_4b3c3a7e-b939-4692-84c3-521ad9e9cdfb" xlink:href="optn-20221231.xsd#optn_StockIssuedDuringPeriodSharesVestedRestrictedStockUnits"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_12ab529b-3609-4f45-b73e-fb51c56c6da5" xlink:to="loc_optn_StockIssuedDuringPeriodSharesVestedRestrictedStockUnits_4b3c3a7e-b939-4692-84c3-521ad9e9cdfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_c9f55fda-3e81-404b-8941-0f1e3680a33c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_12ab529b-3609-4f45-b73e-fb51c56c6da5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_c9f55fda-3e81-404b-8941-0f1e3680a33c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_45f10ca9-b163-47d3-8fec-f046c6dd37fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_12ab529b-3609-4f45-b73e-fb51c56c6da5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_45f10ca9-b163-47d3-8fec-f046c6dd37fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_52136aa7-5d4b-49f2-96d8-b831733cf5e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_12ab529b-3609-4f45-b73e-fb51c56c6da5" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_52136aa7-5d4b-49f2-96d8-b831733cf5e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_97559801-0aa9-4b89-8780-039f8d07fd23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_12ab529b-3609-4f45-b73e-fb51c56c6da5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_97559801-0aa9-4b89-8780-039f8d07fd23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_8aba943d-8f1d-47bd-92e5-1027af50dee9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_12ab529b-3609-4f45-b73e-fb51c56c6da5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_8aba943d-8f1d-47bd-92e5-1027af50dee9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan_31ad68fb-378e-4a0f-bb7e-b6816465063a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_12ab529b-3609-4f45-b73e-fb51c56c6da5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan_31ad68fb-378e-4a0f-bb7e-b6816465063a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan_f6c4ab45-15d1-4f3e-9b36-624bf589dc94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_12ab529b-3609-4f45-b73e-fb51c56c6da5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan_f6c4ab45-15d1-4f3e-9b36-624bf589dc94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_4e6a0f0a-17ed-41ad-be26-3f557e2d2c92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_12ab529b-3609-4f45-b73e-fb51c56c6da5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_4e6a0f0a-17ed-41ad-be26-3f557e2d2c92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_ba48f130-7ae2-4b16-970c-dc599025d690" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_12ab529b-3609-4f45-b73e-fb51c56c6da5" xlink:to="loc_us-gaap_NetIncomeLoss_ba48f130-7ae2-4b16-970c-dc599025d690" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_d1e1a9ab-2d5e-4b9d-9344-2e1de0aa37dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_12ab529b-3609-4f45-b73e-fb51c56c6da5" xlink:to="loc_us-gaap_StockholdersEquity_d1e1a9ab-2d5e-4b9d-9344-2e1de0aa37dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_0d2c0f01-5114-4471-8f4c-b53dee94dbeb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_12ab529b-3609-4f45-b73e-fb51c56c6da5" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_0d2c0f01-5114-4471-8f4c-b53dee94dbeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.optinose.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="optn-20221231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.optinose.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_bc308b58-73a9-4f04-9bef-17d76e53e52b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_f67c76e0-2a53-4d46-9596-cc3d4b07559e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_bc308b58-73a9-4f04-9bef-17d76e53e52b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_f67c76e0-2a53-4d46-9596-cc3d4b07559e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_324ad94d-1e31-40ea-b6a2-67dc11cb7e3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_f67c76e0-2a53-4d46-9596-cc3d4b07559e" xlink:to="loc_us-gaap_NetIncomeLoss_324ad94d-1e31-40ea-b6a2-67dc11cb7e3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_35ecf58a-dba9-43eb-a68b-baa3aa4b260d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_f67c76e0-2a53-4d46-9596-cc3d4b07559e" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_35ecf58a-dba9-43eb-a68b-baa3aa4b260d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_12f180a3-be0f-4d0d-9de1-d6672f65a01f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_35ecf58a-dba9-43eb-a68b-baa3aa4b260d" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_12f180a3-be0f-4d0d-9de1-d6672f65a01f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_a3506929-971d-4bab-9f07-37835ddee468" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_35ecf58a-dba9-43eb-a68b-baa3aa4b260d" xlink:to="loc_us-gaap_ShareBasedCompensation_a3506929-971d-4bab-9f07-37835ddee468" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_f127fa83-8315-4408-8874-089c04a1c042" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_35ecf58a-dba9-43eb-a68b-baa3aa4b260d" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_f127fa83-8315-4408-8874-089c04a1c042" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_5ecd1ef0-49b8-4f8c-93c9-5dfb3d8bcf2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_35ecf58a-dba9-43eb-a68b-baa3aa4b260d" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_5ecd1ef0-49b8-4f8c-93c9-5dfb3d8bcf2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_e4c717fb-6444-4012-bd72-fa8b0f3e1197" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_35ecf58a-dba9-43eb-a68b-baa3aa4b260d" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_e4c717fb-6444-4012-bd72-fa8b0f3e1197" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_7f72c04d-fe83-4445-8fc4-176e41aeee95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_35ecf58a-dba9-43eb-a68b-baa3aa4b260d" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_7f72c04d-fe83-4445-8fc4-176e41aeee95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_559851b5-77b1-481d-825b-def6ffdddedc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_35ecf58a-dba9-43eb-a68b-baa3aa4b260d" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_559851b5-77b1-481d-825b-def6ffdddedc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_db5cb7bc-e314-44c4-a3e4-fc5ad4ddd60a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_559851b5-77b1-481d-825b-def6ffdddedc" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_db5cb7bc-e314-44c4-a3e4-fc5ad4ddd60a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_IncreaseDecreaseInGrantsandOtherReceivables_3e541655-1aa8-47f3-8b90-8aa949260f46" xlink:href="optn-20221231.xsd#optn_IncreaseDecreaseInGrantsandOtherReceivables"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_559851b5-77b1-481d-825b-def6ffdddedc" xlink:to="loc_optn_IncreaseDecreaseInGrantsandOtherReceivables_3e541655-1aa8-47f3-8b90-8aa949260f46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_IncreaseDecreaseinDepositsandOtherAssets_bf981f6e-cb64-4bdd-a3c9-e2a22b19fe2f" xlink:href="optn-20221231.xsd#optn_IncreaseDecreaseinDepositsandOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_559851b5-77b1-481d-825b-def6ffdddedc" xlink:to="loc_optn_IncreaseDecreaseinDepositsandOtherAssets_bf981f6e-cb64-4bdd-a3c9-e2a22b19fe2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_fa32498a-6a58-4e61-b231-b29be11c7554" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_559851b5-77b1-481d-825b-def6ffdddedc" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_fa32498a-6a58-4e61-b231-b29be11c7554" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_eacd828e-acc8-44b9-bb8f-fd3c79f7389c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_559851b5-77b1-481d-825b-def6ffdddedc" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_eacd828e-acc8-44b9-bb8f-fd3c79f7389c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_7f95a1fd-60d5-43a3-bcb5-a9c07118317d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_559851b5-77b1-481d-825b-def6ffdddedc" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_7f95a1fd-60d5-43a3-bcb5-a9c07118317d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_eeb6763c-cc70-4bec-b5c2-f93933cf5cdc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_f67c76e0-2a53-4d46-9596-cc3d4b07559e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_eeb6763c-cc70-4bec-b5c2-f93933cf5cdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_b9f9a0bf-a75c-4968-bd95-4bd5b115a3c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_bc308b58-73a9-4f04-9bef-17d76e53e52b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_b9f9a0bf-a75c-4968-bd95-4bd5b115a3c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0cf62fe0-a5f0-4a01-ac0f-0e3a3764fdd7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_b9f9a0bf-a75c-4968-bd95-4bd5b115a3c8" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0cf62fe0-a5f0-4a01-ac0f-0e3a3764fdd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_4099c920-9222-47f5-a208-030c64170ca7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_b9f9a0bf-a75c-4968-bd95-4bd5b115a3c8" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_4099c920-9222-47f5-a208-030c64170ca7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f575cca9-15f3-49f8-b95e-93a8d617a5d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_b9f9a0bf-a75c-4968-bd95-4bd5b115a3c8" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f575cca9-15f3-49f8-b95e-93a8d617a5d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_58fd49cf-0bae-46c8-9474-2221488d1730" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_bc308b58-73a9-4f04-9bef-17d76e53e52b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_58fd49cf-0bae-46c8-9474-2221488d1730" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_ec0d2353-004d-4711-85a0-d37ded76d654" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_58fd49cf-0bae-46c8-9474-2221488d1730" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_ec0d2353-004d-4711-85a0-d37ded76d654" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_ProceedsfromIssuanceofCommonStockUnderEmployeeStockPurchasePlan_723d8fa5-7ddd-4c68-87a1-fe6af615d2d7" xlink:href="optn-20221231.xsd#optn_ProceedsfromIssuanceofCommonStockUnderEmployeeStockPurchasePlan"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_58fd49cf-0bae-46c8-9474-2221488d1730" xlink:to="loc_optn_ProceedsfromIssuanceofCommonStockUnderEmployeeStockPurchasePlan_723d8fa5-7ddd-4c68-87a1-fe6af615d2d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_c2f5e2e4-964c-44bf-aa88-300126bd5c5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_58fd49cf-0bae-46c8-9474-2221488d1730" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_c2f5e2e4-964c-44bf-aa88-300126bd5c5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts_104cdb1a-25a4-4914-baf9-9fbf1ffff3e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfFinancingCosts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_58fd49cf-0bae-46c8-9474-2221488d1730" xlink:to="loc_us-gaap_PaymentsOfFinancingCosts_104cdb1a-25a4-4914-baf9-9fbf1ffff3e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_918d7dbf-7d2a-4f26-96b0-16c2fb81ce95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_58fd49cf-0bae-46c8-9474-2221488d1730" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_918d7dbf-7d2a-4f26-96b0-16c2fb81ce95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1f3df3cc-094a-4689-9e91-268e39520a1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_bc308b58-73a9-4f04-9bef-17d76e53e52b" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1f3df3cc-094a-4689-9e91-268e39520a1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1673d8c3-edf8-418b-908b-1454c188d88f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_bc308b58-73a9-4f04-9bef-17d76e53e52b" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1673d8c3-edf8-418b-908b-1454c188d88f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8f345d75-4e1c-4dec-b1c4-31941ff1cdfe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_bc308b58-73a9-4f04-9bef-17d76e53e52b" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8f345d75-4e1c-4dec-b1c4-31941ff1cdfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_10a029f1-68b6-4c71-9ff2-6398f05cb637" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_bc308b58-73a9-4f04-9bef-17d76e53e52b" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_10a029f1-68b6-4c71-9ff2-6398f05cb637" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_6b857011-db3a-4590-96e3-d18fc429ea50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_bc308b58-73a9-4f04-9bef-17d76e53e52b" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_6b857011-db3a-4590-96e3-d18fc429ea50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_724e8281-97c2-4a42-a485-b48d395f1933" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_6b857011-db3a-4590-96e3-d18fc429ea50" xlink:to="loc_us-gaap_InterestPaidNet_724e8281-97c2-4a42-a485-b48d395f1933" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_1d0a4c75-e3fb-47e2-82c4-97adb9b6b62e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_bc308b58-73a9-4f04-9bef-17d76e53e52b" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_1d0a4c75-e3fb-47e2-82c4-97adb9b6b62e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1_5ff6aee8-0f75-4413-a1d0-e6343f29679f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_1d0a4c75-e3fb-47e2-82c4-97adb9b6b62e" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1_5ff6aee8-0f75-4413-a1d0-e6343f29679f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_0c4b0e31-c6f5-4c3e-bc35-3b4af93f1806" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_1d0a4c75-e3fb-47e2-82c4-97adb9b6b62e" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_0c4b0e31-c6f5-4c3e-bc35-3b4af93f1806" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_DeferredOfferingCostsWIthinAccountsPayableandAccruedExpenses_bedb4ae0-b953-45b8-ba5f-ed4a462ab182" xlink:href="optn-20221231.xsd#optn_DeferredOfferingCostsWIthinAccountsPayableandAccruedExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_1d0a4c75-e3fb-47e2-82c4-97adb9b6b62e" xlink:to="loc_optn_DeferredOfferingCostsWIthinAccountsPayableandAccruedExpenses_bedb4ae0-b953-45b8-ba5f-ed4a462ab182" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_51d3a7ff-9e1a-4ab9-9070-544d0171466e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_1d0a4c75-e3fb-47e2-82c4-97adb9b6b62e" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_51d3a7ff-9e1a-4ab9-9070-544d0171466e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.optinose.com/role/OrganizationandDescriptionofBusiness" xlink:type="simple" xlink:href="optn-20221231.xsd#OrganizationandDescriptionofBusiness"/>
  <link:presentationLink xlink:role="http://www.optinose.com/role/OrganizationandDescriptionofBusiness" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8185a6e8-b279-429c-a6b8-fe499857e0b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations_a4071a0e-09bc-4414-9d32-5725f4cabdb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NatureOfOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8185a6e8-b279-429c-a6b8-fe499857e0b3" xlink:to="loc_us-gaap_NatureOfOperations_a4071a0e-09bc-4414-9d32-5725f4cabdb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.optinose.com/role/Liquidity" xlink:type="simple" xlink:href="optn-20221231.xsd#Liquidity"/>
  <link:presentationLink xlink:role="http://www.optinose.com/role/Liquidity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5c7bbbb6-c011-473b-a87c-5cb1bfe0f6af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_FutureLiquidityTextBlock_7cd3f9c4-b0e2-4a17-83cd-3b7e62c8128d" xlink:href="optn-20221231.xsd#optn_FutureLiquidityTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5c7bbbb6-c011-473b-a87c-5cb1bfe0f6af" xlink:to="loc_optn_FutureLiquidityTextBlock_7cd3f9c4-b0e2-4a17-83cd-3b7e62c8128d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.optinose.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="optn-20221231.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.optinose.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_642c2768-823f-4037-a8cc-1c2907b5f85c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_835449d4-858e-4773-b3a1-1539911bf3ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_642c2768-823f-4037-a8cc-1c2907b5f85c" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_835449d4-858e-4773-b3a1-1539911bf3ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.optinose.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="optn-20221231.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.optinose.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_dfbf44bd-26e9-49ca-9821-f1a8bb11f58f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_0e782153-c300-41d4-a2f7-a79afebaaf57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_dfbf44bd-26e9-49ca-9821-f1a8bb11f58f" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_0e782153-c300-41d4-a2f7-a79afebaaf57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.optinose.com/role/Inventory" xlink:type="simple" xlink:href="optn-20221231.xsd#Inventory"/>
  <link:presentationLink xlink:role="http://www.optinose.com/role/Inventory" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_caf0e704-c232-4499-9d8e-4c7a79dac29a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_b4d873be-a0d0-4591-a55b-fce416369445" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_caf0e704-c232-4499-9d8e-4c7a79dac29a" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_b4d873be-a0d0-4591-a55b-fce416369445" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.optinose.com/role/PropertyandEquipment" xlink:type="simple" xlink:href="optn-20221231.xsd#PropertyandEquipment"/>
  <link:presentationLink xlink:role="http://www.optinose.com/role/PropertyandEquipment" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_dbd20428-41a6-485f-97d7-876db92ee611" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_0f7610df-4515-459f-b5d9-2565a4cc458c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_dbd20428-41a6-485f-97d7-876db92ee611" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_0f7610df-4515-459f-b5d9-2565a4cc458c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.optinose.com/role/Leases" xlink:type="simple" xlink:href="optn-20221231.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.optinose.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_cf5dbaf9-635a-493d-918b-3ec1e3bf4095" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_4822801e-856c-43b7-b050-7accd95a86b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_cf5dbaf9-635a-493d-918b-3ec1e3bf4095" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_4822801e-856c-43b7-b050-7accd95a86b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.optinose.com/role/AccruedExpensesandOtherCurrentLiabilities" xlink:type="simple" xlink:href="optn-20221231.xsd#AccruedExpensesandOtherCurrentLiabilities"/>
  <link:presentationLink xlink:role="http://www.optinose.com/role/AccruedExpensesandOtherCurrentLiabilities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_7891fecb-1abc-4a28-8f58-3f405d3351a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_b601e5b4-dbf8-4664-866f-b02daed1c39f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_7891fecb-1abc-4a28-8f58-3f405d3351a2" xlink:to="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_b601e5b4-dbf8-4664-866f-b02daed1c39f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.optinose.com/role/LicenseAgreements" xlink:type="simple" xlink:href="optn-20221231.xsd#LicenseAgreements"/>
  <link:presentationLink xlink:role="http://www.optinose.com/role/LicenseAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_4be1dc31-d1fc-4729-b356-a19b2a68bd45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_90d0dd18-29e4-4d3c-9f0a-7042475f0f63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_4be1dc31-d1fc-4729-b356-a19b2a68bd45" xlink:to="loc_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_90d0dd18-29e4-4d3c-9f0a-7042475f0f63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.optinose.com/role/Debtnet" xlink:type="simple" xlink:href="optn-20221231.xsd#Debtnet"/>
  <link:presentationLink xlink:role="http://www.optinose.com/role/Debtnet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_a3b4fe24-28aa-44b6-95b2-ddd3d5fafd10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_7a775694-4ea3-4a08-9e4b-452eef4d7865" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_a3b4fe24-28aa-44b6-95b2-ddd3d5fafd10" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_7a775694-4ea3-4a08-9e4b-452eef4d7865" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.optinose.com/role/EmployeeBenefitPlans" xlink:type="simple" xlink:href="optn-20221231.xsd#EmployeeBenefitPlans"/>
  <link:presentationLink xlink:role="http://www.optinose.com/role/EmployeeBenefitPlans" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_bcf4a47e-dd15-4b7f-b0ab-3cbaf47079a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_55e86745-22ac-4aef-a4ca-d12793d3c1fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_bcf4a47e-dd15-4b7f-b0ab-3cbaf47079a5" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_55e86745-22ac-4aef-a4ca-d12793d3c1fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.optinose.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="optn-20221231.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.optinose.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_76600ae0-c02d-4696-b6c4-6966837c9482" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_a27a58cb-4cad-43a2-8052-51f0eacb81b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_76600ae0-c02d-4696-b6c4-6966837c9482" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_a27a58cb-4cad-43a2-8052-51f0eacb81b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.optinose.com/role/StockholdersEquity" xlink:type="simple" xlink:href="optn-20221231.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.optinose.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_b13a6255-9f7b-4ec8-985d-a7012eaa1bf9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_9bb98917-b6b0-4ffc-869e-4aec45a5811b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_b13a6255-9f7b-4ec8-985d-a7012eaa1bf9" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_9bb98917-b6b0-4ffc-869e-4aec45a5811b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.optinose.com/role/StockbasedCompensation" xlink:type="simple" xlink:href="optn-20221231.xsd#StockbasedCompensation"/>
  <link:presentationLink xlink:role="http://www.optinose.com/role/StockbasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_60aa93eb-f4a8-46ad-aa9b-5da6be461634" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_125f44c9-6c83-47fe-9b75-4a1f572d3c8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_60aa93eb-f4a8-46ad-aa9b-5da6be461634" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_125f44c9-6c83-47fe-9b75-4a1f572d3c8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.optinose.com/role/IncomeTaxes" xlink:type="simple" xlink:href="optn-20221231.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.optinose.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_2e8dad27-38ef-40e3-9cf6-6b17d23da009" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_7c10076c-d521-496e-a440-b9836faebd48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2e8dad27-38ef-40e3-9cf6-6b17d23da009" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_7c10076c-d521-496e-a440-b9836faebd48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.optinose.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="optn-20221231.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.optinose.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ad41a917-a392-460d-8747-0e8f57b3f5f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_70930b65-011c-41ee-8366-813493c8a046" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ad41a917-a392-460d-8747-0e8f57b3f5f1" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_70930b65-011c-41ee-8366-813493c8a046" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_ad13a978-7e5b-4247-a9db-2a6478ff0ffa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ad41a917-a392-460d-8747-0e8f57b3f5f1" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_ad13a978-7e5b-4247-a9db-2a6478ff0ffa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_93c173d5-6f26-4479-9e4b-2b8714ab8a9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ad41a917-a392-460d-8747-0e8f57b3f5f1" xlink:to="loc_us-gaap_UseOfEstimates_93c173d5-6f26-4479-9e4b-2b8714ab8a9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_39401819-405c-4c32-a99d-7b578c0823a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ad41a917-a392-460d-8747-0e8f57b3f5f1" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_39401819-405c-4c32-a99d-7b578c0823a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_2165c50f-dc2d-4958-95ee-61533add32a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ad41a917-a392-460d-8747-0e8f57b3f5f1" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_2165c50f-dc2d-4958-95ee-61533add32a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_b1fba9da-d3c4-458e-a91f-834ab73e98d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ad41a917-a392-460d-8747-0e8f57b3f5f1" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_b1fba9da-d3c4-458e-a91f-834ab73e98d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_8d1d08c7-f52c-4711-9554-c482bba659e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ad41a917-a392-460d-8747-0e8f57b3f5f1" xlink:to="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_8d1d08c7-f52c-4711-9554-c482bba659e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_dc32dc99-2555-40dd-ba70-f7affbfe43a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ad41a917-a392-460d-8747-0e8f57b3f5f1" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_dc32dc99-2555-40dd-ba70-f7affbfe43a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_b84044fa-3947-4e87-8fcd-e7ae36b64b8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ad41a917-a392-460d-8747-0e8f57b3f5f1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_b84044fa-3947-4e87-8fcd-e7ae36b64b8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_95b59e7a-3814-443d-8431-2050dd6c2e41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ad41a917-a392-460d-8747-0e8f57b3f5f1" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_95b59e7a-3814-443d-8431-2050dd6c2e41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_4756c500-232d-469f-880a-c6b0b932e955" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ad41a917-a392-460d-8747-0e8f57b3f5f1" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_4756c500-232d-469f-880a-c6b0b932e955" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_91531e19-c808-43d2-8f45-f5b91d666a3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ad41a917-a392-460d-8747-0e8f57b3f5f1" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_91531e19-c808-43d2-8f45-f5b91d666a3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingCostsPolicyTextBlock_d8a4410b-7313-4dca-8f76-013bb947b508" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvertisingCostsPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ad41a917-a392-460d-8747-0e8f57b3f5f1" xlink:to="loc_us-gaap_AdvertisingCostsPolicyTextBlock_d8a4410b-7313-4dca-8f76-013bb947b508" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_3ca983d6-d6d9-4e87-9f72-c3a452db8cc5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ad41a917-a392-460d-8747-0e8f57b3f5f1" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_3ca983d6-d6d9-4e87-9f72-c3a452db8cc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_ead77faf-8538-4baa-b9e4-e57f8e13e9e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ad41a917-a392-460d-8747-0e8f57b3f5f1" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_ead77faf-8538-4baa-b9e4-e57f8e13e9e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_18ac8a83-0f73-4957-8d91-26bc237eda32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ad41a917-a392-460d-8747-0e8f57b3f5f1" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_18ac8a83-0f73-4957-8d91-26bc237eda32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_b7c16c13-ee2f-493a-97f1-b8877649fe77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ad41a917-a392-460d-8747-0e8f57b3f5f1" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_b7c16c13-ee2f-493a-97f1-b8877649fe77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_db3bd665-2fa2-44e3-a45c-70efa336bc48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ad41a917-a392-460d-8747-0e8f57b3f5f1" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_db3bd665-2fa2-44e3-a45c-70efa336bc48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_79b0aabc-4881-48d7-8647-c1969a293179" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ad41a917-a392-460d-8747-0e8f57b3f5f1" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_79b0aabc-4881-48d7-8647-c1969a293179" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.optinose.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="optn-20221231.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.optinose.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_abdc6c2c-fd71-4ab2-8717-85d0262788c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_bc8ab505-07e8-44ff-aea2-cfc67ed09337" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_abdc6c2c-fd71-4ab2-8717-85d0262788c6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_bc8ab505-07e8-44ff-aea2-cfc67ed09337" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_986641cc-db72-4632-bb5b-c90e323c7684" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_abdc6c2c-fd71-4ab2-8717-85d0262788c6" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_986641cc-db72-4632-bb5b-c90e323c7684" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.optinose.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="optn-20221231.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.optinose.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_df7bb099-bbc3-49c0-b001-cbb84ccdbc20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_4def4013-b447-4b80-b306-13f75619498a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_df7bb099-bbc3-49c0-b001-cbb84ccdbc20" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_4def4013-b447-4b80-b306-13f75619498a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_b0661670-fdd5-4e77-9ee1-e4c8bc32f9d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_df7bb099-bbc3-49c0-b001-cbb84ccdbc20" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_b0661670-fdd5-4e77-9ee1-e4c8bc32f9d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_41d6bc73-cf31-4bb7-9921-0c0637a6ca20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_df7bb099-bbc3-49c0-b001-cbb84ccdbc20" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_41d6bc73-cf31-4bb7-9921-0c0637a6ca20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_f35b3db7-667c-4679-9cb4-7f2f741def35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_df7bb099-bbc3-49c0-b001-cbb84ccdbc20" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_f35b3db7-667c-4679-9cb4-7f2f741def35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.optinose.com/role/InventoryTables" xlink:type="simple" xlink:href="optn-20221231.xsd#InventoryTables"/>
  <link:presentationLink xlink:role="http://www.optinose.com/role/InventoryTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_75183bb2-33f8-4436-a37d-82b15589b6e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_c6867f05-a530-4685-9c7a-4fcecbf16384" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_75183bb2-33f8-4436-a37d-82b15589b6e6" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_c6867f05-a530-4685-9c7a-4fcecbf16384" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.optinose.com/role/PropertyandEquipmentTables" xlink:type="simple" xlink:href="optn-20221231.xsd#PropertyandEquipmentTables"/>
  <link:presentationLink xlink:role="http://www.optinose.com/role/PropertyandEquipmentTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_ca9b695d-d154-4d61-8238-487c1f4a4b17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_06fc8036-7f25-4052-91d3-13ea2d82eeb6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_ca9b695d-d154-4d61-8238-487c1f4a4b17" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_06fc8036-7f25-4052-91d3-13ea2d82eeb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.optinose.com/role/LeasesTables" xlink:type="simple" xlink:href="optn-20221231.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.optinose.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_e878578f-1acd-4007-aca2-996eb1a956cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_AssetsAndLiabilitiesLesseeTableTextBlock_35d28603-45af-47d6-bf9b-1c618c68748d" xlink:href="optn-20221231.xsd#optn_AssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_e878578f-1acd-4007-aca2-996eb1a956cd" xlink:to="loc_optn_AssetsAndLiabilitiesLesseeTableTextBlock_35d28603-45af-47d6-bf9b-1c618c68748d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_3de30189-02c0-4e06-9cef-9c919643ebcb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_e878578f-1acd-4007-aca2-996eb1a956cd" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_3de30189-02c0-4e06-9cef-9c919643ebcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.optinose.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables" xlink:type="simple" xlink:href="optn-20221231.xsd#AccruedExpensesandOtherCurrentLiabilitiesTables"/>
  <link:presentationLink xlink:role="http://www.optinose.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_d0c80326-39e8-4d34-912f-d2f731e2eed8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_1eb4476d-0f23-477b-a998-1143ea737fda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_d0c80326-39e8-4d34-912f-d2f731e2eed8" xlink:to="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_1eb4476d-0f23-477b-a998-1143ea737fda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.optinose.com/role/DebtnetTables" xlink:type="simple" xlink:href="optn-20221231.xsd#DebtnetTables"/>
  <link:presentationLink xlink:role="http://www.optinose.com/role/DebtnetTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_d66f1bbc-cb73-43cf-98ee-7507c4232948" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_fedbd633-6acf-4fc9-8113-d40aae8ba84e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_d66f1bbc-cb73-43cf-98ee-7507c4232948" xlink:to="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_fedbd633-6acf-4fc9-8113-d40aae8ba84e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.optinose.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="optn-20221231.xsd#StockholdersEquityTables"/>
  <link:presentationLink xlink:role="http://www.optinose.com/role/StockholdersEquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_eed924e8-9cf3-4f9e-abd0-4fae97d41ed9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_ScheduleOfGrantDateFairValueOfWarrantValuationAssumptionsTableTextBlock_feca0091-2497-4cfe-9b1c-01e9209863e8" xlink:href="optn-20221231.xsd#optn_ScheduleOfGrantDateFairValueOfWarrantValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_eed924e8-9cf3-4f9e-abd0-4fae97d41ed9" xlink:to="loc_optn_ScheduleOfGrantDateFairValueOfWarrantValuationAssumptionsTableTextBlock_feca0091-2497-4cfe-9b1c-01e9209863e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_22c7b605-fa49-4b7a-8bf2-4c0e5d58c053" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_eed924e8-9cf3-4f9e-abd0-4fae97d41ed9" xlink:to="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_22c7b605-fa49-4b7a-8bf2-4c0e5d58c053" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.optinose.com/role/StockbasedCompensationTables" xlink:type="simple" xlink:href="optn-20221231.xsd#StockbasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.optinose.com/role/StockbasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5a6356c3-e5ef-424a-9067-5153b0d761a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_73372a1e-8088-40c7-a98e-df9ea66162e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5a6356c3-e5ef-424a-9067-5153b0d761a9" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_73372a1e-8088-40c7-a98e-df9ea66162e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_098ef965-7837-4a20-9869-6cc52018b096" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5a6356c3-e5ef-424a-9067-5153b0d761a9" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_098ef965-7837-4a20-9869-6cc52018b096" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_6b226cb4-b8bd-4706-b0d4-6f6811635bfe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5a6356c3-e5ef-424a-9067-5153b0d761a9" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_6b226cb4-b8bd-4706-b0d4-6f6811635bfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_ba561f18-9caa-4e1d-9738-d707e7a97aff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5a6356c3-e5ef-424a-9067-5153b0d761a9" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_ba561f18-9caa-4e1d-9738-d707e7a97aff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.optinose.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="optn-20221231.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://www.optinose.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_3260fc85-da1f-4207-a62d-c46bfcb2d128" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_c90b51c0-28c7-461e-82b2-c3e3acacb2e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3260fc85-da1f-4207-a62d-c46bfcb2d128" xlink:to="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_c90b51c0-28c7-461e-82b2-c3e3acacb2e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_af2414a5-5974-4034-b9ed-24ed42a4f940" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3260fc85-da1f-4207-a62d-c46bfcb2d128" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_af2414a5-5974-4034-b9ed-24ed42a4f940" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_215dab2b-87b6-4891-b030-8bd462acc9c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3260fc85-da1f-4207-a62d-c46bfcb2d128" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_215dab2b-87b6-4891-b030-8bd462acc9c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.optinose.com/role/LiquidityNarrativeDetails" xlink:type="simple" xlink:href="optn-20221231.xsd#LiquidityNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.optinose.com/role/LiquidityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_68573be9-4ab0-4d1e-ae80-74718034fbac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_c1b1d824-8848-48cf-ad83-1b56768d284c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_68573be9-4ab0-4d1e-ae80-74718034fbac" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_c1b1d824-8848-48cf-ad83-1b56768d284c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_667dd1ab-8d82-475a-b135-b264065aba09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_c1b1d824-8848-48cf-ad83-1b56768d284c" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_667dd1ab-8d82-475a-b135-b264065aba09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_915957a1-6539-4e88-8325-bc64dc2b636c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_667dd1ab-8d82-475a-b135-b264065aba09" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_915957a1-6539-4e88-8325-bc64dc2b636c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_97b5590f-79c4-46dc-91f5-5aa76cfd96c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_915957a1-6539-4e88-8325-bc64dc2b636c" xlink:to="loc_us-gaap_SeniorNotesMember_97b5590f-79c4-46dc-91f5-5aa76cfd96c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_00bd15ea-b56d-499c-bfa5-dd74a651bce2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_c1b1d824-8848-48cf-ad83-1b56768d284c" xlink:to="loc_us-gaap_DebtInstrumentAxis_00bd15ea-b56d-499c-bfa5-dd74a651bce2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_e397c2c9-82a5-4593-a68e-f80cde87c64b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_00bd15ea-b56d-499c-bfa5-dd74a651bce2" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_e397c2c9-82a5-4593-a68e-f80cde87c64b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_NotePurchaseAgreementMember_1c1901c5-9b50-49f3-9845-55c9a5afecbc" xlink:href="optn-20221231.xsd#optn_NotePurchaseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e397c2c9-82a5-4593-a68e-f80cde87c64b" xlink:to="loc_optn_NotePurchaseAgreementMember_1c1901c5-9b50-49f3-9845-55c9a5afecbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_505c2e59-8f2f-4453-87d3-23fbb561c159" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_c1b1d824-8848-48cf-ad83-1b56768d284c" xlink:to="loc_us-gaap_SubsidiarySaleOfStockLineItems_505c2e59-8f2f-4453-87d3-23fbb561c159" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_dab71fc1-4dea-446c-ba87-4ec7651f86db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_505c2e59-8f2f-4453-87d3-23fbb561c159" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_dab71fc1-4dea-446c-ba87-4ec7651f86db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_WorkingCapital_982bc1fe-4ecb-4a90-a615-1989822bfd6a" xlink:href="optn-20221231.xsd#optn_WorkingCapital"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_505c2e59-8f2f-4453-87d3-23fbb561c159" xlink:to="loc_optn_WorkingCapital_982bc1fe-4ecb-4a90-a615-1989822bfd6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_bf21c44a-2357-48a9-a00f-e787ba933236" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_505c2e59-8f2f-4453-87d3-23fbb561c159" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_bf21c44a-2357-48a9-a00f-e787ba933236" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayable_bfbd45d2-8384-4969-8c2d-5aa11b8c5515" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_505c2e59-8f2f-4453-87d3-23fbb561c159" xlink:to="loc_us-gaap_NotesPayable_bfbd45d2-8384-4969-8c2d-5aa11b8c5515" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_DebtInstrumentCovenantCashAndCashEquivalents_0085e662-cb8b-4d82-a40a-f1016968854f" xlink:href="optn-20221231.xsd#optn_DebtInstrumentCovenantCashAndCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_505c2e59-8f2f-4453-87d3-23fbb561c159" xlink:to="loc_optn_DebtInstrumentCovenantCashAndCashEquivalents_0085e662-cb8b-4d82-a40a-f1016968854f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.optinose.com/role/SummaryofSignificantAccountingPoliciesConcentrationriskDetails" xlink:type="simple" xlink:href="optn-20221231.xsd#SummaryofSignificantAccountingPoliciesConcentrationriskDetails"/>
  <link:presentationLink xlink:role="http://www.optinose.com/role/SummaryofSignificantAccountingPoliciesConcentrationriskDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_dfdaad1d-a40b-4c7e-99ce-cf73be3eea7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_9effa335-fec0-4d89-9b3a-d53e845fcce3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_dfdaad1d-a40b-4c7e-99ce-cf73be3eea7a" xlink:to="loc_us-gaap_ConcentrationRiskTable_9effa335-fec0-4d89-9b3a-d53e845fcce3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_79d78d0d-1b59-4a07-901f-57ed97290f43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_9effa335-fec0-4d89-9b3a-d53e845fcce3" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_79d78d0d-1b59-4a07-901f-57ed97290f43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_df20937a-5f39-4abe-8984-a1cf27bc0d9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_79d78d0d-1b59-4a07-901f-57ed97290f43" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_df20937a-5f39-4abe-8984-a1cf27bc0d9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_fde23558-93a7-4a40-9d0e-5203a744a39c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_df20937a-5f39-4abe-8984-a1cf27bc0d9a" xlink:to="loc_us-gaap_AccountsReceivableMember_fde23558-93a7-4a40-9d0e-5203a744a39c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_7938f2d2-f42a-4c3b-a760-83d5989ea8a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_df20937a-5f39-4abe-8984-a1cf27bc0d9a" xlink:to="loc_us-gaap_SalesRevenueNetMember_7938f2d2-f42a-4c3b-a760-83d5989ea8a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_5a3e27df-37ea-48f9-bacf-f6c5e411413b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_9effa335-fec0-4d89-9b3a-d53e845fcce3" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_5a3e27df-37ea-48f9-bacf-f6c5e411413b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_4872274b-0bc0-4239-a9df-0aa8e03bd622" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_5a3e27df-37ea-48f9-bacf-f6c5e411413b" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_4872274b-0bc0-4239-a9df-0aa8e03bd622" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_87834a67-9bfe-40e8-9d57-2ad5c86fff4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_4872274b-0bc0-4239-a9df-0aa8e03bd622" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_87834a67-9bfe-40e8-9d57-2ad5c86fff4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_c683d180-a0b3-4c4b-8540-77b56d725eee" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_9effa335-fec0-4d89-9b3a-d53e845fcce3" xlink:to="loc_srt_MajorCustomersAxis_c683d180-a0b3-4c4b-8540-77b56d725eee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_2ab09996-d2b0-4dc6-bdde-7944078bed4a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_c683d180-a0b3-4c4b-8540-77b56d725eee" xlink:to="loc_srt_NameOfMajorCustomerDomain_2ab09996-d2b0-4dc6-bdde-7944078bed4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_FiveCustomersMember_42076563-dd56-4295-9354-b6b251cf22e9" xlink:href="optn-20221231.xsd#optn_FiveCustomersMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_2ab09996-d2b0-4dc6-bdde-7944078bed4a" xlink:to="loc_optn_FiveCustomersMember_42076563-dd56-4295-9354-b6b251cf22e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_e264c9fa-7231-4cf1-b074-e5715df443c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_9effa335-fec0-4d89-9b3a-d53e845fcce3" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_e264c9fa-7231-4cf1-b074-e5715df443c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_NumberOfCustomers_3d9cc762-37a6-4237-a4ab-36212400858e" xlink:href="optn-20221231.xsd#optn_NumberOfCustomers"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_e264c9fa-7231-4cf1-b074-e5715df443c0" xlink:to="loc_optn_NumberOfCustomers_3d9cc762-37a6-4237-a4ab-36212400858e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_685e6462-179a-4d54-ada2-1ffb8cc9c248" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_e264c9fa-7231-4cf1-b074-e5715df443c0" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_685e6462-179a-4d54-ada2-1ffb8cc9c248" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.optinose.com/role/SummaryofSignificantAccountingPoliciesCashandcashequivalentsDetails" xlink:type="simple" xlink:href="optn-20221231.xsd#SummaryofSignificantAccountingPoliciesCashandcashequivalentsDetails"/>
  <link:presentationLink xlink:role="http://www.optinose.com/role/SummaryofSignificantAccountingPoliciesCashandcashequivalentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e9daa951-1c4e-4a93-b8b6-1846e020a2a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashUninsuredAmount_818ef52d-dbb8-486f-bc37-48486932d068" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashUninsuredAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e9daa951-1c4e-4a93-b8b6-1846e020a2a1" xlink:to="loc_us-gaap_CashUninsuredAmount_818ef52d-dbb8-486f-bc37-48486932d068" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.optinose.com/role/SummaryofSignificantAccountingPoliciesAccountsreceivableDetails" xlink:type="simple" xlink:href="optn-20221231.xsd#SummaryofSignificantAccountingPoliciesAccountsreceivableDetails"/>
  <link:presentationLink xlink:role="http://www.optinose.com/role/SummaryofSignificantAccountingPoliciesAccountsreceivableDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9676a66e-560b-4d2a-a119-60453ae6665e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_44fffad4-ef2b-43e8-bb73-7532995e9caf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9676a66e-560b-4d2a-a119-60453ae6665e" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_44fffad4-ef2b-43e8-bb73-7532995e9caf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.optinose.com/role/SummaryofSignificantAccountingPoliciesPropertyandequipmentDetails" xlink:type="simple" xlink:href="optn-20221231.xsd#SummaryofSignificantAccountingPoliciesPropertyandequipmentDetails"/>
  <link:presentationLink xlink:role="http://www.optinose.com/role/SummaryofSignificantAccountingPoliciesPropertyandequipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_5bed6b6e-a3ec-40c3-8b05-d74b6f4c483a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_29173d47-6fe6-4caf-b075-0e6f92a1f874" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5bed6b6e-a3ec-40c3-8b05-d74b6f4c483a" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_29173d47-6fe6-4caf-b075-0e6f92a1f874" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_81819585-e5cd-454d-942a-737a23162843" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_29173d47-6fe6-4caf-b075-0e6f92a1f874" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_81819585-e5cd-454d-942a-737a23162843" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a6ef0a1d-60eb-4445-92b0-9fc92d581755" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_81819585-e5cd-454d-942a-737a23162843" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a6ef0a1d-60eb-4445-92b0-9fc92d581755" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_25f8d453-d61f-434e-a34f-3ce0afcb4db9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a6ef0a1d-60eb-4445-92b0-9fc92d581755" xlink:to="loc_us-gaap_ComputerEquipmentMember_25f8d453-d61f-434e-a34f-3ce0afcb4db9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_47490df9-91a7-4561-bf68-7123bf0bc9b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a6ef0a1d-60eb-4445-92b0-9fc92d581755" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_47490df9-91a7-4561-bf68-7123bf0bc9b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_117efef7-41ef-499b-a7a2-ac0baedf44df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a6ef0a1d-60eb-4445-92b0-9fc92d581755" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_117efef7-41ef-499b-a7a2-ac0baedf44df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_d6d81063-e7d1-4ec6-aed3-89a0ab54bd80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a6ef0a1d-60eb-4445-92b0-9fc92d581755" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_d6d81063-e7d1-4ec6-aed3-89a0ab54bd80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_6792bc8f-d970-442d-85b5-b32212d3aec4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_29173d47-6fe6-4caf-b075-0e6f92a1f874" xlink:to="loc_srt_RangeAxis_6792bc8f-d970-442d-85b5-b32212d3aec4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d41dea6c-1399-4829-85bd-f668f0f13d71" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_6792bc8f-d970-442d-85b5-b32212d3aec4" xlink:to="loc_srt_RangeMember_d41dea6c-1399-4829-85bd-f668f0f13d71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_804decd7-9554-45c1-906c-fe59025634ef" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_d41dea6c-1399-4829-85bd-f668f0f13d71" xlink:to="loc_srt_MinimumMember_804decd7-9554-45c1-906c-fe59025634ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_d0b6bb13-c8ba-4fcc-8693-6b594b313702" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_d41dea6c-1399-4829-85bd-f668f0f13d71" xlink:to="loc_srt_MaximumMember_d0b6bb13-c8ba-4fcc-8693-6b594b313702" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cf3d4762-6680-4c74-819e-777d512e342d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_29173d47-6fe6-4caf-b075-0e6f92a1f874" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cf3d4762-6680-4c74-819e-777d512e342d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_1112789e-04dd-447d-a61e-918780e66d92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cf3d4762-6680-4c74-819e-777d512e342d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_1112789e-04dd-447d-a61e-918780e66d92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.optinose.com/role/SummaryofSignificantAccountingPoliciesLonglivedassetsDetails" xlink:type="simple" xlink:href="optn-20221231.xsd#SummaryofSignificantAccountingPoliciesLonglivedassetsDetails"/>
  <link:presentationLink xlink:role="http://www.optinose.com/role/SummaryofSignificantAccountingPoliciesLonglivedassetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e3a7e419-9a5f-47c2-bb50-726700b0b924" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_5d8f21b5-46a7-45ad-b05c-d134680d6078" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e3a7e419-9a5f-47c2-bb50-726700b0b924" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_5d8f21b5-46a7-45ad-b05c-d134680d6078" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.optinose.com/role/SummaryofSignificantAccountingPoliciesLicensingrevenuesDetails" xlink:type="simple" xlink:href="optn-20221231.xsd#SummaryofSignificantAccountingPoliciesLicensingrevenuesDetails"/>
  <link:presentationLink xlink:role="http://www.optinose.com/role/SummaryofSignificantAccountingPoliciesLicensingrevenuesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_067d2199-5e1e-4a3f-83dc-f4374684052b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_63ec7982-d3db-48b5-9429-34f80d2e49d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_067d2199-5e1e-4a3f-83dc-f4374684052b" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_63ec7982-d3db-48b5-9429-34f80d2e49d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_d20f5d1a-4809-4208-a019-1af6213eef59" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_63ec7982-d3db-48b5-9429-34f80d2e49d3" xlink:to="loc_srt_ProductOrServiceAxis_d20f5d1a-4809-4208-a019-1af6213eef59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_275b5233-200f-4904-8696-59176415ac4e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_d20f5d1a-4809-4208-a019-1af6213eef59" xlink:to="loc_srt_ProductsAndServicesDomain_275b5233-200f-4904-8696-59176415ac4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_d9958409-9382-40b6-af77-1974e159122b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_275b5233-200f-4904-8696-59176415ac4e" xlink:to="loc_us-gaap_LicenseMember_d9958409-9382-40b6-af77-1974e159122b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_4e34a4d4-b68b-4899-bf1a-420adbecab2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_63ec7982-d3db-48b5-9429-34f80d2e49d3" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_4e34a4d4-b68b-4899-bf1a-420adbecab2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_433b134c-6c1f-474e-8c78-4aa682521de0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_4e34a4d4-b68b-4899-bf1a-420adbecab2c" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_433b134c-6c1f-474e-8c78-4aa682521de0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.optinose.com/role/SummaryofSignificantAccountingPoliciesAdvertisingexpenseDetails" xlink:type="simple" xlink:href="optn-20221231.xsd#SummaryofSignificantAccountingPoliciesAdvertisingexpenseDetails"/>
  <link:presentationLink xlink:role="http://www.optinose.com/role/SummaryofSignificantAccountingPoliciesAdvertisingexpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3d4cb014-801e-46ce-8b0d-fa67adff8d12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense_037ada03-fdd3-4c60-bd8f-d5cab6f70db3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvertisingExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3d4cb014-801e-46ce-8b0d-fa67adff8d12" xlink:to="loc_us-gaap_AdvertisingExpense_037ada03-fdd3-4c60-bd8f-d5cab6f70db3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.optinose.com/role/SummaryofSignificantAccountingPoliciesNetincomelosspercommonshareDetails" xlink:type="simple" xlink:href="optn-20221231.xsd#SummaryofSignificantAccountingPoliciesNetincomelosspercommonshareDetails"/>
  <link:presentationLink xlink:role="http://www.optinose.com/role/SummaryofSignificantAccountingPoliciesNetincomelosspercommonshareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_27ea301a-febd-4793-a1f1-bee7d16eb32a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_14bf591f-ec80-4e6b-8805-3913bbb9234d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_27ea301a-febd-4793-a1f1-bee7d16eb32a" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_14bf591f-ec80-4e6b-8805-3913bbb9234d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8ac92316-a773-4759-9873-2a51b3343658" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_14bf591f-ec80-4e6b-8805-3913bbb9234d" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8ac92316-a773-4759-9873-2a51b3343658" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_d670aafb-3f5f-4d8f-b2cf-5e15077b49ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8ac92316-a773-4759-9873-2a51b3343658" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_d670aafb-3f5f-4d8f-b2cf-5e15077b49ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_4a64bbc0-0290-4bcc-bc14-91123bea2947" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_d670aafb-3f5f-4d8f-b2cf-5e15077b49ad" xlink:to="loc_us-gaap_EmployeeStockOptionMember_4a64bbc0-0290-4bcc-bc14-91123bea2947" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_b2fc0ea1-b0bc-4b5f-bbc0-e240c5c1c336" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_d670aafb-3f5f-4d8f-b2cf-5e15077b49ad" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_b2fc0ea1-b0bc-4b5f-bbc0-e240c5c1c336" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_3e9f2b72-dce5-4d80-be94-b96198b36fdb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_d670aafb-3f5f-4d8f-b2cf-5e15077b49ad" xlink:to="loc_us-gaap_WarrantMember_3e9f2b72-dce5-4d80-be94-b96198b36fdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_e8c9415c-8ab6-4f49-95f8-3172a5e3a4ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_14bf591f-ec80-4e6b-8805-3913bbb9234d" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_e8c9415c-8ab6-4f49-95f8-3172a5e3a4ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_34a4dac4-38c9-45a5-a5af-6908d4f71c0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_e8c9415c-8ab6-4f49-95f8-3172a5e3a4ad" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_34a4dac4-38c9-45a5-a5af-6908d4f71c0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.optinose.com/role/FairValueMeasurementsFairvalueassetsandliabilitiesmeasuredonrecurringbasisDetails" xlink:type="simple" xlink:href="optn-20221231.xsd#FairValueMeasurementsFairvalueassetsandliabilitiesmeasuredonrecurringbasisDetails"/>
  <link:presentationLink xlink:role="http://www.optinose.com/role/FairValueMeasurementsFairvalueassetsandliabilitiesmeasuredonrecurringbasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_c2066115-1f8c-44a3-93ff-d7ce7895a462" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_07daf8cc-79f7-45e4-9cd1-3b880cbe7c11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_c2066115-1f8c-44a3-93ff-d7ce7895a462" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_07daf8cc-79f7-45e4-9cd1-3b880cbe7c11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_95b01a8b-e6ef-4b3b-88c2-7c52bd33a79f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_07daf8cc-79f7-45e4-9cd1-3b880cbe7c11" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_95b01a8b-e6ef-4b3b-88c2-7c52bd33a79f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_cf1d3527-29dc-4fc5-b716-f0f80bee4a09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_95b01a8b-e6ef-4b3b-88c2-7c52bd33a79f" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_cf1d3527-29dc-4fc5-b716-f0f80bee4a09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_8b532233-0b6b-48e2-8756-5fc5a7519a83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_cf1d3527-29dc-4fc5-b716-f0f80bee4a09" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_8b532233-0b6b-48e2-8756-5fc5a7519a83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_5f4628cf-a3cb-46cf-8be4-eaa5acd9a516" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_cf1d3527-29dc-4fc5-b716-f0f80bee4a09" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_5f4628cf-a3cb-46cf-8be4-eaa5acd9a516" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_32272661-d7d1-4b40-bd0f-43366209bc9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_cf1d3527-29dc-4fc5-b716-f0f80bee4a09" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_32272661-d7d1-4b40-bd0f-43366209bc9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_0e3fd283-e65d-4fdf-b240-fb37a5366cab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_07daf8cc-79f7-45e4-9cd1-3b880cbe7c11" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_0e3fd283-e65d-4fdf-b240-fb37a5366cab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_032106bb-52aa-42fd-8e90-ec2239592ce9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_0e3fd283-e65d-4fdf-b240-fb37a5366cab" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_032106bb-52aa-42fd-8e90-ec2239592ce9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_c721b215-61a9-42bb-9091-5518c4b43414" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_032106bb-52aa-42fd-8e90-ec2239592ce9" xlink:to="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_c721b215-61a9-42bb-9091-5518c4b43414" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_0661fe38-b993-491a-acbb-9359a40965e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_032106bb-52aa-42fd-8e90-ec2239592ce9" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_0661fe38-b993-491a-acbb-9359a40965e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.optinose.com/role/FairValueMeasurementsFairvalueliabilitiesmeasuredonrecurringbasisusingunobservableinputsDetails" xlink:type="simple" xlink:href="optn-20221231.xsd#FairValueMeasurementsFairvalueliabilitiesmeasuredonrecurringbasisusingunobservableinputsDetails"/>
  <link:presentationLink xlink:role="http://www.optinose.com/role/FairValueMeasurementsFairvalueliabilitiesmeasuredonrecurringbasisusingunobservableinputsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_05853801-9659-4e3b-88cc-7cb6ed4460e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_118590f2-b60e-4e3b-bc73-ecc6a2801134" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_05853801-9659-4e3b-88cc-7cb6ed4460e9" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_118590f2-b60e-4e3b-bc73-ecc6a2801134" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_82217bff-2654-4d51-b83b-1789ac616a76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_118590f2-b60e-4e3b-bc73-ecc6a2801134" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_82217bff-2654-4d51-b83b-1789ac616a76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_1c9c90e2-5baa-4efa-870d-70050e6ce951" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_118590f2-b60e-4e3b-bc73-ecc6a2801134" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_1c9c90e2-5baa-4efa-870d-70050e6ce951" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_1e0f0cb6-0af3-4bac-9d5f-a5de2627c584" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_118590f2-b60e-4e3b-bc73-ecc6a2801134" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_1e0f0cb6-0af3-4bac-9d5f-a5de2627c584" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_ce99c525-5cc1-49c0-bc93-998251a6719a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_118590f2-b60e-4e3b-bc73-ecc6a2801134" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_ce99c525-5cc1-49c0-bc93-998251a6719a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList_d5b10d83-dc20-4c13-98a0-9c5c2d0672b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_05853801-9659-4e3b-88cc-7cb6ed4460e9" xlink:to="loc_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList_d5b10d83-dc20-4c13-98a0-9c5c2d0672b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.optinose.com/role/FairValueMeasurementsValuationofwarrantsDetails" xlink:type="simple" xlink:href="optn-20221231.xsd#FairValueMeasurementsValuationofwarrantsDetails"/>
  <link:presentationLink xlink:role="http://www.optinose.com/role/FairValueMeasurementsValuationofwarrantsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_3fdd6e2a-ce35-43f2-ad07-c85ef7d5118d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_37ef9ec5-27ed-4c3d-8c79-a6fbbab6fbf9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_3fdd6e2a-ce35-43f2-ad07-c85ef7d5118d" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_37ef9ec5-27ed-4c3d-8c79-a6fbbab6fbf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_f7c74647-8ff1-435f-a33f-9354e39fbe9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_37ef9ec5-27ed-4c3d-8c79-a6fbbab6fbf9" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_f7c74647-8ff1-435f-a33f-9354e39fbe9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_285fb883-8ad6-4790-8e58-fd1082938a90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_f7c74647-8ff1-435f-a33f-9354e39fbe9c" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_285fb883-8ad6-4790-8e58-fd1082938a90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputSharePriceMember_94f37320-3e01-4940-9e36-1471da6fc7f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputSharePriceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_285fb883-8ad6-4790-8e58-fd1082938a90" xlink:to="loc_us-gaap_MeasurementInputSharePriceMember_94f37320-3e01-4940-9e36-1471da6fc7f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_MeasurementInputStrikePriceMember_d100b42c-f482-4a0d-9b6b-a83a7e58e321" xlink:href="optn-20221231.xsd#optn_MeasurementInputStrikePriceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_285fb883-8ad6-4790-8e58-fd1082938a90" xlink:to="loc_optn_MeasurementInputStrikePriceMember_d100b42c-f482-4a0d-9b6b-a83a7e58e321" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_cf78af61-b253-420b-8eb1-82a1b62912b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_285fb883-8ad6-4790-8e58-fd1082938a90" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_cf78af61-b253-420b-8eb1-82a1b62912b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_bebc2722-867e-46d3-8fd3-722c472de47a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_285fb883-8ad6-4790-8e58-fd1082938a90" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_bebc2722-867e-46d3-8fd3-722c472de47a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_6ab52b98-caed-4b51-a784-6ce2b2e6db68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_285fb883-8ad6-4790-8e58-fd1082938a90" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_6ab52b98-caed-4b51-a784-6ce2b2e6db68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis_924597c5-c747-4eb9-b723-e1764597a65b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_37ef9ec5-27ed-4c3d-8c79-a6fbbab6fbf9" xlink:to="loc_us-gaap_ValuationTechniqueAxis_924597c5-c747-4eb9-b723-e1764597a65b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_0b720877-a539-4c4d-b6e1-00af91af1d73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueAxis_924597c5-c747-4eb9-b723-e1764597a65b" xlink:to="loc_us-gaap_ValuationTechniqueDomain_0b720877-a539-4c4d-b6e1-00af91af1d73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_MonteCarloSimulationMember_82f613e5-d0c7-4a08-a997-a23060714e61" xlink:href="optn-20221231.xsd#optn_MonteCarloSimulationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueDomain_0b720877-a539-4c4d-b6e1-00af91af1d73" xlink:to="loc_optn_MonteCarloSimulationMember_82f613e5-d0c7-4a08-a997-a23060714e61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_a39e891e-8f05-40c2-9176-8dbe07970219" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_37ef9ec5-27ed-4c3d-8c79-a6fbbab6fbf9" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_a39e891e-8f05-40c2-9176-8dbe07970219" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_235fe769-28ee-4ff0-9e8b-a6587c415d11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_a39e891e-8f05-40c2-9176-8dbe07970219" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_235fe769-28ee-4ff0-9e8b-a6587c415d11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_5203d4fe-625e-435d-8c97-0a63dd877eeb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_a39e891e-8f05-40c2-9176-8dbe07970219" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_5203d4fe-625e-435d-8c97-0a63dd877eeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_FairValueOfWarrant_2aeca7b0-1bb2-4a7f-a398-0e4e36534ae3" xlink:href="optn-20221231.xsd#optn_FairValueOfWarrant"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_a39e891e-8f05-40c2-9176-8dbe07970219" xlink:to="loc_optn_FairValueOfWarrant_2aeca7b0-1bb2-4a7f-a398-0e4e36534ae3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.optinose.com/role/InventoryDetails" xlink:type="simple" xlink:href="optn-20221231.xsd#InventoryDetails"/>
  <link:presentationLink xlink:role="http://www.optinose.com/role/InventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_68ea5a88-55db-4411-96c0-116aa7d931fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials_f53fd714-af1f-44a1-b5cc-709a4cb7f577" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterials"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_68ea5a88-55db-4411-96c0-116aa7d931fc" xlink:to="loc_us-gaap_InventoryRawMaterials_f53fd714-af1f-44a1-b5cc-709a4cb7f577" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess_56a50c97-58f1-4242-88ee-fe7e0e6d1240" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_68ea5a88-55db-4411-96c0-116aa7d931fc" xlink:to="loc_us-gaap_InventoryWorkInProcess_56a50c97-58f1-4242-88ee-fe7e0e6d1240" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_44856536-7ad7-4c85-aff2-5809ec97fcee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_68ea5a88-55db-4411-96c0-116aa7d931fc" xlink:to="loc_us-gaap_InventoryFinishedGoods_44856536-7ad7-4c85-aff2-5809ec97fcee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_dda23565-bc97-4199-a5b3-230db080c8f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_68ea5a88-55db-4411-96c0-116aa7d931fc" xlink:to="loc_us-gaap_InventoryGross_dda23565-bc97-4199-a5b3-230db080c8f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.optinose.com/role/PropertyandEquipmentDetails" xlink:type="simple" xlink:href="optn-20221231.xsd#PropertyandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.optinose.com/role/PropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_c9d42064-0f7d-4f9e-b7fc-02a3492614e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_19a648b9-508b-4bad-ad2c-0c858ea86014" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_c9d42064-0f7d-4f9e-b7fc-02a3492614e7" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_19a648b9-508b-4bad-ad2c-0c858ea86014" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_a9ea1fe6-dd26-49c1-ba9e-3500f371de28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_19a648b9-508b-4bad-ad2c-0c858ea86014" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_a9ea1fe6-dd26-49c1-ba9e-3500f371de28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_1e63c189-9a06-4cfe-8986-26bc7040ca2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_a9ea1fe6-dd26-49c1-ba9e-3500f371de28" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_1e63c189-9a06-4cfe-8986-26bc7040ca2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoriesMember_508d84c7-2a2d-4676-9ff9-1e72de9c1669" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoriesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_1e63c189-9a06-4cfe-8986-26bc7040ca2f" xlink:to="loc_us-gaap_InventoriesMember_508d84c7-2a2d-4676-9ff9-1e72de9c1669" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_8bf5f7e8-fc62-42f7-9cda-9d2a8e242123" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_1e63c189-9a06-4cfe-8986-26bc7040ca2f" xlink:to="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_8bf5f7e8-fc62-42f7-9cda-9d2a8e242123" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b83f6860-2fb3-40ae-8dac-f586b28b842a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_19a648b9-508b-4bad-ad2c-0c858ea86014" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b83f6860-2fb3-40ae-8dac-f586b28b842a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_06c4052c-e0e4-46bb-95d6-92e7f343d973" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b83f6860-2fb3-40ae-8dac-f586b28b842a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_06c4052c-e0e4-46bb-95d6-92e7f343d973" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_ComputerEquipmentandSoftwareMember_cea2f6fd-2e93-4e60-ae76-dbdf0e387e98" xlink:href="optn-20221231.xsd#optn_ComputerEquipmentandSoftwareMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_06c4052c-e0e4-46bb-95d6-92e7f343d973" xlink:to="loc_optn_ComputerEquipmentandSoftwareMember_cea2f6fd-2e93-4e60-ae76-dbdf0e387e98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_eb32abe3-06df-44f8-9d16-e9845bbcdee4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_06c4052c-e0e4-46bb-95d6-92e7f343d973" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_eb32abe3-06df-44f8-9d16-e9845bbcdee4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_e110b2d5-f758-4708-b69a-491662e4db4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_06c4052c-e0e4-46bb-95d6-92e7f343d973" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_e110b2d5-f758-4708-b69a-491662e4db4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_9bc9d7ed-16bf-4a41-9fd3-12b2958eafa2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_06c4052c-e0e4-46bb-95d6-92e7f343d973" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_9bc9d7ed-16bf-4a41-9fd3-12b2958eafa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_a5ed31ee-6f6a-47ed-b046-c802e3b50da6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_06c4052c-e0e4-46bb-95d6-92e7f343d973" xlink:to="loc_us-gaap_ConstructionInProgressMember_a5ed31ee-6f6a-47ed-b046-c802e3b50da6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4cd66e91-9741-493c-8d4b-b3fbcde7e30a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_19a648b9-508b-4bad-ad2c-0c858ea86014" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4cd66e91-9741-493c-8d4b-b3fbcde7e30a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_0b5a4055-da17-4838-ada2-4e7e63031a79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4cd66e91-9741-493c-8d4b-b3fbcde7e30a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_0b5a4055-da17-4838-ada2-4e7e63031a79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_66bd444a-a5ce-4741-b51d-864829df3e37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4cd66e91-9741-493c-8d4b-b3fbcde7e30a" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_66bd444a-a5ce-4741-b51d-864829df3e37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_bc8dabd8-2a08-4cbd-be0c-829e3b81f44c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4cd66e91-9741-493c-8d4b-b3fbcde7e30a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_bc8dabd8-2a08-4cbd-be0c-829e3b81f44c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_060379e9-267b-4e73-a778-e86fd6238700" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4cd66e91-9741-493c-8d4b-b3fbcde7e30a" xlink:to="loc_us-gaap_Depreciation_060379e9-267b-4e73-a778-e86fd6238700" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.optinose.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="optn-20221231.xsd#LeasesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.optinose.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_5a0eb050-03c0-47f4-8537-82bc699f2677" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_ce1aa13d-9f39-4836-b01b-9cfb85650ae3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_5a0eb050-03c0-47f4-8537-82bc699f2677" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_ce1aa13d-9f39-4836-b01b-9cfb85650ae3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_OperatingLeaseCostForExtension_b5f8cfe3-44ad-48d7-bc01-68f6df495946" xlink:href="optn-20221231.xsd#optn_OperatingLeaseCostForExtension"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_5a0eb050-03c0-47f4-8537-82bc699f2677" xlink:to="loc_optn_OperatingLeaseCostForExtension_b5f8cfe3-44ad-48d7-bc01-68f6df495946" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_61f95db0-d6c4-4980-b143-4d7ac18ca670" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_5a0eb050-03c0-47f4-8537-82bc699f2677" xlink:to="loc_us-gaap_LeaseCost_61f95db0-d6c4-4980-b143-4d7ac18ca670" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_986758cd-2e19-4754-b48f-6253ae54e341" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_5a0eb050-03c0-47f4-8537-82bc699f2677" xlink:to="loc_us-gaap_OperatingLeasePayments_986758cd-2e19-4754-b48f-6253ae54e341" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.optinose.com/role/LeasesOperatingleaseassetsandliabilitiesDetails" xlink:type="simple" xlink:href="optn-20221231.xsd#LeasesOperatingleaseassetsandliabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.optinose.com/role/LeasesOperatingleaseassetsandliabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_5956edb9-62f8-4c34-90b6-10137e6a7e0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_e519391b-052e-465e-acd4-56b0c97867bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_5956edb9-62f8-4c34-90b6-10137e6a7e0e" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_e519391b-052e-465e-acd4-56b0c97867bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_OperatingLeaseLiabilityAbstractAbstract_5c6e1e3f-f35e-45d3-a8c2-80e2627b331f" xlink:href="optn-20221231.xsd#optn_OperatingLeaseLiabilityAbstractAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset_e519391b-052e-465e-acd4-56b0c97867bb" xlink:to="loc_optn_OperatingLeaseLiabilityAbstractAbstract_5c6e1e3f-f35e-45d3-a8c2-80e2627b331f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_c93774f3-8b05-4559-8631-f9d09d2c53b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_optn_OperatingLeaseLiabilityAbstractAbstract_5c6e1e3f-f35e-45d3-a8c2-80e2627b331f" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_c93774f3-8b05-4559-8631-f9d09d2c53b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_8530ee8e-ce24-43b6-8575-48451001d44f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_optn_OperatingLeaseLiabilityAbstractAbstract_5c6e1e3f-f35e-45d3-a8c2-80e2627b331f" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_8530ee8e-ce24-43b6-8575-48451001d44f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_b496b5dc-6d14-4119-8c18-bd7bf9e16eeb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_optn_OperatingLeaseLiabilityAbstractAbstract_5c6e1e3f-f35e-45d3-a8c2-80e2627b331f" xlink:to="loc_us-gaap_OperatingLeaseLiability_b496b5dc-6d14-4119-8c18-bd7bf9e16eeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_5797cd16-fe37-49af-803c-d555b51ee703" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_5956edb9-62f8-4c34-90b6-10137e6a7e0e" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_5797cd16-fe37-49af-803c-d555b51ee703" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_6e935df4-94b2-43d1-b364-a417034cfbfc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_5956edb9-62f8-4c34-90b6-10137e6a7e0e" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_6e935df4-94b2-43d1-b364-a417034cfbfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_d0a3f1ec-4c74-485d-85f3-a3bceb7ba914" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_5956edb9-62f8-4c34-90b6-10137e6a7e0e" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_d0a3f1ec-4c74-485d-85f3-a3bceb7ba914" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.optinose.com/role/LeasesWeightedaverageremainingleasetermandweightedaveragediscountrateDetails" xlink:type="simple" xlink:href="optn-20221231.xsd#LeasesWeightedaverageremainingleasetermandweightedaveragediscountrateDetails"/>
  <link:presentationLink xlink:role="http://www.optinose.com/role/LeasesWeightedaverageremainingleasetermandweightedaveragediscountrateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_589a4bf0-e7d2-4d25-81fd-26c0797cee10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_d9adb0fe-ba84-4c7b-aff5-2ae7bb941b4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_589a4bf0-e7d2-4d25-81fd-26c0797cee10" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_d9adb0fe-ba84-4c7b-aff5-2ae7bb941b4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_35f22008-95a8-451e-9522-8d4148c6a0bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_589a4bf0-e7d2-4d25-81fd-26c0797cee10" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_35f22008-95a8-451e-9522-8d4148c6a0bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.optinose.com/role/LeasesOperatingleasematuritiesDetails" xlink:type="simple" xlink:href="optn-20221231.xsd#LeasesOperatingleasematuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.optinose.com/role/LeasesOperatingleasematuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_d7d0edce-30c6-417f-a77e-68f4d08bdec4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_2392d608-e5aa-4d9f-be8d-5cfb96d64a75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d7d0edce-30c6-417f-a77e-68f4d08bdec4" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_2392d608-e5aa-4d9f-be8d-5cfb96d64a75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_b2529a50-948a-4f57-8faa-da41feaae142" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_2392d608-e5aa-4d9f-be8d-5cfb96d64a75" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_b2529a50-948a-4f57-8faa-da41feaae142" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_20f84318-4f7c-4769-bee6-c41a1d02ce9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_2392d608-e5aa-4d9f-be8d-5cfb96d64a75" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_20f84318-4f7c-4769-bee6-c41a1d02ce9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_25717baa-bd29-42eb-8b2e-72433343fcb4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_2392d608-e5aa-4d9f-be8d-5cfb96d64a75" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_25717baa-bd29-42eb-8b2e-72433343fcb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_LesseeOperatingLeaseLiabilityPaymentsDueThereafter_1f31015f-bcf3-4df0-af24-86b265592a00" xlink:href="optn-20221231.xsd#optn_LesseeOperatingLeaseLiabilityPaymentsDueThereafter"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_2392d608-e5aa-4d9f-be8d-5cfb96d64a75" xlink:to="loc_optn_LesseeOperatingLeaseLiabilityPaymentsDueThereafter_1f31015f-bcf3-4df0-af24-86b265592a00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_084ac7a7-437c-4ed6-9e00-02a488a112dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_2392d608-e5aa-4d9f-be8d-5cfb96d64a75" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_084ac7a7-437c-4ed6-9e00-02a488a112dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_86667ca2-fd87-4148-92bf-213578889d04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_2392d608-e5aa-4d9f-be8d-5cfb96d64a75" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_86667ca2-fd87-4148-92bf-213578889d04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_d5e7d23d-4b07-44c2-b8ab-61dc230dcef5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_2392d608-e5aa-4d9f-be8d-5cfb96d64a75" xlink:to="loc_us-gaap_OperatingLeaseLiability_d5e7d23d-4b07-44c2-b8ab-61dc230dcef5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.optinose.com/role/LeasesOperatingleasematuritiesDetails_1" xlink:type="simple" xlink:href="optn-20221231.xsd#LeasesOperatingleasematuritiesDetails_1"/>
  <link:presentationLink xlink:role="http://www.optinose.com/role/LeasesOperatingleasematuritiesDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.optinose.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="optn-20221231.xsd#AccruedExpensesandOtherCurrentLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.optinose.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_227c03fa-304f-4ec0-8530-8d5a1b8ce036" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_63f11ef6-5df1-4fcf-b457-cb4b623c289b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_227c03fa-304f-4ec0-8530-8d5a1b8ce036" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_63f11ef6-5df1-4fcf-b457-cb4b623c289b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_AccruedProductAllowancesCurrent_3ad1b031-651d-44b3-b5a7-587d1d598de3" xlink:href="optn-20221231.xsd#optn_AccruedProductAllowancesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_63f11ef6-5df1-4fcf-b457-cb4b623c289b" xlink:to="loc_optn_AccruedProductAllowancesCurrent_3ad1b031-651d-44b3-b5a7-587d1d598de3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_AccruedSellingGeneralandAdministrativeCurrent_6884ef86-3ceb-48bc-876a-bafc67baebe8" xlink:href="optn-20221231.xsd#optn_AccruedSellingGeneralandAdministrativeCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_63f11ef6-5df1-4fcf-b457-cb4b623c289b" xlink:to="loc_optn_AccruedSellingGeneralandAdministrativeCurrent_6884ef86-3ceb-48bc-876a-bafc67baebe8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_AccruedResearchandDevelopmentCurrent_0978563a-15f0-440a-abc1-6d9ddb793a52" xlink:href="optn-20221231.xsd#optn_AccruedResearchandDevelopmentCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_63f11ef6-5df1-4fcf-b457-cb4b623c289b" xlink:to="loc_optn_AccruedResearchandDevelopmentCurrent_0978563a-15f0-440a-abc1-6d9ddb793a52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent_0959bf46-812a-47f5-adaf-d44cf1de416c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_63f11ef6-5df1-4fcf-b457-cb4b623c289b" xlink:to="loc_us-gaap_AccruedEmployeeBenefitsCurrent_0959bf46-812a-47f5-adaf-d44cf1de416c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_85b41cc1-7b1e-40db-8f16-6961962afefa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_63f11ef6-5df1-4fcf-b457-cb4b623c289b" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_85b41cc1-7b1e-40db-8f16-6961962afefa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_acb8f0f6-3530-4b34-a491-ef28e7641bf0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_63f11ef6-5df1-4fcf-b457-cb4b623c289b" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_acb8f0f6-3530-4b34-a491-ef28e7641bf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrentAbstract_6a14a970-d9de-4956-9157-4dcefe7a4b14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_227c03fa-304f-4ec0-8530-8d5a1b8ce036" xlink:to="loc_us-gaap_OtherLiabilitiesCurrentAbstract_6a14a970-d9de-4956-9157-4dcefe7a4b14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_8ccaae38-c1a9-488d-818f-da17476cbe75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesCurrentAbstract_6a14a970-d9de-4956-9157-4dcefe7a4b14" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_8ccaae38-c1a9-488d-818f-da17476cbe75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_53267a1a-11db-42eb-b114-4d6eeadec4dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesCurrentAbstract_6a14a970-d9de-4956-9157-4dcefe7a4b14" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_53267a1a-11db-42eb-b114-4d6eeadec4dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_4f1342f5-20f8-4b1c-8906-11ab8fdf7afe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_227c03fa-304f-4ec0-8530-8d5a1b8ce036" xlink:to="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_4f1342f5-20f8-4b1c-8906-11ab8fdf7afe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.optinose.com/role/LicenseAgreementsDetails" xlink:type="simple" xlink:href="optn-20221231.xsd#LicenseAgreementsDetails"/>
  <link:presentationLink xlink:role="http://www.optinose.com/role/LicenseAgreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_9988e3f4-7404-41fa-8ace-d3187c083e4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_f7c96407-d11f-4e6d-8880-b507a4606e46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_9988e3f4-7404-41fa-8ace-d3187c083e4b" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_f7c96407-d11f-4e6d-8880-b507a4606e46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_f664a25d-d96c-4c64-b734-49a80a22cfaa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_f7c96407-d11f-4e6d-8880-b507a4606e46" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_f664a25d-d96c-4c64-b734-49a80a22cfaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_b0fd0360-a1e0-438e-873d-f3f90afc8083" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_f664a25d-d96c-4c64-b734-49a80a22cfaa" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_b0fd0360-a1e0-438e-873d-f3f90afc8083" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyAgreementTermsMember_b5b8f686-0a88-4c8a-b10f-e12699590269" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyAgreementTermsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_b0fd0360-a1e0-438e-873d-f3f90afc8083" xlink:to="loc_us-gaap_RoyaltyAgreementTermsMember_b5b8f686-0a88-4c8a-b10f-e12699590269" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_f5a03128-fe8d-44c0-8283-bf04182f97f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_f7c96407-d11f-4e6d-8880-b507a4606e46" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_f5a03128-fe8d-44c0-8283-bf04182f97f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestonePaymentsMaximumEligible_f053c7f6-74dc-446f-9d64-77fe18017f2a" xlink:href="optn-20221231.xsd#optn_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestonePaymentsMaximumEligible"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_f5a03128-fe8d-44c0-8283-bf04182f97f7" xlink:to="loc_optn_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestonePaymentsMaximumEligible_f053c7f6-74dc-446f-9d64-77fe18017f2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.optinose.com/role/DebtnetNarrativeDetails" xlink:type="simple" xlink:href="optn-20221231.xsd#DebtnetNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.optinose.com/role/DebtnetNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_1e8d733b-a005-46a5-b0b0-97169043261c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_5f90692c-d04c-4985-8c55-137630366806" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_1e8d733b-a005-46a5-b0b0-97169043261c" xlink:to="loc_us-gaap_DebtInstrumentTable_5f90692c-d04c-4985-8c55-137630366806" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_c9d1f550-93bf-4260-b2f1-7af641cfbddf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_5f90692c-d04c-4985-8c55-137630366806" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_c9d1f550-93bf-4260-b2f1-7af641cfbddf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_e4c1a176-ac4d-429b-ac72-17a1a7d7592a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_c9d1f550-93bf-4260-b2f1-7af641cfbddf" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_e4c1a176-ac4d-429b-ac72-17a1a7d7592a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_4d821ff7-9e29-4094-91b6-ca69770002c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_e4c1a176-ac4d-429b-ac72-17a1a7d7592a" xlink:to="loc_us-gaap_SeniorNotesMember_4d821ff7-9e29-4094-91b6-ca69770002c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_5c00c79e-0027-4992-b475-40abe0ec6191" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_5f90692c-d04c-4985-8c55-137630366806" xlink:to="loc_us-gaap_DebtInstrumentAxis_5c00c79e-0027-4992-b475-40abe0ec6191" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_b1925a8c-9dd8-453e-98ec-ca0e221de3a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_5c00c79e-0027-4992-b475-40abe0ec6191" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_b1925a8c-9dd8-453e-98ec-ca0e221de3a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_NotePurchaseAgreementMember_300b35f3-4058-4446-a394-d81dd0d0b1fa" xlink:href="optn-20221231.xsd#optn_NotePurchaseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b1925a8c-9dd8-453e-98ec-ca0e221de3a0" xlink:to="loc_optn_NotePurchaseAgreementMember_300b35f3-4058-4446-a394-d81dd0d0b1fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_NotePurchaseAgreementFirstDelayedDrawNotesMember_e21c8ff4-1d66-4d00-a265-d523959dd04d" xlink:href="optn-20221231.xsd#optn_NotePurchaseAgreementFirstDelayedDrawNotesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b1925a8c-9dd8-453e-98ec-ca0e221de3a0" xlink:to="loc_optn_NotePurchaseAgreementFirstDelayedDrawNotesMember_e21c8ff4-1d66-4d00-a265-d523959dd04d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_NotePurchaseAgreementThirdDelayedDrawNotesMember_bce0fa94-d380-47e2-bbfc-b59de542d8c3" xlink:href="optn-20221231.xsd#optn_NotePurchaseAgreementThirdDelayedDrawNotesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b1925a8c-9dd8-453e-98ec-ca0e221de3a0" xlink:to="loc_optn_NotePurchaseAgreementThirdDelayedDrawNotesMember_bce0fa94-d380-47e2-bbfc-b59de542d8c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_MeasurementPeriodAxis_160f18cc-42a3-40a7-8f64-c7ae50c2c436" xlink:href="optn-20221231.xsd#optn_MeasurementPeriodAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_5f90692c-d04c-4985-8c55-137630366806" xlink:to="loc_optn_MeasurementPeriodAxis_160f18cc-42a3-40a7-8f64-c7ae50c2c436" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_MeasurementPeriodDomain_7283f547-6781-4e0d-b806-72fd78604726" xlink:href="optn-20221231.xsd#optn_MeasurementPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_optn_MeasurementPeriodAxis_160f18cc-42a3-40a7-8f64-c7ae50c2c436" xlink:to="loc_optn_MeasurementPeriodDomain_7283f547-6781-4e0d-b806-72fd78604726" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_QuarterEndedDecember312019Member_1e82f7e1-a086-4a29-9cdc-fdaeafef8cdb" xlink:href="optn-20221231.xsd#optn_QuarterEndedDecember312019Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_optn_MeasurementPeriodDomain_7283f547-6781-4e0d-b806-72fd78604726" xlink:to="loc_optn_QuarterEndedDecember312019Member_1e82f7e1-a086-4a29-9cdc-fdaeafef8cdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_QuarterEndedSeptember302020Member_3839b36e-59d0-41bf-9d33-c7821ea4001c" xlink:href="optn-20221231.xsd#optn_QuarterEndedSeptember302020Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_optn_MeasurementPeriodDomain_7283f547-6781-4e0d-b806-72fd78604726" xlink:to="loc_optn_QuarterEndedSeptember302020Member_3839b36e-59d0-41bf-9d33-c7821ea4001c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_0b829804-bc36-4fdd-81eb-12dd1cdf7c73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_5f90692c-d04c-4985-8c55-137630366806" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_0b829804-bc36-4fdd-81eb-12dd1cdf7c73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_e0588736-6f0e-47e4-bb41-30c04e3c6370" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_0b829804-bc36-4fdd-81eb-12dd1cdf7c73" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_e0588736-6f0e-47e4-bb41-30c04e3c6370" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_d2746c84-8c62-4187-ae72-838e730033de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_e0588736-6f0e-47e4-bb41-30c04e3c6370" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_d2746c84-8c62-4187-ae72-838e730033de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_f670a3bb-4dea-4a28-9483-f946dda145f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_e0588736-6f0e-47e4-bb41-30c04e3c6370" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_f670a3bb-4dea-4a28-9483-f946dda145f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_c04c481a-bbeb-4c9b-8021-864baae5ca4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_e0588736-6f0e-47e4-bb41-30c04e3c6370" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_c04c481a-bbeb-4c9b-8021-864baae5ca4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_936db076-936c-4310-a814-d4955570f207" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_5f90692c-d04c-4985-8c55-137630366806" xlink:to="loc_us-gaap_VariableRateAxis_936db076-936c-4310-a814-d4955570f207" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_b337b5d4-7ea8-47e7-b807-eed54227830f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_936db076-936c-4310-a814-d4955570f207" xlink:to="loc_us-gaap_VariableRateDomain_b337b5d4-7ea8-47e7-b807-eed54227830f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_SecuredOvernightFinancingRateMember_551b4b3b-7c28-4bc1-b3de-35e7d863a69f" xlink:href="optn-20221231.xsd#optn_SecuredOvernightFinancingRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_b337b5d4-7ea8-47e7-b807-eed54227830f" xlink:to="loc_optn_SecuredOvernightFinancingRateMember_551b4b3b-7c28-4bc1-b3de-35e7d863a69f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_b307814b-386f-423f-9ede-9c8b730f49fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_b337b5d4-7ea8-47e7-b807-eed54227830f" xlink:to="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_b307814b-386f-423f-9ede-9c8b730f49fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_e0a130af-bd2b-4a68-96d7-f7e7f3d35448" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_5f90692c-d04c-4985-8c55-137630366806" xlink:to="loc_us-gaap_DebtInstrumentLineItems_e0a130af-bd2b-4a68-96d7-f7e7f3d35448" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_c4c4e574-f072-4d06-bbc0-6ee4539a9db7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e0a130af-bd2b-4a68-96d7-f7e7f3d35448" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_c4c4e574-f072-4d06-bbc0-6ee4539a9db7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_1593e3ae-e5eb-4295-9391-b0460e055b43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e0a130af-bd2b-4a68-96d7-f7e7f3d35448" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_1593e3ae-e5eb-4295-9391-b0460e055b43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_DebtInstrumentIssuanceCriteriaTermNetSalesAndRoyaltiesBenchmark_4a62bc5e-356b-4f99-8f5c-8caca1a12460" xlink:href="optn-20221231.xsd#optn_DebtInstrumentIssuanceCriteriaTermNetSalesAndRoyaltiesBenchmark"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e0a130af-bd2b-4a68-96d7-f7e7f3d35448" xlink:to="loc_optn_DebtInstrumentIssuanceCriteriaTermNetSalesAndRoyaltiesBenchmark_4a62bc5e-356b-4f99-8f5c-8caca1a12460" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_TrailingTwelveMonthNetRevenueCovenant_34f461e9-536c-48b2-baed-aba4ad2903c9" xlink:href="optn-20221231.xsd#optn_TrailingTwelveMonthNetRevenueCovenant"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e0a130af-bd2b-4a68-96d7-f7e7f3d35448" xlink:to="loc_optn_TrailingTwelveMonthNetRevenueCovenant_34f461e9-536c-48b2-baed-aba4ad2903c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_FeeDueOnTheMaturityDateOfTheNotePurchaseAgreement_fff38c6d-0593-489d-b724-7c3b3376cbd1" xlink:href="optn-20221231.xsd#optn_FeeDueOnTheMaturityDateOfTheNotePurchaseAgreement"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e0a130af-bd2b-4a68-96d7-f7e7f3d35448" xlink:to="loc_optn_FeeDueOnTheMaturityDateOfTheNotePurchaseAgreement_fff38c6d-0593-489d-b724-7c3b3376cbd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_5f4e22dc-b276-49a7-bcfd-f3271fc40c82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e0a130af-bd2b-4a68-96d7-f7e7f3d35448" xlink:to="loc_us-gaap_DebtInstrumentTerm_5f4e22dc-b276-49a7-bcfd-f3271fc40c82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_db07bae4-35b4-41e3-bc5e-85b0e281fa42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e0a130af-bd2b-4a68-96d7-f7e7f3d35448" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_db07bae4-35b4-41e3-bc5e-85b0e281fa42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_ae864612-c177-4d27-a891-08af35d6cb83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e0a130af-bd2b-4a68-96d7-f7e7f3d35448" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_ae864612-c177-4d27-a891-08af35d6cb83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_PotentialDebtInstrumentInterestRateIncrease_5d19f340-a3d9-4eea-ab0d-5ff60a5a2161" xlink:href="optn-20221231.xsd#optn_PotentialDebtInstrumentInterestRateIncrease"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e0a130af-bd2b-4a68-96d7-f7e7f3d35448" xlink:to="loc_optn_PotentialDebtInstrumentInterestRateIncrease_5d19f340-a3d9-4eea-ab0d-5ff60a5a2161" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_DebtInstrumentMakeWholeProvisionPaymentAccrualPeriod_09cb3090-978e-48d0-9ac1-434f4d101f0c" xlink:href="optn-20221231.xsd#optn_DebtInstrumentMakeWholeProvisionPaymentAccrualPeriod"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e0a130af-bd2b-4a68-96d7-f7e7f3d35448" xlink:to="loc_optn_DebtInstrumentMakeWholeProvisionPaymentAccrualPeriod_09cb3090-978e-48d0-9ac1-434f4d101f0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_DebtInstrumentMaximumAggregateMakeWholePremiumAmount_dc8935cb-cbcb-4aa1-a6c6-b881baae7b6a" xlink:href="optn-20221231.xsd#optn_DebtInstrumentMaximumAggregateMakeWholePremiumAmount"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e0a130af-bd2b-4a68-96d7-f7e7f3d35448" xlink:to="loc_optn_DebtInstrumentMaximumAggregateMakeWholePremiumAmount_dc8935cb-cbcb-4aa1-a6c6-b881baae7b6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_AmendmentFee_254e94d2-d7f5-48da-aa1d-904bf4172009" xlink:href="optn-20221231.xsd#optn_AmendmentFee"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e0a130af-bd2b-4a68-96d7-f7e7f3d35448" xlink:to="loc_optn_AmendmentFee_254e94d2-d7f5-48da-aa1d-904bf4172009" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_AmendmentFeePercentage_133e1277-954f-4080-ad2b-68e0d39f0e09" xlink:href="optn-20221231.xsd#optn_AmendmentFeePercentage"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e0a130af-bd2b-4a68-96d7-f7e7f3d35448" xlink:to="loc_optn_AmendmentFeePercentage_133e1277-954f-4080-ad2b-68e0d39f0e09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_AmendmentFeePayable_c07aa212-8a0f-4af4-9cd9-e2ec670fd5c2" xlink:href="optn-20221231.xsd#optn_AmendmentFeePayable"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e0a130af-bd2b-4a68-96d7-f7e7f3d35448" xlink:to="loc_optn_AmendmentFeePayable_c07aa212-8a0f-4af4-9cd9-e2ec670fd5c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_DebtInstrumentCovenantCashAndCashEquivalents_202fd7f6-2a56-48ca-ae4a-13d7f967f4e3" xlink:href="optn-20221231.xsd#optn_DebtInstrumentCovenantCashAndCashEquivalents"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e0a130af-bd2b-4a68-96d7-f7e7f3d35448" xlink:to="loc_optn_DebtInstrumentCovenantCashAndCashEquivalents_202fd7f6-2a56-48ca-ae4a-13d7f967f4e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_a2d429c8-2c60-4928-b3a7-29dff0cfd3f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e0a130af-bd2b-4a68-96d7-f7e7f3d35448" xlink:to="loc_us-gaap_InterestExpenseDebt_a2d429c8-2c60-4928-b3a7-29dff0cfd3f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_NotePurchaseAgreementCovenantXHANCENetProductSalesAndRoyalties_2363891c-bc22-4e62-88c2-2eacfa1b46b2" xlink:href="optn-20221231.xsd#optn_NotePurchaseAgreementCovenantXHANCENetProductSalesAndRoyalties"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e0a130af-bd2b-4a68-96d7-f7e7f3d35448" xlink:to="loc_optn_NotePurchaseAgreementCovenantXHANCENetProductSalesAndRoyalties_2363891c-bc22-4e62-88c2-2eacfa1b46b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_3c0846db-065e-404e-b0d5-b5ffa7bdaca8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e0a130af-bd2b-4a68-96d7-f7e7f3d35448" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_3c0846db-065e-404e-b0d5-b5ffa7bdaca8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.optinose.com/role/DebtnetARNotePurchaseAgreementDetails" xlink:type="simple" xlink:href="optn-20221231.xsd#DebtnetARNotePurchaseAgreementDetails"/>
  <link:presentationLink xlink:role="http://www.optinose.com/role/DebtnetARNotePurchaseAgreementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_b57d3faa-e484-477d-b2d2-b35251bd107d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_27b37454-475d-476b-9999-7c456b60e090" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_b57d3faa-e484-477d-b2d2-b35251bd107d" xlink:to="loc_us-gaap_DebtInstrumentTable_27b37454-475d-476b-9999-7c456b60e090" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_f5a6e89b-ee10-44c6-90d9-e2d0ab5b78d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_27b37454-475d-476b-9999-7c456b60e090" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_f5a6e89b-ee10-44c6-90d9-e2d0ab5b78d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_25b32f93-2cc8-4ff8-bf7a-efdf44ed1381" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_f5a6e89b-ee10-44c6-90d9-e2d0ab5b78d9" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_25b32f93-2cc8-4ff8-bf7a-efdf44ed1381" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_10278dea-de92-483a-9d38-fad89103ba02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_25b32f93-2cc8-4ff8-bf7a-efdf44ed1381" xlink:to="loc_us-gaap_SeniorNotesMember_10278dea-de92-483a-9d38-fad89103ba02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_TrailingTwelveMonthEndingAxisAxis_db3b516d-875c-49e5-b619-2f70a6f715e8" xlink:href="optn-20221231.xsd#optn_TrailingTwelveMonthEndingAxisAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_27b37454-475d-476b-9999-7c456b60e090" xlink:to="loc_optn_TrailingTwelveMonthEndingAxisAxis_db3b516d-875c-49e5-b619-2f70a6f715e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_TrailingTwelveMonthEndingAxisDomain_3e2046cb-6534-44f3-88f6-7b436f1fcf63" xlink:href="optn-20221231.xsd#optn_TrailingTwelveMonthEndingAxisDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_optn_TrailingTwelveMonthEndingAxisAxis_db3b516d-875c-49e5-b619-2f70a6f715e8" xlink:to="loc_optn_TrailingTwelveMonthEndingAxisDomain_3e2046cb-6534-44f3-88f6-7b436f1fcf63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_March312023Member_9f83f684-02c2-44a5-bed9-a4284ea79260" xlink:href="optn-20221231.xsd#optn_March312023Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_optn_TrailingTwelveMonthEndingAxisDomain_3e2046cb-6534-44f3-88f6-7b436f1fcf63" xlink:to="loc_optn_March312023Member_9f83f684-02c2-44a5-bed9-a4284ea79260" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_June302023Member_5add417d-43d6-4d36-897b-d0f0a7f614bd" xlink:href="optn-20221231.xsd#optn_June302023Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_optn_TrailingTwelveMonthEndingAxisDomain_3e2046cb-6534-44f3-88f6-7b436f1fcf63" xlink:to="loc_optn_June302023Member_5add417d-43d6-4d36-897b-d0f0a7f614bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_September302023Member_cffa3e1d-7a8f-4e8f-8d2e-16c43de1b18f" xlink:href="optn-20221231.xsd#optn_September302023Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_optn_TrailingTwelveMonthEndingAxisDomain_3e2046cb-6534-44f3-88f6-7b436f1fcf63" xlink:to="loc_optn_September302023Member_cffa3e1d-7a8f-4e8f-8d2e-16c43de1b18f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_December312023Member_b7ce9581-75a0-47a8-b8bb-5736e5766ed9" xlink:href="optn-20221231.xsd#optn_December312023Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_optn_TrailingTwelveMonthEndingAxisDomain_3e2046cb-6534-44f3-88f6-7b436f1fcf63" xlink:to="loc_optn_December312023Member_b7ce9581-75a0-47a8-b8bb-5736e5766ed9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_March312024Member_54708063-90ef-4ab5-973e-e7657d7e7468" xlink:href="optn-20221231.xsd#optn_March312024Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_optn_TrailingTwelveMonthEndingAxisDomain_3e2046cb-6534-44f3-88f6-7b436f1fcf63" xlink:to="loc_optn_March312024Member_54708063-90ef-4ab5-973e-e7657d7e7468" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_June302024Member_effda656-00f9-4a55-85a5-3a6875b95b4d" xlink:href="optn-20221231.xsd#optn_June302024Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_optn_TrailingTwelveMonthEndingAxisDomain_3e2046cb-6534-44f3-88f6-7b436f1fcf63" xlink:to="loc_optn_June302024Member_effda656-00f9-4a55-85a5-3a6875b95b4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_September302024Member_d0bf5936-c5ba-409c-af36-0547cac8456f" xlink:href="optn-20221231.xsd#optn_September302024Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_optn_TrailingTwelveMonthEndingAxisDomain_3e2046cb-6534-44f3-88f6-7b436f1fcf63" xlink:to="loc_optn_September302024Member_d0bf5936-c5ba-409c-af36-0547cac8456f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_December312024Member_bda50f91-2af0-4e64-9496-9887752e6eed" xlink:href="optn-20221231.xsd#optn_December312024Member"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_optn_TrailingTwelveMonthEndingAxisDomain_3e2046cb-6534-44f3-88f6-7b436f1fcf63" xlink:to="loc_optn_December312024Member_bda50f91-2af0-4e64-9496-9887752e6eed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_March312025Member_10f350b3-0f38-43c6-8186-9baaf93adc1a" xlink:href="optn-20221231.xsd#optn_March312025Member"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_optn_TrailingTwelveMonthEndingAxisDomain_3e2046cb-6534-44f3-88f6-7b436f1fcf63" xlink:to="loc_optn_March312025Member_10f350b3-0f38-43c6-8186-9baaf93adc1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_June302025Member_002ccdac-25f3-4f4d-92c7-7b6b352a8a31" xlink:href="optn-20221231.xsd#optn_June302025Member"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_optn_TrailingTwelveMonthEndingAxisDomain_3e2046cb-6534-44f3-88f6-7b436f1fcf63" xlink:to="loc_optn_June302025Member_002ccdac-25f3-4f4d-92c7-7b6b352a8a31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_September302025Member_825812f0-9396-4c4d-8ff9-082e86920a88" xlink:href="optn-20221231.xsd#optn_September302025Member"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_optn_TrailingTwelveMonthEndingAxisDomain_3e2046cb-6534-44f3-88f6-7b436f1fcf63" xlink:to="loc_optn_September302025Member_825812f0-9396-4c4d-8ff9-082e86920a88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_December312025Member_1f5dff62-1b2f-41ad-b788-f7daa8b5ac87" xlink:href="optn-20221231.xsd#optn_December312025Member"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_optn_TrailingTwelveMonthEndingAxisDomain_3e2046cb-6534-44f3-88f6-7b436f1fcf63" xlink:to="loc_optn_December312025Member_1f5dff62-1b2f-41ad-b788-f7daa8b5ac87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_March312026Member_ef46824c-fbc9-4420-a657-2b0164060bbb" xlink:href="optn-20221231.xsd#optn_March312026Member"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_optn_TrailingTwelveMonthEndingAxisDomain_3e2046cb-6534-44f3-88f6-7b436f1fcf63" xlink:to="loc_optn_March312026Member_ef46824c-fbc9-4420-a657-2b0164060bbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_June302026Member_a46f6729-6adf-44c1-8009-7aa5ab0710c1" xlink:href="optn-20221231.xsd#optn_June302026Member"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_optn_TrailingTwelveMonthEndingAxisDomain_3e2046cb-6534-44f3-88f6-7b436f1fcf63" xlink:to="loc_optn_June302026Member_a46f6729-6adf-44c1-8009-7aa5ab0710c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_September302026Member_c91365f2-a781-4c93-825b-c4984fe0dc9b" xlink:href="optn-20221231.xsd#optn_September302026Member"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_optn_TrailingTwelveMonthEndingAxisDomain_3e2046cb-6534-44f3-88f6-7b436f1fcf63" xlink:to="loc_optn_September302026Member_c91365f2-a781-4c93-825b-c4984fe0dc9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_December312026Member_7b9d1fd0-22c8-462b-b820-0512ea6effc6" xlink:href="optn-20221231.xsd#optn_December312026Member"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_optn_TrailingTwelveMonthEndingAxisDomain_3e2046cb-6534-44f3-88f6-7b436f1fcf63" xlink:to="loc_optn_December312026Member_7b9d1fd0-22c8-462b-b820-0512ea6effc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_March312027Member_921d313d-0d9c-406e-b75c-6dadb63983c6" xlink:href="optn-20221231.xsd#optn_March312027Member"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_optn_TrailingTwelveMonthEndingAxisDomain_3e2046cb-6534-44f3-88f6-7b436f1fcf63" xlink:to="loc_optn_March312027Member_921d313d-0d9c-406e-b75c-6dadb63983c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_June302027Member_468a2e67-2b6a-4d59-ac21-67bc25c520e2" xlink:href="optn-20221231.xsd#optn_June302027Member"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_optn_TrailingTwelveMonthEndingAxisDomain_3e2046cb-6534-44f3-88f6-7b436f1fcf63" xlink:to="loc_optn_June302027Member_468a2e67-2b6a-4d59-ac21-67bc25c520e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_September302027Member_977d1063-5441-41cc-85b8-863f6bb98672" xlink:href="optn-20221231.xsd#optn_September302027Member"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_optn_TrailingTwelveMonthEndingAxisDomain_3e2046cb-6534-44f3-88f6-7b436f1fcf63" xlink:to="loc_optn_September302027Member_977d1063-5441-41cc-85b8-863f6bb98672" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_8ab9a782-f6d4-41f2-9f72-b42da5d1f04e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_27b37454-475d-476b-9999-7c456b60e090" xlink:to="loc_us-gaap_DebtInstrumentLineItems_8ab9a782-f6d4-41f2-9f72-b42da5d1f04e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_NotePurchaseAgreementCovenantXHANCENetProductSalesAndRoyalties_65becee9-e00c-4f32-8c30-71c4da07c063" xlink:href="optn-20221231.xsd#optn_NotePurchaseAgreementCovenantXHANCENetProductSalesAndRoyalties"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8ab9a782-f6d4-41f2-9f72-b42da5d1f04e" xlink:to="loc_optn_NotePurchaseAgreementCovenantXHANCENetProductSalesAndRoyalties_65becee9-e00c-4f32-8c30-71c4da07c063" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.optinose.com/role/DebtnetScheduleoflongtermdebtDetails" xlink:type="simple" xlink:href="optn-20221231.xsd#DebtnetScheduleoflongtermdebtDetails"/>
  <link:presentationLink xlink:role="http://www.optinose.com/role/DebtnetScheduleoflongtermdebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_23f293c7-e998-4fb5-9fac-28910855b86c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_c1f4beb3-5ec7-4806-a86d-b4d6ef7bb801" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_23f293c7-e998-4fb5-9fac-28910855b86c" xlink:to="loc_us-gaap_DebtInstrumentTable_c1f4beb3-5ec7-4806-a86d-b4d6ef7bb801" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_52c3ab11-8441-415e-af61-bdc92e3afff2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_c1f4beb3-5ec7-4806-a86d-b4d6ef7bb801" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_52c3ab11-8441-415e-af61-bdc92e3afff2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_43d19899-13b8-4492-baba-4327dbd8d690" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_52c3ab11-8441-415e-af61-bdc92e3afff2" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_43d19899-13b8-4492-baba-4327dbd8d690" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_4312fcac-eb47-4864-96f9-ce03889c8ae4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_43d19899-13b8-4492-baba-4327dbd8d690" xlink:to="loc_us-gaap_SeniorNotesMember_4312fcac-eb47-4864-96f9-ce03889c8ae4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_e7d9536f-020c-47e9-9c73-76f9591d3f02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_c1f4beb3-5ec7-4806-a86d-b4d6ef7bb801" xlink:to="loc_us-gaap_DebtInstrumentAxis_e7d9536f-020c-47e9-9c73-76f9591d3f02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_8a061bcb-25b1-4c8f-bca3-9f717578028a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_e7d9536f-020c-47e9-9c73-76f9591d3f02" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_8a061bcb-25b1-4c8f-bca3-9f717578028a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_NotePurchaseAgreementMember_76c92a3c-5bfb-4b7e-afe8-89d8aedbe47b" xlink:href="optn-20221231.xsd#optn_NotePurchaseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8a061bcb-25b1-4c8f-bca3-9f717578028a" xlink:to="loc_optn_NotePurchaseAgreementMember_76c92a3c-5bfb-4b7e-afe8-89d8aedbe47b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_7af04344-05bc-4d42-9a8a-8878852c96ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_c1f4beb3-5ec7-4806-a86d-b4d6ef7bb801" xlink:to="loc_us-gaap_DebtInstrumentLineItems_7af04344-05bc-4d42-9a8a-8878852c96ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_8716f905-5caa-4f07-b70f-4690f3341819" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7af04344-05bc-4d42-9a8a-8878852c96ae" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_8716f905-5caa-4f07-b70f-4690f3341819" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_DebtInstrumentFeeAmountFrontEnd_c957351f-58cb-413c-84cb-4096bfc3695d" xlink:href="optn-20221231.xsd#optn_DebtInstrumentFeeAmountFrontEnd"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7af04344-05bc-4d42-9a8a-8878852c96ae" xlink:to="loc_optn_DebtInstrumentFeeAmountFrontEnd_c957351f-58cb-413c-84cb-4096bfc3695d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnamortizedDebtIssuanceExpense_2cee0e0f-67e0-4883-8732-3f277514f378" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnamortizedDebtIssuanceExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7af04344-05bc-4d42-9a8a-8878852c96ae" xlink:to="loc_us-gaap_UnamortizedDebtIssuanceExpense_2cee0e0f-67e0-4883-8732-3f277514f378" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_DebtInstrumentFeeAmountBackEnd_a24dd61d-d3a1-4b64-9f68-7a956b59c0ed" xlink:href="optn-20221231.xsd#optn_DebtInstrumentFeeAmountBackEnd"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7af04344-05bc-4d42-9a8a-8878852c96ae" xlink:to="loc_optn_DebtInstrumentFeeAmountBackEnd_a24dd61d-d3a1-4b64-9f68-7a956b59c0ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_8d19ef5f-8da5-4fc6-84b3-407dc2d8f07b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7af04344-05bc-4d42-9a8a-8878852c96ae" xlink:to="loc_us-gaap_LongTermDebt_8d19ef5f-8da5-4fc6-84b3-407dc2d8f07b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.optinose.com/role/EmployeeBenefitPlansDetails" xlink:type="simple" xlink:href="optn-20221231.xsd#EmployeeBenefitPlansDetails"/>
  <link:presentationLink xlink:role="http://www.optinose.com/role/EmployeeBenefitPlansDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_41727368-7102-4f78-ac51-0100e20f499c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanTable_0f3a495f-6919-47e4-9103-987c1433a227" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_41727368-7102-4f78-ac51-0100e20f499c" xlink:to="loc_us-gaap_DefinedContributionPlanTable_0f3a495f-6919-47e4-9103-987c1433a227" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_DefinedContributionPlanTranchesAxisAxis_98c791c9-ee0b-43ed-a172-49a82531bb76" xlink:href="optn-20221231.xsd#optn_DefinedContributionPlanTranchesAxisAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedContributionPlanTable_0f3a495f-6919-47e4-9103-987c1433a227" xlink:to="loc_optn_DefinedContributionPlanTranchesAxisAxis_98c791c9-ee0b-43ed-a172-49a82531bb76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_DefinedContributionPlanTranchesAxisDomain_55237285-e96e-4382-87a9-fa53964db4fa" xlink:href="optn-20221231.xsd#optn_DefinedContributionPlanTranchesAxisDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_optn_DefinedContributionPlanTranchesAxisAxis_98c791c9-ee0b-43ed-a172-49a82531bb76" xlink:to="loc_optn_DefinedContributionPlanTranchesAxisDomain_55237285-e96e-4382-87a9-fa53964db4fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_DefinedContributionPlanTrancheOneMember_eb4ee39d-c16b-4331-a510-373d35984d36" xlink:href="optn-20221231.xsd#optn_DefinedContributionPlanTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_optn_DefinedContributionPlanTranchesAxisDomain_55237285-e96e-4382-87a9-fa53964db4fa" xlink:to="loc_optn_DefinedContributionPlanTrancheOneMember_eb4ee39d-c16b-4331-a510-373d35984d36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_DefinedContributionPlanTrancheTwoMember_0a8b399e-5497-456c-b479-f9c3463b854b" xlink:href="optn-20221231.xsd#optn_DefinedContributionPlanTrancheTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_optn_DefinedContributionPlanTranchesAxisDomain_55237285-e96e-4382-87a9-fa53964db4fa" xlink:to="loc_optn_DefinedContributionPlanTrancheTwoMember_0a8b399e-5497-456c-b479-f9c3463b854b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_9b38e63c-6ab3-4eb3-a519-0d2f19d7998f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedContributionPlanTable_0f3a495f-6919-47e4-9103-987c1433a227" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_9b38e63c-6ab3-4eb3-a519-0d2f19d7998f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_dfbdb972-6e72-48a1-ae59-046d56f6abf1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_9b38e63c-6ab3-4eb3-a519-0d2f19d7998f" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_dfbdb972-6e72-48a1-ae59-046d56f6abf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_0540360d-c151-4b79-9a8e-02ad8ffc7558" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_dfbdb972-6e72-48a1-ae59-046d56f6abf1" xlink:to="loc_us-gaap_ForeignPlanMember_0540360d-c151-4b79-9a8e-02ad8ffc7558" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_ef41f4f0-8d27-44d4-94df-61d09a5f8179" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedContributionPlanTable_0f3a495f-6919-47e4-9103-987c1433a227" xlink:to="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_ef41f4f0-8d27-44d4-94df-61d09a5f8179" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_a4b01087-6f91-49e0-9746-adf3d2873f88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_ef41f4f0-8d27-44d4-94df-61d09a5f8179" xlink:to="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_a4b01087-6f91-49e0-9746-adf3d2873f88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_b164d14d-9f64-4118-bdef-697150ae51f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_ef41f4f0-8d27-44d4-94df-61d09a5f8179" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_b164d14d-9f64-4118-bdef-697150ae51f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_b41f5dcc-8e7c-4e30-bb5a-a6063c346136" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_ef41f4f0-8d27-44d4-94df-61d09a5f8179" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_b41f5dcc-8e7c-4e30-bb5a-a6063c346136" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_0f53d084-68bd-483b-b571-6b7dbfb81d0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_ef41f4f0-8d27-44d4-94df-61d09a5f8179" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_0f53d084-68bd-483b-b571-6b7dbfb81d0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.optinose.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="optn-20221231.xsd#CommitmentsandContingenciesDetails"/>
  <link:presentationLink xlink:role="http://www.optinose.com/role/CommitmentsandContingenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_fe42bcfb-0b60-4c8b-a051-e6a72d1c63fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligation_098497b1-caf3-48fb-a92d-31aa364c188f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseObligation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_fe42bcfb-0b60-4c8b-a051-e6a72d1c63fc" xlink:to="loc_us-gaap_PurchaseObligation_098497b1-caf3-48fb-a92d-31aa364c188f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.optinose.com/role/StockholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="optn-20221231.xsd#StockholdersEquityNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.optinose.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_6f9adbe5-db77-4e5a-b75b-eda291c19e3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_b03b9004-7c04-484a-a092-dc82d3ef8780" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_6f9adbe5-db77-4e5a-b75b-eda291c19e3b" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_b03b9004-7c04-484a-a092-dc82d3ef8780" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_13eb4646-fd21-421e-adf2-743068b0fd0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_b03b9004-7c04-484a-a092-dc82d3ef8780" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_13eb4646-fd21-421e-adf2-743068b0fd0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_bb9f6347-a5ac-4f4f-b8e0-b24b5cd7ace7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_13eb4646-fd21-421e-adf2-743068b0fd0e" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_bb9f6347-a5ac-4f4f-b8e0-b24b5cd7ace7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_PublicOfferingMember_f3000cee-375b-4b3c-a7df-1de8add9b5ec" xlink:href="optn-20221231.xsd#optn_PublicOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_bb9f6347-a5ac-4f4f-b8e0-b24b5cd7ace7" xlink:to="loc_optn_PublicOfferingMember_f3000cee-375b-4b3c-a7df-1de8add9b5ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_6dc5a678-fd7e-4549-aa53-79c0bf99933e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_b03b9004-7c04-484a-a092-dc82d3ef8780" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_6dc5a678-fd7e-4549-aa53-79c0bf99933e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_c4c625e7-ad53-4f04-9e23-1bc27d736b33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_6dc5a678-fd7e-4549-aa53-79c0bf99933e" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_c4c625e7-ad53-4f04-9e23-1bc27d736b33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_WarrantsExpiringNovember182024Member_283b1fc5-f906-4911-b140-3dbfa966b296" xlink:href="optn-20221231.xsd#optn_WarrantsExpiringNovember182024Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_c4c625e7-ad53-4f04-9e23-1bc27d736b33" xlink:to="loc_optn_WarrantsExpiringNovember182024Member_283b1fc5-f906-4911-b140-3dbfa966b296" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_WarrantsExpiringSeptember122022Member_ed1e1ad4-5245-41fd-903d-6fa1184c10b4" xlink:href="optn-20221231.xsd#optn_WarrantsExpiringSeptember122022Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_c4c625e7-ad53-4f04-9e23-1bc27d736b33" xlink:to="loc_optn_WarrantsExpiringSeptember122022Member_ed1e1ad4-5245-41fd-903d-6fa1184c10b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_c188bf07-7b13-4e6f-87c8-274228f1692b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_b03b9004-7c04-484a-a092-dc82d3ef8780" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_c188bf07-7b13-4e6f-87c8-274228f1692b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_777aee41-1f45-44e9-9221-8d0557e65f16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_c188bf07-7b13-4e6f-87c8-274228f1692b" xlink:to="loc_us-gaap_EquityComponentDomain_777aee41-1f45-44e9-9221-8d0557e65f16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_a7161601-5fd9-4125-83ad-7b98fbb1ff9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_777aee41-1f45-44e9-9221-8d0557e65f16" xlink:to="loc_us-gaap_CommonStockMember_a7161601-5fd9-4125-83ad-7b98fbb1ff9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_d4e279d9-38e0-45e1-90dc-7fcf3971f3a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_777aee41-1f45-44e9-9221-8d0557e65f16" xlink:to="loc_us-gaap_WarrantMember_d4e279d9-38e0-45e1-90dc-7fcf3971f3a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_fa8f1fd0-856e-4947-8a22-90a4db0859aa" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_b03b9004-7c04-484a-a092-dc82d3ef8780" xlink:to="loc_srt_CounterpartyNameAxis_fa8f1fd0-856e-4947-8a22-90a4db0859aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_822b1eb0-e254-4449-a60f-e78f7f526a30" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_fa8f1fd0-856e-4947-8a22-90a4db0859aa" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_822b1eb0-e254-4449-a60f-e78f7f526a30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_UnderwritersMember_2d916933-6fe7-4231-ac15-500f668dded4" xlink:href="optn-20221231.xsd#optn_UnderwritersMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_822b1eb0-e254-4449-a60f-e78f7f526a30" xlink:to="loc_optn_UnderwritersMember_2d916933-6fe7-4231-ac15-500f668dded4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_64862787-3f43-4da8-809e-c16565e9d9f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_b03b9004-7c04-484a-a092-dc82d3ef8780" xlink:to="loc_us-gaap_ClassOfStockLineItems_64862787-3f43-4da8-809e-c16565e9d9f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_c93e2dac-3de2-40e9-af43-71f22a893bbc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_64862787-3f43-4da8-809e-c16565e9d9f7" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_c93e2dac-3de2-40e9-af43-71f22a893bbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_f39b4fbe-a965-471c-9bf5-481695d38223" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_64862787-3f43-4da8-809e-c16565e9d9f7" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_f39b4fbe-a965-471c-9bf5-481695d38223" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_26fdf71e-f9f4-44cf-925a-3ffbdabe5582" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_64862787-3f43-4da8-809e-c16565e9d9f7" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_26fdf71e-f9f4-44cf-925a-3ffbdabe5582" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_SaleOfStockCommissionsAndExpenses_408f2c64-c363-4ac9-ba34-002bbddb20c2" xlink:href="optn-20221231.xsd#optn_SaleOfStockCommissionsAndExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_64862787-3f43-4da8-809e-c16565e9d9f7" xlink:to="loc_optn_SaleOfStockCommissionsAndExpenses_408f2c64-c363-4ac9-ba34-002bbddb20c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredOfferingCosts_4f3e09ab-cf84-4c43-9be1-0c51d618578f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredOfferingCosts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_64862787-3f43-4da8-809e-c16565e9d9f7" xlink:to="loc_us-gaap_DeferredOfferingCosts_4f3e09ab-cf84-4c43-9be1-0c51d618578f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_33e4993c-4a8b-44c1-873f-cb903f9669ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_64862787-3f43-4da8-809e-c16565e9d9f7" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_33e4993c-4a8b-44c1-873f-cb903f9669ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_VotePerShare_2921bbfa-139a-4fd5-beab-80bf42f0484a" xlink:href="optn-20221231.xsd#optn_VotePerShare"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_64862787-3f43-4da8-809e-c16565e9d9f7" xlink:to="loc_optn_VotePerShare_2921bbfa-139a-4fd5-beab-80bf42f0484a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_c3d40b5a-8038-41e1-9631-2d63eb9b9e98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_64862787-3f43-4da8-809e-c16565e9d9f7" xlink:to="loc_us-gaap_CommonStockDividendsPerShareDeclared_c3d40b5a-8038-41e1-9631-2d63eb9b9e98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_fa413757-39f3-4079-ad17-ba833694bae6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_64862787-3f43-4da8-809e-c16565e9d9f7" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_fa413757-39f3-4079-ad17-ba833694bae6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_948b7d3f-5234-4dc8-a9f8-1f054e917f40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_64862787-3f43-4da8-809e-c16565e9d9f7" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_948b7d3f-5234-4dc8-a9f8-1f054e917f40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_ClassOfWarrantOrRightRestrictionCommonSharesMaximumOwnershipIfExercisedPercent_de40a6c4-f7b2-4936-9d3c-c8ede10bcd4f" xlink:href="optn-20221231.xsd#optn_ClassOfWarrantOrRightRestrictionCommonSharesMaximumOwnershipIfExercisedPercent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_64862787-3f43-4da8-809e-c16565e9d9f7" xlink:to="loc_optn_ClassOfWarrantOrRightRestrictionCommonSharesMaximumOwnershipIfExercisedPercent_de40a6c4-f7b2-4936-9d3c-c8ede10bcd4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_ClassOfWarrantOrRightRestrictionCommonSharesMaximumOwnershipPriorToExecutionPercent_6fa00790-de34-4ff8-965a-d4e1a301e52c" xlink:href="optn-20221231.xsd#optn_ClassOfWarrantOrRightRestrictionCommonSharesMaximumOwnershipPriorToExecutionPercent"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_64862787-3f43-4da8-809e-c16565e9d9f7" xlink:to="loc_optn_ClassOfWarrantOrRightRestrictionCommonSharesMaximumOwnershipPriorToExecutionPercent_6fa00790-de34-4ff8-965a-d4e1a301e52c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_ClassOfWarrantOrRightRestrictionCommonSharesMaximumOwnershipAfterEffectiveWaitingPeriodPercent_6d69c386-dce6-43bc-906e-ff3599ed5112" xlink:href="optn-20221231.xsd#optn_ClassOfWarrantOrRightRestrictionCommonSharesMaximumOwnershipAfterEffectiveWaitingPeriodPercent"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_64862787-3f43-4da8-809e-c16565e9d9f7" xlink:to="loc_optn_ClassOfWarrantOrRightRestrictionCommonSharesMaximumOwnershipAfterEffectiveWaitingPeriodPercent_6d69c386-dce6-43bc-906e-ff3599ed5112" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.optinose.com/role/StockholdersEquityGrantdatefairvalueofwarrantsvaluationassumptionsDetails" xlink:type="simple" xlink:href="optn-20221231.xsd#StockholdersEquityGrantdatefairvalueofwarrantsvaluationassumptionsDetails"/>
  <link:presentationLink xlink:role="http://www.optinose.com/role/StockholdersEquityGrantdatefairvalueofwarrantsvaluationassumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityDisclosureAbstract_d2b035ff-9638-4e11-9a65-1e53907a64d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_59ab6c74-e4f4-45ca-a8a6-a18e7b2669b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityDisclosureAbstract_d2b035ff-9638-4e11-9a65-1e53907a64d2" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_59ab6c74-e4f4-45ca-a8a6-a18e7b2669b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_8fba62a4-3fbb-458e-a630-eeed337cc003" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_59ab6c74-e4f4-45ca-a8a6-a18e7b2669b4" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_8fba62a4-3fbb-458e-a630-eeed337cc003" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_db36615b-6050-48d5-92e4-6743f130c850" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_8fba62a4-3fbb-458e-a630-eeed337cc003" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_db36615b-6050-48d5-92e4-6743f130c850" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_1996c108-530c-40d7-ac62-1ae317cff112" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_db36615b-6050-48d5-92e4-6743f130c850" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_1996c108-530c-40d7-ac62-1ae317cff112" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_daf17837-8e88-4403-b0bc-ed5a4c103ca3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_db36615b-6050-48d5-92e4-6743f130c850" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_daf17837-8e88-4403-b0bc-ed5a4c103ca3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_2de5d485-a47d-4d4c-94d4-82cf47e67f29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_db36615b-6050-48d5-92e4-6743f130c850" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_2de5d485-a47d-4d4c-94d4-82cf47e67f29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_51128778-b5c4-4c0d-a4ea-2200b2c1bbad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_db36615b-6050-48d5-92e4-6743f130c850" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_51128778-b5c4-4c0d-a4ea-2200b2c1bbad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputSharePriceMember_521bf03f-ca5f-4501-9a7a-6a2161a1d6ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputSharePriceMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_db36615b-6050-48d5-92e4-6743f130c850" xlink:to="loc_us-gaap_MeasurementInputSharePriceMember_521bf03f-ca5f-4501-9a7a-6a2161a1d6ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_4f925435-637d-49be-ad03-f458f3cb510c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_59ab6c74-e4f4-45ca-a8a6-a18e7b2669b4" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_4f925435-637d-49be-ad03-f458f3cb510c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_6a92d8ac-5425-4b77-8a6c-fc6eaf9cc048" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_4f925435-637d-49be-ad03-f458f3cb510c" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_6a92d8ac-5425-4b77-8a6c-fc6eaf9cc048" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.optinose.com/role/StockholdersEquityWarrantsOutstandingDetails" xlink:type="simple" xlink:href="optn-20221231.xsd#StockholdersEquityWarrantsOutstandingDetails"/>
  <link:presentationLink xlink:role="http://www.optinose.com/role/StockholdersEquityWarrantsOutstandingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_ae81f266-242b-46d8-ae63-d36fe8e63c39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_21ac55f5-fe31-4ac2-b2e1-6888b8986583" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_ae81f266-242b-46d8-ae63-d36fe8e63c39" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_21ac55f5-fe31-4ac2-b2e1-6888b8986583" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_509b7e95-cb03-4341-ba97-f50d90c14b3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_21ac55f5-fe31-4ac2-b2e1-6888b8986583" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_509b7e95-cb03-4341-ba97-f50d90c14b3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_179832a2-da57-408f-8dee-eb8ab07e12d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_509b7e95-cb03-4341-ba97-f50d90c14b3f" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_179832a2-da57-408f-8dee-eb8ab07e12d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_WarrantsExpiringNovember152024Member_15f0b8a0-7b01-4963-a9e0-775d3c3e3f5a" xlink:href="optn-20221231.xsd#optn_WarrantsExpiringNovember152024Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_179832a2-da57-408f-8dee-eb8ab07e12d1" xlink:to="loc_optn_WarrantsExpiringNovember152024Member_15f0b8a0-7b01-4963-a9e0-775d3c3e3f5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_WarrantsExpiringNovember232027Member_7dec5850-9796-4692-856f-311cd5c90d4a" xlink:href="optn-20221231.xsd#optn_WarrantsExpiringNovember232027Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_179832a2-da57-408f-8dee-eb8ab07e12d1" xlink:to="loc_optn_WarrantsExpiringNovember232027Member_7dec5850-9796-4692-856f-311cd5c90d4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_e2bfe398-dc4e-482f-b79d-5ffeb700e2ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_21ac55f5-fe31-4ac2-b2e1-6888b8986583" xlink:to="loc_us-gaap_ClassOfStockLineItems_e2bfe398-dc4e-482f-b79d-5ffeb700e2ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_6999405f-8be6-4b6b-8784-cc9376d12028" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_e2bfe398-dc4e-482f-b79d-5ffeb700e2ff" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_6999405f-8be6-4b6b-8784-cc9376d12028" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_d5ecce94-cbfb-40eb-a0a5-aedb39a1c0ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_e2bfe398-dc4e-482f-b79d-5ffeb700e2ff" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_d5ecce94-cbfb-40eb-a0a5-aedb39a1c0ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.optinose.com/role/StockbasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="optn-20221231.xsd#StockbasedCompensationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.optinose.com/role/StockbasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2a456ea9-793a-43d5-88af-d477339ac3ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_18921e09-d812-4e84-b7e7-a81ea0fb3792" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2a456ea9-793a-43d5-88af-d477339ac3ea" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_18921e09-d812-4e84-b7e7-a81ea0fb3792" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_82614622-74ab-4909-8dbc-6cbbb409215f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_18921e09-d812-4e84-b7e7-a81ea0fb3792" xlink:to="loc_us-gaap_PlanNameAxis_82614622-74ab-4909-8dbc-6cbbb409215f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_83f4ac11-d10c-4fb6-a06f-dcfb248e061e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_82614622-74ab-4909-8dbc-6cbbb409215f" xlink:to="loc_us-gaap_PlanNameDomain_83f4ac11-d10c-4fb6-a06f-dcfb248e061e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_AmendedandRestated2010StockIncentivePlanMember_33af9df6-221e-41a9-a3ba-d002b010f367" xlink:href="optn-20221231.xsd#optn_AmendedandRestated2010StockIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_83f4ac11-d10c-4fb6-a06f-dcfb248e061e" xlink:to="loc_optn_AmendedandRestated2010StockIncentivePlanMember_33af9df6-221e-41a9-a3ba-d002b010f367" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_NASDAQInducementGrantExceptionMember_07153ec0-42c6-4e7c-9f55-285d99b5693a" xlink:href="optn-20221231.xsd#optn_NASDAQInducementGrantExceptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_83f4ac11-d10c-4fb6-a06f-dcfb248e061e" xlink:to="loc_optn_NASDAQInducementGrantExceptionMember_07153ec0-42c6-4e7c-9f55-285d99b5693a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_TwoThousandSeventeenEmployeeStockPurchasePlanMember_37231a2f-9e1c-4c11-aff9-f9d5c82dd3c0" xlink:href="optn-20221231.xsd#optn_TwoThousandSeventeenEmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_83f4ac11-d10c-4fb6-a06f-dcfb248e061e" xlink:to="loc_optn_TwoThousandSeventeenEmployeeStockPurchasePlanMember_37231a2f-9e1c-4c11-aff9-f9d5c82dd3c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_7b0db9ba-0f49-4bdf-8536-f469387c871e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_18921e09-d812-4e84-b7e7-a81ea0fb3792" xlink:to="loc_us-gaap_AwardTypeAxis_7b0db9ba-0f49-4bdf-8536-f469387c871e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b8cd1087-c610-42e4-be13-1366951f4acd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_7b0db9ba-0f49-4bdf-8536-f469387c871e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b8cd1087-c610-42e4-be13-1366951f4acd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_ServiceBasedStockOptionsMember_1bd6b004-a7ef-459e-82b1-4de92cb3e9eb" xlink:href="optn-20221231.xsd#optn_ServiceBasedStockOptionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b8cd1087-c610-42e4-be13-1366951f4acd" xlink:to="loc_optn_ServiceBasedStockOptionsMember_1bd6b004-a7ef-459e-82b1-4de92cb3e9eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_9c26c306-3a24-4bd5-96c8-41455f1c05f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b8cd1087-c610-42e4-be13-1366951f4acd" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_9c26c306-3a24-4bd5-96c8-41455f1c05f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_RestrictedStockUnitsPerformanceBasedMember_5cb0dbb4-ac2a-4bd4-bbea-601d30124eeb" xlink:href="optn-20221231.xsd#optn_RestrictedStockUnitsPerformanceBasedMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b8cd1087-c610-42e4-be13-1366951f4acd" xlink:to="loc_optn_RestrictedStockUnitsPerformanceBasedMember_5cb0dbb4-ac2a-4bd4-bbea-601d30124eeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_RestrictedStockUnitsServiceBasedMember_157cd6f0-f13f-42aa-af26-1164fa86b407" xlink:href="optn-20221231.xsd#optn_RestrictedStockUnitsServiceBasedMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b8cd1087-c610-42e4-be13-1366951f4acd" xlink:to="loc_optn_RestrictedStockUnitsServiceBasedMember_157cd6f0-f13f-42aa-af26-1164fa86b407" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_MarketBasedStockOptionsMember_3ce3157c-2d10-4c1a-82e3-2a80108ed8ce" xlink:href="optn-20221231.xsd#optn_MarketBasedStockOptionsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b8cd1087-c610-42e4-be13-1366951f4acd" xlink:to="loc_optn_MarketBasedStockOptionsMember_3ce3157c-2d10-4c1a-82e3-2a80108ed8ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_b1a981ba-2ec9-4316-bd43-6a83aa21ecd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_18921e09-d812-4e84-b7e7-a81ea0fb3792" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_b1a981ba-2ec9-4316-bd43-6a83aa21ecd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_034e78a4-d97e-4109-b6c0-8f44a83b6323" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_b1a981ba-2ec9-4316-bd43-6a83aa21ecd6" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_034e78a4-d97e-4109-b6c0-8f44a83b6323" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoriesMember_2d0aae58-9f8c-4982-a56c-1f0aaf00561e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoriesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_034e78a4-d97e-4109-b6c0-8f44a83b6323" xlink:to="loc_us-gaap_InventoriesMember_2d0aae58-9f8c-4982-a56c-1f0aaf00561e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_244febd3-7782-43d6-8990-aeeddbea6999" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_034e78a4-d97e-4109-b6c0-8f44a83b6323" xlink:to="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_244febd3-7782-43d6-8990-aeeddbea6999" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2681e8f8-3512-49d8-bb13-5fffa2a0e18d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_18921e09-d812-4e84-b7e7-a81ea0fb3792" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2681e8f8-3512-49d8-bb13-5fffa2a0e18d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_cb940cd6-d9fe-4ccf-af95-507446a6eeed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2681e8f8-3512-49d8-bb13-5fffa2a0e18d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_cb940cd6-d9fe-4ccf-af95-507446a6eeed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_df40a9b4-fed9-49a5-8ff9-ca03615b146e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2681e8f8-3512-49d8-bb13-5fffa2a0e18d" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_df40a9b4-fed9-49a5-8ff9-ca03615b146e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_CommonStockCapitalSharesReservedforFutureIssuanceYearlyIncrease_d2d8e31c-8dc9-4790-b8e8-d528da5a7122" xlink:href="optn-20221231.xsd#optn_CommonStockCapitalSharesReservedforFutureIssuanceYearlyIncrease"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2681e8f8-3512-49d8-bb13-5fffa2a0e18d" xlink:to="loc_optn_CommonStockCapitalSharesReservedforFutureIssuanceYearlyIncrease_d2d8e31c-8dc9-4790-b8e8-d528da5a7122" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_592b1c61-f122-4f6f-818d-0f2e473e3893" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2681e8f8-3512-49d8-bb13-5fffa2a0e18d" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_592b1c61-f122-4f6f-818d-0f2e473e3893" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_881baac3-51ac-43b1-939b-e8f1f1fa5264" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2681e8f8-3512-49d8-bb13-5fffa2a0e18d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_881baac3-51ac-43b1-939b-e8f1f1fa5264" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_d4a69467-6912-428b-8299-f6841a9f5e92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2681e8f8-3512-49d8-bb13-5fffa2a0e18d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_d4a69467-6912-428b-8299-f6841a9f5e92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_fa54deae-8fe6-4061-a656-b7c3bd0b47ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2681e8f8-3512-49d8-bb13-5fffa2a0e18d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_fa54deae-8fe6-4061-a656-b7c3bd0b47ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_c0a5dd18-f4d5-4297-8dca-c91f5f9b400e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2681e8f8-3512-49d8-bb13-5fffa2a0e18d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_c0a5dd18-f4d5-4297-8dca-c91f5f9b400e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_4ebf74da-6296-4bf2-9c8a-6472bb075310" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2681e8f8-3512-49d8-bb13-5fffa2a0e18d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_4ebf74da-6296-4bf2-9c8a-6472bb075310" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_ea6ab343-ddc7-4f2c-8c93-02ce39565cf4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2681e8f8-3512-49d8-bb13-5fffa2a0e18d" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_ea6ab343-ddc7-4f2c-8c93-02ce39565cf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_6298be41-b60a-42a4-9da9-f7332bd11a2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2681e8f8-3512-49d8-bb13-5fffa2a0e18d" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_6298be41-b60a-42a4-9da9-f7332bd11a2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_b4a373cb-9df1-4f3e-bfdc-dec87767e9e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2681e8f8-3512-49d8-bb13-5fffa2a0e18d" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_b4a373cb-9df1-4f3e-bfdc-dec87767e9e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_5594bc69-1ae4-4f76-9408-e10350526844" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2681e8f8-3512-49d8-bb13-5fffa2a0e18d" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_5594bc69-1ae4-4f76-9408-e10350526844" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_8609c29f-12e7-40cd-b794-8305ce234892" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2681e8f8-3512-49d8-bb13-5fffa2a0e18d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_8609c29f-12e7-40cd-b794-8305ce234892" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_6986d022-5522-4763-9609-56fe90230c6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2681e8f8-3512-49d8-bb13-5fffa2a0e18d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_6986d022-5522-4763-9609-56fe90230c6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_ab6445cb-9895-4148-b3ef-b0f3d984b7dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2681e8f8-3512-49d8-bb13-5fffa2a0e18d" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_ab6445cb-9895-4148-b3ef-b0f3d984b7dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedIncrementEachYear_7e83ae6f-4f85-4753-b4e5-3d25e0b8ae78" xlink:href="optn-20221231.xsd#optn_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedIncrementEachYear"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2681e8f8-3512-49d8-bb13-5fffa2a0e18d" xlink:to="loc_optn_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedIncrementEachYear_7e83ae6f-4f85-4753-b4e5-3d25e0b8ae78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_35e57606-4e0e-487a-a4d5-4dbc4c8e0671" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2681e8f8-3512-49d8-bb13-5fffa2a0e18d" xlink:to="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_35e57606-4e0e-487a-a4d5-4dbc4c8e0671" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeAccruedRightsToPurchaseCommonStock_c8e906c3-3e19-44bc-9924-062e7d4dc7d9" xlink:href="optn-20221231.xsd#optn_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeAccruedRightsToPurchaseCommonStock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2681e8f8-3512-49d8-bb13-5fffa2a0e18d" xlink:to="loc_optn_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeAccruedRightsToPurchaseCommonStock_c8e906c3-3e19-44bc-9924-062e7d4dc7d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_18750214-301e-4484-88c4-ec68ba4bd2cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2681e8f8-3512-49d8-bb13-5fffa2a0e18d" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_18750214-301e-4484-88c4-ec68ba4bd2cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_3d5bebb2-90fb-478f-8ffb-3ada78534ea6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2681e8f8-3512-49d8-bb13-5fffa2a0e18d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_3d5bebb2-90fb-478f-8ffb-3ada78534ea6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.optinose.com/role/StockbasedCompensationServicebasedstockoptionsDetails" xlink:type="simple" xlink:href="optn-20221231.xsd#StockbasedCompensationServicebasedstockoptionsDetails"/>
  <link:presentationLink xlink:role="http://www.optinose.com/role/StockbasedCompensationServicebasedstockoptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7e595fd6-5e18-4b33-b591-9675ea3ab16a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_e169a6b4-27e0-4bd8-8365-2950d97d3f61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7e595fd6-5e18-4b33-b591-9675ea3ab16a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_e169a6b4-27e0-4bd8-8365-2950d97d3f61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0e67f993-b001-4b3f-b658-ca1c4fef7214" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_e169a6b4-27e0-4bd8-8365-2950d97d3f61" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0e67f993-b001-4b3f-b658-ca1c4fef7214" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_170362f1-62d9-40f3-ba3e-fdacfb356d8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_e169a6b4-27e0-4bd8-8365-2950d97d3f61" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_170362f1-62d9-40f3-ba3e-fdacfb356d8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_5070d4dd-d31c-46a0-8985-5ec37fe79c47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_e169a6b4-27e0-4bd8-8365-2950d97d3f61" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_5070d4dd-d31c-46a0-8985-5ec37fe79c47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_877dfa80-522c-44ae-a3ac-c5dea5c31111" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_e169a6b4-27e0-4bd8-8365-2950d97d3f61" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_877dfa80-522c-44ae-a3ac-c5dea5c31111" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_7293e266-541d-4511-9066-95c1a4fd0edd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_e169a6b4-27e0-4bd8-8365-2950d97d3f61" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_7293e266-541d-4511-9066-95c1a4fd0edd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3a0d772b-7290-4864-a07f-2e22b0620af2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_e169a6b4-27e0-4bd8-8365-2950d97d3f61" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3a0d772b-7290-4864-a07f-2e22b0620af2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_8947341c-de7b-440a-9fd5-616f78613583" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7e595fd6-5e18-4b33-b591-9675ea3ab16a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_8947341c-de7b-440a-9fd5-616f78613583" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_148ea89e-f9cd-4d66-abde-631dc7324a55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7e595fd6-5e18-4b33-b591-9675ea3ab16a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_148ea89e-f9cd-4d66-abde-631dc7324a55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_98cd5be3-49bc-49b4-8ad2-3a2b3a03b1ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_148ea89e-f9cd-4d66-abde-631dc7324a55" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_98cd5be3-49bc-49b4-8ad2-3a2b3a03b1ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_3a09081f-f7c4-41bd-aa08-c27680365497" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_148ea89e-f9cd-4d66-abde-631dc7324a55" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_3a09081f-f7c4-41bd-aa08-c27680365497" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_7d290ee0-8b59-4b92-be8a-74d737af199c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_148ea89e-f9cd-4d66-abde-631dc7324a55" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_7d290ee0-8b59-4b92-be8a-74d737af199c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_04588090-db72-40c3-9e66-5743de3c48a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_148ea89e-f9cd-4d66-abde-631dc7324a55" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_04588090-db72-40c3-9e66-5743de3c48a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_690cc8ac-c856-48a0-a374-f159d814560a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_148ea89e-f9cd-4d66-abde-631dc7324a55" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_690cc8ac-c856-48a0-a374-f159d814560a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_9934607b-9665-4063-bca9-97bd515c7c92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_148ea89e-f9cd-4d66-abde-631dc7324a55" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_9934607b-9665-4063-bca9-97bd515c7c92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_d90bf362-e065-49cb-b8a5-6500b3bc5658" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7e595fd6-5e18-4b33-b591-9675ea3ab16a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_d90bf362-e065-49cb-b8a5-6500b3bc5658" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_537f01ea-4045-40cd-94fc-cc687eaeffa2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7e595fd6-5e18-4b33-b591-9675ea3ab16a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_537f01ea-4045-40cd-94fc-cc687eaeffa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_f825239f-32ad-453b-ab9b-c9a14d92c879" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_537f01ea-4045-40cd-94fc-cc687eaeffa2" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_f825239f-32ad-453b-ab9b-c9a14d92c879" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_76e90252-84b7-4e02-8e5b-951bd7d6945f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_537f01ea-4045-40cd-94fc-cc687eaeffa2" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_76e90252-84b7-4e02-8e5b-951bd7d6945f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.optinose.com/role/StockbasedCompensationScheduleofRSUsDetails" xlink:type="simple" xlink:href="optn-20221231.xsd#StockbasedCompensationScheduleofRSUsDetails"/>
  <link:presentationLink xlink:role="http://www.optinose.com/role/StockbasedCompensationScheduleofRSUsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7ef8838f-7aa6-4d7e-9cfe-cb492fad180c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_acc81893-65a4-4beb-a022-0e0cff6cfd85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7ef8838f-7aa6-4d7e-9cfe-cb492fad180c" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_acc81893-65a4-4beb-a022-0e0cff6cfd85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_8e95bfda-675b-4469-bf5d-5e5fdfbab2ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_acc81893-65a4-4beb-a022-0e0cff6cfd85" xlink:to="loc_us-gaap_AwardTypeAxis_8e95bfda-675b-4469-bf5d-5e5fdfbab2ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3b0ee265-c28c-4999-bef1-23ac9f92639f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_8e95bfda-675b-4469-bf5d-5e5fdfbab2ac" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3b0ee265-c28c-4999-bef1-23ac9f92639f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_13d9e043-24a1-4244-8f22-11be637f1167" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3b0ee265-c28c-4999-bef1-23ac9f92639f" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_13d9e043-24a1-4244-8f22-11be637f1167" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_73c64eff-9fce-4a56-a12b-dc232ff9f4dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_acc81893-65a4-4beb-a022-0e0cff6cfd85" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_73c64eff-9fce-4a56-a12b-dc232ff9f4dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_31b98a8a-352f-4cf1-bf36-2b59c7df6162" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_73c64eff-9fce-4a56-a12b-dc232ff9f4dd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_31b98a8a-352f-4cf1-bf36-2b59c7df6162" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_7891b3f4-e66e-4c6f-9a85-0471a72651fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_31b98a8a-352f-4cf1-bf36-2b59c7df6162" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_7891b3f4-e66e-4c6f-9a85-0471a72651fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_9a29f43a-7de9-4dde-a1cf-6530d22511d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_31b98a8a-352f-4cf1-bf36-2b59c7df6162" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_9a29f43a-7de9-4dde-a1cf-6530d22511d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_c0b95973-75f0-4e66-b1b1-6b550e75178a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_31b98a8a-352f-4cf1-bf36-2b59c7df6162" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_c0b95973-75f0-4e66-b1b1-6b550e75178a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_30be3239-2c46-43d0-bb56-041eb104f2df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_31b98a8a-352f-4cf1-bf36-2b59c7df6162" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_30be3239-2c46-43d0-bb56-041eb104f2df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4b13b215-fda6-44d5-8fdd-974293549882" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_31b98a8a-352f-4cf1-bf36-2b59c7df6162" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4b13b215-fda6-44d5-8fdd-974293549882" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestNumber_d303a5a7-b645-4942-b6ab-e7f02a9bc889" xlink:href="optn-20221231.xsd#optn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_31b98a8a-352f-4cf1-bf36-2b59c7df6162" xlink:to="loc_optn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestNumber_d303a5a7-b645-4942-b6ab-e7f02a9bc889" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.optinose.com/role/StockbasedCompensationStockbasedcompensationexpenseDetails" xlink:type="simple" xlink:href="optn-20221231.xsd#StockbasedCompensationStockbasedcompensationexpenseDetails"/>
  <link:presentationLink xlink:role="http://www.optinose.com/role/StockbasedCompensationStockbasedcompensationexpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8068e3b1-ff0c-4eba-846c-d48616ceb35d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_a116fc2f-d914-414f-9052-c2ecddcb0f9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8068e3b1-ff0c-4eba-846c-d48616ceb35d" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_a116fc2f-d914-414f-9052-c2ecddcb0f9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_70d53fc7-c817-45e2-920b-ad347e6e15de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_a116fc2f-d914-414f-9052-c2ecddcb0f9f" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_70d53fc7-c817-45e2-920b-ad347e6e15de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_4dc8fbfb-1d5b-40b6-99e7-83df4d7b93bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_70d53fc7-c817-45e2-920b-ad347e6e15de" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_4dc8fbfb-1d5b-40b6-99e7-83df4d7b93bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_269038bb-5b08-481b-befe-e1d3c653f5e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_4dc8fbfb-1d5b-40b6-99e7-83df4d7b93bd" xlink:to="loc_us-gaap_CostOfSalesMember_269038bb-5b08-481b-befe-e1d3c653f5e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1d0b1eec-e6ef-4c19-9a6c-2ac919d315e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_4dc8fbfb-1d5b-40b6-99e7-83df4d7b93bd" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1d0b1eec-e6ef-4c19-9a6c-2ac919d315e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_09958804-6a46-43c2-ac4c-cfe06471ad14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_4dc8fbfb-1d5b-40b6-99e7-83df4d7b93bd" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_09958804-6a46-43c2-ac4c-cfe06471ad14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_de2a243d-ad69-4a11-8a5a-12c6dcfd425b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_a116fc2f-d914-414f-9052-c2ecddcb0f9f" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_de2a243d-ad69-4a11-8a5a-12c6dcfd425b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_a89cf20c-4284-41d6-972d-22675dc46239" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_de2a243d-ad69-4a11-8a5a-12c6dcfd425b" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_a89cf20c-4284-41d6-972d-22675dc46239" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.optinose.com/role/StockbasedCompensationBlackScholespricingmodeloptionsDetails" xlink:type="simple" xlink:href="optn-20221231.xsd#StockbasedCompensationBlackScholespricingmodeloptionsDetails"/>
  <link:presentationLink xlink:role="http://www.optinose.com/role/StockbasedCompensationBlackScholespricingmodeloptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3f275402-a9bd-483d-bb69-f7c737e6df99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5786bb46-42c5-4976-92fc-bf92c9fa86ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3f275402-a9bd-483d-bb69-f7c737e6df99" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5786bb46-42c5-4976-92fc-bf92c9fa86ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_92e6c664-9199-4771-872f-02816bea9216" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5786bb46-42c5-4976-92fc-bf92c9fa86ed" xlink:to="loc_us-gaap_AwardTypeAxis_92e6c664-9199-4771-872f-02816bea9216" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d0bfd77e-14c2-4c3f-90c0-422b8492958a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_92e6c664-9199-4771-872f-02816bea9216" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d0bfd77e-14c2-4c3f-90c0-422b8492958a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_e2f2839a-225e-4544-bd02-6f028d0cb438" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d0bfd77e-14c2-4c3f-90c0-422b8492958a" xlink:to="loc_us-gaap_EmployeeStockOptionMember_e2f2839a-225e-4544-bd02-6f028d0cb438" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_e5ba88ca-675e-48c6-b8de-a4904ec64956" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5786bb46-42c5-4976-92fc-bf92c9fa86ed" xlink:to="loc_us-gaap_PlanNameAxis_e5ba88ca-675e-48c6-b8de-a4904ec64956" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_60ba95e7-c60d-4e4d-9125-a10c7d68266f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_e5ba88ca-675e-48c6-b8de-a4904ec64956" xlink:to="loc_us-gaap_PlanNameDomain_60ba95e7-c60d-4e4d-9125-a10c7d68266f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_TwoThousandSeventeenEmployeeStockPurchasePlanMember_b4123aa8-9962-499b-ba44-fc0ff6cabd2e" xlink:href="optn-20221231.xsd#optn_TwoThousandSeventeenEmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_60ba95e7-c60d-4e4d-9125-a10c7d68266f" xlink:to="loc_optn_TwoThousandSeventeenEmployeeStockPurchasePlanMember_b4123aa8-9962-499b-ba44-fc0ff6cabd2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d2d514f6-386f-4c2d-8301-68836bdc85db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5786bb46-42c5-4976-92fc-bf92c9fa86ed" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d2d514f6-386f-4c2d-8301-68836bdc85db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_ccb42404-dc5a-4624-8f06-7e347e45e939" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d2d514f6-386f-4c2d-8301-68836bdc85db" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_ccb42404-dc5a-4624-8f06-7e347e45e939" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_df3aa0de-8973-4919-b55a-6c1034202fa7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d2d514f6-386f-4c2d-8301-68836bdc85db" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_df3aa0de-8973-4919-b55a-6c1034202fa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_6924af8a-30b8-46d8-9c0b-0c4291cba855" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d2d514f6-386f-4c2d-8301-68836bdc85db" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_6924af8a-30b8-46d8-9c0b-0c4291cba855" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_2e29916d-0ce9-4a8b-8ddb-c48a864e0aab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d2d514f6-386f-4c2d-8301-68836bdc85db" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_2e29916d-0ce9-4a8b-8ddb-c48a864e0aab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.optinose.com/role/IncomeTaxesScheduleofincomebeforeincometaxdomesticandforeignDetails" xlink:type="simple" xlink:href="optn-20221231.xsd#IncomeTaxesScheduleofincomebeforeincometaxdomesticandforeignDetails"/>
  <link:presentationLink xlink:role="http://www.optinose.com/role/IncomeTaxesScheduleofincomebeforeincometaxdomesticandforeignDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_a22cc944-a57d-4140-8b40-ee1cbfa002e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_a2e06a23-c2da-42b2-ac3f-30f8c705f2a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_a22cc944-a57d-4140-8b40-ee1cbfa002e6" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_a2e06a23-c2da-42b2-ac3f-30f8c705f2a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_09a39d0b-81d4-476c-b716-b066e6e560a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_a22cc944-a57d-4140-8b40-ee1cbfa002e6" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_09a39d0b-81d4-476c-b716-b066e6e560a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_df849f76-c897-4be5-bc5a-4851df8bd0cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_a22cc944-a57d-4140-8b40-ee1cbfa002e6" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_df849f76-c897-4be5-bc5a-4851df8bd0cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.optinose.com/role/IncomeTaxesScheduleofeffectiveincometaxratereconciliationDetails" xlink:type="simple" xlink:href="optn-20221231.xsd#IncomeTaxesScheduleofeffectiveincometaxratereconciliationDetails"/>
  <link:presentationLink xlink:role="http://www.optinose.com/role/IncomeTaxesScheduleofeffectiveincometaxratereconciliationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_44f7cc01-fad4-4af3-ab1e-134680229c8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_7690de4e-1f25-416b-bef8-726aad4d4b1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_44f7cc01-fad4-4af3-ab1e-134680229c8a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_7690de4e-1f25-416b-bef8-726aad4d4b1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_38417630-5636-43d8-8dcb-e29207edf60a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_44f7cc01-fad4-4af3-ab1e-134680229c8a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_38417630-5636-43d8-8dcb-e29207edf60a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_5a0a65dc-a9d2-4a29-8c61-22d28ec2564c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_44f7cc01-fad4-4af3-ab1e-134680229c8a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_5a0a65dc-a9d2-4a29-8c61-22d28ec2564c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_EffectiveIncomeTaxRateReconciliationForeignOperationsImpactPercent_8b5813a7-4719-45ab-ac80-cd7bb51ca6b8" xlink:href="optn-20221231.xsd#optn_EffectiveIncomeTaxRateReconciliationForeignOperationsImpactPercent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_44f7cc01-fad4-4af3-ab1e-134680229c8a" xlink:to="loc_optn_EffectiveIncomeTaxRateReconciliationForeignOperationsImpactPercent_8b5813a7-4719-45ab-ac80-cd7bb51ca6b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_175c68ac-28b9-4cbf-98b4-bbd86d739fc1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_44f7cc01-fad4-4af3-ab1e-134680229c8a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_175c68ac-28b9-4cbf-98b4-bbd86d739fc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_dd33f0fa-5e3d-4ed8-adac-e07601542e1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_44f7cc01-fad4-4af3-ab1e-134680229c8a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_dd33f0fa-5e3d-4ed8-adac-e07601542e1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_EffectiveIncomeTaxRateReconciliationForeignExchangeOtherPercent_dafcf260-603e-4e69-a5a6-72a05138248e" xlink:href="optn-20221231.xsd#optn_EffectiveIncomeTaxRateReconciliationForeignExchangeOtherPercent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_44f7cc01-fad4-4af3-ab1e-134680229c8a" xlink:to="loc_optn_EffectiveIncomeTaxRateReconciliationForeignExchangeOtherPercent_dafcf260-603e-4e69-a5a6-72a05138248e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_5451252d-d8f1-4d43-83c8-b018c7a80374" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_44f7cc01-fad4-4af3-ab1e-134680229c8a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_5451252d-d8f1-4d43-83c8-b018c7a80374" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_EffectiveIncomeTaxRateReconciliationPrepaidRoyaltyWriteOffPercent_ff5bb5e7-8119-4c4a-a19b-7b5a057e81c7" xlink:href="optn-20221231.xsd#optn_EffectiveIncomeTaxRateReconciliationPrepaidRoyaltyWriteOffPercent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_44f7cc01-fad4-4af3-ab1e-134680229c8a" xlink:to="loc_optn_EffectiveIncomeTaxRateReconciliationPrepaidRoyaltyWriteOffPercent_ff5bb5e7-8119-4c4a-a19b-7b5a057e81c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_d507ad5e-5cf4-4a40-a7ee-2ae472c1532d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_44f7cc01-fad4-4af3-ab1e-134680229c8a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_d507ad5e-5cf4-4a40-a7ee-2ae472c1532d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_dd8034aa-34f6-4334-becb-b42113b062b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_44f7cc01-fad4-4af3-ab1e-134680229c8a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_dd8034aa-34f6-4334-becb-b42113b062b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.optinose.com/role/IncomeTaxesScheduleofdeferredtaxassetsandliabilitiesDetails" xlink:type="simple" xlink:href="optn-20221231.xsd#IncomeTaxesScheduleofdeferredtaxassetsandliabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.optinose.com/role/IncomeTaxesScheduleofdeferredtaxassetsandliabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_1dfc39ab-a2c6-433c-9178-d155eeb847a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_f37063eb-8322-450b-ac80-7601115ae827" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1dfc39ab-a2c6-433c-9178-d155eeb847a0" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_f37063eb-8322-450b-ac80-7601115ae827" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpense_ff14b534-0aa9-4659-88aa-bd78a4ec6cd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_f37063eb-8322-450b-ac80-7601115ae827" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpense_ff14b534-0aa9-4659-88aa-bd78a4ec6cd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_DeferredTaxAssetsPrepaidLicenseArrangement_83ccb343-f85d-4431-accb-c000e7067885" xlink:href="optn-20221231.xsd#optn_DeferredTaxAssetsPrepaidLicenseArrangement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_f37063eb-8322-450b-ac80-7601115ae827" xlink:to="loc_optn_DeferredTaxAssetsPrepaidLicenseArrangement_83ccb343-f85d-4431-accb-c000e7067885" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_DeferredTaxAssetsInterestExpense_cbabd376-7169-4d84-8a3d-74d30632a91c" xlink:href="optn-20221231.xsd#optn_DeferredTaxAssetsInterestExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_f37063eb-8322-450b-ac80-7601115ae827" xlink:to="loc_optn_DeferredTaxAssetsInterestExpense_cbabd376-7169-4d84-8a3d-74d30632a91c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_c01eada6-1de9-4a11-b547-3032aa5d4765" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_f37063eb-8322-450b-ac80-7601115ae827" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_c01eada6-1de9-4a11-b547-3032aa5d4765" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_DeferredTaxAssetsLeasingArrangement_566f75a4-df6a-4f51-892f-6aea009c24bf" xlink:href="optn-20221231.xsd#optn_DeferredTaxAssetsLeasingArrangement"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_f37063eb-8322-450b-ac80-7601115ae827" xlink:to="loc_optn_DeferredTaxAssetsLeasingArrangement_566f75a4-df6a-4f51-892f-6aea009c24bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_bf4562f4-6299-4b29-aadb-c4b5057b1cad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_f37063eb-8322-450b-ac80-7601115ae827" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_bf4562f4-6299-4b29-aadb-c4b5057b1cad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_DeferredTaxAssetsFinancingCosts_9f3f2f8a-fb57-4bd8-9803-354f280fd5fe" xlink:href="optn-20221231.xsd#optn_DeferredTaxAssetsFinancingCosts"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_f37063eb-8322-450b-ac80-7601115ae827" xlink:to="loc_optn_DeferredTaxAssetsFinancingCosts_9f3f2f8a-fb57-4bd8-9803-354f280fd5fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_ac5eb8d1-6ab4-437d-b0b9-55b6d22cebee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_f37063eb-8322-450b-ac80-7601115ae827" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_ac5eb8d1-6ab4-437d-b0b9-55b6d22cebee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_b2d6ef73-e3da-4c9f-a621-9b75a8f76365" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_f37063eb-8322-450b-ac80-7601115ae827" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_b2d6ef73-e3da-4c9f-a621-9b75a8f76365" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_33c5ac13-e4c5-4ac9-b726-ee60700c7873" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1dfc39ab-a2c6-433c-9178-d155eeb847a0" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_33c5ac13-e4c5-4ac9-b726-ee60700c7873" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_fe0cd48d-2017-4535-b3d2-e2c8e43779cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_33c5ac13-e4c5-4ac9-b726-ee60700c7873" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_fe0cd48d-2017-4535-b3d2-e2c8e43779cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_46ecdc38-437e-41ad-b448-9a7854eacd1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_33c5ac13-e4c5-4ac9-b726-ee60700c7873" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_46ecdc38-437e-41ad-b448-9a7854eacd1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_b23f1dae-0c4f-4ff7-a6c2-d94190d5a7b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_33c5ac13-e4c5-4ac9-b726-ee60700c7873" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_b23f1dae-0c4f-4ff7-a6c2-d94190d5a7b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_e50cd8e2-b023-4b7f-9ede-0f5f5bbc6ab6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1dfc39ab-a2c6-433c-9178-d155eeb847a0" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_e50cd8e2-b023-4b7f-9ede-0f5f5bbc6ab6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_99de24b5-7ef9-4189-82c8-378666ace512" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1dfc39ab-a2c6-433c-9178-d155eeb847a0" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_99de24b5-7ef9-4189-82c8-378666ace512" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.optinose.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="optn-20221231.xsd#IncomeTaxesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.optinose.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_2dc70a49-a000-404c-8aab-30a1ec3e5772" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_666ea1d4-4539-46d5-993b-6d5d84a738b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2dc70a49-a000-404c-8aab-30a1ec3e5772" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_666ea1d4-4539-46d5-993b-6d5d84a738b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_67a11224-871c-4c62-a7e4-ccfe8d4a4218" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_666ea1d4-4539-46d5-993b-6d5d84a738b8" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_67a11224-871c-4c62-a7e4-ccfe8d4a4218" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_c1ac6684-1bd7-4e7a-92ad-b347c2df2362" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_67a11224-871c-4c62-a7e4-ccfe8d4a4218" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_c1ac6684-1bd7-4e7a-92ad-b347c2df2362" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_0d060e17-1929-40ad-89b1-cea1c64168c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_c1ac6684-1bd7-4e7a-92ad-b347c2df2362" xlink:to="loc_us-gaap_ForeignCountryMember_0d060e17-1929-40ad-89b1-cea1c64168c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_c7ae0c7b-ed75-4743-820f-ed1cbd8ae110" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_c1ac6684-1bd7-4e7a-92ad-b347c2df2362" xlink:to="loc_us-gaap_DomesticCountryMember_c7ae0c7b-ed75-4743-820f-ed1cbd8ae110" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_5028cd02-e0e7-4545-8f2d-5eaa2a5949e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_c1ac6684-1bd7-4e7a-92ad-b347c2df2362" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_5028cd02-e0e7-4545-8f2d-5eaa2a5949e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_e50b1a38-241f-4b7c-bd59-503e070fe486" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_666ea1d4-4539-46d5-993b-6d5d84a738b8" xlink:to="loc_us-gaap_OperatingLossCarryforwardsLineItems_e50b1a38-241f-4b7c-bd59-503e070fe486" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_f31a2b50-2cf3-42f2-b32f-c8ae81b8ec88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_e50b1a38-241f-4b7c-bd59-503e070fe486" xlink:to="loc_us-gaap_OperatingLossCarryforwards_f31a2b50-2cf3-42f2-b32f-c8ae81b8ec88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_3a01d254-4e23-449c-85d6-40c571c92ffa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_e50b1a38-241f-4b7c-bd59-503e070fe486" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_3a01d254-4e23-449c-85d6-40c571c92ffa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_optn_DeferredTaxAssetsTaxCreditCarryforwardsResearchTerm_d5950c99-9f9e-4515-97ca-73b30617df11" xlink:href="optn-20221231.xsd#optn_DeferredTaxAssetsTaxCreditCarryforwardsResearchTerm"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_e50b1a38-241f-4b7c-bd59-503e070fe486" xlink:to="loc_optn_DeferredTaxAssetsTaxCreditCarryforwardsResearchTerm_d5950c99-9f9e-4515-97ca-73b30617df11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_5aa43f10-fab3-4628-8e51-e7db815d273b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_e50b1a38-241f-4b7c-bd59-503e070fe486" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_5aa43f10-fab3-4628-8e51-e7db815d273b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_90554450-23ce-4bb0-ab55-2e6bae9f9428" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_e50b1a38-241f-4b7c-bd59-503e070fe486" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_90554450-23ce-4bb0-ab55-2e6bae9f9428" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>optn-20221231_g1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 optn-20221231_g1.jpg
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M:&]P(#,N,  X0DE-! 0       \< 5H  QLE1QP"   "  ( .$))300E
M   0_.$?B<BWR7@O-&(T!UAWZ__N  Y!9&]B90!DP     '_VP"$  8$! 0%
M! 8%!08)!@4&"0L(!@8("PP*"@L*"@P0# P,# P,$ P.#Q /#@P3$Q04$Q,<
M&QL;'!\?'Q\?'Q\?'Q\!!P<'#0P-&! 0&!H5$14:'Q\?'Q\?'Q\?'Q\?'Q\?
M'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'__  !$( $<!%@,!
M$0 "$0$#$0'_Q "Z   " @,! 0              !P4& P0( @$!  $% 0$
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M9UPD-Q8C*9G7W2011/.O?V)3;&%QH!4I;G "I2MO'Q):0BO$U;H4JXH*X=;
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MK)Y6.. 8FK!HG;;6":IM4F9:7F(<:4T\^XZ@@B"T:&O E15Y=E=N[^+Z;@'
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@]&3A58_%7S:^*MH\-/+2G!9Z2EHH0BA"*$(H0BA"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>optn-20221231_g2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 optn-20221231_g2.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MO#OVL]7TG0/^#@?2=:UW4[>RL[7Q?X8DN;N[G6.*%!869+,S$!0/4G%?>_\
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M"&TEM_$7A'X6>&X_%+6&5EELDL;<PWJE>?,@? +=?+8'($5 %O\ ;^_Y3O\
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MXF\ :/JFH^(/%UU!>7.I:=%.SVT,4"QP?.I^0,9&QZN3Z4 ?1O[4_P#P49^
M/['WPQT+QY\8TU:WU7Q)IZ76D^#+:WC?5&RBLRR)O\N((6"LS/MW A2Q&*^<
MOAQ_P<2?LV^(_%EOHOQ&^#OBGPQIMU(%36A+%>1P@G'F21IM<(,<E Y] :\&
M_:FTG2_CE_P7VTSX9_&^)+OP];:[H]A:Z;>\PR6RZ?%<QP$'ADEGD;*]&,S#
MO7V;_P %G/A5\+?$G_!/;Q=K7B7P_I\5SX5@M+CPS>"!%>QF^U0Q".(X^575
MS&5'!##C(! !]):C\7/AEI7PMD^-M]XXTY?"46C_ -JMKZW :V-GL\P3!ESN
M4KR,9)R  2<5\.S?\'#G[.LOCB?2]$^!?C>_\-VDN+KQ%"D(D2+./.^SEN$[
MC<ZG'4 \5\T:7\0/B->?\&_&IZ/=7=R;&V^*":5 S,?^0=YL-UMS_=^TLP].
MU?;_ /P1'\!> =(_X)S^%=5T31K-KGQ)<:G/XDF\I2UW,M]<0!9>.0L,<:!3
MQC_>Y /CC_@G/X\\*_%+_@MYXL^)/@?5!>Z-KU]XDO\ 2[L1LGG02[W1MK ,
MN5(X(!'>ONH_\%._AH/V]/\ A@7_ (5QKO\ ;WV[[-_;GFP_9-WV'[9G&[?C
M;\O3K[5\(_\ !-_PIX4\"_\ !;WQEX+\"P10Z-I6L>*K33+>#'EPP1R2JD:X
M_A4 */9:VI76/_@Y!#.< ^(@.?4^'L"@#[T_;T_;Z\"?L"^$- \8>._ VKZY
M#K^I26<$6D21*T3)'O+-YC 8QQQ7;R?M.?"S0_V9]/\ VK/B!K \.^%[WPO9
MZY-+J!W/;Q7,,<D<1"9WR$R*@5<EF( SD5\._P#!R)<PK\&?AI:,X\Q_$]XZ
MKGDA;=03_P"/#\ZXO_@K'K_B"P_X)/\ [./A^QFD33M0TK0GU#82 [QZ(IB5
MO4?,[8/=0>U 'HNK_P#!Q=\"8-<F_P"$?_9U\9WVA03B-]7DN;>*3!)P?*RR
M@G&0#("?:O9/C=_P5#^!_P#PP1J/[6GPEN=6U2PU"9M#AAM-EO?:3J,T3A1,
MK-B-XR4<[2<@JRE@03TO[#_P?^"^H?\ !-'P)\/+[PYIK^&O$?PWM9_$L+HJ
MQW$MU:K)>22-_>\QGRQY7:.1M&*/PV^!W[%'P>_92^)&E?L<2:!=:3?>&+VX
MU2;1O%+:LDLJV<P21G::4*<;L8QG'L, 'Y]?\$5/V\]&^"OQDUCX6?$71M=\
M0:[\7O%>CVEOK?VM9#%/YDT;2W#2MO?+7"DD9)VFOV>K\O/^#;*TM)] ^+DT
M]M&[QWVB&-G0$J=E[T/:OU#H **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M ^+O^"M'[)7[:O[:NFZ)\)?@7J'AG3_!-D1?:Q_:NM2P3ZC>@D1JR)"X\J)?
MF&3\SN21\BFO:?V0_P!BOX:_LN_LL6?[-9TJTU6"\L)1XPGF@RFL75Q'MN6<
M'JA'[M5/2-%!R02?:** /S?_ &7O^"77[8O[#/[;-U\4_@#XD\-ZE\-KO4'M
M;S2]3UN6*ZNM'D8-Y;IY)4SPG!1]PW-'R55V%=)\9_\ @FC^T5X^_P""L6F?
MMJ:'>^&QX.M/$6B7TL4^IR+>^5:6MO%+B,1%<[HFP-W(QTK[\HH J>(+&;4]
M!OM-MBHDN+26*,L<#<RD#/YU\$?\$L/^"<G[5?["5_\ $?Q5XS/A.]U'7/#"
M6_AJWL=7EDC>]B,CHLS&%2D98J"PW$#/%?H%10!\#?\ !+?_ ()<?&;]F7X[
M>+_V@_VIM3T#5]<U6P:#2GTZ\>[+2W$QEN[B0R1)M<E$ (SD22=._P!N>,_A
MKX(\?>$-5\"^)O#EK/INM:;/8ZA#Y"CS(9HVC=<XXRK$5NT4 ? ?_!*[_@G9
M^UQ^P9\>/$]QXQUSPUJ'@/Q'I[6\W]GZK*;@S0REK2X,31  [&E4KNX\[J=O
M.C_P2W_X)R_M _L=?M#^/_BC\6KSP])IGB;3I(-.72-2DFE#-=B8;U:) HVC
ML3S7W710!\8_\%:_^"8VJ_MR:/H/CWX/S:58>.]#?[)+-JDS0PW^G,2WENZ(
MQ#1N2R<8Q)(#U&/1?^"7W[+7Q*_9 _92M/@M\6IM+EU>'6[VZD.DW330F.5@
M5&YD4YP.1BOHFB@#\T/VD?\ @B[\=?AK\<;C]HK_ ()O_%:'PS<W$\DY\/2:
MC)8RV+2'+QVTRJ4D@8_\L9-H4<988 X^7_@DM_P4S_;&\>Z7??MS_'ZWM]#T
MM\9DU=;V>.,XWBVMX5$".P !=BIX!(? %?J_10!X5^T'^R1!JW[ ^N_L>?L^
MZ;9:>C>%4TGP_#?W!2)=KH=TL@5B6;#,S8)9F)/6O@;X/_\ !*[_ (+$_L_^
M';CPE\%?VA-!\,Z9=WK7ES9:3XNN(HY)RB(9"!;<L51!GT45^MU% 'YA6/[$
MW_!>.*]ADNOVQK5HEE4R+_PFUR<KGD?\>WI7Z>T44 ?)G_!77]BGXQ?MP?!C
MPSX!^#%SHT5]I'B?^T+LZW>O!&8OLTL?RE(W);<XXP.,U[G^SY\);KP%^RSX
M)^!?Q'L;&]GT;P#IVA:[;)^^MKAHK*.WF0;@-\;%6'(&0>1VKT"B@#\L?!/_
M  0Y^.GP;_;N\/\ Q=^&FO>')_AUX>^(-AK%@E[JDJW\=A%<QS-"4\HAG0!D
M!W_/M#';NP/HO_@J3_P3&U/]ME]"^+/P?\86OA_XA^%X?(L[J]>2."^MQ(94
MC:2,,\,D<A=T< \NP(Y#+]AT4 ?E]XW_ &%?^"S7[8'_  CWPQ_:A^-OA_1_
M"^@WR7+:I:74'G22*K(+C9:1JT\P1F"AVC7YB20237UY^U5^P^?C+^P->_L=
M> O%DL=W;:38PZ+K'B&ZDG::XM9HI0]S)@L3*8V#, =OF$A< +7T+10!\%_\
M$IOV5/\ @I'^ROXJB^'7QU\2Z-%\*]+TZ^&GZ%:ZA;SN+R:9)!+&T<7F%=WF
M'#N /,)"Y-?>E%% 'P'^SA_P30_:+^%/_!4OQ)^V/XGO?#;>$M6\1>(;ZUCM
M=3D>\$5Z9S#NC,04']XNX;CCGK7WY110!X[^W]\"?&W[3'[(/C3X&_#F6Q36
MM?M+:.Q?4IVB@#1W<,S;F56(^6-NQYQ7*_\ !+;]E;XF_L=?LL1?!OXM3Z7)
MJZ>(+R]9M(NVFA\N79M^9D0Y^4Y&*^C** /BK_@IM_P2FU/]KSQCIG[0?P%\
M=6_ACXBZ/!%$9+N22*"_6%M\#^;$"\$\9X60*V0%!V[0:\'\7_\ !/+_ (+'
M_MAQ:7\*OVN/V@]'M?!NG7:22R&ZMY#)M^42>59PH;J0 G;Y[#DD[@2<_J;1
M0!XC<_L#? Q_V*)?V%[*SG@\+/HWV1;SY6N1<^9YPO2<8,OV@"7H%S\N O%?
M$?P6_P""=_\ P60_9:GU3X&_L]_M#>&],\$:K>O(^LM=1/'$& 5IHXIH))K>
M4H!D1<;@/G. U?J510!^=G[!O_!)/X\?LA?MU'XV:WXRTC6_"5OIU[;QZE)?
MR?VA=RS0A3*\1CPNZ0L<>8Q (R6/)7_@H7_P2[_:@\:?M>VW[;G[%OC'3;;Q
M$[VEQ=V5[>+;S6U[;Q)"D\1D4Q21M%&@='QR&X<.0/T2HH _+C]IG_@E;_P4
MT_;$\%:5X[_:"^/'AC6?&5C?"#3/#:3"UT[2]/:-S,^Z&W"O</*L .U2-J<N
MV%5/KGXJ_L$:-^T1^P!X6_9$^*NIQV.KZ!X5TB"TUFQ7SEL-4L[-(?.0-M\R
M,GS$(.TLDC8VD@CZ.HH _*+1/^"?G_!;/X8?#.\_90^'GQNT(_#Z\2:UW0ZS
M"(DMI2?,5));?[7 C;FW)'@?,V,Y.?L#]@3_ ()O>&?V-_V;=?\ A)K7B./5
MO$'C6&0>+=9LXBD9#0O$D$(;DQQK(^&8 LTCL0H(5?IVB@#\M_V+O^";G_!4
M7]BO]H"+3_AUX\\-0^ M1\3:;-XPNK>_A9-7TZVN"Q0)+"TT,AB>5<)MY?!<
M@ U^I%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 '@9K\\?\
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M -D#3K'X7:?;+-/XB\0V;SS7BKA9;@0I<QNEOOW<JKA5&3)P< 'Z745\Y?\
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MGF(/0.<=JDM;'2?V4_\ @X*B\,_#2PBTO1=8\1VUL^FV:".'R]3TV-Y(PBX
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M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 #=#]*_#/\
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M[^R9^VIX3\)>'+/7+N&Y\.7WA>TN[BTNLJ[-(\EI(QWJR.,L?E( QC%>E?\
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M->>:ZU2XA6.6]GED9WE<*2 >0H&3A44=J /R?^*6@?'+_A^7XAT/X;?%33O
M_C._\5W"^'/$FO6$=S! )]./D)Y<L<BL98'6),J?FD7&#@CU#]NS]C_]JWXA
MMX6\'?MX_P#!3'X4VY\VZN/#$6NZ7!I?.(UF820VL7R\Q@[VQG&.17UY^WM_
MP2L^"W[<^KV7C^\\2W_A+QEI]NMO#XCTJ!91/$I+(L\+%?,*$G:RNC#."2
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M@ *J*,*!W8LS 'YP_P#! 6>/X5_MG?$OX)>+9EM=8_L":U6VF.UGGLKU4EC
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6-IGQ
M$\"ZUXSU+X=Z3XLL+C7='MX)]4TJ*X5I[6*8N(F=>H#>6^/]TU\]?\%?_B?\
M2?A/^PWXA\0?#/6[S29[S4K'3]4UO3PWG:=8SSJDTJ%>5)!$>1@CS>"#@CYM
M\-_\$ROV>/B/\4/B'X;_ &3/%DFB:SX;\&>#M8^'7Q"L?$5Q,R7MQ)J9N+IY
M8W(E$X@3=@84J-@7!! /TPHKQ#XW_L9+^U#X$\%Z3\9OC7XTT?6_#6FE-2U#
MX=Z[_9<6I7<D4*SR.IC?*;XBR+QM#L.<U\4?'/\ 8ETV?]KCPE^QA^S-^T[\
M9;O7Y8/[9^(FM:QX]>XM_#^C#  V1QH3<2EEV!FP-\>01)N4 _4:BOFW]J3]
MF'X[_M!_$;P%\(-/^(FI:%\&=+TR23QM-HVO/;ZOK-PBE(+5W4;O)^5"S _,
M7?(RJ,/)?#WA&U_8C_X*2_#3]GG]FOXB>(-1\+>/=#U*3QIX!U77Y=1BT98(
M3)!?H9F9K<NPQDGYA&PR=R@ 'W9117P9XLO/#?[</[3?Q1G_ &D?CI<^$O@E
M\(]9C\,V6B0^*?['MM7U@*?M,UW<!T+!&5E5-PX*XQA]X!]YT5\Q?L/? CQK
M\%/B9XDE^$OQ_L?&_P !-9TV.?PC;W/BE]5O-(U)642PPRA61K8KYA_UN0=G
MRD[W;YC@T_X"?M+?M)_&_P"*?[4'[<'B7X=Z/IOQ)?PWX/T_2_B3%I$4XLH4
MAG=8I0V]>(3N0  LQ.<T ?IS17@7P&^ NE_LX?L_>*]?_98^*/B3XH7VNZ7+
M?^&)O%GC&'4H+J[C@=;>.*X 2-8GDVACNQWR,5Y-\+?^"5T?Q(^%%M\0_P!L
M;XM?$*X^+FKVSWFK:[:>-Y(O[!N7)(AM4@<P*D0VC #(2IVX7  !]K45\P_\
M$D?CM\3/CS^R8=3^*OB=]?U#P[XIO]!MO$TH._6;6W\LQ73-_&2)"A;DMY>6
M)8DGZ>H **** "BBB@ HHHH **** "BBB@#\Z?VV?VA/VIOV@+G]H7PY\'OB
MXG@+P%\$=#6#5H[#3TDU+Q'?/$[LGG,0UK$I1QNC(; 'WMQV?1/[(FK_ +;7
M@GXS>+/V?OVH+A_&GA[3-.AU#PA\58M%CL5OE8JKV<\<?R><N[(*C/[MRS-N
M7'C'_!4#]B(Z3X&^+?[6/P(^-VH^$K[5O"3+\2O"L5M'<V'B*&*(*NY&(-O-
MLZ2 ,>I 4N[-Z9^RO^UM^T?9_M*WO[$O[:O@[P]:^,5\.?VYX8\3^$I)/L&N
M62N8V_=R?-'("KGHH/EN-BX4N 9.K^&O^"T>DVMUJ]]\<_V?[6QM8WFFN+K3
MM01(8E!8L[&'  49)/ Q47_!-G]JK]JKXY>!?''QX_:<USPJ?A[HK3Q>'=?T
M32IK5=16U,ANKU!+\YMPJ8!958D,, J15K_@K3X^\7:_X+\$?L4?##4WM/$/
MQN\3)H]Q=1<M::1&4:]E('.W:Z!A_%'YHKN/VQ/ &A_!K_@FC\0OAG\,=,^Q
M:7H'PLOM/L+>+JELEHR,21U)3<6;J223U- 'EGPP^*'_  4O_;6\$W'[1OP+
M\=>"_AIX0O9YCX$\-:]X=-]=ZQ;1NR+->3$G[.)&4X\L$@<@$8=_?OV,/C;\
M4OCY\"K+QG\;/A#J/@GQ7;7D^GZ[HU]836\;3PM@SVXF&YX'!#*V6 .Y=S;=
MQ^4/V-_V1/VE_P!HC]C?P)\0=5_;=\;^ 9$\*6MOX)\/> YDM=.L;6"(0PR7
MB#Y[V27R_.?<Z@&0J, #'O'_  3,_:2^*'[0?P5UW1?CE);3^-?A[XSOO"OB
M/4+2,)'J$UMLQ<!5 52P?:<  LA8!0P  .L_;J_:DN?V0OV>M0^*VB^$SKNM
MS7MOIGAS2"6"7-].VV,2%>0B@,YQ@D)M!!((\+^*_B/_ (*R?LU?"2]_:>\:
M_%GX<>+;70;,:EXI^'=KX9>UC@M%^:=;:\#;W>-<G+\84G#X"M]JDA068X Z
MDU\/_M/?'+QA_P %&/$^I_L+_L:W?F>%1<);_%GXJ(NZPL;4,"]C:..+B:3;
M@[3@C(!V%W4 ]=^(OC3]L']H3X4?#WXP?L(^+_ NB:;XCT(:GJ\/C^TN))"D
M\4$END?D(P#)F97SWVXSS7SG\<OV@O\ @KS\$?BAX*^",GQ'^#7B+Q?X\OFB
MT?P_X?T6\>:&W0$R7LYE5%BMT .6)).UL [&Q]Y>!/!GA'X.?#72/ 'AI%LM
M#\,:+!8V0GD_U-M;Q!%+L>N%3)8]>37R5_P3'TV[_:;^+OQ)_P""DOC:W=W\
M4ZQ+X>^'45PO_'AH-HX7*9Z&1U ;&/GBD/\ &: /0/VM/VH/CAX/^)/@?]D/
M]FG2-$U#XH>--/DOKW5]:1SIV@Z=""LM[)&IW/N=9%C7IE""&)53C>"O'G_!
M0?\ 9_\ VC/"7PQ_:"FL/BIX*\;F:W_X2_PEX/EM)_#=VBAE^U)%NC6W8L%W
ML1_$Q8;"K>-?'CP_\=?B#_P6DN_AS\(OB,?!\VK?!VWMM0\4QV:SW>GZ2MR)
MIOLBO\JS23*L0<@[!([ 9 KJ?%*?M!_\$XOVD_A=#=?M.^,/B9\./BAXKB\,
M:OIGQ OA>7VF7TY @N(+C (3<Q)0 *%1@0Q960 ^YZ*** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH \Y_:@^,G[/WP;^&J3?M+7=JGAKQ
M+J<6@M;WVE27EO=S7"OMAE14=50JCDL^$&.3D@'X/^*_[#?AKX%?&'X\^//V
M/?BCXC^%%[\,_A_HOBG3+31=8D:PO7=-5FN(+F.9F,D;"T0(I;8A=OD93MK[
M_P#VB?V>_AE^U'\(M6^"OQ<TA[O1M6C7>T$FR:WE4AHYHGP=DB, 0<$'D$%2
M0?C[0/\ @DY\6?$_Q<\7^!?C#^U;\0-3^&=SH?A^V+F6UCNO$L%L]Z187,RD
MR;+;<N6*CS/M/K&" #Z?_9B_:'G^*7[&WA;]I;XDV\>GR7G@Y=6UXQ)MC0QQ
M,9I$4]$.QG49X! R>M>*?\$??">K>./ASXR_;B^(%MN\3_&7Q;=7ZRR'+6VE
MV\KP6ULN>BJRRX]4$7]T&OH_QY\"_"7B[]GO5OV;M!=_#V@ZEX3F\/6W]E(H
M:QLWMS;A8@V1\L9P,YZ5+^S_ /!G0/V>/@KX9^"/A>_GNK#PSI,5C;W5TJB2
M<*.9'"@#<Q))QW- %?Q+\8O@U?\ Q2_X99UOQJL/BW6_#4VH0Z&BS1S2V!+Q
M/,DH78""KX ;=\I('RDU\7?&OX">#O\ @F%^T_\ "3XK_LH7M]9V_P 2_&]K
MX3\9^$M3O7O_ .T[:9U_?Q2SEID="<G#D%C%T&X-]0?M6?L3^"?VGM8\/?$*
MU\:ZYX+\=>$)';PSXV\,3*EW:J_WX9%8%9H6R<H<?>8 @.X;F?A'_P $\H=!
M^,VE_M#?M'_M ^)OBSXN\/0O'X8FU^"&UL=(+##2PVD(V"4_WR>P.-RJP /H
M^OS?_8)_9%^#WQA_;+_:3_X:'\,VWBB7PO\ %*^GT7PQK@\ZRMQ?W%Q(U\;9
MLH[RQQ0J&8' 3W!'U!XE^'7Q&O\ _@I%X:^(GAW7_%W_  C5C\.+N/Q+9322
MQZ&)FGV6@B'"373%YV<#)C2&(G&]<M^/?[ VF_$GXQ-^T?\ !/XV>(_A;\0+
MBP6QU;7?#B130:M;J $6ZMI1LF90JA6R.%7.=JE0#QWX'> O#/[)?_!7+6?@
M'\ ;9M/\#^,OA2/$FO>%K-V:TTS4([IH5FCCR?+RJ#Y1_P _& ,! .\_9,_8
MY_X)F^._!VM_%#X,?#_PY\0[+Q)K=VVHZ_XGL%U*7[1N_>PH;J/,2ACG"J,[
M@<MP:[[]E;]BCPG^S5X@\0_$W6?'^N>.?'WBTQCQ'XV\2R*;F>-,;((D4;8(
M1@?(,_=49PB!>!U7_@F;J?@WQSXA\5?LH?M8^,OA1IWBV_>^\0>&='M+>[L&
MN7^_+;),!]F9O52<8 7"JJ@ XG_@FQHUI\$_VT?VCOV8OAG>RM\-_#&IZ9J&
MC63W#20:3=W,!>>"-F)VC.Y""2?]&&><DN^*GQR^+W_!2[Q;J_[,W['.K3:%
M\+;&Y:P^(WQ@"'%\O273],_YZ%E.&D'!5NH0J9?8O!/_  3\^&'PR_9C\6?L
MX_#[QCX@L;CQS%<'Q5XXN+I;C6-1GG&V:>25EP69"R@   .Q^\68^3^ _P#@
MC_XA^%OA>V\$?#7_ (*&_&G0-&LRYM=*T?6UMK>$LQ=BL<8"C+,2<#DDF@#Z
MI^"GP9^'O[/?PLT7X.?"S1%T_0M"M!!90;MS-R6>1V_BD=RSLW=F)KJ:\Z_9
ME^!7B+]GOP#=>"O$WQV\7?$*XN-6DO5UOQI?_:;J%&CB06ZMVC4QE@/61O6O
M1: "BBB@ HHHH **** "BBB@ HHHH _.7]N[]F/]I']F#PQ^T%\2_@A'H>O_
M  P^+&D7&I>,](U*^:WO]"OF#&:[M\C;,C%W8KG<<A<#8&;W3]FC]FK]HSQA
M^U9?_MR?M@6VA:-KD7A@>'O!G@KP]>FZCTBR,ADDDFGP!),Q9Q\N1B1NF%5?
MJ26**>,Q31JZ,,,K#((^E.H ^=O&/[,7Q-\:?\%,?"/[4>IKIY\&>#_AY<Z=
MIB-=DW*ZI/).LCB/;@*89MN[/\/2O=_&?A+0?'_@_5O GBFR%SIFMZ;/8:E;
M$X$L$T;1R)^*L1^-:5% 'Q1\*/AC_P %/?V,_A^_[-'P7\$^!/B+X7T^6:/P
M1XPUS7VL;C2[:1V=4O+?&9O+9C@1GI@ XP%]*_9T_9A^(O[&'['7BG0?"_C'
M1]9^)>K?VGXDU?Q#K&8M/N==GCW;Y"=I6W4I&I)VDA6;"[L#Z-JIK^@:%XKT
M.\\,^)]&M=1TW4+9[>_T^^MUEAN874J\<B,"KJP)!4@@@XH ^/\ XN']M_\
M;=_X)E>$5^#D^B:7XN^(.G02^+;LW;V$2Z;(LC,MOD.RB4>2#SS&[C^*L3X(
M^"/^"MG[.WPSTSX1_"/]G']GS2=$TJ )!!%J>H[I6P-TLK>=F25SRSGDDU]Q
M6EG::?:16%A:QP001K'##"@5(T48"J!P    !TJ2@#R?XF>&?V@_B;^QAK_@
MO4++0['XD^(? EU83Q:==.MA;ZA/;M$QCD?<P16<D$Y/ JQ^Q9\$=1_9P_93
M\"?!/6HK9-1T#P_%#JBV<F^+[6V9)RK8&X&5W.<#.<UZA10!\U_M@_LK?&C7
M_CAX0_;,_9/UC1H?B%X0T^72K[1/$3.EEX@TJ0LQMGD3F-U9Y&4],N"2NP9Y
M73/V?OVP_P!K?]HCP+\6_P!L+P;X:\#>$?AEJ1U;0O!NAZU_:5SJ>K#'E7$\
MRJ$6.,JK*!\W!4CYBP^OJ* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **\;^/?[6W_"D/&\?@W_A7_P#:F^PCN?M/]J^1C<SKMV^4W3;U
MSWZ5Q/\ P\7_ .J._P#EP_\ W/7YMFGB[X>9+F-7 XW&\E6FW&4?9UG9KI>-
M-I_)M'U6#X)XGQ^%AB*&'YH35T^>"NO1R3^]'TU17S+_ ,/%_P#JCO\ Y</_
M -ST?\/%_P#JCO\ Y</_ -SUP?\ $<?"[_H8?^4J_P#\K.G_ (A]Q?\ ] W_
M )/3_P#DSZ:HKYE_X>+_ /5'?_+A_P#N>C_AXO\ ]4=_\N'_ .YZ/^(X^%W_
M $,/_*5?_P"5A_Q#[B__ *!O_)Z?_P F?35%?,O_  \7_P"J._\ EP__ '/1
M_P /%_\ JCO_ )</_P!ST?\ $<?"[_H8?^4J_P#\K#_B'W%__0-_Y/3_ /DS
MZ:HKYE_X>+_]4=_\N'_[GH_X>+_]4=_\N'_[GH_XCCX7?]##_P I5_\ Y6'_
M !#[B_\ Z!O_ ">G_P#)GTU17S+_ ,/%_P#JCO\ Y</_ -ST?\/%_P#JCO\
MY</_ -ST?\1Q\+O^AA_Y2K__ "L/^(?<7_\ 0-_Y/3_^3/IJBOF7_AXO_P!4
M=_\ +A_^YZ/^'B__ %1W_P N'_[GH_XCCX7?]##_ ,I5_P#Y6'_$/N+_ /H&
M_P#)Z?\ \F?35%?,O_#Q?_JCO_EP_P#W/1_P\7_ZH[_Y</\ ]ST?\1Q\+O\
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M+,LWH86JVHSDHNV]F^ETU^!J?\-B_LX_]%%_\I%Y_P#&:/\ AL7]G'_HHO\
MY2+S_P",U\,45_(W_$R?'7_0-AO_  "K_P#+C]L_XA5P]_S]J_\ @4/_ ) ^
MY_\ AL7]G'_HHO\ Y2+S_P",T?\ #8O[./\ T47_ ,I%Y_\ &:^&**/^)D^.
MO^@;#?\ @%7_ .7!_P 0JX>_Y^U?_ H?_('W/_PV+^SC_P!%%_\ *1>?_&:/
M^&Q?V<?^BB_^4B\_^,U\,44?\3)\=?\ 0-AO_ *O_P N#_B%7#W_ #]J_P#@
M4/\ Y ^Y_P#AL7]G'_HHO_E(O/\ XS1_PV+^SC_T47_RD7G_ ,9KX8HH_P")
MD^.O^@;#?^ 5?_EP?\0JX>_Y^U?_  *'_P @?<__  V+^SC_ -%%_P#*1>?_
M !FC_AL7]G'_ **+_P"4B\_^,U\,44?\3)\=?] V&_\  *O_ ,N#_B%7#W_/
MVK_X%#_Y ^Y_^&Q?V<?^BB_^4B\_^,T?\-B_LX_]%%_\I%Y_\9KX8HH_XF3X
MZ_Z!L-_X!5_^7!_Q"KA[_G[5_P# H?\ R!]S_P##8O[./_11?_*1>?\ QFC_
M (;%_9Q_Z*+_ .4B\_\ C-?#%%'_ !,GQU_T#8;_ , J_P#RX/\ B%7#W_/V
MK_X%#_Y ^Y_^&Q?V<?\ HHO_ )2+S_XS1_PV+^SC_P!%%_\ *1>?_&:^&**/
M^)D^.O\ H&PW_@%7_P"7!_Q"KA[_ )^U?_ H?_('W_X&_:'^#WQ*UY?#'@KQ
M?]MOFB:00?V?<1_*O4[I(U'ZUVM?%O[#/_)>(?\ L%7/\EK[2K^D?"GC+-..
MN%WF6/A",U4E"T%)1LE%K24I.^KZ_(_*N,LBPG#V;K"X:4G'E4O>:;NV^R2Z
M=@HHHK]+/E HHHH **** "BBB@ HHHH **** "BBB@ KA?C_ /M*_ _]ESP6
MOC_X[?$&TT#399Q!;-,CRRW,I!/EQ11*TDK8&<*IP.3@<UW5?$__  4;EN?@
MW^V+\%/VPOB7X#U+Q%\,?!MOJ5KKSZ?8&[&@W<R8BOWB'\()C._^$P#'S^6&
M /5_V4/^"F'[+'[7>M?\(3X$\7RZ=XI+W1B\,:W:R6]S/##+(@EB+J$EW(GF
M%$8N@)W*"K8^@:^$OV$/#W[&7[7O@;P%XC3XAV-WXZ^''CWQ)K^B6FEZJMMJ
M,<%QKUY<Q>="P$KV[QO"Y4@+\^#C)%>W_MR_M#>-O!%AHG[.'[/3QS_%;XE2
MO9>&QU71;0#_ $G5I\9VQPIN*Y^\X& VUEH ]4\ ?'#X3?%/Q/XD\&_#OQW8
MZOJ?@^_6R\2VMDY8V%PV_$3G&-V4<$ G!4@X(Q6!\>/VP?V9/V8YK6T^._QG
MT;PY<WT?F6EC=3,]Q+'G'F"&)6DV9!&[;MR",\5\M?\ !'GX3Z7\"OCG^TC\
M(-&U:[U"W\/>*](LQJ%\^Z:Z98;K?,Y_O.Q9CZ;JP]1^*7P-_8Q_X*<?%?Q_
M^W,+6*+QUIFG7'PV\6W>GMJ$=I90Q&.>T$<2R26[%O+7.P!O()SAAN /N7X4
M?&/X6?'3P?%X^^#WC[2_$>CS2&-;_2KM94608S&V.4<9&58!AD9'-=+7Q!_P
M2XBT3XA_M,?'3]I7X"Z(-&^$'BO4K"W\-6*QK M[?V\6+F[2V',"LY=OF52P
MG''RD+]J:]IUUJ^AWNDV6K3V$UU:20PWUL%,ELS*5$B;@1N4G(R",B@#R7Q_
M_P %"_V)_A;\0)/A=X]_:3\,:=KL$_DW=E)>%Q:R9P4FD13'"P/4.RD=\5Z]
MI>JZ9KFF6^M:)J,%Y9W<"S6EW:S+)%-&P!5T920RD$$$'!!KX[\4Z5_P3S_X
M)9?LRCX,?':>SUQ_$-KJ%Q<IJFA?:M3\5R%R7\PJA7<!+'&&=E50 <CDUY;X
M=\3_ !G_ &0O^""5[K>L:T]KKM[8/#X=\B^$LFG6>HZ@L<:B5"<.L,TDBX.4
M)"\%<  ^L_$?_!1G]AKPE\0&^%_B+]IWPK;:U'<FWG@:^+102@X*23J#%&P/
M!#.,$$'&*[KXM?M _!3X$>&[/QA\8?B=I'AW2M1N5M[&_P!3NPD4\I1G"JW0
MDJK-]!7POI?[0'_!,[X4_LO_ /#+U_\ !#Q9KG@)-,_LCQ3\4-$^'YN=(;4"
MOESW9OC\TDRS999(U<*57R\@**^NO@C^SM^SQ>_LP>"/A?ML/B?X/TC2XI/#
M.J^,;2TU3SH"K&&128A'\L;^6I500@"G/)(!E_\ #R_]@7_H[+P7_P"#9:]B
M\)^*_#?COPQI_C3P=K,&HZ3JUG'=Z;?VK[HKB"10R2*>ZE2"#[U\$?M2?L_?
M ;]IS]LSP[^P-\%_@9X-\/:-X?MHO$GQ?\1^'_"UI:W<=J"K6^FQS11JT32[
MHRV"#ME4C(1U/WWX=\/:%X1T"Q\*^%](M]/TW3;2.UT^QM(@D5O#&H5(T4<*
MJJ  !T H N4444 %%%% !1110 4444 ?&_[>O_);;?\ [ $'_HR6O$Z]L_;U
M_P"2VV__ & (/_1DM>)U_FYXI?\ )P\S_P"OLC^J>$/^28PG^!!1117P1]&%
M%%% !1110 4444 %%%% !1110 4444 %?9/[!7_)$KC_ +#\_P#Z+BKXVK[)
M_8*_Y(E<?]A^?_T7%7[E]'G_ ).&O^O53_VT_/?$W_DF'_CC^I[71117]W'\
MZA1110 5X]^W-_R0>;_L*VW\VKV&O'OVYO\ D@\W_85MOYM7P_B7_P F_P S
M_P"O-3_TEGT'"G_)2X3_ *^1_,^+****_P US^K HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH ]B_89_Y+Q#_ -@JY_DM?:5?%O[#/_)>(?\ L%7/\EK[
M2K^Y_HZ_\F_E_P!?ZG_I,#^>?%#_ )*5?]>X_G(****_>3\Y"BBB@ HHHH *
M*** "BBB@ HHHH **** "O!_CE^VWI/P!_:Q\"?L^_$OPG;Z9X6\=Z1</9^/
M;_5/+MX]1C9@+%D:/:N1Y7SF3DSJ-HQD^\5R_P 7/@K\)OCUX2?P)\9?A[I7
MB327D$@LM5M%E6.0 @2(3S&X!(#*0P!//- 'Y?\ C#PS\(M'\)? GQ;\";33
M+7XY7W[0>LQ6<F@%5O;K21X@U19&NEC^_ %$"!I!_J]R@[ X'TAJ?[)'_!2O
MPI^UG\0/VEOA1\1_@]>3>*YA9Z/<>,(=1FNM,T>)R8+*,11!(EQM:0+G>Z[B
M2>3Z_P#L<_\ !/3]G_\ 8\TUM0\)^!]&N?%#WE^S^*1IY6Y%K-=2R0VZ&1Y&
MC6.!XH258;Q%N89.*]YH _.3_@FOIG[;"_MR?&UM:\3?#MK6W\;V8^*JV]M=
MA[J7R;GRCIN1A5!SN\W!Z8KKO^">]_\ ##3/VQ_VB;?]H.YTN+XLM\1+AK&3
MQ$\:W#^'R/\ 1!:&7GR=F"0G\!@W<;:^S/"'PF^&W@#Q)K_C#P7X+L--U3Q3
M=I=>(KZTA"R:A,@8*\I_B(#-@^YKE/CK^QO^R]^TQ=V^I?'3X)Z)XAO+2/R[
M?4+J QW*1YR(_.B*R%,DG:6P"3QR: /FC]FJ7P-/_P %@/B,_P"RW+9GP1_P
MKBW_ .%A'0BO]F'Q!]I7R]OE_N_.\K=G;_%]HS\VZOJV'X\>!?%?AGQAJ?P;
MUK3_ !GJW@Y;J'4-"T;44:47\*.19.1GRI&=-G(X/;BKOPB^"7PC^ ?A1? _
MP9^'>D^&M*$IE:STFT6(22$ &1R.9'P -S$G  SQ7%_LQ_LW2_ [QG\3O'5W
M8Z-8R_$#QL^JQ:9H(?R+:W2)8HW=G52UQ*1)/*0-H>8JI8+N(!SGP"_;)_9@
M_:]_9P/Q?\;R^&-)M?LL]OXN\.^*+^WE.DE'99(+GSE4;" '!90&5AQ7P]X
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M_P#/VE_X%/\ ^0/N>BOAC_AL7]H[_HHO_E(L_P#XS1_PV+^T=_T47_RD6?\
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M?RE])_\ AY5ZU_\ W"?LOA'\6-_[A_\ MY#1117\F'[.%%%% !1110 4444
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M\(?\DQA/\""BBBO@CZ,**** "BBB@ HHHH **** "BBB@ HHHH *^R?V"O\
MDB5Q_P!A^?\ ]%Q5\;5]D_L%?\D2N/\ L/S_ /HN*OW+Z//_ "<-?]>JG_MI
M^>^)O_),/_'']3VNBBBO[N/YU"BBB@ KQ[]N;_D@\W_85MOYM7L->/?MS?\
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M5[S_ ./5Z;11_J%P+_T*L-_X(I?_ "(?ZQ\0_P#095_\&3_S/,O^&.OV<?\
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M[\L(QA&[W=HI*[LM3SL5C,7CJOM,34E.6UY-R=NUW=A1117><P4444 %%%%
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MX;_97\+^&OVN/$?[7EMXFOY-6\1^%;?0[C2G1/L\443QL)%(&[<?+&<G')H
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MX-,T;1;&.STRPMQA((8U"JHSR>!R3DDY)))S7R7X5_X)+>-? OARR\'^"_\
M@H]\;])TG3K=8+#3=-\0"&"WC7HB(F%4#T KZ6_9^^$NM?!'X7V7P[\0?%KQ
M'XWNK2:9W\1>*[SS[V<22,X5W[A0=J^@ H [2BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
&*** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>optn-20221231_g3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 optn-20221231_g3.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MQG2,J'(V(W0LO7UKTB-TE021ME6 (/J* %HHHH **** "BBB@ HHHH ****
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M@G\5'_8V^+UQ-9Z-XR,-]X2:_P I]EU":%)(XQNZ1W4+1LG8N(]H_>DUL?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M/CG\'OV[?#_Q<^&.N^')OAUX>^(>GZS81WNJ2K?Q6$5U'.T)3RB&= &0'?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 45YA^V+\?];_ &9?V>]=^+?A7X>W_BK6+-(X='T.PMI)3<7,KA$+^6"R
MQ+DNYX^52 02*^;_ (N_%+_@J)^R#\(/^&L/C+\0OA]XNT;39+6;QA\/-/\
M#[6;6%M-+'&RVEX'+22(TBC,@(ZGY\8(!]OT5\__ +6_[5/Q/\#?"?P3=?LN
M_#IO$?BGXG:G9V7A>?4K.4V&F1W"*_VR\,?W$573Y2PR6)Y"$'S'QO\ '/\
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MW%^R_<?M<_L]ZE\)M(\93>'M86Z@U#P_K,+,!;7L#;HRX4Y*$%D;'(#;@"5
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M!'Q(_;)\)^&O W@KX<ZLNLZ/X'T+6CJ5SJFJICRIKB<*(Q%&1D*.2"RD$/N
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M7MJ9;O7-89"IO[^9R\TN#R!DA5SSM1<Y.37J] !1110 4444 %%%% !1110
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MY%\!_@_H_AMM0P+ZYLH2T\Z@Y"O+(6D90>0I; )X% 'H=%%% !1110 4444
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M+HEGXCT.]2YLM0M8[FSN(S\LL3J&1Q[%2#^- %JBBB@ HHHH **** "BBB@
MHKQ/]H7_ (*+?L;?LJ>.X_AG\>_C%_8.MS:='?1V7_"/:C=9MW9T5]]M;R)R
MT;C&[/'(Y%<)_P /K/\ @F5_T<M_Y9NM?_(=>YA^&>),71C6H8*M.$E=2C3F
MTUW34;-'C5^(^'L+6E2K8RE&<=&G4@FGV:;NCZGHKY8_X?6?\$RO^CEO_+-U
MK_Y#H_X?6?\ !,K_ *.6_P#+-UK_ .0ZV_U1XL_Z%]?_ ,%5/_D3'_6KA?\
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MJ***\@]4**** "BBOF#_ (*[?M$?&+]E_P#8\NOBI\#/&']AZ]'XAL;5+_\
ML^WN<12,P==EQ'(G.!SMR.QKT,JRVOG&94<#1:4ZDE%-WM=Z:V3=O1,X,TS"
MCE.75<963<:<7)I6O9=KM*_S1]/T5^!7_#ZS_@IK_P!'+?\ EFZ+_P#(='_#
MZS_@IK_T<M_Y9NB__(=?JO\ Q _BS_G_ $/_  *I_P#*S\R_XC-PO_SYK?\
M@,/_ )8?OK17X%?\/K/^"FO_ $<M_P"6;HO_ ,AT?\/K/^"FO_1RW_EFZ+_\
MAT?\0/XL_P"?]#_P*I_\K#_B,W"__/FM_P" P_\ EA^^M%?@5_P^L_X*:_\
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MQ\ ^'_*^WZYX5U#3['SWVIYTUM)&FXX.!N89/84 >2_\$I?^4>/PK_[%T_\
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MB;_P<*_\GV:;_P!D\T__ -*;ROA6ONK_ (.%?^3[--_[)YI__I3>5\*U_;O
M/_)&8'_KW$_C7CC_ )*[&_\ 7QA1117UY\J%%%% !1110 4444 %%%% !111
M0 4444 %?ME_P;U?\F)ZE_V4/4/_ $FLZ_$VOVR_X-ZO^3$]2_[*'J'_ *36
M=?E'C-_R1C_Z^0_4_3_"+_DKE_U[G^A]U4445_)1_4H4444 %?%G_!?+_E'U
M??\ 8VZ9_P"A/7VG7Q9_P7R_Y1]7W_8VZ9_Z$]?5\#?\EC@/^OL/S/F.-/\
MDDL;_P!>Y?D?AM1117]PG\9!1110 4444 %%%% !1110 4444 %%%% !1110
M!]J?\$#?^4@MC_V*6I_^@I7[D5^&_P#P0-_Y2"V/_8I:G_Z"E?N17\G^-/\
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MD%%%% !1110 4444 %%%% !1110 4444 %%%% 'VI_P0-_Y2"V/_ &*6I_\
MH*5^Y%?AO_P0-_Y2"V/_ &*6I_\ H*5^Y%?R?XT_\EC'_KU#\Y']0>#_ /R2
M<O\ K[+\HA1117Y&?J@4444 %%%% !1110 4444 %%%% !7\MVO_ /(=O?\
MK[D_]"-?U(U_+=K_ /R';W_K[D_]"-?T)X#?'F'I2_\ <A^#^-WP8#_N+_[C
M*E%%%?T0?@84444 %%%% !1110 4444 %%%% !1110 4444 ?U(Z!_R K+_K
MTC_]!%6ZJ:!_R K+_KTC_P#015NO\]9_&S^\H? @HHHJ2@HHHH _$W_@X5_Y
M/LTW_LGFG_\ I3>5\*U]U?\ !PK_ ,GV:;_V3S3_ /TIO*^%:_MW@'_DC,#_
M ->XG\:\<?\ )78W_KXPHHHKZ\^5"BBB@ HHHH **** "BBB@ HHHH ****
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M%G_!?+_E'U??]C;IG_H3U]IU\6?\%\O^4?5]_P!C;IG_ *$]?5\#?\EC@/\
MK[#\SYCC3_DDL;_U[E^1^&U%%%?W"?QD%%%% !1110 4444 %%%% !1110 4
M444 %%%% 'VI_P $#?\ E(+8_P#8I:G_ .@I7[D5^&__  0-_P"4@MC_ -BE
MJ?\ Z"E?N17\G^-/_)8Q_P"O4/SD?U!X/_\ ))R_Z^R_*(4445^1GZH%%%%
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MGS'&G_))8W_KW+\C\-J***_N$_C(**** "BBB@ HHHH **** "BBB@ HHHH
M**** /M3_@@;_P I!;'_ +%+4_\ T%*_<BOPW_X(&_\ *06Q_P"Q2U/_ -!2
MOW(K^3_&G_DL8_\ 7J'YR/Z@\'_^23E_U]E^40HHHK\C/U0**** "BBB@ HH
MHH **** "BBB@ K^6[7_ /D.WO\ U]R?^A&OZD:_ENU__D.WO_7W)_Z$:_H3
MP&^/,/2E_P"Y#\'\;O@P'_<7_P!QE2BBBOZ(/P,**** "BBB@ HHHH ****
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MJO"__0#1_P#!4/\ Y$^6/^'*?_!,K_HVG_R\M:_^3*/^'*?_  3*_P"C:?\
MR\M:_P#DROJ>BC_6[BS_ *&%?_P;4_\ D@_U5X7_ .@&C_X*A_\ (GRQ_P .
M4_\ @F5_T;3_ .7EK7_R91_PY3_X)E?]&T_^7EK7_P F5]3T4?ZW<6?]#"O_
M .#:G_R0?ZJ\+_\ 0#1_\%0_^1/EC_ARG_P3*_Z-I_\ +RUK_P"3*/\ ARG_
M ,$RO^C:?_+RUK_Y,KZGHH_UNXL_Z&%?_P &U/\ Y(/]5>%_^@&C_P""H?\
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MG_R\M:_^3*/^'*?_  3*_P"C:?\ R\M:_P#DROJ>BC_6[BS_ *&%?_P;4_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
:444 %%%% !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>optn-20221231_g4.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 optn-20221231_g4.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" 1O CH# 2(  A$! Q$!_\0
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M'X2O]1O+/3?B%\ [[[9HTLQVG7M GD6.YL-W>:"1DEC'/ 8 ?,2/2=*MWO\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M17[J?BH4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M&=&I*E55I1;379K<****U,PHHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@@$&OA>',ZQ&2YE3QM+>#U7==5\T>OGN44<TP%3!5MIK?L^C^3U/WRHKP_\
M8!_:@3]J'X V.H74J'Q'H^-/UB,'GSE'$N/21<-]<CM7N%?W+E^/HXW#0Q>'
M=X32:^9_&N88&M@L3/"8A6G!M/\ KL^GD%%%%=AQA1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110!E^-O$L?@SP;JVKS8\K2[.6
M[?)P,(A;^E?SZ^)_$L_C3Q3J>LW+,]QJ]W+>R,QY+2.6_K7[3?\ !3'X@?\
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M@VS5YWJTFR<_6OB<]P$8OGB>YA,0W&S.A\&^,9-*NU4M\C'!YKU;1]56^@#
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MRZP<9?BE^39^C=%%%?UV?RP%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% 'X__ /!9_P 4_P!O_MKW-H'W)H^CVML!_=+;I#_Z
M%7SE\++3[;XQM$QGYQ7IO_!2?Q#_ ,)'^W+\0Y-P9;>_6T7'0>7&BUQ/P LO
MM?CRVXZ,*_DG,JGUGB>M-_\ /R7X.Q_5624O89)0AVIQ_%7/JF<>1I<*?W4
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M:TDD[>GD_P#AS=HHHKZ(^9"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M.FM8^[+T^R_D]/FNQ]#4445^M'XT%%%% !1110 4444 %%%% !1110 4444
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MNG'I^54)HO*/N.>3@8K8O+=4DV_>"\D]1ST.?0UF2J&4EL],?_J]J!E&>/+
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MA5!Z)*)T_P" "NJ^&'C27X<?$31-?A9DDT>^ANP5ZX1P3_X[FOYXO/*,WO\
M\^Y_A?\ 6)_2L%#.<DY/^?D+?/I]SLS]N:*KZ5J,>L:7;7<1S%=1+,A]0P!'
M\ZL5_1:=U='\SM-.S"BBB@04444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!P
M/[0^IBV\%16N<-?7"IQZ#YC_ "%>6:7#GJ,]\5VO[16I>?K^FV8;_4Q-*1C.
M"QP/T'ZURNE0# [B@#8T^+"=<@CTJTR@>V>.*2R'[L4^;[E %*<8Z\\]:JR<
M<^@Z5:G8EO6JLI_R* (W=8$9G98XT!=W8X" =23[5X)\1/$MW\9_$<$<2L-"
M@E*:9:.,"^F7K-)_L#J/;ZUWOQR\1YLDT*.0HMQ$;K495?;Y-LO)!/\ M8_*
ML_X-^'%FMAJ\L'E&\0):1;?^/:V'W/H6ZG\* .B^'O@B'P]9 #YYG&Z:95V[
MV] .P]!VKM;.W\OG^G3-5[&#:HY[8],U?M_EP<=NU RS%#N4#T%78U"L.NXC
M'(JO;\D>E7+89?& >.OI0(LQ1G(;!]NU7K([L8[GGCI5>W3?*#CZGU^E7K=.
M1GCG/':@"6%-JEMN1D'G^*I&BPF<CIN)';VI\46Y>>_! IQ3:<9&-NWZB@"A
M<V6].GX>_O7C7[3?[-MA\9O#L\@@CCU:-<K(!S)M]^S#L?SKW":/]T3ZC&!6
M1>(=@/.>6Y]: /F/]DWXY:AX?UV+X:^+;EY;E/DT2_GSNG S_H[D]_[I_"O>
M9G,9(S@L,=>1[^U>,?M<_!P:E#'K6FEK>[603+)$-K13CD=.@.,_45VWP4^*
M0^+GP\MM1EQ_:=D?LNH(!QYPZ/\ 1QSCUS04CI)LJW&0#SS_ $-5+X$JQ)&3
MR 1^E7+AB)1GGUQR/I569-X?Y_+W< XY'UI,HY/Q+ T\0WD!&#$*.V/4?G7&
MSP;) V1@<EO7\*[OQ!%E>O3C;]WZ_A7%7T7D7<FWY,_=!'WA6;-$<_XMT[[?
MID^47<5PI(]?6O;_ /@F_KWG_!C4M%+;GT#5IH1Z!) )!CVRS?K7CU_&);21
M&9B?NJQQQ7:?L!:L-#^*_BK1C+\FI64-]%&1@@QL4<_^/K2CI(<U>)]94445
ML<P4444 ?EM_P7_^' \&?'SX'?%&!4C2[FN_"&I2 ?-()%%Q;Y]E*3C_ +:5
M\XR1Y<QD\-E?SXK]#?\ @O#\.V\9_P#!/#7]6AMUGO/!6I6/B"'/51%.JR8_
MX [5^=6G7XU'3;6Y4\7$*2C\5!K\/\0L*J>9JJEI.*?W:'[WX:XOVN6.DWK"
M3_'4_83]A7QZ?B/^R;X)U%F+S)IZVDS$Y)DA)B;/OE#7K=?)'_!'CQC_ &O^
MS[K6C.WSZ)K4OEKGI%,JRC_QXO7UO7ZOP]B?K&64*KWY5?U6C_%'Y!Q+A?JV
M:XBBME)V]'JOP84445[)X84444 %%%% !1110 4444 %%%</\1OVE? 'PCD,
M?B3QAX?T>8<&&>\02_\ ? );]*SJUJ=*//4DDN[T-*5&I5ER4XMOLE<[BBO*
M- _;C^$OB>[$%GX[T-Y&.T!W:($^F6 %>FZ3K5GKUDMQ8W5O>6[C*RP2"1&^
MA'%8X?'8;$?P*D9>C3_(VQ&"Q.'_ (].4?5-?F6J***ZCE"BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHILTH@A9ST0%C0!X5\4
MM0_M7XC7[9.V$K"O_ 1S^M1::A7;].F*S9+DZGJMS<'DSRM)D]\DFMG38MJ#
M\^: -2!<)VY'6DN#C\*DC'R=/_KU#.>O^% %.X/%57=(U)DXCC!9_91R:L3M
MFL3QI/Y7ANX3G-VR6R^V\\Y_ 4 >1>+I3XG\066F.P^T^+[MKF;KE+2(] W3
M'&*]?TFV^SIM5=JK@!1V X&/PKS#P2#XB^.GB"Z 'V/P_:0Z=;#'RJ6Y.WZ@
M#\Z]:LXS'$O?Z4 6X,;N*M0Y Z>WUKS?]I#]H&Q_9N^&Z:S-IE]XAUG5+V+2
M- T*Q'^E:YJ$V1%;H>BKP6=SPJ@FOGW1_CE\<_&7A'Q-XBLOC7^S?H^I>$,R
MZOX:-O)<Z?HYZ"WN;XN&W9^3S$!7=T!K6%%R5]D%S[4MR<#H?\:T+9-P'N<\
M5XO^Q?\ M1#]JWX77.HWVAS>%O%GAV[_ +,\0Z-(V];2XVAUDA? +P2H0\;X
M&0:]JM>6'K@"HE%Q?*P+]JHR,]>G%7[>/"CCG/&.U4K<<#IUSU_E5^W 5.O/
MK4@6(U^7 XXSFGD;P#QUXXH@^[SQQ3C\O\OI0!6N2H..HYQ[5F7,6]>W)Z'H
M#Z5J7 R>WO[UF7Z%EPFTX/?B@9SOBC3/[<TFZMMI_?(<$ 9R.AKP;X87/_"M
M_C:;+88M-\51M"Q=OE6=>4X'1L@C_@5?0-X\PE!5%?;S\LG./Q%>'?'+2_L,
M5S=1+Y%SI5VE_"Q^8J/O9R/>@#UB>+'(79C@\Y(/K5:>,E"N.O 4]JECO5U*
MWANXR/+NXTGCQR<.H;^M,N%.><$#@,Q_PJ2S%UJW\Y#EL<$9ZC%<+X@B4S+E
M?G(R6!KOM5A#+P">#@)7'>)HV20!^C\KD_KQVJ&:1,&:)B#E?D4_>'//K3O@
MGJP\%?M1>%;C?MAU*2;2F!Z%9(RR<^N]$Q]:)U*LV.5'8'KZ_C7,^++PZ#>Z
M;JT;JL^D7L%\N?O?NW5^ON!@XJ+V9KNK'Z 45':W*7EM'+&=T<JAU/J",BI*
MZ#B"BBB@#SC]L#X:)\8_V5OB)X7>/S?[;\.WMLB?WI#"VS_QX+7X@? ?5FU?
MX0:#(^[S8K80.'^\&3Y37] K#<,'D'@@]Z_ C1O")^$_Q?\ BAX$<MGPCXKO
M[6$-VA\YC&1[%"I'L17Y?XEX=NE1KKHVOOU_0_5_"W%<M>MAWU2?W'W7_P $
M:?&0T_XG^+M!9N-3TZ&]C!/5H7*']''Y5^AM?DA_P3W\?CX>?M:^%)Y'"0:C
M,^FS,3QB9=JY_P"!A:_6^O6\/<5[3*_9=82:^_7]6>3XDX3V6;>VZ3BG]WN_
MH@HHHK[H_/@HHHH **** "BBB@ KD/C9\>/"7[.G@6Y\2>,]<LM"TFV!S+.W
MS2M_<C099W/95!->'?MU_P#!3WPK^R(#X>TB!?&/Q'NEQ;:';2?+:9'$ETXS
ML7H0@^=NP ^8?DW^T#^T;XE^-'C]O$/CO5U\5^*4R+>T_P"87H"_W(XQ\I8>
M@S[DFOA>)^.<)E:=&E[]5=.D?\3[_P!U:^A][PQP)BLSMB,1>G1[]9?X5^KT
M[7/I?]KG_@K?XR^.L4]MX:GOOAG\/Y/DCF&/[?UP?[('^H0\<#GU;G%?(5S\
M5;@WTCZ9;1V+2$L]U<'[5>SG^\\KY.3[5RM]?W6N7S7=Y/+<W$G#RR'H/0#L
M/84^*$KTR/<]Z_GK/.)<9F-7VE>;?Y+T6R_/NV?N^59/A,OI>RPD%%?B_5[O
M^K'46OC+69GW/JU^[-T+2<#\*]3^"_[7?Q"^"6H1W/A[Q!/9LA&Y"NZ*< _=
M=#\I'X9KQ2PF^;]!70Z6^]NO %?-+,,7AY^UHU'&2ZIZGL>PHUX.E6BI1?1J
MZ^X_8+]A?_@I+H7[4\*:%KB6_A[QQ&O_ !Z;_P#1]2 '+V['G/JAY';(YKZ>
MK\ =#NY].OH+JUGGM;JVD$L,T+E9(77D.K#D$>HK]0_^"='_  4+7XZV<'@S
MQG<10^,K:/%K=MA$UE%_03 =1_%U'<5^^>'OB;',91RS-':M]F6RGY/M+\'Z
M[_B/'7AV\%%YCEBO2^U'=Q\UWCWZKTV^NZ***_:#\A"BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "L7XBZI_8_@?4Y\X(@95^K?*/U-;5<
M+\?]1^S^#HK;/_'Y<JI_W5RW\P* /*]*BVJ!@>E=!IJEE''_ -:L734&!6_8
M)L4=A0!<+?)Z^U5;AN*M-PM5+EJ *<S9_P :YWQQ?"UBM5(!V>9=<MC[B\$_
MC702GFO,?VB/$/\ PC_A36[I>7MM/$"!C_&^3@?F* ,;]E33WE\&W^KR,9)M
M>U2>ZW]<H#M7/Y'%>PV_XC/ZUQ/P4\-_\(K\+] LF&'ALX]Y _C8;F_4UW$>
M5^GM0!\\_P#!0'Q(?A'JGPP^)=_#=R^%O!FIWUKK5Q!&9#HBWMHUO%?LH&=D
M4A&YARH;-?-.F? :_P#"NC^ ?'^OG]E.Z\)_#OP^UC;WE[XE=K'4<R^<+Z>.
M,_OY1DE496PQZ9KZA_;D_P""D7PR_8!NO#%C\3;;69;#QU%<I&UG8B\A$<6T
M2+-&>JD,..:?\ /V3_V:/C7X1\/?$[P?\*_"%QI?B%1JNFS3Z>PBW$\2?9V.
MQ&SVVUZ%.4J=)3G%I/9]'O\ \'_(770L_P#!/N_O?B_XA^*7QGETZZT71OBE
MJ%C%H5I<1&$W%E8VYA%ZL9 *),Y8H",E0#7T[:#*@]3ZCM5.UMI)8%>-/W2*
M$&Q,+&!T  Z =A5RU.".H["N*I/FE<9H6OWL=O7TJ[;XSGG/6J=O^! 'YU=@
M;.",=?QJ +48^3Z<\BI9+=D )1E!'&5XIMEA+A"YX##)-?F/:>-?%?P?^-/Q
M%_X6!\<_BM\%-5?Q-=3Z5:WNC'5/#$EBSY@>.9E*E6'50PVUM1H^TO9[?UT
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MD;[6^R^G9Z=CVFBBBOT\_+PHHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MWA;2OV._V@['3K#6M3^'U[XUM8%ANK^>W/AC5KF4#!D*@1%&/7 X!-<5\4/
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M;_>C,D./PQ7Z1,)?LTOD[//\MC%OX4OCY<^V<9KY[/[8?Q.^&BR6OQ=^!?B
M:>"ROK'A&5=?T]HQ_&\'^M08YQM-%*LVK)?<[?@[@?.'PA^.OQ5\0_M8Q_#?
MX0?M*:+\3]%D\/R:_;W/B'1Q?/9M&X0VUS.@5E+ @JW7@Y%0^._V2?'W@_7]
M1\2ZI\%M<M=2OI9+B]USX0>/)[>2X9LEY/L4[;2QY. ,YKZ]_9_^._P3^)U_
M=O\ #_4?!5KK>H+B\M(K*/2M5D4\8EA94E]>HZUP^N_\$V-*T"^N;OX?_$OX
MM?#*\NI)'*:?K1N[/<V22(9PV 2>QJW77-9JWR_.UOR N?\ !/3PQ\/O#7[*
M^F-\,KK7=0T'5+^YO;ZZUMRVJ2ZB6Q<"ZSR)E88(]J]>N 7+'CE>?:N-_9>_
M9ITO]DWX-Q>#M,U/4]:4WMQJUYJ>H./M.HWD[;I9'QP"3VKM+IB8E?!WMV;U
MSR#7%5:<VUJAG"_$NU\RXT^; VOYD#YXW9&<>]5/@C-O^&\5NX(?3+V>VZ\'
MG</YUM?$FU_XDL<RG_CUN(YASG()P3]>U<Y\'V^RZOXLTQE7]U>1W8'3AU(.
M*@?4ZNX?8H]#E<A:S-3C*1@?@I _2M>YCVA=HQY@Y5?X3Z>U95W&) 1N^Z,[
M3T^AJ&:(Y[4T*-*H#;,?=7KBN<O8RYXSO!QENWU%=+J)^?)DSDJ5]1GJ*P-2
MA)G#[<\@ @9)[<U)9F7Z?:+8G \Q5VC X7_$5]#_ +'FM#4_@G:6_&=-GEM>
M.F VX8]L,*^?[Y%^R9?)4GC![YZ'V%>L_L2:C]GC\3Z69"_EW,=V@/8.NTX]
MOEJHD3V/>:***LR"BBB@ HHHH S_ !9X5T[QUX8U#1M8LK?4=*U6W>UN[6XC
M#Q7$3J59&4\$$$U^ W_!0O\ 8UUK_@CM^T-'K6DK?:G\&_%=P1I]TYWM8YY:
MQG/JG)C?^)1Z@U_037#?M(?LZ^$_VK_@MKO@'QMI<6J^'O$%N8)XFX>)NJ2Q
MMU61&PRL.A%>+GF2T<RP[I55KT?8]O(L[K9;B%5IO3K_ %_78_$JV^)^C7GA
M"RUFRN!?6^I1>;9QQM\TH_VC_"!WKA?$WB&Y\5ZLUY<^7YA^4>6NU5 Z#_Z_
M>N8\5?L<>/?^"=W[3WC'X9:]=PZOX(M94N=+U(L-\B39,#*H/R9 (D4X 9<C
M@BMJYD%I'C@N.<+V]Z_F?BO(,=@:RIXE6I/9][;_ #7;YH_I/(.(L+F5#GHO
MWU\2[7_1_P# >I'(1;PYY.<\>I%49I//DS[]!VI\LK2/DANV#ZGWI/*7?CMS
M7R,YJW+'1'L-MB(A8?7I4]I9^<W [U):VC7'&TY(]/Y5U?AOPINVN1WYR.M=
M6$P,ZS\B)24=REX=\*M>2Y8&N^T'PTML@^7FK.D: L$8P,GI]:WX;:/3XM\G
M6OL,-A84HVB<DY.3&V6G+!'OD.,5G^(?%*VL11#@52\3>*_+! / ]ZX+7?$3
M7+$9.*QQ>/A1CH:4Z+>Y=\0>*FN&(#&N8N]2,AY-17=YO/WJH3W/%?(8G&3K
M2\CKTCL3RW>:@DNOESGVJI+<>]5Y;ODY_2N>-,SE5+$USD57>Y.[BJLEUN;
MS["N^^%OPR;4I$O;Y3Y?5(S_ !5[.6934Q=3D@M.K.#$8N-./-)G?_LY6<VE
MZ2T\P*-</D ^@KG_ (F^(DO?B!>LC C<%S]*N?$?XI0?#[3OLUL5:\==H5>D
M8KR.W\5M>3//(Y9G.X^I->_Q11I4L)# TM6K'/E6)E*JZLNI^L7_  0Y\:O/
M\/O%WATS>;!;W,6JP _\L_.#(ZCVW19_&ON^OSS_ ."$N@7,%IXWO'1A##!8
MV1?LTO[V5A]0)%_.OT,K]ZX!4UD-",^B:^2DTC\%X_Y/[=KNGUY7\^57_$**
M**^Q/C0HHHH **** "BBB@ HHHH **** "BBB@#QWX[7WVKQI%#VM[=1^)))
M_I^E8&GCD9JQ\0[XZCX^U%\[E$NQ?; "_P!*CT].E &M:+N4?UJ=B,5%:\BI
M)7R* *US]VJ3#S) /4BK=P<DU2D<(2Y^Z@+?D* /!_CW='Q%XBTC33M?^UO$
M,2<#H$(Z>W%>RVOS2-TSD^XKQ?40=>^/O@JU;:/L*75\XV]  <''UKVBS_7.
M.E %N,XZ?_JJQ$07'N:A0[OSQ4D9Y]: /Y_?^"HVD#XI?\%OM?T/5<FUU'Q5
MHVERH3C$!2$8_$?SK^A.&TATZ**UA58X+2)((E5>%5%"J /0 5^"O_!PA\--
M5^"?_!2"T\<6(,:^*-/LM;T^8# -U:L%=2WKE%_ U^RO[#_[66@_MN?LS^'/
MB%X?GBD-[;I;ZM: _O=,OD4"6%UZCG)&>H-?0YLI3PF&JQ^'EM\]/\OP(CNS
MV& [DZCK5?QM\/-"^+G@?4_"WB:PM]5\/Z["UM>6LJ;E92,;AGHR]0PY!%36
MS_+D^N,5H6J%Y@HP6) SCO7SVVJ+/P@\':%J7_!-7_@JYI>EBY9XO"/B>.T6
M9CC[5IUP=HW>HV,,^XK]_I0B2XC&8B<KGN#R/TK\%/\ @KQXOL?'O_!4_P 3
M/IDB2)I][IFF2O&<@SQ% _/J#_*OWCTK=_9EEDY;[)!N)_B/EKS7LYM>4*-2
M7Q..OX?YDQ[$?C'54T+P+KM_);W%Y'9Z;<SM! <2S*D3$HA'(8XP"*_,/]F+
MPA\9/&OPQTOQQX.A\:ZAX?UK?=Q:?X:^*C3WNFQ%VQ'-!=AAY@[C(]*_3[Q-
M#>7?A/58M/=UU"6RG2T:-PC+,4(CPQX'S8Y-?G)\-?A?:?"F;2M<^,/[-/CS
M2?'6BW(NKWQC\/[C[7::G(KDB:6.W<?,W&\;,$YKDPK7+)==/ZM=#9S'CGXI
MZ#\0M7U/1OB'XN\=:3JOAYDAU-?&OPQM=3_L]W^9-]]9XF3(R00>@S7:_!&3
MXI6EY#+\&/VG_A1XRT["@>'=>N)'$A_NHDS>?$/0 UTGC7XX?"_XH?'74_'?
MPQ_:!;X.>-/$MO!9:_H_BC12EAK1A!$+2P7(4+(H)7<IY!J/XC?LW^.OBWHE
MU-K_ ,'O@!\;[66$B/6/!^H+HVKJ2IPZO]T.#@\-73I9)Z>32_5+\Q'M#?M/
M?$SX40 ?%CX-WZVB >9KO@>X&L6@]7>W.)8Q]-U=W\)/V@O!7[0>AW-_X)\2
M6NMPV;!+N)(WAN;)S_#-%(%=&.#U':L#_@GY\-/%?P2_8\\)>&O&=M/I_B33
MOM#3V\MZUY-!&TA,2R2DG>P3 )Z5Z6^BV5IJ=U>V]E96]W>J/M-Q# D<ESC[
MH=@ 6QGC->;5Y;M)?=M^OYE(Q/'-C]L\,WF5!"1>9M_NX(/'O7#_  _O%C^*
MUUN^?^U])$N,<DHP./K7I6I6:W%O/$PXDC:-E'3D?SZ5Y1X;D2Q^*7A&4+N>
MY26RF;G+$@CD>W%9#/2;F$I)\I49/WB>OU]ZRM2783E3R.",X_\ U^]:]RBL
M.G0$C_9K/OF+1>JGC:_\)]#4LM'+ZD@2%L[22W*A<''^>:QK^$E<JH+*-S-C
M@CUQ73:G&I'/! X!Y+>@K U)$DB+=,' (X_.I*N9KQ9@P2O/S9')(_"NR_98
MU :9\;)XL,O]J:<RD$\9C8$?CC-<O&@%P&QT4L2HZ?45>^&&H'1/B]X8GRQ+
MW7V=G/'RNK+@_G36XGL?65%%%69!1110 445#?ZA!I5E+<W,L=O;P*7DDD8*
MJ*.I)/ % $U?&?[>_P#P4R7X61WWA'X</%J'B==T5[JP3S;;1_4*.DDW.,<J
MIZY(Q7/?MD_M[WWQ(^V^$_AW>SZ?I(W0WFMQ@K)>]BD!ZJGJ_4]N.:^37^'8
MLK=609B7YN."[-Q_^NDV4EW/%O%NB7>OZW=ZGJ%S=7VHW[-<75W/(TLMPYY+
MNQ^8G@#V^@K@[R*73)H(YT(1P3$=OS ?[7MZ5]&:_P"")19-) H.W<NV3@@#
MJ:\O^(/@@_9FMTC57"Y(/R[<#.WW_"O*SC*,-F>$E@\6KQE]Z?1KS7_ V/4R
MG-<1EV*CB\,[27W-=4_)_P#!W.$12X^;\"/TJ[8:4UU)PC9SW%9>A:C]DU#[
M)?,D66V12!=J@'HI]_>O4O#?A$08W*<XR<]Z_F+,N$<3EN.EAL3LM4^DET:_
M5='H?TIDV?8;,\)'%8?YKK%]4_T[K4J>&_"'"E@.F,'H*[72-&6)0% SBK&E
MZ*$0   =<U:O-0BTB''&[%>A2I1IQLCM;<F2N\6E19)&[TKE/$_B_P"5OF_"
MJ?B;Q>7+?-^M<5J>KM<$DM7FX[,HTURQ.BE1OJRQJ^N-<LQW5B75WOR<TRXN
M:I3W&?\ &ODZM:565Y'0VHK0=<7.?K5.XN-@IL]P *I3SYS^M7"F<LZ@MQ<D
M?UJL]PSO@<G^=(V^YF$<0+LW  '6O2?AK\)A:%;[41\P^98ST3W-?0Y3DU7&
M3M%6CU9YF*QD:*NR+X7_  K:]9+V_1@O6.,]_K71_$CXIVO@33_LMH5:\*[0
M%Z1UB_$_XSP^'8GL-+97GQM:1>B?2O%=3U>;4;AI99&DD8Y))KZ_$XNAEM+Z
MMA=9'CQC/$2]I5V[%O6O$,^L7LD\[EY'.[<>U:7@B >;'?SH\L2R!;>!!EKJ
M4D!5"]3\Q'U.!7.6$*7R-<73;--BZGH9SZ#VS^?:OUA_X)$_\$M9-+N-)^,'
MQ.TTQZE&%N/"V@7$>!IH_@NYD/\ RVQRBG[GWOO8(PR#AO$YIB=?5OLN_P#D
MOT,<WSRAEF'=:IOT7=_U]Q]7?\$V_P!FNZ_9E_9=TG3=7B$7B76G;5]87'S1
M3R@8B/O&@1#[J:]\HHK^C,'A:>%H0P])>[%61_/F,Q=3%5YXBJ_>DVW\PHHH
MKI.8**** "BBB@ HHHH **** "BBB@ ILTHAA9ST0%C^%.K*\;ZA_9?A#49\
MX\NW?'UQ@4 >#27'V_4Y[C[WG2M)^9-:E@O'\JR-/7"#\Q6WIZX[?C0!IP#Y
M:69N*(>!3)CSS0!5N#D5E>(+CR-!OWZE;=L8..O']:TYS@5@>/''_"*W"D,?
M-=$P.I.<]?PH \B\ V_]H_M(ZI*VUQHNBK KL26#R,,@^G%>R6@ 4=>G>O)/
M@,%U?Q]X\U0#Y9+Z&R1CUQ&I//YUZ[ ,+T^GO0!.@YZ9]JEC/S?Y&*A3E^F.
M<$>M2+\W<<_K0!\U?\%6O^">\'_!0W]FU]'TXP6GCOPT[ZAX;NI?E5Y,?/:N
MW99  ,]CBOPP_9^_:L^,G_!,'XY:L/#MS?>%/$5A*;;7?#VIPEK2]*G[LT)X
M/LZ\XZ&OWW^)/_!3#X&?!3XW:E\.O&7C^R\,>+-(2*2XM[^"180LJ!T(E *_
M=(KF_P!H[]E']F?_ (*K>'XI-2UCPCK^LK$$LM?T#5X8]5A7H 3D-(OLX-?0
M9;F#PU/V.*IN5*7E^5]U_P .B&KZH^3OV>/^#J/PMXGTR.'XB?"K7-.U2,8E
MG\/7:3V\S=RJ2;2H]LFNI^.W_!QG:^(O!%W9?"7P7JVF:Q>QM&FL:\Z?Z!D8
MWI$A.YQVR<"O(O'?_!J9XJ\*ZU)=> OBEI6H:<\A*0Z[8/%,B^F^+*L1^%='
M\*_^#<7XC?;(D\3?$'PEI5B"!*;&"6XN,9YVAL+^===6&2\WM*3T[.XO>/GC
M_@G[\!M8_:^_;<\+:._VC4C+J7]N:_>RY;9#&_F22R-ZLW ]2:_HCDE6:8F,
M;8R<*O3"C@?I7AG[%/["_@/]A;P'-HWA"UFN+_4V#:GK-[AKW46'0,W\*#L@
MXKW"R@DF^X"W/ [_ )5XF98U8BI>/PK1%15C-^)&F:AK?PN\366DO*FK7FDW
M4%DT;A)%G:)EC(8\ [B.3TK\SO@W\.;/]G[X<Z;%X]\(_M0?"WQ981[-2\1>
M%M8EU_3;V?G=.RPM(H!/)!7CI7Z8_%#P?>>-_A?XDT"VOY]%OM<TJYL+>^12
M'LY)(RJR#Z$YK\_/@=^SGKW[&#>&9-6^ OQ1DUGPM*/.USP#XQ:[L?$$B]9;
MFTED7=YG4J00":G"R2@U?^OO_1C9=L/B1;_%H+IFB_M(_!_XER'Y?[$^*OA:
M&WO<=D+X20-[XK.\3_LP:CX&BN=;O?V>-0TRVB0S-XB^#'CAMP0#+2+9.WS8
M'. .U>N?$K3/B[^V89(+?]G#X8^%-(G^YJ'Q#$=Y?2*>N+> 94^Q>O!M1_91
MU_P;HFJ3Z)X-TZZL+1)DU&Z^#OQ'ET^2%5!$H^PSLX+ !OD!'(Q71&2VO;[O
MT:0C[E_9.\2:1XO_ &:O">IZ!XJUSQOH][;,]MK.KX&H7(W$%9\ ?O(R"IXZ
MBNZF41Q]C[=,_P"%?(?[+/PJ^*O@S]G3POJ?P.^*7AKQ7\.[RS,VCZ-XQT%;
M>6W4N3)&T\!W>8'W!B<\YKZ!^!OBGXA^+/#]]_PLCPCHWA'5K&=8(!I6HF^M
M=1CQDRH6 9>>-K5Y]6FE)M/K\_NT*1UTG\);(8G/S#L/7TKQCQ.LFCZ[IDP#
MA--UW<=@Y568?IST%>U7O[QB?ESP3D\C'2O(?C':M;Q>(MT4CH'ANT5!QV_&
ML1GJ-_:B.\E&T@J[*21G>,\8K*OE<(H7^(X(SSS_ )ZUI0W7]HV-I<+@1S01
MR;@<[MR G(['K52[54+ $G@ _P"R.U(HYS4H4WL(_F+G QW/8\UBW5MM<K(C
M$?P\\,._%;^IIG>V!EL9VG.[;Z>]9,UMMN-_  &X-D<__JI#,Y(O+.U>4R4/
MR]*:?-LKF*Y )-C(C(Q.-C*X;\L"KT%ON)W9RW0KW'7!!X!J5;3[3"Q9,%V9
M'?/!&.* /J.VN%N[:.5?NR*'7Z$9J2N9^$7B>/Q/X%LF5U,]J@MKA <F-T&.
M?J,'\:Z:J,PHHS7C?QP_:RLO!#3:5X=6+5M:VD-+G-K9'I\Q'WF_V1^)[4 =
MW\5_C)X?^"_AXZCKU\MLK96"!1NGNG[)&@Y)_0=R*^*?CI^TCXF_:5NS9,KZ
M%X7.XIIP<[KO'>=L?-S_  CY?KC-0:]8ZGX]\02ZOKU[<:GJ4K ^=(?EB7^X
MH'"KGL,8J_I7A+[-*D;I&'D89VC/Y^M+<M(\XL/!$:0E<;5'<C[Q'8Y_E45W
MX?C6V(:(]<?O/XQ[>A_PKT"?2HXYL@F3:S??49SZCV]JSK[12ZJ/D& 5#*?O
M^YS_ $H \H\2>&$=)&VY=#A"1]P= /UZ^YKS?QSX%A,+QD"2':6C4'B/VSUQ
MFOH36-#64.L7"[0%+-C;]1[UR'BGPBK[Y6A_=<[]HSMXQEO3_P"O0!\=_$WX
M=%X95R=Y4M'LXX[$^W85?_9\^*O]L2KX?UAO)U"#Y;:1^/. _P"69)_C';UK
MV'QK\+]\5P-K;  6$?\ "/X5^E?/OQ?^'EU8W:S6ZF*XA;,6QMOE;3D<_P![
MWKP\]R2EF>&]E/22UB^S_P GU7ZI'O\ #N?ULJQ2K4]8O24>Z_S71_HV>Y:M
MK<>G0E5(!KA?$?BDS.1N_6N.\'_%J7QEI#0W9 U2R_=W'S9\W'&\?7O1>7YD
M/6OYFSZM7P5>6$K+EG'1K^MT]T^J/Z6RVO0Q>'CBJ$N:,E=/^NO1KHR74-3:
M1^3UK,N+G)Z_C3;BXJE-<8^F<U\BW*;O([I2L.GN<CZ52N+C'0TVYNN>M4IK
MCOFNBG3.2=0=--FH["PGUB\6"W1I'<XXJ?0M"N?%.H)!;(6)."<<**]=\+^$
M+#X<Z,UQ<LF\#,DC?R%?5Y+D,\4_:5-(?F>1C,=&DK+5E3P!\,[;PK:?:[TJ
MTR_,6/1*Y3XL_&TRB33]*?$8.UY1_%]*R?BK\9I?$<KVEDS16:\<'F2O-[FZ
MPI]:^@Q^:4\/#ZK@M/,\NG1E.7M:V_8DNKTN[%F.3R233+)K.[F<7LC1QHNX
M  _ONPCXYR3V'7I52""YU;5(+2SM[B[O+V58+>WMXS)+/(QPJ(HR68D@ #FO
MU[_X)/\ _!%V/X0R:7\3/B]907?BY=MUI'A^3;+!H9ZK--C*O<]P.5C]VY7/
MAWA[$YGB$J:]U?%)[+_-^1Q9QGN'RZE[2KOT75_UWZ?@8O\ P2=_X)%S+?Z7
M\5OB[I'E2P[+KPWX8ND_X]>Z75TG3?C!2(_=ZMSP/T_HHK^A<LRRA@:"H4%I
MU?5ONS\.S3-*^/KNO7?HNB79!1117H'FA1110 4444 %%%% !1110 4444 %
M%%% !7(_&^^^Q_#ZY7O<.D0_$Y_I775YU^T/>;=*TZW!^_,SL/8#C^= 'F^G
MQX_STK;L.1]*R+$?*/Y5LV(R!_2@"\/N^_7Z5'.V14B\=N<=ZAG;% %2Y;D]
M/RZUS7Q#?&CVR?=26=F+'H-JY_.NCG;]:X#XX:I_9NB!L@B.TN)2I&<?*<&@
M#E_V6X,^ [R]+;WU35KFX9R?O!2$7^M>JP#Y?\\5Y[^S7IQTGX(>&HWZRVIN
M&&.[NS'^E>AQ<+_.@"8-\OJ*D5L_AT]JB3C^E2(V!_(^E 'Y,?\ !6C_ ((Q
M?'']JO\ ;$\7?$[P/8^&M=T77(;1+>Q?45@O4$,"Q-N5_EZJ<<\BO@/XE?\
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M5##QY8K^OO/Q;&XZOBZSKXB5Y/\ JR\@HHHKK.0**** "BBB@ HHHH ****
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M1LB3L6//I7UF"R2C2HK%XQW5KI*[^_\ JWF9N3O9'FWAB?XU?\%+?VF97?\
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M)7Q]<*,*H. !7KM%%?M]&C3HP5*DK16R1^05JU2K-U*KO)[MA1116AF%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 5\^^+KO^T/&VJ2YZW+ 'Z'
M;_2OH":3RHF8]%!-?-\4QN[B64]99&?GW.: -.P7FM:V&!678C"_TK5MTP@^
MF: )&&5]*JSGFK+\54N.: *S#S)5^HKP+XX,VL?$;PO:E2$O/$8=R""K;!P/
MTKWS_EL.W/)]*^?]4#ZI\?\ P;%@$)+=WC$MZ*1D#\?UH ]J@.XDG).235E&
MX'2JMH/6K0&1^';B@"2-B1^F*E20AOIC%0J>?QJ1!N&/TH _-;]N?_@WPO\
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M7"Z':6QT]Z\W\5:UYD#<KE<;N.U:?B?7UED/3C.5)^[[UYUXJU?$A^;J.F>
M<T 8'BO505)W$9)PV.?IBO*O&VJ+&LC>9C^)AQ@8]_Z5U_C35,QG#;N#T.>1
MVKG?A5\%/$7[37Q1M_"WA>-O-G82WM[(N8=*@'WII#T..BIU9L#U(!F-^S/^
MR#KW[;WQA_L&P::Q\-::R3:]JX_Y<X2<B&/L9I!G:/X1ECT&?V0^%7PKT#X)
M?#[2_"WAC3;?2=#T> 06MM"N JCJ3ZL3DDGDDDFLG]GKX >'OV:/A?8>%O#E
MMY5K:C?/.P'G7T[??FD/=V/Y# ' %=O0#85^>/\ P6I_X(W6W[9N@-\2?AS:
MV^G_ !<T&,2-&F(T\20I_P L7/03 <(YZ_=/&,?H=17-B\)2Q-)T:RNF;X7%
M5,/456D[-'\JUKJES(MU;ZC:SZ=JNF3/;:A9W2&.:TF0X974\J1Z&ONC_@ES
M_P $=M7_ &O9K/QQ\0X;W0_AF&$EM;',-YXEP>B?Q1V_J_!;HO=A^F7QQ_X)
M3?!?]H3]H[1_BAXA\-EO$6FL&O(K>7RK/72O^K^V18Q,4/(/![$D<5]%VUM'
M96T<,,:111*$1$7:J*!@  <  5^?95X>4,/C)5L0^:"?NQ_^2].Q]SF7'-2K
MA8T\,N6;7O/MZ?Y]/RH>#O!NE?#WPM8:)H>G6FDZ1I<*V]I9VL0CAMXU& JJ
M. *TZ**_2DDE9'Y^VV[L****!!1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% &;XPO/[/\)ZE-WCMI&'UVG%?/NFKA5'X5[=\7[K[+\.]1]9
M56(>^Y@#^F:\5LAA<_A]* -6Q&X#^5:D"Y7BLZQ'^?2M&/A!_(4 $O3^=5+@
MYJU+52<_-0!2OI1%:SL3A5B<Y]/E->%^%XC?_M)6.Y#_ ,2[09)0W]WS&"X%
M>V>()C;:!J#J.1;N>>W:O&/A26O?CUXGF(RMGI5K"ISRN]BV/3M0![!!@CC.
M !BI\X7ZU7A&%XZ9]:L*<?2@!ZDE<]/?UJ2(8/'S5%%T_I5FP3==1#CEP?KS
M0!\V_M%_\%>_V>OV5]=OM&\2^.DOO$.FRM!<Z1I-L]W<02K]Z)\#:K ]B:^.
M_C3_ ,'1>FV?FP_#/X4W=Z^#Y-]XCO/)0'WACY_6OSA_X*"3QW7[?WQJ=<*&
M\:Z@)"HY7]]@FON3]@7_ ((3?"+]K[X=0>*X?CS-XJL]JM>:?X?L5M[O36/6
M.99267GC.W![&OL/[,R_"T85L5S.Z7>WX?JS/F;T1\[?&;_@X&_:@^,6MRV,
M'C.P\$Z:_ M_#]BD#[?[ID;+&O,4^*WC'XP7XN/$7B3Q5XIO)3N/VJ\FN3D^
MB@_TK]6?VIO^")W[.7[,/[$7Q3\4Z)X2O]2\4:-X>GN+74]6U*2=X)5 VR(@
MPJFO&O\ @UUTVVU+XM?$FYN+:TN)K;0K4Q//"LAB8R<E=P.#]*Z5CL%]5G7P
ME*W)9=%>_GJ*SO9FS_P0_P#@/XP\._MF^$?$=[X.U_2] LM-O?,U"YL'@@1G
MB(0;F ZFOV4M"%P#DCC<155+R26+:9&V<?+G _+I5B,<>YKY#&8J6(J>TDK&
MB5CY+_;M_:&^-/PT^#/CRSN_@=HGB[PI.@M8-5M;\7=O/:R2HA^TV9_>;BI(
M^3HV#VKQ?P]XJ^'GPDL;6+3/B5^TQ^SF\4:'['KMC<7FCH2!\J^:K@Q@]/FZ
M5]E?MS^%?&OC?]D+QQIGP\EO8_%]U:1_8Q9N([F55D5I8XF/20QA@OO7RY\"
MA<>,O%.G>#/!WQH^/_@#Q9=VV(O#GQ'\-C4K*21$RX#RQ@$=>C\UT4))T^WW
M_BK/\NX/<M? V3XC>'/B)XO\8_#KXQ_ KXUWGCU+=-2LM38:/<SI#&40 (>"
M48@Y'-<-\8?@;K?PV\*WM[X>_9E^(WPT\?HIFTC6?AYXF$^D_;<Y1IDWX\DG
M[V5QMS53X6>'_$_[3T6L_P!M_"S]G'Q]XD\.ZQ=Z-J5C%*WA7Q+$T+[!(-F#
M^\'S*0<<U!\4_">F?!OP#J6F>+]._:I^ 7AG4E^QZC-9:K_PDNB/$Y"E-Y9I
M(U;IG(QFNA:3LM_ZZ)J__@))]^W'PFTSX[?!SPY!\5/"V@:_KD^D6YU19;96
M,-V8QYOERKAU^;/*M75Z#X?M_"/AZRTRP22.QTN);:%'D,CHBXV@L>6(''-0
M?#O2K#P]\,/#&GZ3)--I-EI-K#8//GS)(!&HC9\\[B,$YYR:U&)+=2/<"O'D
MWMT+&2G=+TP/8YS43Q&0$X)+$@"I]F6)&<_7%,EB;)P_.>2/0=JD#PW2(/[*
M^)/@V5R@2/4I;3.[YF)++@_G7N87R#)D%B,;?\_TKPOQRR:9XNM9!M+6GB)'
M (Y(9@3R.G6O>GBVRR8RV&/RYZF@""2)EX.[*CH.@K.U.V\P@MO80@NQ(R#]
M/YXK9V8S_=/7G-4KV D_>8>6<JH/'T]QB@9Y]XDC,=Y,_P IDC)ZGCD?SJ_X
M5?S($;^%DP !_$?Z^]5/&MKLN90#EF)^0' 'UJ[X;W?94)(.!\V&X'U% CHH
MP-AZJ%4 9ZKCKDTR>W"D%54C.<=^>X'<TMD"%*J @+9#$<#_ /75H+')$N <
M$'Y?X<T <VU@"?*E0#YBY;.=V>F:V-,TM(T#-O5]OS#'&*G@LMLQ..">YY'K
MFHM2U-(XV57Y4<L/XAW_  H +[54@AP2!Z'^][BN:U'52F=[$G/&3P:35=6V
MJ<MQV![^E<MK.M;/[O3D9_6@"#Q?K N-.NDR.8RP!/ Q@_TKC]=\0^<BMG&[
MDGTX_G5K4]=\RXV@C]YE>?XL@UYYJ6N^;9ID[=J@.!VQQ0 GB'5Q+O*<GN >
M1_\ 6K@O$NN;=P'S 9/!ZFM#7]720-V)!.<8X^E<DUI?^+O$EOI.DV=QJ&IZ
MC*(+6TB_UDS^WH .2>@ )- %/PMX,UOXQ?$*S\-^'K)[K5=3;;$O\$*#EY7;
MH$4<D_AU-?IU^RS^S-HW[+_PWCT?3\7.HW1$^J:@RXDOI\<D^BCHJ]A[DUB_
ML;_LFV7[,_@C=<^5>^*M516U.^ SCN((SVC7/XG)->RT %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!
MQ/QZN/+\$K'G_77"#'J "W\P*\GLQTX_*O2/VAI_^);IT6>LKR$?0 #_ -"-
M>=67R@4 :EE]VM",<51LDS[?C5Y.!0 R7@53N&JW,<FJ5P<4 8GCAB/"=\ -
MQ<*F!WRP_P *\G^ T!G^(7CV[;DO=V]LI(Y79'ROMC/ KU#XAW'D>&V'_/29
M$!SC'4UYK^S$PO-*\47Y9F-YKTV&(Q\J*%_G0!ZM!R/\*E W#\>E1QX(]<]J
MD!^7_&@"13\W'KS[T]'^;Z']:C4_,.N/7VJ1/F'7W^M 'RC_ ,% /^".WPO_
M &\+>YUA8D\%_$1E/D^(=/B %TPZ"ZB'$H/][[P]:_'+XN_L^_'_ /X(]?'F
MWU5Y=6\)7\4N-.\2Z0[/I>K)V5F^Z01UCD%?T@1' ]#GTK.^(/P_\/\ Q>\$
MWWAKQ7HVG>(_#VIIY=SI]_")8I ?8]&'9A@BO8P&<5<.O95%SP[/]/\ +8EQ
MN?D1J_\ P<&:'^U#^PG\3/AI\4=(_P"$<^(^K>'I;33=2TZ,MINMRG& R=89
M#C_=^E;_ /P:S1D>.OBH3_#I%FI]OG-<C_P4A_X-N=9\&7%]XX_9^FN/$>C0
M[I[KP?=OG4+->K&UD/$RCLA^;ZU\W?\ !./]O'QS_P $Y?BOJ5[H^EV]RE\%
MLO$&@ZK"8GF6-C\N3\T4BG.#7ORH82O@:D<O>LK-Q?1K^O3S(U3U/Z4H.OX_
ME5N(L&YS^=>"?L4?\%!_AU^W-X52X\+7KZ=K\4/F7_A^^PM[:?WF7M)&#_$O
MXU[%XD^(OA_P)<6$.N:WI>CS:K+Y%DMY<"(WDG]Q,_>;V'K7Q<Z<X2Y)*S-3
M@/\ @H!IGBO6_P!C3QW:>"1KS>)YK6);.+1#C4)QYJ^8D)_A9DW#<.17R'X,
M^,'AOX?:=I\=G\?_ (]_!358HE1M(^(6D-J5G#-@;E\R2,DC.>0_2OL7]N"V
M\?7'[*?BY?AC)?P>,EBB>!K$#[:+<2 W/V?/_+;RMVT>M?(7ACXW:6;*#2M(
M_:QU[2M1E10^@?%[PLMQM;&&1C(BD<Y_BKMPJO3^?]='_5Q,T?$OP9UW]HO5
M/[9GM/V:/V@=1G 5M3TK47\->()E'3,D+YW8QC-<MX\^%NJ^#/!FH>&/$FF?
MM6?"OPMJ<?V;48-/OX_%VD31,?F52^Z51[CD5U6I_LPZ]X_+ZA+\&?V?_BO$
MR[CJ_P /O$)T+5'X^\%4A03]:RM/UJ7X&ZC8VC>*_P!IG]G3[1<I;Q_\)/$G
MB+PXDA8!5DN#N"(2<!B1UKH4NB?]>B?_ +:(_0+P'96VE?#OP_9Z>\TMA9Z7
M;P6DEQGSFA6,!#)GG>0!GWK1=]P[CL:;IXDATJU6:>.[F$">9<QC:EPVT9D
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MT![4@/*/CI:AM7N,IE)])9>!EOE8]?IUKNO@_+]N^%/AYLMAM/C! ZD#C/\
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M[,C;G)_Z;$'G^Z.!SFOI&@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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ML<ZLX\T;&Q_"17KNHQ?;-.E1>NS>#MZ%><_SKS;QQI(N]&F"@,5 D1E[#V-
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M86K(! TDC+M?:^<J3S753_MR_$OX"^#K7Q5XJ\2_!?XO> +>X@M]2U;PK?\
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MMM\>/.B!\O!^\.Z'V/Z&@#U#X;R^;X#TENWV9,?E6W7/_"N?[1\/=*;:4_<
M;2.5P2,5T% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<Q\8FV_#K4?7" ?\
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M;;4\?V7XGM%TO4G'HRME5)_W:]&FHJGW7W?C9_FB37U#]OO7?BY\-+_0]?\
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M$=WXR\(J;[0=9$2XC:Z@0$JZ D<CD5Q5\+3I8F5*#YH]'W3U6WE_PP)Z&_\
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MT%NHVP1_]\_,1[UNJVYL<<^W2@"S&V1D !<=*MQD;.GOU_2JL7/.2I./P_\
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MF0_?E<_WF/Y#BH MR3FX<LY^9R3P.!]/\]J(UPF.>E1@[3].F!3XVSGWX^E
M%F+YATZX&?2KD$>3N[^U5(?E&.">#C-6[?.!P>/0=Z +$?S+P<<$<T,<+WZ8
M(Q2*,)Z?2E<9SSCC/'I0!2O5+[LXZ#@5@ZIA 3ALD]*W[U?\YZU@:M\OY<J>
MYH [+X/-GPHPSG;<./Y5U=<E\'"/^$;F _Y^&/3IP*ZV@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MD^N:O0ZPI/)'/4>] '3I>*J]/RJ=+L(?Z]A7,IK@8=?Q!J9=87=RW ZG/ -
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M6.\R<?Y-8T<Y/4Y)-65F/_Z^] &HMSS_ #IXN-HSS68MR64'FI%G+9[KGG%
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MWX(L+<C]X8_-D]V;YC_.@#>HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH ;(@EC*L,AA@CU%?.>H:;_9&MWEJ1\T$SQC(_A!./TQ7T=7A'Q3@&G_$/
M4%Y_>.L@ 'JHH H6+ KU)_KZU;P&7;TX[=ZJ6(#C!S@]LUH*2B\=A@^U %"Z
MBVJ3D# [5FW40!S6O<(,8_NC//:LV[C&>G.,T 9-XH Z<YZ^M4Y8NW(/OVK3
MN(UP>AXJHZ;UP/SH HO#N)ZGN2:9,FYN<9/.,]O6KC)N!YZCGVJ(P@G_  %
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M_P"&:]T4;1@< <"O+/ 5@DWCRT^7)B#RY],+C^;"O5* "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ KQ7XVIL^(4F,\P1MU[\U[57B_QJD#_ !#<
M YQ!&"!Z\T 85A\R^^,C%:"@NO3MQD]:H::@('. .Y'2M(1JJ[?FQG/TH KW
M"<$<<]3C-9UPH#=NG>M.;G/^36;=ISU[XY'2@#-N%V,>.HJJ\)0>N1Q]:OW"
M?-UQQCZ55=,OGD<8 - %=ER?FZXS^%1>4R-SDCK5K9GKP3QP::8]PP>>/RH
MA2+*],\XYIT<9W],CWJ6.+=(#QT[=*D2$$?W<<XZY_\ K4 1Q1>8.@SZ&I%A
MQC. #W_I4L2;WVG)]>.E3I#NR.>>/<T ,@@VD8PO;U_.K*0$#H%!X7CI2QP;
ME &,D\<=ZN6\.XXZ^Q'O0!\M?M01X_;+\#C<RXCLS@?]=3P?8U]47%KBYD;"
M_>) ]>:^9_VI+=A^V7X);+8V62-QT7S3S7U-=0;KN7H/F/- %%;?IU/? [U-
M%;9'KC^=3QV^%[L3[U,EOEE)'?F@"!(,GMZ"IQ%D<YZXX'-30VN\'@ 9XJ=;
M7:F?TZ4 5E@))Z8[''^>:>B$#_:]3VJ=;; R/ISW^M2Q0 CKM[#CI0!%'!V&
M.#R#^E2BWZG&" <^]2>3N/S#;GN/6IH[?8W<GN3ZT ,@@W+\OU QT%78( !S
M]SJV.<TD$&T<'CM5NWMAU&?0C'*T 216^<CC''([^E78853CH<]<=*2WM0TN
M>OMBK\%OC P3^% %:>W\Q1NQ^'>LW5+;$+$\$<@@?E6_Y.U!U./TJAJEMF/!
M&>,=* ,?X>VO_%:RR8Y%LV3ZY*UW]<9X%B\CQ1+UPT! S]5KLZ "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ KP?XJWWVKXCZCC_ )9E8U(/4[17
MN[-M4D]N:^;]2U(ZOX@O[O.X7%P[I_NECB@"_8@NHY7.,?2K_)3^Z.WK533H
ML*"=I(.<#H/2KX&/][^5 %:3)5N<<=15&5<'CL>:T;J/.1D'CD9ZU2F&T]<
M#OVH SIDYQSD XS59TVC![] :O2KNSTY[>M1,NT?=/OZT 573Y<G@^@H\G)[
M?3M5@QECZ@#Y>.10(B3V_P B@"&*(8'!P#4D<9 SUQR*D\K<O8<<C-2HA4#
MQQCIVH 8D!Y[9Y/O4\,6>6/?O3TBW'Z58BA[G//?UH 9;VQ<<''/!Z<U=MDV
MJP.>GS'W]:2*U5CNQN!X('<5:ABV8].,>] 'RW^U;&Z_MA^"'&T[18*%ZGF8
M]?:OJRZM_+O).WSGIVKY>_:KW0?MG^ <;!O%F#N&<_O3T]Z^KIX=UY+Z;STZ
M]: *0M,'H<=3[U.EMGGU''O5D6P8CI@\'ZT]+7#<$?4]J *\< 4X]/?^M/\
ML_RXX';K5N" #J.1VIYMMBDCC=WQG% %7R"KY'T]S3HX"%!8=_3K5B2#"@L5
M'OZ^V*D6+Y/I[]* (A&%Y(R>E31P9/?T)_NU+';%^5Y[C/3ZFI(X23TSSCV-
M #88@_J.^>U6X$YZ<]#38H^Q*^_M5VWC);G(SUSU:@">VA!*X'0=:NP)GCIC
MWZU#;QE!]W('./:KD,?[H8H !'NR/:JFH6NY3G&1T'O6DHX_#MWJ&Z@W#Z4
M<YX=3[/XEB8_\M%9.?SQ^E==7,RQ_8]7CD.?E<$D=^<']":Z:@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH P?B;KW_"-^!=1N=P5_*,4>3CYW^4
M?J?TKP728=D>U1P#W[UZ'^T9XD\R:PT>-EY/VB8=2.H3C_OH_E7#Z7;X/RY7
M/3/4?A0!JZ=&%3C:<]2IJ[Y("-C&#R?;TIEG!Y87CI\Q4=O\:LM'\O\ 7UH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M% &C14=M=)=Q;XSD=/H:DH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M:E>)9!R :SKS1MDOG0,8I!@[AW^M &G15/3M2:X/ES*$E'I]U_I5R@ HHHH
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MDY.:D5L#MZ9H F5P#M)Y]/6GY'ZXP3TJ(?+^/.?7\:>C[>@Z\_6@"<GD#_\
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M<0Y[UG3Q_-]:V+B+(_STJA=P8- &7*-I.._^<5"[?X=:LSQD=OP]*JR'Z=*
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M+H.A6OAC1;73[&%8+2SC$44:CA5 P*XO]G/X'6_P/\"I:L4N-8O2)M1N@/\
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MW8_2C=L<^G4FH%8>O_ZZ59/?_P"MF@"<OAO2E+@.>:KAR!C'XFDWX'7 /7-
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MB:1=UK:GYH])4_HTN.K=N@]3]$4 %%%% !1110 4444 %%%% !1110 4444
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MN>3_ "]JZR@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MQWA\=1,'C\4:X6!& K\#///%?2H\ QNVYHU,G!VL. /6H_\ A6HDE:X\E"6
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M_'+X':T?$NES^!M;\4Z7^[LITNWMXKG[9D7T[*R_(8&;?&O.\+@T >A^(?\
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M^!M=U[XA>-/AII&FZ?KUQID.HVFIB*RMD4XCM[AY2,7@_P"6B#@&OS*U>_\
MAQ9>#OVAO &OZ.NI_M3Z[\0-(M_#LT>F23:M>:C$EAB6SNE4[!$ZS&4AAP?F
MSFNB^#=WX#\$_M/:%K_QYM]%N/A):>,O&-B]SK=I]IT"T\3-)&?-NX\%,O$'
M",X(STH _3[6_C5X(\':/;:EJ_C7PCI.G7MH=1MKN\U6**"XM00#/&Y.&CRP
M!8<9(J_KWQ@\&^#?!EKXEUGQCX4T?PU?A3::O>:K##8W6[D>7,3M;(Z8K\P/
MV$O@EX)^-G[9?PFLM5\*V^M_">5?'&L^ =&URU,EH-,$T B98)>MOYC2M&K?
M+R"!7G_P_P#'7A71O#O@+P=J%I\*M&M?#FL>,1H>M_$R.?4?#&EVRZD8S96F
MGJ"EQ>@'*ACE5P%'- 'Z>>/_ -MSPWX)_:V^$'PN@U'PS>0_%?3;W4XM5_M6
M/$:1+_HZ0J#B0SMPI[XXKT:+XI:1XXE\2Z'X)\2^#O$/C?0;:4OH\6J1SR6=
MR%.R.Y1&+QJ7 4GMFOQL_9JMM.L_A5\ K^XM= ;Q$NF_$31/#FH7NGBW:34P
MS-800!QF&8,^8(B0R%@%P:]/_P""6WPZ\(7?[07[-EWH?QDT_6OB#I23RZIX
M9\._#Y+#5M/ B87T/B*]#^84\PE=TX9FDVE10!^F'[+7QW@_:7^ GA_QG#:?
MV=<:@DD&I6!.?[-OH7:*YM\]]DBL >XQ7H17CKG':OF;_@EYME\'_&>>T_Y
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MH5%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MZU^9'[76K_$WX)>);[X=V?QZ_:%^(GB#P[X5/B;[)X&TF$:G874ZM(LVL7K
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MN5P>M>M:WKW@KRBMCX92-NS2,S8_6N6EO=/5SY=E;#/;RZR=)]S6-==4<>A
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MN9>M5&D"_P">E18UYB]9R_.*Z+0G^85R]E+\U=)HDZAAD_\ UZJ,2)3/JO\
M9*_Y$6?_ *_&_P#017T9X(;I_NM_Z":\ _9A\/7>@^!8Q=QF%[N8W"HPPRH0
M ,CWKVJ;Q;:_#[PQ+J5ZW\#+!"/OW,A& JC^9[5U1V."H[O0\ TX_N+K_KXD
M_P#0C6[\33_QA[X?_P"QDO/_ $6M8</^@:<YE(5F+2R8Z*2<X_"O0?VD/AY=
M_#K]C?X>QW\;PW>L7L^K-&XPT:2C]WD>Z@'\:5'63:'B=(1B]SX;^*'WF^M?
MO;_P:S1[/^"56G\?>\3:J3[_ +T5^"/Q1.UF/?-?T!?\&Q6FIIO_  2C\.[
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MC[L<7DG[Q]3Q7(_"_P#9"L_BMK-M:16/Q!D:2;8SVNEKY4: ?,6?Y@N.>O\
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M% 'PS_P7G_X)TWW[=O[)K:AX4MA/\0? 8EOM+B51YFIVS*/M-FI_O.JJR?\
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M\*^"M)BTS383YDS_ 'I[V4@ RS/U=S@<GH  ,  5WU,@**** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
*HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>optn-20221231_g5.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 optn-20221231_g5.jpg
M_]C_X  02D9)1@ ! 0$!L &P  #__@ _1$E32S$P-CI;,3=:0E8Q+C$W6D)6
M,38U,#$N3U544%5473$U,38U7S%?4$]71%]%1%-?-$-?4$A4+D504__; $,
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_
M !$( /T M ,!(@ "$0$#$0'_Q  ?  $   4% 0              !08'" H!
M P0)"P+_Q  ^$  ! P,# @0$ P8% P4!   ! @,$!081  <A$C$($T%1"10B
M87&!D0H5(S)2L4*AP?#Q%F)R)"4ST>&"_\0 '0$!   ' 0$
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M^X2HC]0"-2K>U552;5K4QE2D/B(J/'5A:5)?F+1$:4@X'UH4]YB>>"@'G0Z
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M96GK;Z5H4E2T*O<JJ,MI\URZ;-X)JK*X:^CDS*EIW"3U-"D\;U=/"[,H26:
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ME3SS$9#*X=NWX:+/W)LLP]M-R;1ONOP>BHHIEN3VX=VP9:6PDNQ;9JWRT^H
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M;@U N]95=<J.M]2>I)\J0&U.=*PXG@@@*6E:0!U=(3KK+W2,O$O$_$^9LO\
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M.M+2MMQ"N0I"TDI4#[@Z@"#>QO;0X8W=---1PQ;M<B\79N"Z" 685%BI41G
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MV&8BHS^"E2'6U$%)'3@I."DIX*5#';C&, <:HO3*LN [Y:U$1G%E142,,.G
M#R>Y#9('GI /4 '0.I&%7 6JZJZW&8"5I-;0V"P%*2I=4;;0C*&BE("Y2&R5
MI//S3(*D]2T$KHFT2EMD%RPV";:CLFNO13?H#;3,WRR>@#/'SR0L+V'Q$J
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MU*GD!?S,%V4P2<=$NFMN26U X(PMCYEE>?\ "ZDXRD8^4MI;3U*. .2K('
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M>_ZD_P!SJ',?+Z7[=_3^N(\HON?0:=K[6[ ?YQPBUG^;&0?OSQ@YX&.P[?\
MYKZ\KD$9"N^>0?L1C_?]M<S32Y';Z#],.4:#70$;]_O];XVT*) "N_OSS[?G
?_?6YK3'X_J?_ +UKJ&)L----,,----,,----,,?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>optn-20221231_g6.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 optn-20221231_g6.jpg
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M Q$ /P#B"_E:<TW^<AKK_I8OK_7O"J)S6\TLA[TU<R.NR4A*EJ*=6+ZS@8
MS7"!DD;D';/<XX;EQ7C/%AY#F_3GI6!Y0?UA\\;*'S X?'H$B>(+IJ75_P M
M]_IY^F)(M'BQ^)^[UKK_ .6^]_3SMO;#G!S1<SH/_E(:\GY'5J^L?C_OWQ/_
M "I.9O\ SC-=O]+=^_Z_XP0E25I"DD%*@"".Q!['B/'?%/3VN(HR#8@Z5((V
ML1L?^_U.+**:FM<0Q$'<'0IOWV)!VQG;^5)S.9_\HS7;Z?QMW[CZ_P#\>S^W
M'RXF1S3\SJ#E/,9KIG_K:L7TOMOL%UU0!^8WXP/P<*((0;B*,$<$(NWRVPHI
MZ<$$0Q C<'PUN/K;]?4XS[_*MYH?\XW7/_2M?'^N^#^5;S0_YQNN?^E:^/\
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M@,G_ --]L\3)U5U//_K$O8DX_P"E%:P 3C(S,\#!QO\ VV$.Q.RL=64^^2
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MXN>//O@]UA4@&GAMQ?PH^-C_ '3QQSO\[8OQS5O5 8QJ-?!!(.]TUHX';/\
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MU?U7! &I=^X&22;NKN=B!M_CQ)'G;!V^?%C')*S_ $0<@_+]_P"SA$ZKJ5U
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MAD>*BB:T*(65I-_WTMB 2?ZH/["FPN26.R9!T_3953*T\<<M;* 9Y&17\/\
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M]]5;W/YUV7Q<^CQ:HJQ_P$-O+X_R[?,'%'ZY(-'1$?[2_(MN8B3;>X]1Y][
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MMCY>^W$1TXW^>._;OO@D9WW\]MN#Y  ^P(S_ />R-]]N^ 0?;?@P3V &,YR
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M@"0& 87 )%^"<,D0Q2/&UBT;LC6W%T8J;$@&UQM<#;MB9(*B !DG(  R22"
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M6IT[X.#CP<;=B1@G)^N_[N$JG^E1P<#<Y.^=SXQMC<[$=^)%N$[GL?(\]_;
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MSSMO\SY[<5Q4E@9[GO@DG<D[_7\-MNW'@Y\>_P#5Q,#D@9/SW.<G.#^X?W/
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M11IU4TYNV?08.FE%J]MPA:!% NN--<M&!;+425#J4IZHT!N/+J+SKVY*U/\
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MS!R<X(VQPD6X3W\[JV\Y]_VG?MW[8#K<'DV.W87M]>W<#ZC#.1O;Y?=YG?\
M"_EMB9QSQD$$YQGISG)\C([X/OG\DV">W;N-\[[;YSGW[@X[#?.)E$ G._\
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M=6F2ZW/AJ?Z'F)"(<)G2K#J351A1YT=14P^SZP! "FUI4MMYE8R<+9D-N-.
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M>B'U8R 2"!A15]?/8C.^_P"P$ R>LO<#<@8 &^^_OG;SW\[=]D)DIZ2.D[9
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M!U-)(P*W6-=2Z@I_;9G"\Z2=+ ='.,WHJ%3!X"54\8#O K(BQJ=.\CV8!BK
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M%90QL5N.#N 00/709A#F"EHED5E2%V611MXZ:U&I696(W#6-KCNI!*-X_?4
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M0"=06_.@SE+U&H&F&N-L7SKG;UQ5ZU&6G8C%3+3DUF@5*<MI$6X9\+"C5*?
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MS6]9]L4]ZK7'=-:IEO4*F1QE^H5>L3&8%/AM9( 7(E/M-A2B$I"BI1 !/!@
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M,TUN_JY1V%.2:=8UFJ==JTRJ5!IF%5:E"B4"(X])FJ2W\=V]KSNG4:\+HO\
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M;MP;@@7N//UN#>_&-<N0-7)V '?M;G@ ;7'';;"53IR1VW\C'X[X&2<GSL"
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M&W(MS;M]>+XV+4.21_ 6'Z\^=@!CT'G1ODX2,D8SVWW()_+;\./(>D D@_0
M#!&-LD#&,=._Y[\)W)REDA.59R!D@#';MV/DC]PQPC4Z5')!. 1DG &<^!M[
M?7?WXE1+;DC?SXX&PM;@FQX MZ'$32!B0#8;=KWXX W/W@>=M\5E.*."#@;>
MP]]P!VW]NWRV'%AZEV1 U+T_O.P:DA#D:[+<JE&'6<>G,DQUFGR0HI5T.1YZ
M([R%@$@HR-\\7IDG[VX\;=^D#?<_L]NW$?O C[Q!R"DY (4""GYY! .1Y\;D
M\2J_ALK*UF5@RD$7!2Q4CDW4@$<<';@%K1"1&C<.R.I1@;6*L &'+>;7'&YV
M/!X]Z[1YUO5JKT&IMEFHT2ISZ3/:.?YN93I3L.2C)"20EYE8!P,C!\\7O:.F
M,^\+=O:XXM?MNGMV50Y5==I-0G/)KE;CPG(@F(H]-C1I#A3':F(><F5!4& 0
MDQVY+DLH8+C/B Z>BP^9.[9,:.6:5?$>!>U."4A#7JU5KT*L$ ) )35XDU:]
M@>IT$G??$NC5S:66Q!OYN^I%\IF77:=3M"G"UH%"EQV(=5,-Y^=+55)T5[[2
MP_#;0U&91TN,N+<4XE:$MJTB>JF?+4JZ-)9)9%I9%2*+QG*M+$9D$?<:"Z,W
M*#4RV8*10.F\JRR;J8Y9GDE)!0B/,XGGKJ\Y=!%,M!5^X3-4"Q-JOW9TC%EF
M?1&]XW=6S5\.BY6K>YJ+*ANNEN/=U.N*SW,E*4K56*6XJ(E74<$_;(S'2$Y4
M%8(SV/;Y*^(IJ-*L[^#\32?1>EW,[HG0- ).IL:GWU(O*1II0HD2$FDJC3KV
MDV@W*G18I:E5!JVD2VC(>=B.,O):+?S\]*[@<L#4^P[P@O. VU>MOUG)2D/H
MB0JRR7 KH*DH6]"4KK';/6E)(R4]D]G1[>K%UVE"N&JFDVE5KEMZ+7*VRM"5
M4NV*E5H354J[;BTK:08%(?D36UK;<0/2"UH6D%*N!U*L\5;120N(361B+4Q5
M51E=HPWB,#X0$=259PPM&S7.DG'2Z9B@>@J8:N(2FCF:=5%V.B54<J%5@) S
MT@8(;AG11:_&P*-\3+5<7!5KOJFENBM>O!G4.\]5M,[EJ]#NEZH:.7SJ#;$&
MU+FJMDM-W2W%F-2:?3H\B)$N>/640ZB%/I6MDB.E-0?B@<S-O:/P=%X;]JN4
M"!I1=VDR*W*AUMRYWHMV32^+M<G-UI$07C;L-;M)MZ<Q!:@1*>^ZEVGOOJ+O
M&S^L\N/*>ZYIWHM<MKV+IQII_*%UDK5E4RE:N-77)UJAT'1^W4Z85ZNW *^N
MLT6/JA-CRC)MZEU6@HJ<BG&)0C1953;6<%5WEM^'U3;[UDA59ABWF>7NE6;K
MW>%K)O>>^W>EI5S3BK-77R_V^&[FJTZ).HVHL*W)M.S69-X4V%=<FBU6HS7H
M++@X\T.8*)-5>ACE14DUO)&SJV7Q5$_BQ-$'!IZ9YE<2@58BIU41+(8(!T8Y
M\J?PC_-LID5?>(M,:2Z-%?+2TRQ2+*5M-4A601DTIDJ68RLIFEQK&Y>N;K4+
MEPHKM!LF@V=5H:]3K!U5]6Y(M8??17=/(M5AT: %4VK4Y*:2^U5I!J+71]L6
MMM@QI4<)6%W[0N?74NBV:FQW;(TXJU#:T6@Z+Q/MD6Y&I<>!1=2)^JMO76F1
M$K[ 5<E%NZ?]I9;]--'EQXL1F;3G2AU;^Q*GZ,:":KS;?K=0LNS-;+]HO*_R
M5P*=I36]:H>E=&MZT;HAW"QJ=>C5R4Z3"?>JFGK*84<-U)=451D$U"N4FK%8
M87A[7_EBY0[+Y)(^I=AS:;*OYBF69.I%\TR_D7._<U\UFZJ]2[RT[F)568M'
MK--MNEPHXA.6]9%&J]-$,5NJS)T.L,,QXIH:^E4RBJ%J>.;0RLP<1I:F(0A"
MAD,2J!X4C^$X\/Q%G"J9XJG+:J6%'HG$M3+2W+(K)XLBK51ER9!((TD>X,L,
M?B#5(D;PJ[(S#F YT[XY@;2G6C4+"TST^AW7J*UJ]J?-L"EUN%4-4=46;?CV
MS&N^Y5UNNUEF$[&I4<^C2Z W3::F9(E2BRKU4MH9?)QT$I.Q&^1N-]MO?/G&
M/ZU'W0=LXR,G;)W[[[#.<]([9V[CA))5MX.>K)P<[ ]P3OW'UW'?'')=VD<N
MYNS: 2%51I1%C0!5 50D:(BJJ@*JA0  !CMPPQPHL4*A$4D@7).IF+,2S%F9
MBQ))8D_("PP=KI3S5])]4*:A'4J=I]=K24X ZE"B2W4[8)W4V/8=OJ.1P_U#
M]P_=QV,77#$^D5J O"DSJ'68A! ^\)5+DL=CD')7@['<]\C?COF,&+*DQU#I
M4P^\RI)R2E33JVRDD@'8I\C..^_%ZZ5-X:M;FRM P!_WU=;]K?L >OKR*'UL
MOVU XX*5*>GPM"P[]P_EVW/&$W!P<'%KQ1L'!P<'!@P<'!P<&#"F),EP)+$V
M#)D0YD5U#\:5%><CR8[S9"FWF)#*D/,NH4 I#C:TK20"",<;!]-OBM\_>E]%
MA6U1.8R]*S;=.CM18-#O54*\8<:.RGH;:9?KD:54D(0C"4I$[8 #C7?P<-9$
M>P=58#<!E#6/F+@X4,R[J2/D2,;1I?QD>?Z1(,F-K"S2EE@L*;IMMTE$<IZR
MM"_L\IN4REUDDAM:$))2>ESK&,6+='Q5N?F[81@5+F*NZ.PL*2XJD1:)2'W4
MJZ@4+?A4UMSI^]MTE)&!@@C)UY\'#!!".(8N;_NX[WV[Z;[6VWV^ZS_%E/\
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MU(NR/?,ZSZQ$HE3KU1I$^FHM]BKPZFQ+N,(?K2A(+K*+FHD>);M6;<(A1QZ
M6JTN4S0G3_F&U+I6F]VZEU2P:K7'S'H4>GV=+N15:?0VIY<5N;&EH9IKW0A:
MO5G13%0A)6MX;IXERK,*;.**2NIR\5/&E6TC3*1(L=&',SQQP>-).2B&2%*9
M9II@5$4;N0F./[1<@J_9?75M%U)+!*^7T%)F53)E:5=>B4]53)4A6B6ECJEE
MIPS15<<E.GN\D<OB$(I?&V>SZ0S6K:I5Y4!^E5FSZFEF)3Z];,IJH4&&(K2&
M(U#>7'R:',A1VVHZ*-5&X<YA#:4%DE.3M"Y%.7=6I=^Q*Y5V$-6Q;#@G3I4D
MJ;C?XJVN2KU5CI"6FVVG)+G40"Q'4U^L\G+(;DY'J+R=Z$ZE:CZ 7=?DK5&W
M:$S679%=J42=;-?I]+FQ)%9IM6L=44T"I1)=-1*!$QJ1*CHZA$DM.J0L>%IE
M\>^RM/\ 0.'IRSRN3*=?M5+C-]5JTK_ATBTZA%:4V]BWZ?4[?J]<I+-<D-H%
M1IKM3E-4N&PF%3Y<EMY2F\(GZ*&=2C/>ELS7J#*??ZFGD\59:*L6MITIJAU;
MWU*=I8FCJH'6H,<+,6:\)9"3[^@_;9TWUMD]<*.*HH9:&=*!Y)H D3JT4;K/
M'#')-+%$ZEEC66WQ1O<KIMAP/QO.?AZTJ% T/TLK4BDW'=M-,>/)ID@QJA:6
MET>6^V[.#S!2_!N&_P"K,NOLRFUMRH='9D*CJ:3)CN<<F4V?-J4IZ;4)<F=,
MD**WY<R0]*DO+/=3LA];CSBCY*UJ)XR1K5JY=FN^J-Y:K7I*5(KUXUE^HN,A
MU2XU+@@ABE42 %X]*FT6FMQJ;"; 3AB.E:\N+6HXM*2/8_122?R!)XV_(\J3
M)\N@HPPDFTB2JF MXU2P'B.!V1;".)?ZL2(O()/#S.N-?5R3V*Q?L01_ZN)?
MV1_S,;NYW)=F-[6Q#@X,'V^7X^W$<'V/Y<=?'/Q#@XCCQ^\@?OQ^7!@]L'/M
MC@P8V7\L?Q#KFTOI],L;5>',O:R*<PS H]7A%A%UVW#:4E#4<N/>FU7J;';*
M@W'EN)GL-H2U'F%M+;*=IEM<Y_+'=4-N7"U;MZF+6,KAW,F9;<]I82"4.,5%
ME+9*=QUM.N-E0RE:D\<PG2=NVXSW&?RSG)\#&3W (X,$?/ SM@C'X9'O^W/'
M$K,AH:N0RCQ*=VW;P"H1FVNS(RL 3R2FFY))!)OBQ4/4V84<8A8154:@!!.&
M+JJ@ *'5@2!8;.&(X! VQU!5GG)Y8:$A;DO6.U912CJ+='5.KCJN^R6Z;$=Z
MEYQ]T*&=\^>,"W3\3?EYHG6B@0+ZO):#]Q4&D1J%&</8$/5N0'N@;G/V8*((
MV[I'/N23_L&.^?;WR?V\&#['\N((^F,N2VMZF:Q!L[JBFUMB(U#<]]>/3+U?
MF;W$4=+""-BL;NP.VXUR%.UQ=.YYQNJ=^*_;@EI#.C=8,#U4A;CMVP_MGH=?
MWU(:33/0]8H[(4LME6 2!OP^7E_YH=,.8V!+79DR93KBIC/VFL6?7$QVJ[ B
M]24"<P6"J-4Z>'%)0J9"4H1UJ2B4VR5)*N7#!QGYX[C/Y=\>,XQG;.>,D:1Z
MG7%HYJ);&H=LONM5&W:DQ*=C(>4RU5*<5I34J/,P%)7#J<3U(KZ%H<2 M+G0
M5(3@JNG*!X7%+&89@I\-O$=E+"QTN'+_  M:Q(LPO?<;%*+JO,8ZA#62+/3L
MUI5\-%9%8@%XRBJ24%R%;4K"Z[$JR[:_BM:>+D6_I5J5&96I=.G5:R:DM()"
M6)X%9I:W.G_Z2B:T@D'=P([CC3'$A=.[[65$@MCJ_4(R,K*3VR4[>,A?8;[-
M^9/XA%F\P&D-=TS3I#7;>FU"H4.K4JMO7C3:FU2YE&J")>3#;MN&\\W(CEZ&
MHMRV5I0X%%2L%)UG?I9D=HB@1O\ ^$ P?? 0/EGQ^9XZ73\4M-1)%6H8I(97
M5$;1(&B8JX8Z&8#=W4 FX*@D8ASBIRR;,Y*N"1JA)8X6&E"JK*@"/XBRHI;X
M45A8$?'L;KCVPU]PX40ZMLI"P=TJ((2I(/E*MP<9(&<';CJKY6K^7J=R_P"E
M-X/K"YTRV(M,JA2GIQ4[><=H<SJ R4K4N EY04<Y<*@!U<<GOZ;3W^S+\;^H
M!]<GHW!&V.-C7*A\0J'R[Z;3=/*[IU5KRCIN6?6Z+,@75"HB:=%J<>/]LI[C
M$NAU,O%4]IR8VZTZRE(?6WZ15]\^?J6B?,:.+W5/%J()@54L 6B==+_'(5%P
MP0W+7LI/.'].9M%15M0U9,8X*B)B6(=T617#(H1$)  :0 JH&YN +8Z)!'CI
M4K#+0S@*Z6D K (.%$)!4D$A0!R 0=AMQ$LM#'\TV$HRI&$(PA1SE2 0.A6Y
MW3@G)WW(XT[#XP-I=SH3<I.__K!I.,;;C_@CGV^7GB=/Q@;/P"K0BYCVV&H=
M'!/S _@CD@^,)_$\4D=/YL%7_P &6.U[S4_IW\46M\K\\V.+J.I,E)-Z\ <B
MT-3N;C>W@_0WY'!'?<*66,$%IH[J606T84M0PI9!!!4H#[Y[JWZSC/%(AM*N
ML-H2X1GKZ$E9!]U8W"L $CN  =ACC3W_ +L!:&X.A%R^3_XP:2",]_\ HCL,
M8]OJ>*1^+Y:)R?XB[FQ\]0:2<;[9_P""7;Z]^ Y!FUC:B;D6O-3\6'_&\S8W
M_P +@_I+DNUZ];C_ (-3SW/[GSQN&6XM)&,8  [9'<GL<>_GO].$TE?5T@JQ
MA)P/8$>,;; >.-/Y^+S::COH9<N,G/\ Q@4@;GQ_S1VP?.1L2#Q2<^+I:2E$
M_P 1ER X[?Q@4D@ # ((M+&#_2QL1MPG]'\W_P!C/_6I_P#^[#AU-D@YKUV&
MWV%38\ 7M!<V_P O7;%.'6[TD@I4?3_^ZO"%#YY2H@]_?;/'(EJO2%T#4_4.
MB+0$*I5[73!Z1G]2/6YK;9W[#TPC ]@,[[G;P_\ %FM1TE0T2N-&3D?\/*2<
M8QC!%J)S[[8[C';C4EK#>U.U*U/O:_:31I% @W=7YU>:H\F8U4'H+E0<]=]I
M4MF-$;?R\I:^M$=H?>P4[<6CI^AK*%Z@5,)C22*(*Q>-KLC$E;([&]FO<@"P
M(YVQ5.J,RR[,(:7W2H6:2*5]:B.5"$=%WO)&J_M*HV)/TQC7@X,'V/ 1C;]Q
M!_:-N+/BF8.#@X.#!@X.#@X,&#@X.#@P8.#@X.#!@X.#@X,&#C;Q\'J[DTG6
MR_[34I0_A78:9#*>K^;#]O51$M1+9V*UL25I!QG QD CC4/P[/D=U ;TWYGM
M+*[(D*CP)E:7;]15ZWHMJBUZ.Y3@E]1(26DR'6%J"B!E(.<@<>',X349?60B
MY+T\FD#<EE76HMW.I1;UQTLGG]VS2@F-K)51!KD !'81N23?8*QOZ>7..NB8
M2"VON>L K)&0=ND=_.", >=N_%/[4K(Z@<'N#@;9_9CWV/UQPADA9;7A75@]
M8(W2H Y!202 GI&4X)[C.,\(6WE8[]6#W.=B"-M\Y_$G'COMC]P/VC;RO<;[
M;DB]O3T%]L;C8DW6X[&QM:P&PXN/K]!C+=!=3^C)KZ2"?14D$XS^L0E(\ D#
M!WR<C?VM];W2.HD_K%) ._<^V,GY>./,H52_WO?;]7IR7$X)SW*CCZ@XP%;9
M._;:'J(4/UDDG!)ZL$[8)['W(Q^6Y'"6WW]/+@_6PVPH%^]K^7<646Y'!-N+
M FV%IDYR"E1&%#];.#C8XQD]P3@X[9\XH%QP@A2P0=B#@ 9SD;8\'Q[^!OPG
M+B %95@C)&^ZB,XZ<]R,>,9![^.$;D@K!Z>K=)&<]L[$G&"/.!CYY[\*+;6M
M];#RWWO8[GB_ VP$J-]B?([G^KWN?/MWMY;K%N)0"2<D8 QG)R<)SX W&<;@
MX.<\)S+)/W4G&3L0-QL"3G)SGQN??YHB=\YSD>=_/<$GW&>^W<9&_ 2D$$$D
MY\[DD8[8VQCN3G?MMOPZPMY@W\[CC:P/D..VQ L#AI9B=MO*U[F]O^_;?TPL
M$H[Y &#Y '?N ?D.W?(QQ-]JW^>,=D]P#G.VP[$_[>$'J(3\B>Y41DY)\Y V
M'UW_  X@%).X)(R<D8W/?N"?EMV_$\)\)Y![ <W/'ZV[<#C":F'F2>//L0-S
M;S^A//=4IYPDD.* ..Q&,Y&>V/V$?(9XE]9T_P#G%9^H.V<Y'TP <X&WO@\)
MPI([=0)W'@9SD>_Y$Y R3C' 7$8/WNP)[@Y/8]R>P_'!]^Y\.VS>>_K;Y\V^
M_;8<(-6W(O\ /TM;YV\^1WYPH]=[)!61MN"H'N<?+P?V>Y!XCZSQR/4(^6V0
M?Z)]]_GYSY((3!Q&=SG/<[8^G?<=L>-B1C@"T[8)\X[=]CWWR,><=\'V 4E0
M/V3]1M?8'S\OP/KA#?\ 1^7H;;#M^!MA3ZKI_P#.$ ]QL1DC<#'GO\M^VW!Z
MKO8NG&Q[ #8C\/&,'8[]]^$_6 1G.<]_!.3C\1MC)&/'8\'6,;]603CMOL!G
MMDC'R)'GS@NO]TD;=N_W][#Y^M\+8]K]N+_3CC%8K4<DKR2._;)\9W_'8?/B
M7J.2"H]]B!V(&1WS[GWSX QO3ZDY'<;=A[ Y^1W.">QV^I!UI ( 5OW/2"?[
M,>_G&1CA-0VL#<6/!X%N+G;:W^/H6/KQ?N=O\.V_?\<50L['KV/ZW<E*O8#.
M^>^#D ?+'$JEDC&2 ,]S\M@-_P \#(SOQ3ZL@'R!CM\QC./(W!)SC ]L@ZQG
M=. ,DY[$]NY]^^-P1PNH>3<>0XV^X$>EOD>3?\-[<=K_ $Q,21L,GR=@ "!C
M(QL0!V(V['SCB(40-_P)R,CW['/UXD*P<@8!^OG8X^FP!QV\';'%'J/E:1]2
M/[_CY^F.%!%@=(&^U_6Q' M?CUV^> +L"6/EY^7D-^>^_/?'#YQ6,A\L",7W
MC&2LNICEQ982X1@N!KJ],+(V*PGJ(VSCBCP<;78'D<;CT/GC  2+V)%Q8V)%
MP>0;<C8;';;%9R0^]TAY]UT)2A"0ZZM82EM/0VE/6HA*4(^Z@# 2G88&W'1)
M\(CE47;-O3>9:\Z<$5BZHCU'TUCR6_YV!;I>=:K%P!"QEMVLOL-18#N H0&'
MG&U=,H<<[+3GI.MN%"'0A:%EMT%3;@2H**'$@I)0L#I6 02DD C.>-_&AOQ>
M[2HFE$RUK_T\;MV[;,LM4&QS:#3BK2N&;2H*8=&I4F XIR50%N%#*W7?5?A.
M);>PMA;B$FM=74>>5_3]3E_3B0-79A)%0U!EJ8J1H,LJ-25DD+3-'$S2J5II
MAXFM:.6J,<4CE'BRSVMP=5YCT\N6=.4,U:E?.L>;20R(:E:57C\.".)F$CQS
MRL#4R1ZO#@B99!X4DC+F#X@WQ")>A6H%"T?L*ET&[%MTN:YJY3:PAQV*[2[@
MIRHL&VF9$=:7(51$.0:HY(05JCK,9IQE:5J3QS6S7(SLR6Y#:6S$<DOKBLND
M*<:CK=6IEIQ2?NJ6VV4H4I.$J*20!GBX+XO.X-1+PN2^;JG.5&XKKK$ZMU>8
MXI1+LR>^IYQ*.M2U)99"@S';ZB&F&VVP<)'%J\=/)<HH>G\JI<GR^*$14R1^
M-5+ D=17U00B>LJ) HE=IY&=XXY6?W>$Q4R'PX4 [W1'1M!T=E,%-!&IS":E
MIQFU6C/:LJHS+(6TDZ=$$E1-%3L%5_ T*Y:PL]?X;C]#B_$!Y*Y-RO4>/;S/
M-)H:Y6G[A7!:H3-+3J'0C.<J[M3(I[=-1'ZU3')A$9# 6ITA )'8=S-<UOPU
MN?OG_IG(GJ]:5U:]61H7S <]VK=[ZFZLR]$=!J!2J#IGH5JHFR.6W0W4/E[@
MVI<-?TCFWU0J/<-OW3?EP5*YJK+ATAJ6U6TOMQV.!K^_O^_B.=\[>? QO\L8
M_9MXXZ<K&6&*']D1&L=6LK?;5"T1@E 8$*U++1+(+;RAWA9EA:5);G$HCGEF
M-V\44J,FID^R@:J\:/4I!M4Q531DG:,J) K2"-H^UVT/A\?!2UU^'A8O-52;
M+I6E-=U+NVRKHK35'YFZC D:6:@5GF(M*PZQR>?PJU<O=JUV:0UIA/J519K=
MSV,_?23)&I2[S:M.&JGMN1N[X0_PEJ1SX6-9L32"S'K$N/E+UGO.CZ#4G6:_
MI%TN:A6IK;'MFR[QNW1^I<Q;.IU[QY^G,QY5(C:0\PK$2]4TY6JK%HT>T2Y1
MD<"/4<8_O_?Q]-NVW$>H[?+Y>W[0=MB#D#88&W#2#J70S*B/.RH3K-I:1J=%
M>1[O)X+E9HRQV:-6 $[25$CU8:7#@.[+$-=E6Q2H69V"*H4&5%:.0*%!\1]O
M""0IU:\DNB?+MR__ !X.=_02QX.C5_Z&6_H3SN67IO9KNLT:IZ;7,*]HK4EV
MSI3%UINO]#2HM2=JM3184BONRE5RVZTW,9:K=3G4PUF4^^Q/A5?";G:Z:ET=
MG1O3R^=5F;7Y)!K+R5U+GD=LFT.26@ZP6_59/-=J?;.L,NZC7]5ZCH&J-0IZ
MJ)7+DNF';4BJN1KDA5ENH0/L_"UDYSMGZ C\L8_9P=1SG;\@?V$8W\^_GA6N
MT67(S,S4-+#2RR$G56)#4YC4E9F!$BQ5#9AIJ DGO(%/&U+5TKO*S@*K+7R!
M%"UL\TZ1@*$I7E@H(4>(%2#)3BA#0W @;QY(ZJFJH@D8^AMHMI-\/-_E,L*T
M-%^5'ECY@J>GD2^*MI=HQJS7M7Z+;5[:NZDV%KK<5'H%IU +K=+=AZCZPZ3P
M8NJC&I$IB+<-FV[*-"L"K46UG&:>%=X\A/PH>;C4GF@U(UXJ%GW-=UNZ;\I5
M@UN196IT2TXW+3I;2_AVVS=3>L5OJMZ^;6LR349&JU*50JM=>H5.ONSS4::B
MP5VLQ<M;;JJ?G? D>W]_[_CV.1MP=1W[;_(?V?L[9W[[\-8.T51&7)::.-4E
M;5J@E2>NF::)%9(D:3WYXB$1"(EMJ+-K4#!9TE5%1%EJ'D@C55CE2<9>O@L6
M5WT1_P W1NA9G/BMJ:\:+$>A[X17(-RP<Z.CFMS%U4&V+QU:TQYT>2IIQ^Y]
M7VM*EPN3NZK^KU,Y@J\8U0NZVJ/.IKM I\9-7JD03+AH#C\$4)^')G,E_;'K
MG\*CX:-F\F>INIB>7ZU+*LZ1HG\0N_Z)SCCFMN--<L+5'0WFGU.L#E1TUM/1
M:N7E4*=JA2M7*#1K?LI52AT:INUAAA4B-48=<9EU*=P_)44]L>/ /8Y'?Y^.
MWRV'&4[YUOU8U+LO2?3N_+ZKMT63H9;=:M#2.W*J\R[3[#MFXKDFW?6Z+0DH
M8;=:@U"Y:E.K#S;[L@IER7"VI".E"7S?:1R*EXWD\(%NR!,J&7O)'IT,K&>&
M#,!&"%:M>HEF>2-C3N1$)(K.-:HVM5V.JV8R5OAN'U*5:*>6C9RK6I(J>%(U
M9%F3J^^&KR_\@W-+\,'DDT_UZTPT>H,!OXDVI-!YE-88NLE-TTU+:<5I!4:S
MH9;5Z5:J5-%0IUKZ]7:;;T,CK3'=MZSZ>_+NVWT42YJC.K3;).=[DIY"[)Y[
MOAPZ8UVFTGDFH/,1$L!SGPT&M'79G6V@\H_Z9UAJ5I"33]7[@J-UO4N1=.F<
M>GWG4*==%3KQLY<H5AXN4B;$B)Y\+)LV[-1KPM73ZP[?JEV7M?%QT6TK0M>B
M1%SZQ<5S7%48])H=$I<)H%R54*I4I<:%$80"IQYY"!@$GC8NCX,?Q.W]9(&@
MT;E"U#F:E5&P)^J$6! J5E3[9_@+2JZ_:M1K\K42'<[^G<%F'=4=VUI$2==+
M%1;N5*:"J)^E'&XJE!M50U!U,!5Q5!A<AHYTI,NB@FIR"MC$5A]ZD0*T<2*E
MHU(J)ZAJ@"FF@"B_NTD(G!?7 U5F,L\<_P"W8.'J!2Q/\#R,Q#2/JBBBZ9Y/
MPF_AW5?F0MRT&N3RR[=OF'H=\0ZYJ#RG6[SK7!J!;^L]@<O%*H4KE0YF+DU8
MI5W+J&E,_7>M/U6AS:7(N"):+M/;1<L:WZ5$266,JZ3_  ??@C7/JIS$4R[(
M%OP;LIU&T%&K'+U2^9F;7Z7R-0;^T$J-\ZP7):-^1K]H3U9DZ<:CLL6X+KU5
MKVIMF6X^W'MZX;<GU&N0I#'-K9GPR/BP<LNCDWF!TZL._-.YNJM(YO= =2K)
MI;U*I&H-(TMT?LZ1(YAH&H=$KDAE5-MFIT"EW1'^Q--N5*I0;;ES(&&:A1%U
M%N&GGPBOB0ZJU611K"Y4-0[@J4;333;5HL-2;4AHE61K!1JA<&ETJF2*E<,.
M-6*]?5#I%3J5N632W9MZ5&) E.MT#^95AL@(B5+E67+41YV!0F66JK:@5BV8
M*5GIVC220.!K@FBHQ0Q0&,NB(#R2?#('K)72(,KK%&D&70&GVOH>FJ4D,<3H
MQ"5D4E8:R:=)%W,<U7)S\+&U^1?56)I!IS;#&NFG7P]N4#FVM;F)I_,+<U8N
M6_-1]3]?+DTGOBP)>E\ZZ*G8K+,NS*33[RK5)H](%?I<VH?:(0HE(3';<RO\
M+KEHY-K>^'$>92GZ?Z>7AJU>G*W\3.A<PG,9=^O$2%7N6J^J5IO6[3T=T=H/
M+G+KT&F7<O4NQJDN[*54WK?JETR:DXJ;;];IC++<-6GNM? E^(]'M3E=N*T]
M$)NH,SFCT@NC6:AT.VJA1X2].K8M>MJIKT+5*NW-4:';MGUJ93I%#K+#%2J;
M$5:KCI%MM39%V?;Z'!U2ZAZ>7WI)?-UZ9:G6A<%A:@V/6Y]M7?9MUTF51;BM
MRNTQXL3J75J7.::E0Y<=Q."AQ ZD*0ZTI;3B%J8YO)7H9 &K!5HL5P/!C9ZJ
M"9$5"EXHUJ(X'\$0AFIXPS>'+/#*]+HM#((S:C:EE\47O*PAIWB9G8./$D>"
M6H3Q_'*B>32OB1131]NW,3\-/X%>CAY0:$Q!IAHO,?<LKEFL;5I&M]SSZ;>0
MU<Y=Z=5].N<2X&6-29J)Z-+>8&10J)6ZA:M LO2-JDW95;;N6SIE6MA4Q?KZ
M?\J/PK9=C77R+/7[95)T*TX^)CR8:'ZGW=$U>C1!S,ZL6=RE7W,U1O5BYJW4
MJO5-.[(U,USEM:8MSK1J-.M*@TV%$EP/L58FJE)X0,GY?D/[X^7;Y;G@ZB/;
M<Y[#\NW;Y=OEMP\_%(78DHU0D[1C0 1#+32PH 4,0".E6SCPC%*]3"6BTT%.
MF(2/LD1?A9(GB$@OKO+%-%,^H$27=6I@K>(98E@F6.4&LF8=X?*_\)GX6>I.
MJVK,3F0Y==.M"=7&+#Y>9%P\E]J<[%?U@I6A-GWU5:]3]5=<V+P@7E:%=M*X
MZ)'ATMV1:^H.H6J=M:7QGF;JNJGUFD5V%38NESX5_*%\-#FBU^YM^5OF&OV!
M9E(TZU%HFLVB7,A7KTG6^FY.730O4>JLZ[Z6J8@5R/:$RXM5-*IM*K=L5R/3
MZA5Z?/H4^70W$17'&U<\'4?K]=^YS^.?.<Y\YXAG&^WY _L(QQ&JR(Y=93^[
MF549?$19GE2:"4ARS,E/)&OV+-IFC>:"5C3NL4<A961D*6U2PN74A'$:1M%/
M$I5=*^\(_P"V%O$Z13(/>$::3M+TTY /AAZE?#>U=YPK1THL&PK_ *L_J]KU
MR[5JBZ^7S<M>L.'IYS,0K>L'0^YZ5>E_P[6366-*::W6KGL&HV9?-YRJ75GK
MQ?U&I:)]'H4?U>?G0/X3.H4OXE///=;=B1M2.7_7WFYY>:_HO;FH]TIC:X:T
MZOWW:43E&YBK5B4:ZD1H5I:>VE7+TK5XT&S W:5;J=CMKGT=,(U1$OB?ZCC&
MWY ]_J._S[XV)P  $D[;>_8;?3;;Z# XD[1K^TD4<D::RQ<B8TB2L\BE2TCT
MU*T0D 5TED6K4BHA1B\RJ5/V2*S5 J'*#2C:!*T47AG4!#'42"7020T8>F($
M$KICJ"^/'R!?#GY1M'.5RN<F[\&GW%==\5^SV*_$U*F7M$UZT=IVG=@5RF:]
M5;]*7C=#4>?(O"MU>EN7-8E!LK3NI)D2*)!M./5+8FR)6YISX,7P=J13N3UR
M\[&TUANNWBBWM39MJ\T=Z.6MK;9E=Y.+JU,IMYF\J_J*F54V/XV+<3'HM\6'
M9ND]M.UAZ;:BK8K4>$ER1\^,J)QG&WL /W>/D-NYQDDF/4?E^*0?W@[?(;>P
MXBE1I(YE61D>2KCJ%EVO'&CQ.T"JH5=$GAN'L GVT@2-$"*D>H7A(10(Z26F
M<"Y\624.HJ6N3:2(./#(^(&*)BY<2-)U<V)R6_#[U)JSFK^D>@-@5R];SY4.
M0_7R@\H-9YSIFGEF:80=6=6=7K9YL-3+=U'OBOM7;6Y^B5#TYTPD0K,N^Z*L
MW;#>J];O2Y+:O.WJ%#H"-(/Q5'+9=^)+SS.68Y07;27S2ZT*MMVUW:6_;KE$
M-ZU3]&KHLBB)32)%-5%]-42134(A/M$.QD(;6E(8'D_+MCL/[._S[_/B!.=_
MW #]@VX?I.H-?8!Q;?\ K%#YVVT[;=SA+[6[WN3MN;;\#SW [8.#@X.'83!P
M<'!P8,'!P<'!@P<'!P<&#!P<'!P8,'"RG3GJ74(%2C$"13IL6=')S@/1'T2&
MB<$' 6VG."#[$'A'P<& &QN.1N,=A?*SK+&UVT/LG4%*6F:A+I_Z,KL1I96B
M)6Z:$QIK(4K!4E1'JH)'96,G!/&8R[Z*E-J&R5*]QL3D8'YYV&YS@=CHS^$G
MK?(A7#=NA55<*X-8@NW;:SBU+4(M3I@":K"""<!N9"=,A/3@^I'.<Y'&\F8Z
MDJ0Z "%'I( P0K&QSOD''R'D8QQDN=T)H<PGC M"[^+!OQ&_Q 7Y.EM2G8[J
M2<;1D>8FORR"?5]L!X,VPOXL>D,2+:1K72VPX8#8VPHI,KTU2F-LA7J $])*
M5YZ?.=]MAC\]^/22^E203L3W2,9!!W[G(\^^Y/8\6BE?IU-G"@E,MOTP?Z/4
M@GI2>H?+OC[NVW'N $!22-P22/8A1"NQW&W]'WQ\N.4UU 8 6L+\7OMQ<?/8
M]P;'>Q[*L)+ WOLQ_P#VWXVV-O/:]QCU2I*1D[CR=SD[8^@R<9R,[\2*D-@E
M)ZL]/? /?.#G(W)/;!W[DG/'GJ<Z!E1))\?+ &.XP"<=QOYR>*1=(..E.=AW
M/GQGOG\/<[XX;K)M8C?8WMOP.!WY[^5K<872J['\+<[?D+#<?X86*D*ZONIR
M-N_G;?.-M^VXQC?8<3"0O;9L[8)P<GR,85Y&,_F,9X\[USN>D#;IR5'()&0,
M;[^?<D?// 'CC9 SC8'.1^?U.!G<^<8X:=9]/3:PM;?\/4FV^' H-OS!/EZ<
M[=OPONO4^HXR$C \ XP=R3OGL" ?/GB0K7GNG![^#Y(^H&V<G?'X<(R\H;=*
M>^/O$[?AW)&![GOV'$4NYQU)2 -B02<?+'G]N^?8\'VFV_XC;@_G^(^6"Z$Z
M?3^'U^I]=\*?47C8I(\=R3N<8/G/8;#MGB;U%9P0/(['!S@]LYV[;[=]QVX3
MAT;[$=O(&!_MV\>?QXB5I&P.2!C)QG;QXW.<'M[CSPFIS;<=A\^//Z<?3887
MX;7MM\P>XVO?T'I^6*Y=4#V!QWV._P @2<9Q^9P/..(%Q9V'3C;8;*_$YV\C
M8G<=N_";UN_<;[';?OWSC/C'R P. /C)]\@;^/PSY^7#AXG8B_UOVVV'I^MK
M-\1/(\6X/%OGQ;OVOZ[J.M1&.KL00=\XSC<]CGQ\_ Q@'4K.,J&<#N?F=O![
M>WG?V";UDD#8?78G/U)W^0.>(^L/([XVSD?O'<[_ (8WX/M/,7\_E;T^O\-L
M)KC/9ON/IZ^H^=_7"CJ5G&5$;]SL._TR#MY)]_/$2I7;))^>=]B>XP,_/]GC
MA,'QY3DCR#@?/&3W &??Q]9@Z/"#@=MQ@DG.WTQG/8#/#27!%R/0[=OT!V^Z
MYPX%#P">_#<?E^NXM>N5*[A1V]LDD>1^/$"HX)ZB2!VR<=SXSW\'Z=O'"4R!
MD9 /?;<8/N.Y)R#@C';&Q(S-ZX]O[< ^=_']O"_'_>'_ &VMVPS7%?@WXX/\
M<5R>W@^=NP'?VS@GO[;C;B&Y[#(\;X/SSC W/^W?BAZ^2.W[\C<'/YC88_'
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M]^X'_M_C;Y8E#N5=)3@XR<G. D^,>X'@G]PXF)(';SD_(>?KX^N-L<'!P]U
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MDJ( &3M^'Y^^^#N<;?D<'#5 8D$ BW'W>6)1\/&WU/\ GB0@YR#^W.-\GQ[
M#';B &2<;Y QX[DX'GOW/CW'!P<*P M;N"-_2UOT/RPQD7:UQ^SP?.V#&<$^
MQQC;<G(('[_[=^(=*LG'1CYI.?V$?LVX.#A4%QOYV[?[O\/T<&A=]K6(&Q/D
&#_V^6/_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>optn-20221231_g7.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 optn-20221231_g7.jpg
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M&J36\/'#U5"[[M5?=7#8Y?GO[M^:[_-5^:K]JKNNZJJJH/Q\7^8/;CO[>_\
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M.IG]8O?^/J/_ *'1T=2 ?C6_B9I_Y_?=]]O_ )P.IGV__P!Q=>QOQ3OB>/\
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M]\33]_WW=_?_ /3]J3_6#]/R^7\B=<?C7OB:+_Y_?=Y_W_ZDI_LR#_K^).F
M/8HW*Q?SFJJ.3[6N1516K]^VWS3V7?KIUFV?D_Y_X'\NIK/R?YWU('^->^)I
M^_[[N_\ O^U)_3__ !!^G_K9.A^->^)I^_Z[N_\ O^U)_K!U'YT.DZ-RO^H_
MS/4@?XU[XFGO_P!OON[]_P#T_:D_P>W_ (0>W\7\/SZX_&O?$T_?]]WG_?\
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MJ[!0/:Z%=R .]$_/;CO[BXC-EV5=EV3YKM[)_"O7&R[;[+MOMO\ 9O\ =O\
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M6LZ+:QX;WU^$4=T^SCU[32;7@H(DFSEL "'+DRI,-7>&+&ED.QL<)7(5\6:
M)XH"Z_[]^/GMTA8*>ZT\_2/<F@2 /<@>W'SU$'T-E_E_ZW_@_3U,%JKH64E'
M%N,-T&LR89%Q>US,V;X]IS*=BAZ.HM8>-W>4DRA*A\?\'L;RBTKL?M+)TYU+
M!N[.NJ+ PITV#%(WK'L<KFW WEPFHEPL5JXN2WH@XU5S(M+CLB?$J67^4%2&
M1L:I?D%E64XYEF]E>:ULJRG&0LZ?'BD<$6+OGXX^?;G^GSWKOTBF2E0!/QR
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M+YKQ^2(B)U];^(6E,1X::*\,?"K&9:9FWM$X%YF;,RDM$S+-JFMXSR8V0>0
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M6J)(#6C'YXLN&Y7\HTASA/9*5CW,>UR$1G+;:7^%*0  D4#P../ZC\[YY('
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M+).[=&1V"><LAZ+NU@G/]V[]68;W5@6BGP9/B#WT6;6Q&=S_ '1Z+=G6EP2
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M-4^+'BYXKXS26D_$&1C6=*Z&FO9)EC&Q($:3JG4Z&&8Z=5:C>AH:,^;-5_\
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M\<^JS=\],GRR/5"PS+];^WR7895I7K!A>183DX:]A5C2\?R:.1;$=U5.DDF
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M0[$FAUA2$[5LSS>=9"O\5TZI+0B&BAD8/DEI-@3'D,/TB3S6I?)$V1DBOL'
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M>3K[R7N(9[GKNJN5=]D3\Y5=[(GR3=RJB?/W]_?KX=4#W/YGOW[^_3>P [T
M/Y#IX'P]OW>_9%^MYVT_TU81U;5_9JG[J;LH_5^U2_I6KNJE7P]OW>_9%^MY
MVT_TU81U;5_9JG[J?LG_ %?M4OZ5J[I[7UC]/[CIJOI/^>_5*KI]_9I9LPG%
MNXK4YR$:3'M.FT(S-1SA>&_))?+!(1'HT0R)""[R\4.Y6H,)$12-5B'R_P!?
MS_2FW_R_3T]K0@!2=MFO(6<E;>YSI'BQ1->K72AV]J^,X;43?DP/JVD,CD:U
M&.3=41%=U9<HH()[J2/N+4GGY/%_8=^EC_\ ,!%$I"U4;]D$@BO?_M\UU?J^
M%'IR71OL5[<L$&2%.!D^B,G5G+V21+,>',<[,3([=IY;V([\K4FK A"JCC1
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M92BF1U$-T<;7M>JF35BK!ODD @5W[50/J]5@<BN>6)@DA"BL!0LD4%))X)'
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MF:<2#C1K)L_UU!&D5J'D*K93/(1B\6JU(5_AS2;0G<WW?LJ3CCP\ARD 7QG
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M"X[HS/S%5 R2*!9VAXH&",0+8P3#&I))7,9R$48V_DAHU([]T15:B+JE1+?
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M:W-J+PJI?7>28,3I"#+,/(5BL(\R-[Q/4+"L2JZK#I=;/RG,+N50"CQK6RG
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MD%0#+LBSFKT^TODVXP0!8IEIE5<QU/M!&DMDPH&&UI)=A1$!)@I.LJKUA$>
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MN@H@51!X_*MD)*GUEK00),!ZU61U<>+;R*2>.1.&>V8XI$UT-SNLQ30AN3J
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M=7,P%D4$1B*L","38$&1LB=-YN<YI&D9R;XV[\0J]$8JIQ1$1O7VCI3P8<\
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M8E?DE81E;>QB2X0XL8T:$&&"=4L1W*7326QV!+(8Y"09.P)(&;M>LK\67&F
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M;$E>.*Y[3K)1HCB:C4' <\?,D5AE11D5B(PG!O'DQ';JFVR,<275$]DC:*'
M)')//)X/R*&VSQTK+R6T^E!M5E5;2JK[!/<)'%WRFB"*JCU794=S,EG%.LR1
M$CQ(T8J<EC^G,Y'&<Y/*CW%%R](I6^-KE&I=_JHJY]E^8<^OG-*Y(,R,T-A*
M.J*ZM&-$5) #I[.:JN?&:YC5(B(TG)41VZ1RJH\89(,9SU++XO#XBN4LB*B(
M\BL:G%P]G.57!>[D]GNU7JB]9*-D<,U4RO*60V1#*E2]%<UL8;@':>,10%1I
M4;,7F C2-W5_-WMR3II;! *18) H=P*0F_Y@FZX/L>1TJ7UH*DJY]/8FK65
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MX %#K97ZD?X&!7_J<Z3_ /$?B/6MVJO[W+_I)O;_ -C;_K]'6R)U(_P,"O\
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M;EI%DRP<*UTO)!WB^DZ^9%1H=F-21=->HWC5/K[-5GC1%5JH)RM:N[W(D:$
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MKPX(Y[FHJ_73I-A3Z@#P4FZ^2*]@!=]_R'\73@Z%(H\DI4E25<$[0-UU9H6
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MTG<0I(-U14384#SR";X%N"K"QO4H"D$T?2D@I/>RFDD\!2540*)Z<KV^Y[D
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MCN37,04QG!47Y*Q6KNF^^_OTWS5%(22*':T\^WN"3[=ZOOSR>D :!)2E2.;
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M)DCCLI'N5%14<Y[W.3BY')MR<K?LV]VK[;I\EZ\OSZB=<#JMU4:HCVX[??\
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*Z'0Z'0Z.CK__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>optn-20221231_g8.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 optn-20221231_g8.jpg
M_]C_X  02D9)1@ ! 0$!L &P  #__@!!1$E32S$P-CI;,3=:0E8Q+C$W6D)6
M,38U,#$N3U544%5473$U,38U7S%?1$5624-%7T903U\T0U]02%0N15!3_]L
M0P ! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$!_]L 0P$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M_\  $0@ U0&Y P$B  (1 0,1 ?_$ !\   $$ @,! 0            @ !@<)
M!0H#! L! O_$ %H0  $# P0! @,$! L#!P@&"P$" P0%!A$ !Q(A"!,Q%")!
M"151818C,G$*%Q@V0EAV@9>UU1DDD24F-#ESH;(I,S5%1Y6QMR=28G>%\#=#
M1%9G@I+!T=3A_\0 ' $  @,! 0$!              $" P0&!0@'_\0 0A$!
M  (! @0$! ,%!@4!"0   0(1(0,Q  02004B46$3,G&!!I&Q!Z'!T? (%"-"
M4F(5,W+A\8(6)"5#4V.2HK+_V@ , P$  A$#$0 _ -(+^5IY3?UD-]?\6+Z_
MUW2_E:>4W]9#?7_%B^O]=T/FEHX."#_E:>4W]9#?7_%B^O\ 7=+^5IY3?UD-
M]?\ %B^O]=T/FEHX."#_ )6GE-_60WU_Q8OK_7=+^5IY3?UD-]?\6+Z_UW0^
M:6C@X(/^5IY3?UD-]?\ %B^O]=TOY6GE-_60WU_Q8OK_ %W0^:6C@X(/^5IY
M3?UD-]?\6+Z_UW2_E:>4W]9#?7_%B^O]=T/FLW0K<K=RS6J?1*;+J,IY:6TM
MQ6''B"I02"0VE1QD_@?^&=,&30*^W]8/?;@X)FUO*[RB<<:Y^1V^:@9#@PK=
M6]U _J1U\]:5GO'7X_W:D,^5?DRE24K\C=[$%9PGENE>0)/?L/OC)/1Z )U-
M&R'V7N[]Z4=FX+KK%.L^ERUMJ1'?<2J86R H.^F[Z9;Y@\0KCUQ)R<?*<U"\
M=_%[Q[4H[AUNEU^HQ6TNN+=^&GNEUI''*&4NJ.>6<)'U)]^]7FMIPC&-,YF$
MC2WBA<_N_/'#>1U-74C.21A19*Q=D BWEWMBE5AVJ5J'E5Y/JDMLM^0&_17S
M));W.OD&2%) 2&\5?DM(4#@I!"B"!^;CMW<7SQO9Y+5#WK\A&D J3ZDK<N_(
MZ7.204K2HU8+2D9P01W['W.+(Z?Y+^*2ZW7$IH\9^31E*9H012H[2W8K?!Q*
M@G& 05J&?FP "3WU%NXOF/7[@J46C[,V*X_ZJFO]Z3#2YZ 22E0)2V4C*0!@
M9QGLCWTYZT]0C!TB/1FY(&\99:%VWOL!CBZ.G#3J]<4")TBZB8N)U,Y(Q&/3
MD(8 %X9MG;7>?$Q##M7\G]TZ8A3/JNH?W8W"?>PLGBA0;K0/R$I5@=GB >NM
M$'1;:\H*+&<:G>4VZ4E]+(YI1N#?Q5UWGD[7^_R ]L#WR-#?)KOEO5Y!G3H#
MU+ARCS86MQJ,$!. @%/$$ I]S[CZ:P<#;SR!J2ILZM7_ !8LN4I3C49,E;B6
M !T%%!/T&..!C.>\]5JL090".2)FU3=!O;-K@.)QAI]3(T=9E$[M"10.GKG"
M(J$8RB759IX+J96?(:0U&I\7R2W@$Z,X%/G].[Y"2D!1(*TU[)&% ]Y'U_ @
M1-U*1YWPZQ,J=O>1.\%0IKCA<:;A[L7XPZA!2E0Y,*K.,!84/?CW@= Y[C5K
M;T4N6'I6X\!3806UIC\N:FUCBKF2HDD='H=?E[Z^2JMY%49E,>@RZ%<<=MYI
MM$J3*90XN$5%:VU(</)2\Y2<D*1],GK2!&B<40W91.TO2-9K)ESWOB<HDDZH
M3B!B4*:P22B2=MZ;HRJ6/%5WA\W**7A4=Z_(1H,#+BT[GWJM ..PDIK1)P<C
MV_/V[TR7?*?RG944/>1.^[2T_M)<W1O="AWCL*K ([.-'? WNOF@2BF_]JH*
MJ,S'2I<MF*XX%^W-2'4-J00??W.>L#VQ,].J?BAO%3F(I;@TVO24IC/4ZJQF
MX3"I+RPE3*9I"4MJY$!!7@Y[P,'5CK4"Z95 L&PJLIYFW&!*?0.,[RL)?)J/
M55],XHKC/FZ$%2O*X=[QQ5+_ "K?*+^L=OG_ (J7K_K.E_*N\H?ZQV^?U_\
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ME:>4W]9#?7_%B^O]=T/FEHX."#_E:>4W]9#?7_%B^O\ 7=+^5IY3?UD-]?\
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MW!3$Z<QNEMB8NBSAN7IY+^6/D'7)#MD0:O0;'65,M,0XJ:6RS%"R6U*D8:R
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M+U3U&M. ,G-MM 49NDH1NJWXXMU=T[>VGH%'V/\ 'YH2I[R5B:W3T*DO.O!
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M&<?7&1KWJ;-_FA;']G*'_E$/2[GT?UCPG8^K^AQY2'\+0_ZXW>#_ .[O9?\
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M9,9K5/?C-S%*^'660([#AR1ZK@[Z4L?3 _[]=6KMP:,[%JM%>0U3)3K94L+
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M_P!*T*WCI9=2^EE7D"SS^V=.U6^U:>I]-;@6Y=*&:W1OAPHQUHDM-JD<%*)
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M /ILK_MW/_$==33DW*2[JO[^%'8^APM%WX1&G,^0-KRYRODAQ:B^TK/ I?\
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M;\-)XN1E!MQ(R^.26GDI4DJ(*@?K8PU*VUV]ID5Q*GOBY$=HN70\\W)D./\
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MX+%D) O.TTK)2DW+0 L@'D@??,,*Z(_: &<?N^O6O>HL_P#FC;7]G:)]<_\
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MH<4I<=C%MLR7&0]R3S=*0M.",C&I/C^/FZTU^.BT]C* U%E--BGUR\I;(0U
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M!QS\W[2>P.AFQ#[/7<ZN77MG6:?466GI%H5^12J3*92W'"XSBW5(#F"E*B.
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M*_[)VRW"HERVC<%%DT>V+-I*VI3%G+G,+CU*76*BE))<0'B]%8;=<+800>.
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M\6XH%,R8_P E24M$  !I8&$ '/U&-:N" N2IQP@+6VA"@!P0DA!2"%)^4D<
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MT20/8Y]ZG_&/9>\]W+RE59ZJR[7H4KXA%3N8@I1)=DK2N3"24E+BG)'S#FD
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M^;M$Z_#_ ))A]:'<;NR7K>\=[/TOB<J2SNN,_:U[@TO??<5\I'^%G\O]L7O
M0< ;?;+#\^0VRMT@@C\!^8/Y:UH@6?U./4*^67^7$I4.6?D!/OQZ(5T3K9=_
MA:&?]L5O".N/\7VRQ(^O+^+*WL$?E@G)'U]^\:UF]'8K9,?]KOTW]L^G RI,
M&(PWSVBV>ET">EG&:1+AX7S=F-Y=(:0PM3:6F4XX!("^&>LG*<I/MGWU=_\
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MOS75*@2T&B)#I4TD8#82<%.,# 3T#T#^/>NFP0M3;#CI:84Z%+5]$DCB5_O
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M#[5G-76')G;N/N<:Z7EQ>+MV[NUM$A3:4V^RBE0F5K6H+;:"4E04#Q*TK"U
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MUM",XCUP34B1J^HHZ8TF&VKIOILWX/'QWMF7O;8M%OV#7FQ&DMXR'4EQEY(
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MUVFQ*);N_P!(J^V=^5"MUS<6K-JNZ@TE^J[64^=8+\-="KU8KZZE&I%09_\
MSG\?K_WZMR\=?._;G:[<[<;RPW&O#R0O;?\ W?5Y U7?+9BF1K+@>._D)<&]
M#-[):@;FUN;<\FLO[:+F76W4+WLJH[>7/5ZLY%<%H73:-1=IU<H]1Q.3[8_+
MO_\ OD]>PR2<8[/OIEYOU_\ ->WI]?6^(-4>N;_@W;OZ.U>_'S2TM+4N%PM+
M2TM'!PM+2TM'!PM+2TM'!PM+2TM'!PM+2TM'!PM+2TM'!PM+2TM'!PM+2TM'
M!PM+2TM'!PL_]W7L!_\ #W_>>]+2TM'!PM+2TM'!PM+2TM'!PM+/T_#\A_\
M'W/]_M]-+2T<'"TM+2T<'"TM+2T<'"TM+2T<'#FLL9N^UQ^-QT(?\:M#U[U5
MG?S.MK^S=$_RB'I:6EW/H_K'B7^7_P!7\./'\_A*/_7;^>']L]L/_D/M;JC+
M2TM$=CZ'Z<1X6EI:6GP<+2TM+1P<+2TM+1P<+2TM+1P<+2TM+1P<+2)R<]?W
M  ?\!@:6EHX.%I:6EHX.%I:6EHX.%I:6EHX.%I:6EHX.%I:6EHX.%I:6EHX.
)%I:6EHX./__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>optn-20221231_g9.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 optn-20221231_g9.jpg
M_]C_X  02D9)1@ ! 0$!L &P  #__@!"1$E32S$P-CI;,3=:0E8Q+C$W6D)6
M,38U,#$N3U544%5473$U,38U7S%?14137T1%5E]&4$]?-$-?4$A4+D504__;
M $,  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M ?_  !$( ,8"C@,!(@ "$0$#$0'_Q  ?    !@,! 0$             !08'
M" D#! H! @O_Q !M$  ! P,# @,% P8'" H+"@\! @,$!081!Q(A  @3,4$)
M%")1815Q@0H6,I&A\!<9(T)8L<$:)"<WEM'7X1@E)C,V.#E2=_$H-#5&1U9R
M='BTMD1(5&)E9G:"AJ2GMRE#15-G<X>4E9?&Q]3_Q  > 0  !P$! 0$
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MU_XI?G\_EGUZ']T(>V6_IX:C?Y :#GT_Z)?4^?R_7U35_P!7[_KZ]'U&?/\
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M7*1^R-=Z365&=AD=X-S(.X!$^8XMS_CYO:]_TY=1?\A-"O\ 1-T/X^;VO?\
M3EU%_P A-"O]$W51G0Z'Q1Y4_FQR]_8MM_NW %TN4Q\(5Y_\743)\P7, #(S
MG."0)MS_ (^;VO?].747_(30K_1-T/X^;VO?].747_(30K_1-U49^_[_ +GH
M??T/BCRI_-CE[^Q;;_=N#%TN8'[H5QZ9K*B?227-R,'UCH<6Y_Q\WM>_Z<FH
MO^0FA7^B;H?Q\WM>_P"G+J+_ )":%?Z)NJC.A^_[_P"KGH?%'E3^;'+W]BVW
M^[<&+G<@ /A&O,"2365'D!MWF^"3,=<SCBW/^/F]KW_3EU%_R$T*_P!$W0_C
MYO:]_P!.347_ "$T*]?_ .$_ZO[>JC.O/P_?TSQQZ_N>A\4>5/YL<O?V+;?[
MMQR;K<Q!-PKR>H%74[QT'>$#(/GCS)'%NG\?-[7O^G+J+_D)H5_HFZ'\?-[7
MO^G+J+_D)H5_HFZJ,Z\'R]?P_7CZ]#XH\J?S8Y>_L6V_W;@OA6Y!4?"-?\V2
M?:ZB09C;O(C!/6(/0\6Z?Q\WM>_Z<NHO^0FA7^B;]_3H?Q\WM>_Z<NHO^0FA
M7^B;JHSH=#XH\J?S8Y>_L6V_W;@_A2Y0)N5<?,BK?@&/1T0)&!UD@S(XNQT[
M_*)_:U:>7##K=2[H%ZG0&9#+DVUM2-,-**E;U48:RMR(\JV[+M.NPVI"<-O.
MTVMPI: 0ZQ)94GXN]?V3'M-;(]I]VTC5JF4%FQ-3[(K+=EZSZ;LS5U*-;-UF
M$B= JU FNI3*FV==M/*ZE;S\U")T9;%3HLXORZ0]*D?D[8&0< D<#.#@>1/.
M1Y<_,]=F7Y'O/F_PD]]U+$EX4Y5B]OU1,$+(C&<+@U<B^]^",(#_ +LD,ES&
MXHX)Y/66]K/)'+;/*M;>[=:J.UW"VNT;G>4#3=,U4,/U3-$XPY3,H;9WJ$/)
M=@K0IO0/"XJ;)RG>;H;FW0U=4Y5TM0AU+8=\;C+J$%Y+@?62XI)2VMM39,>,
M+!\,*IL_*E/^6"UG&?/1WMO5CZBPUC=]P!(^>5<@\$<\$G'CN_\ EJYX/R/X
M>8R?D1UT/_E2?_+!ZT<?^!SMOYYX'YA.9'' !\\'DD CX=W7/!* \=W_ ,M7
MZ^!Y_=\N?V=53EP_L-:!_P!FL_\ S'/Y?Q\;[9S(7A/[7IAOT&L'<9.,[>^,
M<8?U<>7T'GY^G/S/RYZ\_7Z^O[_+GY_3H??Z_O\ CT/49Y_?Y^G&?0]3W$X-
M4[??2#UW'H3)D:@)^:),3Q[^_P"L?,>OT_7]?.O3_8!_:/N_#^WKSC@?]9'Z
M_P"W[SCH<%)(G;I)&9\)$@D@P"1C!.X$0H?/Z?,?//[?ZNO">.0HCUV^8')^
M8^I_7P?(^]>*QA9]=BN1Z8&?VX''E^H=$HZ05'89,;\$XI24$HTA4B-0)3]Z
M"2$^)9@Z8&=S$&>'9N;077"S+SMC3B\]'-4;.U%O>/0)EE6#<]@W1;]Y7?#N
MMY4:UYEL6U5:9&J]<BW'('NU#D4R+*:JL@^!"6\Z%("'NNU[GL>Z:_9-ZVU7
M+-O.U*I+H-T6G<M(G4&XK=K=.<+50I-<HE29CU&E52([E$R!-CL28RR&W6D'
M"1^CWW16)I_W]]XO:YH-;U*I%M=X'LV)'81W?V-6')<6--UJ[5[WFV7_  [6
M.9[B&I!J6GM9I<"\J5 7)]R\941<-M#]8JZE4S7+VS:$W?WP^U_[B>XSM*TJ
MU;LFU_:$W?IQ2M<^[3N\F]JO:I8DBL5@3ZQ:D=BS42-3M3M89\%Q$BC4BVZ7
M78,&*[3FWX<1YQ]4NFTO-@<0M=13%LLT8?73-SWBEOU35/2%E;NA#C;[;B7S
M"Y2F4 %8 X@V[FM#C8#()$K>7WB#K0D)0D!(PA9^:@@ :]2"G5 ''\ 2< $G
MY $G]G^;H8/E@_0<YSQSC[OF/ZNNRZJ>S3]E;HO[1'V@.@EQ4_1UJ?9>GW:_
M>_9II5W?Z\:M:9=LTA_6"TT7-JG1[NUIL]MBZ7:C1I+M*@Z:4ZZ*I[P859"W
MHE:]TFO0(PS_ &9VG]G>TWONT[D]FY4U: T#M31W%T[2R=WTVS#[7*+ ?6:4
MG6Z[.[*HIHU=9[:%56%4H\6V/>4:CIJC;BRB92V!2PZ;YLH72N&7TA%$BM2I
MQ3#0="VV7 TUWCJ=2_E@E1G0E25!2AX=3_X1:4"0E4!H. X@!24* .PGQ!*E
M9 5"5%)CCFNT[TMU$U>N%BS]+;&O/4>])T2J5"GV=I_:U9NZYI5/H4)RH5J?
M&H-!ASJD_!I4!MR?4GVHZF8,%IZ7*4VTVI00:VEMDH<04K0I2%I((4AQ"MJD
M*20"E2%@I4D@*2H%*@E0P.[SM,[5.V30?VK7LOM7^U^U-,M/Z#W0]BW>A>-Y
MVEH-J_>VMN@C-X639M?M655])-0-0H<*[*Q0JHAW;->E1X\-=0IRGJ<P&RN5
M,Y/_ &<E@]I^IW?/HY9?>W6Z[0>VZN7=>;>H-0H3U<A*=D1*979EH4ZOUBVX
MTJNV_9U7NIJFT^[;AI;3<NE4:1(?]\I[9<G1EJ7F%JJ:K:E##@IZ6B8JTMA,
MU!*W*UIUDH!*=:31@I"5*2=>3,CAE35JDK.M*E MI==(,R4I4GP)@: #@[E2
MI3"0$D0 *2" 00?ECD_+''.3D9Y^X] @XS@^O/(' /PY\QY'CS\L?7K;[AO9
MD=N;_<E[,6H6KVE:(T+MM[@>\6U- ]2]8>T#O(NS7_MBUDMVOUA,BDVBB)=+
MC&K&E6I#MN,R5URHLU[[-F+9J$>#*3/CQBV0ZM]F7LV-76O;-]LVAO:5>W;I
MJQ[,.P=6=:=.>X^L:UWG>\[4EK3*X*E'N&Q-0[&N)M5LT2V:NECW#3>/!9=K
M:+>;A5V95YE48F_:":>::-;;3HIZHI6V'7@CV=:J=!J_8X6D/:EK[TI/=-)6
MYH5)2"E82[^$&M((;<)4H!( 24J*@D$J6"4I"9(5. I)285('*$00"2"!@>8
M^>,<^F?3U].>>@4*&,I(W<#*<$_LYSGTX/74)W>=L/L^+#UW[->P[03V?FI^
MI6NG<-979;K3?5]65W#W%2[YJL"_K/\ M^_M(M*Z#=\J;9EIM7W2:54:]<E^
MW=.<@6HJ75IU-C4F#283L-[.\?LM]G-8G9=='=S3>USMZTZKW:GWSZ*Z5:JZ
M4=MW>5J/W+PKGT:N*NTN'?6FO<)=2Y$6W[;UF117YLB2O2ZN3!0ZDU'6W77$
M29,$]'F:G!H@:*M3[>HIIPI+(4H%?=,KT=\5A+[R7&DB)"D$G'!&YT_SL*0%
M)&I*T**)7"M8!U ALH<""D$I4)@&>.0_GZ\<XYRD?7^O(Z'X?7'GQY\X^A'R
MSS\CUU'=WWLL>V;LCTJ]JIW&W[8<JYM)Y%T:&Z:>RW1.N*[8L"34.Y&VX.JT
M>]&:G%K$"5>:]);%JQHRV;@76X$B5;M474V)$D^\JY<3C)QY#@9QG'H3@#D^
MO Y^74G;;I3W5I;]*ESN6UI;*UITA3A;0XM"<DDM%8;<Q <"DSX9+QJH0_J*
M8(2I$3D^,)(C "2-@K 20?(CCS]@/[_Y^@#CR_UC'ECCC\/V]#S^X#U!!_'S
MQSY?4\_0?0<_=U)?KG_CPK[L0-O/YL*$;)VVG! G)' _7Z?M_<>G.>A_U^?X
M]#]_/]_I^_D/W_?]_+H< B8WR)SU7C8P>@S$[1.0>/?+SQY_YO/']7F.?+KY
M5D@G\>1YXP3],^OH.O?7]O\ G],#Z?ZNO%'@_=Z>8],_V_V]&-T^<C\H_+PF
M['=K)DPA85$9\.Q25"?X($;F<!0(_1J_(X_^(3W'?/\ V6]7_5_!#IAC]^,?
M7SZGS^4FX_BSJUGR_APT>S^-6J7SQC]8XSR.H#?D<?\ Q">X_P#]+>K?_BAT
MPYZGS^4G?\F;6R3@?PX:.\^@_P!MJECC//T'S^76)5/^/1$1^S30C>/E&_U_
M3Q!4$#FFBG ^$*?RZZ/+&?KSG,\?GMIXR!CA2OQYSZ^F3\AU]Y(XR.1]#P<_
MM\_U?3KY1D[B>?B5G&..?,Y !S\ASZ>G7T1ZCU. /7G.//CGR\_,=;.HY( S
M./?C\O7S,9QG;V_F#ZX^F0,[^_S\NGISCC.//RQP> <@\GZ_/Y]><<#CTYSY
M<Y^H]2#QCZ>>00,'/(R!GS&1],'(^6/3'KD= 9Y\O4>8R<@\Y^7S^?IUST_7
MTS^OT=8Z_P#7R]Q/60!'J01M' '!^7I]WI^S^OJPSV3#3;GM,^R-2V6G5-:[
M6RIE:VFUN-D0ZPHJ0M2"M! !.01A(R#SU7EG)/(_UCTS@X)SSZ?+RZ-*+6ZW
M;=6I]P6Y6*M;]=I4A$NEURA5*;1ZQ2Y;04&I5-JM.>C3H$IO<=DB(^TZG<H!
M8W'IK6TYJZ.KI4J"34TSK 402D*<04I*A@D)40J!F4B,P>$:AKOZ=]F0.^8>
M:!() +K2D))&Y"5*"HC,;3Q=WVU:DZ>:=>V@UXLW5FWZ#4])>X_7GN([:-2&
M*Q2:3(9IT75F\*W2K8N'QIT1XT^11KO-*W5*,N--98J$A:9*4 [;5^W_ $IL
MKM=[S/9C>S%JMJ6%=5TV#9W<3KAW'3I%&HUP)N>]=2+?OAC3^A5N=/@RG)$>
MDV>RBH,Q5N.1VA*@/(;WQFO#Y:.V[6FP=)M;J;JWK7HS'[F(%+D.W W:%TWM
M<-M^^7['J<"M4"\*O7Z:^NHUEZG5.$Y*GT^HKDQZP)#WOI=6$$R9L#VD>K=J
M>T#K?M'+ILRF7Y?M>N&^)RK4J$NM4NSV(%TVH_8],MBDUIMEYYNG670/=(5+
M;0X[(>7$=<E(0Z^^KJK7*R53KA0R%=VFSAA [U"!5W<(?I:0-(UA:/DJM14I
M0A2TMD*) TUNY6VH??>4T.[9%K<0!WP:0[<6J=^GIBA(6%)46JATN I 4M+2
M@24F+D[^M_5#47LGUYJ??5H+9>DMWZ)=].AUG=FTI&D-L:439%"J.I]#IE=T
M\LIJC4RG*OFQ8UMJ=VU!PU6)6(CTB2^[+5$\9ER[IL1ZS>X[VX>H_:YI/9EW
M]X^DM6T>BZ V;'T[MN]:K:%@7!1:$[J%=6G6F4^GR:34JNU\?BJB4B0^"EL%
M*O> V]RD7SK%JAJ#*AJNS474&X:;1:M/JUIT:X+YNFOTRS'9M0>J"&;6C5>J
M2V:,(*W4-QGZ>U&?;2RT4+1MV@N@:JZI4F\).H=*U-U%IFH$OQ/>[\IU\W/!
MO667FT-.>^77%JK=<E^*VTVVX),YX*;;;2H$-H">CRS4*:<0*QII+A6HTJ$.
MFD0%O6YU30EPNEIY5&X7X6/&\2B4R%=? %1H6DU3:%.=YJ92VM5.E)>HG0VD
M%Q*N[<]F<[Z%>,U"]."HJZ3M/-/>]&\.ZQ[77631SM[[=-9+([!9.JUX52V-
M#:5K!K;7+:74Q1(VI]$[8J6XS2Z=W+R9(<@PJ?5*1"@4ZDK<9DQ)@<;;%@MM
M6VRY[0#V2&J51MJY86HFIW9%W?JU&NJ^-*[8TAU(O2HT/3]I5%J&I-D64TW;
MU"NYN'5I"WZ0P7)E,8G(AOJ2I!9:XM8VL.KL.]I&ID/5?4Z+J5+;4S*U$C:@
MW:Q?<EE: TIF1=K57%??84VD-JCN3E,!"4A+0P,>JUDUB7/I=5<U=U3<JE#-
M<-%J;NHMXNU.BJN4*%R+I50<K2YE,5<06L5TPWV#5TJ4F?XX5@\/\L53[JG!
M5TM.A="[2=U3TSB$I#C;R0@*6\M:V4*<1I0I8$-B$I4E)X*HY?J*@DJJ:9I/
ML;M*$LTZT) =IJEG3)=42TAYYMU""<!I(3I4 KB<WLCQ_P#E2NT$!/\ X?)>
MT)"C@)IEWDD<' "<E6?)())'/5K>EU-U&T][4.^/7GL=TOI&JO>ROVANH5AZ
M@/-Z7T'6/4'3K1<WA79%"3;-C5^FU9+5&NB:M*:O58\$A3<N8XZYF&E43F-H
ME8KUN5BG7#;-;KM!N*G2??J76[=J51I=>I\T!9][IM3I#S53AR@A;F9,1UMX
M)4YN7M6K*FM75/5"QJY/N>QM2M0[+N2L!\56X+2O:Y[:KU4$IQQV3]K56C5.
M%.J"GWG77GU37GUK>6XXH^(M:C)W*RKK:CVA%2@@-432J=Y"RT\BEJ'7G&JC
MNUI46G0X!I21"TA1D0.'M=:W*JH*T/LMGN*=!9<074.(:J''BET(6@Z%I<"2
M(PI(D+3(XZU:]H]9=M=WNO%_:2Z,Z6N=^E)]EC0M:X^A-,M.WJ_1K5[OZU4:
M;#OBIVYIJ^A^@NWW MQ;51%KM4UQ34B67410[*<>7'32C2[OKUS[NNU#4C77
M0CM;T>UII7;#JAJ6]=5[:04ZM:BZB6G:$G[._A!O'MBMU5'#NM-(7/89TXHS
MU)IK;R''I;WCH1X#7-+3[]ORD78+\I5\7G3+Z]]?J/YZTZZZ_"O U&4"F34%
M73'J+==7-DI)$B2NH+<?00AU2T )!R_K!J[*O9C4N5JMJ;)U'B%'NNH4B_[L
M>OF,&T*:;1&NYVKJKL=I*%*:2RU/0QX:EH+92I0,>.6ZM'>:*RF<6NE2PE^I
MIW776/D5-*:8'M 1[-J5*4.]XK2!KU*&KAJBQU;8<TUC*G'*--,'G65N.,PW
MH4TR.\"/9EJ.I0<"W0F4ZR3K'9A9UV7!![@_8D:O3V[P?U!U@U&[N]']0M2=
M9^W;3_0K56^[#50J;5;:@W!I_;L,1;*VS*4P]9+P,2[6J('2XMA%2J#4BO\
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M>N_7W_CD>1G._%O'3T$'TP,;9GW_ )N/G \SS^&?(Y'!(^A!..?3H9Y\CYY
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MN,KD14,&0VG'B,F2E2XZG0  DO-H6MO!.0#G'JL.W[M!@$*L&<_N(UZ1^_\
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M]UIP_$<!*LV:C:K(PH'&TD@X(.-5?L..\QI"G7;BT'+;>WQD(OFL!U/Q;5)
M_,_A>04@<_$!R1G/8NN*J4J=(6A(=0H%DA/P9<<.]QS "B2?B00"H @GD#IN
MJ_%==2ZVEY325-K<E/@X;BQVUE4B6\#A*@E!7X:3N6XZ00/A4H)J^R'[0 ('
MP!)&XLK(/O!#Q(]#TZ=>%D<L6E1$-OS()BKJ2.GDOW>AV]#R3Q?8C]W$XR!%
MN70MQ45I3TE"]1:FTII <#//BV<C>I3Y+*0V5%2P2G*1GI,5WV-G=?;:"[5Z
MII$TRA#+JG8U]U.5AM]:6D*VBU$@D.*""GS))*0KC/27=U6D2[K6W3T2'Z'!
M=CPJ9)(QXC>YI"I+I1M4$$;G$H((+A*U$DY&/5RI35PGZ?! ;244V,R5K4K)
MANI<<DG!W)0E1)RE0._: ,Y/23?V17:&(!79O%_V>% 0!,C6-7JDX@1UGAV>
M3K4HB55>4@B*IX*&T00H$$9VV &9CCG,B>QB[I'TI6NY='81*5+2W4;RK#"7
M"EOQ E+B+14R?@(407VR#P<<CI^*!^3F]_5RT:FUZ'</;K"B5:*W-C1:AJ-<
M+,QIAT$MEYH6.ZE!6D!P /+!0M"@HA0 OGT_M^K/T*GK?47W:\]3@A,F870Q
M%<GML>\LH"G X[,)7XS'PJ881M4%%WJ[NAPVJ31J92H[>&:? BQ$AH$(26F&
MPK8A1)0-Y4< J"0=HX  MG*O;;S[>':CVE=F[IA($HM:6Y7@Z=*7PG<C.\8'
M%:Y@M%!:4LMTRJI3SY)^5JWW%!"")B5X!B,9$;@$\<.W]S8^T"\S=G;./7G4
MNX^/3'_ 3]7.?F?GB<_)MN_]"5;KN[:, @$IU+N+(SY<?F(> ,\GGY<<==SZ
MWDA>"E0Y'&0/F<XSCU'[/GCK1>4-I"EXW'@9)QZ\_/(^IQG& 1U;4]JW-NL)
M"K6"%@3\'@D83F"Z1C?KYF>M34/"HE3Q!2927WH.,A7CR(Q'NZ@'AA_R;/LK
MUE[#NVK7K1G6R;8=2N&O:X,:F4F;I_<4VXJ::+6K%MZV1$FNS:-15QIS$ZTY
M3P0AE\.1Y+14Z"WMZ?/VVNF-W]T_;\GMBLVL4"VZI5+PMS4!5:N&'6ZA!$*P
M4RZI,@MP[?B3:H_-EMR0(S;$=:2I"BL;0#U-_LN.7-11G.!:^<>63]O9] <_
M//R'2KK*&GN[BR$.H0X!9]ZJ1O"5!M:8$%)6D+20'-BB M/Q)"E#)"CTFW?+
MA5U#-[<6TFXO5::A2T,(#(>2L@$,$J1I&D$C G..*TX\JBNJJACPKIE)<:U2
MYXT-H(*BLG49\1*I,Y&>.'&RO8/Z]WY="K8INO&B5,DM6PF[)=8N&V=6:);D
M&F/U)BE4X2:S/MQF(B95IKW@4^)N,EQ3:RZRTG:I4EC^2X]Y^#_A^[9OTCCG
M4CCGUQ0@,XY]>>/7/7<E7*!1*O2IU*JT"-.IM2:]TG0G4I+4EAP@EI82D$$*
MP6RC"D+"'4X6D$(ZRZI4(S3UN5RIPZI,H\J1'@56,& BKT1*S[DXE#+CJ55&
MDHVTBM(4I+B'VFY:D)]ZQU:1SSS&@I2JJIS/S2FAI1!!V(*%'J((/IY3,*YU
MO:O$EQ@01J!8;.\9F-]\1U$#>.)W^Y<.\_G&OO;,1CD[M2> ,#G%" .,X/EC
MZYSUY_<N7>=G!U][9<D^>_4G&,'G;]A'R)/ER?,$8/7=&'6@<?".<*!VCG'K
MCSQR#SP<CSZTW)0(4@J0D!92E6T>?)2/+(/!R<G@<C'/79YYYB&]6SN(^TJ7
MI&_R41MY#T/":>=;Z3]U8CS]G:,[;0/JB=X/'#2?R7+O/!&-?NV7'EDJU(''
MKC_:(XR!]X^7!)]'Y+CWGE.?X?.V<'RX.I!V^>$E0H(!^8P 3Z^779#J-W"6
M?IK<ENVQ66:Q4IU96!-D4BGLRZ=;+$Q:XU#D73,4^TFC,W#4&7:=;ZW4N*J,
MY"T(2EL%SK4JO<O9-NPIM1JM#O>'3($9R?(J MU,F$W'2L)=D+=8F!.QLG W
MA)P4E 4HD=)GGZ^@D*K:<1!CV.E]-X:ZG?;..._CAS 0/&P9R/M9O(P-NN\[
M8W\.#QQT?W+GWH)0<Z^=LZ0< I"M2<$CT % )422>//./(<=)!S\F@[R9$Z5
M3:!K9VY7'*ILEZ'650Y&H4&)2)34<240GY<^@-LR)DA*T);CPO&#)452'&@D
M@=E"^Y.QKE99#51N"W+?=#+GO4R@/Q:S7XTMA83"AQ=_OU$1N4%KFR&D2G6B
MDQPVD!Q1]3=?M+J?2DQ*#"KJX]/BEFEL.PF(;<IJ."A2XDNHS$H<W+RI^6^M
M1==)6XHJ4.B'/U^G%;3!(.?M.E)5$?-AN8!C)\L @A7'0YQOX'SV"3&/9D 9
M(.3OOG3($DZMSQQK0?R8GO"J"G&6M?\ MH3*CJV2XCPU*;E17 D%2%M+M\>(
MV%+2D2&-["@1M</ET9I_)<>],@A.O?;0#Y\*U)(VY !.* ?/R )..0">.NL&
MZM9[HN2H,/VO3K*LNHP6WF(-RUZJ2[DK-.CR=A?6S1:.EBFU'=L2H0)DQV.M
MW&TH(W%B*WJY72F53[TUEOYZO3)TJ*S*MQ^@VQ;L2AML!3ES0:13HKDMEE6]
M4.-&JCRYC=3!Y<9:W!(]H5_&!5,KZ3[%2@*B!C4W.TC8CJ3D@=CFZ_DCY6G&
M!(]F;)GW#!'TSY[\<Q<C\F?[O([%9F+U[[:$P**IMA<Y4F_F(DV85^%(BQ'7
MZ.VE*H+Q0U*?=V,I<4I*2HH6 5H_)P>Y%RHTZFQNZSL]ES:@Z]$:;A7+=DIU
MJ0TRMY##[3-.6^"Z6G6T*2G9XR=BPE2D!71->VL?;#;].I=)>J=K5?$ZF0)$
M6Z[PGU^88$60*Q-9FMR*KX*:C4'HJI*U2&E)*EO?$G>$=14U$[V.RR3 E6S3
MK=TWN2J2G'&H4*P[7"YS4V*^B5!$"I45AN<DMU9"8[KA=49#X<9;\0JZY':%
MS*<!]A4P,45.<3F?DMB(W\B<[<*CFV]F"76MP0?961IP((E>XR9$&>*FKM_)
ME^\JT;7K5SNZV=N57:HT!VHN0*:O4!$N9&CX6^F*[)H2(JEM-;W2%KP4((R%
M%(ZJ>[E>P_6#M@N2F4"ZIUMW3'N&DM5FV[@M--7^RZW 5M3+7'8JL6)48KE.
M6HHF-2H[:R4>(V%-+2L]8&EGM(Z/;544NC6;>T>QXS=0I5]VE7JPXFARJC4*
M!+FKHL&D7)-E5F/<-3CM/N6A&A>%'JDJF/0UMA,L81<NWNUSO"M>FZ;:M7<U
M(N&E3)5P6.:4*I8M_P!M-7%&=5-2A-W-0Y-XL/(?8CAN$VJ$RB.IJFH)0I?7
M0[0N9$J25/L:3\X>PTY(,#204I0 8(P<8))R(Z1S7>T@ZG&%;$%-,V#F)$#4
M,0/H,>8XY_.V'V2&K_==8M>O73[6?16E.VQ$,RMVA<WYZL7%"CN1'IE/D@0J
M3(@R(=0+#T>/,9=+3,I'@/;%%.7C3[!GN4F6S1+CHNM/;W6_SGBLRK<IC50O
M* _4PJ*J7**JC4**S3J?'IL5F1)J<Z8XEF+'C/N$.! 2;Z^S/M5M_L*O6^ZU
M9U5NS4VTM2X5%I4E%>J$&!7;*C4&0]/1#8I-2<8:J]+JB7%.ORC,5):(#+32
M_$*2_,%R2U:E\O6M29,^W[1NRLZB63#F+;%'<L^8U(>NFV*I5E+<982Y EW!
M'CQHR7%1]R&"UX8"1PKM#YDU2BIIBDD8-#3SG.0!N,^L $S!X'QNO!)AQG2-
M,33M1'ET@@X!,'3GH#QS)4GV%'<=5KFMVT!K?V\)J]=F5*D2C$J5[5>ET.Y:
M?;<2[X]N3:I!H(B3I]5MN6FJTMVFJ>B28S:]JRO Z<9O\G@[H%W55K5.OO;I
M]MT:FTBLN1V?X1I<R33ZNN0Q$DPXD:WU/NH3(CKC*.4K3(!:V!22.KE[1%::
MN:]K&7J16+4N:B-V3>FF5&GU!5<BVWJ)2(-6NJQGY%R1*2Q18UH7CIO(51KD
MH)><JWO-;B0F6F6J= :-B^EEXP]5;=MK56TX$BVZ(*;.LK4&UV7GD7&TI$H*
MK=+K[$E!JU#G6)=2WE-A,E-3J-,DM3W F*\VI1CM!YE_SFF$Q,4+&0),?,.!
MZX $"9R2^;KR,]\S'0^SM@2 D@_.@>28!SNJ)XY3-+/R=KNXU=:KTBV-8NWI
M"+8O:OV+<@FSKX+])JU!;:>6_*:8HBBXS4&9$=Z&AA;KR6W?[X+2D*2'E5^2
MX=Z."LZ]]LYQC))U(&W!'&[[ \LCR)],>O'3A#OY';#W T.5.CM0M ^XV;3K
M>N&M"2IV!IQK?!A-T^TYKI2D(A6QJ%1&6J;5*G+4F*S<46$MQY/O+AZM!;*5
MMHW@#<GE)VD*^1)&4G(Y&.#YI)&,N6N>^8EIGVJG"AX2$T5*, F-VR8WC88,
M#'#9SG.^!0*76 DZ5)FG;.1 C<B09 CI!ZR>$[^Y<>]%0!&O?;/@J/\ .U).
M!QY*%!P><C'F..A_<MW>EC UY[:2 2?/4GY#:<B@YQYY!YX\^3UW;!*0  D
M#@# P,?+KT #R 'IP ./ETK\>.8O\Z8Z?Y'2YC:?DN$_CK??XVG_ *LW^;]?
M//'"3_<N'>D,G^'KMF!)_P#VE>1 Y_[@CDG]>.?3KZ5^2W=Z/'^'OMH'&#_C
M*'&"/6@X)Y'/[<]=VFU/_-'ZAT" ?, _> >B^._,7^=,>_V.E](_>ND=.!\=
M+[_'4_\ 5F_3><=/=QPDG\EP[T>!_#WVS\^N=2<CT./]H<GC]N2?D-B-^2^=
MYM+EQ*JYKYVUK;I4V#55H0G4HK6W2I;%16A(-"QO<3%4E&X[0LC<H)R1W7;4
M_P#-'ZAT7U;BEU(@?^X)I_\ NKWRZ)7.W,*DJ2:IB""#]ITHP1&X:D=/JX'Q
MSOJAI+U.0H:3]K-Y!CR&_J.&FT'U(<U/L2GW&Y'3&4XVTUX2 =J2RTEA6"?,
M*6TI:<_%M6G/.0.-K\H>]G7KOW+]]E+U@T]K.GL&UU:!Z>V8&;CK<R)5_M.U
MKBOR5/7[FS19[:8K@N**(S@D%3Q0\5);\-.[K+[),_P-4P$\!QS R>/Y5ST/
MEZ9X'[.H!^T6:BJU6ISDAYIO9:;>Q*CM\7_;)\+0CCDC()R0-I/KCJCGGF^]
MG]*CF/E]5'\))"*/[?I45E.IBJ5I="F%D)4KP)*53*5#4)/$;9>6;5S7=!9[
MLBH50J2Z^12U+M(^E;*06RA]DA:1XR% &%))000>.$='L?\ NF6$G\Y=(DI)
M/*KAJ",;3];8/X8R ,#[]N+['7NJF*+<>Y]'%*Y!+EQSSM ^1_-@!(^0^O'U
MZJ:11F;@<<AM,E BM%Y08CJ60%%0;\=XI#3#;RD%#:GW$)6LE*25@CHABTAV
MG2I"'4A.R2X0VE07X822 ,^1)Y)\SG&".FG^%AVK:0!\5B8!_P 7*;I'X7:9
M&,SCRXNX[".S\*(#=]G_ &_</3!/>"9B?KSY\QB?8L=W2B4BY=%L_"G)NF>D
M\@8&/S8.?,9)'W^76XGV)G>"5$)N31,\Y"A=$Q0^0&3:_!X)\O7)/EUU(LA:
M'VDE2E%2AYDX.1D9W  XX]#R#Z9Z.5.^ZK0ZXHJ QY;0-P.0#RE)_5ZD8^7"
MOLKNU<)U?^RQ (_]W:<R,9@N[1[O+'"K/8)R(22EF^E(!_Z_N0)!CJ') G?Z
M,<<K)]B/WADY-RZ*>H/^ZJ8D8)]<6N>!GS)\A@^7..7[$KN]A)0M^ZM#T)43
MS^=\\;$C!*U_[E0$H ."K)X!SG''5+7+C@T.GOU"4M"6VF7',D  !*3@<\)4
M5< @<GRR>HV&Z[@UPN:':=N&7$H3"E2;AJ;:RT(\#<G8A+J2 7)*FW&VV-WB
M.X7@% ST!]EGVKB(7RI_J_%RGD8'D]O$#KN!D\2C'V//(2VB^Z+^VVD>):;_
M ' DSLD:ED$$]-YV,[<[%!]C'W:7+49]-H]RZ-S#35!$R:FYJ@*<RZ5?"TF8
MJU\+>5P0VE!R/,Y/2L5[##O.0O!N/0\GA6?SPF9^X VL%<8\O7YGKK?H-&I=
MOTR%2J4QX;$6.S'6X<;Y"V4!(><7RIQQ1.5J43SD G)Z/F8;JE)6K:IM6X$G
MD@$^6#R<>>!]2/7 _P +'M6(!/Q6E4?^[M/$F/PL]-YXCW.P;L\!40W?RD'"
ME\P7#5B,F%@3@[ "#MOQQ\O>PZ[RVU[57%HH<XY1=LTI&XG/G:WUY\SY#K;I
MGL+>\BH56!3%7=H- ]^E1XJJA4[RJK5,A(?=2VJ7/=CVC(>;B1PHNR'&HSKB
M6T%0;6<#KK^>I"7DIPK"TD$I&X)4 >1C ]/4CG'(^>PU12W(;>"@E2>1NSMP
M1QDXS\_(8R<>1/7"_LM.UQLI.GE/1J E7+E.93U AX$$A,@Y S]";G8-V=*;
M@JOJ5;@_#U>O2J!I)2MV('ID=,&..0FM^P>[SJ/-FQ%7AH#5&X4MZ*W4:->E
M2D4VH):.U,R X_9T1YV(\ '&5O1V%J21N;3Y=)J5[$7O&AM+?=KNC9:8;<<=
M*+HGKV-H25N+5BV <)2%+5@G"01\AUV6O0PXK#JPI(() .<@^60H#./($\<#
M''7RBG,I'PNAL\XPE)(SD'G;R%#S\S@_+CI _9;=K&I6CXJI3)A'Q=I_"F9
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MDC(QCR(]2_PO^UF/E%<J@"(/Q<I]SY_+?H'7W/5?8Y=FA24MJYD4H@;<PUY
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M4&+284:#'VB(_5%O2);KR6U(=EN .M-+D2%'<\$-I;/DHG/1B9!G(]^=L?\
M#RZ^<K0TS@*7M!4)'@B0<R23L?=IQ.V<+"CU>ITN=3(T>0V]365)CSY-22XF
M8Z%LH6Y+"R4I=2ZIX*#++9\,<H2$)Z6D"ZHSL]4!QQI2@7 I8D(\0E2BEHI9
M&7"MY*5+ "2$I"<G*N(SU'6JX,*8BUA],<JRACW=EN.G"0/A;2T=N =H*<$
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MOVMQ4 /!EYX!1;A 2!E2H&< 2!*CT  SO B)XY;;"U #5&"8W$Q F/Q@8WZ
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M]7F?F.?7HYAR2L(3MP>3N)QY#GX>.3P!GU)\_,Z ;0A+1"<@C./N'D<C!'S
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M%-E,:G1V3X;E6?<3Y.K)6F*R[D*<2VX$X0>FW0#!@>@F(Z;?\3OQ(MM]YU@
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MIHM3DMLM%Q#<<+4!\B>1E1&/BX.WT.0$@'CHW:=1**QM40O"%*+?"@#N!'/
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MIM>RO23537ZKZUWK7:K6Y5.L!AB'7JU,*76J_J3=2UU P3(*,S&+9I(BF<E
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M:I03Y# Q@Y&-PY))*LD'XB=ROTU84H@5N>THEJ8UQMYI(_WRT&R2<#C[7EI
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MVA28%,889C-):;C!3<=M65+.?TW'5K)4XXZ22LJ^(D[@K! Z<J,X4.)*4H2
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M6_=C)BMLOQJ8%+8>99=0428;CB7'6I3",H4@*;)*%+45JPI6-N.L%UU9J%E
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M1(4Q+\B>M]"7&3)ARHC;4J/(*/AZB]V@R+=C:=W"Y1ZK3G*E!E.O75*6S(3
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MLQ+8O^6C8&"EO[#O1N:PX0U+VIL0+@=VD%*1RR4<GPEI44J;(&/T59!/!'F
M/6B:P;GMZF5*?H5?;S%=TRUFF%FR[LB/%;=.N>MPOMRB5-B8E244JFZAI0Q<
M%OO(+ I.I$*OT5KPE2$MBR/M>U7FW5%N?26_)3SFKNCC]/I5U/.*2E=Z6O.;
M4;.U$IP!"G(]5@(;A7 XRV6XMQQI+.<.I473#A,(48\IG!G(GH)DCZ2.&;S?
MWP&VY ^<G$'KD3I5OF"=R>)BLO,H!0LGE.4D #@9'D3G!S_5G/GUAJK#*X<T
M[F^:=.( /*28,GA.3YA1!R?F,^?,4=9^Y>C:*W#:-.K%"J=V4JXZ36:Q)GVG
M'=J-6IR:;,:@4V%3Z/':=%<D59]4I"D-264QUPE+6-C@4&PA]_&F=TMT5R@V
M9K"8U?N"CV2] J&G$Z%-I=4N]54CT.?5%//(]QI2H4)RM3Y2@MB#2#%4\OWN
M2W&Z6+R(*2<I('7T]\B#OT\AL$TM+PH D')(B#$1OD?-C,9W&Q+W]D8_P,TD
MY\R>//&%N#&?4_,_/T''4!_:",-3M=:! =4ZAN3:33;KS>"E#9JLDG<<8(!&
M[!!S@^7GU/KLE24:-TQ!Y4AQQ!.<@E#KJ3M_^+D$I^8(/KU7I[14NLZWT)UE
MW8I-GI&<'.#4Y05P2#Y#Z\>0]#4.=%I1RP2L2GVBF!$Q]^KW]0,>O%VY 2M?
M-*4MF%>SU9$9&&TDQY"-IZYXAG=*J!169M*I:43UN!$9NI/E>YM"2VZ51V@=
MB7"0ME2CG+;C@ R1A!4"E4Z ])EI:\234G"Z\^\I;JPL^:6O$6H,M92G"$!*
M3C)RKX@9(B+?0)+K"E,*\0>,MM6PK2K'PK.#D$#R&#D<@@CK,H [-J4MAL8P
M!C<=N.?4G&<9\O+[\#<*=:M'S<1N,0#&?7\?KQZ,1J" %?./SCYD0!YQ$=.-
MUM@1UAQ*@0%J. ,'*O(_4#'KYC &,<F\-Q3CB23Y*Q@'GR'/EZ _3 \L>A&M
M:DEM()"5-(SQD>6..,\CZ9R.C*$HI;<4/YKFX?0 )X/K^/./KY'F8!.<>4@=
M 3,[C>(S'#II&M&HG; QTVW_ %G@\??4SC: 4J!_G 8(SD^N?KQ^.>F!U8O"
M7/=8L>C%7C3%(55E(5M4IA0!CPU'C:VYDO2 !GPBE!!2LY=BMUMFF4R5/DC#
M<9EYU1!\RV@*2G&/YQ\R<?+!]&"TPI4JZ;JG5^8GQ79,D!I12HA)>62YMP,8
M91L;;&<!(],XZK]U6]6O4MD:>6V+B75U3C,E;-LID!5:9QXUD%@01HU=X-7W
M,Z[V<T5)9:&_]HU=1M5;?*#5(S9*5\2Q6\X7'6+6EQLZO:$VVF_9MP0-+M*P
MWC+H=G3ZSX-IT=$V6G=(* ZXH>;BB"G:?J"  /E@\<$%%Q7#'E/.-O(+1Y#2
M$@E8W%24@>0R/,J(/F>.">EK<-YV33:[^8:Y%6K%R-!GWJF6Q;]9N(TUQQH.
M-HJ\BF1'(-,4I&7 B;+87X:5*"#C!PZ@:'WM<5ES9]E56CT*X)5.D-TR7667
M7$07G$GPGW&DH6LJ *O/!05!S!4C:9ZF89"Z9@ T]$TAMMEMG):I4I0$I3D=
MXK0$A4Z2I1)P=JNR\JHN2Z_F6XO-U=[JC555WJT$EYRH6'':X)0=2TN$J6$M
MI\*5PA)"8XB)J=KA9NE$5,N;+DS)J)"$.1&)#+ZVR,*4I32$K4E(!'PX!)R.
M,'JMK5;5H7+<<BX:9#FR8%1?]Y9157W9#;CBR EAJ"%J\)#6X!#0()*U)&2I
M(ZL[T_['+#A*E5KN-N^)J/7Y+#JGJ)2ZA4J51H<A3IWU%R4#&GU)U4<(4AM2
M8S+;I44I6#TT6F^C%%L>L7M6:[!M^I,V_7WX5C1A_?L9VE^.'8-5CA\N.+4(
MSK#>YTJ6A]AQ*CE.[K0:*JL=!2/JI:E2 I*5N*>1-2"V(B2I2&]2M(+8*R@D
M2HQGT!RM>NS[E=-XKK755-YKZ.BI.YJG6*ANFJG7 E*FJ-=0RG4&U =X"A*D
M:A 4"2F'>F5H=RNH;JC9U'5:-J>)L-;N.G1Z91(I44J<]SBNMIJ\Q3045$,-
M@$$@+Q@]29J/;W?MI1:7-GZT5";7Y =]Z>IE#>-,=5O06VH4>;/:7';03M+D
MG(5\2DI0D@"4\*[*A(?:,D,%I3:4M!*2"E.[..% * ' 2$@<#Y=&UX.M5&!!
M>1">0B.I04K9RYN(W%!.!M!'(Y\S\NJ^]S%75"FFVEK8;[T%4+*G%0" -6E*
M4C,X0#,$&)FN7'M)YBKJT"E-/:Z=3AEMEAMQPZC@+6\DHP#G2TA1,9@D&(=9
MT\HDZS6;6K@6^5R9LF=-<"(TB74)RRZ_.0(ZE-Q7A\*6D1U%" D %0SEDD65
M)MZX8]M5)3TJDU2(VFE3VN7&%9+:%/XR2&L-EQ6<J4HJ5YJZE+=S:)0<A-K\
M)+2R[N5Y;\;<)\LK(_23Z)).3@Y=/2W25-QB)59ZH;T:(QN2W* 6MQ*B4K3'
M*02C&PG*SD8.!Z]66EK'%%E"E'4M*$@G)4HA)A1@;A)).#Y1Q86;W24](U7W
MAQU]QX*+BW4!+:WM,("0G"9*EQ"0G220G  .&M#*3K=HHS8-89_-2XZ3,ITJ
MAW&FFE]")\9GP MZ&@MJ?BSFEE#VQQ"D;RZ<XP8+ZA=DFI%DU*-3V7:+<,14
MI#7VK2Y*FFV(1 /O[T"2$R&4-@@.-H6\X%_"DG(Q8=>MZ0J16J?!H=P*H-OP
MG42+LC2'%F34C"C+3#@Q)C:TNP(;KY+DO9EQ\(:;*T! S&*3JA95EPJU,H%:
MK\J57ILI+=-J0F5C[!]_G!U]^FN/OK9-/92ZZB"TMS+ ;;0KQ#C-SIV:AWN6
MJ@LEE#92D+;*EI"U)6K0KO$Z5:BKQ:50) &9#_EBOYOHR_46AUD6>I>-4U;'
MJ53P"GBSWI]M4^7F4-K0I80E*F(7I2TCPD1.NG1:KT.V7ZBAB#4 W+8B/KCR
M6F9'NJ4.J<DLQWE-R5DK!#NUM2]B<A.!TV,21+HB6JDPB>B%$DK9=<84-YD1
MVC(,8D$J4@M(#KJ< EE)^8P^NH5.O:O*0Q-;"JFPS'ELRD-RH#,F-):4XW+C
ML+2AIUM]G;M*@3R3Z$=-$JFU&GP7Y,H-M+C-1#4&$CQ!(:EAQAZ6IM"OB??:
M"X3K;;?CM*VK 2D)49Y5.E00JG#K*:1G2M:E)6DZ2)6!""-)D$%2I$0<<;C:
MZ[VRE2FN52OUCZ?E>X0 V@C(;RI0)C)R)&!PZ^F&LM<<NFFR7(ZY46(E,AUM
M:FFENL.)*D(02E24A:3\!*>2D$>1ZL<GWY9=]4%BGT6I%=:G06V?LQ;S3;_O
M$G^2"&U*(0Z$.D)5X8W9.$I\SU4M3:-)AR82(5%=;;J$"&J(Y"<#P=1X3RHC
MS[@=4$+6W_)NH.P[VSE&\J4%C9LV[HES4ZGSZ'.CU /&I4=\Q5A3,RG8D%:Y
M"5;6V4EI 4%*(.1P<]5N_P!DH+JRQ[0I:*T_(]^$E ;*R"A1<TC2"D@C4@S(
M /7BC\Y]G]MONFK444U;3MK2RMAPM-*3(.AU&DA8U$D"4G>">DS-3/LF+)IU
MHS9+[$RDL16Y:RI#;<=U#8#C:R5G&Q8!5D\<_(YN:[.546X-':A;#QCO^[.!
MPY+1\5B9%2IIQ /Q!)QRO 2I2LI\^>;B?6Z[J#<E:?K:"W5+AK*XW@J<4IM4
MB9M92VDG!\-2QA"00!N ' ZN;[1;V%N:@_FP\V6&)MOJI\1:5A#*I41M*FF7
M6B2%N.MI6EL!(6DHV<I/%-KD4O+EUL]"REI2H4E]Q]9UO+<*$=X#!," 0G2-
MP9\O+_;OR)1V[D^BHF"GVM5.*YUQ$$N+IUH6I.@JD!1)A6H@0#I)V&HE!N#M
MAU8IVIEJ)4:!4IKL6LTQKX(\J*\Z52(3R5?R83*WEZ"2,,5!A"D\.+S9K:EY
MP+QMZD7-0Y DTVM08\^,X=I6&I#:5A+H'PI>;7XC+[8!\)]EQM7(3EN];;!@
M:@6/5*7)9;+KL=Q;+H1RR[L2MIY"B"$J;="5I.T?$$Y&1U%SLGO.9#%U:25U
MPB?;D^3.I2%E04TP\^J/4HN%9"6HTY+<AM"<[$3%J .[J-I6T\L<W,T+*@FQ
M\XE]^D8$ENAYAHV5^VML)_>Q<-*7F$$^%3?= J U<8_='$]JO9 [S'5CO^>^
MR%VAM=ZJI)JK[V>U[AI[/6U<:3457*M>INUBK=[ZI71]RI]T)"&T6+-30G=X
MIQP-I\CD'GY>GT^OW3+[>W$NVS5R!C%7P><\>[-8\OU]0B4A*P H9 \LC]OJ
M?VY]">IJ=N/-JU@Y.#621]/[U:&/O]"<<]:O8Y%<D$S\BYN "?F[YW&=OIX\
MNW=)31$$R0ZV"?,PK/TQTCU'G4#W!2JQ)[@=<J71VY+#3E[I34Z@VE12PP:)
M2DJ3"42?!EN(<PZ^H%"48#:$JR216A;$2G1O>OB2MQ>%H3AT,)20I#+&=P*U
M'XWU G+BCC]'F0^ORX+NKVIC"TMQVV;E6[/>; 2O8:=3=SKRQR4D!*5A604_
M#QGIF*7)CQ:E!HZUK4W*9FSXH85@MMQY3;DGDI4#M9G1W  H+*% !.=V,2NP
MB[73_:5=OC_*G?/I/F3/&HVQXIM5"T&UB:&DE1&#%,U,;R/3&,P(RMX,5<QU
M/B;V03XC25':ZM*%D!8V[1L2X,D<9PDX//6"OSYM,:?*-D)A+@2U(4"LKR-Z
MR0HE.%**E CXMQ'UZSN52 M:'&JE$BNAP(V2&@LD#(4VD!25M!2@5%>0HG&?
M,=$%X5NA1H(:JLB-)<< \-B$E2'$ I45;/%=>RM:CA3B\8R3M)..F$P/+;J-
MR1^@8&V/I=-TKRU)3I "HVDCH9.T_2=@3GJFJA]GU. [-<DEQ_(3XH*6TI>!
M"6T.9)'Z6"M(^$)*% \XZ82Y]1Z';R*A3Z<TY7:U"B2);Y3-=:BLOI5DLK6D
MYDNJ&T-QDN>$ DH4D#D%]Z74\5RU,.H;,=+RW8R%E*6VU-E+"6FF<-#)2@+)
MW<DE 2!RR+:VS2'%[72_+*G)*7D!+AD+605J6$A#@6/B0H?"E("2K)(""E3&
M((Z@SY8\HW_'GBT4EL2E #@P((C$DQ((G:.DSGZ#C<ONJU:5[Y4J;&2%+#I9
M4ZZAM!W%026VR=J>2D@*^$8R,GI9-:K7 PWX-%B0*<[C#"H[#K\IMH#*RE3>
M]PDD9 .3D< ^72"H- -3J"V7I!BPHB?'J,U2%.-0XY!*23^BMU8!"64;U D*
MQ\*L.0_<MO4)EN):Z%1W6\)?J@0%R7W!Y.>+(2XXM61N"4)0A"3QQCIN'70<
M*QTP.A$=1TWB-NN)D13,IP&T+VPM)4!M/6!,$[3^+@[HU;UXN!QM%*IUU5@%
M)6%/,5"+#*%9!=\:0Y'8+*PL-*Y3\"E!1QT?.Z&UQ#,NOZDW%2*'-DJ+C5)@
M3HM2JB?"0E6Q(AO/1(_A!1"&%.N+.W*L%1'3/2KTJTMY7O-Q560&R  ](D)2
MI()."$N$'!_12E"4@>0SY%,ZOSY#:@U4)3@*M[GB*<4<\;5963GR(&!Y 8)]
M"4H&"4Y'K@SIS$3B//'T<=H9[M84VEEL3X@AO22!L"J2,9^]SYS)X5,FIT6V
M5R(=$@19*W%?'4ZNPB9+?0DDJ5M<3X+#6%G,=I&SUR2,]-17+I<0L+:6EQP%
M:FVXZ$1XR%>(2MQ#3"&VT%((+8VE0!4"I61UY.+CI6IUYQ2B",JWI.#@YP<9
M\N !CUR..FQJ-38=G+BQF9DR0T0A0CQE*;2H#^>YD)X_G%.<<?=UQF0/=,#K
M(\CB9S(VV'#A*94I>22$S)G((P"8WG8_5/&K/N>L5"?&J^'Y,V/(;9A(:2%J
M;"'BH80]E 1DJ4LK24@$DIXZL"I-;TV?TWI*XU0N:X;QJ;7O=P5"Z8%-IZ*+
M+<BQV/LBWX4 K(HD53'BLR9LAYR4\XM]P,)<;:370S&D/+BLR ['<<?<#R4+
M*' D.N;4E:/B"5I4DD @^A!QRXU2N&MKBIIS+JF(("4!IL.-K2$-I0,N+.Y2
M5%))3M0G(S@G'4=9ERBZOD!3M3?[MWBCOI86Q3M)!B/DV6D(! R/+?C4.U)J
M:CL[MB5EMJU=F/)Q2A/WSUTI7KO5O' @NOURAH$@%H+*O%H2=:CUJ*ZTJ&T^
MPPZVX'U>Z JDDA*@TEQ\90IO)*E@#"MP3D;<],!4IKD:*Z^XO=X;96XXIS"]
MH!SQE*5DC..",D\?,]J<YF.LF5_?#@;2$MI27%K5P"E3HVA(QZE)P<$@@8+;
M7A<U5;BK;I-,@API2D>\I5()3R-VU(0VI0\OA'^8V>F2=(3B$QUW&/>($==_
M/RKUHM%2M;0\"$*B%K44S$20 "/*#/41PC;8USH+=7?HCSLUCWI*T^^,Q) ;
M2IM+K*R^\H>"4K4KE+:T I!  SOZ4$_N4EP;OI=G6W5KB@Z>VK;$NY;UOR4B
MGL4-XJ4VB+ C>\-K<$1UQLQ$N1D)*Y#[*$.+;2IXQXK<"OR9[$RO2X[D)A4F
M0W2Z9#,9OWIQ"FV9,H-J_ET,-+6&(ZLMIDK+Y'B) "#NBH56J0T4BF4N)'A+
M<88JK]692N+(893LCLHCK),EL)2LN1 AMM.4D!!0A8M=!0T:GF0A!*'/NQCY
MB GYP'WQDZ2#&X,\7VAY8MCE>VK25M%7RM2XXV&6!$!:"XI*G#JZ)2F(\\<6
M>V)K]:UR!!@UJ545(0[*6Y-=#@2PVZ6UN.> LL-R0K*?#4A+C380I61@J,9N
MJU.E2I3*7T$)#C[;N]M25-K*RR['=.20E(+;J7!L^-)*#PI-2M-O%ZV6IU"H
MD^(EMA;S\9NE/"E%,E;:5?WVTY'DMOLO>&&W'$/-JAI"-[2E;\YX&OS"(*X-
M7J BS'GT*E'^31*:?*REQ"%QRY&<2K. XTL-. >(I+:%[$O;ARRW4_*4Z6VF
M5A"&\R#I"4$R2D2"1@'\_$Y=NSA)>6[;OE$*0@Z'3I=DIR\E)44Z'8UMC5J*
M1Z&+)X599F5YIY\I4ER0R^LA()0WO0H-M*!" GT5M!!). "<=.W,N5$61#EQ
M7!O1*)0P5;@MI)'BY2//*#L S\SDD =5VVIJHF7#7(:>2MB.Q'5'FE:R'T/R
MFVV%.%0"F5I5N\5L?[VM!QD'/3UV9?:KG9?DI<#GV;5)-)2Z'"XAQ<1MA;SB
M"KE.Y:\<$XR?H>L_OMG-%;*Y2T>)#@I2J<^)03$9@*23G('TQQGM9R]4T;+[
MSE.XA5.YW>LH"6U20D)*@J03@CPF 1F3Q-6X&(=?I[10=^4J=:*4DJ!4D+"2
MD?$ "2% '/ QU(/2F\_M^WA2I[I76K>::@SBXM)>D0U(2FESB ,J+S96AWU#
MK94=NXA,,8=SNQ(;#ZD*4T]N:7A7PMD)&"HG 2%?\[*3Y<'S MS4O\U;RAU=
MD'W7*H=1;2L*2["DJ27CLW$%QA8;>;!W$+:QN"5JS5^2+L_RU?5M.K<5;JI2
M&:@A.IMD*T%+FF3J4E1(Q$!*3@[9[S?96[W:'&T-ZJZE233QE2E E3C732%)
M) 5F"H$IX=^JJ-!UFB/-8:9G.I#I\\)EM.,JQP!^DVA0\L^1\AU(J34VVQ\"
MMRE ?"<@#<D$DGG'F"#\O3/E%[4:;'G7I;-5@N(<:EB,^Q(:7N2ZV9S2DN)4
M,X*TN_$!\*% I'!'3W-%2PVHDG<D D\G@$'/SR4@@^GE].MDY*<TW/G:E0B6
MV^9FJ])F!W=VM5'4K4!UU5##J\G/>D0 CQ->V+O*WE'L*OE2B*RM[.'+#4N:
M-"G?BIS3?[;3%>3*A2]P.L!N/%(BW'V:<Q4M[63*0E+:+#2GG.<BZP2?E^C^
M.1^*5[^D*EWY;5#$JIT^/=;,VUJE4J3!DU"5 I-6;C(JDD-0V)"V$-PFW4*E
M/MB.RI:%O/-)YZ//9CDE_6@XP"BP/3U'YW#S_KR<Y^G2:]H37:10KGB&NW3?
M%A4>M6_<5N56_M/VC^<5BTZLTYN/+NY$Y278]'A49@./R:Q*;<8IV6GBTMP(
M0=>I/W,IHSXR/?*UYWWC8?BGCRK7_NM4^])Q_P!TWO\ KOQ&ZD*M+2G3>X(T
M&PJ7I[8^C.MEG4JB5W5=IVXZ#>]%FO1C,O>RHT26S,36WIM0$.W*Q<4B.U1J
MBS4:NAN1'AMH4_\ <L&G5VY*M:,O5N1;52U#IAK%OURESXU+U2M*)&1'@T6)
MI!)>9=M@T6)3853<GR)"9U?N)Z?*=6Q[HAIUN)M.D6O=EOUB1H=.A7'/CMT&
MPJG,N^KP[DHEU7':-%3_ +2W%(J;4NV;EO"?;Z??JT],I[<*GO3FWG#]HK2$
M'=L7C;&LLFLVXJ->,U^D3J'6IT2[M/:L]9.F$NT%Q)CKT:'/CTM5+%4I\9Z#
M1E4&IU%LK7'<<;$5MUCH:O2((DYC=.2#M,]3&PB,<-RG<S'F3TG2-CF003Y&
M<1&9KW?3X56H-/>OJ94+0J]H!JMM7[858J%O,0$H>\$/4NMSF5"?$F,+BSKK
MI%4I;M.75Y*F66'XJ4(+,:I]P=.M"VY#=;%?"Y+C])MRBMB.WJ/?LZ(G;(JD
M6G0E1H\:FS&VD5!-06N'26XKCLJKJI<8(94-2-<8[C2;)TYETFZ+I5;#%W2:
MA4'7G[(L^SY<T0H%:O2;'8>D#[;J $2W+9AQ#7+OD1YB(3<:GPW)IA5=NG6H
MT*X'*$];E[W%<-;?A56X]5V$VO;J[]$V.F<N) NJJ5B7^9%MT.2J-;=(TVCT
M21 ATYFH3)[DVKRH\MH$Y@F(STSD>NV\[3@#KP3:=M0 Z@&9P03@[=#!)WF!
MT9'N"U@O[4^.P;KK-OTX.R6U,63;%457GV8B%.-1C==4+<=F-(@N-^&BGTN,
MS",YP*0J5'2U(<AKWL=ZBM*]*;'T&TR>9>N:Y;><=:B-QXXHJDL+3$JES7!%
MB.L.2:-"JY+5M4^1M3>]QQ'YE2D2:11W8TJ36L\./0Y5,I+D"V+;?EU66P];
MT*INW-6G9U(;*YC;MRF-!:D,4^+("9B8S#TB4XZVY4:BZZTVGKG'NQNM5/4J
M^K^OFHO/5C\Y9I?J$\ABGPZ3394J!%I=.0@I;BTBC4Y#<.GTQAI,>"VZ^I"0
MXZIPT6R-I?[3^;'',^S<M\L,L@_>H<77ON1YA3@25&3E(R9@>A^9@FG^QL[*
M6F E+57VC]I%55P(4Y5TU#RM34ZE'S:IG74(CH9WXF;V=6%IS8]<&KNJ(F7E
M<GB.5@O5:3&2P_5'FO&GUF>ZZM+<BN.@(3%8:90U#2A*XK3*$[!8!0.\#2O4
MG5.5<5TR+'M'3G01,6W;"HE[W9;U(CUG6NX%(K-RWV['FU*&S5:C9UL.4N@4
M.>^S(9IE1J=1F0ELRRXM%%0N/5#5]ZGVAH-:=2K-Q7/58EHVO4$-29/O5:KG
M@TN"[1*&AF0[/;I2E"I2IKC0AQ:=%>E3WD- A769H)H/[+KM;OZU>U%[373:
M9W*U0P&JA7=5],9]Y5?4S4*K6[3[GN5^C:DWQ0*E1*R]*D3'YS=+H,_W&D-O
MLTWP8ZD(93C'V67:S;^0^5&^5T47,5XO_-M!<*QRBY4::?K;5RM9ETOPO<;H
MXLJ5;J&J74II$526'T%INM+FE*=7&6<H<O7&^UCKEOHW:LV]"JAU#++SJPA#
M96\ZE#*5'2RT%J<40 D2%$':M/NQ[[*/<E#L#373F_[6O07)?T6I:CTFR[GI
MM9J5(LJRF3=U,F.SJ?)DQ:;!E7?!H\:?(6ZY-EPTJCM((6Z[U'N_^Z_7R^*4
MJ#9U(ON_+XN:IPJ1:5J6LM5RU]^?5Y:6WZA3J!2Y"ZA5D4.*N76G@XEN,AN,
MVU(=0PM9ZN+]K3VGT?7+3+0OMBT&TZL*SM1M1M8C=S4RU;9H%GNVQ9]B6W,7
M=US+E4"FT];<%:ZK2Z%)6^EQIYVH,LE)/*&6]E9[/9[L:[M+];U4GTVJWY>.
M@]/FZ755RML5+_:N/=SD&_XU(=<*/#JJ2FDF<Q#7[R*6\2M/@+<SG'93VL6[
MD_[$SFCM:L?*-<EZVUUX%'05U4T_47FJ<N%OL]-<*NKIJ-IRGH*5VIJ$]Y2H
M#K#-$^VEU8RL[C0+J;]2VQU]O2ZRVXH@#2T#WCBDI2L@J*NY"O%&\$0D1""S
M=9Z7II=)T"MG0;N29U@E*AU2Z+>K&GIF:J7S<%0I8FLW7<3,VZ!4:M.J\%IZ
M?"A**F(=*Q%ID5F(QM+*=S4G6ZPYL/7J9V_]QFEE@5"70+8U?N"_-/7K1MMY
M:ZFU3K8O>14OMF8Q"K5O(==H4E=1BQV*[1Q C!]R;'A!?3U>G:C7;U[T[&[F
M[IJ^GM;M32^"EC3.U)E,E46X;4N.IT[W"X;RFUJ&VI-WW,EI"(%K"O2&J/;M
M*<=1'9]Z6MUQC_:O:@VC=O;A</:W0*M;]SWOJ[4[/MZX;=A5:!49%LVC)N^A
M,O52NLQ'Y!I;U<K;U'MVW&)"6IM0J,];T)*4PW7V\![/OLF+K<^TWL]3RQRO
M37>NYC9H:CGJJ-?>:I-J:K:AQSFHJ<>[EM^FM]F9;KZA=>S[/35#*F4.U2&&
M:]Z[\S<M62AM%I-#=P^_46E-7<&TK2IJAN2ZI]EJB; ;96R]W#;+SS0#Z$^T
M(AYU841SM=OFLESC4^^-5:!H/W3:JVI>=B6S:UHU[2/0&]:S9]]U6CW-4)=3
M>554*2B4*:V^TVVXY)$)I;TYM*V$-%H7$]L?;QW;:Z:T:97SK%H=([:M!-+;
MTIFI[5*OBY:3+U:U"NZV6Y)LZFQ+,MV768%IVE'DRQ4ZK-KU756G$QT4QFG,
M+4X\+W[-M>FZ?6A;%B6[&;I=!LVWJ-:]*IL!(B0XL&ATZ-36FF8T;PV$ B.5
M+P@%QU2G%E3BRLI"H:V:24W4>GZ0R]3K"@ZJ5&*B9!TZEW#!9NR?'=85(:<;
MI9<\;?(927F6EX?>;PMMI27&RK"NT_[)ZZ]IM^YJNW+G9[16RONM'54RKH:R
M[WVNM=C8H4VP55)3-"CH:%Y-N3]LU=93U[##KJG&!3:6BA"T<MO--LL-KJJT
MTK;E4XS3,J^:TGO:AYX-]XHLLIU+6M6E*4 J<5IGA:W5:EJWO0IELWI;U%NV
MVY[:D2Z%<-+A5FD2@I*D$K@5!F1'\3:M6QU+:7D;B6W$*&>N>[46FSM/.YO7
M/0FFU.HIT^L:K6!6[&C5ZN/R4619-\6K]M-6_3JM5WG73;U"J$:III2)\IQ-
M$AN&G-R#%:89;Z,$+*T)44E!4D$I/&W/F/H1\O\ 7CGJ]H$*90^^>OU!V.)*
MZOVU:;3Y,<N*]W3/AWO<U'CR*A&5\$@/00VEG*5E#<=SE(/5O_Y/;F.XT7;3
M6\N"KK3:+YR??W:F@:J74TAJ[0J@NS%?W 5W2:NF:HJA+-2$%UL.*;"BE:DJ
M8<WM(5:DOX#C-33J1B"0I1;*"3! (5L)(B-.\)JJ/4RNT.8692Z;3H;KOA/.
M0S%J;C;+ZRVMBFOI4LPJD1XZJK.<5)6VI"(++45046]I=R4>B/&/4)$@.O*;
MD1&=BI4<E*@1X49OB/)?=2EIU]0*5M%3:C@'II*U>$FI%J;(EN.R_&:;5!+C
MOB+0F6ML>*MK<'$-(4-_BY+C:&D%6$ EPZ';#MR75!:6M3,%AN,IYWAE!<=>
M4EII<A1RI+JU);,-A"GI16$(3SD?6J_)[CM*Y$(CY6P\X,N!(@!-+06NH0,3
MX5.LJ;'3QJ DI*3=N3?MC['?MRIE^-BCYD[)JJE41ENKJ:OF2B6X!U(9>( "
MO%( @\2JTH\2H4NL/LSJTY]J5$5BL,Q(34A#4X-MMQWH+3C$AEN8R$H81'8>
M$<,!3VQ*-Y)%=+"B[);>I\ER;3H\ZI1IU84HKJ5.D@,N.OQ064/KBOH]W<:C
MAM,!PM;1AP$/9IG1ZE9 :2Z\B*PI0BII<& M@,EQL%32(ZEM*>D,QDMH<E,*
M<.YQ<5L)<"U!O;H*:]<-0%)G&"]#9E,MSA35%Q]MXK2^SX$P$-QE*)2%(2'
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MD3F#!B.(/S:\M<9J$KX6F1\" <A.<Y X& I6"H>GS//1'!JJ7%'("DI61CQ
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M EB0X4-.J9VI:>::)4TYE*D)!2.L#O=-5N7>\+#:G$MW*K"4HR2E50ZH$[0
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MR$@*5X!6 7$J &4DI4I2%'(4H$'K-76W:=5Y,4+5PX5M*VJ"%MJ&_:A1X4I
M6"4\8 5D\'KS[<*=+2EA)(4G6A4 SJ2HIF?.(/O/IQYQK$*I:UYOYSB'"?FS
M"PL   'Q$P($C?23N>'#M]QQ<JF-%UQQF-(C%EM2RL,?R[3RT-DY*4%0)\(>
M0\AY=33@.MNQ6%M+"VRG 5R!G))00<<^9'.2 >//J%6G[+JIM.+WQ+5,7(P
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MU(C6W1<U4EONE!4*'WK+]59ZUI!&H*6T)TDE*5A(JB9,]+)>&X$I"%*RHY)
M(!Y).2,<#'UR.LYB27&@A395YA2D'*,$$?LR.,^9X'!Z23GN0E*FN+"%*3R2
M5?"O.<CD# ]!Z^1\N<_YXO1UAAJ,EUI!"0XK*=V3Y_#QCRP?O^F)< +7,Z0<
M[>[H=AG!R/HXIX1! !$B"9 W$'SG!W_)@RTVHENU$^,IF6IK*PK858&,8&4G
MA6<%1SC)'RZB9=5HH>6^\].>D/DD!+2EJ:!R"H*!^ G(SG)^+ ],=3:KSRZQ
M[R"R4>)DA"=RB5_I#!)XYSCD$#[^F+K-+N6/'=9AMAE'C*6A/N:"XHDD$*4I
M)&W;G ) SZD@=3UNNJJ));0KIDS$93*<3(!'TX&TGBZ6.]/6]"BVM)U%O4TL
M I)2 )&<G<#89V@SQ%P6D E+J*=(W-I.'75@)=<)_FH2=X"L_$>,<XXZ45OV
M;?EXJ?I\FH4NWZ-%  =2G;-=;4=B?!1DC*4I4"X< $ <E62Y2K4NB:0V(BSX
MI*-P:" 2HGG<5#8<^H\O0$>2]MS2^:VTDU>KR(<A!(#20E:2T,A*=Y3N41QG
M)/[!U,MW]TI*P\TV0=()E"ND$K&5'&08F9SUM8Y\N#*-+)HVEX^46UK4(QH!
MQC,A$1CW#A TS1S2>W'8;]9D2:K-BI"7WIP06I#BR,O&.PV$G:<>9.X#*N"1
MTZ%O0JK^;<JOT:W6;9M6,BHQ#*5#2M#,6+(<;54"_'9*66W0EMQ*2"XALA1R
M0</;IK:EET4RIU?BMW1+9DI7#8J+"GH\<(PI*TM(4@;L@9*BH*2,%)S@'>IO
M=;<UKQ5T;3ZE6S[\VI@)I;5/2J&F.Z,+$J*R$.84$JW*&$GR5D;NG5.NLN*5
M.2EY.I*^]^;)"DF ,E2<[S)P('"=)S+S7?Z]NEH*%JYI2XTIWVFI;HJ9PC2I
MU2%+0L" 5:1!41@X!XI<OK66GUZ^)4JCU"K5J52V#3DURJ5&7.B(\!QQMV/2
M(/CIB0V,@A3J(Z5.G/B J!'3<UF[ZU4DB"T4,0GDA6^.TMI2@-V4E>Y12%$A
M2E)4DY0,'GJP>Z]-=+=6*@Q<]6M%ZP+MF34RKF:M=IJGT&L-RG<S99CADB*^
M75I45MX*TJ4"-Z2HE=Q]JMF6@Z9/V37I4.2E:(<9=1D.4]I*DXR7\>(HE"B1
MO/F 0,@]3RP\K26:ZB8;"4)="4EMQ+FD)4DE*2HJ#DI4J949.^.-IM]VM:&6
M:&MIVJ6L6M16PA""A!"T[.(!2ZT<PZ#*R4J@3Q6T_5Y:5+BPWG7G6 E"@I;C
MB%K3P"K.\**0<<\C/XA.JGUF6_(85E2@2%)"5-J3G@#X4YQGXL#R^N<&4-=T
M(J5F0IUT0WU5:'"DN2G81AJ9<:I^\DKWE?\ +JCM[0M12D*0@K(\\IAF/ G[
M+IHU-5(:4=M2AH\)2TEM*1X\0<)>W DEH9<"CC:I//28IJM('M2E=\H)4THD
MN%QB0E2TJR%:29(B2G,#;BR-THKD)**P,MA9UL-$Z.Y,@*2E,A12"F1$@'Z0
MDK'NB8V^NCW([XU#4RMAU,C<I<;:A00[$=42M*DG XW#SXZ5J*A1K8@R5VP6
M'4UJ3%@29(/B2'HR7'74LEQ(;4D%9+B@0"3Y\^9HY;=+JK:GW&W8ZGD_ \UX
M:7H:I*5%MJ0VM 2AQ>0-R@ D*2DX41U@JUMLQJ520W"<8?5-C':8J&5K0PE;
M9>6EI:VU+6I)5XB5%*R KC(!=A=2&U(<!<(2=#IDNI"H&C4<A(B4H.QV.".'
M+]"64(;4[3OAH2VZL%2M!4D@09TD1!WF?H$M>V6H3J5:=8FJDK>D5FX9T=1>
M2EP-4Z#'81&:861O*?$==6O<I>7 <$8QT_,@+EK"SS@@DGC:H#DXXV@GC(XY
M/F.3'?2:C5"+'IT=E(982W(<6P%$!*I"@I2MH(Y4H?$K P<_=U+5B&TEE*%I
M&]:/BQ@@8(!/GG)///KY^G60<R4JEU]45+4W!0!I5!,)3A4$2=I'T>?'D3M#
M2?C9=P'%I^V$2I"M,PP@= <#<#I^+C<TYNZLV1>=%N.ANH1/I+BUL)> <CO-
M/->'(B26U82MA]M:PK(VMJ"5@$IQU*/4G4&!K#J)I(NEMNM/M3*>W5H+@),*
MHNU:,Z]'0O #[8:B!QMY(P6PDJ&3Q$!R*Y%JT3PPE+92%$YXPD$@<>1YSZ<@
M_0%342I52!7J=4*8^6JC#J#,R.^@_$T8ZPH. 'SRC*2D_I!1'/ ZK:ZVH%/2
M65+JUM5U]M>MI2BHKIZ.J:KJE24G<AJF4DR4@]X!. "AR%9F$7'F7G1: W4\
MI\A\U+IJY9\ NE[MCO+ML86(RY4*NM0VR!/C01C6>+[Z:XX(<=(4<AAOT'_-
M(Q\^!Y^7GG R.I]]KRPJSJV-J-PKZE*<&=ZPJ#$ 2LE1!2WL(;VA(2D[>=H4
M:@-%]96+UI[],J#/@UZG--ESE.R8RM(S(9*3N^!> M"P%<_".".K:^TM]Q^S
M;B+A!V7#M2 ,8283! 'S'R_7Z]>J.4[@S<7F:NF=#K#[#JD 3J8B)9=!'A>2
M(UI& ",F3QX$YRM579V'J&M:#;[3K&H"(S,1&"!M],]#%-WM+*1(5K+(K,=A
MPCW>XH+CB4K]S+R54M^.)BTH6H.)!W( 6T?"+A <X'4 =/\ 6JYK9J<H.6ZB
M'!1%^QJDU.?AS:3/BK8;6ZZE+C;WB-C=XL926VI"20O>WM4%7I:\VG3[QU0O
MRF3F7Y:6:P_(,3##T-T&%30W[S&D,NI>/B-MHCE)0677-Y4..H=:B]OE@W[1
MYR7;19MR0W2_L]ERCH%/K\*2P\JH.3W"VTB.N=XC20VVLR%/172E(#:M@RF]
MW-ZWWV\)::#S3]34H+>XDNJU*SUGS&^)!GBXV6FM=3:[0:EEU:VZ5F-"SX5%
M#8F">OD!@9'JQ^G>I-M7(R_ =*HC:0F0W49*5&&AE20W[K&4RR%+6/TFBO<%
MA:3DA"NA7J-0:[(>@JJ(F1$MD>\I2XVPTR=ZE(0A"7'):UJ4GQ<)"@>$'=YL
M%.TTO;3QN1'HDR/68<;XV&UPI#52V)2OXG6X[O@.K*4GQ4M)PVHDA*0DX-[#
MO2H3/#J-)][A5"FN^#,BRVRCW>8@;PD+43XC3FWX"2!M*LC<1BL)KA)UM*:'
M^D4]2,  XC?IC'GQ>&Z="(4TLD%*=()$I$)@&3DQU.Y&1M,=9U*BP;FJE/@J
M>,6+/0TR'UE9. ESXE%*,[5%82"D*3N(5E73P4JF)<;:RPK (6-[3:TDY!R0
M?B4/3U !Y'EA*Z@P2F]Y%1AL*B,U=]$UQIQ*D):F% 5*24J.\)\7&,8X.Y61
MC+H1($UB#$D1L2!M;\8;AA"UD@@%*U$E.$YS@;>?D.D$)#R].J-1G4""<D1)
M_P#7\_%J)^TZ8S)2T,3DF0,G(GZ1G \N#>GT*.ZYE3L>.0D*!1'92?BP"<$H
M/.5)(W''RS@@Q<I5.2M:%26N,I3AV,E:BK _GAQ(P>#D? ",$GR3;$R8^'&Y
M$5)2T"E3K!V$)R 05DE1PH@83@DCRXZV04-I*FVDELE*5 (WN%9QM3A84X@D
M^9'*L<<$CI9;0:60%%6!!@#R\B?+]>D85NB"'#GI(Z:< SO[^NWGP452ETP/
M[-B75IP,(<+Y(S@\-NJP1ZD )^6 0.B!,**J0&(T=3SKB@4--MJ==422D$-M
M@D)!20K=@#D!1.1TNF*/[P4N37/LYHKW);"T-OJ SPII "F]Q.,N')&,@=.1
M!JUITIM/V73HE/EA*$+D".AR0KPFU(*_>'BXZM2W\K)4M0PM12D#II,DP1'O
MSF,1T.#Y;^_@TU#J)"5*4<8R0/R])VD_CEOJ7II5)X:5+C/0&BH904)$A06G
M.XH7\#6  <?$G"@00,]&<W3VC4M2!+F,)RI87N)E.IVISN*&R6VU@_#CXAR,
M$[2.MRI7U/D#:@^,IM9\1Y6\ O Y!\-*AP$X2$8VD $C.<MM5KPJ;^$264^&
MWXC)0HN% 6E6\K24MDHW!: I)).X8P, !<)(G.<>@Z$]/HV_0$EJK'HE91!,
M!+A&\#.,[&-HD\(?4&%&@5&#*A'>4*!)6I*DE3:MZ0$IPCD)*3CG*L9R1A3R
M5M5&FQ)4)WEUE+A;<6E)3YC!V@\@[@>1@C[CTB+@F1I\3PW&0W)2H*:6E:E)
MVJQSCE7B# YY XR.<=8+6><6788=6%LC<T%*X2WD)="1C!P>>,X.201CJ-!-
MOOX4X-#%_H$ *$I2N[VXJ84VV0#W;KU-*T @:RP!G<:ZU3HYM[(Z?9=V[+;W
M4MU"2!WSO*'-+Q-.^8.JH9MG,7>+=)$-(J.\)3K)5Y-IC[KZD2<!&,^&4J.\
MD;2D*P0E202H%61@9PK&.D_<5E0Y]%J,?"(2GH$B.TN.XL+<<FE3?BN%96DE
MMM2B%);0$D)!!!Y=&3$+A2XM2R4D#A2D)4/7(3C<?GQ\P2.>D1<SBHL*6MM1
M0A#(P0<\<Y4#Y93Y<<>6?EU;Z-:7'4E!) @2?/P[=#$9CS]>*9:6JAEU.@P6
MR 1.YP2",YWD'.8)X@]7X$C2^W6+)9EQ51'DW%4J9-F(#CKSDV;(E3-I<=;C
MEYN3+&W8DN>$$.*" =W59%V/UBJ,!*_=&U0S*D.(]VAQ'!(65/RO&<;CL.*(
MCMMX\9)6E9* M:CGJU?5-B->UERK9ENI@5!E]R51JX6&WY5)F+2$>(A2^$LR
MV1[M-0@)7X:TNMJ"D BIR]J#/I-5FTB2E:JG%?2IM493BWY3<B.VM<D!6''F
M9BE/%MPH#02A(/.2="HG:9NV=WWB4N*=6:@:B"LZ@4DC)P1Y1G?''IKD8Q9W
MTI95[0LRYW2])4A1*V\Z5$DZ9 B 0!Y0TU9ICLVES7?"+14ETI5X1#:%[#\9
M4K:<*R/)021QG.#T@J90YD9UAU!<5X18D+7A)*2A8*-A(.P["HN <J"AD I2
M>G'$>X7W7H,&GU*>^L.)\!AI;K9.5(#;^4AK<0 DA:A@@>@&51%MNL4F%):J
ME$6PM]#*I;B2A34(NMI+275!66%+24$E24-*4K:VM:@H!0/*99<*3WB"1"DI
M)&0(!D#<F-\#..'#EK:N5:TL-U#*VVE%Q:D*@J0HJP4@IW\*I(*$D&0!'&K$
MD&;*<JK7C,M-0-C*F\-26W%)+!\R4>:U*"N,H^ G!P=FUA/CHDR8BW&Y<<+G
MQBR IXN)6%K 3D>16,(4%)RKE)QUEH;,=3;D79E"D%#JUJV,I;2AY*5E7.U*
M'$-*R3MSD'C&7 M"U'JC4:>8#T-SQ MX):F-+<24X0D%M 4M0&<X4,*)R<#'
M3A;J4MD/#2@I2XI P()2%;",DP/7SXDFZ.0NL"T+<T.I=)5]\H# 2?O<C8D;
M@[3Q<;V?UJFWY;=.=?F;9JX*8\I+KB&W([J%J4XZ_O*4I<4H+0-Q3A(W)P@X
M,KZ[1[6CTJ4ZIYB2\PI3:7EM)>*QDC<@ DX<)VA:5 <E0^'S@OI4RS9M?MMV
M*M,2HURC/BIQ&D(3$?>AAM#:O=DI0$*4C*5E(S_./Q9S)>JAQ):4'"&'4!U;
M <46_A )"-RB<)QE* 2,\#CK .;?9J&HJZG4 RD]\A!U2XM2E!MD!.K27%C0
M#!C5Y\836<GO\P<\VJRV]92+]<D,+?!A%+3(4MVY5RP,MHHZ=!="4D;$S)GC
M)0JE3Z94FE/NHB#8L,A7Z(W[DA .2$CC('(R<#RX4=3N)2'6Y+'"T *2ILDY
M((4E140,8QD\#T^($9ZBAJ0Q7PK[3I[RTI=46F&VBI*@H#:WC:,C:4Y)/F>?
MB/3O4!4MFUZ2F>I;LQ%,C-N\E3CTEUS8!SYJ4HXP!^B?0CJH*H%45#:RVO3<
M"L>T%,%8JRYWRR<QA:Q*@2(&H$2>(OM%YBHN:^<.9*NC"6[#3I8M=E2G#2;%
M:Z5JUT2FV]FVG&*<OA*20.].YXZ,O903!/C:Q2QC;(A:;2 1D?[ZS=RE#!_Y
MJ@4_@<\^1EWVFZU:D6=!LNGTR;5ZTJ;1GY-8C,3H-!I4V,Q]I7"JF/H6JKRZ
M<RA*J728H1(G5-R*UXK+!><2G?9(-J8@:PQ5@!<6#IFRL9!(4EF[MP)!P3DG
MD ?CZO7W+OJBZZ6E,"T-"#0+JFKD*:0ZN,W%I33KKS <P&7_  @MMJ1D;%+R
M#N2"/<=I4HV"U*<.ISV9CO",@JT>([=#GTCTX\!WE2?A^Y%HI*!4.!)3!24I
M2!B0!T\L'H>K5678-M:96ZS;EAHK-,54?>*]<-4D/ANX+CN:8R&YUQW,7/>H
M4NH.*2&6HR4J@TII*(U.CL-MY-3/?MW:4OM&I=U:_5FIVU=5V6N^WI'H19E;
M:?2:OJM=D!FI736*O%ICS;M2I%IT%<)NO^[I8<;A.BFQW69$I23:VU=B$4.
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M8;#4M,=<EIK^4/&5*2<XPH_+ \O3R\CT3V!>;]3930ITA":E$;"6@Z=JI32
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M A#Z');RT+*U(41AI"$I6H8& DD#(SH%>A"70MATEJH5K2 ZI*D)(2H!22!
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ML_E.*T6>\4K*_M6-^F258-*BD'XN0".1Z=;-V35+_P +/4A4X6>X<=TJ6I2
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M&9+8SY->*D;DX(!&#CG]'C*'OZZ:](6&:)3I>Q'Q*4ZE!:<))4I"'F7%$G:
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M<<3%PY]8J[$JR4UOJV77*5FG6YK2I@MMH25+(DE.K0"D3Z P>+(:,T@04)^
M*=)Q@)P,$GS R,CT//R(Z,TQ!P$J\OT<8QQY^6/7GCRY^_J% UAKT+:TTCPD
ME*2H%:U')X/GP4YX!& .1T3RM>+_ &W@W$B(<84/A5AXJ*0KXBD)003@'CUX
MSC)ZI@1)A4)&<@B-Q@'J!D@[D<9JEM;AU)PA7B22#!!TG&VX,^X8R2>)X%"6
M$JW *W)VCR(\\\@\9Y//H?ET@:BFG1)Z522LO..I4-@ 2E!.%!6W&5*R<<@X
M!QSY1LC:[7"A+*Y,.K3''5(:,5FGJ4LK5Y!*UD)QN4DIXR3@#)."I7[EU"K#
M:YC-JSFMJ0$-RXNQ]/KN*.#GURG('(SG(Z,H R#OC!!P8ZB9))P3 V.(PNTR
ML*)/D=L>6WUS,F?<<30MZTZ7);:JK-4CH1M3(;V842$E64*0"MP9Y2K8E1"N
M @DX# ZGU"E4Z)5:S.H$*KMM+=;C1*G3$*<?6SE7B%$EE:FQN"7&UJ2C<<%*
M00<)6SKQU H[D9URW*Y+?C.AU$5EIMIAQ2#X@:]Y><;::WD!"7C\""K*CYY8
MC6NZ^YNZI,ER%8,*UJ74UI7*@5*XZ/7JP\TE8QX"Z8TIB&E:4I);6I*P<C<>
M>K)RTFG9J4U-15-4P:> T/3J6" 24:<'.PD&!G.!:N2J-:+P*EROI&D-K"5+
M>?\ 9W WJ!4TB$E4QX2H0 !O,<0HJ=RW)=]UU"I52'(IK<^J+8@4YJ.]&@!E
M@EEE$-C"67/ R E;8)"MP'GU.74^C,1=/J935)<DJCTJ,%(0-JEJ1%"AAM.S
M8=^Y2@1D*SG*OBZC;1;'UAK=[T*J7=1'X-#I,QEYE*Y<5;;#:%A;R RV4AM#
MZTA> %K5A63G&947;!;KF3/F>Y4QEL+=>#H2ZX "5A'B (;"@2D*Y6K/P X!
M#_FWFRV4KC,57>-*U=WW2RIY]T1J:8IFR7'%N*! 3*4)W4K>/05Y:NE];L=-
MR_3(N**=%<JXUYJFZ>VV]JF4T.^K:]X%IEM#2BHZI6H>)*2#Q%'32GUFK(]S
MB(F%+4IV,AJ2ZI28K+:@I3CBR-K2<N*5A.=Y(2D<YZD!)FPK.A&)%6BHUYYL
MI6Z %*;"N/B3\2FTI(^!E.5N\*7M (Z3<RZZ31:8:5941,2.2I)F^$IMUYP$
MI6Z@/@NNK4<#WA\!6,%E('(2]OTNLS*C&F/!Q95)2Z5N?&MPEP*45E0*EA22
MH'RY.3U0S15-Y=%;>FGZ*U)6A5-8G%I147!Q)*FG;H6_N2"H_M(N:E-G4XH)
M4GC([IS)9^3%UZ>37V>8><ZL+:K.=PR7+/RX7TMI=I.5.^3IK*ON>\;1=^Z+
M3;JE=WD$&3';&NYI=U5I%7@N.0Y[#>93Z0E2%H>40EE121E2%E2P@D'&4@)\
MYY52VX;=+E22D)2EI9 (WY QN./3!QGU!(^HZ0FA=(I=)A+KM?$2FT]IE*W7
MI12TR%!!7A17MP$@'&S!.0",=/O;$>N]P=R-VKIO313+49D*;FW8N*Z(DI*%
M)4XF,[L4C*\;4;2=R^%D)( FC3F[%#-.TEA:4AIMAEL(;;0@@Z4(3L 21/3&
M3OQ@MYO#-O4XX\\Z&F$=]55+[W>+4Z84^_4.+*G7JJH>*G%J*U%2CI2D  <,
M/8-BS+KN1F#%;4F.M])E/X7B/'!*U$\%()2%!()!40,9 YZ*^SN,Q$T_JT)E
MM"&X=7C1!M2 %B/3(S25G'!44I&X@#XL\=0%1H^WI+%9C.)0](EK0ERH-H#3
MCRP@ !92%;?-1R",[E' YZL![1BG\S;E 4"!<8S]"8$<D?+UXZU_LZL LZU.
M5"N\KZE+A=5*M+;:1\DVE)P  M>09)WV''GKM+YJ',C!-,HFA86R&9))5)$D
MC;= C;88VXHZ[PKG>MSN?UGK;TB2$0+W2W#1@N/..Q*;0GE,H#JDA$/PG'&H
MZ&E)#DAPDA3:5'I[K+N.1/IT2Z*++0TW.@I9IC25*+T: [DRY$EM"B@RGY:E
M1N>6F(Z6EJ"<$PF[SZV\SWK:ZTVN4UQV$F]9<BD-R%/>%-5]@6^&5. H(;@M
M%3[Y=:+@26EY0G!)-]'KRG4NI38M7:D.VU-6@M"G2U/NP)3@:2Y-84V$9944
M!$MAL>[N!MMU"0]XH.4/5+MIYBOH73%:JRXW-#+R2E8:[VM>5K"<G46R4D02
M)]".)YRW(N-CL(4\$IIJ.W/J:2J.^":1J&X28,*A1U8W'4#B8<V?*99="!%?
M 2YXCP8=:?2M0RELD?R*UK\TJ!43ZXX'6.FU6*HL1EQ9K&%)2\HMI=*E+03X
MB<+  )/.2%8)X&,=+:K6HT=/*97X%55-<;F0WIM&<8/OD%FIN36(\V8@M-S4
M1ICL:/[F6UO1UATY\-:"D-["E3(K2E/0'2ZX%N/N,N-OK^%92A*TN*24J2GC
M:D9R#@'!Z8U%,I@@+3XU *P,%*@"# &,[CH9'3#J@>;KD.J4V@AIU32$E(2?
M#N8Q. ,Y$>IXWJH84&62IUY2@GQ2A*0K=XJ24;5I*D8.05#]-/D3UIKJH$;>
MT,G;MQE'PDG..,JSC@@^@.3G !5*JC#TIA;R'6&V2IUUJ0T^VZZVI 4T6%$>
M"5%9&\K<(2,I W;>M@O4V2)"E9"U(+C*4'XD(!!WX0$J6KS&W)(Y^6>D4IU$
M@=/(?\/+S],<28;2  A)&WS1..GXMO.< \;T&0'$J4XDI4I65-\Y4 0HJ)QG
M!')2,<G.>.=D);E+6I3B$MH!26P"3\1RI/F2%*&,G.2.B-AEOWD;'W' $*<(
M:2H (2 G8O>HCQ,D92/BSGX0.M>3*J%/?CH:3%>$E2DCQ4%D'.3@E).7 G/)
M&>/GY]H:=*U)2) "<F1OY].G3.<<=)8=/S5)3@'*M/KU(V_0>-N9;]-09,UA
MMX2Y(+;CJ4I7XAV@-_ #\336 0T" 5 $D'.<-)HSD6.KQUF0M2FR_*<2V'WR
MG(PL(0 V@I/* 23CT&.D[5+LGTEQ;/V)*?7D%@L3$J2]P5.*0V070V@X3O*-
MH)QG..LSE]08=.<+D&KOY!=4Q!AO3'DC:E2QXH+:,A6X$%"1\.,G'#C54@1J
M W&50>F))\XZSO._#M;5R+26])=028TJ$@ )ZS^3R/O*DAR9U#J#U81+GNR/
M#,6E18*W6VX[3Q 4$!*DM!]2202H^$M. LDC(-X0K+*G93JTB;)0OWE*E,.)
M 5D(0O>TI"UJ;P'!L*"L92220-"F5!B;&B2([,H!V,AU3;S*P\VA;"' %ME
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M0:G(7;U9ER%+:I5/5- <ASY2%Y9;$)93$,EP-K274I\MH,BE :20C?J8R?/
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MDJD/V9MW#R1BLRRVI>T!0!()!!'(]>K;.R5*T:-4L*"N7'3DXQP\Z.,$_C@
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M@J ((3\/'3'6DY;]B4&A6I9T*/!I%,B)8#+#I6E;I5XBWPKXCN=4I17DX'
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M9'R:<1Y8X(5E6""*FH!&00\Y,B,SJ]!P^VBO;5HUV]_G%_!+:2[7_.K[+^W
MJNW!6A,^QC/-.Q]NU.H^[>!]I3,^[>%XH<2'=X;;VG]]Z'Z8ZE3X-4O*VS4Z
MC3)#,J!.8J]<I,J*^PXVZVMMZD5* L J;2'6U$M/M[F7T.,K6A0Z'2H0@)TA
M*=(SI@1/G&W"*G'%K+BEJ4LY*RHE1.TE4R< =>(_ZG>SK[.-9K&1IIJAHS"O
M2Q6Y<::S;=7NN^_<69$*JR:W#4PY$N>-+9;B529)EQH[4A,=A3RFFFDL;6@V
M=N^R(]G7:8F)MSMIM^CB>RB/*$.\-21XK2/T02Y>*RA0P#XC92X3R5$]#H=
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MIJEGN*FG9?8)22R\TAQHD*!!T+24X.1C!R.%Z>JJ:1T/TM0_3/I! >8=<9=
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MVW8":91]*8\."E;CH8%S7<\D..XWK!?KCJDJ( 'PD#'IT.AT%<OV)4!5FM9
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5N5#[HAUYUP;PM:E"1L8).W3RX__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140455324776576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 01, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38241<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">OPTINOSE, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">42-1771610<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1020 Stony Hill Road<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Yardley<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">PA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">19067<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">267<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">364-3500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">OPTN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 201.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">111,810,073<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text">Portions of the registrant&#8217;s definitive proxy statement for its 2023 annual meeting of stockholders are incorporated by reference into Part III of this Form 10-K where indicated. Such definitive proxy statement will be filed with the U.S. Securities and Exchange Commission within 120 days after the year ended December 31, 2022.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity central index key</a></td>
<td class="text">0001494650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document fiscal year focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document fiscal period focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140455324767200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_optn_AuditorInformationAbstract', window );"><strong>Auditor Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Ernst & Young LLP<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Philadelphia, PA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">42<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_optn_AuditorInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Auditor Information</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">optn_AuditorInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>optn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140455326231040">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 94,244<span></span>
</td>
<td class="nump">$ 110,502<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">33,932<span></span>
</td>
<td class="nump">35,449<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">9,443<span></span>
</td>
<td class="nump">11,847<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">2,865<span></span>
</td>
<td class="nump">2,581<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">140,484<span></span>
</td>
<td class="nump">160,379<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">795<span></span>
</td>
<td class="nump">1,347<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">2,943<span></span>
</td>
<td class="nump">4,345<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">144,222<span></span>
</td>
<td class="nump">166,071<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">5,291<span></span>
</td>
<td class="nump">8,013<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">44,864<span></span>
</td>
<td class="nump">51,222<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Short term debt, net</a></td>
<td class="nump">128,575<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">178,730<span></span>
</td>
<td class="nump">59,235<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">126,418<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_optn_WarrantLiabilityNonCurrent', window );">Warrant liability</a></td>
<td class="nump">21,490<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities</a></td>
<td class="nump">626<span></span>
</td>
<td class="nump">2,190<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">200,846<span></span>
</td>
<td class="nump">187,843<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Stockholders' deficit:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 200,000,000 shares authorized at December 31, 2022 and 2021; 111,492,761 and 82,238,900 shares issued and outstanding at December 31, 2022 and December 31, 2021, respectively</a></td>
<td class="nump">111<span></span>
</td>
<td class="nump">82<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">628,242<span></span>
</td>
<td class="nump">588,288<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(684,893)<span></span>
</td>
<td class="num">(610,061)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(84)<span></span>
</td>
<td class="num">(81)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' deficit</a></td>
<td class="num">(56,624)<span></span>
</td>
<td class="num">(21,772)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' deficit</a></td>
<td class="nump">$ 144,222<span></span>
</td>
<td class="nump">$ 166,071<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_optn_WarrantLiabilityNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant Liability NonCurrent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">optn_WarrantLiabilityNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>optn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140455324043440">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Shares authorized (in shares)</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Shares issued (in shares)</a></td>
<td class="nump">111,492,761<span></span>
</td>
<td class="nump">82,238,900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Shares outstanding (in shares)</a></td>
<td class="nump">111,492,761<span></span>
</td>
<td class="nump">82,238,900<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140455327625712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 76,276,000<span></span>
</td>
<td class="nump">$ 74,652,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of product sales</a></td>
<td class="nump">9,263,000<span></span>
</td>
<td class="nump">9,151,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">15,260,000<span></span>
</td>
<td class="nump">25,318,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">107,649,000<span></span>
</td>
<td class="nump">106,633,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total costs and expenses</a></td>
<td class="nump">132,172,000<span></span>
</td>
<td class="nump">141,102,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(55,896,000)<span></span>
</td>
<td class="num">(66,450,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other (income) expense:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_optn_UnrealizedGainLossOnFairValueOfWarrants', window );">Unrealized loss on fair value of warrants</a></td>
<td class="nump">1,211,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_optn_GrantAndOtherIncome', window );">Other (income) expense</a></td>
<td class="nump">1,396,000<span></span>
</td>
<td class="num">(75,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="num">(513,000)<span></span>
</td>
<td class="num">(52,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="nump">16,843,000<span></span>
</td>
<td class="nump">15,973,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (74,833,000)<span></span>
</td>
<td class="num">$ (82,296,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net (loss) income per share of common stock,&#160;basic (in dollars per share)</a></td>
<td class="num">$ (0.87)<span></span>
</td>
<td class="num">$ (1.45)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net (loss) income per share of common stock, diluted (in dollars per share)</a></td>
<td class="num">$ (0.87)<span></span>
</td>
<td class="num">$ (1.45)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding, basic (in shares)</a></td>
<td class="nump">85,900,139<span></span>
</td>
<td class="nump">56,851,921<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common shares outstanding, diluted (in shares)</a></td>
<td class="nump">85,900,139<span></span>
</td>
<td class="nump">56,851,921<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Net product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 76,276,000<span></span>
</td>
<td class="nump">$ 73,652,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">Licensing revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_optn_GrantAndOtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Grant And Other Income</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">optn_GrantAndOtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>optn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_optn_UnrealizedGainLossOnFairValueOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unrealized Gain (Loss) on Fair Value Of Warrants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">optn_UnrealizedGainLossOnFairValueOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>optn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140455327812160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (74,833)<span></span>
</td>
<td class="num">$ (82,296)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>Other comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment</a></td>
<td class="num">(3)<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (74,836)<span></span>
</td>
<td class="num">$ (82,292)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140455323037728">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Stockholders' Equity (Deficit) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid -in Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">$ 6,788<span></span>
</td>
<td class="nump">$ 53<span></span>
</td>
<td class="nump">$ 534,585<span></span>
</td>
<td class="num">$ (527,765)<span></span>
</td>
<td class="num">$ (85)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,945,865<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock compensation expense</a></td>
<td class="nump">9,977<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,977<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_optn_StockIssuedDuringPeriodSharesVestedRestrictedStockUnits', window );">Vesting of restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">383,631<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Sale of common stock, net of issuance costs</a></td>
<td class="nump">42,814<span></span>
</td>
<td class="nump">$ 29<span></span>
</td>
<td class="nump">42,785<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Sale of common stock and warrants, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Issuance of warrants in connection with Pharmakon Second Amendment, net of cancellation</a></td>
<td class="nump">534<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">534<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of common stock options</a></td>
<td class="nump">39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of common stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,879<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan', window );">Issuance of common stock under employee stock purchase plan</a></td>
<td class="nump">368<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">368<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan', window );">Issuance of common stock under employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">135,525<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(82,296)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(82,296)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2021</a></td>
<td class="num">$ (21,772)<span></span>
</td>
<td class="nump">$ 82<span></span>
</td>
<td class="nump">588,288<span></span>
</td>
<td class="num">(610,061)<span></span>
</td>
<td class="num">(81)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2021</a></td>
<td class="nump">82,238,900<span></span>
</td>
<td class="nump">82,238,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock compensation expense</a></td>
<td class="nump">$ 8,889<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,889<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_optn_StockIssuedDuringPeriodVestedRestrictedStockUnits', window );">Vesting of restricted stock units</a></td>
<td class="nump">94<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_optn_StockIssuedDuringPeriodSharesVestedRestrictedStockUnits', window );">Vesting of restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">949,857<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Sale of common stock, net of issuance costs</a></td>
<td class="nump">30,446<span></span>
</td>
<td class="nump">$ 28<span></span>
</td>
<td class="nump">30,418<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Sale of common stock and warrants, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,861,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Issuance of warrants in connection with Pharmakon Second Amendment, net of cancellation</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of common stock options (in shares)</a></td>
<td class="nump">95,000<span></span>
</td>
<td class="nump">55,360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan', window );">Issuance of common stock under employee stock purchase plan</a></td>
<td class="nump">$ 554<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">554<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan', window );">Issuance of common stock under employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">387,344<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment</a></td>
<td class="num">(3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(74,833)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(74,833)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2022</a></td>
<td class="num">$ (56,624)<span></span>
</td>
<td class="nump">$ 111<span></span>
</td>
<td class="nump">$ 628,242<span></span>
</td>
<td class="num">$ (684,893)<span></span>
</td>
<td class="num">$ (84)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2022</a></td>
<td class="nump">111,492,761<span></span>
</td>
<td class="nump">111,492,761<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_optn_StockIssuedDuringPeriodSharesVestedRestrictedStockUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Vested Restricted Stock Units</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">optn_StockIssuedDuringPeriodSharesVestedRestrictedStockUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>optn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_optn_StockIssuedDuringPeriodVestedRestrictedStockUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Vested Restricted Stock Units</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">optn_StockIssuedDuringPeriodVestedRestrictedStockUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>optn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123466302&amp;loc=d3e4724-112606<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of capital stock issued (purchased by employees) in connection with an employee stock ownership plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 40<br> -Section 25<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109244457&amp;loc=d3e16649-113920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock issued during the period as a result of employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 40<br> -Section 25<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109244457&amp;loc=d3e16649-113920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140455323922416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (74,833)<span></span>
</td>
<td class="num">$ (82,296)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">532<span></span>
</td>
<td class="nump">646<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">8,877<span></span>
</td>
<td class="nump">10,003<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liability</a></td>
<td class="nump">1,211<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt discount and issuance costs</a></td>
<td class="nump">2,318<span></span>
</td>
<td class="nump">1,795<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Allowance for doubtful accounts</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(233)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Gain on sale of equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(67)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="nump">1,517<span></span>
</td>
<td class="num">(11,823)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_optn_IncreaseDecreaseInGrantsandOtherReceivables', window );">Grants and other receivables</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">43<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_optn_IncreaseDecreaseinDepositsandOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="nump">1,963<span></span>
</td>
<td class="nump">3,543<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="nump">2,492<span></span>
</td>
<td class="num">(2,713)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(2,723)<span></span>
</td>
<td class="nump">2,564<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses and other liabilities</a></td>
<td class="num">(9,005)<span></span>
</td>
<td class="nump">1,603<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Cash used in operating activities</a></td>
<td class="num">(67,651)<span></span>
</td>
<td class="num">(76,935)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(63)<span></span>
</td>
<td class="num">(167)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from sale of property and equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">105<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Cash used in investing activities</a></td>
<td class="num">(63)<span></span>
</td>
<td class="num">(62)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the sale of common stock and warrants</a></td>
<td class="nump">51,086<span></span>
</td>
<td class="nump">43,140<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_optn_ProceedsfromIssuanceofCommonStockUnderEmployeeStockPurchasePlan', window );">Proceeds from the issuance of common stock under employee stock purchase plan</a></td>
<td class="nump">554<span></span>
</td>
<td class="nump">368<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from the exercise of stock options</a></td>
<td class="nump">94<span></span>
</td>
<td class="nump">39<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfFinancingCosts', window );">Cash paid for financing costs</a></td>
<td class="num">(298)<span></span>
</td>
<td class="num">(227)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Cash provided by financing activities</a></td>
<td class="nump">51,436<span></span>
</td>
<td class="nump">43,320<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effects of exchange rate changes on cash and cash equivalents</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net decrease in cash, cash equivalents and restricted cash</a></td>
<td class="num">(16,271)<span></span>
</td>
<td class="num">(33,664)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at beginning of period</a></td>
<td class="nump">110,515<span></span>
</td>
<td class="nump">144,179<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at end of period</a></td>
<td class="nump">94,244<span></span>
</td>
<td class="nump">110,515<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">15,091<span></span>
</td>
<td class="nump">14,170<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental disclosure of noncash activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1', window );">Fixed asset purchases within accounts payable and accrued expenses</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Fair value of warrants issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">534<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_optn_DeferredOfferingCostsWIthinAccountsPayableandAccruedExpenses', window );">Financing costs within accounts payable and accrued expenses</a></td>
<td class="nump">408<span></span>
</td>
<td class="nump">318<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Recognition of right-of-use assets and lease liabilities</a></td>
<td class="nump">$ 704<span></span>
</td>
<td class="nump">$ 157<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_optn_DeferredOfferingCostsWIthinAccountsPayableandAccruedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Offering Costs WIthin Accounts Payable and Accrued Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">optn_DeferredOfferingCostsWIthinAccountsPayableandAccruedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>optn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_optn_IncreaseDecreaseInGrantsandOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Grants and Other Receivables</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">optn_IncreaseDecreaseInGrantsandOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>optn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_optn_IncreaseDecreaseinDepositsandOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) in Deposits and Other Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">optn_IncreaseDecreaseinDepositsandOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>optn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_optn_ProceedsfromIssuanceofCommonStockUnderEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Issuance of Common Stock Under Employee Stock Purchase Plan</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">optn_ProceedsfromIssuanceofCommonStockUnderEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>optn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123466302&amp;loc=d3e4724-112606<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of fixed assets that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for loan and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140455328376352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Description of Business<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Organization and Description of Business</a></td>
<td class="text">Organization and Description of BusinessOptiNose,&#160;Inc. (the Company) was incorporated in Delaware in May 2010 (inception) and has facilities in Yardley, Pennsylvania and Ewing, New Jersey. The Company's predecessor entity, OptiNose AS, was formed under the laws of Norway in September 2000. In 2010, OptiNose AS became a wholly-owned subsidiary of the Company as part of an internal reorganization.  During 2022, the Company's board of directors approved the liquidation of Optionse AS and Optinose UK, which is expected to be completed in 2023, in order to simplify the corporate structure.  <span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is a specialty pharmaceutical company focused on the development and commercialization of products for patients treated by ear, nose and throat (ENT) and allergy specialists. The Company's first commercial product, XHANCE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span> (fluticasone propionate) nasal spray, 93 microgram (mcg), is a therapeutic utilizing the Company's proprietary Exhalation Delivery System (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps and, if approved, chronic rhinosinusitis without nasal polyps (also known as chronic sinusitis). XHANCE was approved by the United States (US) Food and Drug Administration (FDA) in September 2017 for the treatment of nasal polyps in patients 18&#160;years of age or older. XHANCE was made widely available through commercial channels in April 2018.  In January 2023, the indication statement for XHANCE was changed from &#8220;for the treatment of nasal polyps&#8221; to &#8220;for the treatment of chronic rhinosinusitis with nasal polyps&#8221; to reflect current FDA labeling terminology and not based on new XHANCE clinical trial data.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140455328412208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liquidity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_optn_FutureLiquidityTextBlock', window );">Liquidity</a></td>
<td class="text">Liquidity<div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since inception, the Company's operations have focused on organization and staffing, business planning, raising capital, establishing an intellectual property portfolio, conducting preclinical studies and clinical trials, pursuing regulatory approvals and most recently, launching XHANCE in the US. As of December 31, 2022, the Company had cash and cash equivalents of $94,244 and a working capital deficiency of $38,246.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to a number of risks similar to other life sciences companies, including successful discovery, development and commercialization of its products and product candidates, raising additional capital, the development by its competitors of new technological innovations, protection of proprietary technology and market acceptance of the Company's products. The Company has incurred recurring net losses since its inception and has accumulated a deficit of $684,893 as of December 31, 2022.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company entered into a Note Purchase Agreement (the Note Purchase Agreement) on September 12, 2019 with funds managed by Pharmakon Advisors, LP (Pharmakon), the investment manager of the BioPharma Credit Funds (BioPharma) which was subsequently amended on August 13, 2020, March 2, 2021, November 16, 2021, August 10, 2022, and November 9, 2022.  On November 23, 2022, the Company amended and restated the Note Purchase Agreement (the A&amp;R Note Purchase Agreement). Pursuant to the A&amp;R Note Purchase Agreement, the financial covenants requiring the Company to achieve minimum trailing twelve-month consolidated XHANCE net product sales and royalties were modified (See </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a href="#i451bcb3eabba4f87bdc579718207a3b8_163" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Note </a><a href="#i451bcb3eabba4f87bdc579718207a3b8_163" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">10</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">). The principal balance outstanding under the A&amp;R Note Purchase Agreement was $130&#160;million at December 31, 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company's continuation as a going concern is dependent on its ability to maintain compliance with its covenants under the A&amp;R Note Purchase Agreement, including minimum trailing twelve-month consolidated XHANCE net sales and royalties the Company is required to achieve commencing with the trailing twelve months ending March 31, 2024 and its ability to generate sufficient cash flows from operations to meet its obligations and/or obtain additional capital through equity or debt financings, partnerships, collaborations, or other sources, as may be required. The A&amp;R Note Purchase Agreement includes events of default, in certain cases subject to customary periods to cure, following which Pharmakon may accelerate all amounts outstanding pursuant to the Note Purchase Agreement. The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The A&amp;R Note Purchase Agreement also requires the Company to maintain at all times a minimum of $30,000 of cash and cash equivalents. The Company believes that it is probable that its existing cash and cash equivalents will not be adequate to fund its operations and maintain at least $30,000 of cash and cash equivalents as required </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">under the A&amp;R Note Purchase Agreement for at least twelve-months following the filing of this Form 10-K, which will also constitute a default of the liquidity financial covenant under the A&amp;R Note Purchase Agreement if the Company is unable to obtain additional capital or obtain a waiver or modification to this liquidity covenant prior to falling below such $30,000 threshold. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company also believes it is probable that it will not achieve the trailing twelve-month minimum consolidated XHANCE net sales and royalties thresholds under the A&amp;R Note Purchase Agreement for the initial period ending March 31, 2024, which will constitute a default under the A&amp;R Note Purchase Agreement if the Company is unable to obtain a modification or waiver of such minimum consolidated XHANCE net sales and royalties thresholds. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Further, the A&amp;R Note Purchase Agreement includes a requirement that the report and opinion on the consolidated financial statements commencing with the year ending December 31, 2023, not be subject to any statement as to &#8220;going concern.&#8221; In addition, the consolidated financial statements commencing with the quarter ended March 31, 2024, shall also not be subject to any statement as to &#8220;going concern.&#8221; The Company has concluded that it is unlikely that it will be able comply with these provisions in 2024.  Failure to comply with these provisions would also constitute an event of default under the A&amp;R Note Purchase Agreement. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In the event of any of the foregoing defaults, the holders of the Pharmakon Senior Secured Notes may declare an event of default under the A&amp;R Note Purchase</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Agreement and may elect to accelerate the repayment of all unpaid principal, accrued interest and other amounts due, which may require the Company to delay or curtail its operations until additional funding is received.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The terms of the</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">A&amp;R Note Purchase</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Agreement and the Pharmakon Senior Secured Notes, including applicable covenants, are described in </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a href="#i451bcb3eabba4f87bdc579718207a3b8_163" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Note </a><a href="#i451bcb3eabba4f87bdc579718207a3b8_163" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">10</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Management&#8217;s plans to mitigate this risk may include reducing expenses, raising additional capital through equity or debt financings, partnerships, collaborations or other sources and requesting a modification or waiver of the covenants under the A&amp;R Note Purchase Agreement.  However, there can be no assurance that the Company will be successful in reducing expenses, raising additional capital, or obtaining a modification or waiver of the covenants under the A&amp;R Note Purchase Agreement. If the Company is unable to reduce expenses, raise additional capital or obtain a modification or waiver of the covenants under the A&amp;R Note Purchase Agreement, the Company may need to delay or curtail its operations. As a result of these factors, management has concluded that substantial doubt exists about the Company&#8217;s ability to continue as a going concern within one year after the date these consolidated financial statements are issued.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_optn_FutureLiquidityTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future Liquidity [Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">optn_FutureLiquidityTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>optn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140455328444848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of presentation</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements have been prepared in conformity with US generally accepted accounting principles (GAAP). Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification (ASC) and Accounting Standards Updates (ASU) of the Financial Accounting Standards Board (FASB).</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of consolidation</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of OptiNose,&#160;Inc. and its wholly-owned subsidiaries, OptiNose US,&#160;Inc., OptiNose AS and OptiNose UK&#160;Ltd. All inter-company balances and transactions have been eliminated in consolidation.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of estimates</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and reported amounts of expenses during the reporting period. Due to the uncertainty of factors surrounding the estimates or judgments used in the preparation of the consolidated financial statements, actual results may materially vary from these estimates. Estimates and assumptions are periodically reviewed and the effects of revisions are reflected in the consolidated financial statements in the period they are determined to be necessary.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of credit risk</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to concentrations of credit risk are primarily cash and accounts receivable. The Company generally invests its cash in deposits with high credit quality financial institutions. Additionally, the Company performs periodic evaluations of the relative credit standing of these financial institutions.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Customer and supplier concentration</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has exposure to credit risk in accounts receivable from sales of product. XHANCE is sold to wholesale pharmaceutical distributors and preferred pharmacy network (PPN) partners, who, in turn, sell XHANCE to pharmacies, hospitals and other customers.&#160;Five customers represented approximately 52% of the Company's accounts receivable at December 31, 2022 and five customers represented approximately 33% of the Company's net product sales for the year ended December 31, 2022.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The Company purchases XHANCE and its components from several third-party suppliers and manufacturing partners, certain of which are available through a single source. Although the Company could obtain each of these components from alternative third-party suppliers, it would need to qualify and obtain FDA approval for another supplier as a source for each such component.  The Company has initiated the process of qualifying an alternate third-party supplier for select components of XHANCE.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:107%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Alternate third party suppliers of XHANCE components are subject to qualification and approval from the FDA.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and cash equivalents</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All highly liquid investments purchased with an original maturity date of three months or less at the date of purchase are considered to be cash equivalents. The Company maintains its cash and cash equivalent balances at foreign and domestic financial institutions. Bank deposits with Norwegian banks are insured up to approximately 2,000 Norwegian krone by the Norwegian Banks' Guarantee Fund. Bank deposits with US banks are insured up to $250 by the Federal Deposits Insurance Corporation. The Company had uninsured cash balances of $92,988 and $109,017 at December 31, 2022 and 2021, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair value of financial instruments</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures certain assets and liabilities at fair value, which is defined as the price that would be received to sell an asset or paid to transfer a liability (the exit price) in an orderly transaction between market participants at the measurement date. The FASB accounting guidance outlines a valuation framework and creates a fair value hierarchy in order to increase the consistency and comparability of fair value measurements and the related disclosures. In determining fair value, the Company uses quoted prices and observable inputs. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from independent sources. The fair value hierarchy is broken down into three levels based on the source of the inputs as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;1&#160;&#8212; Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;2&#160;&#8212; Valuations based on observable inputs (other than Level&#160;1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;3&#160;&#8212; Valuations based on inputs that are unobservable and models that are significant to the overall fair value measurement.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">At December 31, 2022 and 2021, the Company's financial instruments included cash and cash equivalents, accounts receivable, grants receivable, accounts payable, accrued expenses and certain liability classified warrants. The carrying amounts reported in the Company's financial statements for cash and cash equivalents, accounts receivable, grants receivable, accounts payable and accrued expenses approximates their respective fair values because of the short-term nature of these instruments. In addition, at December 31, 2022, the Company believed </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">the carrying value of debt approximates fair value as the interest rates were reflective of the rate the Company could obtain on debt with similar terms and conditions. At December 31, 2022 and 2021, there were no financial assets or liabilities measured at fair value on a recurring basis other than the liability classified warrants shown below.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2022, the Company issued warrants in connection with the a public offering. Pursuant to the terms of the warrant agreement, the Company could be required to settle the warrants in cash in the event of an acquisition of the Company and, as a result, the warrants are required to be measured at fair value and reported as liability in the consolidated balance sheet. The Company recorded the fair value of the warrants upon issuance using a Monte Carlo simulation and is required to revalue the warrants at each reporting date with any changes in fair value recorded on our statement of operations. The valuation of the warrants is considered under Level 3 of the fair value hierarchy due to the need to use assumptions in the valuation that are both significant to the fair value measurement and unobservable. The change in the fair value of the Level 3 warrants liabilities is reflected in the statement of operations for the years ended December 31, 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts receivable</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable primarily relates to amounts due from customers, which are typically due within 31 to 61 days. The Company analyzes accounts that are past due for collectability. There was no allowance for doubtful accounts related to customers subject to credit risk at December 31, 2022. The Company recognized an allowance for doubtful accounts related to customers subject to credit risk of $444 at December 31, 2021. The accounts receivable balance at December 31, 2021 on the accompanying balance sheet is net of the allowance.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are stated at the lower of cost or net realizable value. Costs of inventories, which include amounts related to materials and manufacturing overhead, are determined on a first-in, first-out basis. An assessment of the recoverability of capitalized inventory is performed during each reporting period and any excess and obsolete inventories are written down to their estimated net realizable value in the period in which the impairment is first identified. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and equipment</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment is recorded at cost less accumulated depreciation. Significant additions or improvements are capitalized and expenditures for repairs and maintenance are charged to expense as incurred. Gains and losses on disposal of assets are included in the consolidated statements of operations. Depreciation is calculated on a straight-line basis over the estimated useful lives of the respective assets.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated useful lives of property and equipment are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:54.031%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.457%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.603%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.603%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.607%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="21" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2-3 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Software</span></td><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Machinery &amp; production equipment</span></td><td colspan="21" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5-10 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Furniture &amp; fixtures</span></td><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3-5 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="21" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shorter of lease term or useful life</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Long lived assets</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future net cash flows expected to be generated. Impairment charges are recognized at the amount by which the carrying amount of an asset exceeds the fair value of the asset. Assets to be disposed of are reported at the lower of the carrying amount or the fair value less costs to sell. The Company did not recognize any impairment or disposition of long-lived assets for the years ended December 31, 2022 and 2021.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the terms of the arrangement. The Company accounts for a contract as a lease when it has the right to control the asset for a period of time while obtaining substantially all of the asset&#8217;s economic benefits. The Company determines the initial classification and measurement of its operating right-of-use (&#8220;ROU&#8221;) assets and operating lease liabilities at the lease commencement date, and thereafter if modified.  The lease term includes any renewal options that the Company is reasonably assured to exercise. The Company&#8217;s policy is to not record leases with a lease term of 12 months or less on its balance sheets. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The ROU asset represents the right to use the leased asset for the lease term. The lease liability represents the present value of the lease payments under the lease. The present value of lease payments is determined by using the interest rate implicit in the lease, if that rate is readily determinable; otherwise, the Company uses its estimated secured incremental borrowing rate for that lease term.  Lease expense for operating leases is recognized on a straight-line basis over the reasonably assured lease term based on the total lease payments and is included in operating expense in the statements of operations. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Payments due under each lease agreement include fixed and variable payments. Variable payments relate to the Company&#8217;s share of the lessor&#8217;s operating costs associated with the underlying asset and are recognized when the event on which those payments are assessed occurs. Variable payments have been excluded from the lease liability and associated right-of-use asset. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:103%">The interest rate implicit in lease agreements is typically not readily determinable, and as such, the Company utilizes the incremental borrowing rate to calculate lease liabilities, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net product revenues</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for revenue in accordance with ASC Topic 606, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ASC 606), which was adopted on January 1, 2018. The Company performs the following five steps to recognize revenue under ASC 606: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only recognizes revenue when it is probable that it will collect the consideration to which it is entitled in exchange for the goods or services that will be transferred to the customer. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company sells XHANCE to preferred pharmacy network partners and wholesalers in the US (collectively, Customers). These Customers subsequently resell the Company&#8217;s products to healthcare providers, patients and other retail pharmacies. In addition to agreements with Customers, the Company enters into arrangements with healthcare providers and payors that provide for government-mandated and/or privately-negotiated rebates, chargebacks and discounts for the purchase of the Company&#8217;s products.  </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue from XHANCE sales at the point Customers obtain control of the product, which generally occurs upon delivery. The transaction price that is recognized as revenue for products includes an estimate of variable consideration which is described below. Payment terms with Customers do not exceed one year and, therefore, the Company does not account for a financing component in its arrangements. The Company expenses incremental costs of obtaining a contract with a Customer (for example, sales commissions) when incurred as the period of benefit is less than one year. Shipping and handling costs for product shipments to Customers are recorded as selling, general and administrative expenses.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Transaction Price, including Estimates of Variable Consideration</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from products is recognized at the estimated net sales price (transaction price), which includes estimates of variable consideration. The Company includes estimated amounts in the transaction price to the extent it is determined probable that a significant reversal of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is resolved. The Company&#8217;s estimates of variable consideration and determination of whether to include estimated amounts in the transaction price are based largely on an assessment </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of its anticipated performance and all information (historical, current and forecasted) that is reasonably available.  The components of the Company's variable consideration include the following:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline">Provider Chargebacks and Discounts.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chargebacks for fees and discounts to providers represent the estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list prices charged to Customers who directly purchase the product from the Company.&#160;Customers charge the Company for the difference between what they pay for the product and the ultimate selling price to the qualified healthcare providers.&#160;These components of variable consideration are established in the same period that the related revenue is recognized, resulting in a reduction of product revenue and accounts receivable.&#160;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt;text-decoration:underline">Trade Discounts and Allowances.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  The Company generally provides Customers with discounts that include incentive fees which are explicitly stated in the Company&#8217;s contracts. These discounts are recorded as a reduction of revenue and accounts receivable in the period in which the related product revenue is recognized. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt;text-decoration:underline">Product Returns.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Consistent with industry practice, the Company has a product returns policy that provides Customers a right of return for product purchased within a specified period prior to and subsequent to the product&#8217;s expiration date. The Company estimates the amount of its products that may be returned and presents this amount as a reduction of revenue in the period the related product revenue is recognized, in addition to establishing a current liability. The Company considers several factors in the estimation process, including expiration dates of product shipped to Customers, inventory levels within the distribution channel, product shelf life, prescription trends and other relevant factors.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt;text-decoration:underline">Government Rebates</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The Company is subject to discount obligations under state Medicaid programs and Medicare. Reserves related to these discount obligations are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability. The Company&#8217;s liability for these rebates consists of estimates of claims for the current reporting period and estimated future claims that will be made for product that has been recognized as revenue but remains in the distribution channel inventories at the end of the reporting period.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt;text-decoration:underline">Payor Rebates.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  The Company contracts with certain third-party payors, primarily health insurance companies and pharmacy benefit managers, for the payment of rebates with respect to utilization of its products. These rebates are based on contractual percentages applied to the amount of product prescribed to patients who are covered by the plan or the organization with which it contracts. The Company estimates these rebates and records such estimates in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt;text-decoration:underline">Patient Assistance.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Other programs that the Company offers include voluntary co-pay patient assistance programs intended to provide financial assistance to eligible patients with prescription drug co-payments required by payors and coupon programs for cash payors.&#160;The calculation of the current liability for this assistance is based on an estimate of claims and the cost per claim that the Company expects to receive associated with product that has been recognized as revenue but remains in the distribution channel inventories at the end of each reporting period.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt;text-decoration:underline">Distribution and Other Fees</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We pay distribution and other fees to certain customers in connection with the sales of our products. We record distribution and other fees paid to our customers as a reduction of revenue, unless the payment is for a distinct good or service from the customer and we can reasonably estimate the fair value of the goods or services received. If both conditions are met, we record the consideration paid to the customer as an operating expense. These costs are typically known at the time of sale, resulting in minimal adjustments subsequent to the period of sale.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Licensing Revenues</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a license agreement with Currax Pharmaceuticals LLC (Currax) (</span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i451bcb3eabba4f87bdc579718207a3b8_160" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note </a><a href="#i451bcb3eabba4f87bdc579718207a3b8_160" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">9</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). This license agreement provides for exclusive licensed rights to certain intellectual property, a non-refundable up-front payment, potential </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">milestone payment(s) and potential royalty payment(s). The Company analyzed the performance obligations under the license agreement, the consideration received to date and the consideration the Company could receive in the future as part of its analysis related to ASC 606. There was no licensing revenue recognized during the year ended December 31, 2022. The Company recognized $1,000 as licensing revenue during the year ended December 31, 2021.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Advertising expenses</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company expenses the costs of advertising, including promotional expenses, as incurred.  Advertising expenses were $16,575</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$15,638 for the years ended December 31, 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and development</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred. Research and development costs consist primarily of device development, clinical trial related costs and regulatory related costs. The Company enters into agreements with contract research organizations (CROs) to facilitate, coordinate and perform agreed upon research and development activities for the Company's clinical trials. These CRO contracts typically call for the payment of fees for services at the initiation of the contract and/or upon the achievement of certain clinical trial milestones. The Company prepays certain CRO fees whereby the prepayments are recorded as a current or non-current prepaid asset and are amortized into research and development expense over the period of time the contracted research and development services were performed. The Company's CRO contracts generally also include other fees such as project management and pass through fees whereby the Company expenses these costs as incurred, using the Company's best estimate. Pass through fees include, but are not limited to, regulatory expenses, investigator fees, travel costs, and other miscellaneous costs. Pass through fees incurred are based on the amount of work completed for the clinical trials and are monitored through reporting provided by the Company's CROs.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-based compensation</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures and recognizes compensation expense for all stock options and restricted stock units (RSUs) awarded to employees and non-employees and shares issued under the employee stock purchase plan based on the estimated fair value of the awards on the respective grant dates. The Company uses the Black-Scholes option pricing model to value its time-based and performance-based stock options and shares issued under the employee stock purchase plan. The Company uses a Monte Carlo simulation to value its market-based stock options.  RSUs are valued at the fair market value per share of the Company's common stock on the date of grant. The Company recognizes compensation expense for time-based awards on a straight-line basis over the requisite service period, which is generally the vesting period of the award. The Company recognizes compensation expense for performance-based awards when the performance condition is probable of achievement. The Company recognizes compensation expense for market-based awards over the derived service period, estimated at the time of the grant. The Company recognizes expense for The Company accounts for forfeitures of stock option awards as they occur.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimating the fair value of options and shares issued under the employee stock purchase plan requires the input of subjective assumptions, including the estimated fair value of the Company's common stock, the expected life of the options, stock price volatility, the risk-free interest rate and expected dividends. The assumptions used in the Company's Black-Scholes option-pricing model and Monte Carlo simulation represent management's best estimates and involve a number of variables, uncertainties and assumptions and the application of management's judgment, as they are inherently subjective.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income taxes</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes are accounted for under the asset and liability method. The Company recognizes deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of the Company's assets and liabilities and the expected benefits of net operating loss carryforwards. The impact of changes in tax rates and laws on deferred taxes, if any, applied during the period in which temporary differences are expected to be settled, is reflected in the Company's financial statements in the period of enactment. The measurement of deferred tax assets is reduced, if necessary, if, based on the weight of the evidence, it is more likely than not that some, or </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">all, of the deferred tax assets will not be realized. As of December 31, 2022 and 2021, the Company concluded that a full valuation allowance was necessary for all of its net deferred tax assets. The Company had no amounts recorded for uncertain tax positions, interest or penalties in the accompanying consolidated financial statements.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net income (loss) per common share</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net income (loss) per common share is determined by dividing net income (loss) applicable to common stockholders by the weighted average common shares outstanding during the period. For the years ended December 31, 2022 and 2021, outstanding common stock options and common stock warrants have been excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive. Therefore, the weighted average shares used to calculate both basic and diluted net loss per share are the same.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Diluted net loss per common share for the periods presented does not reflect the following potential common shares, as the effect would be antidilutive:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.092%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.576%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,364,070&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,958,781&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,477,660&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,959,358&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,768,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,500,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43,609,730&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,418,139&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent accounting pronouncements</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, the FASB issued ASU No. 2022-02, Financial Instruments - Credit Losses (Topic 326): Troubled Debt Restructurings and Vintage Disclosures. Since the issuance of ASU No. 2016-13, Financial Instruments&#8212;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, the Board has provided resources to monitor and assist stakeholders with the implementation of Topic 326. Post-Implementation Review (PIR) activities have included forming a Credit Losses Transition Resource Group, conducting outreach with stakeholders of all types, developing educational materials and staff question-and-answer guidance, conducting educational workshops, and performing an archival review of financial reports. ASU No. 2022-02 is intended to respond to feedback received during the PIR process. The new standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2022, with early adoption permitted. The Company does not expect ASU No. 2022-02 to have a significant impact on its results of operations, financial position and cash flows and related disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140455328388448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">Fair Value Measurements<div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Assets and Liabilities Measured at Fair Value on a Recurring Basis</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company applies the guidance in ASC 820, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to account for financial assets and liabilities measured on a recurring basis. Fair value is measured as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that is determined based on assumptions that market participants would use in pricing an asset or liability.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses a fair value hierarchy, which distinguishes between assumptions based on market data (observable inputs) and an entity's own assumptions (unobservable inputs). The guidance requires that fair value measurements be classified and disclosed in one of the following 3 categories:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level l: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2: Quoted prices in markets that are not active or inputs which are observable, either directly or indirectly, for substantially the full te1m of the asset or liability; and</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span><br/></span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Determining which category an asset or liability falls within the hierarchy requires significant judgment. The Company evaluates its hierarchy disclosures each reporting period. There were no transfers between Level I, 2 and 3 during the years ended December 31, 2022 and December 31, 2021.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents the liabilities (in thousands) measured and recorded in the financial statements at fair value on a recurring basis at December 31, 2022 categorized by the level of inputs used in the valuation of each liability.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:44.635%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.252%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.417%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.252%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.417%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.252%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.417%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.258%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Warrant Liability</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,490&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,490&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total Liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,490&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,490&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As of December 31, 2021, the Company had no assets or liabilities measured and recorded at fair value on a recurring basis.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in Level 3 Liabilities Measured at Fair Value on a Recurring Basis</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Warrant Liability</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliation of the Company's warrant liability measured at fair value on a recurring basis using unobservable inputs (Level 3) is as follows (in thousands):</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:86.528%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.272%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Warrant Liability</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance, December 31, 2021</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Warrants issued</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,279&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzY1L2ZyYWc6MzgyNzViMTRmNmU2NDY1ZjlmNDQ0MmU4MzkxYzE5Y2IvdGFibGU6NWM3ZDZiYjczNjFkNDc5M2E4MTIxMjhkOWM4MWIzZDMvdGFibGVyYW5nZTo1YzdkNmJiNzM2MWQ0NzkzYTgxMjEyOGQ5YzgxYjNkM180LTAtMS0xLTExMDU2NQ_cf1ef344-6e8b-4404-9fc4-62d43ef2dafc">Change in fair value of liability</span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,211&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance, December 31, 2022</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,490&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Assumptions Used in Determining Fair Value of Liability-Classified Warrants</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:105%">The Company utilizes a Monte Carlo simulation valuation model which incorporates assumptions as to the stock price volatility, the expected life of the warrants, a risk-free interest rate, as well as timing and probability of equity financing. The Company values the Warrant Liability at each reporting period, with changes in fair value recognized in the consolidated statements of operations. The estimated fair value of the warrant liability is determined using Level 3 inputs. The inputs and values were as follows:</span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.182%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">November 23, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock price</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.77&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.85&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Strike price</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected life (years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.00</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.90</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value per warrant</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.67&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.71&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140455330028640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventory</a></td>
<td class="text">Inventory<div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory consisted of the following: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:72.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.271%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.420%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.272%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,691&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,504&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,010&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,816&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,742&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,527&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total inventory</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,443&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,847&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are stated at the lower of cost or net realizable value, as determined on a first-in, first-out basis.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI https://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140455328509120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment</a></td>
<td class="text">Property and Equipment<div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net, consisted of:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.607%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.329%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,203&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,173&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">366&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">366&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,067&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,367&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">609&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">609&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Construction in process</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,360&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,630&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,565)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,283)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">795&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,347&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense was $530</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and $645 for the years ended December 31, 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and 2021, respectively. In addition, depreciation expense of $665 was charged to inventory and no depreciation was charged to prepaid expenses and other assets as of December 31, 2022, which represents depreciation expense related to equipment involved in the manufacturing process.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI https://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140455328448432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">LeasesThe Company leases office space, storage space and equipment (primarily vehicles). The Company evaluates renewal options at lease inception on an ongoing basis and includes renewal options that it is reasonably certain to exercise in its expected lease terms when classifying leases and measuring lease liabilities. Lease agreements generally do not require material variable lease payments, residual value guarantees or restrictive covenants. <div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents the operating lease assets and liabilities recognized on the Company's consolidated balance sheets:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.063%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:33.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.689%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.963%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance Sheet Line Item</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-current operating lease assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNTEvZnJhZzoyNzE1YjlkZmFkYWQ0MzJmODM0NjNlNTc4MDU5NjVkNS90YWJsZTplNmRjNTY4MzJmZTU0MjZlODE2Nzg1Yzg1OWM5ZWExMC90YWJsZXJhbmdlOmU2ZGM1NjgzMmZlNTQyNmU4MTY3ODVjODU5YzllYTEwXzEtMi0xLTEtNTgzNzI_24ba613c-7389-4e11-9675-21345271c945"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNTEvZnJhZzoyNzE1YjlkZmFkYWQ0MzJmODM0NjNlNTc4MDU5NjVkNS90YWJsZTplNmRjNTY4MzJmZTU0MjZlODE2Nzg1Yzg1OWM5ZWExMC90YWJsZXJhbmdlOmU2ZGM1NjgzMmZlNTQyNmU4MTY3ODVjODU5YzllYTEwXzEtMi0xLTEtNTgzNzI_68a7407f-9d3d-42c1-b7e8-60a846da90dd">Other assets</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,445&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,051&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Current operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNTEvZnJhZzoyNzE1YjlkZmFkYWQ0MzJmODM0NjNlNTc4MDU5NjVkNS90YWJsZTplNmRjNTY4MzJmZTU0MjZlODE2Nzg1Yzg1OWM5ZWExMC90YWJsZXJhbmdlOmU2ZGM1NjgzMmZlNTQyNmU4MTY3ODVjODU5YzllYTEwXzMtMi0xLTEtNTgzNzI_81e615e1-5430-4b3f-a024-d8c112dd845e"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNTEvZnJhZzoyNzE1YjlkZmFkYWQ0MzJmODM0NjNlNTc4MDU5NjVkNS90YWJsZTplNmRjNTY4MzJmZTU0MjZlODE2Nzg1Yzg1OWM5ZWExMC90YWJsZXJhbmdlOmU2ZGM1NjgzMmZlNTQyNmU4MTY3ODVjODU5YzllYTEwXzMtMi0xLTEtNTgzNzI_c6470abf-49c1-414a-9b43-5932ca6cb8de">Accrued expenses and other current liabilities</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,971&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,094&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Non-current operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNTEvZnJhZzoyNzE1YjlkZmFkYWQ0MzJmODM0NjNlNTc4MDU5NjVkNS90YWJsZTplNmRjNTY4MzJmZTU0MjZlODE2Nzg1Yzg1OWM5ZWExMC90YWJsZXJhbmdlOmU2ZGM1NjgzMmZlNTQyNmU4MTY3ODVjODU5YzllYTEwXzQtMi0xLTEtNTgzNzI_51c56e55-3624-4972-bd9f-e5d6619b61c3"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNTEvZnJhZzoyNzE1YjlkZmFkYWQ0MzJmODM0NjNlNTc4MDU5NjVkNS90YWJsZTplNmRjNTY4MzJmZTU0MjZlODE2Nzg1Yzg1OWM5ZWExMC90YWJsZXJhbmdlOmU2ZGM1NjgzMmZlNTQyNmU4MTY3ODVjODU5YzllYTEwXzQtMi0xLTEtNTgzNzI_f473c9e3-1f7a-40d1-9ce5-a76980ea7120">Other liabilities</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">625&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,190&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Total operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,596&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,284&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The depreciable lives of operating lease asset leasehold improvements are limited by the lease term. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's leases generally do not provide an implicit rate, and therefore, the Company uses its incremental borrowing rate as the discount rate when measuring operating leases liabilities. The incremental borrowing rate represents an estimate of the interest rate the Company would incur at lease commencement to borrow an amount equal to the lease payments on a collateralized basis over the term of a lease. The Company used the incremental borrowing rates as of January 1, 2019 for operating leases that commenced prior to that date. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's weighted average remaining lease term and weighted average discount rate for operating leases as of December 31, 2022 are:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:79.747%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.323%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average remaining lease term (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.04</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below reconciles the undiscounted future minimum lease payments (displayed in aggregate by year) under non-cancelable operating leases with terms of more than one year to the total operating lease liabilities recognized on the consolidated balance sheets as of December 31, 2022:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:80.478%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.592%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,153&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">548&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Total undiscounted future minimum lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,783&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: difference between undiscounted lease payments and discounted operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">187&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Total operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,596&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No operating lease payments include options to extend lease terms that are reasonably certain of being exercised for the year ended December 31, 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease costs were $2,985 and $2,843 for the years ended December 31, 2022 and 2021, respectively. Operating lease costs are included within selling, general and administrative expenses on the consolidated statements of operations. </span></div>Cash paid for amounts included in the measurement of operating lease liabilities were $2,570 and $2,466 for the years ended December 31, 2022 and 2021, respectively. This amount is included in operating activities in the consolidated statements of cash flows.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140455328573376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">Accrued Expenses and Other Current Liabilities</a></td>
<td class="text">Accrued Expenses and Other Current Liabilities<div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities consisted of:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.022%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.914%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Product revenue allowances</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,993&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,521&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Selling, general and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,799&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,124&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Research and development expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,298&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,857&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Payroll expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,888&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,569&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,915&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,057&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;Total accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42,893&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49,128&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Lease liability</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,971&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,094&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;Total other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,971&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,094&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;Total accrued expenses and other current liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44,864&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51,222&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140455328536720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>Research and Development [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock', window );">License Agreements</a></td>
<td class="text">License Agreements<div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Currax License Agreement</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 25, 2019, OptiNose AS entered into a license agreement (the Currax License Agreement) with Currax pursuant to which the Company granted Currax an exclusive license to certain intellectual property for the commercialization of Onzetra Xsail in the US, Canada and Mexico.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, a specified regulatory milestone was met and the Company received a $1,000 milestone payment. The Company does not expect to receive any further payments from Currax under the terms of the License Agreement other than reimbursement for certain expenses.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 730<br> -URI https://asc.fasb.org/subtopic&amp;trid=2197926<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140455328326240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt, net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt, net</a></td>
<td class="text">Debt, net<div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 12, 2019 (the Closing Date), the Company entered into a Note Purchase Agreement with funds managed by Pharmakon Advisors, LP (Pharmakon), the investment manager of BioPharma Credit Funds (BioPharma). The Note Purchase Agreement provided the Company with $130,000 in debt financing, of which $80,000 of senior secured notes (the Pharmakon Senior Secured Notes) was issued on the Closing Date, $30,000 was issued on February 13, 2020 after achieving the $9,000 consolidated XHANCE net sales and royalties threshold for the quarter ended December 31, 2019 and $20,000 was issued on December 1, 2020 after achieving the $14,500 consolidated XHANCE net sales and royalties threshold for the quarter ended September 30, 2020.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 10, 2022, the Company entered into a Third Amendment to the Note Purchase Agreement (the Third Amendment).  The Third Amendment reduced the minimum c</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">onsolidated XHANCE net sales and royalties required to be achieved under the Note Purchase Agreement for the trailing twelve-month period ending December 31, 2022 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">from $90,000 to $85,000 in exchange for a $780 fee due on the repayment of the Pharmakon Senior Secured Notes.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 9, 2022, the Company entered into a Fourth Amendment to the Note Purchase Agreement (the Fourth Amendment).  The Fourth Amendment resulted in the waiver of the minimum consolidated XHANCE net sales and royalties required to be achieved under the Note Purchase Agreement for the trailing twelve-month period ending September 30, 2022 and December 31, 2022 in exchange for a $1,300 fee due upon repayment of the Pharmakon Senior Secured Notes.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On November 23, 2022, the Company amended and restated the Note Purchase Agreement, initially entered into on September 12, 2019 and amended through November 9, 2022, among the Company, its subsidiaries, OptiNose US, Inc., OptiNose AS and OptiNose UK, Ltd. and BioPharma Credit PLC, as collateral agent, and the purchasers party thereto from time to time (the A&amp;R Note Purchase Agreement). Pursuant to the A&amp;R Note Purchase Agreement, certain modifications to the affirmative and negative covenants, events of default and other provisions were made, including, without limitation, (i) the requirement for the Company to deliver quarterly and annual financial statements that, commencing with the Company's consolidated financial statements for the year ending December 31, 2023, are not subject to a &#8220;going concern&#8221; statement (the Going Concern Covenant) and (ii) the removal of certain exceptions to the negative covenants which previously permitted the Company to enter into certain transactions without the consent of the holders of the Pharmakon Senior Secured Notes, including permitted acquisitions, swap contracts, convertible bonds and revolving credit facilities. The financial covenants requiring the Company to achieve minimum trailing twelve-month consolidated XHANCE net product sales and royalties were also modified as follows (in thousands):</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"/><td style="width:2.723%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.455%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.332%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.332%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.728%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trailing Twelve-Months Ending</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Requirement Prior to A&amp;R Note Purchase Agreement</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Requirement under the A&amp;R Note Purchase Agreement</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">September 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">March 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$98,750</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">June 30, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,500</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">September 30, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,250</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">December 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">March 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113,750</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$82,500</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">June 30, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,500</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,000</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">September 30, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,500</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">December 31, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,000</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">March 31, 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,000</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">June 30, 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,000</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">September 30, 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125,000</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">December 31, 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130,000</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">March 31, 2026</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135,000</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">June 30, 2026</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140,000</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">September 30, 2026</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145,000</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">December 31, 2026</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150,000</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">March 31, 2027</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155,000</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">June 30, 2027</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160,000</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">September 30, 2027</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165,000</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The A&amp;R Note Purchase Agreement provided for an extension of the maturity date of the Pharmakon Senior Secured Notes from September 12, 2024 to June 30, 2027 (New Maturity Date), an extension of the interest-only period from September 2023 to September 2025, after which principal repayments will commence starting on September 30, 2025 and will be made in eight equal quarterly installments of principal and interest through the New Maturity Date. As part of the A&amp;R Note Purchase Agreement the Pharmakon Senior Secured Notes will now bear an amended interest rate through the New Maturity Date equal to the 3-month Secured Overnight Financing Rate (subject to a 2.50% floor), determined as of the date that is two business days prior to the commencement of each quarter, plus 8.50% per annum (effective rate of 13.62% at December 31, 2022), which interest rate shall be increased by an additional 3.00% per annum upon the occurrence and during the continuation of any event of default. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In conjunction with the A&amp;R Note Purchase Agreement, a modification was made to the &#8220;make-whole&#8221; premium payment due in connection with any principal prepayments (whether mandatory or voluntary) made prior to the 3-year anniversary of the date of the A&amp;R Note Purchase Agreement. On any such prepayment date, the Company will be required to pay a make-whole premium in the amount of (i) for any prepayment date occurring up until and including the 18-month anniversary of the date of the A&amp;R Note Purchase Agreement, the foregone interest from such prepayment date through the 18-month anniversary of such prepayment date; and (ii) for any prepayment after the 18-month anniversary of the date of the A&amp;R Note Purchase Agreement, the foregone interest from such prepayment date through the 3-year anniversary of the date of the A&amp;R Note Purchase Agreement; provided, however, that in no event shall the amount of all make-whole premium payments exceed $24,000 in the aggregate; </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As an inducement for the holders of the Pharmakon Senior Secured Notes to enter into the A&amp;R Note Purchase Agreement, the Company is required to pay the holders of the Pharmakon Senior Secured Notes an amendment fee of $3,900 (representing 3.00% of the outstanding principal balance of such notes) due on the New Maturity Date or the earlier repayment of the Pharmakon Senior Secured Notes, which amendment fee shall be (i) reduced to $1,300 in the event that the Company repays the Pharmakon Senior Secured Notes in full prior to the one-year anniversary of the date of the A&amp;R Note Purchase Agreement and (ii) reduced to $2,600 in the event that the Company repays the Pharmakon Senior Secured Notes in full on or after the one-year anniversary of the date of the A&amp;R Note Purchase Agreement and prior to second anniversary of the date of the A&amp;R Note Purchase Agreement. Additionally, the $1,300 fee payable under the Fourth Amendment to the Note Purchase Agreement that the Company entered into on November 9, 2022 will be credited against the amendment fee payable in connection with the A&amp;R Note Purchase Agreement.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Pharmakon Senior Secured Notes are secured by a pledge of substantially all of the assets of the Company and the Guarantors and the A&amp;R Note Purchase Agreement contains affirmative and negative covenants customary for financings of this type, including limitations on the Company&#8217;s and its subsidiaries&#8217; ability, among other things, to incur additional debt, grant or permit additional liens, make investments and acquisitions, merge or consolidate with others, dispose of assets, pay dividends and distributions, repay junior indebtedness, incur a material adverse change and enter into affiliate transactions, in each case, subject to certain exceptions. In addition, the A&amp;R Note Purchase Agreement contains financial covenants requiring the Company to maintain certain minimum trailing twelve-month consolidated XHANCE net sales and royalties, tested on a quarterly basis as noted in the table above, and to have at least $30,000 of cash and cash equivalents at all times. The A&amp;R Note Purchase Agreement also includes events of default customary for financings of this type, in certain cases subject to customary periods to cure, following which BioPharma may accelerate all amounts outstanding under the Pharmakon Senior Secured Notes.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company believes that it is probable that it will not achieve the trailing twelve-month minimum consolidated XHANCE net sales and royalties thresholds that it is required to achieve commencing with the period ending March 31, 2024.  Additionally, without additional capital, the Company believes that it is probable that it will not be able to maintain at least $30,000 of cash and cash equivalents for at least twelve-months following the filing of this Form 10-K. In addition, the Company believes that it is unlikely that it will be able to maintain compliance with the Going Concern Covenant in 2024.  As a result, in accordance with FASB Accounting Standards Codification 470, the Company has classified all outstanding principal and the payment of additional fees upon maturity as a current liability in the accompanying consolidated balance sheet as of December 31, 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded interest expense of $16,843 and $15,973 during the years ended December 31, 2022 and 2021, respectively. Interest expense included total coupon interest and the amortization of debt issuance costs. </span></div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The debt balance is comprised of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:76.206%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.588%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.117%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.589%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Face amount</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">130,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">130,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Front end fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(666)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(717)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,739)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,165)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Back end fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,980&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">128,575&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">126,418&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI https://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140455328626416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Employee Benefit Plans</a></td>
<td class="text">Employee Benefit PlansThe Company maintains a defined contribution 401(k) retirement plan, which covers all eligible US employees. Employees are eligible to participate in the plan on the first of the month following their date of hire. Under the 401(k)&#160;retirement plan, participating employees may defer up to 100% of their pre-tax salary, but not more than statutory limits. The Company matches 100% of the first 3% of participating employee contributions and 50% of the next 2% of participating employee contributions, subject to applicable IRC limits. The Company incurred costs of $1,112 and $1,340 related to the Company match applicable to employee contributions for the years ended December 31, 2022 and 2021, respectively. The Company's contributions are made in cash. The Company's common stock is not currently an investment option available to participants in the 401(k) retirement plan.  As of December 31, 2022, approximately $256 was recorded in accrued expenses related to the Company match. For former Norway employees, the Company maintained a defined contribution pension plan which met the statutory requirements. The Company incurred costs of $11 and $6 related to the pension plans for the years ended December 31, 2022 and 2021, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section S99<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=21916913&amp;loc=d3e273930-122802<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI https://asc.fasb.org/topic&amp;trid=2235017<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39689-114964<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140455328417984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Purchase commitments</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, the Company had no material outstanding non-cancellable purchase commitments related to inventory and other goods and services, including pre-commercial manufacturing scale-up and sales and marketing activities.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employment agreements</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into employment contracts with its officers and certain employees that provide for severance and continuation of benefits in the event of termination of employment by the Company without cause or by the employee for good reason. In addition, in the event of termination of employment following a change in control, the vesting of certain equity awards may be accelerated.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liabilities for loss contingencies arising from claims, assessments, litigation, fines, penalties, and other sources are recorded when it is probable that a liability has been incurred and the amount can be reasonably estimated. The Company is not currently a party to any material pending legal proceedings.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140455328498528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">Stockholders' Equity<div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common stock</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 18, 2021, the Company closed an underwritten public offering (the 2021 Offering) of 28,750,000 shares of Company common stock (Common Stock) at a price of $1.60 per share. As a result of the Offering, the Company received $42,842 in net proceeds, after deducting commissions and expenses of $2,860 and offering costs payable by the Company of $298.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On November 23, 2022, the Company closed an underwritten public offering (the 2022 Offering) of 26,320,000 shares of Common Stock at a price of $1.89 per share and accompanying warrants to purchase 26,320,000 shares of Common Stock at a public offering price of $0.01 per warrant. In addition, the Company granted the underwriters an option for a period of 30 days to purchase up to an additional 3,948,000 shares of Common Stock (the Option Shares) and/or warrants to purchase 3,948,000 shares of Common Stock (The Option Warrants). The underwriters exercised their option to purchase the Option Warrants on November 22, 2022. In December 2022, the Underwriter partially exercised the option to purchase an additional 1,541,299 of the Option Shares. As a result of the 2022 Offering and the exercise of the options, the Company received $49,296 in net proceeds, after deducting commissions of $3,238 and offering costs payable by the Company of $359. </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company&#8217;s stockholders. Subject to preferences that may apply to any outstanding preferred stock, holders of common stock are entitled to receive ratably any dividends that the Company&#8217;s board of directors may declare out of funds legally available for that purpose on a non-cumulative basis. No dividends had been declared through December 31, 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common stock warrants</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 18, 2021, in conjunction with the Second Amendment to the original Note Purchase Agreement (Second Amendment), the Company issued warrants to purchase an aggregate of 2,500,000 shares of Common Stock at a per share exercise price of $1.60 and fair value of $2,009.  Upon execution of the Second Amendment, previously issued warrants to purchase 810,357 shares of Common Stock at a per share exercise price of $6.72 which were set to expire on September 12, 2022, were cancelled.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The grant date fair value of the 2,500,000 warrants issued in connection with the Pharmakon Senior Secured Notes was estimated at the time of grant using the Black-Scholes option-pricing model using the following weighted average assumptions:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:83.695%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.105%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.87&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">78.25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Annual dividend yield</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.00&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of common stock</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As part of the 2022 Offering, the Company issued warrants to purchase 30,268,000 shares of Common Stock at a public offering price of $0.01 per warrant (the Warrants). Each Warrant has an exercise price of $2.565 per share of Common Stock and is exercisable until the expiration date, which is the fifth anniversary of the date of issuance (November 23, 2027). After such date, any unexercised Warrants will expire and have no further value. If the Company issues or sells, or is deemed pursuant to the terms of the Warrants to have issued or sold, any shares of Common Stock (which includes, among other things, options and securities convertible into shares of Common Stock), excluding certain issuances defined in the Warrants as "excluded issuances, for a price per share less than the exercise price of the Warrants in effect immediately prior to such issuance or sale or deemed issuance or sale (such event, a dilutive issuance), then immediately after such dilutive issuance the exercise price then in effect of the Warrants shall be reduced to the price of the shares of Common Stock issued or sold or deemed to be issued or sold in the dilutive issuance in the manner set forth in the Warrant.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">A holder of Warrants will not have the right to exercise any portion of a Warrant if the holder (together with its affiliates) would beneficially own in excess of 4.99% (or on election of such holder, prior to the issuance of any Warrants, 9.99%) of the number of shares of Common Stock outstanding immediately after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the Warrants; provided, however, such holder may increase or decrease such percentage to any other percentage not in excess of 19.99%, provided that any increase in such percentage shall not be effective until 61 days after such notice is delivered to the Company.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Pursuant to the terms of the Warrant, the Company could be required to settle the Warrants in cash in the event of a "fundamental transaction" as defined in the Warrant (which includes, among other things, an acquisition of the Company) and, as a result, the Warrants are required to be measured at fair value and reported as liability in the consolidated balance sheet. The Company recorded the fair value of the Warrants upon issuance using a Monte Carlo simulation and are required to revalue the Warrants at each reporting date with any changes in fair value recorded on our statement of operations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, the Company had the following warrants outstanding to purchase shares of Common Stock: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:22.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.847%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.847%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.847%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.931%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercise Price Per Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Expiration Date</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,500,000</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$1.60</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">November 15, 2024</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,268,000</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Liability</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$2.565</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">November 23, 2027</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140455328444848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-based Compensation</a></td>
<td class="text">Stock-based Compensation<div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company issues stock-based awards pursuant to its 2010 Stock Incentive Plan. Effective as of October 12, 2017, the Company's 2010 Stock Incentive Plan was amended and restated (A&amp;R Plan). The A&amp;R Plan provides for the grant of incentive stock options, non-statutory stock options, restricted stock awards, restricted stock units, deferred stock units, performance shares, stock appreciation rights and other equity-based awards. The Company's employees, officers, directors and other persons are eligible to receive awards under the A&amp;R Plan. As of December 31, 2022, 17,299,284 shares of the Company's common stock were authorized to be issued under the A&amp;R Plan, and 3,607,066&#160;shares were reserved for future awards under the A&amp;R Plan. The number of shares of the Company's common stock authorized under the A&amp;R Plan will automatically increase on January&#160;1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">st</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of each year until the expiration of the A&amp;R Plan, in an amount equal to four percent of the total number of shares of the Company's common stock outstanding on December&#160;31</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">st</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the preceding calendar year, subject to the discretion of the Company's board of directors or compensation committee to determine a lesser number of shares shall be added for such year.&#160;</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount, terms of grants, and exercisability provisions are determined and set by the Company's board of directors or compensation committee. The Company measures stock-based awards at grant-date fair value and records compensation expense on a straight-line basis over the vesting period of the award.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock options</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has issued service-based, performance-based and market-based stock options that generally have a contractual life of up to 10&#160;years and may be exercisable in cash or as otherwise determined by the board of directors. Vesting generally occurs over a period of not greater than four years. Performance-based options may vest upon the achievement of certain milestones in connection with the Company's development programs. As of December 31, 2022, all of the performance conditions related to performance-based stock options issued by the Company have been achieved. Market-based options may vest upon the achievement of certain market-based objectives relating to the trading price of the Company's Common Stock.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity related to stock option grants to employees and non-employees for the year ended December 31, 2022:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.326%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.770%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>average<br/>exercise price<br/>per share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>average<br/>remaining<br/>contractual life</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,958,781&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.87&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.50</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,473,370&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.88&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(95,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(947,999)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.56&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,025,082)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding at December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,364,070&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.88&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.05</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercisable at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,521,738&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.98&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.55</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2022, stock options to purchase 3,473,370 shares of common stock were granted to employees that generally vest over four years. Included in the total stock options granted were market-based options to purchase 959,215 shares of Common Stock. The stock options, including the market-based options, had an estimated weighted average grant date fair value of $1.21. The grant date fair value of each service-based and performance-based option grant was estimated at the time of grant using the Black-Scholes option-pricing model. The grant date fair value of each market-based stock option grant was estimated at the time of grant using a Monte Carlo simulation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total aggregate intrinsic value of stock options, other than market-based stock options, exercised during the years ended December 31, 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021 was $111</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and $35, respectively. The aggregate intrinsic value of stock options outstanding and stock options exercisable, other than market-based stock options, as of December 31, 2022 was $81 and $8, respectively. At December 31, 2022, the unrecognized compensation cost related to unvested stock options, other than market-based stock options, expected to vest was $4,368. This unrecognized compensation will be recognized over an estimated weighted-average amortization period of 2.35 years.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2022, market-based options to purchase 959,215 shares of Common Stock were granted to employees and generally become eligible to vest over four years, subject to the achievement of certain market-based objectives relating to the trading price of the Common Stock.  Stock based compensation for these awards is recognized over the derived service period of approximately 2 years.  The grant date fair value of each stock option grant, as well as the derived service period for these awards, was estimated at the time of grant using a Monte Carlo simulation. During the year ended December 31, 2022, 297,677 market-based options vested upon the achievement of certain market-based objectives relating to the trading price of the Company's Common Stock.  </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in the table above are 753,500 options granted outside the A&amp;R Plan. The grants were made pursuant to the Nasdaq inducement grant exception in accordance with Nasdaq Listing Rule 5635(c)(4). </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted stock units</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has issued service-based and performance-based restricted stock units (RSUs). Vesting generally occurs over a period not greater than four years. Vesting of the performance-based RSUs is subject to the achievement of certain milestones in connection with the Company's development programs.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity related to RSUs granted to employees for the year ended December 31, 2022:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:88.227%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.573%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,959,358&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,105,246&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vested and settled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(949,857)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expired/forfeited/canceled</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(637,087)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,477,660&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected to vest at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,477,660&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2022, the Company granted 1,105,246 RSUs at a weighted-average grant date fair value of $1.85, all of which were service-based RSUs. No performance-based RSUs were granted in 2022. As of December 31, 2022, the milestone associated with the previously granted performance based-RSUs was achieved. As a result 248,827 RSUs vested on June 15, 2022. At December 31, 2022, the recognized compensation cost related to vested performance-based RSUs was $1,669. At December 31, 2022, the unrecognized compensation cost related to unvested service-based</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> RSUs expected to vest was </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$3,123</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to be recognized over an estimated weighted-average amortization period of</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 2.24</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> years. The unrecognized compensation cost related to unvested performance-based RSUs was </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$942</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, whic</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">h will be recognized over the remaining service period.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in the table above are 60,000 RSUs granted outside the A&amp;R Plan. The grants were made pursuant to the Nasdaq inducement grant exception in accordance with Nasdaq Listing Rule 5635(c)(4). </span></div><div style="margin-bottom:8pt"><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2017 Employee Stock Purchase Plan </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's 2017 Employee Stock Purchase Plan (the 2017 Plan) became effective on October 12, 2017. As of December 31, 2022,&#160;2,021,813 shares of the Company's common stock were authorized to be issued pursuant to purchase rights granted to its employees or to employees of any of its participating affiliates under the 2017 Plan. 982,989 shares of the Company's common stock were reserved for future issuance under the 2017 Plan. The number of shares of the Company's common stock that may be issued pursuant to rights granted under the 2017 Plan shall automatically increase on January&#160;1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">st</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of each year until the expiration of the 2017 Plan, in an amount equal to one percent of the total number of shares of the Company's common stock outstanding on December&#160;31</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">st </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of the preceding calendar year, subject to the discretion of the board of directors or compensation committee to determine a lesser number of shares shall be added for such year.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the 2017 Plan, eligible employees can purchase the Company&#8217;s common stock through accumulated payroll deductions at such times as are established by the administrator. The 2017 Plan is administered by the compensation committee. Eligible employees may contribute up to 15% of their eligible compensation. A participant may not accrue rights to purchase more than $25 worth of the Company&#8217;s common stock for each calendar year in which such right is outstanding.&#160;</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payroll withholdings accumulate during the following six month offering periods each calendar year while the Purchase Plan is effective:</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">January 1 through June 30, and</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">July 1 through December 31.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the end of each offering period, shares of the Company&#8217;s common stock may be purchased at 85% of the lesser of the average of the high and low sales price of the Company&#8217;s common stock on (i) the first trading day of the relevant offering period and (ii) the last trading day of the relevant offering period (or, if the relevant offering period has multiple purchase periods, the last trading day of the relevant purchase period). In accordance with the guidance in ASC 718-50 &#8211;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;Compensation &#8211; Stock Compensation</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the ability to purchase shares of the Company&#8217;s common stock at the lower of the price on the first day of the offering period or the last day of the offering period (i.e. the purchase date) represents an option and, therefore, the 2017 Plan is a compensatory plan under this guidance. Accordingly, stock-based compensation expense is determined based on the option&#8217;s grant-date fair value as estimated by applying the Black-Scholes option-pricing model and is recognized over the requisite service period of the option. The Company has recognized stock-based compensation expense of $253</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$402 during the years ended December 31, 2022 and 2021, respectively, related to the 2017 Plan.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-based compensation expense</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded stock-based compensation expense in the following expense categories of its accompanying consolidated statements of operations for the years ended December 31, 2022 and 2021:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.844%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of product sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">809&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,079&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,033&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,874&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,877&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,003&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;padding-right:15.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, stock-based compensation expense of $83 was charged to inventory as of December 31, 2022. No stock-based compensation expense was charged to prepaid expenses and other assets as of December 31, 2022. These charges represent the total stock-based compensation expense incurred related to employees involved in the manufacturing process of finished goods and samples during the period. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company utilized the Black-Scholes valuation model for estimating the fair value of stock options issued under the 2017 Plan. The Company calculated the fair value of each option grant and the shares issued under the 2017 Plan on the respective dates of grant using the following weighted average assumptions: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.145%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.387%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2010 A&amp;R Stock Incentive Plan</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2017 Employee Stock Purchase Plan</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk free interest rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.22&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.17&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.08</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.50</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">73.23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">88.13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Annual dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Option valuation methods, including Black-Scholes, require the input of subjective assumptions, which are discussed below.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The expected term of employee options is determined using the "simplified" method, as prescribed in SEC's Staff Accounting Bulletin (SAB) No.&#160;107, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share Based Payment </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(SAB No. 107), whereby the expected life equals the arithmetic average of the vesting term and the original contractual term of the option due to the Company's lack of sufficient historical data. The expected term of non-employee options is equal to the contractual term.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The expected volatility is based on a weighted average of the Company's historical volatility and the volatilities of similar entities within the Company's industry which were commensurate with the expected term assumption as described in SAB No.&#160;107.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The risk-free interest rate is based on the interest rate payable on US Treasury securities in effect at the time of grant for a period that is commensurate with the assumed expected term.</span></div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The expected dividend yield is 0% because the Company has not historically paid, and does not expect for the foreseeable future to pay, a dividend on its common stock.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140455328388448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes<div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes are based on the following book income (loss) before income tax expense:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.151%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.818%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.012%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Domestic operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(72,750)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(78,801)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign operations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,083)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,495)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss before provision for income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(74,833)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(82,296)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of income tax expense (benefit) at the US federal statutory income tax rate and the income tax provision in the financial statements is as follows: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.644%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.505%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.994%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.405%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.852%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income tax expense at statutory rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Permanent items</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Foreign rate differential</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Impact of foreign operations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(14.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;State taxes, net of federal benefit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Tax rate changes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Foreign exchange and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Stock based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Prepaid royalty write off</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Change in valuation allowance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(24.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effective income tax rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The principal components of the Company&#8217;s deferred tax assets and liabilities are as follows: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"><tr><td style="width:1.0%"/><td style="width:54.241%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.523%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.027%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.432%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.177%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Accrued expenses and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,144&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,712&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Prepaid licensing arrangement</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,441&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Interest expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,304&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,708&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Stock compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,193&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,583&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Lease liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">642&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,081&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Research and development credits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,460&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,461&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Capitalized R&amp;D</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,377&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Net operating losses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">83,376&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">87,324&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Total deferred tax assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">116,496&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">126,310&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Fixed assets, including leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(171)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(210)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Right-to-use asset</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(605)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,024)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Total deferred tax liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(776)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,234)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Less: Valuation allowance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(115,720)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(125,076)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total net deferred tax assets (liabilities)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span><br/></span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, the Company had foreign net operating loss (NOL) carry forwards of $9,073, primarily from its operations in Norway. As of December 31, 2022, the Company had federal and state NOLs of $335,009 and $252,324, respectively. These domestic NOL carry forwards may be subject to an annual limitation in the event of cumulative changes in the ownership interests of significant stockholders over a three-year period in excess of 50%. This could limit the amount of NOLs that the Company can utilize annually to offset future domestic taxable income, if any. The amount of the annual limitation, if any, will be determined based on the value of the Company immediately prior to the ownership change. Subsequent ownership changes may further affect the limitation in future years. The federal NOLs generated after 2017 have an indefinite carry forward period. The federal NOLs generated prior to 2018 will expire from 2030 through 2037. Some state NOLs will not expire while other state NOLs expire over various periods depending on the rules of the jurisdiction in which they were generated. The earliest state NOL expiration is in 2030.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. NOL and tax credit carry forwards could expire unused and be unavailable to offset future income tax liabilities because of their limited duration or because of other restrictions under U.S. tax law. Under Sections 382 and 383, if a corporation undergoes an &#8220;ownership change&#8221;, generally defined as a greater than 50% change, by value, in equity ownership during a three-year period, the corporation&#8217;s ability to offset pre-change tax attributes, such as NOLs and R&amp;D tax credits, against post-change income or tax may be limited. We have not performed an analysis under Section 382 and cannot predict or otherwise determine whether utilization of our federal tax attribute carry forwards may be limited. As a result, if we have taxable income in the future, our ability to use existing U.S. NOL and R&amp;D tax credit carry forwards to reduce U.S. taxable income or tax liability may be subject to limitation resulting in increased future tax liabilities. Similar rules at the state level may also limit our ability to use state NOLs. Also, there may be periods when the use of NOLs is suspended or otherwise limited at the state level, which could accelerate or permanently increase state taxes owed.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:103%">The company also has federal and state R&amp;D credit carryforwards of $2,487 which can be carried forward for 20 years beginning to expire in 2031</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:103%">.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC 740 requires the establishment of a valuation allowance to reduce deferred tax assets if, based on the weight of the available positive and negative evidence it is more likely than not that all or a portion of the deferred tax assets will not be realized. There is insufficient positive evidence to overcome the negative evidence attributable to the Company&#8217;s cumulative operating losses. Consequently, the Company established a full valuation allowance against its net deferred tax assets at December 31, 2022 and 2021, respectively, because the Company&#8217;s management was unable to conclude that it is more likely than not that these assets will be fully realized. The Company had a net decrease in its valuation allowance of $9,356 during the year ended December 31, 2022, primarily related to material deferred tax asset write offs from prepaid royalty and equity compensation as well as Norway NOL utilization in the current year.  </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company files income tax returns in Norway, the UK, the US, and various states. The Company is subject to examination by federal, state and foreign jurisdictions. The Company&#8217;s tax years in the US are open under statute from inception to present. All open years may be examined to the extent that tax credits or net operating loss carry forwards are used in future periods. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s policy is to record interest and penalties related to uncertain tax positions in income tax expense.  As of December 31, 2022, the Company had no accrued interest or penalties related to uncertain tax positions and no amounts have been recognized in the Company&#8217;s statement of operations. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (CARES Act) was enacted into law in response to the COVID-19 pandemic. The CARES Act contains income tax provisions, such an enhanced interest deductibility, repeal of the 80% limitation with respect to net operating losses arising in taxable years 2018-2020, and additional depreciation deductions related to qualified improvement property. The Company has concluded the analysis of these provisions as of year-end and the CARES Act did not have a material impact on the Company&#8217;s income taxes for 2021.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 27, 2020, the Consolidated Appropriations Act, 2021 (CAA) was signed into law. Along with providing funding for normal government operations ($1.4 trillion), this bill provides for additional COVID-19 focused relief ($900 billion). The CAA extends certain provisions of the CARES Act, provides additional funding for others and contains new relief provisions. The CAA did not have a material impact on the Company&#8217;s income taxes for 2021.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 16, 2022, the Inflation Reduction Act of 2022 was enacted into law containing corporate income tax provisions such as the corporate alternative minimum tax and an excise tax on the repurchase of corporate stock. These provisions are not expected to have a material impact on the Company's income taxes in the near term.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140455324070544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of presentation</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of presentation</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements have been prepared in conformity with US generally accepted accounting principles (GAAP). Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification (ASC) and Accounting Standards Updates (ASU) of the Financial Accounting Standards Board (FASB).</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of consolidation</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of consolidation</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of OptiNose,&#160;Inc. and its wholly-owned subsidiaries, OptiNose US,&#160;Inc., OptiNose AS and OptiNose UK&#160;Ltd. All inter-company balances and transactions have been eliminated in consolidation.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of estimates</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of estimates</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and reported amounts of expenses during the reporting period. Due to the uncertainty of factors surrounding the estimates or judgments used in the preparation of the consolidated financial statements, actual results may materially vary from these estimates. Estimates and assumptions are periodically reviewed and the effects of revisions are reflected in the consolidated financial statements in the period they are determined to be necessary.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of credit risk</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of credit risk</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to concentrations of credit risk are primarily cash and accounts receivable. The Company generally invests its cash in deposits with high credit quality financial institutions. Additionally, the Company performs periodic evaluations of the relative credit standing of these financial institutions.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Customer and supplier concentration</span></div>The Company has exposure to credit risk in accounts receivable from sales of product. XHANCE is sold to wholesale pharmaceutical distributors and preferred pharmacy network (PPN) partners, who, in turn, sell XHANCE to pharmacies, hospitals and other customers.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and cash equivalents</a></td>
<td class="text">Cash and cash equivalentsAll highly liquid investments purchased with an original maturity date of three months or less at the date of purchase are considered to be cash equivalents. The Company maintains its cash and cash equivalent balances at foreign and domestic financial institutions.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair value of financial instruments</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair value of financial instruments</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures certain assets and liabilities at fair value, which is defined as the price that would be received to sell an asset or paid to transfer a liability (the exit price) in an orderly transaction between market participants at the measurement date. The FASB accounting guidance outlines a valuation framework and creates a fair value hierarchy in order to increase the consistency and comparability of fair value measurements and the related disclosures. In determining fair value, the Company uses quoted prices and observable inputs. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from independent sources. The fair value hierarchy is broken down into three levels based on the source of the inputs as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;1&#160;&#8212; Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;2&#160;&#8212; Valuations based on observable inputs (other than Level&#160;1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;3&#160;&#8212; Valuations based on inputs that are unobservable and models that are significant to the overall fair value measurement.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">At December 31, 2022 and 2021, the Company's financial instruments included cash and cash equivalents, accounts receivable, grants receivable, accounts payable, accrued expenses and certain liability classified warrants. The carrying amounts reported in the Company's financial statements for cash and cash equivalents, accounts receivable, grants receivable, accounts payable and accrued expenses approximates their respective fair values because of the short-term nature of these instruments. In addition, at December 31, 2022, the Company believed </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">the carrying value of debt approximates fair value as the interest rates were reflective of the rate the Company could obtain on debt with similar terms and conditions. At December 31, 2022 and 2021, there were no financial assets or liabilities measured at fair value on a recurring basis other than the liability classified warrants shown below.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2022, the Company issued warrants in connection with the a public offering. Pursuant to the terms of the warrant agreement, the Company could be required to settle the warrants in cash in the event of an acquisition of the Company and, as a result, the warrants are required to be measured at fair value and reported as liability in the consolidated balance sheet. The Company recorded the fair value of the warrants upon issuance using a Monte Carlo simulation and is required to revalue the warrants at each reporting date with any changes in fair value recorded on our statement of operations. The valuation of the warrants is considered under Level 3 of the fair value hierarchy due to the need to use assumptions in the valuation that are both significant to the fair value measurement and unobservable. The change in the fair value of the Level 3 warrants liabilities is reflected in the statement of operations for the years ended December 31, 2022.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Accounts receivable</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts receivable</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable primarily relates to amounts due from customers, which are typically due within 31 to 61 days. The Company analyzes accounts that are past due for collectability. There was no allowance for doubtful accounts related to customers subject to credit risk at December 31, 2022. The Company recognized an allowance for doubtful accounts related to customers subject to credit risk of $444 at December 31, 2021. The accounts receivable balance at December 31, 2021 on the accompanying balance sheet is net of the allowance.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory</a></td>
<td class="text">Inventory Inventories are stated at the lower of cost or net realizable value. Costs of inventories, which include amounts related to materials and manufacturing overhead, are determined on a first-in, first-out basis. An assessment of the recoverability of capitalized inventory is performed during each reporting period and any excess and obsolete inventories are written down to their estimated net realizable value in the period in which the impairment is first identified.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and equipment</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and equipment</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment is recorded at cost less accumulated depreciation. Significant additions or improvements are capitalized and expenditures for repairs and maintenance are charged to expense as incurred. Gains and losses on disposal of assets are included in the consolidated statements of operations. Depreciation is calculated on a straight-line basis over the estimated useful lives of the respective assets.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated useful lives of property and equipment are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:54.031%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.457%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.603%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.603%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.607%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="21" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2-3 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Software</span></td><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Machinery &amp; production equipment</span></td><td colspan="21" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5-10 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Furniture &amp; fixtures</span></td><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3-5 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="21" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shorter of lease term or useful life</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Long lived assets</a></td>
<td class="text">Long lived assetsLong-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future net cash flows expected to be generated. Impairment charges are recognized at the amount by which the carrying amount of an asset exceeds the fair value of the asset. Assets to be disposed of are reported at the lower of the carrying amount or the fair value less costs to sell.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text">Leases <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the terms of the arrangement. The Company accounts for a contract as a lease when it has the right to control the asset for a period of time while obtaining substantially all of the asset&#8217;s economic benefits. The Company determines the initial classification and measurement of its operating right-of-use (&#8220;ROU&#8221;) assets and operating lease liabilities at the lease commencement date, and thereafter if modified.  The lease term includes any renewal options that the Company is reasonably assured to exercise. The Company&#8217;s policy is to not record leases with a lease term of 12 months or less on its balance sheets. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The ROU asset represents the right to use the leased asset for the lease term. The lease liability represents the present value of the lease payments under the lease. The present value of lease payments is determined by using the interest rate implicit in the lease, if that rate is readily determinable; otherwise, the Company uses its estimated secured incremental borrowing rate for that lease term.  Lease expense for operating leases is recognized on a straight-line basis over the reasonably assured lease term based on the total lease payments and is included in operating expense in the statements of operations. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Payments due under each lease agreement include fixed and variable payments. Variable payments relate to the Company&#8217;s share of the lessor&#8217;s operating costs associated with the underlying asset and are recognized when the event on which those payments are assessed occurs. Variable payments have been excluded from the lease liability and associated right-of-use asset. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:103%">The interest rate implicit in lease agreements is typically not readily determinable, and as such, the Company utilizes the incremental borrowing rate to calculate lease liabilities, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Net product revenues and licensing revenues</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net product revenues</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for revenue in accordance with ASC Topic 606, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ASC 606), which was adopted on January 1, 2018. The Company performs the following five steps to recognize revenue under ASC 606: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only recognizes revenue when it is probable that it will collect the consideration to which it is entitled in exchange for the goods or services that will be transferred to the customer. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company sells XHANCE to preferred pharmacy network partners and wholesalers in the US (collectively, Customers). These Customers subsequently resell the Company&#8217;s products to healthcare providers, patients and other retail pharmacies. In addition to agreements with Customers, the Company enters into arrangements with healthcare providers and payors that provide for government-mandated and/or privately-negotiated rebates, chargebacks and discounts for the purchase of the Company&#8217;s products.  </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue from XHANCE sales at the point Customers obtain control of the product, which generally occurs upon delivery. The transaction price that is recognized as revenue for products includes an estimate of variable consideration which is described below. Payment terms with Customers do not exceed one year and, therefore, the Company does not account for a financing component in its arrangements. The Company expenses incremental costs of obtaining a contract with a Customer (for example, sales commissions) when incurred as the period of benefit is less than one year. Shipping and handling costs for product shipments to Customers are recorded as selling, general and administrative expenses.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Transaction Price, including Estimates of Variable Consideration</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from products is recognized at the estimated net sales price (transaction price), which includes estimates of variable consideration. The Company includes estimated amounts in the transaction price to the extent it is determined probable that a significant reversal of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is resolved. The Company&#8217;s estimates of variable consideration and determination of whether to include estimated amounts in the transaction price are based largely on an assessment </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of its anticipated performance and all information (historical, current and forecasted) that is reasonably available.  The components of the Company's variable consideration include the following:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline">Provider Chargebacks and Discounts.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chargebacks for fees and discounts to providers represent the estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list prices charged to Customers who directly purchase the product from the Company.&#160;Customers charge the Company for the difference between what they pay for the product and the ultimate selling price to the qualified healthcare providers.&#160;These components of variable consideration are established in the same period that the related revenue is recognized, resulting in a reduction of product revenue and accounts receivable.&#160;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt;text-decoration:underline">Trade Discounts and Allowances.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  The Company generally provides Customers with discounts that include incentive fees which are explicitly stated in the Company&#8217;s contracts. These discounts are recorded as a reduction of revenue and accounts receivable in the period in which the related product revenue is recognized. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt;text-decoration:underline">Product Returns.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Consistent with industry practice, the Company has a product returns policy that provides Customers a right of return for product purchased within a specified period prior to and subsequent to the product&#8217;s expiration date. The Company estimates the amount of its products that may be returned and presents this amount as a reduction of revenue in the period the related product revenue is recognized, in addition to establishing a current liability. The Company considers several factors in the estimation process, including expiration dates of product shipped to Customers, inventory levels within the distribution channel, product shelf life, prescription trends and other relevant factors.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt;text-decoration:underline">Government Rebates</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The Company is subject to discount obligations under state Medicaid programs and Medicare. Reserves related to these discount obligations are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability. The Company&#8217;s liability for these rebates consists of estimates of claims for the current reporting period and estimated future claims that will be made for product that has been recognized as revenue but remains in the distribution channel inventories at the end of the reporting period.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt;text-decoration:underline">Payor Rebates.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  The Company contracts with certain third-party payors, primarily health insurance companies and pharmacy benefit managers, for the payment of rebates with respect to utilization of its products. These rebates are based on contractual percentages applied to the amount of product prescribed to patients who are covered by the plan or the organization with which it contracts. The Company estimates these rebates and records such estimates in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt;text-decoration:underline">Patient Assistance.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Other programs that the Company offers include voluntary co-pay patient assistance programs intended to provide financial assistance to eligible patients with prescription drug co-payments required by payors and coupon programs for cash payors.&#160;The calculation of the current liability for this assistance is based on an estimate of claims and the cost per claim that the Company expects to receive associated with product that has been recognized as revenue but remains in the distribution channel inventories at the end of each reporting period.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt;text-decoration:underline">Distribution and Other Fees</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We pay distribution and other fees to certain customers in connection with the sales of our products. We record distribution and other fees paid to our customers as a reduction of revenue, unless the payment is for a distinct good or service from the customer and we can reasonably estimate the fair value of the goods or services received. If both conditions are met, we record the consideration paid to the customer as an operating expense. These costs are typically known at the time of sale, resulting in minimal adjustments subsequent to the period of sale.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Licensing Revenues</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a license agreement with Currax Pharmaceuticals LLC (Currax) (</span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i451bcb3eabba4f87bdc579718207a3b8_160" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note </a><a href="#i451bcb3eabba4f87bdc579718207a3b8_160" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">9</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). This license agreement provides for exclusive licensed rights to certain intellectual property, a non-refundable up-front payment, potential </span></div>milestone payment(s) and potential royalty payment(s). The Company analyzed the performance obligations under the license agreement, the consideration received to date and the consideration the Company could receive in the future as part of its analysis related to ASC 606.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvertisingCostsPolicyTextBlock', window );">Advertising expenses</a></td>
<td class="text">Advertising expensesThe Company expenses the costs of advertising, including promotional expenses, as incurred.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and development</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and development</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred. Research and development costs consist primarily of device development, clinical trial related costs and regulatory related costs. The Company enters into agreements with contract research organizations (CROs) to facilitate, coordinate and perform agreed upon research and development activities for the Company's clinical trials. These CRO contracts typically call for the payment of fees for services at the initiation of the contract and/or upon the achievement of certain clinical trial milestones. The Company prepays certain CRO fees whereby the prepayments are recorded as a current or non-current prepaid asset and are amortized into research and development expense over the period of time the contracted research and development services were performed. The Company's CRO contracts generally also include other fees such as project management and pass through fees whereby the Company expenses these costs as incurred, using the Company's best estimate. Pass through fees include, but are not limited to, regulatory expenses, investigator fees, travel costs, and other miscellaneous costs. Pass through fees incurred are based on the amount of work completed for the clinical trials and are monitored through reporting provided by the Company's CROs.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-based compensation</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-based compensation</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures and recognizes compensation expense for all stock options and restricted stock units (RSUs) awarded to employees and non-employees and shares issued under the employee stock purchase plan based on the estimated fair value of the awards on the respective grant dates. The Company uses the Black-Scholes option pricing model to value its time-based and performance-based stock options and shares issued under the employee stock purchase plan. The Company uses a Monte Carlo simulation to value its market-based stock options.  RSUs are valued at the fair market value per share of the Company's common stock on the date of grant. The Company recognizes compensation expense for time-based awards on a straight-line basis over the requisite service period, which is generally the vesting period of the award. The Company recognizes compensation expense for performance-based awards when the performance condition is probable of achievement. The Company recognizes compensation expense for market-based awards over the derived service period, estimated at the time of the grant. The Company recognizes expense for The Company accounts for forfeitures of stock option awards as they occur.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimating the fair value of options and shares issued under the employee stock purchase plan requires the input of subjective assumptions, including the estimated fair value of the Company's common stock, the expected life of the options, stock price volatility, the risk-free interest rate and expected dividends. The assumptions used in the Company's Black-Scholes option-pricing model and Monte Carlo simulation represent management's best estimates and involve a number of variables, uncertainties and assumptions and the application of management's judgment, as they are inherently subjective.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income taxes</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income taxes</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes are accounted for under the asset and liability method. The Company recognizes deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of the Company's assets and liabilities and the expected benefits of net operating loss carryforwards. The impact of changes in tax rates and laws on deferred taxes, if any, applied during the period in which temporary differences are expected to be settled, is reflected in the Company's financial statements in the period of enactment. The measurement of deferred tax assets is reduced, if necessary, if, based on the weight of the evidence, it is more likely than not that some, or </span></div>all, of the deferred tax assets will not be realized. As of December 31, 2022 and 2021, the Company concluded that a full valuation allowance was necessary for all of its net deferred tax assets. The Company had no amounts recorded for uncertain tax positions, interest or penalties in the accompanying consolidated financial statements.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net income (loss) per common share</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net income (loss) per common share</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net income (loss) per common share is determined by dividing net income (loss) applicable to common stockholders by the weighted average common shares outstanding during the period. For the years ended December 31, 2022 and 2021, outstanding common stock options and common stock warrants have been excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive. Therefore, the weighted average shares used to calculate both basic and diluted net loss per share are the same.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent accounting pronouncements</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent accounting pronouncements</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, the FASB issued ASU No. 2022-02, Financial Instruments - Credit Losses (Topic 326): Troubled Debt Restructurings and Vintage Disclosures. Since the issuance of ASU No. 2016-13, Financial Instruments&#8212;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, the Board has provided resources to monitor and assist stakeholders with the implementation of Topic 326. Post-Implementation Review (PIR) activities have included forming a Credit Losses Transition Resource Group, conducting outreach with stakeholders of all types, developing educational materials and staff question-and-answer guidance, conducting educational workshops, and performing an archival review of financial reports. ASU No. 2022-02 is intended to respond to feedback received during the PIR process. The new standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2022, with early adoption permitted. The Company does not expect ASU No. 2022-02 to have a significant impact on its results of operations, financial position and cash flows and related disclosures.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">Fair Value Measurements<div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Assets and Liabilities Measured at Fair Value on a Recurring Basis</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company applies the guidance in ASC 820, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to account for financial assets and liabilities measured on a recurring basis. Fair value is measured as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that is determined based on assumptions that market participants would use in pricing an asset or liability.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses a fair value hierarchy, which distinguishes between assumptions based on market data (observable inputs) and an entity's own assumptions (unobservable inputs). The guidance requires that fair value measurements be classified and disclosed in one of the following 3 categories:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level l: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2: Quoted prices in markets that are not active or inputs which are observable, either directly or indirectly, for substantially the full te1m of the asset or liability; and</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span><br/></span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Determining which category an asset or liability falls within the hierarchy requires significant judgment. The Company evaluates its hierarchy disclosures each reporting period. There were no transfers between Level I, 2 and 3 during the years ended December 31, 2022 and December 31, 2021.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for advertising cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941378&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13279-108611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI https://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 330<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6471895&amp;loc=d3e55923-109411<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126900757&amp;loc=d3e543-108305<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI https://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -URI https://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e4975-111524<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5212-111524<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=SL6953423-111524<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5093-111524<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5033-111524<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140455411702624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment Useful Lives</a></td>
<td class="text"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated useful lives of property and equipment are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:54.031%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.457%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.603%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.603%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.607%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="21" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2-3 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Software</span></td><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Machinery &amp; production equipment</span></td><td colspan="21" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5-10 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Furniture &amp; fixtures</span></td><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3-5 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="21" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shorter of lease term or useful life</span></td></tr></table><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net, consisted of:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.607%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.329%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,203&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,173&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">366&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">366&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,067&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,367&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">609&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">609&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Construction in process</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,360&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,630&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,565)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,283)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">795&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,347&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Shares Excluded from Earnings Per Share</a></td>
<td class="text"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Diluted net loss per common share for the periods presented does not reflect the following potential common shares, as the effect would be antidilutive:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.092%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.576%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,364,070&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,958,781&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,477,660&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,959,358&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,768,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,500,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43,609,730&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,418,139&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140455325717840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Schedule of Fair Value, Assets Measured on Recurring Basis</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents the liabilities (in thousands) measured and recorded in the financial statements at fair value on a recurring basis at December 31, 2022 categorized by the level of inputs used in the valuation of each liability.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:44.635%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.252%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.417%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.252%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.417%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.252%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.417%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.258%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Warrant Liability</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,490&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,490&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total Liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,490&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,490&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock', window );">Schedule of Fair Value, Liabilities Measured on Recurring Basis</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents the liabilities (in thousands) measured and recorded in the financial statements at fair value on a recurring basis at December 31, 2022 categorized by the level of inputs used in the valuation of each liability.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:44.635%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.252%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.417%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.252%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.417%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.252%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.417%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.258%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Warrant Liability</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,490&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,490&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total Liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,490&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,490&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of Fair Value, Liabilities Measured on Recurring Basis, Unobservable Inputs Reconciliation</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliation of the Company's warrant liability measured at fair value on a recurring basis using unobservable inputs (Level 3) is as follows (in thousands):</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:86.528%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.272%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Warrant Liability</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance, December 31, 2021</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Warrants issued</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,279&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzY1L2ZyYWc6MzgyNzViMTRmNmU2NDY1ZjlmNDQ0MmU4MzkxYzE5Y2IvdGFibGU6NWM3ZDZiYjczNjFkNDc5M2E4MTIxMjhkOWM4MWIzZDMvdGFibGVyYW5nZTo1YzdkNmJiNzM2MWQ0NzkzYTgxMjEyOGQ5YzgxYjNkM180LTAtMS0xLTExMDU2NQ_cf1ef344-6e8b-4404-9fc4-62d43ef2dafc">Change in fair value of liability</span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,211&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance, December 31, 2022</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,490&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of Significant Unobservable Inputs in Valuation of Warrants</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.182%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">November 23, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock price</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.77&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.85&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Strike price</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected life (years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.00</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.90</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value per warrant</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.67&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.71&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140455328326240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory</a></td>
<td class="text"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory consisted of the following: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:72.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.271%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.420%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.272%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,691&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,504&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,010&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,816&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,742&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,527&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total inventory</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,443&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,847&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140455328476736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment, Net</a></td>
<td class="text"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated useful lives of property and equipment are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:54.031%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.457%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.603%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.603%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.607%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="21" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2-3 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Software</span></td><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Machinery &amp; production equipment</span></td><td colspan="21" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5-10 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Furniture &amp; fixtures</span></td><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3-5 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="21" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shorter of lease term or useful life</span></td></tr></table><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net, consisted of:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.607%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.329%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,203&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,173&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">366&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">366&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,067&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,367&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">609&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">609&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Construction in process</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,360&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,630&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,565)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,283)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">795&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,347&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140455329341616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_optn_AssetsAndLiabilitiesLesseeTableTextBlock', window );">Schedule of Lease Assets, Liabilities, Term and Discount Rate</a></td>
<td class="text"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents the operating lease assets and liabilities recognized on the Company's consolidated balance sheets:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.063%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:33.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.689%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.963%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance Sheet Line Item</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-current operating lease assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNTEvZnJhZzoyNzE1YjlkZmFkYWQ0MzJmODM0NjNlNTc4MDU5NjVkNS90YWJsZTplNmRjNTY4MzJmZTU0MjZlODE2Nzg1Yzg1OWM5ZWExMC90YWJsZXJhbmdlOmU2ZGM1NjgzMmZlNTQyNmU4MTY3ODVjODU5YzllYTEwXzEtMi0xLTEtNTgzNzI_24ba613c-7389-4e11-9675-21345271c945"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNTEvZnJhZzoyNzE1YjlkZmFkYWQ0MzJmODM0NjNlNTc4MDU5NjVkNS90YWJsZTplNmRjNTY4MzJmZTU0MjZlODE2Nzg1Yzg1OWM5ZWExMC90YWJsZXJhbmdlOmU2ZGM1NjgzMmZlNTQyNmU4MTY3ODVjODU5YzllYTEwXzEtMi0xLTEtNTgzNzI_68a7407f-9d3d-42c1-b7e8-60a846da90dd">Other assets</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,445&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,051&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Current operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNTEvZnJhZzoyNzE1YjlkZmFkYWQ0MzJmODM0NjNlNTc4MDU5NjVkNS90YWJsZTplNmRjNTY4MzJmZTU0MjZlODE2Nzg1Yzg1OWM5ZWExMC90YWJsZXJhbmdlOmU2ZGM1NjgzMmZlNTQyNmU4MTY3ODVjODU5YzllYTEwXzMtMi0xLTEtNTgzNzI_81e615e1-5430-4b3f-a024-d8c112dd845e"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNTEvZnJhZzoyNzE1YjlkZmFkYWQ0MzJmODM0NjNlNTc4MDU5NjVkNS90YWJsZTplNmRjNTY4MzJmZTU0MjZlODE2Nzg1Yzg1OWM5ZWExMC90YWJsZXJhbmdlOmU2ZGM1NjgzMmZlNTQyNmU4MTY3ODVjODU5YzllYTEwXzMtMi0xLTEtNTgzNzI_c6470abf-49c1-414a-9b43-5932ca6cb8de">Accrued expenses and other current liabilities</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,971&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,094&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Non-current operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNTEvZnJhZzoyNzE1YjlkZmFkYWQ0MzJmODM0NjNlNTc4MDU5NjVkNS90YWJsZTplNmRjNTY4MzJmZTU0MjZlODE2Nzg1Yzg1OWM5ZWExMC90YWJsZXJhbmdlOmU2ZGM1NjgzMmZlNTQyNmU4MTY3ODVjODU5YzllYTEwXzQtMi0xLTEtNTgzNzI_51c56e55-3624-4972-bd9f-e5d6619b61c3"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNTEvZnJhZzoyNzE1YjlkZmFkYWQ0MzJmODM0NjNlNTc4MDU5NjVkNS90YWJsZTplNmRjNTY4MzJmZTU0MjZlODE2Nzg1Yzg1OWM5ZWExMC90YWJsZXJhbmdlOmU2ZGM1NjgzMmZlNTQyNmU4MTY3ODVjODU5YzllYTEwXzQtMi0xLTEtNTgzNzI_f473c9e3-1f7a-40d1-9ce5-a76980ea7120">Other liabilities</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">625&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,190&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Total operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,596&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,284&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's weighted average remaining lease term and weighted average discount rate for operating leases as of December 31, 2022 are:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:79.747%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.323%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average remaining lease term (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.04</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Operating Lease Liability Maturities</a></td>
<td class="text"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below reconciles the undiscounted future minimum lease payments (displayed in aggregate by year) under non-cancelable operating leases with terms of more than one year to the total operating lease liabilities recognized on the consolidated balance sheets as of December 31, 2022:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:80.478%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.592%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,153&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">548&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Total undiscounted future minimum lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,783&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: difference between undiscounted lease payments and discounted operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">187&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Total operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,596&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_optn_AssetsAndLiabilitiesLesseeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Assets And Liabilities, Lessee</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">optn_AssetsAndLiabilitiesLesseeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>optn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140455329293088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses and Other Current Liabilities</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities consisted of:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.022%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.914%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Product revenue allowances</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,993&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,521&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Selling, general and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,799&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,124&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Research and development expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,298&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,857&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Payroll expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,888&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,569&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,915&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,057&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;Total accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42,893&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49,128&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Lease liability</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,971&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,094&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;Total other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,971&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,094&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;Total accrued expenses and other current liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44,864&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51,222&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140455328562800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt, net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Schedule of A&amp;R Note Purchase Agreement and long term balance</a></td>
<td class="text">Pursuant to the A&amp;R Note Purchase Agreement, certain modifications to the affirmative and negative covenants, events of default and other provisions were made, including, without limitation, (i) the requirement for the Company to deliver quarterly and annual financial statements that, commencing with the Company's consolidated financial statements for the year ending December 31, 2023, are not subject to a &#8220;going concern&#8221; statement (the Going Concern Covenant) and (ii) the removal of certain exceptions to the negative covenants which previously permitted the Company to enter into certain transactions without the consent of the holders of the Pharmakon Senior Secured Notes, including permitted acquisitions, swap contracts, convertible bonds and revolving credit facilities. The financial covenants requiring the Company to achieve minimum trailing twelve-month consolidated XHANCE net product sales and royalties were also modified as follows (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"/><td style="width:2.723%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.455%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.332%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.332%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.728%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trailing Twelve-Months Ending</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Requirement Prior to A&amp;R Note Purchase Agreement</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Requirement under the A&amp;R Note Purchase Agreement</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">September 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">March 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$98,750</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">June 30, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,500</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">September 30, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,250</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">December 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">March 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113,750</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$82,500</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">June 30, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,500</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,000</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">September 30, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,500</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">December 31, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,000</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">March 31, 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,000</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">June 30, 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,000</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">September 30, 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125,000</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">December 31, 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130,000</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">March 31, 2026</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135,000</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">June 30, 2026</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140,000</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">September 30, 2026</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145,000</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">December 31, 2026</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150,000</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">March 31, 2027</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155,000</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">June 30, 2027</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160,000</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">September 30, 2027</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165,000</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The debt balance is comprised of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:76.206%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.588%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.117%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.589%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Face amount</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">130,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">130,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Front end fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(666)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(717)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,739)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,165)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Back end fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,980&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">128,575&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">126,418&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21506-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21521-112644<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21538-112644<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140455325728032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_optn_ScheduleOfGrantDateFairValueOfWarrantValuationAssumptionsTableTextBlock', window );">Schedule of Grant Date Fair Value of Warrant, Valuation Assumptions</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The grant date fair value of the 2,500,000 warrants issued in connection with the Pharmakon Senior Secured Notes was estimated at the time of grant using the Black-Scholes option-pricing model using the following weighted average assumptions:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:83.695%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.105%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.87&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">78.25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Annual dividend yield</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.00&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of common stock</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of Warrants Outstanding</a></td>
<td class="text"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, the Company had the following warrants outstanding to purchase shares of Common Stock: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:22.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.847%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.847%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.847%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.931%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercise Price Per Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Expiration Date</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,500,000</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$1.60</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">November 15, 2024</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,268,000</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Liability</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$2.565</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">November 23, 2027</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_optn_ScheduleOfGrantDateFairValueOfWarrantValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Grant Date Fair Value Of Warrant, Valuation Assumptions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">optn_ScheduleOfGrantDateFairValueOfWarrantValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>optn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140455326127344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option Activity</a></td>
<td class="text"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity related to stock option grants to employees and non-employees for the year ended December 31, 2022:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.326%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.770%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>average<br/>exercise price<br/>per share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>average<br/>remaining<br/>contractual life</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,958,781&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.87&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.50</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,473,370&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.88&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(95,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(947,999)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.56&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,025,082)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding at December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,364,070&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.88&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.05</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercisable at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,521,738&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.98&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.55</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Schedule of Restricted Stock Unit Activity</a></td>
<td class="text"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity related to RSUs granted to employees for the year ended December 31, 2022:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:88.227%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.573%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,959,358&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,105,246&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vested and settled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(949,857)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expired/forfeited/canceled</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(637,087)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,477,660&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected to vest at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,477,660&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Allocated Stock-based Compensation Expense</a></td>
<td class="text"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded stock-based compensation expense in the following expense categories of its accompanying consolidated statements of operations for the years ended December 31, 2022 and 2021:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.844%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of product sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">809&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,079&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,033&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,874&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,877&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,003&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Fair Value Options using Black-Scholes Pricing Model</a></td>
<td class="text">The Company calculated the fair value of each option grant and the shares issued under the 2017 Plan on the respective dates of grant using the following weighted average assumptions: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.145%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.387%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2010 A&amp;R Stock Incentive Plan</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2017 Employee Stock Purchase Plan</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk free interest rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.22&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.17&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.08</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.50</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">73.23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">88.13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Annual dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140455411702496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of Income (Loss) Before Income Tax, Domestic and Foreign</a></td>
<td class="text"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes are based on the following book income (loss) before income tax expense:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.151%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.818%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.012%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Domestic operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(72,750)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(78,801)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign operations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,083)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,495)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss before provision for income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(74,833)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(82,296)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax Rate Reconciliation</a></td>
<td class="text"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of income tax expense (benefit) at the US federal statutory income tax rate and the income tax provision in the financial statements is as follows: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.644%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.505%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.994%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.405%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.852%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income tax expense at statutory rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Permanent items</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Foreign rate differential</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Impact of foreign operations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(14.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;State taxes, net of federal benefit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Tax rate changes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Foreign exchange and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Stock based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Prepaid royalty write off</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Change in valuation allowance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(24.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effective income tax rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities</a></td>
<td class="text"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The principal components of the Company&#8217;s deferred tax assets and liabilities are as follows: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"><tr><td style="width:1.0%"/><td style="width:54.241%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.523%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.027%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.432%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.177%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Accrued expenses and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,144&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,712&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Prepaid licensing arrangement</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,441&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Interest expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,304&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,708&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Stock compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,193&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,583&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Lease liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">642&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,081&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Research and development credits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,460&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,461&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Capitalized R&amp;D</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,377&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Net operating losses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">83,376&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">87,324&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Total deferred tax assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">116,496&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">126,310&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Fixed assets, including leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(171)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(210)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Right-to-use asset</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(605)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,024)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Total deferred tax liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(776)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,234)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Less: Valuation allowance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(115,720)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(125,076)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total net deferred tax assets (liabilities)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140455322290320">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Liquidity - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Nov. 23, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 94,244<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 110,502<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_optn_WorkingCapital', window );">Working capital</a></td>
<td class="num">(38,246)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(684,893)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (610,061)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=optn_NotePurchaseAgreementMember', window );">Note Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_optn_DebtInstrumentCovenantCashAndCashEquivalents', window );">Debt covenant, cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Principal balance outstanding</a></td>
<td class="nump">130,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | Note Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_optn_DebtInstrumentCovenantCashAndCashEquivalents', window );">Debt covenant, cash and cash equivalents</a></td>
<td class="nump">$ 30<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_optn_DebtInstrumentCovenantCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Cash And Cash Equivalents</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">optn_DebtInstrumentCovenantCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>optn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_optn_WorkingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Working Capital</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">optn_WorkingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>optn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=optn_NotePurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=optn_NotePurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140455324723792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Concentration risk (Details) - Customer Concentration Risk - Five Customers<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>customer</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_optn_NumberOfCustomers', window );">Number of customers (customer)</a></td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="nump">52.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Sales Revenue, Net</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_optn_NumberOfCustomers', window );">Number of customers (customer)</a></td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="nump">33.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_optn_NumberOfCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Customers</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">optn_NumberOfCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>optn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=optn_FiveCustomersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=optn_FiveCustomersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140455325713632">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Cash and cash equivalents (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashUninsuredAmount', window );">Cash, uninsured amount</a></td>
<td class="nump">$ 92,988<span></span>
</td>
<td class="nump">$ 109,017<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashUninsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashUninsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140455321963680">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Accounts receivable (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Allowance for doubtful accounts</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 444,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140455322299056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Property and equipment (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Software</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery &amp; production equipment | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery &amp; production equipment | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture &amp; fixtures | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture &amp; fixtures | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140455325728032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Long lived assets (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf', window );">Impairment or disposition of long-lived assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2611-110228<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140455325002928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Licensing revenues (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 76,276,000<span></span>
</td>
<td class="nump">$ 74,652,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">Licensing revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140455324773296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Advertising expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvertisingExpense', window );">Advertising expense</a></td>
<td class="nump">$ 16,575<span></span>
</td>
<td class="nump">$ 15,638<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140455322297920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Net income (loss) per common share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Securites excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">43,609,730<span></span>
</td>
<td class="nump">12,418,139<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Securites excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">9,364,070<span></span>
</td>
<td class="nump">7,958,781<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Securites excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">1,477,660<span></span>
</td>
<td class="nump">1,959,358<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Common stock warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Securites excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">32,768,000<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140455322303840">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Fair value, assets and liabilities measured on recurring basis (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure', window );">Warrant Liability</a></td>
<td class="nump">$ 21,490<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total Liabilities</a></td>
<td class="nump">21,490<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure', window );">Warrant Liability</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total Liabilities</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure', window );">Warrant Liability</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total Liabilities</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure', window );">Warrant Liability</a></td>
<td class="nump">21,490<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total Liabilities</a></td>
<td class="nump">$ 21,490<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of warrants not settleable in cash classified as equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsNotSettleableInCashFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140455322309680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Fair value liabilities measured on recurring basis using unobservable inputs (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Warrant Liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance, December 31, 2021</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues', window );">Warrants issued</a></td>
<td class="nump">20,279<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value of liability</a></td>
<td class="nump">1,211<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance, December 31, 2022</a></td>
<td class="nump">$ 21,490<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList', window );">Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]</a></td>
<td class="text">Unrealized Gain (Loss) on Fair Value Of Warrants<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement in which net income is reported that includes gain (loss) from liability measured at fair value using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140455319798160">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Valuation of warrants (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Nov. 23, 2022 </div>
<div>$ / shares</div>
</th>
<th class="th"><div>Nov. 18, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAxis=optn_MonteCarloSimulationMember', window );">Monte Carlo Simulation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Expected life (years)</a></td>
<td class="text">4 years 10 months 24 days<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_optn_FairValueOfWarrant', window );">Fair value per warrant</a></td>
<td class="nump">$ 0.71<span></span>
</td>
<td class="nump">$ 0.67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember', window );">Stock price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants outstanding, measurement input</a></td>
<td class="nump">1.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember', window );">Stock price | Monte Carlo Simulation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants outstanding, measurement input</a></td>
<td class="nump">1.85<span></span>
</td>
<td class="nump">1.77<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=optn_MeasurementInputStrikePriceMember', window );">Strike price | Monte Carlo Simulation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants outstanding, measurement input</a></td>
<td class="nump">2.57<span></span>
</td>
<td class="nump">2.57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants outstanding, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.7825<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Expected volatility | Monte Carlo Simulation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants outstanding, measurement input</a></td>
<td class="nump">0.450<span></span>
</td>
<td class="nump">0.450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Risk free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants outstanding, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0087<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Risk free interest rate | Monte Carlo Simulation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants outstanding, measurement input</a></td>
<td class="nump">0.038<span></span>
</td>
<td class="nump">0.038<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember', window );">Expected dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants outstanding, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember', window );">Expected dividend yield | Monte Carlo Simulation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants outstanding, measurement input</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_optn_FairValueOfWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair Value Of Warrant</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">optn_FairValueOfWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>optn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationTechniqueAxis=optn_MonteCarloSimulationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationTechniqueAxis=optn_MonteCarloSimulationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=optn_MeasurementInputStrikePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=optn_MeasurementInputStrikePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140455330125296">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventory (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw materials</a></td>
<td class="nump">$ 1,691<span></span>
</td>
<td class="nump">$ 3,504<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Work-in-process</a></td>
<td class="nump">5,010<span></span>
</td>
<td class="nump">4,816<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="nump">2,742<span></span>
</td>
<td class="nump">3,527<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Total inventory</a></td>
<td class="nump">$ 9,443<span></span>
</td>
<td class="nump">$ 11,847<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140455325092752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 5,360,000<span></span>
</td>
<td class="nump">$ 5,630,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="num">(4,565,000)<span></span>
</td>
<td class="num">(4,283,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">795,000<span></span>
</td>
<td class="nump">1,347,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">530,000<span></span>
</td>
<td class="nump">645,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=optn_ComputerEquipmentandSoftwareMember', window );">Computer equipment and software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">1,203,000<span></span>
</td>
<td class="nump">1,173,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">366,000<span></span>
</td>
<td class="nump">366,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">3,067,000<span></span>
</td>
<td class="nump">3,367,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">609,000<span></span>
</td>
<td class="nump">609,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in process</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">115,000<span></span>
</td>
<td class="nump">$ 115,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_InventoriesMember', window );">Inventories</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">665,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember', window );">Prepaid Expenses and Other Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=optn_ComputerEquipmentandSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=optn_ComputerEquipmentandSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_InventoriesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_InventoriesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140455324035792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]</a></td>
<td class="text">Other assets<span></span>
</td>
<td class="text">Other assets<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_optn_OperatingLeaseCostForExtension', window );">Option to renew, extension of lease term</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Operating lease costs</a></td>
<td class="nump">2,985,000<span></span>
</td>
<td class="nump">$ 2,843,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for amounts included in the measurement of operating lease liabilities</a></td>
<td class="nump">$ 2,570,000<span></span>
</td>
<td class="nump">$ 2,466,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_optn_OperatingLeaseCostForExtension">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Cost for Extension</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">optn_OperatingLeaseCostForExtension</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>optn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes operating lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140455419439744">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Operating lease assets and liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease assets</a></td>
<td class="nump">$ 2,445<span></span>
</td>
<td class="nump">$ 4,051<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_optn_OperatingLeaseLiabilityAbstractAbstract', window );"><strong>Operating lease liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current operating lease liabilities</a></td>
<td class="nump">1,971<span></span>
</td>
<td class="nump">2,094<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Non-current operating lease liabilities</a></td>
<td class="nump">625<span></span>
</td>
<td class="nump">2,190<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">$ 2,596<span></span>
</td>
<td class="nump">$ 4,284<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]</a></td>
<td class="text">Other assets<span></span>
</td>
<td class="text">Other assets<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]</a></td>
<td class="text">Accrued expenses and other current liabilities<span></span>
</td>
<td class="text">Accrued expenses and other current liabilities<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Statement of Financial Position [Extensible List]</a></td>
<td class="text">Other liabilities<span></span>
</td>
<td class="text">Other liabilities<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_optn_OperatingLeaseLiabilityAbstractAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Liability Abstract</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">optn_OperatingLeaseLiabilityAbstractAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>optn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes noncurrent operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes operating lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140455329875616">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Weighted average remaining lease term and weighted average discount rate (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term (years)</a></td>
<td class="text">2 years 14 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate</a></td>
<td class="nump">5.24%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140455419420480">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Operating lease maturities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Operating leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 2,153<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">548<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_optn_LesseeOperatingLeaseLiabilityPaymentsDueThereafter', window );">Thereafter</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total undiscounted future minimum lease payments</a></td>
<td class="nump">2,783<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: difference between undiscounted lease payments and discounted operating lease liabilities</a></td>
<td class="nump">187<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">$ 2,596<span></span>
</td>
<td class="nump">$ 4,284<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_optn_LesseeOperatingLeaseLiabilityPaymentsDueThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, Payments, Due Thereafter</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">optn_LesseeOperatingLeaseLiabilityPaymentsDueThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>optn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140455326252304">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract', window );"><strong>Accrued expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_optn_AccruedProductAllowancesCurrent', window );">Product revenue allowances</a></td>
<td class="nump">$ 27,993<span></span>
</td>
<td class="nump">$ 26,521<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_optn_AccruedSellingGeneralandAdministrativeCurrent', window );">Selling, general and administrative expenses</a></td>
<td class="nump">3,799<span></span>
</td>
<td class="nump">6,124<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_optn_AccruedResearchandDevelopmentCurrent', window );">Research and development expenses</a></td>
<td class="nump">1,298<span></span>
</td>
<td class="nump">6,857<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedEmployeeBenefitsCurrent', window );">Payroll expenses</a></td>
<td class="nump">7,888<span></span>
</td>
<td class="nump">7,569<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">1,915<span></span>
</td>
<td class="nump">2,057<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses</a></td>
<td class="nump">42,893<span></span>
</td>
<td class="nump">49,128<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrentAbstract', window );"><strong>Other current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liability</a></td>
<td class="nump">1,971<span></span>
</td>
<td class="nump">2,094<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Total other current liabilities</a></td>
<td class="nump">1,971<span></span>
</td>
<td class="nump">2,094<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent', window );">Total accrued expenses and other current liabilities</a></td>
<td class="nump">$ 44,864<span></span>
</td>
<td class="nump">$ 51,222<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_optn_AccruedProductAllowancesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Product Allowances, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">optn_AccruedProductAllowancesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>optn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_optn_AccruedResearchandDevelopmentCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Research and Development, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">optn_AccruedResearchandDevelopmentCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>optn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_optn_AccruedSellingGeneralandAdministrativeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Selling, General and Administrative, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">optn_AccruedSellingGeneralandAdministrativeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>optn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedEmployeeBenefitsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedEmployeeBenefitsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140455330050704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License Agreements (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jan. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_RoyaltyAgreementTermsMember', window );">Royalty Agreement Terms</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_optn_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestonePaymentsMaximumEligible', window );">Sales milestone payments eligible to be received (up to)</a></td>
<td class="nump">$ 1,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_optn_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestonePaymentsMaximumEligible">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research And Development Arrangement, Contract To Perform For Others, Milestone Payments, Maximum Eligible</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">optn_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestonePaymentsMaximumEligible</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>optn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_RoyaltyAgreementTermsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_RoyaltyAgreementTermsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140455319037008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt, net - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 21, 2022</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Nov. 23, 2022</div></th>
<th class="th"><div>Nov. 09, 2022</div></th>
<th class="th"><div>Aug. 10, 2022</div></th>
<th class="th"><div>Aug. 09, 2022</div></th>
<th class="th"><div>Dec. 01, 2020</div></th>
<th class="th"><div>Feb. 13, 2020</div></th>
<th class="th"><div>Sep. 12, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=optn_NotePurchaseAgreementMember', window );">Note Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_optn_FeeDueOnTheMaturityDateOfTheNotePurchaseAgreement', window );">Fee due on the maturity date of the note purchase agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="nump">$ 780,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_optn_DebtInstrumentCovenantCashAndCashEquivalents', window );">Debt covenant, cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | Note Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Debt maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 130,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_optn_TrailingTwelveMonthNetRevenueCovenant', window );">Trailing twelve month net revenue covenant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 85,000,000<span></span>
</td>
<td class="nump">$ 90,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Floor interest rate</a></td>
<td class="nump">8.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_optn_PotentialDebtInstrumentInterestRateIncrease', window );">Increase in interest rate</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_optn_DebtInstrumentMaximumAggregateMakeWholePremiumAmount', window );">Make whole premium payment</a></td>
<td class="nump">$ 24,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_optn_AmendmentFeePercentage', window );">Amendment fee, percentage</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_optn_AmendmentFeePayable', window );">Amendment fee payable</a></td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_optn_DebtInstrumentCovenantCashAndCashEquivalents', window );">Debt covenant, cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,843,000<span></span>
</td>
<td class="nump">$ 15,973,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.62%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | Note Purchase Agreement | SOFR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt term</a></td>
<td class="text">3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | Note Purchase Agreement | SOFR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate</a></td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | Note Purchase Agreement | Debt Instrument, Redemption, Period One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_optn_DebtInstrumentMakeWholeProvisionPaymentAccrualPeriod', window );">Debt instrument, make-whole provision, payment accrual period</a></td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_optn_AmendmentFee', window );">Amendment fee</a></td>
<td class="nump">$ 3,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | Note Purchase Agreement | Debt Instrument, Redemption, Period Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_optn_AmendmentFee', window );">Amendment fee</a></td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | Note Purchase Agreement | Debt Instrument, Redemption, Period Three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_optn_DebtInstrumentMakeWholeProvisionPaymentAccrualPeriod', window );">Debt instrument, make-whole provision, payment accrual period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_optn_AmendmentFee', window );">Amendment fee</a></td>
<td class="nump">$ 2,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | Note Purchase Agreement - First Delayed Draw Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | Note Purchase Agreement - First Delayed Draw Notes | Quarter Ended December 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_optn_DebtInstrumentIssuanceCriteriaTermNetSalesAndRoyaltiesBenchmark', window );">Debt issuance criteria term, net sales and royalties benchmark</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | Note Purchase Agreement - Third Delayed Draw Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | Note Purchase Agreement - Third Delayed Draw Notes | Quarter Ended September 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_optn_DebtInstrumentIssuanceCriteriaTermNetSalesAndRoyaltiesBenchmark', window );">Debt issuance criteria term, net sales and royalties benchmark</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_optn_AmendmentFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amendment Fee</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">optn_AmendmentFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>optn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_optn_AmendmentFeePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amendment Fee Payable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">optn_AmendmentFeePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>optn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_optn_AmendmentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amendment Fee, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">optn_AmendmentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>optn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_optn_DebtInstrumentCovenantCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Cash And Cash Equivalents</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">optn_DebtInstrumentCovenantCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>optn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_optn_DebtInstrumentIssuanceCriteriaTermNetSalesAndRoyaltiesBenchmark">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Issuance Criteria Term, Net Sales And Royalties Benchmark</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">optn_DebtInstrumentIssuanceCriteriaTermNetSalesAndRoyaltiesBenchmark</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>optn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_optn_DebtInstrumentMakeWholeProvisionPaymentAccrualPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Make-Whole Provision, Payment Accrual Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">optn_DebtInstrumentMakeWholeProvisionPaymentAccrualPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>optn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_optn_DebtInstrumentMaximumAggregateMakeWholePremiumAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Maximum Aggregate Make Whole Premium Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">optn_DebtInstrumentMaximumAggregateMakeWholePremiumAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>optn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_optn_FeeDueOnTheMaturityDateOfTheNotePurchaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fee Due On The Maturity Date Of The Note Purchase Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">optn_FeeDueOnTheMaturityDateOfTheNotePurchaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>optn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_optn_PotentialDebtInstrumentInterestRateIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Potential Debt Instrument, Interest Rate, Increase</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">optn_PotentialDebtInstrumentInterestRateIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>optn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_optn_TrailingTwelveMonthNetRevenueCovenant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trailing Twelve Month Net Revenue Covenant</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">optn_TrailingTwelveMonthNetRevenueCovenant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>optn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=optn_NotePurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=optn_NotePurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=optn_SecuredOvernightFinancingRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=optn_SecuredOvernightFinancingRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=optn_NotePurchaseAgreementFirstDelayedDrawNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=optn_NotePurchaseAgreementFirstDelayedDrawNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_optn_MeasurementPeriodAxis=optn_QuarterEndedDecember312019Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">optn_MeasurementPeriodAxis=optn_QuarterEndedDecember312019Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=optn_NotePurchaseAgreementThirdDelayedDrawNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=optn_NotePurchaseAgreementThirdDelayedDrawNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_optn_MeasurementPeriodAxis=optn_QuarterEndedSeptember302020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">optn_MeasurementPeriodAxis=optn_QuarterEndedSeptember302020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140455322813120">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt, net - A&amp;R Note Purchase Agreement (Details) - Senior Notes - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Nov. 21, 2022</div></th>
<th class="th"><div>Nov. 20, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">March 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_optn_NotePurchaseAgreementCovenantXHANCENetProductSalesAndRoyalties', window );">XHANCE net product sales and royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 98,750<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">June 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_optn_NotePurchaseAgreementCovenantXHANCENetProductSalesAndRoyalties', window );">XHANCE net product sales and royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">102,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">September 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_optn_NotePurchaseAgreementCovenantXHANCENetProductSalesAndRoyalties', window );">XHANCE net product sales and royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106,250<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">December 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_optn_NotePurchaseAgreementCovenantXHANCENetProductSalesAndRoyalties', window );">XHANCE net product sales and royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">March 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_optn_NotePurchaseAgreementCovenantXHANCENetProductSalesAndRoyalties', window );">XHANCE net product sales and royalties</a></td>
<td class="nump">$ 82,500<span></span>
</td>
<td class="nump">113,750<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">June 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_optn_NotePurchaseAgreementCovenantXHANCENetProductSalesAndRoyalties', window );">XHANCE net product sales and royalties</a></td>
<td class="nump">90,000<span></span>
</td>
<td class="nump">$ 117,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">September 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_optn_NotePurchaseAgreementCovenantXHANCENetProductSalesAndRoyalties', window );">XHANCE net product sales and royalties</a></td>
<td class="nump">102,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">December 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_optn_NotePurchaseAgreementCovenantXHANCENetProductSalesAndRoyalties', window );">XHANCE net product sales and royalties</a></td>
<td class="nump">110,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">March 31, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_optn_NotePurchaseAgreementCovenantXHANCENetProductSalesAndRoyalties', window );">XHANCE net product sales and royalties</a></td>
<td class="nump">115,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">June 30, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_optn_NotePurchaseAgreementCovenantXHANCENetProductSalesAndRoyalties', window );">XHANCE net product sales and royalties</a></td>
<td class="nump">120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">September 30, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_optn_NotePurchaseAgreementCovenantXHANCENetProductSalesAndRoyalties', window );">XHANCE net product sales and royalties</a></td>
<td class="nump">125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">December 31, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_optn_NotePurchaseAgreementCovenantXHANCENetProductSalesAndRoyalties', window );">XHANCE net product sales and royalties</a></td>
<td class="nump">130,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">March 31, 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_optn_NotePurchaseAgreementCovenantXHANCENetProductSalesAndRoyalties', window );">XHANCE net product sales and royalties</a></td>
<td class="nump">135,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">June 30, 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_optn_NotePurchaseAgreementCovenantXHANCENetProductSalesAndRoyalties', window );">XHANCE net product sales and royalties</a></td>
<td class="nump">140,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">September 30, 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_optn_NotePurchaseAgreementCovenantXHANCENetProductSalesAndRoyalties', window );">XHANCE net product sales and royalties</a></td>
<td class="nump">145,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">December 31, 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_optn_NotePurchaseAgreementCovenantXHANCENetProductSalesAndRoyalties', window );">XHANCE net product sales and royalties</a></td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">March 31, 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_optn_NotePurchaseAgreementCovenantXHANCENetProductSalesAndRoyalties', window );">XHANCE net product sales and royalties</a></td>
<td class="nump">155,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">June 30, 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_optn_NotePurchaseAgreementCovenantXHANCENetProductSalesAndRoyalties', window );">XHANCE net product sales and royalties</a></td>
<td class="nump">160,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">September 30, 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_optn_NotePurchaseAgreementCovenantXHANCENetProductSalesAndRoyalties', window );">XHANCE net product sales and royalties</a></td>
<td class="nump">$ 165,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_optn_NotePurchaseAgreementCovenantXHANCENetProductSalesAndRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Note Purchase Agreement Covenant, XHANCE Net Product Sales And Royalties</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">optn_NotePurchaseAgreementCovenantXHANCENetProductSalesAndRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>optn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_optn_TrailingTwelveMonthEndingAxisAxis=optn_March312023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">optn_TrailingTwelveMonthEndingAxisAxis=optn_March312023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_optn_TrailingTwelveMonthEndingAxisAxis=optn_June302023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">optn_TrailingTwelveMonthEndingAxisAxis=optn_June302023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_optn_TrailingTwelveMonthEndingAxisAxis=optn_September302023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">optn_TrailingTwelveMonthEndingAxisAxis=optn_September302023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_optn_TrailingTwelveMonthEndingAxisAxis=optn_December312023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">optn_TrailingTwelveMonthEndingAxisAxis=optn_December312023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_optn_TrailingTwelveMonthEndingAxisAxis=optn_March312024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">optn_TrailingTwelveMonthEndingAxisAxis=optn_March312024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_optn_TrailingTwelveMonthEndingAxisAxis=optn_June302024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">optn_TrailingTwelveMonthEndingAxisAxis=optn_June302024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_optn_TrailingTwelveMonthEndingAxisAxis=optn_September302024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">optn_TrailingTwelveMonthEndingAxisAxis=optn_September302024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_optn_TrailingTwelveMonthEndingAxisAxis=optn_December312024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">optn_TrailingTwelveMonthEndingAxisAxis=optn_December312024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_optn_TrailingTwelveMonthEndingAxisAxis=optn_March312025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">optn_TrailingTwelveMonthEndingAxisAxis=optn_March312025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_optn_TrailingTwelveMonthEndingAxisAxis=optn_June302025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">optn_TrailingTwelveMonthEndingAxisAxis=optn_June302025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_optn_TrailingTwelveMonthEndingAxisAxis=optn_September302025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">optn_TrailingTwelveMonthEndingAxisAxis=optn_September302025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_optn_TrailingTwelveMonthEndingAxisAxis=optn_December312025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">optn_TrailingTwelveMonthEndingAxisAxis=optn_December312025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_optn_TrailingTwelveMonthEndingAxisAxis=optn_March312026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">optn_TrailingTwelveMonthEndingAxisAxis=optn_March312026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_optn_TrailingTwelveMonthEndingAxisAxis=optn_June302026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">optn_TrailingTwelveMonthEndingAxisAxis=optn_June302026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_optn_TrailingTwelveMonthEndingAxisAxis=optn_September302026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">optn_TrailingTwelveMonthEndingAxisAxis=optn_September302026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_optn_TrailingTwelveMonthEndingAxisAxis=optn_December312026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">optn_TrailingTwelveMonthEndingAxisAxis=optn_December312026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_optn_TrailingTwelveMonthEndingAxisAxis=optn_March312027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">optn_TrailingTwelveMonthEndingAxisAxis=optn_March312027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_optn_TrailingTwelveMonthEndingAxisAxis=optn_June302027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">optn_TrailingTwelveMonthEndingAxisAxis=optn_June302027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_optn_TrailingTwelveMonthEndingAxisAxis=optn_September302027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">optn_TrailingTwelveMonthEndingAxisAxis=optn_September302027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140455318972944">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt, net - Schedule of long term debt (Details) - Senior Notes - Note Purchase Agreement - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Face amount</a></td>
<td class="nump">$ 130,000<span></span>
</td>
<td class="nump">$ 130,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_optn_DebtInstrumentFeeAmountFrontEnd', window );">Front end fees</a></td>
<td class="num">(666)<span></span>
</td>
<td class="num">(717)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnamortizedDebtIssuanceExpense', window );">Debt issuance costs</a></td>
<td class="num">(6,739)<span></span>
</td>
<td class="num">(4,165)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_optn_DebtInstrumentFeeAmountBackEnd', window );">Back end fees</a></td>
<td class="nump">5,980<span></span>
</td>
<td class="nump">1,300<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term Debt</a></td>
<td class="nump">$ 128,575<span></span>
</td>
<td class="nump">$ 126,418<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_optn_DebtInstrumentFeeAmountBackEnd">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Fee Amount, Back End</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">optn_DebtInstrumentFeeAmountBackEnd</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>optn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_optn_DebtInstrumentFeeAmountFrontEnd">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Fee Amount, Front End</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">optn_DebtInstrumentFeeAmountFrontEnd</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>optn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnamortizedDebtIssuanceExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnamortizedDebtIssuanceExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=optn_NotePurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=optn_NotePurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140455319749904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanDisclosureLineItems', window );"><strong>Defined Contribution Plan Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent', window );">Maximum annual contributions per employee</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued expenses related to the Company match</a></td>
<td class="nump">$ 256<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Defined contribution plan, cost</a></td>
<td class="nump">1,112<span></span>
</td>
<td class="nump">$ 1,340<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">Foreign Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanDisclosureLineItems', window );"><strong>Defined Contribution Plan Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Defined contribution plan, cost</a></td>
<td class="nump">$ 11<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_optn_DefinedContributionPlanTranchesAxisAxis=optn_DefinedContributionPlanTrancheOneMember', window );">Defined Contribution Plan, Tranche One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanDisclosureLineItems', window );"><strong>Defined Contribution Plan Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent', window );">Maximum annual contributions per employee</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Employer matching contribution</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_optn_DefinedContributionPlanTranchesAxisAxis=optn_DefinedContributionPlanTrancheTwoMember', window );">Defined Contribution Plan, Tranche Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanDisclosureLineItems', window );"><strong>Defined Contribution Plan Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent', window );">Maximum annual contributions per employee</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Employer matching contribution</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage employer matches of the employee's percentage contribution matched.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_optn_DefinedContributionPlanTranchesAxisAxis=optn_DefinedContributionPlanTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">optn_DefinedContributionPlanTranchesAxisAxis=optn_DefinedContributionPlanTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_optn_DefinedContributionPlanTranchesAxisAxis=optn_DefinedContributionPlanTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">optn_DefinedContributionPlanTranchesAxisAxis=optn_DefinedContributionPlanTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140455411846336">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseObligation', window );">Purchase obligation</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140455322342656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Narrative (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Nov. 23, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 18, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>vote </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>vote </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Nov. 21, 2022 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_optn_VotePerShare', window );">Vote per share | vote</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareDeclared', window );">Dividends declared (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_optn_ClassOfWarrantOrRightRestrictionCommonSharesMaximumOwnershipIfExercisedPercent', window );">Class of warrant or right restriction, common shares maximum ownership If exercised, percent</a></td>
<td class="nump">4.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_optn_ClassOfWarrantOrRightRestrictionCommonSharesMaximumOwnershipPriorToExecutionPercent', window );">Class of warrant or right restriction, common shares maximum ownership prior to execution, percent</a></td>
<td class="nump">9.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_optn_ClassOfWarrantOrRightRestrictionCommonSharesMaximumOwnershipAfterEffectiveWaitingPeriodPercent', window );">Class of warrant or right restriction, common shares maximum ownership after effective waiting period, percent</a></td>
<td class="nump">19.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Common stock warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Price per share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.565<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=optn_WarrantsExpiringNovember182024Member', window );">Warrants Expiring November 18, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Common stock warrant exercise price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares called by warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrants and rights outstanding | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,009<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=optn_WarrantsExpiringSeptember122022Member', window );">Warrants Expiring September 12, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Common stock warrant exercise price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares called by warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">810,357<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=optn_PublicOfferingMember', window );">Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Price per share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Consideration received on transaction | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42,842<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_optn_SaleOfStockCommissionsAndExpenses', window );">Commissions | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,860<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Deferred offering costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 298<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=optn_PublicOfferingMember', window );">Public Offering | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued (in shares)</a></td>
<td class="nump">26,320,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Price per share (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 1.89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=optn_PublicOfferingMember', window );">Public Offering | Common Stock | Underwriters</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued (in shares)</a></td>
<td class="nump">3,948,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,541,299<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Consideration received on transaction | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 49,296<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_optn_SaleOfStockCommissionsAndExpenses', window );">Commissions | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,238<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Deferred offering costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 359<span></span>
</td>
<td class="nump">$ 359<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares called by warrants (in shares)</a></td>
<td class="nump">3,948,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=optn_PublicOfferingMember', window );">Public Offering | Common stock warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued (in shares)</a></td>
<td class="nump">30,268,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Common stock warrant exercise price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares called by warrants (in shares)</a></td>
<td class="nump">26,320,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_optn_ClassOfWarrantOrRightRestrictionCommonSharesMaximumOwnershipAfterEffectiveWaitingPeriodPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right Restriction, Common Shares Maximum Ownership After Effective Waiting Period, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">optn_ClassOfWarrantOrRightRestrictionCommonSharesMaximumOwnershipAfterEffectiveWaitingPeriodPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>optn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_optn_ClassOfWarrantOrRightRestrictionCommonSharesMaximumOwnershipIfExercisedPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right Restriction, Common Shares Maximum Ownership If Exercised, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">optn_ClassOfWarrantOrRightRestrictionCommonSharesMaximumOwnershipIfExercisedPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>optn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_optn_ClassOfWarrantOrRightRestrictionCommonSharesMaximumOwnershipPriorToExecutionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right Restriction, Common Shares Maximum Ownership Prior To Execution, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">optn_ClassOfWarrantOrRightRestrictionCommonSharesMaximumOwnershipPriorToExecutionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>optn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_optn_SaleOfStockCommissionsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock, Commissions And Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">optn_SaleOfStockCommissionsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>optn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_optn_VotePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Vote Per Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">optn_VotePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>optn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareDeclared">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends declared during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareDeclared</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.A)<br> -URI https://asc.fasb.org/extlink&amp;oid=122040515&amp;loc=d3e105025-122735<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=optn_WarrantsExpiringNovember182024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=optn_WarrantsExpiringNovember182024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=optn_WarrantsExpiringSeptember122022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=optn_WarrantsExpiringSeptember122022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=optn_PublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=optn_PublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=optn_UnderwritersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=optn_UnderwritersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140455322265648">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' Equity - Grant date fair value of warrants, valuation assumptions (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Nov. 18, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Risk free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants outstanding, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0087<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Expected term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants outstanding, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants outstanding, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.7825<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember', window );">Annual dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants outstanding, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember', window );">Fair value of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants outstanding, measurement input</a></td>
<td class="nump">1.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140455329642400">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' Equity - Warrants Outstanding (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=optn_WarrantsExpiringNovember152024Member', window );">Warrants Expiring November 15, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of warrants outstanding (in shares) | shares</a></td>
<td class="nump">2,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Common stock warrant exercise price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 1.60<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=optn_WarrantsExpiringNovember232027Member', window );">Warrants Expiring November 23, 2027</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of warrants outstanding (in shares) | shares</a></td>
<td class="nump">30,268,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Common stock warrant exercise price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 2.565<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=optn_WarrantsExpiringNovember152024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=optn_WarrantsExpiringNovember152024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=optn_WarrantsExpiringNovember232027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=optn_WarrantsExpiringNovember232027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140455322050912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">3,473,370<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 8,877<span></span>
</td>
<td class="nump">$ 10,003<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent', window );">Maximum annual contributions per employee</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_InventoriesMember', window );">Inventories</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=optn_ServiceBasedStockOptionsMember', window );">Service Based Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Fair value of common stock (in dollars per share)</a></td>
<td class="nump">$ 1.21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value of exercised options</a></td>
<td class="nump">$ 111<span></span>
</td>
<td class="nump">35<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Intrinsic value of options outstanding</a></td>
<td class="nump">81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Intrinsic value of exercisable options</a></td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation cost</a></td>
<td class="nump">$ 4,368<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation, estimated weighted-average amortization period</a></td>
<td class="text">2 years 4 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Shares issued (in shares)</a></td>
<td class="nump">1,105,246<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Price issued (in dollars per share)</a></td>
<td class="nump">$ 1.85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 1,669<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=optn_RestrictedStockUnitsPerformanceBasedMember', window );">Restricted Stock Units, Performance-Based</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation cost</a></td>
<td class="nump">942<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=optn_RestrictedStockUnitsServiceBasedMember', window );">Restricted Stock Units, Service-Based</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation cost</a></td>
<td class="nump">$ 3,123<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation, estimated weighted-average amortization period</a></td>
<td class="text">2 years 2 months 26 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=optn_MarketBasedStockOptionsMember', window );">Market Based Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">959,215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Shares vested (in shares)</a></td>
<td class="nump">297,677<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=optn_AmendedandRestated2010StockIncentivePlanMember', window );">Amended and Restated Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized under plan (shares)</a></td>
<td class="nump">17,299,284<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of shares reserved for future issuance under plan (shares)</a></td>
<td class="nump">3,607,066<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_optn_CommonStockCapitalSharesReservedforFutureIssuanceYearlyIncrease', window );">Yearly increase in shares reserved for future issuance</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Plan options contractual life</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=optn_NASDAQInducementGrantExceptionMember', window );">NASDAQ Inducement Grant Exception | Service Based Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">753,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=optn_NASDAQInducementGrantExceptionMember', window );">NASDAQ Inducement Grant Exception | Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Shares issued (in shares)</a></td>
<td class="nump">60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=optn_TwoThousandSeventeenEmployeeStockPurchasePlanMember', window );">2017 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized under plan (shares)</a></td>
<td class="nump">2,021,813<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of shares reserved for future issuance under plan (shares)</a></td>
<td class="nump">982,989<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 253<span></span>
</td>
<td class="nump">$ 402<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_optn_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedIncrementEachYear', window );">Increase in number of shares issuable each year</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent', window );">Maximum annual contributions per employee</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_optn_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeAccruedRightsToPurchaseCommonStock', window );">Maximum employee accrued rights to purchase common stock (in dollars per share)</a></td>
<td class="nump">$ 25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Purchase price of common stock percent</a></td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_optn_CommonStockCapitalSharesReservedforFutureIssuanceYearlyIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Capital Shares Reserved for Future Issuance, Yearly Increase</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">optn_CommonStockCapitalSharesReservedforFutureIssuanceYearlyIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>optn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_optn_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeAccruedRightsToPurchaseCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement By Share-based Payment Award, Maximum Employee Accrued Rights To Purchase Common Stock</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">optn_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeAccruedRightsToPurchaseCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>optn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_optn_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedIncrementEachYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized Increment Each Year</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">optn_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedIncrementEachYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>optn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_InventoriesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_InventoriesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=optn_ServiceBasedStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=optn_ServiceBasedStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=optn_RestrictedStockUnitsPerformanceBasedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=optn_RestrictedStockUnitsPerformanceBasedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=optn_RestrictedStockUnitsServiceBasedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=optn_RestrictedStockUnitsServiceBasedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=optn_MarketBasedStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=optn_MarketBasedStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=optn_AmendedandRestated2010StockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=optn_AmendedandRestated2010StockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=optn_NASDAQInducementGrantExceptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=optn_NASDAQInducementGrantExceptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=optn_TwoThousandSeventeenEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=optn_TwoThousandSeventeenEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140455322771040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Service-based stock options (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward', window );"><strong>Service-based stock options activity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Shares outstanding, beginning (in shares)</a></td>
<td class="nump">7,958,781<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">3,473,370<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(95,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Expired (in shares)</a></td>
<td class="num">(947,999)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(1,025,082)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Shares outstanding, ending (in shares)</a></td>
<td class="nump">9,364,070<span></span>
</td>
<td class="nump">7,958,781<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable at end of period (in shares)</a></td>
<td class="nump">5,521,738<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract', window );"><strong>Service-based stock options weighted average exercise price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning balance, Weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 8.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted, Weighted average exercise price (in dollars per share)</a></td>
<td class="nump">1.88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised, Weighted average exercise price (in dollars per share)</a></td>
<td class="nump">2.18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Expired, Weighted average exercise price (in dollars per share)</a></td>
<td class="nump">9.56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited, Weighted average exercise price (in dollars per share)</a></td>
<td class="nump">3.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending balance, Weighted average exercise price (in dollars per share)</a></td>
<td class="nump">6.88<span></span>
</td>
<td class="nump">$ 8.87<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options exercisable, Weighted average exercise price per share (in dollars per share)</a></td>
<td class="nump">$ 9.98<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Service-based stock options, additional disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options outstanding, Weighted average remaining contractual life (in years)</a></td>
<td class="text">6 years 18 days<span></span>
</td>
<td class="text">6 years 6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Options exercisable, Weighted average remaining contractual life (in years)</a></td>
<td class="text">4 years 6 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140455325010384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Schedule of RSUs (Details) - Restricted stock units - shares<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 15, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Balance at beginning (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,959,358<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,105,246<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested and settled (in shares)</a></td>
<td class="num">(248,827)<span></span>
</td>
<td class="num">(949,857)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Expired/ forfeited/ canceled (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(637,087)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Balance at ending (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,477,660<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_optn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestNumber', window );">Expected to vest (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,477,660<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_optn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Expected to Vest, Number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">optn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>optn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140455325066656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Stock-based compensation expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 8,877<span></span>
</td>
<td class="nump">$ 10,003<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">35<span></span>
</td>
<td class="nump">50<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">809<span></span>
</td>
<td class="nump">1,079<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 8,033<span></span>
</td>
<td class="nump">$ 8,874<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140455319774368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Black-Scholes pricing model options (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Annual dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=optn_TwoThousandSeventeenEmployeeStockPurchasePlanMember', window );">2017 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="nump">0.17%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">88.13%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Annual dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">2010 A&amp;R Stock Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="nump">2.22%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years 29 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">73.23%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Annual dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Rate of weighted-average expected volatility for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=optn_TwoThousandSeventeenEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=optn_TwoThousandSeventeenEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140455330059776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of income before income tax, domestic and foreign (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">Domestic operations</a></td>
<td class="num">$ (72,750)<span></span>
</td>
<td class="num">$ (78,801)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign operations</a></td>
<td class="num">(2,083)<span></span>
</td>
<td class="num">(3,495)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before provision for income taxes</a></td>
<td class="num">$ (74,833)<span></span>
</td>
<td class="num">$ (82,296)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140455329616560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of effective income tax rate reconciliation (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Income tax expense at statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense', window );">Permanent items</a></td>
<td class="num">(1.50%)<span></span>
</td>
<td class="num">(0.40%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Foreign rate differential</a></td>
<td class="num">(0.70%)<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_optn_EffectiveIncomeTaxRateReconciliationForeignOperationsImpactPercent', window );">Impact of foreign operations</a></td>
<td class="num">(14.50%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State taxes, net of federal benefit</a></td>
<td class="nump">2.60%<span></span>
</td>
<td class="nump">4.70%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate', window );">Tax rate changes</a></td>
<td class="num">(2.90%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_optn_EffectiveIncomeTaxRateReconciliationForeignExchangeOtherPercent', window );">Foreign exchange and other</a></td>
<td class="num">(1.70%)<span></span>
</td>
<td class="num">(0.90%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock based compensation</a></td>
<td class="num">(2.90%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_optn_EffectiveIncomeTaxRateReconciliationPrepaidRoyaltyWriteOffPercent', window );">Prepaid royalty write off</a></td>
<td class="num">(11.80%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">12.40%<span></span>
</td>
<td class="num">(24.50%)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_optn_EffectiveIncomeTaxRateReconciliationForeignExchangeOtherPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Foreign Exchange Other, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">optn_EffectiveIncomeTaxRateReconciliationForeignExchangeOtherPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>optn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_optn_EffectiveIncomeTaxRateReconciliationForeignOperationsImpactPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Foreign Operations Impact, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">optn_EffectiveIncomeTaxRateReconciliationForeignOperationsImpactPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>optn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_optn_EffectiveIncomeTaxRateReconciliationPrepaidRoyaltyWriteOffPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Prepaid Royalty Write Off, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">optn_EffectiveIncomeTaxRateReconciliationPrepaidRoyaltyWriteOffPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>optn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140455322177072">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Schedule of deferred tax assets and liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpense', window );">Accrued expenses and other</a></td>
<td class="nump">$ 5,144<span></span>
</td>
<td class="nump">$ 6,712<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_optn_DeferredTaxAssetsPrepaidLicenseArrangement', window );">Prepaid licensing arrangement</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">9,441<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_optn_DeferredTaxAssetsInterestExpense', window );">Interest expense</a></td>
<td class="nump">14,304<span></span>
</td>
<td class="nump">10,708<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits', window );">Stock compensation</a></td>
<td class="nump">7,193<span></span>
</td>
<td class="nump">8,583<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_optn_DeferredTaxAssetsLeasingArrangement', window );">Lease liability</a></td>
<td class="nump">642<span></span>
</td>
<td class="nump">1,081<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Research and development credits</a></td>
<td class="nump">2,460<span></span>
</td>
<td class="nump">2,461<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_optn_DeferredTaxAssetsFinancingCosts', window );">Capitalized R&amp;D</a></td>
<td class="nump">3,377<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating losses</a></td>
<td class="nump">83,376<span></span>
</td>
<td class="nump">87,324<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">116,496<span></span>
</td>
<td class="nump">126,310<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Fixed assets, including leases</a></td>
<td class="num">(171)<span></span>
</td>
<td class="num">(210)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements', window );">Right-to-use asset</a></td>
<td class="num">(605)<span></span>
</td>
<td class="num">(1,024)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities:</a></td>
<td class="num">(776)<span></span>
</td>
<td class="num">(1,234)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: Valuation allowance</a></td>
<td class="num">(115,720)<span></span>
</td>
<td class="num">(125,076)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Total net deferred tax assets (liabilities)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_optn_DeferredTaxAssetsFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Financing Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">optn_DeferredTaxAssetsFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>optn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_optn_DeferredTaxAssetsInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Interest Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">optn_DeferredTaxAssetsInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>optn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_optn_DeferredTaxAssetsLeasingArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Leasing Arrangement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">optn_DeferredTaxAssetsLeasingArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>optn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_optn_DeferredTaxAssetsPrepaidLicenseArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Prepaid License Arrangement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">optn_DeferredTaxAssetsPrepaidLicenseArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>optn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowances, of deferred tax asset attributable to deductible differences from reserves and accruals, compensation and benefit costs, and other provisions, reserves, and allowances.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesLeasingArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140455319623120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Deferred tax assets tax credit carryforwards research</a></td>
<td class="nump">$ 2,487,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_optn_DeferredTaxAssetsTaxCreditCarryforwardsResearchTerm', window );">Deferred tax assets tax credit carryforwards research term</a></td>
<td class="text">20 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Decrease in valuation allowance</a></td>
<td class="num">$ (9,356,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Unrecognized tax benefits, income tax penalties and interest accrued</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign Tax Authority</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">9,073,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">335,009,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">$ 252,324,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_optn_DeferredTaxAssetsTaxCreditCarryforwardsResearchTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Tax Credit Carryforwards, Research, Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">optn_DeferredTaxAssetsTaxCreditCarryforwardsResearchTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>optn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>optn-20221231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:optn="http://www.optinose.com/20221231"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="optn-20221231.xsd" xlink:type="simple"/>
    <context id="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ied2db99cce6e4199865af70756a669a5_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i94f2af01a3404575802c3ac9b3d117d4_I20230301">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
        </entity>
        <period>
            <instant>2023-03-01</instant>
        </period>
    </context>
    <context id="ie179c2aa474648c5a81e099ecf55e73a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id970dfd2674c4d6b895febb9c14d0fd1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7d7389924c8a481f922afd27c2d98be6_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i86422cbece424367a1550b9f28481643_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ifb05b53856a04e6fb8d77b2615fef7b5_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i0a537887f3924b21a34b339e3a39c085_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4e3006d0e61345298119d94aa76e7fc3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i14c26b9820bc4dfbbdaf3a90822b4aa3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i97d8a5bb4b224ce58ea3ebd003189203_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia1487e10814a476c9f4946ac6b21c5f8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i49ae796ea1484c519d91607656f24c24_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i370c96450d8f471da8faee4fea65af41_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iab515f21eb974f95af61d257257b1b11_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i810445cfd7f9438195dd0d77cfeedd7e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="idacbe771db9246aba4c1a2401b11b0c0_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ibacfe7c370de4063881a058b1ca33cf7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7f0715d972fd4e5cb7aaeea6b7297684_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib5641003d7214a1987d7612d9a529d7f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i789260e8b4914bc7a8d855feb02dc33c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3377b70595804aa5abe93bd7f81df039_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ic9fdf918fabe4dea9acdfa65692fe619_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i8c484ff51d4d492594a9bf004bc92efb_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i342496e82be2474596067223f1d6134a_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i97a20c4e2d9543ea933245a9227cf00f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="idd9a9b2d424d466ca469cf5987572ab0_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id3708c2b1f2b41dfa7d806c5987de5d7_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3cc6af243d904524abfec5259351ae3f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i57b30631121b485ab3ea36fafacd9bba_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i77cd59ff576d44dd94fde4a159bcfd79_I20221123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">optn:NotePurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-23</instant>
        </period>
    </context>
    <context id="iad0d9b5ed2334bfd8a9fd9842e362c70_I20221123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">optn:NotePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-23</instant>
        </period>
    </context>
    <context id="i9c9d8c25cbd84a1dbfec87c26799aca0_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">optn:FiveCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i453f6ff7522f4a12b35a0b401b71aadf_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">optn:FiveCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i096da31e1c4b4962a9749727b86a9251_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i51129fc2a039416488ae6cf33f207331_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i6dceb2856a724c7cb132bb0edc4d035c_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i9941fdaa85054a3a9340530990beb6a2_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i84fb7ecf7b8a41a6af4d113e7add2b46_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ib7a618edb3b34dc88ad18ed5ca86c14d_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia91696961e0b4593a33c03f9b00c5dec_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i12305500621f4b93b85c82aa1da3b266_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i4915e82cfd2f4c5f8a1d6e09c40ecdef_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id7cd0da0eea14521a316e6ae095e19a2_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia3b834ad368d4672b0476f096fe3f60f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7ac7a3a3a80b4d7b8a3d2ffc47f38e20_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i930ccddc00c24cfd9e7d29dd5a34e0aa_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i25abfe2f91764951ba1d5af64bcb7a2a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i32cf8e8f75054575965e3fdf63fcc596_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib72acf71ad414bdb820e66430a66f4f1_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3c2fa1e023784c819a8dc44bb99e322a_I20221123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">optn:MonteCarloSimulationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-23</instant>
        </period>
    </context>
    <context id="i656202f27e9648aa9f71018965d5db85_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">optn:MonteCarloSimulationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i12526027af124d2eaf2e45c5cc5128ba_I20221123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">optn:MeasurementInputStrikePriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">optn:MonteCarloSimulationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-23</instant>
        </period>
    </context>
    <context id="i81d87324f9ac42a2804e01597b73f13e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">optn:MeasurementInputStrikePriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">optn:MonteCarloSimulationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7fd98223b0e8487ab4e9f06a6b0e2e17_I20221123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">optn:MonteCarloSimulationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-23</instant>
        </period>
    </context>
    <context id="ia683400064104d94bb65e13224b47fa4_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">optn:MonteCarloSimulationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i07561160b4b640b58284b5ac37678580_I20221123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">optn:MonteCarloSimulationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-23</instant>
        </period>
    </context>
    <context id="ib8ec0a4f643d4b8691f7c64824d1ef26_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">optn:MonteCarloSimulationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if38bd004cc9c47cb8ed2b5ced602d8de_I20221123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">optn:MonteCarloSimulationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-23</instant>
        </period>
    </context>
    <context id="i77f645c2ad1f45eb87448af2f7350083_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">optn:MonteCarloSimulationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic2035d08305a4a15b86bb7d1dbc471a9_I20221123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">optn:MonteCarloSimulationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-23</instant>
        </period>
    </context>
    <context id="i076a98514cf1491bb4e37cb056d5866a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">optn:MonteCarloSimulationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9ddeb1efeb7744f8bed2dbb7f03f66da_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">optn:ComputerEquipmentandSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic532296dc81545c39388340e3d3dfb1d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">optn:ComputerEquipmentandSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idd6adcb5fdd94a8cafa3e6dcc446470f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6d6764d492fa4ab49a7a65da317dfa94_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i77c83aa040f64e5ab765b0b3cec00b48_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i97b05fd39c994e718b96dc21927444c5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie3474fbb67a5493091eb870124741f97_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i20b9366590cd439eac871165deb4cd22_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iaaea96eb926c4215a782ea03cfe873f7_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5d86a8ea69c742f89c18f27139c4e7e8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3b8fb31b2cb74f1986dbdb60db29474c_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InventoriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i08cfc0852d87426baff11fe941ec7bfa_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i5fd2ee54427b485b93f8b56d2a73b716_D20210101-20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:RoyaltyAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="i62f6f90c47544ada9c32250b077bb99b_I20190912">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">optn:NotePurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-12</instant>
        </period>
    </context>
    <context id="i047f781d92bd40e5b05937913709530f_I20200213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">optn:NotePurchaseAgreementFirstDelayedDrawNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-13</instant>
        </period>
    </context>
    <context id="i2dd470baef924f409cb50332bb1d158a_D20191001-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">optn:NotePurchaseAgreementFirstDelayedDrawNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="optn:MeasurementPeriodAxis">optn:QuarterEndedDecember312019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i2c43759aacc744b2ab7dc2cf4563d669_I20201201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">optn:NotePurchaseAgreementThirdDelayedDrawNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-01</instant>
        </period>
    </context>
    <context id="ib972721f09ce4ecca02118dff9ab3a54_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">optn:NotePurchaseAgreementThirdDelayedDrawNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="optn:MeasurementPeriodAxis">optn:QuarterEndedSeptember302020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ic1354dd9142c4406bb996b9f79066753_I20220809">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">optn:NotePurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-09</instant>
        </period>
    </context>
    <context id="i0ae63187f7984cadbfb811136622697c_I20220810">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">optn:NotePurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-10</instant>
        </period>
    </context>
    <context id="ib61af200b06045878d1f67070415e25a_I20220810">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">optn:NotePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-10</instant>
        </period>
    </context>
    <context id="iaf72692f99ed46b5a83cb937a4981bae_I20221109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">optn:NotePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-09</instant>
        </period>
    </context>
    <context id="i96634d78ca80401db240ea2a9de1645e_I20221120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="optn:TrailingTwelveMonthEndingAxisAxis">optn:March312023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-20</instant>
        </period>
    </context>
    <context id="i50b0b50bbf134c7f97db3df38c151093_I20221120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="optn:TrailingTwelveMonthEndingAxisAxis">optn:June302023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-20</instant>
        </period>
    </context>
    <context id="i2d657bd081aa4998b54cb136b25d210a_I20221120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="optn:TrailingTwelveMonthEndingAxisAxis">optn:September302023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-20</instant>
        </period>
    </context>
    <context id="ie07879a277ed48fc8b5450fd9f7f1ad9_I20221120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="optn:TrailingTwelveMonthEndingAxisAxis">optn:December312023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-20</instant>
        </period>
    </context>
    <context id="ib294e78ab7cc4fb7b0a4c74b9ced9b5f_I20221120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="optn:TrailingTwelveMonthEndingAxisAxis">optn:March312024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-20</instant>
        </period>
    </context>
    <context id="iebab32ba35ab45b7950eabc69c4f19f4_I20221121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="optn:TrailingTwelveMonthEndingAxisAxis">optn:March312024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-21</instant>
        </period>
    </context>
    <context id="ia42f4722c6ea4c0ba9424cbb5b7db442_I20221120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="optn:TrailingTwelveMonthEndingAxisAxis">optn:June302024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-20</instant>
        </period>
    </context>
    <context id="ied0332f696c74d02b9bca94cd69b5f71_I20221121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="optn:TrailingTwelveMonthEndingAxisAxis">optn:June302024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-21</instant>
        </period>
    </context>
    <context id="ie0d86211c30f4dcc99c47c2ccac871ce_I20221121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="optn:TrailingTwelveMonthEndingAxisAxis">optn:September302024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-21</instant>
        </period>
    </context>
    <context id="i33d3c0e47ba74ff5a8b749a97af8db65_I20221121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="optn:TrailingTwelveMonthEndingAxisAxis">optn:December312024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-21</instant>
        </period>
    </context>
    <context id="i9044805836a742b1ad16a4f9886ba9a4_I20221121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="optn:TrailingTwelveMonthEndingAxisAxis">optn:March312025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-21</instant>
        </period>
    </context>
    <context id="i3364391e55a8465f8779312aa2de8ee3_I20221121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="optn:TrailingTwelveMonthEndingAxisAxis">optn:June302025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-21</instant>
        </period>
    </context>
    <context id="i1362d0ef4cda4d66927a9a59de67480a_I20221121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="optn:TrailingTwelveMonthEndingAxisAxis">optn:September302025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-21</instant>
        </period>
    </context>
    <context id="icb311cdcf8a9432c86887963e33e45f4_I20221121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="optn:TrailingTwelveMonthEndingAxisAxis">optn:December312025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-21</instant>
        </period>
    </context>
    <context id="ib965e05b5c0041c399de4fe3b2ae4e52_I20221121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="optn:TrailingTwelveMonthEndingAxisAxis">optn:March312026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-21</instant>
        </period>
    </context>
    <context id="i03d054262028474889eca1899fe6608a_I20221121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="optn:TrailingTwelveMonthEndingAxisAxis">optn:June302026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-21</instant>
        </period>
    </context>
    <context id="i482f0725fc2c4ff7b615761825e52e2e_I20221121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="optn:TrailingTwelveMonthEndingAxisAxis">optn:September302026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-21</instant>
        </period>
    </context>
    <context id="i5b4176cedeca41789b0e80197b83e051_I20221121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="optn:TrailingTwelveMonthEndingAxisAxis">optn:December312026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-21</instant>
        </period>
    </context>
    <context id="ia4c59ac4f7d84023ba6dbab73c1e6899_I20221121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="optn:TrailingTwelveMonthEndingAxisAxis">optn:March312027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-21</instant>
        </period>
    </context>
    <context id="i7f50064d7872407bb6b3b9a2c50c62eb_I20221121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="optn:TrailingTwelveMonthEndingAxisAxis">optn:June302027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-21</instant>
        </period>
    </context>
    <context id="i6fc5337d1b3e406b8ce2787d51ed4dc1_I20221121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="optn:TrailingTwelveMonthEndingAxisAxis">optn:September302027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-21</instant>
        </period>
    </context>
    <context id="i536baadaab72454d98e7f61dc860283b_D20221121-20221121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">optn:NotePurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">optn:SecuredOvernightFinancingRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-21</startDate>
            <endDate>2022-11-21</endDate>
        </period>
    </context>
    <context id="ic6a19df6a9ed4b9a96606c2aeae2cd03_D20221121-20221121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">optn:NotePurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-21</startDate>
            <endDate>2022-11-21</endDate>
        </period>
    </context>
    <context id="i0ec8ef0a77c840fe941543a77bb688a7_I20221121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">optn:NotePurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-21</instant>
        </period>
    </context>
    <context id="ibd48856bcb224069b298e05dfdf34fc8_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">optn:NotePurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4af8cd3923a14bf4bd1655d4e950bb46_D20221121-20221121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">optn:NotePurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-21</startDate>
            <endDate>2022-11-21</endDate>
        </period>
    </context>
    <context id="i4bfb752944e54d3faa2837a8b3afb6b2_D20221121-20221121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">optn:NotePurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-21</startDate>
            <endDate>2022-11-21</endDate>
        </period>
    </context>
    <context id="i94c26246ced94d6ebc3cf4dc56035b01_D20221121-20221121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">optn:NotePurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-21</startDate>
            <endDate>2022-11-21</endDate>
        </period>
    </context>
    <context id="i2f6060dc084947d8b5a97c9542a55c23_I20221121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">optn:NotePurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-21</instant>
        </period>
    </context>
    <context id="i48ae5fa4e9e144c09f6e99f5f4994a45_I20221121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">optn:NotePurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-21</instant>
        </period>
    </context>
    <context id="ida56878d1ff24c82a2ce1db8be8bfdec_I20221121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">optn:NotePurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-21</instant>
        </period>
    </context>
    <context id="i238287e400564d288f6e8227556282ab_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">optn:NotePurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i714fce477c634b15806608bc880b077f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">optn:NotePurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7561e1a29a044dc9ad808ce4adaaca18_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">optn:NotePurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idbd6780d660f4418a87f188eb442ef29_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="optn:DefinedContributionPlanTranchesAxisAxis">optn:DefinedContributionPlanTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i670307f3af404f3b9d62b585c525267b_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="optn:DefinedContributionPlanTranchesAxisAxis">optn:DefinedContributionPlanTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i2d4fcc93e3a14fe6962ee2598dc6066e_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="idad19395ab8f44dd9a2eb5f01f801543_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i35f1c252618f404c810efc41abf15787_D20211118-20211118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">optn:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-18</startDate>
            <endDate>2021-11-18</endDate>
        </period>
    </context>
    <context id="i1fba48bbd9c94f17a4a169948d5b5dfa_I20211118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">optn:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-18</instant>
        </period>
    </context>
    <context id="ic6fffb430e45481abf555ff9d6505776_D20221123-20221123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">optn:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-23</startDate>
            <endDate>2022-11-23</endDate>
        </period>
    </context>
    <context id="i1e2cc5b3626b4c0eb0a50fe312b92bbe_I20221123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">optn:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-23</instant>
        </period>
    </context>
    <context id="iea2a2b3820084672a2ce5363d5379529_I20221123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">optn:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-23</instant>
        </period>
    </context>
    <context id="i056c6dc8158e43c386a653bfe93f59db_D20221123-20221123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">optn:UnderwritersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">optn:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-23</startDate>
            <endDate>2022-11-23</endDate>
        </period>
    </context>
    <context id="i0cf7d2872aa9438888847621f710368c_I20221123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">optn:UnderwritersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">optn:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-23</instant>
        </period>
    </context>
    <context id="id8480f44fd004d44a17fe3165e3accc2_D20221201-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">optn:UnderwritersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">optn:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i26def91352024f8bb0467900afb32de9_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">optn:UnderwritersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">optn:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie839a1db16084835ad6af8b8758ce33c_I20211118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">optn:WarrantsExpiringNovember182024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-18</instant>
        </period>
    </context>
    <context id="iabcd2c4e164b4cb3923eed31231d712e_I20211118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">optn:WarrantsExpiringSeptember122022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-18</instant>
        </period>
    </context>
    <context id="iecd24838e7ea4897a980acb7f05e8f07_I20211118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-18</instant>
        </period>
    </context>
    <context id="i34d7dc335ebb4c258e92af8033ba7854_I20211118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-18</instant>
        </period>
    </context>
    <context id="i81ae26cc8b16489db793cfa1a11fdb41_I20211118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-18</instant>
        </period>
    </context>
    <context id="iad23ea7b6ce14473a74ab1026b1d8111_I20211118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-18</instant>
        </period>
    </context>
    <context id="ib2361c2f31ea4a84ae18d655231f351d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7231baf73d71425f945cdbbe619d491b_D20221123-20221123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">optn:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-23</startDate>
            <endDate>2022-11-23</endDate>
        </period>
    </context>
    <context id="iee3e30fe89cc40238e90a7ecb6f01185_I20221121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-21</instant>
        </period>
    </context>
    <context id="i79d8665c06414820bf676315cc093d4a_I20221123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
        </entity>
        <period>
            <instant>2022-11-23</instant>
        </period>
    </context>
    <context id="i24bb67187a7b4b71897cb83c06184e0c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">optn:WarrantsExpiringNovember152024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia2ede8c8918a4e5a90c0ff1a8e33f0c0_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">optn:WarrantsExpiringNovember232027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic8103889fc054805b787fcb8d7245e95_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">optn:AmendedandRestated2010StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4b3d9a0e4d704073937d74fdc55db85b_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">optn:AmendedandRestated2010StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia6f6f949224a4e3db7362e44a8479806_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">optn:ServiceBasedStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="icdfa0ea8b62148fe8c31ae85f2e9f203_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">optn:MarketBasedStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i6f825eaecdc54225baf8219928d46fdb_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">optn:ServiceBasedStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i28c4ea3872514bf9a8d5fe2d1d621221_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">optn:ServiceBasedStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i34d0a9c04a2f4859a044c9e6cc370e55_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">optn:ServiceBasedStockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">optn:NASDAQInducementGrantExceptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i7dc5537455904ed088d5e7907081fa28_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="idbf17e5750434c4fa4c7af6d79eb5f3b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i15fbdc49b67e41af98201248589f1f68_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="icae44ec705a54e90b329084893ffe064_D20220615-20220615">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-15</startDate>
            <endDate>2022-06-15</endDate>
        </period>
    </context>
    <context id="i4d238e610edc4182b197232b0495fdf4_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">optn:RestrictedStockUnitsServiceBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i516c5d169f6840f49a095d9630b5c9ae_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">optn:RestrictedStockUnitsServiceBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="if23267985b9b470489888a9e025653a4_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">optn:RestrictedStockUnitsPerformanceBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if62b2d5afbd04093b3379124f22b23c5_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">optn:NASDAQInducementGrantExceptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i846ff334c7ce400c8af0db347b91f620_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">optn:TwoThousandSeventeenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="idfcc4aa88cd04b0498643a728bb0b299_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">optn:TwoThousandSeventeenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i412f04e9b5124c22a267cc2e9474aa46_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">optn:TwoThousandSeventeenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iaaa623bfd2b7461d815938764c60cf18_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i1ec6ce002f784a1f8f8a3b2b9b9b06ae_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iaee85c4768314a529b0fa7b1be860d0c_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i1cd280125c384cd5a45521262a35af31_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iff00e227a0ed47e8ac87706a2be40407_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i6c74ce02c1434fc183c30fe05522e194_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9975a7e3c2704c8988c1154b5ae900d4_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i411a7889aa7b40c59ba3d11c1d63d29e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i65dbad508d2444f4bb357feedbc9cad4_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i497d60fef0fd413ba91eb9a5009d1d39_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001494650</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="customer">
        <measure>optn:customer</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="vote">
        <measure>optn:vote</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF80L2ZyYWc6ZTU2MWM2ZWQ2MWUzNDZjZGFmZWJiYWI3ODgwOTMxMTcvdGFibGU6Y2YxNjc5ZGEwZTQ4NDc2YjkxOTUyYTMxYmQ4ZWFjMDMvdGFibGVyYW5nZTpjZjE2NzlkYTBlNDg0NzZiOTE5NTJhMzFiZDhlYWMwM18xLTEtMS0xLTU4Mzcy_cf04982f-cc6e-4f63-a699-37654030d76f">0001494650</dei:EntityCentralIndexKey>
    <dei:DocumentFiscalYearFocus
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF80L2ZyYWc6ZTU2MWM2ZWQ2MWUzNDZjZGFmZWJiYWI3ODgwOTMxMTcvdGFibGU6Y2YxNjc5ZGEwZTQ4NDc2YjkxOTUyYTMxYmQ4ZWFjMDMvdGFibGVyYW5nZTpjZjE2NzlkYTBlNDg0NzZiOTE5NTJhMzFiZDhlYWMwM18yLTEtMS0xLTU4Mzcy_585028bf-3e81-4111-9f31-d41055c55507">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF80L2ZyYWc6ZTU2MWM2ZWQ2MWUzNDZjZGFmZWJiYWI3ODgwOTMxMTcvdGFibGU6Y2YxNjc5ZGEwZTQ4NDc2YjkxOTUyYTMxYmQ4ZWFjMDMvdGFibGVyYW5nZTpjZjE2NzlkYTBlNDg0NzZiOTE5NTJhMzFiZDhlYWMwM18zLTEtMS0xLTU4Mzcy_5c5a16f8-5f85-468c-92b2-391b097aa363">FY</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF80L2ZyYWc6ZTU2MWM2ZWQ2MWUzNDZjZGFmZWJiYWI3ODgwOTMxMTcvdGFibGU6Y2YxNjc5ZGEwZTQ4NDc2YjkxOTUyYTMxYmQ4ZWFjMDMvdGFibGVyYW5nZTpjZjE2NzlkYTBlNDg0NzZiOTE5NTJhMzFiZDhlYWMwM180LTEtMS0xLTU4Mzcy_ffb2dcf8-fffc-431e-9071-dfa058b83094">false</dei:AmendmentFlag>
    <us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzY1L2ZyYWc6MzgyNzViMTRmNmU2NDY1ZjlmNDQ0MmU4MzkxYzE5Y2IvdGFibGU6NWM3ZDZiYjczNjFkNDc5M2E4MTIxMjhkOWM4MWIzZDMvdGFibGVyYW5nZTo1YzdkNmJiNzM2MWQ0NzkzYTgxMjEyOGQ5YzgxYjNkM180LTAtMS0xLTExMDU2NQ_cf1ef344-6e8b-4404-9fc4-62d43ef2dafc">http://www.optinose.com/20221231#UnrealizedGainLossOnFairValueOfWarrants</us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList>
    <us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNTEvZnJhZzoyNzE1YjlkZmFkYWQ0MzJmODM0NjNlNTc4MDU5NjVkNS90YWJsZTplNmRjNTY4MzJmZTU0MjZlODE2Nzg1Yzg1OWM5ZWExMC90YWJsZXJhbmdlOmU2ZGM1NjgzMmZlNTQyNmU4MTY3ODVjODU5YzllYTEwXzEtMi0xLTEtNTgzNzI_24ba613c-7389-4e11-9675-21345271c945">http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent</us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="id970dfd2674c4d6b895febb9c14d0fd1_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNTEvZnJhZzoyNzE1YjlkZmFkYWQ0MzJmODM0NjNlNTc4MDU5NjVkNS90YWJsZTplNmRjNTY4MzJmZTU0MjZlODE2Nzg1Yzg1OWM5ZWExMC90YWJsZXJhbmdlOmU2ZGM1NjgzMmZlNTQyNmU4MTY3ODVjODU5YzllYTEwXzEtMi0xLTEtNTgzNzI_68a7407f-9d3d-42c1-b7e8-60a846da90dd">http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent</us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="id970dfd2674c4d6b895febb9c14d0fd1_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNTEvZnJhZzoyNzE1YjlkZmFkYWQ0MzJmODM0NjNlNTc4MDU5NjVkNS90YWJsZTplNmRjNTY4MzJmZTU0MjZlODE2Nzg1Yzg1OWM5ZWExMC90YWJsZXJhbmdlOmU2ZGM1NjgzMmZlNTQyNmU4MTY3ODVjODU5YzllYTEwXzMtMi0xLTEtNTgzNzI_81e615e1-5430-4b3f-a024-d8c112dd845e">http://fasb.org/us-gaap/2022#AccountsPayableAndOtherAccruedLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNTEvZnJhZzoyNzE1YjlkZmFkYWQ0MzJmODM0NjNlNTc4MDU5NjVkNS90YWJsZTplNmRjNTY4MzJmZTU0MjZlODE2Nzg1Yzg1OWM5ZWExMC90YWJsZXJhbmdlOmU2ZGM1NjgzMmZlNTQyNmU4MTY3ODVjODU5YzllYTEwXzMtMi0xLTEtNTgzNzI_c6470abf-49c1-414a-9b43-5932ca6cb8de">http://fasb.org/us-gaap/2022#AccountsPayableAndOtherAccruedLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
      contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNTEvZnJhZzoyNzE1YjlkZmFkYWQ0MzJmODM0NjNlNTc4MDU5NjVkNS90YWJsZTplNmRjNTY4MzJmZTU0MjZlODE2Nzg1Yzg1OWM5ZWExMC90YWJsZXJhbmdlOmU2ZGM1NjgzMmZlNTQyNmU4MTY3ODVjODU5YzllYTEwXzQtMi0xLTEtNTgzNzI_51c56e55-3624-4972-bd9f-e5d6619b61c3">http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent</us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
      contextRef="id970dfd2674c4d6b895febb9c14d0fd1_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNTEvZnJhZzoyNzE1YjlkZmFkYWQ0MzJmODM0NjNlNTc4MDU5NjVkNS90YWJsZTplNmRjNTY4MzJmZTU0MjZlODE2Nzg1Yzg1OWM5ZWExMC90YWJsZXJhbmdlOmU2ZGM1NjgzMmZlNTQyNmU4MTY3ODVjODU5YzllYTEwXzQtMi0xLTEtNTgzNzI_f473c9e3-1f7a-40d1-9ce5-a76980ea7120">http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent</us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <dei:DocumentType
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xL2ZyYWc6YWY2ZjJmNjZlYjlhNDRlNTg0ZDg3NWQ5YTE4M2MyYzAvdGV4dHJlZ2lvbjphZjZmMmY2NmViOWE0NGU1ODRkODc1ZDlhMTgzYzJjMF84OA_f6b3c3ff-88ac-4168-b0af-1ddac641ebcf">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xL2ZyYWc6YWY2ZjJmNjZlYjlhNDRlNTg0ZDg3NWQ5YTE4M2MyYzAvdGFibGU6YThhMmZiNmEyZDEyNDE0MThiYmQ3YTAwMjVlMDNkZGIvdGFibGVyYW5nZTphOGEyZmI2YTJkMTI0MTQxOGJiZDdhMDAyNWUwM2RkYl8wLTEtMS0xLTU4Mzcy_f6ad109d-261c-4ed3-9b81-31ec66f55abd">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xL2ZyYWc6YWY2ZjJmNjZlYjlhNDRlNTg0ZDg3NWQ5YTE4M2MyYzAvdGV4dHJlZ2lvbjphZjZmMmY2NmViOWE0NGU1ODRkODc1ZDlhMTgzYzJjMF8xMjA_82790ec2-bdaa-4633-80c3-83bc99d2518a">2022-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xL2ZyYWc6YWY2ZjJmNjZlYjlhNDRlNTg0ZDg3NWQ5YTE4M2MyYzAvdGV4dHJlZ2lvbjphZjZmMmY2NmViOWE0NGU1ODRkODc1ZDlhMTgzYzJjMF8xMjA_3a95026a-c8c4-44dd-9b10-aff52fcd32be">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xL2ZyYWc6YWY2ZjJmNjZlYjlhNDRlNTg0ZDg3NWQ5YTE4M2MyYzAvdGFibGU6OTljOGZjN2RhZmM1NGFkMmI3MmI1MTUxOWY1MjE5NDMvdGFibGVyYW5nZTo5OWM4ZmM3ZGFmYzU0YWQyYjcyYjUxNTE5ZjUyMTk0M18wLTEtMS0xLTU4Mzcy_d02ab63c-2384-4876-992d-a5beddaf330b">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xL2ZyYWc6YWY2ZjJmNjZlYjlhNDRlNTg0ZDg3NWQ5YTE4M2MyYzAvdGV4dHJlZ2lvbjphZjZmMmY2NmViOWE0NGU1ODRkODc1ZDlhMTgzYzJjMF8zNDQ2_d1698a48-8aee-406d-be88-ce166532eb7f">001-38241</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xL2ZyYWc6YWY2ZjJmNjZlYjlhNDRlNTg0ZDg3NWQ5YTE4M2MyYzAvdGV4dHJlZ2lvbjphZjZmMmY2NmViOWE0NGU1ODRkODc1ZDlhMTgzYzJjMF8zNDU1_f154de72-1cc1-45b3-833c-7afc2167bb70">OPTINOSE, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xL2ZyYWc6YWY2ZjJmNjZlYjlhNDRlNTg0ZDg3NWQ5YTE4M2MyYzAvdGFibGU6OTJmNjUzZTI3Y2VjNDliYTlkNWZiYTBlMmJlMmQ5ZWIvdGFibGVyYW5nZTo5MmY2NTNlMjdjZWM0OWJhOWQ1ZmJhMGUyYmUyZDllYl8wLTAtMS0xLTU4Mzcy_ec721f1b-c01c-4879-939c-7150d3901147">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xL2ZyYWc6YWY2ZjJmNjZlYjlhNDRlNTg0ZDg3NWQ5YTE4M2MyYzAvdGFibGU6OTJmNjUzZTI3Y2VjNDliYTlkNWZiYTBlMmJlMmQ5ZWIvdGFibGVyYW5nZTo5MmY2NTNlMjdjZWM0OWJhOWQ1ZmJhMGUyYmUyZDllYl8wLTItMS0xLTU4Mzcy_6853fb8d-7b99-4832-ad7f-5394131c6a6d">42-1771610</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xL2ZyYWc6YWY2ZjJmNjZlYjlhNDRlNTg0ZDg3NWQ5YTE4M2MyYzAvdGV4dHJlZ2lvbjphZjZmMmY2NmViOWE0NGU1ODRkODc1ZDlhMTgzYzJjMF8zNDQ1_941c9ad9-fed9-444b-ad6a-8aa46cb484fb">1020 Stony Hill Road</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xL2ZyYWc6YWY2ZjJmNjZlYjlhNDRlNTg0ZDg3NWQ5YTE4M2MyYzAvdGV4dHJlZ2lvbjphZjZmMmY2NmViOWE0NGU1ODRkODc1ZDlhMTgzYzJjMF8zNDQz_0e3865bf-eddb-462f-8012-62b8b3064d1f">Suite 300</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xL2ZyYWc6YWY2ZjJmNjZlYjlhNDRlNTg0ZDg3NWQ5YTE4M2MyYzAvdGV4dHJlZ2lvbjphZjZmMmY2NmViOWE0NGU1ODRkODc1ZDlhMTgzYzJjMF8zNDQ4_415a6ea3-f570-49a4-945d-78955a53b465">Yardley</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xL2ZyYWc6YWY2ZjJmNjZlYjlhNDRlNTg0ZDg3NWQ5YTE4M2MyYzAvdGV4dHJlZ2lvbjphZjZmMmY2NmViOWE0NGU1ODRkODc1ZDlhMTgzYzJjMF8zNDU2_144fd037-678b-4bc6-9755-0488a54944f0">PA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xL2ZyYWc6YWY2ZjJmNjZlYjlhNDRlNTg0ZDg3NWQ5YTE4M2MyYzAvdGV4dHJlZ2lvbjphZjZmMmY2NmViOWE0NGU1ODRkODc1ZDlhMTgzYzJjMF8zNDQ0_4d549ea1-ed88-4764-987a-c63d2dd81ccc">19067</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xL2ZyYWc6YWY2ZjJmNjZlYjlhNDRlNTg0ZDg3NWQ5YTE4M2MyYzAvdGV4dHJlZ2lvbjphZjZmMmY2NmViOWE0NGU1ODRkODc1ZDlhMTgzYzJjMF8zNDQ5_42149492-ef63-4b09-b7bf-1994f90baffe">267</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xL2ZyYWc6YWY2ZjJmNjZlYjlhNDRlNTg0ZDg3NWQ5YTE4M2MyYzAvdGV4dHJlZ2lvbjphZjZmMmY2NmViOWE0NGU1ODRkODc1ZDlhMTgzYzJjMF8zNDUx_ae5809c3-8666-4152-84c7-96871b815215">364-3500</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xL2ZyYWc6YWY2ZjJmNjZlYjlhNDRlNTg0ZDg3NWQ5YTE4M2MyYzAvdGFibGU6MTVjYjUxYWFmNDUzNDQ4NGI2MzIxMjIzYzVjZWJkZTAvdGFibGVyYW5nZToxNWNiNTFhYWY0NTM0NDg0YjYzMjEyMjNjNWNlYmRlMF8xLTAtMS0xLTU4Mzcy_51eeb01f-3876-4982-bcae-75ceed04e157">Common Stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xL2ZyYWc6YWY2ZjJmNjZlYjlhNDRlNTg0ZDg3NWQ5YTE4M2MyYzAvdGFibGU6MTVjYjUxYWFmNDUzNDQ4NGI2MzIxMjIzYzVjZWJkZTAvdGFibGVyYW5nZToxNWNiNTFhYWY0NTM0NDg0YjYzMjEyMjNjNWNlYmRlMF8xLTItMS0xLTU4Mzcy_ce68ec33-81d5-49cd-857b-88c3ba389621">OPTN</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xL2ZyYWc6YWY2ZjJmNjZlYjlhNDRlNTg0ZDg3NWQ5YTE4M2MyYzAvdGFibGU6MTVjYjUxYWFmNDUzNDQ4NGI2MzIxMjIzYzVjZWJkZTAvdGFibGVyYW5nZToxNWNiNTFhYWY0NTM0NDg0YjYzMjEyMjNjNWNlYmRlMF8xLTQtMS0xLTU4Mzcy_df97bed6-8817-43a3-99e1-be5ff593a8ee">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xL2ZyYWc6YWY2ZjJmNjZlYjlhNDRlNTg0ZDg3NWQ5YTE4M2MyYzAvdGV4dHJlZ2lvbjphZjZmMmY2NmViOWE0NGU1ODRkODc1ZDlhMTgzYzJjMF83NjA_4438dbdf-37d7-40c2-b96e-732f55f93532">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xL2ZyYWc6YWY2ZjJmNjZlYjlhNDRlNTg0ZDg3NWQ5YTE4M2MyYzAvdGV4dHJlZ2lvbjphZjZmMmY2NmViOWE0NGU1ODRkODc1ZDlhMTgzYzJjMF83NjA_772280d8-c3c9-4081-afa3-f013aac5c72e">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xL2ZyYWc6YWY2ZjJmNjZlYjlhNDRlNTg0ZDg3NWQ5YTE4M2MyYzAvdGV4dHJlZ2lvbjphZjZmMmY2NmViOWE0NGU1ODRkODc1ZDlhMTgzYzJjMF85MDE_833a2a17-56c2-4140-b1fd-775fe84c1b11">No</dei:EntityVoluntaryFilers>
    <dei:EntityVoluntaryFilers
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xL2ZyYWc6YWY2ZjJmNjZlYjlhNDRlNTg0ZDg3NWQ5YTE4M2MyYzAvdGV4dHJlZ2lvbjphZjZmMmY2NmViOWE0NGU1ODRkODc1ZDlhMTgzYzJjMF85MDE_c876bcf7-05a3-4dba-8f4e-bab2eda74eda">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xL2ZyYWc6YWY2ZjJmNjZlYjlhNDRlNTg0ZDg3NWQ5YTE4M2MyYzAvdGV4dHJlZ2lvbjphZjZmMmY2NmViOWE0NGU1ODRkODc1ZDlhMTgzYzJjMF8xMjU5_9253532e-83a2-4a0f-9478-6621e18f98e5">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityCurrentReportingStatus
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xL2ZyYWc6YWY2ZjJmNjZlYjlhNDRlNTg0ZDg3NWQ5YTE4M2MyYzAvdGV4dHJlZ2lvbjphZjZmMmY2NmViOWE0NGU1ODRkODc1ZDlhMTgzYzJjMF8xMjU5_b745a982-ef78-4669-92d9-e1a5a558aae8">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xL2ZyYWc6YWY2ZjJmNjZlYjlhNDRlNTg0ZDg3NWQ5YTE4M2MyYzAvdGV4dHJlZ2lvbjphZjZmMmY2NmViOWE0NGU1ODRkODc1ZDlhMTgzYzJjMF8xNTg3_792a160b-ad61-4113-8c00-261e15c58f63">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xL2ZyYWc6YWY2ZjJmNjZlYjlhNDRlNTg0ZDg3NWQ5YTE4M2MyYzAvdGFibGU6ZWUxOTAzNGZjZDllNDQxMDkyNGM4NzFkOTJlZmUwMGMvdGFibGVyYW5nZTplZTE5MDM0ZmNkOWU0NDEwOTI0Yzg3MWQ5MmVmZTAwY18xLTAtMS0xLTU4MzcyL3RleHRyZWdpb246MWMyZWE4ODUxYWM2NDEzMDkwNGY3NDk5ZmFlOTEwMWNfNA_60363aac-e8d1-414a-9f32-7e5cfccf0bbe">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xL2ZyYWc6YWY2ZjJmNjZlYjlhNDRlNTg0ZDg3NWQ5YTE4M2MyYzAvdGFibGU6ZWUxOTAzNGZjZDllNDQxMDkyNGM4NzFkOTJlZmUwMGMvdGFibGVyYW5nZTplZTE5MDM0ZmNkOWU0NDEwOTI0Yzg3MWQ5MmVmZTAwY18xLTItMS0xLTU4MzcyL3RleHRyZWdpb246OGI2MTkxOTY4NjMzNDZiZDkwNTEyNGYwYjRiNDAyMmJfNQ_2b41a414-24f2-4bb0-9b73-8627f8d0145e">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xL2ZyYWc6YWY2ZjJmNjZlYjlhNDRlNTg0ZDg3NWQ5YTE4M2MyYzAvdGV4dHJlZ2lvbjphZjZmMmY2NmViOWE0NGU1ODRkODc1ZDlhMTgzYzJjMF8yNzQ4Nzc5MDcyOTA2_55e9218e-bd8c-49eb-bdd9-fac16d525881">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xL2ZyYWc6YWY2ZjJmNjZlYjlhNDRlNTg0ZDg3NWQ5YTE4M2MyYzAvdGV4dHJlZ2lvbjphZjZmMmY2NmViOWE0NGU1ODRkODc1ZDlhMTgzYzJjMF80OTQ3ODAyMzI4NDcw_b3493734-22e7-4af8-b37a-674e1ef296b9">false</dei:EntityExTransitionPeriod>
    <dei:IcfrAuditorAttestationFlag
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xL2ZyYWc6YWY2ZjJmNjZlYjlhNDRlNTg0ZDg3NWQ5YTE4M2MyYzAvdGV4dHJlZ2lvbjphZjZmMmY2NmViOWE0NGU1ODRkODc1ZDlhMTgzYzJjMF8zNDUy_bc88f3ed-2d30-4529-a9a0-d5b80d9a352b">false</dei:IcfrAuditorAttestationFlag>
    <dei:EntityExTransitionPeriod
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xL2ZyYWc6YWY2ZjJmNjZlYjlhNDRlNTg0ZDg3NWQ5YTE4M2MyYzAvdGV4dHJlZ2lvbjphZjZmMmY2NmViOWE0NGU1ODRkODc1ZDlhMTgzYzJjMF8yMTk5MDIzMjU5Mjc3_b3493734-22e7-4af8-b37a-674e1ef296b9">false</dei:EntityExTransitionPeriod>
    <dei:EntityExTransitionPeriod
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xL2ZyYWc6YWY2ZjJmNjZlYjlhNDRlNTg0ZDg3NWQ5YTE4M2MyYzAvdGV4dHJlZ2lvbjphZjZmMmY2NmViOWE0NGU1ODRkODc1ZDlhMTgzYzJjMF8yMTk5MDIzMjYwMDY2_b3493734-22e7-4af8-b37a-674e1ef296b9">false</dei:EntityExTransitionPeriod>
    <dei:EntityShellCompany
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xL2ZyYWc6YWY2ZjJmNjZlYjlhNDRlNTg0ZDg3NWQ5YTE4M2MyYzAvdGV4dHJlZ2lvbjphZjZmMmY2NmViOWE0NGU1ODRkODc1ZDlhMTgzYzJjMF8zNDUw_5e248e19-33e9-45c7-aa82-5292e0810be5">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="ied2db99cce6e4199865af70756a669a5_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xL2ZyYWc6YWY2ZjJmNjZlYjlhNDRlNTg0ZDg3NWQ5YTE4M2MyYzAvdGV4dHJlZ2lvbjphZjZmMmY2NmViOWE0NGU1ODRkODc1ZDlhMTgzYzJjMF8yODc5_116cca2d-6795-4d4e-9728-c8853ed59a89"
      unitRef="usd">201700000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i94f2af01a3404575802c3ac9b3d117d4_I20230301"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xL2ZyYWc6YWY2ZjJmNjZlYjlhNDRlNTg0ZDg3NWQ5YTE4M2MyYzAvdGV4dHJlZ2lvbjphZjZmMmY2NmViOWE0NGU1ODRkODc1ZDlhMTgzYzJjMF8zMDc4_153e96d0-971c-45b2-9d6d-62a1861385b5"
      unitRef="shares">111810073</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xL2ZyYWc6YWY2ZjJmNjZlYjlhNDRlNTg0ZDg3NWQ5YTE4M2MyYzAvdGV4dHJlZ2lvbjphZjZmMmY2NmViOWE0NGU1ODRkODc1ZDlhMTgzYzJjMF8zNDU0_266ca9d9-c84c-46d5-82c6-97a41a8b565f">Portions of the registrant&#x2019;s definitive proxy statement for its 2023 annual meeting of stockholders are incorporated by reference into Part III of this Form 10-K where indicated. Such definitive proxy statement will be filed with the U.S. Securities and Exchange Commission within 120 days after the year ended December 31, 2022.</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorName
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMTIvZnJhZzpmYTM5ODFjMDU5ODE0OWU2YTk0ZThiYzU5M2Q0NmYxMC90YWJsZTo3MGM0ZjM4MjRkYTc0YjBlYjFlYzA2NDRhNWExNDMxYy90YWJsZXJhbmdlOjcwYzRmMzgyNGRhNzRiMGViMWVjMDY0NGE1YTE0MzFjXzMtMC0xLTEtNTgzNzIvdGV4dHJlZ2lvbjpiY2Y1YTJmM2Y1MzQ0NzUxOGY3OTdhYWY2NGMwMTgwZl82MQ_ca3b4c15-d6df-4809-a810-6c5fc08ccc3b">Ernst &amp; Young LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMTIvZnJhZzpmYTM5ODFjMDU5ODE0OWU2YTk0ZThiYzU5M2Q0NmYxMC90YWJsZTo3MGM0ZjM4MjRkYTc0YjBlYjFlYzA2NDRhNWExNDMxYy90YWJsZXJhbmdlOjcwYzRmMzgyNGRhNzRiMGViMWVjMDY0NGE1YTE0MzFjXzMtMC0xLTEtNTgzNzIvdGV4dHJlZ2lvbjpiY2Y1YTJmM2Y1MzQ0NzUxOGY3OTdhYWY2NGMwMTgwZl82NQ_e3f2b122-d215-4c92-9b64-781ea06c8c0e">Philadelphia, PA</dei:AuditorLocation>
    <dei:AuditorFirmId
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMTIvZnJhZzpmYTM5ODFjMDU5ODE0OWU2YTk0ZThiYzU5M2Q0NmYxMC90YWJsZTo3MGM0ZjM4MjRkYTc0YjBlYjFlYzA2NDRhNWExNDMxYy90YWJsZXJhbmdlOjcwYzRmMzgyNGRhNzRiMGViMWVjMDY0NGE1YTE0MzFjXzMtMC0xLTEtNTgzNzIvdGV4dHJlZ2lvbjpiY2Y1YTJmM2Y1MzQ0NzUxOGY3OTdhYWY2NGMwMTgwZl84MA_8739bcd5-7c6d-46a8-8495-890d0cdc82b4">42</dei:AuditorFirmId>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMTgvZnJhZzpjNGZhMzAzZmMzNGM0ZWM1OTBjZGQ0ODcyNDY5NDEyZC90YWJsZTpjOTdjMDFkZTBiNzE0YTU1YmM4MGExNDI1NjYzNTlmNC90YWJsZXJhbmdlOmM5N2MwMWRlMGI3MTRhNTViYzgwYTE0MjU2NjM1OWY0XzQtMS0xLTEtNTgzNzI_e0f1930c-76a4-4276-86e6-a976065ca130"
      unitRef="usd">94244000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="id970dfd2674c4d6b895febb9c14d0fd1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMTgvZnJhZzpjNGZhMzAzZmMzNGM0ZWM1OTBjZGQ0ODcyNDY5NDEyZC90YWJsZTpjOTdjMDFkZTBiNzE0YTU1YmM4MGExNDI1NjYzNTlmNC90YWJsZXJhbmdlOmM5N2MwMWRlMGI3MTRhNTViYzgwYTE0MjU2NjM1OWY0XzQtMy0xLTEtNTgzNzI_13e472e5-78a9-475e-9d5c-c175ad5c3f7b"
      unitRef="usd">110502000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMTgvZnJhZzpjNGZhMzAzZmMzNGM0ZWM1OTBjZGQ0ODcyNDY5NDEyZC90YWJsZTpjOTdjMDFkZTBiNzE0YTU1YmM4MGExNDI1NjYzNTlmNC90YWJsZXJhbmdlOmM5N2MwMWRlMGI3MTRhNTViYzgwYTE0MjU2NjM1OWY0XzUtMS0xLTEtNTgzNzI_d197ab25-87fb-4e16-a378-3b173431f96d"
      unitRef="usd">33932000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="id970dfd2674c4d6b895febb9c14d0fd1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMTgvZnJhZzpjNGZhMzAzZmMzNGM0ZWM1OTBjZGQ0ODcyNDY5NDEyZC90YWJsZTpjOTdjMDFkZTBiNzE0YTU1YmM4MGExNDI1NjYzNTlmNC90YWJsZXJhbmdlOmM5N2MwMWRlMGI3MTRhNTViYzgwYTE0MjU2NjM1OWY0XzUtMy0xLTEtNTgzNzI_bb056244-5335-4ffa-875e-44af21c95b13"
      unitRef="usd">35449000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMTgvZnJhZzpjNGZhMzAzZmMzNGM0ZWM1OTBjZGQ0ODcyNDY5NDEyZC90YWJsZTpjOTdjMDFkZTBiNzE0YTU1YmM4MGExNDI1NjYzNTlmNC90YWJsZXJhbmdlOmM5N2MwMWRlMGI3MTRhNTViYzgwYTE0MjU2NjM1OWY0XzYtMS0xLTEtNTgzNzI_8514d1ae-a243-43ef-ba27-cc4e0cec8de0"
      unitRef="usd">9443000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="id970dfd2674c4d6b895febb9c14d0fd1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMTgvZnJhZzpjNGZhMzAzZmMzNGM0ZWM1OTBjZGQ0ODcyNDY5NDEyZC90YWJsZTpjOTdjMDFkZTBiNzE0YTU1YmM4MGExNDI1NjYzNTlmNC90YWJsZXJhbmdlOmM5N2MwMWRlMGI3MTRhNTViYzgwYTE0MjU2NjM1OWY0XzYtMy0xLTEtNTgzNzI_6b5a0b3b-f9b6-4a29-a967-090f0b5e41e2"
      unitRef="usd">11847000</us-gaap:InventoryNet>
    <us-gaap:OtherAssetsCurrent
      contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMTgvZnJhZzpjNGZhMzAzZmMzNGM0ZWM1OTBjZGQ0ODcyNDY5NDEyZC90YWJsZTpjOTdjMDFkZTBiNzE0YTU1YmM4MGExNDI1NjYzNTlmNC90YWJsZXJhbmdlOmM5N2MwMWRlMGI3MTRhNTViYzgwYTE0MjU2NjM1OWY0XzctMS0xLTEtNTgzNzI_cdc625c9-2659-404a-9fab-a843739331d1"
      unitRef="usd">2865000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="id970dfd2674c4d6b895febb9c14d0fd1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMTgvZnJhZzpjNGZhMzAzZmMzNGM0ZWM1OTBjZGQ0ODcyNDY5NDEyZC90YWJsZTpjOTdjMDFkZTBiNzE0YTU1YmM4MGExNDI1NjYzNTlmNC90YWJsZXJhbmdlOmM5N2MwMWRlMGI3MTRhNTViYzgwYTE0MjU2NjM1OWY0XzctMy0xLTEtNTgzNzI_a0c280c1-a472-4553-82fd-0f13c746b74d"
      unitRef="usd">2581000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMTgvZnJhZzpjNGZhMzAzZmMzNGM0ZWM1OTBjZGQ0ODcyNDY5NDEyZC90YWJsZTpjOTdjMDFkZTBiNzE0YTU1YmM4MGExNDI1NjYzNTlmNC90YWJsZXJhbmdlOmM5N2MwMWRlMGI3MTRhNTViYzgwYTE0MjU2NjM1OWY0XzgtMS0xLTEtNTgzNzI_3e835eab-7366-4406-a91d-383606083910"
      unitRef="usd">140484000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="id970dfd2674c4d6b895febb9c14d0fd1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMTgvZnJhZzpjNGZhMzAzZmMzNGM0ZWM1OTBjZGQ0ODcyNDY5NDEyZC90YWJsZTpjOTdjMDFkZTBiNzE0YTU1YmM4MGExNDI1NjYzNTlmNC90YWJsZXJhbmdlOmM5N2MwMWRlMGI3MTRhNTViYzgwYTE0MjU2NjM1OWY0XzgtMy0xLTEtNTgzNzI_da2b12bf-9dbd-43ba-9134-564ab52ce69e"
      unitRef="usd">160379000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMTgvZnJhZzpjNGZhMzAzZmMzNGM0ZWM1OTBjZGQ0ODcyNDY5NDEyZC90YWJsZTpjOTdjMDFkZTBiNzE0YTU1YmM4MGExNDI1NjYzNTlmNC90YWJsZXJhbmdlOmM5N2MwMWRlMGI3MTRhNTViYzgwYTE0MjU2NjM1OWY0XzktMS0xLTEtNTgzNzI_dc5f6564-8de7-4711-9c45-335938c22fe5"
      unitRef="usd">795000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="id970dfd2674c4d6b895febb9c14d0fd1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMTgvZnJhZzpjNGZhMzAzZmMzNGM0ZWM1OTBjZGQ0ODcyNDY5NDEyZC90YWJsZTpjOTdjMDFkZTBiNzE0YTU1YmM4MGExNDI1NjYzNTlmNC90YWJsZXJhbmdlOmM5N2MwMWRlMGI3MTRhNTViYzgwYTE0MjU2NjM1OWY0XzktMy0xLTEtNTgzNzI_efc666ed-1220-4af4-b872-5574a5421875"
      unitRef="usd">1347000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMTgvZnJhZzpjNGZhMzAzZmMzNGM0ZWM1OTBjZGQ0ODcyNDY5NDEyZC90YWJsZTpjOTdjMDFkZTBiNzE0YTU1YmM4MGExNDI1NjYzNTlmNC90YWJsZXJhbmdlOmM5N2MwMWRlMGI3MTRhNTViYzgwYTE0MjU2NjM1OWY0XzEwLTEtMS0xLTU4Mzcy_f62ff372-1a19-4d89-bd00-54c6335fb0b5"
      unitRef="usd">2943000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="id970dfd2674c4d6b895febb9c14d0fd1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMTgvZnJhZzpjNGZhMzAzZmMzNGM0ZWM1OTBjZGQ0ODcyNDY5NDEyZC90YWJsZTpjOTdjMDFkZTBiNzE0YTU1YmM4MGExNDI1NjYzNTlmNC90YWJsZXJhbmdlOmM5N2MwMWRlMGI3MTRhNTViYzgwYTE0MjU2NjM1OWY0XzEwLTMtMS0xLTU4Mzcy_05eb9c8d-4f17-4550-9fa4-43d20b9b80e8"
      unitRef="usd">4345000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMTgvZnJhZzpjNGZhMzAzZmMzNGM0ZWM1OTBjZGQ0ODcyNDY5NDEyZC90YWJsZTpjOTdjMDFkZTBiNzE0YTU1YmM4MGExNDI1NjYzNTlmNC90YWJsZXJhbmdlOmM5N2MwMWRlMGI3MTRhNTViYzgwYTE0MjU2NjM1OWY0XzExLTEtMS0xLTU4Mzcy_37467284-c290-4473-9592-9244efda0675"
      unitRef="usd">144222000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="id970dfd2674c4d6b895febb9c14d0fd1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMTgvZnJhZzpjNGZhMzAzZmMzNGM0ZWM1OTBjZGQ0ODcyNDY5NDEyZC90YWJsZTpjOTdjMDFkZTBiNzE0YTU1YmM4MGExNDI1NjYzNTlmNC90YWJsZXJhbmdlOmM5N2MwMWRlMGI3MTRhNTViYzgwYTE0MjU2NjM1OWY0XzExLTMtMS0xLTU4Mzcy_6c090f54-f0bf-4ada-8b52-955db21f6e17"
      unitRef="usd">166071000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMTgvZnJhZzpjNGZhMzAzZmMzNGM0ZWM1OTBjZGQ0ODcyNDY5NDEyZC90YWJsZTpjOTdjMDFkZTBiNzE0YTU1YmM4MGExNDI1NjYzNTlmNC90YWJsZXJhbmdlOmM5N2MwMWRlMGI3MTRhNTViYzgwYTE0MjU2NjM1OWY0XzE0LTEtMS0xLTU4Mzcy_99317594-8562-4e1b-84a5-2cc91a3c9289"
      unitRef="usd">5291000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="id970dfd2674c4d6b895febb9c14d0fd1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMTgvZnJhZzpjNGZhMzAzZmMzNGM0ZWM1OTBjZGQ0ODcyNDY5NDEyZC90YWJsZTpjOTdjMDFkZTBiNzE0YTU1YmM4MGExNDI1NjYzNTlmNC90YWJsZXJhbmdlOmM5N2MwMWRlMGI3MTRhNTViYzgwYTE0MjU2NjM1OWY0XzE0LTMtMS0xLTU4Mzcy_efea1ba2-34f8-4444-8953-d34ae9fe2f23"
      unitRef="usd">8013000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent
      contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMTgvZnJhZzpjNGZhMzAzZmMzNGM0ZWM1OTBjZGQ0ODcyNDY5NDEyZC90YWJsZTpjOTdjMDFkZTBiNzE0YTU1YmM4MGExNDI1NjYzNTlmNC90YWJsZXJhbmdlOmM5N2MwMWRlMGI3MTRhNTViYzgwYTE0MjU2NjM1OWY0XzE1LTEtMS0xLTU4Mzcy_6460eb52-de8c-42ce-9fd2-f06e09da99b5"
      unitRef="usd">44864000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent
      contextRef="id970dfd2674c4d6b895febb9c14d0fd1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMTgvZnJhZzpjNGZhMzAzZmMzNGM0ZWM1OTBjZGQ0ODcyNDY5NDEyZC90YWJsZTpjOTdjMDFkZTBiNzE0YTU1YmM4MGExNDI1NjYzNTlmNC90YWJsZXJhbmdlOmM5N2MwMWRlMGI3MTRhNTViYzgwYTE0MjU2NjM1OWY0XzE1LTMtMS0xLTU4Mzcy_22d72502-7996-4f36-a66a-c330fc529dd9"
      unitRef="usd">51222000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMTgvZnJhZzpjNGZhMzAzZmMzNGM0ZWM1OTBjZGQ0ODcyNDY5NDEyZC90YWJsZTpjOTdjMDFkZTBiNzE0YTU1YmM4MGExNDI1NjYzNTlmNC90YWJsZXJhbmdlOmM5N2MwMWRlMGI3MTRhNTViYzgwYTE0MjU2NjM1OWY0XzE2LTEtMS0xLTk5NjA4_7c7c0c13-d36d-4839-8f82-1536b20e583c"
      unitRef="usd">128575000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="id970dfd2674c4d6b895febb9c14d0fd1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMTgvZnJhZzpjNGZhMzAzZmMzNGM0ZWM1OTBjZGQ0ODcyNDY5NDEyZC90YWJsZTpjOTdjMDFkZTBiNzE0YTU1YmM4MGExNDI1NjYzNTlmNC90YWJsZXJhbmdlOmM5N2MwMWRlMGI3MTRhNTViYzgwYTE0MjU2NjM1OWY0XzE2LTMtMS0xLTk5NjE3_3d332f6d-72b1-4517-9095-dbae143334cd"
      unitRef="usd">0</us-gaap:LongTermDebtCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMTgvZnJhZzpjNGZhMzAzZmMzNGM0ZWM1OTBjZGQ0ODcyNDY5NDEyZC90YWJsZTpjOTdjMDFkZTBiNzE0YTU1YmM4MGExNDI1NjYzNTlmNC90YWJsZXJhbmdlOmM5N2MwMWRlMGI3MTRhNTViYzgwYTE0MjU2NjM1OWY0XzE2LTEtMS0xLTU4Mzcy_bca92ab1-2290-45cf-8048-dec3245e00c0"
      unitRef="usd">178730000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="id970dfd2674c4d6b895febb9c14d0fd1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMTgvZnJhZzpjNGZhMzAzZmMzNGM0ZWM1OTBjZGQ0ODcyNDY5NDEyZC90YWJsZTpjOTdjMDFkZTBiNzE0YTU1YmM4MGExNDI1NjYzNTlmNC90YWJsZXJhbmdlOmM5N2MwMWRlMGI3MTRhNTViYzgwYTE0MjU2NjM1OWY0XzE2LTMtMS0xLTU4Mzcy_0d9f8f78-4a86-4ca2-9f6c-c01283563d90"
      unitRef="usd">59235000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMTgvZnJhZzpjNGZhMzAzZmMzNGM0ZWM1OTBjZGQ0ODcyNDY5NDEyZC90YWJsZTpjOTdjMDFkZTBiNzE0YTU1YmM4MGExNDI1NjYzNTlmNC90YWJsZXJhbmdlOmM5N2MwMWRlMGI3MTRhNTViYzgwYTE0MjU2NjM1OWY0XzE3LTEtMS0xLTU4Mzcy_322c99f2-e4ab-4b33-8528-6ee74105a828"
      unitRef="usd">0</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="id970dfd2674c4d6b895febb9c14d0fd1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMTgvZnJhZzpjNGZhMzAzZmMzNGM0ZWM1OTBjZGQ0ODcyNDY5NDEyZC90YWJsZTpjOTdjMDFkZTBiNzE0YTU1YmM4MGExNDI1NjYzNTlmNC90YWJsZXJhbmdlOmM5N2MwMWRlMGI3MTRhNTViYzgwYTE0MjU2NjM1OWY0XzE3LTMtMS0xLTU4Mzcy_efd15c7b-01d7-47fa-8b39-afce4951385a"
      unitRef="usd">126418000</us-gaap:LongTermDebtNoncurrent>
    <optn:WarrantLiabilityNonCurrent
      contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMTgvZnJhZzpjNGZhMzAzZmMzNGM0ZWM1OTBjZGQ0ODcyNDY5NDEyZC90YWJsZTpjOTdjMDFkZTBiNzE0YTU1YmM4MGExNDI1NjYzNTlmNC90YWJsZXJhbmdlOmM5N2MwMWRlMGI3MTRhNTViYzgwYTE0MjU2NjM1OWY0XzE5LTEtMS0xLTEwMDE3NQ_36163005-35ec-4aa3-9b8f-b48ddfc41408"
      unitRef="usd">21490000</optn:WarrantLiabilityNonCurrent>
    <optn:WarrantLiabilityNonCurrent
      contextRef="id970dfd2674c4d6b895febb9c14d0fd1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMTgvZnJhZzpjNGZhMzAzZmMzNGM0ZWM1OTBjZGQ0ODcyNDY5NDEyZC90YWJsZTpjOTdjMDFkZTBiNzE0YTU1YmM4MGExNDI1NjYzNTlmNC90YWJsZXJhbmdlOmM5N2MwMWRlMGI3MTRhNTViYzgwYTE0MjU2NjM1OWY0XzE5LTMtMS0xLTEwMDE4Mw_24b014c0-7b3c-4119-81bd-4b89a4af747c"
      unitRef="usd">0</optn:WarrantLiabilityNonCurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMTgvZnJhZzpjNGZhMzAzZmMzNGM0ZWM1OTBjZGQ0ODcyNDY5NDEyZC90YWJsZTpjOTdjMDFkZTBiNzE0YTU1YmM4MGExNDI1NjYzNTlmNC90YWJsZXJhbmdlOmM5N2MwMWRlMGI3MTRhNTViYzgwYTE0MjU2NjM1OWY0XzE4LTEtMS0xLTU4Mzcy_14c0227c-2d24-444f-a800-115f3782a41a"
      unitRef="usd">626000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="id970dfd2674c4d6b895febb9c14d0fd1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMTgvZnJhZzpjNGZhMzAzZmMzNGM0ZWM1OTBjZGQ0ODcyNDY5NDEyZC90YWJsZTpjOTdjMDFkZTBiNzE0YTU1YmM4MGExNDI1NjYzNTlmNC90YWJsZXJhbmdlOmM5N2MwMWRlMGI3MTRhNTViYzgwYTE0MjU2NjM1OWY0XzE4LTMtMS0xLTU4Mzcy_534a9219-1962-498c-a998-3cad8cff5e97"
      unitRef="usd">2190000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMTgvZnJhZzpjNGZhMzAzZmMzNGM0ZWM1OTBjZGQ0ODcyNDY5NDEyZC90YWJsZTpjOTdjMDFkZTBiNzE0YTU1YmM4MGExNDI1NjYzNTlmNC90YWJsZXJhbmdlOmM5N2MwMWRlMGI3MTRhNTViYzgwYTE0MjU2NjM1OWY0XzE5LTEtMS0xLTU4Mzcy_ea49b819-da49-4773-8432-d06f358d9696"
      unitRef="usd">200846000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="id970dfd2674c4d6b895febb9c14d0fd1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMTgvZnJhZzpjNGZhMzAzZmMzNGM0ZWM1OTBjZGQ0ODcyNDY5NDEyZC90YWJsZTpjOTdjMDFkZTBiNzE0YTU1YmM4MGExNDI1NjYzNTlmNC90YWJsZXJhbmdlOmM5N2MwMWRlMGI3MTRhNTViYzgwYTE0MjU2NjM1OWY0XzE5LTMtMS0xLTU4Mzcy_e76c3ae3-5d10-4953-a5b4-91ab91f338bf"
      unitRef="usd">187843000</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="id970dfd2674c4d6b895febb9c14d0fd1_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMTgvZnJhZzpjNGZhMzAzZmMzNGM0ZWM1OTBjZGQ0ODcyNDY5NDEyZC90YWJsZTpjOTdjMDFkZTBiNzE0YTU1YmM4MGExNDI1NjYzNTlmNC90YWJsZXJhbmdlOmM5N2MwMWRlMGI3MTRhNTViYzgwYTE0MjU2NjM1OWY0XzIyLTAtMS0xLTU4MzcyL3RleHRyZWdpb246ZmM2NTJlYmRkYjRlNDY4NGJjNDA4Mjk0NTU4ODBkZDVfMTg_2c9e7476-f691-49d9-8eb3-5d05cdf7eb26"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMTgvZnJhZzpjNGZhMzAzZmMzNGM0ZWM1OTBjZGQ0ODcyNDY5NDEyZC90YWJsZTpjOTdjMDFkZTBiNzE0YTU1YmM4MGExNDI1NjYzNTlmNC90YWJsZXJhbmdlOmM5N2MwMWRlMGI3MTRhNTViYzgwYTE0MjU2NjM1OWY0XzIyLTAtMS0xLTU4MzcyL3RleHRyZWdpb246ZmM2NTJlYmRkYjRlNDY4NGJjNDA4Mjk0NTU4ODBkZDVfMTg_b61dc5f6-7dcf-4970-8600-d119f49b453d"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="id970dfd2674c4d6b895febb9c14d0fd1_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMTgvZnJhZzpjNGZhMzAzZmMzNGM0ZWM1OTBjZGQ0ODcyNDY5NDEyZC90YWJsZTpjOTdjMDFkZTBiNzE0YTU1YmM4MGExNDI1NjYzNTlmNC90YWJsZXJhbmdlOmM5N2MwMWRlMGI3MTRhNTViYzgwYTE0MjU2NjM1OWY0XzIyLTAtMS0xLTU4MzcyL3RleHRyZWdpb246ZmM2NTJlYmRkYjRlNDY4NGJjNDA4Mjk0NTU4ODBkZDVfMzI_64e6d33b-0fdb-484e-a9a6-8d751b293fbd"
      unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMTgvZnJhZzpjNGZhMzAzZmMzNGM0ZWM1OTBjZGQ0ODcyNDY5NDEyZC90YWJsZTpjOTdjMDFkZTBiNzE0YTU1YmM4MGExNDI1NjYzNTlmNC90YWJsZXJhbmdlOmM5N2MwMWRlMGI3MTRhNTViYzgwYTE0MjU2NjM1OWY0XzIyLTAtMS0xLTU4MzcyL3RleHRyZWdpb246ZmM2NTJlYmRkYjRlNDY4NGJjNDA4Mjk0NTU4ODBkZDVfMzI_83472d63-92bb-47f1-a075-e134bb584817"
      unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMTgvZnJhZzpjNGZhMzAzZmMzNGM0ZWM1OTBjZGQ0ODcyNDY5NDEyZC90YWJsZTpjOTdjMDFkZTBiNzE0YTU1YmM4MGExNDI1NjYzNTlmNC90YWJsZXJhbmdlOmM5N2MwMWRlMGI3MTRhNTViYzgwYTE0MjU2NjM1OWY0XzIyLTAtMS0xLTU4MzcyL3RleHRyZWdpb246ZmM2NTJlYmRkYjRlNDY4NGJjNDA4Mjk0NTU4ODBkZDVfODI0NjMzNzIwODQ1NA_233544f3-2726-41e0-8bc2-c1bfce6d2541"
      unitRef="shares">111492761</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMTgvZnJhZzpjNGZhMzAzZmMzNGM0ZWM1OTBjZGQ0ODcyNDY5NDEyZC90YWJsZTpjOTdjMDFkZTBiNzE0YTU1YmM4MGExNDI1NjYzNTlmNC90YWJsZXJhbmdlOmM5N2MwMWRlMGI3MTRhNTViYzgwYTE0MjU2NjM1OWY0XzIyLTAtMS0xLTU4MzcyL3RleHRyZWdpb246ZmM2NTJlYmRkYjRlNDY4NGJjNDA4Mjk0NTU4ODBkZDVfODI0NjMzNzIwODQ1NA_da3140b7-82d0-45f7-81fa-2b47ecee0256"
      unitRef="shares">111492761</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="id970dfd2674c4d6b895febb9c14d0fd1_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMTgvZnJhZzpjNGZhMzAzZmMzNGM0ZWM1OTBjZGQ0ODcyNDY5NDEyZC90YWJsZTpjOTdjMDFkZTBiNzE0YTU1YmM4MGExNDI1NjYzNTlmNC90YWJsZXJhbmdlOmM5N2MwMWRlMGI3MTRhNTViYzgwYTE0MjU2NjM1OWY0XzIyLTAtMS0xLTU4MzcyL3RleHRyZWdpb246ZmM2NTJlYmRkYjRlNDY4NGJjNDA4Mjk0NTU4ODBkZDVfODI0NjMzNzIwODQ1OA_16ef56c4-09f0-4267-aa8e-708cd032712d"
      unitRef="shares">82238900</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="id970dfd2674c4d6b895febb9c14d0fd1_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMTgvZnJhZzpjNGZhMzAzZmMzNGM0ZWM1OTBjZGQ0ODcyNDY5NDEyZC90YWJsZTpjOTdjMDFkZTBiNzE0YTU1YmM4MGExNDI1NjYzNTlmNC90YWJsZXJhbmdlOmM5N2MwMWRlMGI3MTRhNTViYzgwYTE0MjU2NjM1OWY0XzIyLTAtMS0xLTU4MzcyL3RleHRyZWdpb246ZmM2NTJlYmRkYjRlNDY4NGJjNDA4Mjk0NTU4ODBkZDVfODI0NjMzNzIwODQ1OA_e8ed257d-cded-43ce-852e-cf3f733c9e6c"
      unitRef="shares">82238900</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMTgvZnJhZzpjNGZhMzAzZmMzNGM0ZWM1OTBjZGQ0ODcyNDY5NDEyZC90YWJsZTpjOTdjMDFkZTBiNzE0YTU1YmM4MGExNDI1NjYzNTlmNC90YWJsZXJhbmdlOmM5N2MwMWRlMGI3MTRhNTViYzgwYTE0MjU2NjM1OWY0XzIyLTEtMS0xLTU4Mzcy_28edb870-fd97-49f0-a0f2-0a24f6190eb5"
      unitRef="usd">111000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="id970dfd2674c4d6b895febb9c14d0fd1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMTgvZnJhZzpjNGZhMzAzZmMzNGM0ZWM1OTBjZGQ0ODcyNDY5NDEyZC90YWJsZTpjOTdjMDFkZTBiNzE0YTU1YmM4MGExNDI1NjYzNTlmNC90YWJsZXJhbmdlOmM5N2MwMWRlMGI3MTRhNTViYzgwYTE0MjU2NjM1OWY0XzIyLTMtMS0xLTU4Mzcy_912ae8b2-a8e9-463c-b45c-de16e64e2a21"
      unitRef="usd">82000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMTgvZnJhZzpjNGZhMzAzZmMzNGM0ZWM1OTBjZGQ0ODcyNDY5NDEyZC90YWJsZTpjOTdjMDFkZTBiNzE0YTU1YmM4MGExNDI1NjYzNTlmNC90YWJsZXJhbmdlOmM5N2MwMWRlMGI3MTRhNTViYzgwYTE0MjU2NjM1OWY0XzIzLTEtMS0xLTU4Mzcy_93c3dda8-a376-4b7b-b01a-80949a1e5242"
      unitRef="usd">628242000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="id970dfd2674c4d6b895febb9c14d0fd1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMTgvZnJhZzpjNGZhMzAzZmMzNGM0ZWM1OTBjZGQ0ODcyNDY5NDEyZC90YWJsZTpjOTdjMDFkZTBiNzE0YTU1YmM4MGExNDI1NjYzNTlmNC90YWJsZXJhbmdlOmM5N2MwMWRlMGI3MTRhNTViYzgwYTE0MjU2NjM1OWY0XzIzLTMtMS0xLTU4Mzcy_1f7bf97a-a7c3-4370-85a9-e78549e1a27d"
      unitRef="usd">588288000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMTgvZnJhZzpjNGZhMzAzZmMzNGM0ZWM1OTBjZGQ0ODcyNDY5NDEyZC90YWJsZTpjOTdjMDFkZTBiNzE0YTU1YmM4MGExNDI1NjYzNTlmNC90YWJsZXJhbmdlOmM5N2MwMWRlMGI3MTRhNTViYzgwYTE0MjU2NjM1OWY0XzI0LTEtMS0xLTU4Mzcy_bf2a07f6-22f0-409a-a739-62ac11647867"
      unitRef="usd">-684893000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="id970dfd2674c4d6b895febb9c14d0fd1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMTgvZnJhZzpjNGZhMzAzZmMzNGM0ZWM1OTBjZGQ0ODcyNDY5NDEyZC90YWJsZTpjOTdjMDFkZTBiNzE0YTU1YmM4MGExNDI1NjYzNTlmNC90YWJsZXJhbmdlOmM5N2MwMWRlMGI3MTRhNTViYzgwYTE0MjU2NjM1OWY0XzI0LTMtMS0xLTU4Mzcy_2fcdcfe1-7935-42f8-9496-9c5da6d92979"
      unitRef="usd">-610061000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMTgvZnJhZzpjNGZhMzAzZmMzNGM0ZWM1OTBjZGQ0ODcyNDY5NDEyZC90YWJsZTpjOTdjMDFkZTBiNzE0YTU1YmM4MGExNDI1NjYzNTlmNC90YWJsZXJhbmdlOmM5N2MwMWRlMGI3MTRhNTViYzgwYTE0MjU2NjM1OWY0XzI1LTEtMS0xLTU4Mzcy_ccb2d06b-69c4-4be8-a58f-a16e01b15e45"
      unitRef="usd">-84000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="id970dfd2674c4d6b895febb9c14d0fd1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMTgvZnJhZzpjNGZhMzAzZmMzNGM0ZWM1OTBjZGQ0ODcyNDY5NDEyZC90YWJsZTpjOTdjMDFkZTBiNzE0YTU1YmM4MGExNDI1NjYzNTlmNC90YWJsZXJhbmdlOmM5N2MwMWRlMGI3MTRhNTViYzgwYTE0MjU2NjM1OWY0XzI1LTMtMS0xLTU4Mzcy_4c22cbb8-72ca-408f-810e-36713de2be82"
      unitRef="usd">-81000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMTgvZnJhZzpjNGZhMzAzZmMzNGM0ZWM1OTBjZGQ0ODcyNDY5NDEyZC90YWJsZTpjOTdjMDFkZTBiNzE0YTU1YmM4MGExNDI1NjYzNTlmNC90YWJsZXJhbmdlOmM5N2MwMWRlMGI3MTRhNTViYzgwYTE0MjU2NjM1OWY0XzI2LTEtMS0xLTU4Mzcy_ddc18304-a8cd-4a8e-b00c-0c9735b67808"
      unitRef="usd">-56624000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id970dfd2674c4d6b895febb9c14d0fd1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMTgvZnJhZzpjNGZhMzAzZmMzNGM0ZWM1OTBjZGQ0ODcyNDY5NDEyZC90YWJsZTpjOTdjMDFkZTBiNzE0YTU1YmM4MGExNDI1NjYzNTlmNC90YWJsZXJhbmdlOmM5N2MwMWRlMGI3MTRhNTViYzgwYTE0MjU2NjM1OWY0XzI2LTMtMS0xLTU4Mzcy_5a7157fc-4860-4dea-917c-5730ef51999e"
      unitRef="usd">-21772000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMTgvZnJhZzpjNGZhMzAzZmMzNGM0ZWM1OTBjZGQ0ODcyNDY5NDEyZC90YWJsZTpjOTdjMDFkZTBiNzE0YTU1YmM4MGExNDI1NjYzNTlmNC90YWJsZXJhbmdlOmM5N2MwMWRlMGI3MTRhNTViYzgwYTE0MjU2NjM1OWY0XzI3LTEtMS0xLTU4Mzcy_e29efc67-c77f-48af-ab21-c26d5b5b4935"
      unitRef="usd">144222000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="id970dfd2674c4d6b895febb9c14d0fd1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMTgvZnJhZzpjNGZhMzAzZmMzNGM0ZWM1OTBjZGQ0ODcyNDY5NDEyZC90YWJsZTpjOTdjMDFkZTBiNzE0YTU1YmM4MGExNDI1NjYzNTlmNC90YWJsZXJhbmdlOmM5N2MwMWRlMGI3MTRhNTViYzgwYTE0MjU2NjM1OWY0XzI3LTMtMS0xLTU4Mzcy_a78ab594-3ec0-4044-a91d-c2d321201f36"
      unitRef="usd">166071000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7d7389924c8a481f922afd27c2d98be6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjEvZnJhZzo4NTJiMDQ1MDI0MjM0YWNiYTY5ZGIyOWQwZTg2M2ZiMi90YWJsZTo1MzYwMzE3NzMzM2E0ODBkODRiMTJhNTg4ZGEyMzE0Zi90YWJsZXJhbmdlOjUzNjAzMTc3MzMzYTQ4MGQ4NGIxMmE1ODhkYTIzMTRmXzMtMi0xLTEtNTgzNzI_b298272e-4829-4fba-b3e7-7ed5519c0d2b"
      unitRef="usd">76276000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i86422cbece424367a1550b9f28481643_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjEvZnJhZzo4NTJiMDQ1MDI0MjM0YWNiYTY5ZGIyOWQwZTg2M2ZiMi90YWJsZTo1MzYwMzE3NzMzM2E0ODBkODRiMTJhNTg4ZGEyMzE0Zi90YWJsZXJhbmdlOjUzNjAzMTc3MzMzYTQ4MGQ4NGIxMmE1ODhkYTIzMTRmXzMtNC0xLTEtNTgzNzI_aea095cc-a8c1-4bd5-a630-9438e39655ef"
      unitRef="usd">73652000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifb05b53856a04e6fb8d77b2615fef7b5_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjEvZnJhZzo4NTJiMDQ1MDI0MjM0YWNiYTY5ZGIyOWQwZTg2M2ZiMi90YWJsZTo1MzYwMzE3NzMzM2E0ODBkODRiMTJhNTg4ZGEyMzE0Zi90YWJsZXJhbmdlOjUzNjAzMTc3MzMzYTQ4MGQ4NGIxMmE1ODhkYTIzMTRmXzQtMi0xLTEtNTgzNzI_e8765185-e54a-4df4-bc8b-303cbe7fa6de"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0a537887f3924b21a34b339e3a39c085_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjEvZnJhZzo4NTJiMDQ1MDI0MjM0YWNiYTY5ZGIyOWQwZTg2M2ZiMi90YWJsZTo1MzYwMzE3NzMzM2E0ODBkODRiMTJhNTg4ZGEyMzE0Zi90YWJsZXJhbmdlOjUzNjAzMTc3MzMzYTQ4MGQ4NGIxMmE1ODhkYTIzMTRmXzQtNC0xLTEtNTgzNzI_adca1f7b-00ac-40f9-aedc-9b9d85c6e1c7"
      unitRef="usd">1000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjEvZnJhZzo4NTJiMDQ1MDI0MjM0YWNiYTY5ZGIyOWQwZTg2M2ZiMi90YWJsZTo1MzYwMzE3NzMzM2E0ODBkODRiMTJhNTg4ZGEyMzE0Zi90YWJsZXJhbmdlOjUzNjAzMTc3MzMzYTQ4MGQ4NGIxMmE1ODhkYTIzMTRmXzUtMi0xLTEtNTgzNzI_a3f13825-aee5-43c4-babd-40ee04bbb94f"
      unitRef="usd">76276000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjEvZnJhZzo4NTJiMDQ1MDI0MjM0YWNiYTY5ZGIyOWQwZTg2M2ZiMi90YWJsZTo1MzYwMzE3NzMzM2E0ODBkODRiMTJhNTg4ZGEyMzE0Zi90YWJsZXJhbmdlOjUzNjAzMTc3MzMzYTQ4MGQ4NGIxMmE1ODhkYTIzMTRmXzUtNC0xLTEtNTgzNzI_1c5d13b4-e499-4d4c-bcd8-1b6ffa94b058"
      unitRef="usd">74652000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjEvZnJhZzo4NTJiMDQ1MDI0MjM0YWNiYTY5ZGIyOWQwZTg2M2ZiMi90YWJsZTo1MzYwMzE3NzMzM2E0ODBkODRiMTJhNTg4ZGEyMzE0Zi90YWJsZXJhbmdlOjUzNjAzMTc3MzMzYTQ4MGQ4NGIxMmE1ODhkYTIzMTRmXzctMi0xLTEtNTgzNzI_76e8a4cb-4924-440f-9e02-008a31305a89"
      unitRef="usd">9263000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjEvZnJhZzo4NTJiMDQ1MDI0MjM0YWNiYTY5ZGIyOWQwZTg2M2ZiMi90YWJsZTo1MzYwMzE3NzMzM2E0ODBkODRiMTJhNTg4ZGEyMzE0Zi90YWJsZXJhbmdlOjUzNjAzMTc3MzMzYTQ4MGQ4NGIxMmE1ODhkYTIzMTRmXzctNC0xLTEtNTgzNzI_3e633e64-507a-4b44-a0a2-25bd283c7f01"
      unitRef="usd">9151000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjEvZnJhZzo4NTJiMDQ1MDI0MjM0YWNiYTY5ZGIyOWQwZTg2M2ZiMi90YWJsZTo1MzYwMzE3NzMzM2E0ODBkODRiMTJhNTg4ZGEyMzE0Zi90YWJsZXJhbmdlOjUzNjAzMTc3MzMzYTQ4MGQ4NGIxMmE1ODhkYTIzMTRmXzgtMi0xLTEtNTgzNzI_b00164b4-a58b-43c5-b121-29fe4386c4f8"
      unitRef="usd">15260000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjEvZnJhZzo4NTJiMDQ1MDI0MjM0YWNiYTY5ZGIyOWQwZTg2M2ZiMi90YWJsZTo1MzYwMzE3NzMzM2E0ODBkODRiMTJhNTg4ZGEyMzE0Zi90YWJsZXJhbmdlOjUzNjAzMTc3MzMzYTQ4MGQ4NGIxMmE1ODhkYTIzMTRmXzgtNC0xLTEtNTgzNzI_c321f07b-c6d4-47a9-8243-d85c2557c5ca"
      unitRef="usd">25318000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjEvZnJhZzo4NTJiMDQ1MDI0MjM0YWNiYTY5ZGIyOWQwZTg2M2ZiMi90YWJsZTo1MzYwMzE3NzMzM2E0ODBkODRiMTJhNTg4ZGEyMzE0Zi90YWJsZXJhbmdlOjUzNjAzMTc3MzMzYTQ4MGQ4NGIxMmE1ODhkYTIzMTRmXzktMi0xLTEtNTgzNzI_68807eac-81a9-4c35-aa48-97fe36835a81"
      unitRef="usd">107649000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjEvZnJhZzo4NTJiMDQ1MDI0MjM0YWNiYTY5ZGIyOWQwZTg2M2ZiMi90YWJsZTo1MzYwMzE3NzMzM2E0ODBkODRiMTJhNTg4ZGEyMzE0Zi90YWJsZXJhbmdlOjUzNjAzMTc3MzMzYTQ4MGQ4NGIxMmE1ODhkYTIzMTRmXzktNC0xLTEtNTgzNzI_5d96acad-a774-4812-a28d-cd4d7fa79ce5"
      unitRef="usd">106633000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:CostsAndExpenses
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjEvZnJhZzo4NTJiMDQ1MDI0MjM0YWNiYTY5ZGIyOWQwZTg2M2ZiMi90YWJsZTo1MzYwMzE3NzMzM2E0ODBkODRiMTJhNTg4ZGEyMzE0Zi90YWJsZXJhbmdlOjUzNjAzMTc3MzMzYTQ4MGQ4NGIxMmE1ODhkYTIzMTRmXzEwLTItMS0xLTU4Mzcy_5a715da2-db1e-45fd-8c8f-adfceff5de30"
      unitRef="usd">132172000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjEvZnJhZzo4NTJiMDQ1MDI0MjM0YWNiYTY5ZGIyOWQwZTg2M2ZiMi90YWJsZTo1MzYwMzE3NzMzM2E0ODBkODRiMTJhNTg4ZGEyMzE0Zi90YWJsZXJhbmdlOjUzNjAzMTc3MzMzYTQ4MGQ4NGIxMmE1ODhkYTIzMTRmXzEwLTQtMS0xLTU4Mzcy_66b006e4-076c-4544-a510-61e06ee1095e"
      unitRef="usd">141102000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjEvZnJhZzo4NTJiMDQ1MDI0MjM0YWNiYTY5ZGIyOWQwZTg2M2ZiMi90YWJsZTo1MzYwMzE3NzMzM2E0ODBkODRiMTJhNTg4ZGEyMzE0Zi90YWJsZXJhbmdlOjUzNjAzMTc3MzMzYTQ4MGQ4NGIxMmE1ODhkYTIzMTRmXzExLTItMS0xLTU4Mzcy_500a6c08-ae5b-4859-89fc-d0d66c9c4c2c"
      unitRef="usd">-55896000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjEvZnJhZzo4NTJiMDQ1MDI0MjM0YWNiYTY5ZGIyOWQwZTg2M2ZiMi90YWJsZTo1MzYwMzE3NzMzM2E0ODBkODRiMTJhNTg4ZGEyMzE0Zi90YWJsZXJhbmdlOjUzNjAzMTc3MzMzYTQ4MGQ4NGIxMmE1ODhkYTIzMTRmXzExLTQtMS0xLTU4Mzcy_afb0af3c-b4c8-40e8-98c8-1cd0cc65d946"
      unitRef="usd">-66450000</us-gaap:OperatingIncomeLoss>
    <optn:UnrealizedGainLossOnFairValueOfWarrants
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjEvZnJhZzo4NTJiMDQ1MDI0MjM0YWNiYTY5ZGIyOWQwZTg2M2ZiMi90YWJsZTo1MzYwMzE3NzMzM2E0ODBkODRiMTJhNTg4ZGEyMzE0Zi90YWJsZXJhbmdlOjUzNjAzMTc3MzMzYTQ4MGQ4NGIxMmE1ODhkYTIzMTRmXzEzLTItMS0xLTEwMTg3MQ_0e5ba270-ca01-4e12-9bc3-0f318017c333"
      unitRef="usd">-1211000</optn:UnrealizedGainLossOnFairValueOfWarrants>
    <optn:UnrealizedGainLossOnFairValueOfWarrants
      contextRef="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjEvZnJhZzo4NTJiMDQ1MDI0MjM0YWNiYTY5ZGIyOWQwZTg2M2ZiMi90YWJsZTo1MzYwMzE3NzMzM2E0ODBkODRiMTJhNTg4ZGEyMzE0Zi90YWJsZXJhbmdlOjUzNjAzMTc3MzMzYTQ4MGQ4NGIxMmE1ODhkYTIzMTRmXzEzLTQtMS0xLTEwMTg3OQ_b095b3a0-dcc4-4a20-92bf-f832cd3d6bdb"
      unitRef="usd">0</optn:UnrealizedGainLossOnFairValueOfWarrants>
    <optn:GrantAndOtherIncome
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjEvZnJhZzo4NTJiMDQ1MDI0MjM0YWNiYTY5ZGIyOWQwZTg2M2ZiMi90YWJsZTo1MzYwMzE3NzMzM2E0ODBkODRiMTJhNTg4ZGEyMzE0Zi90YWJsZXJhbmdlOjUzNjAzMTc3MzMzYTQ4MGQ4NGIxMmE1ODhkYTIzMTRmXzEzLTItMS0xLTU4Mzcy_ae75a009-7a84-4bae-bcf0-f5f634a025aa"
      unitRef="usd">-1396000</optn:GrantAndOtherIncome>
    <optn:GrantAndOtherIncome
      contextRef="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjEvZnJhZzo4NTJiMDQ1MDI0MjM0YWNiYTY5ZGIyOWQwZTg2M2ZiMi90YWJsZTo1MzYwMzE3NzMzM2E0ODBkODRiMTJhNTg4ZGEyMzE0Zi90YWJsZXJhbmdlOjUzNjAzMTc3MzMzYTQ4MGQ4NGIxMmE1ODhkYTIzMTRmXzEzLTQtMS0xLTU4Mzcy_d40a41f4-0114-4658-9c60-62563b17b929"
      unitRef="usd">75000</optn:GrantAndOtherIncome>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjEvZnJhZzo4NTJiMDQ1MDI0MjM0YWNiYTY5ZGIyOWQwZTg2M2ZiMi90YWJsZTo1MzYwMzE3NzMzM2E0ODBkODRiMTJhNTg4ZGEyMzE0Zi90YWJsZXJhbmdlOjUzNjAzMTc3MzMzYTQ4MGQ4NGIxMmE1ODhkYTIzMTRmXzE0LTItMS0xLTU4Mzcy_3a899b74-64ee-4323-9fab-db515b2ff0bb"
      unitRef="usd">513000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjEvZnJhZzo4NTJiMDQ1MDI0MjM0YWNiYTY5ZGIyOWQwZTg2M2ZiMi90YWJsZTo1MzYwMzE3NzMzM2E0ODBkODRiMTJhNTg4ZGEyMzE0Zi90YWJsZXJhbmdlOjUzNjAzMTc3MzMzYTQ4MGQ4NGIxMmE1ODhkYTIzMTRmXzE0LTQtMS0xLTU4Mzcy_35e794eb-7eea-4874-bf5b-77e934e9c394"
      unitRef="usd">52000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjEvZnJhZzo4NTJiMDQ1MDI0MjM0YWNiYTY5ZGIyOWQwZTg2M2ZiMi90YWJsZTo1MzYwMzE3NzMzM2E0ODBkODRiMTJhNTg4ZGEyMzE0Zi90YWJsZXJhbmdlOjUzNjAzMTc3MzMzYTQ4MGQ4NGIxMmE1ODhkYTIzMTRmXzE1LTItMS0xLTU4Mzcy_e2c01b69-38f8-4d4c-b7c2-7b975ffdc69c"
      unitRef="usd">16843000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjEvZnJhZzo4NTJiMDQ1MDI0MjM0YWNiYTY5ZGIyOWQwZTg2M2ZiMi90YWJsZTo1MzYwMzE3NzMzM2E0ODBkODRiMTJhNTg4ZGEyMzE0Zi90YWJsZXJhbmdlOjUzNjAzMTc3MzMzYTQ4MGQ4NGIxMmE1ODhkYTIzMTRmXzE1LTQtMS0xLTU4Mzcy_7d5ef8c8-dddb-463b-aef3-df41d19d4c6a"
      unitRef="usd">15973000</us-gaap:InterestExpense>
    <us-gaap:NetIncomeLoss
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjEvZnJhZzo4NTJiMDQ1MDI0MjM0YWNiYTY5ZGIyOWQwZTg2M2ZiMi90YWJsZTo1MzYwMzE3NzMzM2E0ODBkODRiMTJhNTg4ZGEyMzE0Zi90YWJsZXJhbmdlOjUzNjAzMTc3MzMzYTQ4MGQ4NGIxMmE1ODhkYTIzMTRmXzE4LTItMS0xLTU4Mzcy_9942a75e-d81f-4c3e-90c5-f4b721f15483"
      unitRef="usd">-74833000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjEvZnJhZzo4NTJiMDQ1MDI0MjM0YWNiYTY5ZGIyOWQwZTg2M2ZiMi90YWJsZTo1MzYwMzE3NzMzM2E0ODBkODRiMTJhNTg4ZGEyMzE0Zi90YWJsZXJhbmdlOjUzNjAzMTc3MzMzYTQ4MGQ4NGIxMmE1ODhkYTIzMTRmXzE4LTQtMS0xLTU4Mzcy_9e9228fb-8e24-4636-9cbf-b3a7fe535a91"
      unitRef="usd">-82296000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjEvZnJhZzo4NTJiMDQ1MDI0MjM0YWNiYTY5ZGIyOWQwZTg2M2ZiMi90YWJsZTo1MzYwMzE3NzMzM2E0ODBkODRiMTJhNTg4ZGEyMzE0Zi90YWJsZXJhbmdlOjUzNjAzMTc3MzMzYTQ4MGQ4NGIxMmE1ODhkYTIzMTRmXzE5LTItMS0xLTU4Mzcy_627d29a7-8aca-4095-8d50-148962fc4e53"
      unitRef="usdPerShare">-0.87</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjEvZnJhZzo4NTJiMDQ1MDI0MjM0YWNiYTY5ZGIyOWQwZTg2M2ZiMi90YWJsZTo1MzYwMzE3NzMzM2E0ODBkODRiMTJhNTg4ZGEyMzE0Zi90YWJsZXJhbmdlOjUzNjAzMTc3MzMzYTQ4MGQ4NGIxMmE1ODhkYTIzMTRmXzE5LTItMS0xLTU4Mzcy_aa3c7ce3-e009-447d-96d1-486c681b581b"
      unitRef="usdPerShare">-0.87</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjEvZnJhZzo4NTJiMDQ1MDI0MjM0YWNiYTY5ZGIyOWQwZTg2M2ZiMi90YWJsZTo1MzYwMzE3NzMzM2E0ODBkODRiMTJhNTg4ZGEyMzE0Zi90YWJsZXJhbmdlOjUzNjAzMTc3MzMzYTQ4MGQ4NGIxMmE1ODhkYTIzMTRmXzE5LTQtMS0xLTU4Mzcy_17b9e13b-fb8d-42ce-81ba-a99ba3a1179e"
      unitRef="usdPerShare">-1.45</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjEvZnJhZzo4NTJiMDQ1MDI0MjM0YWNiYTY5ZGIyOWQwZTg2M2ZiMi90YWJsZTo1MzYwMzE3NzMzM2E0ODBkODRiMTJhNTg4ZGEyMzE0Zi90YWJsZXJhbmdlOjUzNjAzMTc3MzMzYTQ4MGQ4NGIxMmE1ODhkYTIzMTRmXzE5LTQtMS0xLTU4Mzcy_1ea527e6-b292-45db-bc9b-2cd0e1b57d99"
      unitRef="usdPerShare">-1.45</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjEvZnJhZzo4NTJiMDQ1MDI0MjM0YWNiYTY5ZGIyOWQwZTg2M2ZiMi90YWJsZTo1MzYwMzE3NzMzM2E0ODBkODRiMTJhNTg4ZGEyMzE0Zi90YWJsZXJhbmdlOjUzNjAzMTc3MzMzYTQ4MGQ4NGIxMmE1ODhkYTIzMTRmXzIwLTItMS0xLTU4Mzcy_3ada0b41-0730-4ff9-9810-9c99bf1980f3"
      unitRef="shares">85900139</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjEvZnJhZzo4NTJiMDQ1MDI0MjM0YWNiYTY5ZGIyOWQwZTg2M2ZiMi90YWJsZTo1MzYwMzE3NzMzM2E0ODBkODRiMTJhNTg4ZGEyMzE0Zi90YWJsZXJhbmdlOjUzNjAzMTc3MzMzYTQ4MGQ4NGIxMmE1ODhkYTIzMTRmXzIwLTItMS0xLTU4Mzcy_c63172e5-7468-48b3-a937-7bae97bd7b65"
      unitRef="shares">85900139</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjEvZnJhZzo4NTJiMDQ1MDI0MjM0YWNiYTY5ZGIyOWQwZTg2M2ZiMi90YWJsZTo1MzYwMzE3NzMzM2E0ODBkODRiMTJhNTg4ZGEyMzE0Zi90YWJsZXJhbmdlOjUzNjAzMTc3MzMzYTQ4MGQ4NGIxMmE1ODhkYTIzMTRmXzIwLTQtMS0xLTU4Mzcy_118fa196-953d-4cea-a4e8-3b7d30ef607b"
      unitRef="shares">56851921</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjEvZnJhZzo4NTJiMDQ1MDI0MjM0YWNiYTY5ZGIyOWQwZTg2M2ZiMi90YWJsZTo1MzYwMzE3NzMzM2E0ODBkODRiMTJhNTg4ZGEyMzE0Zi90YWJsZXJhbmdlOjUzNjAzMTc3MzMzYTQ4MGQ4NGIxMmE1ODhkYTIzMTRmXzIwLTQtMS0xLTU4Mzcy_65630f25-0e40-4e05-9e2d-dd3465a8259d"
      unitRef="shares">56851921</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjQvZnJhZzo2YWEyMzgxZjFhODg0OWY2YmZhOGY1Nzc0ODA3NGQ4Ni90YWJsZTo5NjgwNjIwMzVlNjY0ZThmYjAxN2E4YWY5NTZlNzY2MS90YWJsZXJhbmdlOjk2ODA2MjAzNWU2NjRlOGZiMDE3YThhZjk1NmU3NjYxXzItMi0xLTEtNTgzNzI_7713a0be-04f4-435e-a740-f5cf70fe647a"
      unitRef="usd">-74833000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjQvZnJhZzo2YWEyMzgxZjFhODg0OWY2YmZhOGY1Nzc0ODA3NGQ4Ni90YWJsZTo5NjgwNjIwMzVlNjY0ZThmYjAxN2E4YWY5NTZlNzY2MS90YWJsZXJhbmdlOjk2ODA2MjAzNWU2NjRlOGZiMDE3YThhZjk1NmU3NjYxXzItNC0xLTEtNTgzNzI_f18822b0-8b4c-484d-944e-8e220ef5be5a"
      unitRef="usd">-82296000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjQvZnJhZzo2YWEyMzgxZjFhODg0OWY2YmZhOGY1Nzc0ODA3NGQ4Ni90YWJsZTo5NjgwNjIwMzVlNjY0ZThmYjAxN2E4YWY5NTZlNzY2MS90YWJsZXJhbmdlOjk2ODA2MjAzNWU2NjRlOGZiMDE3YThhZjk1NmU3NjYxXzQtMi0xLTEtNTgzNzI_8a8f884c-2fbe-495d-a383-7b75fd3ee438"
      unitRef="usd">-3000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjQvZnJhZzo2YWEyMzgxZjFhODg0OWY2YmZhOGY1Nzc0ODA3NGQ4Ni90YWJsZTo5NjgwNjIwMzVlNjY0ZThmYjAxN2E4YWY5NTZlNzY2MS90YWJsZXJhbmdlOjk2ODA2MjAzNWU2NjRlOGZiMDE3YThhZjk1NmU3NjYxXzQtNC0xLTEtNTgzNzI_daca053a-96a6-4e13-9ed8-6e796c8d07ba"
      unitRef="usd">4000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjQvZnJhZzo2YWEyMzgxZjFhODg0OWY2YmZhOGY1Nzc0ODA3NGQ4Ni90YWJsZTo5NjgwNjIwMzVlNjY0ZThmYjAxN2E4YWY5NTZlNzY2MS90YWJsZXJhbmdlOjk2ODA2MjAzNWU2NjRlOGZiMDE3YThhZjk1NmU3NjYxXzUtMi0xLTEtNTgzNzI_c4d1b9a1-ae59-4c7d-a317-d051d8cd274f"
      unitRef="usd">-74836000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjQvZnJhZzo2YWEyMzgxZjFhODg0OWY2YmZhOGY1Nzc0ODA3NGQ4Ni90YWJsZTo5NjgwNjIwMzVlNjY0ZThmYjAxN2E4YWY5NTZlNzY2MS90YWJsZXJhbmdlOjk2ODA2MjAzNWU2NjRlOGZiMDE3YThhZjk1NmU3NjYxXzUtNC0xLTEtNTgzNzI_3ea2c096-ec83-4771-97f8-36d2cb8c9e5a"
      unitRef="usd">-82292000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i4e3006d0e61345298119d94aa76e7fc3_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjcvZnJhZzpkYjdmMTdjMDhmM2M0NGI3YTA5N2Q4YTkyMjk2MjM5Zi90YWJsZTo2ZmRlN2FiYTY3MWE0MTE2ODc1Y2FlNGVhZTk4MWQ4NC90YWJsZXJhbmdlOjZmZGU3YWJhNjcxYTQxMTY4NzVjYWU0ZWFlOTgxZDg0XzMtMi0xLTEtNTgzNzI_d0e58617-fd1c-43f8-82fc-c6c1e4d4a878"
      unitRef="shares">52945865</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i4e3006d0e61345298119d94aa76e7fc3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjcvZnJhZzpkYjdmMTdjMDhmM2M0NGI3YTA5N2Q4YTkyMjk2MjM5Zi90YWJsZTo2ZmRlN2FiYTY3MWE0MTE2ODc1Y2FlNGVhZTk4MWQ4NC90YWJsZXJhbmdlOjZmZGU3YWJhNjcxYTQxMTY4NzVjYWU0ZWFlOTgxZDg0XzMtNC0xLTEtNTgzNzI_4ab518a7-cefc-4f92-8300-5731a8012381"
      unitRef="usd">53000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i14c26b9820bc4dfbbdaf3a90822b4aa3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjcvZnJhZzpkYjdmMTdjMDhmM2M0NGI3YTA5N2Q4YTkyMjk2MjM5Zi90YWJsZTo2ZmRlN2FiYTY3MWE0MTE2ODc1Y2FlNGVhZTk4MWQ4NC90YWJsZXJhbmdlOjZmZGU3YWJhNjcxYTQxMTY4NzVjYWU0ZWFlOTgxZDg0XzMtNi0xLTEtNTgzNzI_35e0c5de-7f25-4918-8fce-286a1a8a45f6"
      unitRef="usd">534585000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i97d8a5bb4b224ce58ea3ebd003189203_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjcvZnJhZzpkYjdmMTdjMDhmM2M0NGI3YTA5N2Q4YTkyMjk2MjM5Zi90YWJsZTo2ZmRlN2FiYTY3MWE0MTE2ODc1Y2FlNGVhZTk4MWQ4NC90YWJsZXJhbmdlOjZmZGU3YWJhNjcxYTQxMTY4NzVjYWU0ZWFlOTgxZDg0XzMtOC0xLTEtNTgzNzI_87bc3665-a80c-447d-9dbb-ab243c6c0fc7"
      unitRef="usd">-527765000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia1487e10814a476c9f4946ac6b21c5f8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjcvZnJhZzpkYjdmMTdjMDhmM2M0NGI3YTA5N2Q4YTkyMjk2MjM5Zi90YWJsZTo2ZmRlN2FiYTY3MWE0MTE2ODc1Y2FlNGVhZTk4MWQ4NC90YWJsZXJhbmdlOjZmZGU3YWJhNjcxYTQxMTY4NzVjYWU0ZWFlOTgxZDg0XzMtMTAtMS0xLTU4Mzcy_d5e4acb5-7a06-425f-9804-044c1d36a712"
      unitRef="usd">-85000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i49ae796ea1484c519d91607656f24c24_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjcvZnJhZzpkYjdmMTdjMDhmM2M0NGI3YTA5N2Q4YTkyMjk2MjM5Zi90YWJsZTo2ZmRlN2FiYTY3MWE0MTE2ODc1Y2FlNGVhZTk4MWQ4NC90YWJsZXJhbmdlOjZmZGU3YWJhNjcxYTQxMTY4NzVjYWU0ZWFlOTgxZDg0XzMtMTItMS0xLTU4Mzcy_4752d24d-2fe4-4a0d-8011-3aab52a1f824"
      unitRef="usd">6788000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i370c96450d8f471da8faee4fea65af41_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjcvZnJhZzpkYjdmMTdjMDhmM2M0NGI3YTA5N2Q4YTkyMjk2MjM5Zi90YWJsZTo2ZmRlN2FiYTY3MWE0MTE2ODc1Y2FlNGVhZTk4MWQ4NC90YWJsZXJhbmdlOjZmZGU3YWJhNjcxYTQxMTY4NzVjYWU0ZWFlOTgxZDg0XzQtNi0xLTEtNTgzNzI_945c1efc-903f-4cbe-a3ea-73a6ad4cf32a"
      unitRef="usd">9977000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjcvZnJhZzpkYjdmMTdjMDhmM2M0NGI3YTA5N2Q4YTkyMjk2MjM5Zi90YWJsZTo2ZmRlN2FiYTY3MWE0MTE2ODc1Y2FlNGVhZTk4MWQ4NC90YWJsZXJhbmdlOjZmZGU3YWJhNjcxYTQxMTY4NzVjYWU0ZWFlOTgxZDg0XzQtMTItMS0xLTU4Mzcy_b7355e5f-f943-4005-b232-3a19bc79823e"
      unitRef="usd">9977000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <optn:StockIssuedDuringPeriodSharesVestedRestrictedStockUnits
      contextRef="iab515f21eb974f95af61d257257b1b11_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjcvZnJhZzpkYjdmMTdjMDhmM2M0NGI3YTA5N2Q4YTkyMjk2MjM5Zi90YWJsZTo2ZmRlN2FiYTY3MWE0MTE2ODc1Y2FlNGVhZTk4MWQ4NC90YWJsZXJhbmdlOjZmZGU3YWJhNjcxYTQxMTY4NzVjYWU0ZWFlOTgxZDg0XzUtMi0xLTEtNTgzNzI_7b1cd858-e523-42c4-a524-79c7078d77e7"
      unitRef="shares">383631</optn:StockIssuedDuringPeriodSharesVestedRestrictedStockUnits>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="iab515f21eb974f95af61d257257b1b11_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjcvZnJhZzpkYjdmMTdjMDhmM2M0NGI3YTA5N2Q4YTkyMjk2MjM5Zi90YWJsZTo2ZmRlN2FiYTY3MWE0MTE2ODc1Y2FlNGVhZTk4MWQ4NC90YWJsZXJhbmdlOjZmZGU3YWJhNjcxYTQxMTY4NzVjYWU0ZWFlOTgxZDg0XzYtMi0xLTEtNTgzNzI_d225faad-61d3-471b-b560-0dd213930e2b"
      unitRef="shares">28750000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="iab515f21eb974f95af61d257257b1b11_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjcvZnJhZzpkYjdmMTdjMDhmM2M0NGI3YTA5N2Q4YTkyMjk2MjM5Zi90YWJsZTo2ZmRlN2FiYTY3MWE0MTE2ODc1Y2FlNGVhZTk4MWQ4NC90YWJsZXJhbmdlOjZmZGU3YWJhNjcxYTQxMTY4NzVjYWU0ZWFlOTgxZDg0XzYtNC0xLTEtNTgzNzI_93a15b1d-ad7b-4d78-be5b-cf0e6d7f5080"
      unitRef="usd">29000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i370c96450d8f471da8faee4fea65af41_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjcvZnJhZzpkYjdmMTdjMDhmM2M0NGI3YTA5N2Q4YTkyMjk2MjM5Zi90YWJsZTo2ZmRlN2FiYTY3MWE0MTE2ODc1Y2FlNGVhZTk4MWQ4NC90YWJsZXJhbmdlOjZmZGU3YWJhNjcxYTQxMTY4NzVjYWU0ZWFlOTgxZDg0XzYtNi0xLTEtNTgzNzI_d0bca345-f5b8-4db8-a0c3-e32e77af6a17"
      unitRef="usd">42785000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjcvZnJhZzpkYjdmMTdjMDhmM2M0NGI3YTA5N2Q4YTkyMjk2MjM5Zi90YWJsZTo2ZmRlN2FiYTY3MWE0MTE2ODc1Y2FlNGVhZTk4MWQ4NC90YWJsZXJhbmdlOjZmZGU3YWJhNjcxYTQxMTY4NzVjYWU0ZWFlOTgxZDg0XzYtMTItMS0xLTU4Mzcy_38ec32b6-d181-43b0-92c1-fc1dbf7a3ca8"
      unitRef="usd">42814000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="i370c96450d8f471da8faee4fea65af41_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjcvZnJhZzpkYjdmMTdjMDhmM2M0NGI3YTA5N2Q4YTkyMjk2MjM5Zi90YWJsZTo2ZmRlN2FiYTY3MWE0MTE2ODc1Y2FlNGVhZTk4MWQ4NC90YWJsZXJhbmdlOjZmZGU3YWJhNjcxYTQxMTY4NzVjYWU0ZWFlOTgxZDg0XzctNi0xLTEtNTgzNzI_4d36cf5f-a188-4149-8742-d2004935541c"
      unitRef="usd">534000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjcvZnJhZzpkYjdmMTdjMDhmM2M0NGI3YTA5N2Q4YTkyMjk2MjM5Zi90YWJsZTo2ZmRlN2FiYTY3MWE0MTE2ODc1Y2FlNGVhZTk4MWQ4NC90YWJsZXJhbmdlOjZmZGU3YWJhNjcxYTQxMTY4NzVjYWU0ZWFlOTgxZDg0XzctMTItMS0xLTU4Mzcy_83dd47cc-e2b3-4bae-8002-0d3fdb1a8f88"
      unitRef="usd">534000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="iab515f21eb974f95af61d257257b1b11_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjcvZnJhZzpkYjdmMTdjMDhmM2M0NGI3YTA5N2Q4YTkyMjk2MjM5Zi90YWJsZTo2ZmRlN2FiYTY3MWE0MTE2ODc1Y2FlNGVhZTk4MWQ4NC90YWJsZXJhbmdlOjZmZGU3YWJhNjcxYTQxMTY4NzVjYWU0ZWFlOTgxZDg0XzgtMi0xLTEtNTgzNzI_2806b335-f385-479b-a29f-40f770634f13"
      unitRef="shares">23879</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i370c96450d8f471da8faee4fea65af41_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjcvZnJhZzpkYjdmMTdjMDhmM2M0NGI3YTA5N2Q4YTkyMjk2MjM5Zi90YWJsZTo2ZmRlN2FiYTY3MWE0MTE2ODc1Y2FlNGVhZTk4MWQ4NC90YWJsZXJhbmdlOjZmZGU3YWJhNjcxYTQxMTY4NzVjYWU0ZWFlOTgxZDg0XzgtNi0xLTEtNTgzNzI_09023a23-d135-428d-865e-27138fe2ff2d"
      unitRef="usd">39000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjcvZnJhZzpkYjdmMTdjMDhmM2M0NGI3YTA5N2Q4YTkyMjk2MjM5Zi90YWJsZTo2ZmRlN2FiYTY3MWE0MTE2ODc1Y2FlNGVhZTk4MWQ4NC90YWJsZXJhbmdlOjZmZGU3YWJhNjcxYTQxMTY4NzVjYWU0ZWFlOTgxZDg0XzgtMTItMS0xLTU4Mzcy_ed9e4919-908b-47f9-97b4-ceb3920eb1b0"
      unitRef="usd">39000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan
      contextRef="iab515f21eb974f95af61d257257b1b11_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjcvZnJhZzpkYjdmMTdjMDhmM2M0NGI3YTA5N2Q4YTkyMjk2MjM5Zi90YWJsZTo2ZmRlN2FiYTY3MWE0MTE2ODc1Y2FlNGVhZTk4MWQ4NC90YWJsZXJhbmdlOjZmZGU3YWJhNjcxYTQxMTY4NzVjYWU0ZWFlOTgxZDg0XzktMi0xLTEtNTgzNzI_28ac3c9a-d991-4219-9438-10d0d578be9a"
      unitRef="shares">135525</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan
      contextRef="i370c96450d8f471da8faee4fea65af41_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjcvZnJhZzpkYjdmMTdjMDhmM2M0NGI3YTA5N2Q4YTkyMjk2MjM5Zi90YWJsZTo2ZmRlN2FiYTY3MWE0MTE2ODc1Y2FlNGVhZTk4MWQ4NC90YWJsZXJhbmdlOjZmZGU3YWJhNjcxYTQxMTY4NzVjYWU0ZWFlOTgxZDg0XzktNi0xLTEtNTgzNzI_efbf184e-4aaa-4b7d-9443-da07c408fbcc"
      unitRef="usd">368000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan
      contextRef="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjcvZnJhZzpkYjdmMTdjMDhmM2M0NGI3YTA5N2Q4YTkyMjk2MjM5Zi90YWJsZTo2ZmRlN2FiYTY3MWE0MTE2ODc1Y2FlNGVhZTk4MWQ4NC90YWJsZXJhbmdlOjZmZGU3YWJhNjcxYTQxMTY4NzVjYWU0ZWFlOTgxZDg0XzktMTItMS0xLTU4Mzcy_be7b4aed-ef68-4f78-af17-587b5fba7dda"
      unitRef="usd">368000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i810445cfd7f9438195dd0d77cfeedd7e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjcvZnJhZzpkYjdmMTdjMDhmM2M0NGI3YTA5N2Q4YTkyMjk2MjM5Zi90YWJsZTo2ZmRlN2FiYTY3MWE0MTE2ODc1Y2FlNGVhZTk4MWQ4NC90YWJsZXJhbmdlOjZmZGU3YWJhNjcxYTQxMTY4NzVjYWU0ZWFlOTgxZDg0XzEwLTEwLTEtMS05ODYyMg_1e49a756-20a5-414d-a9be-f6cc6f9422e9"
      unitRef="usd">4000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjcvZnJhZzpkYjdmMTdjMDhmM2M0NGI3YTA5N2Q4YTkyMjk2MjM5Zi90YWJsZTo2ZmRlN2FiYTY3MWE0MTE2ODc1Y2FlNGVhZTk4MWQ4NC90YWJsZXJhbmdlOjZmZGU3YWJhNjcxYTQxMTY4NzVjYWU0ZWFlOTgxZDg0XzEwLTEyLTEtMS05OTg1Mg_de0d2471-334f-4531-affe-2d9edf7a482e"
      unitRef="usd">4000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="idacbe771db9246aba4c1a2401b11b0c0_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjcvZnJhZzpkYjdmMTdjMDhmM2M0NGI3YTA5N2Q4YTkyMjk2MjM5Zi90YWJsZTo2ZmRlN2FiYTY3MWE0MTE2ODc1Y2FlNGVhZTk4MWQ4NC90YWJsZXJhbmdlOjZmZGU3YWJhNjcxYTQxMTY4NzVjYWU0ZWFlOTgxZDg0XzEwLTgtMS0xLTU4Mzcy_eaef1b98-2bc7-4b41-b680-f0a4bf1127a1"
      unitRef="usd">-82296000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjcvZnJhZzpkYjdmMTdjMDhmM2M0NGI3YTA5N2Q4YTkyMjk2MjM5Zi90YWJsZTo2ZmRlN2FiYTY3MWE0MTE2ODc1Y2FlNGVhZTk4MWQ4NC90YWJsZXJhbmdlOjZmZGU3YWJhNjcxYTQxMTY4NzVjYWU0ZWFlOTgxZDg0XzEwLTEyLTEtMS01ODM3Mg_7d2718b4-dbd7-44da-a24c-5af74fea4420"
      unitRef="usd">-82296000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ibacfe7c370de4063881a058b1ca33cf7_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjcvZnJhZzpkYjdmMTdjMDhmM2M0NGI3YTA5N2Q4YTkyMjk2MjM5Zi90YWJsZTo2ZmRlN2FiYTY3MWE0MTE2ODc1Y2FlNGVhZTk4MWQ4NC90YWJsZXJhbmdlOjZmZGU3YWJhNjcxYTQxMTY4NzVjYWU0ZWFlOTgxZDg0XzExLTItMS0xLTU4Mzcy_a0399363-d416-42f9-9bb1-cc76d317ccc5"
      unitRef="shares">82238900</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ibacfe7c370de4063881a058b1ca33cf7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjcvZnJhZzpkYjdmMTdjMDhmM2M0NGI3YTA5N2Q4YTkyMjk2MjM5Zi90YWJsZTo2ZmRlN2FiYTY3MWE0MTE2ODc1Y2FlNGVhZTk4MWQ4NC90YWJsZXJhbmdlOjZmZGU3YWJhNjcxYTQxMTY4NzVjYWU0ZWFlOTgxZDg0XzExLTQtMS0xLTU4Mzcy_d7102ec9-56ab-477e-adf7-d19997250e3f"
      unitRef="usd">82000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7f0715d972fd4e5cb7aaeea6b7297684_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjcvZnJhZzpkYjdmMTdjMDhmM2M0NGI3YTA5N2Q4YTkyMjk2MjM5Zi90YWJsZTo2ZmRlN2FiYTY3MWE0MTE2ODc1Y2FlNGVhZTk4MWQ4NC90YWJsZXJhbmdlOjZmZGU3YWJhNjcxYTQxMTY4NzVjYWU0ZWFlOTgxZDg0XzExLTYtMS0xLTU4Mzcy_3144a545-2b04-4df2-b96b-bd1a9b9108fc"
      unitRef="usd">588288000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib5641003d7214a1987d7612d9a529d7f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjcvZnJhZzpkYjdmMTdjMDhmM2M0NGI3YTA5N2Q4YTkyMjk2MjM5Zi90YWJsZTo2ZmRlN2FiYTY3MWE0MTE2ODc1Y2FlNGVhZTk4MWQ4NC90YWJsZXJhbmdlOjZmZGU3YWJhNjcxYTQxMTY4NzVjYWU0ZWFlOTgxZDg0XzExLTgtMS0xLTU4Mzcy_0961a458-62e0-4caa-b503-32e08301797c"
      unitRef="usd">-610061000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i789260e8b4914bc7a8d855feb02dc33c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjcvZnJhZzpkYjdmMTdjMDhmM2M0NGI3YTA5N2Q4YTkyMjk2MjM5Zi90YWJsZTo2ZmRlN2FiYTY3MWE0MTE2ODc1Y2FlNGVhZTk4MWQ4NC90YWJsZXJhbmdlOjZmZGU3YWJhNjcxYTQxMTY4NzVjYWU0ZWFlOTgxZDg0XzExLTEwLTEtMS01ODM3Mg_bf4f4952-ddb7-4068-b0ad-2214f6a93b26"
      unitRef="usd">-81000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id970dfd2674c4d6b895febb9c14d0fd1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjcvZnJhZzpkYjdmMTdjMDhmM2M0NGI3YTA5N2Q4YTkyMjk2MjM5Zi90YWJsZTo2ZmRlN2FiYTY3MWE0MTE2ODc1Y2FlNGVhZTk4MWQ4NC90YWJsZXJhbmdlOjZmZGU3YWJhNjcxYTQxMTY4NzVjYWU0ZWFlOTgxZDg0XzExLTEyLTEtMS01ODM3Mg_1def60f8-4a4e-49fa-95d8-08a91d2962f0"
      unitRef="usd">-21772000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i3377b70595804aa5abe93bd7f81df039_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjcvZnJhZzpkYjdmMTdjMDhmM2M0NGI3YTA5N2Q4YTkyMjk2MjM5Zi90YWJsZTo2ZmRlN2FiYTY3MWE0MTE2ODc1Y2FlNGVhZTk4MWQ4NC90YWJsZXJhbmdlOjZmZGU3YWJhNjcxYTQxMTY4NzVjYWU0ZWFlOTgxZDg0XzEyLTYtMS0xLTU4Mzcy_f375f0d4-4265-41a8-a8cd-670c5194a8cf"
      unitRef="usd">8889000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjcvZnJhZzpkYjdmMTdjMDhmM2M0NGI3YTA5N2Q4YTkyMjk2MjM5Zi90YWJsZTo2ZmRlN2FiYTY3MWE0MTE2ODc1Y2FlNGVhZTk4MWQ4NC90YWJsZXJhbmdlOjZmZGU3YWJhNjcxYTQxMTY4NzVjYWU0ZWFlOTgxZDg0XzEyLTEyLTEtMS01ODM3Mg_075286ee-5288-4f4a-a3f4-ed72cb576cb8"
      unitRef="usd">8889000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <optn:StockIssuedDuringPeriodSharesVestedRestrictedStockUnits
      contextRef="ic9fdf918fabe4dea9acdfa65692fe619_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjcvZnJhZzpkYjdmMTdjMDhmM2M0NGI3YTA5N2Q4YTkyMjk2MjM5Zi90YWJsZTo2ZmRlN2FiYTY3MWE0MTE2ODc1Y2FlNGVhZTk4MWQ4NC90YWJsZXJhbmdlOjZmZGU3YWJhNjcxYTQxMTY4NzVjYWU0ZWFlOTgxZDg0XzEzLTItMS0xLTU4Mzcy_67e582e9-91c8-48d6-86a9-57d21456be7b"
      unitRef="shares">949857</optn:StockIssuedDuringPeriodSharesVestedRestrictedStockUnits>
    <optn:StockIssuedDuringPeriodVestedRestrictedStockUnits
      contextRef="ic9fdf918fabe4dea9acdfa65692fe619_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjcvZnJhZzpkYjdmMTdjMDhmM2M0NGI3YTA5N2Q4YTkyMjk2MjM5Zi90YWJsZTo2ZmRlN2FiYTY3MWE0MTE2ODc1Y2FlNGVhZTk4MWQ4NC90YWJsZXJhbmdlOjZmZGU3YWJhNjcxYTQxMTY4NzVjYWU0ZWFlOTgxZDg0XzEzLTQtMS0xLTU4Mzcy_170f6f61-b9e3-4298-be46-408b90955b98"
      unitRef="usd">1000</optn:StockIssuedDuringPeriodVestedRestrictedStockUnits>
    <optn:StockIssuedDuringPeriodVestedRestrictedStockUnits
      contextRef="i3377b70595804aa5abe93bd7f81df039_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjcvZnJhZzpkYjdmMTdjMDhmM2M0NGI3YTA5N2Q4YTkyMjk2MjM5Zi90YWJsZTo2ZmRlN2FiYTY3MWE0MTE2ODc1Y2FlNGVhZTk4MWQ4NC90YWJsZXJhbmdlOjZmZGU3YWJhNjcxYTQxMTY4NzVjYWU0ZWFlOTgxZDg0XzEzLTYtMS0xLTU4Mzcy_6e50d0a3-6bc9-413a-9f31-a00ba62fb244"
      unitRef="usd">93000</optn:StockIssuedDuringPeriodVestedRestrictedStockUnits>
    <optn:StockIssuedDuringPeriodVestedRestrictedStockUnits
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjcvZnJhZzpkYjdmMTdjMDhmM2M0NGI3YTA5N2Q4YTkyMjk2MjM5Zi90YWJsZTo2ZmRlN2FiYTY3MWE0MTE2ODc1Y2FlNGVhZTk4MWQ4NC90YWJsZXJhbmdlOjZmZGU3YWJhNjcxYTQxMTY4NzVjYWU0ZWFlOTgxZDg0XzEzLTEyLTEtMS01ODM3Mg_f314854c-d0a8-486b-babc-04950ed28277"
      unitRef="usd">94000</optn:StockIssuedDuringPeriodVestedRestrictedStockUnits>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ic9fdf918fabe4dea9acdfa65692fe619_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjcvZnJhZzpkYjdmMTdjMDhmM2M0NGI3YTA5N2Q4YTkyMjk2MjM5Zi90YWJsZTo2ZmRlN2FiYTY3MWE0MTE2ODc1Y2FlNGVhZTk4MWQ4NC90YWJsZXJhbmdlOjZmZGU3YWJhNjcxYTQxMTY4NzVjYWU0ZWFlOTgxZDg0XzE0LTItMS0xLTU4Mzcy_9abed966-81b8-426f-8b02-00daaea5e822"
      unitRef="shares">27861300</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ic9fdf918fabe4dea9acdfa65692fe619_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjcvZnJhZzpkYjdmMTdjMDhmM2M0NGI3YTA5N2Q4YTkyMjk2MjM5Zi90YWJsZTo2ZmRlN2FiYTY3MWE0MTE2ODc1Y2FlNGVhZTk4MWQ4NC90YWJsZXJhbmdlOjZmZGU3YWJhNjcxYTQxMTY4NzVjYWU0ZWFlOTgxZDg0XzE0LTQtMS0xLTU4Mzcy_ccaf6379-78ca-49d7-999d-25cd849cf55b"
      unitRef="usd">28000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i3377b70595804aa5abe93bd7f81df039_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjcvZnJhZzpkYjdmMTdjMDhmM2M0NGI3YTA5N2Q4YTkyMjk2MjM5Zi90YWJsZTo2ZmRlN2FiYTY3MWE0MTE2ODc1Y2FlNGVhZTk4MWQ4NC90YWJsZXJhbmdlOjZmZGU3YWJhNjcxYTQxMTY4NzVjYWU0ZWFlOTgxZDg0XzE0LTYtMS0xLTU4Mzcy_985f829c-2d61-4f0a-9a89-156ce9493f0c"
      unitRef="usd">30418000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjcvZnJhZzpkYjdmMTdjMDhmM2M0NGI3YTA5N2Q4YTkyMjk2MjM5Zi90YWJsZTo2ZmRlN2FiYTY3MWE0MTE2ODc1Y2FlNGVhZTk4MWQ4NC90YWJsZXJhbmdlOjZmZGU3YWJhNjcxYTQxMTY4NzVjYWU0ZWFlOTgxZDg0XzE0LTEyLTEtMS01ODM3Mg_36e8a6aa-4e2b-41ee-9312-92fd8e1a81f6"
      unitRef="usd">30446000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ic9fdf918fabe4dea9acdfa65692fe619_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjcvZnJhZzpkYjdmMTdjMDhmM2M0NGI3YTA5N2Q4YTkyMjk2MjM5Zi90YWJsZTo2ZmRlN2FiYTY3MWE0MTE2ODc1Y2FlNGVhZTk4MWQ4NC90YWJsZXJhbmdlOjZmZGU3YWJhNjcxYTQxMTY4NzVjYWU0ZWFlOTgxZDg0XzE2LTItMS0xLTU4Mzcy_49bc0b3f-c1c8-481d-932d-a32761378f09"
      unitRef="shares">55360</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan
      contextRef="ic9fdf918fabe4dea9acdfa65692fe619_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjcvZnJhZzpkYjdmMTdjMDhmM2M0NGI3YTA5N2Q4YTkyMjk2MjM5Zi90YWJsZTo2ZmRlN2FiYTY3MWE0MTE2ODc1Y2FlNGVhZTk4MWQ4NC90YWJsZXJhbmdlOjZmZGU3YWJhNjcxYTQxMTY4NzVjYWU0ZWFlOTgxZDg0XzE3LTItMS0xLTU4Mzcy_f21189c5-593d-4d84-9857-17ae2fa21e73"
      unitRef="shares">387344</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan
      contextRef="i3377b70595804aa5abe93bd7f81df039_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjcvZnJhZzpkYjdmMTdjMDhmM2M0NGI3YTA5N2Q4YTkyMjk2MjM5Zi90YWJsZTo2ZmRlN2FiYTY3MWE0MTE2ODc1Y2FlNGVhZTk4MWQ4NC90YWJsZXJhbmdlOjZmZGU3YWJhNjcxYTQxMTY4NzVjYWU0ZWFlOTgxZDg0XzE3LTYtMS0xLTU4Mzcy_82e89b60-537e-4b16-8dbe-6ccd9afb11d3"
      unitRef="usd">554000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjcvZnJhZzpkYjdmMTdjMDhmM2M0NGI3YTA5N2Q4YTkyMjk2MjM5Zi90YWJsZTo2ZmRlN2FiYTY3MWE0MTE2ODc1Y2FlNGVhZTk4MWQ4NC90YWJsZXJhbmdlOjZmZGU3YWJhNjcxYTQxMTY4NzVjYWU0ZWFlOTgxZDg0XzE3LTEyLTEtMS01ODM3Mg_630c9b50-e382-44c7-bde5-a95e80f0300c"
      unitRef="usd">554000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i8c484ff51d4d492594a9bf004bc92efb_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjcvZnJhZzpkYjdmMTdjMDhmM2M0NGI3YTA5N2Q4YTkyMjk2MjM5Zi90YWJsZTo2ZmRlN2FiYTY3MWE0MTE2ODc1Y2FlNGVhZTk4MWQ4NC90YWJsZXJhbmdlOjZmZGU3YWJhNjcxYTQxMTY4NzVjYWU0ZWFlOTgxZDg0XzE5LTEwLTEtMS01ODM3Mg_0d97d483-51a3-43c2-8721-82245fc316fe"
      unitRef="usd">-3000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjcvZnJhZzpkYjdmMTdjMDhmM2M0NGI3YTA5N2Q4YTkyMjk2MjM5Zi90YWJsZTo2ZmRlN2FiYTY3MWE0MTE2ODc1Y2FlNGVhZTk4MWQ4NC90YWJsZXJhbmdlOjZmZGU3YWJhNjcxYTQxMTY4NzVjYWU0ZWFlOTgxZDg0XzE5LTEyLTEtMS01ODM3Mg_f85fae6b-e33a-401b-8b56-1995771966de"
      unitRef="usd">-3000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="i342496e82be2474596067223f1d6134a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjcvZnJhZzpkYjdmMTdjMDhmM2M0NGI3YTA5N2Q4YTkyMjk2MjM5Zi90YWJsZTo2ZmRlN2FiYTY3MWE0MTE2ODc1Y2FlNGVhZTk4MWQ4NC90YWJsZXJhbmdlOjZmZGU3YWJhNjcxYTQxMTY4NzVjYWU0ZWFlOTgxZDg0XzIwLTgtMS0xLTU4Mzcy_214efbef-bd77-4e4f-b25f-93b047211714"
      unitRef="usd">-74833000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjcvZnJhZzpkYjdmMTdjMDhmM2M0NGI3YTA5N2Q4YTkyMjk2MjM5Zi90YWJsZTo2ZmRlN2FiYTY3MWE0MTE2ODc1Y2FlNGVhZTk4MWQ4NC90YWJsZXJhbmdlOjZmZGU3YWJhNjcxYTQxMTY4NzVjYWU0ZWFlOTgxZDg0XzIwLTEyLTEtMS01ODM3Mg_e79701ca-f69b-44b3-8e9d-48cf2c6a156e"
      unitRef="usd">-74833000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i97a20c4e2d9543ea933245a9227cf00f_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjcvZnJhZzpkYjdmMTdjMDhmM2M0NGI3YTA5N2Q4YTkyMjk2MjM5Zi90YWJsZTo2ZmRlN2FiYTY3MWE0MTE2ODc1Y2FlNGVhZTk4MWQ4NC90YWJsZXJhbmdlOjZmZGU3YWJhNjcxYTQxMTY4NzVjYWU0ZWFlOTgxZDg0XzIxLTItMS0xLTU4Mzcy_dac37852-58ca-44d2-a91a-bd54d0f32a92"
      unitRef="shares">111492761</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i97a20c4e2d9543ea933245a9227cf00f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjcvZnJhZzpkYjdmMTdjMDhmM2M0NGI3YTA5N2Q4YTkyMjk2MjM5Zi90YWJsZTo2ZmRlN2FiYTY3MWE0MTE2ODc1Y2FlNGVhZTk4MWQ4NC90YWJsZXJhbmdlOjZmZGU3YWJhNjcxYTQxMTY4NzVjYWU0ZWFlOTgxZDg0XzIxLTQtMS0xLTU4Mzcy_5083ee69-47d2-4b00-bfba-5862ec9f915c"
      unitRef="usd">111000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="idd9a9b2d424d466ca469cf5987572ab0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjcvZnJhZzpkYjdmMTdjMDhmM2M0NGI3YTA5N2Q4YTkyMjk2MjM5Zi90YWJsZTo2ZmRlN2FiYTY3MWE0MTE2ODc1Y2FlNGVhZTk4MWQ4NC90YWJsZXJhbmdlOjZmZGU3YWJhNjcxYTQxMTY4NzVjYWU0ZWFlOTgxZDg0XzIxLTYtMS0xLTU4Mzcy_8b4b522e-6ae2-49ca-ae7d-a4bc43a70a52"
      unitRef="usd">628242000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id3708c2b1f2b41dfa7d806c5987de5d7_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjcvZnJhZzpkYjdmMTdjMDhmM2M0NGI3YTA5N2Q4YTkyMjk2MjM5Zi90YWJsZTo2ZmRlN2FiYTY3MWE0MTE2ODc1Y2FlNGVhZTk4MWQ4NC90YWJsZXJhbmdlOjZmZGU3YWJhNjcxYTQxMTY4NzVjYWU0ZWFlOTgxZDg0XzIxLTgtMS0xLTU4Mzcy_e32db113-3c23-405f-a751-7f053ffe447a"
      unitRef="usd">-684893000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3cc6af243d904524abfec5259351ae3f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjcvZnJhZzpkYjdmMTdjMDhmM2M0NGI3YTA5N2Q4YTkyMjk2MjM5Zi90YWJsZTo2ZmRlN2FiYTY3MWE0MTE2ODc1Y2FlNGVhZTk4MWQ4NC90YWJsZXJhbmdlOjZmZGU3YWJhNjcxYTQxMTY4NzVjYWU0ZWFlOTgxZDg0XzIxLTEwLTEtMS01ODM3Mg_a74c76af-7b82-47d2-a90b-d9a0c347a274"
      unitRef="usd">-84000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMjcvZnJhZzpkYjdmMTdjMDhmM2M0NGI3YTA5N2Q4YTkyMjk2MjM5Zi90YWJsZTo2ZmRlN2FiYTY3MWE0MTE2ODc1Y2FlNGVhZTk4MWQ4NC90YWJsZXJhbmdlOjZmZGU3YWJhNjcxYTQxMTY4NzVjYWU0ZWFlOTgxZDg0XzIxLTEyLTEtMS01ODM3Mg_7d37360d-9f2e-4dc8-90f6-51471aacb039"
      unitRef="usd">-56624000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMzAvZnJhZzo3YTVjZGEzNmQ0YTU0MTA4YmM0ZTViMWQ0MmE5N2EyNS90YWJsZTo2YTkzZmY3ODU0ZDg0YmM0ODY5MWFiNzliMGZjNjlhNy90YWJsZXJhbmdlOjZhOTNmZjc4NTRkODRiYzQ4NjkxYWI3OWIwZmM2OWE3XzMtMS0xLTEtNTgzNzI_414a191f-9779-49ed-9731-4dca7e285444"
      unitRef="usd">-74833000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMzAvZnJhZzo3YTVjZGEzNmQ0YTU0MTA4YmM0ZTViMWQ0MmE5N2EyNS90YWJsZTo2YTkzZmY3ODU0ZDg0YmM0ODY5MWFiNzliMGZjNjlhNy90YWJsZXJhbmdlOjZhOTNmZjc4NTRkODRiYzQ4NjkxYWI3OWIwZmM2OWE3XzMtMy0xLTEtNTgzNzI_ce5a870b-5173-4bdf-a383-36c29bebb199"
      unitRef="usd">-82296000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMzAvZnJhZzo3YTVjZGEzNmQ0YTU0MTA4YmM0ZTViMWQ0MmE5N2EyNS90YWJsZTo2YTkzZmY3ODU0ZDg0YmM0ODY5MWFiNzliMGZjNjlhNy90YWJsZXJhbmdlOjZhOTNmZjc4NTRkODRiYzQ4NjkxYWI3OWIwZmM2OWE3XzUtMS0xLTEtNTgzNzI_e90f3341-b82b-4f72-9341-c484146fe30e"
      unitRef="usd">532000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMzAvZnJhZzo3YTVjZGEzNmQ0YTU0MTA4YmM0ZTViMWQ0MmE5N2EyNS90YWJsZTo2YTkzZmY3ODU0ZDg0YmM0ODY5MWFiNzliMGZjNjlhNy90YWJsZXJhbmdlOjZhOTNmZjc4NTRkODRiYzQ4NjkxYWI3OWIwZmM2OWE3XzUtMy0xLTEtNTgzNzI_c6fe8e3f-5a6c-43cc-82f2-9390f62ce2e1"
      unitRef="usd">646000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMzAvZnJhZzo3YTVjZGEzNmQ0YTU0MTA4YmM0ZTViMWQ0MmE5N2EyNS90YWJsZTo2YTkzZmY3ODU0ZDg0YmM0ODY5MWFiNzliMGZjNjlhNy90YWJsZXJhbmdlOjZhOTNmZjc4NTRkODRiYzQ4NjkxYWI3OWIwZmM2OWE3XzYtMS0xLTEtNTgzNzI_71071b5a-8eb2-430a-973f-c1707e3587c2"
      unitRef="usd">8877000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMzAvZnJhZzo3YTVjZGEzNmQ0YTU0MTA4YmM0ZTViMWQ0MmE5N2EyNS90YWJsZTo2YTkzZmY3ODU0ZDg0YmM0ODY5MWFiNzliMGZjNjlhNy90YWJsZXJhbmdlOjZhOTNmZjc4NTRkODRiYzQ4NjkxYWI3OWIwZmM2OWE3XzYtMy0xLTEtNTgzNzI_96f51a0b-8eff-44a1-bde3-cb675bb15c44"
      unitRef="usd">10003000</us-gaap:ShareBasedCompensation>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMzAvZnJhZzo3YTVjZGEzNmQ0YTU0MTA4YmM0ZTViMWQ0MmE5N2EyNS90YWJsZTo2YTkzZmY3ODU0ZDg0YmM0ODY5MWFiNzliMGZjNjlhNy90YWJsZXJhbmdlOjZhOTNmZjc4NTRkODRiYzQ4NjkxYWI3OWIwZmM2OWE3XzctMS0xLTEtMTAwMDEw_c05a3bfb-78d4-4441-b318-5b43911cc646"
      unitRef="usd">1211000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMzAvZnJhZzo3YTVjZGEzNmQ0YTU0MTA4YmM0ZTViMWQ0MmE5N2EyNS90YWJsZTo2YTkzZmY3ODU0ZDg0YmM0ODY5MWFiNzliMGZjNjlhNy90YWJsZXJhbmdlOjZhOTNmZjc4NTRkODRiYzQ4NjkxYWI3OWIwZmM2OWE3XzctMy0xLTEtMTAwMDE1_5d9907c2-a38d-425b-9cdf-fbc118b06a04"
      unitRef="usd">0</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMzAvZnJhZzo3YTVjZGEzNmQ0YTU0MTA4YmM0ZTViMWQ0MmE5N2EyNS90YWJsZTo2YTkzZmY3ODU0ZDg0YmM0ODY5MWFiNzliMGZjNjlhNy90YWJsZXJhbmdlOjZhOTNmZjc4NTRkODRiYzQ4NjkxYWI3OWIwZmM2OWE3XzctMS0xLTEtNTgzNzI_251ee55d-39fc-410e-90d2-0823467dd47c"
      unitRef="usd">2318000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMzAvZnJhZzo3YTVjZGEzNmQ0YTU0MTA4YmM0ZTViMWQ0MmE5N2EyNS90YWJsZTo2YTkzZmY3ODU0ZDg0YmM0ODY5MWFiNzliMGZjNjlhNy90YWJsZXJhbmdlOjZhOTNmZjc4NTRkODRiYzQ4NjkxYWI3OWIwZmM2OWE3XzctMy0xLTEtNTgzNzI_05e2262e-67bf-492b-8ef5-dee9d2a3f832"
      unitRef="usd">1795000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMzAvZnJhZzo3YTVjZGEzNmQ0YTU0MTA4YmM0ZTViMWQ0MmE5N2EyNS90YWJsZTo2YTkzZmY3ODU0ZDg0YmM0ODY5MWFiNzliMGZjNjlhNy90YWJsZXJhbmdlOjZhOTNmZjc4NTRkODRiYzQ4NjkxYWI3OWIwZmM2OWE3XzgtMS0xLTEtNTgzNzI_3a1d81c8-5062-4bc4-b64c-3d7dd46eefac"
      unitRef="usd">0</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMzAvZnJhZzo3YTVjZGEzNmQ0YTU0MTA4YmM0ZTViMWQ0MmE5N2EyNS90YWJsZTo2YTkzZmY3ODU0ZDg0YmM0ODY5MWFiNzliMGZjNjlhNy90YWJsZXJhbmdlOjZhOTNmZjc4NTRkODRiYzQ4NjkxYWI3OWIwZmM2OWE3XzgtMy0xLTEtNTgzNzI_c5ded295-9911-4642-8213-9b2473faa7f5"
      unitRef="usd">-233000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMzAvZnJhZzo3YTVjZGEzNmQ0YTU0MTA4YmM0ZTViMWQ0MmE5N2EyNS90YWJsZTo2YTkzZmY3ODU0ZDg0YmM0ODY5MWFiNzliMGZjNjlhNy90YWJsZXJhbmdlOjZhOTNmZjc4NTRkODRiYzQ4NjkxYWI3OWIwZmM2OWE3XzEwLTEtMS0xLTU4Mzcy_38c568ab-496c-48ce-97ff-53650a2229c6"
      unitRef="usd">0</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMzAvZnJhZzo3YTVjZGEzNmQ0YTU0MTA4YmM0ZTViMWQ0MmE5N2EyNS90YWJsZTo2YTkzZmY3ODU0ZDg0YmM0ODY5MWFiNzliMGZjNjlhNy90YWJsZXJhbmdlOjZhOTNmZjc4NTRkODRiYzQ4NjkxYWI3OWIwZmM2OWE3XzEwLTMtMS0xLTU4Mzcy_f26ed884-4a29-4816-bacb-c07c66d4e402"
      unitRef="usd">67000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMzAvZnJhZzo3YTVjZGEzNmQ0YTU0MTA4YmM0ZTViMWQ0MmE5N2EyNS90YWJsZTo2YTkzZmY3ODU0ZDg0YmM0ODY5MWFiNzliMGZjNjlhNy90YWJsZXJhbmdlOjZhOTNmZjc4NTRkODRiYzQ4NjkxYWI3OWIwZmM2OWE3XzEyLTEtMS0xLTU4Mzcy_9a8c7fee-9d9b-4562-982e-858f9e6c86ba"
      unitRef="usd">-1517000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMzAvZnJhZzo3YTVjZGEzNmQ0YTU0MTA4YmM0ZTViMWQ0MmE5N2EyNS90YWJsZTo2YTkzZmY3ODU0ZDg0YmM0ODY5MWFiNzliMGZjNjlhNy90YWJsZXJhbmdlOjZhOTNmZjc4NTRkODRiYzQ4NjkxYWI3OWIwZmM2OWE3XzEyLTMtMS0xLTU4Mzcy_fcd002d2-ed67-4c3e-afbf-fbbc57314194"
      unitRef="usd">11823000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <optn:IncreaseDecreaseInGrantsandOtherReceivables
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMzAvZnJhZzo3YTVjZGEzNmQ0YTU0MTA4YmM0ZTViMWQ0MmE5N2EyNS90YWJsZTo2YTkzZmY3ODU0ZDg0YmM0ODY5MWFiNzliMGZjNjlhNy90YWJsZXJhbmdlOjZhOTNmZjc4NTRkODRiYzQ4NjkxYWI3OWIwZmM2OWE3XzEzLTEtMS0xLTU4Mzcy_47e4298f-1f32-47f9-bc74-b7b572f89dd0"
      unitRef="usd">0</optn:IncreaseDecreaseInGrantsandOtherReceivables>
    <optn:IncreaseDecreaseInGrantsandOtherReceivables
      contextRef="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMzAvZnJhZzo3YTVjZGEzNmQ0YTU0MTA4YmM0ZTViMWQ0MmE5N2EyNS90YWJsZTo2YTkzZmY3ODU0ZDg0YmM0ODY5MWFiNzliMGZjNjlhNy90YWJsZXJhbmdlOjZhOTNmZjc4NTRkODRiYzQ4NjkxYWI3OWIwZmM2OWE3XzEzLTMtMS0xLTU4Mzcy_ea1a9f62-f9c4-45b3-a22c-8e48fbd219bc"
      unitRef="usd">-43000</optn:IncreaseDecreaseInGrantsandOtherReceivables>
    <optn:IncreaseDecreaseinDepositsandOtherAssets
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMzAvZnJhZzo3YTVjZGEzNmQ0YTU0MTA4YmM0ZTViMWQ0MmE5N2EyNS90YWJsZTo2YTkzZmY3ODU0ZDg0YmM0ODY5MWFiNzliMGZjNjlhNy90YWJsZXJhbmdlOjZhOTNmZjc4NTRkODRiYzQ4NjkxYWI3OWIwZmM2OWE3XzE0LTEtMS0xLTU4Mzcy_ec743599-bd50-4230-b221-ca99cff0ac33"
      unitRef="usd">-1963000</optn:IncreaseDecreaseinDepositsandOtherAssets>
    <optn:IncreaseDecreaseinDepositsandOtherAssets
      contextRef="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMzAvZnJhZzo3YTVjZGEzNmQ0YTU0MTA4YmM0ZTViMWQ0MmE5N2EyNS90YWJsZTo2YTkzZmY3ODU0ZDg0YmM0ODY5MWFiNzliMGZjNjlhNy90YWJsZXJhbmdlOjZhOTNmZjc4NTRkODRiYzQ4NjkxYWI3OWIwZmM2OWE3XzE0LTMtMS0xLTU4Mzcy_2fbef4bd-9da2-4c2c-903a-4164b4f1bb7a"
      unitRef="usd">-3543000</optn:IncreaseDecreaseinDepositsandOtherAssets>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMzAvZnJhZzo3YTVjZGEzNmQ0YTU0MTA4YmM0ZTViMWQ0MmE5N2EyNS90YWJsZTo2YTkzZmY3ODU0ZDg0YmM0ODY5MWFiNzliMGZjNjlhNy90YWJsZXJhbmdlOjZhOTNmZjc4NTRkODRiYzQ4NjkxYWI3OWIwZmM2OWE3XzE1LTEtMS0xLTU4Mzcy_b2f67c74-a3f1-416c-9dc9-c3d72ba19ce2"
      unitRef="usd">-2492000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMzAvZnJhZzo3YTVjZGEzNmQ0YTU0MTA4YmM0ZTViMWQ0MmE5N2EyNS90YWJsZTo2YTkzZmY3ODU0ZDg0YmM0ODY5MWFiNzliMGZjNjlhNy90YWJsZXJhbmdlOjZhOTNmZjc4NTRkODRiYzQ4NjkxYWI3OWIwZmM2OWE3XzE1LTMtMS0xLTU4Mzcy_9b3cc84a-4a2b-4746-8bac-611e737b3d86"
      unitRef="usd">2713000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMzAvZnJhZzo3YTVjZGEzNmQ0YTU0MTA4YmM0ZTViMWQ0MmE5N2EyNS90YWJsZTo2YTkzZmY3ODU0ZDg0YmM0ODY5MWFiNzliMGZjNjlhNy90YWJsZXJhbmdlOjZhOTNmZjc4NTRkODRiYzQ4NjkxYWI3OWIwZmM2OWE3XzE2LTEtMS0xLTU4Mzcy_6a30ddb8-90f1-49a5-8b15-ad0cca3d47ee"
      unitRef="usd">-2723000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMzAvZnJhZzo3YTVjZGEzNmQ0YTU0MTA4YmM0ZTViMWQ0MmE5N2EyNS90YWJsZTo2YTkzZmY3ODU0ZDg0YmM0ODY5MWFiNzliMGZjNjlhNy90YWJsZXJhbmdlOjZhOTNmZjc4NTRkODRiYzQ4NjkxYWI3OWIwZmM2OWE3XzE2LTMtMS0xLTU4Mzcy_f37de849-800f-4491-9576-de1bf7e4bf90"
      unitRef="usd">2564000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMzAvZnJhZzo3YTVjZGEzNmQ0YTU0MTA4YmM0ZTViMWQ0MmE5N2EyNS90YWJsZTo2YTkzZmY3ODU0ZDg0YmM0ODY5MWFiNzliMGZjNjlhNy90YWJsZXJhbmdlOjZhOTNmZjc4NTRkODRiYzQ4NjkxYWI3OWIwZmM2OWE3XzE3LTEtMS0xLTU4Mzcy_024cc48d-7f29-4e0c-b702-1df1698a8916"
      unitRef="usd">-9005000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMzAvZnJhZzo3YTVjZGEzNmQ0YTU0MTA4YmM0ZTViMWQ0MmE5N2EyNS90YWJsZTo2YTkzZmY3ODU0ZDg0YmM0ODY5MWFiNzliMGZjNjlhNy90YWJsZXJhbmdlOjZhOTNmZjc4NTRkODRiYzQ4NjkxYWI3OWIwZmM2OWE3XzE3LTMtMS0xLTU4Mzcy_be767b78-6b0f-4d7b-a19b-0874bbdb5bf9"
      unitRef="usd">1603000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMzAvZnJhZzo3YTVjZGEzNmQ0YTU0MTA4YmM0ZTViMWQ0MmE5N2EyNS90YWJsZTo2YTkzZmY3ODU0ZDg0YmM0ODY5MWFiNzliMGZjNjlhNy90YWJsZXJhbmdlOjZhOTNmZjc4NTRkODRiYzQ4NjkxYWI3OWIwZmM2OWE3XzE4LTEtMS0xLTU4Mzcy_5b22e1e9-10b6-4d31-bc62-af280c0d8c9b"
      unitRef="usd">-67651000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMzAvZnJhZzo3YTVjZGEzNmQ0YTU0MTA4YmM0ZTViMWQ0MmE5N2EyNS90YWJsZTo2YTkzZmY3ODU0ZDg0YmM0ODY5MWFiNzliMGZjNjlhNy90YWJsZXJhbmdlOjZhOTNmZjc4NTRkODRiYzQ4NjkxYWI3OWIwZmM2OWE3XzE4LTMtMS0xLTU4Mzcy_4fd25622-ab8b-4452-aaa6-3158482df028"
      unitRef="usd">-76935000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMzAvZnJhZzo3YTVjZGEzNmQ0YTU0MTA4YmM0ZTViMWQ0MmE5N2EyNS90YWJsZTo2YTkzZmY3ODU0ZDg0YmM0ODY5MWFiNzliMGZjNjlhNy90YWJsZXJhbmdlOjZhOTNmZjc4NTRkODRiYzQ4NjkxYWI3OWIwZmM2OWE3XzIwLTEtMS0xLTU4Mzcy_5baa0da9-6ce0-4fdd-baf0-1cfad9bccdff"
      unitRef="usd">63000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMzAvZnJhZzo3YTVjZGEzNmQ0YTU0MTA4YmM0ZTViMWQ0MmE5N2EyNS90YWJsZTo2YTkzZmY3ODU0ZDg0YmM0ODY5MWFiNzliMGZjNjlhNy90YWJsZXJhbmdlOjZhOTNmZjc4NTRkODRiYzQ4NjkxYWI3OWIwZmM2OWE3XzIwLTMtMS0xLTU4Mzcy_eb2ef311-8e9f-4946-b47c-be90c56e9434"
      unitRef="usd">167000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMzAvZnJhZzo3YTVjZGEzNmQ0YTU0MTA4YmM0ZTViMWQ0MmE5N2EyNS90YWJsZTo2YTkzZmY3ODU0ZDg0YmM0ODY5MWFiNzliMGZjNjlhNy90YWJsZXJhbmdlOjZhOTNmZjc4NTRkODRiYzQ4NjkxYWI3OWIwZmM2OWE3XzIxLTEtMS0xLTU4Mzcy_2e265af1-47a2-42d0-9fb0-e74034669f7a"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMzAvZnJhZzo3YTVjZGEzNmQ0YTU0MTA4YmM0ZTViMWQ0MmE5N2EyNS90YWJsZTo2YTkzZmY3ODU0ZDg0YmM0ODY5MWFiNzliMGZjNjlhNy90YWJsZXJhbmdlOjZhOTNmZjc4NTRkODRiYzQ4NjkxYWI3OWIwZmM2OWE3XzIxLTMtMS0xLTU4Mzcy_bfc5759b-4087-48dc-a961-8b0c986b8d17"
      unitRef="usd">105000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMzAvZnJhZzo3YTVjZGEzNmQ0YTU0MTA4YmM0ZTViMWQ0MmE5N2EyNS90YWJsZTo2YTkzZmY3ODU0ZDg0YmM0ODY5MWFiNzliMGZjNjlhNy90YWJsZXJhbmdlOjZhOTNmZjc4NTRkODRiYzQ4NjkxYWI3OWIwZmM2OWE3XzIyLTEtMS0xLTU4Mzcy_6b58de48-bf3f-49f7-82ca-c1e2cbbfaf9b"
      unitRef="usd">-63000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMzAvZnJhZzo3YTVjZGEzNmQ0YTU0MTA4YmM0ZTViMWQ0MmE5N2EyNS90YWJsZTo2YTkzZmY3ODU0ZDg0YmM0ODY5MWFiNzliMGZjNjlhNy90YWJsZXJhbmdlOjZhOTNmZjc4NTRkODRiYzQ4NjkxYWI3OWIwZmM2OWE3XzIyLTMtMS0xLTU4Mzcy_bbf7fcc4-9f38-4925-8f9e-6975447aa215"
      unitRef="usd">-62000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMzAvZnJhZzo3YTVjZGEzNmQ0YTU0MTA4YmM0ZTViMWQ0MmE5N2EyNS90YWJsZTo2YTkzZmY3ODU0ZDg0YmM0ODY5MWFiNzliMGZjNjlhNy90YWJsZXJhbmdlOjZhOTNmZjc4NTRkODRiYzQ4NjkxYWI3OWIwZmM2OWE3XzI0LTEtMS0xLTU4Mzcy_0afd5d53-e833-430e-9ba2-af1c1685f1e5"
      unitRef="usd">51086000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMzAvZnJhZzo3YTVjZGEzNmQ0YTU0MTA4YmM0ZTViMWQ0MmE5N2EyNS90YWJsZTo2YTkzZmY3ODU0ZDg0YmM0ODY5MWFiNzliMGZjNjlhNy90YWJsZXJhbmdlOjZhOTNmZjc4NTRkODRiYzQ4NjkxYWI3OWIwZmM2OWE3XzI0LTMtMS0xLTU4Mzcy_3e12bf88-2f6c-4d70-9a97-d87369137af5"
      unitRef="usd">43140000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <optn:ProceedsfromIssuanceofCommonStockUnderEmployeeStockPurchasePlan
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMzAvZnJhZzo3YTVjZGEzNmQ0YTU0MTA4YmM0ZTViMWQ0MmE5N2EyNS90YWJsZTo2YTkzZmY3ODU0ZDg0YmM0ODY5MWFiNzliMGZjNjlhNy90YWJsZXJhbmdlOjZhOTNmZjc4NTRkODRiYzQ4NjkxYWI3OWIwZmM2OWE3XzI3LTEtMS0xLTU4Mzcy_2a58ba9e-1c08-42ac-9f49-79670d4d85bf"
      unitRef="usd">554000</optn:ProceedsfromIssuanceofCommonStockUnderEmployeeStockPurchasePlan>
    <optn:ProceedsfromIssuanceofCommonStockUnderEmployeeStockPurchasePlan
      contextRef="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMzAvZnJhZzo3YTVjZGEzNmQ0YTU0MTA4YmM0ZTViMWQ0MmE5N2EyNS90YWJsZTo2YTkzZmY3ODU0ZDg0YmM0ODY5MWFiNzliMGZjNjlhNy90YWJsZXJhbmdlOjZhOTNmZjc4NTRkODRiYzQ4NjkxYWI3OWIwZmM2OWE3XzI3LTMtMS0xLTU4Mzcy_1bc55c41-5055-425b-8776-e1832c29159b"
      unitRef="usd">368000</optn:ProceedsfromIssuanceofCommonStockUnderEmployeeStockPurchasePlan>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMzAvZnJhZzo3YTVjZGEzNmQ0YTU0MTA4YmM0ZTViMWQ0MmE5N2EyNS90YWJsZTo2YTkzZmY3ODU0ZDg0YmM0ODY5MWFiNzliMGZjNjlhNy90YWJsZXJhbmdlOjZhOTNmZjc4NTRkODRiYzQ4NjkxYWI3OWIwZmM2OWE3XzI4LTEtMS0xLTU4Mzcy_0994672d-73e0-4ca0-88ec-56dcbe18a78d"
      unitRef="usd">94000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMzAvZnJhZzo3YTVjZGEzNmQ0YTU0MTA4YmM0ZTViMWQ0MmE5N2EyNS90YWJsZTo2YTkzZmY3ODU0ZDg0YmM0ODY5MWFiNzliMGZjNjlhNy90YWJsZXJhbmdlOjZhOTNmZjc4NTRkODRiYzQ4NjkxYWI3OWIwZmM2OWE3XzI4LTMtMS0xLTU4Mzcy_bbe3390a-ed78-4d5a-b4df-c218368a98f2"
      unitRef="usd">39000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMzAvZnJhZzo3YTVjZGEzNmQ0YTU0MTA4YmM0ZTViMWQ0MmE5N2EyNS90YWJsZTo2YTkzZmY3ODU0ZDg0YmM0ODY5MWFiNzliMGZjNjlhNy90YWJsZXJhbmdlOjZhOTNmZjc4NTRkODRiYzQ4NjkxYWI3OWIwZmM2OWE3XzI5LTEtMS0xLTU4Mzcy_28485965-c021-4844-beb0-47e815f41fef"
      unitRef="usd">298000</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMzAvZnJhZzo3YTVjZGEzNmQ0YTU0MTA4YmM0ZTViMWQ0MmE5N2EyNS90YWJsZTo2YTkzZmY3ODU0ZDg0YmM0ODY5MWFiNzliMGZjNjlhNy90YWJsZXJhbmdlOjZhOTNmZjc4NTRkODRiYzQ4NjkxYWI3OWIwZmM2OWE3XzI5LTMtMS0xLTU4Mzcy_e0003e80-9ddd-4127-b615-1ee3f718ae89"
      unitRef="usd">227000</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMzAvZnJhZzo3YTVjZGEzNmQ0YTU0MTA4YmM0ZTViMWQ0MmE5N2EyNS90YWJsZTo2YTkzZmY3ODU0ZDg0YmM0ODY5MWFiNzliMGZjNjlhNy90YWJsZXJhbmdlOjZhOTNmZjc4NTRkODRiYzQ4NjkxYWI3OWIwZmM2OWE3XzMxLTEtMS0xLTU4Mzcy_bbd34802-9e6d-43c0-8c5e-03eb2be038d1"
      unitRef="usd">51436000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMzAvZnJhZzo3YTVjZGEzNmQ0YTU0MTA4YmM0ZTViMWQ0MmE5N2EyNS90YWJsZTo2YTkzZmY3ODU0ZDg0YmM0ODY5MWFiNzliMGZjNjlhNy90YWJsZXJhbmdlOjZhOTNmZjc4NTRkODRiYzQ4NjkxYWI3OWIwZmM2OWE3XzMxLTMtMS0xLTU4Mzcy_33e8239a-bad3-49eb-90a2-ee46f31295f1"
      unitRef="usd">43320000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMzAvZnJhZzo3YTVjZGEzNmQ0YTU0MTA4YmM0ZTViMWQ0MmE5N2EyNS90YWJsZTo2YTkzZmY3ODU0ZDg0YmM0ODY5MWFiNzliMGZjNjlhNy90YWJsZXJhbmdlOjZhOTNmZjc4NTRkODRiYzQ4NjkxYWI3OWIwZmM2OWE3XzMyLTEtMS0xLTU4Mzcy_9600e440-02d5-4359-81ad-9d8d2ed7e283"
      unitRef="usd">7000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMzAvZnJhZzo3YTVjZGEzNmQ0YTU0MTA4YmM0ZTViMWQ0MmE5N2EyNS90YWJsZTo2YTkzZmY3ODU0ZDg0YmM0ODY5MWFiNzliMGZjNjlhNy90YWJsZXJhbmdlOjZhOTNmZjc4NTRkODRiYzQ4NjkxYWI3OWIwZmM2OWE3XzMyLTMtMS0xLTU4Mzcy_9bba47a5-a477-42d5-813c-5648eb7a23fb"
      unitRef="usd">13000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMzAvZnJhZzo3YTVjZGEzNmQ0YTU0MTA4YmM0ZTViMWQ0MmE5N2EyNS90YWJsZTo2YTkzZmY3ODU0ZDg0YmM0ODY5MWFiNzliMGZjNjlhNy90YWJsZXJhbmdlOjZhOTNmZjc4NTRkODRiYzQ4NjkxYWI3OWIwZmM2OWE3XzMzLTEtMS0xLTU4Mzcy_5222a3b2-42a8-4671-b2fe-45f8e71e969e"
      unitRef="usd">-16271000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMzAvZnJhZzo3YTVjZGEzNmQ0YTU0MTA4YmM0ZTViMWQ0MmE5N2EyNS90YWJsZTo2YTkzZmY3ODU0ZDg0YmM0ODY5MWFiNzliMGZjNjlhNy90YWJsZXJhbmdlOjZhOTNmZjc4NTRkODRiYzQ4NjkxYWI3OWIwZmM2OWE3XzMzLTMtMS0xLTU4Mzcy_064c57fe-b53c-4d16-bd6a-2a9272568427"
      unitRef="usd">-33664000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="id970dfd2674c4d6b895febb9c14d0fd1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMzAvZnJhZzo3YTVjZGEzNmQ0YTU0MTA4YmM0ZTViMWQ0MmE5N2EyNS90YWJsZTo2YTkzZmY3ODU0ZDg0YmM0ODY5MWFiNzliMGZjNjlhNy90YWJsZXJhbmdlOjZhOTNmZjc4NTRkODRiYzQ4NjkxYWI3OWIwZmM2OWE3XzM0LTEtMS0xLTU4Mzcy_4ad2f0fe-8248-4738-be50-e558070ab48b"
      unitRef="usd">110515000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i49ae796ea1484c519d91607656f24c24_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMzAvZnJhZzo3YTVjZGEzNmQ0YTU0MTA4YmM0ZTViMWQ0MmE5N2EyNS90YWJsZTo2YTkzZmY3ODU0ZDg0YmM0ODY5MWFiNzliMGZjNjlhNy90YWJsZXJhbmdlOjZhOTNmZjc4NTRkODRiYzQ4NjkxYWI3OWIwZmM2OWE3XzM0LTMtMS0xLTU4Mzcy_311b42a2-c752-46ba-a7fb-b9b57270d352"
      unitRef="usd">144179000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMzAvZnJhZzo3YTVjZGEzNmQ0YTU0MTA4YmM0ZTViMWQ0MmE5N2EyNS90YWJsZTo2YTkzZmY3ODU0ZDg0YmM0ODY5MWFiNzliMGZjNjlhNy90YWJsZXJhbmdlOjZhOTNmZjc4NTRkODRiYzQ4NjkxYWI3OWIwZmM2OWE3XzM1LTEtMS0xLTU4Mzcy_56ec4438-05be-4bed-8b1f-33335d5052f7"
      unitRef="usd">94244000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="id970dfd2674c4d6b895febb9c14d0fd1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMzAvZnJhZzo3YTVjZGEzNmQ0YTU0MTA4YmM0ZTViMWQ0MmE5N2EyNS90YWJsZTo2YTkzZmY3ODU0ZDg0YmM0ODY5MWFiNzliMGZjNjlhNy90YWJsZXJhbmdlOjZhOTNmZjc4NTRkODRiYzQ4NjkxYWI3OWIwZmM2OWE3XzM1LTMtMS0xLTU4Mzcy_4156d3bd-6d4c-4344-950f-1467b8070fed"
      unitRef="usd">110515000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMzAvZnJhZzo3YTVjZGEzNmQ0YTU0MTA4YmM0ZTViMWQ0MmE5N2EyNS90YWJsZTo2YTkzZmY3ODU0ZDg0YmM0ODY5MWFiNzliMGZjNjlhNy90YWJsZXJhbmdlOjZhOTNmZjc4NTRkODRiYzQ4NjkxYWI3OWIwZmM2OWE3XzM3LTEtMS0xLTU4Mzcy_0b17cd2f-c313-43ee-998d-926a770d0200"
      unitRef="usd">15091000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMzAvZnJhZzo3YTVjZGEzNmQ0YTU0MTA4YmM0ZTViMWQ0MmE5N2EyNS90YWJsZTo2YTkzZmY3ODU0ZDg0YmM0ODY5MWFiNzliMGZjNjlhNy90YWJsZXJhbmdlOjZhOTNmZjc4NTRkODRiYzQ4NjkxYWI3OWIwZmM2OWE3XzM3LTMtMS0xLTU4Mzcy_1dbfa608-2ee4-4d29-ab33-4df1f3432c07"
      unitRef="usd">14170000</us-gaap:InterestPaidNet>
    <us-gaap:NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMzAvZnJhZzo3YTVjZGEzNmQ0YTU0MTA4YmM0ZTViMWQ0MmE5N2EyNS90YWJsZTo2YTkzZmY3ODU0ZDg0YmM0ODY5MWFiNzliMGZjNjlhNy90YWJsZXJhbmdlOjZhOTNmZjc4NTRkODRiYzQ4NjkxYWI3OWIwZmM2OWE3XzM5LTEtMS0xLTU4Mzcy_04c48690-58c8-4804-a2e6-c1033edd256f"
      unitRef="usd">4000</us-gaap:NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1>
    <us-gaap:NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
      contextRef="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMzAvZnJhZzo3YTVjZGEzNmQ0YTU0MTA4YmM0ZTViMWQ0MmE5N2EyNS90YWJsZTo2YTkzZmY3ODU0ZDg0YmM0ODY5MWFiNzliMGZjNjlhNy90YWJsZXJhbmdlOjZhOTNmZjc4NTRkODRiYzQ4NjkxYWI3OWIwZmM2OWE3XzM5LTMtMS0xLTU4Mzcy_85ccd148-16fd-42c3-b296-5c9d8d203934"
      unitRef="usd">11000</us-gaap:NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMzAvZnJhZzo3YTVjZGEzNmQ0YTU0MTA4YmM0ZTViMWQ0MmE5N2EyNS90YWJsZTo2YTkzZmY3ODU0ZDg0YmM0ODY5MWFiNzliMGZjNjlhNy90YWJsZXJhbmdlOjZhOTNmZjc4NTRkODRiYzQ4NjkxYWI3OWIwZmM2OWE3XzQwLTEtMS0xLTU4Mzcy_f1bc4d0c-69ad-44e1-93ee-72682157b66c"
      unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMzAvZnJhZzo3YTVjZGEzNmQ0YTU0MTA4YmM0ZTViMWQ0MmE5N2EyNS90YWJsZTo2YTkzZmY3ODU0ZDg0YmM0ODY5MWFiNzliMGZjNjlhNy90YWJsZXJhbmdlOjZhOTNmZjc4NTRkODRiYzQ4NjkxYWI3OWIwZmM2OWE3XzQwLTMtMS0xLTU4Mzcy_636a5057-4155-4ed0-ac4c-760d192fed6d"
      unitRef="usd">534000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <optn:DeferredOfferingCostsWIthinAccountsPayableandAccruedExpenses
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMzAvZnJhZzo3YTVjZGEzNmQ0YTU0MTA4YmM0ZTViMWQ0MmE5N2EyNS90YWJsZTo2YTkzZmY3ODU0ZDg0YmM0ODY5MWFiNzliMGZjNjlhNy90YWJsZXJhbmdlOjZhOTNmZjc4NTRkODRiYzQ4NjkxYWI3OWIwZmM2OWE3XzQyLTEtMS0xLTU4Mzcy_bf9e6072-cf1c-4183-9e36-a7f2f1d4c67b"
      unitRef="usd">408000</optn:DeferredOfferingCostsWIthinAccountsPayableandAccruedExpenses>
    <optn:DeferredOfferingCostsWIthinAccountsPayableandAccruedExpenses
      contextRef="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMzAvZnJhZzo3YTVjZGEzNmQ0YTU0MTA4YmM0ZTViMWQ0MmE5N2EyNS90YWJsZTo2YTkzZmY3ODU0ZDg0YmM0ODY5MWFiNzliMGZjNjlhNy90YWJsZXJhbmdlOjZhOTNmZjc4NTRkODRiYzQ4NjkxYWI3OWIwZmM2OWE3XzQyLTMtMS0xLTU4Mzcy_09fa99d3-e7d2-4a08-9e01-2e8a20730158"
      unitRef="usd">318000</optn:DeferredOfferingCostsWIthinAccountsPayableandAccruedExpenses>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMzAvZnJhZzo3YTVjZGEzNmQ0YTU0MTA4YmM0ZTViMWQ0MmE5N2EyNS90YWJsZTo2YTkzZmY3ODU0ZDg0YmM0ODY5MWFiNzliMGZjNjlhNy90YWJsZXJhbmdlOjZhOTNmZjc4NTRkODRiYzQ4NjkxYWI3OWIwZmM2OWE3XzQzLTEtMS0xLTU4Mzcy_4562336a-6ce6-4ca0-bf43-46e735a566b8"
      unitRef="usd">704000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMzAvZnJhZzo3YTVjZGEzNmQ0YTU0MTA4YmM0ZTViMWQ0MmE5N2EyNS90YWJsZTo2YTkzZmY3ODU0ZDg0YmM0ODY5MWFiNzliMGZjNjlhNy90YWJsZXJhbmdlOjZhOTNmZjc4NTRkODRiYzQ4NjkxYWI3OWIwZmM2OWE3XzQzLTMtMS0xLTU4Mzcy_f99a4914-502f-4e75-b53e-ed4f11035d10"
      unitRef="usd">157000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:NatureOfOperations
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMzYvZnJhZzo3MDRiYmExYWU0ZmM0MDdmYmYyOWFiNDEwY2Q0MTBmOC90ZXh0cmVnaW9uOjcwNGJiYTFhZTRmYzQwN2ZiZjI5YWI0MTBjZDQxMGY4XzEyNTU_9bb09213-984d-4723-b6bd-fa4a716fe198">Organization and Description of BusinessOptiNose,&#160;Inc. (the Company) was incorporated in Delaware in May 2010 (inception) and has facilities in Yardley, Pennsylvania and Ewing, New Jersey. The Company's predecessor entity, OptiNose AS, was formed under the laws of Norway in September 2000. In 2010, OptiNose AS became a wholly-owned subsidiary of the Company as part of an internal reorganization.  During 2022, the Company's board of directors approved the liquidation of Optionse AS and Optinose UK, which is expected to be completed in 2023, in order to simplify the corporate structure.  &lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is a specialty pharmaceutical company focused on the development and commercialization of products for patients treated by ear, nose and throat (ENT) and allergy specialists. The Company's first commercial product, XHANCE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt; (fluticasone propionate) nasal spray, 93 microgram (mcg), is a therapeutic utilizing the Company's proprietary Exhalation Delivery System (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps and, if approved, chronic rhinosinusitis without nasal polyps (also known as chronic sinusitis). XHANCE was approved by the United States (US) Food and Drug Administration (FDA) in September 2017 for the treatment of nasal polyps in patients 18&#160;years of age or older. XHANCE was made widely available through commercial channels in April 2018.  In January 2023, the indication statement for XHANCE was changed from &#x201c;for the treatment of nasal polyps&#x201d; to &#x201c;for the treatment of chronic rhinosinusitis with nasal polyps&#x201d; to reflect current FDA labeling terminology and not based on new XHANCE clinical trial data.</us-gaap:NatureOfOperations>
    <optn:FutureLiquidityTextBlock
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMzkvZnJhZzoyODhkZDRlNTdmN2Q0ODE2OTA2ZGNiNzlmMjllMjUzYi90ZXh0cmVnaW9uOjI4OGRkNGU1N2Y3ZDQ4MTY5MDZkY2I3OWYyOWUyNTNiXzIzOTI_1e428b65-956c-408f-973d-0c3c85ac3e32">Liquidity&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Since inception, the Company's operations have focused on organization and staffing, business planning, raising capital, establishing an intellectual property portfolio, conducting preclinical studies and clinical trials, pursuing regulatory approvals and most recently, launching XHANCE in the US. As of December 31, 2022, the Company had cash and cash equivalents of $94,244 and a working capital deficiency of $38,246.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to a number of risks similar to other life sciences companies, including successful discovery, development and commercialization of its products and product candidates, raising additional capital, the development by its competitors of new technological innovations, protection of proprietary technology and market acceptance of the Company's products. The Company has incurred recurring net losses since its inception and has accumulated a deficit of $684,893 as of December 31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company entered into a Note Purchase Agreement (the Note Purchase Agreement) on September 12, 2019 with funds managed by Pharmakon Advisors, LP (Pharmakon), the investment manager of the BioPharma Credit Funds (BioPharma) which was subsequently amended on August 13, 2020, March 2, 2021, November 16, 2021, August 10, 2022, and November 9, 2022.  On November 23, 2022, the Company amended and restated the Note Purchase Agreement (the A&amp;amp;R Note Purchase Agreement). Pursuant to the A&amp;amp;R Note Purchase Agreement, the financial covenants requiring the Company to achieve minimum trailing twelve-month consolidated XHANCE net product sales and royalties were modified (See &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"&gt;&lt;a href="#i451bcb3eabba4f87bdc579718207a3b8_163" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"&gt;Note &lt;/a&gt;&lt;a href="#i451bcb3eabba4f87bdc579718207a3b8_163" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"&gt;10&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;). The principal balance outstanding under the A&amp;amp;R Note Purchase Agreement was $130&#160;million at December 31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company's continuation as a going concern is dependent on its ability to maintain compliance with its covenants under the A&amp;amp;R Note Purchase Agreement, including minimum trailing twelve-month consolidated XHANCE net sales and royalties the Company is required to achieve commencing with the trailing twelve months ending March 31, 2024 and its ability to generate sufficient cash flows from operations to meet its obligations and/or obtain additional capital through equity or debt financings, partnerships, collaborations, or other sources, as may be required. The A&amp;amp;R Note Purchase Agreement includes events of default, in certain cases subject to customary periods to cure, following which Pharmakon may accelerate all amounts outstanding pursuant to the Note Purchase Agreement. The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The A&amp;amp;R Note Purchase Agreement also requires the Company to maintain at all times a minimum of $30,000 of cash and cash equivalents. The Company believes that it is probable that its existing cash and cash equivalents will not be adequate to fund its operations and maintain at least $30,000 of cash and cash equivalents as required &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;under the A&amp;amp;R Note Purchase Agreement for at least twelve-months following the filing of this Form 10-K, which will also constitute a default of the liquidity financial covenant under the A&amp;amp;R Note Purchase Agreement if the Company is unable to obtain additional capital or obtain a waiver or modification to this liquidity covenant prior to falling below such $30,000 threshold. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company also believes it is probable that it will not achieve the trailing twelve-month minimum consolidated XHANCE net sales and royalties thresholds under the A&amp;amp;R Note Purchase Agreement for the initial period ending March 31, 2024, which will constitute a default under the A&amp;amp;R Note Purchase Agreement if the Company is unable to obtain a modification or waiver of such minimum consolidated XHANCE net sales and royalties thresholds. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Further, the A&amp;amp;R Note Purchase Agreement includes a requirement that the report and opinion on the consolidated financial statements commencing with the year ending December 31, 2023, not be subject to any statement as to &#x201c;going concern.&#x201d; In addition, the consolidated financial statements commencing with the quarter ended March 31, 2024, shall also not be subject to any statement as to &#x201c;going concern.&#x201d; The Company has concluded that it is unlikely that it will be able comply with these provisions in 2024.  Failure to comply with these provisions would also constitute an event of default under the A&amp;amp;R Note Purchase Agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In the event of any of the foregoing defaults, the holders of the Pharmakon Senior Secured Notes may declare an event of default under the A&amp;amp;R Note Purchase&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Agreement and may elect to accelerate the repayment of all unpaid principal, accrued interest and other amounts due, which may require the Company to delay or curtail its operations until additional funding is received.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The terms of the&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;A&amp;amp;R Note Purchase&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Agreement and the Pharmakon Senior Secured Notes, including applicable covenants, are described in &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"&gt;&lt;a href="#i451bcb3eabba4f87bdc579718207a3b8_163" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"&gt;Note &lt;/a&gt;&lt;a href="#i451bcb3eabba4f87bdc579718207a3b8_163" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"&gt;10&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Management&#x2019;s plans to mitigate this risk may include reducing expenses, raising additional capital through equity or debt financings, partnerships, collaborations or other sources and requesting a modification or waiver of the covenants under the A&amp;amp;R Note Purchase Agreement.  However, there can be no assurance that the Company will be successful in reducing expenses, raising additional capital, or obtaining a modification or waiver of the covenants under the A&amp;amp;R Note Purchase Agreement. If the Company is unable to reduce expenses, raise additional capital or obtain a modification or waiver of the covenants under the A&amp;amp;R Note Purchase Agreement, the Company may need to delay or curtail its operations. As a result of these factors, management has concluded that substantial doubt exists about the Company&#x2019;s ability to continue as a going concern within one year after the date these consolidated financial statements are issued.&lt;/span&gt;&lt;/div&gt;</optn:FutureLiquidityTextBlock>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMzkvZnJhZzoyODhkZDRlNTdmN2Q0ODE2OTA2ZGNiNzlmMjllMjUzYi90ZXh0cmVnaW9uOjI4OGRkNGU1N2Y3ZDQ4MTY5MDZkY2I3OWYyOWUyNTNiXzM3Mg_e0f1930c-76a4-4276-86e6-a976065ca130"
      unitRef="usd">94244000</us-gaap:CashEquivalentsAtCarryingValue>
    <optn:WorkingCapital
      contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMzkvZnJhZzoyODhkZDRlNTdmN2Q0ODE2OTA2ZGNiNzlmMjllMjUzYi90ZXh0cmVnaW9uOjI4OGRkNGU1N2Y3ZDQ4MTY5MDZkY2I3OWYyOWUyNTNiXzIxOTkwMjMzNzU0MzQ_21bdbfb0-c7ec-447b-b18c-07d0beef53d4"
      unitRef="usd">-38246000</optn:WorkingCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMzkvZnJhZzoyODhkZDRlNTdmN2Q0ODE2OTA2ZGNiNzlmMjllMjUzYi90ZXh0cmVnaW9uOjI4OGRkNGU1N2Y3ZDQ4MTY5MDZkY2I3OWYyOWUyNTNiXzIxOTkwMjMzNzU1NTE_842e30e2-37f4-4b8d-8f69-1c11479681e5"
      unitRef="usd">-684893000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:NotesPayable
      contextRef="i57b30631121b485ab3ea36fafacd9bba_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMzkvZnJhZzoyODhkZDRlNTdmN2Q0ODE2OTA2ZGNiNzlmMjllMjUzYi90ZXh0cmVnaW9uOjI4OGRkNGU1N2Y3ZDQ4MTY5MDZkY2I3OWYyOWUyNTNiXzIxOTkwMjMzNzU3Mzc_7cccc1c6-1198-45bd-bb59-4e17f18e774b"
      unitRef="usd">130000000</us-gaap:NotesPayable>
    <optn:DebtInstrumentCovenantCashAndCashEquivalents
      contextRef="i77cd59ff576d44dd94fde4a159bcfd79_I20221123"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMzkvZnJhZzoyODhkZDRlNTdmN2Q0ODE2OTA2ZGNiNzlmMjllMjUzYi90ZXh0cmVnaW9uOjI4OGRkNGU1N2Y3ZDQ4MTY5MDZkY2I3OWYyOWUyNTNiXzIxOTkwMjMzNzgwMzk_5c3a882c-6182-4199-8983-fbe174e9baad"
      unitRef="usd">30000000</optn:DebtInstrumentCovenantCashAndCashEquivalents>
    <optn:DebtInstrumentCovenantCashAndCashEquivalents
      contextRef="i77cd59ff576d44dd94fde4a159bcfd79_I20221123"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMzkvZnJhZzoyODhkZDRlNTdmN2Q0ODE2OTA2ZGNiNzlmMjllMjUzYi90ZXh0cmVnaW9uOjI4OGRkNGU1N2Y3ZDQ4MTY5MDZkY2I3OWYyOWUyNTNiXzIxOTkwMjMzNzgyMjQ_cd4aae9b-9cf9-4390-a7df-91751eef346d"
      unitRef="usd">30000000</optn:DebtInstrumentCovenantCashAndCashEquivalents>
    <optn:DebtInstrumentCovenantCashAndCashEquivalents
      contextRef="iad0d9b5ed2334bfd8a9fd9842e362c70_I20221123"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xMzkvZnJhZzoyODhkZDRlNTdmN2Q0ODE2OTA2ZGNiNzlmMjllMjUzYi90ZXh0cmVnaW9uOjI4OGRkNGU1N2Y3ZDQ4MTY5MDZkY2I3OWYyOWUyNTNiXzIxOTkwMjMzNzg2MzA_2dcc569f-b8ed-4776-b778-2fd6c00e7aa7"
      unitRef="usd">30000000</optn:DebtInstrumentCovenantCashAndCashEquivalents>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDIvZnJhZzo5M2I1YmRhMDg4ZWQ0ZWFlYjc4M2I1ZTU0N2JkZjA5My90ZXh0cmVnaW9uOjkzYjViZGEwODhlZDRlYWViNzgzYjVlNTQ3YmRmMDkzXzI1MDM2_97ab9bbb-d721-4977-9b3e-da9bf5f79f99">Summary of Significant Accounting Policies&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying consolidated financial statements have been prepared in conformity with US generally accepted accounting principles (GAAP). Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification (ASC) and Accounting Standards Updates (ASU) of the Financial Accounting Standards Board (FASB).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Principles of consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements include the accounts of OptiNose,&#160;Inc. and its wholly-owned subsidiaries, OptiNose US,&#160;Inc., OptiNose AS and OptiNose UK&#160;Ltd. All inter-company balances and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and reported amounts of expenses during the reporting period. Due to the uncertainty of factors surrounding the estimates or judgments used in the preparation of the consolidated financial statements, actual results may materially vary from these estimates. Estimates and assumptions are periodically reviewed and the effects of revisions are reflected in the consolidated financial statements in the period they are determined to be necessary.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentration of credit risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk are primarily cash and accounts receivable. The Company generally invests its cash in deposits with high credit quality financial institutions. Additionally, the Company performs periodic evaluations of the relative credit standing of these financial institutions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Customer and supplier concentration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has exposure to credit risk in accounts receivable from sales of product. XHANCE is sold to wholesale pharmaceutical distributors and preferred pharmacy network (PPN) partners, who, in turn, sell XHANCE to pharmacies, hospitals and other customers.&#160;Five customers represented approximately 52% of the Company's accounts receivable at December 31, 2022 and five customers represented approximately 33% of the Company's net product sales for the year ended December 31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;The Company purchases XHANCE and its components from several third-party suppliers and manufacturing partners, certain of which are available through a single source. Although the Company could obtain each of these components from alternative third-party suppliers, it would need to qualify and obtain FDA approval for another supplier as a source for each such component.  The Company has initiated the process of qualifying an alternate third-party supplier for select components of XHANCE.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:107%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;Alternate third party suppliers of XHANCE components are subject to qualification and approval from the FDA.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All highly liquid investments purchased with an original maturity date of three months or less at the date of purchase are considered to be cash equivalents. The Company maintains its cash and cash equivalent balances at foreign and domestic financial institutions. Bank deposits with Norwegian banks are insured up to approximately 2,000 Norwegian krone by the Norwegian Banks' Guarantee Fund. Bank deposits with US banks are insured up to $250 by the Federal Deposits Insurance Corporation. The Company had uninsured cash balances of $92,988 and $109,017 at December 31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair value of financial instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company measures certain assets and liabilities at fair value, which is defined as the price that would be received to sell an asset or paid to transfer a liability (the exit price) in an orderly transaction between market participants at the measurement date. The FASB accounting guidance outlines a valuation framework and creates a fair value hierarchy in order to increase the consistency and comparability of fair value measurements and the related disclosures. In determining fair value, the Company uses quoted prices and observable inputs. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from independent sources. The fair value hierarchy is broken down into three levels based on the source of the inputs as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level&#160;1&#160;&#x2014; Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level&#160;2&#160;&#x2014; Valuations based on observable inputs (other than Level&#160;1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level&#160;3&#160;&#x2014; Valuations based on inputs that are unobservable and models that are significant to the overall fair value measurement.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;At December 31, 2022 and 2021, the Company's financial instruments included cash and cash equivalents, accounts receivable, grants receivable, accounts payable, accrued expenses and certain liability classified warrants. The carrying amounts reported in the Company's financial statements for cash and cash equivalents, accounts receivable, grants receivable, accounts payable and accrued expenses approximates their respective fair values because of the short-term nature of these instruments. In addition, at December 31, 2022, the Company believed &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;the carrying value of debt approximates fair value as the interest rates were reflective of the rate the Company could obtain on debt with similar terms and conditions. At December 31, 2022 and 2021, there were no financial assets or liabilities measured at fair value on a recurring basis other than the liability classified warrants shown below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2022, the Company issued warrants in connection with the a public offering. Pursuant to the terms of the warrant agreement, the Company could be required to settle the warrants in cash in the event of an acquisition of the Company and, as a result, the warrants are required to be measured at fair value and reported as liability in the consolidated balance sheet. The Company recorded the fair value of the warrants upon issuance using a Monte Carlo simulation and is required to revalue the warrants at each reporting date with any changes in fair value recorded on our statement of operations. The valuation of the warrants is considered under Level 3 of the fair value hierarchy due to the need to use assumptions in the valuation that are both significant to the fair value measurement and unobservable. The change in the fair value of the Level 3 warrants liabilities is reflected in the statement of operations for the years ended December 31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounts receivable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts receivable primarily relates to amounts due from customers, which are typically due within 31 to 61 days. The Company analyzes accounts that are past due for collectability. There was no allowance for doubtful accounts related to customers subject to credit risk at December 31, 2022. The Company recognized an allowance for doubtful accounts related to customers subject to credit risk of $444 at December 31, 2021. The accounts receivable balance at December 31, 2021 on the accompanying balance sheet is net of the allowance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Inventory &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories are stated at the lower of cost or net realizable value. Costs of inventories, which include amounts related to materials and manufacturing overhead, are determined on a first-in, first-out basis. An assessment of the recoverability of capitalized inventory is performed during each reporting period and any excess and obsolete inventories are written down to their estimated net realizable value in the period in which the impairment is first identified. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment is recorded at cost less accumulated depreciation. Significant additions or improvements are capitalized and expenditures for repairs and maintenance are charged to expense as incurred. Gains and losses on disposal of assets are included in the consolidated statements of operations. Depreciation is calculated on a straight-line basis over the estimated useful lives of the respective assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated useful lives of property and equipment are as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.031%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.457%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.607%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Computer equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2-3 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Machinery &amp;amp; production equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5-10 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Furniture &amp;amp; fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3-5 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Shorter of lease term or useful life&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Long lived assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future net cash flows expected to be generated. Impairment charges are recognized at the amount by which the carrying amount of an asset exceeds the fair value of the asset. Assets to be disposed of are reported at the lower of the carrying amount or the fair value less costs to sell. The Company did not recognize any impairment or disposition of long-lived assets for the years ended December 31, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the terms of the arrangement. The Company accounts for a contract as a lease when it has the right to control the asset for a period of time while obtaining substantially all of the asset&#x2019;s economic benefits. The Company determines the initial classification and measurement of its operating right-of-use (&#x201c;ROU&#x201d;) assets and operating lease liabilities at the lease commencement date, and thereafter if modified.  The lease term includes any renewal options that the Company is reasonably assured to exercise. The Company&#x2019;s policy is to not record leases with a lease term of 12 months or less on its balance sheets. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The ROU asset represents the right to use the leased asset for the lease term. The lease liability represents the present value of the lease payments under the lease. The present value of lease payments is determined by using the interest rate implicit in the lease, if that rate is readily determinable; otherwise, the Company uses its estimated secured incremental borrowing rate for that lease term.  Lease expense for operating leases is recognized on a straight-line basis over the reasonably assured lease term based on the total lease payments and is included in operating expense in the statements of operations. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Payments due under each lease agreement include fixed and variable payments. Variable payments relate to the Company&#x2019;s share of the lessor&#x2019;s operating costs associated with the underlying asset and are recognized when the event on which those payments are assessed occurs. Variable payments have been excluded from the lease liability and associated right-of-use asset. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:103%"&gt;The interest rate implicit in lease agreements is typically not readily determinable, and as such, the Company utilizes the incremental borrowing rate to calculate lease liabilities, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net product revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for revenue in accordance with ASC Topic 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(ASC 606), which was adopted on January 1, 2018. The Company performs the following five steps to recognize revenue under ASC 606: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only recognizes revenue when it is probable that it will collect the consideration to which it is entitled in exchange for the goods or services that will be transferred to the customer. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company sells XHANCE to preferred pharmacy network partners and wholesalers in the US (collectively, Customers). These Customers subsequently resell the Company&#x2019;s products to healthcare providers, patients and other retail pharmacies. In addition to agreements with Customers, the Company enters into arrangements with healthcare providers and payors that provide for government-mandated and/or privately-negotiated rebates, chargebacks and discounts for the purchase of the Company&#x2019;s products.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes revenue from XHANCE sales at the point Customers obtain control of the product, which generally occurs upon delivery. The transaction price that is recognized as revenue for products includes an estimate of variable consideration which is described below. Payment terms with Customers do not exceed one year and, therefore, the Company does not account for a financing component in its arrangements. The Company expenses incremental costs of obtaining a contract with a Customer (for example, sales commissions) when incurred as the period of benefit is less than one year. Shipping and handling costs for product shipments to Customers are recorded as selling, general and administrative expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Transaction Price, including Estimates of Variable Consideration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue from products is recognized at the estimated net sales price (transaction price), which includes estimates of variable consideration. The Company includes estimated amounts in the transaction price to the extent it is determined probable that a significant reversal of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is resolved. The Company&#x2019;s estimates of variable consideration and determination of whether to include estimated amounts in the transaction price are based largely on an assessment &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;of its anticipated performance and all information (historical, current and forecasted) that is reasonably available.  The components of the Company's variable consideration include the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline"&gt;Provider Chargebacks and Discounts.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Chargebacks for fees and discounts to providers represent the estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list prices charged to Customers who directly purchase the product from the Company.&#160;Customers charge the Company for the difference between what they pay for the product and the ultimate selling price to the qualified healthcare providers.&#160;These components of variable consideration are established in the same period that the related revenue is recognized, resulting in a reduction of product revenue and accounts receivable.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x25e6;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt;text-decoration:underline"&gt;Trade Discounts and Allowances.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;  The Company generally provides Customers with discounts that include incentive fees which are explicitly stated in the Company&#x2019;s contracts. These discounts are recorded as a reduction of revenue and accounts receivable in the period in which the related product revenue is recognized. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x25e6;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt;text-decoration:underline"&gt;Product Returns.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;  Consistent with industry practice, the Company has a product returns policy that provides Customers a right of return for product purchased within a specified period prior to and subsequent to the product&#x2019;s expiration date. The Company estimates the amount of its products that may be returned and presents this amount as a reduction of revenue in the period the related product revenue is recognized, in addition to establishing a current liability. The Company considers several factors in the estimation process, including expiration dates of product shipped to Customers, inventory levels within the distribution channel, product shelf life, prescription trends and other relevant factors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x25e6;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt;text-decoration:underline"&gt;Government Rebates&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.  The Company is subject to discount obligations under state Medicaid programs and Medicare. Reserves related to these discount obligations are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability. The Company&#x2019;s liability for these rebates consists of estimates of claims for the current reporting period and estimated future claims that will be made for product that has been recognized as revenue but remains in the distribution channel inventories at the end of the reporting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x25e6;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt;text-decoration:underline"&gt;Payor Rebates.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;  The Company contracts with certain third-party payors, primarily health insurance companies and pharmacy benefit managers, for the payment of rebates with respect to utilization of its products. These rebates are based on contractual percentages applied to the amount of product prescribed to patients who are covered by the plan or the organization with which it contracts. The Company estimates these rebates and records such estimates in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x25e6;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt;text-decoration:underline"&gt;Patient Assistance.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;  Other programs that the Company offers include voluntary co-pay patient assistance programs intended to provide financial assistance to eligible patients with prescription drug co-payments required by payors and coupon programs for cash payors.&#160;The calculation of the current liability for this assistance is based on an estimate of claims and the cost per claim that the Company expects to receive associated with product that has been recognized as revenue but remains in the distribution channel inventories at the end of each reporting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x25e6;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt;text-decoration:underline"&gt;Distribution and Other Fees&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. We pay distribution and other fees to certain customers in connection with the sales of our products. We record distribution and other fees paid to our customers as a reduction of revenue, unless the payment is for a distinct good or service from the customer and we can reasonably estimate the fair value of the goods or services received. If both conditions are met, we record the consideration paid to the customer as an operating expense. These costs are typically known at the time of sale, resulting in minimal adjustments subsequent to the period of sale.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Licensing Revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has a license agreement with Currax Pharmaceuticals LLC (Currax) (&lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#i451bcb3eabba4f87bdc579718207a3b8_160" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Note &lt;/a&gt;&lt;a href="#i451bcb3eabba4f87bdc579718207a3b8_160" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;9&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;). This license agreement provides for exclusive licensed rights to certain intellectual property, a non-refundable up-front payment, potential &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;milestone payment(s) and potential royalty payment(s). The Company analyzed the performance obligations under the license agreement, the consideration received to date and the consideration the Company could receive in the future as part of its analysis related to ASC 606. There was no licensing revenue recognized during the year ended December 31, 2022. The Company recognized $1,000 as licensing revenue during the year ended December 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Advertising expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company expenses the costs of advertising, including promotional expenses, as incurred.  Advertising expenses were $16,575&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$15,638 for the years ended December 31, 2022&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs are expensed as incurred. Research and development costs consist primarily of device development, clinical trial related costs and regulatory related costs. The Company enters into agreements with contract research organizations (CROs) to facilitate, coordinate and perform agreed upon research and development activities for the Company's clinical trials. These CRO contracts typically call for the payment of fees for services at the initiation of the contract and/or upon the achievement of certain clinical trial milestones. The Company prepays certain CRO fees whereby the prepayments are recorded as a current or non-current prepaid asset and are amortized into research and development expense over the period of time the contracted research and development services were performed. The Company's CRO contracts generally also include other fees such as project management and pass through fees whereby the Company expenses these costs as incurred, using the Company's best estimate. Pass through fees include, but are not limited to, regulatory expenses, investigator fees, travel costs, and other miscellaneous costs. Pass through fees incurred are based on the amount of work completed for the clinical trials and are monitored through reporting provided by the Company's CROs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-based compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company measures and recognizes compensation expense for all stock options and restricted stock units (RSUs) awarded to employees and non-employees and shares issued under the employee stock purchase plan based on the estimated fair value of the awards on the respective grant dates. The Company uses the Black-Scholes option pricing model to value its time-based and performance-based stock options and shares issued under the employee stock purchase plan. The Company uses a Monte Carlo simulation to value its market-based stock options.  RSUs are valued at the fair market value per share of the Company's common stock on the date of grant. The Company recognizes compensation expense for time-based awards on a straight-line basis over the requisite service period, which is generally the vesting period of the award. The Company recognizes compensation expense for performance-based awards when the performance condition is probable of achievement. The Company recognizes compensation expense for market-based awards over the derived service period, estimated at the time of the grant. The Company recognizes expense for The Company accounts for forfeitures of stock option awards as they occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Estimating the fair value of options and shares issued under the employee stock purchase plan requires the input of subjective assumptions, including the estimated fair value of the Company's common stock, the expected life of the options, stock price volatility, the risk-free interest rate and expected dividends. The assumptions used in the Company's Black-Scholes option-pricing model and Monte Carlo simulation represent management's best estimates and involve a number of variables, uncertainties and assumptions and the application of management's judgment, as they are inherently subjective.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income taxes are accounted for under the asset and liability method. The Company recognizes deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of the Company's assets and liabilities and the expected benefits of net operating loss carryforwards. The impact of changes in tax rates and laws on deferred taxes, if any, applied during the period in which temporary differences are expected to be settled, is reflected in the Company's financial statements in the period of enactment. The measurement of deferred tax assets is reduced, if necessary, if, based on the weight of the evidence, it is more likely than not that some, or &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;all, of the deferred tax assets will not be realized. As of December 31, 2022 and 2021, the Company concluded that a full valuation allowance was necessary for all of its net deferred tax assets. The Company had no amounts recorded for uncertain tax positions, interest or penalties in the accompanying consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net income (loss) per common share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net income (loss) per common share is determined by dividing net income (loss) applicable to common stockholders by the weighted average common shares outstanding during the period. For the years ended December 31, 2022 and 2021, outstanding common stock options and common stock warrants have been excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive. Therefore, the weighted average shares used to calculate both basic and diluted net loss per share are the same.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Diluted net loss per common share for the periods presented does not reflect the following potential common shares, as the effect would be antidilutive:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.092%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,364,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,958,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,477,660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,959,358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Common stock warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;32,768,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,500,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;43,609,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,418,139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent accounting pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2022, the FASB issued ASU No. 2022-02, Financial Instruments - Credit Losses (Topic 326): Troubled Debt Restructurings and Vintage Disclosures. Since the issuance of ASU No. 2016-13, Financial Instruments&#x2014;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, the Board has provided resources to monitor and assist stakeholders with the implementation of Topic 326. Post-Implementation Review (PIR) activities have included forming a Credit Losses Transition Resource Group, conducting outreach with stakeholders of all types, developing educational materials and staff question-and-answer guidance, conducting educational workshops, and performing an archival review of financial reports. ASU No. 2022-02 is intended to respond to feedback received during the PIR process. The new standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2022, with early adoption permitted. The Company does not expect ASU No. 2022-02 to have a significant impact on its results of operations, financial position and cash flows and related disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDIvZnJhZzo5M2I1YmRhMDg4ZWQ0ZWFlYjc4M2I1ZTU0N2JkZjA5My90ZXh0cmVnaW9uOjkzYjViZGEwODhlZDRlYWViNzgzYjVlNTQ3YmRmMDkzXzI1MDEx_88cdafc9-0806-40de-911b-5a6bf6a13c99">&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying consolidated financial statements have been prepared in conformity with US generally accepted accounting principles (GAAP). Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification (ASC) and Accounting Standards Updates (ASU) of the Financial Accounting Standards Board (FASB).&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDIvZnJhZzo5M2I1YmRhMDg4ZWQ0ZWFlYjc4M2I1ZTU0N2JkZjA5My90ZXh0cmVnaW9uOjkzYjViZGEwODhlZDRlYWViNzgzYjVlNTQ3YmRmMDkzXzI1MDE1_ff273b1d-a7d3-4700-8c5a-52daaeefff12">&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Principles of consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements include the accounts of OptiNose,&#160;Inc. and its wholly-owned subsidiaries, OptiNose US,&#160;Inc., OptiNose AS and OptiNose UK&#160;Ltd. All inter-company balances and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDIvZnJhZzo5M2I1YmRhMDg4ZWQ0ZWFlYjc4M2I1ZTU0N2JkZjA5My90ZXh0cmVnaW9uOjkzYjViZGEwODhlZDRlYWViNzgzYjVlNTQ3YmRmMDkzXzI1MDAx_7d5e8302-2b73-46d2-a052-9c56ecc4e5a7">&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and reported amounts of expenses during the reporting period. Due to the uncertainty of factors surrounding the estimates or judgments used in the preparation of the consolidated financial statements, actual results may materially vary from these estimates. Estimates and assumptions are periodically reviewed and the effects of revisions are reflected in the consolidated financial statements in the period they are determined to be necessary.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDIvZnJhZzo5M2I1YmRhMDg4ZWQ0ZWFlYjc4M2I1ZTU0N2JkZjA5My90ZXh0cmVnaW9uOjkzYjViZGEwODhlZDRlYWViNzgzYjVlNTQ3YmRmMDkzXzI1MDA2_71acbfee-2500-453f-a45e-6f0250c5fd51">&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentration of credit risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk are primarily cash and accounts receivable. The Company generally invests its cash in deposits with high credit quality financial institutions. Additionally, the Company performs periodic evaluations of the relative credit standing of these financial institutions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Customer and supplier concentration&lt;/span&gt;&lt;/div&gt;The Company has exposure to credit risk in accounts receivable from sales of product. XHANCE is sold to wholesale pharmaceutical distributors and preferred pharmacy network (PPN) partners, who, in turn, sell XHANCE to pharmacies, hospitals and other customers.</us-gaap:ConcentrationRiskCreditRisk>
    <optn:NumberOfCustomers
      contextRef="i9c9d8c25cbd84a1dbfec87c26799aca0_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDIvZnJhZzo5M2I1YmRhMDg4ZWQ0ZWFlYjc4M2I1ZTU0N2JkZjA5My90ZXh0cmVnaW9uOjkzYjViZGEwODhlZDRlYWViNzgzYjVlNTQ3YmRmMDkzXzIxNTg_94dd223d-1f6b-4625-8bee-3901377e8a1d"
      unitRef="customer">5</optn:NumberOfCustomers>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i9c9d8c25cbd84a1dbfec87c26799aca0_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDIvZnJhZzo5M2I1YmRhMDg4ZWQ0ZWFlYjc4M2I1ZTU0N2JkZjA5My90ZXh0cmVnaW9uOjkzYjViZGEwODhlZDRlYWViNzgzYjVlNTQ3YmRmMDkzXzIxOTc_51697396-a8b1-47f3-874c-36ba918ff775"
      unitRef="number">0.52</us-gaap:ConcentrationRiskPercentage1>
    <optn:NumberOfCustomers
      contextRef="i453f6ff7522f4a12b35a0b401b71aadf_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDIvZnJhZzo5M2I1YmRhMDg4ZWQ0ZWFlYjc4M2I1ZTU0N2JkZjA5My90ZXh0cmVnaW9uOjkzYjViZGEwODhlZDRlYWViNzgzYjVlNTQ3YmRmMDkzXzIyNDc_4d30cc8c-d45a-45a8-bdfe-55ca2f26efeb"
      unitRef="customer">5</optn:NumberOfCustomers>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i453f6ff7522f4a12b35a0b401b71aadf_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDIvZnJhZzo5M2I1YmRhMDg4ZWQ0ZWFlYjc4M2I1ZTU0N2JkZjA5My90ZXh0cmVnaW9uOjkzYjViZGEwODhlZDRlYWViNzgzYjVlNTQ3YmRmMDkzXzIyODY_21983b8a-9143-41b5-8a54-0ca8a4b6b3b3"
      unitRef="number">0.33</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDIvZnJhZzo5M2I1YmRhMDg4ZWQ0ZWFlYjc4M2I1ZTU0N2JkZjA5My90ZXh0cmVnaW9uOjkzYjViZGEwODhlZDRlYWViNzgzYjVlNTQ3YmRmMDkzXzI1MDE3_a1a8bcc4-117c-446b-8eda-1ff49323f6d3">Cash and cash equivalentsAll highly liquid investments purchased with an original maturity date of three months or less at the date of purchase are considered to be cash equivalents. The Company maintains its cash and cash equivalent balances at foreign and domestic financial institutions.</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashUninsuredAmount
      contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDIvZnJhZzo5M2I1YmRhMDg4ZWQ0ZWFlYjc4M2I1ZTU0N2JkZjA5My90ZXh0cmVnaW9uOjkzYjViZGEwODhlZDRlYWViNzgzYjVlNTQ3YmRmMDkzXzM1MDY_d671709c-0050-4c36-b675-fd93b2d9e2a1"
      unitRef="usd">92988000</us-gaap:CashUninsuredAmount>
    <us-gaap:CashUninsuredAmount
      contextRef="id970dfd2674c4d6b895febb9c14d0fd1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDIvZnJhZzo5M2I1YmRhMDg4ZWQ0ZWFlYjc4M2I1ZTU0N2JkZjA5My90ZXh0cmVnaW9uOjkzYjViZGEwODhlZDRlYWViNzgzYjVlNTQ3YmRmMDkzXzM1MTM_b5fb02d0-cfe8-4d53-a274-80d13b3fd616"
      unitRef="usd">109017000</us-gaap:CashUninsuredAmount>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDIvZnJhZzo5M2I1YmRhMDg4ZWQ0ZWFlYjc4M2I1ZTU0N2JkZjA5My90ZXh0cmVnaW9uOjkzYjViZGEwODhlZDRlYWViNzgzYjVlNTQ3YmRmMDkzXzI1MDA3_65e78607-2919-4a09-9514-f456808a84da">&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair value of financial instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company measures certain assets and liabilities at fair value, which is defined as the price that would be received to sell an asset or paid to transfer a liability (the exit price) in an orderly transaction between market participants at the measurement date. The FASB accounting guidance outlines a valuation framework and creates a fair value hierarchy in order to increase the consistency and comparability of fair value measurements and the related disclosures. In determining fair value, the Company uses quoted prices and observable inputs. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from independent sources. The fair value hierarchy is broken down into three levels based on the source of the inputs as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level&#160;1&#160;&#x2014; Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level&#160;2&#160;&#x2014; Valuations based on observable inputs (other than Level&#160;1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level&#160;3&#160;&#x2014; Valuations based on inputs that are unobservable and models that are significant to the overall fair value measurement.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;At December 31, 2022 and 2021, the Company's financial instruments included cash and cash equivalents, accounts receivable, grants receivable, accounts payable, accrued expenses and certain liability classified warrants. The carrying amounts reported in the Company's financial statements for cash and cash equivalents, accounts receivable, grants receivable, accounts payable and accrued expenses approximates their respective fair values because of the short-term nature of these instruments. In addition, at December 31, 2022, the Company believed &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;the carrying value of debt approximates fair value as the interest rates were reflective of the rate the Company could obtain on debt with similar terms and conditions. At December 31, 2022 and 2021, there were no financial assets or liabilities measured at fair value on a recurring basis other than the liability classified warrants shown below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2022, the Company issued warrants in connection with the a public offering. Pursuant to the terms of the warrant agreement, the Company could be required to settle the warrants in cash in the event of an acquisition of the Company and, as a result, the warrants are required to be measured at fair value and reported as liability in the consolidated balance sheet. The Company recorded the fair value of the warrants upon issuance using a Monte Carlo simulation and is required to revalue the warrants at each reporting date with any changes in fair value recorded on our statement of operations. The valuation of the warrants is considered under Level 3 of the fair value hierarchy due to the need to use assumptions in the valuation that are both significant to the fair value measurement and unobservable. The change in the fair value of the Level 3 warrants liabilities is reflected in the statement of operations for the years ended December 31, 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDIvZnJhZzo5M2I1YmRhMDg4ZWQ0ZWFlYjc4M2I1ZTU0N2JkZjA5My90ZXh0cmVnaW9uOjkzYjViZGEwODhlZDRlYWViNzgzYjVlNTQ3YmRmMDkzXzI1MDI5_ac9368c3-1072-42f0-987a-88eee3ae2777">&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounts receivable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts receivable primarily relates to amounts due from customers, which are typically due within 31 to 61 days. The Company analyzes accounts that are past due for collectability. There was no allowance for doubtful accounts related to customers subject to credit risk at December 31, 2022. The Company recognized an allowance for doubtful accounts related to customers subject to credit risk of $444 at December 31, 2021. The accounts receivable balance at December 31, 2021 on the accompanying balance sheet is net of the allowance.&lt;/span&gt;&lt;/div&gt;</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDIvZnJhZzo5M2I1YmRhMDg4ZWQ0ZWFlYjc4M2I1ZTU0N2JkZjA5My90ZXh0cmVnaW9uOjkzYjViZGEwODhlZDRlYWViNzgzYjVlNTQ3YmRmMDkzXzQ5NDc4MDIzNjY0Nzk_5fca00a5-ad3a-410d-860b-d2ee3eee009c"
      unitRef="usd">0</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="id970dfd2674c4d6b895febb9c14d0fd1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDIvZnJhZzo5M2I1YmRhMDg4ZWQ0ZWFlYjc4M2I1ZTU0N2JkZjA5My90ZXh0cmVnaW9uOjkzYjViZGEwODhlZDRlYWViNzgzYjVlNTQ3YmRmMDkzXzYwOTE_11887530-df85-4a93-bffb-e998d163116f"
      unitRef="usd">444000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:InventoryPolicyTextBlock
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDIvZnJhZzo5M2I1YmRhMDg4ZWQ0ZWFlYjc4M2I1ZTU0N2JkZjA5My90ZXh0cmVnaW9uOjkzYjViZGEwODhlZDRlYWViNzgzYjVlNTQ3YmRmMDkzXzI1MDA4_a1b44337-a224-43d3-8e2a-38d4ab8da344">Inventory Inventories are stated at the lower of cost or net realizable value. Costs of inventories, which include amounts related to materials and manufacturing overhead, are determined on a first-in, first-out basis. An assessment of the recoverability of capitalized inventory is performed during each reporting period and any excess and obsolete inventories are written down to their estimated net realizable value in the period in which the impairment is first identified.</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDIvZnJhZzo5M2I1YmRhMDg4ZWQ0ZWFlYjc4M2I1ZTU0N2JkZjA5My90ZXh0cmVnaW9uOjkzYjViZGEwODhlZDRlYWViNzgzYjVlNTQ3YmRmMDkzXzI1MDE0_1d4c4084-8c02-410e-bfe6-2dd5910dcd50">&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment is recorded at cost less accumulated depreciation. Significant additions or improvements are capitalized and expenditures for repairs and maintenance are charged to expense as incurred. Gains and losses on disposal of assets are included in the consolidated statements of operations. Depreciation is calculated on a straight-line basis over the estimated useful lives of the respective assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated useful lives of property and equipment are as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.031%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.457%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.607%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Computer equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2-3 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Machinery &amp;amp; production equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5-10 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Furniture &amp;amp; fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3-5 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Shorter of lease term or useful life&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDIvZnJhZzo5M2I1YmRhMDg4ZWQ0ZWFlYjc4M2I1ZTU0N2JkZjA5My90ZXh0cmVnaW9uOjkzYjViZGEwODhlZDRlYWViNzgzYjVlNTQ3YmRmMDkzXzI1MDA5_99d53f5b-4b4a-4ea8-84b2-bc1ba1c2a8b2">&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated useful lives of property and equipment are as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.031%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.457%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.607%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Computer equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2-3 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Machinery &amp;amp; production equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5-10 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Furniture &amp;amp; fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3-5 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Shorter of lease term or useful life&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net, consisted of:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.607%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.329%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Machinery and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,067&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Construction in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4,565)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4,283)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i096da31e1c4b4962a9749727b86a9251_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDIvZnJhZzo5M2I1YmRhMDg4ZWQ0ZWFlYjc4M2I1ZTU0N2JkZjA5My90YWJsZTo4ODQyNjI5ZDUxNmI0MTg3OGQ0YjNjZmE3NDNmZDI4MS90YWJsZXJhbmdlOjg4NDI2MjlkNTE2YjQxODc4ZDRiM2NmYTc0M2ZkMjgxXzAtMS0xLTEtNTgzNzIvdGV4dHJlZ2lvbjpiOTUzMjE2NjkzMTI0MTY3YjAxMGUyMTA2NzNlZDJmZl80_1763b6af-113b-47d3-b538-9ca3f8dbad9d">P2Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i51129fc2a039416488ae6cf33f207331_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDIvZnJhZzo5M2I1YmRhMDg4ZWQ0ZWFlYjc4M2I1ZTU0N2JkZjA5My90YWJsZTo4ODQyNjI5ZDUxNmI0MTg3OGQ0YjNjZmE3NDNmZDI4MS90YWJsZXJhbmdlOjg4NDI2MjlkNTE2YjQxODc4ZDRiM2NmYTc0M2ZkMjgxXzAtMS0xLTEtNTgzNzIvdGV4dHJlZ2lvbjpiOTUzMjE2NjkzMTI0MTY3YjAxMGUyMTA2NzNlZDJmZl83_3d8b19a3-5fde-4a0c-b696-f34df2983381">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i6dceb2856a724c7cb132bb0edc4d035c_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDIvZnJhZzo5M2I1YmRhMDg4ZWQ0ZWFlYjc4M2I1ZTU0N2JkZjA5My90YWJsZTo4ODQyNjI5ZDUxNmI0MTg3OGQ0YjNjZmE3NDNmZDI4MS90YWJsZXJhbmdlOjg4NDI2MjlkNTE2YjQxODc4ZDRiM2NmYTc0M2ZkMjgxXzEtMS0xLTEtNTgzNzIvdGV4dHJlZ2lvbjpiMDMzYjFhYzFmODQ0ZjM4YTQ5ZDBhMWYzNGZjMjY5OV80_3f95017b-cc74-4782-917e-4e3ee469e5c6">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i9941fdaa85054a3a9340530990beb6a2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDIvZnJhZzo5M2I1YmRhMDg4ZWQ0ZWFlYjc4M2I1ZTU0N2JkZjA5My90YWJsZTo4ODQyNjI5ZDUxNmI0MTg3OGQ0YjNjZmE3NDNmZDI4MS90YWJsZXJhbmdlOjg4NDI2MjlkNTE2YjQxODc4ZDRiM2NmYTc0M2ZkMjgxXzItMS0xLTEtNTgzNzIvdGV4dHJlZ2lvbjpjMmExNDlmYzE2NmM0NmUzODU4NDg1M2UyMmJlZDNhMl80_38f6c67f-19b8-4c10-b4ff-fef199424fb2">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i84fb7ecf7b8a41a6af4d113e7add2b46_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDIvZnJhZzo5M2I1YmRhMDg4ZWQ0ZWFlYjc4M2I1ZTU0N2JkZjA5My90YWJsZTo4ODQyNjI5ZDUxNmI0MTg3OGQ0YjNjZmE3NDNmZDI4MS90YWJsZXJhbmdlOjg4NDI2MjlkNTE2YjQxODc4ZDRiM2NmYTc0M2ZkMjgxXzItMS0xLTEtNTgzNzIvdGV4dHJlZ2lvbjpjMmExNDlmYzE2NmM0NmUzODU4NDg1M2UyMmJlZDNhMl83_d80d435c-0e6e-4fa2-bd30-981d4c6644ef">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ib7a618edb3b34dc88ad18ed5ca86c14d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDIvZnJhZzo5M2I1YmRhMDg4ZWQ0ZWFlYjc4M2I1ZTU0N2JkZjA5My90YWJsZTo4ODQyNjI5ZDUxNmI0MTg3OGQ0YjNjZmE3NDNmZDI4MS90YWJsZXJhbmdlOjg4NDI2MjlkNTE2YjQxODc4ZDRiM2NmYTc0M2ZkMjgxXzMtMS0xLTEtNTgzNzIvdGV4dHJlZ2lvbjozMTM0YWVkMGVjYzc0YTg5OTljOTU5YzEyNGMyNzkyMF80_422de7bf-6659-48e4-9efe-fc1fab821ec9">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ia91696961e0b4593a33c03f9b00c5dec_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDIvZnJhZzo5M2I1YmRhMDg4ZWQ0ZWFlYjc4M2I1ZTU0N2JkZjA5My90YWJsZTo4ODQyNjI5ZDUxNmI0MTg3OGQ0YjNjZmE3NDNmZDI4MS90YWJsZXJhbmdlOjg4NDI2MjlkNTE2YjQxODc4ZDRiM2NmYTc0M2ZkMjgxXzMtMS0xLTEtNTgzNzIvdGV4dHJlZ2lvbjozMTM0YWVkMGVjYzc0YTg5OTljOTU5YzEyNGMyNzkyMF83_08970b6b-71a5-40c0-bfd9-91a1abdcaf60">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDIvZnJhZzo5M2I1YmRhMDg4ZWQ0ZWFlYjc4M2I1ZTU0N2JkZjA5My90ZXh0cmVnaW9uOjkzYjViZGEwODhlZDRlYWViNzgzYjVlNTQ3YmRmMDkzXzI1MDQw_a8d72945-49cb-43b7-bc04-86f9f361109e">Long lived assetsLong-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future net cash flows expected to be generated. Impairment charges are recognized at the amount by which the carrying amount of an asset exceeds the fair value of the asset. Assets to be disposed of are reported at the lower of the carrying amount or the fair value less costs to sell.</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDIvZnJhZzo5M2I1YmRhMDg4ZWQ0ZWFlYjc4M2I1ZTU0N2JkZjA5My90ZXh0cmVnaW9uOjkzYjViZGEwODhlZDRlYWViNzgzYjVlNTQ3YmRmMDkzXzc4MDc_25af8a9d-0cbb-49be-a5a8-85958e521b66"
      unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDIvZnJhZzo5M2I1YmRhMDg4ZWQ0ZWFlYjc4M2I1ZTU0N2JkZjA5My90ZXh0cmVnaW9uOjkzYjViZGEwODhlZDRlYWViNzgzYjVlNTQ3YmRmMDkzXzc4MDc_6790e29f-0289-4458-bb6e-3cd3eb5f850c"
      unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDIvZnJhZzo5M2I1YmRhMDg4ZWQ0ZWFlYjc4M2I1ZTU0N2JkZjA5My90ZXh0cmVnaW9uOjkzYjViZGEwODhlZDRlYWViNzgzYjVlNTQ3YmRmMDkzXzQ5NDc4MDIzNzcyMDQ_f33d7bf9-d72e-47de-b059-8267f3ecc499">Leases &lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the terms of the arrangement. The Company accounts for a contract as a lease when it has the right to control the asset for a period of time while obtaining substantially all of the asset&#x2019;s economic benefits. The Company determines the initial classification and measurement of its operating right-of-use (&#x201c;ROU&#x201d;) assets and operating lease liabilities at the lease commencement date, and thereafter if modified.  The lease term includes any renewal options that the Company is reasonably assured to exercise. The Company&#x2019;s policy is to not record leases with a lease term of 12 months or less on its balance sheets. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The ROU asset represents the right to use the leased asset for the lease term. The lease liability represents the present value of the lease payments under the lease. The present value of lease payments is determined by using the interest rate implicit in the lease, if that rate is readily determinable; otherwise, the Company uses its estimated secured incremental borrowing rate for that lease term.  Lease expense for operating leases is recognized on a straight-line basis over the reasonably assured lease term based on the total lease payments and is included in operating expense in the statements of operations. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Payments due under each lease agreement include fixed and variable payments. Variable payments relate to the Company&#x2019;s share of the lessor&#x2019;s operating costs associated with the underlying asset and are recognized when the event on which those payments are assessed occurs. Variable payments have been excluded from the lease liability and associated right-of-use asset. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:103%"&gt;The interest rate implicit in lease agreements is typically not readily determinable, and as such, the Company utilizes the incremental borrowing rate to calculate lease liabilities, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDIvZnJhZzo5M2I1YmRhMDg4ZWQ0ZWFlYjc4M2I1ZTU0N2JkZjA5My90ZXh0cmVnaW9uOjkzYjViZGEwODhlZDRlYWViNzgzYjVlNTQ3YmRmMDkzXzI1MDI1_14cb746c-cd03-4857-975f-1800756ab2e4">&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net product revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for revenue in accordance with ASC Topic 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(ASC 606), which was adopted on January 1, 2018. The Company performs the following five steps to recognize revenue under ASC 606: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only recognizes revenue when it is probable that it will collect the consideration to which it is entitled in exchange for the goods or services that will be transferred to the customer. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company sells XHANCE to preferred pharmacy network partners and wholesalers in the US (collectively, Customers). These Customers subsequently resell the Company&#x2019;s products to healthcare providers, patients and other retail pharmacies. In addition to agreements with Customers, the Company enters into arrangements with healthcare providers and payors that provide for government-mandated and/or privately-negotiated rebates, chargebacks and discounts for the purchase of the Company&#x2019;s products.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes revenue from XHANCE sales at the point Customers obtain control of the product, which generally occurs upon delivery. The transaction price that is recognized as revenue for products includes an estimate of variable consideration which is described below. Payment terms with Customers do not exceed one year and, therefore, the Company does not account for a financing component in its arrangements. The Company expenses incremental costs of obtaining a contract with a Customer (for example, sales commissions) when incurred as the period of benefit is less than one year. Shipping and handling costs for product shipments to Customers are recorded as selling, general and administrative expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Transaction Price, including Estimates of Variable Consideration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue from products is recognized at the estimated net sales price (transaction price), which includes estimates of variable consideration. The Company includes estimated amounts in the transaction price to the extent it is determined probable that a significant reversal of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is resolved. The Company&#x2019;s estimates of variable consideration and determination of whether to include estimated amounts in the transaction price are based largely on an assessment &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;of its anticipated performance and all information (historical, current and forecasted) that is reasonably available.  The components of the Company's variable consideration include the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline"&gt;Provider Chargebacks and Discounts.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Chargebacks for fees and discounts to providers represent the estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list prices charged to Customers who directly purchase the product from the Company.&#160;Customers charge the Company for the difference between what they pay for the product and the ultimate selling price to the qualified healthcare providers.&#160;These components of variable consideration are established in the same period that the related revenue is recognized, resulting in a reduction of product revenue and accounts receivable.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x25e6;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt;text-decoration:underline"&gt;Trade Discounts and Allowances.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;  The Company generally provides Customers with discounts that include incentive fees which are explicitly stated in the Company&#x2019;s contracts. These discounts are recorded as a reduction of revenue and accounts receivable in the period in which the related product revenue is recognized. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x25e6;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt;text-decoration:underline"&gt;Product Returns.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;  Consistent with industry practice, the Company has a product returns policy that provides Customers a right of return for product purchased within a specified period prior to and subsequent to the product&#x2019;s expiration date. The Company estimates the amount of its products that may be returned and presents this amount as a reduction of revenue in the period the related product revenue is recognized, in addition to establishing a current liability. The Company considers several factors in the estimation process, including expiration dates of product shipped to Customers, inventory levels within the distribution channel, product shelf life, prescription trends and other relevant factors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x25e6;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt;text-decoration:underline"&gt;Government Rebates&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.  The Company is subject to discount obligations under state Medicaid programs and Medicare. Reserves related to these discount obligations are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability. The Company&#x2019;s liability for these rebates consists of estimates of claims for the current reporting period and estimated future claims that will be made for product that has been recognized as revenue but remains in the distribution channel inventories at the end of the reporting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x25e6;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt;text-decoration:underline"&gt;Payor Rebates.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;  The Company contracts with certain third-party payors, primarily health insurance companies and pharmacy benefit managers, for the payment of rebates with respect to utilization of its products. These rebates are based on contractual percentages applied to the amount of product prescribed to patients who are covered by the plan or the organization with which it contracts. The Company estimates these rebates and records such estimates in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x25e6;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt;text-decoration:underline"&gt;Patient Assistance.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;  Other programs that the Company offers include voluntary co-pay patient assistance programs intended to provide financial assistance to eligible patients with prescription drug co-payments required by payors and coupon programs for cash payors.&#160;The calculation of the current liability for this assistance is based on an estimate of claims and the cost per claim that the Company expects to receive associated with product that has been recognized as revenue but remains in the distribution channel inventories at the end of each reporting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x25e6;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt;text-decoration:underline"&gt;Distribution and Other Fees&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. We pay distribution and other fees to certain customers in connection with the sales of our products. We record distribution and other fees paid to our customers as a reduction of revenue, unless the payment is for a distinct good or service from the customer and we can reasonably estimate the fair value of the goods or services received. If both conditions are met, we record the consideration paid to the customer as an operating expense. These costs are typically known at the time of sale, resulting in minimal adjustments subsequent to the period of sale.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Licensing Revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has a license agreement with Currax Pharmaceuticals LLC (Currax) (&lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#i451bcb3eabba4f87bdc579718207a3b8_160" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Note &lt;/a&gt;&lt;a href="#i451bcb3eabba4f87bdc579718207a3b8_160" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;9&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;). This license agreement provides for exclusive licensed rights to certain intellectual property, a non-refundable up-front payment, potential &lt;/span&gt;&lt;/div&gt;milestone payment(s) and potential royalty payment(s). The Company analyzed the performance obligations under the license agreement, the consideration received to date and the consideration the Company could receive in the future as part of its analysis related to ASC 606.</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifb05b53856a04e6fb8d77b2615fef7b5_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDIvZnJhZzo5M2I1YmRhMDg4ZWQ0ZWFlYjc4M2I1ZTU0N2JkZjA5My90ZXh0cmVnaW9uOjkzYjViZGEwODhlZDRlYWViNzgzYjVlNTQ3YmRmMDkzXzY1OTcwNjk4MDgxNjI_7112d885-ac27-493f-a496-ff95dcc4115b"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0a537887f3924b21a34b339e3a39c085_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDIvZnJhZzo5M2I1YmRhMDg4ZWQ0ZWFlYjc4M2I1ZTU0N2JkZjA5My90ZXh0cmVnaW9uOjkzYjViZGEwODhlZDRlYWViNzgzYjVlNTQ3YmRmMDkzXzE1Mzgw_adca1f7b-00ac-40f9-aedc-9b9d85c6e1c7"
      unitRef="usd">1000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:AdvertisingCostsPolicyTextBlock
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDIvZnJhZzo5M2I1YmRhMDg4ZWQ0ZWFlYjc4M2I1ZTU0N2JkZjA5My90ZXh0cmVnaW9uOjkzYjViZGEwODhlZDRlYWViNzgzYjVlNTQ3YmRmMDkzXzI1MDQx_afb8ff27-c186-4cd5-8897-2275c5704aa5">Advertising expensesThe Company expenses the costs of advertising, including promotional expenses, as incurred.</us-gaap:AdvertisingCostsPolicyTextBlock>
    <us-gaap:AdvertisingExpense
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDIvZnJhZzo5M2I1YmRhMDg4ZWQ0ZWFlYjc4M2I1ZTU0N2JkZjA5My90ZXh0cmVnaW9uOjkzYjViZGEwODhlZDRlYWViNzgzYjVlNTQ3YmRmMDkzXzE1NTkz_e5cf7dd2-7941-4c67-8607-94e71459efa1"
      unitRef="usd">16575000</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDIvZnJhZzo5M2I1YmRhMDg4ZWQ0ZWFlYjc4M2I1ZTU0N2JkZjA5My90ZXh0cmVnaW9uOjkzYjViZGEwODhlZDRlYWViNzgzYjVlNTQ3YmRmMDkzXzE1NjAw_ec25a8a4-a5af-42cc-93fc-48536d5488ed"
      unitRef="usd">15638000</us-gaap:AdvertisingExpense>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDIvZnJhZzo5M2I1YmRhMDg4ZWQ0ZWFlYjc4M2I1ZTU0N2JkZjA5My90ZXh0cmVnaW9uOjkzYjViZGEwODhlZDRlYWViNzgzYjVlNTQ3YmRmMDkzXzI1MDM4_955c1806-4ec2-4a2d-88d1-61691928e44c">&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs are expensed as incurred. Research and development costs consist primarily of device development, clinical trial related costs and regulatory related costs. The Company enters into agreements with contract research organizations (CROs) to facilitate, coordinate and perform agreed upon research and development activities for the Company's clinical trials. These CRO contracts typically call for the payment of fees for services at the initiation of the contract and/or upon the achievement of certain clinical trial milestones. The Company prepays certain CRO fees whereby the prepayments are recorded as a current or non-current prepaid asset and are amortized into research and development expense over the period of time the contracted research and development services were performed. The Company's CRO contracts generally also include other fees such as project management and pass through fees whereby the Company expenses these costs as incurred, using the Company's best estimate. Pass through fees include, but are not limited to, regulatory expenses, investigator fees, travel costs, and other miscellaneous costs. Pass through fees incurred are based on the amount of work completed for the clinical trials and are monitored through reporting provided by the Company's CROs.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDIvZnJhZzo5M2I1YmRhMDg4ZWQ0ZWFlYjc4M2I1ZTU0N2JkZjA5My90ZXh0cmVnaW9uOjkzYjViZGEwODhlZDRlYWViNzgzYjVlNTQ3YmRmMDkzXzI1MDE5_3465a9b4-c0d3-443e-b60c-cffbd1621046">&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-based compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company measures and recognizes compensation expense for all stock options and restricted stock units (RSUs) awarded to employees and non-employees and shares issued under the employee stock purchase plan based on the estimated fair value of the awards on the respective grant dates. The Company uses the Black-Scholes option pricing model to value its time-based and performance-based stock options and shares issued under the employee stock purchase plan. The Company uses a Monte Carlo simulation to value its market-based stock options.  RSUs are valued at the fair market value per share of the Company's common stock on the date of grant. The Company recognizes compensation expense for time-based awards on a straight-line basis over the requisite service period, which is generally the vesting period of the award. The Company recognizes compensation expense for performance-based awards when the performance condition is probable of achievement. The Company recognizes compensation expense for market-based awards over the derived service period, estimated at the time of the grant. The Company recognizes expense for The Company accounts for forfeitures of stock option awards as they occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Estimating the fair value of options and shares issued under the employee stock purchase plan requires the input of subjective assumptions, including the estimated fair value of the Company's common stock, the expected life of the options, stock price volatility, the risk-free interest rate and expected dividends. The assumptions used in the Company's Black-Scholes option-pricing model and Monte Carlo simulation represent management's best estimates and involve a number of variables, uncertainties and assumptions and the application of management's judgment, as they are inherently subjective.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDIvZnJhZzo5M2I1YmRhMDg4ZWQ0ZWFlYjc4M2I1ZTU0N2JkZjA5My90ZXh0cmVnaW9uOjkzYjViZGEwODhlZDRlYWViNzgzYjVlNTQ3YmRmMDkzXzI1MDIw_ef9db5ad-637d-485c-839b-6ea6b9b31a85">&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income taxes are accounted for under the asset and liability method. The Company recognizes deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of the Company's assets and liabilities and the expected benefits of net operating loss carryforwards. The impact of changes in tax rates and laws on deferred taxes, if any, applied during the period in which temporary differences are expected to be settled, is reflected in the Company's financial statements in the period of enactment. The measurement of deferred tax assets is reduced, if necessary, if, based on the weight of the evidence, it is more likely than not that some, or &lt;/span&gt;&lt;/div&gt;all, of the deferred tax assets will not be realized. As of December 31, 2022 and 2021, the Company concluded that a full valuation allowance was necessary for all of its net deferred tax assets. The Company had no amounts recorded for uncertain tax positions, interest or penalties in the accompanying consolidated financial statements.</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDIvZnJhZzo5M2I1YmRhMDg4ZWQ0ZWFlYjc4M2I1ZTU0N2JkZjA5My90ZXh0cmVnaW9uOjkzYjViZGEwODhlZDRlYWViNzgzYjVlNTQ3YmRmMDkzXzI1MDA0_7f9bfd99-9c4d-4567-94df-5164e1a2a40e">&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net income (loss) per common share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net income (loss) per common share is determined by dividing net income (loss) applicable to common stockholders by the weighted average common shares outstanding during the period. For the years ended December 31, 2022 and 2021, outstanding common stock options and common stock warrants have been excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive. Therefore, the weighted average shares used to calculate both basic and diluted net loss per share are the same.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDIvZnJhZzo5M2I1YmRhMDg4ZWQ0ZWFlYjc4M2I1ZTU0N2JkZjA5My90ZXh0cmVnaW9uOjkzYjViZGEwODhlZDRlYWViNzgzYjVlNTQ3YmRmMDkzXzI1MDI4_91a39996-035b-4fba-a74d-b4cc9c531c1e">&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Diluted net loss per common share for the periods presented does not reflect the following potential common shares, as the effect would be antidilutive:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.092%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,364,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,958,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,477,660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,959,358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Common stock warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;32,768,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,500,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;43,609,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,418,139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i12305500621f4b93b85c82aa1da3b266_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDIvZnJhZzo5M2I1YmRhMDg4ZWQ0ZWFlYjc4M2I1ZTU0N2JkZjA5My90YWJsZTo0ZGQ0Yzg0MGYyMGY0YmJhYTg4YmUyN2ZlZDNjNGNmNS90YWJsZXJhbmdlOjRkZDRjODQwZjIwZjRiYmFhODhiZTI3ZmVkM2M0Y2Y1XzItMi0xLTEtNTgzNzI_d31f1028-264c-49c0-a4d6-660925336022"
      unitRef="shares">9364070</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i4915e82cfd2f4c5f8a1d6e09c40ecdef_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDIvZnJhZzo5M2I1YmRhMDg4ZWQ0ZWFlYjc4M2I1ZTU0N2JkZjA5My90YWJsZTo0ZGQ0Yzg0MGYyMGY0YmJhYTg4YmUyN2ZlZDNjNGNmNS90YWJsZXJhbmdlOjRkZDRjODQwZjIwZjRiYmFhODhiZTI3ZmVkM2M0Y2Y1XzItNC0xLTEtNTgzNzI_31648c53-349b-4feb-80c2-5ad798c9cc14"
      unitRef="shares">7958781</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="id7cd0da0eea14521a316e6ae095e19a2_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDIvZnJhZzo5M2I1YmRhMDg4ZWQ0ZWFlYjc4M2I1ZTU0N2JkZjA5My90YWJsZTo0ZGQ0Yzg0MGYyMGY0YmJhYTg4YmUyN2ZlZDNjNGNmNS90YWJsZXJhbmdlOjRkZDRjODQwZjIwZjRiYmFhODhiZTI3ZmVkM2M0Y2Y1XzMtMi0xLTEtNTgzNzI_13537c67-d518-43fd-8cfb-29916b49d092"
      unitRef="shares">1477660</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ia3b834ad368d4672b0476f096fe3f60f_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDIvZnJhZzo5M2I1YmRhMDg4ZWQ0ZWFlYjc4M2I1ZTU0N2JkZjA5My90YWJsZTo0ZGQ0Yzg0MGYyMGY0YmJhYTg4YmUyN2ZlZDNjNGNmNS90YWJsZXJhbmdlOjRkZDRjODQwZjIwZjRiYmFhODhiZTI3ZmVkM2M0Y2Y1XzMtNC0xLTEtNTgzNzI_c6cc1517-2e28-4caa-b0a3-981cf52d0af0"
      unitRef="shares">1959358</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i7ac7a3a3a80b4d7b8a3d2ffc47f38e20_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDIvZnJhZzo5M2I1YmRhMDg4ZWQ0ZWFlYjc4M2I1ZTU0N2JkZjA5My90YWJsZTo0ZGQ0Yzg0MGYyMGY0YmJhYTg4YmUyN2ZlZDNjNGNmNS90YWJsZXJhbmdlOjRkZDRjODQwZjIwZjRiYmFhODhiZTI3ZmVkM2M0Y2Y1XzQtMi0xLTEtNTgzNzI_fc448ef4-cb69-4e35-871c-942f2de33b03"
      unitRef="shares">32768000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i930ccddc00c24cfd9e7d29dd5a34e0aa_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDIvZnJhZzo5M2I1YmRhMDg4ZWQ0ZWFlYjc4M2I1ZTU0N2JkZjA5My90YWJsZTo0ZGQ0Yzg0MGYyMGY0YmJhYTg4YmUyN2ZlZDNjNGNmNS90YWJsZXJhbmdlOjRkZDRjODQwZjIwZjRiYmFhODhiZTI3ZmVkM2M0Y2Y1XzQtNC0xLTEtNTgzNzI_cad6ece1-c991-4238-a68e-a837c86f01b9"
      unitRef="shares">2500000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDIvZnJhZzo5M2I1YmRhMDg4ZWQ0ZWFlYjc4M2I1ZTU0N2JkZjA5My90YWJsZTo0ZGQ0Yzg0MGYyMGY0YmJhYTg4YmUyN2ZlZDNjNGNmNS90YWJsZXJhbmdlOjRkZDRjODQwZjIwZjRiYmFhODhiZTI3ZmVkM2M0Y2Y1XzYtMi0xLTEtNTgzNzI_8952d089-8711-4342-aa42-66765d821994"
      unitRef="shares">43609730</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDIvZnJhZzo5M2I1YmRhMDg4ZWQ0ZWFlYjc4M2I1ZTU0N2JkZjA5My90YWJsZTo0ZGQ0Yzg0MGYyMGY0YmJhYTg4YmUyN2ZlZDNjNGNmNS90YWJsZXJhbmdlOjRkZDRjODQwZjIwZjRiYmFhODhiZTI3ZmVkM2M0Y2Y1XzYtNC0xLTEtNTgzNzI_743a39e1-8ada-4b7c-a94e-837cb9fe6162"
      unitRef="shares">12418139</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDIvZnJhZzo5M2I1YmRhMDg4ZWQ0ZWFlYjc4M2I1ZTU0N2JkZjA5My90ZXh0cmVnaW9uOjkzYjViZGEwODhlZDRlYWViNzgzYjVlNTQ3YmRmMDkzXzI1MDIx_2467f89c-2037-47d3-a4fe-952ed5d3927a">&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent accounting pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2022, the FASB issued ASU No. 2022-02, Financial Instruments - Credit Losses (Topic 326): Troubled Debt Restructurings and Vintage Disclosures. Since the issuance of ASU No. 2016-13, Financial Instruments&#x2014;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, the Board has provided resources to monitor and assist stakeholders with the implementation of Topic 326. Post-Implementation Review (PIR) activities have included forming a Credit Losses Transition Resource Group, conducting outreach with stakeholders of all types, developing educational materials and staff question-and-answer guidance, conducting educational workshops, and performing an archival review of financial reports. ASU No. 2022-02 is intended to respond to feedback received during the PIR process. The new standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2022, with early adoption permitted. The Company does not expect ASU No. 2022-02 to have a significant impact on its results of operations, financial position and cash flows and related disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzY1L2ZyYWc6MzgyNzViMTRmNmU2NDY1ZjlmNDQ0MmU4MzkxYzE5Y2IvdGV4dHJlZ2lvbjozODI3NWIxNGY2ZTY0NjVmOWY0NDQyZTgzOTFjMTljYl81NDk3NTU4MTU0NDQ3_56b97942-b9bc-479a-95c9-1a8da301990a">Fair Value Measurements&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Assets and Liabilities Measured at Fair Value on a Recurring Basis&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company applies the guidance in ASC 820, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to account for financial assets and liabilities measured on a recurring basis. Fair value is measured as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that is determined based on assumptions that market participants would use in pricing an asset or liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses a fair value hierarchy, which distinguishes between assumptions based on market data (observable inputs) and an entity's own assumptions (unobservable inputs). The guidance requires that fair value measurements be classified and disclosed in one of the following 3 categories:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level l: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 2: Quoted prices in markets that are not active or inputs which are observable, either directly or indirectly, for substantially the full te1m of the asset or liability; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Determining which category an asset or liability falls within the hierarchy requires significant judgment. The Company evaluates its hierarchy disclosures each reporting period. There were no transfers between Level I, 2 and 3 during the years ended December 31, 2022 and December 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below presents the liabilities (in thousands) measured and recorded in the financial statements at fair value on a recurring basis at December 31, 2022 categorized by the level of inputs used in the valuation of each liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.635%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.252%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.417%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.252%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.417%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.252%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.417%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.258%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Warrant Liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;As of December 31, 2021, the Company had no assets or liabilities measured and recorded at fair value on a recurring basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Changes in Level 3 Liabilities Measured at Fair Value on a Recurring Basis&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Warrant Liability&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The reconciliation of the Company's warrant liability measured at fair value on a recurring basis using unobservable inputs (Level 3) is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.528%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.272%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Warrant Liability&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Warrants issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzY1L2ZyYWc6MzgyNzViMTRmNmU2NDY1ZjlmNDQ0MmU4MzkxYzE5Y2IvdGFibGU6NWM3ZDZiYjczNjFkNDc5M2E4MTIxMjhkOWM4MWIzZDMvdGFibGVyYW5nZTo1YzdkNmJiNzM2MWQ0NzkzYTgxMjEyOGQ5YzgxYjNkM180LTAtMS0xLTExMDU2NQ_cf1ef344-6e8b-4404-9fc4-62d43ef2dafc"&gt;Change in fair value of liability&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Assumptions Used in Determining Fair Value of Liability-Classified Warrants&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;The Company utilizes a Monte Carlo simulation valuation model which incorporates assumptions as to the stock price volatility, the expected life of the warrants, a risk-free interest rate, as well as timing and probability of equity financing. The Company values the Warrant Liability at each reporting period, with changes in fair value recognized in the consolidated statements of operations. The estimated fair value of the warrant liability is determined using Level 3 inputs. The inputs and values were as follows:&lt;/span&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.182%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;November 23, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock price&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Strike price&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;45.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;45.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected life (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.90&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fair value per warrant&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzY1L2ZyYWc6MzgyNzViMTRmNmU2NDY1ZjlmNDQ0MmU4MzkxYzE5Y2IvdGV4dHJlZ2lvbjozODI3NWIxNGY2ZTY0NjVmOWY0NDQyZTgzOTFjMTljYl81NDk3NTU4MTU0NDQ4_598e6f1f-f17a-47eb-a1a8-a358961cdc18">Fair Value Measurements&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Assets and Liabilities Measured at Fair Value on a Recurring Basis&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company applies the guidance in ASC 820, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to account for financial assets and liabilities measured on a recurring basis. Fair value is measured as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that is determined based on assumptions that market participants would use in pricing an asset or liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses a fair value hierarchy, which distinguishes between assumptions based on market data (observable inputs) and an entity's own assumptions (unobservable inputs). The guidance requires that fair value measurements be classified and disclosed in one of the following 3 categories:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level l: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 2: Quoted prices in markets that are not active or inputs which are observable, either directly or indirectly, for substantially the full te1m of the asset or liability; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Determining which category an asset or liability falls within the hierarchy requires significant judgment. The Company evaluates its hierarchy disclosures each reporting period. There were no transfers between Level I, 2 and 3 during the years ended December 31, 2022 and December 31, 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzY1L2ZyYWc6MzgyNzViMTRmNmU2NDY1ZjlmNDQ0MmU4MzkxYzE5Y2IvdGV4dHJlZ2lvbjozODI3NWIxNGY2ZTY0NjVmOWY0NDQyZTgzOTFjMTljYl80OTQ3ODAyMzQwNTU2_aaf6abb4-2d9c-456b-b792-dcaee15734ac">&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below presents the liabilities (in thousands) measured and recorded in the financial statements at fair value on a recurring basis at December 31, 2022 categorized by the level of inputs used in the valuation of each liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.635%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.252%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.417%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.252%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.417%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.252%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.417%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.258%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Warrant Liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzY1L2ZyYWc6MzgyNzViMTRmNmU2NDY1ZjlmNDQ0MmU4MzkxYzE5Y2IvdGV4dHJlZ2lvbjozODI3NWIxNGY2ZTY0NjVmOWY0NDQyZTgzOTFjMTljYl80OTQ3ODAyMzQwNTU2_d61cd3c9-1fd6-4a20-b366-03776b13ca94">&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below presents the liabilities (in thousands) measured and recorded in the financial statements at fair value on a recurring basis at December 31, 2022 categorized by the level of inputs used in the valuation of each liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.635%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.252%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.417%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.252%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.417%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.252%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.417%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.258%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Warrant Liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock>
    <us-gaap:WarrantsNotSettleableInCashFairValueDisclosure
      contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzY1L2ZyYWc6MzgyNzViMTRmNmU2NDY1ZjlmNDQ0MmU4MzkxYzE5Y2IvdGFibGU6MGY5YjJjYzE5MTEyNDcyN2ExZjEyZjViYTg2YzA5NDUvdGFibGVyYW5nZTowZjliMmNjMTkxMTI0NzI3YTFmMTJmNWJhODZjMDk0NV83LTEtMS0xLTExMDU3Mw_a57eadd8-395d-4f68-acdf-d36e7b5b70f4"
      unitRef="usd">21490000</us-gaap:WarrantsNotSettleableInCashFairValueDisclosure>
    <us-gaap:WarrantsNotSettleableInCashFairValueDisclosure
      contextRef="i25abfe2f91764951ba1d5af64bcb7a2a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzY1L2ZyYWc6MzgyNzViMTRmNmU2NDY1ZjlmNDQ0MmU4MzkxYzE5Y2IvdGFibGU6MGY5YjJjYzE5MTEyNDcyN2ExZjEyZjViYTg2YzA5NDUvdGFibGVyYW5nZTowZjliMmNjMTkxMTI0NzI3YTFmMTJmNWJhODZjMDk0NV83LTMtMS0xLTExMDA4NQ_0f2f0807-6eeb-4097-badd-23f9e2d597f8"
      unitRef="usd">0</us-gaap:WarrantsNotSettleableInCashFairValueDisclosure>
    <us-gaap:WarrantsNotSettleableInCashFairValueDisclosure
      contextRef="i32cf8e8f75054575965e3fdf63fcc596_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzY1L2ZyYWc6MzgyNzViMTRmNmU2NDY1ZjlmNDQ0MmU4MzkxYzE5Y2IvdGFibGU6MGY5YjJjYzE5MTEyNDcyN2ExZjEyZjViYTg2YzA5NDUvdGFibGVyYW5nZTowZjliMmNjMTkxMTI0NzI3YTFmMTJmNWJhODZjMDk0NV83LTUtMS0xLTExMDA4NQ_7605841f-3fe2-4d26-8814-b28abe0acb22"
      unitRef="usd">0</us-gaap:WarrantsNotSettleableInCashFairValueDisclosure>
    <us-gaap:WarrantsNotSettleableInCashFairValueDisclosure
      contextRef="ib72acf71ad414bdb820e66430a66f4f1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzY1L2ZyYWc6MzgyNzViMTRmNmU2NDY1ZjlmNDQ0MmU4MzkxYzE5Y2IvdGFibGU6MGY5YjJjYzE5MTEyNDcyN2ExZjEyZjViYTg2YzA5NDUvdGFibGVyYW5nZTowZjliMmNjMTkxMTI0NzI3YTFmMTJmNWJhODZjMDk0NV83LTctMS0xLTExMDExMA_864b6a6c-bf0b-4411-936f-12c505767cdd"
      unitRef="usd">21490000</us-gaap:WarrantsNotSettleableInCashFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzY1L2ZyYWc6MzgyNzViMTRmNmU2NDY1ZjlmNDQ0MmU4MzkxYzE5Y2IvdGFibGU6MGY5YjJjYzE5MTEyNDcyN2ExZjEyZjViYTg2YzA5NDUvdGFibGVyYW5nZTowZjliMmNjMTkxMTI0NzI3YTFmMTJmNWJhODZjMDk0NV84LTEtMS0xLTExMDU3Mw_414ab5bc-7905-4414-aa52-775c7cf5bc3b"
      unitRef="usd">21490000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i25abfe2f91764951ba1d5af64bcb7a2a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzY1L2ZyYWc6MzgyNzViMTRmNmU2NDY1ZjlmNDQ0MmU4MzkxYzE5Y2IvdGFibGU6MGY5YjJjYzE5MTEyNDcyN2ExZjEyZjViYTg2YzA5NDUvdGFibGVyYW5nZTowZjliMmNjMTkxMTI0NzI3YTFmMTJmNWJhODZjMDk0NV84LTMtMS0xLTExMDU3Mw_ede0b701-73df-48a9-bd06-6bcac0e71d12"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i32cf8e8f75054575965e3fdf63fcc596_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzY1L2ZyYWc6MzgyNzViMTRmNmU2NDY1ZjlmNDQ0MmU4MzkxYzE5Y2IvdGFibGU6MGY5YjJjYzE5MTEyNDcyN2ExZjEyZjViYTg2YzA5NDUvdGFibGVyYW5nZTowZjliMmNjMTkxMTI0NzI3YTFmMTJmNWJhODZjMDk0NV84LTUtMS0xLTExMDU3Mw_5b172c4b-768d-45ea-ad7e-6da9c078a574"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ib72acf71ad414bdb820e66430a66f4f1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzY1L2ZyYWc6MzgyNzViMTRmNmU2NDY1ZjlmNDQ0MmU4MzkxYzE5Y2IvdGFibGU6MGY5YjJjYzE5MTEyNDcyN2ExZjEyZjViYTg2YzA5NDUvdGFibGVyYW5nZTowZjliMmNjMTkxMTI0NzI3YTFmMTJmNWJhODZjMDk0NV84LTctMS0xLTExMDU3Mw_0562b0b7-63fd-472d-a17c-89e95bf65e61"
      unitRef="usd">21490000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzY1L2ZyYWc6MzgyNzViMTRmNmU2NDY1ZjlmNDQ0MmU4MzkxYzE5Y2IvdGV4dHJlZ2lvbjozODI3NWIxNGY2ZTY0NjVmOWY0NDQyZTgzOTFjMTljYl80OTQ3ODAyMzQwNTU3_e4bc1699-91f1-4700-b584-6e9d6eb3c14c">&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The reconciliation of the Company's warrant liability measured at fair value on a recurring basis using unobservable inputs (Level 3) is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.528%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.272%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Warrant Liability&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Warrants issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzY1L2ZyYWc6MzgyNzViMTRmNmU2NDY1ZjlmNDQ0MmU4MzkxYzE5Y2IvdGFibGU6NWM3ZDZiYjczNjFkNDc5M2E4MTIxMjhkOWM4MWIzZDMvdGFibGVyYW5nZTo1YzdkNmJiNzM2MWQ0NzkzYTgxMjEyOGQ5YzgxYjNkM180LTAtMS0xLTExMDU2NQ_cf1ef344-6e8b-4404-9fc4-62d43ef2dafc"&gt;Change in fair value of liability&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="id970dfd2674c4d6b895febb9c14d0fd1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzY1L2ZyYWc6MzgyNzViMTRmNmU2NDY1ZjlmNDQ0MmU4MzkxYzE5Y2IvdGFibGU6NWM3ZDZiYjczNjFkNDc5M2E4MTIxMjhkOWM4MWIzZDMvdGFibGVyYW5nZTo1YzdkNmJiNzM2MWQ0NzkzYTgxMjEyOGQ5YzgxYjNkM18yLTEtMS0xLTExMDExOQ_e8ea3ed9-67af-4c16-bd52-d7c477437138"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzY1L2ZyYWc6MzgyNzViMTRmNmU2NDY1ZjlmNDQ0MmU4MzkxYzE5Y2IvdGFibGU6NWM3ZDZiYjczNjFkNDc5M2E4MTIxMjhkOWM4MWIzZDMvdGFibGVyYW5nZTo1YzdkNmJiNzM2MWQ0NzkzYTgxMjEyOGQ5YzgxYjNkM18zLTEtMS0xLTExMDExOQ_e8b9bed7-65b9-4595-9526-c7d37358dd5a"
      unitRef="usd">20279000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzY1L2ZyYWc6MzgyNzViMTRmNmU2NDY1ZjlmNDQ0MmU4MzkxYzE5Y2IvdGFibGU6NWM3ZDZiYjczNjFkNDc5M2E4MTIxMjhkOWM4MWIzZDMvdGFibGVyYW5nZTo1YzdkNmJiNzM2MWQ0NzkzYTgxMjEyOGQ5YzgxYjNkM180LTEtMS0xLTExMDExOQ_f56247ba-fd5d-43db-9020-0d54b5a888fa"
      unitRef="usd">1211000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzY1L2ZyYWc6MzgyNzViMTRmNmU2NDY1ZjlmNDQ0MmU4MzkxYzE5Y2IvdGFibGU6NWM3ZDZiYjczNjFkNDc5M2E4MTIxMjhkOWM4MWIzZDMvdGFibGVyYW5nZTo1YzdkNmJiNzM2MWQ0NzkzYTgxMjEyOGQ5YzgxYjNkM181LTEtMS0xLTExMDU1OA_a30e457b-4906-4fc1-8f7b-a85be2b8cec9"
      unitRef="usd">21490000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzY1L2ZyYWc6MzgyNzViMTRmNmU2NDY1ZjlmNDQ0MmU4MzkxYzE5Y2IvdGV4dHJlZ2lvbjozODI3NWIxNGY2ZTY0NjVmOWY0NDQyZTgzOTFjMTljYl80OTQ3ODAyMzQwNTU4_53249423-1f55-45e6-b6ff-c04177d751e2">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.182%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;November 23, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock price&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Strike price&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;45.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;45.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected life (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.90&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fair value per warrant&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i3c2fa1e023784c819a8dc44bb99e322a_I20221123"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzY1L2ZyYWc6MzgyNzViMTRmNmU2NDY1ZjlmNDQ0MmU4MzkxYzE5Y2IvdGFibGU6NjcwYTJmYWY2ZTgwNDAzOWI1ZGQ2MGQzMmI5OTRjOTIvdGFibGVyYW5nZTo2NzBhMmZhZjZlODA0MDM5YjVkZDYwZDMyYjk5NGM5Ml8yLTEtMS0xLTExMDIyNA_6308b115-7b49-4b37-a74b-0c19260b5c78"
      unitRef="number">1.77</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i656202f27e9648aa9f71018965d5db85_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzY1L2ZyYWc6MzgyNzViMTRmNmU2NDY1ZjlmNDQ0MmU4MzkxYzE5Y2IvdGFibGU6NjcwYTJmYWY2ZTgwNDAzOWI1ZGQ2MGQzMmI5OTRjOTIvdGFibGVyYW5nZTo2NzBhMmZhZjZlODA0MDM5YjVkZDYwZDMyYjk5NGM5Ml8yLTMtMS0xLTExMDIyNA_e073deda-f1a9-466f-a692-2bd857ae13e4"
      unitRef="number">1.85</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i12526027af124d2eaf2e45c5cc5128ba_I20221123"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzY1L2ZyYWc6MzgyNzViMTRmNmU2NDY1ZjlmNDQ0MmU4MzkxYzE5Y2IvdGFibGU6NjcwYTJmYWY2ZTgwNDAzOWI1ZGQ2MGQzMmI5OTRjOTIvdGFibGVyYW5nZTo2NzBhMmZhZjZlODA0MDM5YjVkZDYwZDMyYjk5NGM5Ml8zLTEtMS0xLTExMDIyNA_942dd72c-8295-46f1-b5a4-bd423a7d04db"
      unitRef="number">2.57</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i81d87324f9ac42a2804e01597b73f13e_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzY1L2ZyYWc6MzgyNzViMTRmNmU2NDY1ZjlmNDQ0MmU4MzkxYzE5Y2IvdGFibGU6NjcwYTJmYWY2ZTgwNDAzOWI1ZGQ2MGQzMmI5OTRjOTIvdGFibGVyYW5nZTo2NzBhMmZhZjZlODA0MDM5YjVkZDYwZDMyYjk5NGM5Ml8zLTMtMS0xLTExMDIyNA_38b71ab7-bdff-4765-a646-c4eabf4a1db8"
      unitRef="number">2.57</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i7fd98223b0e8487ab4e9f06a6b0e2e17_I20221123"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzY1L2ZyYWc6MzgyNzViMTRmNmU2NDY1ZjlmNDQ0MmU4MzkxYzE5Y2IvdGFibGU6NjcwYTJmYWY2ZTgwNDAzOWI1ZGQ2MGQzMmI5OTRjOTIvdGFibGVyYW5nZTo2NzBhMmZhZjZlODA0MDM5YjVkZDYwZDMyYjk5NGM5Ml80LTEtMS0xLTExMDIyNA_ed609ca9-3c82-4145-a359-9e047f10e0be"
      unitRef="number">0.450</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="ia683400064104d94bb65e13224b47fa4_I20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzY1L2ZyYWc6MzgyNzViMTRmNmU2NDY1ZjlmNDQ0MmU4MzkxYzE5Y2IvdGFibGU6NjcwYTJmYWY2ZTgwNDAzOWI1ZGQ2MGQzMmI5OTRjOTIvdGFibGVyYW5nZTo2NzBhMmZhZjZlODA0MDM5YjVkZDYwZDMyYjk5NGM5Ml80LTMtMS0xLTExMDIyNA_29822c1f-250e-44a4-9dac-559472bcc1e3"
      unitRef="number">0.450</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i07561160b4b640b58284b5ac37678580_I20221123"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzY1L2ZyYWc6MzgyNzViMTRmNmU2NDY1ZjlmNDQ0MmU4MzkxYzE5Y2IvdGFibGU6NjcwYTJmYWY2ZTgwNDAzOWI1ZGQ2MGQzMmI5OTRjOTIvdGFibGVyYW5nZTo2NzBhMmZhZjZlODA0MDM5YjVkZDYwZDMyYjk5NGM5Ml81LTEtMS0xLTExMDIyNA_c5a080c9-95d7-4908-879d-7362dad8ec7e"
      unitRef="number">0.038</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="ib8ec0a4f643d4b8691f7c64824d1ef26_I20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzY1L2ZyYWc6MzgyNzViMTRmNmU2NDY1ZjlmNDQ0MmU4MzkxYzE5Y2IvdGFibGU6NjcwYTJmYWY2ZTgwNDAzOWI1ZGQ2MGQzMmI5OTRjOTIvdGFibGVyYW5nZTo2NzBhMmZhZjZlODA0MDM5YjVkZDYwZDMyYjk5NGM5Ml81LTMtMS0xLTExMDIyNA_83556df8-c9d4-48cc-896c-ed4ecb067acf"
      unitRef="number">0.038</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="if38bd004cc9c47cb8ed2b5ced602d8de_I20221123"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzY1L2ZyYWc6MzgyNzViMTRmNmU2NDY1ZjlmNDQ0MmU4MzkxYzE5Y2IvdGFibGU6NjcwYTJmYWY2ZTgwNDAzOWI1ZGQ2MGQzMmI5OTRjOTIvdGFibGVyYW5nZTo2NzBhMmZhZjZlODA0MDM5YjVkZDYwZDMyYjk5NGM5Ml82LTEtMS0xLTExMDIyNA_d5d5729a-1faa-45ab-b073-bb121b42180f"
      unitRef="number">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i77f645c2ad1f45eb87448af2f7350083_I20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzY1L2ZyYWc6MzgyNzViMTRmNmU2NDY1ZjlmNDQ0MmU4MzkxYzE5Y2IvdGFibGU6NjcwYTJmYWY2ZTgwNDAzOWI1ZGQ2MGQzMmI5OTRjOTIvdGFibGVyYW5nZTo2NzBhMmZhZjZlODA0MDM5YjVkZDYwZDMyYjk5NGM5Ml82LTMtMS0xLTExMDIyNA_7f5f1986-f486-4dc2-8f69-579c42921eb5"
      unitRef="number">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="ic2035d08305a4a15b86bb7d1dbc471a9_I20221123"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzY1L2ZyYWc6MzgyNzViMTRmNmU2NDY1ZjlmNDQ0MmU4MzkxYzE5Y2IvdGFibGU6NjcwYTJmYWY2ZTgwNDAzOWI1ZGQ2MGQzMmI5OTRjOTIvdGFibGVyYW5nZTo2NzBhMmZhZjZlODA0MDM5YjVkZDYwZDMyYjk5NGM5Ml83LTEtMS0xLTExMDIyNA_593f996e-5dae-4c5f-8139-83fbc1c7af8b">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="i076a98514cf1491bb4e37cb056d5866a_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzY1L2ZyYWc6MzgyNzViMTRmNmU2NDY1ZjlmNDQ0MmU4MzkxYzE5Y2IvdGFibGU6NjcwYTJmYWY2ZTgwNDAzOWI1ZGQ2MGQzMmI5OTRjOTIvdGFibGVyYW5nZTo2NzBhMmZhZjZlODA0MDM5YjVkZDYwZDMyYjk5NGM5Ml83LTMtMS0xLTExMDIyNA_ea354c76-4bf1-4be8-87e4-0a737872b7ca">P4Y10M24D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <optn:FairValueOfWarrant
      contextRef="ic2035d08305a4a15b86bb7d1dbc471a9_I20221123"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzY1L2ZyYWc6MzgyNzViMTRmNmU2NDY1ZjlmNDQ0MmU4MzkxYzE5Y2IvdGFibGU6NjcwYTJmYWY2ZTgwNDAzOWI1ZGQ2MGQzMmI5OTRjOTIvdGFibGVyYW5nZTo2NzBhMmZhZjZlODA0MDM5YjVkZDYwZDMyYjk5NGM5Ml84LTEtMS0xLTExMDIyNA_ef3a8a4a-c552-4a8e-b06c-54df0bf581c6"
      unitRef="usdPerShare">0.67</optn:FairValueOfWarrant>
    <optn:FairValueOfWarrant
      contextRef="i076a98514cf1491bb4e37cb056d5866a_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzY1L2ZyYWc6MzgyNzViMTRmNmU2NDY1ZjlmNDQ0MmU4MzkxYzE5Y2IvdGFibGU6NjcwYTJmYWY2ZTgwNDAzOWI1ZGQ2MGQzMmI5OTRjOTIvdGFibGVyYW5nZTo2NzBhMmZhZjZlODA0MDM5YjVkZDYwZDMyYjk5NGM5Ml84LTMtMS0xLTExMDIyNA_bf772c62-e68a-4b08-a7bd-72d15b626e19"
      unitRef="usdPerShare">0.71</optn:FairValueOfWarrant>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDUvZnJhZzo0Yzk0ZDY1OGMwODQ0MDY2OTk0Yzk0NGU2M2Q5OGUxYS90ZXh0cmVnaW9uOjRjOTRkNjU4YzA4NDQwNjY5OTRjOTQ0ZTYzZDk4ZTFhXzU4_9218f3fc-4144-4614-b4dc-baabd69a4c72">Inventory&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory consisted of the following: &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.271%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.272%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,504&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Work-in-process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,816&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories are stated at the lower of cost or net realizable value, as determined on a first-in, first-out basis.&lt;/span&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDUvZnJhZzo0Yzk0ZDY1OGMwODQ0MDY2OTk0Yzk0NGU2M2Q5OGUxYS90ZXh0cmVnaW9uOjRjOTRkNjU4YzA4NDQwNjY5OTRjOTQ0ZTYzZDk4ZTFhXzU5_f5f38e62-2ce5-45ac-bcf3-66928a7e45b4">&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory consisted of the following: &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.271%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.272%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,504&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Work-in-process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,816&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterials
      contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDUvZnJhZzo0Yzk0ZDY1OGMwODQ0MDY2OTk0Yzk0NGU2M2Q5OGUxYS90YWJsZToyZTMyMTI2OTA0Mjg0OTg1OTI1Y2VkMjY2YWU4M2Y2Yi90YWJsZXJhbmdlOjJlMzIxMjY5MDQyODQ5ODU5MjVjZWQyNjZhZTgzZjZiXzItMS0xLTEtNTgzNzI_de764f50-7486-4482-b4db-e64fae7dc6ec"
      unitRef="usd">1691000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryRawMaterials
      contextRef="id970dfd2674c4d6b895febb9c14d0fd1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDUvZnJhZzo0Yzk0ZDY1OGMwODQ0MDY2OTk0Yzk0NGU2M2Q5OGUxYS90YWJsZToyZTMyMTI2OTA0Mjg0OTg1OTI1Y2VkMjY2YWU4M2Y2Yi90YWJsZXJhbmdlOjJlMzIxMjY5MDQyODQ5ODU5MjVjZWQyNjZhZTgzZjZiXzItMy0xLTEtNTgzNzI_a893edc7-320c-41b5-a889-14ce24fb6f0a"
      unitRef="usd">3504000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryWorkInProcess
      contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDUvZnJhZzo0Yzk0ZDY1OGMwODQ0MDY2OTk0Yzk0NGU2M2Q5OGUxYS90YWJsZToyZTMyMTI2OTA0Mjg0OTg1OTI1Y2VkMjY2YWU4M2Y2Yi90YWJsZXJhbmdlOjJlMzIxMjY5MDQyODQ5ODU5MjVjZWQyNjZhZTgzZjZiXzMtMS0xLTEtNTgzNzI_39e4a5bc-0add-4f9c-9daa-b6cc4d1d5728"
      unitRef="usd">5010000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryWorkInProcess
      contextRef="id970dfd2674c4d6b895febb9c14d0fd1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDUvZnJhZzo0Yzk0ZDY1OGMwODQ0MDY2OTk0Yzk0NGU2M2Q5OGUxYS90YWJsZToyZTMyMTI2OTA0Mjg0OTg1OTI1Y2VkMjY2YWU4M2Y2Yi90YWJsZXJhbmdlOjJlMzIxMjY5MDQyODQ5ODU5MjVjZWQyNjZhZTgzZjZiXzMtMy0xLTEtNTgzNzI_b0838f9b-c271-4cb5-a410-5b889a3e79b9"
      unitRef="usd">4816000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryFinishedGoods
      contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDUvZnJhZzo0Yzk0ZDY1OGMwODQ0MDY2OTk0Yzk0NGU2M2Q5OGUxYS90YWJsZToyZTMyMTI2OTA0Mjg0OTg1OTI1Y2VkMjY2YWU4M2Y2Yi90YWJsZXJhbmdlOjJlMzIxMjY5MDQyODQ5ODU5MjVjZWQyNjZhZTgzZjZiXzQtMS0xLTEtNTgzNzI_c87ac3dc-e6d7-40db-b9bd-dbc927e663f6"
      unitRef="usd">2742000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods
      contextRef="id970dfd2674c4d6b895febb9c14d0fd1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDUvZnJhZzo0Yzk0ZDY1OGMwODQ0MDY2OTk0Yzk0NGU2M2Q5OGUxYS90YWJsZToyZTMyMTI2OTA0Mjg0OTg1OTI1Y2VkMjY2YWU4M2Y2Yi90YWJsZXJhbmdlOjJlMzIxMjY5MDQyODQ5ODU5MjVjZWQyNjZhZTgzZjZiXzQtMy0xLTEtNTgzNzI_7bbd3635-9212-4a36-8b79-4dfa3073f618"
      unitRef="usd">3527000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryGross
      contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDUvZnJhZzo0Yzk0ZDY1OGMwODQ0MDY2OTk0Yzk0NGU2M2Q5OGUxYS90YWJsZToyZTMyMTI2OTA0Mjg0OTg1OTI1Y2VkMjY2YWU4M2Y2Yi90YWJsZXJhbmdlOjJlMzIxMjY5MDQyODQ5ODU5MjVjZWQyNjZhZTgzZjZiXzUtMS0xLTEtNTgzNzI_55186063-74d3-41b1-a16d-76f51e5dc0d6"
      unitRef="usd">9443000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="id970dfd2674c4d6b895febb9c14d0fd1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDUvZnJhZzo0Yzk0ZDY1OGMwODQ0MDY2OTk0Yzk0NGU2M2Q5OGUxYS90YWJsZToyZTMyMTI2OTA0Mjg0OTg1OTI1Y2VkMjY2YWU4M2Y2Yi90YWJsZXJhbmdlOjJlMzIxMjY5MDQyODQ5ODU5MjVjZWQyNjZhZTgzZjZiXzUtMy0xLTEtNTgzNzI_94e70164-1214-4862-b97c-c9cb9a158541"
      unitRef="usd">11847000</us-gaap:InventoryGross>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDgvZnJhZzo1OGY0OGY2ZmFlNTk0NTJjOWI0OWRlNjAwYmNmMzQyYS90ZXh0cmVnaW9uOjU4ZjQ4ZjZmYWU1OTQ1MmM5YjQ5ZGU2MDBiY2YzNDJhXzM5MA_4cdd2bb4-aa03-418c-af2a-269f52be343d">Property and Equipment&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net, consisted of:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.607%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.329%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Machinery and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,067&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Construction in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4,565)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4,283)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation expense was $530&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and $645 for the years ended December 31, 2022&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and 2021, respectively. In addition, depreciation expense of $665 was charged to inventory and no depreciation was charged to prepaid expenses and other assets as of December 31, 2022, which represents depreciation expense related to equipment involved in the manufacturing process.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i9ddeb1efeb7744f8bed2dbb7f03f66da_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDgvZnJhZzo1OGY0OGY2ZmFlNTk0NTJjOWI0OWRlNjAwYmNmMzQyYS90YWJsZTo5NWVkNDExN2Q0NjI0YmJlYmM4MjNlNGM4OWYzNzU0NC90YWJsZXJhbmdlOjk1ZWQ0MTE3ZDQ2MjRiYmViYzgyM2U0Yzg5ZjM3NTQ0XzItMS0xLTEtNTgzNzI_4b3425bf-e90f-4669-a092-ab6de4094bee"
      unitRef="usd">1203000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ic532296dc81545c39388340e3d3dfb1d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDgvZnJhZzo1OGY0OGY2ZmFlNTk0NTJjOWI0OWRlNjAwYmNmMzQyYS90YWJsZTo5NWVkNDExN2Q0NjI0YmJlYmM4MjNlNGM4OWYzNzU0NC90YWJsZXJhbmdlOjk1ZWQ0MTE3ZDQ2MjRiYmViYzgyM2U0Yzg5ZjM3NTQ0XzItMy0xLTEtNTgzNzI_33c09cb7-fd75-4667-877a-c6c44aba7d8c"
      unitRef="usd">1173000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="idd6adcb5fdd94a8cafa3e6dcc446470f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDgvZnJhZzo1OGY0OGY2ZmFlNTk0NTJjOWI0OWRlNjAwYmNmMzQyYS90YWJsZTo5NWVkNDExN2Q0NjI0YmJlYmM4MjNlNGM4OWYzNzU0NC90YWJsZXJhbmdlOjk1ZWQ0MTE3ZDQ2MjRiYmViYzgyM2U0Yzg5ZjM3NTQ0XzMtMS0xLTEtNTgzNzI_43f663ab-f430-42e2-a9b4-8ab2574a3122"
      unitRef="usd">366000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i6d6764d492fa4ab49a7a65da317dfa94_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDgvZnJhZzo1OGY0OGY2ZmFlNTk0NTJjOWI0OWRlNjAwYmNmMzQyYS90YWJsZTo5NWVkNDExN2Q0NjI0YmJlYmM4MjNlNGM4OWYzNzU0NC90YWJsZXJhbmdlOjk1ZWQ0MTE3ZDQ2MjRiYmViYzgyM2U0Yzg5ZjM3NTQ0XzMtMy0xLTEtNTgzNzI_c801acd2-e2a8-4df4-8b3e-306722d03055"
      unitRef="usd">366000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i77c83aa040f64e5ab765b0b3cec00b48_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDgvZnJhZzo1OGY0OGY2ZmFlNTk0NTJjOWI0OWRlNjAwYmNmMzQyYS90YWJsZTo5NWVkNDExN2Q0NjI0YmJlYmM4MjNlNGM4OWYzNzU0NC90YWJsZXJhbmdlOjk1ZWQ0MTE3ZDQ2MjRiYmViYzgyM2U0Yzg5ZjM3NTQ0XzQtMS0xLTEtNTgzNzI_31c5bc03-d0ac-4094-8bf5-c9677904389f"
      unitRef="usd">3067000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i97b05fd39c994e718b96dc21927444c5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDgvZnJhZzo1OGY0OGY2ZmFlNTk0NTJjOWI0OWRlNjAwYmNmMzQyYS90YWJsZTo5NWVkNDExN2Q0NjI0YmJlYmM4MjNlNGM4OWYzNzU0NC90YWJsZXJhbmdlOjk1ZWQ0MTE3ZDQ2MjRiYmViYzgyM2U0Yzg5ZjM3NTQ0XzQtMy0xLTEtNTgzNzI_9b411d9a-f6b4-45a8-9d7d-aa4a6de55085"
      unitRef="usd">3367000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ie3474fbb67a5493091eb870124741f97_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDgvZnJhZzo1OGY0OGY2ZmFlNTk0NTJjOWI0OWRlNjAwYmNmMzQyYS90YWJsZTo5NWVkNDExN2Q0NjI0YmJlYmM4MjNlNGM4OWYzNzU0NC90YWJsZXJhbmdlOjk1ZWQ0MTE3ZDQ2MjRiYmViYzgyM2U0Yzg5ZjM3NTQ0XzUtMS0xLTEtNTgzNzI_8e1f0f73-7efd-496e-8d4e-74365d6a941f"
      unitRef="usd">609000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i20b9366590cd439eac871165deb4cd22_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDgvZnJhZzo1OGY0OGY2ZmFlNTk0NTJjOWI0OWRlNjAwYmNmMzQyYS90YWJsZTo5NWVkNDExN2Q0NjI0YmJlYmM4MjNlNGM4OWYzNzU0NC90YWJsZXJhbmdlOjk1ZWQ0MTE3ZDQ2MjRiYmViYzgyM2U0Yzg5ZjM3NTQ0XzUtMy0xLTEtNTgzNzI_c608d6d0-10e2-4734-89d7-d6ba7e01d32a"
      unitRef="usd">609000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="iaaea96eb926c4215a782ea03cfe873f7_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDgvZnJhZzo1OGY0OGY2ZmFlNTk0NTJjOWI0OWRlNjAwYmNmMzQyYS90YWJsZTo5NWVkNDExN2Q0NjI0YmJlYmM4MjNlNGM4OWYzNzU0NC90YWJsZXJhbmdlOjk1ZWQ0MTE3ZDQ2MjRiYmViYzgyM2U0Yzg5ZjM3NTQ0XzYtMS0xLTEtNTgzNzI_ce6325b0-01c1-4fdd-87a5-1a0c8b23316b"
      unitRef="usd">115000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i5d86a8ea69c742f89c18f27139c4e7e8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDgvZnJhZzo1OGY0OGY2ZmFlNTk0NTJjOWI0OWRlNjAwYmNmMzQyYS90YWJsZTo5NWVkNDExN2Q0NjI0YmJlYmM4MjNlNGM4OWYzNzU0NC90YWJsZXJhbmdlOjk1ZWQ0MTE3ZDQ2MjRiYmViYzgyM2U0Yzg5ZjM3NTQ0XzYtMy0xLTEtNTgzNzI_542d1830-4db0-41a6-b376-0c014cd355f4"
      unitRef="usd">115000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDgvZnJhZzo1OGY0OGY2ZmFlNTk0NTJjOWI0OWRlNjAwYmNmMzQyYS90YWJsZTo5NWVkNDExN2Q0NjI0YmJlYmM4MjNlNGM4OWYzNzU0NC90YWJsZXJhbmdlOjk1ZWQ0MTE3ZDQ2MjRiYmViYzgyM2U0Yzg5ZjM3NTQ0XzctMS0xLTEtNTgzNzI_40c989aa-d357-458d-874b-e8734d3059ee"
      unitRef="usd">5360000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="id970dfd2674c4d6b895febb9c14d0fd1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDgvZnJhZzo1OGY0OGY2ZmFlNTk0NTJjOWI0OWRlNjAwYmNmMzQyYS90YWJsZTo5NWVkNDExN2Q0NjI0YmJlYmM4MjNlNGM4OWYzNzU0NC90YWJsZXJhbmdlOjk1ZWQ0MTE3ZDQ2MjRiYmViYzgyM2U0Yzg5ZjM3NTQ0XzctMy0xLTEtNTgzNzI_6349cb20-f9c1-466a-a3ac-46fffc66d936"
      unitRef="usd">5630000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDgvZnJhZzo1OGY0OGY2ZmFlNTk0NTJjOWI0OWRlNjAwYmNmMzQyYS90YWJsZTo5NWVkNDExN2Q0NjI0YmJlYmM4MjNlNGM4OWYzNzU0NC90YWJsZXJhbmdlOjk1ZWQ0MTE3ZDQ2MjRiYmViYzgyM2U0Yzg5ZjM3NTQ0XzgtMS0xLTEtNTgzNzI_dfc3d68f-d53b-4829-8b5c-d54c71c58861"
      unitRef="usd">4565000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="id970dfd2674c4d6b895febb9c14d0fd1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDgvZnJhZzo1OGY0OGY2ZmFlNTk0NTJjOWI0OWRlNjAwYmNmMzQyYS90YWJsZTo5NWVkNDExN2Q0NjI0YmJlYmM4MjNlNGM4OWYzNzU0NC90YWJsZXJhbmdlOjk1ZWQ0MTE3ZDQ2MjRiYmViYzgyM2U0Yzg5ZjM3NTQ0XzgtMy0xLTEtNTgzNzI_13673de7-e3b4-4af9-a503-ccbdf7b41c18"
      unitRef="usd">4283000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDgvZnJhZzo1OGY0OGY2ZmFlNTk0NTJjOWI0OWRlNjAwYmNmMzQyYS90YWJsZTo5NWVkNDExN2Q0NjI0YmJlYmM4MjNlNGM4OWYzNzU0NC90YWJsZXJhbmdlOjk1ZWQ0MTE3ZDQ2MjRiYmViYzgyM2U0Yzg5ZjM3NTQ0XzktMS0xLTEtNTgzNzI_17a3d850-2639-4dc2-979c-74a140fa71cd"
      unitRef="usd">795000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="id970dfd2674c4d6b895febb9c14d0fd1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDgvZnJhZzo1OGY0OGY2ZmFlNTk0NTJjOWI0OWRlNjAwYmNmMzQyYS90YWJsZTo5NWVkNDExN2Q0NjI0YmJlYmM4MjNlNGM4OWYzNzU0NC90YWJsZXJhbmdlOjk1ZWQ0MTE3ZDQ2MjRiYmViYzgyM2U0Yzg5ZjM3NTQ0XzktMy0xLTEtNTgzNzI_02847002-4134-472d-adbd-526016ade19e"
      unitRef="usd">1347000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDgvZnJhZzo1OGY0OGY2ZmFlNTk0NTJjOWI0OWRlNjAwYmNmMzQyYS90ZXh0cmVnaW9uOjU4ZjQ4ZjZmYWU1OTQ1MmM5YjQ5ZGU2MDBiY2YzNDJhXzEwMA_838ef037-8a3a-4b19-ae92-4639d1903527"
      unitRef="usd">530000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDgvZnJhZzo1OGY0OGY2ZmFlNTk0NTJjOWI0OWRlNjAwYmNmMzQyYS90ZXh0cmVnaW9uOjU4ZjQ4ZjZmYWU1OTQ1MmM5YjQ5ZGU2MDBiY2YzNDJhXzEwNw_c9735527-9883-4471-8a97-82ccd944a38f"
      unitRef="usd">645000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i3b8fb31b2cb74f1986dbdb60db29474c_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDgvZnJhZzo1OGY0OGY2ZmFlNTk0NTJjOWI0OWRlNjAwYmNmMzQyYS90ZXh0cmVnaW9uOjU4ZjQ4ZjZmYWU1OTQ1MmM5YjQ5ZGU2MDBiY2YzNDJhXzE5Mg_2dcd75e0-b4b9-4298-92c7-1caa0881c38b"
      unitRef="usd">665000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i08cfc0852d87426baff11fe941ec7bfa_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNDgvZnJhZzo1OGY0OGY2ZmFlNTk0NTJjOWI0OWRlNjAwYmNmMzQyYS90ZXh0cmVnaW9uOjU4ZjQ4ZjZmYWU1OTQ1MmM5YjQ5ZGU2MDBiY2YzNDJhXzQ5NDc4MDIzMjU2Nzc_758ffe19-5b61-4528-95d9-9eb54ac7f236"
      unitRef="usd">0</us-gaap:Depreciation>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNTEvZnJhZzoyNzE1YjlkZmFkYWQ0MzJmODM0NjNlNTc4MDU5NjVkNS90ZXh0cmVnaW9uOjI3MTViOWRmYWRhZDQzMmY4MzQ2M2U1NzgwNTk2NWQ1XzI5NjQ_aa56d47b-ff38-4cd9-873d-801282548fe2">LeasesThe Company leases office space, storage space and equipment (primarily vehicles). The Company evaluates renewal options at lease inception on an ongoing basis and includes renewal options that it is reasonably certain to exercise in its expected lease terms when classifying leases and measuring lease liabilities. Lease agreements generally do not require material variable lease payments, residual value guarantees or restrictive covenants. &lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below presents the operating lease assets and liabilities recognized on the Company's consolidated balance sheets:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.063%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.689%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.963%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance Sheet Line Item&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Non-current operating lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNTEvZnJhZzoyNzE1YjlkZmFkYWQ0MzJmODM0NjNlNTc4MDU5NjVkNS90YWJsZTplNmRjNTY4MzJmZTU0MjZlODE2Nzg1Yzg1OWM5ZWExMC90YWJsZXJhbmdlOmU2ZGM1NjgzMmZlNTQyNmU4MTY3ODVjODU5YzllYTEwXzEtMi0xLTEtNTgzNzI_24ba613c-7389-4e11-9675-21345271c945"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNTEvZnJhZzoyNzE1YjlkZmFkYWQ0MzJmODM0NjNlNTc4MDU5NjVkNS90YWJsZTplNmRjNTY4MzJmZTU0MjZlODE2Nzg1Yzg1OWM5ZWExMC90YWJsZXJhbmdlOmU2ZGM1NjgzMmZlNTQyNmU4MTY3ODVjODU5YzllYTEwXzEtMi0xLTEtNTgzNzI_68a7407f-9d3d-42c1-b7e8-60a846da90dd"&gt;Other assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,051&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Current operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNTEvZnJhZzoyNzE1YjlkZmFkYWQ0MzJmODM0NjNlNTc4MDU5NjVkNS90YWJsZTplNmRjNTY4MzJmZTU0MjZlODE2Nzg1Yzg1OWM5ZWExMC90YWJsZXJhbmdlOmU2ZGM1NjgzMmZlNTQyNmU4MTY3ODVjODU5YzllYTEwXzMtMi0xLTEtNTgzNzI_81e615e1-5430-4b3f-a024-d8c112dd845e"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNTEvZnJhZzoyNzE1YjlkZmFkYWQ0MzJmODM0NjNlNTc4MDU5NjVkNS90YWJsZTplNmRjNTY4MzJmZTU0MjZlODE2Nzg1Yzg1OWM5ZWExMC90YWJsZXJhbmdlOmU2ZGM1NjgzMmZlNTQyNmU4MTY3ODVjODU5YzllYTEwXzMtMi0xLTEtNTgzNzI_c6470abf-49c1-414a-9b43-5932ca6cb8de"&gt;Accrued expenses and other current liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Non-current operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNTEvZnJhZzoyNzE1YjlkZmFkYWQ0MzJmODM0NjNlNTc4MDU5NjVkNS90YWJsZTplNmRjNTY4MzJmZTU0MjZlODE2Nzg1Yzg1OWM5ZWExMC90YWJsZXJhbmdlOmU2ZGM1NjgzMmZlNTQyNmU4MTY3ODVjODU5YzllYTEwXzQtMi0xLTEtNTgzNzI_51c56e55-3624-4972-bd9f-e5d6619b61c3"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNTEvZnJhZzoyNzE1YjlkZmFkYWQ0MzJmODM0NjNlNTc4MDU5NjVkNS90YWJsZTplNmRjNTY4MzJmZTU0MjZlODE2Nzg1Yzg1OWM5ZWExMC90YWJsZXJhbmdlOmU2ZGM1NjgzMmZlNTQyNmU4MTY3ODVjODU5YzllYTEwXzQtMi0xLTEtNTgzNzI_f473c9e3-1f7a-40d1-9ce5-a76980ea7120"&gt;Other liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,596&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The depreciable lives of operating lease asset leasehold improvements are limited by the lease term. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's leases generally do not provide an implicit rate, and therefore, the Company uses its incremental borrowing rate as the discount rate when measuring operating leases liabilities. The incremental borrowing rate represents an estimate of the interest rate the Company would incur at lease commencement to borrow an amount equal to the lease payments on a collateralized basis over the term of a lease. The Company used the incremental borrowing rates as of January 1, 2019 for operating leases that commenced prior to that date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's weighted average remaining lease term and weighted average discount rate for operating leases as of December 31, 2022 are:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.747%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.323%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted average remaining lease term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.04&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below reconciles the undiscounted future minimum lease payments (displayed in aggregate by year) under non-cancelable operating leases with terms of more than one year to the total operating lease liabilities recognized on the consolidated balance sheets as of December 31, 2022:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:80.478%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.592%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Total undiscounted future minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: difference between undiscounted lease payments and discounted operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,596&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;No operating lease payments include options to extend lease terms that are reasonably certain of being exercised for the year ended December 31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease costs were $2,985 and $2,843 for the years ended December 31, 2022 and 2021, respectively. Operating lease costs are included within selling, general and administrative expenses on the consolidated statements of operations. &lt;/span&gt;&lt;/div&gt;Cash paid for amounts included in the measurement of operating lease liabilities were $2,570 and $2,466 for the years ended December 31, 2022 and 2021, respectively. This amount is included in operating activities in the consolidated statements of cash flows.</us-gaap:LesseeOperatingLeasesTextBlock>
    <optn:AssetsAndLiabilitiesLesseeTableTextBlock
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNTEvZnJhZzoyNzE1YjlkZmFkYWQ0MzJmODM0NjNlNTc4MDU5NjVkNS90ZXh0cmVnaW9uOjI3MTViOWRmYWRhZDQzMmY4MzQ2M2U1NzgwNTk2NWQ1XzI5NjU_a7f84bf7-6efb-4ef0-92b7-fc23643fc73a">&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below presents the operating lease assets and liabilities recognized on the Company's consolidated balance sheets:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.063%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.689%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.963%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance Sheet Line Item&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Non-current operating lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNTEvZnJhZzoyNzE1YjlkZmFkYWQ0MzJmODM0NjNlNTc4MDU5NjVkNS90YWJsZTplNmRjNTY4MzJmZTU0MjZlODE2Nzg1Yzg1OWM5ZWExMC90YWJsZXJhbmdlOmU2ZGM1NjgzMmZlNTQyNmU4MTY3ODVjODU5YzllYTEwXzEtMi0xLTEtNTgzNzI_24ba613c-7389-4e11-9675-21345271c945"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNTEvZnJhZzoyNzE1YjlkZmFkYWQ0MzJmODM0NjNlNTc4MDU5NjVkNS90YWJsZTplNmRjNTY4MzJmZTU0MjZlODE2Nzg1Yzg1OWM5ZWExMC90YWJsZXJhbmdlOmU2ZGM1NjgzMmZlNTQyNmU4MTY3ODVjODU5YzllYTEwXzEtMi0xLTEtNTgzNzI_68a7407f-9d3d-42c1-b7e8-60a846da90dd"&gt;Other assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,051&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Current operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNTEvZnJhZzoyNzE1YjlkZmFkYWQ0MzJmODM0NjNlNTc4MDU5NjVkNS90YWJsZTplNmRjNTY4MzJmZTU0MjZlODE2Nzg1Yzg1OWM5ZWExMC90YWJsZXJhbmdlOmU2ZGM1NjgzMmZlNTQyNmU4MTY3ODVjODU5YzllYTEwXzMtMi0xLTEtNTgzNzI_81e615e1-5430-4b3f-a024-d8c112dd845e"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNTEvZnJhZzoyNzE1YjlkZmFkYWQ0MzJmODM0NjNlNTc4MDU5NjVkNS90YWJsZTplNmRjNTY4MzJmZTU0MjZlODE2Nzg1Yzg1OWM5ZWExMC90YWJsZXJhbmdlOmU2ZGM1NjgzMmZlNTQyNmU4MTY3ODVjODU5YzllYTEwXzMtMi0xLTEtNTgzNzI_c6470abf-49c1-414a-9b43-5932ca6cb8de"&gt;Accrued expenses and other current liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Non-current operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNTEvZnJhZzoyNzE1YjlkZmFkYWQ0MzJmODM0NjNlNTc4MDU5NjVkNS90YWJsZTplNmRjNTY4MzJmZTU0MjZlODE2Nzg1Yzg1OWM5ZWExMC90YWJsZXJhbmdlOmU2ZGM1NjgzMmZlNTQyNmU4MTY3ODVjODU5YzllYTEwXzQtMi0xLTEtNTgzNzI_51c56e55-3624-4972-bd9f-e5d6619b61c3"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNTEvZnJhZzoyNzE1YjlkZmFkYWQ0MzJmODM0NjNlNTc4MDU5NjVkNS90YWJsZTplNmRjNTY4MzJmZTU0MjZlODE2Nzg1Yzg1OWM5ZWExMC90YWJsZXJhbmdlOmU2ZGM1NjgzMmZlNTQyNmU4MTY3ODVjODU5YzllYTEwXzQtMi0xLTEtNTgzNzI_f473c9e3-1f7a-40d1-9ce5-a76980ea7120"&gt;Other liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,596&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's weighted average remaining lease term and weighted average discount rate for operating leases as of December 31, 2022 are:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.747%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.323%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted average remaining lease term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.04&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</optn:AssetsAndLiabilitiesLesseeTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNTEvZnJhZzoyNzE1YjlkZmFkYWQ0MzJmODM0NjNlNTc4MDU5NjVkNS90YWJsZTplNmRjNTY4MzJmZTU0MjZlODE2Nzg1Yzg1OWM5ZWExMC90YWJsZXJhbmdlOmU2ZGM1NjgzMmZlNTQyNmU4MTY3ODVjODU5YzllYTEwXzEtNC0xLTEtNTgzNzI_b8339169-f135-43f0-a47a-af7ea9d39e87"
      unitRef="usd">2445000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="id970dfd2674c4d6b895febb9c14d0fd1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNTEvZnJhZzoyNzE1YjlkZmFkYWQ0MzJmODM0NjNlNTc4MDU5NjVkNS90YWJsZTplNmRjNTY4MzJmZTU0MjZlODE2Nzg1Yzg1OWM5ZWExMC90YWJsZXJhbmdlOmU2ZGM1NjgzMmZlNTQyNmU4MTY3ODVjODU5YzllYTEwXzEtNi0xLTEtNTgzNzI_6be045cd-0f9a-43ff-a543-3fd54fee9ff5"
      unitRef="usd">4051000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNTEvZnJhZzoyNzE1YjlkZmFkYWQ0MzJmODM0NjNlNTc4MDU5NjVkNS90YWJsZTplNmRjNTY4MzJmZTU0MjZlODE2Nzg1Yzg1OWM5ZWExMC90YWJsZXJhbmdlOmU2ZGM1NjgzMmZlNTQyNmU4MTY3ODVjODU5YzllYTEwXzMtNC0xLTEtNTgzNzI_30666a05-c851-4c0f-b2dc-d961069bb4f4"
      unitRef="usd">1971000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="id970dfd2674c4d6b895febb9c14d0fd1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNTEvZnJhZzoyNzE1YjlkZmFkYWQ0MzJmODM0NjNlNTc4MDU5NjVkNS90YWJsZTplNmRjNTY4MzJmZTU0MjZlODE2Nzg1Yzg1OWM5ZWExMC90YWJsZXJhbmdlOmU2ZGM1NjgzMmZlNTQyNmU4MTY3ODVjODU5YzllYTEwXzMtNi0xLTEtNTgzNzI_7055b1a5-c521-46e8-9680-3055af72441e"
      unitRef="usd">2094000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNTEvZnJhZzoyNzE1YjlkZmFkYWQ0MzJmODM0NjNlNTc4MDU5NjVkNS90YWJsZTplNmRjNTY4MzJmZTU0MjZlODE2Nzg1Yzg1OWM5ZWExMC90YWJsZXJhbmdlOmU2ZGM1NjgzMmZlNTQyNmU4MTY3ODVjODU5YzllYTEwXzQtNC0xLTEtNTgzNzI_dea14e16-2d67-4d37-b632-8e8916acc6af"
      unitRef="usd">625000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="id970dfd2674c4d6b895febb9c14d0fd1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNTEvZnJhZzoyNzE1YjlkZmFkYWQ0MzJmODM0NjNlNTc4MDU5NjVkNS90YWJsZTplNmRjNTY4MzJmZTU0MjZlODE2Nzg1Yzg1OWM5ZWExMC90YWJsZXJhbmdlOmU2ZGM1NjgzMmZlNTQyNmU4MTY3ODVjODU5YzllYTEwXzQtNi0xLTEtNTgzNzI_8e60968e-7774-48cc-93f5-9da0e3b484e7"
      unitRef="usd">2190000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNTEvZnJhZzoyNzE1YjlkZmFkYWQ0MzJmODM0NjNlNTc4MDU5NjVkNS90YWJsZTplNmRjNTY4MzJmZTU0MjZlODE2Nzg1Yzg1OWM5ZWExMC90YWJsZXJhbmdlOmU2ZGM1NjgzMmZlNTQyNmU4MTY3ODVjODU5YzllYTEwXzUtNC0xLTEtNTgzNzI_f13c2655-b757-4da1-a1af-9828a91c3a88"
      unitRef="usd">2596000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="id970dfd2674c4d6b895febb9c14d0fd1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNTEvZnJhZzoyNzE1YjlkZmFkYWQ0MzJmODM0NjNlNTc4MDU5NjVkNS90YWJsZTplNmRjNTY4MzJmZTU0MjZlODE2Nzg1Yzg1OWM5ZWExMC90YWJsZXJhbmdlOmU2ZGM1NjgzMmZlNTQyNmU4MTY3ODVjODU5YzllYTEwXzUtNi0xLTEtNTgzNzI_1de565a3-712a-4253-a748-c09bd094e4f7"
      unitRef="usd">4284000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNTEvZnJhZzoyNzE1YjlkZmFkYWQ0MzJmODM0NjNlNTc4MDU5NjVkNS90YWJsZTo5ZGQyYTVhZWVmYzY0OGE5OWE1YTRlMmE1ZTA0N2QyNC90YWJsZXJhbmdlOjlkZDJhNWFlZWZjNjQ4YTk5YTVhNGUyYTVlMDQ3ZDI0XzEtMi0xLTEtNTgzNzI_78e29987-7013-4253-813c-d2d46a471ac9">P2Y14D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNTEvZnJhZzoyNzE1YjlkZmFkYWQ0MzJmODM0NjNlNTc4MDU5NjVkNS90YWJsZTo5ZGQyYTVhZWVmYzY0OGE5OWE1YTRlMmE1ZTA0N2QyNC90YWJsZXJhbmdlOjlkZDJhNWFlZWZjNjQ4YTk5YTVhNGUyYTVlMDQ3ZDI0XzItMi0xLTEtNTgzNzI_cc3d1e85-9f0b-4a85-8363-72e1c8089fcb"
      unitRef="number">0.0524</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNTEvZnJhZzoyNzE1YjlkZmFkYWQ0MzJmODM0NjNlNTc4MDU5NjVkNS90ZXh0cmVnaW9uOjI3MTViOWRmYWRhZDQzMmY4MzQ2M2U1NzgwNTk2NWQ1XzI5Njc_ed589b59-18c9-4db8-b0bb-32b6b69bdd63">&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below reconciles the undiscounted future minimum lease payments (displayed in aggregate by year) under non-cancelable operating leases with terms of more than one year to the total operating lease liabilities recognized on the consolidated balance sheets as of December 31, 2022:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:80.478%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.592%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Total undiscounted future minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: difference between undiscounted lease payments and discounted operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,596&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNTEvZnJhZzoyNzE1YjlkZmFkYWQ0MzJmODM0NjNlNTc4MDU5NjVkNS90YWJsZTozY2UyYWE4NmJjNzA0YjZlOTllYWI5MGFiYzM5ZWQ3Ny90YWJsZXJhbmdlOjNjZTJhYTg2YmM3MDRiNmU5OWVhYjkwYWJjMzllZDc3XzEtMi0xLTEtNTgzNzI_d9fe76dc-d38d-42b9-bc5b-263e57491e8d"
      unitRef="usd">2153000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNTEvZnJhZzoyNzE1YjlkZmFkYWQ0MzJmODM0NjNlNTc4MDU5NjVkNS90YWJsZTozY2UyYWE4NmJjNzA0YjZlOTllYWI5MGFiYzM5ZWQ3Ny90YWJsZXJhbmdlOjNjZTJhYTg2YmM3MDRiNmU5OWVhYjkwYWJjMzllZDc3XzItMi0xLTEtNTgzNzI_87e5c745-83eb-4c25-b471-6f3a44f9c31a"
      unitRef="usd">548000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNTEvZnJhZzoyNzE1YjlkZmFkYWQ0MzJmODM0NjNlNTc4MDU5NjVkNS90YWJsZTozY2UyYWE4NmJjNzA0YjZlOTllYWI5MGFiYzM5ZWQ3Ny90YWJsZXJhbmdlOjNjZTJhYTg2YmM3MDRiNmU5OWVhYjkwYWJjMzllZDc3XzMtMi0xLTEtNTgzNzI_4f807406-7442-4149-8a16-00d6028f56df"
      unitRef="usd">82000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <optn:LesseeOperatingLeaseLiabilityPaymentsDueThereafter
      contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNTEvZnJhZzoyNzE1YjlkZmFkYWQ0MzJmODM0NjNlNTc4MDU5NjVkNS90YWJsZTozY2UyYWE4NmJjNzA0YjZlOTllYWI5MGFiYzM5ZWQ3Ny90YWJsZXJhbmdlOjNjZTJhYTg2YmM3MDRiNmU5OWVhYjkwYWJjMzllZDc3XzQtMi0xLTEtNTgzNzI_b8a887e0-439a-447c-acc8-3c6958e8589e"
      unitRef="usd">0</optn:LesseeOperatingLeaseLiabilityPaymentsDueThereafter>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNTEvZnJhZzoyNzE1YjlkZmFkYWQ0MzJmODM0NjNlNTc4MDU5NjVkNS90YWJsZTozY2UyYWE4NmJjNzA0YjZlOTllYWI5MGFiYzM5ZWQ3Ny90YWJsZXJhbmdlOjNjZTJhYTg2YmM3MDRiNmU5OWVhYjkwYWJjMzllZDc3XzUtMi0xLTEtNTgzNzI_3834103b-ca0b-4d4a-a204-89a76ded3afb"
      unitRef="usd">2783000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNTEvZnJhZzoyNzE1YjlkZmFkYWQ0MzJmODM0NjNlNTc4MDU5NjVkNS90YWJsZTozY2UyYWE4NmJjNzA0YjZlOTllYWI5MGFiYzM5ZWQ3Ny90YWJsZXJhbmdlOjNjZTJhYTg2YmM3MDRiNmU5OWVhYjkwYWJjMzllZDc3XzYtMi0xLTEtNTgzNzI_67495460-3f1b-4568-98b6-068659245465"
      unitRef="usd">187000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNTEvZnJhZzoyNzE1YjlkZmFkYWQ0MzJmODM0NjNlNTc4MDU5NjVkNS90YWJsZTozY2UyYWE4NmJjNzA0YjZlOTllYWI5MGFiYzM5ZWQ3Ny90YWJsZXJhbmdlOjNjZTJhYTg2YmM3MDRiNmU5OWVhYjkwYWJjMzllZDc3XzctMi0xLTEtNTgzNzI_468cd6bc-2577-43fd-a927-73ae13103c0f"
      unitRef="usd">2596000</us-gaap:OperatingLeaseLiability>
    <optn:OperatingLeaseCostForExtension
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNTEvZnJhZzoyNzE1YjlkZmFkYWQ0MzJmODM0NjNlNTc4MDU5NjVkNS90ZXh0cmVnaW9uOjI3MTViOWRmYWRhZDQzMmY4MzQ2M2U1NzgwNTk2NWQ1XzIzNzg_4375f90f-b815-4c6f-8586-0e7d2a35d13f"
      unitRef="usd">0</optn:OperatingLeaseCostForExtension>
    <us-gaap:LeaseCost
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNTEvZnJhZzoyNzE1YjlkZmFkYWQ0MzJmODM0NjNlNTc4MDU5NjVkNS90ZXh0cmVnaW9uOjI3MTViOWRmYWRhZDQzMmY4MzQ2M2U1NzgwNTk2NWQ1XzI1NDE_1a132c1a-2d0b-479f-9eeb-4121651e6214"
      unitRef="usd">2985000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNTEvZnJhZzoyNzE1YjlkZmFkYWQ0MzJmODM0NjNlNTc4MDU5NjVkNS90ZXh0cmVnaW9uOjI3MTViOWRmYWRhZDQzMmY4MzQ2M2U1NzgwNTk2NWQ1XzI1NDg_c5d2f81c-54d9-45fc-90de-17ed72c85bd6"
      unitRef="usd">2843000</us-gaap:LeaseCost>
    <us-gaap:OperatingLeasePayments
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNTEvZnJhZzoyNzE1YjlkZmFkYWQ0MzJmODM0NjNlNTc4MDU5NjVkNS90ZXh0cmVnaW9uOjI3MTViOWRmYWRhZDQzMmY4MzQ2M2U1NzgwNTk2NWQ1XzI4MTY_e5d89f19-09e4-4f4d-9673-f2ee69535de2"
      unitRef="usd">2570000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNTEvZnJhZzoyNzE1YjlkZmFkYWQ0MzJmODM0NjNlNTc4MDU5NjVkNS90ZXh0cmVnaW9uOjI3MTViOWRmYWRhZDQzMmY4MzQ2M2U1NzgwNTk2NWQ1XzI4MjM_dc6ef342-0d09-4423-a0fe-15e81bd911fb"
      unitRef="usd">2466000</us-gaap:OperatingLeasePayments>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNTcvZnJhZzoxN2I3ZmRiMGZlM2E0ZDlmYTVjYzA4ODU5NjVmNWI1Ni90ZXh0cmVnaW9uOjE3YjdmZGIwZmUzYTRkOWZhNWNjMDg4NTk2NWY1YjU2XzExNw_3efc7cf8-e8e2-40ba-84f0-5df30034f24c">Accrued Expenses and Other Current Liabilities&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses and other current liabilities consisted of:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.022%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.914%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued expenses:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Product revenue allowances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Selling, general and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,799&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Payroll expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,888&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,915&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,057&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;Total accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;42,893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;49,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other current liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Lease liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;Total other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;Total accrued expenses and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;44,864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;51,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNTcvZnJhZzoxN2I3ZmRiMGZlM2E0ZDlmYTVjYzA4ODU5NjVmNWI1Ni90ZXh0cmVnaW9uOjE3YjdmZGIwZmUzYTRkOWZhNWNjMDg4NTk2NWY1YjU2XzExOQ_72681ee3-8839-40a7-af95-56371272fa68">&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses and other current liabilities consisted of:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.022%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.914%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued expenses:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Product revenue allowances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Selling, general and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,799&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Payroll expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,888&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,915&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,057&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;Total accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;42,893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;49,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other current liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Lease liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;Total other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;Total accrued expenses and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;44,864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;51,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <optn:AccruedProductAllowancesCurrent
      contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNTcvZnJhZzoxN2I3ZmRiMGZlM2E0ZDlmYTVjYzA4ODU5NjVmNWI1Ni90YWJsZTphNTNhOTQxMjIxYjg0ODk3YjFmN2Y3NzJjYjNiODAzMC90YWJsZXJhbmdlOmE1M2E5NDEyMjFiODQ4OTdiMWY3Zjc3MmNiM2I4MDMwXzMtMS0xLTEtNTgzNzI_ecb823f0-c845-4199-be38-25d1ffcbe827"
      unitRef="usd">27993000</optn:AccruedProductAllowancesCurrent>
    <optn:AccruedProductAllowancesCurrent
      contextRef="id970dfd2674c4d6b895febb9c14d0fd1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNTcvZnJhZzoxN2I3ZmRiMGZlM2E0ZDlmYTVjYzA4ODU5NjVmNWI1Ni90YWJsZTphNTNhOTQxMjIxYjg0ODk3YjFmN2Y3NzJjYjNiODAzMC90YWJsZXJhbmdlOmE1M2E5NDEyMjFiODQ4OTdiMWY3Zjc3MmNiM2I4MDMwXzMtMy0xLTEtNTgzNzI_f65f7ca1-cf47-4eb5-9eed-4abb82f457b1"
      unitRef="usd">26521000</optn:AccruedProductAllowancesCurrent>
    <optn:AccruedSellingGeneralandAdministrativeCurrent
      contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNTcvZnJhZzoxN2I3ZmRiMGZlM2E0ZDlmYTVjYzA4ODU5NjVmNWI1Ni90YWJsZTphNTNhOTQxMjIxYjg0ODk3YjFmN2Y3NzJjYjNiODAzMC90YWJsZXJhbmdlOmE1M2E5NDEyMjFiODQ4OTdiMWY3Zjc3MmNiM2I4MDMwXzQtMS0xLTEtNTgzNzI_db268b25-c291-4556-803e-8fb66eaa4ae2"
      unitRef="usd">3799000</optn:AccruedSellingGeneralandAdministrativeCurrent>
    <optn:AccruedSellingGeneralandAdministrativeCurrent
      contextRef="id970dfd2674c4d6b895febb9c14d0fd1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNTcvZnJhZzoxN2I3ZmRiMGZlM2E0ZDlmYTVjYzA4ODU5NjVmNWI1Ni90YWJsZTphNTNhOTQxMjIxYjg0ODk3YjFmN2Y3NzJjYjNiODAzMC90YWJsZXJhbmdlOmE1M2E5NDEyMjFiODQ4OTdiMWY3Zjc3MmNiM2I4MDMwXzQtMy0xLTEtNTgzNzI_c0ba9b2b-3835-41b7-a034-8a8fed28308e"
      unitRef="usd">6124000</optn:AccruedSellingGeneralandAdministrativeCurrent>
    <optn:AccruedResearchandDevelopmentCurrent
      contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNTcvZnJhZzoxN2I3ZmRiMGZlM2E0ZDlmYTVjYzA4ODU5NjVmNWI1Ni90YWJsZTphNTNhOTQxMjIxYjg0ODk3YjFmN2Y3NzJjYjNiODAzMC90YWJsZXJhbmdlOmE1M2E5NDEyMjFiODQ4OTdiMWY3Zjc3MmNiM2I4MDMwXzUtMS0xLTEtNTgzNzI_28a0d79b-5492-49dc-a541-525d67785f67"
      unitRef="usd">1298000</optn:AccruedResearchandDevelopmentCurrent>
    <optn:AccruedResearchandDevelopmentCurrent
      contextRef="id970dfd2674c4d6b895febb9c14d0fd1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNTcvZnJhZzoxN2I3ZmRiMGZlM2E0ZDlmYTVjYzA4ODU5NjVmNWI1Ni90YWJsZTphNTNhOTQxMjIxYjg0ODk3YjFmN2Y3NzJjYjNiODAzMC90YWJsZXJhbmdlOmE1M2E5NDEyMjFiODQ4OTdiMWY3Zjc3MmNiM2I4MDMwXzUtMy0xLTEtNTgzNzI_c1d68098-fd82-41aa-a35f-060af3d61e95"
      unitRef="usd">6857000</optn:AccruedResearchandDevelopmentCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNTcvZnJhZzoxN2I3ZmRiMGZlM2E0ZDlmYTVjYzA4ODU5NjVmNWI1Ni90YWJsZTphNTNhOTQxMjIxYjg0ODk3YjFmN2Y3NzJjYjNiODAzMC90YWJsZXJhbmdlOmE1M2E5NDEyMjFiODQ4OTdiMWY3Zjc3MmNiM2I4MDMwXzYtMS0xLTEtNTgzNzI_637e4872-bd90-4bfd-b8bd-4fc825f2b519"
      unitRef="usd">7888000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="id970dfd2674c4d6b895febb9c14d0fd1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNTcvZnJhZzoxN2I3ZmRiMGZlM2E0ZDlmYTVjYzA4ODU5NjVmNWI1Ni90YWJsZTphNTNhOTQxMjIxYjg0ODk3YjFmN2Y3NzJjYjNiODAzMC90YWJsZXJhbmdlOmE1M2E5NDEyMjFiODQ4OTdiMWY3Zjc3MmNiM2I4MDMwXzYtMy0xLTEtNTgzNzI_9ab24173-bbbc-4bd2-8683-6e340aca45ae"
      unitRef="usd">7569000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNTcvZnJhZzoxN2I3ZmRiMGZlM2E0ZDlmYTVjYzA4ODU5NjVmNWI1Ni90YWJsZTphNTNhOTQxMjIxYjg0ODk3YjFmN2Y3NzJjYjNiODAzMC90YWJsZXJhbmdlOmE1M2E5NDEyMjFiODQ4OTdiMWY3Zjc3MmNiM2I4MDMwXzctMS0xLTEtNTgzNzI_fe777c0a-57e6-4fce-98b6-85b57c0cad39"
      unitRef="usd">1915000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="id970dfd2674c4d6b895febb9c14d0fd1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNTcvZnJhZzoxN2I3ZmRiMGZlM2E0ZDlmYTVjYzA4ODU5NjVmNWI1Ni90YWJsZTphNTNhOTQxMjIxYjg0ODk3YjFmN2Y3NzJjYjNiODAzMC90YWJsZXJhbmdlOmE1M2E5NDEyMjFiODQ4OTdiMWY3Zjc3MmNiM2I4MDMwXzctMy0xLTEtNTgzNzI_eb38846a-4d16-4320-986e-8b1e49396ae9"
      unitRef="usd">2057000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNTcvZnJhZzoxN2I3ZmRiMGZlM2E0ZDlmYTVjYzA4ODU5NjVmNWI1Ni90YWJsZTphNTNhOTQxMjIxYjg0ODk3YjFmN2Y3NzJjYjNiODAzMC90YWJsZXJhbmdlOmE1M2E5NDEyMjFiODQ4OTdiMWY3Zjc3MmNiM2I4MDMwXzgtMS0xLTEtNTgzNzI_138c1823-1e3f-4905-941a-692b955809e6"
      unitRef="usd">42893000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="id970dfd2674c4d6b895febb9c14d0fd1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNTcvZnJhZzoxN2I3ZmRiMGZlM2E0ZDlmYTVjYzA4ODU5NjVmNWI1Ni90YWJsZTphNTNhOTQxMjIxYjg0ODk3YjFmN2Y3NzJjYjNiODAzMC90YWJsZXJhbmdlOmE1M2E5NDEyMjFiODQ4OTdiMWY3Zjc3MmNiM2I4MDMwXzgtMy0xLTEtNTgzNzI_02ebca83-f6f1-4667-b191-32404bf15691"
      unitRef="usd">49128000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNTcvZnJhZzoxN2I3ZmRiMGZlM2E0ZDlmYTVjYzA4ODU5NjVmNWI1Ni90YWJsZTphNTNhOTQxMjIxYjg0ODk3YjFmN2Y3NzJjYjNiODAzMC90YWJsZXJhbmdlOmE1M2E5NDEyMjFiODQ4OTdiMWY3Zjc3MmNiM2I4MDMwXzEwLTEtMS0xLTU4Mzcy_1b4bee0f-e598-4fdb-9701-26890475605a"
      unitRef="usd">1971000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="id970dfd2674c4d6b895febb9c14d0fd1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNTcvZnJhZzoxN2I3ZmRiMGZlM2E0ZDlmYTVjYzA4ODU5NjVmNWI1Ni90YWJsZTphNTNhOTQxMjIxYjg0ODk3YjFmN2Y3NzJjYjNiODAzMC90YWJsZXJhbmdlOmE1M2E5NDEyMjFiODQ4OTdiMWY3Zjc3MmNiM2I4MDMwXzEwLTMtMS0xLTU4Mzcy_c9719e03-4359-47f4-ad16-f21a0e521642"
      unitRef="usd">2094000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNTcvZnJhZzoxN2I3ZmRiMGZlM2E0ZDlmYTVjYzA4ODU5NjVmNWI1Ni90YWJsZTphNTNhOTQxMjIxYjg0ODk3YjFmN2Y3NzJjYjNiODAzMC90YWJsZXJhbmdlOmE1M2E5NDEyMjFiODQ4OTdiMWY3Zjc3MmNiM2I4MDMwXzExLTEtMS0xLTU4Mzcy_d041681f-f6fc-4dab-af9b-f8eae869bb30"
      unitRef="usd">1971000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="id970dfd2674c4d6b895febb9c14d0fd1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNTcvZnJhZzoxN2I3ZmRiMGZlM2E0ZDlmYTVjYzA4ODU5NjVmNWI1Ni90YWJsZTphNTNhOTQxMjIxYjg0ODk3YjFmN2Y3NzJjYjNiODAzMC90YWJsZXJhbmdlOmE1M2E5NDEyMjFiODQ4OTdiMWY3Zjc3MmNiM2I4MDMwXzExLTMtMS0xLTU4Mzcy_f9db6424-2a01-47c9-8e17-d9a16b45fcf3"
      unitRef="usd">2094000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent
      contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNTcvZnJhZzoxN2I3ZmRiMGZlM2E0ZDlmYTVjYzA4ODU5NjVmNWI1Ni90YWJsZTphNTNhOTQxMjIxYjg0ODk3YjFmN2Y3NzJjYjNiODAzMC90YWJsZXJhbmdlOmE1M2E5NDEyMjFiODQ4OTdiMWY3Zjc3MmNiM2I4MDMwXzEyLTEtMS0xLTU4Mzcy_90726ddd-3d74-4de8-b97b-73d94c573d60"
      unitRef="usd">44864000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent
      contextRef="id970dfd2674c4d6b895febb9c14d0fd1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNTcvZnJhZzoxN2I3ZmRiMGZlM2E0ZDlmYTVjYzA4ODU5NjVmNWI1Ni90YWJsZTphNTNhOTQxMjIxYjg0ODk3YjFmN2Y3NzJjYjNiODAzMC90YWJsZXJhbmdlOmE1M2E5NDEyMjFiODQ4OTdiMWY3Zjc3MmNiM2I4MDMwXzEyLTMtMS0xLTU4Mzcy_b347b14a-47ca-4cba-81c4-2e41d03ecf04"
      unitRef="usd">51222000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNjAvZnJhZzozOWY1MDRmNjYzMjk0MWYyYmNhZWY0MGVjNjE0MjE5NC90ZXh0cmVnaW9uOjM5ZjUwNGY2NjMyOTQxZjJiY2FlZjQwZWM2MTQyMTk0XzIzOTY_b9be10b5-7916-4b56-a768-d43f383261f4">License Agreements&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Currax License Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 25, 2019, OptiNose AS entered into a license agreement (the Currax License Agreement) with Currax pursuant to which the Company granted Currax an exclusive license to certain intellectual property for the commercialization of Onzetra Xsail in the US, Canada and Mexico.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2021, a specified regulatory milestone was met and the Company received a $1,000 milestone payment. The Company does not expect to receive any further payments from Currax under the terms of the License Agreement other than reimbursement for certain expenses.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock>
    <optn:ResearchAndDevelopmentArrangementContractToPerformForOthersMilestonePaymentsMaximumEligible
      contextRef="i5fd2ee54427b485b93f8b56d2a73b716_D20210101-20210131"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNjAvZnJhZzozOWY1MDRmNjYzMjk0MWYyYmNhZWY0MGVjNjE0MjE5NC90ZXh0cmVnaW9uOjM5ZjUwNGY2NjMyOTQxZjJiY2FlZjQwZWM2MTQyMTk0Xzc4Mg_2cd48ba5-9990-4c1f-b34f-875d380e75dd"
      unitRef="usd">1000000</optn:ResearchAndDevelopmentArrangementContractToPerformForOthersMilestonePaymentsMaximumEligible>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNjMvZnJhZzo2MDhmMjg1NzYwMTY0NDM2OGExYTY4NmEyNjgwZGYyYi90ZXh0cmVnaW9uOjYwOGYyODU3NjAxNjQ0MzY4YTFhNjg2YTI2ODBkZjJiXzY3NzE_f50530b3-4d68-42c5-9b25-f918bcef11e9">Debt, net&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 12, 2019 (the Closing Date), the Company entered into a Note Purchase Agreement with funds managed by Pharmakon Advisors, LP (Pharmakon), the investment manager of BioPharma Credit Funds (BioPharma). The Note Purchase Agreement provided the Company with $130,000 in debt financing, of which $80,000 of senior secured notes (the Pharmakon Senior Secured Notes) was issued on the Closing Date, $30,000 was issued on February 13, 2020 after achieving the $9,000 consolidated XHANCE net sales and royalties threshold for the quarter ended December 31, 2019 and $20,000 was issued on December 1, 2020 after achieving the $14,500 consolidated XHANCE net sales and royalties threshold for the quarter ended September 30, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 10, 2022, the Company entered into a Third Amendment to the Note Purchase Agreement (the Third Amendment).  The Third Amendment reduced the minimum c&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;onsolidated XHANCE net sales and royalties required to be achieved under the Note Purchase Agreement for the trailing twelve-month period ending December 31, 2022 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;from $90,000 to $85,000 in exchange for a $780 fee due on the repayment of the Pharmakon Senior Secured Notes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 9, 2022, the Company entered into a Fourth Amendment to the Note Purchase Agreement (the Fourth Amendment).  The Fourth Amendment resulted in the waiver of the minimum consolidated XHANCE net sales and royalties required to be achieved under the Note Purchase Agreement for the trailing twelve-month period ending September 30, 2022 and December 31, 2022 in exchange for a $1,300 fee due upon repayment of the Pharmakon Senior Secured Notes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;On November 23, 2022, the Company amended and restated the Note Purchase Agreement, initially entered into on September 12, 2019 and amended through November 9, 2022, among the Company, its subsidiaries, OptiNose US, Inc., OptiNose AS and OptiNose UK, Ltd. and BioPharma Credit PLC, as collateral agent, and the purchasers party thereto from time to time (the A&amp;amp;R Note Purchase Agreement). Pursuant to the A&amp;amp;R Note Purchase Agreement, certain modifications to the affirmative and negative covenants, events of default and other provisions were made, including, without limitation, (i) the requirement for the Company to deliver quarterly and annual financial statements that, commencing with the Company's consolidated financial statements for the year ending December 31, 2023, are not subject to a &#x201c;going concern&#x201d; statement (the Going Concern Covenant) and (ii) the removal of certain exceptions to the negative covenants which previously permitted the Company to enter into certain transactions without the consent of the holders of the Pharmakon Senior Secured Notes, including permitted acquisitions, swap contracts, convertible bonds and revolving credit facilities. The financial covenants requiring the Company to achieve minimum trailing twelve-month consolidated XHANCE net product sales and royalties were also modified as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.723%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.455%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.332%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.332%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.728%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Trailing Twelve-Months Ending&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Requirement Prior to A&amp;amp;R Note Purchase Agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Requirement under the A&amp;amp;R Note Purchase Agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$98,750&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102,500&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106,250&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113,750&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$82,500&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,500&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102,500&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;March 31, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;June 30, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;140,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;September 30, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;December 31, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;March 31, 2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;155,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;June 30, 2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;September 30, 2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;165,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The A&amp;amp;R Note Purchase Agreement provided for an extension of the maturity date of the Pharmakon Senior Secured Notes from September 12, 2024 to June 30, 2027 (New Maturity Date), an extension of the interest-only period from September 2023 to September 2025, after which principal repayments will commence starting on September 30, 2025 and will be made in eight equal quarterly installments of principal and interest through the New Maturity Date. As part of the A&amp;amp;R Note Purchase Agreement the Pharmakon Senior Secured Notes will now bear an amended interest rate through the New Maturity Date equal to the 3-month Secured Overnight Financing Rate (subject to a 2.50% floor), determined as of the date that is two business days prior to the commencement of each quarter, plus 8.50% per annum (effective rate of 13.62% at December 31, 2022), which interest rate shall be increased by an additional 3.00% per annum upon the occurrence and during the continuation of any event of default. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In conjunction with the A&amp;amp;R Note Purchase Agreement, a modification was made to the &#x201c;make-whole&#x201d; premium payment due in connection with any principal prepayments (whether mandatory or voluntary) made prior to the 3-year anniversary of the date of the A&amp;amp;R Note Purchase Agreement. On any such prepayment date, the Company will be required to pay a make-whole premium in the amount of (i) for any prepayment date occurring up until and including the 18-month anniversary of the date of the A&amp;amp;R Note Purchase Agreement, the foregone interest from such prepayment date through the 18-month anniversary of such prepayment date; and (ii) for any prepayment after the 18-month anniversary of the date of the A&amp;amp;R Note Purchase Agreement, the foregone interest from such prepayment date through the 3-year anniversary of the date of the A&amp;amp;R Note Purchase Agreement; provided, however, that in no event shall the amount of all make-whole premium payments exceed $24,000 in the aggregate; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;As an inducement for the holders of the Pharmakon Senior Secured Notes to enter into the A&amp;amp;R Note Purchase Agreement, the Company is required to pay the holders of the Pharmakon Senior Secured Notes an amendment fee of $3,900 (representing 3.00% of the outstanding principal balance of such notes) due on the New Maturity Date or the earlier repayment of the Pharmakon Senior Secured Notes, which amendment fee shall be (i) reduced to $1,300 in the event that the Company repays the Pharmakon Senior Secured Notes in full prior to the one-year anniversary of the date of the A&amp;amp;R Note Purchase Agreement and (ii) reduced to $2,600 in the event that the Company repays the Pharmakon Senior Secured Notes in full on or after the one-year anniversary of the date of the A&amp;amp;R Note Purchase Agreement and prior to second anniversary of the date of the A&amp;amp;R Note Purchase Agreement. Additionally, the $1,300 fee payable under the Fourth Amendment to the Note Purchase Agreement that the Company entered into on November 9, 2022 will be credited against the amendment fee payable in connection with the A&amp;amp;R Note Purchase Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Pharmakon Senior Secured Notes are secured by a pledge of substantially all of the assets of the Company and the Guarantors and the A&amp;amp;R Note Purchase Agreement contains affirmative and negative covenants customary for financings of this type, including limitations on the Company&#x2019;s and its subsidiaries&#x2019; ability, among other things, to incur additional debt, grant or permit additional liens, make investments and acquisitions, merge or consolidate with others, dispose of assets, pay dividends and distributions, repay junior indebtedness, incur a material adverse change and enter into affiliate transactions, in each case, subject to certain exceptions. In addition, the A&amp;amp;R Note Purchase Agreement contains financial covenants requiring the Company to maintain certain minimum trailing twelve-month consolidated XHANCE net sales and royalties, tested on a quarterly basis as noted in the table above, and to have at least $30,000 of cash and cash equivalents at all times. The A&amp;amp;R Note Purchase Agreement also includes events of default customary for financings of this type, in certain cases subject to customary periods to cure, following which BioPharma may accelerate all amounts outstanding under the Pharmakon Senior Secured Notes.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company believes that it is probable that it will not achieve the trailing twelve-month minimum consolidated XHANCE net sales and royalties thresholds that it is required to achieve commencing with the period ending March 31, 2024.  Additionally, without additional capital, the Company believes that it is probable that it will not be able to maintain at least $30,000 of cash and cash equivalents for at least twelve-months following the filing of this Form 10-K. In addition, the Company believes that it is unlikely that it will be able to maintain compliance with the Going Concern Covenant in 2024.  As a result, in accordance with FASB Accounting Standards Codification 470, the Company has classified all outstanding principal and the payment of additional fees upon maturity as a current liability in the accompanying consolidated balance sheet as of December 31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded interest expense of $16,843 and $15,973 during the years ended December 31, 2022 and 2021, respectively. Interest expense included total coupon interest and the amortization of debt issuance costs. &lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The debt balance is comprised of the following:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.206%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.588%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.117%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.589%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Face amount&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;130,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;130,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Front end fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(666)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(717)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6,739)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4,165)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Back end fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Debt, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;128,575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;126,418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i62f6f90c47544ada9c32250b077bb99b_I20190912"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNjMvZnJhZzo2MDhmMjg1NzYwMTY0NDM2OGExYTY4NmEyNjgwZGYyYi90ZXh0cmVnaW9uOjYwOGYyODU3NjAxNjQ0MzY4YTFhNjg2YTI2ODBkZjJiXzIxOTkwMjMyODY5NjI_680237c7-1eb9-41ec-bca3-58a71f39d6cc"
      unitRef="usd">130000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i62f6f90c47544ada9c32250b077bb99b_I20190912"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNjMvZnJhZzo2MDhmMjg1NzYwMTY0NDM2OGExYTY4NmEyNjgwZGYyYi90ZXh0cmVnaW9uOjYwOGYyODU3NjAxNjQ0MzY4YTFhNjg2YTI2ODBkZjJiXzIxOTkwMjMyODQwNzM_e9444fee-7295-4ac8-ab07-b2615790f30f"
      unitRef="usd">80000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i047f781d92bd40e5b05937913709530f_I20200213"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNjMvZnJhZzo2MDhmMjg1NzYwMTY0NDM2OGExYTY4NmEyNjgwZGYyYi90ZXh0cmVnaW9uOjYwOGYyODU3NjAxNjQ0MzY4YTFhNjg2YTI2ODBkZjJiXzIxOTkwMjMyODQwNzc_aa0e820c-025f-4c18-b86b-30796bfb1d00"
      unitRef="usd">30000000</us-gaap:DebtInstrumentFaceAmount>
    <optn:DebtInstrumentIssuanceCriteriaTermNetSalesAndRoyaltiesBenchmark
      contextRef="i2dd470baef924f409cb50332bb1d158a_D20191001-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNjMvZnJhZzo2MDhmMjg1NzYwMTY0NDM2OGExYTY4NmEyNjgwZGYyYi90ZXh0cmVnaW9uOjYwOGYyODU3NjAxNjQ0MzY4YTFhNjg2YTI2ODBkZjJiXzIxOTkwMjMyODQwODU_2c49136f-bc59-4444-a597-d06ca2dbc22e"
      unitRef="usd">9000000</optn:DebtInstrumentIssuanceCriteriaTermNetSalesAndRoyaltiesBenchmark>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i2c43759aacc744b2ab7dc2cf4563d669_I20201201"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNjMvZnJhZzo2MDhmMjg1NzYwMTY0NDM2OGExYTY4NmEyNjgwZGYyYi90ZXh0cmVnaW9uOjYwOGYyODU3NjAxNjQ0MzY4YTFhNjg2YTI2ODBkZjJiXzIxOTkwMjMyODQwODE_f5747d37-129a-4778-9167-2e83797beceb"
      unitRef="usd">20000000</us-gaap:DebtInstrumentFaceAmount>
    <optn:DebtInstrumentIssuanceCriteriaTermNetSalesAndRoyaltiesBenchmark
      contextRef="ib972721f09ce4ecca02118dff9ab3a54_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNjMvZnJhZzo2MDhmMjg1NzYwMTY0NDM2OGExYTY4NmEyNjgwZGYyYi90ZXh0cmVnaW9uOjYwOGYyODU3NjAxNjQ0MzY4YTFhNjg2YTI2ODBkZjJiXzIxOTkwMjMyODQwODk_fa8b5fe5-189a-4e94-903f-da9dfedeadd1"
      unitRef="usd">14500000</optn:DebtInstrumentIssuanceCriteriaTermNetSalesAndRoyaltiesBenchmark>
    <optn:TrailingTwelveMonthNetRevenueCovenant
      contextRef="ic1354dd9142c4406bb996b9f79066753_I20220809"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNjMvZnJhZzo2MDhmMjg1NzYwMTY0NDM2OGExYTY4NmEyNjgwZGYyYi90ZXh0cmVnaW9uOjYwOGYyODU3NjAxNjQ0MzY4YTFhNjg2YTI2ODBkZjJiXzIxOTkwMjMyODQxNDU_1913a767-539a-46ac-88eb-c28f12ede5e0"
      unitRef="usd">90000000</optn:TrailingTwelveMonthNetRevenueCovenant>
    <optn:TrailingTwelveMonthNetRevenueCovenant
      contextRef="i0ae63187f7984cadbfb811136622697c_I20220810"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNjMvZnJhZzo2MDhmMjg1NzYwMTY0NDM2OGExYTY4NmEyNjgwZGYyYi90ZXh0cmVnaW9uOjYwOGYyODU3NjAxNjQ0MzY4YTFhNjg2YTI2ODBkZjJiXzIxOTkwMjMyODQxMTc_77107892-8531-4981-9765-b9cf2e7c4982"
      unitRef="usd">85000000</optn:TrailingTwelveMonthNetRevenueCovenant>
    <optn:FeeDueOnTheMaturityDateOfTheNotePurchaseAgreement
      contextRef="ib61af200b06045878d1f67070415e25a_I20220810"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNjMvZnJhZzo2MDhmMjg1NzYwMTY0NDM2OGExYTY4NmEyNjgwZGYyYi90ZXh0cmVnaW9uOjYwOGYyODU3NjAxNjQ0MzY4YTFhNjg2YTI2ODBkZjJiXzIxOTkwMjMyODQxMjk_a48fca13-717a-4723-8fe9-db9cb7ca4650"
      unitRef="usd">780000</optn:FeeDueOnTheMaturityDateOfTheNotePurchaseAgreement>
    <optn:FeeDueOnTheMaturityDateOfTheNotePurchaseAgreement
      contextRef="iaf72692f99ed46b5a83cb937a4981bae_I20221109"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNjMvZnJhZzo2MDhmMjg1NzYwMTY0NDM2OGExYTY4NmEyNjgwZGYyYi90ZXh0cmVnaW9uOjYwOGYyODU3NjAxNjQ0MzY4YTFhNjg2YTI2ODBkZjJiXzIxOTkwMjMyODQxMzc_b6f20e8d-edae-4c66-92ae-dfa8e31f7985"
      unitRef="usd">1300000</optn:FeeDueOnTheMaturityDateOfTheNotePurchaseAgreement>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNjMvZnJhZzo2MDhmMjg1NzYwMTY0NDM2OGExYTY4NmEyNjgwZGYyYi90ZXh0cmVnaW9uOjYwOGYyODU3NjAxNjQ0MzY4YTFhNjg2YTI2ODBkZjJiXzQ5NDc4MDIzNDUzNDE_2971321d-c8f5-411b-9db5-004274fbe35a">Pursuant to the A&amp;amp;R Note Purchase Agreement, certain modifications to the affirmative and negative covenants, events of default and other provisions were made, including, without limitation, (i) the requirement for the Company to deliver quarterly and annual financial statements that, commencing with the Company's consolidated financial statements for the year ending December 31, 2023, are not subject to a &#x201c;going concern&#x201d; statement (the Going Concern Covenant) and (ii) the removal of certain exceptions to the negative covenants which previously permitted the Company to enter into certain transactions without the consent of the holders of the Pharmakon Senior Secured Notes, including permitted acquisitions, swap contracts, convertible bonds and revolving credit facilities. The financial covenants requiring the Company to achieve minimum trailing twelve-month consolidated XHANCE net product sales and royalties were also modified as follows (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.723%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.455%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.332%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.332%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.728%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Trailing Twelve-Months Ending&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Requirement Prior to A&amp;amp;R Note Purchase Agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Requirement under the A&amp;amp;R Note Purchase Agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$98,750&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102,500&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106,250&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113,750&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$82,500&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,500&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102,500&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;March 31, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;June 30, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;140,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;September 30, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;December 31, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;March 31, 2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;155,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;June 30, 2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;September 30, 2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;165,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The debt balance is comprised of the following:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.206%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.588%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.117%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.589%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Face amount&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;130,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;130,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Front end fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(666)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(717)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6,739)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4,165)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Back end fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Debt, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;128,575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;126,418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <optn:NotePurchaseAgreementCovenantXHANCENetProductSalesAndRoyalties
      contextRef="i96634d78ca80401db240ea2a9de1645e_I20221120"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNjMvZnJhZzo2MDhmMjg1NzYwMTY0NDM2OGExYTY4NmEyNjgwZGYyYi90YWJsZTphN2FkMTY1NWFlOWY0ZGE0Yjc5YWFhOTkyM2ZjOTFhYi90YWJsZXJhbmdlOmE3YWQxNjU1YWU5ZjRkYTRiNzlhYWE5OTIzZmM5MWFiXzQtMi0xLTEtOTk4ODk_1f481ffa-80bc-4e65-bb5d-a222e83f1f8a"
      unitRef="usd">98750000</optn:NotePurchaseAgreementCovenantXHANCENetProductSalesAndRoyalties>
    <optn:NotePurchaseAgreementCovenantXHANCENetProductSalesAndRoyalties
      contextRef="i50b0b50bbf134c7f97db3df38c151093_I20221120"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNjMvZnJhZzo2MDhmMjg1NzYwMTY0NDM2OGExYTY4NmEyNjgwZGYyYi90YWJsZTphN2FkMTY1NWFlOWY0ZGE0Yjc5YWFhOTkyM2ZjOTFhYi90YWJsZXJhbmdlOmE3YWQxNjU1YWU5ZjRkYTRiNzlhYWE5OTIzZmM5MWFiXzUtMi0xLTEtOTk4ODk_e66ae27e-c264-40f1-9744-488e0f08af4a"
      unitRef="usd">102500000</optn:NotePurchaseAgreementCovenantXHANCENetProductSalesAndRoyalties>
    <optn:NotePurchaseAgreementCovenantXHANCENetProductSalesAndRoyalties
      contextRef="i2d657bd081aa4998b54cb136b25d210a_I20221120"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNjMvZnJhZzo2MDhmMjg1NzYwMTY0NDM2OGExYTY4NmEyNjgwZGYyYi90YWJsZTphN2FkMTY1NWFlOWY0ZGE0Yjc5YWFhOTkyM2ZjOTFhYi90YWJsZXJhbmdlOmE3YWQxNjU1YWU5ZjRkYTRiNzlhYWE5OTIzZmM5MWFiXzYtMi0xLTEtOTk4ODk_5b9040a9-5427-4106-8f2e-a4fe60946aed"
      unitRef="usd">106250000</optn:NotePurchaseAgreementCovenantXHANCENetProductSalesAndRoyalties>
    <optn:NotePurchaseAgreementCovenantXHANCENetProductSalesAndRoyalties
      contextRef="ie07879a277ed48fc8b5450fd9f7f1ad9_I20221120"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNjMvZnJhZzo2MDhmMjg1NzYwMTY0NDM2OGExYTY4NmEyNjgwZGYyYi90YWJsZTphN2FkMTY1NWFlOWY0ZGE0Yjc5YWFhOTkyM2ZjOTFhYi90YWJsZXJhbmdlOmE3YWQxNjU1YWU5ZjRkYTRiNzlhYWE5OTIzZmM5MWFiXzctMi0xLTEtOTk4ODk_8d06964d-afbe-48b2-80b2-87c993fffea1"
      unitRef="usd">110000000</optn:NotePurchaseAgreementCovenantXHANCENetProductSalesAndRoyalties>
    <optn:NotePurchaseAgreementCovenantXHANCENetProductSalesAndRoyalties
      contextRef="ib294e78ab7cc4fb7b0a4c74b9ced9b5f_I20221120"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNjMvZnJhZzo2MDhmMjg1NzYwMTY0NDM2OGExYTY4NmEyNjgwZGYyYi90YWJsZTphN2FkMTY1NWFlOWY0ZGE0Yjc5YWFhOTkyM2ZjOTFhYi90YWJsZXJhbmdlOmE3YWQxNjU1YWU5ZjRkYTRiNzlhYWE5OTIzZmM5MWFiXzgtMi0xLTEtOTk4ODk_c0df1fbb-5c16-4d40-a120-2d6efddf7b1f"
      unitRef="usd">113750000</optn:NotePurchaseAgreementCovenantXHANCENetProductSalesAndRoyalties>
    <optn:NotePurchaseAgreementCovenantXHANCENetProductSalesAndRoyalties
      contextRef="iebab32ba35ab45b7950eabc69c4f19f4_I20221121"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNjMvZnJhZzo2MDhmMjg1NzYwMTY0NDM2OGExYTY4NmEyNjgwZGYyYi90YWJsZTphN2FkMTY1NWFlOWY0ZGE0Yjc5YWFhOTkyM2ZjOTFhYi90YWJsZXJhbmdlOmE3YWQxNjU1YWU5ZjRkYTRiNzlhYWE5OTIzZmM5MWFiXzgtNC0xLTEtOTk4OTE_cfb36eda-9fbe-4cbd-a658-d82e021a1b61"
      unitRef="usd">82500000</optn:NotePurchaseAgreementCovenantXHANCENetProductSalesAndRoyalties>
    <optn:NotePurchaseAgreementCovenantXHANCENetProductSalesAndRoyalties
      contextRef="ia42f4722c6ea4c0ba9424cbb5b7db442_I20221120"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNjMvZnJhZzo2MDhmMjg1NzYwMTY0NDM2OGExYTY4NmEyNjgwZGYyYi90YWJsZTphN2FkMTY1NWFlOWY0ZGE0Yjc5YWFhOTkyM2ZjOTFhYi90YWJsZXJhbmdlOmE3YWQxNjU1YWU5ZjRkYTRiNzlhYWE5OTIzZmM5MWFiXzktMi0xLTEtOTk4ODk_dcf87d0a-e17f-4550-9830-3aa222cdfde8"
      unitRef="usd">117500000</optn:NotePurchaseAgreementCovenantXHANCENetProductSalesAndRoyalties>
    <optn:NotePurchaseAgreementCovenantXHANCENetProductSalesAndRoyalties
      contextRef="ied0332f696c74d02b9bca94cd69b5f71_I20221121"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNjMvZnJhZzo2MDhmMjg1NzYwMTY0NDM2OGExYTY4NmEyNjgwZGYyYi90YWJsZTphN2FkMTY1NWFlOWY0ZGE0Yjc5YWFhOTkyM2ZjOTFhYi90YWJsZXJhbmdlOmE3YWQxNjU1YWU5ZjRkYTRiNzlhYWE5OTIzZmM5MWFiXzktNC0xLTEtOTk4OTE_30f85e1a-5494-4cf3-886e-f4768a521415"
      unitRef="usd">90000000</optn:NotePurchaseAgreementCovenantXHANCENetProductSalesAndRoyalties>
    <optn:NotePurchaseAgreementCovenantXHANCENetProductSalesAndRoyalties
      contextRef="ie0d86211c30f4dcc99c47c2ccac871ce_I20221121"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNjMvZnJhZzo2MDhmMjg1NzYwMTY0NDM2OGExYTY4NmEyNjgwZGYyYi90YWJsZTphN2FkMTY1NWFlOWY0ZGE0Yjc5YWFhOTkyM2ZjOTFhYi90YWJsZXJhbmdlOmE3YWQxNjU1YWU5ZjRkYTRiNzlhYWE5OTIzZmM5MWFiXzEwLTQtMS0xLTk5ODkx_d2f34158-dd16-49af-81d1-5aaf7017f67b"
      unitRef="usd">102500000</optn:NotePurchaseAgreementCovenantXHANCENetProductSalesAndRoyalties>
    <optn:NotePurchaseAgreementCovenantXHANCENetProductSalesAndRoyalties
      contextRef="i33d3c0e47ba74ff5a8b749a97af8db65_I20221121"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNjMvZnJhZzo2MDhmMjg1NzYwMTY0NDM2OGExYTY4NmEyNjgwZGYyYi90YWJsZTphN2FkMTY1NWFlOWY0ZGE0Yjc5YWFhOTkyM2ZjOTFhYi90YWJsZXJhbmdlOmE3YWQxNjU1YWU5ZjRkYTRiNzlhYWE5OTIzZmM5MWFiXzExLTQtMS0xLTk5ODkx_acc45d1c-6ccf-4e6a-816b-b03231396f14"
      unitRef="usd">110000000</optn:NotePurchaseAgreementCovenantXHANCENetProductSalesAndRoyalties>
    <optn:NotePurchaseAgreementCovenantXHANCENetProductSalesAndRoyalties
      contextRef="i9044805836a742b1ad16a4f9886ba9a4_I20221121"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNjMvZnJhZzo2MDhmMjg1NzYwMTY0NDM2OGExYTY4NmEyNjgwZGYyYi90YWJsZTphN2FkMTY1NWFlOWY0ZGE0Yjc5YWFhOTkyM2ZjOTFhYi90YWJsZXJhbmdlOmE3YWQxNjU1YWU5ZjRkYTRiNzlhYWE5OTIzZmM5MWFiXzEyLTQtMS0xLTk5ODkx_b2165f51-0c3b-41a6-91d1-da19c44b28d9"
      unitRef="usd">115000000</optn:NotePurchaseAgreementCovenantXHANCENetProductSalesAndRoyalties>
    <optn:NotePurchaseAgreementCovenantXHANCENetProductSalesAndRoyalties
      contextRef="i3364391e55a8465f8779312aa2de8ee3_I20221121"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNjMvZnJhZzo2MDhmMjg1NzYwMTY0NDM2OGExYTY4NmEyNjgwZGYyYi90YWJsZTphN2FkMTY1NWFlOWY0ZGE0Yjc5YWFhOTkyM2ZjOTFhYi90YWJsZXJhbmdlOmE3YWQxNjU1YWU5ZjRkYTRiNzlhYWE5OTIzZmM5MWFiXzEzLTQtMS0xLTk5ODkx_2dd99f41-4067-423a-9564-f0506a6342fc"
      unitRef="usd">120000000</optn:NotePurchaseAgreementCovenantXHANCENetProductSalesAndRoyalties>
    <optn:NotePurchaseAgreementCovenantXHANCENetProductSalesAndRoyalties
      contextRef="i1362d0ef4cda4d66927a9a59de67480a_I20221121"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNjMvZnJhZzo2MDhmMjg1NzYwMTY0NDM2OGExYTY4NmEyNjgwZGYyYi90YWJsZTphN2FkMTY1NWFlOWY0ZGE0Yjc5YWFhOTkyM2ZjOTFhYi90YWJsZXJhbmdlOmE3YWQxNjU1YWU5ZjRkYTRiNzlhYWE5OTIzZmM5MWFiXzE0LTQtMS0xLTk5ODkx_3be3befb-6784-47fc-a41d-45d5186ee204"
      unitRef="usd">125000000</optn:NotePurchaseAgreementCovenantXHANCENetProductSalesAndRoyalties>
    <optn:NotePurchaseAgreementCovenantXHANCENetProductSalesAndRoyalties
      contextRef="icb311cdcf8a9432c86887963e33e45f4_I20221121"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNjMvZnJhZzo2MDhmMjg1NzYwMTY0NDM2OGExYTY4NmEyNjgwZGYyYi90YWJsZTphN2FkMTY1NWFlOWY0ZGE0Yjc5YWFhOTkyM2ZjOTFhYi90YWJsZXJhbmdlOmE3YWQxNjU1YWU5ZjRkYTRiNzlhYWE5OTIzZmM5MWFiXzE1LTQtMS0xLTk5ODkx_f0542d7b-a6ed-4569-abc9-e0be53817bfc"
      unitRef="usd">130000000</optn:NotePurchaseAgreementCovenantXHANCENetProductSalesAndRoyalties>
    <optn:NotePurchaseAgreementCovenantXHANCENetProductSalesAndRoyalties
      contextRef="ib965e05b5c0041c399de4fe3b2ae4e52_I20221121"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNjMvZnJhZzo2MDhmMjg1NzYwMTY0NDM2OGExYTY4NmEyNjgwZGYyYi90YWJsZTphN2FkMTY1NWFlOWY0ZGE0Yjc5YWFhOTkyM2ZjOTFhYi90YWJsZXJhbmdlOmE3YWQxNjU1YWU5ZjRkYTRiNzlhYWE5OTIzZmM5MWFiXzE2LTQtMS0xLTk5ODkx_1ed5f5ea-9ea2-4533-9a63-5bc1c07c86e8"
      unitRef="usd">135000000</optn:NotePurchaseAgreementCovenantXHANCENetProductSalesAndRoyalties>
    <optn:NotePurchaseAgreementCovenantXHANCENetProductSalesAndRoyalties
      contextRef="i03d054262028474889eca1899fe6608a_I20221121"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNjMvZnJhZzo2MDhmMjg1NzYwMTY0NDM2OGExYTY4NmEyNjgwZGYyYi90YWJsZTphN2FkMTY1NWFlOWY0ZGE0Yjc5YWFhOTkyM2ZjOTFhYi90YWJsZXJhbmdlOmE3YWQxNjU1YWU5ZjRkYTRiNzlhYWE5OTIzZmM5MWFiXzE3LTQtMS0xLTk5ODkx_e1311190-11e7-48cb-82fe-cc485fb4415c"
      unitRef="usd">140000000</optn:NotePurchaseAgreementCovenantXHANCENetProductSalesAndRoyalties>
    <optn:NotePurchaseAgreementCovenantXHANCENetProductSalesAndRoyalties
      contextRef="i482f0725fc2c4ff7b615761825e52e2e_I20221121"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNjMvZnJhZzo2MDhmMjg1NzYwMTY0NDM2OGExYTY4NmEyNjgwZGYyYi90YWJsZTphN2FkMTY1NWFlOWY0ZGE0Yjc5YWFhOTkyM2ZjOTFhYi90YWJsZXJhbmdlOmE3YWQxNjU1YWU5ZjRkYTRiNzlhYWE5OTIzZmM5MWFiXzE4LTQtMS0xLTk5ODkx_dd042c83-7720-4e94-a8fe-8930834463a9"
      unitRef="usd">145000000</optn:NotePurchaseAgreementCovenantXHANCENetProductSalesAndRoyalties>
    <optn:NotePurchaseAgreementCovenantXHANCENetProductSalesAndRoyalties
      contextRef="i5b4176cedeca41789b0e80197b83e051_I20221121"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNjMvZnJhZzo2MDhmMjg1NzYwMTY0NDM2OGExYTY4NmEyNjgwZGYyYi90YWJsZTphN2FkMTY1NWFlOWY0ZGE0Yjc5YWFhOTkyM2ZjOTFhYi90YWJsZXJhbmdlOmE3YWQxNjU1YWU5ZjRkYTRiNzlhYWE5OTIzZmM5MWFiXzE5LTQtMS0xLTk5ODkx_7d5edd70-fa8d-40e8-88bb-346166f30edf"
      unitRef="usd">150000000</optn:NotePurchaseAgreementCovenantXHANCENetProductSalesAndRoyalties>
    <optn:NotePurchaseAgreementCovenantXHANCENetProductSalesAndRoyalties
      contextRef="ia4c59ac4f7d84023ba6dbab73c1e6899_I20221121"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNjMvZnJhZzo2MDhmMjg1NzYwMTY0NDM2OGExYTY4NmEyNjgwZGYyYi90YWJsZTphN2FkMTY1NWFlOWY0ZGE0Yjc5YWFhOTkyM2ZjOTFhYi90YWJsZXJhbmdlOmE3YWQxNjU1YWU5ZjRkYTRiNzlhYWE5OTIzZmM5MWFiXzIwLTQtMS0xLTk5ODkx_141a198b-a44a-4d55-bc73-7f5d63a0b3c8"
      unitRef="usd">155000000</optn:NotePurchaseAgreementCovenantXHANCENetProductSalesAndRoyalties>
    <optn:NotePurchaseAgreementCovenantXHANCENetProductSalesAndRoyalties
      contextRef="i7f50064d7872407bb6b3b9a2c50c62eb_I20221121"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNjMvZnJhZzo2MDhmMjg1NzYwMTY0NDM2OGExYTY4NmEyNjgwZGYyYi90YWJsZTphN2FkMTY1NWFlOWY0ZGE0Yjc5YWFhOTkyM2ZjOTFhYi90YWJsZXJhbmdlOmE3YWQxNjU1YWU5ZjRkYTRiNzlhYWE5OTIzZmM5MWFiXzIxLTQtMS0xLTk5ODkx_c2a2508f-b849-458a-a729-3535d922e3a2"
      unitRef="usd">160000000</optn:NotePurchaseAgreementCovenantXHANCENetProductSalesAndRoyalties>
    <optn:NotePurchaseAgreementCovenantXHANCENetProductSalesAndRoyalties
      contextRef="i6fc5337d1b3e406b8ce2787d51ed4dc1_I20221121"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNjMvZnJhZzo2MDhmMjg1NzYwMTY0NDM2OGExYTY4NmEyNjgwZGYyYi90YWJsZTphN2FkMTY1NWFlOWY0ZGE0Yjc5YWFhOTkyM2ZjOTFhYi90YWJsZXJhbmdlOmE3YWQxNjU1YWU5ZjRkYTRiNzlhYWE5OTIzZmM5MWFiXzIyLTQtMS0xLTk5ODkx_0697273b-8b7c-4b14-9c37-4091a0bf1ce1"
      unitRef="usd">165000000</optn:NotePurchaseAgreementCovenantXHANCENetProductSalesAndRoyalties>
    <us-gaap:DebtInstrumentTerm
      contextRef="i536baadaab72454d98e7f61dc860283b_D20221121-20221121"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNjMvZnJhZzo2MDhmMjg1NzYwMTY0NDM2OGExYTY4NmEyNjgwZGYyYi90ZXh0cmVnaW9uOjYwOGYyODU3NjAxNjQ0MzY4YTFhNjg2YTI2ODBkZjJiXzIxOTkwMjMyODQxNjA_7807bc47-d943-4f5b-b5d6-5dbf3375aa55">P3M</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="ic6a19df6a9ed4b9a96606c2aeae2cd03_D20221121-20221121"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNjMvZnJhZzo2MDhmMjg1NzYwMTY0NDM2OGExYTY4NmEyNjgwZGYyYi90ZXh0cmVnaW9uOjYwOGYyODU3NjAxNjQ0MzY4YTFhNjg2YTI2ODBkZjJiXzIxOTkwMjMyODQxNjQ_0e8c5bc2-ce08-4e44-9a27-63e44f301500"
      unitRef="number">0.0250</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i0ec8ef0a77c840fe941543a77bb688a7_I20221121"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNjMvZnJhZzo2MDhmMjg1NzYwMTY0NDM2OGExYTY4NmEyNjgwZGYyYi90ZXh0cmVnaW9uOjYwOGYyODU3NjAxNjQ0MzY4YTFhNjg2YTI2ODBkZjJiXzIxOTkwMjMyODQxNjg_4854bed4-6459-4ad8-abb8-4e5cdfbd5fd9"
      unitRef="number">0.0850</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="ibd48856bcb224069b298e05dfdf34fc8_I20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNjMvZnJhZzo2MDhmMjg1NzYwMTY0NDM2OGExYTY4NmEyNjgwZGYyYi90ZXh0cmVnaW9uOjYwOGYyODU3NjAxNjQ0MzY4YTFhNjg2YTI2ODBkZjJiXzIxOTkwMjMyOTIwODE_ea6a7264-89fb-418b-888e-6c8d11db503d"
      unitRef="number">0.1362</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <optn:PotentialDebtInstrumentInterestRateIncrease
      contextRef="i4af8cd3923a14bf4bd1655d4e950bb46_D20221121-20221121"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNjMvZnJhZzo2MDhmMjg1NzYwMTY0NDM2OGExYTY4NmEyNjgwZGYyYi90ZXh0cmVnaW9uOjYwOGYyODU3NjAxNjQ0MzY4YTFhNjg2YTI2ODBkZjJiXzIxOTkwMjMyODQxNzI_5ffbcd7e-f7e9-4eaf-b023-58069b9309ff"
      unitRef="number">0.0300</optn:PotentialDebtInstrumentInterestRateIncrease>
    <optn:DebtInstrumentMakeWholeProvisionPaymentAccrualPeriod
      contextRef="i4bfb752944e54d3faa2837a8b3afb6b2_D20221121-20221121"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNjMvZnJhZzo2MDhmMjg1NzYwMTY0NDM2OGExYTY4NmEyNjgwZGYyYi90ZXh0cmVnaW9uOjYwOGYyODU3NjAxNjQ0MzY4YTFhNjg2YTI2ODBkZjJiXzIxOTkwMjMyODQxODg_d1162dbd-cbe6-424a-b341-d45e0f272081">P18M</optn:DebtInstrumentMakeWholeProvisionPaymentAccrualPeriod>
    <optn:DebtInstrumentMakeWholeProvisionPaymentAccrualPeriod
      contextRef="i4bfb752944e54d3faa2837a8b3afb6b2_D20221121-20221121"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNjMvZnJhZzo2MDhmMjg1NzYwMTY0NDM2OGExYTY4NmEyNjgwZGYyYi90ZXh0cmVnaW9uOjYwOGYyODU3NjAxNjQ0MzY4YTFhNjg2YTI2ODBkZjJiXzIxOTkwMjMyODQxOTI_1f317d93-06ca-43ab-96fe-8e055bbc2520">P18M</optn:DebtInstrumentMakeWholeProvisionPaymentAccrualPeriod>
    <optn:DebtInstrumentMakeWholeProvisionPaymentAccrualPeriod
      contextRef="i94c26246ced94d6ebc3cf4dc56035b01_D20221121-20221121"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNjMvZnJhZzo2MDhmMjg1NzYwMTY0NDM2OGExYTY4NmEyNjgwZGYyYi90ZXh0cmVnaW9uOjYwOGYyODU3NjAxNjQ0MzY4YTFhNjg2YTI2ODBkZjJiXzIxOTkwMjMyODQxODQ_4b3859ae-849c-463b-8ba6-5755aa40e19c">P3Y</optn:DebtInstrumentMakeWholeProvisionPaymentAccrualPeriod>
    <optn:DebtInstrumentMaximumAggregateMakeWholePremiumAmount
      contextRef="i0ec8ef0a77c840fe941543a77bb688a7_I20221121"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNjMvZnJhZzo2MDhmMjg1NzYwMTY0NDM2OGExYTY4NmEyNjgwZGYyYi90ZXh0cmVnaW9uOjYwOGYyODU3NjAxNjQ0MzY4YTFhNjg2YTI2ODBkZjJiXzIxOTkwMjMyODQxOTU_e33e0a4a-e910-4d92-896d-11052cdd6ca8"
      unitRef="usd">24000000</optn:DebtInstrumentMaximumAggregateMakeWholePremiumAmount>
    <optn:AmendmentFee
      contextRef="i2f6060dc084947d8b5a97c9542a55c23_I20221121"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNjMvZnJhZzo2MDhmMjg1NzYwMTY0NDM2OGExYTY4NmEyNjgwZGYyYi90ZXh0cmVnaW9uOjYwOGYyODU3NjAxNjQ0MzY4YTFhNjg2YTI2ODBkZjJiXzIxOTkwMjMyODQyMTI_5abbea9e-8f8e-4bcb-9d13-2c30cc86c510"
      unitRef="usd">3900000</optn:AmendmentFee>
    <optn:AmendmentFeePercentage
      contextRef="i4af8cd3923a14bf4bd1655d4e950bb46_D20221121-20221121"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNjMvZnJhZzo2MDhmMjg1NzYwMTY0NDM2OGExYTY4NmEyNjgwZGYyYi90ZXh0cmVnaW9uOjYwOGYyODU3NjAxNjQ0MzY4YTFhNjg2YTI2ODBkZjJiXzIxOTkwMjMyODQyMDQ_d97575ae-0a4e-4ab1-a255-ca54b794a7db"
      unitRef="number">0.0300</optn:AmendmentFeePercentage>
    <optn:AmendmentFee
      contextRef="i48ae5fa4e9e144c09f6e99f5f4994a45_I20221121"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNjMvZnJhZzo2MDhmMjg1NzYwMTY0NDM2OGExYTY4NmEyNjgwZGYyYi90ZXh0cmVnaW9uOjYwOGYyODU3NjAxNjQ0MzY4YTFhNjg2YTI2ODBkZjJiXzIxOTkwMjMyODQyMDg_2e73e502-8b87-421b-9074-585708a1b9e5"
      unitRef="usd">1300000</optn:AmendmentFee>
    <optn:AmendmentFee
      contextRef="ida56878d1ff24c82a2ce1db8be8bfdec_I20221121"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNjMvZnJhZzo2MDhmMjg1NzYwMTY0NDM2OGExYTY4NmEyNjgwZGYyYi90ZXh0cmVnaW9uOjYwOGYyODU3NjAxNjQ0MzY4YTFhNjg2YTI2ODBkZjJiXzIxOTkwMjMyODQyMjA_99beb63f-862f-4874-85d9-5f131c26d001"
      unitRef="usd">2600000</optn:AmendmentFee>
    <optn:AmendmentFeePayable
      contextRef="i0ec8ef0a77c840fe941543a77bb688a7_I20221121"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNjMvZnJhZzo2MDhmMjg1NzYwMTY0NDM2OGExYTY4NmEyNjgwZGYyYi90ZXh0cmVnaW9uOjYwOGYyODU3NjAxNjQ0MzY4YTFhNjg2YTI2ODBkZjJiXzIxOTkwMjMyODQyMTY_37240b54-81ee-40ab-bf09-24cee952536a"
      unitRef="usd">1300000</optn:AmendmentFeePayable>
    <optn:DebtInstrumentCovenantCashAndCashEquivalents
      contextRef="ibd48856bcb224069b298e05dfdf34fc8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNjMvZnJhZzo2MDhmMjg1NzYwMTY0NDM2OGExYTY4NmEyNjgwZGYyYi90ZXh0cmVnaW9uOjYwOGYyODU3NjAxNjQ0MzY4YTFhNjg2YTI2ODBkZjJiXzQ5NDc4MDIzNjE2NjM_8469fb6c-7f39-4d0b-975e-8fbbbf47b9f2"
      unitRef="usd">30000</optn:DebtInstrumentCovenantCashAndCashEquivalents>
    <optn:DebtInstrumentCovenantCashAndCashEquivalents
      contextRef="ibd48856bcb224069b298e05dfdf34fc8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNjMvZnJhZzo2MDhmMjg1NzYwMTY0NDM2OGExYTY4NmEyNjgwZGYyYi90ZXh0cmVnaW9uOjYwOGYyODU3NjAxNjQ0MzY4YTFhNjg2YTI2ODBkZjJiXzQ5NDc4MDIzNjE2NzI_9bf3ee5f-b51a-4f1c-805f-425c064ffca7"
      unitRef="usd">30000</optn:DebtInstrumentCovenantCashAndCashEquivalents>
    <us-gaap:InterestExpenseDebt
      contextRef="i238287e400564d288f6e8227556282ab_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNjMvZnJhZzo2MDhmMjg1NzYwMTY0NDM2OGExYTY4NmEyNjgwZGYyYi90ZXh0cmVnaW9uOjYwOGYyODU3NjAxNjQ0MzY4YTFhNjg2YTI2ODBkZjJiXzY1NjA_0884df73-0810-48fc-9a28-fe1710227d03"
      unitRef="usd">16843000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="i714fce477c634b15806608bc880b077f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNjMvZnJhZzo2MDhmMjg1NzYwMTY0NDM2OGExYTY4NmEyNjgwZGYyYi90ZXh0cmVnaW9uOjYwOGYyODU3NjAxNjQ0MzY4YTFhNjg2YTI2ODBkZjJiXzY1Njc_5169fdbc-fbc8-4611-b11c-0dfd9bf245bc"
      unitRef="usd">15973000</us-gaap:InterestExpenseDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ibd48856bcb224069b298e05dfdf34fc8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNjMvZnJhZzo2MDhmMjg1NzYwMTY0NDM2OGExYTY4NmEyNjgwZGYyYi90YWJsZTo5MWMyMmY0MWQwNzA0ZGM5OTFlMGMwZGQ1NjM2YWMzZC90YWJsZXJhbmdlOjkxYzIyZjQxZDA3MDRkYzk5MWUwYzBkZDU2MzZhYzNkXzMtMS0xLTEtNTgzNzI_5be662ab-e449-4951-83e9-b014a9370318"
      unitRef="usd">130000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i7561e1a29a044dc9ad808ce4adaaca18_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNjMvZnJhZzo2MDhmMjg1NzYwMTY0NDM2OGExYTY4NmEyNjgwZGYyYi90YWJsZTo5MWMyMmY0MWQwNzA0ZGM5OTFlMGMwZGQ1NjM2YWMzZC90YWJsZXJhbmdlOjkxYzIyZjQxZDA3MDRkYzk5MWUwYzBkZDU2MzZhYzNkXzMtMy0xLTEtNTgzNzI_9097d54c-af55-4c38-be2a-14d1a50bc798"
      unitRef="usd">130000000</us-gaap:DebtInstrumentCarryingAmount>
    <optn:DebtInstrumentFeeAmountFrontEnd
      contextRef="ibd48856bcb224069b298e05dfdf34fc8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNjMvZnJhZzo2MDhmMjg1NzYwMTY0NDM2OGExYTY4NmEyNjgwZGYyYi90YWJsZTo5MWMyMmY0MWQwNzA0ZGM5OTFlMGMwZGQ1NjM2YWMzZC90YWJsZXJhbmdlOjkxYzIyZjQxZDA3MDRkYzk5MWUwYzBkZDU2MzZhYzNkXzQtMS0xLTEtNTgzNzI_c44ee488-1425-4eb5-b16a-c955b851bdf5"
      unitRef="usd">666000</optn:DebtInstrumentFeeAmountFrontEnd>
    <optn:DebtInstrumentFeeAmountFrontEnd
      contextRef="i7561e1a29a044dc9ad808ce4adaaca18_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNjMvZnJhZzo2MDhmMjg1NzYwMTY0NDM2OGExYTY4NmEyNjgwZGYyYi90YWJsZTo5MWMyMmY0MWQwNzA0ZGM5OTFlMGMwZGQ1NjM2YWMzZC90YWJsZXJhbmdlOjkxYzIyZjQxZDA3MDRkYzk5MWUwYzBkZDU2MzZhYzNkXzQtMy0xLTEtNTgzNzI_226299d6-ec2b-4550-af0a-4eb487981e43"
      unitRef="usd">717000</optn:DebtInstrumentFeeAmountFrontEnd>
    <us-gaap:UnamortizedDebtIssuanceExpense
      contextRef="ibd48856bcb224069b298e05dfdf34fc8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNjMvZnJhZzo2MDhmMjg1NzYwMTY0NDM2OGExYTY4NmEyNjgwZGYyYi90YWJsZTo5MWMyMmY0MWQwNzA0ZGM5OTFlMGMwZGQ1NjM2YWMzZC90YWJsZXJhbmdlOjkxYzIyZjQxZDA3MDRkYzk5MWUwYzBkZDU2MzZhYzNkXzUtMS0xLTEtNTgzNzI_a5c91282-c95b-4802-bfaf-61aa8309aba9"
      unitRef="usd">6739000</us-gaap:UnamortizedDebtIssuanceExpense>
    <us-gaap:UnamortizedDebtIssuanceExpense
      contextRef="i7561e1a29a044dc9ad808ce4adaaca18_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNjMvZnJhZzo2MDhmMjg1NzYwMTY0NDM2OGExYTY4NmEyNjgwZGYyYi90YWJsZTo5MWMyMmY0MWQwNzA0ZGM5OTFlMGMwZGQ1NjM2YWMzZC90YWJsZXJhbmdlOjkxYzIyZjQxZDA3MDRkYzk5MWUwYzBkZDU2MzZhYzNkXzUtMy0xLTEtNTgzNzI_dc36670e-74a5-43de-ba68-70e2ae85cfa6"
      unitRef="usd">4165000</us-gaap:UnamortizedDebtIssuanceExpense>
    <optn:DebtInstrumentFeeAmountBackEnd
      contextRef="ibd48856bcb224069b298e05dfdf34fc8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNjMvZnJhZzo2MDhmMjg1NzYwMTY0NDM2OGExYTY4NmEyNjgwZGYyYi90YWJsZTo5MWMyMmY0MWQwNzA0ZGM5OTFlMGMwZGQ1NjM2YWMzZC90YWJsZXJhbmdlOjkxYzIyZjQxZDA3MDRkYzk5MWUwYzBkZDU2MzZhYzNkXzYtMS0xLTEtNTgzNzI_ef6f3c3a-f76b-41be-90ec-fc5ea415bd8d"
      unitRef="usd">5980000</optn:DebtInstrumentFeeAmountBackEnd>
    <optn:DebtInstrumentFeeAmountBackEnd
      contextRef="i7561e1a29a044dc9ad808ce4adaaca18_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNjMvZnJhZzo2MDhmMjg1NzYwMTY0NDM2OGExYTY4NmEyNjgwZGYyYi90YWJsZTo5MWMyMmY0MWQwNzA0ZGM5OTFlMGMwZGQ1NjM2YWMzZC90YWJsZXJhbmdlOjkxYzIyZjQxZDA3MDRkYzk5MWUwYzBkZDU2MzZhYzNkXzYtMy0xLTEtNTgzNzI_70f71053-226b-40f8-af90-4a5f91149b2e"
      unitRef="usd">1300000</optn:DebtInstrumentFeeAmountBackEnd>
    <us-gaap:LongTermDebt
      contextRef="ibd48856bcb224069b298e05dfdf34fc8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNjMvZnJhZzo2MDhmMjg1NzYwMTY0NDM2OGExYTY4NmEyNjgwZGYyYi90YWJsZTo5MWMyMmY0MWQwNzA0ZGM5OTFlMGMwZGQ1NjM2YWMzZC90YWJsZXJhbmdlOjkxYzIyZjQxZDA3MDRkYzk5MWUwYzBkZDU2MzZhYzNkXzctMS0xLTEtNTgzNzI_bfa595c1-0653-4aaa-927a-e699249a8a6b"
      unitRef="usd">128575000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i7561e1a29a044dc9ad808ce4adaaca18_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNjMvZnJhZzo2MDhmMjg1NzYwMTY0NDM2OGExYTY4NmEyNjgwZGYyYi90YWJsZTo5MWMyMmY0MWQwNzA0ZGM5OTFlMGMwZGQ1NjM2YWMzZC90YWJsZXJhbmdlOjkxYzIyZjQxZDA3MDRkYzk5MWUwYzBkZDU2MzZhYzNkXzctMy0xLTEtNTgzNzI_5d3d04af-82f0-4832-86b7-c20913a104f8"
      unitRef="usd">126418000</us-gaap:LongTermDebt>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNjYvZnJhZzo5NDNlMGRmMGJhMGQ0Zjk0YjExNzgyMzc1ODQ5YmI3My90ZXh0cmVnaW9uOjk0M2UwZGYwYmEwZDRmOTRiMTE3ODIzNzU4NDliYjczXzEzMTQ_f00b9fe1-3b37-4b17-9c33-6631888f834d">Employee Benefit PlansThe Company maintains a defined contribution 401(k) retirement plan, which covers all eligible US employees. Employees are eligible to participate in the plan on the first of the month following their date of hire. Under the 401(k)&#160;retirement plan, participating employees may defer up to 100% of their pre-tax salary, but not more than statutory limits. The Company matches 100% of the first 3% of participating employee contributions and 50% of the next 2% of participating employee contributions, subject to applicable IRC limits. The Company incurred costs of $1,112 and $1,340 related to the Company match applicable to employee contributions for the years ended December 31, 2022 and 2021, respectively. The Company's contributions are made in cash. The Company's common stock is not currently an investment option available to participants in the 401(k) retirement plan.  As of December 31, 2022, approximately $256 was recorded in accrued expenses related to the Company match. For former Norway employees, the Company maintained a defined contribution pension plan which met the statutory requirements. The Company incurred costs of $11 and $6 related to the pension plans for the years ended December 31, 2022 and 2021, respectively.</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNjYvZnJhZzo5NDNlMGRmMGJhMGQ0Zjk0YjExNzgyMzc1ODQ5YmI3My90ZXh0cmVnaW9uOjk0M2UwZGYwYmEwZDRmOTRiMTE3ODIzNzU4NDliYjczXzMyMQ_9c3feae2-1b39-4e7f-a148-d00c00094982"
      unitRef="number">1</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
      contextRef="idbd6780d660f4418a87f188eb442ef29_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNjYvZnJhZzo5NDNlMGRmMGJhMGQ0Zjk0YjExNzgyMzc1ODQ5YmI3My90ZXh0cmVnaW9uOjk0M2UwZGYwYmEwZDRmOTRiMTE3ODIzNzU4NDliYjczXzQwNQ_1405d309-302e-455c-bd46-24fb5f406ca6"
      unitRef="number">1</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
      contextRef="idbd6780d660f4418a87f188eb442ef29_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNjYvZnJhZzo5NDNlMGRmMGJhMGQ0Zjk0YjExNzgyMzc1ODQ5YmI3My90ZXh0cmVnaW9uOjk0M2UwZGYwYmEwZDRmOTRiMTE3ODIzNzU4NDliYjczXzQyMQ_e83b36a1-a565-4b66-ab80-bf8d23727a0a"
      unitRef="number">0.03</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
      contextRef="i670307f3af404f3b9d62b585c525267b_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNjYvZnJhZzo5NDNlMGRmMGJhMGQ0Zjk0YjExNzgyMzc1ODQ5YmI3My90ZXh0cmVnaW9uOjk0M2UwZGYwYmEwZDRmOTRiMTE3ODIzNzU4NDliYjczXzQ2OA_3432d7f1-0344-4d6f-b2af-a23561555a79"
      unitRef="number">0.50</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
      contextRef="i670307f3af404f3b9d62b585c525267b_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNjYvZnJhZzo5NDNlMGRmMGJhMGQ0Zjk0YjExNzgyMzc1ODQ5YmI3My90ZXh0cmVnaW9uOjk0M2UwZGYwYmEwZDRmOTRiMTE3ODIzNzU4NDliYjczXzQ4Mw_20f0785c-3345-496b-b46a-c6071a827681"
      unitRef="number">0.02</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNjYvZnJhZzo5NDNlMGRmMGJhMGQ0Zjk0YjExNzgyMzc1ODQ5YmI3My90ZXh0cmVnaW9uOjk0M2UwZGYwYmEwZDRmOTRiMTE3ODIzNzU4NDliYjczXzU5MQ_31851a2f-4345-4e7e-9f8b-e36f8a2f9c55"
      unitRef="usd">1112000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNjYvZnJhZzo5NDNlMGRmMGJhMGQ0Zjk0YjExNzgyMzc1ODQ5YmI3My90ZXh0cmVnaW9uOjk0M2UwZGYwYmEwZDRmOTRiMTE3ODIzNzU4NDliYjczXzU5OA_c66b54b0-ba8a-4df4-b62a-eeba9d6a569c"
      unitRef="usd">1340000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNjYvZnJhZzo5NDNlMGRmMGJhMGQ0Zjk0YjExNzgyMzc1ODQ5YmI3My90ZXh0cmVnaW9uOjk0M2UwZGYwYmEwZDRmOTRiMTE3ODIzNzU4NDliYjczXzkwNQ_e2335c77-37ad-45f4-a17b-c06bd8216a0d"
      unitRef="usd">256000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="i2d4fcc93e3a14fe6962ee2598dc6066e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNjYvZnJhZzo5NDNlMGRmMGJhMGQ0Zjk0YjExNzgyMzc1ODQ5YmI3My90ZXh0cmVnaW9uOjk0M2UwZGYwYmEwZDRmOTRiMTE3ODIzNzU4NDliYjczXzEyMjk_c383101a-1866-474f-95b8-0f4ad7a99908"
      unitRef="usd">11000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="idad19395ab8f44dd9a2eb5f01f801543_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNjYvZnJhZzo5NDNlMGRmMGJhMGQ0Zjk0YjExNzgyMzc1ODQ5YmI3My90ZXh0cmVnaW9uOjk0M2UwZGYwYmEwZDRmOTRiMTE3ODIzNzU4NDliYjczXzEyMzY_53aba448-53c4-44f2-b7d8-9f31af640e2d"
      unitRef="usd">6000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNjkvZnJhZzozODM3NjU3NDA4ODE0ZjM5OTFlOWFjNGFhYjU5YTJlNC90ZXh0cmVnaW9uOjM4Mzc2NTc0MDg4MTRmMzk5MWU5YWM0YWFiNTlhMmU0XzEwMTk_cb805a92-19df-4a49-8d28-fcb256ee00d1">Commitments and Contingencies&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Purchase commitments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2022, the Company had no material outstanding non-cancellable purchase commitments related to inventory and other goods and services, including pre-commercial manufacturing scale-up and sales and marketing activities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Employment agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has entered into employment contracts with its officers and certain employees that provide for severance and continuation of benefits in the event of termination of employment by the Company without cause or by the employee for good reason. In addition, in the event of termination of employment following a change in control, the vesting of certain equity awards may be accelerated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Liabilities for loss contingencies arising from claims, assessments, litigation, fines, penalties, and other sources are recorded when it is probable that a liability has been incurred and the amount can be reasonably estimated. The Company is not currently a party to any material pending legal proceedings.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:PurchaseObligation
      contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNjkvZnJhZzozODM3NjU3NDA4ODE0ZjM5OTFlOWFjNGFhYjU5YTJlNC90ZXh0cmVnaW9uOjM4Mzc2NTc0MDg4MTRmMzk5MWU5YWM0YWFiNTlhMmU0Xzg2_0e8eef5d-b26e-46cf-abb0-b7ed661485ac"
      unitRef="usd">0</us-gaap:PurchaseObligation>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzIvZnJhZzo1ZmQ5ZDMzNzdkYTk0ZGNiODViODcwZDU1NTM4YmIxNi90ZXh0cmVnaW9uOjVmZDlkMzM3N2RhOTRkY2I4NWI4NzBkNTU1MzhiYjE2XzIyODU_4d667e22-b958-41af-ab09-a3ae04d214f7">Stockholders' Equity&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Common stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 18, 2021, the Company closed an underwritten public offering (the 2021 Offering) of 28,750,000 shares of Company common stock (Common Stock) at a price of $1.60 per share. As a result of the Offering, the Company received $42,842 in net proceeds, after deducting commissions and expenses of $2,860 and offering costs payable by the Company of $298.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;On November 23, 2022, the Company closed an underwritten public offering (the 2022 Offering) of 26,320,000 shares of Common Stock at a price of $1.89 per share and accompanying warrants to purchase 26,320,000 shares of Common Stock at a public offering price of $0.01 per warrant. In addition, the Company granted the underwriters an option for a period of 30 days to purchase up to an additional 3,948,000 shares of Common Stock (the Option Shares) and/or warrants to purchase 3,948,000 shares of Common Stock (The Option Warrants). The underwriters exercised their option to purchase the Option Warrants on November 22, 2022. In December 2022, the Underwriter partially exercised the option to purchase an additional 1,541,299 of the Option Shares. As a result of the 2022 Offering and the exercise of the options, the Company received $49,296 in net proceeds, after deducting commissions of $3,238 and offering costs payable by the Company of $359. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company&#x2019;s stockholders. Subject to preferences that may apply to any outstanding preferred stock, holders of common stock are entitled to receive ratably any dividends that the Company&#x2019;s board of directors may declare out of funds legally available for that purpose on a non-cumulative basis. No dividends had been declared through December 31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Common stock warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 18, 2021, in conjunction with the Second Amendment to the original Note Purchase Agreement (Second Amendment), the Company issued warrants to purchase an aggregate of 2,500,000 shares of Common Stock at a per share exercise price of $1.60 and fair value of $2,009.  Upon execution of the Second Amendment, previously issued warrants to purchase 810,357 shares of Common Stock at a per share exercise price of $6.72 which were set to expire on September 12, 2022, were cancelled.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The grant date fair value of the 2,500,000 warrants issued in connection with the Pharmakon Senior Secured Notes was estimated at the time of grant using the Black-Scholes option-pricing model using the following weighted average assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:83.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.105%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Risk free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;78.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Annual dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fair value of common stock&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;As part of the 2022 Offering, the Company issued warrants to purchase 30,268,000 shares of Common Stock at a public offering price of $0.01 per warrant (the Warrants). Each Warrant has an exercise price of $2.565 per share of Common Stock and is exercisable until the expiration date, which is the fifth anniversary of the date of issuance (November 23, 2027). After such date, any unexercised Warrants will expire and have no further value. If the Company issues or sells, or is deemed pursuant to the terms of the Warrants to have issued or sold, any shares of Common Stock (which includes, among other things, options and securities convertible into shares of Common Stock), excluding certain issuances defined in the Warrants as "excluded issuances, for a price per share less than the exercise price of the Warrants in effect immediately prior to such issuance or sale or deemed issuance or sale (such event, a dilutive issuance), then immediately after such dilutive issuance the exercise price then in effect of the Warrants shall be reduced to the price of the shares of Common Stock issued or sold or deemed to be issued or sold in the dilutive issuance in the manner set forth in the Warrant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;A holder of Warrants will not have the right to exercise any portion of a Warrant if the holder (together with its affiliates) would beneficially own in excess of 4.99% (or on election of such holder, prior to the issuance of any Warrants, 9.99%) of the number of shares of Common Stock outstanding immediately after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the Warrants; provided, however, such holder may increase or decrease such percentage to any other percentage not in excess of 19.99%, provided that any increase in such percentage shall not be effective until 61 days after such notice is delivered to the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Pursuant to the terms of the Warrant, the Company could be required to settle the Warrants in cash in the event of a "fundamental transaction" as defined in the Warrant (which includes, among other things, an acquisition of the Company) and, as a result, the Warrants are required to be measured at fair value and reported as liability in the consolidated balance sheet. The Company recorded the fair value of the Warrants upon issuance using a Monte Carlo simulation and are required to revalue the Warrants at each reporting date with any changes in fair value recorded on our statement of operations.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2022, the Company had the following warrants outstanding to purchase shares of Common Stock: &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.847%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.847%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.847%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.931%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Exercise Price Per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Expiration Date&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,500,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Equity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$1.60&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;November 15, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30,268,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$2.565&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;November 23, 2027&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i35f1c252618f404c810efc41abf15787_D20211118-20211118"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzIvZnJhZzo1ZmQ5ZDMzNzdkYTk0ZGNiODViODcwZDU1NTM4YmIxNi90ZXh0cmVnaW9uOjVmZDlkMzM3N2RhOTRkY2I4NWI4NzBkNTU1MzhiYjE2Xzg5MA_48e71ac5-a57e-4f43-bf85-903c7dad4643"
      unitRef="shares">28750000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i1fba48bbd9c94f17a4a169948d5b5dfa_I20211118"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzIvZnJhZzo1ZmQ5ZDMzNzdkYTk0ZGNiODViODcwZDU1NTM4YmIxNi90ZXh0cmVnaW9uOjVmZDlkMzM3N2RhOTRkY2I4NWI4NzBkNTU1MzhiYjE2Xzk1Mw_cb270a28-a401-48eb-a100-bd9ac057ea7d"
      unitRef="usdPerShare">1.60</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i35f1c252618f404c810efc41abf15787_D20211118-20211118"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzIvZnJhZzo1ZmQ5ZDMzNzdkYTk0ZGNiODViODcwZDU1NTM4YmIxNi90ZXh0cmVnaW9uOjVmZDlkMzM3N2RhOTRkY2I4NWI4NzBkNTU1MzhiYjE2XzEwMTc_cf48cbbc-e852-4c48-b7ff-628a798c3842"
      unitRef="usd">42842000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <optn:SaleOfStockCommissionsAndExpenses
      contextRef="i35f1c252618f404c810efc41abf15787_D20211118-20211118"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzIvZnJhZzo1ZmQ5ZDMzNzdkYTk0ZGNiODViODcwZDU1NTM4YmIxNi90ZXh0cmVnaW9uOjVmZDlkMzM3N2RhOTRkY2I4NWI4NzBkNTU1MzhiYjE2XzIxOTkwMjMyNzA1MzI_88ade87a-bb57-4e25-996c-951749709be5"
      unitRef="usd">2860000</optn:SaleOfStockCommissionsAndExpenses>
    <us-gaap:DeferredOfferingCosts
      contextRef="i1fba48bbd9c94f17a4a169948d5b5dfa_I20211118"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzIvZnJhZzo1ZmQ5ZDMzNzdkYTk0ZGNiODViODcwZDU1NTM4YmIxNi90ZXh0cmVnaW9uOjVmZDlkMzM3N2RhOTRkY2I4NWI4NzBkNTU1MzhiYjE2XzExMjk_b4858808-cdd9-4873-9f50-4f02072a4b79"
      unitRef="usd">298000</us-gaap:DeferredOfferingCosts>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="ic6fffb430e45481abf555ff9d6505776_D20221123-20221123"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzIvZnJhZzo1ZmQ5ZDMzNzdkYTk0ZGNiODViODcwZDU1NTM4YmIxNi90ZXh0cmVnaW9uOjVmZDlkMzM3N2RhOTRkY2I4NWI4NzBkNTU1MzhiYjE2XzIxOTkwMjMyNjkwMjU_631ae3ae-9937-40b9-b0f4-dfb5abdc7874"
      unitRef="shares">26320000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i1e2cc5b3626b4c0eb0a50fe312b92bbe_I20221123"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzIvZnJhZzo1ZmQ5ZDMzNzdkYTk0ZGNiODViODcwZDU1NTM4YmIxNi90ZXh0cmVnaW9uOjVmZDlkMzM3N2RhOTRkY2I4NWI4NzBkNTU1MzhiYjE2XzIxOTkwMjMyNjkwOTY_11de2a8c-7b3f-4aee-bef6-f84176ede735"
      unitRef="usdPerShare">1.89</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="iea2a2b3820084672a2ce5363d5379529_I20221123"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzIvZnJhZzo1ZmQ5ZDMzNzdkYTk0ZGNiODViODcwZDU1NTM4YmIxNi90ZXh0cmVnaW9uOjVmZDlkMzM3N2RhOTRkY2I4NWI4NzBkNTU1MzhiYjE2XzIxOTkwMjMyNjkxNDg_aa307f37-3d04-47a6-b3d8-7ea6de154119"
      unitRef="shares">26320000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="iea2a2b3820084672a2ce5363d5379529_I20221123"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzIvZnJhZzo1ZmQ5ZDMzNzdkYTk0ZGNiODViODcwZDU1NTM4YmIxNi90ZXh0cmVnaW9uOjVmZDlkMzM3N2RhOTRkY2I4NWI4NzBkNTU1MzhiYjE2XzIxOTkwMjMyNjkyMDU_1079900c-8402-4805-84b7-0ab40e063abe"
      unitRef="usdPerShare">0.01</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i056c6dc8158e43c386a653bfe93f59db_D20221123-20221123"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzIvZnJhZzo1ZmQ5ZDMzNzdkYTk0ZGNiODViODcwZDU1NTM4YmIxNi90ZXh0cmVnaW9uOjVmZDlkMzM3N2RhOTRkY2I4NWI4NzBkNTU1MzhiYjE2XzIxOTkwMjMyNjkzMzk_918b5d2f-f86f-4111-88a4-b42824f81607"
      unitRef="shares">3948000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i0cf7d2872aa9438888847621f710368c_I20221123"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzIvZnJhZzo1ZmQ5ZDMzNzdkYTk0ZGNiODViODcwZDU1NTM4YmIxNi90ZXh0cmVnaW9uOjVmZDlkMzM3N2RhOTRkY2I4NWI4NzBkNTU1MzhiYjE2XzIxOTkwMjMyNjkzOTQ_2cb843c6-7f77-4a35-a4d5-f6fd453ac213"
      unitRef="shares">3948000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="id8480f44fd004d44a17fe3165e3accc2_D20221201-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzIvZnJhZzo1ZmQ5ZDMzNzdkYTk0ZGNiODViODcwZDU1NTM4YmIxNi90ZXh0cmVnaW9uOjVmZDlkMzM3N2RhOTRkY2I4NWI4NzBkNTU1MzhiYjE2XzIxOTkwMjMyNjk2MDU_a2801f6e-1380-4ca6-ad46-267f237d4b6a"
      unitRef="shares">1541299</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="id8480f44fd004d44a17fe3165e3accc2_D20221201-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzIvZnJhZzo1ZmQ5ZDMzNzdkYTk0ZGNiODViODcwZDU1NTM4YmIxNi90ZXh0cmVnaW9uOjVmZDlkMzM3N2RhOTRkY2I4NWI4NzBkNTU1MzhiYjE2XzIxOTkwMjMyNjk3NDQ_efcbf1cd-c1f1-43e2-9834-e59679cf22aa"
      unitRef="usd">49296000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <optn:SaleOfStockCommissionsAndExpenses
      contextRef="id8480f44fd004d44a17fe3165e3accc2_D20221201-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzIvZnJhZzo1ZmQ5ZDMzNzdkYTk0ZGNiODViODcwZDU1NTM4YmIxNi90ZXh0cmVnaW9uOjVmZDlkMzM3N2RhOTRkY2I4NWI4NzBkNTU1MzhiYjE2XzIxOTkwMjMyNjk3OTY_4f9c1bab-fd66-4a09-b0cf-b3fd60adfd43"
      unitRef="usd">3238000</optn:SaleOfStockCommissionsAndExpenses>
    <us-gaap:DeferredOfferingCosts
      contextRef="i26def91352024f8bb0467900afb32de9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzIvZnJhZzo1ZmQ5ZDMzNzdkYTk0ZGNiODViODcwZDU1NTM4YmIxNi90ZXh0cmVnaW9uOjVmZDlkMzM3N2RhOTRkY2I4NWI4NzBkNTU1MzhiYjE2XzIxOTkwMjMyNjk4NDU_5f8e69a3-a17f-40de-82fe-1fc06281eb1f"
      unitRef="usd">359000</us-gaap:DeferredOfferingCosts>
    <optn:VotePerShare
      contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzIvZnJhZzo1ZmQ5ZDMzNzdkYTk0ZGNiODViODcwZDU1NTM4YmIxNi90ZXh0cmVnaW9uOjVmZDlkMzM3N2RhOTRkY2I4NWI4NzBkNTU1MzhiYjE2XzExODM_b88e9ec2-2b04-4dfb-a119-ad69c14731ca"
      unitRef="vote">1</optn:VotePerShare>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzIvZnJhZzo1ZmQ5ZDMzNzdkYTk0ZGNiODViODcwZDU1NTM4YmIxNi90ZXh0cmVnaW9uOjVmZDlkMzM3N2RhOTRkY2I4NWI4NzBkNTU1MzhiYjE2XzE1MjY_d2a1e5a2-3c82-4cbd-bc16-5a5b8d19f4f1"
      unitRef="usdPerShare">0</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="ie839a1db16084835ad6af8b8758ce33c_I20211118"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzIvZnJhZzo1ZmQ5ZDMzNzdkYTk0ZGNiODViODcwZDU1NTM4YmIxNi90ZXh0cmVnaW9uOjVmZDlkMzM3N2RhOTRkY2I4NWI4NzBkNTU1MzhiYjE2XzIxOTkwMjMyNjc5MDk_06d83d12-6a66-46ad-a25a-90cd76c4446a"
      unitRef="shares">2500000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="ie839a1db16084835ad6af8b8758ce33c_I20211118"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzIvZnJhZzo1ZmQ5ZDMzNzdkYTk0ZGNiODViODcwZDU1NTM4YmIxNi90ZXh0cmVnaW9uOjVmZDlkMzM3N2RhOTRkY2I4NWI4NzBkNTU1MzhiYjE2XzIxOTkwMjMyNjc5MTc_fdd7d2a4-142c-497b-8ae1-307e9484ebc2"
      unitRef="usdPerShare">1.60</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="ie839a1db16084835ad6af8b8758ce33c_I20211118"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzIvZnJhZzo1ZmQ5ZDMzNzdkYTk0ZGNiODViODcwZDU1NTM4YmIxNi90ZXh0cmVnaW9uOjVmZDlkMzM3N2RhOTRkY2I4NWI4NzBkNTU1MzhiYjE2XzIxOTkwMjMyNjc5MjE_229f712b-7b79-47d8-86b2-09587ad9644c"
      unitRef="usd">2009000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="iabcd2c4e164b4cb3923eed31231d712e_I20211118"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzIvZnJhZzo1ZmQ5ZDMzNzdkYTk0ZGNiODViODcwZDU1NTM4YmIxNi90ZXh0cmVnaW9uOjVmZDlkMzM3N2RhOTRkY2I4NWI4NzBkNTU1MzhiYjE2XzE4NTc_dc7f9d26-055e-4532-81da-40fba12ad29f"
      unitRef="shares">810357</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="iabcd2c4e164b4cb3923eed31231d712e_I20211118"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzIvZnJhZzo1ZmQ5ZDMzNzdkYTk0ZGNiODViODcwZDU1NTM4YmIxNi90ZXh0cmVnaW9uOjVmZDlkMzM3N2RhOTRkY2I4NWI4NzBkNTU1MzhiYjE2XzE4ODA_0f1c7f83-d62b-4b0f-bca7-855ec521b8b0"
      unitRef="usdPerShare">6.72</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <optn:ScheduleOfGrantDateFairValueOfWarrantValuationAssumptionsTableTextBlock
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzIvZnJhZzo1ZmQ5ZDMzNzdkYTk0ZGNiODViODcwZDU1NTM4YmIxNi90ZXh0cmVnaW9uOjVmZDlkMzM3N2RhOTRkY2I4NWI4NzBkNTU1MzhiYjE2XzIyODE_c470c35f-bfb4-4a37-8239-3a19e43b4348">&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The grant date fair value of the 2,500,000 warrants issued in connection with the Pharmakon Senior Secured Notes was estimated at the time of grant using the Black-Scholes option-pricing model using the following weighted average assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:83.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.105%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Risk free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;78.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Annual dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fair value of common stock&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</optn:ScheduleOfGrantDateFairValueOfWarrantValuationAssumptionsTableTextBlock>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="ie839a1db16084835ad6af8b8758ce33c_I20211118"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzIvZnJhZzo1ZmQ5ZDMzNzdkYTk0ZGNiODViODcwZDU1NTM4YmIxNi90ZXh0cmVnaW9uOjVmZDlkMzM3N2RhOTRkY2I4NWI4NzBkNTU1MzhiYjE2XzIxOTkwMjMyNjc5Mjk_250d590c-15df-41d5-85b4-455ea939d0a8"
      unitRef="shares">2500000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="iecd24838e7ea4897a980acb7f05e8f07_I20211118"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzIvZnJhZzo1ZmQ5ZDMzNzdkYTk0ZGNiODViODcwZDU1NTM4YmIxNi90YWJsZTo4NmRjNWM0NGEyYzk0MDQ0ODBiNTA3ZGYwNmM5Y2EwOC90YWJsZXJhbmdlOjg2ZGM1YzQ0YTJjOTQwNDQ4MGI1MDdkZjA2YzljYTA4XzAtMS0xLTEtNTgzNzI_d3ee246d-cb8a-4545-8e0b-bd434159d566"
      unitRef="number">0.0087</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i34d7dc335ebb4c258e92af8033ba7854_I20211118"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzIvZnJhZzo1ZmQ5ZDMzNzdkYTk0ZGNiODViODcwZDU1NTM4YmIxNi90YWJsZTo4NmRjNWM0NGEyYzk0MDQ0ODBiNTA3ZGYwNmM5Y2EwOC90YWJsZXJhbmdlOjg2ZGM1YzQ0YTJjOTQwNDQ4MGI1MDdkZjA2YzljYTA4XzEtMS0xLTEtNTgzNzI_84c8b053-d62d-48eb-95af-b46ad82d1c72"
      unitRef="number">3</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i81ae26cc8b16489db793cfa1a11fdb41_I20211118"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzIvZnJhZzo1ZmQ5ZDMzNzdkYTk0ZGNiODViODcwZDU1NTM4YmIxNi90YWJsZTo4NmRjNWM0NGEyYzk0MDQ0ODBiNTA3ZGYwNmM5Y2EwOC90YWJsZXJhbmdlOjg2ZGM1YzQ0YTJjOTQwNDQ4MGI1MDdkZjA2YzljYTA4XzItMS0xLTEtNTgzNzI_5af9d8a5-b249-4afa-9080-fd12644f8bc2"
      unitRef="number">0.7825</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="iad23ea7b6ce14473a74ab1026b1d8111_I20211118"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzIvZnJhZzo1ZmQ5ZDMzNzdkYTk0ZGNiODViODcwZDU1NTM4YmIxNi90YWJsZTo4NmRjNWM0NGEyYzk0MDQ0ODBiNTA3ZGYwNmM5Y2EwOC90YWJsZXJhbmdlOjg2ZGM1YzQ0YTJjOTQwNDQ4MGI1MDdkZjA2YzljYTA4XzMtMS0xLTEtNTgzNzI_df53d32c-50bd-4976-8b50-58c10f46e0ce"
      unitRef="number">0.0000</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="ib2361c2f31ea4a84ae18d655231f351d_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzIvZnJhZzo1ZmQ5ZDMzNzdkYTk0ZGNiODViODcwZDU1NTM4YmIxNi90YWJsZTo4NmRjNWM0NGEyYzk0MDQ0ODBiNTA3ZGYwNmM5Y2EwOC90YWJsZXJhbmdlOjg2ZGM1YzQ0YTJjOTQwNDQ4MGI1MDdkZjA2YzljYTA4XzQtMS0xLTEtNTgzNzI_3f1bc9d4-5469-473f-bbc9-2e3c23adcab5"
      unitRef="number">1.60</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i7231baf73d71425f945cdbbe619d491b_D20221123-20221123"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzIvZnJhZzo1ZmQ5ZDMzNzdkYTk0ZGNiODViODcwZDU1NTM4YmIxNi90ZXh0cmVnaW9uOjVmZDlkMzM3N2RhOTRkY2I4NWI4NzBkNTU1MzhiYjE2XzIxOTkwMjMyNjk4NTE_e367a367-3783-4e78-ad36-909dc9d9542e"
      unitRef="shares">30268000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="iea2a2b3820084672a2ce5363d5379529_I20221123"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzIvZnJhZzo1ZmQ5ZDMzNzdkYTk0ZGNiODViODcwZDU1NTM4YmIxNi90ZXh0cmVnaW9uOjVmZDlkMzM3N2RhOTRkY2I4NWI4NzBkNTU1MzhiYjE2XzIxOTkwMjMyNjUwMzc_1079900c-8402-4805-84b7-0ab40e063abe"
      unitRef="usdPerShare">0.01</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="iee3e30fe89cc40238e90a7ecb6f01185_I20221121"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzIvZnJhZzo1ZmQ5ZDMzNzdkYTk0ZGNiODViODcwZDU1NTM4YmIxNi90ZXh0cmVnaW9uOjVmZDlkMzM3N2RhOTRkY2I4NWI4NzBkNTU1MzhiYjE2XzIxOTkwMjMyNjgwMjE_dae2c96f-fec1-44b8-89ac-e395cff44b9d"
      unitRef="usdPerShare">2.565</us-gaap:SaleOfStockPricePerShare>
    <optn:ClassOfWarrantOrRightRestrictionCommonSharesMaximumOwnershipIfExercisedPercent
      contextRef="i79d8665c06414820bf676315cc093d4a_I20221123"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzIvZnJhZzo1ZmQ5ZDMzNzdkYTk0ZGNiODViODcwZDU1NTM4YmIxNi90ZXh0cmVnaW9uOjVmZDlkMzM3N2RhOTRkY2I4NWI4NzBkNTU1MzhiYjE2XzQ5NDc4MDIzMzc0ODk_ca27ac15-1ff7-47e5-9b9c-bfd62a735bab"
      unitRef="number">0.0499</optn:ClassOfWarrantOrRightRestrictionCommonSharesMaximumOwnershipIfExercisedPercent>
    <optn:ClassOfWarrantOrRightRestrictionCommonSharesMaximumOwnershipPriorToExecutionPercent
      contextRef="i79d8665c06414820bf676315cc093d4a_I20221123"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzIvZnJhZzo1ZmQ5ZDMzNzdkYTk0ZGNiODViODcwZDU1NTM4YmIxNi90ZXh0cmVnaW9uOjVmZDlkMzM3N2RhOTRkY2I4NWI4NzBkNTU1MzhiYjE2XzQ5NDc4MDIzMzc0OTY_e6b95719-ef4e-478c-a703-53c31ac64ec4"
      unitRef="number">0.0999</optn:ClassOfWarrantOrRightRestrictionCommonSharesMaximumOwnershipPriorToExecutionPercent>
    <optn:ClassOfWarrantOrRightRestrictionCommonSharesMaximumOwnershipAfterEffectiveWaitingPeriodPercent
      contextRef="i79d8665c06414820bf676315cc093d4a_I20221123"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzIvZnJhZzo1ZmQ5ZDMzNzdkYTk0ZGNiODViODcwZDU1NTM4YmIxNi90ZXh0cmVnaW9uOjVmZDlkMzM3N2RhOTRkY2I4NWI4NzBkNTU1MzhiYjE2XzQ5NDc4MDIzMzc1MDM_156be3a5-d43a-4137-8918-cf79f7a62859"
      unitRef="number">0.1999</optn:ClassOfWarrantOrRightRestrictionCommonSharesMaximumOwnershipAfterEffectiveWaitingPeriodPercent>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzIvZnJhZzo1ZmQ5ZDMzNzdkYTk0ZGNiODViODcwZDU1NTM4YmIxNi90ZXh0cmVnaW9uOjVmZDlkMzM3N2RhOTRkY2I4NWI4NzBkNTU1MzhiYjE2XzIyODI_25fe3c16-2e27-4c59-8c33-232ab836447a">&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2022, the Company had the following warrants outstanding to purchase shares of Common Stock: &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.847%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.847%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.847%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.931%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Exercise Price Per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Expiration Date&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,500,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Equity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$1.60&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;November 15, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30,268,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$2.565&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;November 23, 2027&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i24bb67187a7b4b71897cb83c06184e0c_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzIvZnJhZzo1ZmQ5ZDMzNzdkYTk0ZGNiODViODcwZDU1NTM4YmIxNi90YWJsZTowY2E0Njc5ODRhMzI0ZjI3ODkzZTk0ZWU0YTllNjhmYS90YWJsZXJhbmdlOjBjYTQ2Nzk4NGEzMjRmMjc4OTNlOTRlZTRhOWU2OGZhXzEtMC0xLTEtNTgzNzI_9c59f624-24bb-450a-98e5-26f7b13a5984"
      unitRef="shares">2500000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i24bb67187a7b4b71897cb83c06184e0c_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzIvZnJhZzo1ZmQ5ZDMzNzdkYTk0ZGNiODViODcwZDU1NTM4YmIxNi90YWJsZTowY2E0Njc5ODRhMzI0ZjI3ODkzZTk0ZWU0YTllNjhmYS90YWJsZXJhbmdlOjBjYTQ2Nzk4NGEzMjRmMjc4OTNlOTRlZTRhOWU2OGZhXzEtMi0xLTEtNTgzNzI_313b6659-4317-4c27-acb6-d4be2398e275"
      unitRef="usdPerShare">1.60</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="ia2ede8c8918a4e5a90c0ff1a8e33f0c0_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzIvZnJhZzo1ZmQ5ZDMzNzdkYTk0ZGNiODViODcwZDU1NTM4YmIxNi90YWJsZTowY2E0Njc5ODRhMzI0ZjI3ODkzZTk0ZWU0YTllNjhmYS90YWJsZXJhbmdlOjBjYTQ2Nzk4NGEzMjRmMjc4OTNlOTRlZTRhOWU2OGZhXzItMC0xLTEtMTAyNTY3_0d3b02cb-a444-45ed-8223-f3a232d62884"
      unitRef="shares">30268000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="ia2ede8c8918a4e5a90c0ff1a8e33f0c0_I20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzIvZnJhZzo1ZmQ5ZDMzNzdkYTk0ZGNiODViODcwZDU1NTM4YmIxNi90YWJsZTowY2E0Njc5ODRhMzI0ZjI3ODkzZTk0ZWU0YTllNjhmYS90YWJsZXJhbmdlOjBjYTQ2Nzk4NGEzMjRmMjc4OTNlOTRlZTRhOWU2OGZhXzItMi0xLTEtMTAzMzk3_75bf05bf-9872-441f-92da-e5e0c9ab0e1d"
      unitRef="usdPerShare">2.565</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90ZXh0cmVnaW9uOjM5ZTVmMjgzN2UzNjRmMWQ4NDA3OGY1NTkyYjA5YzA0Xzk3OTQ_70ab806a-be13-442c-8063-bf7297a7a186">Stock-based Compensation&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company issues stock-based awards pursuant to its 2010 Stock Incentive Plan. Effective as of October 12, 2017, the Company's 2010 Stock Incentive Plan was amended and restated (A&amp;amp;R Plan). The A&amp;amp;R Plan provides for the grant of incentive stock options, non-statutory stock options, restricted stock awards, restricted stock units, deferred stock units, performance shares, stock appreciation rights and other equity-based awards. The Company's employees, officers, directors and other persons are eligible to receive awards under the A&amp;amp;R Plan. As of December 31, 2022, 17,299,284 shares of the Company's common stock were authorized to be issued under the A&amp;amp;R Plan, and 3,607,066&#160;shares were reserved for future awards under the A&amp;amp;R Plan. The number of shares of the Company's common stock authorized under the A&amp;amp;R Plan will automatically increase on January&#160;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;st&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; of each year until the expiration of the A&amp;amp;R Plan, in an amount equal to four percent of the total number of shares of the Company's common stock outstanding on December&#160;31&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;st&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; of the preceding calendar year, subject to the discretion of the Company's board of directors or compensation committee to determine a lesser number of shares shall be added for such year.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amount, terms of grants, and exercisability provisions are determined and set by the Company's board of directors or compensation committee. The Company measures stock-based awards at grant-date fair value and records compensation expense on a straight-line basis over the vesting period of the award.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has issued service-based, performance-based and market-based stock options that generally have a contractual life of up to 10&#160;years and may be exercisable in cash or as otherwise determined by the board of directors. Vesting generally occurs over a period of not greater than four years. Performance-based options may vest upon the achievement of certain milestones in connection with the Company's development programs. As of December 31, 2022, all of the performance conditions related to performance-based stock options issued by the Company have been achieved. Market-based options may vest upon the achievement of certain market-based objectives relating to the trading price of the Company's Common Stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the activity related to stock option grants to employees and non-employees for the year ended December 31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.326%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.864%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.770%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;average&lt;br/&gt;exercise price&lt;br/&gt;per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;average&lt;br/&gt;remaining&lt;br/&gt;contractual life&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,958,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.50&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,473,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(95,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(947,999)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,025,082)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,364,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.05&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Exercisable at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,521,738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.55&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December 31, 2022, stock options to purchase 3,473,370 shares of common stock were granted to employees that generally vest over four years. Included in the total stock options granted were market-based options to purchase 959,215 shares of Common Stock. The stock options, including the market-based options, had an estimated weighted average grant date fair value of $1.21. The grant date fair value of each service-based and performance-based option grant was estimated at the time of grant using the Black-Scholes option-pricing model. The grant date fair value of each market-based stock option grant was estimated at the time of grant using a Monte Carlo simulation.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total aggregate intrinsic value of stock options, other than market-based stock options, exercised during the years ended December 31, 2022&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2021 was $111&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and $35, respectively. The aggregate intrinsic value of stock options outstanding and stock options exercisable, other than market-based stock options, as of December 31, 2022 was $81 and $8, respectively. At December 31, 2022, the unrecognized compensation cost related to unvested stock options, other than market-based stock options, expected to vest was $4,368. This unrecognized compensation will be recognized over an estimated weighted-average amortization period of 2.35 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December 31, 2022, market-based options to purchase 959,215 shares of Common Stock were granted to employees and generally become eligible to vest over four years, subject to the achievement of certain market-based objectives relating to the trading price of the Common Stock.  Stock based compensation for these awards is recognized over the derived service period of approximately 2 years.  The grant date fair value of each stock option grant, as well as the derived service period for these awards, was estimated at the time of grant using a Monte Carlo simulation. During the year ended December 31, 2022, 297,677 market-based options vested upon the achievement of certain market-based objectives relating to the trading price of the Company's Common Stock.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Included in the table above are 753,500 options granted outside the A&amp;amp;R Plan. The grants were made pursuant to the Nasdaq inducement grant exception in accordance with Nasdaq Listing Rule 5635(c)(4). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted stock units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has issued service-based and performance-based restricted stock units (RSUs). Vesting generally occurs over a period not greater than four years. Vesting of the performance-based RSUs is subject to the achievement of certain milestones in connection with the Company's development programs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the activity related to RSUs granted to employees for the year ended December 31, 2022:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:88.227%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,959,358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,105,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Vested and settled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(949,857)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expired/forfeited/canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(637,087)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,477,660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected to vest at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,477,660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December 31, 2022, the Company granted 1,105,246 RSUs at a weighted-average grant date fair value of $1.85, all of which were service-based RSUs. No performance-based RSUs were granted in 2022. As of December 31, 2022, the milestone associated with the previously granted performance based-RSUs was achieved. As a result 248,827 RSUs vested on June 15, 2022. At December 31, 2022, the recognized compensation cost related to vested performance-based RSUs was $1,669. At December 31, 2022, the unrecognized compensation cost related to unvested service-based&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; RSUs expected to vest was &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$3,123&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to be recognized over an estimated weighted-average amortization period of&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; 2.24&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; years. The unrecognized compensation cost related to unvested performance-based RSUs was &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$942&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, whic&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;h will be recognized over the remaining service period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Included in the table above are 60,000 RSUs granted outside the A&amp;amp;R Plan. The grants were made pursuant to the Nasdaq inducement grant exception in accordance with Nasdaq Listing Rule 5635(c)(4). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2017 Employee Stock Purchase Plan &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's 2017 Employee Stock Purchase Plan (the 2017 Plan) became effective on October 12, 2017. As of December 31, 2022,&#160;2,021,813 shares of the Company's common stock were authorized to be issued pursuant to purchase rights granted to its employees or to employees of any of its participating affiliates under the 2017 Plan. 982,989 shares of the Company's common stock were reserved for future issuance under the 2017 Plan. The number of shares of the Company's common stock that may be issued pursuant to rights granted under the 2017 Plan shall automatically increase on January&#160;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;st&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; of each year until the expiration of the 2017 Plan, in an amount equal to one percent of the total number of shares of the Company's common stock outstanding on December&#160;31&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;st &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;of the preceding calendar year, subject to the discretion of the board of directors or compensation committee to determine a lesser number of shares shall be added for such year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the 2017 Plan, eligible employees can purchase the Company&#x2019;s common stock through accumulated payroll deductions at such times as are established by the administrator. The 2017 Plan is administered by the compensation committee. Eligible employees may contribute up to 15% of their eligible compensation. A participant may not accrue rights to purchase more than $25 worth of the Company&#x2019;s common stock for each calendar year in which such right is outstanding.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payroll withholdings accumulate during the following six month offering periods each calendar year while the Purchase Plan is effective:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;January 1 through June 30, and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;July 1 through December 31.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the end of each offering period, shares of the Company&#x2019;s common stock may be purchased at 85% of the lesser of the average of the high and low sales price of the Company&#x2019;s common stock on (i) the first trading day of the relevant offering period and (ii) the last trading day of the relevant offering period (or, if the relevant offering period has multiple purchase periods, the last trading day of the relevant purchase period). In accordance with the guidance in ASC 718-50 &#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;Compensation &#x2013; Stock Compensation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the ability to purchase shares of the Company&#x2019;s common stock at the lower of the price on the first day of the offering period or the last day of the offering period (i.e. the purchase date) represents an option and, therefore, the 2017 Plan is a compensatory plan under this guidance. Accordingly, stock-based compensation expense is determined based on the option&#x2019;s grant-date fair value as estimated by applying the Black-Scholes option-pricing model and is recognized over the requisite service period of the option. The Company has recognized stock-based compensation expense of $253&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$402 during the years ended December 31, 2022 and 2021, respectively, related to the 2017 Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-based compensation expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded stock-based compensation expense in the following expense categories of its accompanying consolidated statements of operations for the years ended December 31, 2022 and 2021:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.285%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cost of product sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,079&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,874&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,003&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-right:15.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, stock-based compensation expense of $83 was charged to inventory as of December 31, 2022. No stock-based compensation expense was charged to prepaid expenses and other assets as of December 31, 2022. These charges represent the total stock-based compensation expense incurred related to employees involved in the manufacturing process of finished goods and samples during the period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company utilized the Black-Scholes valuation model for estimating the fair value of stock options issued under the 2017 Plan. The Company calculated the fair value of each option grant and the shares issued under the 2017 Plan on the respective dates of grant using the following weighted average assumptions: &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.145%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.387%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2010 A&amp;amp;R Stock Incentive Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2017 Employee Stock Purchase Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Risk free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.08&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.50&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;73.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;88.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Annual dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Option valuation methods, including Black-Scholes, require the input of subjective assumptions, which are discussed below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;The expected term of employee options is determined using the "simplified" method, as prescribed in SEC's Staff Accounting Bulletin (SAB) No.&#160;107, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Share Based Payment &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(SAB No. 107), whereby the expected life equals the arithmetic average of the vesting term and the original contractual term of the option due to the Company's lack of sufficient historical data. The expected term of non-employee options is equal to the contractual term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;The expected volatility is based on a weighted average of the Company's historical volatility and the volatilities of similar entities within the Company's industry which were commensurate with the expected term assumption as described in SAB No.&#160;107.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;The risk-free interest rate is based on the interest rate payable on US Treasury securities in effect at the time of grant for a period that is commensurate with the assumed expected term.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;The expected dividend yield is 0% because the Company has not historically paid, and does not expect for the foreseeable future to pay, a dividend on its common stock.&lt;/span&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="ic8103889fc054805b787fcb8d7245e95_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90ZXh0cmVnaW9uOjM5ZTVmMjgzN2UzNjRmMWQ4NDA3OGY1NTkyYjA5YzA0XzU5MQ_b3d0025a-4e1a-495e-9b39-6cb5ffb4188b"
      unitRef="shares">17299284</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="ic8103889fc054805b787fcb8d7245e95_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90ZXh0cmVnaW9uOjM5ZTVmMjgzN2UzNjRmMWQ4NDA3OGY1NTkyYjA5YzA0XzY4NA_bf8dc365-f13e-4ae2-8480-6796e2003c9f"
      unitRef="shares">3607066</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <optn:CommonStockCapitalSharesReservedforFutureIssuanceYearlyIncrease
      contextRef="ic8103889fc054805b787fcb8d7245e95_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90ZXh0cmVnaW9uOjM5ZTVmMjgzN2UzNjRmMWQ4NDA3OGY1NTkyYjA5YzA0Xzk0Mw_40405c4e-132e-4369-ad76-8bcfa5c86d0b"
      unitRef="number">0.04</optn:CommonStockCapitalSharesReservedforFutureIssuanceYearlyIncrease>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="i4b3d9a0e4d704073937d74fdc55db85b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90ZXh0cmVnaW9uOjM5ZTVmMjgzN2UzNjRmMWQ4NDA3OGY1NTkyYjA5YzA0XzE3NjM_ef7578c4-dbd8-44ed-a9fc-7f6efa3d03e1">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i4b3d9a0e4d704073937d74fdc55db85b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90ZXh0cmVnaW9uOjM5ZTVmMjgzN2UzNjRmMWQ4NDA3OGY1NTkyYjA5YzA0XzE5MTY_704bad17-386e-40df-915a-ae352cd6df2e">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90ZXh0cmVnaW9uOjM5ZTVmMjgzN2UzNjRmMWQ4NDA3OGY1NTkyYjA5YzA0Xzk3OTk_4061887b-74ab-4769-9b3a-ecfb5ec576a3">&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the activity related to stock option grants to employees and non-employees for the year ended December 31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.326%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.864%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.770%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;average&lt;br/&gt;exercise price&lt;br/&gt;per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;average&lt;br/&gt;remaining&lt;br/&gt;contractual life&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,958,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.50&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,473,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(95,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(947,999)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,025,082)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,364,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.05&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Exercisable at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,521,738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.55&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="id970dfd2674c4d6b895febb9c14d0fd1_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90YWJsZTpiMzZkNWQ1ZmYxOTA0NjJiOTM0NGI1YjU5YjAyNTA2ZC90YWJsZXJhbmdlOmIzNmQ1ZDVmZjE5MDQ2MmI5MzQ0YjViNTliMDI1MDZkXzEtMS0xLTEtNTgzNzI_f3c13ed2-2a5d-4ec8-adbd-30236161411d"
      unitRef="shares">7958781</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="id970dfd2674c4d6b895febb9c14d0fd1_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90YWJsZTpiMzZkNWQ1ZmYxOTA0NjJiOTM0NGI1YjU5YjAyNTA2ZC90YWJsZXJhbmdlOmIzNmQ1ZDVmZjE5MDQ2MmI5MzQ0YjViNTliMDI1MDZkXzEtMy0xLTEtNTgzNzI_10500763-4ee2-4fa8-b384-70b14df08ae3"
      unitRef="usdPerShare">8.87</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90YWJsZTpiMzZkNWQ1ZmYxOTA0NjJiOTM0NGI1YjU5YjAyNTA2ZC90YWJsZXJhbmdlOmIzNmQ1ZDVmZjE5MDQ2MmI5MzQ0YjViNTliMDI1MDZkXzEtNS0xLTEtNTgzNzI_ab288be0-3890-4a66-b0b7-c46d571e6887">P6Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90YWJsZTpiMzZkNWQ1ZmYxOTA0NjJiOTM0NGI1YjU5YjAyNTA2ZC90YWJsZXJhbmdlOmIzNmQ1ZDVmZjE5MDQ2MmI5MzQ0YjViNTliMDI1MDZkXzItMS0xLTEtNTgzNzI_322875bf-04cc-410a-b450-39250c44ccec"
      unitRef="shares">3473370</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90YWJsZTpiMzZkNWQ1ZmYxOTA0NjJiOTM0NGI1YjU5YjAyNTA2ZC90YWJsZXJhbmdlOmIzNmQ1ZDVmZjE5MDQ2MmI5MzQ0YjViNTliMDI1MDZkXzItMy0xLTEtNTgzNzI_209cd7b0-cffb-4dff-8edc-83ce3eac4f3e"
      unitRef="usdPerShare">1.88</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90YWJsZTpiMzZkNWQ1ZmYxOTA0NjJiOTM0NGI1YjU5YjAyNTA2ZC90YWJsZXJhbmdlOmIzNmQ1ZDVmZjE5MDQ2MmI5MzQ0YjViNTliMDI1MDZkXzMtMS0xLTEtNTgzNzI_4e145989-af71-4d3e-837a-8046d8635cff"
      unitRef="shares">95000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90YWJsZTpiMzZkNWQ1ZmYxOTA0NjJiOTM0NGI1YjU5YjAyNTA2ZC90YWJsZXJhbmdlOmIzNmQ1ZDVmZjE5MDQ2MmI5MzQ0YjViNTliMDI1MDZkXzMtMy0xLTEtNTgzNzI_0d11dbcd-4a71-4d7c-baa5-c99ff2074408"
      unitRef="usdPerShare">2.18</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90YWJsZTpiMzZkNWQ1ZmYxOTA0NjJiOTM0NGI1YjU5YjAyNTA2ZC90YWJsZXJhbmdlOmIzNmQ1ZDVmZjE5MDQ2MmI5MzQ0YjViNTliMDI1MDZkXzQtMS0xLTEtNTgzNzI_8c9b570e-d737-4f71-8d83-ba7a9fa4f8f0"
      unitRef="shares">947999</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90YWJsZTpiMzZkNWQ1ZmYxOTA0NjJiOTM0NGI1YjU5YjAyNTA2ZC90YWJsZXJhbmdlOmIzNmQ1ZDVmZjE5MDQ2MmI5MzQ0YjViNTliMDI1MDZkXzQtMy0xLTEtNTgzNzI_8e5f0f93-899a-4db6-b23c-15997546c8fa"
      unitRef="usdPerShare">9.56</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90YWJsZTpiMzZkNWQ1ZmYxOTA0NjJiOTM0NGI1YjU5YjAyNTA2ZC90YWJsZXJhbmdlOmIzNmQ1ZDVmZjE5MDQ2MmI5MzQ0YjViNTliMDI1MDZkXzUtMS0xLTEtNTgzNzI_144fa648-2760-4a39-ad26-29cbb2af20d6"
      unitRef="shares">1025082</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90YWJsZTpiMzZkNWQ1ZmYxOTA0NjJiOTM0NGI1YjU5YjAyNTA2ZC90YWJsZXJhbmdlOmIzNmQ1ZDVmZjE5MDQ2MmI5MzQ0YjViNTliMDI1MDZkXzUtMy0xLTEtNTgzNzI_885f5296-39b5-41b5-84e9-dc3ee45aa33a"
      unitRef="usdPerShare">3.35</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90YWJsZTpiMzZkNWQ1ZmYxOTA0NjJiOTM0NGI1YjU5YjAyNTA2ZC90YWJsZXJhbmdlOmIzNmQ1ZDVmZjE5MDQ2MmI5MzQ0YjViNTliMDI1MDZkXzYtMS0xLTEtNTgzNzI_79952eaa-8bfb-463e-9a7f-9f3efab76984"
      unitRef="shares">9364070</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90YWJsZTpiMzZkNWQ1ZmYxOTA0NjJiOTM0NGI1YjU5YjAyNTA2ZC90YWJsZXJhbmdlOmIzNmQ1ZDVmZjE5MDQ2MmI5MzQ0YjViNTliMDI1MDZkXzYtMy0xLTEtNTgzNzI_5a651216-23d4-4d7f-ac4c-274241e21ab5"
      unitRef="usdPerShare">6.88</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90YWJsZTpiMzZkNWQ1ZmYxOTA0NjJiOTM0NGI1YjU5YjAyNTA2ZC90YWJsZXJhbmdlOmIzNmQ1ZDVmZjE5MDQ2MmI5MzQ0YjViNTliMDI1MDZkXzYtNS0xLTEtNTgzNzI_acec959c-4aa1-4c4f-90e6-bd5cb92efb74">P6Y18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90YWJsZTpiMzZkNWQ1ZmYxOTA0NjJiOTM0NGI1YjU5YjAyNTA2ZC90YWJsZXJhbmdlOmIzNmQ1ZDVmZjE5MDQ2MmI5MzQ0YjViNTliMDI1MDZkXzctMS0xLTEtNTgzNzI_b787a838-0ebb-4943-aa31-4f180455efbc"
      unitRef="shares">5521738</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90YWJsZTpiMzZkNWQ1ZmYxOTA0NjJiOTM0NGI1YjU5YjAyNTA2ZC90YWJsZXJhbmdlOmIzNmQ1ZDVmZjE5MDQ2MmI5MzQ0YjViNTliMDI1MDZkXzctMy0xLTEtNTgzNzI_3bb8b0a5-7a20-4bdb-a305-1384491a524c"
      unitRef="usdPerShare">9.98</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90YWJsZTpiMzZkNWQ1ZmYxOTA0NjJiOTM0NGI1YjU5YjAyNTA2ZC90YWJsZXJhbmdlOmIzNmQ1ZDVmZjE5MDQ2MmI5MzQ0YjViNTliMDI1MDZkXzctNS0xLTEtNTgzNzI_0e34aa10-21d7-4ad8-a265-9c6e8605e764">P4Y6M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90ZXh0cmVnaW9uOjM5ZTVmMjgzN2UzNjRmMWQ4NDA3OGY1NTkyYjA5YzA0XzI1ODY_322875bf-04cc-410a-b450-39250c44ccec"
      unitRef="shares">3473370</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="ia6f6f949224a4e3db7362e44a8479806_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90ZXh0cmVnaW9uOjM5ZTVmMjgzN2UzNjRmMWQ4NDA3OGY1NTkyYjA5YzA0XzI2NjM_11d51337-05b4-458d-a7f9-1dfeb20eafa5">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="icdfa0ea8b62148fe8c31ae85f2e9f203_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90ZXh0cmVnaW9uOjM5ZTVmMjgzN2UzNjRmMWQ4NDA3OGY1NTkyYjA5YzA0XzgyNDYzMzcyMTgzMDU_13cd829d-1402-46eb-a401-4f072aad0c14"
      unitRef="shares">959215</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ia6f6f949224a4e3db7362e44a8479806_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90ZXh0cmVnaW9uOjM5ZTVmMjgzN2UzNjRmMWQ4NDA3OGY1NTkyYjA5YzA0XzI3Mzg_2d42a2a3-ae9c-42ef-8ac9-2457f2bf4694"
      unitRef="usdPerShare">1.21</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="ia6f6f949224a4e3db7362e44a8479806_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90ZXh0cmVnaW9uOjM5ZTVmMjgzN2UzNjRmMWQ4NDA3OGY1NTkyYjA5YzA0XzI5NzI_1426ce04-ffd3-43de-866e-01023e075bad"
      unitRef="usd">111000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i6f825eaecdc54225baf8219928d46fdb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90ZXh0cmVnaW9uOjM5ZTVmMjgzN2UzNjRmMWQ4NDA3OGY1NTkyYjA5YzA0XzI5Nzk_0fb4a8c2-6a15-448b-a8fb-245998a316c1"
      unitRef="usd">35000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i28c4ea3872514bf9a8d5fe2d1d621221_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90ZXh0cmVnaW9uOjM5ZTVmMjgzN2UzNjRmMWQ4NDA3OGY1NTkyYjA5YzA0XzMwNjk_cb2cdc57-acfb-41e7-b75b-33e62cf44619"
      unitRef="usd">81000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i28c4ea3872514bf9a8d5fe2d1d621221_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90ZXh0cmVnaW9uOjM5ZTVmMjgzN2UzNjRmMWQ4NDA3OGY1NTkyYjA5YzA0XzgyNDYzMzcyMTg1MDE_19e4776f-82a7-4edd-874c-33c4d2d4e665"
      unitRef="usd">8000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="i28c4ea3872514bf9a8d5fe2d1d621221_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90ZXh0cmVnaW9uOjM5ZTVmMjgzN2UzNjRmMWQ4NDA3OGY1NTkyYjA5YzA0XzMyMzE_456c7d58-4bb3-4b59-9b0d-aacb300f2821"
      unitRef="usd">4368000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="ia6f6f949224a4e3db7362e44a8479806_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90ZXh0cmVnaW9uOjM5ZTVmMjgzN2UzNjRmMWQ4NDA3OGY1NTkyYjA5YzA0XzMzNDM_44a833b9-4f29-477c-b236-1637acfb9da2">P2Y4M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="icdfa0ea8b62148fe8c31ae85f2e9f203_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90ZXh0cmVnaW9uOjM5ZTVmMjgzN2UzNjRmMWQ4NDA3OGY1NTkyYjA5YzA0XzgyNDYzMzcyMjAwNzc_13cd829d-1402-46eb-a401-4f072aad0c14"
      unitRef="shares">959215</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="icdfa0ea8b62148fe8c31ae85f2e9f203_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90ZXh0cmVnaW9uOjM5ZTVmMjgzN2UzNjRmMWQ4NDA3OGY1NTkyYjA5YzA0XzgyNDYzMzcyMTk4NDM_6fea3222-ac21-4f6f-99c5-a4ca345f2604">P2Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="icdfa0ea8b62148fe8c31ae85f2e9f203_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90ZXh0cmVnaW9uOjM5ZTVmMjgzN2UzNjRmMWQ4NDA3OGY1NTkyYjA5YzA0XzgyNDYzMzcyMjAzNjg_42c4ca62-1403-4e3a-8f86-93ffecbce529"
      unitRef="shares">297677</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i34d0a9c04a2f4859a044c9e6cc370e55_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90ZXh0cmVnaW9uOjM5ZTVmMjgzN2UzNjRmMWQ4NDA3OGY1NTkyYjA5YzA0XzMzODU_ba197acd-e89c-4a05-bde9-61cf2b0de91e"
      unitRef="shares">753500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i7dc5537455904ed088d5e7907081fa28_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90ZXh0cmVnaW9uOjM5ZTVmMjgzN2UzNjRmMWQ4NDA3OGY1NTkyYjA5YzA0XzM3MTg_6c9b3191-58fe-4c60-8679-2ef4fe740c20">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90ZXh0cmVnaW9uOjM5ZTVmMjgzN2UzNjRmMWQ4NDA3OGY1NTkyYjA5YzA0Xzk4MDE_957cbbd9-1589-4fb9-a9fd-9f03e72d5c15">&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the activity related to RSUs granted to employees for the year ended December 31, 2022:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:88.227%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,959,358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,105,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Vested and settled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(949,857)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expired/forfeited/canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(637,087)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,477,660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected to vest at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,477,660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="idbf17e5750434c4fa4c7af6d79eb5f3b_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90YWJsZTo2NjI1YzY1YmM2ZjU0NzJiYjQ4MGFiNmViYTA2NjIwNi90YWJsZXJhbmdlOjY2MjVjNjViYzZmNTQ3MmJiNDgwYWI2ZWJhMDY2MjA2XzEtMS0xLTEtNTgzNzI_d809ee36-c9fc-4e67-9d6f-ea513672dcea"
      unitRef="shares">1959358</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i7dc5537455904ed088d5e7907081fa28_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90YWJsZTo2NjI1YzY1YmM2ZjU0NzJiYjQ4MGFiNmViYTA2NjIwNi90YWJsZXJhbmdlOjY2MjVjNjViYzZmNTQ3MmJiNDgwYWI2ZWJhMDY2MjA2XzItMS0xLTEtNTgzNzI_486c76a7-307d-4444-ac65-ee3e187651a3"
      unitRef="shares">1105246</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i7dc5537455904ed088d5e7907081fa28_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90YWJsZTo2NjI1YzY1YmM2ZjU0NzJiYjQ4MGFiNmViYTA2NjIwNi90YWJsZXJhbmdlOjY2MjVjNjViYzZmNTQ3MmJiNDgwYWI2ZWJhMDY2MjA2XzMtMS0xLTEtNTgzNzI_f5dc86d8-51dd-4d69-86cb-8320d7d4b704"
      unitRef="shares">949857</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i7dc5537455904ed088d5e7907081fa28_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90YWJsZTo2NjI1YzY1YmM2ZjU0NzJiYjQ4MGFiNmViYTA2NjIwNi90YWJsZXJhbmdlOjY2MjVjNjViYzZmNTQ3MmJiNDgwYWI2ZWJhMDY2MjA2XzQtMS0xLTEtNTgzNzI_76aff7f4-0b05-4d24-98a6-68ef31cf6d34"
      unitRef="shares">637087</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i15fbdc49b67e41af98201248589f1f68_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90YWJsZTo2NjI1YzY1YmM2ZjU0NzJiYjQ4MGFiNmViYTA2NjIwNi90YWJsZXJhbmdlOjY2MjVjNjViYzZmNTQ3MmJiNDgwYWI2ZWJhMDY2MjA2XzUtMS0xLTEtNTgzNzI_94391573-c22f-4b22-b85e-b559b0f5131a"
      unitRef="shares">1477660</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <optn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestNumber
      contextRef="i15fbdc49b67e41af98201248589f1f68_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90YWJsZTo2NjI1YzY1YmM2ZjU0NzJiYjQ4MGFiNmViYTA2NjIwNi90YWJsZXJhbmdlOjY2MjVjNjViYzZmNTQ3MmJiNDgwYWI2ZWJhMDY2MjA2XzYtMS0xLTEtNTgzNzI_d4c9da1f-adff-49f9-8f82-6b4aed66f0ee"
      unitRef="shares">1477660</optn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i7dc5537455904ed088d5e7907081fa28_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90ZXh0cmVnaW9uOjM5ZTVmMjgzN2UzNjRmMWQ4NDA3OGY1NTkyYjA5YzA0XzQwMTg_9441b548-98fb-4407-ab63-7d085fb77a4f"
      unitRef="shares">1105246</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i7dc5537455904ed088d5e7907081fa28_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90ZXh0cmVnaW9uOjM5ZTVmMjgzN2UzNjRmMWQ4NDA3OGY1NTkyYjA5YzA0XzQwNzM_55424e5f-74a3-4cd5-8d44-e97df76e665e"
      unitRef="usdPerShare">1.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="icae44ec705a54e90b329084893ffe064_D20220615-20220615"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90ZXh0cmVnaW9uOjM5ZTVmMjgzN2UzNjRmMWQ4NDA3OGY1NTkyYjA5YzA0XzgyNDYzMzcyMTg5MjY_1c644461-3a28-46f9-9f00-f68d658cf93f"
      unitRef="shares">248827</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i7dc5537455904ed088d5e7907081fa28_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90ZXh0cmVnaW9uOjM5ZTVmMjgzN2UzNjRmMWQ4NDA3OGY1NTkyYjA5YzA0XzgyNDYzMzcyMTg5MzE_a12f7874-b1a6-414a-a5c4-f8343ba8d3fa"
      unitRef="usd">1669000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="i4d238e610edc4182b197232b0495fdf4_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90ZXh0cmVnaW9uOjM5ZTVmMjgzN2UzNjRmMWQ4NDA3OGY1NTkyYjA5YzA0XzQ0NjY_8eb0d99e-c4e1-41ee-8c54-f25d8eb41e13"
      unitRef="usd">3123000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i516c5d169f6840f49a095d9630b5c9ae_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90ZXh0cmVnaW9uOjM5ZTVmMjgzN2UzNjRmMWQ4NDA3OGY1NTkyYjA5YzA0XzQ1NDU_f953ac69-9d06-420c-9d9c-68ec9663c2e0">P2Y2M26D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="if23267985b9b470489888a9e025653a4_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90ZXh0cmVnaW9uOjM5ZTVmMjgzN2UzNjRmMWQ4NDA3OGY1NTkyYjA5YzA0XzQ2Mzc_d5969539-afe5-45c4-8782-2a60cc0d7188"
      unitRef="usd">942000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="if62b2d5afbd04093b3379124f22b23c5_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90ZXh0cmVnaW9uOjM5ZTVmMjgzN2UzNjRmMWQ4NDA3OGY1NTkyYjA5YzA0XzQ4Mjc_11ae6615-76e2-46e8-8216-78ff743adf28"
      unitRef="shares">60000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i846ff334c7ce400c8af0db347b91f620_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90ZXh0cmVnaW9uOjM5ZTVmMjgzN2UzNjRmMWQ4NDA3OGY1NTkyYjA5YzA0XzUxMzY_bea89dcd-2a68-4d7c-9db4-289ebdd72aba"
      unitRef="shares">2021813</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i846ff334c7ce400c8af0db347b91f620_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90ZXh0cmVnaW9uOjM5ZTVmMjgzN2UzNjRmMWQ4NDA3OGY1NTkyYjA5YzA0XzUzMzQ_cb090a7c-71a6-47cd-b8a0-70b5f8a4e053"
      unitRef="shares">982989</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <optn:SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedIncrementEachYear
      contextRef="idfcc4aa88cd04b0498643a728bb0b299_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90ZXh0cmVnaW9uOjM5ZTVmMjgzN2UzNjRmMWQ4NDA3OGY1NTkyYjA5YzA0XzU2NjQ_fb581b6f-5cda-4dfc-a766-cc85d4a6da34"
      unitRef="number">0.01</optn:SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedIncrementEachYear>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
      contextRef="idfcc4aa88cd04b0498643a728bb0b299_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90ZXh0cmVnaW9uOjM5ZTVmMjgzN2UzNjRmMWQ4NDA3OGY1NTkyYjA5YzA0XzYyMTg_8b2ee76c-6b9b-40da-b600-821518086be4"
      unitRef="number">0.15</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent>
    <optn:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeAccruedRightsToPurchaseCommonStock
      contextRef="i846ff334c7ce400c8af0db347b91f620_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90ZXh0cmVnaW9uOjM5ZTVmMjgzN2UzNjRmMWQ4NDA3OGY1NTkyYjA5YzA0XzYzMTE_1e0e77ba-fa60-46f3-9d1c-b6322f7a871f"
      unitRef="usdPerShare">25</optn:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeAccruedRightsToPurchaseCommonStock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="idfcc4aa88cd04b0498643a728bb0b299_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90ZXh0cmVnaW9uOjM5ZTVmMjgzN2UzNjRmMWQ4NDA3OGY1NTkyYjA5YzA0XzY3MDA_ea332e52-db37-4ee4-b5b3-a6840ba9bd31"
      unitRef="number">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="idfcc4aa88cd04b0498643a728bb0b299_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90ZXh0cmVnaW9uOjM5ZTVmMjgzN2UzNjRmMWQ4NDA3OGY1NTkyYjA5YzA0Xzc3MDc_6845a954-af23-4cb3-bba1-4b6da502902d"
      unitRef="usd">253000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i412f04e9b5124c22a267cc2e9474aa46_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90ZXh0cmVnaW9uOjM5ZTVmMjgzN2UzNjRmMWQ4NDA3OGY1NTkyYjA5YzA0Xzc3MTQ_55901ddb-4c21-4bc7-9063-b6c1d8607bff"
      unitRef="usd">402000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90ZXh0cmVnaW9uOjM5ZTVmMjgzN2UzNjRmMWQ4NDA3OGY1NTkyYjA5YzA0Xzk3OTY_9dd3a29c-2431-4de9-af7b-a6c777b287fb">&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded stock-based compensation expense in the following expense categories of its accompanying consolidated statements of operations for the years ended December 31, 2022 and 2021:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.285%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cost of product sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,079&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,874&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,003&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iaaa623bfd2b7461d815938764c60cf18_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90YWJsZTo2Nzc3OTc1ZTkxMzM0ZTc3ODNlOTU1MjM0Y2Y4MDg5Yi90YWJsZXJhbmdlOjY3Nzc5NzVlOTEzMzRlNzc4M2U5NTUyMzRjZjgwODliXzItMS0xLTEtNTgzNzI_54176db1-b1ac-4c5b-bbc4-a04d90e1d126"
      unitRef="usd">35000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i1ec6ce002f784a1f8f8a3b2b9b9b06ae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90YWJsZTo2Nzc3OTc1ZTkxMzM0ZTc3ODNlOTU1MjM0Y2Y4MDg5Yi90YWJsZXJhbmdlOjY3Nzc5NzVlOTEzMzRlNzc4M2U5NTUyMzRjZjgwODliXzItMy0xLTEtNTgzNzI_da124212-9e76-4347-a02f-4cdeae8bda9e"
      unitRef="usd">50000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iaee85c4768314a529b0fa7b1be860d0c_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90YWJsZTo2Nzc3OTc1ZTkxMzM0ZTc3ODNlOTU1MjM0Y2Y4MDg5Yi90YWJsZXJhbmdlOjY3Nzc5NzVlOTEzMzRlNzc4M2U5NTUyMzRjZjgwODliXzMtMS0xLTEtNTgzNzI_bd14ffbb-2535-4b9d-8bfb-cd63e93f4ab8"
      unitRef="usd">809000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i1cd280125c384cd5a45521262a35af31_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90YWJsZTo2Nzc3OTc1ZTkxMzM0ZTc3ODNlOTU1MjM0Y2Y4MDg5Yi90YWJsZXJhbmdlOjY3Nzc5NzVlOTEzMzRlNzc4M2U5NTUyMzRjZjgwODliXzMtMy0xLTEtNTgzNzI_a39e0581-3ccb-46f6-a4ed-d93210a34daa"
      unitRef="usd">1079000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iff00e227a0ed47e8ac87706a2be40407_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90YWJsZTo2Nzc3OTc1ZTkxMzM0ZTc3ODNlOTU1MjM0Y2Y4MDg5Yi90YWJsZXJhbmdlOjY3Nzc5NzVlOTEzMzRlNzc4M2U5NTUyMzRjZjgwODliXzQtMS0xLTEtNTgzNzI_27d2e5ef-2b03-4718-a568-bbef0c7e8fca"
      unitRef="usd">8033000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i6c74ce02c1434fc183c30fe05522e194_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90YWJsZTo2Nzc3OTc1ZTkxMzM0ZTc3ODNlOTU1MjM0Y2Y4MDg5Yi90YWJsZXJhbmdlOjY3Nzc5NzVlOTEzMzRlNzc4M2U5NTUyMzRjZjgwODliXzQtMy0xLTEtNTgzNzI_b2b0dfeb-4352-4706-ba72-abbbf5141293"
      unitRef="usd">8874000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90YWJsZTo2Nzc3OTc1ZTkxMzM0ZTc3ODNlOTU1MjM0Y2Y4MDg5Yi90YWJsZXJhbmdlOjY3Nzc5NzVlOTEzMzRlNzc4M2U5NTUyMzRjZjgwODliXzUtMS0xLTEtNTgzNzI_35bd53d8-ccff-4bbe-a17e-c820dd046ecb"
      unitRef="usd">8877000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90YWJsZTo2Nzc3OTc1ZTkxMzM0ZTc3ODNlOTU1MjM0Y2Y4MDg5Yi90YWJsZXJhbmdlOjY3Nzc5NzVlOTEzMzRlNzc4M2U5NTUyMzRjZjgwODliXzUtMy0xLTEtNTgzNzI_d845a06a-d1c2-489a-a378-7cdcc97f1d09"
      unitRef="usd">10003000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i3b8fb31b2cb74f1986dbdb60db29474c_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90ZXh0cmVnaW9uOjM5ZTVmMjgzN2UzNjRmMWQ4NDA3OGY1NTkyYjA5YzA0XzgwNTM_1822c6ac-be63-4934-9c8d-4d2bbf98b4c6"
      unitRef="usd">83000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90ZXh0cmVnaW9uOjM5ZTVmMjgzN2UzNjRmMWQ4NDA3OGY1NTkyYjA5YzA0Xzk3ODk_31ec80b9-788c-4b82-bde7-a6f6c9c1cb22">The Company calculated the fair value of each option grant and the shares issued under the 2017 Plan on the respective dates of grant using the following weighted average assumptions: &lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.145%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.387%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2010 A&amp;amp;R Stock Incentive Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2017 Employee Stock Purchase Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Risk free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.08&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.50&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;73.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;88.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Annual dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90ZXh0cmVnaW9uOjM5ZTVmMjgzN2UzNjRmMWQ4NDA3OGY1NTkyYjA5YzA0Xzk4MDA_cd34f8c2-12d3-4d62-b20b-dda4508a7d7c">The Company calculated the fair value of each option grant and the shares issued under the 2017 Plan on the respective dates of grant using the following weighted average assumptions: &lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.145%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.387%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2010 A&amp;amp;R Stock Incentive Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2017 Employee Stock Purchase Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Risk free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.08&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.50&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;73.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;88.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Annual dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i9975a7e3c2704c8988c1154b5ae900d4_D20220101-20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90YWJsZTpkNTc2ZTg2MWNjN2I0NjY2ODAwZTNiNzQ4NzM3MmZhZi90YWJsZXJhbmdlOmQ1NzZlODYxY2M3YjQ2NjY4MDBlM2I3NDg3MzcyZmFmXzItMS0xLTEtNTgzNzI_8aab67e1-3e5a-4299-b300-8ab99360fcd3"
      unitRef="number">0.0222</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="idfcc4aa88cd04b0498643a728bb0b299_D20220101-20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90YWJsZTpkNTc2ZTg2MWNjN2I0NjY2ODAwZTNiNzQ4NzM3MmZhZi90YWJsZXJhbmdlOmQ1NzZlODYxY2M3YjQ2NjY4MDBlM2I3NDg3MzcyZmFmXzItMy0xLTEtNTgzNzI_65db4a36-3d3e-4303-b651-d63eeedb5f2f"
      unitRef="number">0.0017</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i9975a7e3c2704c8988c1154b5ae900d4_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90YWJsZTpkNTc2ZTg2MWNjN2I0NjY2ODAwZTNiNzQ4NzM3MmZhZi90YWJsZXJhbmdlOmQ1NzZlODYxY2M3YjQ2NjY4MDBlM2I3NDg3MzcyZmFmXzMtMS0xLTEtNTgzNzI_3172d46d-b892-4218-87b5-990551eeda68">P6Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="idfcc4aa88cd04b0498643a728bb0b299_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90YWJsZTpkNTc2ZTg2MWNjN2I0NjY2ODAwZTNiNzQ4NzM3MmZhZi90YWJsZXJhbmdlOmQ1NzZlODYxY2M3YjQ2NjY4MDBlM2I3NDg3MzcyZmFmXzMtMy0xLTEtNTgzNzI_530c1afc-aa2c-4d9b-a531-d0003a4b577d">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="i9975a7e3c2704c8988c1154b5ae900d4_D20220101-20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90YWJsZTpkNTc2ZTg2MWNjN2I0NjY2ODAwZTNiNzQ4NzM3MmZhZi90YWJsZXJhbmdlOmQ1NzZlODYxY2M3YjQ2NjY4MDBlM2I3NDg3MzcyZmFmXzQtMS0xLTEtNTgzNzI_38687dc1-8eea-4605-a842-aeebac3161f7"
      unitRef="number">0.7323</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="idfcc4aa88cd04b0498643a728bb0b299_D20220101-20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90YWJsZTpkNTc2ZTg2MWNjN2I0NjY2ODAwZTNiNzQ4NzM3MmZhZi90YWJsZXJhbmdlOmQ1NzZlODYxY2M3YjQ2NjY4MDBlM2I3NDg3MzcyZmFmXzQtMy0xLTEtNTgzNzI_41d5eba2-d90c-4157-859a-30a56a11b0ba"
      unitRef="number">0.8813</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i9975a7e3c2704c8988c1154b5ae900d4_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90YWJsZTpkNTc2ZTg2MWNjN2I0NjY2ODAwZTNiNzQ4NzM3MmZhZi90YWJsZXJhbmdlOmQ1NzZlODYxY2M3YjQ2NjY4MDBlM2I3NDg3MzcyZmFmXzUtMS0xLTEtNTgzNzI_356bcdf2-8125-4501-b5bb-c794b5275983"
      unitRef="number">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="idfcc4aa88cd04b0498643a728bb0b299_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90YWJsZTpkNTc2ZTg2MWNjN2I0NjY2ODAwZTNiNzQ4NzM3MmZhZi90YWJsZXJhbmdlOmQ1NzZlODYxY2M3YjQ2NjY4MDBlM2I3NDg3MzcyZmFmXzUtMy0xLTEtNTgzNzI_66fa7b15-a966-4fe4-abf5-615f873c29e9"
      unitRef="number">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzUvZnJhZzozOWU1ZjI4MzdlMzY0ZjFkODQwNzhmNTU5MmIwOWMwNC90ZXh0cmVnaW9uOjM5ZTVmMjgzN2UzNjRmMWQ4NDA3OGY1NTkyYjA5YzA0Xzk2NTQ_47b867da-7daf-455e-af0e-3ec47973624a"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzgvZnJhZzpkNjc4MzlkZGQwMzU0YWI1OTRmOGFjMDE4ZDQzYzRkYy90ZXh0cmVnaW9uOmQ2NzgzOWRkZDAzNTRhYjU5NGY4YWMwMThkNDNjNGRjXzUyNzg_8e94a139-7173-406b-990e-7f7d7a7700dc">Income Taxes&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income taxes are based on the following book income (loss) before income tax expense:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.818%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.012%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Domestic operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(72,750)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(78,801)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Foreign operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,083)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,495)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Loss before provision for income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(74,833)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(82,296)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of income tax expense (benefit) at the US federal statutory income tax rate and the income tax provision in the financial statements is as follows: &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.644%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.505%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.994%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.405%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.852%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Income tax expense at statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Permanent items&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Foreign rate differential&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Impact of foreign operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(14.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;State taxes, net of federal benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Tax rate changes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Foreign exchange and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Stock based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Prepaid royalty write off&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(11.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(24.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Effective income tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The principal components of the Company&#x2019;s deferred tax assets and liabilities are as follows: &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.241%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.523%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.027%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.432%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.177%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Accrued expenses and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Prepaid licensing arrangement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,708&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Stock compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Research and development credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,461&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Capitalized R&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Net operating losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;83,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;87,324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;116,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;126,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Fixed assets, including leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(171)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(210)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Right-to-use asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(605)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,024)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Total deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(776)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,234)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Less: Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(115,720)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(125,076)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total net deferred tax assets (liabilities)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2022, the Company had foreign net operating loss (NOL) carry forwards of $9,073, primarily from its operations in Norway. As of December 31, 2022, the Company had federal and state NOLs of $335,009 and $252,324, respectively. These domestic NOL carry forwards may be subject to an annual limitation in the event of cumulative changes in the ownership interests of significant stockholders over a three-year period in excess of 50%. This could limit the amount of NOLs that the Company can utilize annually to offset future domestic taxable income, if any. The amount of the annual limitation, if any, will be determined based on the value of the Company immediately prior to the ownership change. Subsequent ownership changes may further affect the limitation in future years. The federal NOLs generated after 2017 have an indefinite carry forward period. The federal NOLs generated prior to 2018 will expire from 2030 through 2037. Some state NOLs will not expire while other state NOLs expire over various periods depending on the rules of the jurisdiction in which they were generated. The earliest state NOL expiration is in 2030.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The U.S. NOL and tax credit carry forwards could expire unused and be unavailable to offset future income tax liabilities because of their limited duration or because of other restrictions under U.S. tax law. Under Sections 382 and 383, if a corporation undergoes an &#x201c;ownership change&#x201d;, generally defined as a greater than 50% change, by value, in equity ownership during a three-year period, the corporation&#x2019;s ability to offset pre-change tax attributes, such as NOLs and R&amp;amp;D tax credits, against post-change income or tax may be limited. We have not performed an analysis under Section 382 and cannot predict or otherwise determine whether utilization of our federal tax attribute carry forwards may be limited. As a result, if we have taxable income in the future, our ability to use existing U.S. NOL and R&amp;amp;D tax credit carry forwards to reduce U.S. taxable income or tax liability may be subject to limitation resulting in increased future tax liabilities. Similar rules at the state level may also limit our ability to use state NOLs. Also, there may be periods when the use of NOLs is suspended or otherwise limited at the state level, which could accelerate or permanently increase state taxes owed.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:103%"&gt;The company also has federal and state R&amp;amp;D credit carryforwards of $2,487 which can be carried forward for 20 years beginning to expire in 2031&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:103%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASC 740 requires the establishment of a valuation allowance to reduce deferred tax assets if, based on the weight of the available positive and negative evidence it is more likely than not that all or a portion of the deferred tax assets will not be realized. There is insufficient positive evidence to overcome the negative evidence attributable to the Company&#x2019;s cumulative operating losses. Consequently, the Company established a full valuation allowance against its net deferred tax assets at December 31, 2022 and 2021, respectively, because the Company&#x2019;s management was unable to conclude that it is more likely than not that these assets will be fully realized. The Company had a net decrease in its valuation allowance of $9,356 during the year ended December 31, 2022, primarily related to material deferred tax asset write offs from prepaid royalty and equity compensation as well as Norway NOL utilization in the current year.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company files income tax returns in Norway, the UK, the US, and various states. The Company is subject to examination by federal, state and foreign jurisdictions. The Company&#x2019;s tax years in the US are open under statute from inception to present. All open years may be examined to the extent that tax credits or net operating loss carry forwards are used in future periods. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s policy is to record interest and penalties related to uncertain tax positions in income tax expense.  As of December 31, 2022, the Company had no accrued interest or penalties related to uncertain tax positions and no amounts have been recognized in the Company&#x2019;s statement of operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (CARES Act) was enacted into law in response to the COVID-19 pandemic. The CARES Act contains income tax provisions, such an enhanced interest deductibility, repeal of the 80% limitation with respect to net operating losses arising in taxable years 2018-2020, and additional depreciation deductions related to qualified improvement property. The Company has concluded the analysis of these provisions as of year-end and the CARES Act did not have a material impact on the Company&#x2019;s income taxes for 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 27, 2020, the Consolidated Appropriations Act, 2021 (CAA) was signed into law. Along with providing funding for normal government operations ($1.4 trillion), this bill provides for additional COVID-19 focused relief ($900 billion). The CAA extends certain provisions of the CARES Act, provides additional funding for others and contains new relief provisions. The CAA did not have a material impact on the Company&#x2019;s income taxes for 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 16, 2022, the Inflation Reduction Act of 2022 was enacted into law containing corporate income tax provisions such as the corporate alternative minimum tax and an excise tax on the repurchase of corporate stock. These provisions are not expected to have a material impact on the Company's income taxes in the near term.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzgvZnJhZzpkNjc4MzlkZGQwMzU0YWI1OTRmOGFjMDE4ZDQzYzRkYy90ZXh0cmVnaW9uOmQ2NzgzOWRkZDAzNTRhYjU5NGY4YWMwMThkNDNjNGRjXzUyODE_a6a6dbdd-3bab-45bd-8b1e-24f985f12b3b">&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income taxes are based on the following book income (loss) before income tax expense:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.818%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.012%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Domestic operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(72,750)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(78,801)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Foreign operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,083)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,495)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Loss before provision for income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(74,833)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(82,296)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzgvZnJhZzpkNjc4MzlkZGQwMzU0YWI1OTRmOGFjMDE4ZDQzYzRkYy90YWJsZTpkMzNlOTkwNDU1OTY0ZWYwODU2MmE0MjJhN2Y0MjExYi90YWJsZXJhbmdlOmQzM2U5OTA0NTU5NjRlZjA4NTYyYTQyMmE3ZjQyMTFiXzItMi0xLTEtNTgzNzI_82b9f9e2-ba61-4b36-b6ad-a650d268b0e4"
      unitRef="usd">-72750000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzgvZnJhZzpkNjc4MzlkZGQwMzU0YWI1OTRmOGFjMDE4ZDQzYzRkYy90YWJsZTpkMzNlOTkwNDU1OTY0ZWYwODU2MmE0MjJhN2Y0MjExYi90YWJsZXJhbmdlOmQzM2U5OTA0NTU5NjRlZjA4NTYyYTQyMmE3ZjQyMTFiXzItNC0xLTEtNTgzNzI_b308934f-338f-4424-8e7b-e83dd1dd35a6"
      unitRef="usd">-78801000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzgvZnJhZzpkNjc4MzlkZGQwMzU0YWI1OTRmOGFjMDE4ZDQzYzRkYy90YWJsZTpkMzNlOTkwNDU1OTY0ZWYwODU2MmE0MjJhN2Y0MjExYi90YWJsZXJhbmdlOmQzM2U5OTA0NTU5NjRlZjA4NTYyYTQyMmE3ZjQyMTFiXzMtMi0xLTEtNTgzNzI_60b3b708-f989-452d-b95b-ca00f58386ff"
      unitRef="usd">-2083000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzgvZnJhZzpkNjc4MzlkZGQwMzU0YWI1OTRmOGFjMDE4ZDQzYzRkYy90YWJsZTpkMzNlOTkwNDU1OTY0ZWYwODU2MmE0MjJhN2Y0MjExYi90YWJsZXJhbmdlOmQzM2U5OTA0NTU5NjRlZjA4NTYyYTQyMmE3ZjQyMTFiXzMtNC0xLTEtNTgzNzI_d2209b3c-8bbf-4ecc-9214-f08ad2454b3d"
      unitRef="usd">-3495000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzgvZnJhZzpkNjc4MzlkZGQwMzU0YWI1OTRmOGFjMDE4ZDQzYzRkYy90YWJsZTpkMzNlOTkwNDU1OTY0ZWYwODU2MmE0MjJhN2Y0MjExYi90YWJsZXJhbmdlOmQzM2U5OTA0NTU5NjRlZjA4NTYyYTQyMmE3ZjQyMTFiXzQtMi0xLTEtNTgzNzI_092d5f5a-f223-4648-9e9a-55f994cad1cf"
      unitRef="usd">-74833000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzgvZnJhZzpkNjc4MzlkZGQwMzU0YWI1OTRmOGFjMDE4ZDQzYzRkYy90YWJsZTpkMzNlOTkwNDU1OTY0ZWYwODU2MmE0MjJhN2Y0MjExYi90YWJsZXJhbmdlOmQzM2U5OTA0NTU5NjRlZjA4NTYyYTQyMmE3ZjQyMTFiXzQtNC0xLTEtNTgzNzI_85abdbfa-7b8e-4d96-8164-0dba7a697632"
      unitRef="usd">-82296000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzgvZnJhZzpkNjc4MzlkZGQwMzU0YWI1OTRmOGFjMDE4ZDQzYzRkYy90ZXh0cmVnaW9uOmQ2NzgzOWRkZDAzNTRhYjU5NGY4YWMwMThkNDNjNGRjXzUyODI_098ea10f-b723-4a50-9944-1d9d6be7ee09">&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of income tax expense (benefit) at the US federal statutory income tax rate and the income tax provision in the financial statements is as follows: &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.644%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.505%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.994%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.405%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.852%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Income tax expense at statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Permanent items&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Foreign rate differential&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Impact of foreign operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(14.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;State taxes, net of federal benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Tax rate changes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Foreign exchange and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Stock based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Prepaid royalty write off&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(11.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(24.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Effective income tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzgvZnJhZzpkNjc4MzlkZGQwMzU0YWI1OTRmOGFjMDE4ZDQzYzRkYy90YWJsZTo1NTJkMmQzODNiODU0N2Q2OGFlM2Y5YzlkNTk1NDE4Ni90YWJsZXJhbmdlOjU1MmQyZDM4M2I4NTQ3ZDY4YWUzZjljOWQ1OTU0MTg2XzItMi0xLTEtNTgzNzI_40535a25-c182-46a1-a98b-9833d9469b68"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzgvZnJhZzpkNjc4MzlkZGQwMzU0YWI1OTRmOGFjMDE4ZDQzYzRkYy90YWJsZTo1NTJkMmQzODNiODU0N2Q2OGFlM2Y5YzlkNTk1NDE4Ni90YWJsZXJhbmdlOjU1MmQyZDM4M2I4NTQ3ZDY4YWUzZjljOWQ1OTU0MTg2XzItNC0xLTEtNTgzNzI_8909c27c-131d-4003-b95c-6fddf5d17608"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzgvZnJhZzpkNjc4MzlkZGQwMzU0YWI1OTRmOGFjMDE4ZDQzYzRkYy90YWJsZTo1NTJkMmQzODNiODU0N2Q2OGFlM2Y5YzlkNTk1NDE4Ni90YWJsZXJhbmdlOjU1MmQyZDM4M2I4NTQ3ZDY4YWUzZjljOWQ1OTU0MTg2XzMtMi0xLTEtNTgzNzI_ff0f0ec9-2da1-45e8-b1a1-01b92f3aa880"
      unitRef="number">-0.015</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzgvZnJhZzpkNjc4MzlkZGQwMzU0YWI1OTRmOGFjMDE4ZDQzYzRkYy90YWJsZTo1NTJkMmQzODNiODU0N2Q2OGFlM2Y5YzlkNTk1NDE4Ni90YWJsZXJhbmdlOjU1MmQyZDM4M2I4NTQ3ZDY4YWUzZjljOWQ1OTU0MTg2XzMtNC0xLTEtNTgzNzI_81072896-99a2-4529-9050-8f098d29bb55"
      unitRef="number">-0.004</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzgvZnJhZzpkNjc4MzlkZGQwMzU0YWI1OTRmOGFjMDE4ZDQzYzRkYy90YWJsZTo1NTJkMmQzODNiODU0N2Q2OGFlM2Y5YzlkNTk1NDE4Ni90YWJsZXJhbmdlOjU1MmQyZDM4M2I4NTQ3ZDY4YWUzZjljOWQ1OTU0MTg2XzQtMi0xLTEtNTgzNzI_24fe6602-2f92-4935-a671-c3ba014f0c10"
      unitRef="number">-0.007</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzgvZnJhZzpkNjc4MzlkZGQwMzU0YWI1OTRmOGFjMDE4ZDQzYzRkYy90YWJsZTo1NTJkMmQzODNiODU0N2Q2OGFlM2Y5YzlkNTk1NDE4Ni90YWJsZXJhbmdlOjU1MmQyZDM4M2I4NTQ3ZDY4YWUzZjljOWQ1OTU0MTg2XzQtNC0xLTEtNTgzNzI_cab2594c-d34d-4281-8b85-7aac0323ebee"
      unitRef="number">0.001</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <optn:EffectiveIncomeTaxRateReconciliationForeignOperationsImpactPercent
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzgvZnJhZzpkNjc4MzlkZGQwMzU0YWI1OTRmOGFjMDE4ZDQzYzRkYy90YWJsZTo1NTJkMmQzODNiODU0N2Q2OGFlM2Y5YzlkNTk1NDE4Ni90YWJsZXJhbmdlOjU1MmQyZDM4M2I4NTQ3ZDY4YWUzZjljOWQ1OTU0MTg2XzUtMi0xLTEtNTgzNzI_069e6e43-23f1-4dc8-af7d-ed8cdbd53ced"
      unitRef="number">-0.145</optn:EffectiveIncomeTaxRateReconciliationForeignOperationsImpactPercent>
    <optn:EffectiveIncomeTaxRateReconciliationForeignOperationsImpactPercent
      contextRef="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzgvZnJhZzpkNjc4MzlkZGQwMzU0YWI1OTRmOGFjMDE4ZDQzYzRkYy90YWJsZTo1NTJkMmQzODNiODU0N2Q2OGFlM2Y5YzlkNTk1NDE4Ni90YWJsZXJhbmdlOjU1MmQyZDM4M2I4NTQ3ZDY4YWUzZjljOWQ1OTU0MTg2XzUtNC0xLTEtNTgzNzI_0514c75d-3ecf-4740-bf1e-9cb6fb071009"
      unitRef="number">0</optn:EffectiveIncomeTaxRateReconciliationForeignOperationsImpactPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzgvZnJhZzpkNjc4MzlkZGQwMzU0YWI1OTRmOGFjMDE4ZDQzYzRkYy90YWJsZTo1NTJkMmQzODNiODU0N2Q2OGFlM2Y5YzlkNTk1NDE4Ni90YWJsZXJhbmdlOjU1MmQyZDM4M2I4NTQ3ZDY4YWUzZjljOWQ1OTU0MTg2XzYtMi0xLTEtNTgzNzI_cdb1d96c-6e95-4d78-9870-bc6680cfa4d6"
      unitRef="number">0.026</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzgvZnJhZzpkNjc4MzlkZGQwMzU0YWI1OTRmOGFjMDE4ZDQzYzRkYy90YWJsZTo1NTJkMmQzODNiODU0N2Q2OGFlM2Y5YzlkNTk1NDE4Ni90YWJsZXJhbmdlOjU1MmQyZDM4M2I4NTQ3ZDY4YWUzZjljOWQ1OTU0MTg2XzYtNC0xLTEtNTgzNzI_4034f5d8-2618-4fcf-b094-174dc9e814a5"
      unitRef="number">0.047</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzgvZnJhZzpkNjc4MzlkZGQwMzU0YWI1OTRmOGFjMDE4ZDQzYzRkYy90YWJsZTo1NTJkMmQzODNiODU0N2Q2OGFlM2Y5YzlkNTk1NDE4Ni90YWJsZXJhbmdlOjU1MmQyZDM4M2I4NTQ3ZDY4YWUzZjljOWQ1OTU0MTg2XzctMi0xLTEtNTgzNzI_45a8c4af-a943-46f5-87bf-3fa107a364b4"
      unitRef="number">-0.029</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
      contextRef="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzgvZnJhZzpkNjc4MzlkZGQwMzU0YWI1OTRmOGFjMDE4ZDQzYzRkYy90YWJsZTo1NTJkMmQzODNiODU0N2Q2OGFlM2Y5YzlkNTk1NDE4Ni90YWJsZXJhbmdlOjU1MmQyZDM4M2I4NTQ3ZDY4YWUzZjljOWQ1OTU0MTg2XzctNC0xLTEtNTgzNzI_48854fe5-7a5b-461a-8957-227937a420e4"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <optn:EffectiveIncomeTaxRateReconciliationForeignExchangeOtherPercent
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzgvZnJhZzpkNjc4MzlkZGQwMzU0YWI1OTRmOGFjMDE4ZDQzYzRkYy90YWJsZTo1NTJkMmQzODNiODU0N2Q2OGFlM2Y5YzlkNTk1NDE4Ni90YWJsZXJhbmdlOjU1MmQyZDM4M2I4NTQ3ZDY4YWUzZjljOWQ1OTU0MTg2XzgtMi0xLTEtNTgzNzI_7eca5bfa-39c7-468c-9dbe-f566e4918988"
      unitRef="number">-0.017</optn:EffectiveIncomeTaxRateReconciliationForeignExchangeOtherPercent>
    <optn:EffectiveIncomeTaxRateReconciliationForeignExchangeOtherPercent
      contextRef="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzgvZnJhZzpkNjc4MzlkZGQwMzU0YWI1OTRmOGFjMDE4ZDQzYzRkYy90YWJsZTo1NTJkMmQzODNiODU0N2Q2OGFlM2Y5YzlkNTk1NDE4Ni90YWJsZXJhbmdlOjU1MmQyZDM4M2I4NTQ3ZDY4YWUzZjljOWQ1OTU0MTg2XzgtNC0xLTEtNTgzNzI_4cfbd1a7-097e-49d3-ace6-1095d7391570"
      unitRef="number">-0.009</optn:EffectiveIncomeTaxRateReconciliationForeignExchangeOtherPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzgvZnJhZzpkNjc4MzlkZGQwMzU0YWI1OTRmOGFjMDE4ZDQzYzRkYy90YWJsZTo1NTJkMmQzODNiODU0N2Q2OGFlM2Y5YzlkNTk1NDE4Ni90YWJsZXJhbmdlOjU1MmQyZDM4M2I4NTQ3ZDY4YWUzZjljOWQ1OTU0MTg2XzktMi0xLTEtMTEwNzA1_97a3cd2d-a5b6-4c43-9b32-64909923da30"
      unitRef="number">0.029</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzgvZnJhZzpkNjc4MzlkZGQwMzU0YWI1OTRmOGFjMDE4ZDQzYzRkYy90YWJsZTo1NTJkMmQzODNiODU0N2Q2OGFlM2Y5YzlkNTk1NDE4Ni90YWJsZXJhbmdlOjU1MmQyZDM4M2I4NTQ3ZDY4YWUzZjljOWQ1OTU0MTg2XzktNC0xLTEtMTExMDUy_b3b73a30-d0f4-4db9-bcc6-daf283350268"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <optn:EffectiveIncomeTaxRateReconciliationPrepaidRoyaltyWriteOffPercent
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzgvZnJhZzpkNjc4MzlkZGQwMzU0YWI1OTRmOGFjMDE4ZDQzYzRkYy90YWJsZTo1NTJkMmQzODNiODU0N2Q2OGFlM2Y5YzlkNTk1NDE4Ni90YWJsZXJhbmdlOjU1MmQyZDM4M2I4NTQ3ZDY4YWUzZjljOWQ1OTU0MTg2XzEwLTItMS0xLTExMzI3MQ_c31056e2-1622-42a8-961c-36efb7b0ef7d"
      unitRef="number">-0.118</optn:EffectiveIncomeTaxRateReconciliationPrepaidRoyaltyWriteOffPercent>
    <optn:EffectiveIncomeTaxRateReconciliationPrepaidRoyaltyWriteOffPercent
      contextRef="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzgvZnJhZzpkNjc4MzlkZGQwMzU0YWI1OTRmOGFjMDE4ZDQzYzRkYy90YWJsZTo1NTJkMmQzODNiODU0N2Q2OGFlM2Y5YzlkNTk1NDE4Ni90YWJsZXJhbmdlOjU1MmQyZDM4M2I4NTQ3ZDY4YWUzZjljOWQ1OTU0MTg2XzEwLTQtMS0xLTExMzI0NA_0d4c928b-13f8-4e7f-9518-c73ce2aecad9"
      unitRef="number">0</optn:EffectiveIncomeTaxRateReconciliationPrepaidRoyaltyWriteOffPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzgvZnJhZzpkNjc4MzlkZGQwMzU0YWI1OTRmOGFjMDE4ZDQzYzRkYy90YWJsZTo1NTJkMmQzODNiODU0N2Q2OGFlM2Y5YzlkNTk1NDE4Ni90YWJsZXJhbmdlOjU1MmQyZDM4M2I4NTQ3ZDY4YWUzZjljOWQ1OTU0MTg2XzktMi0xLTEtNTgzNzI_30cb48e8-9e63-4add-bb21-22a8d0844488"
      unitRef="number">0.124</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzgvZnJhZzpkNjc4MzlkZGQwMzU0YWI1OTRmOGFjMDE4ZDQzYzRkYy90YWJsZTo1NTJkMmQzODNiODU0N2Q2OGFlM2Y5YzlkNTk1NDE4Ni90YWJsZXJhbmdlOjU1MmQyZDM4M2I4NTQ3ZDY4YWUzZjljOWQ1OTU0MTg2XzktNC0xLTEtNTgzNzI_c61b3605-fe61-415a-b502-5d742b1a1b50"
      unitRef="number">-0.245</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzgvZnJhZzpkNjc4MzlkZGQwMzU0YWI1OTRmOGFjMDE4ZDQzYzRkYy90YWJsZTo1NTJkMmQzODNiODU0N2Q2OGFlM2Y5YzlkNTk1NDE4Ni90YWJsZXJhbmdlOjU1MmQyZDM4M2I4NTQ3ZDY4YWUzZjljOWQ1OTU0MTg2XzEwLTItMS0xLTU4Mzcy_2e53db7a-addf-410d-a145-9ed3e31c600c"
      unitRef="number">0.000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="ia77a243c9ffc4784b041c2eb52cd0dc4_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzgvZnJhZzpkNjc4MzlkZGQwMzU0YWI1OTRmOGFjMDE4ZDQzYzRkYy90YWJsZTo1NTJkMmQzODNiODU0N2Q2OGFlM2Y5YzlkNTk1NDE4Ni90YWJsZXJhbmdlOjU1MmQyZDM4M2I4NTQ3ZDY4YWUzZjljOWQ1OTU0MTg2XzEwLTQtMS0xLTU4Mzcy_c3c34ca7-2437-49a5-bebb-e6b1a54fad6d"
      unitRef="number">0.000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzgvZnJhZzpkNjc4MzlkZGQwMzU0YWI1OTRmOGFjMDE4ZDQzYzRkYy90ZXh0cmVnaW9uOmQ2NzgzOWRkZDAzNTRhYjU5NGY4YWMwMThkNDNjNGRjXzUyNzY_40bb4e00-80c7-4d7f-b67a-9e4e38f67a22">&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The principal components of the Company&#x2019;s deferred tax assets and liabilities are as follows: &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.241%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.523%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.027%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.432%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.177%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Accrued expenses and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Prepaid licensing arrangement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,708&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Stock compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Research and development credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,461&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Capitalized R&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Net operating losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;83,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;87,324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;116,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;126,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Fixed assets, including leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(171)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(210)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Right-to-use asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(605)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,024)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Total deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(776)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,234)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Less: Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(115,720)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(125,076)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total net deferred tax assets (liabilities)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpense
      contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzgvZnJhZzpkNjc4MzlkZGQwMzU0YWI1OTRmOGFjMDE4ZDQzYzRkYy90YWJsZTplNWZmMjEzNzdjNmY0Y2YyYmViNDA2N2JkMmEyMmYxYy90YWJsZXJhbmdlOmU1ZmYyMTM3N2M2ZjRjZjJiZWI0MDY3YmQyYTIyZjFjXzMtMi0xLTEtNTgzNzI_5a25d944-bcc5-4357-bc1e-fd8d0cf4dcb6"
      unitRef="usd">5144000</us-gaap:DeferredTaxAssetsTaxDeferredExpense>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpense
      contextRef="id970dfd2674c4d6b895febb9c14d0fd1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzgvZnJhZzpkNjc4MzlkZGQwMzU0YWI1OTRmOGFjMDE4ZDQzYzRkYy90YWJsZTplNWZmMjEzNzdjNmY0Y2YyYmViNDA2N2JkMmEyMmYxYy90YWJsZXJhbmdlOmU1ZmYyMTM3N2M2ZjRjZjJiZWI0MDY3YmQyYTIyZjFjXzMtNC0xLTEtNTgzNzI_58675629-6649-425e-8da2-2e595c984362"
      unitRef="usd">6712000</us-gaap:DeferredTaxAssetsTaxDeferredExpense>
    <optn:DeferredTaxAssetsPrepaidLicenseArrangement
      contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzgvZnJhZzpkNjc4MzlkZGQwMzU0YWI1OTRmOGFjMDE4ZDQzYzRkYy90YWJsZTplNWZmMjEzNzdjNmY0Y2YyYmViNDA2N2JkMmEyMmYxYy90YWJsZXJhbmdlOmU1ZmYyMTM3N2M2ZjRjZjJiZWI0MDY3YmQyYTIyZjFjXzQtMi0xLTEtNTgzNzI_a37b6de3-21fa-4012-8cc3-881d5c93f84a"
      unitRef="usd">0</optn:DeferredTaxAssetsPrepaidLicenseArrangement>
    <optn:DeferredTaxAssetsPrepaidLicenseArrangement
      contextRef="id970dfd2674c4d6b895febb9c14d0fd1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzgvZnJhZzpkNjc4MzlkZGQwMzU0YWI1OTRmOGFjMDE4ZDQzYzRkYy90YWJsZTplNWZmMjEzNzdjNmY0Y2YyYmViNDA2N2JkMmEyMmYxYy90YWJsZXJhbmdlOmU1ZmYyMTM3N2M2ZjRjZjJiZWI0MDY3YmQyYTIyZjFjXzQtNC0xLTEtNTgzNzI_c2092f73-2dd4-44ca-a4bf-896f05bacfa3"
      unitRef="usd">9441000</optn:DeferredTaxAssetsPrepaidLicenseArrangement>
    <optn:DeferredTaxAssetsInterestExpense
      contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzgvZnJhZzpkNjc4MzlkZGQwMzU0YWI1OTRmOGFjMDE4ZDQzYzRkYy90YWJsZTplNWZmMjEzNzdjNmY0Y2YyYmViNDA2N2JkMmEyMmYxYy90YWJsZXJhbmdlOmU1ZmYyMTM3N2M2ZjRjZjJiZWI0MDY3YmQyYTIyZjFjXzUtMi0xLTEtNTgzNzI_60dd2a7a-adee-44d1-b09f-0edafb4c72b7"
      unitRef="usd">14304000</optn:DeferredTaxAssetsInterestExpense>
    <optn:DeferredTaxAssetsInterestExpense
      contextRef="id970dfd2674c4d6b895febb9c14d0fd1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzgvZnJhZzpkNjc4MzlkZGQwMzU0YWI1OTRmOGFjMDE4ZDQzYzRkYy90YWJsZTplNWZmMjEzNzdjNmY0Y2YyYmViNDA2N2JkMmEyMmYxYy90YWJsZXJhbmdlOmU1ZmYyMTM3N2M2ZjRjZjJiZWI0MDY3YmQyYTIyZjFjXzUtNC0xLTEtNTgzNzI_c3954307-7ad4-458a-a18a-a29910ea071e"
      unitRef="usd">10708000</optn:DeferredTaxAssetsInterestExpense>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
      contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzgvZnJhZzpkNjc4MzlkZGQwMzU0YWI1OTRmOGFjMDE4ZDQzYzRkYy90YWJsZTplNWZmMjEzNzdjNmY0Y2YyYmViNDA2N2JkMmEyMmYxYy90YWJsZXJhbmdlOmU1ZmYyMTM3N2M2ZjRjZjJiZWI0MDY3YmQyYTIyZjFjXzYtMi0xLTEtNTgzNzI_641a3d15-6f2f-438a-898d-648d4bea0a99"
      unitRef="usd">7193000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
      contextRef="id970dfd2674c4d6b895febb9c14d0fd1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzgvZnJhZzpkNjc4MzlkZGQwMzU0YWI1OTRmOGFjMDE4ZDQzYzRkYy90YWJsZTplNWZmMjEzNzdjNmY0Y2YyYmViNDA2N2JkMmEyMmYxYy90YWJsZXJhbmdlOmU1ZmYyMTM3N2M2ZjRjZjJiZWI0MDY3YmQyYTIyZjFjXzYtNC0xLTEtNTgzNzI_7164fe1a-6e54-45d7-9bfa-8353e331b050"
      unitRef="usd">8583000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits>
    <optn:DeferredTaxAssetsLeasingArrangement
      contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzgvZnJhZzpkNjc4MzlkZGQwMzU0YWI1OTRmOGFjMDE4ZDQzYzRkYy90YWJsZTplNWZmMjEzNzdjNmY0Y2YyYmViNDA2N2JkMmEyMmYxYy90YWJsZXJhbmdlOmU1ZmYyMTM3N2M2ZjRjZjJiZWI0MDY3YmQyYTIyZjFjXzctMi0xLTEtNTgzNzI_fc59fc54-ebf8-4193-8915-a41b02936e61"
      unitRef="usd">642000</optn:DeferredTaxAssetsLeasingArrangement>
    <optn:DeferredTaxAssetsLeasingArrangement
      contextRef="id970dfd2674c4d6b895febb9c14d0fd1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzgvZnJhZzpkNjc4MzlkZGQwMzU0YWI1OTRmOGFjMDE4ZDQzYzRkYy90YWJsZTplNWZmMjEzNzdjNmY0Y2YyYmViNDA2N2JkMmEyMmYxYy90YWJsZXJhbmdlOmU1ZmYyMTM3N2M2ZjRjZjJiZWI0MDY3YmQyYTIyZjFjXzctNC0xLTEtNTgzNzI_82d11050-3109-4ecf-b54c-b4e48a821409"
      unitRef="usd">1081000</optn:DeferredTaxAssetsLeasingArrangement>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzgvZnJhZzpkNjc4MzlkZGQwMzU0YWI1OTRmOGFjMDE4ZDQzYzRkYy90YWJsZTplNWZmMjEzNzdjNmY0Y2YyYmViNDA2N2JkMmEyMmYxYy90YWJsZXJhbmdlOmU1ZmYyMTM3N2M2ZjRjZjJiZWI0MDY3YmQyYTIyZjFjXzgtMi0xLTEtNTgzNzI_74d6ad5e-a0d0-4420-bef1-f9def8fe78bb"
      unitRef="usd">2460000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="id970dfd2674c4d6b895febb9c14d0fd1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzgvZnJhZzpkNjc4MzlkZGQwMzU0YWI1OTRmOGFjMDE4ZDQzYzRkYy90YWJsZTplNWZmMjEzNzdjNmY0Y2YyYmViNDA2N2JkMmEyMmYxYy90YWJsZXJhbmdlOmU1ZmYyMTM3N2M2ZjRjZjJiZWI0MDY3YmQyYTIyZjFjXzgtNC0xLTEtNTgzNzI_aeb2286c-b11c-4b10-9535-29e4f1345eeb"
      unitRef="usd">2461000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <optn:DeferredTaxAssetsFinancingCosts
      contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzgvZnJhZzpkNjc4MzlkZGQwMzU0YWI1OTRmOGFjMDE4ZDQzYzRkYy90YWJsZTplNWZmMjEzNzdjNmY0Y2YyYmViNDA2N2JkMmEyMmYxYy90YWJsZXJhbmdlOmU1ZmYyMTM3N2M2ZjRjZjJiZWI0MDY3YmQyYTIyZjFjXzktMi0xLTEtMTEwNzIx_412e46a5-4d40-47c8-98ca-f77e1f6cc594"
      unitRef="usd">3377000</optn:DeferredTaxAssetsFinancingCosts>
    <optn:DeferredTaxAssetsFinancingCosts
      contextRef="id970dfd2674c4d6b895febb9c14d0fd1_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzgvZnJhZzpkNjc4MzlkZGQwMzU0YWI1OTRmOGFjMDE4ZDQzYzRkYy90YWJsZTplNWZmMjEzNzdjNmY0Y2YyYmViNDA2N2JkMmEyMmYxYy90YWJsZXJhbmdlOmU1ZmYyMTM3N2M2ZjRjZjJiZWI0MDY3YmQyYTIyZjFjXzEwLTQtMS0xLTExMTA1Ng_4a7890cf-4feb-4f15-a31d-10be32b44efa"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzgvZnJhZzpkNjc4MzlkZGQwMzU0YWI1OTRmOGFjMDE4ZDQzYzRkYy90YWJsZTplNWZmMjEzNzdjNmY0Y2YyYmViNDA2N2JkMmEyMmYxYy90YWJsZXJhbmdlOmU1ZmYyMTM3N2M2ZjRjZjJiZWI0MDY3YmQyYTIyZjFjXzktMi0xLTEtNTgzNzI_c5efbbf1-c17d-4ebe-a8a4-7e8446174549"
      unitRef="usd">83376000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="id970dfd2674c4d6b895febb9c14d0fd1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzgvZnJhZzpkNjc4MzlkZGQwMzU0YWI1OTRmOGFjMDE4ZDQzYzRkYy90YWJsZTplNWZmMjEzNzdjNmY0Y2YyYmViNDA2N2JkMmEyMmYxYy90YWJsZXJhbmdlOmU1ZmYyMTM3N2M2ZjRjZjJiZWI0MDY3YmQyYTIyZjFjXzktNC0xLTEtNTgzNzI_808e9de6-50cb-445a-9027-314af3202479"
      unitRef="usd">87324000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzgvZnJhZzpkNjc4MzlkZGQwMzU0YWI1OTRmOGFjMDE4ZDQzYzRkYy90YWJsZTplNWZmMjEzNzdjNmY0Y2YyYmViNDA2N2JkMmEyMmYxYy90YWJsZXJhbmdlOmU1ZmYyMTM3N2M2ZjRjZjJiZWI0MDY3YmQyYTIyZjFjXzEwLTItMS0xLTU4Mzcy_05d0dbfd-70bd-446c-adaf-f67a4ea63276"
      unitRef="usd">116496000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="id970dfd2674c4d6b895febb9c14d0fd1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzgvZnJhZzpkNjc4MzlkZGQwMzU0YWI1OTRmOGFjMDE4ZDQzYzRkYy90YWJsZTplNWZmMjEzNzdjNmY0Y2YyYmViNDA2N2JkMmEyMmYxYy90YWJsZXJhbmdlOmU1ZmYyMTM3N2M2ZjRjZjJiZWI0MDY3YmQyYTIyZjFjXzEwLTQtMS0xLTU4Mzcy_c39ffa8b-4cfb-49a2-ad05-c4874883d19f"
      unitRef="usd">126310000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzgvZnJhZzpkNjc4MzlkZGQwMzU0YWI1OTRmOGFjMDE4ZDQzYzRkYy90YWJsZTplNWZmMjEzNzdjNmY0Y2YyYmViNDA2N2JkMmEyMmYxYy90YWJsZXJhbmdlOmU1ZmYyMTM3N2M2ZjRjZjJiZWI0MDY3YmQyYTIyZjFjXzEyLTItMS0xLTU4Mzcy_7e85e40d-ea45-43e6-9799-408c1b915908"
      unitRef="usd">171000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="id970dfd2674c4d6b895febb9c14d0fd1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzgvZnJhZzpkNjc4MzlkZGQwMzU0YWI1OTRmOGFjMDE4ZDQzYzRkYy90YWJsZTplNWZmMjEzNzdjNmY0Y2YyYmViNDA2N2JkMmEyMmYxYy90YWJsZXJhbmdlOmU1ZmYyMTM3N2M2ZjRjZjJiZWI0MDY3YmQyYTIyZjFjXzEyLTQtMS0xLTU4Mzcy_26914e17-b418-4d22-a948-d86be1b3f10b"
      unitRef="usd">210000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzgvZnJhZzpkNjc4MzlkZGQwMzU0YWI1OTRmOGFjMDE4ZDQzYzRkYy90YWJsZTplNWZmMjEzNzdjNmY0Y2YyYmViNDA2N2JkMmEyMmYxYy90YWJsZXJhbmdlOmU1ZmYyMTM3N2M2ZjRjZjJiZWI0MDY3YmQyYTIyZjFjXzEzLTItMS0xLTU4Mzcy_1a178044-b292-416f-9739-f3511e56d3e6"
      unitRef="usd">605000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="id970dfd2674c4d6b895febb9c14d0fd1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzgvZnJhZzpkNjc4MzlkZGQwMzU0YWI1OTRmOGFjMDE4ZDQzYzRkYy90YWJsZTplNWZmMjEzNzdjNmY0Y2YyYmViNDA2N2JkMmEyMmYxYy90YWJsZXJhbmdlOmU1ZmYyMTM3N2M2ZjRjZjJiZWI0MDY3YmQyYTIyZjFjXzEzLTQtMS0xLTU4Mzcy_666fd347-49c2-4a59-9237-f0fca7b6953b"
      unitRef="usd">1024000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzgvZnJhZzpkNjc4MzlkZGQwMzU0YWI1OTRmOGFjMDE4ZDQzYzRkYy90YWJsZTplNWZmMjEzNzdjNmY0Y2YyYmViNDA2N2JkMmEyMmYxYy90YWJsZXJhbmdlOmU1ZmYyMTM3N2M2ZjRjZjJiZWI0MDY3YmQyYTIyZjFjXzE0LTItMS0xLTU4Mzcy_2b92e62d-50d7-4179-bcf4-ae39a2abdbd5"
      unitRef="usd">776000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="id970dfd2674c4d6b895febb9c14d0fd1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzgvZnJhZzpkNjc4MzlkZGQwMzU0YWI1OTRmOGFjMDE4ZDQzYzRkYy90YWJsZTplNWZmMjEzNzdjNmY0Y2YyYmViNDA2N2JkMmEyMmYxYy90YWJsZXJhbmdlOmU1ZmYyMTM3N2M2ZjRjZjJiZWI0MDY3YmQyYTIyZjFjXzE0LTQtMS0xLTU4Mzcy_5d0ae4e6-e216-407b-a132-f17f8bfcb833"
      unitRef="usd">1234000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzgvZnJhZzpkNjc4MzlkZGQwMzU0YWI1OTRmOGFjMDE4ZDQzYzRkYy90YWJsZTplNWZmMjEzNzdjNmY0Y2YyYmViNDA2N2JkMmEyMmYxYy90YWJsZXJhbmdlOmU1ZmYyMTM3N2M2ZjRjZjJiZWI0MDY3YmQyYTIyZjFjXzE1LTItMS0xLTU4Mzcy_fd0dada4-3373-4780-9b24-d52fcb7b8afb"
      unitRef="usd">115720000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="id970dfd2674c4d6b895febb9c14d0fd1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzgvZnJhZzpkNjc4MzlkZGQwMzU0YWI1OTRmOGFjMDE4ZDQzYzRkYy90YWJsZTplNWZmMjEzNzdjNmY0Y2YyYmViNDA2N2JkMmEyMmYxYy90YWJsZXJhbmdlOmU1ZmYyMTM3N2M2ZjRjZjJiZWI0MDY3YmQyYTIyZjFjXzE1LTQtMS0xLTU4Mzcy_8fabdad7-001f-49d0-8a9f-705406d4b426"
      unitRef="usd">125076000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzgvZnJhZzpkNjc4MzlkZGQwMzU0YWI1OTRmOGFjMDE4ZDQzYzRkYy90YWJsZTplNWZmMjEzNzdjNmY0Y2YyYmViNDA2N2JkMmEyMmYxYy90YWJsZXJhbmdlOmU1ZmYyMTM3N2M2ZjRjZjJiZWI0MDY3YmQyYTIyZjFjXzE2LTItMS0xLTU4Mzcy_6fdfb8d5-e112-47b9-9af4-6dc25baf9ffe"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="id970dfd2674c4d6b895febb9c14d0fd1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzgvZnJhZzpkNjc4MzlkZGQwMzU0YWI1OTRmOGFjMDE4ZDQzYzRkYy90YWJsZTplNWZmMjEzNzdjNmY0Y2YyYmViNDA2N2JkMmEyMmYxYy90YWJsZXJhbmdlOmU1ZmYyMTM3N2M2ZjRjZjJiZWI0MDY3YmQyYTIyZjFjXzE2LTQtMS0xLTU4Mzcy_63cf7259-f442-4ca7-aa85-cfb20ae62786"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i411a7889aa7b40c59ba3d11c1d63d29e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzgvZnJhZzpkNjc4MzlkZGQwMzU0YWI1OTRmOGFjMDE4ZDQzYzRkYy90ZXh0cmVnaW9uOmQ2NzgzOWRkZDAzNTRhYjU5NGY4YWMwMThkNDNjNGRjXzQ1Mg_565a2e7e-00f5-4526-9d61-acb7862c24c6"
      unitRef="usd">9073000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i65dbad508d2444f4bb357feedbc9cad4_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzgvZnJhZzpkNjc4MzlkZGQwMzU0YWI1OTRmOGFjMDE4ZDQzYzRkYy90ZXh0cmVnaW9uOmQ2NzgzOWRkZDAzNTRhYjU5NGY4YWMwMThkNDNjNGRjXzU0OA_524ad29a-7bf7-40b6-9a3f-f6b7df785a60"
      unitRef="usd">335009000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i497d60fef0fd413ba91eb9a5009d1d39_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzgvZnJhZzpkNjc4MzlkZGQwMzU0YWI1OTRmOGFjMDE4ZDQzYzRkYy90ZXh0cmVnaW9uOmQ2NzgzOWRkZDAzNTRhYjU5NGY4YWMwMThkNDNjNGRjXzU1NQ_6d08ca67-da6b-47e0-8844-3459be63ae30"
      unitRef="usd">252324000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzgvZnJhZzpkNjc4MzlkZGQwMzU0YWI1OTRmOGFjMDE4ZDQzYzRkYy90ZXh0cmVnaW9uOmQ2NzgzOWRkZDAzNTRhYjU5NGY4YWMwMThkNDNjNGRjXzI3NTk_3ff3378e-1a8a-4b38-982d-05acf7b0bb42"
      unitRef="usd">2487000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <optn:DeferredTaxAssetsTaxCreditCarryforwardsResearchTerm
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzgvZnJhZzpkNjc4MzlkZGQwMzU0YWI1OTRmOGFjMDE4ZDQzYzRkYy90ZXh0cmVnaW9uOmQ2NzgzOWRkZDAzNTRhYjU5NGY4YWMwMThkNDNjNGRjXzI3OTU_3c753210-2b68-4918-8053-6b05ba087396">P20Y</optn:DeferredTaxAssetsTaxCreditCarryforwardsResearchTerm>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzgvZnJhZzpkNjc4MzlkZGQwMzU0YWI1OTRmOGFjMDE4ZDQzYzRkYy90ZXh0cmVnaW9uOmQ2NzgzOWRkZDAzNTRhYjU5NGY4YWMwMThkNDNjNGRjXzM1NDA_cba4e985-ce94-4741-9bcb-5fb668a1cb24"
      unitRef="usd">-9356000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="ie179c2aa474648c5a81e099ecf55e73a_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1MWJjYjNlYWJiYTRmODdiZGM1Nzk3MTgyMDdhM2I4L3NlYzo0NTFiY2IzZWFiYmE0Zjg3YmRjNTc5NzE4MjA3YTNiOF8xNzgvZnJhZzpkNjc4MzlkZGQwMzU0YWI1OTRmOGFjMDE4ZDQzYzRkYy90ZXh0cmVnaW9uOmQ2NzgzOWRkZDAzNTRhYjU5NGY4YWMwMThkNDNjNGRjXzQwOTI_08ca9907-c5ef-4249-8310-fc2175c5d26b"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>96
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MGL\BD?U%V_S:2]Q"?BHDB_?!T((X3/+_Y&T/XB3@RJD(P/L _"[ [54$>/L
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M<L_*^!Q65KXFXT7J\NU%%,?8 >N1PRA)QFJW)V8\3<Q.TVZ6W_GX8_=(P3<
M^.1\ \#BX$#,GD;^1>4CKQ0HV(-1A)>)B8/<'_#M;[38-F=D:Z&U*)O+G%&#
MVPJ8_Q^$T*\W]MBM.V9=_0=02P,$%     @ 4X1G5GF=GD:? @  0 <  !@
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M*'.V[JBAZ43)+5$V&MGLP.7&H=$-$_84%T;A6X8XD\ZDT)*SG!K(R2WE5&1
M%I9.DXLY52!, 89EE%^2C^0]\8DN<%5/?(.[6PX_:W>Z;7:*CNQT!UF/Q.$5
MB8(H.@"?G0\/]^$^>NZ,1YWQR/'%1_@6!BUC.1HB5^2>"33.*"=SJ9FKKY\W
M2VT45MFO0U8;[OYA;OOEC75%,YAZ^&EI4!OPT@_OPB3X=,CX?R+;2T/<I2%^
MBQW/ORS1+=99]GA%*JK(AO(:R 43))><4Z5)!:HY]<M#J6CX1X[?]HQ-&O2"
M (]HL^OQ5-2>^'XGOO^F^(4K14)K4TC%_F(%6]E-@1[4VM E.RJPVS6_%WK/
MB=S3/.@T#\[1S+2N3^L=O%(1AF'_.AHF+_/[.G(41?'H^IC<I).;G",7^[\V
M5.1,K$]I3L[6_#KRB&9_I[_9N^4K56LF-.&P0FC0&Z)[U?3K9F)DY5K>4AIL
MH&Y8X!4'R@;@^Y64YGEBNVAW::;_ %!+ P04    " !3A&=6X8>2V]8$  #H
M$P  &    'AL+W=O<FMS:&5E=',O<VAE970U+GAM;*U8VV[C-A#]%4(MB@1(
M+)&Z.K4-;)P676"W&R1-]YF1:%N()+HD;:?]^@XE6[(CBHW1O-BZS(S.X7#F
MD)SLN'B1*\84>BV+2DZ=E5+K&]>5Z8J55([XFE7P9L%%217<BJ4KUX+1K'8J
M"Y=X7N26-*^<V:1^=B]F$[Y115ZQ>X'DIBRI^/N6%7PW=;!S>/"0+U=*/W!G
MDS5=LD>FGM;W N[<-DJ6EZR2.:^08(NI\PG?S(FO'6J+/W.VDT?72%-YYOQ%
MWWS.IHZG$;&"I4J'H/"W97-6%#H2X/AK']1IOZD=CZ\/T7^MR0.99RK9G!??
M\TRMID[BH(PMZ*90#WSW&]L3"G6\E!>R_D6[QC:.')1NI.+EWAD0E'G5_-/7
M_4 <.> A![)W(&\=@@$'?^]0CYS;(*MIW5%%9Q/!=TAH:XBF+^JQJ;V!35[I
M-#XJ 6]S\%.S.:\D+_*,*I:A1P5_D",E$5^@;VLFJ!YKB:[1T^,=NOCQ<N(J
M^*AV==/]!VZ;#Y"!#V""OO)*K23ZI<I8=AK !;0M9'* ?$NL$>]8.D(^OD+$
M(\0 :/Y^=VR!X[<CZ-?Q@H%X?W!%"YC16U9MF#0-4.,?U_ZZK+:S.")QY'G>
MQ-T> S<8!E%(C@U/( 8MQ*#V] >3+"&EM,H0>X7ZETS>F' &-IZZG]S(-4W9
MU(&&(9G8,F?VTP\X\GXV)>&#@IWP#5N^H34EFJ^>P6O!LTVJD*2%.3--F.AH
MP,<D\ON),=CA$ _F)6IQ1E:<#\"<BG15IR:#&53PM2X_$]2H!P&'1,^AMUC[
MAB3T<3((-F[!QE:PC]!J\VIYA9:L@L90U*!I!CTIETHWBBTSX8[[N+TX"L9]
MX";+*/+]0>1)BSQY1X6FO2(PP4WZ('R"8]*':[ ,,/:&JW7<PAU;X7[A4J*%
MX"7B;0<V01WW %R'83(V]!6#910%H3<(%7N=?'C6UO)-K9A %WF5\I)='H;6
MV%[VD3ZHOWQ4M%/>1[*)K4EZJF#15.3_@&H6.E^P(EG07* M+39,]YX=%8*"
MDAI' O?G#L&XGSB#X5#&2(><6)&;,V:$20S%8)I?!L/K.!R>79VT8KNV?JX4
M@^PIU* U@O0-98 -/=QH.%RMN!-7;-6R#J1M*(/^4$9)8()IL S'\7 7Q)TJ
M8KLL_@Z[ CU9C0##WMKC.@X2WX308)H0<CHQ3B%V@HCMBJ@A7FB,E_N4(VB!
M2*ZHJ(L*GI10:; J3E^NFFJ&-7R>ZNF,,EX45,C.P[Q:;0",C]%[HR1^2])@
MAD=!.$"P$U%L5]%S"*(L+S9Z77X&N_A][ QF%G:=T&*[TGZO=TV F&Y!N9:L
MY:,!0Y/<**E @>ME1)>XYJV93U]EDQ#6#M"'WE+J6X91$N*Q7N0;675ZC.V"
M? ZKXY39>/4E>8A7W]+.BW3:3:P:6<_%PQ+9MG^QASE7N#\JVBGI3KB)7;C_
M>[NV#_"._9K)TK=MV$BGTL2NTE_R5)^55$L[5&N0LS/S0=%.*7=B3_[O1IKT
M-\B]E/1-]+JJGQ'WZ,RD9&)9'R5)*.U-I9JSB/9I>USUJ3ZD>?/\%M_,FT.G
M+DQS!O:5BF5>252P!83T1C$(IVB.E9H;Q=?UR<PS5XJ7]>6*T8P);0#O%YRK
MPXW^0'NX-_L74$L#!!0    ( %.$9U;CT@>1QP(   ((   8    >&PO=V]R
M:W-H965T<R]S:&5E=#8N>&ULK55=;],P%/TK5I@02&QIDC89)8VT9B F,9A6
M!@^(!S>Y;<(<N[/==OOW7#MI:+NTXF$O]4?N.3[WH_?&:R'O50&@R6/%N!HY
MA=:+H>NJK("*JC.Q (Y?9D)65.-1SEVUD$!S"ZJ8Z_=ZH5O1DCM);.]N9!*+
MI68EAQM)U+*JJ'P: Q/KD>,YFXO;<EYH<^$F\8+.80+Z;G$C\>2V+'E9 5>E
MX$3";.1<>,,T,O;6X$<):[6U)\:3J1#WYG"5CYR>$00,,FT8*"XK2($Q0X0R
M'AI.IWW2 +?W&_9/UG?T94H5I(+]+'-=C)QSA^0PHTNF;\7Z,S3^# Q?)IBR
MOV1=VT;X8K946E0-&,]5R>N5/C9QV )XX0& WP#\?4#_ "!H (%UM%9FW;JD
MFB:Q%&LBC36RF8V-C46C-R4W69QHB5]+Q.DD%5P)5N940TXF&A=,D59$S$@J
M*BR,PF1L!>2+4(J<DKO))7ES\I:<D)*3[X58*LIS%;L:M1A&-VO>'=?O^@?>
M]7QR+;@N%/G(<\AW"5QTHO7$WW@R]H\R7D)V1@+O'?%[OM\A*/U_N'=$3M &
M-K!\P0&^-I;/0WG%,U$!^74Q55IB'?_N"E_-WN]F-__MH5K0#$8.$BN0*W"2
MUZ^\L/>AR_47(ML)1+\-1/\8>_(56Q'#XNERLD9&%FGZS2HYC?KG01"[JVWY
M'6;GOO\^;,UVA U:88.C&?JF"Y DVTF-$3KL4CIXR72\$-F.UV'K=7@T'=C\
ML+5Q["U2 L^>")8@5XS6337_@RW'5&U7#&KB<#L-^YEZ;M+O3E+4RHV.RDV?
MI:=+6=1=1^&>N@XS4T?^GD1WJYU6(.=VRBBLE"77=3]J;]M!=F'[]][]& =<
M/8_^T=33\9K*><D583!#RMY9A"4AZXE3'[18V*8]%1I'@-T6.*1!&@/\/A-"
M;P[F@7;L)W\!4$L#!!0    ( %.$9U9I[5)_> <  ,0V   8    >&PO=V]R
M:W-H965T<R]S:&5E=#<N>&ULO5MM;]LV$/XKA%=L#5#7%O7J+C'0VA)68"]!
MTW:?58FQM4BB)]%Q\N]'RHIED31C(9?U0R/;=\^1]XCD\1%UN:/57;TFA*&'
M(B_KJ]&:L<V'R:1.UJ2(Z_=T0TK^RRVMBICQC]5J4F\J$J>-4Y%/\'3J38HX
M*T?SR^:[ZVI^2;<LSTIR7:%Z6Q1Q]?B)Y'1W-;)&3U]\R59K)KZ8S"\W\8K<
M$/9M<UWQ3Y,#2IH5I*PS6J**W%Z-/EH?(KMQ:"R^9V17'UTCT94?E-Z)#Y_3
MJ]%4M(CD)&$"(N9_[LF"Y+E XNWXMP4='6(*Q^/K)_2HZ3SOS(^X)@N:_YVE
M;'TU"D8H);?Q-F=?Z.XWTG;(%7@)S>OF?[1K;:<CE&QK1HO6F;>@R,K]W_BA
M3<21@V6?<,"M S[7P6X=;,D!!R<<G-;!D1U.]<%M'5S)P?9/.'BM@]?D?I^L
M)M/+F,7SRXKN4"6L.9JX:.AJO'F"LU+<63>LXK]FW(_-%[2L:9ZE,2,INF'\
M#[]M6(WH+5JLXW)%:I25_ >:W*UIGI*J_@6%_VXS]HC>+LEMEF3L HW1MYLE
M>OOF KT1UE_7=%O'95I?3AAOH@@T2=KF?-HW!Y]HSE?*XESCMC"[+6A1T+:9
M&N^EV?MCFF;B-H]S=!UG*1KS/BSB3:9O2O@,6))LBVW>Y+--D 8D.A_D+[8F
M%>(]Y#/'6@SI>X)^I[64W GG_4 ^/I"/FS#.B3"?R"HKRZQ<\<&9QV5"4,QX
MHY/WR+;>(3S%4QV#>TR_P103U_W<\X/@<G)_S)=JY-I]DZ7.Q'$#MV\6JF9C
M%_N^)]E%&KLCK%Y^[$-^[('Y><MOC7H=5Z2^."M71GRQ:GRH-W%"KD:<W)I4
M]V0T__DGRYO^JAL#>S#O.&%XQC,FIV()&36$!(N P'IL.@<VG0;=/L'FYS+A
M:V]-Q,2UO[HX-;?IJ'0@J80$6T*"A9!@$1!8CV[W0+=K'+P-KRCA\R:?-..F
MC"$/XIKHV'65L36;^;XTJ1D##F7MG(@A9,0("*S'AG=@PS.R\9W43$RDO*[@
MX*S*$K&VU0U'VS+C%<?1U*HCR @_=/AY2N[MP/9L2YI'(6.&D& 1$%B/2O]
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M+GAM;*U:VW+CN!']%92RE4JJ5B,"("G)L57ET:PW^["):YQ-GB$2LI A"2X
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M"".@?]]SKMYOS N&OU9L_@M02P,$%     @ 4X1G5J@FHBC" P  +0@  !@
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MFEFD3DHL\!NCD]P:(+>V=#[M& ,27:"EQ[(KZH^!(VW4_SV-W?,Q*2/1YM7
ME.:<6EV/9$X0%YB8!F^%\SMI[=V[=.3  &06W8F01$S13-NBMPD3* &#4H7U
M,QWRQ^BP=<SQEG2L73&KB)=:4-X4G1\\YT^4I:.\C4&2DZ^F76\<!EFQ7DDA
MO,0)<Z8Y\;@GUNM5<FPR5E5;"T:(#[$% SMPCC!OXIVQ6V6S\B&E!E!QM.!T
M)G6<X%LSG*P%]D_JY\E'N?0D@$=5-H*T)$/.CL[%?-R8Y7"',_P'/P-S ^C
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M%PL\HK9BL^6>AO1P QU;DZ,Z^;NW=?=NY._GX=RXTUXWJ@3S+.FGJ/"T[Z[
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M23"W_ZJI2DSM6N$1P1M-940TAOYI'>#K",_IQ='I^1YXY 6U>V#Z.;<Z^4C
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M!(RO-8Z.[0-OT']/NOX_4$L#!!0    ( %2$9U8D4M%LI@(  *\%   9
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M<:$9KSC_S)0AM1)2VR+##@L2G9'3)-Z=ZOR,G*B72%0-(*.$F^=U#5-4-)
MD0$ZL*AQ(LHXO&$::B_C/^I*"<0^SMW43EWBJ#POZEJ^H4UGU!(UV(J1V[8Z
MCL0DX)A:$0_9\Q'68>Y+LX($DFU>H[R&)4NFOI>O*&PLA^.8LVLZOZ"&E*R3
MJ_KR+S[0KH-.Z1X=G0Z^%K/<& NS9\I3D2I#TH[B9H$3Z7$Y1GT X*]PPU?.
M86;M2*4A,8=:&2Q8HVR%0E.;(Q'+O'+B@BDNZ2H-4%.( S6;*6Y9!IFQ:S@^
M.AM]+4!Q)_>"R>!%746YA0SN /-:!7-P?X;TFF5<9Z&H\=&@0YCO!,2T2:$R
MRXY'7I%53<6DJJR!O'P, [ZXW4;9(BX\ IJFA;]59>B_-O#K09 J._"4^P_L
MSE&9$5;!C=2S%6"'JC$5$$ZA(4%]G:$;CF8F2M7B@;C=./RR%6T'JX5B)%M
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M9(< YWK9[JVU6FJN>>446"9T-#Q_&?C<;H#&22&GU#19UTW3T,\#(9!,R#E
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MK1?@[PMC:+?Q!KHWV/0?4$L#!!0    ( %2$9U:F\Q<IW0,  +T(   9
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M]@G/71ZV^+[@( ;8;[Q/QXD$&+]85E\!4$L#!!0    ( %2$9U:?#.;[GPD
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M&SH!> (#7;BT'(6,V2Z:ZCSM&QT7"I08>8:N@E3YY4YB44GUD <[ND53&A\
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MN92Z E#6QKI64@@8Y026!C(.T1F(WY5/.H([%*;K# 8"_I/%UNHV+"$$703
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MKT_V#OV5VK0Z[&3OSO]_!W+6+!ND4#+NL]F[:E%X)-^W2&84P4)N6$[F?+"
M;&L'U=,O<&PWA_:'6EA3P);*MV>H);IL2E_F&=%TR4:# CUIKT/4N@&?23]@
M[ 3QO5U[J=C/DEJU-S(J"TGYM_SXCP,/!N:MJ)&A*75PZN7D5>_%<:GJ);\>
MYRN3ROEWR-W3[@W\S+]XWBWWK^]!VTO"1J$6V!H/)M=GHO:OQ/T79];\&GIN
MG#,E?UPIB8)."_#[PAC7?J$#NO\OX?9_4$L#!!0    ( %2$9U;?G6%9+2$
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MB7Q_*PQ9>U<:-@PGIOBW(Y<.CP/^;:-_)_@0\Y\#^AR'876<+<0.).<2C<&
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M8F$5.\L\*[)0 9;D5B(L%L6LY$5[:YHD[,V3B-;&I?4.QVL,75)H!1&(M23
M<9)SQ6!A2B,4H/SJ&9 P3&]VN@)*:=5:CS-?"908NAHG#-&/*GK$J6.'5AI*
M 58LL!DZS)E9GZ$O>4+1THMG;WY^2Y^6ST[33%$<Q8"9*(#@!\#$.RR+"DF8
MA<]I@*&S1M&KUQA,98N%CI4(8E&0KF"?H%7WJ$/3NHX\7H/6$\@+D#Y[\H:M
MU]/*5MKE6>< W0Z+#&DTO(IBC T/WH=DG<M,/:R+Y>4XDXFJN'>YW2]X A@*
M45@E56PC\ADD3T2+U D%]1D\4OC$<,MH4OF2RQP>TY5[J?.@4$-X<.Y+=?*!
MHT&4_ OF]VHO(9B#2"/J'"S;[+U90_,L$-&$,GZ'<%6C_^LG19WQC(-Y]]I-
M);$0P-$4<1@&)..I8I(&VEAA+N">J!E781"6?09#DD7!=L-71M3LO/4I6N##
M1M4$V27TDLLB@_L<@5:B5:D]&/?D=SJ.E!S8A3=^.G3H&<7DL_!B(=P8/#$P
MD\0 O@,]RU$)F>*\^'7\DSAL/EPTYB*W+6U";LX9&Y[%L[!. A@9M%]]W4"_
ME?TVK-:(_,FQRM4QB=\DUAE](9-!TRIQ_1#LX"_8R?,DI77O!>Z^-.F QZ0F
MR>\Z$Y6BSW^9Y8,1#HC$8AR'I<XA.RQD8<K<C1BBU^C >)%_E 50.7G_X%!8
M)XG]D OPK@R9)C09<P"&A]!1%\<I88$RRPR01F?+1&&%CJ>8L3AIDW%!PZGV
M3EO3DG:>,UEBX>EROECT)TQ7L_^ EK%J!^6+'2HL]4<XR<^3=LWL[-,EU)-+
M'K4TY U.PZ+B(?U!?'%U>UW\8H!(BB<73Q9@3O.;1*778IZ(@KH.<2^L!L;W
M3SUN,8!7UJ83__ ?93M@&1Y%KY9?YZ9$J(LB@Y*\-RHM0(?0]:IS'$@7C@Q[
M9V$C"S\M3O2ICT/LO6-+FSUQIUZ?^D#=,WA[_+KL@JLR5HW>E%E0V\]&0V%L
MT$HL8),B$4I/XVMWIQ1UJWRNZ^ E3Z0?O322T E,>P@,DE(G:/[!:4E:P<E
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M9 :?=WSE[#C]Y55 8J*T=:RX&-_F#?(377Q/90=,EP;_?$T^\(&MSS"*LI<
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MA!NM+$9=LHXXJH2YX98KUVU@KNZ%8JH03,("-SFRU%GXYVIIG4&>_7LL11V
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M+#0\FTT\4(.9A\#(IC?01AIKQWY8V?\/E4NPZX649A>X#<8?-?T+4$L#!!0
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MADL# M>D.CB;C +0;7-M-U9M?4-;*4OMT2\K^H]0.P&Z7RME]QMGH/_A%G\
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MGWES\M)T)#O49Q%;)B4KZV8.. .N!ZC[.Z:2MNWHXXWN_"O^#U!+ P04
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M,!E<7U)BNS[N-MXTL156QF-CQ>4:1Q_8X(#GI3%^MPG=M1^F^6]02P,$%
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MKKG2/< .2]VE49@$O9YSK@X3LT'7]Y,_4$L#!!0    ( %2$9U;6;''K? ,
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M2 Y!UNQG-">"%O66P#,5@F;UX1;("E@5(.^O*16'D^H!W:[2XE]02P,$%
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M1N:,N=5!J?;U*V9SDG!Y',PDJ'71DL<ERSK";")HJINJ"16R1=/#4';1P%2
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MOY:B; MM3N0>FA80Y>9@TZ8 YT+VL9(NEBT0^YPD6;98^OMC/0ZK.+)KLW>
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M<YLX'L;_%8UOYZZ=Z=H@L&/WDLQL#9K;%]OK;+:[KPF68Z88>4&VVYG[XT^
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MP:Q8C;[PHM0*$9ZYQFK6OT.ZYO2^!-4GR=BG))[ .I(<-Y(<#]K@5VUX9/9
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M#HR:LOH8456T*-QY_E9H+7)77 ,Q!WC;P;0OA=!/%?N)H/DDM/@-4$L#!!0
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M)^C[X#6V(;0BD1'1OQ#;Q \]_8G=[0!=:.G"HW1+5A3J40M]<GM !#O@*1&
M*DY2,(@9HQ1S@2H5BH'4M#_S;XBX%9[WB,>C:)@VLK314Y/3#TQR3H=(CCI]
MXO5/+?+T+Y-S^@QT,TLW^Q?).?LC.0//CV8'LW-N\>;_*SM;X5G_/8W"*/R-
MU^U5!%U</V.^(:5 %-;*SAM-59+SMF"U \DJ4R163*J28[JYJO' ]0:UOF9,
M[@>Z[MA_#<D/4$L#!!0    ( %2$9U9SA;-0A@@   $[   9    >&PO=V]R
M:W-H965T<R]S:&5E=#8S+GAM;,6;6V_;-A3'OPKA#4,+M+%$76QWB8%<NJT/
M[;)FW;!'1J)MH;IX%.4DPS[\2$H6=?.)K4G-2V++XN'Y'U+DC^31^4/"OJ8;
M2CEZC,(XO9AL.-^^FTY3;T,CDIXE6QJ+7U8)BP@77]EZFFX9);XJ%(53;!CN
M-")!/%F>JVNW;'F>9#P,8GK+4)I%$6%/5S1,'BXFYF1_X7.PWG!Y8;H\WY(U
MO:/\R_:6B6_3THH?1#1.@R1&C*XN)I?FNVO7D 74'7\$]"&M?$92RGV2?)5?
M/O@7$T-Z1$/J<6F"B'\[>DW#4%H2?OQ=&)V4=<J"U<][ZS\I\4+,/4GI=1+^
M&?A\<S&93Y!/5R0+^>?DX1=:"'*D/2\)4_47/13W&A/D92E/HJ*P\" *XOP_
M>2P"42F G0,%<%$ -PJ8]H$"5E' 4D)SSY2L&\+)\IPE#XC)NX4U^4'%1I46
M:H)8-N,=9^+70)3CRSN>>%_?RD#XZ#J)1.](B8KO6_2),$9DD-&K&\I)$*:O
MQ=4O=S?HU?>OT?=HBM(-831%08R^Q %/WXB+XO/OFR1+2>RGYU,N/)3U3+W"
MFZO<&WS &Q.CCTG,-REZ'_O4KQN8"FFE/KS7=X5!BS?4.T.6^09A ^,.AZZ/
M+VX"[EAEN"UESSH4;AFQKG!?BEC':RH>$([NGU#UOEORI"Y?/A#F=\4TK]+N
MKE*. ^_2+?'HQ40\Z"EE.SI9_O"=Z1H_=L5C(&.UZ-AE=&S(^O)G$0,N%+\2
MO2CO6Z^[].9&7&5$#E.[I67/+&MFG$]W52E@93VE.*44!Y12?:Z\:D/31_F9
M=NG*+<XJNN;SV:PAJGV3:1B&5=Y5\]8MO75!;S^2QR#*(D3B.".A<#CF++C/
MI,,IVE*&:+0-DR?:Z79NVC2J+C6<!FOOV1*S4ML,U/9>!-R3O<H/=H%/8Q\]
M!33L?)!F;27-/@76U5/)O%0R!Y5\B'=B'$A80#N'5K#PJ</ 0,9J.A>ESL6W
M'R070T9G(&.UZ)B&GK*-P<>6PF1M<+$:?1NNMJ^L"HF8L"QA,? HNE+"E$CT
MZU:-09V*0&NGMNA0UNK:L=:.OWV7+^H<*D(#6:M'2(.3"9+'4JE$.YKR(%[+
M.2E(ND7#9FST1 GKZE#7<,F^ C7[F##\_$0"AG8DS"A*5O*YCD3SI^HID#SD
M)V$H'%>SL6*C3C0JZEA4Y^(SW)R.84_Z*M5H9,)L]$'2A5@(>EHN?:3,"V2O
M3H GOH-]S)8VITV'3C<=F1J/3)B/.CPN_$1B:9QRL=H1O;+39[?ESKSE\AAX
M9&H^,F% .MP<Y#ZD8(/,VN*:VL8 )E,3DPDCTY>842]9Q\$_S;G22U+>J6G>
MZF2VY;9DC<%'I@8D$R2,P[+>(#E 1D3R[H/:PJ#^6[*CC*PI(E'">/!/KA\8
M0>&Z<3Z"(AM%^5+=13YYZAY1Q^ DK#D)PYST6<2"!8K]\W$TD[L479)A0Z?.
ME$-9J\O6'(7-;\\2>%#:&LI:/4*:MC#(*D>SQ#-F ): 2_85J&$)PY1S5VS,
MI6GV_'9*8<NM3:N&@VVW,>C!E?85I0$)PX!TR^3JH*+I."3"74@T=YK:QD B
MK)$(#[]=A#MPR'4736%@Q7V%:7+",#E5QN!\15?L%-]2ILX@8H^^50N^3H4#
M@5$1B3$P"VO,PK,7&)8'PJLB0F/ &M:PAH>&M<)@=>A:V+CY!(S!:EBS&H9Y
MZ= 34&QW +U_T"VKH:S5CSTTBUG&"QQ\#(IM0UFK1TACFP5O?YW>^PN#U0G
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M\0MH?J6U>^IX!]U_@O0_4$L#!!0    ( %2$9U:0^#Z=O0(  #<'   9
M>&PO=V]R:W-H965T<R]S:&5E=#8X+GAM;*U576_:,!3]*U963:W4-E\0: >1
M"JQJI56J2KL]3'LPR8583>S,=H#]^UT[(:,H97O8"_&U[SD^YV)?CS9"OJH,
M0)-MD7,U=C*MRVO754D&!567H@2.*TLA"ZHQE"M7E1)H:D%%[@:>%[D%9=R)
M1W;N4<8C4>F<<7B41%5%0>6O">1B,W9\9S?QQ%:9-A-N/"KI"N:@7\I'B9';
MLJ2L *Z8X$3"<NS<^-?3R.3;A*\,-FIO3(R3A1"O)KA/QXYG!$$.B38,%#]K
MF$*>&R*4\;/A=-HM#7!_O&._M=[1RX(JF(K\&TMU-G:&#DEA2:M</XG-'31^
M^H8O$;FROV33Y'H.22JE1=& 44'!>/VEVZ8.>P _>@<0-(#@$-![!Q V@- :
MK9596S.J:3R28D.DR48V,["UL6ATP[CY%^=:XBI#G([O>2(*(,]T"XI<D#F>
MDK3*@8@E8?72 O"LP"[2='M.4APIS1)">4K,*EMQ<CH#35FNSI#F93XCIR=G
MY 1AY#D3E<),-7(U*C;[NDFC;E*K"]Y1YP?D07"=*?*9IY"^)7#1:NLWV/F=
M!$<99Y!<DM _)X$7!!V"IO\.]X_("=ORAY8O_&OYR8RI)!>JPEI_OUDH+?&$
M_^@J6<W8ZV8TM_Y:E32!L8/76H%<@Q-__.!'WJ<NN_^)[(WY7FN^=XP]GNV.
M$?8D2<VM[CPB-<G DIBFM(XO!L&@[XW<];Z3KK3AT//;M#<:^ZW&_E&-M\WI
M/BZQYHCV]PZ\87B@L",K[%WUNP5&K<#HJ, O0JG='2VE6#/;7S'<N['0*3KJ
M*%AO&!ZJ[D@;!L%5="#;W>M!!<B5;<V*)*+BNKZ>[6S;_6]LTSN8G^"K4#?Q
M/S3UD_) Y8IQ17)8(J5W.<""RKI-UX$6I>UT"Z&Q;]IAAB\;2). ZTLA]"XP
M&[1O9?P;4$L#!!0    ( %2$9U;K?+-LR0,  "4-   9    >&PO=V]R:W-H
M965T<R]S:&5E=#8Y+GAM;*U7VV[C-A#]%4)%"Q?86A<KMI/:!A)G%]V'!8+-
M;OM0](&61C81BG1)^I*_[Y"2Y<M2LA_Z8HL4Y_"<X7!F--E)]:97 (;L2R[T
M-%@9LWX(0YVMH*2Z+]<@\$TA54D-#M4RU&L%-'=&)0^3*!J&)64BF$W<W(N:
M3>3&<";@11&]*4NJWI^ R]TTB(/#Q%>V7!D[$<XF:[J$5S#?UR\*1V&#DK,2
MA&92$ 7%-'B,'^9Q:@W<BC\9[/3),[%2%E*^V<'G?!I$EA%PR(R%H/BWA3EP
M;I&0Q[\U:-#L:0U/GP_HGYQX%+.@&N:2_\5RLYH&XX#D4- --U_E[@^H!=U9
MO$QR[7[)KEH[PL791AM9UL;(H&2B^J?[VA$G!O&PQ2"I#9)+@[3%8% ;#)S0
MBIF3]4P-G4V4W!%E5R.:?7"^<=:HA@E[C*]&X5N&=F;V662R!/*-[D&3W\@K
MADF^X4!D0: HP#F9L&J1H7NBJ $\ODR*C'%&W5'TGL%0QO6OD] @)0L<9O7V
M3]7V2<OV<4*^2&%6FGP4.>3G "%J:00E!T%/22?B,V1],H@_D"1*$@^A^>WF
M<0>=0>/?@<,;7/4O>68ZXU)O%)"_'Q?:* SA?WPNJQ!3/Z*]UP]Z33.8!GAQ
M-:@M!+-??HJ'T>\^N?\3V)GXM!&?=J$?Q-NX@3TF'@V$&J(--1LCU;L+)I\#
M*M0X<K V$6UG4=\>Q_94V;559Y3O&LIWG91? '.# &$(,U!J'[MN@%[<OXM^
M]EV%^17#J)_^8'BF8=AH&'8B87[#["6JNYHSO,8*!3'*?6JZH9#4J$5-91BG
M9^Z/HA;_CQKNH^Z0*3$:C4T_1:T"*Y9R><9[&-UHO3AM/8V1)WS\W,<-]W'G
M;J_&.MS85/J!"*A40([T.5F @((9GX2QUY')\"+<_<O2D9_S?</YOI/SMT-.
MSU94+,'KXVZ$7M*_;W'Q_<TNCJ-CO8IN"F[85XP)%3F19@7*6WVZP?"RMH7W
M-<O(H_I<TDD)CJ_$C<S>7#.2$TR8-E&Z@/<*ZH;J.(S:\J;32([4D^YTJ6!-
M64Z4?*?<O).=PK2)<5]XN7=C]>*X/VXCG]Q._EB:X\[B-YM7 <0$V5*^J7H9
MRK&QI2+SUJ4:[^(.QDEZ<56O[-M+?%GI7,2QQ,;=-?9C6Y?F%>"KF9?D.]=4
M+,.3AK,$M71]N,;@W0A3M6K-;-/K/[H.]V+^R7X#N$;V"%-]0'RA:LF$)AP*
MA,0RA-5353UY-3!R[=K:A338)+O'%7['@+(+\'TAI3D,[ ;-E]'L/U!+ P04
M    " !4A&=6 JW.4AT$  #0#@  &0   'AL+W=O<FMS:&5E=',O<VAE970W
M,"YX;6RMEVV/FS@0Q[^*Q575KM0L& @D:1*I353=2KUJM=GV7GO!2:P%S-G.
M0^_3WQBRA&"']J1]D_ P,_[-V)X_GAZX>)%;2A4ZYEDA9\Y6J7+BNC+9TIS(
M.U[2 MZLN<B)@ENQ<64I*$DKISQS?<^+W)RPPIE/JV</8C[E.Y6Q@CX()'=Y
M3L3/SS3CAYF#G=<'CVRS5?J!.Y^69$-75'TO'P3<N4V4E.6TD(P72-#US/F$
M)PL<:X?*X@>C!]FZ1CJ59\Y?],U].G,\340SFB@=@L#?GBYHENE(P/'/*:C3
MC*D=V]>OT;]4R4,RST32!<_^9JG:SIR1@U*Z)KM,/?+#G_24T%#'2W@FJU]T
M.-EZ#DIV4O'\Y P$.2OJ?W(\%:+E@,,K#O[)P?]=A^#D$%2)UF156DNBR'PJ
M^ $);0W1]$55F\H;LF&%GL:5$O"6@9^:WQ<)SREZ(D<JT0"M8)FDNXPBOM;%
MH$+0%"ER1$1*JB0B18HR1IY9QA0#CYLE581E\A9\OZ^6Z.;=+7J'6(&>MGPG
MP5I.7068>C W.2%]KI'\*TA+FMRA '] ON?[%O?%[[OC2W<7BM-4R&\JY%?Q
M@JOQC#),;$G544)[%+T;)[(D"9TYL-TD%7OJS-__@2/OHRW%-PIVD7#0)!ST
M19]_2A*Q@WSI$7J%I/6D<[6EPI9V'2NN8NF>L9\/<1A.W7T['=,HBK'?&%U@
MA@UFV(OY(&A)F%Z.B>XJQ081(4BQH=!DE(VT#A>U(+P.IFDQ#D-LQQPVF,->
MS/M"49@C]5I.&]G0&!>'@=<MHL7*B[V1'2]J\*)>O)7BR0N"'J#AB.ZL-L#(
M&#K&XZ##9QJ-AJ/ CA<W>'$OWE<*+;KI.#]M;+$Q;!3Z'333!GNC*Q,[:M!&
MO6B/L/&(2+;5]DCI'A2QU$L/)= LF+(VOI'!X8=1=Q5:C:[ CAO8<2_L@I1,
MD8S]"_OZ\3W)RX]+&]_8&#H(XKC#USN2O3>AGK:$O;-4>;U)?(.O&OA^$;!,
M8;=G''JQ75X\<R5"'E$G#YM9'/BAO=*XI:BX%_.)0Z5MZFEEQ>;2Q%$X-F M
M=GX48.\*[5G=\/^0MY:T6S4.OZG(O56TR\S/,H?[=>X+.T+:]=1\@&^6)-NE
MU<+2/<<^68$Q"0,<X^Y46:S\JQ-UECO<KW?5%_9 \<$..F)%;44T-6P0><,N
MHL4*>U>7_EGK<+_869;^+Y>4*6N#V-RK%BOL!]> S^J'^^7O*Y5R@GZ0;$?J
M4T4&YQI2)%:9QJ;"#3 >QGZW@UL-_:'72NN2]RR'N%\/ZP(7T AM7^<WK6+?
M6C.(C0\Q@[W/I*9V6\<-?=;[BX@-*R1LG#7X>'<Q3):HCT_UC>)E=0)YY@K.
M,]7E%HZ<5&@#>+_F7+W>Z$--<XB=_P=02P,$%     @ 5(1G5D:/7-5W P
MB0P  !D   !X;"]W;W)K<VAE971S+W-H965T-S$N>&ULM5=M;]LV$/XKA%8,
M+=!&$F7+<6H;R,N&94C7H%FV#\4^,-+9(DJ1+DG9R7[]CI0C.[/,HD'SQ28I
MWG//W>E>-%DK_<54 );<UT*::519NSR)8U-44#-SI)8@\<E<Z9I9W.I%;)8:
M6.F%:A'3),GCFG$9S2;^[%K/)JJQ@DNXUL0T=<WTPQD(M9Y&:?1X\(DO*NL.
MXMEDR19P _9V>:UQ%W<H):]!&JXDT3"?1J?IR5F:.P%_XR\.:[.S)LZ4.Z6^
MN,UE.8T2QP@$%-9!,/Q;P3D(X9"0Q]<-:-3I=(*[ZT?T7[WQ:,P=,W"NQ-^\
MM-4T.HY("7/6"/M)K7^#C4%#AU<H8?PO6;=W\W%$BL9856^$D4'-9?O/[C>.
MV!&@](  W0A0S[M5Y%E>,,MF$ZW61+O;B.86WE0OC>2X=%&YL1J?<I2SLTM9
MJ!K(G^P>#'E'_F!:,^<G\OH"+./"O)G$%O6XVW&QP3QK,>D!S)22#TK:RI!?
M9 GE4X 8"78LZ2/+,QI$O(#BB&3I6T(32LGMS05Y_>I- #?KK,\\;G8 ]^,2
MG+ER0:Z4,>0<K7_ -WW-=&G(YRN\32XMU.:?/B>TT(-^:)=-)V;)"IA&F"X&
M] JBV<\_I7GR/D!\T!$?A-#1(7/0&DIBV3UAQH U?EG@&;>D>&*(4\]T4?49
MT:H9>34N@U<S.C@>)4DRB5<]_(8=O^&/YT<LZ+J/9%@73<@#RIN 6_..=OX-
MVD@0<YQP259,-*RM' )K%Y,%]''+]QSX;IP-\X,>''541D$JMU)#H1:2_[OQ
MXAU(F'-KWB(YG[/N$(LS$Y9C[C)9X@/T(!B+M:[0S?\SK^7;:LUW^!X@>MP1
M/0X2Q>*(I4^Z$D).&ULIS>U#G^8@S#/S9=R1'+]<HH]?@'B:; MT$O3OEKIP
MU)^D3F]M3O8B/$Y&V<$7,MUI%6DX._"M,Y87WPYU&.BY+J-;HO3EHKW!_L'<
MMQTI#?:-[P]WMA?N+!LFR?APP+=-)@UWF1O++/C*<J4*)LCOC>:FY'Z>ZN42
MA'NNZ[8])QV^8-B#3>:YW+>-)PUWGN\.^W[?H4.:T<%^V..=Z; &O? S,*I0
MC;3MH-B==G/V:3M=;J^W0_H'IA=<&B)@CJ+)T0B=IMNYM]U8M?2SYIVR.+GZ
M987?"J#=!7P^5\H^;IR"[NMC]A]02P,$%     @ 5(1G5LW;<!Y6 P  LA4
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MB6/S'MQY'P6K]U2P_B_M\ E02P,$%     @ 5(1G5I>*NQS     $P(   L
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MGV5GF_XMGXW_FCQ_ 5!+ 0(4 Q0    ( %.$9U8'04UB@0   +$    0
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M965T,RYX;6Q02P$"% ,4    " !3A&=6>9V>1I\"  ! !P  &
M    @(%3&   >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @
M4X1G5N&'DMO6!   Z!,  !@              ("!*!L  'AL+W=O<FMS:&5E
M=',O<VAE970U+GAM;%!+ 0(4 Q0    ( %.$9U;CT@>1QP(   ((   8
M          " @30@  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4
M    " !3A&=6:>U2?W@'  #$-@  &               @($Q(P  >&PO=V]R
M:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @ 4X1G5AO_W-EO!P  9B$
M !@              ("!WRH  'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+
M 0(4 Q0    ( %.$9U:H)J(HP@,  "T(   8              " @80R  !X
M;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4    " !3A&=6:2<K4=0)
M  !Z'   &0              @(%\-@  >&PO=V]R:W-H965T<R]S:&5E=#$P
M+GAM;%!+ 0(4 Q0    ( %.$9U:CY8)&B2$  !]I   9              "
M@8=   !X;"]W;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @ 4X1G
M5GG9/)<)!P  6Q(  !D              ("!1V(  'AL+W=O<FMS:&5E=',O
M<VAE970Q,BYX;6Q02P$"% ,4    " !4A&=6)%+1;*8"  "O!0  &0
M        @(&':0  >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0
M   ( %2$9U8RWRR#0P,  %X'   9              " @61L  !X;"]W;W)K
M<VAE971S+W-H965T,30N>&UL4$L! A0#%     @ 5(1G5MPH;XKH!0  4P\
M !D              ("!WF\  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q0
M2P$"% ,4    " !4A&=6Z7 5K^\"   '!P  &0              @(']=0
M>&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( %2$9U8M>GEZ
M* ,  .L&   9              " @2-Y  !X;"]W;W)K<VAE971S+W-H965T
M,3<N>&UL4$L! A0#%     @ 5(1G5NJ$Z,(=#0  G"D  !D
M ("!@GP  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4    " !4
MA&=6Q#&<+]T#  "/"0  &0              @('6B0  >&PO=V]R:W-H965T
M<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( %2$9U:F\Q<IW0,  +T(   9
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M970R-"YX;6Q02P$"% ,4    " !4A&=63H?,14,$  !M"0  &0
M    @($.V@  >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    (
M %2$9U93^0$Z' 0  .4,   9              " @8C>  !X;"]W;W)K<VAE
M971S+W-H965T,C8N>&UL4$L! A0#%     @ 5(1G5A$V/%=Z @  704  !D
M             ("!V^(  'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"
M% ,4    " !4A&=60:X57",#   1!P  &0              @(&,Y0  >&PO
M=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( %2$9U9K7EN+]P,
M &P*   9              " @>;H  !X;"]W;W)K<VAE971S+W-H965T,CDN
M>&UL4$L! A0#%     @ 5(1G5@@(S5<  P  [08  !D              ("!
M%.T  'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q02P$"% ,4    " !4A&=6
M] KJ?S,%  !H#   &0              @(%+\   >&PO=V]R:W-H965T<R]S
M:&5E=#,Q+GAM;%!+ 0(4 Q0    ( %2$9U98?LNCH ,   $(   9
M      " @;7U  !X;"]W;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#%
M  @ 5(1G5ERKE),_!0  $0T  !D              ("!C/D  'AL+W=O<FMS
M:&5E=',O<VAE970S,RYX;6Q02P$"% ,4    " !4A&=6"8!1&3L%  !_#
M&0              @($"_P  >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+
M 0(4 Q0    ( %2$9U9^74_*K0,   L3   9              " @70$ 0!X
M;"]W;W)K<VAE971S+W-H965T,S4N>&UL4$L! A0#%     @ 5(1G5H,<=""N
M @  5 @  !D              ("!6 @! 'AL+W=O<FMS:&5E=',O<VAE970S
M-BYX;6Q02P$"% ,4    " !4A&=65UGA*6D"  !H!0  &0
M@($]"P$ >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( %2$
M9U87^U&S6P(  %@%   9              " @=T- 0!X;"]W;W)K<VAE971S
M+W-H965T,S@N>&UL4$L! A0#%     @ 5(1G5I^?)\55 P  _Q   !D
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M=#0S+GAM;%!+ 0(4 Q0    ( %2$9U:LIB&3S@(  #T+   9
M  " @0@@ 0!X;"]W;W)K<VAE971S+W-H965T-#0N>&UL4$L! A0#%     @
M5(1G5D \A&T; P  M@<  !D              ("!#2,! 'AL+W=O<FMS:&5E
M=',O<VAE970T-2YX;6Q02P$"% ,4    " !4A&=6&[39EC@%  #2*@  &0
M            @(%?)@$ >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4
M Q0    ( %2$9U:<X\+/?P(  ,,&   9              " @<XK 0!X;"]W
M;W)K<VAE971S+W-H965T-#<N>&UL4$L! A0#%     @ 5(1G5D6I\4."!
M81H  !D              ("!A"X! 'AL+W=O<FMS:&5E=',O<VAE970T."YX
M;6Q02P$"% ,4    " !4A&=6<)L@)_X"  !@"   &0              @($]
M,P$ >&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0    ( %2$9U;>
M%@>I*0,  *,+   9              " @7(V 0!X;"]W;W)K<VAE971S+W-H
M965T-3 N>&UL4$L! A0#%     @ 5(1G5D('[AX? @  \P0  !D
M     ("!TCD! 'AL+W=O<FMS:&5E=',O<VAE970U,2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( %2$9U9CQCW_$ 8  &XX   9              "
M@6]2 0!X;"]W;W)K<VAE971S+W-H965T-38N>&UL4$L! A0#%     @ 5(1G
M5N[[+LG" @  J@<  !D              ("!ME@! 'AL+W=O<FMS:&5E=',O
M<VAE970U-RYX;6Q02P$"% ,4    " !4A&=6T@GK-K$#  "1$0  &0
M        @(&O6P$ >&PO=V]R:W-H965T<R]S:&5E=#4X+GAM;%!+ 0(4 Q0
M   ( %2$9U9#Z3G]_@$  "<$   9              " @9=? 0!X;"]W;W)K
M<VAE971S+W-H965T-3DN>&UL4$L! A0#%     @ 5(1G5CH)%*5B"   )5$
M !D              ("!S&$! 'AL+W=O<FMS:&5E=',O<VAE970V,"YX;6Q0
M2P$"% ,4    " !4A&=607\V\X4#   >$@  &0              @(%E:@$
M>&PO=V]R:W-H965T<R]S:&5E=#8Q+GAM;%!+ 0(4 Q0    ( %2$9U:6X LB
MJ (  $$(   9              " @2%N 0!X;"]W;W)K<VAE971S+W-H965T
M-C(N>&UL4$L! A0#%     @ 5(1G5G.%LU"&"    3L  !D
M ("! '$! 'AL+W=O<FMS:&5E=',O<VAE970V,RYX;6Q02P$"% ,4    " !4
MA&=6S)JGR'X$   G%@  &0              @(&]>0$ >&PO=V]R:W-H965T
M<R]S:&5E=#8T+GAM;%!+ 0(4 Q0    ( %2$9U9%4,W26 ,  &4*   9
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M970V.2YX;6Q02P$"% ,4    " !4A&=6 JW.4AT$  #0#@  &0
M    @($/D $ >&PO=V]R:W-H965T<R]S:&5E=#<P+GAM;%!+ 0(4 Q0    (
M %2$9U9&CUS5=P,  (D,   9              " @6.4 0!X;"]W;W)K<VAE
M971S+W-H965T-S$N>&UL4$L! A0#%     @ 5(1G5LW;<!Y6 P  LA4   T
M             ( !$9@! 'AL+W-T>6QE<RYX;6Q02P$"% ,4    " !4A&=6
MEXJ[',     3 @  "P              @ &2FP$ 7W)E;',O+G)E;'-02P$"
M% ,4    " !4A&=6C?MN^5T%  #"+@  #P              @ %[G $ >&PO
M=V]R:V)O;VLN>&UL4$L! A0#%     @ 5(1G5K % +TV @  '"H  !H
M         ( !!:(! 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#
M%     @ 5(1G5N'+1LC] 0  /2D  !,              ( !<Z0! %M#;VYT
D96YT7U1Y<&5S72YX;6Q02P4&     $\ 3P"@%0  H:8!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>173</ContextCount>
  <ElementCount>340</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>90</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="optn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.optinose.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="optn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.optinose.com/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="optn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.optinose.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="optn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.optinose.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="optn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.optinose.com/role/ConsolidatedStatementsofOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="optn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - Consolidated Statements of Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.optinose.com/role/ConsolidatedStatementsofComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="optn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Statement - Consolidated Statements of Changes in Stockholders' Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.optinose.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit</Role>
      <ShortName>Consolidated Statements of Changes in Stockholders' Equity (Deficit)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="optn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.optinose.com/role/ConsolidatedStatementsofCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="optn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - Organization and Description of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.optinose.com/role/OrganizationandDescriptionofBusiness</Role>
      <ShortName>Organization and Description of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="optn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Liquidity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.optinose.com/role/Liquidity</Role>
      <ShortName>Liquidity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="optn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.optinose.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="optn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.optinose.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="optn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Inventory</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.optinose.com/role/Inventory</Role>
      <ShortName>Inventory</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="optn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.optinose.com/role/PropertyandEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="optn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.optinose.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="optn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Accrued Expenses and Other Current Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.optinose.com/role/AccruedExpensesandOtherCurrentLiabilities</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="optn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - License Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.optinose.com/role/LicenseAgreements</Role>
      <ShortName>License Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="optn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Debt, net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.optinose.com/role/Debtnet</Role>
      <ShortName>Debt, net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="optn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Employee Benefit Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.optinose.com/role/EmployeeBenefitPlans</Role>
      <ShortName>Employee Benefit Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="optn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.optinose.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="optn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.optinose.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="optn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - Stock-based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.optinose.com/role/StockbasedCompensation</Role>
      <ShortName>Stock-based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="optn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.optinose.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="optn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.optinose.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.optinose.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="optn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.optinose.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.optinose.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="optn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.optinose.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.optinose.com/role/FairValueMeasurements</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="optn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - Inventory (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.optinose.com/role/InventoryTables</Role>
      <ShortName>Inventory (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.optinose.com/role/Inventory</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="optn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0000028 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.optinose.com/role/PropertyandEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.optinose.com/role/PropertyandEquipment</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="optn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0000029 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.optinose.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.optinose.com/role/Leases</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="optn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0000030 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.optinose.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.optinose.com/role/AccruedExpensesandOtherCurrentLiabilities</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="optn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0000031 - Disclosure - Debt, net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.optinose.com/role/DebtnetTables</Role>
      <ShortName>Debt, net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.optinose.com/role/Debtnet</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="optn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0000032 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.optinose.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.optinose.com/role/StockholdersEquity</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="optn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>0000033 - Disclosure - Stock-based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.optinose.com/role/StockbasedCompensationTables</Role>
      <ShortName>Stock-based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.optinose.com/role/StockbasedCompensation</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="optn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>0000034 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.optinose.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.optinose.com/role/IncomeTaxes</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="optn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>0000035 - Disclosure - Liquidity - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.optinose.com/role/LiquidityNarrativeDetails</Role>
      <ShortName>Liquidity - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="optn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>0000036 - Disclosure - Summary of Significant Accounting Policies - Concentration risk (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.optinose.com/role/SummaryofSignificantAccountingPoliciesConcentrationriskDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Concentration risk (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="optn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>0000037 - Disclosure - Summary of Significant Accounting Policies - Cash and cash equivalents (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.optinose.com/role/SummaryofSignificantAccountingPoliciesCashandcashequivalentsDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Cash and cash equivalents (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="optn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>0000038 - Disclosure - Summary of Significant Accounting Policies - Accounts receivable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.optinose.com/role/SummaryofSignificantAccountingPoliciesAccountsreceivableDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Accounts receivable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="optn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>0000039 - Disclosure - Summary of Significant Accounting Policies - Property and equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.optinose.com/role/SummaryofSignificantAccountingPoliciesPropertyandequipmentDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Property and equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="optn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>0000040 - Disclosure - Summary of Significant Accounting Policies - Long lived assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.optinose.com/role/SummaryofSignificantAccountingPoliciesLonglivedassetsDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Long lived assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="optn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>0000041 - Disclosure - Summary of Significant Accounting Policies - Licensing revenues (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.optinose.com/role/SummaryofSignificantAccountingPoliciesLicensingrevenuesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Licensing revenues (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="optn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>0000042 - Disclosure - Summary of Significant Accounting Policies - Advertising expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.optinose.com/role/SummaryofSignificantAccountingPoliciesAdvertisingexpenseDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Advertising expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="optn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>0000043 - Disclosure - Summary of Significant Accounting Policies - Net income (loss) per common share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.optinose.com/role/SummaryofSignificantAccountingPoliciesNetincomelosspercommonshareDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Net income (loss) per common share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="optn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>0000044 - Disclosure - Fair Value Measurements - Fair value, assets and liabilities measured on recurring basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.optinose.com/role/FairValueMeasurementsFairvalueassetsandliabilitiesmeasuredonrecurringbasisDetails</Role>
      <ShortName>Fair Value Measurements - Fair value, assets and liabilities measured on recurring basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="optn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>0000045 - Disclosure - Fair Value Measurements - Fair value liabilities measured on recurring basis using unobservable inputs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.optinose.com/role/FairValueMeasurementsFairvalueliabilitiesmeasuredonrecurringbasisusingunobservableinputsDetails</Role>
      <ShortName>Fair Value Measurements - Fair value liabilities measured on recurring basis using unobservable inputs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="optn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>0000046 - Disclosure - Fair Value Measurements - Valuation of warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.optinose.com/role/FairValueMeasurementsValuationofwarrantsDetails</Role>
      <ShortName>Fair Value Measurements - Valuation of warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="optn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>0000047 - Disclosure - Inventory (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.optinose.com/role/InventoryDetails</Role>
      <ShortName>Inventory (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.optinose.com/role/InventoryTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="optn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>0000048 - Disclosure - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.optinose.com/role/PropertyandEquipmentDetails</Role>
      <ShortName>Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.optinose.com/role/PropertyandEquipmentTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="optn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>0000049 - Disclosure - Leases - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.optinose.com/role/LeasesNarrativeDetails</Role>
      <ShortName>Leases - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="optn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>0000050 - Disclosure - Leases - Operating lease assets and liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.optinose.com/role/LeasesOperatingleaseassetsandliabilitiesDetails</Role>
      <ShortName>Leases - Operating lease assets and liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="optn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>0000051 - Disclosure - Leases - Weighted average remaining lease term and weighted average discount rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.optinose.com/role/LeasesWeightedaverageremainingleasetermandweightedaveragediscountrateDetails</Role>
      <ShortName>Leases - Weighted average remaining lease term and weighted average discount rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="optn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>0000052 - Disclosure - Leases - Operating lease maturities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.optinose.com/role/LeasesOperatingleasematuritiesDetails</Role>
      <ShortName>Leases - Operating lease maturities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="optn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>0000053 - Disclosure - Accrued Expenses and Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.optinose.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.optinose.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="optn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>0000054 - Disclosure - License Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.optinose.com/role/LicenseAgreementsDetails</Role>
      <ShortName>License Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.optinose.com/role/LicenseAgreements</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="optn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>0000055 - Disclosure - Debt, net - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.optinose.com/role/DebtnetNarrativeDetails</Role>
      <ShortName>Debt, net - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="optn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>0000056 - Disclosure - Debt, net - A&amp;R Note Purchase Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.optinose.com/role/DebtnetARNotePurchaseAgreementDetails</Role>
      <ShortName>Debt, net - A&amp;R Note Purchase Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="optn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>0000057 - Disclosure - Debt, net - Schedule of long term debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.optinose.com/role/DebtnetScheduleoflongtermdebtDetails</Role>
      <ShortName>Debt, net - Schedule of long term debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="optn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>0000058 - Disclosure - Employee Benefit Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.optinose.com/role/EmployeeBenefitPlansDetails</Role>
      <ShortName>Employee Benefit Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.optinose.com/role/EmployeeBenefitPlans</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="optn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>0000059 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.optinose.com/role/CommitmentsandContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.optinose.com/role/CommitmentsandContingencies</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="optn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>0000060 - Disclosure - Stockholders' Equity - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.optinose.com/role/StockholdersEquityNarrativeDetails</Role>
      <ShortName>Stockholders' Equity - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="optn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>0000061 - Disclosure - Stockholders' Equity - Grant date fair value of warrants, valuation assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.optinose.com/role/StockholdersEquityGrantdatefairvalueofwarrantsvaluationassumptionsDetails</Role>
      <ShortName>Stockholders' Equity - Grant date fair value of warrants, valuation assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="optn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>0000062 - Disclosure - Stockholders' Equity - Warrants Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.optinose.com/role/StockholdersEquityWarrantsOutstandingDetails</Role>
      <ShortName>Stockholders' Equity - Warrants Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="optn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>0000063 - Disclosure - Stock-based Compensation - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.optinose.com/role/StockbasedCompensationNarrativeDetails</Role>
      <ShortName>Stock-based Compensation - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="optn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>0000064 - Disclosure - Stock-based Compensation - Service-based stock options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.optinose.com/role/StockbasedCompensationServicebasedstockoptionsDetails</Role>
      <ShortName>Stock-based Compensation - Service-based stock options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="optn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>0000065 - Disclosure - Stock-based Compensation - Schedule of RSUs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.optinose.com/role/StockbasedCompensationScheduleofRSUsDetails</Role>
      <ShortName>Stock-based Compensation - Schedule of RSUs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="optn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>0000066 - Disclosure - Stock-based Compensation - Stock-based compensation expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.optinose.com/role/StockbasedCompensationStockbasedcompensationexpenseDetails</Role>
      <ShortName>Stock-based Compensation - Stock-based compensation expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="optn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>0000067 - Disclosure - Stock-based Compensation - Black-Scholes pricing model options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.optinose.com/role/StockbasedCompensationBlackScholespricingmodeloptionsDetails</Role>
      <ShortName>Stock-based Compensation - Black-Scholes pricing model options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="optn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>0000068 - Disclosure - Income Taxes - Schedule of income before income tax, domestic and foreign (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.optinose.com/role/IncomeTaxesScheduleofincomebeforeincometaxdomesticandforeignDetails</Role>
      <ShortName>Income Taxes - Schedule of income before income tax, domestic and foreign (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="optn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>0000069 - Disclosure - Income Taxes - Schedule of effective income tax rate reconciliation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.optinose.com/role/IncomeTaxesScheduleofeffectiveincometaxratereconciliationDetails</Role>
      <ShortName>Income Taxes - Schedule of effective income tax rate reconciliation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="optn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>0000070 - Disclosure - Income Taxes - Schedule of deferred tax assets and liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.optinose.com/role/IncomeTaxesScheduleofdeferredtaxassetsandliabilitiesDetails</Role>
      <ShortName>Income Taxes - Schedule of deferred tax assets and liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="optn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>0000071 - Disclosure - Income Taxes - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.optinose.com/role/IncomeTaxesNarrativeDetails</Role>
      <ShortName>Income Taxes - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[dq-0540-EntityEmergingGrowthCompany-Value] In submission type 10-K, EntityEmergingGrowthCompany value "True", is not equivalent to header element emergingGrowthCompanyFlag value "false" in the Required Context. optn-20221231.htm 4</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-K" original="optn-20221231.htm">optn-20221231.htm</File>
    <File>auditorconsentex2312022.htm</File>
    <File>descriptionofsecuritiesex4.htm</File>
    <File>formindemnificationagreeme.htm</File>
    <File>listofsubsidiariesex2112022.htm</File>
    <File>optn-20221231.xsd</File>
    <File>optn-20221231_cal.xml</File>
    <File>optn-20221231_def.xml</File>
    <File>optn-20221231_lab.xml</File>
    <File>optn-20221231_pre.xml</File>
    <File>optn12-31x202210xkex311.htm</File>
    <File>optn12-31x202210xkex312.htm</File>
    <File>optn12-31x202210xkex321.htm</File>
    <File>optn12-31x202210xkex322.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>optn-20221231_g1.jpg</File>
    <File>optn-20221231_g2.jpg</File>
    <File>optn-20221231_g3.jpg</File>
    <File>optn-20221231_g4.jpg</File>
    <File>optn-20221231_g5.jpg</File>
    <File>optn-20221231_g6.jpg</File>
    <File>optn-20221231_g7.jpg</File>
    <File>optn-20221231_g8.jpg</File>
    <File>optn-20221231_g9.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="543">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="44">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>102
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "optn-20221231.htm": {
   "axisCustom": 3,
   "axisStandard": 25,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 543,
    "http://xbrl.sec.gov/dei/2022": 44
   },
   "contextCount": 173,
   "dts": {
    "calculationLink": {
     "local": [
      "optn-20221231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "optn-20221231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "optn-20221231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "optn-20221231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "optn-20221231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "optn-20221231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 563,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 7,
    "http://xbrl.sec.gov/dei/2022": 4,
    "total": 11
   },
   "keyCustom": 51,
   "keyStandard": 289,
   "memberCustom": 44,
   "memberStandard": 43,
   "nsprefix": "optn",
   "nsuri": "http://www.optinose.com/20221231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "optn-20221231.htm",
      "contextRef": "i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover Page",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.optinose.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "optn-20221231.htm",
      "contextRef": "i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "optn-20221231.htm",
      "contextRef": "i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "optn:FutureLiquidityTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000010 - Disclosure - Liquidity",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://www.optinose.com/role/Liquidity",
     "shortName": "Liquidity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "optn-20221231.htm",
      "contextRef": "i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "optn:FutureLiquidityTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "optn-20221231.htm",
      "contextRef": "i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000011 - Disclosure - Summary of Significant Accounting Policies",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.optinose.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "optn-20221231.htm",
      "contextRef": "i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "optn-20221231.htm",
      "contextRef": "i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000012 - Disclosure - Fair Value Measurements",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.optinose.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "optn-20221231.htm",
      "contextRef": "i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "optn-20221231.htm",
      "contextRef": "i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000013 - Disclosure - Inventory",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://www.optinose.com/role/Inventory",
     "shortName": "Inventory",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "optn-20221231.htm",
      "contextRef": "i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "optn-20221231.htm",
      "contextRef": "i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000014 - Disclosure - Property and Equipment",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://www.optinose.com/role/PropertyandEquipment",
     "shortName": "Property and Equipment",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "optn-20221231.htm",
      "contextRef": "i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "optn-20221231.htm",
      "contextRef": "i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000015 - Disclosure - Leases",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://www.optinose.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "optn-20221231.htm",
      "contextRef": "i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "optn-20221231.htm",
      "contextRef": "i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000016 - Disclosure - Accrued Expenses and Other Current Liabilities",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://www.optinose.com/role/AccruedExpensesandOtherCurrentLiabilities",
     "shortName": "Accrued Expenses and Other Current Liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "optn-20221231.htm",
      "contextRef": "i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "optn-20221231.htm",
      "contextRef": "i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000017 - Disclosure - License Agreements",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://www.optinose.com/role/LicenseAgreements",
     "shortName": "License Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "optn-20221231.htm",
      "contextRef": "i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "optn-20221231.htm",
      "contextRef": "i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000018 - Disclosure - Debt, net",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://www.optinose.com/role/Debtnet",
     "shortName": "Debt, net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "optn-20221231.htm",
      "contextRef": "i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "optn-20221231.htm",
      "contextRef": "i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000019 - Disclosure - Employee Benefit Plans",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://www.optinose.com/role/EmployeeBenefitPlans",
     "shortName": "Employee Benefit Plans",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "optn-20221231.htm",
      "contextRef": "i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "optn-20221231.htm",
      "contextRef": "i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "false",
     "longName": "0000002 - Document - Audit Information",
     "menuCat": "Cover",
     "order": "2",
     "role": "http://www.optinose.com/role/AuditInformation",
     "shortName": "Audit Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "optn-20221231.htm",
      "contextRef": "i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "optn-20221231.htm",
      "contextRef": "i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000020 - Disclosure - Commitments and Contingencies",
     "menuCat": "Notes",
     "order": "20",
     "role": "http://www.optinose.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "optn-20221231.htm",
      "contextRef": "i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "optn-20221231.htm",
      "contextRef": "i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000021 - Disclosure - Stockholders' Equity",
     "menuCat": "Notes",
     "order": "21",
     "role": "http://www.optinose.com/role/StockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "optn-20221231.htm",
      "contextRef": "i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "optn-20221231.htm",
      "contextRef": "i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000022 - Disclosure - Stock-based Compensation",
     "menuCat": "Notes",
     "order": "22",
     "role": "http://www.optinose.com/role/StockbasedCompensation",
     "shortName": "Stock-based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "optn-20221231.htm",
      "contextRef": "i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "optn-20221231.htm",
      "contextRef": "i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000023 - Disclosure - Income Taxes",
     "menuCat": "Notes",
     "order": "23",
     "role": "http://www.optinose.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "optn-20221231.htm",
      "contextRef": "i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "optn-20221231.htm",
      "contextRef": "i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000024 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "menuCat": "Policies",
     "order": "24",
     "role": "http://www.optinose.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "optn-20221231.htm",
      "contextRef": "i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "optn-20221231.htm",
      "contextRef": "i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000025 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "menuCat": "Tables",
     "order": "25",
     "role": "http://www.optinose.com/role/SummaryofSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "optn-20221231.htm",
      "contextRef": "i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "optn-20221231.htm",
      "contextRef": "i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000026 - Disclosure - Fair Value Measurements (Tables)",
     "menuCat": "Tables",
     "order": "26",
     "role": "http://www.optinose.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "optn-20221231.htm",
      "contextRef": "i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "optn-20221231.htm",
      "contextRef": "i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000027 - Disclosure - Inventory (Tables)",
     "menuCat": "Tables",
     "order": "27",
     "role": "http://www.optinose.com/role/InventoryTables",
     "shortName": "Inventory (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "optn-20221231.htm",
      "contextRef": "i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "optn-20221231.htm",
      "contextRef": "i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000028 - Disclosure - Property and Equipment (Tables)",
     "menuCat": "Tables",
     "order": "28",
     "role": "http://www.optinose.com/role/PropertyandEquipmentTables",
     "shortName": "Property and Equipment (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": null
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "optn-20221231.htm",
      "contextRef": "i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "optn:AssetsAndLiabilitiesLesseeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000029 - Disclosure - Leases (Tables)",
     "menuCat": "Tables",
     "order": "29",
     "role": "http://www.optinose.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "optn-20221231.htm",
      "contextRef": "i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "optn:AssetsAndLiabilitiesLesseeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "optn-20221231.htm",
      "contextRef": "ie179c2aa474648c5a81e099ecf55e73a_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000003 - Statement - Consolidated Balance Sheets",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.optinose.com/role/ConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "optn-20221231.htm",
      "contextRef": "ie179c2aa474648c5a81e099ecf55e73a_I20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "optn-20221231.htm",
      "contextRef": "i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000030 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)",
     "menuCat": "Tables",
     "order": "30",
     "role": "http://www.optinose.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables",
     "shortName": "Accrued Expenses and Other Current Liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "optn-20221231.htm",
      "contextRef": "i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "optn-20221231.htm",
      "contextRef": "i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000031 - Disclosure - Debt, net (Tables)",
     "menuCat": "Tables",
     "order": "31",
     "role": "http://www.optinose.com/role/DebtnetTables",
     "shortName": "Debt, net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "optn-20221231.htm",
      "contextRef": "i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "optn-20221231.htm",
      "contextRef": "i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "optn:ScheduleOfGrantDateFairValueOfWarrantValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000032 - Disclosure - Stockholders' Equity (Tables)",
     "menuCat": "Tables",
     "order": "32",
     "role": "http://www.optinose.com/role/StockholdersEquityTables",
     "shortName": "Stockholders' Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "optn-20221231.htm",
      "contextRef": "i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "optn:ScheduleOfGrantDateFairValueOfWarrantValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "optn-20221231.htm",
      "contextRef": "i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000033 - Disclosure - Stock-based Compensation (Tables)",
     "menuCat": "Tables",
     "order": "33",
     "role": "http://www.optinose.com/role/StockbasedCompensationTables",
     "shortName": "Stock-based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "optn-20221231.htm",
      "contextRef": "i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "optn-20221231.htm",
      "contextRef": "i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000034 - Disclosure - Income Taxes (Tables)",
     "menuCat": "Tables",
     "order": "34",
     "role": "http://www.optinose.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "optn-20221231.htm",
      "contextRef": "i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "optn-20221231.htm",
      "contextRef": "ie179c2aa474648c5a81e099ecf55e73a_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000035 - Disclosure - Liquidity - Narrative (Details)",
     "menuCat": "Details",
     "order": "35",
     "role": "http://www.optinose.com/role/LiquidityNarrativeDetails",
     "shortName": "Liquidity - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "optn-20221231.htm",
      "contextRef": "ie179c2aa474648c5a81e099ecf55e73a_I20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "optn:WorkingCapital",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "optn-20221231.htm",
      "contextRef": "i9c9d8c25cbd84a1dbfec87c26799aca0_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "optn:NumberOfCustomers",
      "reportCount": 1,
      "unique": true,
      "unitRef": "customer",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000036 - Disclosure - Summary of Significant Accounting Policies - Concentration risk (Details)",
     "menuCat": "Details",
     "order": "36",
     "role": "http://www.optinose.com/role/SummaryofSignificantAccountingPoliciesConcentrationriskDetails",
     "shortName": "Summary of Significant Accounting Policies - Concentration risk (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "optn-20221231.htm",
      "contextRef": "i9c9d8c25cbd84a1dbfec87c26799aca0_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "optn:NumberOfCustomers",
      "reportCount": 1,
      "unique": true,
      "unitRef": "customer",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "optn-20221231.htm",
      "contextRef": "ie179c2aa474648c5a81e099ecf55e73a_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashUninsuredAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000037 - Disclosure - Summary of Significant Accounting Policies - Cash and cash equivalents (Details)",
     "menuCat": "Details",
     "order": "37",
     "role": "http://www.optinose.com/role/SummaryofSignificantAccountingPoliciesCashandcashequivalentsDetails",
     "shortName": "Summary of Significant Accounting Policies - Cash and cash equivalents (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "optn-20221231.htm",
      "contextRef": "ie179c2aa474648c5a81e099ecf55e73a_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashUninsuredAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:TradeAndOtherAccountsReceivablePolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "optn-20221231.htm",
      "contextRef": "ie179c2aa474648c5a81e099ecf55e73a_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000038 - Disclosure - Summary of Significant Accounting Policies - Accounts receivable (Details)",
     "menuCat": "Details",
     "order": "38",
     "role": "http://www.optinose.com/role/SummaryofSignificantAccountingPoliciesAccountsreceivableDetails",
     "shortName": "Summary of Significant Accounting Policies - Accounts receivable (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:TradeAndOtherAccountsReceivablePolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "optn-20221231.htm",
      "contextRef": "ie179c2aa474648c5a81e099ecf55e73a_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "optn-20221231.htm",
      "contextRef": "i096da31e1c4b4962a9749727b86a9251_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000039 - Disclosure - Summary of Significant Accounting Policies - Property and equipment (Details)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://www.optinose.com/role/SummaryofSignificantAccountingPoliciesPropertyandequipmentDetails",
     "shortName": "Summary of Significant Accounting Policies - Property and equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "optn-20221231.htm",
      "contextRef": "i096da31e1c4b4962a9749727b86a9251_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "optn-20221231.htm",
      "contextRef": "ie179c2aa474648c5a81e099ecf55e73a_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000004 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.optinose.com/role/ConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "optn-20221231.htm",
      "contextRef": "ie179c2aa474648c5a81e099ecf55e73a_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "optn-20221231.htm",
      "contextRef": "i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000040 - Disclosure - Summary of Significant Accounting Policies - Long lived assets (Details)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://www.optinose.com/role/SummaryofSignificantAccountingPoliciesLonglivedassetsDetails",
     "shortName": "Summary of Significant Accounting Policies - Long lived assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "optn-20221231.htm",
      "contextRef": "i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "optn-20221231.htm",
      "contextRef": "i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000041 - Disclosure - Summary of Significant Accounting Policies - Licensing revenues (Details)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://www.optinose.com/role/SummaryofSignificantAccountingPoliciesLicensingrevenuesDetails",
     "shortName": "Summary of Significant Accounting Policies - Licensing revenues (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "optn-20221231.htm",
      "contextRef": "i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdvertisingExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000042 - Disclosure - Summary of Significant Accounting Policies - Advertising expense (Details)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://www.optinose.com/role/SummaryofSignificantAccountingPoliciesAdvertisingexpenseDetails",
     "shortName": "Summary of Significant Accounting Policies - Advertising expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "optn-20221231.htm",
      "contextRef": "i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdvertisingExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "optn-20221231.htm",
      "contextRef": "i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000043 - Disclosure - Summary of Significant Accounting Policies - Net income (loss) per common share (Details)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://www.optinose.com/role/SummaryofSignificantAccountingPoliciesNetincomelosspercommonshareDetails",
     "shortName": "Summary of Significant Accounting Policies - Net income (loss) per common share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "optn-20221231.htm",
      "contextRef": "i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "optn-20221231.htm",
      "contextRef": "ie179c2aa474648c5a81e099ecf55e73a_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:WarrantsNotSettleableInCashFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000044 - Disclosure - Fair Value Measurements - Fair value, assets and liabilities measured on recurring basis (Details)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://www.optinose.com/role/FairValueMeasurementsFairvalueassetsandliabilitiesmeasuredonrecurringbasisDetails",
     "shortName": "Fair Value Measurements - Fair value, assets and liabilities measured on recurring basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "optn-20221231.htm",
      "contextRef": "ie179c2aa474648c5a81e099ecf55e73a_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:WarrantsNotSettleableInCashFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "optn-20221231.htm",
      "contextRef": "id970dfd2674c4d6b895febb9c14d0fd1_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000045 - Disclosure - Fair Value Measurements - Fair value liabilities measured on recurring basis using unobservable inputs (Details)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://www.optinose.com/role/FairValueMeasurementsFairvalueliabilitiesmeasuredonrecurringbasisusingunobservableinputsDetails",
     "shortName": "Fair Value Measurements - Fair value liabilities measured on recurring basis using unobservable inputs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "optn-20221231.htm",
      "contextRef": "id970dfd2674c4d6b895febb9c14d0fd1_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "optn-20221231.htm",
      "contextRef": "i076a98514cf1491bb4e37cb056d5866a_I20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:WarrantsAndRightsOutstandingTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000046 - Disclosure - Fair Value Measurements - Valuation of warrants (Details)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://www.optinose.com/role/FairValueMeasurementsValuationofwarrantsDetails",
     "shortName": "Fair Value Measurements - Valuation of warrants (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "optn-20221231.htm",
      "contextRef": "i076a98514cf1491bb4e37cb056d5866a_I20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:WarrantsAndRightsOutstandingTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "optn-20221231.htm",
      "contextRef": "ie179c2aa474648c5a81e099ecf55e73a_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000047 - Disclosure - Inventory (Details)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://www.optinose.com/role/InventoryDetails",
     "shortName": "Inventory (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "optn-20221231.htm",
      "contextRef": "ie179c2aa474648c5a81e099ecf55e73a_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "optn-20221231.htm",
      "contextRef": "ie179c2aa474648c5a81e099ecf55e73a_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000048 - Disclosure - Property and Equipment (Details)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://www.optinose.com/role/PropertyandEquipmentDetails",
     "shortName": "Property and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "optn-20221231.htm",
      "contextRef": "ie179c2aa474648c5a81e099ecf55e73a_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "optn-20221231.htm",
      "contextRef": "i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "optn:OperatingLeaseCostForExtension",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000049 - Disclosure - Leases - Narrative (Details)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://www.optinose.com/role/LeasesNarrativeDetails",
     "shortName": "Leases - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "optn-20221231.htm",
      "contextRef": "i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "optn:OperatingLeaseCostForExtension",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "optn-20221231.htm",
      "contextRef": "i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000005 - Statement - Consolidated Statements of Operations",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.optinose.com/role/ConsolidatedStatementsofOperations",
     "shortName": "Consolidated Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "optn-20221231.htm",
      "contextRef": "i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "optn:AssetsAndLiabilitiesLesseeTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "optn-20221231.htm",
      "contextRef": "ie179c2aa474648c5a81e099ecf55e73a_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000050 - Disclosure - Leases - Operating lease assets and liabilities (Details)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://www.optinose.com/role/LeasesOperatingleaseassetsandliabilitiesDetails",
     "shortName": "Leases - Operating lease assets and liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "optn:AssetsAndLiabilitiesLesseeTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "optn-20221231.htm",
      "contextRef": "ie179c2aa474648c5a81e099ecf55e73a_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "optn-20221231.htm",
      "contextRef": "ie179c2aa474648c5a81e099ecf55e73a_I20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000051 - Disclosure - Leases - Weighted average remaining lease term and weighted average discount rate (Details)",
     "menuCat": "Details",
     "order": "51",
     "role": "http://www.optinose.com/role/LeasesWeightedaverageremainingleasetermandweightedaveragediscountrateDetails",
     "shortName": "Leases - Weighted average remaining lease term and weighted average discount rate (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "optn-20221231.htm",
      "contextRef": "ie179c2aa474648c5a81e099ecf55e73a_I20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "optn-20221231.htm",
      "contextRef": "ie179c2aa474648c5a81e099ecf55e73a_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000052 - Disclosure - Leases - Operating lease maturities (Details)",
     "menuCat": "Details",
     "order": "52",
     "role": "http://www.optinose.com/role/LeasesOperatingleasematuritiesDetails",
     "shortName": "Leases - Operating lease maturities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "optn-20221231.htm",
      "contextRef": "ie179c2aa474648c5a81e099ecf55e73a_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "optn-20221231.htm",
      "contextRef": "ie179c2aa474648c5a81e099ecf55e73a_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "optn:AccruedProductAllowancesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000053 - Disclosure - Accrued Expenses and Other Current Liabilities (Details)",
     "menuCat": "Details",
     "order": "53",
     "role": "http://www.optinose.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails",
     "shortName": "Accrued Expenses and Other Current Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "optn-20221231.htm",
      "contextRef": "ie179c2aa474648c5a81e099ecf55e73a_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "optn:AccruedProductAllowancesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "optn-20221231.htm",
      "contextRef": "i5fd2ee54427b485b93f8b56d2a73b716_D20210101-20210131",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "optn:ResearchAndDevelopmentArrangementContractToPerformForOthersMilestonePaymentsMaximumEligible",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000054 - Disclosure - License Agreements (Details)",
     "menuCat": "Details",
     "order": "54",
     "role": "http://www.optinose.com/role/LicenseAgreementsDetails",
     "shortName": "License Agreements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "optn-20221231.htm",
      "contextRef": "i5fd2ee54427b485b93f8b56d2a73b716_D20210101-20210131",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "optn:ResearchAndDevelopmentArrangementContractToPerformForOthersMilestonePaymentsMaximumEligible",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "optn-20221231.htm",
      "contextRef": "iaf72692f99ed46b5a83cb937a4981bae_I20221109",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "optn:FeeDueOnTheMaturityDateOfTheNotePurchaseAgreement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000055 - Disclosure - Debt, net - Narrative (Details)",
     "menuCat": "Details",
     "order": "55",
     "role": "http://www.optinose.com/role/DebtnetNarrativeDetails",
     "shortName": "Debt, net - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "optn-20221231.htm",
      "contextRef": "iaf72692f99ed46b5a83cb937a4981bae_I20221109",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "optn:FeeDueOnTheMaturityDateOfTheNotePurchaseAgreement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "optn-20221231.htm",
      "contextRef": "i96634d78ca80401db240ea2a9de1645e_I20221120",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "optn:NotePurchaseAgreementCovenantXHANCENetProductSalesAndRoyalties",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000056 - Disclosure - Debt, net - A&R Note Purchase Agreement (Details)",
     "menuCat": "Details",
     "order": "56",
     "role": "http://www.optinose.com/role/DebtnetARNotePurchaseAgreementDetails",
     "shortName": "Debt, net - A&R Note Purchase Agreement (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "optn-20221231.htm",
      "contextRef": "i96634d78ca80401db240ea2a9de1645e_I20221120",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "optn:NotePurchaseAgreementCovenantXHANCENetProductSalesAndRoyalties",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "optn-20221231.htm",
      "contextRef": "ibd48856bcb224069b298e05dfdf34fc8_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000057 - Disclosure - Debt, net - Schedule of long term debt (Details)",
     "menuCat": "Details",
     "order": "57",
     "role": "http://www.optinose.com/role/DebtnetScheduleoflongtermdebtDetails",
     "shortName": "Debt, net - Schedule of long term debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "optn-20221231.htm",
      "contextRef": "ibd48856bcb224069b298e05dfdf34fc8_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "optn-20221231.htm",
      "contextRef": "i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000058 - Disclosure - Employee Benefit Plans (Details)",
     "menuCat": "Details",
     "order": "58",
     "role": "http://www.optinose.com/role/EmployeeBenefitPlansDetails",
     "shortName": "Employee Benefit Plans (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "optn-20221231.htm",
      "contextRef": "ie179c2aa474648c5a81e099ecf55e73a_I20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "optn-20221231.htm",
      "contextRef": "ie179c2aa474648c5a81e099ecf55e73a_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PurchaseObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000059 - Disclosure - Commitments and Contingencies (Details)",
     "menuCat": "Details",
     "order": "59",
     "role": "http://www.optinose.com/role/CommitmentsandContingenciesDetails",
     "shortName": "Commitments and Contingencies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "optn-20221231.htm",
      "contextRef": "ie179c2aa474648c5a81e099ecf55e73a_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PurchaseObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "optn-20221231.htm",
      "contextRef": "i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000006 - Statement - Consolidated Statements of Comprehensive Loss",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://www.optinose.com/role/ConsolidatedStatementsofComprehensiveLoss",
     "shortName": "Consolidated Statements of Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "optn-20221231.htm",
      "contextRef": "i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ComprehensiveIncomeNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "optn-20221231.htm",
      "contextRef": "ie179c2aa474648c5a81e099ecf55e73a_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "optn:VotePerShare",
      "reportCount": 1,
      "unitRef": "vote",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000060 - Disclosure - Stockholders' Equity - Narrative (Details)",
     "menuCat": "Details",
     "order": "60",
     "role": "http://www.optinose.com/role/StockholdersEquityNarrativeDetails",
     "shortName": "Stockholders' Equity - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "optn-20221231.htm",
      "contextRef": "i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:CommonStockDividendsPerShareDeclared",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "optn:ScheduleOfGrantDateFairValueOfWarrantValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "optn-20221231.htm",
      "contextRef": "iecd24838e7ea4897a980acb7f05e8f07_I20211118",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000061 - Disclosure - Stockholders' Equity - Grant date fair value of warrants, valuation assumptions (Details)",
     "menuCat": "Details",
     "order": "61",
     "role": "http://www.optinose.com/role/StockholdersEquityGrantdatefairvalueofwarrantsvaluationassumptionsDetails",
     "shortName": "Stockholders' Equity - Grant date fair value of warrants, valuation assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "optn:ScheduleOfGrantDateFairValueOfWarrantValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "optn-20221231.htm",
      "contextRef": "i34d7dc335ebb4c258e92af8033ba7854_I20211118",
      "decimals": "2",
      "lang": "en-US",
      "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "optn-20221231.htm",
      "contextRef": "i24bb67187a7b4b71897cb83c06184e0c_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000062 - Disclosure - Stockholders' Equity - Warrants Outstanding (Details)",
     "menuCat": "Details",
     "order": "62",
     "role": "http://www.optinose.com/role/StockholdersEquityWarrantsOutstandingDetails",
     "shortName": "Stockholders' Equity - Warrants Outstanding (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "optn-20221231.htm",
      "contextRef": "i24bb67187a7b4b71897cb83c06184e0c_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "optn-20221231.htm",
      "contextRef": "i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000063 - Disclosure - Stock-based Compensation - Narrative (Details)",
     "menuCat": "Details",
     "order": "63",
     "role": "http://www.optinose.com/role/StockbasedCompensationNarrativeDetails",
     "shortName": "Stock-based Compensation - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "optn-20221231.htm",
      "contextRef": "i3b8fb31b2cb74f1986dbdb60db29474c_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "optn-20221231.htm",
      "contextRef": "id970dfd2674c4d6b895febb9c14d0fd1_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000064 - Disclosure - Stock-based Compensation - Service-based stock options (Details)",
     "menuCat": "Details",
     "order": "64",
     "role": "http://www.optinose.com/role/StockbasedCompensationServicebasedstockoptionsDetails",
     "shortName": "Stock-based Compensation - Service-based stock options (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "optn-20221231.htm",
      "contextRef": "i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "optn-20221231.htm",
      "contextRef": "idbf17e5750434c4fa4c7af6d79eb5f3b_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000065 - Disclosure - Stock-based Compensation - Schedule of RSUs (Details)",
     "menuCat": "Details",
     "order": "65",
     "role": "http://www.optinose.com/role/StockbasedCompensationScheduleofRSUsDetails",
     "shortName": "Stock-based Compensation - Schedule of RSUs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "optn-20221231.htm",
      "contextRef": "idbf17e5750434c4fa4c7af6d79eb5f3b_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "optn-20221231.htm",
      "contextRef": "i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000066 - Disclosure - Stock-based Compensation - Stock-based compensation expense (Details)",
     "menuCat": "Details",
     "order": "66",
     "role": "http://www.optinose.com/role/StockbasedCompensationStockbasedcompensationexpenseDetails",
     "shortName": "Stock-based Compensation - Stock-based compensation expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "optn-20221231.htm",
      "contextRef": "iaaa623bfd2b7461d815938764c60cf18_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "optn-20221231.htm",
      "contextRef": "i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000067 - Disclosure - Stock-based Compensation - Black-Scholes pricing model options (Details)",
     "menuCat": "Details",
     "order": "67",
     "role": "http://www.optinose.com/role/StockbasedCompensationBlackScholespricingmodeloptionsDetails",
     "shortName": "Stock-based Compensation - Black-Scholes pricing model options (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "optn-20221231.htm",
      "contextRef": "idfcc4aa88cd04b0498643a728bb0b299_D20220101-20221231",
      "decimals": "4",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "optn-20221231.htm",
      "contextRef": "i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000068 - Disclosure - Income Taxes - Schedule of income before income tax, domestic and foreign (Details)",
     "menuCat": "Details",
     "order": "68",
     "role": "http://www.optinose.com/role/IncomeTaxesScheduleofincomebeforeincometaxdomesticandforeignDetails",
     "shortName": "Income Taxes - Schedule of income before income tax, domestic and foreign (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "optn-20221231.htm",
      "contextRef": "i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "optn-20221231.htm",
      "contextRef": "i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000069 - Disclosure - Income Taxes - Schedule of effective income tax rate reconciliation (Details)",
     "menuCat": "Details",
     "order": "69",
     "role": "http://www.optinose.com/role/IncomeTaxesScheduleofeffectiveincometaxratereconciliationDetails",
     "shortName": "Income Taxes - Schedule of effective income tax rate reconciliation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "optn-20221231.htm",
      "contextRef": "i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "optn-20221231.htm",
      "contextRef": "i49ae796ea1484c519d91607656f24c24_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000007 - Statement - Consolidated Statements of Changes in Stockholders' Equity (Deficit)",
     "menuCat": "Statements",
     "order": "7",
     "role": "http://www.optinose.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit",
     "shortName": "Consolidated Statements of Changes in Stockholders' Equity (Deficit)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "optn-20221231.htm",
      "contextRef": "i49ae796ea1484c519d91607656f24c24_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "optn-20221231.htm",
      "contextRef": "ie179c2aa474648c5a81e099ecf55e73a_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000070 - Disclosure - Income Taxes - Schedule of deferred tax assets and liabilities (Details)",
     "menuCat": "Details",
     "order": "70",
     "role": "http://www.optinose.com/role/IncomeTaxesScheduleofdeferredtaxassetsandliabilitiesDetails",
     "shortName": "Income Taxes - Schedule of deferred tax assets and liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "optn-20221231.htm",
      "contextRef": "ie179c2aa474648c5a81e099ecf55e73a_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "optn-20221231.htm",
      "contextRef": "ie179c2aa474648c5a81e099ecf55e73a_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000071 - Disclosure - Income Taxes - Narrative (Details)",
     "menuCat": "Details",
     "order": "71",
     "role": "http://www.optinose.com/role/IncomeTaxesNarrativeDetails",
     "shortName": "Income Taxes - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "optn-20221231.htm",
      "contextRef": "ie179c2aa474648c5a81e099ecf55e73a_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "optn-20221231.htm",
      "contextRef": "i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000008 - Statement - Consolidated Statements of Cash Flows",
     "menuCat": "Statements",
     "order": "8",
     "role": "http://www.optinose.com/role/ConsolidatedStatementsofCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "optn-20221231.htm",
      "contextRef": "i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "optn-20221231.htm",
      "contextRef": "i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000009 - Disclosure - Organization and Description of Business",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://www.optinose.com/role/OrganizationandDescriptionofBusiness",
     "shortName": "Organization and Description of Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "optn-20221231.htm",
      "contextRef": "i5ac6c65594d5433a973f7b4139e616ec_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 90,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.optinose.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r593",
      "r594",
      "r595"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID",
        "terseLabel": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.optinose.com/role/AuditInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r593",
      "r594",
      "r595"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location",
        "terseLabel": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.optinose.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r593",
      "r594",
      "r595"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name",
        "terseLabel": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.optinose.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.optinose.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.optinose.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r593",
      "r594",
      "r595"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.optinose.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document fiscal period focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.optinose.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document fiscal year focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.optinose.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.optinose.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r596"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.optinose.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.optinose.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r591"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.optinose.com/role/CoverPage"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.optinose.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.optinose.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.optinose.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.optinose.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.optinose.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r590"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity central index key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.optinose.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding (in shares)"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.optinose.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.optinose.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r590"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.optinose.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r599"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.optinose.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.optinose.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r590"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.optinose.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.optinose.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r597"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.optinose.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.optinose.com/role/CoverPage"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r590"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.optinose.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r590"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.optinose.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r590"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.optinose.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r590"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.optinose.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.optinose.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r598"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.optinose.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r593",
      "r594",
      "r595"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.optinose.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.optinose.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r589"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.optinose.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r592"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.optinose.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.optinose.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "optn_AccruedProductAllowancesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.optinose.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Product Allowances, Current",
        "label": "Accrued Product Allowances, Current",
        "terseLabel": "Product revenue allowances"
       }
      }
     },
     "localname": "AccruedProductAllowancesCurrent",
     "nsuri": "http://www.optinose.com/20221231",
     "presentation": [
      "http://www.optinose.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "optn_AccruedResearchandDevelopmentCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.optinose.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Research and Development, Current",
        "label": "Accrued Research and Development, Current",
        "terseLabel": "Research and development expenses"
       }
      }
     },
     "localname": "AccruedResearchandDevelopmentCurrent",
     "nsuri": "http://www.optinose.com/20221231",
     "presentation": [
      "http://www.optinose.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "optn_AccruedSellingGeneralandAdministrativeCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.optinose.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Selling, General and Administrative, Current",
        "label": "Accrued Selling, General and Administrative, Current",
        "terseLabel": "Selling, general and administrative expenses"
       }
      }
     },
     "localname": "AccruedSellingGeneralandAdministrativeCurrent",
     "nsuri": "http://www.optinose.com/20221231",
     "presentation": [
      "http://www.optinose.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "optn_AmendedandRestated2010StockIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amended and Restated 2010 Stock Incentive Plan [Member]",
        "label": "Amended and Restated 2010 Stock Incentive Plan [Member]",
        "verboseLabel": "Amended and Restated Plan"
       }
      }
     },
     "localname": "AmendedandRestated2010StockIncentivePlanMember",
     "nsuri": "http://www.optinose.com/20221231",
     "presentation": [
      "http://www.optinose.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "optn_AmendmentFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment Fee",
        "label": "Amendment Fee",
        "terseLabel": "Amendment fee"
       }
      }
     },
     "localname": "AmendmentFee",
     "nsuri": "http://www.optinose.com/20221231",
     "presentation": [
      "http://www.optinose.com/role/DebtnetNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "optn_AmendmentFeePayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment Fee Payable",
        "label": "Amendment Fee Payable",
        "terseLabel": "Amendment fee payable"
       }
      }
     },
     "localname": "AmendmentFeePayable",
     "nsuri": "http://www.optinose.com/20221231",
     "presentation": [
      "http://www.optinose.com/role/DebtnetNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "optn_AmendmentFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment Fee, Percentage",
        "label": "Amendment Fee, Percentage",
        "terseLabel": "Amendment fee, percentage"
       }
      }
     },
     "localname": "AmendmentFeePercentage",
     "nsuri": "http://www.optinose.com/20221231",
     "presentation": [
      "http://www.optinose.com/role/DebtnetNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "optn_AssetsAndLiabilitiesLesseeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assets And Liabilities, Lessee",
        "label": "Assets And Liabilities, Lessee [Table Text Block]",
        "terseLabel": "Schedule of Lease Assets, Liabilities, Term and Discount Rate"
       }
      }
     },
     "localname": "AssetsAndLiabilitiesLesseeTableTextBlock",
     "nsuri": "http://www.optinose.com/20221231",
     "presentation": [
      "http://www.optinose.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "optn_AuditorInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Auditor Information",
        "label": "Auditor Information [Abstract]"
       }
      }
     },
     "localname": "AuditorInformationAbstract",
     "nsuri": "http://www.optinose.com/20221231",
     "xbrltype": "stringItemType"
    },
    "optn_ClassOfWarrantOrRightRestrictionCommonSharesMaximumOwnershipAfterEffectiveWaitingPeriodPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrant Or Right Restriction, Common Shares Maximum Ownership After Effective Waiting Period, Percent",
        "label": "Class Of Warrant Or Right Restriction, Common Shares Maximum Ownership After Effective Waiting Period, Percent",
        "terseLabel": "Class of warrant or right restriction, common shares maximum ownership after effective waiting period, percent"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightRestrictionCommonSharesMaximumOwnershipAfterEffectiveWaitingPeriodPercent",
     "nsuri": "http://www.optinose.com/20221231",
     "presentation": [
      "http://www.optinose.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "optn_ClassOfWarrantOrRightRestrictionCommonSharesMaximumOwnershipIfExercisedPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrant Or Right Restriction, Common Shares Maximum Ownership If Exercised, Percent",
        "label": "Class Of Warrant Or Right Restriction, Common Shares Maximum Ownership If Exercised, Percent",
        "terseLabel": "Class of warrant or right restriction, common shares maximum ownership If exercised, percent"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightRestrictionCommonSharesMaximumOwnershipIfExercisedPercent",
     "nsuri": "http://www.optinose.com/20221231",
     "presentation": [
      "http://www.optinose.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "optn_ClassOfWarrantOrRightRestrictionCommonSharesMaximumOwnershipPriorToExecutionPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrant Or Right Restriction, Common Shares Maximum Ownership Prior To Execution, Percent",
        "label": "Class Of Warrant Or Right Restriction, Common Shares Maximum Ownership Prior To Execution, Percent",
        "terseLabel": "Class of warrant or right restriction, common shares maximum ownership prior to execution, percent"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightRestrictionCommonSharesMaximumOwnershipPriorToExecutionPercent",
     "nsuri": "http://www.optinose.com/20221231",
     "presentation": [
      "http://www.optinose.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "optn_CommonStockCapitalSharesReservedforFutureIssuanceYearlyIncrease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock, Capital Shares Reserved for Future Issuance, Yearly Increase",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance, Yearly Increase",
        "terseLabel": "Yearly increase in shares reserved for future issuance"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedforFutureIssuanceYearlyIncrease",
     "nsuri": "http://www.optinose.com/20221231",
     "presentation": [
      "http://www.optinose.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "optn_ComputerEquipmentandSoftwareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Computer Equipment and Software [Member]",
        "label": "Computer Equipment and Software [Member]",
        "terseLabel": "Computer equipment and software"
       }
      }
     },
     "localname": "ComputerEquipmentandSoftwareMember",
     "nsuri": "http://www.optinose.com/20221231",
     "presentation": [
      "http://www.optinose.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "optn_DebtInstrumentCovenantCashAndCashEquivalents": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Cash And Cash Equivalents",
        "label": "Debt Instrument, Covenant, Cash And Cash Equivalents",
        "terseLabel": "Debt covenant, cash and cash equivalents"
       }
      }
     },
     "localname": "DebtInstrumentCovenantCashAndCashEquivalents",
     "nsuri": "http://www.optinose.com/20221231",
     "presentation": [
      "http://www.optinose.com/role/DebtnetNarrativeDetails",
      "http://www.optinose.com/role/LiquidityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "optn_DebtInstrumentFeeAmountBackEnd": {
     "auth_ref": [],
     "calculation": {
      "http://www.optinose.com/role/DebtnetScheduleoflongtermdebtDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Fee Amount, Back End",
        "label": "Debt Instrument, Fee Amount, Back End",
        "terseLabel": "Back end fees"
       }
      }
     },
     "localname": "DebtInstrumentFeeAmountBackEnd",
     "nsuri": "http://www.optinose.com/20221231",
     "presentation": [
      "http://www.optinose.com/role/DebtnetScheduleoflongtermdebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "optn_DebtInstrumentFeeAmountFrontEnd": {
     "auth_ref": [],
     "calculation": {
      "http://www.optinose.com/role/DebtnetScheduleoflongtermdebtDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Fee Amount, Front End",
        "label": "Debt Instrument, Fee Amount, Front End",
        "negatedTerseLabel": "Front end fees"
       }
      }
     },
     "localname": "DebtInstrumentFeeAmountFrontEnd",
     "nsuri": "http://www.optinose.com/20221231",
     "presentation": [
      "http://www.optinose.com/role/DebtnetScheduleoflongtermdebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "optn_DebtInstrumentIssuanceCriteriaTermNetSalesAndRoyaltiesBenchmark": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Issuance Criteria Term, Net Sales And Royalties Benchmark",
        "label": "Debt Instrument, Issuance Criteria Term, Net Sales And Royalties Benchmark",
        "terseLabel": "Debt issuance criteria term, net sales and royalties benchmark"
       }
      }
     },
     "localname": "DebtInstrumentIssuanceCriteriaTermNetSalesAndRoyaltiesBenchmark",
     "nsuri": "http://www.optinose.com/20221231",
     "presentation": [
      "http://www.optinose.com/role/DebtnetNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "optn_DebtInstrumentMakeWholeProvisionPaymentAccrualPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Make-Whole Provision, Payment Accrual Period",
        "label": "Debt Instrument, Make-Whole Provision, Payment Accrual Period",
        "terseLabel": "Debt instrument, make-whole provision, payment accrual period"
       }
      }
     },
     "localname": "DebtInstrumentMakeWholeProvisionPaymentAccrualPeriod",
     "nsuri": "http://www.optinose.com/20221231",
     "presentation": [
      "http://www.optinose.com/role/DebtnetNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "optn_DebtInstrumentMaximumAggregateMakeWholePremiumAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Maximum Aggregate Make Whole Premium Amount",
        "label": "Debt Instrument, Maximum Aggregate Make Whole Premium Amount",
        "terseLabel": "Make whole premium payment"
       }
      }
     },
     "localname": "DebtInstrumentMaximumAggregateMakeWholePremiumAmount",
     "nsuri": "http://www.optinose.com/20221231",
     "presentation": [
      "http://www.optinose.com/role/DebtnetNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "optn_December312023Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "December 31, 2023",
        "label": "December 31, 2023 [Member]",
        "terseLabel": "December 31, 2023"
       }
      }
     },
     "localname": "December312023Member",
     "nsuri": "http://www.optinose.com/20221231",
     "presentation": [
      "http://www.optinose.com/role/DebtnetARNotePurchaseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "optn_December312024Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "December 31, 2024",
        "label": "December 31, 2024 [Member]",
        "terseLabel": "December 31, 2024"
       }
      }
     },
     "localname": "December312024Member",
     "nsuri": "http://www.optinose.com/20221231",
     "presentation": [
      "http://www.optinose.com/role/DebtnetARNotePurchaseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "optn_December312025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "December 31, 2025",
        "label": "December 31, 2025 [Member]",
        "terseLabel": "December 31, 2025"
       }
      }
     },
     "localname": "December312025Member",
     "nsuri": "http://www.optinose.com/20221231",
     "presentation": [
      "http://www.optinose.com/role/DebtnetARNotePurchaseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "optn_December312026Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "December 31, 2026",
        "label": "December 31, 2026 [Member]",
        "terseLabel": "December 31, 2026"
       }
      }
     },
     "localname": "December312026Member",
     "nsuri": "http://www.optinose.com/20221231",
     "presentation": [
      "http://www.optinose.com/role/DebtnetARNotePurchaseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "optn_DeferredOfferingCostsWIthinAccountsPayableandAccruedExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Offering Costs WIthin Accounts Payable and Accrued Expenses",
        "label": "Deferred Offering Costs WIthin Accounts Payable and Accrued Expenses",
        "terseLabel": "Financing costs within accounts payable and accrued expenses"
       }
      }
     },
     "localname": "DeferredOfferingCostsWIthinAccountsPayableandAccruedExpenses",
     "nsuri": "http://www.optinose.com/20221231",
     "presentation": [
      "http://www.optinose.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "optn_DeferredTaxAssetsFinancingCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.optinose.com/role/IncomeTaxesScheduleofdeferredtaxassetsandliabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Financing Costs",
        "label": "Deferred Tax Assets, Financing Costs",
        "terseLabel": "Capitalized R&amp;D"
       }
      }
     },
     "localname": "DeferredTaxAssetsFinancingCosts",
     "nsuri": "http://www.optinose.com/20221231",
     "presentation": [
      "http://www.optinose.com/role/IncomeTaxesScheduleofdeferredtaxassetsandliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "optn_DeferredTaxAssetsInterestExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.optinose.com/role/IncomeTaxesScheduleofdeferredtaxassetsandliabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Interest Expense",
        "label": "Deferred Tax Assets, Interest Expense",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "DeferredTaxAssetsInterestExpense",
     "nsuri": "http://www.optinose.com/20221231",
     "presentation": [
      "http://www.optinose.com/role/IncomeTaxesScheduleofdeferredtaxassetsandliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "optn_DeferredTaxAssetsLeasingArrangement": {
     "auth_ref": [],
     "calculation": {
      "http://www.optinose.com/role/IncomeTaxesScheduleofdeferredtaxassetsandliabilitiesDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Leasing Arrangement",
        "label": "Deferred Tax Assets, Leasing Arrangement",
        "terseLabel": "Lease liability"
       }
      }
     },
     "localname": "DeferredTaxAssetsLeasingArrangement",
     "nsuri": "http://www.optinose.com/20221231",
     "presentation": [
      "http://www.optinose.com/role/IncomeTaxesScheduleofdeferredtaxassetsandliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "optn_DeferredTaxAssetsPrepaidLicenseArrangement": {
     "auth_ref": [],
     "calculation": {
      "http://www.optinose.com/role/IncomeTaxesScheduleofdeferredtaxassetsandliabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Prepaid License Arrangement",
        "label": "Deferred Tax Assets, Prepaid License Arrangement",
        "terseLabel": "Prepaid licensing arrangement"
       }
      }
     },
     "localname": "DeferredTaxAssetsPrepaidLicenseArrangement",
     "nsuri": "http://www.optinose.com/20221231",
     "presentation": [
      "http://www.optinose.com/role/IncomeTaxesScheduleofdeferredtaxassetsandliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "optn_DeferredTaxAssetsTaxCreditCarryforwardsResearchTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Tax Credit Carryforwards, Research, Term",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research, Term",
        "terseLabel": "Deferred tax assets tax credit carryforwards research term"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearchTerm",
     "nsuri": "http://www.optinose.com/20221231",
     "presentation": [
      "http://www.optinose.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "optn_DefinedContributionPlanTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined Contribution Plan, Tranche One [Member]",
        "label": "Defined Contribution Plan, Tranche One [Member]",
        "terseLabel": "Defined Contribution Plan, Tranche One"
       }
      }
     },
     "localname": "DefinedContributionPlanTrancheOneMember",
     "nsuri": "http://www.optinose.com/20221231",
     "presentation": [
      "http://www.optinose.com/role/EmployeeBenefitPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "optn_DefinedContributionPlanTrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined Contribution Plan, Tranche Two [Member]",
        "label": "Defined Contribution Plan, Tranche Two [Member]",
        "terseLabel": "Defined Contribution Plan, Tranche Two"
       }
      }
     },
     "localname": "DefinedContributionPlanTrancheTwoMember",
     "nsuri": "http://www.optinose.com/20221231",
     "presentation": [
      "http://www.optinose.com/role/EmployeeBenefitPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "optn_DefinedContributionPlanTranchesAxisAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined Contribution Plan Tranches Axis [Axis]",
        "label": "Defined Contribution Plan Tranches Axis [Axis]",
        "terseLabel": "Defined Contribution Plan Tranches Axis [Axis]"
       }
      }
     },
     "localname": "DefinedContributionPlanTranchesAxisAxis",
     "nsuri": "http://www.optinose.com/20221231",
     "presentation": [
      "http://www.optinose.com/role/EmployeeBenefitPlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "optn_DefinedContributionPlanTranchesAxisDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Domain] for Defined Contribution Plan Tranches Axis [Axis]",
        "label": "Defined Contribution Plan Tranches Axis [Domain]",
        "terseLabel": "Defined Contribution Plan Tranches Axis [Domain]"
       }
      }
     },
     "localname": "DefinedContributionPlanTranchesAxisDomain",
     "nsuri": "http://www.optinose.com/20221231",
     "presentation": [
      "http://www.optinose.com/role/EmployeeBenefitPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "optn_EffectiveIncomeTaxRateReconciliationForeignExchangeOtherPercent": {
     "auth_ref": [],
     "calculation": {
      "http://www.optinose.com/role/IncomeTaxesScheduleofeffectiveincometaxratereconciliationDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Foreign Exchange Other, Percent",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Exchange Other, Percent",
        "terseLabel": "Foreign exchange and other"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationForeignExchangeOtherPercent",
     "nsuri": "http://www.optinose.com/20221231",
     "presentation": [
      "http://www.optinose.com/role/IncomeTaxesScheduleofeffectiveincometaxratereconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "optn_EffectiveIncomeTaxRateReconciliationForeignOperationsImpactPercent": {
     "auth_ref": [],
     "calculation": {
      "http://www.optinose.com/role/IncomeTaxesScheduleofeffectiveincometaxratereconciliationDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Foreign Operations Impact, Percent",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Operations Impact, Percent",
        "terseLabel": "Impact of foreign operations"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationForeignOperationsImpactPercent",
     "nsuri": "http://www.optinose.com/20221231",
     "presentation": [
      "http://www.optinose.com/role/IncomeTaxesScheduleofeffectiveincometaxratereconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "optn_EffectiveIncomeTaxRateReconciliationPrepaidRoyaltyWriteOffPercent": {
     "auth_ref": [],
     "calculation": {
      "http://www.optinose.com/role/IncomeTaxesScheduleofeffectiveincometaxratereconciliationDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Prepaid Royalty Write Off, Percent",
        "label": "Effective Income Tax Rate Reconciliation, Prepaid Royalty Write Off, Percent",
        "terseLabel": "Prepaid royalty write off"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationPrepaidRoyaltyWriteOffPercent",
     "nsuri": "http://www.optinose.com/20221231",
     "presentation": [
      "http://www.optinose.com/role/IncomeTaxesScheduleofeffectiveincometaxratereconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "optn_FairValueOfWarrant": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value Of Warrant",
        "label": "Fair Value Of Warrant",
        "terseLabel": "Fair value per warrant"
       }
      }
     },
     "localname": "FairValueOfWarrant",
     "nsuri": "http://www.optinose.com/20221231",
     "presentation": [
      "http://www.optinose.com/role/FairValueMeasurementsValuationofwarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "optn_FeeDueOnTheMaturityDateOfTheNotePurchaseAgreement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fee Due On The Maturity Date Of The Note Purchase Agreement",
        "label": "Fee Due On The Maturity Date Of The Note Purchase Agreement",
        "terseLabel": "Fee due on the maturity date of the note purchase agreement"
       }
      }
     },
     "localname": "FeeDueOnTheMaturityDateOfTheNotePurchaseAgreement",
     "nsuri": "http://www.optinose.com/20221231",
     "presentation": [
      "http://www.optinose.com/role/DebtnetNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "optn_FiveCustomersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Five Customers",
        "label": "Five Customers [Member]",
        "terseLabel": "Five Customers"
       }
      }
     },
     "localname": "FiveCustomersMember",
     "nsuri": "http://www.optinose.com/20221231",
     "presentation": [
      "http://www.optinose.com/role/SummaryofSignificantAccountingPoliciesConcentrationriskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "optn_FutureLiquidityTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future Liquidity [Text Block]",
        "label": "Future Liquidity [Text Block]",
        "terseLabel": "Liquidity"
       }
      }
     },
     "localname": "FutureLiquidityTextBlock",
     "nsuri": "http://www.optinose.com/20221231",
     "presentation": [
      "http://www.optinose.com/role/Liquidity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "optn_GrantAndOtherIncome": {
     "auth_ref": [],
     "calculation": {
      "http://www.optinose.com/role/ConsolidatedStatementsofOperations": {
       "order": 4.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Grant And Other Income",
        "label": "Grant And Other Income",
        "negatedTerseLabel": "Other (income) expense"
       }
      }
     },
     "localname": "GrantAndOtherIncome",
     "nsuri": "http://www.optinose.com/20221231",
     "presentation": [
      "http://www.optinose.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "optn_IncreaseDecreaseInGrantsandOtherReceivables": {
     "auth_ref": [],
     "calculation": {
      "http://www.optinose.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Grants and Other Receivables",
        "label": "Increase (Decrease) In Grants and Other Receivables",
        "negatedTerseLabel": "Grants and other receivables"
       }
      }
     },
     "localname": "IncreaseDecreaseInGrantsandOtherReceivables",
     "nsuri": "http://www.optinose.com/20221231",
     "presentation": [
      "http://www.optinose.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "optn_IncreaseDecreaseinDepositsandOtherAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.optinose.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) in Deposits and Other Assets",
        "label": "Increase (Decrease) in Deposits and Other Assets",
        "negatedTerseLabel": "Prepaid expenses and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseinDepositsandOtherAssets",
     "nsuri": "http://www.optinose.com/20221231",
     "presentation": [
      "http://www.optinose.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "optn_June302023Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "June 30, 2023",
        "label": "June 30, 2023 [Member]",
        "terseLabel": "June 30, 2023"
       }
      }
     },
     "localname": "June302023Member",
     "nsuri": "http://www.optinose.com/20221231",
     "presentation": [
      "http://www.optinose.com/role/DebtnetARNotePurchaseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "optn_June302024Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "June 30, 2024",
        "label": "June 30, 2024 [Member]",
        "terseLabel": "June 30, 2024"
       }
      }
     },
     "localname": "June302024Member",
     "nsuri": "http://www.optinose.com/20221231",
     "presentation": [
      "http://www.optinose.com/role/DebtnetARNotePurchaseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "optn_June302025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "June 30, 2025",
        "label": "June 30, 2025 [Member]",
        "terseLabel": "June 30, 2025"
       }
      }
     },
     "localname": "June302025Member",
     "nsuri": "http://www.optinose.com/20221231",
     "presentation": [
      "http://www.optinose.com/role/DebtnetARNotePurchaseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "optn_June302026Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "June 30, 2026",
        "label": "June 30, 2026 [Member]",
        "terseLabel": "June 30, 2026"
       }
      }
     },
     "localname": "June302026Member",
     "nsuri": "http://www.optinose.com/20221231",
     "presentation": [
      "http://www.optinose.com/role/DebtnetARNotePurchaseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "optn_June302027Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "June 30, 2027",
        "label": "June 30, 2027 [Member]",
        "terseLabel": "June 30, 2027"
       }
      }
     },
     "localname": "June302027Member",
     "nsuri": "http://www.optinose.com/20221231",
     "presentation": [
      "http://www.optinose.com/role/DebtnetARNotePurchaseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "optn_LesseeOperatingLeaseLiabilityPaymentsDueThereafter": {
     "auth_ref": [],
     "calculation": {
      "http://www.optinose.com/role/LeasesOperatingleasematuritiesDetails_1": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, Payments, Due Thereafter",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Thereafter",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueThereafter",
     "nsuri": "http://www.optinose.com/20221231",
     "presentation": [
      "http://www.optinose.com/role/LeasesOperatingleasematuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "optn_March312023Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "March 31, 2023",
        "label": "March 31, 2023 [Member]",
        "terseLabel": "March 31, 2023"
       }
      }
     },
     "localname": "March312023Member",
     "nsuri": "http://www.optinose.com/20221231",
     "presentation": [
      "http://www.optinose.com/role/DebtnetARNotePurchaseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "optn_March312024Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "March 31, 2024",
        "label": "March 31, 2024 [Member]",
        "terseLabel": "March 31, 2024"
       }
      }
     },
     "localname": "March312024Member",
     "nsuri": "http://www.optinose.com/20221231",
     "presentation": [
      "http://www.optinose.com/role/DebtnetARNotePurchaseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "optn_March312025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "March 31, 2025",
        "label": "March 31, 2025 [Member]",
        "terseLabel": "March 31, 2025"
       }
      }
     },
     "localname": "March312025Member",
     "nsuri": "http://www.optinose.com/20221231",
     "presentation": [
      "http://www.optinose.com/role/DebtnetARNotePurchaseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "optn_March312026Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "March 31, 2026",
        "label": "March 31, 2026 [Member]",
        "terseLabel": "March 31, 2026"
       }
      }
     },
     "localname": "March312026Member",
     "nsuri": "http://www.optinose.com/20221231",
     "presentation": [
      "http://www.optinose.com/role/DebtnetARNotePurchaseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "optn_March312027Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "March 31, 2027",
        "label": "March 31, 2027 [Member]",
        "terseLabel": "March 31, 2027"
       }
      }
     },
     "localname": "March312027Member",
     "nsuri": "http://www.optinose.com/20221231",
     "presentation": [
      "http://www.optinose.com/role/DebtnetARNotePurchaseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "optn_MarketBasedStockOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Market Based Stock Options",
        "label": "Market Based Stock Options [Member]",
        "terseLabel": "Market Based Stock Options"
       }
      }
     },
     "localname": "MarketBasedStockOptionsMember",
     "nsuri": "http://www.optinose.com/20221231",
     "presentation": [
      "http://www.optinose.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "optn_MeasurementInputStrikePriceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement Input Strike Price",
        "label": "Measurement Input Strike Price [Member]",
        "terseLabel": "Strike price"
       }
      }
     },
     "localname": "MeasurementInputStrikePriceMember",
     "nsuri": "http://www.optinose.com/20221231",
     "presentation": [
      "http://www.optinose.com/role/FairValueMeasurementsValuationofwarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "optn_MeasurementPeriodAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement Period",
        "label": "Measurement Period [Axis]",
        "terseLabel": "Measurement Period [Axis]"
       }
      }
     },
     "localname": "MeasurementPeriodAxis",
     "nsuri": "http://www.optinose.com/20221231",
     "presentation": [
      "http://www.optinose.com/role/DebtnetNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "optn_MeasurementPeriodDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement Period",
        "label": "Measurement Period [Domain]",
        "terseLabel": "Measurement Period [Domain]"
       }
      }
     },
     "localname": "MeasurementPeriodDomain",
     "nsuri": "http://www.optinose.com/20221231",
     "presentation": [
      "http://www.optinose.com/role/DebtnetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "optn_MonteCarloSimulationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Monte Carlo Simulation",
        "label": "Monte Carlo Simulation [Member]",
        "terseLabel": "Monte Carlo Simulation"
       }
      }
     },
     "localname": "MonteCarloSimulationMember",
     "nsuri": "http://www.optinose.com/20221231",
     "presentation": [
      "http://www.optinose.com/role/FairValueMeasurementsValuationofwarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "optn_NASDAQInducementGrantExceptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "NASDAQ Inducement Grant Exception",
        "label": "NASDAQ Inducement Grant Exception [Member]",
        "terseLabel": "NASDAQ Inducement Grant Exception"
       }
      }
     },
     "localname": "NASDAQInducementGrantExceptionMember",
     "nsuri": "http://www.optinose.com/20221231",
     "presentation": [
      "http://www.optinose.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "optn_NotePurchaseAgreementCovenantXHANCENetProductSalesAndRoyalties": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Note Purchase Agreement Covenant, XHANCE Net Product Sales And Royalties",
        "label": "Note Purchase Agreement Covenant, XHANCE Net Product Sales And Royalties",
        "terseLabel": "XHANCE net product sales and royalties"
       }
      }
     },
     "localname": "NotePurchaseAgreementCovenantXHANCENetProductSalesAndRoyalties",
     "nsuri": "http://www.optinose.com/20221231",
     "presentation": [
      "http://www.optinose.com/role/DebtnetARNotePurchaseAgreementDetails",
      "http://www.optinose.com/role/DebtnetNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "optn_NotePurchaseAgreementFirstDelayedDrawNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Note Purchase Agreement - First Delayed Draw Notes",
        "label": "Note Purchase Agreement - First Delayed Draw Notes [Member]",
        "terseLabel": "Note Purchase Agreement - First Delayed Draw Notes"
       }
      }
     },
     "localname": "NotePurchaseAgreementFirstDelayedDrawNotesMember",
     "nsuri": "http://www.optinose.com/20221231",
     "presentation": [
      "http://www.optinose.com/role/DebtnetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "optn_NotePurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Note Purchase Agreement [Member]",
        "label": "Note Purchase Agreement [Member]",
        "terseLabel": "Note Purchase Agreement"
       }
      }
     },
     "localname": "NotePurchaseAgreementMember",
     "nsuri": "http://www.optinose.com/20221231",
     "presentation": [
      "http://www.optinose.com/role/DebtnetNarrativeDetails",
      "http://www.optinose.com/role/DebtnetScheduleoflongtermdebtDetails",
      "http://www.optinose.com/role/LiquidityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "optn_NotePurchaseAgreementThirdDelayedDrawNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Note Purchase Agreement - Third Delayed Draw Notes",
        "label": "Note Purchase Agreement - Third Delayed Draw Notes [Member]",
        "terseLabel": "Note Purchase Agreement - Third Delayed Draw Notes"
       }
      }
     },
     "localname": "NotePurchaseAgreementThirdDelayedDrawNotesMember",
     "nsuri": "http://www.optinose.com/20221231",
     "presentation": [
      "http://www.optinose.com/role/DebtnetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "optn_NumberOfCustomers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Customers",
        "label": "Number Of Customers",
        "terseLabel": "Number of customers (customer)"
       }
      }
     },
     "localname": "NumberOfCustomers",
     "nsuri": "http://www.optinose.com/20221231",
     "presentation": [
      "http://www.optinose.com/role/SummaryofSignificantAccountingPoliciesConcentrationriskDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "optn_OperatingLeaseCostForExtension": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease, Cost for Extension",
        "label": "Operating Lease, Cost for Extension",
        "terseLabel": "Option to renew, extension of lease term"
       }
      }
     },
     "localname": "OperatingLeaseCostForExtension",
     "nsuri": "http://www.optinose.com/20221231",
     "presentation": [
      "http://www.optinose.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "optn_OperatingLeaseLiabilityAbstractAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease, Liability Abstract",
        "label": "Operating Lease, Liability Abstract [Abstract]",
        "terseLabel": "Operating lease liabilities:"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityAbstractAbstract",
     "nsuri": "http://www.optinose.com/20221231",
     "presentation": [
      "http://www.optinose.com/role/LeasesOperatingleaseassetsandliabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "optn_PotentialDebtInstrumentInterestRateIncrease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential Debt Instrument, Interest Rate, Increase",
        "label": "Potential Debt Instrument, Interest Rate, Increase",
        "terseLabel": "Increase in interest rate"
       }
      }
     },
     "localname": "PotentialDebtInstrumentInterestRateIncrease",
     "nsuri": "http://www.optinose.com/20221231",
     "presentation": [
      "http://www.optinose.com/role/DebtnetNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "optn_ProceedsfromIssuanceofCommonStockUnderEmployeeStockPurchasePlan": {
     "auth_ref": [],
     "calculation": {
      "http://www.optinose.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from Issuance of Common Stock Under Employee Stock Purchase Plan",
        "label": "Proceeds from Issuance of Common Stock Under Employee Stock Purchase Plan",
        "terseLabel": "Proceeds from the issuance of common stock under employee stock purchase plan"
       }
      }
     },
     "localname": "ProceedsfromIssuanceofCommonStockUnderEmployeeStockPurchasePlan",
     "nsuri": "http://www.optinose.com/20221231",
     "presentation": [
      "http://www.optinose.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "optn_PublicOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Public Offering [Member]",
        "label": "Public Offering [Member]",
        "terseLabel": "Public Offering"
       }
      }
     },
     "localname": "PublicOfferingMember",
     "nsuri": "http://www.optinose.com/20221231",
     "presentation": [
      "http://www.optinose.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "optn_QuarterEndedDecember312019Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quarter Ended December 31, 2019",
        "label": "Quarter Ended December 31, 2019 [Member]",
        "terseLabel": "Quarter Ended December 31, 2019"
       }
      }
     },
     "localname": "QuarterEndedDecember312019Member",
     "nsuri": "http://www.optinose.com/20221231",
     "presentation": [
      "http://www.optinose.com/role/DebtnetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "optn_QuarterEndedSeptember302020Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quarter Ended September 30, 2020",
        "label": "Quarter Ended September 30, 2020 [Member]",
        "terseLabel": "Quarter Ended September 30, 2020"
       }
      }
     },
     "localname": "QuarterEndedSeptember302020Member",
     "nsuri": "http://www.optinose.com/20221231",
     "presentation": [
      "http://www.optinose.com/role/DebtnetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "optn_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestonePaymentsMaximumEligible": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research And Development Arrangement, Contract To Perform For Others, Milestone Payments, Maximum Eligible",
        "label": "Research And Development Arrangement, Contract To Perform For Others, Milestone Payments, Maximum Eligible",
        "terseLabel": "Sales milestone payments eligible to be received (up to)"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersMilestonePaymentsMaximumEligible",
     "nsuri": "http://www.optinose.com/20221231",
     "presentation": [
      "http://www.optinose.com/role/LicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "optn_RestrictedStockUnitsPerformanceBasedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted Stock Units, Performance-Based",
        "label": "Restricted Stock Units, Performance-Based [Member]",
        "terseLabel": "Restricted Stock Units, Performance-Based"
       }
      }
     },
     "localname": "RestrictedStockUnitsPerformanceBasedMember",
     "nsuri": "http://www.optinose.com/20221231",
     "presentation": [
      "http://www.optinose.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "optn_RestrictedStockUnitsServiceBasedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted Stock Units, Service-Based",
        "label": "Restricted Stock Units, Service-Based [Member]",
        "terseLabel": "Restricted Stock Units, Service-Based"
       }
      }
     },
     "localname": "RestrictedStockUnitsServiceBasedMember",
     "nsuri": "http://www.optinose.com/20221231",
     "presentation": [
      "http://www.optinose.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "optn_SaleOfStockCommissionsAndExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of Stock, Commissions And Expenses",
        "label": "Sale of Stock, Commissions And Expenses",
        "terseLabel": "Commissions"
       }
      }
     },
     "localname": "SaleOfStockCommissionsAndExpenses",
     "nsuri": "http://www.optinose.com/20221231",
     "presentation": [
      "http://www.optinose.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "optn_ScheduleOfGrantDateFairValueOfWarrantValuationAssumptionsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Grant Date Fair Value Of Warrant, Valuation Assumptions",
        "label": "Schedule Of Grant Date Fair Value Of Warrant, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Grant Date Fair Value of Warrant, Valuation Assumptions"
       }
      }
     },
     "localname": "ScheduleOfGrantDateFairValueOfWarrantValuationAssumptionsTableTextBlock",
     "nsuri": "http://www.optinose.com/20221231",
     "presentation": [
      "http://www.optinose.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "optn_SecuredOvernightFinancingRateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Secured Overnight Financing Rate",
        "label": "Secured Overnight Financing Rate [Member]",
        "terseLabel": "SOFR"
       }
      }
     },
     "localname": "SecuredOvernightFinancingRateMember",
     "nsuri": "http://www.optinose.com/20221231",
     "presentation": [
      "http://www.optinose.com/role/DebtnetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "optn_September302023Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "September 30, 2023",
        "label": "September 30, 2023 [Member]",
        "terseLabel": "September 30, 2023"
       }
      }
     },
     "localname": "September302023Member",
     "nsuri": "http://www.optinose.com/20221231",
     "presentation": [
      "http://www.optinose.com/role/DebtnetARNotePurchaseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "optn_September302024Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "September 30, 2024",
        "label": "September 30, 2024 [Member]",
        "terseLabel": "September 30, 2024"
       }
      }
     },
     "localname": "September302024Member",
     "nsuri": "http://www.optinose.com/20221231",
     "presentation": [
      "http://www.optinose.com/role/DebtnetARNotePurchaseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "optn_September302025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "September 30, 2025",
        "label": "September 30, 2025 [Member]",
        "terseLabel": "September 30, 2025"
       }
      }
     },
     "localname": "September302025Member",
     "nsuri": "http://www.optinose.com/20221231",
     "presentation": [
      "http://www.optinose.com/role/DebtnetARNotePurchaseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "optn_September302026Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "September 30, 2026",
        "label": "September 30, 2026 [Member]",
        "terseLabel": "September 30, 2026"
       }
      }
     },
     "localname": "September302026Member",
     "nsuri": "http://www.optinose.com/20221231",
     "presentation": [
      "http://www.optinose.com/role/DebtnetARNotePurchaseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "optn_September302027Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "September 30, 2027",
        "label": "September 30, 2027 [Member]",
        "terseLabel": "September 30, 2027"
       }
      }
     },
     "localname": "September302027Member",
     "nsuri": "http://www.optinose.com/20221231",
     "presentation": [
      "http://www.optinose.com/role/DebtnetARNotePurchaseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "optn_ServiceBasedStockOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Service Based Stock Options [Member]",
        "label": "Service Based Stock Options [Member]",
        "verboseLabel": "Service Based Stock Options"
       }
      }
     },
     "localname": "ServiceBasedStockOptionsMember",
     "nsuri": "http://www.optinose.com/20221231",
     "presentation": [
      "http://www.optinose.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "optn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Expected to Vest, Number",
        "label": "Share-Based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Expected to Vest, Number",
        "terseLabel": "Expected to vest (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestNumber",
     "nsuri": "http://www.optinose.com/20221231",
     "presentation": [
      "http://www.optinose.com/role/StockbasedCompensationScheduleofRSUsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "optn_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeAccruedRightsToPurchaseCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement By Share-based Payment Award, Maximum Employee Accrued Rights To Purchase Common Stock",
        "label": "Share-based Compensation Arrangement By Share-based Payment Award, Maximum Employee Accrued Rights To Purchase Common Stock",
        "terseLabel": "Maximum employee accrued rights to purchase common stock (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeAccruedRightsToPurchaseCommonStock",
     "nsuri": "http://www.optinose.com/20221231",
     "presentation": [
      "http://www.optinose.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "optn_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedIncrementEachYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized Increment Each Year",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized Increment Each Year",
        "terseLabel": "Increase in number of shares issuable each year"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedIncrementEachYear",
     "nsuri": "http://www.optinose.com/20221231",
     "presentation": [
      "http://www.optinose.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "optn_StockIssuedDuringPeriodSharesVestedRestrictedStockUnits": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Shares, Vested Restricted Stock Units",
        "label": "Stock Issued During Period, Shares, Vested Restricted Stock Units",
        "terseLabel": "Vesting of restricted stock units (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesVestedRestrictedStockUnits",
     "nsuri": "http://www.optinose.com/20221231",
     "presentation": [
      "http://www.optinose.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "optn_StockIssuedDuringPeriodVestedRestrictedStockUnits": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Vested Restricted Stock Units",
        "label": "Stock Issued During Period, Vested Restricted Stock Units",
        "terseLabel": "Vesting of restricted stock units"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodVestedRestrictedStockUnits",
     "nsuri": "http://www.optinose.com/20221231",
     "presentation": [
      "http://www.optinose.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "optn_TrailingTwelveMonthEndingAxisAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trailing Twelve Month Ending Axis",
        "label": "Trailing Twelve Month Ending Axis [Axis]",
        "terseLabel": "Trailing Twelve Month Ending Axis [Axis]"
       }
      }
     },
     "localname": "TrailingTwelveMonthEndingAxisAxis",
     "nsuri": "http://www.optinose.com/20221231",
     "presentation": [
      "http://www.optinose.com/role/DebtnetARNotePurchaseAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "optn_TrailingTwelveMonthEndingAxisDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trailing Twelve Month Ending Axis [Domain]",
        "label": "Trailing Twelve Month Ending Axis [Domain]",
        "terseLabel": "Trailing Twelve Month Ending Axis [Domain]"
       }
      }
     },
     "localname": "TrailingTwelveMonthEndingAxisDomain",
     "nsuri": "http://www.optinose.com/20221231",
     "presentation": [
      "http://www.optinose.com/role/DebtnetARNotePurchaseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "optn_TrailingTwelveMonthNetRevenueCovenant": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trailing Twelve Month Net Revenue Covenant",
        "label": "Trailing Twelve Month Net Revenue Covenant",
        "terseLabel": "Trailing twelve month net revenue covenant"
       }
      }
     },
     "localname": "TrailingTwelveMonthNetRevenueCovenant",
     "nsuri": "http://www.optinose.com/20221231",
     "presentation": [
      "http://www.optinose.com/role/DebtnetNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "optn_TwoThousandSeventeenEmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Thousand Seventeen Employee Stock Purchase Plan [Member]",
        "label": "Two Thousand Seventeen Employee Stock Purchase Plan [Member]",
        "terseLabel": "2017 Employee Stock Purchase Plan",
        "verboseLabel": "2017 Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "TwoThousandSeventeenEmployeeStockPurchasePlanMember",
     "nsuri": "http://www.optinose.com/20221231",
     "presentation": [
      "http://www.optinose.com/role/StockbasedCompensationBlackScholespricingmodeloptionsDetails",
      "http://www.optinose.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "optn_UnderwritersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Underwriters",
        "label": "Underwriters [Member]",
        "terseLabel": "Underwriters"
       }
      }
     },
     "localname": "UnderwritersMember",
     "nsuri": "http://www.optinose.com/20221231",
     "presentation": [
      "http://www.optinose.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "optn_UnrealizedGainLossOnFairValueOfWarrants": {
     "auth_ref": [],
     "calculation": {
      "http://www.optinose.com/role/ConsolidatedStatementsofOperations": {
       "order": 5.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unrealized Gain (Loss) on Fair Value Of Warrants",
        "label": "Unrealized Gain (Loss) on Fair Value Of Warrants",
        "negatedTerseLabel": "Unrealized loss on fair value of warrants"
       }
      }
     },
     "localname": "UnrealizedGainLossOnFairValueOfWarrants",
     "nsuri": "http://www.optinose.com/20221231",
     "presentation": [
      "http://www.optinose.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "optn_VotePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vote Per Share",
        "label": "Vote Per Share",
        "terseLabel": "Vote per share"
       }
      }
     },
     "localname": "VotePerShare",
     "nsuri": "http://www.optinose.com/20221231",
     "presentation": [
      "http://www.optinose.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "optn_WarrantLiabilityNonCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.optinose.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrant Liability NonCurrent",
        "label": "Warrant Liability NonCurrent",
        "terseLabel": "Warrant liability"
       }
      }
     },
     "localname": "WarrantLiabilityNonCurrent",
     "nsuri": "http://www.optinose.com/20221231",
     "presentation": [
      "http://www.optinose.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "optn_WarrantsExpiringNovember152024Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants Expiring November 15, 2024",
        "label": "Warrants Expiring November 15, 2024 [Member]",
        "terseLabel": "Warrants Expiring November 15, 2024"
       }
      }
     },
     "localname": "WarrantsExpiringNovember152024Member",
     "nsuri": "http://www.optinose.com/20221231",
     "presentation": [
      "http://www.optinose.com/role/StockholdersEquityWarrantsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "optn_WarrantsExpiringNovember182024Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants Expiring November 18, 2024",
        "label": "Warrants Expiring November 18, 2024 [Member]",
        "terseLabel": "Warrants Expiring November 18, 2024"
       }
      }
     },
     "localname": "WarrantsExpiringNovember182024Member",
     "nsuri": "http://www.optinose.com/20221231",
     "presentation": [
      "http://www.optinose.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "optn_WarrantsExpiringNovember232027Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants Expiring November 23, 2027",
        "label": "Warrants Expiring November 23, 2027 [Member]",
        "terseLabel": "Warrants Expiring November 23, 2027"
       }
      }
     },
     "localname": "WarrantsExpiringNovember232027Member",
     "nsuri": "http://www.optinose.com/20221231",
     "presentation": [
      "http://www.optinose.com/role/StockholdersEquityWarrantsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "optn_WarrantsExpiringSeptember122022Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants Expiring September 12, 2022",
        "label": "Warrants Expiring September 12, 2022 [Member]",
        "terseLabel": "Warrants Expiring September 12, 2022"
       }
      }
     },
     "localname": "WarrantsExpiringSeptember122022Member",
     "nsuri": "http://www.optinose.com/20221231",
     "presentation": [
      "http://www.optinose.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "optn_WorkingCapital": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Working Capital",
        "label": "Working Capital",
        "terseLabel": "Working capital"
       }
      }
     },
     "localname": "WorkingCapital",
     "nsuri": "http://www.optinose.com/20221231",
     "presentation": [
      "http://www.optinose.com/role/LiquidityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r205",
      "r206",
      "r292",
      "r322",
      "r556",
      "r558"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.optinose.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r256",
      "r573",
      "r628",
      "r680"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.optinose.com/role/SummaryofSignificantAccountingPoliciesConcentrationriskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r276",
      "r277",
      "r278",
      "r279",
      "r419",
      "r530",
      "r540",
      "r553",
      "r554",
      "r570",
      "r581",
      "r588",
      "r627",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.optinose.com/role/SummaryofSignificantAccountingPoliciesPropertyandequipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r276",
      "r277",
      "r278",
      "r279",
      "r419",
      "r530",
      "r540",
      "r553",
      "r554",
      "r570",
      "r581",
      "r588",
      "r627",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.optinose.com/role/SummaryofSignificantAccountingPoliciesPropertyandequipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r256",
      "r573",
      "r628",
      "r680"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.optinose.com/role/SummaryofSignificantAccountingPoliciesConcentrationriskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r254",
      "r532",
      "r571",
      "r587",
      "r622",
      "r623",
      "r628",
      "r679"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.optinose.com/role/ConsolidatedStatementsofOperations",
      "http://www.optinose.com/role/SummaryofSignificantAccountingPoliciesLicensingrevenuesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r254",
      "r532",
      "r571",
      "r587",
      "r622",
      "r623",
      "r628",
      "r679"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.optinose.com/role/ConsolidatedStatementsofOperations",
      "http://www.optinose.com/role/SummaryofSignificantAccountingPoliciesLicensingrevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r276",
      "r277",
      "r278",
      "r279",
      "r370",
      "r419",
      "r450",
      "r451",
      "r452",
      "r529",
      "r530",
      "r540",
      "r553",
      "r554",
      "r570",
      "r581",
      "r588",
      "r621",
      "r627",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Range [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.optinose.com/role/SummaryofSignificantAccountingPoliciesPropertyandequipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r276",
      "r277",
      "r278",
      "r279",
      "r370",
      "r419",
      "r450",
      "r451",
      "r452",
      "r529",
      "r530",
      "r540",
      "r553",
      "r554",
      "r570",
      "r581",
      "r588",
      "r621",
      "r627",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Range [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.optinose.com/role/SummaryofSignificantAccountingPoliciesPropertyandequipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r205",
      "r206",
      "r292",
      "r322",
      "r557",
      "r558"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.optinose.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.",
        "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]",
        "terseLabel": "Accrued Expenses and Other Current Liabilities"
       }
      }
     },
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/AccruedExpensesandOtherCurrentLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.optinose.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.optinose.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.",
        "label": "Accounts Payable and Other Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses and other current liabilities",
        "totalLabel": "Total accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "AccountsPayableAndOtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails",
      "http://www.optinose.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r17",
      "r586"
     ],
     "calculation": {
      "http://www.optinose.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [
      "r548"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]",
        "terseLabel": "Accounts Receivable"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/SummaryofSignificantAccountingPoliciesConcentrationriskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r257",
      "r258"
     ],
     "calculation": {
      "http://www.optinose.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedEmployeeBenefitsCurrent": {
     "auth_ref": [
      "r21"
     ],
     "calculation": {
      "http://www.optinose.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Employee Benefits, Current",
        "terseLabel": "Payroll expenses"
       }
      }
     },
     "localname": "AccruedEmployeeBenefitsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r21"
     ],
     "calculation": {
      "http://www.optinose.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "totalLabel": "Total accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities [Abstract]",
        "terseLabel": "Accrued expenses:"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrentAndNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r71",
      "r171"
     ],
     "calculation": {
      "http://www.optinose.com/role/PropertyandEquipmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedTerseLabel": "Less: accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r29",
      "r30",
      "r31",
      "r178",
      "r537",
      "r545",
      "r546"
     ],
     "calculation": {
      "http://www.optinose.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r28",
      "r31",
      "r119",
      "r525",
      "r541",
      "r542",
      "r606",
      "r607",
      "r608",
      "r615",
      "r616",
      "r617"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r9"
     ],
     "calculation": {
      "http://www.optinose.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r459",
      "r460",
      "r461",
      "r615",
      "r616",
      "r617",
      "r665"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid -in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r103",
      "r104",
      "r422"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "auth_ref": [
      "r77",
      "r83",
      "r90"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.",
        "label": "Adjustments to Additional Paid in Capital, Warrant Issued",
        "terseLabel": "Issuance of warrants in connection with Pharmakon Second Amendment, net of cancellation",
        "verboseLabel": "Fair value of warrants issued"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.optinose.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdvertisingCostsPolicyTextBlock": {
     "auth_ref": [
      "r464"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for advertising cost.",
        "label": "Advertising Cost [Policy Text Block]",
        "terseLabel": "Advertising expenses"
       }
      }
     },
     "localname": "AdvertisingCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AdvertisingExpense": {
     "auth_ref": [
      "r465"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.",
        "label": "Advertising Expense",
        "terseLabel": "Advertising expense"
       }
      }
     },
     "localname": "AdvertisingExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/SummaryofSignificantAccountingPoliciesAdvertisingexpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r454"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/StockbasedCompensationNarrativeDetails",
      "http://www.optinose.com/role/StockbasedCompensationStockbasedcompensationexpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivable": {
     "auth_ref": [
      "r179",
      "r261",
      "r265",
      "r266",
      "r268"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable.",
        "label": "Accounts Receivable, Allowance for Credit Loss",
        "terseLabel": "Allowance for doubtful accounts"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/SummaryofSignificantAccountingPoliciesAccountsreceivableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "auth_ref": [
      "r311",
      "r511",
      "r568",
      "r569",
      "r609"
     ],
     "calculation": {
      "http://www.optinose.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "terseLabel": "Amortization of debt discount and issuance costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r228"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Securites excluded from computation of earnings per share (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/SummaryofSignificantAccountingPoliciesNetincomelosspercommonshareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r56"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/SummaryofSignificantAccountingPoliciesNetincomelosspercommonshareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/SummaryofSignificantAccountingPoliciesNetincomelosspercommonshareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r56"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/SummaryofSignificantAccountingPoliciesNetincomelosspercommonshareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r140",
      "r153",
      "r173",
      "r202",
      "r245",
      "r248",
      "r252",
      "r263",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r489",
      "r491",
      "r502",
      "r586",
      "r625",
      "r626",
      "r670"
     ],
     "calculation": {
      "http://www.optinose.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r167",
      "r183",
      "r202",
      "r263",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r489",
      "r491",
      "r502",
      "r586",
      "r625",
      "r626",
      "r670"
     ],
     "calculation": {
      "http://www.optinose.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r425",
      "r426",
      "r427",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/StockbasedCompensationBlackScholespricingmodeloptionsDetails",
      "http://www.optinose.com/role/StockbasedCompensationNarrativeDetails",
      "http://www.optinose.com/role/StockbasedCompensationScheduleofRSUsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/PropertyandEquipmentDetails",
      "http://www.optinose.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r121",
      "r122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/PropertyandEquipmentDetails",
      "http://www.optinose.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r51"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r45",
      "r50",
      "r55"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r45",
      "r134"
     ],
     "calculation": {
      "http://www.optinose.com/role/ConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net decrease in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r601"
     ],
     "calculation": {
      "http://www.optinose.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/ConsolidatedBalanceSheets",
      "http://www.optinose.com/role/LiquidityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashUninsuredAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation.",
        "label": "Cash, Uninsured Amount",
        "terseLabel": "Cash, uninsured amount"
       }
      }
     },
     "localname": "CashUninsuredAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/SummaryofSignificantAccountingPoliciesCashandcashequivalentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/StockholdersEquityNarrativeDetails",
      "http://www.optinose.com/role/StockholdersEquityWarrantsOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r91",
      "r93"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]",
        "terseLabel": "Class of Warrant or Right [Axis]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/StockholdersEquityNarrativeDetails",
      "http://www.optinose.com/role/StockholdersEquityWarrantsOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
        "label": "Class of Warrant or Right [Domain]",
        "terseLabel": "Class of Warrant or Right [Domain]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/StockholdersEquityNarrativeDetails",
      "http://www.optinose.com/role/StockholdersEquityWarrantsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Common stock warrant exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/StockholdersEquityNarrativeDetails",
      "http://www.optinose.com/role/StockholdersEquityWarrantsOutstandingDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Number of shares called by warrants (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Outstanding",
        "verboseLabel": "Number of warrants outstanding (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/StockholdersEquityWarrantsOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r75",
      "r274",
      "r275",
      "r549",
      "r624"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r26"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Number of shares reserved for future issuance under plan (shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockDividendsPerShareDeclared": {
     "auth_ref": [
      "r90"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.",
        "label": "Common Stock, Dividends, Per Share, Declared",
        "terseLabel": "Dividends declared (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockDividendsPerShareDeclared",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r615",
      "r616",
      "r665"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit",
      "http://www.optinose.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r8",
      "r83"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "terseLabel": "Shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.optinose.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r8",
      "r586"
     ],
     "calculation": {
      "http://www.optinose.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.001 par value; 200,000,000 shares authorized at December 31, 2022 and 2021; 111,492,761 and 82,238,900 shares issued and outstanding at December 31, 2022 and December 31, 2021, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]",
        "terseLabel": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Assets [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxAssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/IncomeTaxesScheduleofdeferredtaxassetsandliabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Liabilities [Abstract]",
        "terseLabel": "Deferred tax liabilities:"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/IncomeTaxesScheduleofdeferredtaxassetsandliabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r32",
      "r185",
      "r187",
      "r193",
      "r533",
      "r538"
     ],
     "calculation": {
      "http://www.optinose.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]",
        "terseLabel": "Other comprehensive loss:"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computer equipment"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/SummaryofSignificantAccountingPoliciesPropertyandequipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r60",
      "r61",
      "r131",
      "r132",
      "r256",
      "r548"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/SummaryofSignificantAccountingPoliciesConcentrationriskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r60",
      "r61",
      "r131",
      "r132",
      "r256",
      "r547",
      "r548"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/SummaryofSignificantAccountingPoliciesConcentrationriskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r60",
      "r61",
      "r131",
      "r132",
      "r256",
      "r548",
      "r681"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/SummaryofSignificantAccountingPoliciesConcentrationriskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r150",
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of credit risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Concentration Risk [Line Items]",
        "terseLabel": "Concentration Risk"
       }
      }
     },
     "localname": "ConcentrationRiskLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/SummaryofSignificantAccountingPoliciesConcentrationriskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r60",
      "r61",
      "r131",
      "r132",
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Concentration risk"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/SummaryofSignificantAccountingPoliciesConcentrationriskDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTable": {
     "auth_ref": [
      "r58",
      "r60",
      "r61",
      "r62",
      "r131",
      "r133",
      "r548"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Concentration Risk [Table]",
        "terseLabel": "Concentration Risk [Table]"
       }
      }
     },
     "localname": "ConcentrationRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/SummaryofSignificantAccountingPoliciesConcentrationriskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r60",
      "r61",
      "r131",
      "r132",
      "r256",
      "r548"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/SummaryofSignificantAccountingPoliciesConcentrationriskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r117",
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Principles of consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress [Member]",
        "terseLabel": "Construction in process"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r37",
      "r532"
     ],
     "calculation": {
      "http://www.optinose.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of product sales"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing cost of sales.",
        "label": "Cost of Sales [Member]",
        "terseLabel": "Cost of product sales"
       }
      }
     },
     "localname": "CostOfSalesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/StockbasedCompensationStockbasedcompensationexpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://www.optinose.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total costs and expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r59",
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration Risk"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/SummaryofSignificantAccountingPoliciesConcentrationriskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r78",
      "r200",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r305",
      "r312",
      "r313",
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "verboseLabel": "Debt, net"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/Debtnet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r2",
      "r3",
      "r4",
      "r141",
      "r143",
      "r152",
      "r207",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r295",
      "r301",
      "r302",
      "r303",
      "r304",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r512",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r611"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/DebtnetNarrativeDetails",
      "http://www.optinose.com/role/DebtnetScheduleoflongtermdebtDetails",
      "http://www.optinose.com/role/LiquidityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Variable rate"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/DebtnetNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r4",
      "r143",
      "r152",
      "r316"
     ],
     "calculation": {
      "http://www.optinose.com/role/DebtnetScheduleoflongtermdebtDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-Term Debt, Gross",
        "verboseLabel": "Face amount"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/DebtnetScheduleoflongtermdebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r136",
      "r138",
      "r289",
      "r512",
      "r566",
      "r567"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "verboseLabel": "Face amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/DebtnetNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "auth_ref": [
      "r23",
      "r136",
      "r318",
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "terseLabel": "Effective rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/DebtnetNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r23",
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "verboseLabel": "Floor interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/DebtnetNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/DebtnetARNotePurchaseAgreementDetails",
      "http://www.optinose.com/role/DebtnetNarrativeDetails",
      "http://www.optinose.com/role/DebtnetScheduleoflongtermdebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r24",
      "r207",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r295",
      "r301",
      "r302",
      "r303",
      "r304",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r512",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r611"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/DebtnetNarrativeDetails",
      "http://www.optinose.com/role/DebtnetScheduleoflongtermdebtDetails",
      "http://www.optinose.com/role/LiquidityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodAxis": {
     "auth_ref": [
      "r148"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about timing of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period [Axis]",
        "terseLabel": "Debt Instrument, Redemption, Period [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/DebtnetNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodDomain": {
     "auth_ref": [
      "r148"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period as defined under terms of the debt agreement for debt redemption features.",
        "label": "Debt Instrument, Redemption, Period [Domain]",
        "terseLabel": "Debt Instrument, Redemption, Period [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/DebtnetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodOneMember": {
     "auth_ref": [
      "r148"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period one representing most current period of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period One [Member]",
        "terseLabel": "Debt Instrument, Redemption, Period One"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodOneMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/DebtnetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodThreeMember": {
     "auth_ref": [
      "r148"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period three representing third most current period of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period Three [Member]",
        "terseLabel": "Debt Instrument, Redemption, Period Three"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodThreeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/DebtnetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodTwoMember": {
     "auth_ref": [
      "r148"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period two representing second most current period of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period Two [Member]",
        "terseLabel": "Debt Instrument, Redemption, Period Two"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodTwoMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/DebtnetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r24",
      "r84",
      "r87",
      "r88",
      "r89",
      "r135",
      "r136",
      "r138",
      "r149",
      "r207",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r295",
      "r301",
      "r302",
      "r303",
      "r304",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r314",
      "r512",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r611"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/DebtnetARNotePurchaseAgreementDetails",
      "http://www.optinose.com/role/DebtnetNarrativeDetails",
      "http://www.optinose.com/role/DebtnetScheduleoflongtermdebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Term",
        "terseLabel": "Debt term"
       }
      }
     },
     "localname": "DebtInstrumentTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/DebtnetNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r5",
      "r6",
      "r142",
      "r151",
      "r473"
     ],
     "calculation": {
      "http://www.optinose.com/role/IncomeTaxesScheduleofdeferredtaxassetsandliabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Liabilities, Gross",
        "negatedTotalLabel": "Total deferred tax liabilities:"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/IncomeTaxesScheduleofdeferredtaxassetsandliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredOfferingCosts": {
     "auth_ref": [
      "r620"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.",
        "label": "Deferred Offering Costs",
        "terseLabel": "Deferred offering costs"
       }
      }
     },
     "localname": "DeferredOfferingCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r474"
     ],
     "calculation": {
      "http://www.optinose.com/role/IncomeTaxesScheduleofdeferredtaxassetsandliabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/IncomeTaxesScheduleofdeferredtaxassetsandliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "auth_ref": [
      "r114",
      "r662"
     ],
     "calculation": {
      "http://www.optinose.com/role/IncomeTaxesScheduleofdeferredtaxassetsandliabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.",
        "label": "Deferred Tax Assets, in Process Research and Development",
        "terseLabel": "Research and development credits"
       }
      }
     },
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/IncomeTaxesScheduleofdeferredtaxassetsandliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r661"
     ],
     "calculation": {
      "http://www.optinose.com/role/IncomeTaxesScheduleofdeferredtaxassetsandliabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Total net deferred tax assets (liabilities)"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/IncomeTaxesScheduleofdeferredtaxassetsandliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r114",
      "r662"
     ],
     "calculation": {
      "http://www.optinose.com/role/IncomeTaxesScheduleofdeferredtaxassetsandliabilitiesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating losses"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/IncomeTaxesScheduleofdeferredtaxassetsandliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "auth_ref": [
      "r112",
      "r114",
      "r662"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "terseLabel": "Deferred tax assets tax credit carryforwards research"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpense": {
     "auth_ref": [
      "r114",
      "r662"
     ],
     "calculation": {
      "http://www.optinose.com/role/IncomeTaxesScheduleofdeferredtaxassetsandliabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowances, of deferred tax asset attributable to deductible differences from reserves and accruals, compensation and benefit costs, and other provisions, reserves, and allowances.",
        "label": "Deferred Tax Assets, Tax Deferred Expense",
        "terseLabel": "Accrued expenses and other"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/IncomeTaxesScheduleofdeferredtaxassetsandliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits": {
     "auth_ref": [
      "r114",
      "r662"
     ],
     "calculation": {
      "http://www.optinose.com/role/IncomeTaxesScheduleofdeferredtaxassetsandliabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits",
        "terseLabel": "Stock compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/IncomeTaxesScheduleofdeferredtaxassetsandliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r475"
     ],
     "calculation": {
      "http://www.optinose.com/role/IncomeTaxesScheduleofdeferredtaxassetsandliabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedTerseLabel": "Less: Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/IncomeTaxesScheduleofdeferredtaxassetsandliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesLeasingArrangements": {
     "auth_ref": [
      "r114",
      "r662"
     ],
     "calculation": {
      "http://www.optinose.com/role/IncomeTaxesScheduleofdeferredtaxassetsandliabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.",
        "label": "Deferred Tax Liabilities, Leasing Arrangements",
        "negatedTerseLabel": "Right-to-use asset"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesLeasingArrangements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/IncomeTaxesScheduleofdeferredtaxassetsandliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "auth_ref": [
      "r114",
      "r662"
     ],
     "calculation": {
      "http://www.optinose.com/role/IncomeTaxesScheduleofdeferredtaxassetsandliabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "negatedTerseLabel": "Fixed assets, including leases"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/IncomeTaxesScheduleofdeferredtaxassetsandliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "auth_ref": [
      "r418"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost for defined contribution plan.",
        "label": "Defined Contribution Plan, Cost",
        "terseLabel": "Defined contribution plan, cost"
       }
      }
     },
     "localname": "DefinedContributionPlanCostRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/EmployeeBenefitPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Defined Contribution Plan Disclosure [Line Items]",
        "terseLabel": "Defined Contribution Plan Disclosure"
       }
      }
     },
     "localname": "DefinedContributionPlanDisclosureLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/EmployeeBenefitPlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage employer matches of the employee's percentage contribution matched.",
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Match",
        "terseLabel": "Employer matching contribution"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/EmployeeBenefitPlansDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.",
        "label": "Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent",
        "terseLabel": "Maximum annual contributions per employee"
       }
      }
     },
     "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/EmployeeBenefitPlansDetails",
      "http://www.optinose.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedContributionPlanTable": {
     "auth_ref": [
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about defined contribution pension plans or defined contribution other postretirement plans, separately for pension plans and other postretirement benefit plans.",
        "label": "Defined Contribution Plan [Table]",
        "terseLabel": "Defined Contribution Plan [Table]"
       }
      }
     },
     "localname": "DefinedContributionPlanTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/EmployeeBenefitPlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r48",
      "r69"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r48",
      "r244"
     ],
     "calculation": {
      "http://www.optinose.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/SummaryofSignificantAccountingPoliciesLicensingrevenuesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r347",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/SummaryofSignificantAccountingPoliciesLicensingrevenuesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r424",
      "r455",
      "r456",
      "r458",
      "r463",
      "r582"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/StockbasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]",
        "terseLabel": "Disclosure of Compensation Related Costs, Share-based Payments [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "Domestic Tax Authority"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r194",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r221",
      "r223",
      "r225",
      "r226",
      "r227",
      "r229",
      "r495",
      "r496",
      "r534",
      "r539",
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net (loss) income per share of common stock,\u00a0basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r194",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r223",
      "r225",
      "r226",
      "r227",
      "r229",
      "r495",
      "r496",
      "r534",
      "r539",
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net (loss) income per share of common stock, diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r56",
      "r57"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net income (loss) per common share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r503"
     ],
     "calculation": {
      "http://www.optinose.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations",
        "terseLabel": "Effects of exchange rate changes on cash and cash equivalents"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r468"
     ],
     "calculation": {
      "http://www.optinose.com/role/IncomeTaxesScheduleofeffectiveincometaxratereconciliationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Effective income tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/IncomeTaxesScheduleofeffectiveincometaxratereconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r204",
      "r468",
      "r484"
     ],
     "calculation": {
      "http://www.optinose.com/role/IncomeTaxesScheduleofeffectiveincometaxratereconciliationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Income tax expense at statutory rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/IncomeTaxesScheduleofeffectiveincometaxratereconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r660",
      "r663"
     ],
     "calculation": {
      "http://www.optinose.com/role/IncomeTaxesScheduleofeffectiveincometaxratereconciliationDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/IncomeTaxesScheduleofeffectiveincometaxratereconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate": {
     "auth_ref": [
      "r484",
      "r660"
     ],
     "calculation": {
      "http://www.optinose.com/role/IncomeTaxesScheduleofeffectiveincometaxratereconciliationDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent",
        "terseLabel": "Tax rate changes"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/IncomeTaxesScheduleofeffectiveincometaxratereconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": {
     "auth_ref": [
      "r660",
      "r663"
     ],
     "calculation": {
      "http://www.optinose.com/role/IncomeTaxesScheduleofeffectiveincometaxratereconciliationDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent",
        "terseLabel": "Foreign rate differential"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/IncomeTaxesScheduleofeffectiveincometaxratereconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense": {
     "auth_ref": [
      "r660",
      "r663"
     ],
     "calculation": {
      "http://www.optinose.com/role/IncomeTaxesScheduleofeffectiveincometaxratereconciliationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent",
        "terseLabel": "Permanent items"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/IncomeTaxesScheduleofeffectiveincometaxratereconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "auth_ref": [
      "r660",
      "r663"
     ],
     "calculation": {
      "http://www.optinose.com/role/IncomeTaxesScheduleofeffectiveincometaxratereconciliationDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent",
        "negatedTerseLabel": "Stock based compensation"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/IncomeTaxesScheduleofeffectiveincometaxratereconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r660",
      "r663"
     ],
     "calculation": {
      "http://www.optinose.com/role/IncomeTaxesScheduleofeffectiveincometaxratereconciliationDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "terseLabel": "State taxes, net of federal benefit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/IncomeTaxesScheduleofeffectiveincometaxratereconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r21"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued expenses related to the Company match"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/EmployeeBenefitPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/StockbasedCompensationStockbasedcompensationexpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Unrecognized compensation, estimated weighted-average amortization period"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [
      "r659"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation cost"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock options",
        "verboseLabel": "2010 A&amp;R Stock Incentive Plan"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/StockbasedCompensationBlackScholespricingmodeloptionsDetails",
      "http://www.optinose.com/role/SummaryofSignificantAccountingPoliciesNetincomelosspercommonshareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r83",
      "r165",
      "r189",
      "r190",
      "r191",
      "r208",
      "r209",
      "r210",
      "r212",
      "r218",
      "r220",
      "r231",
      "r264",
      "r337",
      "r459",
      "r460",
      "r461",
      "r480",
      "r481",
      "r494",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r525",
      "r541",
      "r542",
      "r543"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit",
      "http://www.optinose.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "auth_ref": [
      "r48",
      "r79"
     ],
     "calculation": {
      "http://www.optinose.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.",
        "label": "Fair Value Adjustment of Warrants",
        "terseLabel": "Change in fair value of warrant liability"
       }
      }
     },
     "localname": "FairValueAdjustmentOfWarrants",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]",
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/FairValueMeasurementsValuationofwarrantsDetails",
      "http://www.optinose.com/role/StockholdersEquityGrantdatefairvalueofwarrantsvaluationassumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "auth_ref": [
      "r125"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/FairValueMeasurementsValuationofwarrantsDetails",
      "http://www.optinose.com/role/StockholdersEquityGrantdatefairvalueofwarrantsvaluationassumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "auth_ref": [
      "r125"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "terseLabel": "Schedule of Significant Unobservable Inputs in Valuation of Warrants"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r123",
      "r124"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Fair Value, Assets Measured on Recurring Basis"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "terseLabel": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/FairValueMeasurementsFairvalueassetsandliabilitiesmeasuredonrecurringbasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "auth_ref": [
      "r126",
      "r128"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of assets using significant unobservable inputs (level 3). Such reconciliation, separately presenting changes during the period, at a minimum, may include, but is not limited to: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income, and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset.",
        "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "terseLabel": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table]"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/FairValueMeasurementsFairvalueassetsandliabilitiesmeasuredonrecurringbasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r303",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r497",
      "r526",
      "r527",
      "r528",
      "r566",
      "r567",
      "r578",
      "r579",
      "r580"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/FairValueMeasurementsFairvalueassetsandliabilitiesmeasuredonrecurringbasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r501"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r303",
      "r373",
      "r378",
      "r497",
      "r526",
      "r578",
      "r579",
      "r580"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/FairValueMeasurementsFairvalueassetsandliabilitiesmeasuredonrecurringbasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r303",
      "r373",
      "r378",
      "r497",
      "r527",
      "r566",
      "r567",
      "r578",
      "r579",
      "r580"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/FairValueMeasurementsFairvalueassetsandliabilitiesmeasuredonrecurringbasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r303",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r497",
      "r528",
      "r566",
      "r567",
      "r578",
      "r579",
      "r580"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/FairValueMeasurementsFairvalueassetsandliabilitiesmeasuredonrecurringbasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r123",
      "r124"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Fair Value, Liabilities Measured on Recurring Basis"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "terseLabel": "Warrant Liability"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/FairValueMeasurementsFairvalueliabilitiesmeasuredonrecurringbasisusingunobservableinputsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r126",
      "r128"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Fair Value, Liabilities Measured on Recurring Basis, Unobservable Inputs Reconciliation"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "auth_ref": [
      "r500"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "terseLabel": "Change in fair value of liability"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/FairValueMeasurementsFairvalueliabilitiesmeasuredonrecurringbasisusingunobservableinputsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues": {
     "auth_ref": [
      "r127"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances",
        "terseLabel": "Warrants issued"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/FairValueMeasurementsFairvalueliabilitiesmeasuredonrecurringbasisusingunobservableinputsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r126"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "Balance, December 31, 2022",
        "periodStartLabel": "Balance, December 31, 2021"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/FairValueMeasurementsFairvalueliabilitiesmeasuredonrecurringbasisusingunobservableinputsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r303",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r526",
      "r527",
      "r528",
      "r566",
      "r567",
      "r578",
      "r579",
      "r580"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/FairValueMeasurementsFairvalueassetsandliabilitiesmeasuredonrecurringbasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r129",
      "r130"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair value of financial instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList": {
     "auth_ref": [
      "r500"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement in which net income is reported that includes gain (loss) from liability measured at fair value using unobservable input (level 3).",
        "label": "Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "terseLabel": "Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]"
       }
      }
     },
     "localname": "FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/FairValueMeasurementsFairvalueliabilitiesmeasuredonrecurringbasisusingunobservableinputsDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_ForeignCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile.",
        "label": "Foreign Tax Authority [Member]",
        "terseLabel": "Foreign Tax Authority"
       }
      }
     },
     "localname": "ForeignCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignPlanMember": {
     "auth_ref": [
      "r630",
      "r631",
      "r632"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location of employer sponsoring plan, designed to provide retirement benefits, not determined as principal place of business. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Foreign Plan [Member]",
        "terseLabel": "Foreign Plan"
       }
      }
     },
     "localname": "ForeignPlanMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/EmployeeBenefitPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture &amp; fixtures",
        "verboseLabel": "Furniture and fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/PropertyandEquipmentDetails",
      "http://www.optinose.com/role/SummaryofSignificantAccountingPoliciesPropertyandequipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://www.optinose.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "negatedLabel": "Gain on sale of equipment"
       }
      }
     },
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r35"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/StockbasedCompensationStockbasedcompensationexpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf": {
     "auth_ref": [
      "r48",
      "r68"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.",
        "label": "Impairment of Long-Lived Assets to be Disposed of",
        "terseLabel": "Impairment or disposition of long-lived assets"
       }
      }
     },
     "localname": "ImpairmentOfLongLivedAssetsToBeDisposedOf",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/SummaryofSignificantAccountingPoliciesLonglivedassetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r67",
      "r73"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Long lived assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "auth_ref": [
      "r203",
      "r483"
     ],
     "calculation": {
      "http://www.optinose.com/role/IncomeTaxesScheduleofincomebeforeincometaxdomesticandforeignDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "terseLabel": "Domestic operations"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/IncomeTaxesScheduleofincomebeforeincometaxdomesticandforeignDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r33",
      "r139",
      "r145",
      "r159",
      "r245",
      "r247",
      "r251",
      "r253",
      "r535",
      "r564"
     ],
     "calculation": {
      "http://www.optinose.com/role/IncomeTaxesScheduleofincomebeforeincometaxdomesticandforeignDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before provision for income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/IncomeTaxesScheduleofincomebeforeincometaxdomesticandforeignDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "auth_ref": [
      "r203",
      "r483"
     ],
     "calculation": {
      "http://www.optinose.com/role/IncomeTaxesScheduleofincomebeforeincometaxdomesticandforeignDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "terseLabel": "Foreign operations"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/IncomeTaxesScheduleofincomebeforeincometaxdomesticandforeignDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r272",
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/StockbasedCompensationStockbasedcompensationexpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/StockbasedCompensationStockbasedcompensationexpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r204",
      "r469",
      "r471",
      "r478",
      "r482",
      "r485",
      "r486",
      "r487",
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r188",
      "r466",
      "r467",
      "r471",
      "r472",
      "r477",
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://www.optinose.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://www.optinose.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedTerseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://www.optinose.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued expenses and other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://www.optinose.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedTerseLabel": "Inventory"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r137",
      "r147",
      "r192",
      "r243",
      "r510"
     ],
     "calculation": {
      "http://www.optinose.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseDebt": {
     "auth_ref": [
      "r40",
      "r309",
      "r319",
      "r568",
      "r569"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.",
        "label": "Interest Expense, Debt",
        "verboseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpenseDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/DebtnetNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r196",
      "r198",
      "r199"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoriesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property held for sale in the ordinary course of business, or in process of, or to be consumed in, production for sale.",
        "label": "Inventories [Member]",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoriesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/PropertyandEquipmentDetails",
      "http://www.optinose.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]",
        "terseLabel": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/Inventory"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoods": {
     "auth_ref": [
      "r602"
     ],
     "calculation": {
      "http://www.optinose.com/role/InventoryDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.",
        "label": "Inventory, Finished Goods, Gross",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoods",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryGross": {
     "auth_ref": [
      "r605"
     ],
     "calculation": {
      "http://www.optinose.com/role/InventoryDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Inventory, Gross",
        "totalLabel": "Total inventory"
       }
      }
     },
     "localname": "InventoryGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r181",
      "r555",
      "r586"
     ],
     "calculation": {
      "http://www.optinose.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r169",
      "r180",
      "r230",
      "r269",
      "r270",
      "r271",
      "r531",
      "r560"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryRawMaterials": {
     "auth_ref": [
      "r604"
     ],
     "calculation": {
      "http://www.optinose.com/role/InventoryDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Raw Materials, Gross",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterials",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcess": {
     "auth_ref": [
      "r603"
     ],
     "calculation": {
      "http://www.optinose.com/role/InventoryDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.",
        "label": "Inventory, Work in Process, Gross",
        "terseLabel": "Work-in-process"
       }
      }
     },
     "localname": "InventoryWorkInProcess",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r39",
      "r242"
     ],
     "calculation": {
      "http://www.optinose.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "negatedTerseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r522",
      "r585"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "terseLabel": "Operating lease costs"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r70"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r669"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Operating Lease Liability Maturities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r523"
     ],
     "calculation": {
      "http://www.optinose.com/role/LeasesOperatingleasematuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.optinose.com/role/LeasesOperatingleasematuritiesDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total undiscounted future minimum lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/LeasesOperatingleasematuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r523"
     ],
     "calculation": {
      "http://www.optinose.com/role/LeasesOperatingleasematuritiesDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/LeasesOperatingleasematuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r523"
     ],
     "calculation": {
      "http://www.optinose.com/role/LeasesOperatingleasematuritiesDetails_1": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/LeasesOperatingleasematuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r523"
     ],
     "calculation": {
      "http://www.optinose.com/role/LeasesOperatingleasematuritiesDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/LeasesOperatingleasematuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r523"
     ],
     "calculation": {
      "http://www.optinose.com/role/LeasesOperatingleasematuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "verboseLabel": "Less: difference between undiscounted lease payments and discounted operating lease liabilities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/LeasesOperatingleasematuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r524"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r20",
      "r202",
      "r263",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r490",
      "r491",
      "r492",
      "r502",
      "r563",
      "r625",
      "r670",
      "r671"
     ],
     "calculation": {
      "http://www.optinose.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r13",
      "r144",
      "r156",
      "r586",
      "r612",
      "r619",
      "r668"
     ],
     "calculation": {
      "http://www.optinose.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' deficit"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and stockholders' deficit"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r22",
      "r168",
      "r202",
      "r263",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r490",
      "r491",
      "r492",
      "r502",
      "r586",
      "r625",
      "r670",
      "r671"
     ],
     "calculation": {
      "http://www.optinose.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "auth_ref": [
      "r123"
     ],
     "calculation": {
      "http://www.optinose.com/role/FairValueMeasurementsFairvalueassetsandliabilitiesmeasuredonrecurringbasisDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial and nonfinancial obligations.",
        "label": "Liabilities, Fair Value Disclosure",
        "totalLabel": "Total Liabilities"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/FairValueMeasurementsFairvalueassetsandliabilitiesmeasuredonrecurringbasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Fair Value Disclosure [Abstract]",
        "terseLabel": "Liabilities"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/FairValueMeasurementsFairvalueassetsandliabilitiesmeasuredonrecurringbasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicenseMember": {
     "auth_ref": [
      "r629"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.",
        "label": "License [Member]",
        "terseLabel": "Licensing revenues"
       }
      }
     },
     "localname": "LicenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/ConsolidatedStatementsofOperations",
      "http://www.optinose.com/role/SummaryofSignificantAccountingPoliciesLicensingrevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r18"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Debt maximum borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/DebtnetNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r4",
      "r143",
      "r154",
      "r302",
      "r317",
      "r566",
      "r567"
     ],
     "calculation": {
      "http://www.optinose.com/role/DebtnetScheduleoflongtermdebtDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.",
        "label": "Long-Term Debt",
        "totalLabel": "Long-term Debt"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/DebtnetScheduleoflongtermdebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtCurrent": {
     "auth_ref": [
      "r19"
     ],
     "calculation": {
      "http://www.optinose.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-Term Debt, Current Maturities",
        "terseLabel": "Short term debt, net"
       }
      }
     },
     "localname": "LongTermDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r174"
     ],
     "calculation": {
      "http://www.optinose.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.",
        "label": "Long-Term Debt, Excluding Current Maturities",
        "terseLabel": "Long-term debt, net"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r24"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-Term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/DebtnetARNotePurchaseAgreementDetails",
      "http://www.optinose.com/role/DebtnetNarrativeDetails",
      "http://www.optinose.com/role/DebtnetScheduleoflongtermdebtDetails",
      "http://www.optinose.com/role/LiquidityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r24",
      "r76"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-Term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/DebtnetARNotePurchaseAgreementDetails",
      "http://www.optinose.com/role/DebtnetNarrativeDetails",
      "http://www.optinose.com/role/DebtnetScheduleoflongtermdebtDetails",
      "http://www.optinose.com/role/LiquidityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MachineryAndEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.",
        "label": "Machinery and Equipment [Member]",
        "terseLabel": "Machinery &amp; production equipment",
        "verboseLabel": "Machinery and equipment"
       }
      }
     },
     "localname": "MachineryAndEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/PropertyandEquipmentDetails",
      "http://www.optinose.com/role/SummaryofSignificantAccountingPoliciesPropertyandequipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputExpectedDividendRateMember": {
     "auth_ref": [
      "r666"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year.",
        "label": "Measurement Input, Expected Dividend Rate [Member]",
        "terseLabel": "Expected dividend yield",
        "verboseLabel": "Annual dividend yield"
       }
      }
     },
     "localname": "MeasurementInputExpectedDividendRateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/FairValueMeasurementsValuationofwarrantsDetails",
      "http://www.optinose.com/role/StockholdersEquityGrantdatefairvalueofwarrantsvaluationassumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "auth_ref": [
      "r666"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date.",
        "label": "Measurement Input, Expected Term [Member]",
        "terseLabel": "Expected term (in years)"
       }
      }
     },
     "localname": "MeasurementInputExpectedTermMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/StockholdersEquityGrantdatefairvalueofwarrantsvaluationassumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "auth_ref": [
      "r666"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.",
        "label": "Measurement Input, Price Volatility [Member]",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "MeasurementInputPriceVolatilityMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/FairValueMeasurementsValuationofwarrantsDetails",
      "http://www.optinose.com/role/StockholdersEquityGrantdatefairvalueofwarrantsvaluationassumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "auth_ref": [
      "r666"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.",
        "label": "Measurement Input, Risk Free Interest Rate [Member]",
        "terseLabel": "Risk free interest rate"
       }
      }
     },
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/FairValueMeasurementsValuationofwarrantsDetails",
      "http://www.optinose.com/role/StockholdersEquityGrantdatefairvalueofwarrantsvaluationassumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputSharePriceMember": {
     "auth_ref": [
      "r666"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using share price of saleable stock.",
        "label": "Measurement Input, Share Price [Member]",
        "terseLabel": "Fair value of common stock",
        "verboseLabel": "Stock price"
       }
      }
     },
     "localname": "MeasurementInputSharePriceMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/FairValueMeasurementsValuationofwarrantsDetails",
      "http://www.optinose.com/role/StockholdersEquityGrantdatefairvalueofwarrantsvaluationassumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r498"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/FairValueMeasurementsValuationofwarrantsDetails",
      "http://www.optinose.com/role/StockholdersEquityGrantdatefairvalueofwarrantsvaluationassumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/FairValueMeasurementsValuationofwarrantsDetails",
      "http://www.optinose.com/role/StockholdersEquityGrantdatefairvalueofwarrantsvaluationassumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r233",
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "Nature of Operations [Text Block]",
        "terseLabel": "Organization and Description of Business"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/OrganizationandDescriptionofBusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r197"
     ],
     "calculation": {
      "http://www.optinose.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r197"
     ],
     "calculation": {
      "http://www.optinose.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r45",
      "r46",
      "r49"
     ],
     "calculation": {
      "http://www.optinose.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r34",
      "r49",
      "r146",
      "r158",
      "r166",
      "r184",
      "r186",
      "r191",
      "r202",
      "r211",
      "r213",
      "r214",
      "r215",
      "r216",
      "r219",
      "r220",
      "r224",
      "r245",
      "r247",
      "r251",
      "r253",
      "r263",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r496",
      "r502",
      "r564",
      "r625"
     ],
     "calculation": {
      "http://www.optinose.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.optinose.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.optinose.com/role/ConsolidatedStatementsofOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.optinose.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit",
      "http://www.optinose.com/role/ConsolidatedStatementsofComprehensiveLoss",
      "http://www.optinose.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent accounting pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash Investing and Financing Items [Abstract]",
        "terseLabel": "Supplemental disclosure of noncash activities:"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1": {
     "auth_ref": [
      "r52",
      "r53",
      "r54"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of fixed assets that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Noncash or Part Noncash Acquisition, Fixed Assets Acquired",
        "terseLabel": "Fixed asset purchases within accounts payable and accrued expenses"
       }
      }
     },
     "localname": "NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other (income) expense:"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NotesPayable": {
     "auth_ref": [
      "r4",
      "r143",
      "r154"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.",
        "label": "Notes Payable",
        "terseLabel": "Principal balance outstanding"
       }
      }
     },
     "localname": "NotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/LiquidityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Costs and expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r245",
      "r247",
      "r251",
      "r253",
      "r564"
     ],
     "calculation": {
      "http://www.optinose.com/role/ConsolidatedStatementsofOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid [Abstract]",
        "terseLabel": "Operating leases"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/LeasesOperatingleasematuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r514"
     ],
     "calculation": {
      "http://www.optinose.com/role/LeasesOperatingleaseassetsandliabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.optinose.com/role/LeasesOperatingleasematuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Total operating lease liabilities",
        "totalLabel": "Total operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/LeasesOperatingleaseassetsandliabilitiesDetails",
      "http://www.optinose.com/role/LeasesOperatingleasematuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r514"
     ],
     "calculation": {
      "http://www.optinose.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.optinose.com/role/LeasesOperatingleaseassetsandliabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Current operating lease liabilities",
        "verboseLabel": "Lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails",
      "http://www.optinose.com/role/LeasesOperatingleaseassetsandliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes current operating lease liability.",
        "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/LeasesOperatingleaseassetsandliabilitiesDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r514"
     ],
     "calculation": {
      "http://www.optinose.com/role/LeasesOperatingleaseassetsandliabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Non-current operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/LeasesOperatingleaseassetsandliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes noncurrent operating lease liability.",
        "label": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Operating Lease, Liability, Statement of Financial Position [Extensible List]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/LeasesOperatingleaseassetsandliabilitiesDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r516",
      "r518"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Cash paid for amounts included in the measurement of operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r513"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/LeasesOperatingleaseassetsandliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes operating lease right-of-use asset.",
        "label": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/LeasesNarrativeDetails",
      "http://www.optinose.com/role/LeasesOperatingleaseassetsandliabilitiesDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r521",
      "r585"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/LeasesWeightedaverageremainingleasetermandweightedaveragediscountrateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r520",
      "r585"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average remaining lease term (years)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/LeasesWeightedaverageremainingleasetermandweightedaveragediscountrateDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r112"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Operating loss carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Loss Carryforwards [Line Items]",
        "terseLabel": "Operating Loss Carryforwards [Line Items]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "auth_ref": [
      "r113"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.",
        "label": "Operating Loss Carryforwards [Table]",
        "terseLabel": "Operating Loss Carryforwards [Table]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r0",
      "r120"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r21"
     ],
     "calculation": {
      "http://www.optinose.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r182",
      "r586"
     ],
     "calculation": {
      "http://www.optinose.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r172"
     ],
     "calculation": {
      "http://www.optinose.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r115",
      "r116",
      "r118"
     ],
     "calculation": {
      "http://www.optinose.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Foreign currency translation adjustment"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit",
      "http://www.optinose.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r21",
      "r586"
     ],
     "calculation": {
      "http://www.optinose.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "totalLabel": "Total other current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Liabilities, Current [Abstract]",
        "terseLabel": "Other current liabilities:"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r25"
     ],
     "calculation": {
      "http://www.optinose.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]",
        "terseLabel": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsOfFinancingCosts": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.optinose.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for loan and debt issuance costs.",
        "label": "Payments of Financing Costs",
        "negatedLabel": "Cash paid for financing costs"
       }
      }
     },
     "localname": "PaymentsOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://www.optinose.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedTerseLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "auth_ref": [
      "r370",
      "r372",
      "r378",
      "r396",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r416",
      "r417",
      "r418",
      "r420",
      "r580"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for retirement benefits.",
        "label": "Retirement Benefits [Text Block]",
        "terseLabel": "Employee Benefit Plans"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/EmployeeBenefitPlans"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/StockbasedCompensationBlackScholespricingmodeloptionsDetails",
      "http://www.optinose.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/StockbasedCompensationBlackScholespricingmodeloptionsDetails",
      "http://www.optinose.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing prepaid expenses and other current assets.",
        "label": "Prepaid Expenses and Other Current Assets [Member]",
        "verboseLabel": "Prepaid Expenses and Other Assets"
       }
      }
     },
     "localname": "PrepaidExpensesAndOtherCurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/PropertyandEquipmentDetails",
      "http://www.optinose.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://www.optinose.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from the sale of common stock and warrants"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.optinose.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.",
        "label": "Proceeds from Sale of Property, Plant, and Equipment",
        "terseLabel": "Proceeds from sale of property and equipment"
       }
      }
     },
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r43",
      "r101"
     ],
     "calculation": {
      "http://www.optinose.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from the exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r571"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "terseLabel": "Net product revenues"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]",
        "terseLabel": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r72"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/PropertyandEquipmentDetails",
      "http://www.optinose.com/role/SummaryofSignificantAccountingPoliciesPropertyandequipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r74",
      "r550",
      "r551",
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/PropertyandEquipment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r70",
      "r170"
     ],
     "calculation": {
      "http://www.optinose.com/role/PropertyandEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/PropertyandEquipmentDetails",
      "http://www.optinose.com/role/SummaryofSignificantAccountingPoliciesPropertyandequipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r72",
      "r157",
      "r536",
      "r586"
     ],
     "calculation": {
      "http://www.optinose.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.optinose.com/role/PropertyandEquipmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/ConsolidatedBalanceSheets",
      "http://www.optinose.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r72",
      "r550",
      "r551"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r72"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Property and Equipment, Net",
        "verboseLabel": "Schedule of Property and Equipment Useful Lives"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/PropertyandEquipmentTables",
      "http://www.optinose.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r70"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/PropertyandEquipmentDetails",
      "http://www.optinose.com/role/SummaryofSignificantAccountingPoliciesPropertyandequipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Useful life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/SummaryofSignificantAccountingPoliciesPropertyandequipmentDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "auth_ref": [
      "r195",
      "r267"
     ],
     "calculation": {
      "http://www.optinose.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.",
        "label": "Accounts Receivable, Credit Loss Expense (Reversal)",
        "terseLabel": "Allowance for doubtful accounts"
       }
      }
     },
     "localname": "ProvisionForDoubtfulAccounts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PurchaseObligation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.",
        "label": "Purchase Obligation",
        "terseLabel": "Purchase obligation"
       }
      }
     },
     "localname": "PurchaseObligation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development [Abstract]",
        "terseLabel": "Research and Development [Abstract]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "auth_ref": [
      "r107",
      "r108"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by form of arrangement related to research and development.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/LicenseAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Research and Development Arrangement, Contract to Perform for Others [Line Items]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others [Line Items]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/LicenseAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "auth_ref": [
      "r107",
      "r108"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/LicenseAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r106",
      "r160",
      "r678"
     ],
     "calculation": {
      "http://www.optinose.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/StockbasedCompensationStockbasedcompensationexpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock": {
     "auth_ref": [
      "r161"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.",
        "label": "Research, Development, and Computer Software Disclosure [Text Block]",
        "terseLabel": "License Agreements"
       }
      }
     },
     "localname": "ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/LicenseAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted stock units"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/StockbasedCompensationNarrativeDetails",
      "http://www.optinose.com/role/StockbasedCompensationScheduleofRSUsDetails",
      "http://www.optinose.com/role/SummaryofSignificantAccountingPoliciesNetincomelosspercommonshareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r10",
      "r90",
      "r155",
      "r544",
      "r546",
      "r586"
     ],
     "calculation": {
      "http://www.optinose.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/ConsolidatedBalanceSheets",
      "http://www.optinose.com/role/LiquidityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r165",
      "r208",
      "r209",
      "r210",
      "r212",
      "r218",
      "r220",
      "r264",
      "r459",
      "r460",
      "r461",
      "r480",
      "r481",
      "r494",
      "r541",
      "r543"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetirementPlanSponsorLocationAxis": {
     "auth_ref": [
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r397",
      "r400",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r630",
      "r631",
      "r632"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Retirement Plan Sponsor Location [Axis]",
        "terseLabel": "Retirement Plan Sponsor Location [Axis]"
       }
      }
     },
     "localname": "RetirementPlanSponsorLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/EmployeeBenefitPlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetirementPlanSponsorLocationDomain": {
     "auth_ref": [
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r397",
      "r400",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r630",
      "r631",
      "r632"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Retirement Plan Sponsor Location [Domain]",
        "terseLabel": "Retirement Plan Sponsor Location [Domain]"
       }
      }
     },
     "localname": "RetirementPlanSponsorLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/EmployeeBenefitPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r240",
      "r241",
      "r246",
      "r249",
      "r250",
      "r254",
      "r255",
      "r256",
      "r346",
      "r347",
      "r532"
     ],
     "calculation": {
      "http://www.optinose.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Total revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/ConsolidatedStatementsofOperations",
      "http://www.optinose.com/role/SummaryofSignificantAccountingPoliciesLicensingrevenuesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r348",
      "r561"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Net product revenues and licensing revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r519",
      "r585"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Recognition of right-of-use assets and lease liabilities"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RoyaltyAgreementTermsMember": {
     "auth_ref": [
      "r107",
      "r108"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Terms of the royalty agreement under research and development arrangements.",
        "label": "Royalty Agreement Terms [Member]",
        "terseLabel": "Royalty Agreement Terms"
       }
      }
     },
     "localname": "RoyaltyAgreementTermsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/LicenseAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Consideration received on transaction"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Number of shares issued (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Price per share (in dollars per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SalesRevenueNetMember": {
     "auth_ref": [
      "r256",
      "r618"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue Benchmark [Member]",
        "terseLabel": "Sales Revenue, Net"
       }
      }
     },
     "localname": "SalesRevenueNetMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/SummaryofSignificantAccountingPoliciesConcentrationriskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.",
        "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Expenses and Other Current Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r56"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/SummaryofSignificantAccountingPoliciesNetincomelosspercommonshareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r56"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Antidilutive Shares Excluded from Earnings Per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
     "auth_ref": [
      "r24",
      "r84",
      "r87",
      "r88",
      "r89",
      "r135",
      "r136",
      "r138",
      "r149",
      "r566",
      "r568",
      "r614"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.",
        "label": "Schedule of Long-Term Debt Instruments [Table Text Block]",
        "verboseLabel": "Schedule of A&amp;R Note Purchase Agreement and long term balance"
       }
      }
     },
     "localname": "ScheduleOfDebtInstrumentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/DebtnetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r111"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Deferred Tax Assets and Liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Effective Income Tax Rate Reconciliation"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r99",
      "r102"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/StockbasedCompensationStockbasedcompensationexpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of Allocated Stock-based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/StockbasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "auth_ref": [
      "r613"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.",
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "terseLabel": "Schedule of Income (Loss) Before Income Tax, Domestic and Foreign"
       }
      }
     },
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r1",
      "r14",
      "r15",
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Schedule of Inventory"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/InventoryTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r72"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/PropertyandEquipmentDetails",
      "http://www.optinose.com/role/SummaryofSignificantAccountingPoliciesPropertyandequipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable": {
     "auth_ref": [
      "r107",
      "r108"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A schedule reflecting the terms of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others (including royalty arrangements, purchase provisions, license agreements, and commitments to provide additional funding), aggregated by similar arrangements or individually if necessary to understand the effects on the financial statements.",
        "label": "Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]",
        "terseLabel": "Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]"
       }
      }
     },
     "localname": "ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/LicenseAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r421",
      "r423",
      "r425",
      "r426",
      "r427",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/StockbasedCompensationBlackScholespricingmodeloptionsDetails",
      "http://www.optinose.com/role/StockbasedCompensationNarrativeDetails",
      "http://www.optinose.com/role/StockbasedCompensationScheduleofRSUsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "auth_ref": [
      "r94"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Schedule of Restricted Stock Unit Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/StockbasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r94",
      "r95",
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/StockbasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r98"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Fair Value Options using Black-Scholes Pricing Model"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/StockbasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r80",
      "r81",
      "r82",
      "r84",
      "r85",
      "r86",
      "r87",
      "r88",
      "r89",
      "r90",
      "r175",
      "r176",
      "r177",
      "r232",
      "r320",
      "r321",
      "r322",
      "r324",
      "r328",
      "r333",
      "r335",
      "r570",
      "r600",
      "r610"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/StockholdersEquityNarrativeDetails",
      "http://www.optinose.com/role/StockholdersEquityWarrantsOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "auth_ref": [
      "r91",
      "r93"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]",
        "terseLabel": "Schedule of Warrants Outstanding"
       }
      }
     },
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember": {
     "auth_ref": [
      "r664"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fixed rate on U.S. dollar, constant-notional interest rate swap that has its variable-rate leg referenced to Secured Overnight Financing Rate (SOFR) with no additional spread over SOFR on variable-rate leg.",
        "label": "Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member]",
        "terseLabel": "SOFR"
       }
      }
     },
     "localname": "SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/DebtnetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.optinose.com/role/ConsolidatedStatementsofOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SeniorNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors.",
        "label": "Senior Notes [Member]",
        "terseLabel": "Senior Notes"
       }
      }
     },
     "localname": "SeniorNotesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/DebtnetARNotePurchaseAgreementDetails",
      "http://www.optinose.com/role/DebtnetNarrativeDetails",
      "http://www.optinose.com/role/DebtnetScheduleoflongtermdebtDetails",
      "http://www.optinose.com/role/LiquidityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://www.optinose.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r582"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Award vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]",
        "terseLabel": "Service-based stock options weighted average exercise price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/StockbasedCompensationServicebasedstockoptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedTerseLabel": "Expired/ forfeited/ canceled (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/StockbasedCompensationScheduleofRSUsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Shares issued (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/StockbasedCompensationNarrativeDetails",
      "http://www.optinose.com/role/StockbasedCompensationScheduleofRSUsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Price issued (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r437",
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Balance at ending (in shares)",
        "periodStartLabel": "Balance at beginning (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/StockbasedCompensationScheduleofRSUsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/StockbasedCompensationScheduleofRSUsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Vested and settled (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/StockbasedCompensationScheduleofRSUsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield",
        "verboseLabel": "Annual dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/StockbasedCompensationBlackScholespricingmodeloptionsDetails",
      "http://www.optinose.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r452"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/StockbasedCompensationBlackScholespricingmodeloptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate": {
     "auth_ref": [
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rate of weighted-average expected volatility for award under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/StockbasedCompensationBlackScholespricingmodeloptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/StockbasedCompensationBlackScholespricingmodeloptionsDetails",
      "http://www.optinose.com/role/StockbasedCompensationNarrativeDetails",
      "http://www.optinose.com/role/StockbasedCompensationScheduleofRSUsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]",
        "terseLabel": "Service-based stock options activity"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/StockbasedCompensationServicebasedstockoptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r584"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "terseLabel": "Number of shares authorized under plan (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Service-based stock options, additional disclosures"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/StockbasedCompensationServicebasedstockoptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Exercisable at end of period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/StockbasedCompensationServicebasedstockoptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Options exercisable, Weighted average exercise price per share (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/StockbasedCompensationServicebasedstockoptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r444"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Intrinsic value of exercised options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "auth_ref": [
      "r436"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period",
        "negatedTerseLabel": "Expired (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/StockbasedCompensationServicebasedstockoptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "negatedTerseLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/StockbasedCompensationServicebasedstockoptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "verboseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/StockbasedCompensationNarrativeDetails",
      "http://www.optinose.com/role/StockbasedCompensationServicebasedstockoptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r443"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Fair value of common stock (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r100"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Intrinsic value of options outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r429",
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Shares outstanding, ending (in shares)",
        "periodStartLabel": "Shares outstanding, beginning (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/StockbasedCompensationServicebasedstockoptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r429",
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Ending balance, Weighted average exercise price (in dollars per share)",
        "periodStartLabel": "Beginning balance, Weighted average exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/StockbasedCompensationServicebasedstockoptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r425",
      "r426",
      "r427",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Equity Award [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/StockbasedCompensationBlackScholespricingmodeloptionsDetails",
      "http://www.optinose.com/role/StockbasedCompensationNarrativeDetails",
      "http://www.optinose.com/role/StockbasedCompensationScheduleofRSUsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised, Weighted average exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/StockbasedCompensationServicebasedstockoptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r436"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Expired, Weighted average exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/StockbasedCompensationServicebasedstockoptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Forfeited, Weighted average exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/StockbasedCompensationServicebasedstockoptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted, Weighted average exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/StockbasedCompensationServicebasedstockoptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r428",
      "r447",
      "r448",
      "r449",
      "r450",
      "r453",
      "r462",
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r583"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "terseLabel": "Plan options contractual life"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r449"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/StockbasedCompensationBlackScholespricingmodeloptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r100"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Intrinsic value of exercisable options"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r100"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Options exercisable, Weighted average remaining contractual life (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/StockbasedCompensationServicebasedstockoptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r97"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Options outstanding, Weighted average remaining contractual life (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/StockbasedCompensationServicebasedstockoptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options vested.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares",
        "terseLabel": "Shares vested (in shares)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent",
        "terseLabel": "Purchase price of common stock percent"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use.",
        "label": "Software and Software Development Costs [Member]",
        "terseLabel": "Software"
       }
      }
     },
     "localname": "SoftwareAndSoftwareDevelopmentCostsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/SummaryofSignificantAccountingPoliciesPropertyandequipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State and Local Jurisdiction"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r27",
      "r83",
      "r165",
      "r189",
      "r190",
      "r191",
      "r208",
      "r209",
      "r210",
      "r212",
      "r218",
      "r220",
      "r231",
      "r264",
      "r337",
      "r459",
      "r460",
      "r461",
      "r480",
      "r481",
      "r494",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r525",
      "r541",
      "r542",
      "r543"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit",
      "http://www.optinose.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit",
      "http://www.optinose.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r208",
      "r209",
      "r210",
      "r231",
      "r532"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit",
      "http://www.optinose.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan": {
     "auth_ref": [
      "r7",
      "r8",
      "r83",
      "r90",
      "r105"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of capital stock issued (purchased by employees) in connection with an employee stock ownership plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Ownership Plan",
        "terseLabel": "Issuance of common stock under employee stock purchase plan (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r7",
      "r8",
      "r83",
      "r90"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Sale of common stock and warrants, net of issuance costs (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r7",
      "r8",
      "r83",
      "r90",
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedTerseLabel": "Exercised (in shares)",
        "verboseLabel": "Exercise of common stock options (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit",
      "http://www.optinose.com/role/StockbasedCompensationServicebasedstockoptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan": {
     "auth_ref": [
      "r7",
      "r8",
      "r83",
      "r90",
      "r105"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate value of stock issued during the period as a result of employee stock ownership plan (ESOP).",
        "label": "Stock Issued During Period, Value, Employee Stock Ownership Plan",
        "terseLabel": "Issuance of common stock under employee stock purchase plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r7",
      "r8",
      "r83",
      "r90"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Sale of common stock, net of issuance costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r27",
      "r83",
      "r90"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercise of common stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r8",
      "r11",
      "r12",
      "r66",
      "r586",
      "r612",
      "r619",
      "r668"
     ],
     "calculation": {
      "http://www.optinose.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders' deficit"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/ConsolidatedBalanceSheets",
      "http://www.optinose.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]",
        "terseLabel": "Stockholders' deficit:"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r92",
      "r201",
      "r321",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r334",
      "r337",
      "r493"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Different names of stock transactions and the different attributes of each transaction.",
        "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]",
        "terseLabel": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]"
       }
      }
     },
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/LiquidityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Subsidiary, Sale of Stock [Line Items]",
        "terseLabel": "Subsidiary, Sale of Stock"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/LiquidityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosure of cash flow information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquityDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity Disclosure [Abstract]"
       }
      }
     },
     "localname": "TemporaryEquityDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "auth_ref": [
      "r162",
      "r163",
      "r164",
      "r259",
      "r260",
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for accounts receivable.",
        "label": "Accounts Receivable [Policy Text Block]",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_UnamortizedDebtIssuanceExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.optinose.com/role/DebtnetScheduleoflongtermdebtDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset.",
        "label": "Unamortized Debt Issuance Expense",
        "negatedTerseLabel": "Debt issuance costs"
       }
      }
     },
     "localname": "UnamortizedDebtIssuanceExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/DebtnetScheduleoflongtermdebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "auth_ref": [
      "r470"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued",
        "terseLabel": "Unrecognized tax benefits, income tax penalties and interest accrued"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r63",
      "r64",
      "r65",
      "r234",
      "r235",
      "r237",
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r476"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "terseLabel": "Decrease in valuation allowance"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationTechniqueAxis": {
     "auth_ref": [
      "r125"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by valuation approach and technique.",
        "label": "Valuation Approach and Technique [Axis]",
        "terseLabel": "Valuation Approach and Technique [Axis]"
       }
      }
     },
     "localname": "ValuationTechniqueAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/FairValueMeasurementsValuationofwarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ValuationTechniqueDomain": {
     "auth_ref": [
      "r125"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation approach and technique.",
        "label": "Valuation Approach and Technique [Domain]",
        "terseLabel": "Valuation Approach and Technique [Domain]"
       }
      }
     },
     "localname": "ValuationTechniqueDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/FairValueMeasurementsValuationofwarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]",
        "terseLabel": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/DebtnetNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/DebtnetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Common stock warrants"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/StockholdersEquityNarrativeDetails",
      "http://www.optinose.com/role/SummaryofSignificantAccountingPoliciesNetincomelosspercommonshareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantsAndRightsOutstanding": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.",
        "label": "Warrants and Rights Outstanding",
        "terseLabel": "Warrants and rights outstanding"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": {
     "auth_ref": [
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.",
        "label": "Warrants and Rights Outstanding, Measurement Input",
        "terseLabel": "Warrants outstanding, measurement input"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/FairValueMeasurementsValuationofwarrantsDetails",
      "http://www.optinose.com/role/StockholdersEquityGrantdatefairvalueofwarrantsvaluationassumptionsDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "auth_ref": [
      "r667"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Warrants and Rights Outstanding, Term",
        "terseLabel": "Expected life (years)"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/FairValueMeasurementsValuationofwarrantsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_WarrantsNotSettleableInCashFairValueDisclosure": {
     "auth_ref": [
      "r123"
     ],
     "calculation": {
      "http://www.optinose.com/role/FairValueMeasurementsFairvalueassetsandliabilitiesmeasuredonrecurringbasisDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of warrants not settleable in cash classified as equity.",
        "label": "Warrants Not Settleable in Cash, Fair Value Disclosure",
        "terseLabel": "Warrant Liability"
       }
      }
     },
     "localname": "WarrantsNotSettleableInCashFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/FairValueMeasurementsFairvalueassetsandliabilitiesmeasuredonrecurringbasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r222",
      "r227"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted average common shares outstanding, diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r221",
      "r227"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted average common shares outstanding, basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.optinose.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 6
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "40",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=109244457&loc=d3e16649-113920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "e",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "730",
   "Topic": "985",
   "URI": "https://asc.fasb.org/subtopic&trid=2197926",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5212-111524",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5093-111524",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(5))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "https://asc.fasb.org/extlink&oid=126900757&loc=d3e543-108305",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e4975-111524",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "https://asc.fasb.org/topic&trid=2126998",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130561-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130564-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "https://asc.fasb.org/topic&trid=49130388",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(10)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(8)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(9)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(8)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(j)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(l)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(o)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(p)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2439-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2919-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "https://asc.fasb.org/topic&trid=2235017",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(a)",
   "Topic": "720",
   "URI": "https://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(b)",
   "Topic": "720",
   "URI": "https://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918631-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/subtopic&trid=77888251",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "330",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r589": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r590": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r591": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r592": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r593": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r594": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r595": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r596": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r597": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r598": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r599": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.A)",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=122040515&loc=d3e105025-122735",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=29639808&loc=d3e29008-114946",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450691-114947",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=124256753&loc=SL5864739-113975",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r668": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r669": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2611-110228",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "https://asc.fasb.org/topic&trid=2155823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466302&loc=d3e4724-112606",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org/topic&trid=2208564",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>103
<FILENAME>0001494650-23-000020-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001494650-23-000020-xbrl.zip
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MHZG< H:@2Q4#%<)V(9/T%TD2#Q283N6MA+'$YE,"\NB]@]DLASZ%P'9=3OY
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M3W1W?2D;3&GCJL#"0C*E*'R#*?!6SG'YH*S*AQS:T<EC+W%LHEX#!J I=?Y
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M,\'MTI5,JDNE\[U,DFJK_\=N8$C= AC+V)#7%CVZMRR9PZEB2[%0)\ HB>;
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MD*=VN97<=;D7QU:;7:.D%SJMGU!+ P04    " !4A&=6K]C-D7T5! "1CB$
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M [P_^E!C$N4)HU8BQ@E3VCO#P5"A'"M'GP_"/;4'>'\DXZFF**'@EF/-!#B
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MOO.-VW7:4YAN1?@;]B6^.*-2ON_!\G[P;/)[2HY,> +C>9(ZF3"AE 2Y1E@
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MYY].E]X*NC$\&M^0U/#E&9M9>;A>.+<1$-:5HSN4]\X+N<*KNZRAE#L-8D7
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MEIJE"%!3"*&D0X0GG*IG)&_O7>'S8J"&BR5S/B&:6*[ ]$ ,2:HI3258'9[
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M9!C=%Q;-DXET-S-T'<@1J."S$O@FFCA51%61]V/83?5;@UMUF.\J#EGX)1[
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M]L$V_RP)#VZ1BP6HE)@IY&/)4A$G"<$."R^%XX^@2AJ"S BB4\95V$%R'LC
MDD3&DE@9.ZRXXEPHY<32Z\JRG7>=\J0JY0DLWZ#GGWK-GU*/L[OI\>_*9GO,
MDK0OWMEQE-?=DEX5KE^]F>O:6SPNMI\J_QM=7*)T"<;QZ/HEWWKQ1_WW?G&Q
M";8'YF3AU&&L/&CM5ZI_ IHR-%AYV#>.+(31%06[ TR.038:@:52[:D4^3!L
MY_4GD3MVQ23:"+M\RE19XFMJI*+U.K1PQ1J[&.-RK.%R4'W3[8W[=>7E5MR+
M?@N\E/Y!*%D^C[IG54>.H]"1XS:K++HG@ZR>[[F)Y<K?'\UVNK2>83FGFOL7
M4]4P)OV<2G#"$U25,&)PPS&-A4$H="=WF!LN?$)O4=6_LII(OM<PF(/GOQ?K
MX(>LHGM]^ 6P#BY5W<SS]O7WJ:EJ,[>O"G#=E3&@I@H5=$U [K"3.[SQUP@0
M([[Q0#D _09W*6;N$L#\ !Y]\B)$#V X<+3#-L!>M%?D)Z/]V>'E:,NY:F[5
MSG%EJE0552'+G\!CWC+#ZC#^8W;:-T^X?7ZS$T/P8'KR+7.=G3G;V\9$QV06
M$[D<"%D^9^J%29-/^#(C=^O-_%T)[6(95/F]#TN7,;M;*OS]-I(>9-;VW:,F
M8[T+ E##]"4FKW^H.'WV&K&K>/9#J=9%N.\<///*E]+\/![K)AH]$']^3XN5
M^<X8O&@*6ZP"0^SEQ>2&A,'JI(I5S/2DA<X=W/VT?=KMK9QUWH 'L-;O=]8^
MG+;7#B>=-VW6.5L_[/; 1QALG[3??-D@_*B_VVOQ]EH;[0XZA]U/VZBSUCKI
M]C;0SMD>;</]VH./@]W>RLD.OIXV_HYN]MW?FY/=3_9($Y:T/[7A<XMUUT(>
M8YO 6&<PCY/.FQW:63ODNX/U?K?7.FE_ZOC.RN<$T21D4<1.V.!],!5+3TF<
M.FZ\,1YI7257W&!#7,LWG-KE-\5'[J\!^65YN:$LL *.1X6(K=I,J9_ZW%:I
MOTZMD%]F+::D?VAHJ9;\KW$)]R_+9_AJM,?#DHVO8DDWY#[W#F$N.ZQST#[K
MK.UFNP%+>BV8R\[)SL%FUEE;F;0';WWGPV<"=%0 (3%AGL1,:Q1+G88J9Y)Z
M81%FW'W[Q6H7,O*U/F1S[=7YX#T]N!2TIB[/F\KC6:VAYEE)PP]'UB:=LP\@
M*08DP4Q DLAGSITD6+A86V%B)IV&3Z&#F#(XL9QP(?#2ZR^\R&L:[MQ!SNZ:
ME!9"RU5 &;1FR$X;Y=&XK+UGX(;Z)6XWO%(!'/!PK_XD3.8D X<6;AL-W4EP
MS0MWG)65%AZJH0%V#<YV:"T;3@XO+[>JL&44&@UE]K9T>/J;^OU&1_AI(TL/
M+C2G%V\4J=]L][S>5O/#(H.ZO0^T&\#\;(-UULS)9TV9I"D%."<NC9GR(M8T
M57&2,H>=)S+1\MMOGIGG/;R[O>YCGK-@O[*A-<T=FH;/0MUS")>IT<B%-F0!
M P .0O]W6$RU5R75G+?I4&4)EE7X:081SGM7[=8,I^V3PI59V,09 OX$.2WR
M?I2#@7H)EBXB=V-8MHL\6X;8I<X66ZK0"H:-NZ=]-ZFRDG[#/-I>WEI>78Y2
MDH0V&+^'![]XRFF9C^X#2%P"/Y\5@WKGZPCNK<))@)=5K8NM9JS&-AM-YQ7V
MNIX2[!X0ZS:,+U;"H^;%R@7!U_MJKT&[\SX\D\_:".$IK "Q%,6,$QDKJ5!L
MN1;(2D4YN<.[M>Z&<-]AL#YBHQY,:GNUO$@/!*GYWL8TM]I#E^'I A:J-HAU
M$E]^/8N_Z@=4EZ/5ETU3_WQ5ZAA^,GE1N/-VSV&CHBA",F >I/XXR\=E?S(3
M^IONNOQ48E^M=F/B/)E7 +XL> 0;9R%%KGU@Z*.:./,, %^7WN!Z5(*:@^=2
MR]J%",X XY)05PKX/,\D6" FKY)HP-#H3\JLG'9I#R'@XY#F'IR9X.ZX85E;
M)B'7!0Y5F<WG=[\,$^>6RJ7>C?_[CX01+O\PKB@O9\X4X'\=!V@YG\?4R[H,
M;=-$'(:6,5J+,>!;@Q*_/$KLG+37=LB\HL2<^R!5MD*Y[_K]6=@D^NUZM?FT
M8.'RMCP8%+\O-T5W3__X3_6JT?J^\Y '_30,\/#[)T$JOQ(P_@51/SB$)Y^Y
M(TPX+&-*G02'T*2Q4H+$X!D2AP1&.M2QW&D'8TY#7@M:!+Y2V8QOQ\/P<H@7
M46#MZ+>@+/JA^DM/MP(CJVZP%?]91H.\K,P_F#NXAE5DW86(/+B]^3 XB:4!
M#_&_X_I%B"^J =3>'HP1U-V@:J]3-UB[<7A3]V0K0T^V"&2KLENKO#L?W%<8
MHZQRK]7149&?9B!M#J;Q/U,Y7Z_RH.'Z\3"KI7Q<@C%V1>R=)59+:8Q+',-2
MBH0KGZ*4)RI)I.*?-RJQ3RA: @UKX!;]\E]+,;\N^^^KH-EZ/U=?O*=].![$
M-A_%T\N7HK F<&GR:P'!!'[CGS%.C%'$@HTG><PL<[%,B8B-$)PZRZ428/(!
MSBZ?=\^>D7$J:,#Z_4#4VKO)ZV!&Q:UU]#%P'ZQO:$-O[L!5TP&^TOXIG')%
M0):_T2CZ9VS/1^]J'WI?U2VCPUJ5^^!T5I!P=9'&HVK[J^HF7:V+V8]PM1JT
M$L!;):X>\ NAD\P3Y1%6E"'&4RX0,509J:G%.+6L$CJ**,*7A6ZCLWY#96(U
MS:IIXU9UJ^[%5.\FANC7$L.S]IIAGS$(FTPL N$++W3DFL32)B"51&&18"JX
M!GV,,7X!NOD%2NDU89RRRC?>0/_=6>-S_B;XM>[J=KO5Z6V%UQAW-]]W-U=Z
MK;7HKYUHL[7>VFQU5ENW@\.WGNU1Y?X!;>&UW(RK@-7%BUJ=_6L"8[O"#8WK
MP8W^ZH/$_F*2!Y8P^DR2Q"AI)6@\!I*76!X+4KVL1S&LA.8)]TN1 W Z"D(4
M,DQ>OP^;?=-:@%O"=;.*@>.@^/+3R454OLIY"%MT%5BKX7 ,"F[@7+6O%R _
M8.=^WK<ANA="CMDEJ@5[JYC1+6Q+YM%[L.6BC8V-\Z*Z=0#9"*/XWR%@45U?
M1S/L<K05"N"^,K63\/JX\VX+53I&>+ZP0WFYL4+87SU/I0B(GY5ET#+A@BSL
MFJ!@H,)YH02S&F'B5!'522!K8)U6ZHWBJ?K^\7?JW/0"FH4I:Y!B6:*[E35,
M,[&_J+RE]?-^K<7K]%'(E2ZO ;YN;0&++G6!O=)*]NLM-:\NG;B*I>*NVF9^
M2HK#V!48,HZUT=0IK17S(M76\!2TM" H552+SQ@M/7@=\@TJR/M[5D&U+($U
M-GVA[*LJE2&<!3-13SR#:+\(FO ?=R-'KX( P,,_7ZI%F_MJ4/R@JZNI?[WP
M_ XR][A@*.4R>(T_@H5B.47W7XHE\++$R0.\LH13\@"C"O)C[X+YZHM0EBF^
MV\+>L=KGYUZ8<5-R?\U"MR;W?\NKN%]11D\.A%^?P7> "5UZW>GV6N )O5G9
M7-OHO(G6NYN?X&/\KMO]=_B^U0-OJ7*?;D";>WUWRJ-SS3=*0NZ=9$_&&F W
M?R]7X%NHW2# ,T. 9.GUYL;6OZ/UE=5>=S/:VFZW5S9W&EG_560=Z$\;6?\U
M9%TNO0;A_G>K]R+:Z*QM;_4V=Z*5SEK4[?W=VHS65GHKC=S_*G(/O, ;N?\E
MY)Z0I=?O5S9[T48T1_)]/7#X7<'+1YS<@S[R/8E._8ZMQPL&/B/IX$NO-\#%
MC?#R#TG'?;8V:6AT.XW^VM[:Z+2VFC#$KV*B!*+_I(G2@.=#"Z:8@>=*@Y[S
M3*1+,9X&07\9! 7",]1 Z%Q+)\4S"/VK@=!Y)M)V9[.UU7WWL;46-L76UZ/5
M;OO'-\:^2ZX>)<40W5 8T8#]PH!]8%'!&K"?;QQA4[ G#=;/,XW>;W;?MS9[
M&ZT&W!MPGP=P9PVXSS]PI%-PIPVXSS.-WK7>K+R+ .)76ZV0\]9@?(/Q\X#Q
M:8/Q<X\?#$TQGC48/\\T:F]T6M'6RGJKMQ.M;6RMONMN;6^V&J!O@/[I@3[P
MY\\"_9-NQSPG5O^1G)R'6M$F[>U>U0"=I;UM-+C?Y.0U.7D+)+K)U,KF#VIE
M-P3Z&0+5I02A8#"4#VYL]397.KU_;E7;HMU.U/JPO=';>0''WE7]5K9ZW=5_
M_]U]M];:C-HKO5YK<ZLJ/MC8VMJ&G]YO;Z[^O;+5VHJZZ]-KHZW6ZO;FQ@]'
MX9N4E06TC9,F"#+_TB^G\)PT09!YIM%F:ZNU^;&UUIB_#;3/ ;3+!MKG'C8X
MF4)[VD#[/-.HO=)9>5/UY0"+.P2XM[>V-L#J#A8U''JWL[516=+K&YV5SNK&
MRCLPRSMK8$M/SP'5L/VN5YT2,EU6PH%F'[31$W.@)P)[-WIBSC$HF24RIDWA
MSUP3Z</V2J>WT0. _]BJD!]^>#?[?K$S&JW\U=WN1=.83J@6:I1!HPR>7AD$
M%I:B40;SC3.SQ$?1Z()YIM&%,W#1U:_2"5O;[]^_J[ZO;.[\>".@!OT;]+]?
M]$\;])][9$EG*9&R0?]YIM'JWRN=-ZWP%HP*\\'V7WFSV9IJ@4\;O;^CE=75
M[C;H@/!#B!/57T,7V'#!A?9H$BH;-3%/:B)P=Z,FYAV"Z$Q--!&CN2;2:K?3
MV^R^JSV#JDIJ#9"^V1QHH'X>H)XV4#__*#)+WY0/V]*FH=#/4*CN^KS16>]N
MMJO]WP;A&X2? X0'UI2R0?CYQH]9!JA<;1!^;BET:7OWR@M^6AMO.M';[<V-
MK;6-U2KS)^K]O=(#8[_UL=7I@4[8>M]:_6&5T.3=+R#JRI^WJYN:U*8FM4'E
MKXJ9.'\5PP\6I<Y/$60C[4T%ZC,6U/.W0J#&P)U;"JUM;+:JEN8OHM9_6JO;
M55)C=WU]8W567;K:W7S?W5SIM:(WW8^MS;"#V6Q:-A;W'%C<@7^;.,>\@\SY
M^RT>]NU #85^AD(7V+_:;;]O=;::<'8#\_,"\\"?,$Z#\W.-(O+\)1P/VYB]
MH=#/4&C:#V8GZG[J@('_]\;[4+\*MGYO9:,3_=7JM,#R#PF*]?'* ;@HE)W6
MO=[:C:;1%XV^>'I]$?C\1GWQ[65\_:<N7C9:9HXQ;%8TBQ^V0WQ#H9^AT$R?
M5*HB;(Z"GMFZHCQ"I[.ME7KG],4TF;X.1(7WJK?  UEK-7&F1J',AT)AC4)Y
MMG U*[S%#]N.OJ'0SU#H_>9&9W7C/?@E%P56T7JK-:V];6U^W%AM6ES^.H"<
MWB$B-'N0INMRD^&R4( ' \U27#[.$:0UG<T;BVT^Q&-6!HF;WN9S3*+6?_[>
M^&MCVA[EAKXIT=;JWZVU[7>-W?;+V&T57S2&6V.X/5?8DTNOMS;>=%9ZH6#D
M_<J;'PM@-O9;(VJ-J-W9PJAV#/XSUY+V<J1TW]T0-AZH8B\;QK4]\4K \DU_
M ::IOGX'K]SOG@4)9L7GV_[<&@>_^D#\Z@/QHZ_%Q;]_E,=9A.UAWY5E--IW
M0/1A($B4PY?B)"M=5+C_CK/"E2\BU>_#-^\*-S2NC+(A7)&5T7I>#"*,XG]'
MHSQ:ZAZ-LF%>NA=+T=)J/H!GF(2/)]4/XQ+^5D,;+>7C8JD>+%P5+NJ$BZ*-
MH5FNSLA&952.=9G93!69*Y>C.Z[EK\-BCS']KZ%IKU#6P<P.HTX.ZL MPO/
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M=6+UJ&#CC9S9'\)\]T":_FCX_3[XO2)/7PV'L+PJV+(U5 &F'8V+<IQ5^*1
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MPEQXPZ5393Y4%;5S'3;_:M<H' /SI]H&=*/SJ-3L].A8P?-4-PP1D:ED'P,
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MD!#.(MGW)@-Q($ _]GG:%F^[7;=UQ-HK7VH&>I;W,U+U?.5/_;8Z7\2K7(G
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MKQB1ZX4D(WH9O#-O G\A,)<[[&"A%&,'GM=5+/>  2 H]U_S KH_ _2&(2B
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MS,R9"%66I^?T9832K7K]05=C7*$R (+XEVK4S&IIXO(4A&J<]+"5.9:-]2E
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MXY4E;6&DN!R)J!AC;4F_;O!V[".CM,^9+ 6CM,0Z,9?A<O04(C:FZX/>7TA
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M94LOQ)<,W?O"?!R;,A+OO>"X *\M8A&2($@M4*5)CO:^%R1_H[S?>2F9/H:
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M<"SVW(J+5\8)JU:A$1TN^"J8GF;KM*2.3K^DF%W)O"JWT.[5G["G9PO;;[2
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M.K=#+W[&<+#OGL']NL@;O5EI97NN$F>3DG$9UNISL7SN2"LB OO'@\&C1 O
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M$?UQ9.@5I,N="4BZ>MO%B"$S^UO(S*;#3AX69&8S=)\B&?/Z4LC65(LA0,V
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M'F:[YK(Z_[DCA+ZFROCSZ>J[X?N?Q5E_'X+SF34$&X8&!C[Z5VC"%Q:>^DZ
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M_?_9>]/EMK%L7?!5$*Z3E5(TQ10UNWQ.1LBRG>FZE6D=RY79_:L#)#=%E$&
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MFTRE(+.2A8A9VV2>%'+&:\68Y+JB43)"'][JLX,[&X)+#JB(:6BL XL1'1Q
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MO.;K,1L,!^XGS(0\YNS2\K)*=2.Y&"GZ=KYGP8,+.W@WWCGH1Z>8/L@NQ67
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M+*JDU?1?T?!$:0/-N.D7]+IJZ6<_[Q]U.?!-SR-_YSGPASSN(+[9^^;:X:-
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M _K2;SAE[AM2V(J&W$#<:0E>:0O>(.]'^1WL*4W@"LKY4"DQ0N$>38OI/TW
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M1!*J=$B^8*V>,<I?]8-R82'FC2@FD2D"2UY7&W2NSJ!P<JY#:1T-=)#2Q#*
ME,9+<Q$\;&_?_'_?_?C^:/*_+1U"*<&@TK&+R%9@=FA5>D?Y5E;<ALJ=V=^]
M^F!MR=RE7#$7+3W0A[06$Q_LLB(.2GBA7I,<09A1]U5S+-D%(O,@4"^9V.&
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M6H/=NY6?'F,PRNO H?4V*XC$4"4TD9PZV8T79[.?Q4]]JK4F<@<INA6G1.6
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MIKG<H^\"SQQIGSNM+ZHPL-:FT*^P$9;'/,^;)E>P[\K&NSVE=9Q@4^I*4,@
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MA,*WDLG^QT1C3.7E+N7F95I -71"6TM6*W"Q"G'O: JB8U? 9C)13%"N7WV
M!:WJ Z:DI,_:R/3.2GJC_**F@N*D3IV4CTMCX#[3TYI/8.C73!=@PMU"0*^$
MBN$^GKE>:"BW4?;O3G6Y6M!:7]&S"LFB$.[*^V:I1&PI;F"ISI-7#G2Q^@XD
MP49"'"B(IT$I)3#>RJY=\O\*/^5.!+@?A/?8Y .$;_D2O9&Z2I)RF4O6B02=
M/K1CF*[D;:^O"?>YDIK88^\&&H4[$CFG4H9J^4&3;'MH57,<Q8,2R$Y[7,[&
MC*W[E)>8F%V9FW*Y*F8\.TSX:8_WLE[2X(P8K,])).PT-H:'2C9*\\O694F#
M)QHM4<9BYU,@,/(J13A^"#=<"%$S>@2R_W5#>YRE8VD;%>5*%RC]YK0\+GGS
M0&N4)3L1R @)+^C=0?6<Z.'E(P)ZUU#@.9PDGH3JTF)$Z#@B\Y1?;T3H]I#X
M4,)L%OX\G!R1T8OCS"_W"^XA%+AQLC'\4>)P3(PD;Y72MOT3!-7*Y&L87^3W
M.)?)B2E'\?OHL1"1D;GI-)E-]QS\G<F6*S7LRBM,7WOT>WNEJ*Z"&Y>SYR:4
M=IVGH;M5]<B;TA)BWN3 [YLOVCI9\3B!MNNQZ/,[_G8C-T\?7Z?KOA&QQ[FE
M9PY3^X ^GQ5QT'@<GGRMU,%Y53$=-@25C5$=YIT]OID*M.S$+=V?W+G*"+CA
MD>MA&^&L7=%QVY4+/3O-D>.[/?IF^_-=Z:F$1KDI3MC'",HS\Z9>BGGM/YU7
M.-[V$&,_=.MHY,5E_=R:%WMRL"GRYA<^PG,[V&89'5KGY(<UF3A<M&YI6XAC
M)E) B&1D46O^)"[ZL&G">N;C@O;)[QX_=?&CVM/\A.Y/ 0EMKBVGW)<-#HU+
M/YKTTCN^.#CFY&3F_*IYHKF*+=0[/A)/(O/AMY>/8X'@5*@V]4# Q@YO#E$?
M/ZD0LHN7+#%;2'&JZ'-ZB;GI,.42M?UYD4\_3CY,>0;;R3_SQ;H8._Y216L*
M V[OI$E)U.E2AX.8XB$-3=J. @CL;^?!(=QLBB:MU>91A9Z<_V,.!B"[XC1V
MX;6LR?MVCB8V4)@J\[3GG'XDQZ_)3Q#00Y9.4]$<AA<BBAY\$D@&B$\B[J)$
M=?!B5BPWN:Z@Y,T93F:WY^QT$!&IQ3V"[V][D[\ID<P%6N=(&^%V./"<2@:=
M/29RV+*RF*F3BQ/!RQ.&7PY&>RI_[9'=_ANL[GV]K^[=]@K9;ZNZ=SOB]/>Y
MB#>Y9,HT7Y5\O")M!%'/6;E8F_ 56Y?BY[*%T?3&+\I'BYK32A516I'F2H]+
M>A#.,YY:"4$O' H&I<@5:2F!'J.:H<C47F#,OM"XCML;BEYF-81K)!,$*:>E
M)EEIS14-#W5++RTA,?LU]'+_@$\O<DK(]T/]S/F'%.328$Q.B@H*:KZ0-L%A
MMBY")-P6Q4<,=UZFZ3*;8?-K\^2810!:GO'5$>*OCQ?E-*A:T<'42,X= ;]F
MJ/ !,FK'NI,X>]SQ(Y[0C\EK+=79JF9:/L*J8^?F1#*HAY,?:U6EZGR>\]*G
MY]]8)B=J;_E4-9XT)H.RR08K])S&L#TM5S$$,.D=+'AVSBTK)5)!2^C9<JQ5
MT$O0K68Z8J;-14<^#4^!-\7S#W2O<&==]"Q)YK?0X>15.J26(2;'@"5R5+\H
M*(RQLA%%,!S1R(HA;]5\3I\H%;<C2W)@&E:W(BH:=[CZ)J,[_ ]QR$0M".BI
MF-49QTZI(%B\%_V*=9H+3F_^'($$B?Y;SQV*/XZZQ"-2]7$<8K6FM5RK2\D+
MZLL]+S]M=LF/U%7ER;;ZYT6E3%?Q3'*[/?2FOF18)N5RE4\'-03._J[UX^ :
MB\K5Q@V.@+R."Y1T*,B@P;7W$+T]2[0/'OIP\AHBB^=%HT4"*0BP#\E#ZB<4
M]D5=X]HBGDMO<#?,MHS"P.3 .@>#T[=SC&<8F+I,J@I<F\R;CT4GL8?#O,2%
MU+>$EI(MFQF2CS!9:M,EO$F.T#,*(.$Y;3]+LY&3E.\OLI)V</!;%+D('TO!
M7Q<ZMH.80+%JJLDVS\]H%%1,<2WBEQT,5$X^5,'#PA$=*MIB!2(FA*ULT9;X
M^1U9'$<MU-=8XWE1GV<CR0+%*&O,ID*;J.#3"7T0C&P,E+'O$BE&^>EH*J)D
MJ 7-(I=I6U1=L?'59.M<6@8>R3:--^UX<O60O),[M?(RNSX#OW39]LR.VRAZ
M_H1+&;HI6EKG2OJSY7/57880_,?BK6G!KJ7X%$@">HE*0;3S>*SZ<J?:;Y54
MW#+!L=(;QTO@ [P=]<25[$ Z_&TJ_;IM?&Y'\F?+-M@V*%E 081ABE5G<JU8
MAA09FK&]@51?5&'-0OW$W)VP>G5'!)<5FRT95=2W:</@5&>K-N/\+,H,\K';
M,9Q:B0"=G?>+VNV!GB/OXY&KM*.7(<]0='+-%Y5E-301.:2/PQH=" 9WISBQ
MG1U@14=RHJI!@DN4@N>E)L;)W)1P>?!%.=/BBP]S3F.E.?)L9R$C."M9A)ZW
MQ%B(8BZN^OJT7A88+OK6^9:7%2E:G=A\QJT\275XEX&.9VP>P3OFDU4FW2J8
MF>WO?A3>8\$:U=M#;!ST57'NDGJZ6.+H]$P]$OGAY2;S(A\W#[<RV_ V=6LY
MM\"CQ^*;T4DFIY),"$T(TIDTVS/O3'?YSW1XB1=5A.&"ZU[,;MTP;'4D:"8'
M0E'8)Z?Y;/*/PP^'-+,S@%-&!N?^F[=_?] ?(H[ 5K1C?RZ7 M;YW9,GSSR(
MT"M?DTWD K]N%MR/!A9_I>"(T\P\XLEST!(LT)DO2L!GY#:L1,;N/8I=KQY@
M;@0 )OJSCP^?VNT/__,_'GW]\/E/V,?(8YO;HI>G5^J_$:+QY#/$(61%2G[!
M++D.GI4O@M!14&ACURM^7O$Y4\[AP=+)M*")FWE=XJ;MY%L:W(>:*]F^QP^?
M/+17T=HT3Q@4C\=> :/P[/'ADS@-XW-O;65;K\19G[I:;&SJ=)K4'K?YTGX+
M] *?KO3Y1@(ZRQ;--)^Q5KES]BBY&M.VUC9HQ\H&&XM'B#:7#9($_>F$J'[S
MF:K[ IJ)!^)G\>B2P;AB-!]_TSLI>"K?T+4IEF(P B_"OR4*PAD&O*O9?'(-
ME_RU;0/_[>&C78?]@BMI&D_7#4,HPE3PV+0*?)99D1.S=2-.K\GODR,IQ0/Q
MCPIPF;_1BIK5R\Q@"G30\)*VH#[:-+X"&\ICI$ST$%KDY^X\!XB8!P>#B69:
M^-<E*U_/-PIW:U:UI R[AEQ/VO<RVL<USR/*9 T]!PI+;$?."DE])8FN^2X3
M),NOY&(TOYD,$-)8]#R%OA)#0,9JFK?28+_M&YAHZ0;[%'&NKI9UA?7!O^"U
M4EU@@W4_\X47I9R1):(S2<&'*,%6Q6S=A.2C^Y(<DDF>26"99N-YZ7">>090
MCG[ER3>/\9!/OGEB/L;K2G/4[S4Y\+*>X0Z/OOWF:_'!EXPOG4WN"WQN5CQ
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MX3+G=;/@+W(M3"@E*>1\".^Z/\P<IU+HRM],+C;,O Z>S5?Q6\;I])9WG*P
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MBV6M_72@QY2)WD_)C6TQ/:T !*'8*N_E7K*8F1&WEJPG^#MH+HU,[[BHBKE
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M.*P[3=/_8?Q*EO/*)K3(3D'-@Z&NYQ3924\#7_"_<WK"9M-GXM!181QY;&Y
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MUFI5-L$LJ$VTIT4.9$"#RC<XSUFUYE71KLI.TA+]A2!S[@PBB])<OLPQR.M
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M3/'4ZS_N"D6S<OA,WZNF@N7$ KEDS-M).&(#G1%VK-(V2*3-Y.Q],:\VQI2
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M@ AGA!X*3/MC0'O1#R2? ,6=F1#?=N B3UY*ZC(A&6\\F4(IY%_K#^VP)43
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MPY'Q:6RST@/5*C%5?2XY()>=2 1]8BX(*MY;#NK]U-[(U'*1:];06;H8F=E
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M:=)2O1;O A)I0[LA<ZJ0E*!'1MKNKH0DSXIZ'W&2"S!"Q+'(MTC(56^ZIKE
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M$0Y0:9O2+++;^H*.P J[5D@=F+U%4NE:-6$(%0'VHLL;[6]44Z3K!$"A^9Q
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MXM&V;GL.(C^, "]?DFNH07,&-U5E'%+L(WAA(*6TW=55$),SPY=4#[6Y)?
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M$"'^NJSK%3GB3;?QL_..DK#$\[PH:]:R4^9^5M=3%?"0183AGC7\7%BX)'2
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MYE<"G4W_GIMB#^^AW _+DANT0@4BA<>&=3>D#(T@N=!I%ZI4!%<4]F[AGC-
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MXD(->%@]%GHCZ<9L!<B;IXG9)-GL([V\#P8_&<V81-32ZSZ>[7@J.)G@^"@
M;IO"O\4S0,E$"B ) V"BE8YJWCFQ52_Q1"?QP 27\$_FS2*-M?B'Z'3O]EQF
ML@#&U"M*:4U0 %XNR$7H@\RM#(FA9]NXG.Y!LUD/N!NPGHMMLI3A%81$*Q]7
MH#E7,92\W+?278M.<3(7?M26CAO/71OO3FKD9,\ND-+,XBDO;'/)Q(T(Y\3@
M+<U @U<0[>;WY "(R.>K*9Z"G /L$S96?MN>A!J*_Y9?,.I91 ]/B0@TN$GU
M2=+21L:%T5%:))8*,U-6)7\IH0>;*,Q.5' /&L8A54\*F$_2!D9/EK-6B1>K
MYV!T]:L]N]AQH#+KK.,$"\9;CRHH1UO48Y:69+/Q4Z*)%H!5FPI!$^$!X"%M
M(^37! 6Y\\_O-W[C)UYI'/N6+;,_3@,+&HZ=3&().2RXRFD<(],0.RSD.+FK
M7M?@JI*59E]P8&4$%DJY^!4=&V@*9CXI+,3@OP5J,&&QN<[C**#/Z.@O*'FI
M,5AAS:^<09!+OE(]$GI\;>"(?D.VB'+BPU'P]JJ1?)&<:O= 4?5@=G-TQ-^0
M!4%D+FDQT+1>U4WYVR%?'W])=6,X:%E,N4C.E$,B"RWTB^S&;>;C$&3RU6,<
MYZ^S*<X+P7V:=*Y>[>"P!CA5\')&V'@Q]P@_D<EH^83,*W%Y$HJDP4$?">)V
M< F73&O5<DIJ",B3+(LNBL.@?L0)C'-29LD(;2J+M>#<F$EM$LZG219T)2$;
M@J=-_#6;R4 ^$>U'"=4=Y2IB(4)(UHU,3B0#L/UUL9FXB.WE"5@N2F@EE'41
M*V8U?YFESU[+L/4E/JU!N8:O^#.J;.ML9EXL55E -/Y4R8&DWWGAUW&>+?XG
MIQU(3_YLX\U]QDX2V<3>WZ+1O#DRD33:W)7 N>R8([PB[*QB(.C8\>M .QC"
M"P+22Y[7DD\R/L[%K+83?>K/E-6V*_?!E<'S*9$$#?(*4,F(0&-F%4[ KZ3C
M0/H9XJ.%V\? +#I&',4%HH+Y4&>JA4XVCKH>)EXND(0^L'<SAG*0LJXTW='3
M@T#"]MUQ9ED0%<-;4!S>' $ #[[Y\LD1 '#7B^C_Y@" C^G>D*-J3\(0HR5G
M%!69"LUB1>16%(]LA"8O854D2YQV:O3M(/00N'J*'N<,C)90D _3MJZ)_KDZ
MM'!QRMP?*J9SC,_IO8H01Q9)$VL$ TE'B6L:>MZ8"=+G&-TZ ULL?\EV8$L]
M*T?^MR9W47LOS3A+\X9M]M*X*^2_;./)S B)*R7=OONISBL3(FH'8W.0<VK<
MTAE:CKCGS?)\QA/-;0-P0QJ^-0CB]V[=<$V-()E(B)9.0)E2GUX[O]KHN%Y2
M*E7KX46+Q#_&=9-+@RWUMIP#QE@*.723]ZN^A"> BFI^[DIN%U!0YXJ+7NP=
MH@R2<?K,\G?2'R\:+JP6U:KW$[L_N:(SF.N*%CXOC=;H/N)-H;/0N%TO\JCK
MNHGDPR/W!,5K:B &A83WVI;>[)!?1OX,^GG6_@*"G1%TR#6L<:AQQ;@B-,';
M;EUMUDQ>W705A][/6">:O&N2Z-5"D5;T L9%RJ2A?!E6R3A@4 =YE6_1>1H6
M</#C\JN\62%.1ZTYLZLWX=7:>J?6#^1=!+K,R#Q@4J*N$S?1#C)4QAXR.P&S
M60V4OY2S7T5 2'IA57OGFBYA$U-K%YGN8R(_"4_(O90$\06E#"M(_Y8AE7+A
M=W%H(YI^TF6L9E.B"\O>T1:H "Q>"X1C0M6^36.E.S>3,PSZU"KLS9BE[Z"A
M1NFW<E=^]/A?>57UZ !0FCR=.*&5M^.-[]158O'3,G23P@40E!:K-#-K;W)H
M.D/H83OC*+D0<3O8GPJ?H/@<>+.D@#M^2@:QC)^%YA_W./A06M,;KI1\4?7;
M<]=()G"TYB%V,;W6)^B!0_%CJCLE, C@S8"Z#E$N'4]\+FN7+7IA"F\S0X#'
M9\%@N1/FR^ ASOVUZTJ!966^:P?C.LV',N!<1]#)(LW,:-&Y8=4[)HTX*R&P
M)7MZW[DM-VT\W\XW@C%FP6;_ P).CR:3$9"9+ZZCH.@,%BLP609#%Z@V),_.
MQ:5F +FX:T/[7KRH>OSTNS$/:DB )QR9+,L1.(-""[0VSQQ*HVH\,<ESJJ2H
MH\I"RG41"SF#--+/FZ)TUA$?]E#0;B*"$[^FEC!^_4J]E? AD<:7S'KO7<_"
M71IEKKX=(E;L'8(_=,-[+-9^ ?,;AP9@PY7A?B$@ ^R-+85\^CF,^+/3Q1L^
MEKDM]^F73QZZ1RERE!<S7T>35M(U97&K2N*_MZQF@1!S'W1?)GA-L0:22J(M
M4,L/OGM^AG85LTY>5O]T79,O_K<%JF'4WG+]8O(?74#]K*O)DQQ3M$F  D*S
MT,2=3PX \X4IF*^/S "M<J0 Q4@$XG;(/W_\^</S1P^?/K(=0O[Z&Y*+TJXB
MQG>>H*BX"NVF/E;:^$C3NQ:-G_O:VY&>DFVM\F#*(IM]^Z)31@P+CE'H?KYX
MI:SV_*0O_H;D;.QWE9GY\?F9+:<Q<#$4^5]__SQ1"J+/_I)WR\W)S_DOU/!^
M1K6 ^-U".CY%NBH2)9P(D8(X$THGAMO'$Y#O#O1ERX\]/5L2D-CYDBWTV>?\
MNU6^9_1LUX+4J=AU NJSU7X[()DN5)#@<81,'BUM&2!4+M5_GUD!]"JAT9UH
M_;WE:''73Q_;OOF,6[\F.MJ(!<UU7>DLL8"^*Y#:C#DE[&YK0.+I2LY;,5<%
MF1=%5 G:Z,48GT*OE&[@@ .3%\]!8.+':;F'8H<\((/')U>WH<6@_YQ9Z?[Q
M SM-H*8)ABXLX,5P[;;&K&#QQFGEMKG)+\^L=-VEW55]8,'B:]^5-?(F?_GN
M;/$0$,:P\EOSRI_0'B[\N>7'S=_TD2[V=OX9(+XWN=0%K#6UTA=8Y%B@9HG3
M=,;QF%CB,0'X+TR=Y")6_ES8&PI".&LDI6*S$8)Q;4WYE<D=A14\396$RQ#R
M)Q5D*41P04&SLOPG6+:GR)^)E)QC*0./L=?'RY@;3'=L3,#"M8=S^L:Q5)8T
M;[X]K (Z<S')'<86F8"E]\;F$]LM$PZ.H=,4X2*#3ASK<C,NV"1\Y'[L3T]<
M55)%,)OWQ!M^J[ [U1^3DN]AN)ZNNO.B'K* I6R%DG,L#(A2@%*,D.EJH0Q1
MP IV=J9H$H8EY6#9'*#GS,,P_IS#Q .YQ!F=@1%'02PF)WBKE!LC01GST@]9
MB=/%CSY,;R@/$+K=-3=X@&%L$CZL"IAIX14U_=#,5;ARE:K"D2=IZNCTIH,F
M;11&!B&FK/>)9BYK>L^)*FH!V+X "T:LIM/\?FGOV?W8'E92"XGH.IJ!I'C^
M27M-@'WE;-XPIK5"[EK+\EP/I[/!7%[9] M*RP\[3*<7\NGB+_65LZ#(04T_
M4!P:Z*X!;2?99Z,+P&#N.DH *"-.? 4QZ*'X!2Z9B/FF"V3'DOV#;[Y\>BS9
MW_6R][]YR?Y.6MTN$L5JLPZUQ H%C$N;Q"]0WAU0I.:<U+.XNA0U?-!3L%(B
M?4A^J.!&L-A#JVG1YY%)UM)>2LIPPJ<-I^I0#>M:ZID@DQF@#/[/RPTR=OY&
MZZ*S7,O";!\9.'N)GN0RS)O-%TH+YJUWY'+!24>%2D+F,?\DWC">-4[U)YG;
M28JN(^B")?ABTEBEWJ]#X2YI8 @!T-8'GW"^$:BL"NYH_VD>@I>>P:P78+V]
M\WV@.4/?:FBSNNEYF^*[#79^#B\_?*(>S!18.%"'-J\=WE9*R5E"I!=?HFL<
M_5P+SJCJ^"W=5&[O0R,NTQ5CIP95?$JE"8F=P@FI7WJM<L+K@6O(G:2#=72S
MP0+P#^5_V\]FVWU"!UHBP9K(E@_K#V *4^:GH<N<=#<G#5<NBF?-=!C532(P
MUB[2]AHIN6D#S@QE_3WQ>-]N6/J);=\"\H^:L8#=1!F*R_K#/N<0;NMJMY#G
M6.J;B\IC2Q\U]H8N&FJ9HQ1>%K>*V1F9\+F$Y[B2;H=+)YJZL;GODQ9]D16G
M7-XDS66SS+QJ]SH9F)8A/LRI/\Z#H)W7VGP@T:_4*>:.NHY80+%\S)OX[UX@
M#&YB8S,9-#%F4H[0BFAHX-09J;4XAR@A9%;'3S@Q4;JB!UW"8[T7P>]DDB=B
M<%#K\H926=4J24,IUH?G9^+D"@'-\$AY:SKP()1U\S8\^J>TXH5.O.S#MN+5
M-VG%"_,>>^U:;\%<:U9@Z+KCFB.5R>Y>G#P#]CF\AP;LUC?FM!Y1?]^,U?K.
M#=K!2G0R:)""1/,9/$5X97[9"_N!U5S7$EE2&TO@>>JH:OWB?,\UC@X&Y.S'
MYV=)$8%@2^[*@$KIQ-1"-5_$&9I_X9M^_?US.#LN9TES)QC/D6@!BHLCXA(N
M1Z,O,$NI+!A,V"6^2.IJ3AENC%]XXSB08XAM[$</(4).Q2<C#6O%VRT;/3*)
MIHQKU),F7!WQB&6EPTT4_HR1=VH]9SYV,<V<ES/#EM%<$B*P-:Z?D% 'H&*
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M%371^/4,,T+]OOD50X7]7^7(IM#"X'R3U@79)OZ'EE#-7\3FJPS$EUT9IO1
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M0I ,;QYH=01A7(3CC$D,B!V)"%6:D1YCJPK2G4@WY?:6G[1R^>-*NWV[@E-
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M]+DC\GRRR1VZ\QA2#J9,G RPTPCC_&!;#358*58OKPI2 V7@=E0I7?*1\RE
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M=N&"4X9?2%T%N=N;9Q%$\"J&/=/I<>A)4TNOQ!E3Q&%NK_!,Z0RZ(V!W&&G
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M=5<]W"TW>!7). 3M_ST<P&6+1L[[ UM39S)=W3F-&BEO=2FF@.VR81!L:<N
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MBT!^2LX5_JT%5@;O[@7L+ Z\D5VTS%5;\^X:;QM6DMTI>B+AH7%)KHA>@U6
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MNV7TR<T 4RW4N:A^Y?,]ZQY1)9:.Z%1&CVDUOLO@S5.&10K&'F-/*#R<^D:
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M5)WM?*VSLKC::G[HK)W4!'717D=M\62B<%);?" T0P7^XSGK4*L EI/[\JP
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MU=Q8'RUQ&$-JY*8L.GOU-J5U429"D-8GD]8IDR!1L82**) *E0 JL0!2) Q
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MZACE"UZ/J^Y-H4;BJ:R.\8I_ZLC>8+UGML:+7D94 _C< WQ^S)9!Z#A-'-(
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MIPI2I+%5,=8&&DV#3;1LP#!M$R$=&T04!98*X7P>JIW/8SA *DE3*1S%8^Z
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M@->E$.$ KX$V@3:O)^T>5-\"5=],JCTA4 L50V )QX!2S8 R-@92Q)9#9\=
M7W96+^47\NSASK>>9W^?%^[77J2'16%[^BP:%.YAG:HEJ;QH]A72[4L2.0ZT
M";0)M FT";1Y$[2Y3W]_KBFG:1HC0PT5V'E=4J@40JJTP#95<WA;-S3ZWQFT
M;>%[?1:V;7O][*>MSBX?&1<;(]MBSYL6U3C7>V;OTM"X;"K:LH.==$^>?LJ+
M\L)@4&1J.)"J8_?R3](]9A"\M?MY:_$U1Y] (YBAG( 820(HT1APAA'@&-,X
MU00EJ3-]9UOPW/N$@"#^M1'_!01;@O@OI_C/M"/A<2IMHH!U?  H1 IP%2<
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M(*0A#'*-%4JQHLBDDAD.$^UAT]C8L)M1\X;88X#/IX;/J=R.)=@HA @@&A-
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M;LDN5RF6G:UU(LFQY6397U1SE6!3A!9 6I9^_=L],P !DKK9NE RUJHD-DD
M@YGI[J=[NI]F(8U$KK6@:4:Y3P,1*AZ'0OI24*.!@D8#!8,&6@L-=-;70$+%
M+$M]3N(@C0CE4A,691&)$A'F7'$>Y/FSEUDX"O/E;L>/F=IGK8';G-S*G-94
M"@1/%&/E31RBPT_QSP(CJK-:2:^8>.5MNTZ/$M@_@'?T*.?I-AV@(%]'*=I2
M)R YA:.EGDB/'2-%W+GYX,(]\X28_AZRJT)W\N'/8^4H_#8[:S!8[QM9[P]+
M_H/*?1U%-" \"SFA.@U)CG]%TM: )EI%OGKV,HYNJ^QBC3R(GUQ>;P%\#_)Z
M]_*ZB+9!)#,5:1*S1""%KB!9J%%H,3DK%"I4P;.7"5V&VH^^K>P:XP23GD@X
M0QB-R5)J4G\_1'ADA$</VG@)^3Y^QVE_U9GUP=^_/0WT<0DQI(&?!CQF)%,\
M! WD,XPX:B*"U$]5%&>I",'?'V5IND9-EP;&LK7$#(, WX, +T"(/-%QP'P.
M JPUH90%V#,M(H(G:<QY$ L\,@C\D>\O'QFL;=NT)Q!M>'7$)H<*XW":%97W
M%=L'8M+C*:LJ-IEZXX+Q8EQ,SX;(P]W"BC<P_:9YXSR*NJ?_L:LPG";<HG(2
M+;J ,9WN;+T^/1!^S"*N.4DS24$[86@B"C(2<QKE02 $^#:@G4;AK='G#"&)
M2P1YOSA6M;>K3KUWY3&;/%J@<0.1UL4W)<FYJLI!AJ\GPV<]&0X.8IGG/K@!
M>! H"0UC3G(A-=%<!$'&_83YM&4Q7B,I?OJ!BFXL#J&%5'SJR:(6\%93<\)1
MU/7,,*B*LIY>W"3DY_1_;AUI=-=C3[^Q9723PU<X]YL3N>569@ ==P(Z&H\H
MC .EXEB2*->"T,!7)/=E2/PLC&B22DE3\>QE. (<LD8.T1#26$ND,8CT0V*0
M1J3]6(5A@I1R*=>$YJ$)=\0PORJ7(8MT%B$S\2C-XS42Z:<?X]@<C\M3@R]@
M]YL:_ZF>C4V-^6SRG7ACB&Q<&V^\K<JO10U/?5-66V[R-\4JA=3U@@9== -=
M=+@$+R(6R"P0&8G]!/F !24\H8)$$J%% MJ#B75TAYYL4..I9#E?+LV#U-Y,
M:A<S+6*I9)C'),^#@-"$A@0$-"(Y#RFH8<92'8-3L"YE%5= AX8V ,:I+I?O
M^_KETP^V_,$PI1J>Q2Q5B/K/K#C!R.,05;E;E(,3CX4?>Y/W,/5[&O3D"<S'
MV=LQFTQ?-ZLPX)U;T9PMW^*<D#;*1)QDC(/?A4EJF5 D3[4F<93$/@O#,!?)
MK0&>(:+R! '/]\GS(+<WE-N=OMSJ,%$RRRBA+,Q!;H.$P,;E1/BI2!))%?61
MAW\YK^LQ][!;8P!A$T+JA<JLNE;3VIS5- DAWUVEM7I&UE#]_$"5UG6]TZ<Z
M3[>)L\-X7<L=G=>+A8ZJ^(JD: /(OB>VA^V)J!2KU9:R_]V>-*OQKEV,X;#C
M%@WWV1+@SEDF4JT 9DML0!LG(<FS4)$LSC2LK\@2SO"T(PZ&G.Q'(=@/"K<'
M@;Y_@5Y$XK!T?BA#HF22$BHB19CFF$'%19Q& 0URS-$.1EGXM#I*KS?,^,.D
M"QKL74Z/5-6!&\/1Y1T%]<J3Z62%2K)+ 2NQAPLQ5TS#,>8M*:7S)91!4T7#
M/-,DT!$V4M$YX2*EA*<\3D.=Y5+ZPSGF4Q7HVS_&O+ED#Q)\0PE>@!6*!2S7
MX!WH7%#P$WA$6!@*DBF::2[#(.?BV4OZPV5?:YJ3O;:XXFVE3E@A/?4-:R!5
M%V'8<-\0S+CC8,9*750@CP7V&FFUT:99C<'YN44MY2_A# 6@(HIS0!<R]@D-
M(Y]P6$0B6)X+K7TFH@BC&7FR3O6I0S3C$:&,0;+O1[(7\$>HN=*42Y)+!AZ$
M .B1^Q$C-$@HISK@'#O51J/XQR'($-JXF8QN3[ZJR;2LAN+RASLW:=:@6(QB
M#(KHAQ11L 0Q>*B3%&,7+-(!JA]01%+D1$0R#3D+<J%"K/BB^4!\]R@D>LT.
M3 9)OC-)7H 4.8^$R"C#G"5.L.$LR6 WDR0(5!JE/))9@I*<!H\C4?MI!#3:
M?(P3=O:S)&.L1^^-BP]OW]JE&/31+>JC< E9)"SRI>2F63(@BYS%H(^"F##I
M"\$B25.EC#Y:EX/;(6ZQ)G&+08X?5(X7,S"B5*J,YB3S?63)RP.2QVD"$QQP
MG2K*=>ZC',?)<O?S(51QU^"BFJF5IR6=C.B?(8ZQQI #5^C/^6H,VNH6M56T
MA#K\D I!,TE2C94;RA>$IWY( JF#),]8E@?@!>4CWU^FNWC,7<">HE"O'>H8
M1/E.17D!>'"5)BE/,Y)P!!XRY80%.2=^EE+.)8\!>>#I9_+C[+Q#^?E3+C]_
M=55GKQ\)RES8SO?1J-GUP$Z[:HKK9)@\I)*_GWV !=N>M#VL-]O5&M3N+:I=
MNH2@8AZ&*E Y"7R>@-J- L)%$A*FP\P7OLQ$SK'V=93$R\3#-P[<7$]\'E%(
MY]KMO9^*2KC3WJ6#2G@0E;" Q*B689R$H -XQ@FE,?R)L81$09S1+)3:#[-G
M+]-DE$<_XE7=5((>.#:T?D '#UOK6^E:ZM[XVMIY#778>E3*/[$9_!DZ!K^=
M5>*(83BUU-Z)8U@QH=6?BK?JGMV"!4(_=F9:-N^7FP(FO5(]IIO-B1S(;K[/
MNF\ODU3%G#%?LIPD0OD$;+TDG&F?!$(SF7,AI-8 ^(=3VJ<DL;<>,!TD]@XE
M=K%ZC8=*1T% ,I4CIS=-"*>I(%SEOH@3E=,(B^*?(C_5VH*&JH0)D[6GJ_*X
M);J\1?3P=,]N[H+;VZS%&UB*%3QY?5TTU,C?AH[ZMH0J0A4F,</,KQ0K7$+I
MDUQSGZB4^A%-DEQCA<M0(_\T9?KVX<5-9'J0W1O*[N+)JQ9Q&B.!EI^EA&92
M$)8G #>X+_(LX9D,4FR,^L,=0]8TF_P1'&,6*T)]=W*,^52/+>[])+,-SG:/
M+09-=1--M<SWE_ XDXIFA.L(/2&=DBP4C(A A8)SS;0YK+R%V,6=GTH,9Y6/
M(NHQ"/W]"_TB/.$ZU4)0<"BB#%N:Q039/4F2IS$%=X.%00Q"OURPNGY"_V2/
M(MMV?W=^%/EHS]+6Z33RT4[B3W$@V8LM3H]4&U\4Y?$Q]M69EN*+B3&>ND;>
M/\,!Y;J$&+==H^@]_<HLQWM<C2$CZ18AP#(SEL^TC&4<$95%$:$1-BKF#),4
M Q$D6:P#!1 @#D9^EJQ15=IP>+GVP<5!FN]!FA< ?:2"D.LL(Z'&-EDR]4D.
M.IK(+(V2/(A2AAT&:30*J+]&TOS42CT>W8"?X,DQHKO"J: EA <OJBI/'9^,
MRS.EW(<G+EW-@]F;#$?+=\B]WJR4[IB)LFLF/N#ZO';+8SYI<@GQD&JP$S>S
M$\O%O2&+,\YR10+A9X2&3)!<TYRD>9+ZDLHLYAI07_S#1 3#>?*:"?*M0;Y!
MD!]$D!< 7\!%' L:D-B/8Q#DF),L31.B@BP*19@',1[;1$FV1H+\<T::U#=5
MB:(V6,3B#9 @6(@APG2?26PX\7MVWE^[!9&#%KJ9%EJN=/7SG"9I*$D:8>*[
M8#[),B5(G$C!016Q-)//7N;K1&LT!)#6"DT,PGIWPKITZ*NB*/<943(%["]C
M1CB5FH@0,$.2L3S3(4"&?(V$=0BWK"'$,5ETIL>,+BM/M\?4HJR_\]CLD7E=
M:U'7MZ?;!(%7./&#?KR9?HR78R,9S>(\B8D BT5H1BGAB@.L2546Q)H&6NEG
M+\-\V:4::,\>KX#>61G?(* _+*"+17NP52*5^2274A(:A"GA21"30"E0JN!M
MJ"P' 0U_I&AOX#%[\@4 )R[#U.-G'?0R% &L1=#F@BS@5I4.C$5WH6QWEJL/
M.9<1S?R0P$J"LHV$3S(1*P(:F(=<^5$F Y,?1*/;R@\:"@0>OT*X=3@U*(2'
M4@B+*48 O<(H9X0S&1&:*TYRGX5$*9KH* CS6 <FQ2@*;RO%:"@>^%Z)?:VU
M$E/#OZ2^B2,V.51>Q:;*LW^&+R:>0#"$*<_F#\BM\!4DY'M3GV^:'_]$]-VM
M R"[<GOZM5NV=[!J>Q-4@?C/Z_DJO5/UM"K$5$G\8G,B^Q]T?CGHOIOION4B
MR3SQ?46I3_Q0Q@0["I,L8-A[-).ADJD*L^C9RV6_\_O.VM<&!]UBZ.AGTPNW
MCH,&O; .>F&I8R!G-&4Q@7^G2-$2@UZ(\/R;9HK##H@T?_9R1;O -54,MQ0!
M6C\\!%X$2I=I1('D#PAY1DO QZ"AJA47\_U/'PU:#TJ('U)T;^'%2[G<D$2,
M9[@$795JU>S@2MZBVCQ?YLL,PY!%'$FM6$9HD@:$AUH1&NM,I8'*DUPA^]XH
M3.^2('\(*ST>S7)WO!.#9GG,FF4!D/D)%7$*JH3'$=;!!0GA,F$D9'F8AG&2
MT3!]]C**1LF*7HOKIUF>;'SJU;7QE\>F'E>'Q62"IW3("&I$[F?(,[J!>I1Y
MZDLMPR2E@LJ$9WFL%>>Y"*CTM0P.MJ_G9?Z@/SGHMEO3;<L5^Y3)4/N@V[*0
M FI*HXQP%?M$Q7'FIS[C-$-G,_!'<;!.O()#HM)M2#C-F4KS1+& 9F#C@ESF
ML*!I$B<ZI"*D1L+]0<(?E80O'K$% 0>7*"0BC<$Y2C@C+-6<\)S':0@:/HI#
MD'!*1T'ZPVG:ZU?8]=AABL+>T1<!E+OUZ-9CNO[K[E[Z<2MO!?(J0L9H2A.:
MB9AE@?+S7 D=QRJ-F%'>US@<')3WNBCO8#FHE2A!*8 R/^:*4*XDR7B@203_
MBV7LQZ%.L19N%-+;JH=[+)&M0??]Q+IO<$V?H.Y;;&\9Q(F,N"2)I(+0B%*2
MQ[XF 4U2CLZI5O+67-,A^/:#POM^=G(R5EBDPL:>+&HQ+NM99<F2$,KJ<7GJ
M%1,K,;! M\4Z&\%"R'+&QVIIG7Z$DO66:5VO.\K;K):(-QY!I6<!2AV]GA\I
M!'Y*!OP)V>A;SV+<=GOE+6R>736<>MVF^5UF]?)YD H9:B*B +E<E2)YGDF2
MAPE+ 7WYH>^#^8U'?KY\GO[HJ3@&_?/H]<^M9TL.^N=.]<\B&9GDFB5^1D*E
M**$RS GCR"HM=: C&H7"QVY7&+9^1.RS3Q+@P\S;</7M])1XE!T/'L"_>)3S
M]#/P];W!AJ4>JVLU;7F :^^TF!X5$Q 2 :\WK<$'.F/H$.+!#WQ8S> :]>U$
M3>KE<O$!CCQZ.'+[5>U6Z^Y5;UDU=7\Q3;[K L=B-N$F[L':M?Z6P8!*;H9*
MEOE\?"IHEN0^B3.1$9KYE+!0)40$?A0I*<,XT<]>/D%NPD$#/7H-=/ME](,&
MN@<-M. 79;$0,J 9"1(M"0U%1'B8)R06IG#4C_*(XK'(&JF@GX' \ TK*N\K
M&\^,1]0T_#)-(]3U\W:NFVJX'N]\?66ZZKT>MS*]=3BW*3_/ZJEA>=LO-V&>
M< 1LC,&F[<DK=E* W_V/W5;;9E/UXT\:E2TY5U4YJ-@;J=B_3I= G@ZXH-(7
M),D9J%BJ I)C_#L-DRP,XI0GB4#G%OX2_K9&*9.W%(,8M-.CUTZW#O6^0SL-
M6NB&6F@!Z"51PF(_3@D-L!N'DCYA@@J2)KX,\E KF<AG+^-HG=KJ_-3TE&L+
M3?MLVD,@\N<. ]QN][4MI54%GOV>AO\VM,3_;.,.VW0;[*W=7["]-NWN>NTV
MUV C;F8CECFDN(9%\].0"!T(,!191'(5)5CA$^I 4I&D_-E+ZO]PQZ8A(#EH
MHO5%J8,FNG]-M$B2D&N6YS(B*I4AH<S/0!/APJF,A7X:^4&</7L9!>NDB7Z&
MN.0[)<K#B7'7,#!I9H64FLQJ94^H;>7AV)!8C0O&B_%*PO(A*/#HU>VMARS?
MX3CV](=:F5.>/3YE,#ZY/6DH:MZ4U=Z)JM@49O!/W&%_N@UV-BC<FRG<9;XK
M&B=A%"6,)$(EMDT>US0B-%%I%+,X23@HW-1?I_# $* <=-$=!2@'772?NF@!
M_.D\9S0/*(G]4!.JTABYLA11DNH@\*-8!J96X+;(C'_>4.4O4W1@X+^R^/KR
M?^!?S17'K#HL)L2^XZ\9R*O[!,O/LK[Z$PHSV6]',P3^5:HA--G#2IF XS$\
M\0Q#D9-RJFIO6J):,&66#%DO7.L<-H91P0?'/>;XQ5=V#Z"AA=XGI4T[^;52
M8Y#RK^JWTT).CQK=U+G039(_OX1Q&,-L>O$E#SM[;TC>GX7NOW&41FW1..""
M1XHA@;#.4BY%G.9ID('_Q2*>'011]*RYZJAJAG["#A7AE6)?"-/P9K^R\2D[
MJY_]TM]?L)6:,06A*2U<G*L+9T3K6YX1NYG!')25+2:=86=X_!6,A#WP"+RC
M"DW<_[G&>H!2W#>A=_#,7J%Y--N=O;QPR]_7-DQ7;D-LG[M;UFIDM?;V1&RL
MZ4AW&^WRJJM=WK3:Y?W5VN5A7^!Y,?&F1^4,[B'K$?;;4%B/?L0J>TX#2,;]
M#5Z-O5BE'6Y@'-RKO?P?7OVR8O-=5[LDS[[_V?<SK<&&YT#J[NP8;B%NP4->
MR(EDTUFE]K3#FK#]'AQ4?FQ!Y0X"N^/7 .H ( (XA/L>?SS^>+:' ''K]>G'
M$(#E_N_'>Z]R_]._CWQQ_/>$_9//]CZ+T]T_<&QOCC[!^  <GNZ&GXI/G[=C
M (AXS>=/6W]]V_GC(_WW.8#2_0](8^_G81"1/*.2T#2,"$^XA-6D+ T2K8(\
MLTY!,9DIN8EY3"GX C23"@GI:,9C)A,:Z!@,3HAAQ>29IP"JGZ!T5C/0]7O5
M(9L4YV:>C5ALP?=5<=)$NWZ?U; %ZKJ!G6[1+]:O#[195UM]W*EN?NP;FGUT
M]1SUYS2)P+/R$Z83Q2F'2RD702)S$<<ZB&F^4JU[SZ='"I2G@6LOO%-6>\4$
M;-T)FCO0I*"=M@!EG:("@C_OL#,/Q<(#M86*"@;[PJS'$5RHF7 Q1?SI1U;)
ML3H;>6_59%*?C;_" C+SV]>G@ M'WJXZ]?ZEJEJ=;7C[\T'\=^V=5 H,+BQG
M67F@D<%S&WG-V+W-]R,S3,R)@P$:<^SA2\ H3<NBW;("6(-#> \C5,<<O@]A
MV3:\[8D9?.]F'E<"Y-ICWNE1.1Z?D?(4O$FOGO&ZD 6KSO"6G3GR&)ZC5U/\
M&/:'H368@*&I5-G9HQN>MS7#LPD/U<>H>P-X/U["W. -9%$I,2VKVF,GV%@2
M'FS>I/C/#"V9V]RNF;T9+<X?_GV"H__P_V JC@IQY!6U.<@WA')@#+GR$(&/
ME5M"&$0TPC\8H@K\15W UX4^,\]KUQNV>S43J-?@!8PL=;?E#:3IHCU]Y1Y=
MU!,9%S*0B8[RA"+S3RRHST(6)K&64O)[%=/.)L4)!_@),PYWG9YY)V"ACYE0
M,^.&>L[]@3TJ9C4L03DQ\RS55S4N3Q".V-99Y3&H*;Q%H]J0 + JY0R[;R%K
MQ@E\;$@#IP#;I[;KJ&+5R#/KC_>8'E4EFWK/7^_N6TEDX[&J#L^:P17UM%Z4
M+UU4];3S].:9(^_?_[NY^^IUL\ZW,+6)<2"N!-G++AWJ81*9JQ>]>U8KZP&
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M*Z7C2-)G+Z,,]D2RM"<N/BU8*[NPX-#7,_X9<29 3N;!WD %:#+IZB\U!DP
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M"=VKFA1/A(<6BV"-1K= I2TQ*6=3G#J,'+0GL>!H@OHPAUL&"9HVX/B+^=P
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MW(]SDH5)JB,E!,WSI3*B1(1Q)  JQ9H*EC,1@ON<:IV(*!/Y,H0T<W]%#='
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M/UB@S9JP\1GZ_)<5]G98?19M[&B%-]'X(^;0"1V9>>RB5VC;"S3/QK(-6+A
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M7P5@O%43[ITBJKF)E?G!]A;+5J8SK-=V5(,1N<B([.Y_.3]0L= IX'F2YC0
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M49SE22"D"++%]<XC&K/43P,6*$HSFOLRHS+/-9=<AF&VN-ZX()Y9D2ZV6-$
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MQ+!+.([?+N.=-&T)-FV/A%&7-!8I"/NDPMWKS(LL<'4T/'A=BE3SNU5CL9.
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MYG:&%KI8;+#1Z0G1#W&L"N?A3Y958!/).)\WKAP;?8H\UM8P=]L9S:TYMIU
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M8Z@==;OA?OS@N22F/ $_&,_VNSS9%<XL#V?>S_$#KY7U+'@49<[QQ\$A9UQ
MP7E#5922)?GB%=U0G*Y0F$:54+:2_*#2V\?3VQE^H)P+3#*!#  KXI9)I)TR
MB(=D&5:@M407W@6Z2E&;S]:!L-<=V%:M>1UD<S?N537-KIIF/R7!>M?K5@;<
M,@'ZTQRQ$H)HB25#B@>6W;\$62(#4C()$D7P. "Q,AN<LV?3Z?J)RFM7:%FA
MY5/2V@HMEX^6,W36\*@PD1P12G(-*4G!#%4>>>.=L41HP<F+5X1L:+ZL M\_
M'BZ_G6RP(DD"WP[4;<9^+;<++KJ[A]PX/L?JMKKGL9<#=WVW/ZAU>[5.'-1Z
M$>;@L@C9+;(]BS;V$VW<0:EM+35[_0%J=C9&OW6'@YK+[79GVD,O[M1^VR0,
MO?))&/+1DS#^ZG7/0#@O_FK9SF"K$][\9]@\RU5?5C$IXV@,:@!F^W@WMR)N
MOVTU ,P:>W^<['[>P;N?/[0:)UOG^^U&NW[Y_F(^4OX3/SAY#_\=M '$ -1@
MS.V<T/1>'&0PW/X=QK-_V=C^X_B?R[JH;QUR'P)UCB-K<69PVB.;J$54FB2H
MBXRS,)N6(10)*CJ6;*YVRBU\BLI$&"$YPU+BV=CZ\2H4W;>OEN >.1K?O?%2
M.G<GF3!+,3@C/%S56Y;E36KGG ^1R"?%H*FYB^.YV\A@LS&5/_#RQR0,/*2S
M--N4^%$R!C#C2\\8P)OB<=I@,VJJC(%E9PS\ (OG^YM>\62+>=Q= O47,+-5
M7,*')C5,/N9#\AK69[I^DM2&U]WVV1#F_'H[*S:W?C<-SH%F5\D.56CPE0U@
M0HB.Q!2=4AP,'1<##<ZIS-"D#+=V"M]H"*R5V^-^%L+([2$:G_\^;6R_^=J@
M[W'C9 ?OM_]H[;?K<(]&J_&NSG<_@V5P^0DW7L^Z/4[)P>?WN+[WAAULOZ?U
MDP\PUK^;^Y?P//03AG_%P4F=-?;>XT59#]PQ3H5+*!J<<OM9@RPV%%DG0^38
M<!=CSGJ@^,%.XBKKH8*V=8$V+QBE1@:OB>#",\-T;I$466 A.1)NZ\&MH.T)
MH6W&H\N8Q\8[A5)0N3^L5$@K99&7GG/KK JZ2.@B:FV@[=E&+[P=]D 9A[U8
ML,T$Z@"_5UD0,\=*0=K@G4@A&&ZUMRE[OX('<99<X;0LOE7ASAUP9S[A@6?V
MRZQ#B3.,.(W IHSC2%M'A>*6$4I?O&)RE<*FJW2'92BH#%))'KBAR<(.PXU5
M5HH *ZY"LH8OBS54"GHW!;V8C3C&Q/I 4:16YWA%T$W'(F)8*DH#9EB(55/0
M9^MPJEM_#"_V9@Y1J@2'F;8;7C.;ZY\ER:.P3DGAL&,^>HP=UY6K9=5@9S[1
M@1$OG,<,!6P]RKX5@)TDD#=2*8,YTR9W*=O S[',[4^NOT8Y#+R=&6]RH!'1
M+CL7*#%4<<Z]J/P)*ZB_LQ%BCA,2C$5) IOG KB#"2H@F\,;0A0"ZTP;-MA*
MZ>^S=1G\&6T_'G=;H=9LG_6Z7XJ&497+8"9NGW'%DW-26<$-PX;DEEV84'B9
M)*,JE\$/@);Y4'T=2<)),:1B"HCGAC8Z\(@49V _2C ="5 #B<T*6225RV 9
M"DJQ,V!I"H-]X,Q$Z[4B!!8].@XF*JU<!C]&06==!A+K( -&!$>*N&+ W6'S
M1T$ZJR(F@5&[:@KZ;%T&K[N=_J W+'6KV:D]I&;2\S4YK(T6-A)GJ/2<$F&5
MIM%BYE/4.5B[VOI_ ++LSY<_B))1X3#"Q!/$4PA( UE#Q&*O'66,2)?S3L0*
MV1253V 9"BJ"EE9'*XU7G"9M/-&)*L*,YU%%76W]/T9!9[9^P6D@.I_D!=!2
M3JQ$CBF)L,<$*!H3(O%54]"'&OT/(>D/BXM:/S5>5FI\Y=I[*AWW\T?VV!MM
MK$6@S@IQH?,FS!W*3(D'AH7)49!B@\EEU2A<F2C(2O-_>)IWI?E/J/DSN[MD
MW'A',4HFTV\I+;(L'\])D&@O93!,9LV7;&TT_]G:_7^"D?^R9KT?MH>M(ML[
MQ+,>*$*1'_HSF/^__ !>LG4]W]L3TPV_MV+^!0!KJ]V%B;DL7K\1S"H<6QZ.
M'<UWKTB>!:D3"H(YQ#4U2#OAX4_N%?%":TERM58AY^V47RL?PMIJ^;(X2*7E
M*ZGE,VR%,*E8B I%ED,0;#+("LR0]RX4Y3=\KKG(-ZB>3VGX(5J^;$=$59BK
M*LRURKZ:1AQ4('<GD#N=HS)$61:TP(A*ELO)>HH,+!M2W!*.DP4Z$UZ\4N;!
M#M>5*<-5@6,%CC\>'!_=G56 8T4/EXB<,_004\T5QA1QPH >*AJ0#2X@024F
MTH9(3)',SYYS"</IHGRK4F1O<0&Q25.K%K^>Q4X_ULYMO_9?=SE'OD\IOF\I
M\.2HUEXG[U^"[\UY?>M0,QT39@IIRRSBCH#%%0UH&'"30 QF@JH7K\0"[_!8
ME6XI37O-=NS7&O&\]J';MIV'R57MCC=?@BCG[*V[2*U5RE+.O$G)<Z6YPV"]
MTN@$]0$'SPNI)6.IO<6V4TGM2&H;YX<>,$" 9"*C-4.<*P+R:T"(J??!<&Z9
MSO'$?)Y"Y_VYJ*!Z$6VO7XN=$$-MLN!;;;)TV$\DVUD(-VJ]V#^+,%-?8NMB
ML[;3J>4=+$_<QM19Q!66=].=E((YG1PCCGJG>")&2]B^G<3!40,V:P7E]U4*
M43\ZI,$')2)&CCNP*ZG1R%"O$/'68JV)9]J!4BQPD!=;LC\&G@#*,.A>=]DH
M<E;OL+Y8^^2Q%C1HQ:ET-B5"4C2<1*]<LM]9WYW&VV\O\"2Y3LVO,:#+V.M>
M+3S^Z1;^O6AL>U[?WKFLGWRBC4M_J(1."8@P$DX2Q 4%*1#!( -;#[=>)9H/
M?#O=>2&84O 9B8!WSBPPVY'>]PO!Z *.]FJVWX^#?BXU#6 PAZ0;M?/CIC\&
M8(%+]',&TV(@Z<7RQ!/N=5V9#^2PV_H"KS8[!68#M@X3#'?8 U8]#HM>9MUJ
M05:^;K5Z]+K5^1@ZQEVP<6$".T=%'EI_92I5[[T9J]@%O$?V3UJGH&*G^]FL
MO/P#[E4'DQ3,T+VL%I]$XP1,U3D5VX%Q_-T$5005^W ,INAEO;W/01TIF*$P
MSJ-S4%G:^/R>_'.Y ]=X?VBMD($KAU)B&G%@&4@K%I#&A&HJN$Z1SI:J=CX"
M 83WO4U<1.\<XQ$^QZ1,/@HW6ZJZG.EOEZ;^\6*YF$(LKF;]_1F8GK$0*!!E
MK!GFN1>GU99HV#8 TH*,U(07K_8 !G(-3]NYJ+6*^0+824T?:_"L/F[ TW9[
M]FCTYW3-A=HO9SW8:7KPS+4O$6"I%?N_;M8F+QESX7P HCX 4B>>VU:M>Y8?
MIY\+[Q?W RSRL7BMJ*>??QYU,QP51?2+&\(G6L.PX!J#8[A*$_Z?W[+];@>L
M^HN:!_/?9H0#Z/L:>[Y9W 0^UR_0T6=8+&^=*_GW 5!CI^9;@+O-=)'O/)J'
M?.LV_%JB8_F-5M.Z9@L87.QOU@KYJMFC7BQS26M',+Z>;<$80K?6Z>8. C!7
MO0RT90/[VA>8K:*D=WFY,WM1?+,@BLTP+#[1&L;:T=#V+,!07HY>?G, HIMI
M)"PP< EX"^Z_R'UQ@VR/9(OG,N!GW7Y!05\6>P1<\[KZ]W]/%UT?J0*^_HIU
M_6YK.+CY*W/%>)]4:]XB8F:VKXF?Q[WKRM)'$3F0F5-D$PSRI6V=VXO^BW]/
M P+H_OCRA&[FN9M][!L?+J4E/USIY@)NU^T5:_UR"*96+W\*1F)_\ AJQ[V\
M6_[K%I0  ^84&@#LYG7>:8LD;'NSZ#Z51"VF![L -8UN/VZ4_LZ=CM]<T9$V
MNAEF ?1RNEMVFQ;\[VT3P,)GZ/F8&YY,Y[ROU@/\4K#2[A"N$0 1X]>\+]3Z
MQW94Y0\(U.@O>#3[ZR(]7[AI?G<3G*,9/  W(9:1P"T)6M(0>0J.R!"34?=I
M3/$(]!(VP<[+K<)8V.J$/Z\WII)O%DKV<[/,3X=6)<U=4DC&Y!!0)0PF?*[P
MZ8$R<9:\8G9V^:T@/%G&@K21<Z(-QHXZ \L?.8A!G&693[B]9695=@1QL=4]
MKUV9@-F8ZXX-C!&W&-N1H#D3K 6XA.\>=>"F1?^BP357^]]^T8+D"CF<;0%R
M /$[CG"=]>M(PN!-R=:D=0ACFYK?=T#?>H_I^W5/^6:?$[XI]>WZG/SXF25L
MT]Q2#![:E.5!'UWA;A:_CY#@8T:"VI_P?FT'J,0M^H$\KWFX\5CCIYV!GZ3)
M2:/;07[8ZV6?Q^)M]C:]<>X=JGZ+:]RW8<YJS._4G> :'C6_HF,@[K'S<NTX
M:QG4<]9J%-?-_/2/]L'>)UP_.6CM;K^AP%/)/ORW^[DN#CZ_^5J?#>II?Z+%
M,YP< ;\]@.N_OVBT/_'ZWC[;W?[[)#<IW;]LM?;WWIS_<_EF4&].!_6 L6,E
M81XII@UP7D*0D4H@2A@75!%ON*BF?*E3+K55'*N$3& !<>H)<BIJ),'8Y#)8
M@T-X\6IWXGCG"B^F_UF%=B3/+W#S;D^\WD&9RXI8GSZN^I 'LYL^]6/A<%B3
MJ,PU09/&ZVDT<9HQ0Z1!B3"!.$L8P7):9).*%A#&1*U>O*(;?$$XSI+[D*Q2
MYEX%:#\EH"TKRKP"M*<#M%EZY"+FP@>$D[$9T!*R@C/$4A \Q6A2$CD+$0NR
M%H#V;$LD[\[8MA-^XY?WXJBW+19376,YUWBV'I@2!LJ?KV_PQ$Q(ZX]VQZS\
M?%;F_[WWM_J<^0\FEB0B$B2*!EZ.P?Z&*4=!>R F(6@N9L\)JRE_V)3[W,#.
MNH1X48:)<(N, THA#*/>2N]T@"G?\KXWC NC;,?NW$6@\6@^F>=8?.2'^R;&
MD0\7HWVAXO++5+Q9YP3#4DJ+!?):@.)YG)"CP:-@),'2.,>+ZJ8;1BV+RZ^0
M"^(GU]_',<4K_7U4_9W9.!46PA$+^BMHKE\8-3)28Y1[&-JD*.<D9N<B-GR%
M]/?96MR3=LVW3ID?:ML\@N&YLG-:$>U[X\7[.:(MB!<R"H&8!(N&&T61"R:A
M*(*4Q#A)/*NF?*E3GKABWD2&2%(6<1P(,CX*9)4T&D>K",7CT^3EFB]5ZZ4?
M:+X _/LQ ZI(SITT:-9("=$2'HE$-$B%>& *.<DHTE$;(JWWTN9R!G19%<%6
MJ*;73ZZCCVRB3.IH9:4L48%G/:I18C!+(E)* >O0WB/#DD F6)Q+F6H>BQ (
M8I959;TJI'Y+*V7RYUYW4&3CKOPYS&-<XY9GT%7UQ,>:E?7>J1Z935;[T_+V
MIT]S!#,1YJD$J]BIW/\G6((LL0D93;4U8!);K?/^)(Q<;D3+&A2=K6"S@LVU
M)?@5;"X5-F=H/0E12&$94H1:Q*E@R"JND<?&!6QR>K4JVQ$LZ_#AQ\/F7+W9
MJ5)$*UV#**>;CXN+%35KFE^*\D"+<^#*WX^[K5!KML]ZW2^CHCBY8$.KV6X6
M.>471<;Y=?6=S=J-Q2A6;BJN\^1'!8+FROWDIVZ&7*TB3T&KZ9N#&DQ4W"@"
M3[+#-@*\P)\3:?>U8;Y4+D[4[/A>,6=@4X%8]KKG>8;S]W,QN/R5T.Q[$/+R
MHF7=HNL"13.+TI^N590?X!LWF"@G!X./_4$SERS*:STHO@AK!2^6GYT<_'EW
MV"H*- U[UQ6=?+<-=_'%K7)!DO)>^<*V70P__B=7.H)WKH5A7 FI* )5*^H(
M#/+D%H4*RE)0(%%EJ=$L.'EHMOSN=,4IF,XP&O1-3SLNKO>'[0QM[Z)6Y+(2
M4Y0RG9O%HL;4^(D"+'$S%SSMEJ_G2@D/$^&%%4N^6X+BQXE^^5&8" NKD>N"
MP1S;9N<:"XK%R>(^]\EIZ5TXV3<4/<P8LGX%*)395%RM2YD$M<EH52;A\<H#
M/%OGX.=;(<(O17WHN9Y2*Y,G_ZUY7BTK:6$=J;MXD[YE"(T7<ZM<RP_CI2S>
MW(.%)%,64C[J?QF&O;RX:VT3=<7!N_<7^WM_'Q]\_KN]?YEK#;\1NY_A.GL?
M6O7V&W*PMX4;%.R=N1X<<)_M/XX;G]^V#CX?G#1.WO/]O5.1K]5X]RE?LU7?
M?L\.MG?PHMQQI2,U1BND,&&E3:1S]GZ@@4M83V*]>?&*;F)^8R'39QTA-0<O
M4S2B"G-XH(>E,\Q;UE)\T_Q.T+(]6L8/L(I_Q9Z?C'M M *36X#)SGQ:A&>!
M1"V02=@A;N$WS21#BD;B-=8F>??BE=BD#_:O+.?8],GD_[_GP7*Y/8">OH3X
ME<^R;G,!]\%%5?'QQ!_&(+1QPB"B?6X&Z#1RV#G$J)-.&A>"9"M4P3%78^SX
M9BN6#AY0L!$LPH:7AK"NL=8& M8>MF?])+^,+-RRFK\].NK%HVQ7NXNB%<NO
MM:(Z;ZV3@XIS];96671WUN(^;PZ.1W6PP?)N=WO9OU-4X2Y;NHR]-(/O'?4O
M*"SYC7*2-UGZZV?E:[S)E5X7*U]N"D,K*[^R\N^Z@<*3LBHE<F6C0+Y)$/X:
M[1G;P]B .^^=Q]:76(=A'/=_AO/.[N4^!>K\^0UOM/\X:5QNX?U\WKG7@K'N
MB/H[N/]E/N]\SQH7LW2\<7*P]\?Q_MX1W6_767W[0[/1_@14_N_C_9/3<_CL
M2?VRU3K8]FR1;1],BDKF[$BF<UTX9Y#SPN5&Q5$H;H"JAR*,4<RW7Z^2K1X#
MPWCE,%A[#-L'6KIWWJW0Z4[H-.\LT"H*KWAV$42'N*<"N=SY429F.4_&,V)?
MO!)<KX:OX-GS*U'QJ^>!3<>]&"MTNA,ZS5=XX4ECQ;%$BO/<H)P;I"V1".,@
M,=5)R)!>O-*T(DZ/KW![.7*I:)15T:>5@ZBB#]!M\>EZ);_;_+4"KML UWSZ
MMM-6 [7"B+-<[9(KCZSW&C$OC=!1"VUB3JG2L*:_5=3J:;/7RHRUV[O9?S0E
M>UBRP\\'AG?E:Y7_:WE0^&D."IEFG&#FD+?Y.#IPBRS%'&ECE0PQ,)M<]G\I
MO2S_U].$\S]'CI<UYF4M-%,"AI /ZEP<G,?8F0;+F4/('.<[\>Z/JEI4$<='
MP\I/$ZO_YFON#[]5Q/!7V'@G;-R?[QFCN!%<8L02 6P44B.C'=BW4DMA*(?W
MQ(M71*N*(OX(BOC$10VJK-@J*W8%MH*?."OVJ78"/^_IE-H'Z3RB0JG<'B,@
M:ZA"L&Z1,.#/'J?G5DQ@C;-B[Z"6]XK\O-;/G<;;*2??M':^[O8';[N]-U\'
ML=.'@7S7H8?75#\?$!(*^G5TR)D2R>1"U9H(Q+U,2 L-3"NJ0"T3@;"4>WS.
M*=<<";BR>YH=WQJ&'$Z9/]C/09(QKT.82'D:I8[F].<>O-CM@+!?U#QHA6UV
M<O"CB_G*\6OL^69.6LT9D3ELL@B[A&O!2W/!9IOKD2X]VTC&@ZSFW%&8B_]Z
M.OU99.J,%.=Y[V@/T!C2V'YS2"QAU!.+:,A^&V42,C''"!!*I"!14L+SCF3T
M? 7%PB=PET6V2EG*F3<I>:XT=Y@33Z,3U <</"\6F8P7^1:E/:I%OL4B'QUZ
M$6C2Q"/!@P$#-'ED<(B(J!@4]5JX(/,B:S[OG)O"JOY-8%6(0EZS#4# _EF$
M[WZ)K8O-VF)XR$@Y M90Q*4#3/9C"]#E:&-<:Z&XI W96=\?Y&M\B=?=/1:%
MG?<'\,^HLL!5X0KXP&S6_GP6R*IBZ^*2 2Y7PPF<6$8"MR1H24/D*3@B0TQ&
MO7CUVO:/80=KEAM-68FA?SWAS7+RRGH29>F&!94^)@/^?SR<3Q.BL5N_4OL;
MU#[7Z3F,(FB3B$'81(YXXB&WAV8HT1BE$4"'(BVL#35?6O/'8WNUXG=<\9/Z
M8? R)L8IP@$#T'/*D,4)@%Y$35PPA)2G,%S.VY</!/J]XV9_7/2E.0TVU\B2
M;_6EA)3F=Q'<9Q1+K>YY?W,>LV^NQ#)"4)ZS@<ZZ_6;^^,M>;!4[R'424(;7
MB6^- !]??\4Z&-AP</-7YC)6GG1O> MJ-+.O3?S,PRPT@ OBO&/1.F=YTLH%
M+Y111%.L+'/ZD CU8ORMX]YU=LY11 Z,F5-4A)"\M*US>]%_\>_IS1+VQ?&@
M"-W,,SX[63=.24I+GI+2+0%(T"WW_9=%5ES^%(S$_N 1U(Y[&27_=8OUP"]>
M[94)?*GV.B-L$9M@7]TH\$\EAW-)4B/[;]!L=/MQH_1/[73\S8;KCQUIHYOK
M08']_GH2<]XV.[;CX>*UCU?HLZ(/\$N!F=TA7"/T-X ,^Y@]=L>936=8!I@=
M_06/9G]=A X_GNDN?C0-)/UQ\ZJW?'&TV0<BD;5KU"_PSVN2N]4)1:.-B9=R
MX8)6-Y/D4<.JU4FY]F-^\;5!=]A!^T.S_NZ@5:?PO>U6>W_O[Y/]RRV^6W*+
M=N,S&(+-67[QANV?A/;!NYWS@_:G2QCCZ>[G@^/&Y\9)??N(E]QB'[C+)_K/
MY9NOC?-#%I-7/FD4=:2(8V>1Y@DC$1+#F/%$N2]I(>S3,6QEEJ932&!PZJA(
MY%I*S;FEAAH3#2=&I-D,[7$CQS>3C1S+#BCC;K!_3A[0W5 HI9#VA>;3=P?T
MV!G^'_UQ#,-6W$VS,MD)\V*Y8JG^3R]WN^\/%96:Q,B0U@QH+;8*6(D12$BF
M"%4T6:GG,OU_/-0M)FYWZU1:$.1FOPBY22_OM#&M35Z]8IN@*LO/@(<W&5^7
M='VR:<CM!OO0='VSKCGX=TF__X%Q*-^G/!.!*+>),+G#">TJ+N%<Y80'/.9M
M"@*N_W21GZ/0Q.Q.^/(AX59+$Y\?4I/RQD$^VR#D^19#?_6Z8>@'M5[\$L%\
MJ-E6JWN>"PG='(9710/?.XULI'RC2=^ZFNLU:\U\/WMDU!WAN+'7.-[=>_^U
M?K+S=?_D".]NGX)M\K;=H/NL<5F,N[F[O74YWQWA#8%[B,;VFXOZR5OXS'N^
MNQ>:]<_[[.#$LWJ[T<S/5-^N%ZV9ZQ^GX\"B=YHRL)R]Y@*!V6F0BTPC*@))
MR;NH:6YZIC:,>7"Z1-6X<,74]Z%]32KU?7+UO9CI"25%4MX2Y!-7B$<G<M!,
M0-PZT.O$A7($U%=NB$SE5D9]GRV1G.<2'^\03'(O=E'5T;@-/(V6X5VY"+ &
M6U-+4('5TL'J_1S7"(Y*[:A GAJ"N! 2:<PBTLE)&6&=;8X"81O*F!4JL%'5
MQ%DUJE'I\@_0Y1GBX;&SQE&'F&;9;G *6<PXTE:G&*AF6,<7K^0&>7C5[ZI8
MSGUXQX?8C[;GC\MTZ?@EMKIG18#E@\C&\[6%EDDVQG,/4[]]/?,5+BT=ES[-
M<0RJ+0[*."2XH8B;X)$5G"!!19!*:9&D>O&*;%"S2A4&*W?&JG&,2H6?3H5G
MJ04)4F.C40HZ%^&S%EDF$L(2V\2")-&(3"VTJ,H4_)CC$7O1Z[9:E=OB<?/B
M1TCTIGW6ZE[$^#N8.ZDYJ/RJR\>@_3D:(9F*7"N*7# 8<9<"<MH%Q)/75"3J
M!#$O7JD-K1],(RI7Q8KI[[*ZO5?Z^X3Z.\,AC'64$\60<\Z#_@:*M-0,R<@X
MMMYR86/67R%7R=7X$[DGBCCJR@7Q. 5U\MS.QV]7P+-TX/%SQ"%%I93'%@D5
M9:8+L:RPIH43\+JW@9GL?S!DOHI!Y7]8;_U=%G&H]/<)]7>&.$3'M.;2(AX(
MZ"^C&/171J0=B=PP(VW,G9$W<.5\^#'$8?YG63O1SH3P/L0I<;N&[<\$M9;L
MKJ@ ZS$!ZVB.<!"F/=&4(1)90MQ@@0PG%DE#G1%"8Q/EBU><;NB'!W#>23W6
MR(GQ4^G[DMT;E;X_LK[/$!1,H_-6,Y1D(HA+J9 CAB!&.>8N$2$- 7TW&X0N
MRS7YN/K^;)T>NS=ETMXONVCTV-]?C'NE!=W6LEO^"'\B[OKG5#FSBX>X&)]3
M1>VJ)O9M:V)7.^S2=]@WYWEW+5GU)UZ_]!>'Q'$7(TXH"J-1KF>(@#,11*4V
MF"LAL;"%#T\].*=B]0[_*A!:>Q!:FA^R J$G!*'Z- AY0!<3,4.<"8.X2AS9
M[)),E%@<!262%R4SL:D"K%?*$7EC 9V'G';^5!Z*I9Z#5OZ)1P6NKW/L*6!.
MI"8I.R@\XL&Z7"++H:2CC5H:YQA>$GNZDW*LT=GH3Z7M2STUK;3]L;5]AJ8D
M$QPP$8ZH!0N)*V^0!OQ&P5@B72[PG]B2:,J3:/M/Y(VZ[4GJM\L"+K4-U$.0
M;S6F>;GMY&X['^N] RSQ!'JFB&D52?-D6\/%'!$T6%$90D L* Y$,&KDC')(
ML6"X%_"/!"+(^8:6RS)AEZ%,*^Y_J_"SPL_'.]&O\/,'XN<,M7:,*T>XS:P:
M?OA<XYQX8-J1DX 9;(^8OW@ER ;-54W7'C^GNW->]<>:*JG^K7Y9-W5$>/5_
MKO?O!3TK;MF4).]1*]ZRP#QZRX)Q-O1$*C2@P^MN^VP($_VQFP;GMA>OFQ2L
M3)7XDZVQ[E_N?MXG]>T/[09H>_WD%(,>7NRW&\<'G_=Q_=W?)XV3-[A^ OKZ
M>K9*?%T<G'PZ;[S;IXV3^D7&@H,3&"M]VSHX>7]^\+E.ZWOO+^I[ISAW_]S=
MVS]TQD6"G4#*Y"AB)R2R2FH4.$M,,RI)XK/M"6 ;T)'[G*84N"&9!3M!I93
ME21A8K:L_)]-G\VSVM91+XZ;A=RY!<%W;WHGJ9_4^)-A?]!,%T]8T/Y;;7?R
MCF6_UN;F[):=3<53MS+MU#[&LT%9;YR*W/"*F(W:N,--;>MCK8"XHJO5H%NS
M8)&73V;'3U;[)3>UNNFY?RUZ'8[?/AOV^D,+WX%+G1\W_7'1$"NKM^U<U(YZ
M\!;<:?1AF(/XU;>&_5RY;GQ;^.*XR2P,*+9:T0^&ME4[Z^666X.+JY9>OMMN
MY]ZS("27I1QV4VVW<QD'/5O[IV^;K7$_KD\?-VJO;<<&6S@@ZO%KTW=OVXKV
MJ1=LIU/[PX)F]2Y&+<EL+;<D:Z8F3%PO'@U;=M"%-^&&L3_H=F+MW/9K[3@H
MGFURMGO11YC9 %>X4YM#X'\Q"LXI0+L6SK"D 78"M8HY1>1,TSM,OED$8XSW
M6U/5+[9@_3M'A?SD=E!Y5'O=OV(OL\"WW5Y!%OOU\1..^^35[==F>]A^ ZC0
MA+U]34CCDV\<GM>/#JD/7#LKD#$Y[=R3A( %)J25"$SC"/^$?'8"(CS?->]:
MMD8MHW,KO&O!"MW8KW6Z90$H7^CZ2-9J^>TT[!4NOJMVTZG7;8]UOD#20DS+
M)M.@L_F/.5@9N0D'QZ!WO=AL.P"6\HVL_V.$&#L69Y3Y0=U0;]YZ'LK_V,KS
M/X(?G0!N1S=817I7'VLIK6\?M^LG1W#=_?/ZWCYN;-?I[KLW7_?W]GFC_>:B
M<7)T?O .-'>N"=#^^2Z\#N8? ZV':^;&F/M\?^_M,7R'[N_MT-WMWT^SYOYS
MF4V^-X=)8,&P8PBL;8TX]:"PN:YE,D0['Q,AT<S2.QJII(HQS57@Q!-'@O#"
M)^&$P46WJFEZEV=\H]:)@WNPNN_?:WILC$OFM?"&*,)#DD[C)'32W$>6>W6N
M< ^C*:9$:,F41MP'A#6W^MRV@_CKQM0F.T.><C^^VE_#7.YI"LT*CI0 _&"K
M!B9R!-]P%[6_CBUL8*<PV5OA2[/?[?4W:G_^5?OEZO71S9J=+X#'Q87*;_<R
M;O[>[)8?K+V&$30'M;?%]7^Y>OW7$K9O&A,PJB_-W,YT\GF*@=Z%+DB:9#+8
M<P64 2B6\8Q2@1U6RCEC7'89$8,-H9,L8:?Q=J[O.:S(;BH?Y:WU18#8:,?_
MO=OK=<]A!5[;,WAG<+$N6_]3@\K.U]V]T_-ZI@C;^Z)QLG,H-:9,>85(= 9Q
M$CURWC(DM%4D,1.D]X#[#"]F K#'!H"/6BH[2N;JTR!Y);-_?"F9=RQF+-OI
M] '8L@B#F,2MHCUO)1#?%XCWYXW+^F$TG/,4(U+4",2MU\C",B!')0'"@A/#
MZ<4K?8,\P.+W8Z<)%*P?_3 #7Z?H0%K Y#6<?2P_\W'TF:)+Z:^%H=+L]_.)
M\*C7_22P;MQ)H#!726D2#'6!XR@<%H8I0YC"!G;45'BJ,=@GK!*HQQ0H?V@M
MCD!R/<)4I&QI:.2T=(AA9:1+P!@P?O'J)H"9EHFWT?4*TY>PHC4WKA6=FFO6
M'S?CERPI66KN(B<T!*ZPLS$9RA/'QCN!&:,.QD4 !#-C)8;@@K'"+]\NZ3@M
M+3O][.OP\76O"8-LVCVP:!IQ\!%$(W=>_="]L*U\R/%[[/AC8#:GE5#=1JC@
M.V"^<M!E"4:KSS'+\#]DA5$H8.DM#<Y3"LS6+):IJ?[K__Q_6XW7;S+]K?7S
MPA1NDMYX:4">>K%_W&V%*[_2?T  L\PM;!8/C#!__TX2Z#E3PECKO>+<4>M4
M\-0G+B0+4IH2J8"#?N=,K4*JAPE5-K84F#$,N! U^2Q,:62(5(A&#5N'<K#4
M+O>JNPU27<D%61)0.:.HHB0!0D4>O;?YH%6'E(QUS I>F-88J]*TQM@P7 '5
MCY:IT\-DM1,I"D1TEBE@5\A@EA!0W)!BB#8$,'H)WQ"/C537QBOLM85,WM;%
M_>,-[ZWAT; _J)%RX/2;)O;><;,7:EL@UZ$P8^'%P3>LW(*9SGP'#./",IZ]
M%-QEZ$<&<>X# :9GS8\G<7)";@PI?=R9NH.T].)_ALT\:S ]+HYP"?Z\]K_>
M-&%CZ1KT;+-5(-EY;'V)J W#.ZZ=P<B[(8M<P=NG=T=*:XMFZW$GI? NWP5I
M/6&"AV (AZV98YD-4.E, N-'2B58&22(-3;? -B]T>SL%9-3SW,#B/JA;//X
MN@O_V&IKOA6,?FT WP/FS:R"O5BP#*/2>J1U=,A3G0@%'!41C ASP]8,,GXG
MV]%&R8@& ])H[FT (T43 G134BJ-\F,!(-_:82L!6)H U/?\H5($*VTHTH(1
MQ(TFR"@ID#,^T:C '-#TQ2LM;G13Q:^YQ/Y1+/#K;B>>3A*;@%(Y+#$76NE
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M-V'W&[FX8+<K_%0PB$Z<&$/>Z:Z]4F<3+K%?SH\CW*$'M^O 0G9[%S6PV[[
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MN=?44A])<-I%[1*(5"6<CR.<)UN'QKCH)$M(2YH0UR"76@2#1"*,@(T<,";
M9C?D4PAG/@'M37B*EBF?5X(/AG<7_GZHIWCKZH"_=5%2SR>W\Z;8@;W(1V:5
MX-^.(.X?LIQ7YP2(.XE &[!UR"5L$ !0!*Y&!9/V1E3.N_)9.>.UXHBS$("W
MW6%O<%R[6I8QS-X<+3NC,87!4X;"=K,R-+I?RB@44P:A7)TZ>/A4,Y_=V2.;
M WU'CHE)TC >WH*#E]O(]XW69=OVCIJ=<5R[!I-P],J@>Y;_?-+#_+U;V'"]
MF%6^>"6'YM3.6C$<C4B=RZPOQ\>T+@IOSDCY;;\?!U=&XGAU,HKDO]\-;0^^
MU>WUKU[Z'@!EW<\+!=B6FED_<W!9_G(G.P'R'WZ4U=.O>;#9N^T,2]EP3N/P
MU]%P<ESCQ5G<F#@/:C7;S4%Q1-<?\]+1D/.!'%&_E>-LPK7S$S=#T_::L3]Z
MLV9=LP7T=2,[MG+<>7'P!C>"6VYD"88;#7N3\4PA.C"VC_(<9+@^RV&8@\D/
M //MP'>S:PR^_27V!Z4_+(_">C#*RTB1_)'8.RHXL[\^D"YEM!@&?"(T^V?=
M?K%<Y:IL%+8\"&0S@+B7%X4/#7I--QQ=M=AX:B?#0AJ:G3S>&'(4Z,;X87)>
M0<SB!\/.FP#,_['M')5K,N%VR,O5:A:.97C<?JG^Q67*<%$/R[Q1FPA)]K&7
M%WIT,IT_O%G;N8X&V[B;M*2KD_EK\2B]&N-SP+%LPJW;\)7BWN,QM)N=[/C+
M0X>'R%\XCZTO<>29]Y,A &4N&4CCH-;/:63%//3&B60P:EA#^!A(EYU(,7 Y
MWCE'WV;#*(S90)&] E(%(]XH%:1;.[99W@>U5K0 5G?9*.\72_E-A^@X@>ZU
M[1]O=4+^YPW,Z1=X<)C@V^V@^*?;0=^+QK;G]>V=R\;)&PKW/]1<FN2D1RHQ
M@WC 8-<HD3TNSKG$E3.)@N&].'\Y*S1HSW$A(<4O\7H-LJ@4[O:<O+E9NTTF
M$2Q[=X2)(+X%(^U/1-#='E6OU"?K=G]*MZ\N468 ]<L7>_"UU&VUNN=9QTK[
M_?=FM]R60"MAX_ ^MF(1+YJ?JCQ Z$\Y':Y)Q+>WL_E]^:E3NL:(XR+ _)?L
MJ"V.2HJ(^[->UQ7:/WYME.P#R^./\Z=+@%B(1V.TN@,NY=.^V,\NW:E13/I]
MQ_<=!?L7*S2F0*,\KEBNP%3]);Y9FR'X^5NP8)/;G+=GL.^VIOW.=YL6EX&R
M%:?@NX+)9P23ESN'QB46HTC("6(13\0CC>%/3H7'DJ?DK;HG3!9A%F-QF=2F
M_@0B%4?HI<*-L>XM+%V-8/3_%I"3;PGRL--JGL;6Q;0@+Q)BT+<S($[9>WJE
M;^^Z>0RON_!BKU,;BU>&W+'&@7Z#]O8!KPLD!MSL]L+U1=YN??R]M@4O#DO'
M_,>,GK8'VO]Z,DZ-*SS]*+!5U'P+Z"-\)MM,F>@O=/B.Z?R$SW9"W\&JZI<1
MW5=9J3:/N(SLAF5HCJCTU2&?]^4(\EVF<&WL6>X?1X"V,G]I+N5@C6RP:Y=/
M7K')9,[X]0R,@;N?G#%-M8IP1R%YH%HG&36E2@A)-;6CO$U,\.@4Y49@&R?3
MC%,>WI3CR5!7^4H60]@^R7F<6&L>DF((ZWS,K9//27H:I4@4@2E7 ;-<WF!#
M<S8/6UF3[K+>BL N%;E27C+N2$ZSD%@[KS5V6*E4K#<9KS>IUOO_9^_+G]HZ
MLK;_%17O,DX5S?2^)%^YB@0[Y:D1Q Y.!O]"]6H$0N*5D#'\]=_IOE="&[L
M831320!)5_=VG_.<I<\YSX+WV^\+ MY\<!XE6'7$)2'($;!5&'P(,&&4"Y>'
M\(MUH^;L]UA#2T[8]AM53_<,IA7!R#N8H_3^2=7%UC[/=F@*,&I?/GMQIR4
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MSH,W-FBL?>1Y5&9FURV@=HLT^PK4G@S4SB=!S6"C@N >V20$XIYIY"*UB/!
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M>1E#?.:W:M^\(I,K*%QF5DXQRBBX3,9(#>ZI!3_5P]?*-#DL:#@L*L]0"K"
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M:Y&=R; _M;['@"YBK[M$-%=/#0%?Z3Z..L8D G)41L2E3PBL$X3_*@8I"=<
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M=*:9L20X(C%$$DR 8;#@%VHEM(^,^5O7-JYR@8_N6'K1W#K:QS)H%@A%TN;
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MMZHP:K58MZS8OWNUVOW@:%7H^#P@U)JJ=R?,20D!-&<DA](03UOO) K<1<H
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M;G[B)9&.ZY*F]_+_%C3E>1ZJ#G=H%S:(S#+JA4'OO%#MK<#U1G"=;7QC1-'
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MM. $2XF26&0TRT)N)*==X.5KL.[=#[S<U+B[@,QVC+[A-F#T'X^?O9Z?8DT
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M2K:Z\AVO+E+SY5YPF0\&N*K&P@H,@2V80,D2?HZK-;J0@YEMVFD&F@^'UN0
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M4\FT"@4F@7FT?I"Z"?FA4OMP7Q49V9#JO4H6>RZ+AC0&O8>=*]]X#7-P66#
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M#[M81+W9('#&;$*__/0_4$L#!!0    ( %2$9U9W)COB^!T  (P> 0 5
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M?#%-LV-\.9O/?\?%J_(./H^R3$F1QF,@(\U!=!0#&X<LQ2)*+D:6'-L[W;M
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MD.<&K<]RWPAH*_I\9SGF=A*ZCWTY#D-&&\E-R\AKA3#-O"&D2,!Y"(0ZMZX
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M:U_\3D"'9,UZ8=N5IN*]B[-ODS?*7&GG8CTI4%N1>AM8D#(S[X7U2@'RYIO
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MYA/>)A0XA76Q>S5<[EZ]QB>D,! EL@SUG&@HR+SUF2DC$[<Z8LRP"R&V>^S
MU&)/S.A!!&V; %\_]!R<4[P>:B(3SK1'S4*L29-":()5(J7F6X%V<"OO-^O0
MEC$]2*2UV5P7L_B%F%S&BS-,R$OBQ0!#3UZ"ABR8C\1<GH!#U"*2G>_'=EZ#
M:$B)A7Y8TE B3<W-ZVZ63]+B\60R^U1/DY\ADMD+G7)B& JOZ]L4'%B7F?7
M41FEE-XNS73+@X;4?Z$_D])DFML:D0VCQ*)\D(XS;CFQL%9,]H);EGE4D1,)
MO6R]?+E5K-Y\;V#R3O @.9GNI&OC1T,1DO-,ILR-%J;HT#PIL??>P(-M(6W
MCAWW!NXBCU[SID\Q+J:X>)N.,)],<%8FL^G[!7;'F7ZQ1ZYTJ_NVR(_N/H!6
M>R3H.>_H.17 R!ET)23BAE:9HJ>L&82(S!J_["\#Q)G6ZV'GGK^O]OAC"JM#
M%_541ERL*ZV<)IU'&KDR1406E2JU45=F,:%G+H9:ZL^0_FZ]VG<SHAVU1[]G
M9>Y,A,LZHZ$4&K9E)"!3B@1/ELD"Z+HOM;K/:DN@%M[&2*X;N7(TV)(C^0<B
ML"318N"<F^;[#6[",Z1@O1DIF@F@C1=]$<YSQ!62Y]ULNG@VS:,<T24/A$-8
MMUI1CHELIA,Q&&E4%G*[O-TM#QI4#;6]A=U\:GL5]B^0_JJ ,-J2@A-,!B*>
M3HH3^Q0--RG'50K)1[V/K$^?,Z18N5=)WV5>>R[94WL"OX//./_J7XV7%R.6
M68>K[Q?P.=-_\\4XP30OK[^?[E7E9__'MBD,U'CXS6H)K5LUU[)X3T@]C*<G
M9!1.8X[9=/[+$MXY_,\^+SJ@=V4\A>[+"Z+XO!YFH[^D@=;4[XLIN<PTA!%I
MD5!\I9W04+E'[@;PQ"1ZJ4I6-H4>6O3T-9P&'6EVA?;TE JC&'*)0*\M-[4L
M3TD4XGGP+!GIHW#9^^:]JO> .Z1X?"C\WM#OYB!L:-E0:5? SU?J:V25!L'!
M,6>D8-H&P8*KO9F-B *\,JKYNLK=T0[)\?^.R'L7+AS>'\%2L!:;_6J-NUH:
M#6D"TWBR+B_1UAG9Y9F]>2)W'G@C-^39^OEGZ-[0\S<QJZXF</)I$XN%*Z9!
M%Q:BTRSG0.K0!1F:'TW?'MV^6G;SD]Y<D,-C\O)S75Q_NX#%2:W>=>'#(T&!
MG%"8&6J@-UM5;S\JQ4 :'0V/L7U^O@'L(3D-/;'QLAH]M+";^0+; ">S0VKA
MA#X6)V=I1^FLX(5KYJ2LY24A4Y1K)3/)*IL=]U*W/FI[5ZQ#\@,&Q,>]Q7I0
M$IYZ'1<^\71,?U@7SL8P&2D004!V3* CY"HABRH5!L)Y#U:)P%N[IBUP#VEC
MT(#(V53<!R5JU>YU<_)+NMODG(<V4BF35UP",];7*5.%>1\,,^2[VZ@%][%U
M6]%]\ XIOSH@8C81[T$)^>0(IN_I \^FD!:8U^Z&MC'8VA=#%5<WY!G.HD7%
M0H@QH1#%FM85Q.Z.=DB[HP9$Q@:BO1<J/D52Y-T2\.-E\<#:GF ES_7.L!&I
M].AC*:P>P*G-$$C!8TG,&YM\"M*T[\S4> C;D-;^^Y*V-0G:+&[NX)P\^YR6
M0UEN%'N-75H>F+#&Q?KNZ5BKH(80:/:TK-VK,D\Y);ME6\,]@6Q#/O=]D._@
M<CLXT[Y.T(OC#Z3JUZ"M<)FF)S(A,B$OTK! [@?S25@PGEO5GFS78-F&;_[?
MDV\MI'?O"9^W1]#A+S#'_&1V7*^L=/EL3J\.!$6$LJRHVK9 T*OC+05EW-K,
MH03O;.N"[>U'L0U_PZ%V#@W(6O?(A<.IT=<=?H!Q?C/[ I/%ES\[FOU7I:S?
M0X-22:$%RR7:FDH(#.@KLSZ@<B'PK%PS+7HCE*TRY_S?3(NV$][A5R'SJ8^[
M@,^-B[_O\[C>UA[O,MQ&RXY7HHE5WPH#QH"(@I54%U50:!92]HRC(N4$(131
M?B_R)B1[[KB\=,M+W7*S _ B&>9]3C1*0[$^S\LC5-9'FER$;;?7WOB@(:WL
M-1#XI=V7[>:XX3[[2Z#HF_6U4V-\W@0_GN;UB<J1T<"#\9F1 JP3H<@2^Z1K
M'581-+F>.O;._*W1#FF)KB&Q#BS&5MN[+X%=;S1:KQ$Z85%E)9EUT9/)-9%!
MM,ALR*%H)X)(V_E+MSUI2&MCO:N;?6;YD/J&/"ZKG*G!*LI06[,;TH$I,@60
MA<PQ1MZZ!_H6L(:T7'4_&F0GP?2D*DY]]9?C5!$]KBV)W^.J,9.+(<I((8*J
M9Y*"22S42A 8DI!&:)[L=JFJ[9\YI$6CWM5'FYGO3Y&<=25=UQMZ?*'>T"A+
M5$EZBAE+;53I-"<:&\F(RF!SL8"A]?:-73$.:3WG$"JFI<CZ(];7(_4T <N#
MD&76?8(NST>V:"]EC*S(ZCO5?H4QV<AR)O>=^X)%MMY?N@.\(:W0'().C035
MD^6J!1GJ"=ISBK.JRNQK[UQRNTEQ0F$>A& A@]32T!V4N)O)NOJP(2V?]&ZK
M]ISKYKKD+)=UKMK'* B.0F!@O/9!T4HX1N$_P>+D2VGAP5S."C=3'IOP--2;
MY^YZ0R--2,I(>@>C1,>T$)Z<R1"8=#*@E5'HWH:_)<0A)J/V9M(-6K2YV/JP
MR>= 7GW+YZ-DG:Z!:TUD%*9SH:F@H(5QY4VA]]^5T'I3S];@AIB#.A"?]A55
M?][=.9"UQ[!;'H)'0<;!&Z:+U<PG"G')1N@B,)J"K4_/W@*I^8A7QC9&%8RM
MZ641D7SK8*IX S-*Q2 $7;T<+A]DW6(86K8%.VYU5W>7PV'\$@X\<4X>&$^J
MNF$4?P%@JIUA,+E2DO.M:TIM[Y?<<W_R0Q!D;Z'TIRPW;*!,7)I@)1$V:]+B
M5I'3;G1F*(R0F(I0O'6)TT8[8P]6IN>@6F5/$6VY@^'T>OT288X__^W_ 5!+
M P04    " !4A&=6P&+-LR!7  "LK , %0   &]P=&XM,C R,C$R,S%?9&5F
M+GAM;.R]6W-;QY(F^MZ_PL?S>G*[[I<=O7M"UF6/3MB21I*]>YX0=<D2,28!
M-0#*4O_ZDP4"%"\ N<!5"Z @.QP2"5)K?97Y555F5F;6O__/SV>G/WS"V7P\
MG?SC1_XW]N,/.$G3/)Y\^,>/O[U_ >['__D?__9O__[_ /SGSV]_^>'9-)V?
MX63QP],9A@7F'_X<+TY^^%?&^1\_E-GT[(=_36=_C#\%@/]8_J.GTX]?9N,/
M)XL?!!/RYD]G?[?2Q51B@J!2!!69AB"] 9N%]BG&)$7\?S_\W4>M8BD1F#<"
ME'<%Z",+.DNKK&,Z!;=\Z.EX\L??ZQ\QS/$'&MQDOOSV'S^>+!8?__[33W_^
M^>??/L?9Z=^FLP\_"<;D3^O?_G'UZY]O_?Z?<OG;W'O_T_*GE[\Z'V_Z17HL
M_^D_?_WE73K!LP#CR7P1)NGK"^CU>7'Y#Z^BT3]=_)!^=3[^^WSY[W^9IK!8
MJN?>(?RP]3?J=[#^-:@? 1<@^=\^S_./__%O/_QP(;DP2[/I*;[%\L/JR]_>
MOKR-=#Q9_)3'9S^M?N>G<'I*B)=/6'SYB/_X<3X^^WB*Z\].9EBVHE\/N8+2
M%<[_J$_[J3>F$P(R2^<1@3[%225X0XR;GMX?\^6S(&,)YZ>+AHAO/[LIWNE9
M&+<4\*U'-T"[?!"<X5G$64NHUYY[!><:Y$V$]9'3CXOQ9#K'OZ7IV4]+>$^G
MD_GT=)SKLOIN07_6=78^+:^):<L%8'X_9GKJA( )P<7%W/X?'9YZ!3%18SP9
MUX]_H6]7CZ[H&F/'SPN<9,P__C#.__AQK%$RZ8(N')E2F(,(B6'RPC!%?]A1
MA^?70:R'<3I-UUYW6I?0Z:7.3T/$T^6GH_,Y? CAX^CRH31N?$E?SD>2Y^0E
M!I#9&%"I<'#),W BA&"=*MKEVXR9KQE8PCPN.;-ZQ4]5+3_AZ6*^_F2IJ*62
MMJ.X4,[#Q_46/^'D'%_0UDPR7,Q"6OR+=NRGY_/%] QGSS^GT_.ZV3^9SY'^
MS^_#YY&51LH4(@2T%A0+"+0/)Y"N!)<8"X6)Q@-_ ,SKDOE*W">SM8Q6\_Z!
M"T.U9IIR9#'=KVHN*$)C_/&'Z2SC[!\_LKYL6DVWR8?GGS_2ZHSS)W&^!#ZB
M@3)GHP)9(MEQ)B'0%,Z01:(YG:.W/C;FS%8PWSPSVHCYMOYY7_T_G<X7K\L_
MI],\?S+)[W#V:9QP_FYZFD=DF$LRWQ.PK ,HP1"\U@DXT=)P8VU(NC$!MJ/9
M/P,:J6PZB+P'8,);G",]\(1@/:-U['3ZL=)_-?B1I)5)%A] <TO@C#40,7KP
MQGAD44K.9?,=Y Y Q\*'=E*_30G1EQ+O\)1^].&?.*&AGQ+$)_F,Y%R'O1A_
MPDN45A=E? &FR(M7R@2(G"2AHT_>T]JHBV]M5G5"=BPD&4 /M]DB6VPE=5%;
M#WVDDS-&* .F+F.*R0P^2D>#Y\Q'%TWQ:8 -Y"J&8V% +]G>UK5J9C:^G)#'
MB+],Y_-1X#)+9!ZXH5$I&P7M7]6P%8*IPI/1IK5WM0'&\9B*#Q3M /O J^ED
M>AW5BH=?N:URB$%:XK9@!) '"$8&,-+$*+37Y-,TUOV]H+YY)K05>\,5O\:D
M1K]-9AA.Q_^-^9\DFTK3UY,783S[/9R>X^ORKS";A<F"N$L@M'4:E$;ZH\A8
M)9 AA,R-T,9K9N\+>>WRPOVKO;&>I@,+N:'OL,3XSPJ!]J;7BQ.<78Q_)!S'
MHKRB_<C0IL2XHP7+>A!1I4"627)9=5+ZAH<?E8+["F^ U?[EY!/.%W49N\#S
M<K+ &7TR,M(JE3)Y(X71(#5/$&1P0+Z(T2++F')IO,AOPW(L'&@J\P%L^C6.
MM8L1'>U@S#N(U?94AA7P5I$!FF..B5OI7.M \@T(QZ?YATMX ,/^%2ZNV)TF
MV!*T*!!4(+M314<#\]68<2$S[<B=::WN:P"^?1/NP>(<0+?/PVQ"')Z_P=F[
MDS##G\-\G$8\>2V7SFAF@D )HIXI$DJ.3!KN#6ONMFT$\LWKNK]X;^M<M];Y
ML_'I^0+S*#N99(@2N%>2;(S$P6<4P+ARE@54(K4^W=D"Y>CT_A 1W]:\Z:OY
M?V%-TL+\Y!/M71_PU7D5RNNRA#A_?;ZH&4SU,/*"IHC9Z93(W/21EB9.QD;D
MG &/BG/KF>&B=0QW)X#?/$N&4\=M[MB!N+-B]BW,(Y%%]#J1QU+CS41L#5'9
M##;3>F><3>2Z[(<]VR >*W^:J.0V@USOHZ/UZ-^'>(HC[8PV&#AD%NI!5D3P
M+%E2JY4LLXB9MS8DKR-HJ/\KJ9&#:[V'&#>%>7ZX2'3[>SJ=SC'_X\?%[!R_
M?C@E5^3SXOGI\H7_^'&.'^H7#V7"?+88O9E-\WE:O)ZM#KJ??!Z3/!R:DI@&
MK;DF9FH)3@8!S@C!6-&LF$Y;#;W@"@_HNZ\<V/;NABRX(QGU#E8\0(W3AN)L
M&/J[@N=J)L.SY>+8"=3H1D9L?UW?!M)RV=^6R?M5W6UT=%OAC02\-^U[@1)=
M,<1OY* *$K^S9K4BP'BA8PZ1?7M:OY8/?1"E[R+7 3*$5L!^71H^HR1=$.@%
M%!3+="4'/F@-HI"1FABS/-C&6_HU /NSZ!HJ9=I*H@.D@OY"@YK,<06F6 PF
M"0-:24M6BPT0O91@>$*K43CA.LWA'=1[#< QJ/?A$MTZ>__]IQOR(#OSC];U
M"4]/PN0#SL>3=XMI^N-D>DH(YL__ZWR\^/*,7IS&':I8NM<M='C;@/4,NX[U
M1IU#25EQ:95D1JL8D^?>Z<)XR"$PYLW6.H<.[VU>_Z"LYU$X!X9%#\JF DY[
M"YP9B\5'8GKKC-[V]0\O)VF&88[/\.+OEQLD^'9Z>OIB.OLSS/*(BQ"U\!&D
M833HHL@1MA*A1,V3-LGDT'K0.T)\%+&)7;AQ^PQK.)4,L-'=!C="59BE*0R.
MT\!IZPUDIJD$7'GGL^?.Q]!\9MQ$L7\>#*JX6Z&,7E(?I/;A[&QZ,>+;\3.D
M$3)+^S[MSA*4HXTZ8DD00A(E6?11MD]>W8[GN+G13!,#I,,\R?_W_"(U8_Y^
M^B3GI=C#Z9LPSB\G3\/'\2*<+D'7.NQ,(ZGG^,L*QK=(0IJ/%[@R*=_@;#S-
M;S%-/UPH;YG%-?)&)A]H5-IP!BH(!2$Z)#E:G[E12HC6P?.AQW3<;'U4C&B=
MUKD4V\OY_!SSL_,9S;\+C+_CG S8M_3G;)R6IBS]VF\$>C[R,B@R?!TP'<E#
M,DA^#4,#QM$ZSCQ/5NC[?(.'O?HX:;8'-31,+KD+[<5:?@=F%>L1N<7J")-X
MR*$&IQ+Q7I #Y=&G7&(?ZMP'X/LC4%.5#)"OLHWW=5U\A7\N?S(?)5^T+CF
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M,Y)]':WL2_6[B_>Q')#<&LK/7W[&23JA3?>/I<UN?;8NLUS]=5\;45@@DZR
MMIB]%9X5-3AG;F Z5%BDA=KO8U(?\>]C(;E$MS+[N^ ;*.QQ'[;#A#_::O1>
MNC10QR%HDXM@GHPET*6&C^D)X,BS@\!3$38FEGWKYD2'H<L]09+#LF47+0S
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M7K^>LS DL40[('T&4C-6I.491>N8_S8LA^]<WE+QTP$4,( )L@G7*C#1!=E
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M9(DIE,E(.VPL=Y_DV2FN>QCN[**/O7/F]61]?U(65IGD%"VZ]:I'[FR]/TF
MDPZM9$S*C'NES26T0\>%6NAU)^(\3"F#'QG?A/G^S^D*9C&6!1DCJ(RAVMD.
MO'(2BE<FY\"5+JUON.H([;OCSL.4LO=UYSW1X/+F-K+WE..!1%![?R4?P3'!
MP1E5BQUU"JIUIE%G<-\??QZHF '2%ZZVZ%ANU5Z:VJC#@%\V>9*<07!<059>
M:VU9$:QUX\:;&([%8>HEVP%ZYES%L^)X%T0#.4.WT1S&]>FGI3M4WD/$ VP5
M&Y#5OEQ19P460[VB#VT-%5E S%H)89UDK9/0]Z7T>UR6H76^BV1;A[[?83J?
M87[]"6>3\8>3Q8OQ)$S2>/*AXEMM.EKSJ**,8!-9+"HF#I&L7) :;79&!N-O
M:'Y+5+3#R_:_N_=5R'1 :0YQF])=$-]-R^SR)R\G&3^_^S-\O (^2F:)Z1&D
M,S7?6A;P9*Z 3RZ2]U.4+[GQ(M +\#=+I_VK:^O*,D0G^2=O-Z9E].\K?\^#
MVW69WV4$-WK.2V,YZF*9$X8TX)PC%FCI70R117W9<_Z>5PS3@=Z%Z(-U HK)
MM>]>$>"+K9F6(@>=>2%O9E#7[Y<F]Q_V+#,V.F)"](",T0Y?I"!#7C*P/*D<
MF$W,],BX^@;KO7>A1<MZ[UT4,7BX[<+)$S9*JS1)P>I,?Y@(GOZC_5QI$VMO
M=#]L-/]1%.L^A!"MI/JHBW6+#@:=C[2]DU^@5"(W@2T[W606HH[6Y=;E6H^]
M6'<GW78IUMU%QONKS^R"ZGLMUMU)8]T*-1\B[OV10>@H1?$21$ID])?B(!8;
M $LN2F'FTK4NY'OLQ;H#<& 7*>^E6)<S\N?JZ4Y&+T Y&6K6DX,2LO.<R1A8
MZP;BC[=8=R?MW%NLNXMH6Z<.;KCRXODDTP>5V$MRYRBCYO6J5ZMKZ!\U1,,]
M"/+S@BF6:W2=/(9[7_6M[^P#"'0/%\=\1;<B=Q=\.^7Q=WCI 7+Z&RNJ,P=Z
M2+EUC+P+3HF"*9,B&%TO&25'%9PK!FQ4TA1>4ND8,#@8"^ZJ 3@P"781;O-"
M#WK424UA%W*U#_GB9#%. 1.)]B$5:*A(9DQ0PBD,UHN.EXO=>O2>D\*;BW[:
M3&ZM]^__[WR"R^ST-1@=<E;<TIXE<ZW_E :<MQ$R*RS88KB*W:IM;S[YF'38
M2VKM3RJO5AFL$:52@D2>P0970"']X;) X"811N21NZYGDQL>?TS*["^_UE;6
MU0*A2T#1)O3:<; ZU.K;0#Z#BQ&TE0:U-09OAL^VME^^_?1CTF=OZ34O>+U<
M\=5ZN5"6.68DN?E8FWY'#=Y*!+1&VVS1*M/-)[KUZ&-29#^Y-2R,N;[FK\%@
M*3D8;8"QX@F,UN T[=TR&++UHM>Q8U^*FT\^)AWVDEK#Y+T-*_T:46:Q:$\[
M=M(QU%YG"4*A;QFQ+87DR&%_R$YYA,KL+[_;&GUPX^G;:_T:4,Q!$[DXB%!8
M;86MP"MOP#MGK19H$+M-S$U//R9]]I;>;77VNR?NZXJO+V.;16H6)=#?CJSK
M1(8U=X0FAE"\##GQ;MV>;CWZF!393VZWM=COBK?+-7\-IK:+3#DD$,N>4T5E
M\")9&I>)4HO@@NQVI=_-)Q^3#GM)[;8*^]V_=GVE7R-R@BQH46I365H05&TT
MZ@KMXLP)=,8+%EPWLW7CXX])F?WEMR%*T"_2<VVQOUPFBLZE& $\"C*H>:C7
M33L'Q>807-2T?=O=M\HC5&AOZ6W09ZOXJ[DTK<G]$2I!B8E,:R48D*5M043&
MC6*&Q=BM&<NM1Q^3)OO);8,:^\5Z+I?]-9J@3#%6># AEYH,P,$QYL&&H$-D
MEK.TXV9YA$KL);4-.NP7X+F^VJ\A)<^ET45 6+:029X&)W2$I+Q3!5E.OMMT
MW/CX8])F?_EM4&F_:,^U]7Z-R,;:53\S$**F;1@1(3I:+9CF H/!4E*W'F:;
MGGY,"NTMO0WZ[!?Z^;KJV_6IF^!9<IF!99^ EGFDS5LG,#GD:*1WLJ,R;SWZ
MF#393VX;U-@OWG.Y[J_1T,X=!)JZ69L *FL/(0D.QL8D=-*"8;?[YVX^^9B4
MV$MJ&W38+\AS?;6_I)6UF=?0OE:*5GN>$C@='3@CBXG1.]K='[!;'J$V^\MO
M@TK=<"5M[]()YO-3G);3539DIA_TKVB[^[GM"MIVP'^CGBU:&[EW@663%3(6
M=!)*:2LS=R'8-.KTAF'*V6PH3$FE:/N-M(QG)< '%XB#Y,%JD;P)C[R<;?-C
MGX;9[$N=:1?7TSO+3?%,@TZ!5KK"+.U6]:)EXUF14G''6Q>=W(7G\=2M[:+_
MN\N4>DB\=3;3=6 O$"\PO9C1"DP+,+D4-/DT+Z =+;R*2UHD5?V*>1-+DL;K
MKB=#=[[HVU9S<U$.4&#PVR2<36>+\7_7=KJ$=#X_#Y.$JVN51R(A,B36&8L,
ME'.TN5HI0!9AK>:TV=K6]\O>C>C;9L0 4F^?,[61KS^']$>E:Q J9\,S9!G(
M/(KU5+,8!S9X;:+VB74^$[[K/=^VFEL+LF$BU=6"FO>K@IJ1R]QCT34S+VC:
M:NHAIXJUZ[K-261'>T]L/,NOOO_;5G9OB0[>>?BBDB;QHB(2!HW)TJ+"# 1G
M,D25#18;HV/#7OSW**K*VYEKNTOU45>5T]AEB)P33Y=^KT8(Q7"(.7F!,I12
M6M<5/O:J\IUTVZ6J?!<9[Z^0N NJ[[6J?">-=:LH?HBX]T<&)6GG<MX#E['>
M:%>O0 PU'5$*FV-VV33O/?+8J\H'X, N4MY+5;F27)04$F!4=:FKUJ@I'A(R
MZ9Q/+F#K;LZ/MZI\)^W<?P7T#J(=O,'0DM!HL]?2%&"BMCRR6*_(L1(LP=*>
M9UF:MQ!XW%= ]]GH>\IW@![*6V\X[(+K>[T">B>==;WZ]R$"'[PM^Q5\+C##
M8XH@=*R9(:Y 3$'6/EO<:NN8<,-V87]\5T /PH-=Y-RZJO6NZXNM(0LFR 0Z
ME@@JVFK9H /G,^U*.:*Z&??9I0GAX^BF_U U=+T">A<9;MW>FQX7/S_[>#K]
M@O@S3NAYBS>G83+O<4I\U^,:' YW1GOC3#@%2Q/3,2F<5AQ3E"FZE+E2UD6&
M9G37@_NNIS14S$^GD\5L',^7%RG0TY^-YS6*<S[#K^$F+(ILB\)JS3-9%BK7
M(J!<P/#,?-#%<=O^V+0KNO[[RL8W_1H^C\_.SYY,)N?A].H/YV]PMM8*?9EH
M$HV"BHPS9\'44BGED8&W]1KU7&06SLIRLQ1B* 'M OL0B]H@G+N]A>U7I8,X
M/!N'L$(Y^S4LTLEX\N':SR^0OR[+'XXB-XH6DEP/9&KG4>[(UT<2H+=<LX":
ME_;]5WN"_MX8.9 Z!["^U]/C+9Z&!>9?QB&.3\>U]_#3\]FL3IBH:@%,331#
M2S8G2@8QZ@#!,".35(;?O'V]-]_N!76T?&JKCD'<]XUR>#J=+]YBFGZ8U*R!
M$2M:9N84&!=S[548(6K+P42;R1!U)(G6EZ5T G:TO&FOE@%.];> O(ARL2*#
M\KHN?-Q?7"!6NUJ"=S9Q)640HO556G?AV=])\"'YL;OH#WU*O$I>V3R:69BD
M$YQ?=N7S+EG/DP=$1MZOQ R!6T%67W!"2QZC[5K)T^F%AXL:M]+N=& IMXX?
M=<"XOEFL \J=^I5V?O4!NI8.HKH=N=%#[H=CB=9"6N$TH#=(:)T 9X.'$K3T
M9*A'5;HU(CDP.^[J9OJ(R+&+N/=+BJ\W'F-4B-)G2-Q4,4@.07,&TLHLM7>U
M#60#2AS@<NDAE=6=#P^3=/N:@KLP?KW#F 47I?<(6GDRPK1)$)4E(?CJ>\GH
MM.IV*-'QA=\;&QXFZ0$"(V]Q,9XM;=:*[MW'Z60^G?U2_UF5_G)]C-(A^=Q@
M0LV=K2?T1%</+(O"?;;>W^R]VMMCN1?4T5B@PZAA@(#(G0#7-E 'B .E-G2
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M%DQ24&RL2532@,]D*B6'&3F+*:MN%]"UQ?4M4^C0:FI^>T^?L9!1/IV]G]*
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MRY4'']3W.0,>#4TVU%_U/J*]TC#IOK'.MPWVHKT2=UYP9!ZRJW)&FM+1HH5
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MNK2NC[\3T'?,I?8*:[W<;$+V!F=E.CNKW0^7 EK?@)?J.AV)]$F$"I,$$#&
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M-#1M*=X!@B=O9O@QC/.JU'%.EM2R"O?I^6Q6=\7Y'!>72)4J&+,$:PFDDMF
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M?6!G+L6BU/'JV6]!JR7&"YOCL@6YE9<Q\46E/!E__^31(J.KRGV5M,WLOYD
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M#1>R;@$2+T3<>-N%G.UK@H\OZ0HV.JM1NT:\,(F Q5<$>H2ULMW]P" KWEL
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M ?7F/,)XKIIRD1/--]%T&?KSTT^/U<*5 TUPP^68BL/DS0WP*83ZW?-\>R!
M?8V")8S+,,TF]D!7%^$"-_)"4$H3VT[7UKSR[=FCIJ&OM@2?J3+J[G3:0B]2
MX!6NO]R9DN*3$VC"4RA?NW=0?VU43<HC]24[>N6XXL8ZW.NS ,FY%SV_10RG
MG-P#\54#J=2[9+5,\_)G>,36P,/+"SUWM=M-!LP^IL4,6HL>3IHMWLX%]&!,
MJ7;Z2581^KH0RH*I&&_7M]!96!<2(OXD]DWG1Z_'3^B--_9K]V>\?R1[,S3[
M%Y@7(;H'XH'JLB<P5'=P.EJX2X3IC!;8V,%(6#D;-+>K+E$57"PS4Z/P I\L
M#N@-7?X-MZ]B2NC0'P 8DIYE[H(%?>Y84W+CD^NN'=-AW!'O_2Q<= ?M%98_
MJ*B8&Y]0:^+$W6]6@UGX?0S5WAX7!,^2.U;6&4YP?/+G>[ZB/,7"+3-6Y=#K
MQOO<FM*"@\[+:>+/ZSN<]T "$J@Q+[OD1H/ 4X #*=3Q_ QO_8UCY]L2S:<T
M';S,5O[N^WJKI%<\8\11E-0IS196I3H3]T";:YSC[M.J>N#)"]Y>07'\J7Y\
M3V]#U[5T7)IC"FV[ES7;3>JZ^1X3N 9BAY@2%@2[WLZ+],-?D!&D<%#0[LL*
M$EC>YV1L9'7PQ+GQ4-'S^K>0/U G!FV':AZNGX#8LJ?W0-0+F 18W4Z?JL@0
M1F'*K64&Z5!5^>4A830$@;]T\WF#?CIN-&W?E3<?&3'<,G4*V*==*NB>?DQ#
M>!K3,_PYTQ:P)&%$@UM<^)R"'&6_WDJ,^.:@%'HK2>61>#P7EI]5W5AJ1"YB
MRB^>!0)I75KMU.WF]HHYK_66CC[M^G7:Y2$N@12'P+SZ3H6/?9WQG-+']Q1P
MI;;T8ZC.X?(AOMI4-D9V//E*8RMUC'!/=O,ZXY*Q(.G(7]>9CP%VO(?(ZA)<
M?PHK:)'$P@)JLW-VR\J1J:+>"T%[H(5:;&UWB%]@PT=I_LL_73JR_)\F<.G(
M4C?QU%MKFQM&.3J3?YSOH2QPU.47K6TTF8.">1J?K+8:"HF6V9^J5$]8N8\I
MP?O!:;,8:OA@5<6RSU*)<GB&4.6)CT/LDRLW+;PC6?C&!O"Y&?H>B"D)Z?;E
MFH01GK)E9^XX*8V]13I$5(^3'#HJ#6(.XR^?D/,]*B(:\>SB(&SE*P\Y%]"!
MY5KIT1S9(K&D\72HP S?SVPL')'/R6OMDO6QGQT[)YK?B;YW.:(NN=+U T:]
MB$M)HO_9 Z5PXC(YXBTG&<:W;^(7RV["_)?ID.9 Y19R^.@4M@FIR?$6/+4J
MV4J$H\=.6E$B4X3W_/<%MSI2C=/A%='86STJ^:]M6]FRH -TKX6"+S#@**_)
M4QZ2^M%MJ%KW,W G+-QY<:,;\\[HOBE8 ;'5O=#U7AQ7[1#(ZW4Z3^_TL-JO
ML6^'%(94W,-U*$>I#=:L)QRN%AI(_.^L+(EW\2+S&P\=7ZF.A\M^-!Y6.;T_
MYL/9C'ONVH\33/+@XAS$\:'H$+8'DU*81?Z(EEXY]C9V7^BT]!XH%_RI%0?H
MJ>%((F! B^/T9")#\863Y?G)1IUI<RF>CCB-QP6==A\I2<LG*2?4,FLX6PW@
MN:_,[M\#W4?3HVBE]&1>DL7,U_<M&6>E;B'?U"=&/!!-P-R@.V?CJ9=@]SA.
MWJ.42PFF%JZYS>B;"958IR@[%>XLG*LP/2=S]LU<-EE;A:*C7G/PRLGC1ILP
M*IK05<[1Y 15IV]T2SP82\1*,BV:,/WOVG2'(@QF7@_':F6SMHPQ^K$^%7F-
MUW+[PN_AZ^QZMN8=2;8%#!6'9S[!%BL*G:TS^R<Z7!;J'77G/TK91A>?KU*N
MRPI4ZP-!,'"JC?/BN"V@1WOH 7C2Y&UGD2??,GUIOKG!X;6L6G]CYV].RHZW
M)IMW1B\?U/(O?8D+K/GUFRU6W]B(.0&\-Z5/M _%/U>8_RQ5%;!EO8 [__T_
MZ_(2#VD+T+/;+&#<8"^TA:53BPB^Y<126(_Y:3@'>K5-OW-^M9)X^L:'!ZV_
MGL,?^S,_?<W[=1 ;S'JP![J&2\'5;VW6!3+,2G6G7!-_]5X@"WU+.OC&Y[)=
M\^I3M5=V/V><[2=.#O-B@IXGP"SV0 %;@/8L)9,AREZT@,NP0<##OKBBOI#.
MDY1PTTYG[T*]FEHU6['5MECML]2G,O%]D7;#KM&RD\A 3DT.8D_X0CGO=<&8
MYI>I=XEUA UGR:"BR0%HE<;*7[?"9IIC6K]-9-O^[N4/0V<8OS) U201Q:;C
M_ RG9EVMUL;" Z,J8A]?B+*CJ'9,J3ZVT###E=WKO@>29+J238B6RW:7J;W>
MP(V5(?="^Q6ZIN;SCX.R!Q6O/7NW=&)<=I?/!H04XSA)"X>%R\CKK"<H2P2.
MGL2J;CK.XSYKYLV?=";^&.WGJ&.$<>%/DK660]/P:5#65P<=#HH)0XP3L8E6
M\40Q]^ZN_=35-[MA32_'_5Y9?SWP>U^Q>?;L$;)NOQM%AHL*X50_MM \XS*J
M!Z-FY1Q!5HWL\TI-8-I5-77@YW??O"2,B5;6&HHZ28 V@R^]_6GULRK\&(SJ
MB 9TC"@\#%749S8,J*#=^-TW&5RV?^I%TCD?39?\8&NSN<?A;NG<V15U5K/+
M=\X+#,*H;CA@OWD-XW;0+C@7!1ZK]$!L6:/K'<VK3:S%V$_[6PI_IO6;ACGJ
M*/3G\TS[<<I\$;Y^MA\[ST-W:00,:#="#7U\5</H/ZQ?+)M^?KQZY5*8_\6G
MXK9ZWXL/\/RVIN=Q]&3(P>$AM$$R/8/S(9SIEMIG82$]?)3ZISBK\/!<8ZJ1
M:N-(I=:]7&;=PZ +@QY7Q*$<%-["E!FG#])^%L4S(IFHEI;/?UH&_6>^T!'D
M(RL&M<0+W)8@KFA=!&]JM^PNS@:$<*<(,+1.UJ"Z=[<V8QG0]6:O.(ODBPY4
MIL4.GX;/V]0[]7S7/-]]'$OT?/SP2Q<_ .,8D9-2$_O9XVS55FI1#WQ!^B3U
MTY.8N-DB<R_GS+<:.0XC&HJ"<DMUETYB;&1WEVU J*L>['X\U?<(]FK^!GVP
M*:C0]; 1<_^LCEZ9'?-NG/LZ1>:\P# '@,#GJLCRE!ZJ7Q^4"S".K+")?X'
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M-]T_>8NY?!K;]_N!.?[P862_.D4_W]P\7W#W6 :(^7P"1L!@J-ZP%(CH%BP
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MR2B[!2_7Q8V:5E,'8D)?+8]:M;F55BJ^:/[MT9BWN*3=;Z 2J,47@!05?7"
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M]<HSK@+8H06Y#.[Y(+&JX\\\[@D,2PU''<TQ21#,/D^X=8F0^QIW(W?.D2!
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M4;4$:EFHD1XGQ)03_9FR%);,K-/QV4KTJ;[U[?B5\^+'>4/F*JL:EN[[9(/
M(GL7K-B%4*_<3=N"-;L OC>%Y:F%E"Q*$89IRS(M N\V17BFGG%.;/,L5-[G
MFJ)G&E1VY^M&^5UK[-Q<1/N]4MGF/;-HL,R]X&92@"IRQXK-61A)"+OO(W=/
M!S$#>N'2>\DDN>EPF<RGY2K[PAQ]V?<BS^29?/2WU.HX+S81@4A27_JT2O.O
MD-W<7(LZ%S$;.TMXCNRWK:VG CY%EWT<OQ_[T._0U=R*@H'@(7I7W#0*^OI5
MK5A>4([@^>BU#S3MG"(+__2((L**-GS %R&P=ZF_/?G9;ZHXSC)#]VS:-TY
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MO:J0'?:Q)C?Q@XJB0J#ZG0S*]RC%X$BSI47XR>760F ^ :[:A*+#MKGK4,_
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MH%Q9%U7&LV.H4 A@C' )T!TO:5O/$5%%FKNTZ(1YW^HV@H3G]L>K[,MY6"B
MZ\K2+>X,PZ91@\C'WGBRQUB9!K-41KG@UN3FWM%GUTE]I<[Z(V$=MID:RG1:
MY_5C1P%O/Q.R%<<9D0Q/A4D<:?(1 1WVZ@ZA!F_K;:@H_G:2&.9TIY,1TO>)
MH?#DY)?JVXO7HEEZI[E40A]T& OKS"H-HSN,A=HO@$BI.448)?)V;MP;%C&@
M0[,^->%X0V)H2;J=N?;P$M,PITV]S:-$'4N"JMCH22VV-!52B[YWC=(RVLV.
M+B:$=\KJ&&LS/5VF3A'9\G';/F)>#4I*/CFPKJQW1O:#EF^9":N@0*5BKBA"
M_5P,[[X@, _#=66_6WZ]=<@VUFNH;C$A.];K34ICUVU O'%5Q6T1AR)@XTZ5
MB?_-4^KV5_F'?>HI4J 3T<\#J^"C-7A%6]2*E#00=5XUMV%]LW)4M>G#_%:)
M:HUYCP#U_!6T*X),L.L9DS 2S54L!&6GB.'&.IRDJKNK'>--6(U!)OGE9BO;
MM39%F?N8E73M,\HJU1<I\:G"9EB78IAWN^TC^)>1MEFSVK,U0=$LC\+(*]60
MNY+XI='W\_D,OXN+I=Z_6;W_A3N#PS7UPW?ET/ 9C;%?2?+PLO2\FF]/;Y;)
M%.>M?S=X53Y [+UATGF4[@LVT71.=.ZYB9M[#>FW<OFW(PMI&FI.0+]+?_R
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M*]-SK\_Q Q/*-?:A8OL_#+Q+]N'\,BF!#17B @_FL)NYP-O.6_CE"6=\(&4
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M6HC]9X]<70!GVG 2X'F:A&T;10KKZ)W[L\:YS.GEM.N2\'CTSI&TA4BAXP>
M#=9%?B",.E=9VZ$A9 6RN5/0ERQBC!#V1TJR3<J.][!-QA/]_#$F60<.@!Z/
M:#QYL1HBY4**A@[9Y3P9M(W8WT\@NW">U^DR:N >Z$:-4#WJ=B:UUV)SYM,M
MND1%OZY=&K6+G2.5B7&*TZ8&6B-VC0.@PD1G:Q"H2VGKC"4C2 9>(.)0S3=C
MW>0-F+3]49(O]9YWSZ7K.NY1D>9Y^$/R&W! BM$3,X<392BPY;6/]!IG*;B
M6G2E)NOH<>'MN=^("[U%L[T/3^W-#OSJLN-Z\<[ZC2T^4!>A3&CN]_LQAC+[
MF51.(L6&S) 8BS1V4L88-&?H!P45N^L*)IV:.HI]U>T'>/!)$U%AI_GNT'%$
M!A=@(CA5$!+J5#/E/+=P8!C0*"W#_N U?X+2R+TLU_T] 1JN0<L)?'H!)*V&
M>@YMD\TA<A>J A%CL>DL76&\('$6JU]@6^2'E P]95"!F?UZ>L1.]<&P1ICU
M2'OU[N-7#*_L(2+!$RPS7 ]%#>\'LP&N'U7I%4M;$!O&B!VNJ:0K1)9+'**4
M*YCJEH9W/$G@O[0ULC"K5U*VH'/9M,U)&#Y$BB2"::NW0BZ2*,48UZ/=L]C5
MH>QK?=_V/TF2%/RA:!D+A!FP-V1 QR;H1*BEFPOD;^@OQ.+ 0>K"8!NU\P[)
M%.3\4'**,_Y14^UX;53S\_V2YAA6I\9F<2IO?:K@X1#*6W(#41'7B2]UC2*)
M8VWD<]WHT/V "I[SJ"?R7&#7_C4/OBM-DKT=T!>O76 *:R^F8,*^$3%TM9&$
MZ%MV$L/0KA5MZ^L\HB"?L2M@@Z>=:OV#&D=#S?3OK8)M[:UV /;8!#(15;8*
ME]DY? )%C:0+?1T3Z[4R9KO3YX7B9BM^OLBP[4[?Y^^I-&K3/O#,^%&#KQ5S
M_$ER#NPL^3H^ACTD[*I?T$A1_54S[*,F2[^=-;Y[N;;EP<"7-%\:[<'6-94=
MBB<ZY98-YD)A$F>#N@PCIC\C+I(D@OM"D"PGROMEVMH^GY;&>'WY_(P0<K_1
MAS:*!!;W%"6+X^!BE@C$GT. %_7Q#9G;8[?74L,/F[:XXM2ZGR=TO,Q_X]-_
M*X=(V/PIVGJA0TYQQEHM[9*Q,XB04D,SK]#CN4#M)"=C+8#8@;[M^!+?])X+
MG,?//:,,:C-3XSXM6?WHG/.HPR%GR.[K;CAEF%D]-H/"J'.3]/ZF[@O&R:!]
M__@J6W.#D))+IS9^@+E&\%VT\N287NV?(AX!?S\ /4TGWB.?U9=A6H)AX^G?
M@K#*<EE3MRSLC4\WO/8PVEV3XKI[R?,'I<H<^T-=!; V)5,+4.>XP&T +&%R
M:E$TQ+OAVA=<(,-[HC9HPM-@UMH@;A9-3_ +)\':1+3#9ND&9Y8+>#?T4_I(
MH6 !_1XDZLOR!C=T,,]RGEDH4O%\F(,_Y@? I58E05+_#:7><D.]V^:.$=55
MAF9;K;RG$G(C<I_[9+K>ON:(DO1Q<0@X7S#4%N =A!R-U^G9ILX4!=@ZO+W_
M@%G(NV3Z%2*;<.D)%[BPY,0%OCWY"+J0IF'M%HN?9!E36-J9>.C!F&MC!:>V
M'K6X_PQ^9L1IPFLWK)!J82^B-QZSDUN9^OA/,1$WB&]XCUX\=S.#\\ 29FV'
M-S.,7>3+9.H8<6VGI2/T4>TY%\CK"UVS3Z L[D>MKR%Z.*A&@S7=#$XXX6=$
MKYVLZ^(QSL'?O:$<PYNMT $=6XF 0QOXF L\MXPH0,OC&[#D[TA7"G/7+\*Z
M3'\OW92=OANQSD)\6DLRAI?I""_3Z_L:\G;/,3O\%4*KC9WL49Y_,H2&"'1K
MRMH!_61.O#L!BG[(2D'?AH7=/^[[ ,$S?SB/7%]!?+%?$8KA HL.'1"I8_$.
M[(XUQ?5G?[Y/CZT*AJ$['Y93WD-?F-W0MR=>IMM@[2U\O?2*30.2,>5UFT_G
M<YE7T*NS4Z[I_9.W\OW'^K\?Z2^K6"W;O7.PV#4]A!-2M_6JU\AB0E# W'6B
M_^OAZA6M_YC$],KX=QI3F_ ?$)E_[#Q0O6HP'3^/P+/E3G"!%,3_D<[C.6U!
M%(-NW-4]B#G1E*YTP=2US.MT2\&0IJ[)IR]>;H_4>?)N:#U.UG/0S%PC_&?/
M\!_K&?[7PFDXABE^YO@(&7(@*J4D(=I0PHITXSQEY-_NE;$/_P$L5EW9*KI<
M0'L01KQ!"Y@*EU\LDN2(<V,\L)N,^."*',<K,=K8#P<HZV!CO Z1:'7RG]Z,
M8W9 $C BI<GTD&>?3R/7#WNC[U:PX%Y$< 7_X>XTFGET!<'94D;\:'$)GGTG
M%^AOQQ7\@J3Q'TZ39T;@9F&^4">'G)H\??1W7T^\AZ*2T(O)KQ=8RM<Z.2(S
M<V9@&23VG0OHK).X0$G5(2[P-9M$C")/EM3C^P=PWI^""]BIIRCKJP;M[%TY
M\;JL6Y#AOWIGO%4/'!)!N#NQN8R?/0Z_6)8ECL2S3?^T%W)B%$".&^$UO\2%
MH%Y:(&$+CJ!7F.@'>V&OM'?V\L;K//O;(*?/X2';*O+*JC9TRW\]A?B]%NZ^
M[\\M<"(^P+%4@F[1E2<^66[%S]O2\<HD<2%."Q<8N7@0=D,.HK[Q3U/^MX&8
MMK>&9Y++X-R$L_I9?)6S,6*-QPW?GX=?%WX="MWLG/!>?6#%#P.RPV\D%1H/
M^F.D:\A4&GK-ZK,I].$' 59"I@_I1?A .H*=\@BYOBH#]B>A)HM;8;-;X9DB
MPA:?_S-41E>BZ4&N[$?9,&Q>1!R%&<K?C'V8.&P FKZ&#CD=_WU=_27^ETD6
M[MB$*3LE&2+9KJ"<8/8\"$?4:VH=&0I#,OL!_OA?%(6%\U]@D0L\B$#C!X9?
MX'\ZH7W[6PATM,&:?>\J)['&&[JULH*5X ):27P0J6G)ZGPB:C+U]T*K<?:T
M"MECZ!%MQOU_\2@6#[. +64*'1<[#XNL] +8A_FX25<:^0\[%_&)J,53;=![
MVZ44C@VLF]FI(5R 6,K.@7V"VX][^:<KI'+L*AA"%E5A?4.L1BUKH'L2\?I#
M\+%Q0?B9>2>.</^R=B1%[>PO1RX0@HP!1^EG4/,&T,0VV T<*9S@O[KZBC]N
M)L2.?$.>^8;B\#O7O'J&;Q?M@-YKP 5AYT%<ZL,KH^J>T]5SXK<=_)WG*!G\
MWX,<T<L%A$1A=F3ZDIE.,$URMM818_U9-R+QDPGUL!_?$5KK8!K4NFX*D7;
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M;7AQ@CB,R%]5*9@'*O^9Y9U^+P%HBU\PR23&$6@5? (T_V45_<]:1:[]H6C
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M^H$(/G:P9\KJA 1$]2=SL;/43B45((CQ/#&3H0<ZQN;=!NZ*('>6#XPU ID
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MAHAB]Z%)'2!;HA3Z"$80H@(^LKGLQI1<3B %R?;8G3K4T8TUV=PJSSQ7^J6
M B(;B4?ZY%M8;Z+W]0ZX&)U-.=MLQ$QX$%EJ<:P)+G6$H&+#FWO"=A)!AK.S
M(+C%TKDUK#7\PZL37DI=#>6#B[X@='!"S!4B312DS)SF1T 5"2F&A!#9FE.5
MJ:2^DNJ"W^[#WH(,E^G&[H:J:@16YR^!"?6/9ZWN&TBQ1"HRY3 -A+9#>HC
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MT8CC0W#.@>B?*%@Y%;"0-*4S@R&Z+%47>8;.=U=4QP ).^+IQFD;2(&MWU3
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MBAZ.$H7T5X(,3:F ]QWB!_>[!%V1Z;M^Q]VHD23&LRHL0U*Z@1[B;:['EP:
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M9?P]D452JY[@D_LT.K(#4<S9EIDR.C')INB.KZ(9\*Y4P$1V.2O"SM-'<%E
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M^S[_<E9K4O'VPU?WGI\/17^3$^;W67(1>A%#VC+^#599*_&N;_J8QGB[8+]
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M_;WDNN]%&Q:Q@1TI;G[LO2!CB:Y@=8#6?A$7^4KFZ""I?]CPGQ82AG]5VO(
M5JK]E&SDXBKU&!]GS@AD^TH%W+1YD=>:E:N*MT9L<Q4$G%+2'7C)^@9WKO9?
MX&,;@%;]W7C*<G'IO;PLX7>FU[F#(OUO08[Q=R0B=]K5W.L><N9?Q:)5G8LS
MO->53 LFD@\+R[/W;I]YX!/"DYFL,,#M9_?^O8\0$?0!\@0O.=\!8V_FTVU]
M_.%9FGUN[(6-E.(AV&\EN'N)'XJO42M=:"#WT_>9)V^K>$R/3N1[NAEH40#_
M6T%A)7@Z5%]K_!V@B3]CH5%#42V)G#F]L@EC!JPC^0FW!-A> -0",MZFV5LW
M3 ]<;!WP+1WKG^]9.WW7!RH+=8X/LAN6@\ZO-'>^'6&IX%3^PO8(9/>T6&E'
MD"\:X=[-G^0U88]_[X_=>!@CK>G%RS1=95.N7!:_EJ5D&O1N_K;":38XSZ;&
M4--_3<7WVWE;@T++MYJ/U@B%FC'G,^+3/UYO*L!KU 7L-I_)>.[4H2F_?1H-
MR/&V;U*"\E,.,>#*^:UI6WQZ:T77C7A5"[F_74SWW8ZW6LM(V!D1^/&3T]B7
M9AI+U]_O9UEF6P!.X$<&A)5?_C#KF$5$S%L;RR\GLGHG^_4>,I3XY6/*!DE\
MSL&;1U!!0GH\87?;1IIH1>*[]D4::^'D$E3U2;_\B7SE\W@MP_<8H+%U3;-1
MM/K26FN/FZ85S&E2H'SS'!._QSH5H,6'&9?EC/_L6N3YB4V%"E WE0H1:TM(
M[&* )GDM1GUQS+;R4DLR>STGL+9W['%14<!"/S<1+\&JHAY =U6:6=EN!.K3
M@6;LIG_]TLMR'%>ZV\9N'WB <9\]I7"U@S66K;MKEM&S#,&++RJ>>%,DAY'S
M/XV^6+=[_("#+8ZH (((I6F-='6D\MET]L/1GV&!#)_.,ZJ6]YV.P\$=PI4)
M/%^SZXL]VWVS?U\IE@5&4\0&8U$B>?:L!\8)'UA<C=$4M<K<'Y%R_MDOC#6X
MRGK_<6NH):P91N%C8X1 "-?QFF>UAW9<4.><G]'M:PL9>[IGV]^AU97JI/W8
MA)7>U[A),#J:_ _@P9&4W7EHO%)%CFS!ZY.UWVR1!(^ZB39E-RP2 2Y<'#T9
MS0?':1E4U3UO;[MSFV1RC01LDQ#+3RTL<%+(/WX#/5XLE9I:B4\,;#'"CY##
MR.&00*@@I1MY?N1%3&]:X)1^VW+J31$1-/+I>,EXMP!."WZ5"G"AH.O'8K?W
MU]-&D!9K/YZ+_07BEPX/FZ"(UHGL8OLO8DTGIF0S.%YKF4\O_+3:)>I[]3/?
M@T!$<SBGL4WWXO^]DP#$AN<]2L(QM2BR0(7PD9$' 9&,/+N7]*@ R!G+@^+-
ML7Q=E4.ASSL'LGF:>2^\GL>XEX.4H\7_RK)-PQ>E/NZT78$J#\QI*C_T>Q.B
MEOKR;.#;Q)(7V#$]3SL?]X"W&'&)R^?9D6&>YHOX"5<MG)BF31RP:YK]0]LB
M%0 W-#XT@-H7TEA?_-/_=5;G.A1UTU'UTA59ND4P9Q7;-CAJ?#NQ^O)O!(G!
M^W3$PIEK^F CNN_S\F9@25_S,EI<)W%>*&UR^-54Z/[J>[D;5J)OM2ST0N$M
M/V(AF<#30Y8U!.'I6>70=E,_[9%4A?A[+\A?O)S;MM/:\#\HH(@=CHS9<DNI
MZOU^&-U#?HVE#:./I$?V/Y79*@G([5('[)?*J /68;Y733"=:J*2F^E4T7M.
M7_H0>$MC:_,-0@PF/^KN>P$['/F'DL_OSK]Y=<K0;VS]3<[],GQZ\QL/KRQT
M[(B-*-+GUXPUSA]](G]SA3GL1FP4]_T$^T>^&)5Z-23+RMP&RW-)"YMDM\Q9
M+VIV]&[Y)8(,'J0H0KSQ*6$0@R5QJ3A8!11>X*]^?Y-R37[/:N-4<5URQSTF
M8C8[L?<AR.^AB[FQ%VCR++I*LOO/.JRC4C+1@W]-!11#::=ER$OD(BBWU>:#
M*;ZY*WC'R+=40(6*>J[V]-@0YHW/9^X_4@R_U#L(/(Q-A>/)_+5GOAM[0HHO
M'!7>EQG/YX+.J=S&9.#C1W5G/)1\T. 5T/8?$RRZ1/N*(#B%/EXF+8#WCXH/
M)OH&L1'?KD!"]6P\Y"K5#8W/S0@RL^^U'*\1S5EGRW.V8LF:HQRF0L-3SE<N
M'"^%9.Q&RZ*W^T0VIYW(>WR7&+V4KN'<([B!N!**?+IDA.2#=N-*"6ND:6:
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MX %QUE:F3_XWCA%_XGA;1!>!-&>(YF?PFL3!HW>W;5FG!!1C7P=QBFF5<9W
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M2$"YV?U0)X%?@4>Z;4Q,9:'=H9VHZF4$Q9PJ7=/\BE-3Z/>'\P6OIOF3.HM
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M3&VC<P+&@%1.,/UB12"%E?H,EHA@+DU A?D:H)1LA\N&#^T$&I/J4Y_Z5&?
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M4-CF]@YKW))F$#?CO< $%ZU-7O@JLDBYOE55L3A_>;FE^53<U:C7R-]@?B<
MM@,@H]5&4 1N=TA";+_,3$O=WL+2&&*75^9YO$.]YJ#_3Z;<G0ZD&I"K"7]W
MU_7X?R#*^!HU^I-UHSS'SV5WEV%MQESF9 ;&J&'UIZVT3T!W[+"$_CUV@-YK
MP/JR,#U'U3>W-(Q-UQ1+?[?F.KNA_C$UZ@():5?'V"NH8A=2DD!+1SE^DR$9
MDI6X(JOZP29CGV>G7;"9V3GX+=6$Q:T&2R#_6;#+EO27+ZD$_UK' \P-+(=9
MUI15;I9,9R/D'A[\E<'UZ)-FP$Q25O H.$+.@^S!T1@!?-*</85D^M9Q-(;M
M_ HA)Z/O(<@'=8DO!]Y=; /9C0Y @1Z5ZW3)81[S0_.DF?#A:&-6<::1]6V@
M/?Q1ZA^KOA'\'6Y@Q">0/K8>_L8V3_#%DCD97%C]VK9;^)P[)4\-#,XM<HQ9
MJ987&RIB^0WT#<+5]X[W9LLU\;]N#-'R:?AXM/MJ0#_U@&==@L'X?4;'%N;&
MV?-Z6_UZCJ^/0[Z/9[')FK]I78!UFO\[ 50L5RF (OS2J$Z&V=9VJB\4%^!O
M[R(1.TFA/>D]Q@%M.]G1X^:E],Y,^ 2>J)GV2F9I&NT71F)M--)HL2I*TH '
M?H\5[XOXOS<37#X!< :8&Q&Q40HL?!:5M2,^968S6^Y;[D)L')U&!98\X'-7
M#$,98&T/3P .MJ[T"UN41SIESA(AQ50^HFT;;\CPMRV';*MN[_6L+W/DST&1
MD'^&GG-5T9L;"Z!)U'Q-XSR0S]G+I460R%@?$? U^F-#?D6M:1+?Y5)5=COI
MP.3!OE_;J:9(G7'2KN1VC76,J7.SZ@D @G4@BD_A0A,"%YBE'/_.0ZS7GP76
M>'7/R>?1\J@W_,NY.F=OUA/M2K'IFI OH<^6RD>?JK+144'+ZJ84_H!#^L49
M"C@ O9#6[,^*G(^S-%XQ&(ECV16>N'NO"'3[_BTMY3/I0A$2+LL/G 65I57:
M28?(Y5")/[+CO'^S1:Q2)@YK3@ *4\OP-?7(F%_UJ:Q!,G.0JUNPP1- :U#2
M'ZTFE<45]:"DYXXIF!1-&I,+M+(*GLQ7PU9\F+^;'JKF#1%2*7F'?AS,4G/K
MYLN#-9-)RZ/^UAUCJTD%-)^1[C[==)3LT?ZUIE[@Z,^&K<63RQN@6R(B G_M
M! @E=@9IYQNWF#H,WD8N+9>N\9YMXV[M63LH([OE#>/F1*THEQ4YK^>]R4I)
M2>%[72C)OO,)SX'  :^7E6I=F3>5N1: [#W'T'I8SFQ+O&93P:-<ZA5 ?I88
M]7FUMMZ_4U#<->J&;+G]CO$]04,M_\ FVGJN!H9CESOKU8;!GXTAM6N]_ID1
M!LAT%=+/Y.G@T4#W(Q6:1+9\W]+S"H4!+?/@E,;8$I&QY5;,KW+*@D?'[9%\
M@ZDE3<CS^!, 1["*HXD)ETDRLU'I?*<]WDA]R E&4;'L+UB34F_-L]&\KQEQ
M.O,?6VX9S,5PE<9?F.8"Z=<3@;C/0+:JG=_6'*YHVUSS?/NFQ+DNMT YC%":
MDQJ\6&&'J,7[_->GUJ'1$OXCL]O&/]=[BX^[3MFA0BS!$"A=LP)R@;^LI[M^
MMK)1?^]%"A619CAAO)06E/II?G_?P-C'F:W4Y//R\EV+":[-(3K)#/A4&#*
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M"=!^VIB])%*94=][]<)BL)?EY?VO7_3U=E-Y0 '9*$C0WY'TERHF?^;C\2<
M[([5H5BIJL\Y.,E5\RA.:[TP 4D5_3=2.=B[KGN5<V#(X%VNIQ<]L-25K&?S
M,^*ODIQ#A(:7K6(A;Q+F'.N9Q=J<4A:]J[IQ/FVM0O"!_)(,).>+-@E,?U*/
M$*&\EV0Q<CZ#6!GPJY=67'CO$Y@G(1R8*&?3](:Q]:V/<6?1V@%'\$)4C@\X
M;I8;(6DP$_(MB[C;4#E/]QG#!0/_N_[A^.!_=KUQL-!SSZ>^ENKOJYB::BU8
M3-:^5)17+$Q@!!A">.BS)P""B0C94N#P?2B_NE7T1ZR/><,OL.*4SL$E53TE
M9;1X8;ENE_=<#7AK)X0HM-5RC>P?K(G(3_@WZ^H546E'NG-FO7B=!G970:9
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M>]C_^MB%3)[=ZR>*Q&ODAE4<5YP -LS+S&.@+QHI'IW6Y=Z+MQ[+3L6? *P
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M\2SLQ/HN( ,!)$0\%QO;G->B^T" FT>#.Q,N#-G9NJW6-OFYOV4KSAI4P$N
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MR)%UT:@49@KO*"JL[P4+8!D_ BU/G(M3,>7)[(<<=XY@>'+@M]VT7U)*B\>
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M28"@80E<;A,7YR\<_,?6@F;9+U[5&']W4#QMC(>9-O\ZOG;--VKQ)[2E*/2
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M[\3!$.SF+16!#.$I9?-@"JU#H2W K<G!]/H,E5&.VOR6N)32(%R:N6Z(,&P
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M7WJ&X.:!9HAO/T4MS3M#W3-MR<33EVO\:"P'$4R)[\.J>AYS@FI%Y:^]A=9
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ML%K ,[T/HV!&^RDM]C3>R/D^^L*BP(JB[<U![L.3#/9+((!73W9I)-M-^E6
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M(TBA:(J^M_S7XHW436N+V((:,%&VU;TQU\YAY.&<N&Z/UNI;]='9$)(/@7]
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M5;\;Y?F<7()UE6_SR-X_RUGX[;A[Y_KG=P>OGSD+BL=19LE'I60(Z3.!*_Q
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M/6-4)/>H!E3(&,7W8;^MT=NH$\/9W\69!:[6%E%UL_LQ5R:J:-.>GA=>_D.
M ;?66"_[V,*WQ1GD_(*XEM0F4O+7B CN-X6Z&\;*>NQ7GAO1YALY^_).O-#@
M$U+WNQ^;MI*HK91*.J!;H=AJ/0.=1<K&B:#?U*?'U_>N (=</+?%Y,0'5UKT
MOP.+0H-.>.%=M0@>L ODLFN>-#F'BV%QF:P&11?T.^9\<!RZH-:52%^1YMM
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M]-^%O^L 8G5E-64 VC]I0&L  /[^ <B^4M/7$!00DS(3%#=5,!+D^Z](3%1
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MW-RGB(6(6T\XU7M5 ,P-AZVP-[ @Z(JHXR&R,AF%+@I>G36$0$U10P9E+UG
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M$;]ZDGSW\0XVC.&WPM5TAVY-?JR<2)G18QDU3CH;J3I?06AGX4ZGNL:$=HG
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M@+"(WD/.POH@*S?O:E-%!] OPX2]M)/>W^&>O737#X?9K!II;JYW$?=W:\&
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M=]YX33NRRY-]M!N6YF>_/W.=87WV>ITJS0.UZYV"Y;SW>1'8Z"L'82L9+I7
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M'T'WH#&%.E6VZ!V9ZH**=F.:-*6M_ X(-Z[QM9I>2S+*O;@U)7^[^(ENNIK
M&GG_+K8H(WHT!2R'S<^;!@1LG]V?\+KRC^:!4.L82&HEY,5[MU\)E"8AZI2
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M5C:FI'6S(=995;3##Q>Z:)G=^3J!PB)TRL-#==*<WSM3K=L%TZ+1)^VL<'Q
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M2!.1,JZ='%?'$E_GC*TIY?4*I%+?<"@1:5UK_W"5#L)Z::/^$[CNMH'L>N]
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M-'KUZDK#U82<$MS!GZD8$TJY3MWG'XNYX"MZH[O3-HH-6V@Y[X_\BVYVFV?
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MD<&"8J&SK_,I!^VGMV%Q05/K_HS\?1AHCZJ(.)5$D+K6*9EK&X?!NJOIDMN
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M#569B=&W;$6"BN@(GMQ)WZ FA;<*WGO;2&""[:YHUF%4Z?H]_K*XU+E4!.A
MM]>\'2\?E79\GH+[$*7J29?:_@8H*.:1;2:O[MG_=-:\_RJ3E7/H)?%G\/IO
MQ;80U6+-OO$-<EQBJMR$?>J.]^B''']+J#WR^8?WN.+!1ZZ7*[VO*.7P<?=S
M6#;TW&GC*)5_\5N(M925=EJ5);:2^\/EG.#FLN^OB(V!$Q^0<JO_@XFK_&K"
M =>C)14$E)3NH32,[FWDQJ@!"A+2,%)04%&Z!Z,;-MCH+@$1Z1Y=HE)2HJ2
MZ/W=<^Z'^_P#[WF?<]XGOKP;&5T?S]B[_-3V\(=P-PP9XU @3=^QM9V:B@7S
M0?FZ\Q",N%$%3)?YS'?/>>2#-&C%2I 4:"U-N'V+Y1?+N%"U;HDXFQ87X"$2
M5%+\0+W-7&@/D)H#YI5:S<F89=9XIEOW2\4Z"YV@X<?YUV\+E]=AVV+#'BK9
M86!IQ+1CAYSOY*R8",WS&HT,0-KY99K5P"L"\;X_1&(?0KV=@6U A%48@LW?
MC39IA_V[N"D4=M5%(OKA?B_ R9&;<I'K/>-*_#\ 3$+59.:JC)VR$KG051F
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MU=W$[TQ\O."I)ST7>+RXWJ?SEX .9CN6)E%M(.%)6AJX=IR\6WTJX,A?RR'
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MRP#V 7Q?:1A RO#\$R;1?09I-L,_U.$ -%W5<8/SB_KQ]:=<[CI$N\A&/GH
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M&\'6GX@&ENBU*GW!>6HMO67!C-K(DU^JPX(>"4%7IH8=>#SSA"%=+*4J=/\
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MA(!)&QVW'8;[[=]M^^>%)OL+VV'??Z7(YXMA!8$;$F][7N-[6Y!^[CT.(+=
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MW1_K*%!(&0.!"R@:B5X@$%, _&KB&D[1\&XA(A3/(Z55G(GQ#@_+R<?\R-:
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MYL'5LV0!=?X>$P62E3W"?6(-ZZ7\_J/>B_U ,>>5@&L$^F?W;2L]\RSLQ3U
M2M48[2*I&.Q:/!_ 1IG2NEK!B&9ZC7\>D.R;5',T<D9P!4D.*0JZN+J:3"50
MHU?P$9WT:)7,NV!H1%DI !].MQ*>)"Z?2UR,#.?Z])X_4-:4LKE5F%]@DGK=
M<[U&= ]0W-R"-& NZ2PUJK;O 1.D)&Z--*RN_&CX>##"U;_NG"_7.0 @S'IX
M%,^0>'NQ)F6 :R\Z&8*[@3JBLV:S'K;NG>.'Z[T#8KI[[%N5AD=2T!-/ZB^4
MZ;P/+BX:KJZ13ZP7;]O@TXG\!K6*;/5LB;=-@?8APY8GZV;%J8^3@CXR?*1A
M.-D/.EE]ZJ)1*<HPM!S3('K%,$&XYWV=[%7R$*!W.ZG$><-_@*:A7A,BJB$:
M3,(/@_)Y+R)16P;71\%HET,,/&284F9BN-[Z>GE4I2MTXNH@(AE_G%ZE-)4_
M%3#I<;SP;Y;B3^,/!B5K0@/#$I'\\:B1)7*/>!+GB!I[S]6G:?D#Y_M!-RA7
MQ2<5?B*,L@G=JXJEW8II(?T!;HOW #4U9;JG!9P6 &9K5CI2?"OAO4#4QRA2
M$2SAR,C%GL?9NDR#.]Z#ZZL%U'8#/L-WAL9!QN)-!R:P%!R%WDZD(+/P#.N>
M/VND?V*>9-KM^W"/T'H3O;DA@N[&7@R3Y.H),/$0#%[$V]1T?-D<S"!?H^;#
MZ^AZTR3,3;C#ZHR*$Z>'>..G#*%^7:$ N)\64MRLK>1[-^C<A>D86@?MV20O
ME/PN3 E52)-WJPU4C#5D'32,/JIH)G6$OB'/B\9;\E0^_+BIY?VS2R3+:2*7
MS*"C2$)QVN#8^,[[48>95]5@#VECQG)-=[^6A5AHX8.87(BI0 S]7C.Z9!=*
MP?(KJM 6]DX;BEOQLG @/%6S :3W +<DF6#"%SD4C37#<'%\5FNIOQ6'+G<Z
MC_-J.GM\$%ROY8Z&<#VV_%T)M@"6LVM2K<ER>R%U+]7980VM5.OD3J:FBOGZ
MI[?JYM.Q./IVY/*RFK:5<2E?Q[F$V&V2FW_2JTU5&CG$Q-9^V*SB'V3][-LT
MZ>3J968]/9[AN?ETMM(<-)RC_/2CHUZZF10QP;H=N;C'6,_,*&,],4&6#2-%
MJL!?DH\B R_,HAP?/5'<XS+%VS/V;*]SW!1NB&&(P_"MEG/QT#EDD<UELNC(
MB>)5;$125H%^V.7:.OQ+1(2^F<3OC4)E'9P'W%5WX\9+7@T5U\Y69N2"@W<R
M$+8OP6F1%27)>+YMKS]-K,ZH]FUT0RLG=*#<=8T@F/Z7]<^JWSB[RW-50#,M
M[!DR$?R('98R.DB#:\I@]; &^]A+_Q"NTM'CRT(R;;9@(7!/RHS^+.X+_['8
MA[&FY2EYJ$2]$)_(0;68_BC @:>BPB]/;^U'@F25/SA*RVE:C-XN-E6]Y8EJ
M3BN7(]=Y3RGV2/]0D#NCX=O\)51*]M/1@XVZ]V-GC!+?)P6S:3<=;J)<C0K?
MJJH7_HI'<^W/C)3#WLL%MZBY6Y(E]QCEL0!2%GS>FLQAA=IOT'=9(_GU1OIZ
M78:TSW_@2RS" G:@->._&?"^@BM ]H5&%3FL&<M$,Y)FJXN91"%*?Y$Z7!+]
M+LLBF[W@]JJFM2G:C%G(:QA#(AX<#C]8%T6*^1WRP\>I;W-\4>7<-)9Q3'_(
M:(?UFF ('5ZR<$UJTEI57O(1WN^%*U2V4:7*4+>7B7YV(BX4X&*.,HVFL*KO
M'\Y>X<WRZPK:Y!5SL3V>(EB4G(>0Q SWJIH&,U*]%M+)X4LO%5I6[72N+FJ>
M9<KJB">D-:R@S+?BY29N'$4?5NN_]J[U=B!RB+Q.E\]>GK26"F(;I?W<^;-:
MG;82TT[7N49RF%'BL69MV"@8_L-_H.U*=2Y@(NGK3)X=O,24SY&RLK81D\-W
MU.D97/K#&)07,%Q0_I91]X5P\LGC =59P4W':JH$QM]\6BD]25I#4O"+HU-$
MZY)B!>;X*B#XE_="1+(P-9WK%''IKQ\526)<SVH6C13*Y?T8#SC#-^WB&_\4
MZP'4IW24SBQ+^T/WQTGG;8TI*@SSPKFB\'3T$J4+WQTQN1"PO9JM9^O@'(>]
MO@<P$ON<D@]'%.O?11M?/YO8S"P[=^KX25M>-O^F_D.MLO?$Y\&YG/I3P8H6
M3L<600,P]_Z8KCNB5H0_H]I+=*;?\//-GD:4?A_4N\/1E"&/;GH<K9O5<L5&
M.SYJJIJOZ)PCFVI$W&!\9B@^[QCTK49@O]A\UC\QK$KHL7]%^GCJ=@Q$J:J=
M=B/*$%J(LX?EM4&+V6\18!N3_O3.>.3!F4,LJ9&3\'S*NM^V(S]^S @V3(VS
M<.I:R6I_F4G/"B/GT27ZXE!!R/D]3(,./#O5.3;QL)HW,(R"U_E$/26T\)69
MP4L6Q8^4S*/J+V5E79E=&)5V*JN*"*FOZ3ZTI@6*(S<%^IH%S=,9#:["R\M3
M7L>U9GX8JIEO"?X$,5OLK!2FZEC2\7]4KOFD=FHYIN*ZO^30:J>8-N751QA1
M#G1,D/MAK7Q+KET^Y8IX)/:E7]M,_@<A5C,NJJ"?/L8=+F.Z$<8IMHZ>JNHB
MO"!CU4MOA(BV_Z!+U4HWQ$G@O8)"-3A=IMK4/TJ]>^]$JZRHU[1F<-P86E60
M=\@6$!)R<'DN2N?JQ7#C<LSTYT;,/OCF<([XMXZ"248V<)8=8O0UG;,NJRR6
M,I7-0>)JG86,(!92\<U)\XWAE*Z\G*$CHQ*KKL&F\I!9]Q,J_2"R>X"(PI9A
M[F5M93TMCV+A0:0^\U*#1W%Q]M+@[+O6UPQ&TXR>?EP.P_M!YDXJF4_2.JON
MZK5%P^NI9Y]T+!9/E'5*EP^]-ZLD56O[0"R%JUD0P^'!?MNX6]!7O%9L=VQ?
MV?$EW[Q6E6LBI2B$M/,N=@+XMQ7UWKUOEH'H;X%V#;&.Y]ST;\?-3<URQRAN
M_9>"3L%CNBH,M&48RVC*%T(*#&Y97J^6I-CE)1I1/1*)BB$%B4C>&!KUJ[E;
M@YG.U\JG^]CN:IA\6F'&LN.O*3'WJA.^Z3TQN_5VCN6S#E["EY8PHPC-=D?M
M:A+AFZ;'MJ.NK26LI82!2 ?ZN,R$C<,PZ,@S+IJ 4<:\IS7VT4][% CT:OUC
M[?Q8K=4WY-CB)H2JA%M,$ZOM!/0NH4S@] _E&0FYU4:I7+Y@(1O#M.J#Z/K7
MV @/U</>C32-LUTU0?^(!_!8X9)??I_GJ#M&WT^_5W48='BD\*TP8W9;KTKG
MMV:YT?69=XZ++&LM_S*LYCK@>!\11*&:70QJ1K"A U+S9?;R [KI0=:F95-^
M'%]/R,A[/ J(\)J]_N1!OAXG7=L;..HEIVG,WH07>W6IIGANY_H'H37+32E!
M1]\R7^HQ\H$Y!C[F!_+D"._-./7-3N\2(ZM,,UN.W'Y#N&7FB^1,K@<'/4QT
MJ4^S&<@S";^:I&M6Z90.19%%/BQG]".@QLT7YDN*8!K W-J$??W=+C,CFIVN
MU<"Y$VE RJ6G<V-_^42E#NXXXW3<0LXP<9?7:\<PRX PDE.>5Z6DVM<I"Z\H
M**6'<GVFTY75]'I#Z:9#;1*=Z%DR7A3NZ/YX84"/R3_E8;/;B])B,!=GA6/H
MJ[+0E_!.98+<Y_,XNG8"D_3W )C%VLXC'HU#\?@!P:2JET7;^1I]+FO+^G]E
MEIII-X['82Y?_!F.B-LKQ,N-O^^:T(:Y[$J$C0]R17&G$]OQO3<H-1VO<%"[
M]:F5TBW\63K2]L*(;QHA/TZ++)53MHVO+KD'X"/#A2:K<@>T^4:HL'1->0J_
MM*KIN\!763GFI<=">'>_5!).:IZS%P<KP#]HZ-EL#Q4W#;;Q=>G6.T*RH))+
M ?YK,,X9I^02_I^U68<CEPWNX\5I?F'3U<38Z?:.:J6_%])>7*.E72HECD2L
MJI[!$RFL7S[0QLC5*=GJ(.S*I4N7R>X&IJ$Z59J0=@]FR^PH,B^JM?("@OI8
MXJI9&ZT:/ATAXM5*A>GWPK-%_6"(TH=T&Z='M(6N#IY5-G'I_<1"5EU!FMN4
MH/1VFZGE''\=*^G/NYXD?W6C1PABP9N&[C.*>6$RMAE5K5_U>+^\,MQ>%$R5
M7G4*_U Q^%23>KR(63PU4 "_)GV*>6R7P@'/]$'YXC5C=BD;_\#6 +L-6(]V
MM%SYN0?]K+O'86/+U?-9@^QWY<+]M-OEYB103='6EO;8\I,G'GI\QB=:9U+F
M?.\YNWD(_<U!6Y4+-=_X?I1,'W#-<B0I45Z;+,8LLCQF9^%'>'!C^=H_;"RN
M7+HQVKZZ#BG/C*XURZW%JFV9]'G0^.P.*.GN&]57Z>7,8208?B^2\+GO_G+(
M=#_C&ZKDVRO568'M9*IEI\7EN,QMQS<M"3GLMQRR7R8IMHB:MM5*D.94O!4M
MGGI2;%CA*>98J!C9!6KE]5^LK)>9Y<+\U"I$M 8YVH+DB9OZ*;ERR/2J$U,@
M+<+R?\ZOZ1G .XSYYO[*@<O^MI5S4;V6CD1)Q@40TW/(O'*Z?%OM&(9_?6#'
MU"A3M*Q4-I-A8+5P@+CD%7%S:?,Z59GH]_0MFP?5CXQX]'%Z$_*K"%,H'YN]
MG"L",O621COZ]HO$\!R.G7;P/@U_ZRA<FCGX_'L-2[EO5EY$$KEBN%'D$=:]
MR$^P/I9"6Q$!XY<BD@HS2V34_*#VKHSV-?\%3YUA#<1( ;9TL@U+GITPW9X-
M J')5VT3E+-CMZ96+&PT*]([HJJEFTX3JM[_T6W=-P;9&BWH#%Y?AXPE];6:
M)G@=\YS=V((]N=4E.<2_? @N7_XMY"_X[L=$C>%2J;F'D,*9U=_:F:JS]V)-
M0F]--EO*>">:'05W52+>1Y&;D#3J<52!?:5'KX)E;U";B,WVU1U6A$=^_S$&
M\:\%(Y&BB%I(3=!,:[:6QI7E%6SX^NBI-&NI,? P'MREQEXT_4[]2V12DYQY
M5"KG1Z77=<>#@MJ27^4RO1PM:M=IK PX##;QFNP8UH[AAUF7ACOJU8X_U&U$
MO:9K"6>'>"3-;$S$,Q=S]_3/PM,+A8/.=.NUS_1-%KXSF^E%>4^U;:6L32VG
M..T0%SKFM90>Y=OM=%2>9<M[4PKS94I28@L#!46+YO<A5\9_:6_#[,""NUH?
MLG\6F8SHURO/74/5305?:^W4['9G5'ZD'#F/'/^D*U@%X8(YZ[-.[U#Z!UY3
M7'F*D%$.T^F+,RCNGB';)U$%HA.!Z(_V=)@KG!N"8;*JD4136ZG.+%V:0#G#
M?)UL0B7W'Z,:;$[G/(MV"7_#]03W&Q59;&UL7D' ?9LSD6ZT"K\UR---N0\(
M[@&M5$<@>0$27X5L]:G3Z622:,;20)$6GUQN114>NL?W@&JIZL6S\1;'3_69
M/\?-&M:VT6]):W?Q9??]=;=#^EO2#*U5'&KGZ@+PBNW,17*K3 UW!V\52HN"
M&*.89M%HZ;MGH*C7Z]J3$G/+L71@T9#Y%:B?7_U65WO%A8JU4W3SSNV%@]PF
MW9=J/7;:';D/>AGYB[KC4RV^OYQ[EDN-*Q<P=4$,;Q*TR"\+=H!#R&2)NV+X
M9+<P)P! KHX(.*<+$D9LO0&F-3O=*%.X*V2//W]AK93Z;:145>ETII8T^9%G
MAGPUF(M%X;5 I?:Y4LWLP\(QHI>+N+449C0SN/PS2NR_E(FH_:UPR3NL*UXG
M,3&;$P=K-7NDCZ$Y#GK+E_1-C\R_+=0/S%1F-K_W_[WHG;= .6;7I0M7,1.1
MU4*/?.?V\C?.%(I]U]2\7Y)%_C(9 CQ3M7*.-<[V6!T\]"[1;I=P/VELGJ.K
M6WD):Q&&5/]DV-JLK6VU]4G[5*W]"I;UO?HZ+DM76"KADQO_%FPPQFY;HAEC
MN=U:5!LWXZOLKC@97Y%K3Q< D/))2D:T#RES2"AN7I8PK1 C66 -ZZ^T2A)M
M#6D85=IVJ$SKZ3\<B4E7%>K+Y=/%-!">3^$FD+XH\8]:8Z$@V&8O<^4+-&0G
M+BJM>U_R$?AO?0B+X^ S49KR\K!R-SZ\F<G^E@TO\<>QT']M/)E.+'MV'#%&
M9)^[G>UGYQ#)8#B;9];JUS S[J-U$'>C#X$&QVJ>HM789+[QW135+#>L5,\=
MJ*8N?L?L4( >"D8<Z;C_\5E7G7R;8?WY.83]1+7V<>MRRW(I'-HN)U*K?>JX
MU?0R]OT+>2&M("&YE/<R+)*_B8=DZ(S U(P:XZUB)'L')P<GZ[CHD"7 ;024
MJ62'*"C4#7(/J-&\0D#$($MKKULZ5S8P[:U8$HD>S']V1V,LW_SW?]O_=1?@
M?]=,N3;EB>Z8RCQ2X7\H#W(V_#TZ@?.;22XZMA?_ :0<R'Q#ZJO8VQM*1Y>H
M@&*(.OY6T]B"D-W+>Z=B9%?(5W MT$E6FE[$#LU^1NO$HM(+UE&L"E>TM>;$
M/?HRWAWW>3%Z%-PU-+!A$>RW /4(6]B:7..L/68Q$8%&Z9IP1QB$8Q!.P!9>
M&5[U+P\=&\()>Z VG&J1IZO7*1,>*4/'=J#4$A" 1;$D](U,8^/$%3X3RX8U
MO4W[,F'A#\[X)S('Z[UP,OC HRN0,3@O<4=YZ'?*7PXX3WB0N3-^A'#?'8^_
M+#EOB9,I;\-:Z +B\2N!+B$5:^<H_]!G4RKZ^06B2$BTE,3E:>JU3K+ZP(72
MT#O\8#3K9/?&N;C1*_-R;?O'A&JMMV]"BF?"_<'^,>/=DOL(MWV -%AIB5SI
MG$6.NW$)<LL4&-BV*32#!S#JPYK=N+F=+%S@#0<PCC6D]JS<\-\#SI$)K<(G
MBQ?49RJI*6EMQSZB8M9; FZY\0<#<<D+[)S5$A*')(&K:%9W#6>&FU2/X?QR
M$)Z.,N?P.,"ZK8>38>C.W;?$E!E5*KK@(QEHWQU"XM$-A#9!K$065A"'0(:K
M@TTGMZBIZD8L[P0RN6$I))J*2Z:C>\==^  -.4F 8=J&1!;<WB1WM3ICPEW=
M ^,MS13>7L7;)XG-B^4G"V^/:HVPV3QU@1?\\R7Q!ZB$Y+<)81.*Z#,@S=+5
M$-!A+DA"N*$%AI50;KUT?2F,[94TR\4@#KMW9ZX3!<C?B./$,XR*H1N8F21]
MDVO]]G,9[TA2);]"<O..+EWCOQ?"5 )0!\]@:TLI8?L!Y_3R?&@&924<JW><
M3#Q^MYWHA<.@,L0=*Y0$?9F4\:00%"05,[\3Y--7H.6[4)+T3W.NQ=6D90,F
MG^.,,I=4/'$8'RCQ+:_3!18T#'T6HW!#AABA9L(@A@N&/Z:7.!,K48\.>1^A
M/'(95U"3A)4_80PQDTE2Y4SOHY^OM6!@/QA13LA?_L$&=:::$F'#08GW &;E
M(;>K7!+@^J/!O!AUX07G^@&T"ZN5#T/G8<[<P9)+(R+X]B3^<GCD*3'@<O1B
MA.X2^Q:]V1\3N_#IU@4!B2G?=1(9T& =;!,W1@]VGL/K=D S"J!.TG=(X(2(
M1&)@(/:I!8/*A$!A+C'ZK_=A0( ?<H'C+%5Z(<B;4PKL<X63S[I+PMHM/*%X
MP#!Q#X@66;W1X ^12N^2A/<[<[1-VMTDE==77"'G'X/2<VWE7);VQ&X%B%>4
M+TX&5-(1; 7Y/@OY*!PIJ3^HR-ZC35'6$2"3N,T%P!XY/&>Q=1@1AG +5YY
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M**H/O__NM<MB/VH%T >^]J_EM3SE@YB??,W0.A]$923.:A\_/:\^0]N?V?Z
M&$5>]SD-.5DZ?E _NHY?C9"144/Z9\5_9D[LPE48S;V]?WA%L><_*'Z=XT2<
M^AAX)_:8.]*RMQ10=%,P.6FY^_@" .Q_3-]H/^-Z$+P_OG"<7D8N8;]_>?7C
MIYRW_= SKJ<7@,&J?]ZKQEI7(7<BQ_^=6 '_:-N)([IVM;+[*O'/6/[_Q-S-
M/YA[/@Q9NPT8_U=Z)IBA[S]:_/Q'BZ?/=\^YK8^V:SC"G9[SGM#7^4MP%7I^
MSR=EST?/:WF=?[4?_[JY-0=.3#_W5"#\(\C^NL_)1=!,W@M@[6I@T^"_+ABH
M_*]]C&[%CEX T/*GUUDYL@3_':X]"<Q^/<MIX#;*J>/-P],3XFV=WW_L9_3G
M&$$M^04PBC$3<+5LMW/I\'?EYD8#+ G#"Y!K>SAJ>?!O4_73FJ#(DV?K\^P0
M;MW_.'"F?9M-XD80\+2& QDN7PF8*;/O'-*R"SF16JKKW%2YS2OR9@\P6'?>
M[DF_]I]I;ZU=X@KL1E*R;F-JN6B^@>&L%:+8"7]3G!>$@3_42+U+S,(CS,T.
MM1M2IC]X<R)Y'],;MQ6GL0."X9&NEB[R=E_35O-88244)E/VX[_)+IBUQV_3
M -)HS&*OX!E#9 UY$M^Y1M^T/O-6XF2I3V[\M1,B)26];IL7</TH/5KDD>,H
MR)C_;&TC6?=>QOHMTO>PGSV*7^H-U,@O2(S'RA6@ NI2MUD;S'?T/S^<;JH>
M]#NID<3DYL5P%)J>-6K=\HHB6YB1QI-+KF/+I=Y*&ZCUV.L.ORO<H'[S L!S
MC!J<''Y^@G;:@,"DM:^!1S'=3;F%\@%O,+IC[RHS=ZGT2>H?O%=(QZS->T9'
M2].OP5X :LTP_=SAO%#R%\"C<)LL-.EWQ2*.,7H2>(0=^^_4&+[,Y'&H1U^5
M:,G*42"=8T8HF$NZQN:=XG:;7>1<V-.,T2[1\[G[T+ZP</(4S)OO4P]CO B3
MMEX-U8X9);7"FR%C.1^!96MKYP@])WMP4#YN2OD[_G*NHBV:* Z-==OQ1-*[
MN!\C40&T$=1#UO8_4FHP+"38N/.E\&A<Y.10:@I?%706N,&XIG7RC8BHOB\@
M,<Q9=,A8A>KT9&^9SA(8*LW_-$RR'_E6NE J>Z#CSOG6@+K/3M.X(".(*GN@
ME<!(3(0Y$(>69E+PX?@.2+XEJ?2GB<M,<7[I!3#%5F=90?'GL]9SF8#R"P!X
M&Z\[C?;T.^_^^ 7@[=.SOZ9\<U;S^.D%$+CFN3:.H1Y8;?"VO^5?K_-?"^1C
M57QN<*=XPH) BM\%XL5'%<UZG%Q >R67W .=,M-F;@PZ' :;7WWBNDQ?<./;
M&;=CX\W-RDE;)?W*+QO=D^;5OQ6)CHTG4*VMBN/<%2&*,.Z<MSV"EK<QMFR-
M6AL-;TM3G@KZ>KE&:F>_2T ?ECGNQG_"?F_5]+ME&=F7?S!E4_A$5]'6=F_!
M6N(&C#J5^O"WBSEC^GCJP?\X1MJ-1JWZ\GP7U%I^]+"AO#SRO>4CAQV))"@9
M&IL.?T* VUMOSU$8$F/2.FM!O&R)/G;HZFJR8,&<+MO+O80TZ*R/G',U"3-&
M;#B7L=V,WUTZ>MXX*%.A=)X06EFC](#OVCVQN(]6[F_]CRE67P!\9 K/]:^^
M_[^GWT#MMDPFQU MT\O%]E1K'B/+9?<QB-&*A]Z2!QP3?NF>.^D*H2T4L?>A
M(9I,/81 V>5]6TAYIE0%##.'<KSR?9DQ-PQ]<HO!1<5 ,D)37R3WD0QJ]_,H
MI-%?<\+:-[5HM"E&$TI9,^.5Z>C_5J-D=U%GI8.HFC_EP)ZST"/.9"%,24%<
M6&1 3R%J/3.UQKM4&*O_O$Z5T<0&-]OWK8]VOF)0P!KU0.=%6VU0DF*@:(L#
M*NA<T BY[PJK,\YUP[)Y;>EFY>8B>&;L!9!^&A,0\;^=#>OU;!U&1=LS5R9&
MB%B3]NY5.I\-%VV%'K&@B(>+%TJG9/0C%RR;ZB:;9+^U]U/I;6N_.7_-*1>;
MB]2^3H'MA< 9%1/_*O0Q%=+4,1<.*-D/!RGPD@_6,KEG3&MMWDF+*8 =TJ^:
M>%O<G=A)X*7TV(PU=4>#L6=3DU*G;/7,R3^4T:+1TD9:4]$0#8OQCZM*'RQ&
M;=1VW=SM="J/Y)>&K<!$2YP"EQ:AE]<O .+=WHF;IQO?DQ? *HHZSFM8%?Y_
M8/C3?S&<-1,4 )KX-T4\W'7M6U[%%-S.B_R;KTX<GT\%OCZ9W#R+%+T _DD9
MKZ*=49F!NZ\6>G6C5WOX=[XZJ?NA8Y_@AM<+@ +KZ:$C,!%"(^3_RT:O1=(1
M)+69R#8N_7!FY/:$'O/=IZGVE3)(N:;#@"(VG2[N5/Y9USDI-RB.!%,R*4S?
MF&9[*4W?%2?3#E*^<PZ=XY]:O7O[67?RY%MK(<UR>8Z;KJ529P4G1G@4A_.9
MJ61RXM"V9<>RG0<#T1NXH:]HYV1J*J/:?RE_--HYR**I4KH3S](I248@4 BR
MIPZ-QL?UK)_%LBG),">EU$>>4@Y\9/*1F*FI6'\OKKD9+?^N:-[B44V$X7@%
MIS/@1-T^576E>U\=#%0/#- A=H:)6$'M*G/7/!,Z7R-MO6$U^RNS >T=USPO
ML'Y:$9X5&8TY6G)[(F'R95<[JWP!(&?H@M%KYY:(1YCB5.7(N\\[J>O2B=+4
M,<E-I<^)95Q1:QV!M&',Y+DYZSO":3_;BKY0X$]P,O$WT,X*D&XT<XMSP6CX
M0L7X9*$.=#3D<=+^&HJ).(X!)82?V&1D!^;:9'3W#)R_^#(^5, R=7WOD(T[
M?JQ%Q=\.D$81?JA 4\A59R(WAL-Z,_8CC#Q$<T_8.M_U]^7SCRDB W9FQJBG
MD_!43DWB $$07M. @]J9#B:; AV^=FPK2\EIA'UJ=7.5&JZ/Z]HKSS;_EV>+
M_&GB")R]E7@!#/PO9.PB5.3-L65@)!+O4CLV\JOR*J:;&22[/1"<*+5=C;I'
M+#R2/+?_?]!RBG]<[/QY[;_>U/+J8/\36L__1>'-?U#X LA;FE]E[S/=,).(
MBUE;\WQ@IS,4[MI7JQTSS8:Z#H([:8TRV5<C:R7WA>\G3*DC;8?S1YUUJ2<@
M#+>WA57HTO%F6M2/LTM,=I5;&J^A6:,!2Z!$(08/71Z/7@(XU9200J7,ES95
M4GZ:4ER.A],%2!Y0;?MC7D9&F3!MZQ0:HXHJIXJ&SY*9SZ)SL]^=TW"PVR>H
M@2'E:;F6YW52FSF/;6[;-*VR]B"G?=-'@^?@[>Q"_;-?@T0W,EJ+1J0J9URJ
MO/.=_-#Y9IE?SFY#,>3S.Z7Y-[+,O>:FV2B(^5 KPCQMWW8\7BDE^8Z1Z?9;
M(X^1.)OD^DH.LR0.[W2O=1CQ$]-S&MNL:I!3'RX.OI!8DK&'XE9G3"8O6JQK
M;LQLU)5>0QQG>C&,Q4^/*)@+O*0Q='5GG=!T4>U0M<#Y%9];@@=7#,8M8UO$
M_=;4\%*FE>]AP^OAP<N+ZX'9JPGEEY27;?SLY-E9?D,YIV-/=,6IRS<P6=B6
M^?!(=RJY)$@&:\B_W)58WQ,EC8H;MX3YKSW> \??3R<1 10[CQIG!-K6:^^$
ME/E6I.(=%:EVG01LI2S->!_"8$-ZMWQAJ37*E68IPT,3QLW6=AT1A"P'!7-L
MCP',N@K)R@.UT/T3:J8/6^[>6P?7A7%)?[[7V:)/85W5K'0<^? ?N=@?K[1(
M2KTY ]]F!8^)WURL7(#'9!H"FS'49FMMCB-W*LWTF/RFW?8_=S#X$$2-=Y=:
M>#@]0]H'-'NG-_M5"\BHB7Z[T@AM@$T'Z,:>ZB,C^TD=I=N?E6T&5IQT$+P6
MJTW[=^.BMUWJ'6F6>9@JJ2N;JAHK2Q\>;S0.IIL"!)5%<9"J+V/3]*?:IDA@
M0MQN?"U:[QKWB7.(F-7E%.H7$_X^8L;ML_6KF\[IJ4>?&_@6N';@'1RIKJ<5
M)\2&:\FUOV$<_4"L0)2MI,1I:>P2H.[PPW0X&<GJT4T-8*'G<(AF;5_"1;$P
MT;N[P9Q^4P>[9DBY&5IQ$(LS:Y^^OI)(^+UTT%&D7 $M:ID]%.A8S)U#C+GY
MXF^>C882)H*9ALW](T+(&IY2_EI@E.(;X 2E;7P1FG $G]?2L=G4(KGO(OQV
M1H_E2YV".Q?;KZK:0U,;?2M5.];\S>9Z&FW%F#=1^-RMXHR;_5I!M(21TAWI
M%&\=5TY@! ?>2\J7LZ'NMGFPEH!]\J'.1_B9SCT58:<<ER=-DO^?1 CA_Y3S
MGW^E/GR26NR!9*O4]$LG=?<)6=25A4R%6Q1@/$])ET*:CCZ#MGA(+=)IWF^E
MT::>IA= ^$[>_AQ["6[[+Z.;LI6 NL_\UZ:JL2+(U:8&/_M^?VV+6EPM'VRL
MS&P&Z4:4$<6MZA1')0DHVMD]*,=!),T^6N!CI80&L44)AP4:'4TGH0D1;[FZ
MZ]\<"[H#F%_);V83F*"S]@2H"L8C,&IB@*D&/G\^B.]O/^.^>P$XKGD&WCQ5
MB!X^4BY5F$_7A1G9W3&8"G?8YN:;Z$)1A&9890^OCS>IIYZD*H=$&Z6S;BB6
MYSR+B3IHPB5&/U3S2C;879#W6K^G,UUP<A=D&79B:517K-%, >N D4B1U%4[
ML,DJUMO.*K:ZOR=K-,VQHMC<JU;?J\(\<FV>34-LT\J6=]HGE'^3B;?_J)D=
M Q;,C?%%%-^FB/;HV0LGAII/L58K$PA5C%=S6\Z1,_[PWY_8/@PLWWE&4=B_
M$QU=>"VTG&\Z>LJE_RG+E%_+LK77-V2C?!7R&K&?7ZO9 VCGP_-,W@&*.M#W
M].>MG_'D58@RE=&^194Y-F=\K 5_L<^T<C6?O1)[_-RC,+<,VIP_16-33R4'
M1O3*Q]:1NIJ:RT[N1*TDC4VM]6!+[_!(US6=/:R[FVZ"1DPCID-'[+X_![7Y
M,[9*X# 3HKE*L 5'0X[0C '3N*]T7"UQ\HH27NXN88!HD"KX>B!U(CW)T.1'
M7ZEOR*IU&&*V!-?HF;!RG$D=?,>6J\2/0]%SE"T9*>;G0B_DZC70T1UPZ:DM
MY 7PSWLRZ#RZ6=EM><YKHA--MWLM9>\QS@QO,]E;KI]NO!]UGRH8KT\N/@43
M'+X>WB_5Y]1/0=!W^GC.MVNF!FO*ICI6URA,H@>AK+56(77*(FQN5& :L["U
M\!@YZ8(0@FFEG=8L6:_XL?=L6&L4GT3*&0/8V)#G+^?X/I:KY&3:+F;K!< U
M<3>@AG([W_&_VU0_ +0653J<]\H;=SN?\ZZ8 P-; U$]E3<TE@[W17VVB7?9
MQFQ: [:DP'>%_GDEJJ)AJ@*& 2^ 78HE2(PHPUUN,<99G9\BGC_TM=0/A#Z(
MVF@M-?IUHO(\B)SDOIZDSO!O'IYR5'#D^N#)#?0W/W!P2M#HBHRPF]N!1B7$
M_9Y?[XH@L\G;KL:2HJ9MH#Q#L[U.#+H/==L9.%LAV#I*Y%%\2O54;'^:=DA=
M5.0:.__J+ ..6EPBGSS4GD+0>P_:\@W-3DTVY A#GJ.NBNQ/=K.ITJTLCZF(
MZ=GF>GM'^-/M,?F7;//GGF36B2LT>7N.)6=99I7B\B"T0R]AK60>4OR8Z5*9
M\-_H(F;I2\8H5HA3.;IP5()1@"1XN^@V-\G;&C]%XBO)DP/H42*!N4' 3&EE
MT]!$H%VPB/559B>WPY)]BP'.1NL92,/@U0!GJN71G;<O@)D2&([9BN>@\//$
M5*?#\Q/W4BSG)IGWAL'T</!&FNRN]9?K,/,XS[."5"!YC2U8NT9C9VRY$Z14
MSQ9"$K+P.XYX"RQ-HQTS ADLORE*Q</S3_=/U+K3$\1)Z)?5UX^54Z'C0;Z=
MIFDGNM3YPU@VM13D5*N1.*R(\&MOLJ0O+5286)V]OL$J0#!X3I,/-P+82A]&
MTI8/1WEY*4I\TSO]2JP];UX EZ\!8^[M]/E=(+7[P.8_2'P.]%\-7'LN+GO@
M?'O_3+L7)!S-RTQPD5D)46ZJE=+0K%MK7N.^-KC?F[//2WX._!/(5OKM/##G
MBC(PSG?#^I5O05\ G4=R3Z(O@'<!>?<P 8K_]$/_T_]<[TZ1@Y5<Y-*Y+SKZ
MWTFO!-^QX_CI/]K\>HT$H>1K?8^B(C_^$PMN_G,5]!H+RI\.4J3 ," X8$MQ
M_LF ##] ^4)85B@P>J+W]P#A"Z#E!#JV>M1Y'S@3WQHX/,A7MG=M]#NZ/&HR
M+@]7-,KHF][:B9>2:[J9S<%U0:+^]D.K ;_7@T/<'8C7R#&@J+'\/0Q5O.$Q
M,[I02HE5QOZX=BOWH?#,$C;B_RPW?7;$WNP;YSHT26'$.DOC(@W\>J61I-A"
M  <MXS;5O=1J5;&_\:FDT:KME-[3R6QA6N7AA,5.D7@82M P&NJS&/((B&^-
MI^TAL7Y?]$(\WY@)GS8'S\HE45A)Q6/CCI8J4W'RB.)$#7!6\+-T*+F6FY +
M()KE3 PE[/?/T&)CD^I0O=>2;]+JQ=AH\>9L0U2ZA4[@'.G7A+O:UA9%OM58
M@^R8]VAY\@.)N3VVMK)\V:4$UZ(<^VA(ZE-U7-?BO3]8]/"&JYC9EI:$_5K(
MQH4F4]GP.:PY5_FO1L_[\JZPJL(H?GUCGQVE&8MLS-7WP?A;7ZR[0IN>U+Z:
M0)^9\&5Q6BZ#4)'RH\3WQ(P[&96HOY>NF5_\U)Y1;W3ME4A@/*"05,8D0I($
M*2%D'C/"XY2FY")E4ZSY%$SG(J'X#^,?H#&SA](UUO<'U\:#-GRYI'O*.);#
M\T2DRSG"$<-;'UHM+@TMU:3,&04,XI16&;,1^-&POR91MC^,S;+V5G*-OE6(
MO!P0PCS+PYX>'N,HG"]?%^-GZ0SSROG8F_?.F7#.E#\QB^IOI/M@$N>/4<=T
M&JHRHB07<GD#_;=]LO:#.9IQ:W@3446&._\FR3SP<.[]*]!,*@,?/E8\YJ[M
M_R>%_G,AN?+/G4?Q*\T7L/;>P; .T8;-&4Y]JDXDERP_4V;B[V>,BV?HN@,J
MU7R4)\G-[8>O(AJ)F8QI=,MPCT\<&.L=2X;D]C302WKW&T'.\9=J^!:'<5.I
MK.6#OR^ )%5)M0R=B=6Y"&TTM'X_>OY.)W9O"BNPTA5/$D^R.@W,B7>(T"\"
M!\AV6L)N2O<>*TX>R9_(4ZC7 M^U/#Q^NO-UR,NZ+FNYO]?\CC]!,M#4(GOL
MDJFK]],$JNJ,O04B2'5B93QDQ'#'9RVV)=Y;Y^9/),,2,U21P^F]-'%1G!0(
MJO<N0?B8.^O&@O4TM%E6\CD%,O=Q-[H1:6U[8K'3,,L([P50HASX1_%&X_JN
MK-$]N>1'RT"-K6.Y79FZ@892E*6ZHPZ/E'F.>2P:0BIZ=W,_4=%HB !I?NR9
M10^?N13?@@JAN:E^6E;%-"M:]2W/HTFM5"&QE*#F]]?B:06UOWYYX5;ZO;_X
MM#WW#&86D,SJ+ 8&4O"/VD@KK/L9@:I]55\(P^_O"XL=+ #[O@">(MD=GBH\
MJ7 Z]A4#?K-BS@FE!=\S,Q,IJDQCTHADQ;\2P@LO L[W"*F_E[%RS!8DOMQ%
MU'[V_Y38KWZA2>V.OR:>AEI<3M\^=K1[I-?Z^(,!MF6OJDP;I!@\@!BX_*SO
M=Z;X<P0*V0-A9VL_Y]_@U,#&/L2EDZ7>0:IVO3_@P9[<695<NEE7Q?CZXS+
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M_4CC%T+]3=CEB&M&_PLY6H& 8I3N>(PM.<F:4:CJBLBXL*\B_?R7+[19_'8
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M"2M &B@T.35O@B :-&_=)*M)G R F#<8<8RI)-LPTYQ\1-8NOX8D43#P.J2
M=JI$,/W*_TDS^KL)XT.?]A-?P.*WE,0R67GH.O%*4)J,"J8ESV"<X'LF;S.6
MKHC@_%^ZZSQXX FXJLF'7Q"9Y "G>#:)!.O6D_D)A5828C4OX'!PCMF"9RW>
ML'?@X\S7- NSM.!+=LX*#4'1H0!-(<_M=XJ1CX<*E",__UPK'4(%/;9)Z7H+
M.49^B P/#GO;T>CE?,P;P)B;W4>?P_:E<!D<X31]""AH4"" RAFPG"MP;TL$
M?(TQK/UM8&!@)DZ1<1:C@@&SK!W_LK!_P\)',$(>0=ZSGWN"2!-@Z(E_ZL5)
M59;67!H )9*T*KR-Q@&P4+;NCU.0E3W8/[>?K"NMAL+"42''6BA+R)_-:GIM
MF&"+M9VD:,F?*N^WAQ/0IQGUV]P+^^20S:%I9D*BG21[ZF6Y9WO,BI)^IG<6
M6JVTK1NQ1E/)KH25JY8-!^25AN7 8*J^<@$_0V@38R[:W]1#T8G#44ZE9(T$
M8^$*[)D([>!T!,3S6:5@AV;$!9::A)./D4HV@\&^Z<=:5VQ.5[+YP<.YX% @
MC3/O(IMKN=BTEC9G;\EW!'[MK(12ETFZG627&:@2)<Y^.6;"_.:4.,[[GJS)
M#",!>M\"\UY/J/MSMUU16,$_;>MY/IRVKS8)KNY$2[QB O*(0[*FLMI99VUB
M\??RC4I-I.\R(@7*9?RLU3N&7[,X@@FMU2,RA\;UJ K(^8J<9/E+IK[$6L-=
MU9\</5&HH>Q:.LIH Q2AU^@3ON)M28S44^=U]EJR1"[5Q_"[O[_1$^JH9-6#
M-YL8>-W8 *)*=@-$IO 0F>MDR%?(0VB.(ZWG#R!',W7#!!_T66*Y#Z27:%%F
M32;ZQIKZQ;MHTD /P54GR:VO9.1;#U%V)K!3B$D[99%CCX31XER0KLAS6EF*
M2L:7K6+6A%*)EMIV.A!?;8N49HV&*AU(<WSB4GPR'!(EAL^Z96($FO,'X#-O
MF"QNC.;J8?"/!KX3]?<FN4QD)OI2OI^?,/:.JNZYV"*2T;"PV^.5_.I2U6GT
ME7)@;.%IEO  F+'$-9#(0*QDSW%Z>;@G&[57D#18Y-G.(+$L$G><R(?%PQDD
M?0K43*3A"6A(FC?6'"8G6_:IC\F[5\[B:Z132(?ZBI'9B?GJEP514 @<3AO\
M!ZCIVI_FK^+_XR<+&2JOTZ1IV+/(V^_PM>.,</A+R7;RK5Z99$$ -CB5B^K7
MNAXJY0\^3#OY\DO7-D<>5Y80UC&#&^)42UU?GEO]N&N-1 JSB8XN[GD$^[.'
MYBX=>GHFN(H[7-ZZ5'+;ZENGSP;"O%^%U7B_F*KW4!G7BK9U,&N\LW^/T_T#
MJ^X+R E-.25-M43^73D?Q:V^@4$UHW+":E/1ZAF1TAR% '/*M#E^:_5H]<3=
MFLJ(W_F67Q#'1W/Q8.R@^*1"R&9Y+E+4O$)=@JR\GGWJ@99@E'Y@$:FHP;#9
M)LP.SNJEWI/B !Q9NF\*_!X*9]HAV0!O=<&Y2^OTA!(0D.D+E)M@0@<+X&K^
M\=[)5S_CW)IG4=M2XE7] FO!\ ':*)4?#:W3W <)5,FZ"UL@YF13K'%^!BW9
M[."J1JMV(FCJJUUG)X^R6!;3^RPJD7KCKZ,&QF^9(TWJZK_.I=(_8$F.],JR
M>:N=] @TF7!)D!&YGIL92\\T9C[B*,;MWOXV MN&7G G+LROC@5 FAB&+/]&
M_BAG]L,S]%<663,7Y7$N)%84"QBERXU+"2S:*RMN$DW-/OW(\L]&]J\)$'ZM
M$O=#550UG3;*F^1"%JVIO+'@<00<I:=C.,%H7LML#$4A%#49/QZ7M53!P$!Z
M:O607\IG6@K_])X4<)S S4S95U[Z0CUX%A2&*)($KH_7H\1T[^U#(84&JL**
M/A-[?<TZ@LYZ-==)3?*O-0&%PNY=7RL>%4CB5@P5R<I_[>EKM^S967J#I;_L
M3BQ*_#"JL<R[1!LZ0B[D>JPZF;$NG(2E5W4L@3_F[G>E5,Q=[1^22U#\5E^F
MUNI:4NZ<WG>BUYN>]*H^!'*;2_,+[R[<W@U=GQ9T!=*L_16@YZ<_8^H;'3\*
M&5<V8[]1I1N6B(U+$ &##&KCCJX_MIU D]Q>VGV.Y^YSDX.HTBX-ST"EI7,]
M)FQ35'(&7:#D?3;;E5\@ X6@[_' VXJ<UY4T7"["PBE] ;\U4[]\E^IP=*04
MEO'US^_]QY&>&(M>T]5QZ]SHO$(=^]^V,1.JWVT42?X3!!RZOS$31RU<1OT'
M&!( 23OS\<-..R[.O$2Y0%Z*C;%X- MG.MX6^PI-7-)*P]K2F *HI-((,=G8
M0YF/V@8)#['YW9K>I7300V%:5&>Z40;Q7'D^-%0GR/8(&0@<U#P*!3I#9KP_
M5(U??U]2SFEW*\9R&V<V4?BD74(-C34$9D4R\,FFG#1XK7BUDC*'C#5.)-KC
M86::KO%E@N8BQ!B5H/4T2P_8:]JR+!*.+/@LV+(9HZ)#LBV:,JU1<A:P98(/
M[J$%Q5*V&_7[*@&)M7=9W &;-);:7WHE10FH1QG5;=OG,^EJ*BOY7UR9+XB?
MC65"EDI:,XW]J;!G<G_:5G&X/*KJS?[L!HRG\)BR9I*?,E=]P)3S[4G%^RY6
M44&O2ADJT[N>7+!]Z'\O:C:.8L(IBD-/ O-&(L#!]]Q[%]?-^YG"D]*X3KU3
M/*$VVP8VXEDX#8_K>X/7ZSUX%]3^+3COW>SG3C\X[SOI="XMS2U5#+.F -N=
M-M7V=8FO36S-D=0T0TB$S?K>?A1ZYIHF3=7+F,N$Q#*KY=.O\2.Z2JMH4V\3
M/%=(E2\JJG]])V1#"7]O?&TM@,GEX)FG2K#/'V-D2T7?]BLU9AYRKH2AW*]=
MRY0>*H$7VW[Q<);XM^>\ZMEI4*RMX6Q)RE?*YC] [7W-5Y6E+;W:_UT9J/G_
MEH$6\ZW^>GG/8\?_QG3^/P/2J7WK[7_Z^"*6=QEMKK&I:/*)6KC">J[C/\#P
MB\IY =]$"'4II(6A$7Q*O?DX0(<=73#*FB!G+\*Z%17DBRDII8[:W!6]4;<L
M^SF0@+LEOV-::)$M*QQTNX ]9_VCJ03:B9:&>6).*6D<98[CG4E 5,LS)^\9
M'$WT!:E!N?]05(I8_*[Q,O##YQ*#L9\J*6[!3"D>7'G'&H]ICF_V:P\CSET3
M>9TX8S=;W)=$O(NA4L7'*<26U'V!M 8M-R>\YL*]OTBYIS632JUSI /G)!+F
M.>N'KD&/T??G.YJ#C'*W!<&2WV/K!(#6<K>3O:PHNY0<P]XAH+1:7Y:T;71:
MQ#< \(FD93TWVF'$'<1"&0G<W"<)_FKS+S918LEM^.5B[-1EA>3BLMD4VPCG
MFGQ"8EII01;^C1=-7&$.<RHG\X!#A,<[[BY<$2]UWPUR_'U57:/7H86KE+QB
MT8FF\"8Z=4>G=FF%3V8'5T)U@IB_KN"89&X1-^\GO=G^U@3T_MQLZ)!_*/R&
M'5-RVG =[^9[F%[ I3[YYUM]8B6MBLHXZ@X#X(W"3F'E;+]*F$DJQ:S8-VT#
ME(>T\WUY5TJG&,LGYIYP<"H"DJS#!@^4=D2WHJ-8X1!Q4\^4--LSR*;Q[A9?
M,+GGMLM4\K.N]7<)2J+(KQ<8HVC;,SW"N60\N0;0*$@FC7IOBC26J:;QL/!W
MF@H[M.@T&IG!CW(KF"02OJ&>ZVI_9%*_04V[EIA(6*%M'V8*TLFL;&CDNHIG
MDO$*/#1X*NM(WKT[$6MIN@C3=U:[V6YS_7M05SS??%G(+&DZ:!:(F##B!AWJ
MPYHZ)XH^)-=.@UZ -*F)3*DB+F"G<Q52#*H4I3X<LV^;N'75%1;'^7]3M!#X
M;,CP"BR.[RXA9O[LCD8"8B*.ZLXIAA0HGDJYN'0)B.#?72:C>L0,@>^918EK
M?GLQ%?'H B<GUP:G:E./#4-6;5)H@&:^&3G?Z=IM@C]Q)[R#$Z8/',0@BZ"1
MD^G<>CT^,@J?9BTT?>'\'G7VQ43()F=$]CO,>JU735M9UKT+Q2EN;.P!Z]NX
MB O"72&@R'X>#NL1](<UR!P^^]%3&?$$(Y09MX>M<_;YH*/5( )A"E&#A+L;
M::9[E/3+D!4IVJ^'']ME7<]DM##HZ1FF2;2@*%>2P#&47R_/:8EJ'&4<V]2_
MWK-4J](5V:F*D LM2\>0HS)^ZT*!C KC?Q)J8.V<4?"TZJRVR]>:?H.+%GTD
M]!XQY(I":TX5:HV6<+C^)ZB)]P$*J'+8/-8,%LW!=6HTWG.IQ+[LP%0Q,-*R
M_KN<:(T7&^U"7XY^K5;]N_62L!/3OM5HROTKB7/^=$B2 6/SOR9=0^,5<YOF
M7+*FIM,Q(&LG=-"0%$D4<ZYS(G&DX@ ;FD0!-*Q0WVB;72]O4XEX)TV'?.%"
M2?O]Z*Z65LTD7Q>N1%=#F5%*Z.R 2@R""Y;F?;B]"/+YZWLM@^ZQ]%M[@,"&
M($(F,''?T[3I@, ,$10N01'I/EY@>-^H351Y6?]AO>;N8VGMF,M0XII"MC7+
M&Z>D6BY?# ,C&3ZJWN!U:XKGIIQW\?@02($S?^%'?=SZ',XVZ:?/3#<^HWPS
MWHSJ5HE_+I2.T.M8X/\!JA,.&7/'>U9@4[*SP'*E5&LD'[M!I4$O/AKFG'KO
M3<*1L!E98+T >IT3_?:25WO"^:*CN)(@CK=B^]/UX@3JYW 516L]C/.1&U$J
MSY:YW15U@=__8.H+/4<T^4C#TBU-+1 ;I%D&"#T1=:X9"Z5U_)LP_CP\Q2=G
M>S!8886A%G)QZO+!EN(O:X?&5LN1]@4^0</Y\3[X1-"*'I"^5SK*%WF^%**H
M'6@ZUAJ%8?JY.SN9JLM;X+X1&,N<']N&&FKM/4[DL/^3'SCD(GJ%QP8\<B?^
M'!2A(A!C0$]LPT;2)[BVW',VN4=;%Z2>9"4RPU>TH8V>23_#YM'U7;$UW2-=
M+=5&I@?&\7SX682>QK05QA%(MGH31Z\4G+3=+OG];WW+7)<J*, W? SAO8[%
M6/VCLX,<>ZJ 'RB4-=O4L^M$''/]A#XY92F@)J.FIYI$1L \[GY]A7VL8@Z&
M3#F*\MB%B"T]-U-6(.SX T(URP7(XYJI1ZV/T$\7NF))^/68/IV1K:U>7Y%+
M\ZW6MZW]%!G,,%'E^!!^*2PUYL&--L/#XX6IXA^&9X[&YJ:,XGFN9MQIE6Q\
MI"ZO7YXO)?.S19QXWI"N.0U:ZI1^T956++A(.;2TU3 ?UJ5BK(1=I11AY(HI
MG0CZ3989EZXB3*7.#SW#%2\S3:BUQHO'&Q;0%<^9._,"I@VAB<8(^1;D^.K8
MLV:Y>/2F9/OR#)K$P:\']L"\Y2)UF(&S!_0!M1P_P<XLHMY>8A@"GY+R+;VR
M+AOS4(AUV'+\H^:Y->8Z&@WW&D>]"Z*#(=O_8Y9Q'<;B"D[G?!6M1=W+JTO'
MO;)[&87,5=K?CR1IPE15'/OQ;.SM6B&9'*2*],C73SUO=JKC(O\!>!@-AV54
M(Z8BJVK$Q-9@84AVR$.5K/L",WOKD/JFO/QWF2GI"Y<VWA"#F*'?GK<,[0<S
MIE3TF9""J]1]Y:\<PQ[SV+8B-]E)IV^UNZMN4A4K689G/<$D,TPGN#Q84U@:
M3=XK=E4_1ER8#;4V$:MUO5/2XRV#U\J$T)\V$ZIXI3*BJ4P*$JLWF8EA-]T]
MXXDY>OI'A*MYL)"IP*D]RU4)C">)UY,MK\V)&]?", %T#?AETQKI&L/.J .K
M?"^\*3$N!;LG;>M&>^V)AMKG?CF47M'>1K;SA^V[72X(!6MJ&LL[&N@=!FC&
M)0S;JW=67J&S;@>V8"N?S\!$=@_1"G? 'HJZ3+U>H1SMJ]NS[BR![.N+PW_&
M)WNUDAALP/Y]WT%Z64+>[N^G_>77=3B@?.8.@=/EOY/P7A\+"WQY@1)+CCVX
M@B"T'Y/KARO'%3-LGL,#F09\9E;MIKRF*E]XQ^V5J'JTK472O3;SWAXU$@ 5
M-D\P%<A*10A*\G'YA6KWJX&.<^L^S;+0S*)O?;H"5R??65#IP.+-K;7],A_9
MGXP4Z(?Z*76&U:-G=IO,&(@Q?Q,L*J9N9D-BX4PK8?PFWI?Y4!P!H;JB0P!5
M#,]L0(H2KHRFBLG&PN@I<E:BNNFI4+5+]BECMHX6W?F50;VBO4GKLD*R.CI4
M%M7\*179QDOM$6_M.CE%43C8R>=D[SX<XT(F\(EJ">SBO9HOA5.95E<CU/4L
MDU%FGB=17)S/1,A5=!%K*OYXH<HQ3U6L< -+&QWE<<GVO,%LF[.<>/^-913V
MXS5R?I8A)3ER>(J%V]5;K6F2NSF"8G@[34L-'25F^18O7CA@A?_&-$NAR]2,
MDJ%M4,DYD<H"/=O6U;<*S<B'M#XOQ!*7N3IF=Q]@SGDXZ%3#&POTQ.0(RN'&
M @EL<(H["K:F(12_IXP8(CC*NPTRU'SB=:=6Z FB&'IE<2;W !VEK4H-7I5I
MUA/$F%>==9^5(3R?(>!;R2AR2FK14I=D2XPFQL)FI1U8_K6Y_CHX+;R"N1E>
MGHK^8=;]N0;X<S^?*557>46OXC] U:#VSW4'BC?Z]M6U/I>(]8@3EVZ\)6K3
MY=-DTO/_ !SC8P)J#K[(N,.>8APG5':%.2^MX OFT-KYY9C2M@O;$DAJ&:Q6
M5=1K!!U/G[.BK +B_0@Y;7W[%F(>/+%@RO$Y184',43SXU9I76$9[DK*3ZE%
M/W<2C:X7-Z<4=%LD)P51JC=H^+:[4='H^))W=EA%GV]F!EX[]7D[;@WR::8[
MN4XF..\G8K$0\UV+6^(G',[DQ\)WH31<U?D,\X+]Z+2<[94,*=R\]#,;/-U*
M.M;'69*TFA50$F!R&]<L:QGGLK&6D9=SBK"VGH'%#,LA!,$C7IV&A3Y!G'I3
M\V*0'AAOMA5W&18GZG!3)3]9)T^+S5 @7B-[><4@W)B*JZ,M:UU_ISY%[P;R
M@87):JHFX+7@PP;<JDG+ D+H]Y$%KE.FGL@B<%W>A@@]8!*Z08XS<OQ2HG+R
M^"\^1.]N17Z7">L92]5?SZ!K*0G62OE9=2TR &N0*I<KX5H4\UY,SJIRSYEL
MES-0LEHJ\#\ R;G,<K7H/YQ 6VO#+*W1<27>_$'CN'=KC=S<ZY!I!LZ$.=5L
M0I%H?#!96:L^;W8F_X^9:P$NL@Q854T,&:_SAIE=FD9@,PL*1H?:T"TA?<YR
M:6W1&#N):7YIM^^@N?]&G7Q+:["=/I?H.5U:SQ*,R7.,D4I0[M""@T !&N7_
ML1Y:>Y9XL?S5_N/J$%Y]T8JF:,$B@<T)PCEN79$.-MPK&KL,;@3KU<E_P.[P
M- D][WB<8ZSW7B@;00^MYMUKY3!)>5XH;MF)7U/S.=M,P?$IDAK93%+&9PV(
M/60)\(S).O7P,OPCBMVS:ACR@*WB94,53&@<F"%%ZNWVP>@49ZOO^Y*3@JO8
MZ178MJ)<N\+16A(<ZN)?7I4!C@.!G-BI$H^\O PDXQ[$?>2/<SE<H$633>==
M(=F/4HH*6)19ADQ5^)JW*GP:#VZ+3OB5GIMU3NXC?8K]B=IAI1S ?I#0G_X%
MW]'*_P")?X54/]'+C\7/5-DX6.ZNDUMBI%#Z%YQ63;\*J%4,1F[8*C-S"]M*
M!BP345RPDE,0W5;8%'\V2;.;-J9*9U"]8'_2%-NC=)_2G:?RG6^-%JG@RJQ3
M0513>QRLU?MM7#L7MN^,0+N#SXI>7"]ZO7^M01/ ZNL(_<Y/]U 7Q)L@2./'
MZ?-_@.*'-XM"L_\ G\2:+.P,TJXN#L-(G]XDQ8!^NF!:W$$\!MU!L7%\KI,S
ML.&-36Z"T#J^ !6;G<'3/G5$@+;Y8;+%T5EX&"V^[WZ'$^Z^3V7>)V#M<U7)
MQ100DSH :=-=<K'W4U=^/&+(.O)!B+GWP,>P/-[]DL:UHQS)JW%4EHG3$<W$
MC6==7'<1^H3JYA[Y\"YQ/Z,&I21TJ9;CY@]^B1Q8M.Z9!:-R0,3YG;,=#%F!
M,1!$==C[<'I)J69E_Q@BWI&%3_H?@'2^UR#$'LD+V.C%@?DDNL5L&Z+%)O.G
MD4Z>%YT.@UK(-,K(5C_?K7';UT4BEA!:VG(3.CB ""Z_%,3[<5_?6H/+3.^(
MRBFC3!R BM&0<,  _0\@QN0K7[3VMT3 1::[U7RW>KSR29IO!RW;YA;S\:H5
M>:&W\;>U;'%G3JS#2(NE?!X\2TY1CAZ5T9+#;/M@.5"U(LBDO%.4.RF/-GU[
M^_>*$+8()I6X4 "36GB?Y<<"GZQ];8P7D>0X?8D=(^BB!\51N2]%36U L5M0
M2:KTPN2+!.[ .CV4C55QC/?< GX^!MEMS8M1"VI-\]R4XHT6ZR9-#/N<0Y*M
M0Z=2R&>:(J7!B5&2OE-L'X@&MA4A<.IN.M_GXRD^^=O:4D+XO,(T5K8F#6V&
M&!)]>DWEE_ CGGAI%RJA>\-?)I2S*EQP'EU+F(^F_P5I]U*9QZL0_R<^KRR4
MB:42<<!!!\(7,RNO4$OO6FC%>@VGXUP5R4.A40GO$X*6)6K<"!P9FG'=/ZO
M>?66%C*\E )M(:2\(H)NWF;#50:\V^9N9*L/9?)],\=:>%'A(0%*_P$$K=$L
M$8PA4WR+KE=##'PB51DJA_0$/>'W4$D1*;^Q+%'W3 ?]$F,K.?WI;YCJ29Y(
MGG&9"R4UA20+2-V)8Q)XA"/TYJ,D"=,)HX&9)$M6QD?RZ80DR+6L"G!B9WJF
M*J&?22D<:%(%NVZC@M]P,.E9+LGD8([&P,.F.DIE]@-!=*D73:M X,/C,5D
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M%*P@G@AGG8ZF90A/*Q>@&_1%10@>N_Y:& ^,CJJIHC!Q9Z-RZ:'=)M"C]/5
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MOHDF=1*3#6P>C%3P%AOB]=-3:@R#*"_=GTI\2<1/OIKV[OPD&P)9C27'%.I
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MK=4AT5])W\34(C6:N0R^^WNDIGK)//Y5(=_;4RRNA9SO(.0+J0*F?=]MXJ@
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M%V]<QE'X.Z$&@EN#@Z?MVQHP;\49TW91/3LRNN>;<W1%ZJCJ/-Q!+V.X89U
MJ_^0-L_6G!1""T\#CG.]*=DZY#5;[.63+QS>*]<J>,ZT+U(@(-*F@3P888D_
MH))8A'2>?E"AH<89=VUF,+U!1QJEWR[GEG>!LCU'><[<,:NFIC8'U=Q/TH6
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MH41!J9G[EG.5Z'C"[.#*4C4/6J>>"4<EN*$>7\]5>_.I@WI:J+*U@G:TTC_
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M( PE'/HMWN,_'85^M2J6DALC-O."DS+OJ<BZYKAHF!0B_;4.03XW!P/MF@2
M00^EMNC8"$M>I,-6PO^UFL?X+0,<YC?S63[DD:1>#<#L)4:87OSRMRONRFIM
MO_O^EXJP7G$F]>?&C3XF*1U/YFWW[>/95%2>G?(U/BBLSM2S;#0R 1/MD>8S
M$/?)J^=.0HM]"AV#[T@7MG?]>4W%/AHU90<MKX>@3M2XLBJR#:9M)"=5+'*8
M<FUBW8X.LB&_LRO;Y%_R-\0P;9/6.<KS(QVUU4^W7VEOFI8%35?W==J#QIK@
M D,W#QCV48CO86J.ULQUM;"O].24#X+W.4GQ5'V:SJ\JN[(K[F:B*B/4WN7(
MNR$V.2:L34'_U5$9:@LW,Q,GZ2%&F%2=TU7W-UL*>>8M>FZ#F&PN0UJX?X5[
M[N$E?,/8]8EP 6"^ILH(JSD/8GA@:&023/.J+L"].Q=SP,T938A81"K<,^5^
M5S%[^T<J(O \RRP,=T D^EN!A^W7MR_FN7E$>KPV;@,U*]9=<3SKUD.:A>H6
MA_CF !U\V=JT5TK; ==0T'Z[,=JOUJ_V^X#H)N+:^.95-S51.&;[,BL4W]6X
M_JS)<8@UKT"W=? AS-S4 /0A0B<XK5PC!1P;8_\/(+37NS(V>[7NXRK@:OCF
MC6ZR=])SFOHXL++]1:VWI;VY6@>T(T4?P-%N3 QTW0\')R[1=7GK>[QO6SG^
MT/PJNVV+>%0X"SJ__ZK3Y>S46:*6IR[I(,M<O=R!;QSEN?_D$KHIO,T18JLL
MAGH*<4Y,C5"U[AJK]NDU?QB)18/;3$\WG,+:1B?6L6XJE&$27(1&SSLZ:[G/
MN"SDQ#V>6Y8Z9EM"P;=298?VFFQ06E:-VLQE>+7DM!L&JXY!PN_3P>\H2U9F
M2=]:WV[N4JG,KJ^\-A9,#"<GS)+24Z\DPEWF(G_6A\010IJVN>K%)K"]YG!C
M6;(%F;Z[59$+E)HM[-WM3@F7:C6,B"YH0G>KHD=U!51)5)!.M+'[<1 DARFC
MA1C<Q'T6\%D'MI,AZ6-3_MJ/?7QFGU3X]-B&O)!R?&X4<SPIX$J^[6".\"%D
M%Q0J[1J*_P=@ XJ_6W)>(B[15BA6./B"B[(/!#+\.L"!KN,"*B068*!B)&"'
MFYLI(U2? :FZBMV EBO?HP).QD1@>:,<Y_1UR3B:1_%?:3[;'Z]+L2#G"X_1
MJ$M6>FZ0QH0&7N/K7XK( .]S>67R/O'>/A<:91N8=)X:;AHZ$*X]?$NLETH?
M$0525][08&&*3G_DVC56S,5K.VO 5X%]A1_Z-5S@61CC+QCN9V]R-5>\0I6.
MM7>R+'EFUCP[[(Z<'P_+E)[TRP$>0E6NQWSCJ*+-1,LI*(#\UF_E*#C?D[R,
M-"Q/:V<4+1#8X)ID47>*A ;,7/'PZ>O-M<^;VQR[GBXNX-<KRKB=K^M]7VAL
M&L!]7/$%?)!BM'CS!)[5<]PTCNM%Y0P"X(TWZ_J,4&XP#A#$CXV(D%(G\"YN
MJ03X^<_BM1)%?:RLCDAV2ZVFRW>U99FM3F)/NG&V#NIM]X+S#+FHVQ"GI(DS
M]MT[9/V6$ZN<)3_'T^5)VI9WS[(V=Y<,ML@^ON7)_/%"D1YB*AF_LMH)OI,C
M9_>/UJ*]*J;B2F7^QM.1J3U5/C/Q2+@H?^C?WT7R*V H_I%F\":[V\&]&!G-
MO )]@&/;]-;Y]C,U="'?%^'@#MM3=V_=M>$0,4@1\'LX(SW>3JP$K:25GM0_
MS5CI8++VZPC-;J/.Z@2^80\L/9%WP(H;]W5=5O!A]'K<C#T!%,U@+%%8C>N#
MO&2);7%UDK=86A!2U2I7#7&%<XB/\M))F;5P*Z<W$-N%\"PL[4S30';K3R*U
M'F_?EM<"X=?1NHMD@^N9;X\54TTZ2GH1-:%)&?I+^#\KB >)D2:[#\Z6/J9S
MBRM[>E*IPL@2PC:.<8TW2U]]Y:"6*5L8JWWJUYTS[XMM5\9DJV^#M[.CT_79
MR*9AJZ=DZ/P85K8$D.?K%"/(@2V/>E]UJF_(G\QR=[G=Q?KV ,&2T6($G65P
M<9PFJ8<LEQH#Y0%;\@G9H"^X7M1:'!*\)"UW-ZB8;KXZ/5Y]&5\?$)(K=<B5
MJ0Q4W=O%-3P0GBR#YM<))75[Q=GR?N^O^@G=W;L]"A5@^65TV;CE>5\X+DIE
M1(X>LN#U9 ]C:T^G,WPV.(:N7 LAU#*I*&L0M' ;K&@2:296<@R[7)RTC+75
MUNO.R*(ZUO(\K+&U_(35GDG9RL68I+08]UK=]1N[8WM.&YA_A<)XPM/3.=:^
MA$"^,S5&Y&CUS'UYP"^WEIZ1955HN8Q<26I>H^&USKYL>>QBA,)K^L7ZVACK
M\3/S)K9AWNVA\J#+F])TB5_A?K2!J%BA]2N>/JK44YTW&G>T!YMJ)WV)%IEI
M[W.LB*/CC]5RY[H<,F)4'$?=5^?Y#)M(\VTF@ CW;H_U]QMZ&*>UBI2S( (/
MM^+1)&P670\N87LAEZ]4%I:.<5?4]MG1^(X$J:JNN @(&V2[JD86,+;3]*N&
M]!;W]YWZ"R;AA-0$0DIGV?WWGM8KB[^_FMY0Y[)HNS%H(67;TFM&2*,R<,S=
M)'>/\^OZ!!_3</+>0I\['79)*$$GXM=X1C.S(],_CIOSZ.\7*KM[ZJ:W(DU:
M?S;F:Q&#-&@D? X/GK3(X%I>]0\Z&*!QI89N0)JVN8;TMCPG2Z(*IK6?#PD+
MS.K4"O&;FNL&?:W))<1"C+)9#!U)MU*?CFZ/#J2ZO6!PS>Q[04Z!JTW@A%S@
M2_B5NQ26$<KOT'E7;W0D87ZGS#/[HH0FDT6@YGCYCL]!%O8UW\$G]R;< 8QX
M+N8# :2H2TWTF)Y+?*RY!KC;?\D[$FUC>U95DE7L4YHBDF8$"LT2%>KL5*J=
M-$5@A"9IY[89S)N"8>!-";+07Y%H=#GFGKC&H)00XKH3LPH?R#LCX&PZ72#U
M("3$7I2B#"[6+72UGJ/TBF(V,^]Q73B_=MRCSL!.M2',E5X7@8]HA7Q^G1P"
M)=: %(M-CB*4/0PK?8@4D=&&I61;-/KQ4T1VY2#7+0$?T[ :K]'S8EO5TG(!
M&E/G!"N)#W4JN$W9*0CUE,W)UURV'_0("ZBKZV7B)^H\2_N9,IQU2<2@3I>7
MG8#Z+F>/Q$?M!^DU^A9K1^)G)!J;M[*Q#+E#;#!8U3_ V?NJ]TDW;[7.$O3J
M><FI5, T)L]H7MQ<_O9)MJ%%4.#@EB7>?S#?.)"65TY<D3MSSPAY&J7O_A )
M(#G(H(Q4;#CJ>1Y)/7AP@=-1;2@6!B%_B]8EP0,%]0HXI+FUOX :DK3H/4F$
M]:(*[=<L9 2?JEOQX'"T%Q\J?1!C#P:RPY9K-#C%SR%7K!>.<WFR4&'D::B,
MC"RG?&,15DHY8=R/]P1,T"V;WD\$*!OE $4I6A=35)_*(JT=/MS\R/?FQYOY
M;^WF,F#SPM*5PTRDP+0#=@-?@KZ'.7)_)!6?%#H54MZ%"A(M_$Y!/P*UY)2#
MU"P:!OE46CPM<DL_IIT*6FP7C]TL)5<!I=\0@"K 3KPYO\10TX9S:AA1N6'%
M,HT#/Z/?X;9:VO5"R_)N^1$\5EAD3&;YZ:!Z-S=T^ %QY>*:.<T(6KKR]VK3
MAL\]J)'.4U,;YK.,C*U1Y=8PCD>CO:/6QV5M;O*#LLI]?T2H/0TB;,I8G:DB
MO2>NQ7T] E=.'PT=F?PV_-YE'34K2\ZW3P;;9FY^<^?[))5-T+1CM+:%#-/3
M9OC^:_?9![$O3J9-\MXF^Q?Y$,BW O-1B^J>ZY_!1W2>GMRE7T.!X:;]HKF[
MC;#?Z*%V=81"-L2MU7A"+XYM]<!"(-.!L<&/H2^H,C79-AY[#+QDN2,:@#^S
MT*FN8O-7*T6MBG&MAXJN8_F8K;K^F>> T3ZAL3LA+BE@/V ^"B<:'_<?@ RO
MNIR%RTC+(^%)977Y&TELHP9*@NY2.15R0@7N_,-MI]3/9O^IZ: O1/IQ(BSQ
M===I=VU&T!K%=8;-6=*5[B8FZ?K^_OYT=PEG\^_K_K=__T@VXO0!7B*/=\+E
M^H/ZG>SJOWJ^7# E6VI[]ZKFL::'ZX]=F_:#:<-)A=US[ZWO:S2G(1OZ-TNQ
M 9YV:YBW)V\G_@',SHW^9M1VA]F9_WG9>8QYT/_U?8FG.^)/KD4+P4@/;/$K
M"[U.F%Z>DJ@X<#?8>X+]:I"%[-L<41*^P-6E<I=E# $9)=R4Y>H?P&[VIO++
M[WY]?7<E@%'@VGN6U^R>%W[EP4TJ*[4V7(%W[U-VVRC>ZCRO=25"J+71'FP9
MDMDL97$51X?5L%WP:WX]N'SG\*4B];^;E4REG-_$>PTWFO?+WR_B2P\?*$-]
M;1C.S#KX2)WBP'3RB1-+^7UHE18FX)B,L(A,8*'5*N)WO68M-BD&(:;P,LV&
M50O,#W^1<EU^Q)ASFO\390?,+GQ7GMFA$4@.^D8C_E,\W>PR9"DV@[0M[613
MLDI2"+6^G&%]"_50C S\I1SG&)S$9G74^.KC*)>[#4)I_'/V1@+.TX;8P;]$
MM9::\0RL76XG^ &Q4AJ2S(:CIO5:XD,?K6\?U<(Z%J<M>\OBJK+KMTL^#=U<
MOPA61C50Z)Z(/;P1219ETY3>PZQ3>?8^'&.!,%6Z?^I^Q!G6#S@N_@/D:A3O
M47K<\YKO$![]F8[$\QNS5"#&:#QM-SL<FXX://]^N7KSJ\?I_!^@P^NAAV8A
MY&$E%A;A!36+7#SRNWRTN#&][U+5$3$S.F'!(SL#6M^AGFK8Q>TCK$*6//F=
M\\YXCD(YU+U#,R)& C6KSA:FPT=\!.YD@E&<8L/^J89M=%<\M]X$[Q%D Q$F
MO96-%:"]: JHQM@K+0/=1&9>>O*1L#WAV=^TMZS^VPL_IAQ,YH[7U54:1+K^
M^B ^G$VMDR5-H-5D:,^=\S*J>^147E* NYC,WE+RON^FM:&NKR-1SCE8X&N(
M,^7:NQ+0-*KE*88HF+U<T,D53R-4._I1+O&DNB&T)00[?3.#Q=^*) _W#_<=
M-W-T-."@JK-\#HB'^UW+!/^)AB:N301SE-J@[A=<IM^^WA@U9]J+EX:O-+M]
M0C?WL;'L;?']3IR6I\;FC>DDQ*SP P4T^1%T%5DZFLHLPQ9"PPY]31R)RJ97
M_-"\'"A2^,SMV0F77L;E^RVYBAMB!LL>$H*I(5J]H\4K?")?M$B$NN#RFF]J
M)?BH:+=CI>-G?7W8\81#E)L-8RT1OOA2,Y\&=_NMF0[%4QFB0">)*7'C]>#Y
M330YBYPQ4+)EJIS<?XPU!R8[FT]+*),2G*IB::651_-!EZJ:7>HC:-7,P)H.
MW_-^=\_Q4HW7V(3TJ[U65*,F=;#>'J88LE$(;C@ N%9S%Q)&&[3"-PAK.!$&
M^MR$Y[.^3TB"P[>*[O;3-M$2S>:6QH;+3^=-!9/,U[*)"$K5D\0R,PV.<_6-
M':AF$9^EE2<H1I?VAAWEZOTV)[]?;KJ3M$Q>6<<:3%(_Y3$UV*\47*!1>J9J
MB%B4L$>.\=W2@?)C@I*:8AV(/^"QS34$[F>0CVDW?AD228^Z]9V@BH9N,+5+
M<9)Q#$%5>L9@2Z%DEUN#E5"J[[[O5;QV>R);LXJ,H$KU)8'B<=U&V*2(TO?\
MK>=%' ,7;C7Z4BQ@>T Y50.>(.T<(O 3=G3ZA_T8$R07[@K.T<!=K>S]R;R$
MQ.=:0"Q:%ZUUFJ:>=_X%5MN0IV9LX5SDMJPNNR#()Z+3_;<O(Y)#-MJ_+9]4
M)>J8N3>.F9::)7L<!_USP'Z3DS>8=_7#\5T61&_"RS^/<:*Z?/?GH<>$]&UA
M;\58Y0%U  5@@UC@8]W$"8?C4GRPC94SFFN.WX[>H4\!@T?+^ J3EY8BT75N
MC:-_@<.:I9IP//+$Q)26]O-U.V$+D,^'#<ZA%^!Y^&YG$=>!OLRCIAE_K$DB
MWT;\I^_8V3^ LHS-4L%K#TNX\^(FI]!L6QC]=/EH@:JN5:59BXAEO7B,#9[]
MFK-TCJW69[O1_@Q63798V/J/1C<0,,A>DS/M6$O5JQ&OFN0WR5@CB![D_WD=
M>Z!!TY"S*%2&.$UE"=-9; 0&^6O OSQ_\^L?8(?&M:!-/^W']=D,)H^BIJ5T
M(:]M5)QZ'9;'R-[D77DRS4"<;['VI8S38C(!_H(F2@""8A3+?-MX8NYX(=II
MNRBB$[4ZFF]_%XP0AW]"C3%W5*06O*:F;FZHD+_2\T0=Q32V='7WA$V[N&K=
MB-$U0TK-4)-!W#GQ3<XB(IXZ%W@<6?0=S#-Y8=F"R;$\TL%-40+H1B$LXNI5
M1\\81Y6&X.P[SJ>1RCX4 ?%*EH6NH!EPD?@\_KZ6V-Y5NH71^+$(N^_SI5LF
M=2KZ>XYO_P"^G#US[(C1/9-@K< _/%@L[LV:/'V3LDO70<HGG45&J%:Q='39
M*3L(7N:BT7.S#B?1OZ2\-KF][BUJ2S!8-G<D#W@&&J_()R76?VUAI8RS!>
M)9@21ZNX6GYGL3M@48 ;]GJ_0YD-/&W1KZXI %\=3(KY>WSJ<J%F9J346DW!
M]1'_[+YA,PUX.J;V06.X0EIVQ$Q:$+BJ ="$36B"8\DLR";G?WZ:3F7142?R
M]/DRH%5*N^#DYK,%H5N8C*F9O^X.CK*66&&;K&C_D!O@]ZJ.'A\[ 7\/&3C
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MD=]F '&.0[6(+MN4AS!8IVP(ZJ82!35_6:?MT<R:=$KXB7E< [9F>+39K6-
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M)Y(/R*5H@$%C_!LH0!E% 6'MN+V]IV1N!EV:=OW73"+#"+7&Z96,4$;ZR;!
MZ,0J/ 4P&44Z<".D]*E2$'HRAD5Q8N07=PCW$]8<&S4M<?;B+'<T1B>,\)YF
M'&MDV<#N&_%;9-K6E3Y,+&XSH.40F%)US\:)3WQ;R"^S__[B;#'G=,-7!%UB
MO42G4LWK:#P>M]1%')V5$<[:K# N"2,<E_\+Z=2;*O*E^:04X'US<"!0._YN
MM2-5,;8N<C-_:89)^]]33'2V3>NQR'+GKN9()*IMQ_(_M%,J0A!"8R4/1:W?
MBD%M*4L-,LPI'&]*[[ADF5:B-HV?*J15_##@.&Y?TTZ<XT_>LEQ%JXM/))^T
M:;)WV\*'EX8!&/G%:UGL@((#YCE6F6(/UH:_VDG5J<7A"_]0Q/KLTKEG'X(H
MXLZ-!7 (+S!^._B7?TGGRY@ _U?#HA!^(RYU1+NK>GI6PFDU)DZSC&K<>;M5
M%R)5A=61&'RV!5)85R?^]BV*<)\DMWG,&#?1[_7^K6L&U$+XTUO1C\R^%RT@
M'CB_L&):E/[J0 .<X106A 0/[?8BT0_BCZ6AYU)9$!7GL*]H"D\F\64>MS^Q
MG'M?5X*#TM_/B&F3$#EFI>W\#K&(5AL;ML@BG_3K0(2R-F7;=5$:4GZN*E;5
M3[/Z]6,^2O_%YIJ(*#UFGV!@U4IBV_#<_Y<[A.8CKY%>I0&-( G^CWWO9ENQ
M@]NMJ5X:,*6<7"6E/+/.AV9O([GV*:^F%8ME,U;%=22+26R<<)WD)&.]-L2-
M,:&YK/><8X/N3*2T%$3I_ZSW6P738Q@I.8V_74#5%8O$=%/!W!F9O(H#T\CL
M3S$KN/9X8V>2"VR*G7LS>SANL.6T-VSYSED2.O9ZX"4L'9 =#.>ZW-5%@,=F
M1AN3[U)XG4<"^:BHY.,SY_RDHK\/B CU:9<<8HMJ)*W%(F+17'Z&-WK:JNQ\
MIDUHE^&!0C<"6DDHH/4JK74JK?5*+Y7P@^,+O&>C@Z:-'EX=R6?9 +,VI)6&
MR7F#)'N=GZ__=CRC=OQ2AW"9CMWP.ZYLUO8<L+6?7L5X;$>UB^*_F^1?,?\(
M[6\D?(;^4HT4:7$Y5'[=[#8]\!1/+J@+Y %OD9@I0:C&9A.X)!S:V21O#3-;
M9>-O:45)6S_AU&,05>@>93N+.!*&!BF7Q/PY@,%<>U+$:5ERM[AGX,"0FR$8
M-37*U7A\5,HCQ3K)?SBU^3<_;[5 =&;5;\> ]PAE[ ZD>?1RWYQREB!UHUNL
M1@7@@)J!.W'#=\Z[)=77#C>U-4YY&Y$O?2GM8\K,;9J29RI%F"+IK\"I 4BA
M=6@UN[MZ@B+N?Z!42B_7F+VL,FDCEXL!Y\O_Z,[^FJPB!@>\.HA<>)3S5KA1
M E=[ZB^\Q>G)TT_ 5A(?RQ=S[S)^U*H#SS(Z&VANR)\DC5HP*(H]Q7[49.%%
M>Z%:W_[0-_4+81D#&#1%.)6UE"P4,S+[A.-J.K*K^%=$]_D7?QKWZ8=?CZIL
M-H^ZZDAN]FJWBM49_W+7+\9-A,&1QST<I9 ,E4*K1!$2Q%K(BD32;<3U;E10
M%=#>JCJI;SO35_FYL,3%SX\O+>V#;[XYW*5-DB:QGYP(PK0:T.OG\!'96=;D
MF5A/FU&]\!E5D248KW:0\M6<(?IC2HWFZQ\R/!EE&=7#6,1.*IT-'S(0U8A4
MEUJ+PH#SZK[)K\8[;QL_"VO7).U7PJ]^C9V'4'<\2&DN7E6A/FLI**[W_!.O
M;-[0-#]D H+W)A+/ U/JT5JYI&+C7OJDDH3+KG=ISWH5/WL9E&D/'6@+ZCH[
M-IUXC;54(L>;:SS34='UJ#!V.C+&W#><[=GPFO3+L1?4%S&/.,4O:R7WYA48
M#>;]K%NISY7;<+W^_]#TJ[I$?VV=?V^0V-.CH'B[0T%!(;WD:[AAL.7XJ//!
M\:>2/^ YK5BV?;[YZ>5/@UCC_,V_7@N<'[4YNBLO$&$BBV<^-9$UI)MT;G <
M8S-$O%6G+B\#DLC+I_;*EFJHADB/ '^49>$D8;GA<1BV@J+1RS1V6.1YIUHV
MK#E3N&J?0\EL7%YJNHH## %1O8OC7QRG'R:>.%L=:G,F^<93IAI[])FS=3/.
M)\=,.O?A?IO0JSB//O7H_H]U/JZ[LQK,V<A)?E4S5@]>CILL\41TMQB_QB]H
MTS(%]MK@_K!37#%/!,K2B&%JJVP>!@-4',7C?L[*$K2.N3E.U?M$"TAS@<Y'
MF%;6.P=RZ&(, 3F]5,*CZ9.DQ!\V&,/>EY?T<W(R)OUR6+\[1WXNAWOJX-._
MT"+VGS==ZMREC+7(-+:P\L(2AML$&[\<;$I[%>HIY7(DB.+U9;PCHVH/"2WK
MC$WR,L?T_C))\S1%UE$%TDS53J.I;_2OFE-.6K54C5"V);JD-_<1T=L;08R!
M\5LU>\=>=39O_^D) RLHU*44GLH4Z1V!C"N%O:I;?4T;"I;L_4=[BKL$+25Y
M)BYF!%2+ZP"O.77CKS[+ X2U#RWQ7TE.,*WUI!FGI_K /*[]T+F%XO ;JR5K
MIQ&/-RP+Z.54AU])QW#%/W07OR, OG)<\S %YU9?\C./VS4E-@3-9$=F%^T^
M*B760C,5NM%TT,B4BH,[M3&!+DWOO=$;0H7X+G7>ANT07Q691;CF6*)R^XH.
M\XJTA;8V@PJ^V1D 2.Q0_3G,R*YJ7GM0\V!^FQ)DKE<TVQX:Y<J*9[)$XC/E
M.V^"?#$6NVP7"I..63P-->%J3F$:_[GEFB$W=L%5 K5U=O5QX<.O"?6'V8R<
MXH)GI&+LFM+ HCTZNDUUZ@VU1#GFLIPSO(>Z^%*NYIP#P\-W!2_@\&J,:-)8
M)=MLM:FAVLY6$P$N8;.#^V#RQ1=VA>[<^>NG)X;J:GH0413@HYZK)%%CS^2%
M/%H9ED^YE-&YFT)6"!O%=9D "<VN*@+V'QJI,ZL'$V,)-%(?MQO-\J\AJ,3U
M-#S*H=$_QP7JU5)NVB0NY2ZIWHE)*MZ7!W%K3&[KI-02>;VJ=EIC23[C@R\B
M.</Z1SCEI8PL+:&2N<RD>H1QL\%C:KM20(92OF[#R=Z'E?^T)GL9N9E>EO<-
MI<D\CGB#0S+H%O!>R)-^OVR$+H^Z %%:(1'LZ>8*^?5N)#A"9,QB.&7>7FD.
M@Q^' C)X<84)0E&9C?6'A12N*.UXF8RXFN86)0<0)\FLWDQF9T.2QVJ'7Y$,
MZ;9/K"5K>W<X&$1@'U,S#!IL[4+3]&>_[1R&BS-:CQ8/T*),^X(:<CC (F9M
MG+=R&U+I.(ONZJP^ UJ16OE^Q%=2]OI?"L#+D=]GT5QXOB>NHD/P$Y,3[7DL
MX'>SODE+Z<V1$")%:OH!Y'JE43)^?.G)/P! .7>EX4VZ(0;OQ-?\7IG%)Y$#
M3'2[/&>XL<#RLSR-AL-01.PJS#*&!)T-7QN)N(^&A.NI/$R^-JBPU!Z[^\>M
MJ,)4#NYI+F]NJC3JXFKQIN77T9-=(&9CB5R(YP :=<F<K8GOIM@L-PZ*7:%6
M)]XLW7?X7$FHD9@MHQ^WXN%/ S/?1D2WX1G6X$LF'E.C/F7.''MKYY*VDI?&
M;X<R/J BUI]#,HWPCB;9'&K*.IWQ].CA'-!+27?F^2 $1LH 1EMM^=>.&93$
M8+T114?+XORP .ZWNS4=,[ WDY>4ENHK4W5 ]?6TK7VZ";!2S8]ST)G5=$,K
MHZNUU%CB[^NAYAXVY-#@,P-5 G&86\JW+ZPU1DO+W%E.HZX'A=>V 8O2'"BQ
M,I?.:: 4Q)]J;N0&5548+-[Z"^EE3\J-S$GZIIE;+<X*O>X>\L9*5:&]S;7K
MG#7R-H3^*TX"S7!\V=$L$:EE((?\?66JG^Y=-N <XFR!>"BW&[T"Q;-UEH,H
ML-^27.S4VJ(X\30<+MPP;\=6:)#*WA]B]!I0*^D2=4-_M4'+[>1N0*[/9(KI
M989\B3+EX5D7:,4EJ9_],2H]?SC<F]0]XY$4L2Q,1B7(X#5RIUFRD7>YUVN2
MKJPUC;Y6Y&8D'^[")RUW3&WT^J/H\9QX6:57!U8:_O$?FNW+)V!+!J=SRP,F
M(C!-:"*UTHVJDSQG=E)9^X23U;:48"4\%B+"@2EL/_Y=RZOG#2Y=:!"^T);@
M6MV&2#:++9")0#B="4(=&"OT?BXX]\[E<BA,JUZ^UBR)[T&AQ@>D0Y@>1U1=
M[LE5>*\ L,V@-$>)CS!63.L10/028"PM?$')+%:\9QV<:D+A?:%<)NRI.$N^
M:HS>;@\,10C](?5L7=5#0AA'49G'I=J7*S16LEE\6Z. XOZ#FRA6G&D-[B5S
M.VIB7AT1O4(*'^VA88^))\F_UDP#:\(-1FQGB1YI%VOU?C5?BC0*[>^?*%3M
M9.J_(;O0RQ'?3#N/TP-X:<12F*=H*24KA)KS_7AG@W>K&VCH*R!PN,/[B3VW
MSJF?.B8G#>E(-!CYS5BR2\L""J3)@&&R1L5#0J*ZUVG0V-JZ0SA9N;H:CRQR
MQ9^MB +6%5F+#P=KL$DG]D=AJ[TBY=95D0_":5V,K*XNDIUM0G?'*?Y!'%![
M\>XIS,]_"8,BS'R.]3GR<WF!+*8W#D:)!ZHXR-5W;1V>->Y@<B=9+QU#@.:D
MNVUSK8-?#LZ=+W?#@[ )G8$F%BDB0OZ,CX0'7F_^SI@^4UTKB\).0>V7S2%O
M==_#B]72\ 0;!Y/R\0R1]S@:L>LQ225[B[9(+:TD*E.24??4F.:*Y8ZI0 P?
MI7N5_KP#S!&V38??7Q5)^Y3L>=62PV_>$&9\9U3,HQ>W4O*+AN)W*>;6V0T'
M&_N+US-@K9',,JDM%8$(EOZRO]:ZQUL%[V4'VX0R11SI#IN%BJ<Y8-ZNKE3W
MQ'MQ3@F*Q1KUIGHN8*6I<HK B3GE=A(E\7Y=J_QTQJ3%WBRIKAA(+Z_R+_\F
M$E8>F;^?\$<A@KR!'$W\D(;_Q<_38MBX18=DL.F\"\'3("U1.;+$8K;2&'X5
M=UR5M6AD/&F.-L@34<KP;<8:O1@L,&.//)]7Y_5]-LX/ 1^ *LK:DHMK-<&<
M9;V5XF!J]R1KQ^2M\12ZQAO<N/<8W&X"*]2'P86C=E6]NZY $>6&?++*]3\*
M3GDG,40X\ WG<V-FH\EN ?E0+V)>I[,3 Z5F6_7HR?+4;SAS#I_8^;2GR=:D
M/FCY;"MLQN:^-7K2&DG(:OW&E>7IREJ>5@YA55_]HZN \-%C :1R"1_\F97O
MU0M-&N8V K$G3T:K)<_5Z!Q\'AY1FX[7N]<$C%&L7UTMF@1M!I;L7@K=-K1[
MM&R8F@ ).#NNJ=?NOL<'"8+_:6WSOB$K''0L/Z/TR@3V5K':WI)4]F=AT$PC
M5[,&%.LHB1=[1CC?$W9LI0KU9A<U[>>(03[\44Q"V2=SQY;I7*NVE\6N@KG,
MB;))-?6$-*D6+'2\?V\FWP:*_;7LLI)P+(KWI[7<?N?18>42V+3&%D<@%.BK
MRR4L[V])A<%=@:%JB.DJ'W \I'3=.@!FP1[Y0%^<:9'F:K&RTZ#D Y513RPH
M_0^-AO=OR&VE[C 5MP,;DV#2WPV2'H/?'_6'R&+@B5SCFL.<U=/FA.().10O
M/O5"I5L>HV;$ZOH2WU>U',Q6\I,=89O>O$=(<$6VPH@_71YP,BS$6H##K%15
MXR2#1%T5E/Q3 Z'[LS@^*(4RUHHZ&X-3MYN65SP@9S]K) 2B7V$89\K:(M][
MF;A>SU54KQP<UR6Z Y60\569OTTVUVD&Y A,N[N<"IR[=$%39BL&"VBZ"#S1
M*_2G!3*HHOXWB7J7SA%C(3<(B1YBUI 9I/V.+-TOF[&1!*8T[B!2M:X)'0J1
ML4R.::OAR58?.J@8R8%IV, ^2XR/)> P82HIQ0&I,_KQMQ6^<'I+/4QS)I<#
M734C?Z@ZJBHL S;U8>_]*A\/#)1C#1YKBAATF$FQ25Q? 5[,)+.FQK_US<VV
MXKA,Z,A<QB8KVT+QO\^!.0$]=E3_Y[G.H/:Z:O9N2R^X8]5=@2*ITN1P[>#C
M&U,*^S\6P53F>;<5IFK)8ZWTM!19RM$8DM/=OU-,5AMU<\*X!C;CH92O6F*_
MXR/?[\$PXH\]C5N:\1L"K-AO2-L+UB\!8X\"LU;=_E>!;DY%"Q^.REMZ:C=?
M#S^"TU$H"G9Q?)]-'?JM.B?SK&RG1C8*D@\.=-RU]D@:PPKP2U:+KU^;-ODO
MDA 5)=S,TE%7ZY].N2\&:CPUW&><+KZ"/+'Y*<"VW?3JBTG"<4%CNB="L"Z\
MVBWC_[4_SNGK_;^XNXM_P7[SC:>R58]T4@W+%<2,:[^O ;6.@O)?T8PPU>^R
M3:M-=-Y%?4 DJPB?.'JWFJRQ;#X@_,)2!_W8BOOW>M?/9SXP2MBW;+[5!Z10
MG1I!H9<1NF;3Z%:$98"VM>'F3X+%'4ITP<7Z_0YDJ3M^7;+%;[6__M&,,3LP
M2H^IZH]=.?A9S4N57G< ZA\U)*'QZI05BG!I7-FAG/W^FFCOE[/OK>6S@W &
MGGE9SMATR_+!W=G$NDJI4O'0OC>5#=G:*N4AOOA["&'ZV6&\%Y3H\),NB@:D
M_8^0$Y^UH$E.OC^8,O/7=OY!DA<Y>5;E0&GYPM'D/<:?E+7OIUT8W8F7T;X?
MI6>=-WZZ<5^[=F89LR:X2T^Y=N$S0HD#7FH=6&ONLUN(60>"5AS\O/:W)LJ+
MQ<EB@YW$RK5\127K1H68.B7"X91YP4C %G.F%5.ZOSCF#&+1L3XB"P/O[6E>
M:LK@KT#<,0J]Q'&*63NONJ=>S5Z[\3T'?[:8.)L.E>K!TCPS <Q (*N/?%O=
M$*'8Q::E0'UBG*F\?44+R1O"3%QZU7IC)3^YQ^5</X"3B-+/)WV.IER$X7MF
M)&'+R4AS$T:L81H^3#(LSR9QQ#7E5*51I?-C#,^6,\XZVV7XC\S=[G0<G-:P
M4(N6\OP?MT_I(I$>XZX8_3Z_MAK;?:2'=#*JE@.)'.V=[\HMU0JLJ\3NL$G/
M'MQ#!^G\JMM(K%326V=#,@V7(C]5_!E/33_H9:#;AEF*S0LS4S+0OEF<)1>F
M5':%"+>L;82Z5P IF5\;BW#_?/*9&]]TS#YG@LZGZTV@.16,L8TZTR]_H&[0
M>BMT*:O7$/-!](J/D/.:XT.T+Z""B.VXK.[GY^:PEEJU,*1SX6!S%)Q)?86+
MW\,^:>C&';@J<"P08^QCD/9MP9"2WE06B"1RI65D'4BOC^QKMTO5-+HT>3&G
M6S2]E[LH//S:PL2(68QO&+ GVA(AE]1P7!PH95H=^3+*H/MJ2A<7'>*,KD36
M*<^:BB_W!7)V2GXY#0'+;!MC+[I%<6 [@@339&4_0HP-L(MS86":EAC/S4$6
M1295ZM:9\#[?U-5R7V<JT=^[+S$QRP00><85I:23!-LDJ+)LH?RGA1,U;8&0
M*-!ZJBG)^GW6,B?4;B(8D.;:R2O;3U/G#UC1HEXJ]'8_G)ZL_%VLX>\(VYKH
M[P-6G#\1JK19C+5R#9G]WBH&.'%[OGGGY463:@@QX6/31HYYO8?1K!.AT5SU
MIH1=CWRB8<EO\+%B4@F):)W<E_B\@PQNU <"U5R6I>7J8"(;^/4C1-N6(6OM
M>C4#D3>U)S=;JCC-3$+HSZ2B).^:..\B*^)T=D,^Z31W_9G&Q+;-VFD:Y%;_
M,14:RI-5C%X"4%&!!?\LC4^QF1*(]F!$H<7SB[D6=B^$@BN3%&V.=PI8X;;@
MT,,4Q%\FD2/-J(1618 >.3%G_K,X'KDW!HL],[W#8PNZO1X]%JK.E3$AIZ]T
M3D;:V 0?<<J=K(\M@19#!H0GQG'K!:K69WMHVIH=W?#_[LXOJ9((UX2M&OF(
M>159)Z_'DMAJ>$Y:>B^-E:!?E^&-_" F!U,YWA#$8\2DH:U-?\7^5M&1Q20O
M8[<EIY]%*V<PC2OG-4H<S5@=;K1'^-DLN[R<4X[+F?$#EC*>T6"K!\>7EAB>
M]^KZAA6<G'?125#,*$B5?VP'31A!:2+AA4D_VENJ)'M[NDE@YR]/\5"MF%"Z
M.D]%6TH/]G*QYLM+D+7->.^&T+I17+'(UX'_T&2R;9!5QM^ATY'8\M4"KJZ_
ML*@\2FPB4=&"VT[2=)VBVY>H0^/:_!BC1I,+T9ZZ3'.(0>(WF1")4QAP8]MC
M S/#T>V._"LGKI#@YECS*S#)SQ%[*)G9J ]T9'5[=24ZJCO(B$8@GFV4!(IR
MR&3)?2,8.^+-7UV-<ETO "V00'?"DG]_^F)^U8[%RTHAFC[SC@ALN)$QX1D]
MDKQ(O.R4?MO03:=?5"10E6V.WI-H;N#L'DL:%I!Z*3BJ.4TM==<N($:@&"CF
M[!2LSZA(I*:^K0>'Y]")/; B%VELQV@4&[N.A,/T$[/V7-D-9\PQ1LVDPC.&
M#&N1+ LJE+&F%2!=+=O$FS8NK(: _1'YVM1'\1B%*B*>[Y:2N4ZT-&TE.IS[
M1TAW@>YME:Y2#<>O#.-GW&FXZ75?5! AP:4.4)77II9B2U@$ JA\=!OJ&)^"
MV&6U))MW@_/U92,-!GEP/\-4%O996I3DR"6K#]U9*%@X%?88Y-D] 2D51B3"
M=!W$''49P#PAUINWNV(I+!-/T2#1$.:IK.7;?$,H;0%/%"-+8'&9ZS8]CY7Q
M6*]I]&+ N^O%2.2?$L-!OU<D6?M,]M?S-6K>!GOEE1 X(].J[K(_L4,7O&U_
M6!-4W2,SBO+I%&*G,DA=[')R<"K(/I=C1U4H.S)Q.-0\YJGGXE.B8HU()S4N
MT-J'2..<.HU]S?J-J"@[551HQ/8;Y.Q:[2GY4HQD6/GUA\!+*[A0E^,1#+,M
M/&:WTW<N'3 +XYYJN+'FI2AA:Y;+X30PER!R Z(PTPU0(P:L=4)1H/!H-4*;
MW&5% HX4CDZI,(CT3TN%)( X<ZEBUO2ZM]*!LBYA*:U#ZN!]'97Y08/K >$K
M2IA4'%[B47D:2_S:6X%>^2KD^-#&PC+%'/5/1UR[$'!0,T4J,^D@0MG! /?B
MO3I*V:69CIKFWB?O&J,S0=U;(==#"INUH]TB"JNU%4VL+22FGJ30"U6A[E:-
M15H**]75S]>Q5F2AW]3?-+J]H7,4R@,;Q3D0D\,KMPG+HROD/-'(T:'%01\$
MG^-GW"ITWQAZ3H&4,">-2[12B<\:$W@#)JC)\%@BF/&N*1*=1-C+TY]DC*5^
M!2%:'L/7S0Z-=&MP[/T_MJOD.";9;>#9[BXY(<>PI_+T!W=P9@U\UQ=B_TR;
MM&.1A(K]J*%E3#&<.\KPFEG,74@SF0Z:T#^*N&PVC/[CKT%ZW525#33@R&5U
MW<)7R(,EK]'MBN095.9[6N]1KI!S>OL;=NTKU4$8E1F3-)P)SCWK7E$(POK,
MQG!G!^>8Q;K?.MJ!C-_IN *.2OPJY(K8KR[4G.S7J\HG?4B$)T8K!'^?H*.:
M.0F?"-)XEDF:6]"<\3! H(AQ!]CQ 0NX*H=ZO0Z5;YN%*L7Y5@ZZNE60.L+E
M;739,MFL@,GC6YV.#R)%Y9(B5,:8[3I9DR\UKEW^Q*<*:XUQ%AHGL[8/W:A/
M5RK](7WX'.,""3RDYZE3B-4DS?K@<L]CF?'(D'T26V9"NI_-$P;1$R,WSJVM
MK#Y>7S9)]W8CB2&(2OC*W!OE:QN58#]I5!8[LF/^:J?OF(I[]Z3FEF JGV=.
M/,^^8]6,BK0."Y>\$YM:=ZHG4R"#G#7UM4;!A-_E^\K.ZM]I@5JG^$=8-5G#
MS]-M*Z%ZR]PP/TOIG#VAGV<OULR^^ZP38(B42I2=ZJ]4M$A#FO?<489KMX X
M+OBEST=_RU7$_.D;^COLVJO_T$:/KJDZ\BP4S'V$=D7<)GW 1 Z&MQ^&(Z>
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M""0L6NA)6W+0[.PB] _:VEM6EUN]HZPR5B+RR8-M:S,N 48QA^Q X^#19(?
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MXY</S&=:EK=<P=3O4MLTVU:5O-$#9KEZO ! =A1!9! @7J65YLZH,>&L&N%
M;YGI;/':7RN*F9K[:#YW2Y[8Q_4[QZ*%W6J>:3>FFLR7N9US%P&4YYA1CS5T
M5#J= Q%!<8/H;GI##NJU9I#&]31/_/&9H\H3Y:Z*5_H&T.CYC\'+X7:IKGI
M*&$S_D@EU0T$2'YKNB[322EM&'1&9=4UE=TWD9HI>QI2ZLU-Q<,=R0EW6N>Z
MLAE)NT$#'F[J)0RWQ9"T_$D9>F8;JT%1 0>;Q;"DK?)L7<:JH4[0I?+"AATS
M(7'>ABAFV]?\A#XLLJ\F2XT.[DG<BHP9:9+-[#>-I[*DOR ;!BH2N%A72WVR
M(V'O8R'2@&8XM/[F:[YJ=H:55@V0GX]5,_^9C53#8Y.MN)066^E.5TX'$>=@
M,D/NV;R+0LNXY+2\S_GY!OU*N8@I?R7#09B%.7FZXVY$ U?C0A";(+"R@OP?
M8T>[0ZF-(I>^;@>_D=2QOIEK3O(EF?A^<=%"%[S]X/2)ZH%-7+SU+5-"'O5_
M:-U4KNPD[RV,&;M; ];ZR4T4<B<G09DD>)K1DS(1[V5$,Y;P$91EXLYW<RW&
M?L+92!5):B+O1$FNO0$.F-9HQ/9#D#QU_?NEB<= <6_[AU40_6;+P=MQ&YN8
MZ;RZOLR0KZ3+N*Y4'<\5*ZVA>J!W*E'HR 3A6:#<NJF E"-@B%D\13EUYI,I
MA[.R03;2@.O#&&*8'N@:QSZ-E<BONI$<#!AD"EG /;I<NW6:U5JA9??:&5UQ
M;,O.CX(?(NN0TP>O2+<MY\E0$YALG66!%M%DTXPN"Z+Q^2FI; 2RIF6H?E$'
M*?)KG]%&NF^7P;(U7L6D=BQAMQ[<RJ/C8S/'-T !Y&] %H>NZ3OAQ )@89NK
M>&;VN5K%Y +3D+M6#RJ[W[Q'Z3IXZ!.Z$!N?:/P*C8M2H8= @O."V2<]66S?
M'E\I!Q.:(()5;]QETK7DN/B/KTWJ@I^P_T/SGW*N-%%LRLV6T)(<7[YP&;%3
M8H.-<'/'4IS>J#U$*C>WQC&_Z-6^ZUC3^SVA^@YM9$TAT0D2N9_5#&#@G#C)
MF0>U_N3.E&2#2[ *6(U)R% G>N;K?X9Q#\AEFV*EW[#TLYW,OG2WNS![*?GK
M\$E?BG3-T9YR7:BHF*],4!QN%$(H67 '!>#VZ8VNG1D_%(G#C:DQ]Q(EA%5O
MA#L.N\JOALK>E\5ZNIS3&Q(X)1S \"KH(B=3#UT[<R/(L( W^8JMV'>04@&+
MON_[[^([4\1EB#(7 Y?H>E3$202]O>J;(E@8K6#[&TXVZH?8!7;JIK!%1\[/
ME>O*3^<R02^9)608^[P5RT'_H3%%>N7FY_#WM#&\A<'NX KA'=<T"J@*AK@D
M9L,X$XMCMC \>">;84Z!C,9)VWP\U)\VO,XO1I:WO(ZK-UY^EOQ*U5DL9:'P
M5;[]7Q+<%!+,/H&$%/^W\5.IBC/281.GMR:+/C02H+IE[\UZI+"!BY%4#N3N
M0[V;8FF7D+,<3>"4N(++[/ZA2D>Q=DZ!YDU31H<))+0015Y#4EXJ!,8EBR;R
M#8BAEA:+/QD)"22E4/'' EQS@:@022[9HEHYX_J3-NB.;)+<S<]Z+'@>0FYZ
M7H1?Y)_4FEB:"^DA'<B,S]12N]H6/3J$U>6V)786'%?VCG:J+PY2*UJ"]EVP
MS&9"/-"X5!R,<FJ)G?[:P*,A&T:K+W1#Y:OCOLJ0 3S1:47UIQJGYUZ^XA#O
MX<_C$=ML$XL1!J)SN9/G<^TPT[@B.BI-\6=N+OLQE),E!%N!202B2_PF'S^K
M1'%&:+"&9[IJ4?7HSW#[J%&Y*R560E(F.79:44BB\^)(X>S"H]G%V)%);F30
M;43+AHK4-7B1I\Y62"<#G/OY>LXU_Q>K+VQP@A1D@:J]C#M<\NS54%V=9SIG
M46@=V>U3!H1$EK BI'T#D0M*J +Z-J%H.,DJH1@Z,-Y*U:FT[')Q]V3OX3^T
MC; O2ZO9H%__H1&<WBT;PV&A,A!W*W-JLCH'"PJSI?@/59@N;>AJ)Y0(<$+X
M3>Z\?^T[*9VQ@)*$G%*_(Z9XL2*5;2G[#6ZE/+U^_TK[]+WI/$Y'-M/D;,!$
MSX'7=WU,/XBCIMA/HOJ_C;BMVDU7;PR^-K1HHHY9#_8=J/.J;L\K3O*JM=O:
MC=&;ANM:Z7WFF27,)I@(9!:'#TG-/%3&'D1?I)^_+UZX+TUM4I'9&:/@T8[N
MYW8:T6+-*33$MI%^&B3;%4MJ;A\QD50H5FK)5ZK4W5;(?DH+YW"\_5SO5TX"
M!QP6T;3K1S>N^0^(5KV)@JJ^_]#L2OG,NKN=?UEM)N%G$P1)<L1 **$1=<JL
MR5E'6Y $_DQJ<+.)_DCZQ(&;:@5(-7$41(;J-7W>R[LN'=*H]+WK.H5K-U41
MUDTT^W B]4?NFM3OKR!?_R27,'.P!F)B-+,1,QFS'H5[+>J%6=,3GO5CVFK^
MAQ:]6D+\@A,!_[M5!1:CM)IR^4N7YE<B7'G3,6-!\GRK_96GYKVV&8W#X;H@
ME<$"RG[36U-':T*T],78TU%(L\HSC-7A,Y_NNQ[V:?"+<8%GUZ? %(:<21DB
M+X'IC$/A6$M'LP0FS=;GP8G4OOLJB2>Z@/ YZR8E:U]C]J_&1\L[4)D[I:</
M2^K#P:<7UKKL*O7#][4XO24"U;^_,9GD+:)$47>I0^/$*#&/!Z-QIL*[G0/7
M_!6K_._!WTFDV.6;P42)^S.!!&=ND7Z84W_NFA %]F@L!.]7O5_B:7Y'%3"J
M>_;4E[!:#:6*>+'\=H<<B"2.U!1JTP>LFDVSWNI>;;Y6[7PK4 ]>W+5::6?
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M8 43M%G=OW9U'>,#):I1\J&Y<3N\S81;^</-Z0+$3P9C$KHS/]Y]01.+#$.
MI./QR)71%<,##S8',7T7]]3IU)59,8'2PS'JE)_["--?U;.F1'64*6[Y.ZE2
M%4$UW]7^?XR\9U 33O0V&A$14) @D19:"!U%.J$H+53IA%ZD2B^A-U$Z 0*A
M=Z1#Z)V @*#TWCLHA"I%D"*@<'__]YW[X<Y[[\S]M+.SL^?L*;OGV9DS3RP:
M]4S.XP]%& %G]I;+/FJ*XJ,.1UN3<8.HWD&'.V_G5/AIKZZ%2ICB SU^4@7Q
M-_Z]CL2^?0A%18^8*Y$KJ5G"J!\5F;.R<0T+-U*8#67-3R<?"')BF4M'5CI%
M4]:&-#DXA*.JMP^SL;,*D"LV/:/-NAU59G HE4*_H3221^EWUPR_$KM3@24%
M:OYSG.GJK;C$#K.LMS,"5'E4:'+$O' 8Z%S >PIG_"==C/O,"V)35J*7X;#'
MMM]_NSKTD76!--]"IWV Q5JPW".]!&/J)?..Z&7&)AQZ[ED[9"V8[.J(OG5)
MN%!EO;0BGOCL,'.A(>SBF;@UQ:(:\/&[=*9F5ML)1KB".4RF,.E=K*L,#[BL
MRX<="Y,2D]A02B/IMT^@(L;I7F# WXV@A'YCU8ZTM4\81B@B>TEV]+$=0!!U
MT9H)+D-!UAZ)DAUMKW<GE@,RWB)5L'.?T1M99-@YUC3;IBH-:_GE3\S-;<<-
M2(7O]BPJ(/G?TO?7$ZCNX8'3<\4'300I7"9H.XI,0]9,]B_+<F%)"MWL<:]*
MR$:7TW\4?(TG5ZP^[0@4  [%/4* M(R*S2OUVO?Y0_6%M89;U#\LBBDR,KQ5
M600U?K?JIHWSL(3M@T[\]3N&XM_B64TJY5<?ML\'NR20 GI+(FW84._@U!GC
MG(S=Y"I13I1R">?Z/"':!Q=9SDOS!W$.QRV+3D[*9F+5 >KU6@5BF7$R7SSZ
M1S &-G!:4%0L!]$)_IOW?I93K#O;[--%5KO\+U"DAF3NDX'\YG$&'CZVQFM-
M9SV$L0KVAO"2!&QZFLF,PDKIVRAZ"!CVBH]@*"65)E'9J:]+!3%]'DE#\>[P
MX2DNXTW'9 ?36RSWSN)[B_&:["D<\TCLQ(**>$%;HY6\;L+]TH9,[$Z?8_HL
M!"*4G0)<+D)BXVFL0VG'M8<W?OU!;?%&E46=\M!EFTAE;^D_.,)?!#29E758
M%UJ[C>H.G:;*6<MQZW: 1ITL6A_:;P*E=>VU&JC3B:=$O8)% Y#JF<:$!)BW
M"9P^! E9MV^SJI_4X3W+@^RX57!G%^Q5-M*Y3@E*+,+6$Z3Y;Q_X/2^>[U6.
M*K$J44YE5^(-UQYXVOM-D,=@QD*)0#$VU*$P8G1E!Q+ 9TCZ.42&@^?>(*$2
MNS^%!1?'@_ZW,U-T,C @&\2W(!\TID\VMM4+;B^BK!JW54D/U4-960Y\H$K5
M-;_/J,B3046T:$X_A*)R\_4-@5_J(O3.H7L&R5$3BYQU1>';]U'WR90&K;P/
MW=(1)Y_6YNL \?K""FB/Y0:C"L:Q+W22"3#&;X8B:NYR+5V@-5=)M%UR *:;
M\%I7(J9 HQ\ ; 5.#1/\XJ$Z/"$>H_PX"IUK[2QX4X:_EL'VPT;HE?H*B>=X
M,'1E\::S6B2S6H4SY$,,L:RJ7URW,!:D$BDQ"+$I(YA<(GZQ.IR<.KFNV<S]
M,3L0;3J+_O)/@M'FS&$/O=E+;&3X$J/VS&119HO%YN!'$PUVUI["A54GTPW)
MS:/#9Y4J6]17HO^IEVG:4#56I)Q8:R1A$BLI[6@\*'GLP$J]WV+C@]EKX_[(
MK3ZI.',OO]^CFZB[G>%+W9#:Q9[*U"<22 +QBLRSH(<6:MZ0ZE$FN.']HLY-
MWOK0<B32JP,3</8F!!&QN#^5&61C0B2#[JD;T] D_##YS2-J2YN_['#:4[V(
M5:E)VUG>!++O-P@6W!DL,V2C&+/09>B_+_G</P#LKD[-$_%-/_N-8M,(W$?K
M@UC=H?6 'UI\+EN[."W&S#HPD<J.!D",*5/,Z'U'B?OZMB=<\7A3UR.U;1BB
M8WFFLFCY>,6KP& "I9=KGES7^O''RY3E]*CLS'AZ!0A,ZYME'<@?[#G8%LP2
M,?HMGRU:9O>&T=GX#D"ZK_E;@,89CJ\_=2Y^</7*@:J&2Q8U";=W,=:!M+90
M4$WI%K.\:"S)-A7[.HFG*J+.Y%*-UE'AL9]A+F,Q]J^OZ1'<E+%?1#?LO[]7
MAM.5B"/&!.N0;G0]?_G)!D6,(>K!(PB!O23.%9JG"[NQ5E:+/51VO3*TL1+>
M@(OEU;4P'YT/>OOL,;;G. 4^7LVE4H\YLC !)0),2&UE0G<F_9^6X)HK#N&!
M7PFABZOV?,Z?Z0-101<Z0!N44_GI08$\AX#2-J4XCX&/"W;W=$(C$,WS12GT
MTG%M7CG-DN'?3W6TV?<V*;ETC:]N5_H-V8XT(A>8R@.K09(XT[A4Z35V(F8\
M^ /:EL=(]*7<6Z+VCKG?_BXN;0E].LI;0G-Y\SA<>'1KY7 &R'Y4+<&"S"7H
MXJ3UZJG0M@[K30_4=U$!;VVIH<=HA#3H?LT<F[#<L^5F;Y_]HHFVV9VFU7VQ
M_R?83"H[58>>1+V)48AWQA W0/;NY1\#=VAY:<'C]SI  GG.N.Q&8JW\_A62
ME'UU4-C<LQVV@7UN1X! \C2[ 9PX?=)M%?8Y2@AQ"H$DA+KL1Z$1IHF?NIB"
MHRN\-)0;;A=NO+O*0M5],47XMH_<=FLM'C^7%C'?->6!?U+K"<<I_?OS&:Q@
MQ6][,(6Q)1_&#CJABQ'@2YTO X).&YVR/61KD@<AIM'EVM*,V@9CDJ>J;XFW
M'#\_]M[O'!(E&<KJ$75O&X_81YAD1"0EXFE3]\Z$<94<WZ+C:R.<0N7$B$[Z
MTZY>$;/@F Z$D%+EIXN3[Q\[Q()WA--BVRID^R*+#?OW)5]'BHD*TNSA BO8
M!.I<\$TOE+G>F__8_IKP][$>#\%7%PU+B@$-?T$D:XVJJ8,KN9!N)3KQU[9Z
MZ8F@+MY\V#ZIQM)RPTHH-4%VR4$R=DZ<QP^<M)C1^::X_EM&DON!U50+7I!L
M)0G(8)%F V-7M+$.6&[WN_ C&*(<:,K@F57EV42B_\.QU==1?; "I@=6=)T'
MJPB**.8$;'V:RZO\LHIVG5.TOY0.>K"M F&2K044,;U8!/I*7@D8;=-$G7E<
M82N,!_4/U)6BVB$W!UD!6.S?^9H$XHN.6/AB-:NHQ@\/K> TZUNRCN95G]]7
MO\$Y+^1;3!).\>*;6*3.3PR+H[L-W+6SW7@LZPZ@-7N=C2B;G=@R='[<N*PD
MYYS?//4A8IG860*NXUR2N.2XIQ+$^?V>7%7*->:6Z$'POD?1'>"$*>J\:NE_
ML^;]]]-?6+[M4C2&>+'^?4SZ_TZ]IREX?AOYKPWQC^/L=K,RL0 +*T-M>2"J
M'#C:<#HHB/,%%NN4=51QNF]^0S-T4-$TKSDG.2VKRD#R==<9!9&Z [04+G1G
MLF=D,>.5M!6T7L+EKX<NN6NH79_YZA+CZX-F0].'LMT+&S.+Y?7 A?[^8IPQ
M!S6)GBZ[7?^,&<NR#F=*O8>>[>4FVEPW( ?"A@0W(JSDA)P5$+'')[KW"'1W
M-@.1F0X=/E8F,J+O:AB+ OV56%OSKQ*?G!&,;[]:5:/2CFS*Z=^QHY*X(*Q8
MSB0\D1W_UVL3V2AE2*<@0O: 5["/PJB4-L_>_94$L27_F$S./LCOR[8;TQR]
M4=PBXN'A.B^=;483)GNR[TN!-:0JL?A[7?X_H$C?B!,?'V7FFS-B3:OO< I-
M9UW%@*LF'C:46(NZ+BFZ "1.*HO[&O?\5V=",F>\O\0^;NK-NJ@(CZ1=>TV[
MCXL1/(D7S&/*!V78N%;OM-:U\[;2AD^;%?K.ONH<U?.=!!F5<? 8M7<,8/(!
MS=5\>RJ.K6S*#X]\A65OSNU=$O8IGK@5 X^EW;U,!^K,]H2MZCV*1SX/>O@)
M(Z;,EHT3EPT:A^!.P;!-9=8H!!*I\+G4LN8%9^[ #G<!-^ZYR$RV*%@(M3^B
M_%S@#XB@#,/F?(\N^42.)[9P@5:+KH?4K,?>Z&OR8\3&]N]%.CTFD6&Z>(L$
M:=:-T3RM=^14.7GM1EQO W>B1U>-=@!\J(K!H7CQ=D]YQ)[.E_CX["L]QW<F
M GWEWTK6=;\!3;[(MRA"%7H$^+44'JK)9-"<<7<,[<!,L&A5\D^4:N[2T'L*
MW?<QW<SW33 #4(_NDF$4O38G9Y4*<^D'D9"JB!2%1%W?X@5F;)54_=_.':&Y
M@$<CZ%^72?80A6+"1CH*S>_2M/?I'FO'NT*YTP;<6!EVBQ+F6L-<QGSD#S+/
MDEPJH2S)\2C^$-C"V=_&P?M*3K'4<4.A'FN_TZM6@:'7!XK<U;V5,E!G9R?]
MBDP?2AD3].VV]U6Q%!YYPVI6[+;8BS ZS#SB/+RF^%F\H&!70=?SAR[ +TZ6
M#%N?,KQ!&C<PG_^9#4[W.<NE_4;"5EPZ+/P1LY.*SKL]^HA-+WGZS15#*B4I
MV6(N>=31<;K4C#()V<5A-^,%26T%F]1SSZ4**W/RET<4VC^G7GZ23QY=Z:>D
M<^-AE]9W2X=*W+:$ XEG]%/,L%EMN<N-C(R6]%DPV&.O3PT>M#Q@7]T'80..
M7#QXDH')."49(/$4QPN-_Q[T,_RVUX=)Y3JR.)4^R^6Y7M2?DRTJ>=]E_F..
M[">L;Z!V^MXT [,.*6+<+MG^66OS;CR#1M8+TV_[FULS!_H]]VOYP^,H7UZX
MC?$W97%C><S:#]".&/KA1(Z93J =V)N'J"HX2PZYD,8H?L+E+T'ZD=2*]MU&
MB5P\["7)4T/GR%4D?1V"1N!:MXEK(K6?BS8[+:J3V2I0J*?Y=-7\F+K>O5!*
MN!(MQ\!$OC(KZ]2#:MGHR_P]4O=G+D]UT(L>\)RS\LKS)V'%=%IF6Y$BP]M/
MP@Q<^[\IIGKF^<MVW&6:T*[SBV59U?NY-S5J%S>F6Y9;@]8+VG)/P[R<"!//
MSY]I7%+/G[XX#&"<]<?M;SD( VG.'?C'<_?G=,4?&?G(4LGT(Y,%S/J$OC$K
M;">\1S@ RZ+B/9*\-/*T)%;["G5:?5U@J-P"B\?*'L['1+OU-G/)Y*[XI7!+
M;)T)]K)I=X?G3ZW#/&O6?,?8S*CEV5CIC)_(U& <6I6?G2U?JCE;52;]"4T<
M#L0'&L* B0M4E96="/;I55+F7D=?R^2\3IBD8U7=85152L,,C?9S"?!3AOXN
M:8[^E9G$AC0[S9<+Y0F\I%GGBJ[F4C:N$4HN$H^L2,V0EO&"?B#[2K&L[#B@
MY A&;?H'/TH/ \;W3BZQX]JYXT9]J'1W<TP3'P/Z-@H&'[WK3H'V[PS)/5;D
M/Z6;12 9'HSPS[@@I<840=C/H YV 5.;8+8#0?FI_GMDX%"',"041"./Y =5
M.XZ@%>.&>BV%$0@Q7+NO.7.*CL4"[)NSET"!I-I*E5.1A]$/W '^ V90-Q1A
M3H)I1UXY7YV4_\Z00F1F9(ZJ"=8+R*F]4$P>">:/JH1(RE\!E2URJD10-AVC
M(ANKKW70STUSGS#%?^FVHHV-A73;M=4NN/=?2+ <?QO4QL-<!O33-SYZO:U2
M)CD@T%#E5?5S(#EWA5QEL1R&B(TIC+:@+RO(MR%\HIEB*C]@N4,[PKMLBT#_
ML6=[)T7^U#@XV Y5:9D/5GS&+1R;'K5%SRA\7U9?RJRB[61# :?%XR)'UCQ9
M^C6#>12U#8ST\$DHD"Q5IAKX9J75PXSS!<?J*C95P_$5QSM/H2MT]I9EZY2\
M]<9O?->F!P,DHRRY<<3S+P_590VVU8VE!J+;G.<EZF^N?0ES-P8)<'\CB7KS
M'/)KS20)E]"G:%)$-_T5%TBV1Z-OS756E89OQ3]X^<4O>:\\M&(Q[012L1?1
MG8R /'&+?@A^<%U]H2^,/<;F@E%OP#$,9TDA+TE[*(AU&M;>OL/"$JQ1RG1H
M/$M#S,IG$XM?CA>KY5,^Q@E#X!C22 8Z]JM #+D>KQ6QVFFO(LCXG'&JE9>^
M'X=   ?.'#I>I5QH'A4L:G#3SY$8!& WA ^):<%J!GF*&-,O81[O:\B)=W!E
M%>?310LZ^X!?VBZ=2C5O'ZP'#P13JY.'0^*AQ<K:B&X)Z54OV_ /<(,'\A]D
M"K6-QLO+SZD%\)N+<QP:UD:J<R[<5UI+5#'/"&U9<]'&#OV@1-ES>3^303)*
M/@[/Q#UUTW<Q!IF2/D,6+XI[,"0A=&)J=:1%'S-(+UG3HQFF[K-4.B9\]:\S
M_;TR78[SM/^U.=]H!;/^1CP.KC'7(N:-'5]^ I?7=26*JPS(K!A%6PJW'Y4W
MD]&2I.BJ6N7^F!L)_-A'*\DF2-@I=NRX6KO4AZU U9@Y"'V/V[@XMR!YD%)N
MS^H.=3]9#EV42%9#2LS^G@:[*[L#&"FU\UZ:)JH\X"RY9.B8T2;8+8DF*A)Q
M;O2QJ1Q8^MV?HZ\WV$)(>:J<C/G^AA_\ V>R 79&*LI)T6WSZZ!.+_7X'R)<
M6::WA&9[*> ))LJU.E';CRSKA^36M@G)%(3!9ZS&[8A09$,F! .N>;U/]"GQ
M\0TE8I'4.C;Q$^(TG?*SJ]/K-PJL8Z.S ]L\GZ.P>#E@[*/,2C-3D7FA.%Y7
M>AAAV8RTH'.$C4-!$R.JBM[L1W[$3 !&K&1__7WSV=JG,?L,#6NW#!*QJT2(
M5#Q2CON!8S17[?0AESJ+M3^!',\#[K?YQ4(Z6Z+-$8[TZ)'Z%7"80G&?@XZ.
MG'K!,F6Z^XOZHRE9)\X'7/+)"4ULW\JY-3E@&4&-!V8BW)[@J*9F]3JGKY\C
M&^UR>^$H_62TU::$#3/">-"@;"9 S'6.I,!=_:+ZT"D"5+<TT1HE^_BMDQ9A
MG&.'N/#X.S;3M<IW+Y1/?P*?J29$Z$'ZGBH0444NA*]B%86'8D[]9A$UR_MU
MV0B0;X'73ZK2,BO6!.Q<7:"L(R;.S-J* @OWR(S8GCDI!,_JTB)VU\!:BR8E
M.D)G]C##&CP4'DI/]RV:Y[>Y Y5M<S^:@8M;TYY-^9'1W+F6NXWL=<ACL=;M
M%1="[XTF;N.I7&?.I115SV)7B<:X:&Z#1\I.5.R7SDIL;.(#?M!(UJS>(?S%
ML@MG/VVU0Y#>0186>:$V2]?. 1^+NY)#*!4%8,:TV5=,/@=S]SU-Z]K!T<TX
M=F!@W+C.90XX.2ZM5[QZ)6OS>/""\?*B>L6KB!Q?=.(UZLT^+A7Y_@Z0=OKD
M_O\W<9KY5),/@OO_M<?JXO_NL9HVNN[?^]>OU%5TF[?BI5*-SD1&O/GY3$Q+
M?]+D:ZW@)()"ZRT&JBR8 @+1O*S;WX*ONT0'<8O%<M4Z/H"4FQQD\2>FK[UF
M&)%WM,K4A+\R5NH<*%H%S+!^6Z=7PNM#L,5?%V((>I'O'3<W<9U?F-RGC9XU
M7@(HE!F^$/VYR?UBNLB@&F]]Q8_U9-(B]V@3MHFHM<D .1)O.<%8TU6P4Y\K
M\5%VSAC&5]WTB&U6XDKOT55@CN]@-/L=@/US!LNTZ2LSS44^QP6# 5+IVK>^
MC&ML)[2;#G75"J<4DZ)6_V8M@E)$DO:\\^R]WN0W/_I1[UR9_$B-6Z;@7J+2
MH*6N1_K5LU$8CC67D5O(<6V[9"38V.-I1!R>&ZI*GV34)UVV/)*PK<J_=J9K
MA:A.[F5ZH:8K4UI?$."ES+6REQ^0TB_DT'^^,?XPYN:\I'"KZ=Q0!;#9-'$8
M#)UE5(*2[BYS<$FT2PT?V.:,- P[G;3M\3EPI]H_L;;W8-R!_)D-B2/FIPM'
M4LFJ@T&^./JY#'FA2CGHH/40,8_;H"<'KR$AQR.%9M5)3&9WTS%+0L339,X9
M?7X8F0ZJ(.#4>"ZRY0TKO4/*<?W@$P=A?(U"&\TXB?RMNEJFNH7OP@RR::C=
M=9"Z@)Z78P/TJ<:RH)>A8?P=[?X4X%M=%=CKE&-.]OH>V= ZJP\XY&B-.VY_
M2IM4EU+DR,N:0-$Z69.H]5J),""!^VBW;>MY?054(,%AD)Q+HD//CDEO4SX<
M2@&3%+^.<_>LU)O1G3U;4&(M'AD>-D"^6:X?ITBNQFA#'3H[+3"0_C@!E?=J
MXXA%GTMG S8<\_RJR2C74L,PQ'V+85>.9NCR<Z<VEHLQT<3+,>JB)E.1;;7B
M<$[]R(GT.=W9Q$>*Y@P1;:.-5;)*0X%=1X*].%>IF4HYT$D(@J<E89*[T%N1
M.XF&3PXE#PY'DGML-C%F73&2$/H5%1I4>QA-\%=Y@+,\5A%5IBFZ<O9+;==Z
M&YH/W]]K6#$->>)^%0.&K!B2<7=K4SS3Y80^@-QBSY;\V,M630]7(,;#X>)@
M?.)NHB*+LX(MW[S2Y,B'T.Z1]]\\HZTAG%E?3[GQ/HM3U2M3B.]D$7@UX$,G
M"$J^M2S4J418RH@BW\-$.IW=%1-V?ZTO776T?#R1K>"3U(JYJ9D=&\J/%T61
MGXLBGESHZ0]0N2BE)3X[*6.,=2A'[+<7SKI_JN7DK7RFQ";Y]Q\'H3;7S\*4
M0Q(V146G^2&U69HXB##='2"SIEY%,R747%OG\!P:DO#0A?.&D<QG17JOJK+)
M;-"=.>\:\=;TI,6]%B!D1U#@E- Z:S@_:W&6ITJKH73S>V):.7&&*HK3?@SF
MA/HW2<&J7R$)<3=B1XJ,PA>A3^_-8&8GY^W#%51?_&;+ F^7Q "EX6$T!Q:%
M*="<X5:5]:3LM<>.*U%XN,/Y4_%(:P,D#S\@H^AC_(Q\A'X!_V3QF\0[@"G$
MH["4OUY5<P0M2Z9P[I:-7NU"Z.5PCYY\%A^K8-/$ZR"5SU0-6;X:+-?S&-F*
M88A+X.BI3Y.^K]^536+G>*C?=Y;_4OSVUU80'">8XW'_/A-P%VDX:*,<U;R9
MQB[UG&H*6L'!/(046'SQ@B.)=CY+B[=?%K39R6*?W69;(55:M#.+>0]>0+)L
M,*QM#@6E5S8G?]Z3M7A)(S? M<S2I"3W8B+883F]\<B^R5?Y5P[<1MBFT9M[
M;L#.2.)A140<!/=WPLE*_R=F+)BH#F@4/:AER:HM"--I0$2+C#2[;RS6DH8G
M<_&>\7%@[<-L*SZ"5+R(%0?+?A.B=?V;@"#)08&*0-2UT^!%$MO0O2(B,!*H
M[D7_MXC74#([5+K6R9%NLB)E**8;L>QI%'\O/O8&1OX4BI9;YZK2573N[F2I
MY9S5QXW#MQA^7HD(^W9@\0JG:^R^'8_XJ85+/'/9#)S>'#1HKPW4/3<^5:M?
M'OV<_,T5R?HM@[=!^%-DJK<(O1?QBRJNGW7IAZ89P2H[@?(SZ/W8L>SI,8NZ
ML@Q0R%^:7%]O.BB>DMZ'A9L0'O7*,_5^8UC(?DS 4.'92CL2#UQN+?[*G<F:
MN5-(5*#%ZYVM5&5A)&\7\M##]A"_P^^M=YX2:F?,!*[_Y5X!8=J;:AT:F/G]
M"$^C/*@3_<TZ0)I2N/RH;!0SCI#7J^[_Y7L+BTOPG0]<H65T7<)JXIB "K;<
M)R2,AW$T \)T%=GS[K;#60P;XFT#0[-.)"/BZ<>*KX0$KC!]X+0&5\YT>4LR
M(';;#>ZR>Z3\NV<93%B$5"RC7WW[P'U!BW#R4F,%W9YP12^;3!"-*$)_,4I4
MGZ#D!9!&'R[*MG@6EJA8/2[?UE?G#K\#8!02')[0Y=-0 /W<'![MM^\71IPB
M'5JLY>3;0Q6;PCS"]_U8(R[!H8Z64=P;(GX;PJA"@*::S&=T,*$ECZ3#%EQ>
MC4!!'WTRU6.Y$+X1D;W4R71?0>]$C_7-2<X!\T;[SU;E*]$7X\BR9V]]=,LW
MLK49.6X70[2Y4$L]=8J<&*V?-P9LXCALCW!@_/70%OM0Y6E<2!Z"XLE"R,..
M66#W)IZ",XWME(R7*J?]R_W$A!>[JT8RA=:ATB%PSP(SM+>RJY$#K2R1HJ:@
M6K6$KAH8VU]'Y_O0=&U>T9=&]]'\398)WK)DH /8I#>7:^-E[;^M5I%F(;S3
MV0\N=1)XU?F:;C%<5Z%9OD0H#"U8!\;'XRUQU8H<"IG&;?LSI<VA8.?H%RR9
M_ .^B8A =SC";4AMDK$_H48ZWB8 P=#FT@$Q?"\]@G(OBH.SBS'L?<^ ?PEG
M258ZXQ#-IT%?C\(1< ]-&]>&G,:3D):P!/(I*6NC*1^*HE ON/R"IN0I2>>#
M5NZ>OG-.4AFA("[FHLOZ3&7)!VRZT@7^R([.'1Q@9F8S1737/W.^:%+RZ&S_
MI*Z!9VDGQL8.4M=//&#M1\/:5#;[=BFJ(<F88Z^:@RY([3.*U_]Z0[=L9L-A
M0<;=,OS)*ZK[L$[W3,]$OJ<U[!(]%PU!V6.9ZBG&7_HL5A@]Y^2<RZ4D4%YG
MIT3'M :8Y<?MC1\4W?W>'"G-!A#-%>H7$&FE_A/8;7).Z)F8&WZ9SP50H!AR
M;XK4B][% C\&NCH(OKM*WZE;EH@TK4Z;7TI3&;=?"4S\JT<UE$*JG<>?YR(
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M?)(^TM?FYB&6CV2P9"!QM$NDEM_8/>EYER_F#'%_;][G"*7&/R@T^\+[\2V
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M#&;]N]C5.=']U#EY@R@,62X?N%I^]/Y?%4O)QV[W[3\0P07&G<#+6G^_A&<
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MUHQ7/"C^GY#O_XD[>&Q9SG!QX 0TS6KDX4M!U;"']F^N%K:-_RG"Y9+I]>_
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MI )WX]<) I\!BGYOG@$!RX;=#Q(9\W[J,_L2F6>BCX7W6Y(%S@W_PKG%P,#
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M5)VPSY6HE[:,;N!0*XZLRI6R85Z(:$+=<K^A!V'RQ5,W*&_%GG#OMZQ&ZKB
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MSOW!_O9Y2*,0$2YB@!"3N#6SR'?O,9=O,6LGU(;1*GO,C5"K^F$</?N?/1/
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M ,HAZ\%6ROYX6M_:.@_YO"U[U=G8_1&VL>WZ.T3'[ONF'J'<^C^L>,M>6_\
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MXP0.O;1(;*UJF;J[<Q4R7&ZG684,0JA3I"1ZK<A:./-YA1!2HJ!RI)(4??\
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MSKI[;D6%"X29BGEM]EAE0*RI'( *XA76<]D:A.HU2H52AV[5*:RL,520Z_<
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M>$J0D<2#CHLJ1YB>,%KW.IFK;C09;-,BKDH>C,KEQ26PHHB-+6L%U3A !2,
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M7?U) Z&M]!IJ8E((B5:M=29LJ-Q<4BF95QEMG,+N$9=<A4"$;=.RZ>I_Q#
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M403GK]D?17[O8Z]Z>SOYHVS_ &=HG^4P]>"M9*2;MMA?6$W);Z3V <JJT0C
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MX+%D) O.TTK)2DW+0 L@'D@??,,*Z(_: &<?N^O6O>HL_P#FC;7]G:)]<_\
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MH<4I<=C%MLR7&0]R3S=*0M.",C&I/C^/FZTU^.BT]C* U%E--BGUR\I;(0U
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M!QS\W[2>P.AFQ#[/7<ZN77MG6:?466GI%H5^12J3*92W'"XSBW5(#F"E*B.
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M*_[)VRW"HERVC<%%DT>V+-I*VI3%G+G,+CU*76*BE))<0'B]%8;=<+800>.
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M\6XH%,R8_P E24M$  !I8&$ '/U&-:N" N2IQP@+6VA"@!P0DA!2"%)^4D<
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MT20/8Y]ZG_&/9>\]W+RE59ZJR[7H4KXA%3N8@I1)=DK2N3"24E+BG)'S#FD
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M^;M$Z_#_ ))A]:'<;NR7K>\=[/TOB<J2SNN,_:U[@TO??<5\I'^%G\O]L7O
M0< ;?;+#\^0VRMT@@C\!^8/Y:UH@6?U./4*^67^7$I4.6?D!/OQZ(5T3K9=_
MA:&?]L5O".N/\7VRQ(^O+^+*WL$?E@G)'U]^\:UF]'8K9,?]KOTW]L^G RI,
M&(PWSVBV>ET">EG&:1+AX7S=F-Y=(:0PM3:6F4XX!("^&>LG*<I/MGWU=_\
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MOS75*@2T&B)#I4TD8#82<%.,# 3T#T#^/>NFP0M3;#CI:84Z%+5]$DCB5_O
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M#[5G-76')G;N/N<:Z7EQ>+MV[NUM$A3:4V^RBE0F5K6H+;:"4E04#Q*TK"U
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MUM",XCUP34B1J^HHZ8TF&VKIOILWX/'QWMF7O;8M%OV#7FQ&DMXR'4EQEY(
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M.*Q2DJ;D.;C/9 2A/@/BK*8_G4%(T%1P46JLZHAI?SSS^X:"&$!>N'W85_L
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M(G27TJ13651,JRSU"R-:=<"(86X\I3,L-9N--L@T0IA"$J[N,Q=M;NQ*FK1
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M0_UU18H5(136:Z=$'MQ:.74)67^6D1>2K#&.S=;>BV?=5T&O\BB%J+[/OP!
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M:H?O?Y[C _\OX?\/\GMX$@X #*?T]*FI<4S_623Z_X:J%U/_!5!+ P04
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M8K]!C#[A[=L<@4Z0*'PZ)9S>WMTCT.P7!>\?XLX79D:T__+]H^F^Q);OR;3
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MY,PQ?N;]B7R$/$V-Y_?<I#)]Q.[<)6#0<G,QB+@@=M5?C6V [R<BK];LCY>
MH1>GX9SW\ 7]=@QG=CF>HV[DWNEO\#MOO&,/O9</.,+""LY'!HLZB6'=/3V#
M2"2ZY)APE1S)FAAGY,+J^G<$#636F K2LJ"G$L#Q<B"UDN*TU-"$X^K*N]"^
M>O0A,70338P(=SGKH<%O#LMS'J82+@$M._)K7F"]PG9]%B0%/077)UX'LFTR
MC=B1]7U.Y8N%C<W/@4N"R;;=CWW"'#;"[<G[SR;COS,C_$52UR.1,Y%]V1OL
M]$DI4'\6B1ZR/QD9](G<8!Y3/F P!;<J7X[B8^<7M,ZQ3BNCMEX?Q94<C,55
MV+#WE,P\ P\HLLRC7_R2T^X)LOV[W9+).IG[W-H<]LRURT>TCRNDB5I;\D%%
M]0>:2 I/1<:(V'9\2%%?N]N1T::[Y8.984RU0?$<<^&@7J%Z:^WTG,)GK$:Z
M32DT-]FLW/R^4H9AI*P2O<.#5W-P<@K.MPN^%OS(X^-Y<;<\*D]P%?-D(,?/
M./:7 >$.%FS9S-)SKGB[XWS'2P#UA$+1']845UC(H_)/G56F=P1F.QVU;&1'
MB4_KRB$R@S.R5UOQWS/[L[AMJ<9:86P'_^31RSF"-VA2%:_4F3]=[YK%&__M
ML<D[6.JOCV8\D"8E*^=>;WI!3()'MFWT#9'&E858NE5.:+N[N"PY;1,&PCPH
M_>00+:?R)XL(@1[$9':44,N>>?#MW\JH,"6Q(GTMN^VFF1C1SPN:MP^,KJ6@
MT%#3^\P<YGH3X(:)*C0EY_Q$[T4BL$0B<!2>7Q*]''W MJK\(KEC!5A3-UA=
M]!/HZ)%PIH4H5J3PAASX51W9(?U[0H[@Y;8+F]]KX=G/QSDG;AG=D:T:V\;#
M/\X\7?=_JY.&%Z;.@]3%HSKOFJ>TE%ITC;N-\MR^BDU_Y-0\.F0;W::2GRGC
M0D7:)!UPQWA\8.Y@YN&93>DGA%-&H4>'TH?*BD1;Y^88\R?0M]^:5999D_+>
M>CPH=12--*#.7_EQ!_0[>YQ.*QY3]>WAJ*]HLPV5S+QBH<'IXTR6T4P^=1 '
MN\D%'5PM)5/-19Z:ZSH?)6!+X"M]^;/K&E"P0Y);XXZ!'X-E'?,#HFA#O8IN
MEX!6-53HR!\YC<UO7\DT*='P*8$A6:/58Q7+SEFA-V:18$3EAM-MYJ)L(:/&
MZ0Q:-[A[6BPMN%%(#Z;'K>=-.5TFQ'LMD_MQN3Z7D/!U80K33]O[C<-8I6>C
MX:Z3'\XLS^R;I =-UE1&CT3G8W!!TS"JFN/FYC4>N9ATITG\(W,$+X9*(Y9R
MZYUI]>N YY/ENLE4?I0^1:B']T0RI=(O <Y\T=-AJ("1MUGV(7[M>/+FC>6Y
MH)9*&4H&;#_(7PODZ.]88EP_(=HZ7M-,++1LSZM ;\^\RD+[K$/A])S'/T(<
M!\:RRE>8J_-JJS2I*8-A_,+COPPQ]"TB,+^T")!?V5A42J:0@)UA_^],&=>T
MC[7"IJ+EDWI2?$+@4(K(8M+H-G#YPQ1Z+8 05X0Z^7*2R2#;B_34HC#<*!=.
M7K5SCQQPKK#/H9L,?( (GMF^-Y4ZDT\<")%P9:Z'PW@T\"VM'+ON1J28KB=X
MTLZ$C_9G3R<,_'NL#..-2E]G&[QQ_9[IJMF,D[2TJ?QH=R;[=*I2-UI("O==
M-&5CP<GN9Z*MVXS<C.RKH\P0__4:CB$E<@L_E'%(\CLWV]6084Q6XX_%*MW6
MYT::#77\V.=CHGGM5L=4<LG7L]U<6O)C;',M<Z%//:<I4'DN$S/&\<&EF<WL
M@3Q3$]6^K#T.,64J56X[(!/?<8N5&'T](2N#GI>LXS?=/T.+Z0'ZH/@H=6$K
M/B&*-"9Y2GW]&#VV$EHUWJ@;Y#FG.#:",WH2711\G?+N#[VY3S^\3+96%0X6
M#S$" 87OSU0?J 1L3;['DQV%N8:5NZ&\)BP=V]$(>PM+KV,FL=/J3SWO_BF7
M^/OC[50+PNZY\";$.-R<]7 @; Y=$.DJ; OSDY7AI^)G>#\_O'LF>O3"JC#;
MEGT6'6*#WS2NF:LZ'BEM-Z]N-YL)"((ESW:*('7JA/%B[(<579]M#5*9%YH/
M<QDM5_K3NL3J#!D5T\TFYOR^ZJ>3'03E%;!RN=1 \!M"*$H#;M!U!%ID;('I
M9?>>#?P^KQ!9@9?.JLG^^[+KO*Z@T=(X&Q$K<E/N#['7*-6%3'-N!"X!D?5L
MN((R1'@]3\D)PGNU#RE/H-L; ?),FLTMA#P(<=I*!G55%WY?:&:KR==?LF6]
M5U$TZ&O<6O?K/2]&*;5Y<:,Q9"RO /:5PC+O(.M;#:OD5.L=Z\C[YAU06Z,X
M>I/.FFR&-P5!U#>\"X(9(A14.ZG#;/5G/#*.+;*(PC;;UC!K$9AOC+RU9H*&
MC[XHTZO9K^37TE59Q%DK-0GQCU]6T2FH/DSC ? F1KVG5]_C208^!O:<$@"X
M0:(#AQ4N^<O1@?+%HHHZ^>Y^GZH]9&0400X, -O7A>,^=V^IS8RL?'[YO+"Y
M@%: UPMHC\(3^U *:^&3JR<'P'#@POK9*<W",?&\G>T:OUQ_P:&=[,/@VU_Q
M#"F!QX,C'.$K^WV'04FA[:<6>@*[2T$X,J+4YIKB\>31)0"))EV_J.LT6R3.
M%SF@@3/$KKMSJCY P?-._JT -WY#[B=F+'^WP%"!$RZ=%2_&FT36'I[D"VZ5
MOM!+P)2G)=&^ESK'X1C'::^*&EGFQYU\K'FT=\$F'0),A)7O?P=:X923BN66
MO"\!7P5:+P%$T8V%"T'?+T57EP7"!_*M>1?#J5F51HHO >[55W>)Y"/+$WR0
M"Q4ZNC/IT43<\CUBN DME%:A(MY+E1:UM_EVD(6P7S#"630=V'_W-^@\:*2^
MPJ3?[SA-OG\)04,.;!DY1"B>ZAC_"3K)+'!("AU6(P=RCZ!0]EK!R9 (E:!A
MY9/5P9$AOX^52Q%2\L>XO<-]B0)G3\\5FCK57%*EL_/S]N 725)7U<(KD)QK
M+ZP'B+3S_H1#%YR^0%8><NTFHXK42<F5WT0B)5(/>OM/'= <;>PD1:%=NCD#
M_<JKR_NG!+\1DTDTL'YL0O$2,#DX:_((H%M%YLY&TGL:C)A'?B00WH\\^V+4
MAI?:2C1P1$$G.JR%'=W@3:U3M)N4PAJ8J$9:$@6R)SQ<^]@@9]X]X(2*5'34
MBQ'4X.!;D*A'BSNVZOAZFU6-]>$T]*5!^:2@N5!C\#<Q:W7U*NATK<(:NACD
MZ3UUGP>O6/B#Q,%[O=9=H>9M33DHRLA(ZMUU6I!&@3H(](J"PHPR,E?O3>]O
MUE<=A("I%*45#A=Z"D#[>$J:SA(?B/+UD+NR[8([+!V5YX<OGDR0LW G4)GH
MAR1/%OU1<L&\$F',,WP%'_-S^EL[7IL0^[V0#F>2JM/Q4\0/)(DS<HQ_&5,!
M,J6>L<1? D#/ZR9#AHX<KFIN<WF,GZTL5>&L<6L NZ(V:Z(7_VJ7W_V%[KMH
M I.'[XED02I'NO.'^&@)"USJ-'VQ\JOC[VY?EM\VX^'O??.MJ]I;:H.E.-M>
M,[91SU)-WS'">\V$G8;U57VJ-16G[ K+(VS(9%=AY8U!2)/*.L/@3RG'W=D6
MM(:Y[U7*@EM<0]0VP\8&*X8J[+/QP;^[!80QE0:UX*TC+EO9MT<JDK_*)O(=
M5_-1CWQI?&,,W*F5N)>_^@WH:=9WUU5/BO!!ZA@EF>8JAN^J[9A&6@;<#,M*
MD4Y\XG(JW,0DI,'8V*P11VKDL>Q>B3C.&-V>8FZA)0]EU6QAKEI 50CJ68&A
ML$K?5DHU\/AX)!^_F/%%RZ&F68C 9!X2 ;OEN"ZZ4&I[L.97.-58!J=J*&=X
M9EJMB-2LL/3=^^&::(@2/FUPL'8-<%?_8AYG]?H@3KQ#U$S9R::CXFOPSVVE
MF=A*8AU<)3?@.+FLR9TCH5CV.4*I>0=66_+8AA'&T![C!Y_(-4$-E&&J\:%A
MPJ5@7E5*Z^O"QQ$SLV7VBM^J6:.%6>M^:F/NO<K7KC&I@?FZ19VVNQT,2DPU
MD5??=)I(M*PV<'K#58N18R&$F"'='S2:-KI/WRIVK:L">U(HQH(P<]H5KF0]
M#/,[/_SV7_1V.6;G:QJ'+$\R5\_YV,?/&#4OIBLL5LRX"Y/)1A0E/\ (H6A%
M6.%B3)7C)=1Y6M>[//R,*+S:84%0CSN_';[O"F;T6]H#H"XP(X@+I'"E CR-
M-<[(KBRD*KM#7X<?<7K1'1/X4^-@L;*F#*^,GC_PI-[DF+1]-C8\?^8[8<#S
M_I%B;:"Y:")5N=N-YDG1<LPW>EG4F-+3\M:?8H6SG;G<_0^K#D%:@HP;H%DG
M0_W([S/,M]RMG[?A 4=ZKIDZTVU/7/E1_MISA";6C6[INE_C['I=PM(J0#@4
M]JILBAEB-(,1:6OU@]\*2^GU<92(ZW]%2"MCAOV9D'V_L:4TK5.AB448)U2!
M9R"23?2RQ7/O['T>P4A!3MK36!O+A2=&9;*5V\80$@H] TU2CII',G$OUOTL
M90*@L]6F/[W&7#TV1/_@C>-K,@1M$LJA;+5BCA*6M+!OOE\0T9:@C-P+>0L:
MFKUOD.VJ7DL#XYC1#OTY"%K^99G\S,!-2NM!V)1&@4Z&T&/-I_29? )1E<N$
M^"A0-3S/I*$#1/]3<32%O:+*V3 ;:J 7M#*G0?$)SJT(O=9:,-^_>PE8!N')
MR*YV_3V[T92W$7F.\_IL;(""3.<!KC1=%=A\-L3OGDF(Z4ZR70C[.$&G^OA#
MCXM'B55PQ'ZPO?J$BCJZ]HY<C+\VA>S/1/L*;!J6=2VOL:+>/)DL1D[,(:DM
M!PXU=G#)C#]LLT+9R/[TZ%!OK1I'$+*M6US-66V#D=+7D2$5F'4:&4BL(+>'
MDZ&N=2"?L8<=MD;8S1)ZJ/&]SJ1MRQV$41);>D?^S6*QL=ZM:+K>G S%YF\R
MC87)&#-N1"&#)NT0$#N$6Y"'_-L_HJZ2 2+"FZXJ)4R"7#):XU7S&H,F][-*
M)@M<WW; H#!?^1L9J;?TS%))8YLF6H2K*4?/1(O^%%[/IK75?.U:TA=O>Q-&
M'5/^*8V'4B^EL1]7"SM*?N0_&="^&PX7>[/N5D@ ([*D1=V22Z0'C>?KQVKM
M=C;-69\K_4%YP&O6PJ+PQ]=FK<WIW)J,O(WTLFRU3+=0'#:^XXEB._4V9^UX
M3;#,I(:2]1@>7N[_I9HUZQ ; K^NV%39'@>?I@\;OJ#UY/A5BS7[TH[6LSEB
M0<=+8?+</+G[RKMP)1RD-N/HG9F]5/];>YFA=KZ#FPOVE1?!Z+KV<Y%/&,=K
MN3+7;24V1"<M94'Z]+QUQ2V<ZC?]#-0HR,4W;]3]Z,K!M,%JJS[X<7#KMF\P
M)EQL!9^^N:>1YTY7M^JZ4=<'%P3G&8B::'*P9D5-@3)N!RZW-P;DB0@5P-;!
MG^VK4'Z35J=,TA4Y'*-T6].90II=?QHCZ\&OZEA+^RQ^O3!R$/;^(8TF+W3T
MD!^2*S&25/J4[ 1+*B>_-D>1L<F[R9[S:-*QE[P5^%2GWL3C;[BI7[191\<8
M40-3Z(R?,3D0,??LH((*NUM,1WO!B1VWM3\T#Y4_/$S[*R$V41DY_N>7-J@8
M$W\)P ;>^8F;<6YQW=Z^WY>@CV7E[SK"&91!70GVFA]JCHZ08:&&%3-8F+2>
M;Z"QVM-:)RGZH'=?13M\FZVKH9QYYYGRW2_<%!MJ[MQN93*(AC:IMIC&V(5M
M54 W _#+D'S*C5#IH?RB3-,J<SL?F<^XYY)#\7,*1QNWX!6Y_FJ:<+6]KIK@
M!C^Q/[9CU<')/G5_&<OF-EO%.TH;:QJD&6^L/5T]TZGBEED:R]?S2#VJ=JS(
MBVR^^^RVKV";[0]MV8\67Y*X&=?!T<*@]%D[EK:(R"I]P(<8=(3:-76.:V6[
MWU1BOF-B^$LR-?+XEG@W0??:;T7 &ZK4>&4>D%621?%2\6DF#<&GW:%QL]W9
M1TWN1SL53/8./]T^WK6TG:E*6H^I$1X- C]G+;3KJ<':!@:SO%/'! 9 ))ZV
MW+9$*[FX6C_G-B9GC8(%U)I33X7<.=(W/]"816N;8"^VF]X:UMW;WABOD=QI
M%W/G];1:0D/<*;%]NOFRM^]5IXHQ8!7&V(VTC;XF?7TDD;]KVNV>AT5 G_YX
M892#P>LX&!=Z&W>AAA8"(/Y2->#/$RA17O,8$O5OOSUD'S-;=(JZ5X6F^=D%
MQ*\W'S(%N(^VRY3+$ I1>N9?+,V%)ZKT@^B?0=VKX;G;OD([_1J<8;9".6D<
M*2^5<?'>W+8W%![I1YI9Q%KOT):74,DGG<N9P";#=B'#KM5^?D956$ &'&5X
MK58Q6%=<WC?6-0\"A_"YOV(NZYF#8"511<+!1IH5);>\]4DH'[S]?-,X=P3_
MI &O(G>4%!#@9#6!EQQO@L.J<9B:X#BJ:L3]G+QO'9X3*TTFT>RB?;'LA!@-
MF^^XAR]U70;LHZ993?7JE7=7'@;AV%*NYD?5@@-WV_I)L?AO&K_;:C(3DGK,
M P>J+3TH"S;F/*H$7._1NYK#TO=0PZF_2T1/QI\I+FK01Q1G<%U+HE9N91FY
MVE%6]^ZR!9_2!S>!I=N#0;  9EMK1LQ6[>QYZ;1CHV@0;Z$C:Z<6\DZ\,1KS
MO*XH-XO-J[TY#]XD[P?"O!J-*M4WRZ2%/DM/Y]WIZ]S=+#A-5E58/23LOOEK
MHH;CW5W>PR$?2BT?$U6W(PFIJ>L1Y%LX@2,")_=HKSQN9#"Y9_F8(_S1NE=8
M<CVZ<J2;!QWX>QC(K/)K6C5)A>SQ?G0?#W#JX.Q#*$&Z^(67]8*$CW6XX26@
MG=+#6+FS>S>R;Z3T'5MDY-XAL)'ML;/ ,?L]ZTO WZAY#F1!U@)7T-4R>=";
M%&:3OA3$[O7[5*: M.31C 0[(IQ%((G]+.\2@+&8_X.8XU%=9^C;7#>Z!#1R
MAZ^DAIX CSKL'-#UPPQ[5>'+6A7A:ZC22T#-?H=EVT4/=G+M^-\WPP_]V\]_
M X6S+Z @9^ 9YL":=*?#[VH]<0;&0NV^AO<Y76TJ,I> U"1EQ'!X*T[B",>B
M%-IG[/,P#!G -G-Q"5@EVE+'[A#:V4,8WE0XW<XD:0#H'W_5'\+3FN0L^BIR
M]NR<$7R!X=C1Q0_!).0<UC?) <-/E5\Y1TX6[)Y=J-J%5_KM:);TG@X[R:8W
MI[XG7SA)XMV-PV9]_QW=N[C("V"$-M7(@^A)P!E>]/3F2S1@0N+6)6"G_0\*
M(GP@-G164FOF1LMEOLZ4)Q;MBC#.AU9@>>3$D+)(5=$/!X_>.VD%Q9GQ]GE_
M+^M#5-T6_5X ^BJ? W(8 AM3/NV*3D\QH'Z3I&H7UM8G/V([?J;1--/$+N79
MT,[1?HS%L^/SM@I_V7N:NR(2IWE;\M!Y<R0_(&.I+RPU1$SIQ<E7&F3)4)8L
M@>7JY6GK\C??[F=+VCRGGA:JQ1A9*/@8#;C!<FIKO%/5OJEH@.!K&&93T]U;
MWK"TZ#]@WY/6G/>P=0_75N&J8YB12(8^B'[_@6P)N(6VRGLE"Q3WW$7C&N7K
MFV0,14!WL<&0;YCK-D+OE1YMWSB631R$?MANA.6I5,J19G7AM" NM;!L2B%I
M"H/26=\8Q=$JLVH-Y1/5^[>S6.<+&N]X9&\D1@>+&XO7*G8]P&MY&,J+_<I6
M07F->I*!JD2IT X)=BCC!!N;^/PZOO;@>U%O%9[)W>QNXA,HOV5BZR=B0HQF
M[]O(2M@,:S"KHYQL*G&I<!WW=,5750<XUMM4C,][('Y[C8O<-F=_-_L^-T9V
M[?6R_M>AJNQ[ULE"5.)5$JCIMOI)N_2S:R$#K=)@W/9QYVO%Y#D^KK%G4H:*
M@[5=7;^ [C+&K?/ULS5)>8EVO:A^;?^Q-C=*,W,MX;+83E#!P(]HY=V@)^;&
M/9X?@(;8X>[A0<':L*R&'^U*1NY3XD \F226)ZZE=; .=,M8?KX4S'B[_EL[
M>8*1C+FO8Q\<]DY,**M:Z(M!%0H%T1-MJ?5,=M'7RSPA,>.-T'T07#LM[J](
MY3FV_=,=_]':MVBB7DQ)VCK!]&!XI]&E29^!Q$;/VQ6;9VAU(_3E=68NY3-(
M(2B 7Z%/,%%X3!0^F?=39VY,E!]C:]D*EQZSJAIMG!]L]0QN9-7ME+H)K5!K
M$3JDD'B<FW;W-9_RC'L(NM]%).AS\&_,8-'0CG63)YRM^[/2TG94/03UZ] 6
MLOWVPS"QMGQ#R?^PS7.BAF%;1[KBO)W.RM-0C))/A^TD0V;&+[@Z+U.O'%U1
MG9<S6BTALKD7M)D9$MR$5V\5)=0:Q]J6G#ULZF[3>3>.TBO#K!WF^>G'87[4
M2OI:/DHW0E(:F*U\R?KRLX/J:"8H.RHM\SI<86-I571AVX]Y$R&S\H-("FII
MPV\%Z-<=:<2*"%4SU#9G"9M\[$37E1PTEY?H8>AI0[*K[K7/",Z\J_5?L)F#
M):R;2^45H&Y1&#!1<4LVO(7\S/JDD<$@S*TM;5_#WK-Y%-UAY&S="#&7CB1,
ML]MRJ*+@^)FG=16OY,B-E&<;\Q[GF=Z#3>1L>,,]Q:HHU$'M\!102F9&:JLS
MLF?U#:>-0UWQF1!F#KYC_6L?K]&DU(C9K+>LM55ZT;(Q_')#K'%RX\XL46G"
MH&C1->V+_[<9GZ%,B,/\4H<6E"!B3FXZZXK!<.D^74SY&L<]-_F18:JD+"OV
MQ5PWYY'RNEBU/Z[XMBWA25V:TI=J&Y7>C>YF,W>7.U0:V(GN:6>NL0>#DN>9
M?*;NL>MB'V6EQ-&V4;#CDUJ_43QW/&O?N\D$SQ!_5%N;5DM0F&MEP6,I5S\F
M"IDD=&6 6P<$(C]^*RF;OOPEXVJTKI R@<Y6&]:@0[S/87#'2EO38S!O/.35
M:STPJXB^X$T*,]+/9+O3Q@O*;U(DHM.@:GJD+ J\0<$OEONMYUCMJYJ-ZAWL
M[X0A[62[TJO>.V$._FRUBE9_NS_?(]0X<#,.4CEU&/]21^B8E_)9"RQ!U99#
MJ^*^7E"%+<S6@AQ\)/Y1_ .5>N5:0*-1HB0CI],XL2B@QXNP7+'15<^D4WXL
M4CY4\;7>Y4S.H6G]C@.-I7A>I^([/?@[S70Q(TH;O2&M&(D'A2*WWO\4VMZ>
M.B\JY.W8S#ZDQFS?,^K([VB2S#SGG9<YH7.?D\MDWD]U@B>RKM5:NL!\\@;-
M(%J6*WYB!3&-3=BR[YF0E[-UF2\:$P("H^;8G;WU\!KB0D&YP7&^1QWX7H)I
MEAW4$GSOWJLJLMKF&42,JZDO8_2/INM-,>8?+#989/<^]VMV+9O?HO!SL_:"
MSS'%4>ED,Y:]*ROD*C+YJ\9"GJ*@P$*X.%V=+(F2*$CN=)#'+1-M?96,QI.=
M48B\\K>L=TKFWFQZNC M'_>Y^>_[N2[G(VP5$\K,:X4SO50,:M%-'%W!*BH6
M69U8H5&.L*E( P.Z;T8'W/NJTO7^\.6CI".#K;7&#O?MJ#_C@HA6%^;6H[YJ
M:+ZE ?XGWXX8:I9]LC[K0<B;Z18;%5?T]))/E\P$# SS^:W-FBK@:N.$D-2P
M331)*_V(*+6.<>Q>L'3K&)^P:)\Q@!N9=6Q%E1Q55=F%?H1U&6'D]_09?R^_
MCRCO?$DVPJ8TR&2$[C"-KQ;(<V^2GTYKB0UC=0<%"8G N875U,?9! UB#075
M<=D+"\=$VW^^Q.P*+K\NZJH'$-**  !>1$<4 ?K[22-N+NORGD[$Y/1'8SS)
M*U,[.7I,F-ZKTW,EHEN%[W+U#GU5NZ]SQD&N63*ZYA44^;IP1>*A_\:SOAZO
M0';2)>_5]:M6?7PQ'(Z=[**F).GG%ZB35/M.O9C:0$Y:29X,Y#P\G (NA5P"
M$I/.PM=66W:(*.Q\Z]3F!\_^DTO /?:C2\#8B.?"F4E-E[/MNZLWQP\O 57N
M5TV<^4+@U"Z,O3@5>Y&*= J8E?UT4+C((83;*[M:J*,FD'5)1[-!P///OL]N
M)VOH>.E6A''1*.V%XV,[VQ[QK*YO;JX?^XU>7=7'G2PVH5;/:?SGHO<X<\26
MG%>,J5745-_R%%%P[NR\^+Z_NKF\1W0&KFSR+??,NIF<*2!_Z)J,G))SI'P$
M7!ON:W7@I>4WYWB@+G^/+;7[_/'JY%EH'Q)8HVK?4G(6'G[59:ZFG,BS_9'!
MS<U#SC#5H#[(N3% :D6.ZYK>WQW5CL2W #B_+@I]W'=TN(-$;9P2PGKVB7,T
MFU>LF9UU]N'W1P@]]O5%\@<CG.^6O"2YU-)T2/B?D2II#3_USA'XPK/YKU\P
MT*44JR\YD$:I'\Y*2D2F?O[@Y9TX1;ZYFA:T/[)#="XY.TW&GR/")[1,.BZD
M+@'U;$(4WL(:\5%Z#)1"4 >?^X;1/-7ZY&2[3]-4JMA7^K=7ONZT)9J5FW5D
MHT-4)]";'JO%4QD@(ZI-,70SWR/,F6N7\W?/+58BOWN/HI;BDF*TF].[<CG1
MB:E4YOO3]E/=4TFGM=<#;LSF'278'PPOR]29^ 1\ZZF>)D7!4I];MQ.%;DO[
M.1B)YI<B91.>V3:D4M/_5OX*BE%DRS'CES QS(K'FA?9VZEN.1_WGH=== KJ
M7[CJG^*4@PC$56# 9K)YQ>SB>+NB ]6'SY2Y5\.XE6*>!I.@$%4U8PH%A9"A
M%C5+ D+!HI+W+07(YB9KJ+":U393%2R2BV6\V)S/7G(F'=^\L^U?O7FC>GZ2
MXXUKP<7B5J',>[_I7JPH %TSHR?CDUTFP?L%_:-IO>)07B-1<KL%-Y2"MI06
M]\KDSI1CU11)9KZ;9&U\-'J,OV6WW?V'?T'1V<NRWNA.Y%6WUM\6O??!U;:C
MIY@QIDZ;0;]D[<-][:9U"W=F@S3>3[&WGF&!DCY.!MD<H5E&X&5UZ\_)<86]
M04I1G;US R.3R/IZ>SXA!3ZNI:7=%6,3^?U5 ?(WAWV?FM\R>);0?H;O@FXW
M7V/X4/"P5E##[Z9%1KGD-? U>+':+?T=1D8],F 9'_(:^%>\7^ 3BEX 601)
M;H)-P(S) BZOMH1UZ-MF&:9CH3E?P$)Z1GNNV(4_;\;WEKB)3!*#[TSUCUCX
M#*;=MO.PZUK!%\8SC5LIGVL#$U]^3=F;11BK;\]VY$W,HV6:1[<YU<2=MT2M
M/CB;\XV)W1V%']X<=.IB-KP5E6A1BN4!E5NX$XBJONT(NU2S^*U'9NR_E.6L
MGZS<]?S":4BX*#GV(J\(WC_>_^=O3;]^MU/RI_VY][;"G8:GP^^F"UEKG#>,
M[3J(TAAERZ5ED* @+!##X%$!BKM^R$"VZ27L8UY!"N<53-/C_=Q,^I5J&C[9
M=&Q9W[UQ=K=5Z4UF^?2+Z;[G".Q4UQ=+Z9IF%8I&W[HAIHG--P/=?JQ^"4_>
M?SDN/ -7Y+K'T:_(K_"-,![QM"DLO_LR386OWS9H%XGN('*@!\?'2X^^U!-J
M [J7>[7&1$2,FSJ@C3#1/DF[W$?!+972T[[6W1UZ):.W64.D?Z!_U"#R!GU!
M7<;N,F(Z8<D*G&^+@I1?;/9AZ'H/N!;?>$_^4.,L+>PDW/;1'=G&*:AVGA[T
M6XG"@VCB==2?1,PI!8-AFC'#AR:"C&FH6T4//PJ3*U@FO(SI/$\Q<]<$#\;%
MJ%,*O2QF%.+B@SU[0*5-8@MZ@WMWIJ7TON98Z:T*CDH?-=X1,:ID;[@U)]TA
MZ)_88Q0+:CXHG4UUA?FV9[;G))EMOA.;R5=,\.8O0P^T/C7.F,5PT@F[$[!(
M-UU?!-;J6.XY8<QKS3_7?[!VNN:I7?!'M;'NB8-M=)RGY>.YOQN3S'5F</]T
M6C%6[#:A(-W+IDZ_=K!F/CZ2(V;'S$'YGD=E/VXM#)<Z4I^-BZ)1 4@L222%
MV=GIKH4V#*S>52U4.!&;9YR)2LJ0[]=[XIA2.@ :K(0$Z8'RO3*;GX++A=2B
MRDW<6CXLQI+&F::ES53MTE"0!%<-C'(! '<!I$7B(=-G>+KQ.IRT9T/8P!D<
MRVXTX0[8R@=9%1M-B)I\=()_"[!J>CA6 FL08W[W(RH;6F'J?D\1>23:/??D
MO@-_/?A-++\<DTQP)NU5J9SLVSE3;C^#)%B1&( C/E& XR@ C\FB]  TZF^"
M2=,G^W";)V$]XJKD2&3Q9@>"5'8:"GY87M4HU$<YF^CFM\S4W@0GD2Q/\P)<
M P"H[Y272Z]QZX(GRC>L(M(H,8T999P4N_0?2/BTXBA(N,)&P%XF6_WGRFVJ
M".I8S>41U$A!4'C-]OH.M0X]SQ- 1C2@4 IP1ES1\6:[G=QW3'0FQ"X4=9V'
MV3<&A7'8!"-H- L<SLAS"4AQ_'?ESLZ1HZ#DA?.%,$7V<'N3&O=7BG])TD@>
M4@Q%4-]PHC \\3*\^6M@\6H'I^DC.ARK!(8F[YSL1_;-JQ8&(Q!AW>'J>[C!
M$:+FL@WUC=#6@XN1J<V#M>^X>7FC<:461N-;;F3"-^FI]3:CBQKN*H<EVJ?V
M)1^1'7,FKWM;$L-[J7.<CU?/R CG95=;-+.?&TO?7]S;LMV]&FA/^(**FGW_
MGTO :Q/O2X#QMO EX$)0^@NR(O2*< CF]/RJ*Y]*N=G9X[[HODA/O@080+O^
M06G7(%R_NVZ/KVAW%N/9=__*U',.+QTA/C')O:'J;',[B"V":X \><2/ES[P
MPN<5M0YU>"5G!U"L.P[@%72X#UA%#X7NKB"!?>_@JT&K!]B-T$A2U;!GI[CU
M@4T!9"[0/J>OOXA:]_=QZO>A2DS ,4TQX0 Y2>JI^Y,SFV5/)9RS79Z,S4NY
MX;N),D?0"(?S)*==,*=M&X===WC@)]SRWMY::._P0X5AKR <"]ONDMXGH/<:
MPY+WF\>/=Y.!AO3Z_?M[O,ZK8U1$[WN'KW]=M&VR^1$N3/JV(U?1R4!+Y.'I
MZBBG:FAG5W!HB.OH8$);8?@8D:1QY6OYY*''>>FOOZY8,M%^:6^(=;W1NR''
MIG+/CZ"*[]DRWOE@F_1%OI<IMI2W ^HW#\X^'@>].$8HVL/M4/,$@2H+L;KU
M)K@_GEAQ;'1_KU%$Z F]V8TV;83X-Q\M79^A7YX"WQ)D>;Y\SJ37W)W0L)EE
M"!*OC7\Y7BL*K2X\@+2^E^9>_E#&#<J]*SS[YB[4D)HNM/V1WP/:[ 2/&UD^
MM$=15K#WH=R+,;3JE'I"/%^?_O&L=TY^=ES;-J_=-MW<=DSCO4GSI!EK=XS]
M-9WN,@7=!%J^$Q%N/B0WWX2I"&<T&A6;U[9P8]">7ULG<.84> B+-\>ZZ-1/
MU;!96Q#:($2O0QA?KRN6"*ZP2NEX,5IK4@:OM<.@J\6*@*Y0=^&7(4X7U= U
M.CK?KG=^?/)F_EK'Y=,_-). C$JB;GZFL8\0-9.O4/#MSFE8R RG!Z)UGAT+
MB>%IIWHRKB?GD#WQ#EPD#K0HT_98JARLL,+D9X7&,7@(-FJ!?(K;)$U17_;8
M<RISYP+\Y6+]CYG3;;(S:YY/@Z43-*1WU"H;1(.8].E<C[;S/_LS\;=!SQYY
MB%9WJ;<,IEN]@I"@ (:^&64<U5#FS<'L>^[:6!.A/-98#@U[1&R!^[=QR9@'
M51E<0DU0;E<G $0/[,]_W2EMSL?6G.>PVNO#CXTO[LHX,2&R<<A#.U@^R!IL
M:5H=,1K12";"52F;>UI*C#^R4C+#D[>%+<N\: 4I7ZPU5>R.KOF+I<Y,&*F_
M;HKW^U7S-/,%HM:K,1L.964 /2WQX7.IPKAZ#CX5Y7N-EUTW6R[<&A]3>M'&
M\?? !.(4X%8K&>*.$=9.=YZ9:X074E19&G'4#<$W._T8(#N2PSGP/RX'Z[M:
M>7R@>DI;HXFR'RC1"7_I'!JI+H.- $_B._\]/-(EP;EQSK[-+^EG786V,WZF
MNLW7)F4;#LTO+^^$[ZZ;\7WV4'86HI(3]2[@^Q9[33\3TE4G5[MY\</5^/W1
MM^+I 537N.LAN6W---S7PD\XSG.*D.ENMN[K:K/A#IZHA8BTR'3G' 2'[(MV
MO (_';HJ_N)R+,<.@BI&0W$>M7I!RT(XTWMZU8Y%BZ&\8V4/$ND!I<*@T:8*
M]8A&42$VP7VYAOG:%G9O8R73Q@]L[MW+-UM+?'O)N"BD88=\ND*L7L5,7]][
M_EIXFU%W*',):(F#H:I:FAB,.D+1B*!Q!&]SM:*96P!3[?@A-WU&K4++IIRC
M?B'0%C3*>&IB+ISQ=8!A.HRFX\.XC7B=]$0'R1@K3>B!\5R-6<AR\\'*VW(?
M&6JC3 O\9W/K-CF/2N^L^L4_,PF:B8HCK97B0WKPX$$V_N\1C=7L(&OGS_GC
MBMM'[VR"D;4!'/6N"_"YA@U1R9,Q)0:M>B/%RO'M=A4^WY^*T*\SV4[Y\[[M
M:9YS]]K^#]MF%1:%&ZSQI04DI!0$I&$7046Z.Y9>E@:1DFZ6;BF16);NCEU8
MD"Z1D$:Z=^D4$)&6]/S/W;DX]_/=S'SOS/M[YIF2NM??(<ZH$<LV0DFC \ZA
M,547IQ=8&?1+)YB,KE;"/DV>0+G/H.D1 [?KA &,1+\Q@:S55J%2?W_BP.Q@
M=D4S!396*1M[_KGNI@1A2-_8\P2"DS&-6Y CY^\F>5BQWO26&&59'X/5_C2+
M? 32*P/K<MH3_\B(IJ)T2+16A:1N>"BOK>!G8%T=$6$%3<-JO+ =*C2O/;<N
MI*F/Q?C8Z=N$)O]18%>![7R=$9GC#U[#UN&5_ADG<87EMPPP\V_5)#LQI1E.
M9>U1>MH[T"/@U%X+!S4Q;X"^T*ZI^KCPM:>$("F6*QR;-W%U^/[R#&9P<#G6
M5&5RYKUT8;+2NORJ&?AZ#6UV^O$\?>_+'?X0>*-YFIKM;;PP9E8!W OAA'4<
M17?]:E]P$"(E;=9:%;P)7](?0\$2GM55[UV0TS;'\:,P:;Q@M.ORA#9Z]N B
MINB-GN>7G>GM*9.:!4JDOB(G16LXXWW>S7>;_<%&F18RE[DJ1)+5XBR?A^=5
M)[]C]IH2^7*XKE*(31O$7 '"4?S8 8;_.NJO*Q^/GE*O0%-,X^S5@8E3PUS1
MC Z?HVU,!/Q"KO(#:D>G%Q)]P61+Z[Q-2UW.*>O>07/%E5.## :;[F+6*V"D
MZHE7U7.&[2.!I:41Q3.SZVIF^RP'\>IHK<M GR)W!Q$?BLN2ZIN)P$,[FX4=
M\N4YL!;*Y!+=8GT@U6G>-5-1S]ONWLZ05Z5'[698JA)W<U@3XZB6 'H?-BK
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M(8I(K0Z-%%_HHQT&/.>AE/>*S]<?$(Y/@-T" A?EC$3H/D:DTG+?L<QK;4+
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MH]U44#K?/X"+D(<R3 \2N3*FD.+WY?2%E:@KM6/D"#L2Y4@LG[&@T,AO T9
M;QFTQYF_:ZF^%H1#4@'OXQG?(SS92[W,CU@./**<Y33?OM_ED)U]@_?SS:[H
MWEGS"YOHVBMSJX5:<^GY8-HR"6?%M[P^46/7!_W])!+)S%G:"'R01JP ZRPI
MA4K2FPQUC1&5L,M^FITM[2]V;6KI8U1;Q8?:;K"N<;__OBPP ?J*AV*VMQAE
M5HQ*D(\;$R]@SJ'-HG+T*A=-MQJ,OXT4I:1RJVV0GG-YZ*TU_=UDI^\ZIMG8
MQ$]+E\9)>Q#YC!8+$B)4F)DBB]-4&V"HFC[XY*'5Q?,#FA[[N''Z3AYQU^.I
M;E!V>H%62Y%>:W0=&2\V?KW+5Z?B.9$Y&U.38X4T@"S;1K;AFO<P2]H/>^A>
ML48L1..JD!Q19 F!00YQ:L\$!<]RMW%:)ZH!&CWK0:Y?J2P'O!/>"!XI^GM'
MD..\]MXKE/3B5+ND\64R:$-C99U"W8BK%CY D53QX+0CP[+)WR;!+53'2:Z:
M*+G"V)2*.9<V!]3T2CGR)\):N+.*MWM_P.W43Z+0?,Z@2>O;Y?[E"D..:G4;
M4\$&@]FPX$W[]ALJ#=%D](7T 36;^!;/#J]&F,DB#4*\+5#1(+NMUHD^(-FH
MB=^1W4=SOQSJ<$%@R(8-^*3ZT:"]VF[;+!GX4M?:Y&EBSI ^PW9A1FY5X)@K
M!Y>)+<J;,.'SONT6A;X+UDG?192*KYVE?+R^B7#!=B_9H[$43(*>/ORE)E>E
MLV>4 5G5LQ30TZN<X6B2ZLZL%2Y[=D24%3KN$-G73TJ/JQ'T/?PP#)\X%W'=
M?OIV[2T314,S?AB"8CQ\.Y-( L6=J"?8<.K3T3HW7S7-EV!UM/^H^97C_6=/
MXH;:B'LNM)Q+1?I=>68Q3^N87-:3U>AHNL-AE[7CB&EX:4R:!6)C-9%DO/-R
MW",> 6-QZ6%TO<4;91\JT @XF8F4N&;Z<H6GD"8NH=-(T;K4>!BP@28&^1#F
M.@4]TYPY$JM)+66CK:N$*IN4SX$\9S.KEW4M^093COF9T03U:<T)ZV3#.]P.
M)-=4RA!/L6?KUZ7)\6U.^=>?' H<*TB8J:B5P*^)$[!<(@G1CQ^[+XU[?2/
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M86M\IV,EGBZKJ^,VZ%<J^-T-2$"&O*),JTXM38L09_VLZI,'DF=2U1KFI\1
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MWBIYL7]P!@S.?>A*D]L:K[VSTWXI'3,\5P_&_$Y(SW099.)IYZZUME<S_6S
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M+4.>JXPD063]+R1K:NK'/ZW/'3)&] M8-UWQ6"C= RSWO:G%$+<-#,Z=H_%
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M$JR;;>TTJVGE21T"]!&JWV[$GGM&=W4Y>>C@]63DXRBURJK20PKM *I4)9.
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MAI;CC8;:G@BO^0PC'U5K)"[S\:_;.!4. _R$2F@6GSN-[\ZM7&]WU7K97/O
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M9 TYZ#G_ U+""^8XG&:01?'5C,WL'7/GZM!Q6-;$.(UO]9-R8W+" ;J+W??
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MRRG@9E33ROY)<PX[;#XG$&6B&Z#['3H_WUTE7<[(#F\$2N!S'W3HN:*HV9.
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M/1_HT^0[06I>L\H/7[BW'H[DBK3#.O>#WZQ4(SZ\P .%ZP*KB!<\1?^,7 ?
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M%W@R]@@ #<G=OJH><MQW>I?:CP?O=I%<MQ0&(VPQXH[0-$BT=V<[ZV4?"8D
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ME#RBN;OK'DO?C69.B..&<G##K)HN[(Z;KQD<G88PQ X7A!GN ?9I,CWRSUO
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MXB@9%0;H89UY3UMI8N/HX%$9)MSFM\*J0EL-6'/0,HJ9/C_CU_+IV6;T_I6
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M(PZLENFIL2U=F$)A#>0UOVIX=K+P9D'2"C+M]J7;G_V5;S<?Z_)0$K2HQ7U
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M,4A@UR-X?/!^2N[J7FIK\@)8C?\BPE7%1QM(FL#;4T+74\X@<M(BI 'G;S9
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M%.WV'6_'<'+_!UC4D^1+]!U//?#%'%G>J;7#_OH./CF;/DPY$Q-NKWE)5.W
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MW7+-L_FO'0GYF_?+Y]B)FM84F_F+Q0RH@,O]C]:'X'\9M@PCR%(DILXLC8O
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M>N!T5#&&WE9;[\RLN'IS>Z/&V95!2_ MP$STZ<VZVO0.57R.4X0SGO#0(N$
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M,H0KK',B@_(AZ#4;* !T$O,8_CXT,V@STK]*4]>9O Q^MTODQ"UF;SXL2R>
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M::]KUD.?WA8G (E\!,+F!EYGQ] ')54Z0;R8Z.['PQY4-9E&*Q7J_,$JPYI
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MJEYS[9I2'>Y R,GI="[**:K=7A_EC')8+X\]>Y0>MB 9.P0-0,Y6PR&)+<8
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M!_>/_HE3[Z)^OBVD ]-F [=7I %-!F)^Q?EFZQQ/FI]=K95U:-=*M_OF9AU
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MS*(CF"]"-HNE;C_^?T_+YGC >P;M1./\%,3@$#%Q74/,8SQ60<_(^GIUB7V
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M E-0-(@#* C3S(,(@1G& @8L2A.>",6HTVVP*^@P-T9K-0&KK2I'XI[*3AW
MM_J 9:Z:&*@G24O70G77^'XL=VGS_BHF/*<?6)E[$_ST_NA'U84\;=  .W
M@X?G\*?KC*7/"*B)-9@^".HZ0W0T#NI*H@PLYFIZ_ZS?K1./"!D0F80)#(*
M0Z*2 #(9,\CC2&FKG+$P="O*NMOZW%:N6CA@I!N4L64?.;N583 >(W.V/13N
MI4>/J>RKA.A>V].6 CVFUD%)SZ,/#9NH[^3:'-O5VW,AQ:]/OVL*>5-L;N?>
M\G7^K4Y[O4 ,ISP6!-) 2DBB+(4T9DK_DQ 4X4 (+A9KXRVTF\7V73M-\8T
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ME+"MR-ZL :!L%6I*--4J@;S5R>&V^J6#U[\03#TD(S-^HTESA_VF,_T;?J_
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M7M]OK82AT(V2RM&B^RLF=[0'IS_=HT,[$X=.O,T+^<;<E5XH%6I[11(8!$1
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M890%+(U1C$)DE0OV>/-SFW:U@ "C>E\:NR3=.0#.XOSB(CA&GH/[2 S*0W0
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MF.PV2^[*CTR0M_T:.^^$]A7TM/5I&YUTK[.OR//-S;/?^LC.OPEX2M(@B)7
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M890$K-:F<5!4QL6J_PGRYG+;VF@WY/K?.$-M:T/-8@!'M\7J$?K)Z/DS,%P
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M2UI5[U5;X?A]^='D;GOW:$X[WJMM28H7FJQ,1J2N$G+[8+50.)8BYMJTEUD
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M!Z 6K-VSS]@C=WP> ,MQT^<A#QD4U%#O!=?;P/7)TJ<GRX]=D'Y*=)8S*8&
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M_#P EVJ0]]PY,'I)"%L"J#+NA)K7.[,?U:8-F)@)JG"F* 6$*P(@S@O &=$
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M,_G.F/'),/29B'[FB8+KZW4>O5LF>Q WS=\_1X?8(R\Q$M0C)2F&A-PO9W$
M;KT)C#[/&R^;<8"6!ZF-0^Z_LF:676DV/VU%T=6R7F[LN0Q3"A4XY4#F]O J
ME0@P+!4H"RTD+;A&S"O5L7>TJ1F4C8S)3LA!M7;Z 78S)X/!%IG)O1$;7GVK
M#XG0Q;A.CO4ZM;GZU#Y;JJOWIH&T<;H&\:XX]J\_=Y>TM;-O;=1JFZ/][H=:
MBWEE&>P?:O[MP9AMM]_5FGU3[;^H^_5<J!F'&M$2*\ 5-M9GJC$@QID%6&BN
M(8$YDEXN[4AR3XW*N@($:B?^3=(ID+!&@^Y?5?)D=4B>C %063"27^;+1*X6
M"[:N=K\]OX_]JF^,(Z-.[SV(S,W[Q>P/V@_L*9WPG\G)HO=6\YNNC(6M>W_J
M-6H!Z/Y5)34$ ;E_W#D+M8J,)/6XZ]&X4W&TLHT\?*0ULKHHYM-\7=]4W2V;
M2OZ]U(<$DBG!'#">E7;_E]N=8 2(8(*5&<L(]"J6.;8"4ULU:_%M-X]+*^4H
MZV/HMR700OF*[\ $5LS*?<G<PF!3<QH@IK1X1IK'L5;1T.)/:SF--#G>ZVHL
M.?P66*GFL[?M1NG[>278XC\46[\WOZEFG!<<E[@$)<F(<1@) KSD*8"R(!R)
MDC'M5!ZF9XRI+5.=F(FNY4Q^&D$3;25U6X'ZX.Q?) *!%)G'M_@T(B96QN1]
M+S[.].J P D&K)3XEV^K[W\U=S?D9W[8<5[?,T>A)0>E.N9PN71@6O)J;9BC
MSLIHXXT101SR3(.BA!) )(FQ; L%))095IQ+BKWB,H]&F-J'W0I8)Q%YINT>
M@>=F[5T%2>3/>!^-&)7>SJD>*@WUZ/GCIHR>4^\HO?/LA<.^8QO\Q*J'^_7J
M^UPJ^>O/OQO3X6ZY+>QR:XLBU[FCV])D!")-"Y$#@LTW#H46@%"< Y8*323#
M0C'D\Z'[BS U)MB5*V);63VKP V8!S?.B(MN9%(QPB=U#%0GOO7G?K$:&"_M
M+\D.]YT646K,#0<Q$#T-$&!4_AH.T$N"N^))5QZQ?]@V9"LD*SF2'*"2<0!)
M20'110Y*(7-5%CB%63[H7/W#5+O?[75D^C"TU=T)(#W/SP?!$WN;R0^9X4?F
M1\J'/B?_\#H]Z<XK>/9$_/C*89]V5U3G=BD_VVV.ZM/SIMJPI30\\E6M'V<Y
M+LHL+R&@A ACRJ0,4,%*D):PD%P9_\6O6NVE :?VV=L.V<+N;R[F6B6_V*V)
MRG-C_"+&;AP0$KG(C-")6@?B-<(F>]+>)%;>< 3ABDP@NK@XW*CDX:K\2RIQ
MOF]Z1=EFN"B0R%@.,-8%@#+7@*BL %F)A.*(92SU.B>,*>S4".VJHER>]D[4
ME\!Q0V@B4QM[;RG.K$ZJOEKH_:R8HOX_4TWM["[;&&->E[A\SW[:I]VV(>?F
MU^MGM2]FEVU+$3</RG(@<DH +#0U-FXF049REF%6B!Q[M4CT%6!J2T0K:*)^
MV"-4M9\EU-5N'URKW7MR"IJG5$$%TLSNI3*1 5+J$A"BF#)&0)8C/MNL-FPQ
M@<G9BA%O<K[:,1(VI2ER6XEC A]Y==UFL+>R[R48==_*GOP1<]=]L0N<S^X\
M_*ODN/N"<R[OW?LY@2KWWRWOURNAJFU=;"/!6_5=+59/UIB;$<E@49K%*5?,
M1D>B E"J*-"22TTD)H)X=O+U$V!JRU0G9?TURIV<;?%^3];SG@XWUHL)<F36
M.UFHWX;^-?(G!_COJ1"Q4K\C>+%*]5\:_G5K]3N"<[%8O^MS1DZ\:I+ =KV)
MJYJ=OSZP91N[9_R+[ZK:*/GQN6DAC%5:%ER!4@O=-EJ#* 420_/N0UT6DLR>
MZAB_+QNVWCB>5(TEOP\3O-0B'BG\RA9UO1ZV2;CZ-E_:VE-U^'@=,NZ[-3[>
MRX!):G3#.=!9@>V!)01<(@4PQ(JA(C4O1=Z^#.^,+_MG?Q4Z'49Y$52]:?QG
M> L<3UNG.*^Q#W&OSZYKDZ?WU&]]I(T!8)=(L,7 _%BC,($$NZ$3]]HI=MYR
M3RLK(/1T!$NS&RS ,)OHW]EZ;EW.SVRCWJX>V7PYLV6=%2LRH'!: ,A0#A@R
M?^24EC13!./"J^SS\1!3<^<Z"1,K8O)[(Z3G@=,)(-TH_SIX(G.S)S+>M'E>
M^4#\=F* 48GHO((O&:/GRBO/P7_]N?WQ_Y^KM?6K?GZP7E5=1H73''+-!"B)
M0@!*J@$O,P@*DE(.4XPI]RH3X3;LU"A@[Q1S*VR]N_#Q]M\'U:YQ1-_S*#D8
MIN,="GO#.?SDUPF=T&>X_8.^SFFL$Q!GSU7=[AZX!Z,6YE^__::6YL&+VZ6\
ME8_SY=P&"V_FW]6[YE!I)K"@J"P08"G* ,2< @X+"60F2UTHJB6A7D&^3L-.
MC91:J6^2;XW<]1?$#B3W='?=T'?T58-C&MO1[.#\;0_.0Z&35NJ CJ$72J&\
M.K=!QW7)O( X\J?\[AY&3H<=L^O8Q$_Z[U43:#(K"LAS!G.0D3(%$%$(J,IS
MP+$F7*BL2/T.P7I'FQH5[;)Y%G7QRZ9AM1_[],/K1CK!0(O,-3N\:D%OFEAD
ML-+ "-L<:87C&"=0 E%+_UBC,HJ3VB^)Q.VF8?QQOU[)9[%ITX93+:4BE(&T
M1!) 41! &+.M<1160N0T)YD/7QP\?6K\8),!GQH!D[6Q%9?/OK$_A^"YL<%@
M2")__:U<$5*M3VH<Z-,^?/:HG_))M5Y^NJ<O&ARIV?6LJ3=8[2[M6CT8(\)8
M$W=+L7I4[9NH4U007.@ZV 5 E6E 4VZ_:EZH0I<$IL0S1--MY*E]XOO]F)K3
ME0/1Z^8IWN%^CI/@1@=1H(U,%;>?WMPEMYNFE6J]U;I9)?>LCJ,,3Q_>"(4+
MXW,<=^SX/3\X3@3N>3Y@0,N)-PMC;7_2;=K4IW5MM'Q6QO>9"WLD9 9]7"WK
MXZ3J;^S'_/'Y\=,?QD^J'N9/=[JK&B7OS7]M]%@J<D@UHJ!@N; I3 3P3&>
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ME1>O@NDE8U[WL '1.U^8K3M?!PS6966JR@81WR[EN[:7HO'1E")0&F-,%0Q
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MC;O]<5GEHXT,AUN&UK.SYNWZ:;6NS=2ZZ69])K+^^68EU2SC'*O<6(DB1QA
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M@#%,0&K; +)""BB\^ASW#38U_N]DK1E =8+6QY!^[-Z+,%,Y151(P#*< 5C
M#!":"_/7HL0"0JDQ].E=% SA$1H8C8.PVT(8"K?(*UHGIO$:K* U<N]VR'WL
M0<Y[Y7&!)- 2TCO4J&N!B](O2=WIG@$[O/_GF:T-T[VSV1=OE:BW.XHL3S/:
M;JBE" M!& 8"Y8:>-5: $$8 *FF!M2QU2KGS)N^ET:;&SZV\22UPTDF<%-E-
M8H7VV+6\B+/#?F](]")SR 7@ANS[7D308^LW))(C[?X.?17]MH!=@>G=!;[X
MD/$V@EWU.=@+=KYI8$NYQH-;?ON@;-7+YFBOFF78,&E1&*)-,0(PHPQ0JLQ/
M6A">,E9PYI5%=GJ8J3%L[>L^L;E,]&IM:Z[7"4?SI5@\V_=\ODPV#RIY-"H\
MKYN3?N-IKSK5DH75[8J.E*>GPLV<NQ[@R"2\%3"I);SIHB("[AST8Q"J.=WI
M0<;M3M>KZ%%[NOZKA_'&>S9?_SM;/*N_[;Z&?\PW#W]?KGBEUM]M#L/=\NG9
M.O;[\7'F;\_KM1&FWEGNLJA^_L;FRP^KJKIKO[6[Y3NVMI5\JAE#)"4E$X 7
MG!LJ*BA@I>  \8PAA!@M,J]^$*-)/CEV:S8$#8MI T'RW6)@":PC+,]HM/'>
M #<&G.2\1B95JW-2*WV3[*F=_&'T3O853QK-CT*9M\HGM?8WVZQ9XW!;!))?
M+ 9_2>[VUL .AW#$/?K4!5H+QI-[U.5E].EXN6*-+\# @\O'I\7JIU)[01J=
M^X<((D5> "I)"6#),&"<$,"Y%ESC%(I2>QT_GAMI:HO,E_TX9\]#P;-HIEJE
M6N <",F-#T(S"B@J%%"98!@2J'.A9]_5FJ]&Q7-_Q'B(&E<O36[_)WM\^K?/
M;:25>9'-%V%35>P.7"B4'0]00R 7>5F\6""H#;^^N/'C?WAY"9U01Y!GQQGW
M(/&2ND?'@1=O&-I9CF]VP<>?E52/]</OZUJ5;U>/9@F8<4P+K90 5"D"(,F-
M3Y&KU!Y"25H@5FCN=;CG,NC4^-G*O)=O8"W 3NPZ=<TV#?V]$=VWXX;+%+AQ
M3&A@(]--$$P'-)MS!RE8LSF'(4=N-N<.PG&S.8][!Z;M69J[JZIG)=\^6\.T
M>79MV^Y']K:--I6<I;B$C$@(,B0I@'E! %/F#T1ESI%@NDR=3K@&2S UPNH$
M.VH*-\C&])\0-\:*"G-L:ZFQ*6OADT;ZEK5NNKV%PSR)K1(!$]*&XA<JL<Q[
M_'$3Q(;"<Y3H-?A!(^<M'^>3V:I;7Q]8FV]6O5^MM9IOK#??Z#!#>2DS9=QM
MGF8<6 _;N-LH SG264I8@306 VKFCJB"$RF,7TSWW8^G^5K)O]I3L4;@OR:"
MF1=WH5ZCP_R 5\.1Q"<VTW^:C.;C-.:V!N/&0+ K[KY%P>XB-SA,(*5Y^.2]
M=E+S ,G_'&G-PZ<D6&+S%2(,"'R[V*Z4GVE7VM2O7^E;*>?V%K9HNF;</F\>
M5NOY?UOQ1+.!_HZ)A_]0;#U3BJ0E(RG(1:X!Q,16^"A+(#G.,D;*K,R=8CM&
MEWQJKDDMH WY,'2VK-6Q3DJS&"9S8V35)V_*2)_\-.)[A)>-^C[T+XZ3GN51
MED;NN#3RD\4^MN_%#H*D[6RS R'9HI!8&)+_F/#KXA'9.-779J0HR6F^/GXQ
MF*\QA;WQG*,*-%YLZ&O@?!!G^BH"#-M4^+!:?C-^[Z/=P)T51$&5&3<_Y9P
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M<A&D\"54S@_Y6K54+H+04U3E\KU#2M(;^>NTR"(U2)9MHFQ6IK99G@0I8SF
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MDMT+4:L\@?;IKK/RVLW2+\KYYVB-[@IWL$;HS@,&W@_82TG5."_+G!; 6M
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M^A]E1JTFNM8M3HVA.F-K]2NQ-;>K=NZBOVJ%N$4\&1K'X>>VQERP!^6.Q3?
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M?@'LAIM7[-:AYPS].K\W1A?-"*N(>KK0%G@U?MV VR<CJ B^&K= [5? 2<-
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M& UNZ[.D^H=WPZ/L<+!@*+1'.D40%'6W P,^R/6>#G!ZX'A' 7S\W,O[]WJ
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MUKI[6YL:[;]ICI;K0$X9"91OQFX3O7UO[-UD(9^O0^R!N!V%!\-Q8/[=:L>
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M,D'G]ZX<Z7)K;QU\U@%GY1AQ7@3?CA!" CHP0=2F&B"[(KG+%:C-U;':UN"
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M!IW5(,8WP!CN$'5986X1MH9&<F"VLP#1)V/<"DV'0#8TJB-%L]>\HF[!K M
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M_NWS[)>ON%Q-%_-__QO_5_:W7W">%GDZ__3O?_OCXRMP?_OO__$O__+?_@^
M__G;^S>_O%BDT\\X7__R?(EAC?F7OZ;KDU_^S+CZYR]EN?C\RY^+Y3^G7P/
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M48]!$L+I:I)Y\>389LB(A&H7/+@8)/"H'5.&N)1= U#<_?;]L-%]#+(!:[N
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MK_M0YJ%,[ (!!-W/-9=\D?[YX838MGI[NJZ]!>H=SL0P*546!:*TU6$*A.=
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MZ41UM4%5&Y9W@)WGB]7Z;?G[8I&O'O\?%K,\8=Y(%5D"EO7&FB/UKG4"3EO
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MDLPJLAIZ;5UF^7@J.\D(/Q9!=YA30XJK YOKNL$HA0K9UP9!*.M5?$U%,D&
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M)#='1=W0RX(;G30KD%.]>_/:@==D%!BNI0PY2Q%:^[1[$3;NF*\.@-A<>AU
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M+\P,-DAYJ&-K,+[WFI*PWP2XYXO-7.CEYG7+Z>J?1^0M'/G&)YQ[M]^JN\J
MR"6'D'FN0"1()HO@?4)(I5XH2\1@6[<WZB(#XIJHWI.HMOZQQU*GGVHH6)NF
M9>?!1QD@:XE.Z9(2MD[VNIN2GR$KX3'8NN45'B^?#FRV6ZOX[?MO.$\GI$O^
MN0D36Y^MRRS7 $S-WF 6/.,%M,7LK?"LJ,'Q=H.F<9'70NX/0>D8(70)JO/5
MG,68<Q',2QM %[E)"4(@IUE!X*D(&Q/+OK5.?XBFSD!U% (>A-<1XN@ 7N<=
M]MYCPNEF/,[9+4/)2)ZR=N!EJ$6XBH'/#$$+1M\@1UKZUNDJNVCI#4['2'PQ
M /L[@%%ULV@1Y ^=XN]X?E-EO20/BUSJHD0@DT!&"-8P\K"S]LYC<*%Y#XN[
M"!DWACHH@(YG? ?HN4-C7Z2&Z2!1V%Q VGHCX(J'6'OR%9,T*LX5E\VO9G:3
MTQF2!C&7#F)]CRBZDC.FG!7"J@@L5A8)VF?!T\I8" Z9C-F(UCE2]Y#3VX%V
MH,@?=.(.XW\/4#I=K1>?<7EK26?ZU5DG53!D-\9Z:<5JV[6L+8B0=7*FE*):
MCXYX@*3.('6HZ&]"JJ$<1H35:KF>_"/\K\7R?#VKS69+ALYC[A@$%B6=TL0C
MI\G0L[:FD5FA$?=J[T*/OX(@^M<E>NY^\[CW@ U/L0:,'1D6-5GL;;FVAK-]
M(T*=_^@-9+&I\DD&8LX(UBO%K(N8U5Y^_0/HV$G .!JEA407K=D[]G7?J^E7
MO.#'F>JK9;5&&PDY:T-JU6MR%;6":*+0U7$0>"-O;L>MWAT/'T_TC>2U:,B\
M'LR1FQKS\BH3A5')EP!6U'G%J=2Z9ZL M>4Z%Z5D:MU883<UXR8*/(5W=!CC
MQ]8?OY]6U+\M%]M@(K-/R1H!=:9U-<HL!!4B2$/:0=6;:_?@3>W=C^[,$#U0
M8(MFW.M1?;S#9?U&^(2\%A.C4;06;CUY?)FT8,B!_EE*=+5M@F@^7N,^>CH+
ML!P'G^8"^,'31,+J),QSHK_P,D]F^%R1>U_[E DC^Z^_JZP1]#D$KSGPI+!F
MY\K:<=( =\H@$RR(YF'\/K)&2%!_S*?SVMPF/_M<I3EQW&'1(D..L994F (Q
MU2ZUCK[V4F1FFJO+VV3\#/DBCT'5754$QTCFQ]:CYY>&RXM+P\%UZ.Y7/J'^
MW'/=7>E.;ZP)QB!H4[.BL@@0./=@F-(RH#%&MV[AW(7NK&V,_Z*'XZL%>?"G
M<5U.9[<ONR=*%?+.,IE111![R".#6 =Z62V%]QI]"JV;^.Y'V<^@81^#O5N)
M">WE]V,KW?.Q\&3 X?E$^,'5[GTO?4+%N_?:&ZG>.U3_1=_IB-E$PG20F.J4
M# DN,@W9JFB*2LK)UMENNZEIUZ3RG,/O9E4 \_SRG,W;&);PW,JL+)B"AIS/
M4*KSJ8&A*9[LI.+L<"U_[Z=M7$79""F[NU V%$P'D:"=J[F2 D!V-/?::4!=
M)Y=KE<'7+"(K;2#M981KGJ2\!UDC%T0/@H?%L,+I&6]7\@."P<("SV26()D0
M2FGP]8K'E^1%UHY;W;JX<0^R1IZLW1H*^T+M0+ET +4ZP^*4'G>QE+.K/J&+
MR[7"+YO:C%BJ>B"H C(A"R5%E6/K_B([2.D44H>*_%:,^WC^=P"C#XNR_HL8
M2APZ__(%?L79XLNVXG.UOKA#MLJS7#QX7C.TM>$0BW%@R<:/A<7D8_.6]OL2
M-^XMRM!0&T9&'8#O'X$X.\?E]ZM,.^_ZQ"T156@5O [<\;ZF= <!(;$8L%Y
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M8)DQ+1?220#PI]I$[9#S Y]!.YCP]S"=OUFL5J_GVSS2U_/SQ-$)1U88F0G
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M)+8^JYVF>A;WXLL"+T>%'7(7Z+%GM3F-W8K21H>$F^34BUO)J2N8>>\<RJ+
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M)9<96/8):"=#\FUT I-#CD9Z)[<$PKU'CW2UZ)C>P3Y"'!L"5UO;AGAR;()
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MEUDM,R(O2LO,G +C8JY3Y")$;3F8:',LT9'D6J=@MB)L[)*=,>W? 2KJM:O
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M:TP)/?$52ZQ-S>JDU* IE,U1^L 3B\T;<0_6WN+(5XF:XZ^IMKK.2,:PK//
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MFG&65P(1*+SG)I,$:@^>X"*XG"/4V;C.*&0A=!/>;,O4B?:UZ' Q'0R9AEF
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M:69X9_'E',@FDW3>$:ESAYMT#I$>B[02*FO5I(.W#%-D+*@>Q2_&+DI^N+B
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MQ+TS0?.<L[7<;_*$G\KWGL4UF[GPZ_T)4$L#!!0    ( %2$9U;<@5 7\P0
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M:71I97-E>#0N:'1M4$L! A0#%     @ 5(1G5EXS&\\C2@  !@$" !X
M         ( !C14  &9O<FUI;F1E;6YI9FEC871I;VYA9W)E96UE+FAT;5!+
M 0(4 Q0    ( %2$9U80(*IA#@,  "L2   ?              "  >Q?  !L
M:7-T;V9S=6)S:61I87)I97-E>#(Q,3(P,C(N:'1M4$L! A0#%     @ 5(1G
M5J_8S9%]%00 D8XA !$              ( !-V,  &]P=&XM,C R,C$R,S$N
M:'1M4$L! A0#%     @ 5(1G5HD<HZ_R%   !^D  !$              ( !
MXW@$ &]P=&XM,C R,C$R,S$N>'-D4$L! A0#%     @ 5(1G5G<F.^+X'0
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M;BTR,#(R,3(S,5]G,BYJ<&=02P$"% ,4    " !4A&=6R+=WI/E4  !P;0
M%               @ ';C@4 ;W!T;BTR,#(R,3(S,5]G,RYJ<&=02P$"% ,4
M    " !4A&=6U "J2-Y$ 0"@60$ %               @ $&Y 4 ;W!T;BTR
M,#(R,3(S,5]G-"YJ<&=02P$"% ,4    " !4A&=6D*76NZ5)  "G2@  %
M            @ $6*0< ;W!T;BTR,#(R,3(S,5]G-2YJ<&=02P$"% ,4
M" !4A&=6+N8M!0[M   U[@  %               @ 'M<@< ;W!T;BTR,#(R
M,3(S,5]G-BYJ<&=02P$"% ,4    " !4A&=6ZV*V:ZM" 0!I10$ %
M        @ $M8 @ ;W!T;BTR,#(R,3(S,5]G-RYJ<&=02P$"% ,4    " !4
MA&=6SI3:GMOG  #3Z0  %               @ $*HPD ;W!T;BTR,#(R,3(S
M,5]G."YJ<&=02P$"% ,4    " !4A&=6LH9>^7^4 0!]E@$ %
M    @ $7BPH ;W!T;BTR,#(R,3(S,5]G.2YJ<&=02P$"% ,4    " !4A&=6
MX?[;4MP$ 0!W_PH %0              @ '('PP ;W!T;BTR,#(R,3(S,5]L
M86(N>&UL4$L! A0#%     @ 5(1G5GP)7(6"EP  X=$& !4
M ( !UR0- &]P=&XM,C R,C$R,S%?<')E+GAM;%!+ 0(4 Q0    ( %2$9U8H
M.S4(^@<  +<@   ;              "  8R\#0!O<'1N,3(M,S%X,C R,C$P
M>&ME>#,Q,2YH=&U02P$"% ,4    " !4A&=6C$4"0P$(  !7(   &P
M        @ &_Q T ;W!T;C$R+3,Q>#(P,C(Q,'AK97@S,3(N:'1M4$L! A0#
M%     @ 5(1G5K (S2[9!   2Q0  !L              ( !^<P- &]P=&XQ
M,BTS,7@R,#(R,3!X:V5X,S(Q+FAT;5!+ 0(4 Q0    ( %2$9U;<@5 7\P0
M -L3   ;              "  0O2#0!O<'1N,3(M,S%X,C R,C$P>&ME>#,R
;,BYH=&U02P4&     !< %P N!@  -]<-

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
